PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Wilson, JF				Wilson, JF			Angiogenesis therapy moves beyond cancer	ANNALS OF INTERNAL MEDICINE			English	Article												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	11	16	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					165	168		10.7326/0003-4819-141-2-200407200-00027	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262679				2022-12-28	WOS:000222758200018
J	Peto, J; Gilham, C; Fletcher, O; Matthews, FE				Peto, J; Gilham, C; Fletcher, O; Matthews, FE			The cervical cancer epidemic that screening has prevented in the UK	LANCET			English	Article							CARCINOMA IN-SITU; HUMAN-PAPILLOMAVIRUS; UTERINE CERVIX; ENGLAND; MORTALITY; WOMEN; RATES; ADENOCARCINOMA; CLEARANCE; BEHAVIOR	Background Recent reports suggest that the reduction in mortality achieved by the UK national cervical screening programme is too small to justify its financial and psychosocial costs, except perhaps in a few high-risk women. Methods We analysed trends in mortality before 1988, when the British national screening programme was launched, to estimate what future trends in cervical cancer mortality would have been without any screening. Findings Cervical cancer mortality in England and Wales in women younger than 35 years rose three-fold from 1967 to 1987. By 1988, incidence in this age-range was among the highest in the world despite substantial opportunistic screening. Since national screening was started in 1988, this rising trend has been reversed. Interpretation Cervical screening has prevented an epidemic that would have killed about one in 65 of all British women born since 1910 and culminated in about 6110 deaths per year in this country. However, these estimates are subject to substantial uncertainty, particularly in relation to the effects of oral contraceptives and changes in sexual behaviour. 80% or more of these deaths (up to 5000 deaths per year) are likely to be prevented by screening, which means that about 100 000 (one in 80) of the 8 million British women born between 1951 and 1970 will be saved from premature death by the cervical screening programme at a cost per life saved of about pound36 000. The birth cohort trends also provide strong evidence that the death rate throughout life is substantially lower in women who were first screened when they were younger.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England; Inst Canc Res, Sutton, Surrey, England; Inst Publ Hlth, MRC, Biostat Unit, Cambridge, England	University of London; London School of Hygiene & Tropical Medicine; University of London; Institute of Cancer Research - UK; MRC Biostatistics Unit; University of Cambridge	Peto, J (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	julian.peto@lshtm.ac.uk	Matthews, Fiona/O-6932-2015	Matthews, Fiona/0000-0002-1728-2388; Fletcher, Olivia/0000-0001-9387-7116				Akker-van Marle MEV, 2003, BRIT J CANCER, V88, P1054, DOI 10.1038/sj.bjc.6600843; [Anonymous], 1986, Br Med J (Clin Res Ed), V293, P659; Anttila A, 1999, INT J CANCER, V83, P59, DOI 10.1002/(SICI)1097-0215(19990924)83:1<59::AID-IJC12>3.3.CO;2-E; Botting B, 2000, Popul Trends, P32; BRESLOW NE, 1987, IARC SCI PUBLICATION, V82; Castellsague X, 2002, VIRUS RES, V89, P191, DOI 10.1016/S0168-1702(02)00188-0; Deacon JM, 2000, BRIT J CANCER, V83, P1565, DOI 10.1054/bjoc.2000.1523; Department of Health, 1994, CERV CYT 1992 93 SUM; Dillner J, 2000, J CLIN VIROL, V19, P7, DOI 10.1016/S1386-6532(00)00126-8; Elfgren K, 2002, OBSTET GYNECOL, V100, P965, DOI 10.1016/S0029-7844(02)02280-9; Green J, 2003, BRIT J CANCER, V89, P2078, DOI 10.1038/sj.bjc.6601296; Green JA, 2001, LANCET, V358, P781, DOI 10.1016/S0140-6736(01)05965-7; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KINLEN LJ, 1978, LANCET, V2, P463; KITCHENER HC, 2004, 21 INT PAP C 2004 FE; KOSS LG, 1963, CANCER, V16, P1160, DOI 10.1002/1097-0142(196309)16:9<1160::AID-CNCR2820160910>3.0.CO;2-4; LEA R, 2000, HEALTHCARE UK NEED R; Levi F, 2000, EUR J CANCER, V36, P2266, DOI 10.1016/S0959-8049(00)00346-4; MCINDOE WA, 1984, OBSTET GYNECOL, V64, P451; Miller AB, 2002, EUR J CANCER, V38, P321, DOI 10.1016/S0959-8049(01)00374-4; Nobbenhuis MAE, 2001, LANCET, V358, P1782, DOI 10.1016/S0140-6736(01)06809-X; *OFF NAT STAT, 1984, SOC TRENDS; *OFF NAT STAT, 2001, STAT B DEP HLTH; *OFF NAT STAT, 2002, SOC TRENDS; PARKIN DM, 1985, BRIT J OBSTET GYNAEC, V92, P150, DOI 10.1111/j.1471-0528.1985.tb01067.x; PARKIN DM, 2000, IARC SCI PUBLICATION, V143; PETO J, IN PRESS BR J CANC; Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998; *PHLS DHSS PS SCOT, 1995, SEX TRANSM INF UK NE; Quinn M, 1999, BRIT MED J, V318, P904, DOI 10.1136/bmj.318.7188.904; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; Redburn JC, 2001, BRIT J OBSTET GYNAEC, V108, P388; Sasieni P, 2001, LANCET, V357, P1490, DOI 10.1016/S0140-6736(00)04646-8; Sasieni P, 1999, BRIT MED J, V318, P1244; Sasieni P, 2003, BRIT J CANCER, V89, P88, DOI 10.1038/sj.bjc.6600974; Simms I, 1997, GENITOURIN MED, V73, P365; Smith JS, 2003, LANCET, V361, P1159, DOI 10.1016/S0140-6736(03)12949-2; Swerdlow AJ, 2001, CANC INCIDENCE MORTA; van Ballegooijen M, 2000, EUR J CANCER, V36, P2177, DOI 10.1016/S0959-8049(00)00330-0; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; World Health Organization, WHO STAT INF SYST WH	42	546	565	2	34	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					249	256		10.1016/S0140-6736(04)16674-9	http://dx.doi.org/10.1016/S0140-6736(04)16674-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262102				2022-12-28	WOS:000222784900027
J	Stein, DJ; Gureje, O				Stein, DJ; Gureje, O			Depression and anxiety in the developing world: is it time to medicalise the suffering?	LANCET			English	Editorial Material							COMMON MENTAL-DISORDERS; CARE		Univ Stellenbosch, Dept Psychiat, ZA-7505 Cape Town, South Africa; Univ Ibadan, Dept Psychiat, Ibadan, Nigeria	Stellenbosch University; University of Ibadan	Stein, DJ (corresponding author), Univ Stellenbosch, Dept Psychiat, ZA-7505 Cape Town, South Africa.	djs2@sun.ac.za	Adewuya, Abiodun/N-4997-2017; Gureje, Oye/J-1183-2014; Stein, Dan/A-1752-2008	Adewuya, Abiodun/0000-0002-7611-6953; Gureje, Oye/0000-0003-0094-5947; Stein, Dan/0000-0001-7218-7810				Araya R, 2003, LANCET, V361, P995, DOI 10.1016/S0140-6736(03)12825-5; Bolton P, 2003, JAMA-J AM MED ASSOC, V289, P3117, DOI 10.1001/jama.289.23.3117; Carey PD, 2003, J NERV MENT DIS, V191, P230, DOI 10.1097/00005053-200304000-00003; Charney DS, 2004, AM J PSYCHIAT, V161, P195, DOI 10.1176/appi.ajp.161.2.195; Chisholm D, 2004, BRIT J PSYCHIAT, V184, P393, DOI 10.1192/bjp.184.5.393; Conrad P., 1980, DEVIANCE MED BADNESS; Demyttenaere K, 2004, JAMA-J AM MED ASSOC, V291, P2581, DOI 10.1001/jama.291.21.2581; Foucault M., 1977, NASCIMENTO CLIN BIRT; Global Forum for Health Research, 2005, 10 90 REP HLTH RES 2, P25; Gureje O, 2000, B WORLD HEALTH ORGAN, V78, P475; Kessler RC, 2000, ACTA PSYCHIAT SCAND, V102, P7, DOI 10.1111/j.0065-1591.2000.acp29[dash]02.x; Nesse RM, 2000, ARCH GEN PSYCHIAT, V57, P14, DOI 10.1001/archpsyc.57.1.14; Patel V, 2003, LANCET, V361, P33, DOI 10.1016/S0140-6736(03)12119-8; Patel V, 2003, B WORLD HEALTH ORGAN, V81, P609; Resnik D B, 2001, Dev World Bioeth, V1, P11, DOI 10.1111/1471-8847.00004; Stein DJ, 2001, DEPRESS ANXIETY, V13, P105, DOI 10.1002/da.1025; *UNAIDS, 2003, ACC ACT AIDS AFR; Ustun TB, 2004, BRIT J PSYCHIAT, V184, P386, DOI 10.1192/bjp.184.5.386; YEHUDA R, 1995, AM J PSYCHIAT, V152, P1705; Zungu-Dirwayi N, 2004, J NERV MENT DIS, V192, P255, DOI 10.1097/01.nmd.0000121155.28299.f8	20	24	24	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					233	234		10.1016/S0140-6736(04)16693-2	http://dx.doi.org/10.1016/S0140-6736(04)16693-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	839KV	15262087				2022-12-28	WOS:000222784900010
J	Bakkenist, CJ; Kastan, MB				Bakkenist, CJ; Kastan, MB			Initiating cellular stress responses	CELL			English	Review							DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; ATM ACTIVATION; ATAXIA-TELANGIECTASIA; CATALYTIC SUBUNIT; BINDING; REPLICATION; CHECKPOINT; COMPLEX; PHOSPHORYLATION	The phosphoinositide 3-kinase related kinases (PIKKs) mediate responses to diverse stresses, including DNA double-strand breaks (DSBs), abnormal replication fork progression, the recognition of premature termination codons in mRNAs, and inadequate nutrient availability. Rigorous control of these kinases limits cellular damage and promotes cell viability in the presence of stress. Control mechanisms include the localization of PIKKs into multiprotein complexes at the sites of damage and mediation of protein-protein contacts such that substrates are allowed access to the PIKK catalytic domains.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale, Memphis, TN 38105 USA.	michael.kastan@stjude.org						Abraham RT, 2002, NAT CELL BIOL, V4, pE277, DOI 10.1038/ncb1202-e277; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; DeFazio LG, 2002, EMBO J, V21, P3192, DOI 10.1093/emboj/cdf299; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Ellison V, 2003, PLOS BIOL, V1, P231, DOI 10.1371/journal.pbio.0000033; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hanakahi LA, 2002, EMBO J, V21, P2038, DOI 10.1093/emboj/21.8.2038; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hekmat-Nejad M, 2000, CURR BIOL, V10, P1565, DOI 10.1016/S0960-9822(00)00855-1; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Lupardus PJ, 2002, GENE DEV, V16, P2327, DOI 10.1101/gad.1013502; Ma YM, 2002, J BIOL CHEM, V277, P10756, DOI 10.1074/jbc.C200030200; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Michael WM, 2000, SCIENCE, V289, P2133, DOI 10.1126/science.289.5487.2133; Mochan TA, 2003, CANCER RES, V63, P8586; Nakada D, 2003, GENE DEV, V17, P1957, DOI 10.1101/gad.1099003; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PETRINI JH, 2002, CURR OPIN CELL BIOL, V12, P293; SCHIEVEN G, 1988, J BIOL CHEM, V263, P15590; Sorensen CS, 2004, CELL CYCLE, V3, P941; Theunissen JWF, 2003, MOL CELL, V12, P1511, DOI 10.1016/S1097-2765(03)00455-6; Unsal-Kacmaz K, 2004, MOL CELL BIOL, V24, P1292, DOI 10.1128/MCB.24.3.1292-1300.2003; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Yamashita A, 2001, GENE DEV, V15, P2215, DOI 10.1101/gad.913001; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	53	393	407	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					9	17		10.1016/j.cell.2004.06.023	http://dx.doi.org/10.1016/j.cell.2004.06.023			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242640	Bronze			2022-12-28	WOS:000222626800004
J	Farr, MA; Basson, CT				Farr, MA; Basson, CT			Sparking the failing heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CHANNEL RYANODINE RECEPTOR; FAILURE		Cornell Univ, Weill Med Coll, Mol Cardiol Lab, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Congest Heart Failure Ctr, Greenberg Cardiol Div,Dept Med, New York, NY USA	Cornell University; Cornell University	Farr, MA (corresponding author), Cornell Univ, Weill Med Coll, Mol Cardiol Lab, New York, NY 10021 USA.							Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Priori SG, 2001, CIRCULATION, V103, P196; Reiken S, 2001, CIRCULATION, V104, P2843, DOI 10.1161/hc4701.099578; Wehrens XHT, 2004, SCIENCE, V304, P292, DOI 10.1126/science.1094301; Yano M, 2003, CIRCULATION, V107, P477, DOI 10.1161/01.CIR.0000044917.74408.BE	5	15	25	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					185	187		10.1056/NEJMcibr041466	http://dx.doi.org/10.1056/NEJMcibr041466			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247360				2022-12-28	WOS:000222470700015
J	Honour, JW				Honour, JW			The fight for fair play	NATURE			English	Editorial Material							SUPPLEMENTS		UCL Hosp, Dept Clin Biochem, London W1T 4EU, England	University College London Hospitals NHS Foundation Trust; University of London; University College London	Honour, JW (corresponding author), UCL Hosp, Dept Clin Biochem, 60 Whitfield St, London W1T 4EU, England.							Abbott A, 2004, NATURE, V429, P689, DOI 10.1038/429689a; Catlin DH, 2000, JAMA-J AM MED ASSOC, V284, P2618, DOI 10.1001/jama.284.20.2618; Geyer H, 2004, INT J SPORTS MED, V25, P124, DOI 10.1055/s-2004-819955; Knight J, 2003, NATURE, V426, P114, DOI 10.1038/426114a	4	3	3	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					143	144		10.1038/430143a	http://dx.doi.org/10.1038/430143a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241389				2022-12-28	WOS:000222470600019
J	Curti, BD				Curti, BD			Renal cell carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AUTOLOGOUS TUMOR VACCINE; RADICAL NEPHRECTOMY; SUPPRESSOR GENE; SURVIVAL; CANCER; TRIAL; STRATIFICATION; CLASSIFICATION; PROGRESSION; THERAPY		Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, Portland, OR 97213 USA	Providence Portland Medical Center	Curti, BD (corresponding author), Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Res Ctr, 4805 NE Glisan St,5F40, Portland, OR 97213 USA.	brendan.curti@providence.org						Atzpodien J, 2003, BRIT J CANCER, V88, P348, DOI 10.1038/sj.bjc.6600768; Bui MHT, 2003, CLIN CANCER RES, V9, P802; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Chow WH, 1999, JAMA-J AM MED ASSOC, V281, P1628, DOI 10.1001/jama.281.17.1628; Cohen L, 2002, UROL ONCOL, V7, P119, DOI 10.1016/S1078-1439(01)00182-X; DODERLEIN A, 1894, SEX ORGANE, V3, P88; Fenton RG, 1996, J IMMUNOTHER, V19, P364, DOI 10.1097/00002371-199609000-00006; Fisher RI, 1997, CANCER J SCI AM, V3, pS70; Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013; Fossa SD, 2000, SEMIN ONCOL, V27, P187; Gitlitz BJ, 2003, J IMMUNOTHER, V26, P412, DOI 10.1097/00002371-200309000-00004; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Javidan J, 1999, J UROLOGY, V162, P1277, DOI 10.1016/S0022-5347(05)68264-X; Jocham D, 2004, LANCET, V363, P594, DOI 10.1016/S0140-6736(04)15590-6; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leibovich BC, 2003, CANCER-AM CANCER SOC, V97, P1663, DOI 10.1002/cncr.11234; Linehan WM, 2003, J UROLOGY, V170, P2163, DOI 10.1097/01.ju.0000096060.92397.ed; MALDAZYS JD, 1986, J UROLOGY, V136, P376, DOI 10.1016/S0022-5347(17)44873-7; MONTIE JE, 1977, J UROLOGY, V117, P272, DOI 10.1016/S0022-5347(17)58429-3; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; RABINOVITCH RA, 1994, J CLIN ONCOL, V12, P206, DOI 10.1200/JCO.1994.12.1.206; Reuter VE, 2000, SEMIN ONCOL, V27, P124; Saika T, 2003, UROLOGY, V62, P1018, DOI 10.1016/j.urology.2003.07.009; Schwaab T, 2004, J UROLOGY, V171, P1036, DOI 10.1097/01.ju.0000113275.91953.5d; SHUIN T, 1994, CANCER RES, V54, P2852; UPTON MP, 2003, P AN M AM SOC CLIN, V851, P3420; VOGELZANG NJ, 1996, COMPREHENSIVE TXB GE; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Zisman A, 2002, J CLIN ONCOL, V20, P1368, DOI 10.1200/JCO.20.5.1368	29	108	115	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					97	100		10.1001/jama.292.1.97	http://dx.doi.org/10.1001/jama.292.1.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238597				2022-12-28	WOS:000222448100033
J	Petersen, JL; Mahaffey, KW; Hasselblad, V; Antman, EM; Cohen, M; Goodman, SG; Langer, A; Blazing, MA; Le-Moigne-Amrani, A; de Lemos, JA; Nessel, CC; Harrington, RA; Ferguson, JJ; Braunwald, E; Califf, RM				Petersen, JL; Mahaffey, KW; Hasselblad, V; Antman, EM; Cohen, M; Goodman, SG; Langer, A; Blazing, MA; Le-Moigne-Amrani, A; de Lemos, JA; Nessel, CC; Harrington, RA; Ferguson, JJ; Braunwald, E; Califf, RM			Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes - A systematic overview	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							MOLECULAR-WEIGHT HEPARIN; WAVE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ASPIRIN; TIROFIBAN; SAFETY; INTERVENTION; CLOPIDOGREL; MANAGEMENT; REGISTRY	Context Antithrombin therapy has become a guidelines-recommended standard of care in the treatment of acute coronary syndromes (ACS), but recent trials comparing use of enoxaparin and unfractionated heparin in ACS have yielded less robust efficacy and safety results than have earlier trials of these antithrombin therapies. Objective To systematically evaluate the end points of all-cause death and nonfatal myocardial infarction (MI), transfusion, and major bleeding observed in the 6 randomized controlled trials comparing enoxaparin and unfractionated heparin in treatment of ACS. DataSources The primary data sets for ESSENCE, A to Z, and SYNERGY were available at the Duke Clinical Research Institute. Baseline characteristics and event frequencies for TIMI 11B, ACUTE II, and INTERACT were provided by the principal investigator of each study. Study Selection All 6 randomized controlled trials comparing enoxaparin and unfractionated heparin in non-ST-segment elevation ACS were selected for analysis. Data Extraction Efficacy and safety end points were extracted from the overall trial populations and the subpopulation receiving no antithrombin therapy prior to randomization. Data Synthesis Systematic evaluation of the outcomes for 21946 patients was performed using a random-effects empirical Bayes model. No significant difference was found in death at 30 days for enoxaparin vs unfractionated heparin (3.0% vs 3.0%; odds ratio [OR], 1.00; 95% confidence interval [CI], 0.85-1.17). A statistically significant reduction in the combined end point of death or nonfatal MI at 30 days was observed for enoxaparin vs unfractionated heparin in the overall trial populations (10.1% vs 11.0%; OR, 0.91; 95% Cl, 0.83-0.99; number needed to treat, 107). A statistically significant reduction in the combined end point of death or MI at 30 days was also observed for enoxaparin in the populations receiving no prerandomization antithrombin therapy (8.0% vs 9.4%; OR, 0.81; 95% Cl, 0.70-0.94; number needed to treat, 72). No significant difference was found in blood transfusion (OR, 1.01; 95% Cl, 0.89-1.14) or major bleeding (OR, 1.04; 95% Cl, 0.83-1.30) at 7 days after randomization in the overall safety population or in the population of patients receiving no prerandomization antithrombin therapy. Conclusion In a systematic overview of approximately 22000 patients across the spectrum of ACS, enoxaparin is more effective than unfractionated heparin in preventing the combined end point of death or MI.	Duke Clin Res Inst, Dept Med, Div Cardiol, Durham, NC 27715 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; Newark Beth Israel Med Ctr, Div Cardiol, Newark, NJ USA; Univ Toronto, St Michaels Hosp, Div Cardiol, Terrence Donnelly Heart Ctr, Toronto, ON M5B 1W8, Canada; Univ Toronto, St Michaels Hosp, Div Cardiol, Canadian Heart Res Ctr, Toronto, ON M5B 1W8, Canada; Univ Texas, Div Cardiol, Dallas, TX 75230 USA; Aventis Inc, Bridgewater, MA USA; St Lukes Episcopal Hosp, Texas Heart Inst, Houston, TX USA	Duke University; Harvard University; Brigham & Women's Hospital; Newark Beth Israel Medical Center; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Canadian Heart Research Centre; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Texas System; University of Texas Dallas; Sanofi-Aventis; Saint Lukes Episcopal Hospital; Texas Heart Institute	Mahaffey, KW (corresponding author), Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27715 USA.	mahaf002@mc.duke.edu	de Lemos, James/ABD-6669-2021					Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Antman EM, 1999, CIRCULATION, V100, P1602, DOI 10.1161/01.CIR.100.15.1602; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Blazing MA, 2001, AM HEART J, V142, P211, DOI 10.1067/mhj.2001.116959; Braunwald E, 2002, J AM COLL CARDIOL, V40, P1366, DOI 10.1016/S0735-1097(02)02336-7; Budaj A, 2003, AM HEART J, V146, P999, DOI 10.1016/S0002-8703(03)00509-X; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Cohen M, 2002, AM HEART J, V144, P470, DOI 10.1067/mhj.2002.126115; EDDY DM, 1992, FAST PRO SOTWARE MET; Eikelboom JW, 2000, LANCET, V355, P1936, DOI 10.1016/S0140-6736(00)02324-2; Ferguson JJ, 2004, JAMA-J AM MED ASSOC, V292, P45; Ferguson JJ, 2002, AM HEART J, V143, P952, DOI 10.1067/mhj.2002.122120; Fox KAA, 2002, LANCET, V360, P743, DOI 10.1016/S0140-6736(02)09894-X; Goodman SG, 2003, CIRCULATION, V107, P238, DOI 10.1161/01.CIR.0000050144.67910.13; HEDGES LV, 1985, STAT METHODS METAANA, P200; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; Mehta SR, 2001, LANCET, V358, P527, DOI 10.1016/S0140-6736(01)05701-4; Pieper KS, 2004, CIRCULATION, V109, P641, DOI 10.1161/01.CIR.0000112570.97220.89; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Shadish W., 1994, HDB RES SYNTHESIS, P265; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; Yusuf S, 2001, NEW ENGL J MED, V345, P494	24	229	243	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					89	96		10.1001/jama.292.1.89	http://dx.doi.org/10.1001/jama.292.1.89			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238596				2022-12-28	WOS:000222448100032
J	Greenhalgh, T; Kostopoulou, O; Harries, C				Greenhalgh, T; Kostopoulou, O; Harries, C			Making decisions about benefits and harms of medicines	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHOICE; PERCEPTION		UCL, Dept Primary Care & Populat, London N19 5LW, England; Univ Birmingham, Dept Primary Care & Gen Practice, Birmingham, W Midlands, England; Univ Birmingham, Dept Hlth R&D, Birmingham, W Midlands, England; UCL, Dept Psychol, London WC1E 6BT, England	University of London; University College London; University of Birmingham; University of Birmingham; University of London; University College London	Greenhalgh, T (corresponding author), UCL, Dept Primary Care & Populat, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Kostopoulou, Olga/0000-0001-9643-0838				AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ances BM, 2002, OBSTET GYNECOL, V99, P125, DOI 10.1016/S0029-7844(01)01662-3; Bandura A., 1986, SOCIAL FDN THOUGHT A; Bandura A., 1977, SOCIAL LEARNING THEO, V1; BASTANI B, 1989, PSYCHOPHARMACOLOGY, V99, pS122, DOI 10.1007/BF00442576; Berwick DM, 1997, JOINT COMM J QUAL IM, V23, P245, DOI 10.1016/S1070-3241(16)30314-5; Bruner J. S., 1990, ACTS MEANING; CHAPMAN LJ, 1969, J ABNORM PSYCHOL, V74, P271, DOI 10.1037/h0027592; Denning Stephen, 2001, SPRINGBOARD STORYTEL; Doust J, 2004, BRIT MED J, V328, P474, DOI 10.1136/bmj.328.7438.474; Edwards A, 2001, J HEALTH COMMUN, V6, P61, DOI 10.1080/10810730150501413; Ernst E, 2004, J ROY SOC MED, V97, P41, DOI 10.1258/jrsm.97.1.41; FREUD S, 1977, INHIBITIONS SYMPTOMS; Gigerenzer G, 2003, BMJ-BRIT MED J, V327, P741, DOI 10.1136/bmj.327.7417.741; Gigerenzer G., 1999, SIMPLE HEURISTICS MA, P3; Gigerenzer G., 2001, BOUNDED RATIONALITY; GREENHALGH T, 2004, IN PRESS ACAD BASIS; Hall AJ, 2001, OCL-OL CORPS GRAS LI, V8, P15, DOI 10.1051/ocl.2001.0015; Hampson SE, 2001, PERS INDIV DIFFER, V30, P167, DOI 10.1016/S0191-8869(00)00025-8; Hsee CK, 1997, J EXP PSYCHOL GEN, V126, P45, DOI 10.1037/0096-3445.126.1.45; Jefferson T, 2004, LANCET INFECT DIS, V4, P135, DOI 10.1016/S1473-3099(04)00934-X; KAHNEMAN D, 1979, ECONOMETRICA, V47, P263, DOI 10.2307/1914185; Lloyd AJ, 2001, QUAL HEALTH CARE, V10, pI14; Lomas J, 1997, IMPROVING RES DISSEM; Marshall KG, 1996, CAN MED ASSOC J, V154, P1493; Mayer EA, 2003, EXPERT OPIN PHARMACO, V4, P2089, DOI 10.1517/eoph.4.11.2089.22364; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MONTGOMERY AA, QUALITY HLTH CARE, V10, P39; MONTGOMERY AA, 2001, QUAL HEALTH CARE, V10, P39; NEWMAN T, 2003, BRIT MED J, V327, P1444; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38, DOI 10.4278/0890-1171-12.1.38; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Simon H. A., 1982, MODELS BOUNDED RATIO; TETLOCK PE, 1991, THEOR PSYCHOL, V1, P451, DOI 10.1177/0959354391014004; Tucker G, 2004, BMJ-BRIT MED J, V329, P4, DOI 10.1136/bmj.329.7456.4; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; VISCUSI WK, 1987, RAND J ECON, V18, P465, DOI 10.2307/2555636	38	22	22	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					47	50B		10.1136/bmj.329.7456.47	http://dx.doi.org/10.1136/bmj.329.7456.47			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	836PP	15231628	Green Submitted, Green Published			2022-12-28	WOS:000222568300028
J	Stinchcombe, J; Bossi, G; Griffiths, GM				Stinchcombe, J; Bossi, G; Griffiths, GM			Linking albinism and immunity: The secrets of secretory lysosomes	SCIENCE			English	Review							HERMANSKY-PUDLAK-SYNDROME; DENDRITIC CELL MATURATION; CLASS-II TRANSPORT; GRISCELLI-SYNDROME; MYOSIN-VA; GRANULE EXOCYTOSIS; AP-3 ADAPTER; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; IMMUNOLOGICAL SYNAPSE; MULTIVESICULAR BODIES	Lysosomes are membrane-bound organelles that are found in all mammalian cells and contain hydrolases and lipases required for protein and membrane degradation. In many cells of the immune system, lysosomes also contain secretory proteins that can be released by regulated exocytosis in response to an external stimulus, providing different cell types with a wide range of effector functions. Melanosomes also use a lysosome-related organelle to secrete melanin for pigmentation. Links between albinism and immunity in patients have uncovered a number of key proteins required for lysosomal secretion and have revealed a versatile secretory mechanism that can be fine-tuned by distinct interactions in different cell types.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Griffiths, GM (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	gillian.griffiths@path.ox.ac.uk		stinchcombe, jane/0000-0003-1459-9299; Griffiths, Gillian/0000-0003-0434-5842				Anderson PD, 2003, HUM GENET, V113, P10, DOI 10.1007/s00439-003-0933-5; Andrews NW, 2002, J CELL BIOL, V158, P389, DOI 10.1083/jcb.200205110; Anikster Y, 2002, AM J HUM GENET, V71, P407, DOI 10.1086/341606; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; BAETZ K, 1995, J IMMUNOL, V154, P6122; Baram D, 2001, IMMUNOL REV, V179, P25, DOI 10.1034/j.1600-065X.2001.790103.x; Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Chen D, 2000, BLOOD, V95, P921, DOI 10.1182/blood.V95.3.921.003k17_921_929; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Desnos C, 2003, J CELL BIOL, V163, P559, DOI 10.1083/jcb.200302157; Detter JC, 2000, P NATL ACAD SCI USA, V97, P4144, DOI 10.1073/pnas.080517697; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Flaumenhaft R, 1999, J BIOL CHEM, V274, P2492, DOI 10.1074/jbc.274.4.2492; GFIFFITHS GM, UNPUB; Gonzallez-Gaitan M, 2003, NAT REV MOL CELL BIO, V4, P213, DOI 10.1038/nrm1053; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Hannah MJ, 2003, J CELL SCI, V116, P3939, DOI 10.1242/jcs.00711; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Huizing M, 2002, PIGM CELL RES, V15, P405, DOI 10.1034/j.1600-0749.2002.02074.x; Huizing M, 2002, PEDIATR RES, V51, P150, DOI 10.1203/00006450-200202000-00006; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Hutt DM, 2002, BIOL REPROD, V66, P50, DOI 10.1095/biolreprod66.1.50; Jaiswal JK, 2002, J CELL BIOL, V159, P625, DOI 10.1083/jcb.200208154; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Kierszenbaum AL, 2004, BIOL REPROD, V70, P1400, DOI 10.1095/biolreprod.103.025346; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Lemons PP, 2000, BIOCHEM BIOPH RES CO, V267, P875, DOI 10.1006/bbrc.1999.2039; Li W, 2003, NAT GENET, V35, P84, DOI 10.1038/ng1229; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Marsh M, 2003, NAT MED, V9, P1262, DOI 10.1038/nm1003-1262; Marti-Verdeaux S, 2003, J CELL SCI, V116, P325, DOI 10.1242/jcs.00216; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; MATTEONI R, 1987, J CELL BIOL, V105, P1253, DOI 10.1083/jcb.105.3.1253; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Menasche G, 2003, J CLIN INVEST, V112, P450, DOI 10.1172/JCI200318264; MULLER M, 1972, J CELL BIOL, V52, P478, DOI 10.1083/jcb.52.2.478; Murk JL, 2002, SEMIN CELL DEV BIOL, V13, P303, DOI 10.1016/S1084952102000605; Pastural E, 2000, GENOMICS, V63, P299, DOI 10.1006/geno.1999.6081; Paumet F, 2000, J IMMUNOL, V164, P5850, DOI 10.4049/jimmunol.164.11.5850; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Pelchen-Matthews A, 2003, J CELL BIOL, V162, P443, DOI 10.1083/jcb.200304008; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; RAO S, UNPUB; Raposo G, 2002, TRAFFIC, V3, P718, DOI 10.1034/j.1600-0854.2002.31004.x; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stepp SE, 2000, IMMUNOL TODAY, V21, P254, DOI 10.1016/S0167-5699(00)01622-4; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; Swank RT, 1998, PIGM CELL RES, V11, P60, DOI 10.1111/j.1600-0749.1998.tb00713.x; Swank RT, 2000, PIGM CELL RES, V13, P59, DOI 10.1034/j.1600-0749.13.s8.12.x; Tolmachova T, 2004, MOL BIOL CELL, V15, P332, DOI 10.1091/mbc.e03-07-0452; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Ward Diane McVey, 2002, Current Molecular Medicine (Hilversum), V2, P469, DOI 10.2174/1566524023362339; Ward DM, 2003, TRAFFIC, V4, P403, DOI 10.1034/j.1600-0854.2003.00093.x; Waselle L, 2003, MOL BIOL CELL, V14, P4103, DOI 10.1091/mbc.E03-01-0022; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XF, 2001, J CELL SCI, V114, P1091; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Zhen LJ, 1999, BLOOD, V94, P146, DOI 10.1182/blood.V94.1.146.413k39_146_155	74	276	288	2	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					55	59		10.1126/science.1095291	http://dx.doi.org/10.1126/science.1095291			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232098				2022-12-28	WOS:000222386000031
J	ter Meulen, J; Bakker, ABH; van den Brink, EN; Weverling, GJ; Martina, BEE; Haagmans, BL; Kuiken, T; de Kruif, J; Preiser, W; Spaan, W; Gelderblom, HR; Goudsmit, J; Osterhaus, ADME				ter Meulen, J; Bakker, ABH; van den Brink, EN; Weverling, GJ; Martina, BEE; Haagmans, BL; Kuiken, T; de Kruif, J; Preiser, W; Spaan, W; Gelderblom, HR; Goudsmit, J; Osterhaus, ADME			Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets	LANCET			English	Article								SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3.3 logs (95% Cl 2.6-4.0 logs; p<0.001), completely prevented the development of SARS coronavirus-induced macroscopic lung pathology (p=0.013), and abolished shedding of virus in pharyngeal secretions. The data generated in this animal model show that administration of a human monoclonal antibody might offer a feasible and effective prophylaxis for the control of human SARS coronavirus infection.	Crucell Holland BV, NL-2301 CA Leiden, Netherlands; Univ Frankfurt, Inst Med Virol, D-6000 Frankfurt, Germany; Robert Koch Inst, D-1000 Berlin, Germany; Leiden Univ, Med Ctr, Dept Med Microbiol, Leiden, Netherlands; Erasmus Med Ctr, Dept Virol, Rotterdam, Netherlands	Johnson & Johnson; Goethe University Frankfurt; Robert Koch Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC	ter Meulen, J (corresponding author), Crucell Holland BV, POB 2048, NL-2301 CA Leiden, Netherlands.	j.termeulen@crucell.com	Preiser, Wolfgang/J-4875-2016; Haagmans, Bart/E-9791-2015; Bakker, Arnold B./F-8494-2010	Preiser, Wolfgang/0000-0002-0254-7910; Haagmans, Bart/0000-0001-6221-2015; Bakker, Arnold B./0000-0003-1489-1847; Osterhaus, Albert/0000-0002-6074-1172				Guan Y, 2003, SCIENCE, V302, P276, DOI 10.1126/science.1087139; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Parnes C, 2003, PEDIATR PULM, V35, P484, DOI 10.1002/ppul.10288; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Tsang OTY, 2003, EMERG INFECT DIS, V9, P1381, DOI 10.3201/eid0911.030400	5	202	217	1	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2139	2141		10.1016/S0140-6736(04)16506-9	http://dx.doi.org/10.1016/S0140-6736(04)16506-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220038	Green Published, Bronze			2022-12-28	WOS:000222268300013
J	Jutzi, P; Mix, A; Rummel, B; Schoeller, WW; Neumann, B; Stammler, HG				Jutzi, P; Mix, A; Rummel, B; Schoeller, WW; Neumann, B; Stammler, HG			The (Me5C5)Si+ cation: A stable derivative of HSi+	SCIENCE			English	Article							DECAMETHYLSILICOCENE; IDENTIFICATION; SIH+	The reaction of decamethylsilicocene, (Me-5 C-5)(2)Si, with the proton-transfer reagent Me5C5H2+ B(C6F5)(4)- produces the salt (Me5C5)Si+ B(C6F5)(4)- (2), which can be isolated as a colorless solid that is stable in the absence of air and moisture. The crystal structure reveals the presence of a cationic pi complex with an eta(5)-pentamethylcyclopentadienyl ligand bound to a bare silicon center. The Si-29 nuclear magnetic resonance at very high field (delta = -400.2 parts per million) is typical of a pi complex of divalent silicon. The (eta(5)-Me5C5)Si+ cation in 2 can be regarded as the "resting state" of a silyliumylidene-type (eta(1)-Me5C5)Si+ cation. The availability of 2 opens new synthetic avenues in organosilicon chemistry. For example, 2 reacted with lithium bis(trimethylsilyl)amide to give the disilene E-{(eta(1)-Me5C5)[N(SiMe3)(2)]Si}(2) (3).	Univ Bielefeld, Fac Chem, D-33615 Bielefeld, Germany	University of Bielefeld	Jutzi, P (corresponding author), Univ Bielefeld, Fac Chem, Univ Str 25, D-33615 Bielefeld, Germany.	peter.jutzi@uni-bielefeld.de	Schoeller, Wolfgang W/A-5755-2011					[Anonymous], 2002, ANGEW CHEM, V114, P2379; BRUNA PJ, 1983, B SOC CHIM BELG, V92, P525; Budzelaar PHM, 2003, ORGANOMETALLICS, V22, P1562, DOI 10.1021/om020928v; *CCDC, 242267 CCDC; DOUGLAS AE, 1970, CAN J PHYS, V48, P247, DOI 10.1139/p70-034; Frisch M.J., 2016, GAUSSIAN 16 REVISION; GASPAR PP, 1998, CHEM ORGANIC SILIC 3, V2, pCH43; GEHRHUS B, 2001, J ORGANOMET CHEM, V209, P617; GREVESSE N, 1970, ASTRON ASTROPHYS, V9, P232; Haaf M, 2000, ACCOUNTS CHEM RES, V33, P704, DOI 10.1021/ar950192g; Jutzi P, 2000, J CHEM SOC DALTON, P2237, DOI 10.1039/b001365j; JUTZI P, 1988, J CHEM SOC CHEM COMM, P305, DOI 10.1039/c39880000305; Jutzi P, 1999, CHEM REV, V99, P969, DOI 10.1021/cr941099t; Jutzi P, 2000, ORGANOMETALLICS, V19, P1442, DOI 10.1021/om990612w; JUTZI P, IN PRESS ORGANOSILIC, V6; Jutzi P., 1986, ANGEW CHEM, V98, P163; Kuhler T, 2003, ADV ORGANOMET CHEM, V49, P1, DOI 10.1016/S0065-3055(03)49001-1; Okazaki R., 1996, ADV ORGANOMET CHEM, V39, P231, DOI DOI 10.1016/S0065-3055(08)60469-4; REED AE, 1988, CHEM REV, V88, P899, DOI 10.1016/0030-4018(75)90085-1; SANNIGRAHI AB, 1995, CHEM PHYS LETT, V237, P204, DOI 10.1016/0009-2614(95)00307-P; SINGH PD, 1978, ASTRON ASTROPHYS, V66, P87	21	149	149	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	2004	305	5685					849	851		10.1126/science.1099879	http://dx.doi.org/10.1126/science.1099879			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843RT	15232074				2022-12-28	WOS:000223104900044
J	Nitz, N; Gomes, C; Rosa, AD; D'Souza-Ault, MR; Moreno, F; Lauria-Pires, L; Nascimento, RJ; Teixeira, ARL				Nitz, N; Gomes, C; Rosa, AD; D'Souza-Ault, MR; Moreno, F; Lauria-Pires, L; Nascimento, RJ; Teixeira, ARL			RETRACTED: Heritable integration of kDNA minicircle sequences from Trypanosoma cruzi into the avian genome: Insights into human Chagas disease (Retracted article. See vol 122, pg 969, 2005)	CELL			English	Article; Retracted Publication							DNA; RABBITS; AMPLIFICATION; RETROTRANSPOSITION; CLASSIFICATION; AUTOIMMUNITY; DIAGNOSIS; CELLS	We demonstrate the genetic transfer of DNA between eukaryotes from different kingdoms. The mitochondrial kinetoplast DNA (kDNA) of the intracellular parasite Trypanosoma cruzi is transferred to human patients with Chagas disease. This transfer was reproduced experimentally in rabbits and chickens. The kDNA is integrated into the host genome. In the human chromosomes, five loci were identified as integration sites, and the beta-globin locus and LINE-1 retrotransposons were frequently targeted. Short repeated sequences in the parasite and the target host DNAs favor kDNA integration by homologous recombination. Introduced kDNA was present in offspring of chronically infected rabbits and in chickens hatched from T. cruzi-inoculated eggs. kDNA incorporated into the chicken germline was inherited through the F2 generation in the absence of persistent infection. kDNA integration represents a potential cause for the autoimmune response that develops in a percentage of chronic Chagas patients, which can now be approached experimentally.	Univ Brasilia, Fac Med, Chagas Dis Multidisciplinary Res Lab, Brasilia, DF, Brazil	Universidade de Brasilia	Teixeira, ARL (corresponding author), Univ Brasilia, Fac Med, Chagas Dis Multidisciplinary Res Lab, Brasilia, DF, Brazil.	ateixeir@unb.br	de Araújo, Nadjar Nitz Silva Lociks/O-4052-2019; Nitz, Nadjar/J-5794-2014	de Araújo, Nadjar Nitz Silva Lociks/0000-0001-7820-0027; Nitz, Nadjar/0000-0001-7820-0027				Buckner FS, 1999, INFECT IMMUN, V67, P403, DOI 10.1128/IAI.67.1.403-409.1999; Campbell DA, 2003, MICROBES INFECT, V5, P1231, DOI 10.1016/j.micinf.2003.09.005; Chagas C, 1909, MEM I OSWALDO CRUZ, V1, P159, DOI DOI 10.1590/S0074-02761909000200008; Chagas Carlos, 1911, Memorias do Instituto Oswaldo Cruz, V3; DARWIN C, 1932, BEAGLE, P328; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Evans D.A., 1985, Parasitology Today, V1, P172, DOI 10.1016/0169-4758(85)90176-0; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Ginsburg M, 1997, POULTRY SCI, V76, P91, DOI 10.1093/ps/76.1.91; Girones N, 2003, TRENDS PARASITOL, V19, P19, DOI 10.1016/S1471-4922(02)00006-5; Hannaert V, 2003, P NATL ACAD SCI USA, V100, P1067, DOI 10.1073/pnas.0335769100; Kagami H, 1997, MOL REPROD DEV, V48, P501, DOI 10.1002/(SICI)1098-2795(199712)48:4&lt;501::AID-MRD11&gt;3.0.CO;2-W; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; KLEIN J, 2002, WHERE DO WE COME FRO, P67; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lauria-Pires L, 2000, AM J TROP MED HYG, V63, P111, DOI 10.4269/ajtmh.2000.63.111; Leon JS, 2003, FRONT BIOSCI-LANDMRK, V8, pE315, DOI 10.2741/1023; Lukes J, 2002, EUKARYOT CELL, V1, P495, DOI 10.1128/EC.1.4.495-502.2002; MARGULIS L, 2002, ACQUIRING GENOMES TH, P25; Miki Y, 1998, J HUM GENET, V43, P77, DOI 10.1007/s100380050045; MOSER DR, 1989, J CLIN MICROBIOL, V27, P1477, DOI 10.1128/JCM.27.7.1477-1482.1989; MURTHY VK, 1992, MOL CELL PROBE, V6, P237, DOI 10.1016/0890-8508(92)90022-P; Penfold LM, 2001, REPRODUCTION, V121, P267, DOI 10.1530/rep.0.1210267; PEREZMORGA DL, 1993, CELL, V74, P703, DOI 10.1016/0092-8674(93)90517-T; Prata A, 2001, Lancet Infect Dis, V1, P92, DOI 10.1016/S1473-3099(01)00065-2; PRICE DK, 1992, GENOMICS, V14, P320, DOI 10.1016/S0888-7543(05)80222-8; REQUENA JM, 1992, MOL BIOCHEM PARASIT, V51, P271, DOI 10.1016/0166-6851(92)90077-W; Rudi K, 1999, BIOTECHNIQUES, V27, P1170, DOI 10.2144/99276st03; Sambrook J., 2001, MOL CLONING LAB MANU, P7; Schenone Hugo, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P231, DOI 10.1590/S0036-46652001000400011; STURM NR, 1989, MOL BIOCHEM PARASIT, V33, P205, DOI 10.1016/0166-6851(89)90082-0; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; TEIXEIRA ARL, 1978, J CLIN INVEST, V62, P1132, DOI 10.1172/JCI109232; TEIXEIRA ARL, 1986, AM J PATHOL, V124, P363; TEIXEIRA ARL, 1983, AM J TROP MED HYG, V32, P258, DOI 10.4269/ajtmh.1983.32.258; TEIXEIRA ARL, 1990, AM J TROP MED HYG, V43, P146, DOI 10.4269/ajtmh.1990.43.146; TEIXEIRA ARL, 1994, MUTAT RES, V305, P197, DOI 10.1016/0027-5107(94)90240-2; TEIXEIRA ARL, 1987, IMMUNE RESPONSES PAR, P125; TEIXEIRA ARL, 1996, MICROORGANISMS AUTOI, P233; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; Vianna Gaspar, 1911, Memorias do Instituto Oswaldo Cruz, V3	42	37	42	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					175	186		10.1016/j.cell.2004.07.001	http://dx.doi.org/10.1016/j.cell.2004.07.001			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260988	Bronze			2022-12-28	WOS:000222966000007
J	Godlee, F; Pakenham-Walsh, N; Ncayiyana, D; Cohen, B; Packer, A				Godlee, F; Pakenham-Walsh, N; Ncayiyana, D; Cohen, B; Packer, A			Can we achieve health information for all by 2015?	LANCET			English	Article							DEVELOPING-COUNTRIES	Universal access to information for health professionals is a prerequisite for meeting the Millennium Development Goals and achieving Health for All. However, despite the promises of the information revolution, and some successful initiatives, there is little if any evidence that the majority of health professionals in the developing world are any better informed than they were 10 years ago. Lack of access to information remains a major barrier to knowledge-based health care in developing countries. The development of reliable, relevant, usable information can be represented as a system that requires cooperation among a wide range of professionals including health-care providers, policy makers, researchers, publishers, information professionals, indexers, and systematic reviewers. The system is not working because it is poorly understood, unmanaged, and under-resourced. This Public Health article proposes that WHO takes the lead in championing the goal of "Universal access to essential health-care information by 2015" or "Health Information for All". Strategies for achieving universal access include funding for research into barriers to use of information, evaluation and replication of successful initiatives, support for interdisciplinary networks, information cycles, and communities of practice, and the formation of national policies on health information.	BMJ Publishing Grp, BMJ Knowledge, London WC1H 9JR, England; INASP, Oxford OX1 1ST, England; Durban Inst Technol, ZA-4000 Durban, South Africa; Publ Lib Sci, San Francisco, CA 94107 USA; BIREME, BR-04023901 Sao Paulo, Brazil	BMJ Publishing Group Ltd; Durban University of Technology	Godlee, F (corresponding author), BMJ Publishing Grp, BMJ Knowledge, BMA House,Tavistock Sq, London WC1H 9JR, England.	fgodlee@bmjgroup.com	Packer, Abel Laerte L/J-9350-2012; Packer, Abel/C-1705-2009	Packer, Abel Laerte L/0000-0001-9610-5728; 				ADAMSON S, WHAT IS ACCESS CONTI; Dawes M, 2003, INT J MED INFORM, V71, P9, DOI 10.1016/S1386-5056(03)00023-6; Edejer TTT, 2000, BRIT MED J, V321, P797, DOI 10.1136/bmj.321.7264.797; Gibbs W. W, 1995, SCI AM, V273, P76; *GLOB FOR HLTH RES, 1090 REP HLTH RES 20; HAINES A, 2002, GETTING RES PRACTICE; *HIN IND, WEB BAS IN HLTH WORK; Horton R, 2000, LANCET, V355, P2231, DOI 10.1016/S0140-6736(00)02414-4; HUNT JM, 1996, J ADV NURS, V23, P42325; KALE R, 1994, BRIT MED J, V309, P939, DOI 10.1136/bmj.309.6959.939; Liverpool School of Tropical Medicine, EFF HLTH CAR ALL PRO; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; PakenhamWalsh N, 1997, BRIT MED J, V314, P90, DOI 10.1136/bmj.314.7074.90; Smith R, 1996, BRIT MED J, V313, P1062; Swingler GH, 2003, BRIT MED J, V327, P1083, DOI 10.1136/bmj.327.7423.1083; Tamber PS, 2003, LANCET, V362, P1575, DOI 10.1016/S0140-6736(03)14748-4; *TDR, FAME CONST; Werner D., 1992, THERE IS NO DOCTOR; World Health Organization, 2004, WORLD REP KNOWL BETT; 1998, AFR J LIB ARCH INFO, V8, P13	20	113	115	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					295	300		10.1016/S0140-6736(04)16681-6	http://dx.doi.org/10.1016/S0140-6736(04)16681-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262109	Green Submitted			2022-12-28	WOS:000222784900034
J	Wurmser, AE; Nakashima, K; Summers, RG; Toni, N; D'Amour, KA; Lie, DC; Gage, FH				Wurmser, AE; Nakashima, K; Summers, RG; Toni, N; D'Amour, KA; Lie, DC; Gage, FH			Cell fusion-independent differentiation of neural stem cells to the endothelial lineage	NATURE			English	Article							BONE-MARROW; PROGRESSION; PROGENITOR; MECHANISMS; INVITRO; PROTEIN; SYSTEM; MUSCLE; BLOOD; VIVO	Somatic stem cells have been claimed to possess an unexpectedly broad differentiation potential ( referred to here as plasticity) that could be induced by exposing stem cells to the extracellular developmental signals of other lineages in mixed-cell cultures(1-6). Recently, this and other experimental evidence supporting the existence of stem-cell plasticity have been refuted because stem cells have been shown to adopt the functional features of other lineages by means of cell-fusion-mediated acquisition of lineage-specific determinants (chromosomal DNA) rather than by signal-mediated differentiation(1,2,5,7,8). In this study we co-cultured mouse neural stem cells (NSCs), which are committed to become neurons and glial cells(9,10), with human endothelial cells, which form the lining of blood vessels(11). We show that in the presence of endothelial cells six per cent of the NSC population converted to cells that did not express neuronal or glial markers, but instead showed the stable expression of multiple endothelial markers and the capacity to form capillary networks. This was surprising because NSCs and endothelial cells are believed to develop from the ectoderm and mesoderm, respectively. Experiments in which endothelial cells were killed by fixation before co-culture with live NSCs (to prevent cell fusion) and karyotyping analyses, revealed that NSCs had differentiated into endothelial-like cells independently of cell fusion. We conclude that stem-cell plasticity is a true characteristic of NSCs and that the conversion of NSCs to unanticipated cell types can be accomplished without cell fusion.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; Kumamoto Univ, Inst Mol Embryol & Genet, Dept Cell Fate Modulat, Kumamoto 8600811, Japan	Salk Institute; Kumamoto University	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gage@salk.edu	Lie, Dieter Chichung/S-7914-2017; Lie, Dieter Chichung/AAS-8604-2020; Toni, Nicolas/M-2057-2014	Lie, Dieter Chichung/0000-0002-6035-6442; Lie, Dieter Chichung/0000-0002-6035-6442; Toni, Nicolas/0000-0001-5585-268X				Alexanian AR, 2003, NEUROSCIENCE, V118, P1, DOI 10.1016/S0306-4522(02)00994-6; Bardin N, 2001, BLOOD, V98, P3677, DOI 10.1182/blood.V98.13.3677; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; CHEN TR, 1979, CYTOGENET CELL GENET, V23, P221, DOI 10.1159/000131332; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Condorelli G, 2001, P NATL ACAD SCI USA, V98, P10733, DOI 10.1073/pnas.191217898; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; GRANT DS, 1991, IN VITRO CELL DEV B, V27, P327; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; NEWMAN PJ, 1992, NOUV REV FR HEMATOL, V34, P9; Palmer TD, 1999, J NEUROSCI, V19, P8487; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHALL D, 1978, SOMAT CELL GENET, V4, P661, DOI 10.1007/BF01543157; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; St Croix B, 2000, SCIENCE, V289, P1197; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VACQUIER VD, 1979, DEV GROWTH DIFFER, V21, P61; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; WAGNER DD, 1982, J CELL BIOL, V95, P355, DOI 10.1083/jcb.95.1.355; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WEIBEL ER, 1964, J CELL BIOL, V23, P101, DOI 10.1083/jcb.23.1.101; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	30	277	297	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					350	356		10.1038/nature02604	http://dx.doi.org/10.1038/nature02604			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254537				2022-12-28	WOS:000222631200041
J	Kottilil, S; Polis, MA; Kovacs, JA				Kottilil, S; Polis, MA; Kovacs, JA			HIV infection, hepatitis C infection, and HAART - Hard clinical choices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ANTIRETROVIRAL THERAPY; LIVER FIBROSIS; RISK-FACTORS; PEGINTERFERON ALPHA-2B; PLUS RIBAVIRIN; HEPATOTOXICITY; LAMIVUDINE; TENOFOVIR; TOXICITY	Abnormalities in hepatic function have become one of the most common complications occurring among human immunodeficiency virus (HIV)infected individuals receiving highly active antiretroviral therapy (HAART), and liver disease has become an increasingly important cause of morbidity and mortality in HIV-infected patients. We present a case of a patient with HIV infection and hepatotoxicity that exemplifies the complications currently observed during the treatment of such patients. Hepatotoxicity can be a result of several factors, including a direct effect of HAART, substance abuse, and coinfection with either hepatitis C virus (HCV) or hepatitis B virus. Imaging studies may be helpful in determining the etiology; however, a liver biopsy is often necessary to be able to more accurately determine the relative contributions of different processes. Although coinfection with HCV and HIV has become a common clinical problem, optimal treatment of such patients remains to be defined and must be individualized to maximize benefit and tolerance.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NIH, Warren G Magnuson Clin Ctr, Dept Crit Care Med, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Kovacs, JA (corresponding author), Bldg 10,Room 7D43,MSC 1662, Bethesda, MD 20892 USA.	jkovacs@nih.gov	Kottilil, Shyam/ABF-7605-2021; Kovacs, Joseph/AAU-6105-2021	Kovacs, Joseph/0000-0002-5191-9880; Polis, Michael/0000-0002-9151-2268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000390, Z01AI000390, ZIAAI000886, Z01AI000886] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aceti A, 2002, J ACQ IMMUN DEF SYND, V29, P41, DOI 10.1097/00042560-200201010-00005; Altfeld M, 1998, J HEPATOL, V29, P306, DOI 10.1016/S0168-8278(98)80017-2; Becker S, 2004, CLIN INFECT DIS, V38, pS49, DOI 10.1086/381447; Beld M, 2002, J CLIN MICROBIOL, V40, P788, DOI 10.1128/JCM.40.3.788-793.2002; Benhamou Y, 2001, HEPATOLOGY, V34, P283, DOI 10.1053/jhep.2001.26517; Benhamou Y, 2004, CLIN INFECT DIS, V38, pS98, DOI 10.1086/381451; Boelsterli UA, 2002, DRUG SAFETY, V25, P633, DOI 10.2165/00002018-200225090-00003; Carr A, 2000, AIDS, V14, pF25, DOI 10.1097/00002030-200002180-00001; CHUNG R, 2004, 11 C RETR OPP INF FE; Dieterich DT, 2004, CLIN INFECT DIS, V38, pS80, DOI 10.1086/381450; Fonquernie L, 2001, CLIN INFECT DIS, V32, P297, DOI 10.1086/318478; HORVATH J, 1994, CLIN INFECT DIS, V18, P339, DOI 10.1093/clinids/18.3.339; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; Jain MK, 2003, CLIN INFECT DIS, V36, P1030, DOI 10.1086/368186; Kontorinis Nickolas, 2003, AIDS Reviews, V5, P36; KOTTILIL S, 2003, 43 INT C ANT AG CHEM; KOTTILIL S, 2003, 2 INT AIDS C PATH HI; Kuo A, 2004, CLIN GASTROENTEROL H, V2, P266, DOI 10.1016/S1542-3565(04)00017-5; LEBOVICS E, 1988, AM J GASTROENTEROL, V83, P1; Leen CLS, 2004, INT J STD AIDS, V15, P289, DOI 10.1258/095646204323012724; Lessells R, 2004, EUR J CLIN MICROBIOL, V23, P366, DOI 10.1007/s10096-004-1127-3; Macias J, 2004, AIDS, V18, P767, DOI [10.1097/01.aids.0000111417.91384.fd, 10.1097/00002030-200403260-00007]; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; Mauss S, 1998, INFECTION, V26, P20; Melvin DC, 2000, AIDS, V14, P463, DOI 10.1097/00002030-200003100-00023; Miller KD, 2000, ANN INTERN MED, V133, P192, DOI 10.7326/0003-4819-133-3-200008010-00010; Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450, DOI 10.1097/00126334-200108150-00005; Myers RP, 2001, CAN J GASTROENTEROL, V15, P599, DOI 10.1155/2001/378980; Nelson M, 2003, AIDS, V17, pF7, DOI 10.1097/00002030-200301030-00002; Nunez M, 2001, J ACQ IMMUN DEF SYND, V27, P426, DOI 10.1097/00126334-200108150-00002; Nunez M, 2003, CLIN INFECT DIS, V37, P1678, DOI 10.1086/379774; Olga O. Znoiko, 2003, Current Pharmaceutical Biotechnology, V4, P195, DOI 10.2174/1389201033489810; Orenstein R, 2002, PHARMACOTHERAPY, V22, P1468, DOI 10.1592/phco.22.16.1468.33702; *PAN CLIN PRACT TR, GUID US ANT AG HIV 1; Perez-Olmeda M, 2003, AIDS, V17, P1023, DOI 10.1097/00002030-200305020-00011; PERRONNE C, 2004, 11 C RETR OPP INF FE; Petrella Marco, 2002, AIDS Reviews, V4, P224; PHAM TVL, 1997, ACETAMINOPHEN HEPATO; Pol S, 2004, CLIN INFECT DIS, V38, pS65, DOI 10.1086/381499; Poles MA, 1997, GASTROENTEROL CLIN N, V26, P291, DOI 10.1016/S0889-8553(05)70296-X; Poynard T, 2003, HEPATOLOGY, V38, P481, DOI 10.1053/jhep.2003.50319; Poynard T, 2001, J HEPATOL, V34, P730, DOI 10.1016/S0168-8278(00)00097-0; Rodriguez-Rosado R, 1998, AIDS, V12, P1256, DOI 10.1097/00002030-199810000-00025; Selik RM, 2002, J ACQ IMMUN DEF SYND, V29, P378, DOI 10.1097/00126334-200204010-00009; SELIK RM, 2003, NAT HIV PREV C JUL 2; Sherman KE, 2002, CLIN INFECT DIS, V34, P831, DOI 10.1086/339042; Soriano V, 2004, AIDS, V18, P1, DOI 10.1097/00002030-200401020-00001; Spengler U, 2002, J HEPATOL, V36, P283, DOI 10.1016/S0168-8278(01)00311-7; Sulkowski MS, 2004, CLIN INFECT DIS, V38, pS90, DOI 10.1086/381444; Sulkowski MS, 2003, SEMIN LIVER DIS, V23, P183; Sulkowski MS, 2002, HEPATOLOGY, V35, P182, DOI 10.1053/jhep.2002.30319; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P74, DOI 10.1001/jama.283.1.74; Thomas DL, 2002, HEPATOLOGY, V36, pS201, DOI 10.1053/jhep.2002.36380; Tien Phyllis C, 2002, Semin Gastrointest Dis, V13, P47; TORRIANI FJ, 2004, 11 C RETR OPP INF FE; U.S. Food and Drug Administration, HIV AIDS HIST TIM LI; Walker UA, 2002, AIDS, V16, P2165, DOI 10.1097/00002030-200211080-00009; Wit FWNM, 2002, J INFECT DIS, V186, P23, DOI 10.1086/341084; Zoulim F, 2002, DRUG SAFETY, V25, P497, DOI 10.2165/00002018-200225070-00004; Zucker SD, 2001, P NATL ACAD SCI USA, V98, P12671, DOI 10.1073/pnas.231140698	60	24	25	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					243	250		10.1001/jama.292.2.243	http://dx.doi.org/10.1001/jama.292.2.243			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249574				2022-12-28	WOS:000222579300030
J	O'Donoghue, K; Chan, J; de la Fuente, J; Kennea, N; Sandison, A; Anderson, JR; Roberts, IAG; Fisk, NM				O'Donoghue, K; Chan, J; de la Fuente, J; Kennea, N; Sandison, A; Anderson, JR; Roberts, IAG; Fisk, NM			Microchimerism in female bone marrow and bone decades after fetal mesenchymal stem-cell trafficking in pregnancy	LANCET			English	Article							MATERNAL BLOOD	Fetal cells enter maternal blood during pregnancy and persist in women with autoimmune disease. The frequency of subsequent fetomaternal microchimerism in healthy women and its cell type is unknown. To test the hypothesis that fetal mesenchymal stem cells persist in maternal organs, we studied female bone marrow and ribs. Male cells were identified by XY fluorescence in-situ hybridisation in marrow-derived mesenchymal stem cells and in rib sections from all women with male pregnancies, but not in controls (9/9 vs 0/5, p=0.0005). We conclude that fetal stem cells transfer-red into maternal blood engraft in marrow, where they remain throughout life. This finding has implications for normal pregnancy, for obstetric complications that increase fetomaternal trafficking, and for graft survival after transplantation.	Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Div Paediat Obstet & Gynaecol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Haematol, Div Invest Sci, London W12 0NN, England; Charing Cross Hosp, Dept Histopathol, London W6 8RF, England; Hammersmith Hosp, Dept Cardiothorac Surg, London W12 0NN, England	Imperial College London; Imperial College London; Imperial College London; Imperial College London	O'Donoghue, K (corresponding author), Univ London Imperial Coll Sci Technol & Med, Inst Reprod & Dev Biol, Div Paediat Obstet & Gynaecol, Hammersmith Campus, London W12 0NN, England.	k.odonoghue@imperial.ac.uk	Fisk, Nicholas M/B-2126-2009	Fisk, Nicholas M/0000-0003-0031-7975; de la Fuente, Josu/0000-0002-0974-1249; O'Donoghue, Keelin/0000-0002-4616-2887				Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Khosrotehrani K, 2003, CURR OPIN OBSTET GYN, V15, P195, DOI 10.1097/00001703-200304000-00014; Nelson JL, 2002, ARTHRITIS RHEUM-US, V46, P291, DOI 10.1002/art.501; O'Donoghue K, 2003, MOL HUM REPROD, V9, P497, DOI 10.1093/molehr/gag063; Srivatsa B, 2001, LANCET, V358, P2034, DOI 10.1016/S0140-6736(01)07099-4	5	177	187	0	12	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					179	182		10.1016/S0140-6736(04)16631-2	http://dx.doi.org/10.1016/S0140-6736(04)16631-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246731				2022-12-28	WOS:000222612200029
J	Ehrenreich, H				Ehrenreich, H			A boost for translational neuroscience	SCIENCE			English	Editorial Material							CEREBRAL-ISCHEMIA; ERYTHROPOIETIN; NEUROPROTECTION; NEURONS; BRAIN		Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany	Max Planck Society	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Div Clin Neurosci, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de		Ehrenreich, Hannelore/0000-0001-8371-5711				Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Colognato H, 2002, NAT CELL BIOL, V4, P833, DOI 10.1038/ncb865; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598	11	18	18	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					184	185		10.1126/science.1100891	http://dx.doi.org/10.1126/science.1100891			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247460	Green Submitted			2022-12-28	WOS:000222501000031
J	Gauthier, LR; Charrin, BC; Borrell-Pages, M; Dompierre, JP; Rangone, H; Cordelieres, FP; De Mey, J; MacDonald, ME; Lessmann, V; Humbert, S; Saudou, F				Gauthier, LR; Charrin, BC; Borrell-Pages, M; Dompierre, JP; Rangone, H; Cordelieres, FP; De Mey, J; MacDonald, ME; Lessmann, V; Humbert, S; Saudou, F			Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules	CELL			English	Article							AXONAL-TRANSPORT; PROTEIN-1 HAP1; DISEASE; BRAIN; DYNACTIN; LOCALIZATION; DISRUPTION; APOPTOSIS; MOVEMENT; SUBUNIT	Polyglutamine expansion (polyQ) in the protein huntingtin is pathogenic and responsible for the neuronal toxicity associated with Huntington's disease (HD). Although wild-type huntingtin possesses antiapoptotic properties, the relationship between the neuroprotective functions of huntingtin and pathogenesis of HD remains unclear. Here, we show that huntingtin specifically enhances vesicular transport of brain-derived neurotrophic factor (BDNF) along microtubules. Huntingtin-mediated transport involves huntingtin-associated protein-1 (HAP1) and the p150(Glued) subunit of dynactin, an essential component of molecular motors. BDNF transport is attenuated both in the disease context and by reducing the levels of wild-type huntingtin. The alteration of the huntingtin/HAP1/p150(Glued) complex correlates with reduced association of motor proteins with microtubules. Finally, we find that the polyQ-huntingtin-induced transport deficit results in the loss of neurotrophic support and neuronal toxicity. Our findings indicate that a key role of huntingtin is to promote BDNF transport and suggest that loss of this function might contribute to pathogenesis.	Ctr Univ, Inst Curie, CNRS, Unite Mixte Rech 146, F-91405 Orsay, France; Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, D-55128 Mainz, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; Harvard University; Massachusetts General Hospital; Johannes Gutenberg University of Mainz	Saudou, F (corresponding author), Ctr Univ, Inst Curie, CNRS, Unite Mixte Rech 146, Bldg 110, F-91405 Orsay, France.	sandrine.humbert@curie.u-psud.fr; frederic.saudou@curie.u-psud.fr	SAUDOU, Frédéric/L-3454-2014; Leßmann, Volkmar/E-8125-2013; Humbert, Sandrine/S-2981-2016; Borrell-Pages, Maria/Q-6307-2019; Cordelières, Fabrice P/G-3574-2017; Gauthier, Laurent/ABC-7614-2021	SAUDOU, Frédéric/0000-0001-6107-1046; Leßmann, Volkmar/0000-0002-6863-323X; Borrell-Pages, Maria/0000-0002-1759-9756; Cordelières, Fabrice P/0000-0002-5383-5816; Gauthier, Laurent/0000-0003-4644-7660; Humbert, Sandrine/0000-0002-9501-2658; Charrin, Benedicte/0000-0003-3843-4157	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH031862] Funding Source: NIH RePORTER; NIMH NIH HHS [MH/NS 31862] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Baquet ZC, 2004, J NEUROSCI, V24, P4250, DOI 10.1523/JNEUROSCI.3920-03.2004; Bertaux F, 1998, FEBS LETT, V426, P229, DOI 10.1016/S0014-5793(98)00352-4; BlockGalarza J, 1997, NEUROREPORT, V8, P2247, DOI 10.1097/00001756-199707070-00031; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cordonnier MN, 2001, MOL BIOL CELL, V12, P4013, DOI 10.1091/mbc.12.12.4013; Deacon SW, 2003, J CELL BIOL, V160, P297, DOI 10.1083/jcb.200210066; DiFiglia M, 2002, MOL CELL, V10, P224, DOI 10.1016/S1097-2765(02)00609-3; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; Engelender S, 1997, HUM MOL GENET, V6, P2205, DOI 10.1093/hmg/6.13.2205; Ferrer I, 2000, BRAIN RES, V866, P257, DOI 10.1016/S0006-8993(00)02237-X; Gunawardena S, 2003, NEURON, V40, P25, DOI 10.1016/S0896-6273(03)00594-4; Gutekunst CA, 1998, J NEUROSCI, V18, P7674, DOI 10.1523/jneurosci.18-19-07674.1998; Hafezparast M, 2003, SCIENCE, V300, P808, DOI 10.1126/science.1083129; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Hartmann M, 2001, EMBO J, V20, P5887, DOI 10.1093/emboj/20.21.5887; Hoffner G, 2002, J CELL SCI, V115, P941; Humbert S, 2002, DEV CELL, V2, P831, DOI 10.1016/S1534-5807(02)00188-0; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; King SJ, 2000, NAT CELL BIOL, V2, P20, DOI 10.1038/71338; Kohara K, 2001, SCIENCE, V291, P2419, DOI 10.1126/science.1057415; LaMonte BH, 2002, NEURON, V34, P715, DOI 10.1016/S0896-6273(02)00696-7; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; Lee WCM, 2004, P NATL ACAD SCI USA, V101, P3224, DOI 10.1073/pnas.0400243101; Li SH, 1998, J NEUROSCI, V18, P1261, DOI 10.1523/jneurosci.18-04-01261.1998; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lione LA, 1999, J NEUROSCI, V19, P10428; Piccioni F, 2002, FASEB J, V16, P1418, DOI 10.1096/fj.01-1035fje; Puls I, 2003, NAT GENET, V33, P455, DOI 10.1038/ng1123; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Schroer TA, 1996, SEMIN CELL DEV BIOL, V7, P321, DOI 10.1006/scdb.1996.0041; Smith MA, 2000, NATURE, V403, P544, DOI 10.1038/35000576; Stepanova T, 2003, J NEUROSCI, V23, P2655; Stowers RS, 2002, NEURON, V36, P1063, DOI 10.1016/S0896-6273(02)01094-2; Szebenyi G, 2003, NEURON, V40, P41, DOI 10.1016/S0896-6273(03)00569-5; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; Tukamoto T, 1997, MOL BRAIN RES, V51, P8, DOI 10.1016/S0169-328X(97)00205-2; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	45	819	863	1	58	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					127	138		10.1016/j.cell.2004.06.018	http://dx.doi.org/10.1016/j.cell.2004.06.018			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242649	Bronze			2022-12-28	WOS:000222626800013
J	Morens, DM; Folkers, GK; Fauci, AS				Morens, DM; Folkers, GK; Fauci, AS			The challenge of emerging and re-emerging infectious diseases	NATURE			English	Review							INFLUENZAE BIOGROUP AEGYPTIUS; CREUTZFELDT-JAKOB-DISEASE; BRAZILIAN PURPURIC FEVER; NILE-VIRUS-INFECTION; IDENTIFICATION; OUTBREAK; VACCINES; EPIDEMIOLOGY; MORTALITY; ETIOLOGY	Infectious diseases have for centuries ranked with wars and famine as major challenges to human progress and survival. They remain among the leading causes of death and disability worldwide. Against a constant background of established infections, epidemics of new and old infectious diseases periodically emerge, greatly magnifying the global burden of infections. Studies of these emerging infections reveal the evolutionary properties of pathogenic microorganisms and the dynamic relationships between microorganisms, their hosts and the environment.	NIAID, NIH, US Dept HHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Morens, DM (corresponding author), NIAID, NIH, US Dept HHS, 9000 Rockville Pike, Bethesda, MD 20892 USA.	afauci@niaid.nih.gov	Ulatan, Jeffrey/AAM-5560-2020	Ulatan, Jeffrey/0000-0002-3756-0568				ALIBEK K, 1999, BIOHAZARD CHILING TR; ANDERSON RM, 1995, P ROY SOC B-BIOL SCI, V261, P147, DOI 10.1098/rspb.1995.0129; [Anonymous], PREV EM INF DIS STRA; [Anonymous], 2013, WHOCDSCSRGAR2003; Baker D, 2001, SCIENCE, V294, P93, DOI 10.1126/science.1065659; Beisel CE, 2004, CLIN INFECT DIS, V38, P697, DOI 10.1086/381028; Bendelac A, 2002, J EXP MED, V195, pF19, DOI 10.1084/jem.20020073; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; Bushnell O. A., 1993, GIFTS CIVILIZATION G; Butler JC, 2001, EMERG INFECT DIS, V7, P554; Casalone C, 2004, P NATL ACAD SCI USA, V101, P3065, DOI 10.1073/pnas.0305777101; *CDCP, 2003, MMWR-MORBID MORTAL W, P537; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P565; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chapman LE, 2003, CURR TOP MICROBIOL, V278, P23; Chua KB, 2000, SCIENCE, V288, P1432, DOI 10.1126/science.288.5470.1432; CLIFF A, 2000, ISLAND EPIDEMICS, P165; Cockburn A., 1963, EVOLUTION ERADICATIO; Cromley EK, 2003, ANNU REV PUBL HEALTH, V24, P7, DOI 10.1146/annurev.publhealth.24.012902.141019; Crosby A., 1972, COLUMBIAN EXCHANGE B; DALEY CL, 1999, AIDS KNOWLEDGE BASE, P23; Darling RG, 2002, EMERG MED CLIN N AM, V20, P273, DOI 10.1016/S0733-8627(02)00005-6; De Bevoise K., 1995, AGENTS APOCALYPSE EP; DEMING WC, 1994, NY MED J, V59, P710; Desselberger U, 2000, J INFECTION, V40, P3, DOI 10.1053/jinf.1999.0624; DUFFY JOHN, 1951, BULL HIST MED, V25, P324; Dybul M, 2002, ANN INTERN MED, V137, P381, DOI 10.7326/0003-4819-137-5_Part_2-200209031-00001; Espinal MA, 2003, TUBERCULOSIS, V83, P44, DOI 10.1016/S1472-9792(02)00058-6; Faruque SM, 2002, MICROBIOL IMMUNOL, V46, P59, DOI 10.1111/j.1348-0421.2002.tb02659.x; Fauci AS, 2003, NATURE, V421, P787, DOI 10.1038/nature01480; Fauci AS, 2001, CLIN INFECT DIS, V32, P675, DOI 10.1086/319235; Feldmann H, 2002, MED MICROBIOL IMMUN, V191, P63, DOI 10.1007/s00430-002-0122-5; Fraser CM, 2002, J BACTERIOL, V184, P6403, DOI 10.1128/JB.184.23.6403-6405.2002; Fredricks DN, 1998, CURR CLIN TOPICS INF, V18, P180; Ghani AC, 2003, STAT METHODS MED RES, V12, P191, DOI 10.1191/0962280203sm327ra; Gluck R, 2002, VACCINE, V20, pB10, DOI 10.1016/S0264-410X(02)00513-3; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Guerrant RL, 1999, CLIN INFECT DIS, V28, P966, DOI 10.1086/514765; HENSCHEL AW, 1842, ARCH GESAMMTE MED, V2, P26; HJELLE B, 1994, J VIROL, V68, P592, DOI 10.1128/JVI.68.2.592-596.1994; Hopkins DR, 1983, PRINCES PEASANTS SMA, P204; Jernigan DB, 2002, EMERG INFECT DIS, V8, P1019, DOI 10.3201/eid0810.020353; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; *JOINT UN PROGR HI, 2003, AIDS EP UPD DEC 2003; Jones J L, 1999, MMWR CDC Surveill Summ, V48, P1; KATZ AR, 1992, CLIN INFECT DIS, V14, P298, DOI 10.1093/clinids/14.1.298; Koch R, 1876, BEITR BIOL PFLANZ, V2, P277; KOHN GG, 1995, WORDSWORTH ENCY PLAG, P25; Komar Nicholas, 2003, Adv Virus Res, V61, P185; Kovats RS, 2003, LANCET, V362, P1481, DOI 10.1016/S0140-6736(03)14695-8; Krause Richard M., 1981, RESTLESS TIDE PERSIS; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; Lederberg J., 1992, I MED US COMMITTEE; Lee JH, 2003, APPL ENVIRON MICROB, V69, P6489, DOI 10.1128/AEM.69.11.6489-6494.2003; LEOPOLDT JG, 1759, NUTZLICHE ERFAHRUNG, P348; Li MS, 2003, MOL MICROBIOL, V47, P1101, DOI 10.1046/j.1365-2958.2003.03359.x; MACARTHUR N, 1968, ISLAND POPULATIONS P; Massey A., 1933, EPIDEMIOLOGY RELATIO; McMichael T., 2001, HUMAN FRONTIERS ENV; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Morens D. M., 1998, Pacific Health Dialog, V5, P147; Morens D. M., 1998, Pacific Health Dialog, V5, P119; MORENS DM, 1992, T AM PHILOL ASSOC, V122, P271, DOI 10.2307/284374; MORENS DM, 1994, CLIN INFECT DIS, V19, P500, DOI 10.1093/clinids/19.3.500; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; Musser JM, 1998, BIOMED RES REP, P185; MUSSER JM, 1990, J INFECT DIS, V161, P130, DOI 10.1093/infdis/161.1.130; Nash D, 2001, NEW ENGL J MED, V344, P1807, DOI 10.1056/NEJM200106143442401; *NAT I ALL INF DIS, 2002, JORD REP 20 ANN ACC; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; *NIH BIOENG CONS, 2002, NAN NAN SHAP BIOM RE; O'Hagan DT, 2003, NAT REV DRUG DISCOV, V2, P727, DOI 10.1038/nrd1176; Parsonnet J, 1999, MICROBES MALIGNANCY; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; Platonov AE, 2001, EMERG INFECT DIS, V7, P128, DOI 10.3201/eid0701.010118; Pollard AJ, 2000, CURR OPIN INFECT DIS, V13, P265, DOI 10.1097/00001432-200006000-00011; Porter R., 1997, GREATEST BENEFIT MAN; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; Reid AH, 2003, J GEN VIROL, V84, P2285, DOI 10.1099/vir.0.19302-0; Reid SD, 2001, J CLIN INVEST, V107, P393, DOI 10.1172/JCI11972; RONALD AR, 1995, INFECT DIS CLIN N AM, V9, P287; Sanders Michael K, 2002, Curr Gastroenterol Rep, V4, P448, DOI 10.1007/s11894-002-0019-x; Sharp PM, 2001, PHILOS T R SOC B, V356, P867, DOI 10.1098/rstb.2001.0863; Shortridge KF, 2003, J APPL MICROBIOL, V94, p70S; Singh N, 2003, LANCET INFECT DIS, V3, P156, DOI 10.1016/S1473-3099(03)00546-2; Smolinsky M.S., 2003, MICROBIAL THREATS HL; Stephens DS, 1998, AM J MED SCI, V315, P64, DOI 10.1097/00000441-199802000-00002; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; Subbarao K, 2000, CELL MOL LIFE SCI, V57, P1770, DOI 10.1007/PL00000657; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Torok TJ, 1997, JAMA-J AM MED ASSOC, V278, P389, DOI 10.1001/jama.278.5.389; Vento S, 2003, LANCET ONCOL, V4, P595, DOI 10.1016/S1470-2045(03)01218-X; Webster RG, 2001, SCIENCE, V293, P1773; Wellems TE, 2003, NEW ENGL J MED, V349, P1496, DOI 10.1056/NEJMp038127; Williams ES, 2003, CLIN LAB MED, V23, P139, DOI 10.1016/S0272-2712(02)00040-9; Worboys Michael, 2000, SPREADING GERMS DIS; World Health Organization, 2004, WORLD HLTH REP 2004; Zhu H, 2003, ANNU REV BIOCHEM, V72, P783, DOI 10.1146/annurev.biochem.72.121801.161511	98	1164	1230	15	244	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					242	249		10.1038/nature02759	http://dx.doi.org/10.1038/nature02759			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241422	Green Published, Bronze			2022-12-28	WOS:000222470600052
J	Deechongkit, S; Nguyen, H; Powers, ET; Dawson, PE; Gruebele, M; Kelly, JW				Deechongkit, S; Nguyen, H; Powers, ET; Dawson, PE; Gruebele, M; Kelly, JW			Context-dependent contributions of backbone hydrogen bonding to beta-sheet folding energetics	NATURE			English	Article							WW DOMAIN; STAPHYLOCOCCAL NUCLEASE; THERMODYNAMIC STABILITY; AMINO-ACIDS; PROTEIN; STATE; DEPSIPEPTIDES; TEMPERATURE; LANDSCAPE; PEPTIDES	Backbone hydrogen bonds (H-bonds) are prominent features of protein structures; however, their role in protein folding remains controversial because they cannot be selectively perturbed by traditional methods of protein mutagenesis(1-3). Here we have assessed the contribution of backbone H-bonds to the folding kinetics and thermodynamics of the PIN WW domain, a small beta-sheet protein(4), by individually replacing its backbone amides with esters. Amide-to-ester mutations site-specifically perturb backbone H-bonds in two ways: a H-bond donor is eliminated by replacing an amide NH with an ester oxygen, and a H-bond acceptor is weakened by replacing an amide carbonyl with an ester carbonyl(5-13). We perturbed the 11 backbone H-bonds of the PIN WW domain by synthesizing 19 amide-to-ester mutants. Thermodynamic studies on these variants show that the protein is most destabilized when H-bonds that are enveloped by a hydrophobic cluster are perturbed. Kinetic studies indicate that native-like secondary structure forms in one of the protein's loops in the folding transition state, but the backbone is less ordered elsewhere in the sequence. Collectively, our results provide an unusually detailed picture of the folding of a beta-sheet protein.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Univ Illinois, Dept Chem Phys, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kelly, JW (corresponding author), Scripps Res Inst, Dept Chem, 10440 N Torrey Pines Rd,BCC 506, La Jolla, CA 92037 USA.	jkelly@scripps.edu		Powers, Evan/0000-0001-8185-8487	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051105] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Beligere GS, 2000, J AM CHEM SOC, V122, P12079, DOI 10.1021/ja001648e; Blankenship JW, 2002, BIOCHEMISTRY-US, V41, P15676, DOI 10.1021/bi026862p; BRAMSON HN, 1985, J BIOL CHEM, V260, P5452; Chapman E, 1997, J AM CHEM SOC, V119, P7151, DOI 10.1021/ja970826+; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Crane JC, 2000, J MOL BIOL, V298, P283, DOI 10.1006/jmbi.2000.3665; Deechongkit S, 2004, ORG LETT, V6, P497, DOI 10.1021/ol036102m; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Ferguson N, 2001, P NATL ACAD SCI USA, V98, P13002, DOI 10.1073/pnas.221467198; Ferguson N, 2001, P NATL ACAD SCI USA, V98, P13008, DOI 10.1073/pnas.221467398; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; Gruebele M, 1998, ACCOUNTS CHEM RES, V31, P699, DOI 10.1021/ar970083x; Haque TS, 1996, J AM CHEM SOC, V118, P6975, DOI 10.1021/ja960429j; HONIG B, 1995, ADV PROTEIN CHEM, V46, P27, DOI 10.1016/S0065-3233(08)60331-9; Jager M, 2001, J MOL BIOL, V311, P373, DOI 10.1006/jmbi.2001.4873; Joseph James D, 2003, Prog Cell Cycle Res, V5, P477; Kaul R, 2002, J AM CHEM SOC, V124, P11900, DOI 10.1021/ja020675x; Koepf EK, 1999, PROTEIN SCI, V8, P841, DOI 10.1110/ps.8.4.841; Koh JT, 1997, BIOCHEMISTRY-US, V36, P11314, DOI 10.1021/bi9707685; Kowalski JA, 2002, BIOPOLYMERS, V63, P111, DOI 10.1002/bip.10020; Myers JK, 1996, BIOPHYS J, V71, P2033, DOI 10.1016/S0006-3495(96)79401-8; Nguyen H, 2003, P NATL ACAD SCI USA, V100, P3948, DOI 10.1073/pnas.0538054100; Nymeyer H, 2000, P NATL ACAD SCI USA, V97, P634, DOI 10.1073/pnas.97.2.634; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Shin IJ, 1997, J AM CHEM SOC, V119, P12667, DOI 10.1021/ja972820q; Silinski P, 2003, BIOCHEMISTRY-US, V42, P6620, DOI 10.1021/bi020700b; Sudol M, 1996, PROG BIOPHYS MOL BIO, V65, P113, DOI 10.1016/S0079-6107(96)00008-9; THORSON JS, 1995, J AM CHEM SOC, V117, P9361, DOI 10.1021/ja00141a032; Wales TE, 2001, J AM CHEM SOC, V123, P7709, DOI 10.1021/ja010775n	30	231	231	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					101	105		10.1038/nature02611	http://dx.doi.org/10.1038/nature02611			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229605				2022-12-28	WOS:000222356800052
J	Grim, P				Grim, P			Semper Fi	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Naval Hosp, Parris Isl, SC 29905 USA	United States Department of Defense; United States Navy	Grim, P (corresponding author), Naval Hosp, Parris Isl, SC 29905 USA.								0	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					3	5		10.1056/NEJMp048075	http://dx.doi.org/10.1056/NEJMp048075			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229299				2022-12-28	WOS:000222352200001
J	Smith, GCS; Pell, JP; Pasupathy, D; Dobbie, R				Smith, GCS; Pell, JP; Pasupathy, D; Dobbie, R			Factors predisposing to perinatal death related to uterine rupture during attempted vaginal birth after caesarean section: retrospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY; RISK; LABOR; WOMEN	Objective To determine the factors associated with an increased risk of perinatal death related to uterine rupture during attempted vaginal birth after caesarean section. Design Population based retrospective cohort study. Setting Data from the linked Scottish Morbidity Record and Stillbirth and Infant Death Survey of births in Scotland, 1985-98. Participants All women with one previous caesarean delivery who gave birth to a singleton infant at term by a means other than planned repeat caesarean section (n = 35 854). Main outcome measures All intrapartum uterine rupture and uterine rupture resulting in perinatal death (that is, death of the fetus or neonate). Results The overall proportion of vaginal births was 74.2% and of uterine rupture was 0.35%. The risk of intrapartum uterine rupture was higher among women who had not previously given birth vaginally (adjusted odds ratio 2.5, 95% confidence interval 1.6 to 3.9, P < 0.001) and those whose labour was induced with prostaglandin (2.9, 2.0 to 4.3, P < 0.001). Both factors were also associated with an increased risk of perinatal death due to uterine rupture. Delivery in a hospital with < 3000 births a year did not increase the overall risk of uterine rupture (1.1, 0.8 to 1.5, P = 0.67). However, the risk of perinatal death due to uterine rupture was significantly higher in hospitals with < 3000 births a year (one per 1300 births) than in hospitals with greater than or equal to3000 births a year (one per 4700; 3.4, 1.0 to 14.3, P = 0.04). Conclusion Women who have not previously given birth vaginally and those whose labour is induced with prostaglandin are at increased risk of uterine rupture when attempting vaginal birth after caesarean section. The risk of consequent death of the infant is higher in units with lower annual numbers of births.	Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2QQ, England; Greater Glasgow NHS Board, Dept Publ Hlth, Glasgow G3 8YU, Lanark, Scotland; Addenbrookes NHS Trust, Dept Obstet, Cambridge CB2 2SW, England; Addenbrookes NHS Trust, Dept Gynaecol, Cambridge CB2 2SW, England; Common Serv Agcy, Informat & Stat Div, Edinburgh EH5 3SE, Midlothian, Scotland	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital	Smith, GCS (corresponding author), Univ Cambridge, Dept Obstet & Gynaecol, Cambridge CB2 2QQ, England.	gcss2@cam.ac.uk	Pasupathy, Dharmintra/N-9586-2019; Smith, Gordon/A-8070-2008	Pasupathy, Dharmintra/0000-0002-6722-1006; Smith, Gordon/0000-0003-2124-0997; Pell, Jill/0000-0002-8898-7035				COLE SK, 1980, PERINATAL AUDIT SURV, P39; Flamm BL, 2001, BEST PRACT RES CL OB, V15, P81, DOI 10.1053/beog.2000.0150; Gregory KD, 1999, OBSTET GYNECOL, V94, P985, DOI 10.1016/S0029-7844(99)00422-6; Guise JM, 2004, BMJ-BRIT MED J, V329, P19, DOI 10.1136/bmj.329.7456.19; HEY EN, 1986, BRIT J OBSTET GYNAEC, V93, P1213, DOI 10.1111/j.1471-0528.1986.tb07854.x; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101; MCILWAINE GM, 1985, BRIT J OBSTET GYNAEC, V92, P9, DOI 10.1111/j.1471-0528.1985.tb01041.x; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; Oster RA, 2002, AM STAT, V56, P235, DOI 10.1198/00031300274; Rageth JC, 1999, OBSTET GYNECOL, V93, P332, DOI 10.1016/S0029-7844(98)00446-3; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; Zelop CM, 2000, AM J OBSTET GYNECOL, V183, P1184, DOI 10.1067/mob.2000.109048	13	81	86	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	2004	329	7462					375	377		10.1136/bmj.38160.634352.55	http://dx.doi.org/10.1136/bmj.38160.634352.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15262772	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000223433600016
J	Umemori, H; Linhoff, MW; Ornitz, DM; Sanes, JR				Umemori, H; Linhoff, MW; Ornitz, DM; Sanes, JR			FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain	CELL			English	Article							FIBROBLAST-GROWTH-FACTOR; CULTURED NEURONS; STOP SIGNAL; RECEPTOR; DIFFERENTIATION; SPECIFICITY; INDUCTION; BINDING; CELLS; LIMB	Target-derived cues promote local differentiation of axons into nerve terminals at sites of synaptic contact. Using clustering of synaptic vesicles in cultured neurons as an assay, we purified putative target-derived presynaptic organizing molecules from mouse brain and identified FGF22 as a major active species. FGF7 and FGF10, the closest relatives of FGF22, share this activity; other FGFs have distinct effects. FGF22 is expressed by cerebellar granule cells during the period when they receive synapses. Its receptor, FGFR2, is expressed by pontine and vestibular neurons when their axons (mossy fibers) are making synapses on granule cells. Neutralization of FGF7, -10, and -22 inhibits presynaptic differentiation of mossy fibers at sites of contact with granule cells in vivo. Inactivation of FGFR2 has similar effects. These results indicate that FGF22 and its relatives are presynaptic organizing molecules in the mammalian brain and suggest new functions for this family of signaling molecules.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Washington University (WUSTL); Washington University (WUSTL); Harvard University	Sanes, JR (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	sanesj@mcb.harvard.edu		Umemori, Hisashi/0000-0001-7198-2062; Ornitz, David/0000-0003-1592-7629				Altman J, 1997, DEV CEREBELLAR SYSTE; BAIRD DH, 1992, J NEUROSCI, V12, P619; Belluardo N, 1997, J COMP NEUROL, V379, P226; Bellusci S, 1997, DEVELOPMENT, V124, P4867; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; Beyer TA, 2003, EXP CELL RES, V287, P228, DOI 10.1016/S0014-4827(03)00139-3; Biederer T, 2002, SCIENCE, V297, P1525, DOI 10.1126/science.1072356; Buffelli M, 2003, NATURE, V424, P430, DOI 10.1038/nature01844; DAI ZS, 1995, J NEUROSCI, V15, P5466; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; De Paola V, 2003, NAT NEUROSCI, V6, P491, DOI 10.1038/nn1046; Dono R, 2003, AM J PHYSIOL-REG I, V284, pR867, DOI 10.1152/ajpregu.00533.2002; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Guo CY, 2002, GENESIS, V32, P8, DOI 10.1002/gene.10021; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HENDERSON CE, 2003, MOL CELL NEUROSCI, V22, P430; Li AJ, 2002, EUR J NEUROSCI, V16, P1313, DOI 10.1046/j.1460-9568.2002.02193.x; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Murthy VN, 2003, ANNU REV NEUROSCI, V26, P701, DOI 10.1146/annurev.neuro.26.041002.131445; Nakatake Y, 2001, BBA-GENE STRUCT EXPR, V1517, P460, DOI 10.1016/S0167-4781(00)00302-X; NOAKES PG, 1995, NATURE, V374, P258, DOI 10.1038/374258a0; Ornitz DM, 2001, GENOME BIOL, V2; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PORTER BE, 1995, NEURON, V14, P549, DOI 10.1016/0896-6273(95)90311-9; Post M, 1996, DEVELOPMENT, V122, P3107; Reuss B, 2003, CELL TISSUE RES, V313, P139, DOI 10.1007/s00441-003-0756-7; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Scheiffele P, 2003, ANNU REV NEUROSCI, V26, P485, DOI 10.1146/annurev.neuro.26.043002.094940; Scheiffele P, 2000, CELL, V101, P657, DOI 10.1016/S0092-8674(00)80877-6; Son YJ, 1999, EUR J NEUROSCI, V11, P3457, DOI 10.1046/j.1460-9568.1999.00766.x; VAUGHN JE, 1989, SYNAPSE, V3, P255, DOI 10.1002/syn.890030312; WERLE MJ, 1991, RES NEUROL, V5, P269; Xu XL, 1998, DEVELOPMENT, V125, P753; Yamagata M, 2003, CURR OPIN CELL BIOL, V15, P621, DOI 10.1016/S0955-0674(03)00107-8; Yeh BK, 2003, P NATL ACAD SCI USA, V100, P2266, DOI 10.1073/pnas.0436500100; Yu K, 2003, DEVELOPMENT, V130, P3063, DOI 10.1242/dev.00491; YUZAKI M, 1992, J NEUROSCI, V12, P4253	42	206	213	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					257	270		10.1016/j.cell.2004.06.025	http://dx.doi.org/10.1016/j.cell.2004.06.025			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260994	Bronze			2022-12-28	WOS:000222966000013
J	Montalescot, G; Borentain, M; Payot, L; Collet, JP; Thomas, D				Montalescot, G; Borentain, M; Payot, L; Collet, JP; Thomas, D			Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction - A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLATELET-RICH CLOTS; TO-BALLOON TIME; PRIMARY ANGIOPLASTY; IMMEDIATE THROMBOLYSIS; RECEPTOR BLOCKADE; EMERGENCY-ROOM; ABCIXIMAB; MORTALITY; REPERFUSION; TIROFIBAN	Context Glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors improve myocardial reperfusion and clinical outcomes of patients undergoing primary percutaneous coronary intervention (PCI), but optimal timing of administration remains unclear. No systematic reviews have comprehensively examined the effects of early vs delayed administration of these agents. Objective To perform a meta-analysis of randomized trials of early (prior to transfer to the catheterization laboratory) vs late (at the time of PCI) intravenous administration of Gp IIb/IIIa inhibitors in acute ST-segment elevation myocardial infarction (STEMI). Data Sources MEDLINE and the Cochrane Controlled Trials Register search of the literature over the past 10 years; papers presented at major cardiac conferences; consultation with national and international colleagues as well as Gp IIb/IIIa inhibitor drug manufacturers; and text and journal article bibliographies. Study Selection and Data Extraction We examined trials of randomized comparisons between early administration at the point of initial contact (emergency department or ambulance) and late administration (catheterization laboratory) of Gp IIb/IIIa inhibitors in STEMI. Outcome data had to be available on both culprit artery patency evaluated by Thrombolysis in Myocardial Infarction (TIMI) flow grades on admission and mortality. Two authors independently reviewed abstracts or complete articles. Six studies met inclusion criteria. Independent data extraction was performed by 2 reviewers and confirmed by consensus. Data Synthesis The 6 trials enrolled 931 STEMI patients treated with abciximab (3 trials) or tirofiban (3 trials) in combination with primary PCI. TIMI grade 2 or 3 flow (41.7% [194/465 vs 29.8% [139/466]) as well as TIMI grade 3 flow (20.3% [84/413] vs 12.2% [51/418]) were significantly more frequent in the early group compared with the late group (odds ratio [OR], 1.69; 95% confidence interval [Cl], 1.28-2.22; P<.001; and OR, 1.85; 95% Cl, 1.26-2.71; P<.001, respectively). The early administration of Gp IIb/IIIa inhibitors was associated with a 28% reduction of mortality from 4.7% to 3.4%, which was not significant but consistent with similar trends for reinfarction and the composite ischemic end point. Conclusions In a meta-analysis of 6 randomized trials, early administration of Gp IIb/IIIa inhibitors in STEMI appeared to improve coronary patency with favorable trends for clinical outcomes. These findings are supportive of a strategy of facilitated PCI. Further evaluations in adequately powered large trials are awaited to confirm the clinical benefit of this strategy.	Pitie Salpetriere Univ Hosp, Inst Cardiol, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Montalescot, G (corresponding author), Pitie Salpetriere Univ Hosp, Inst Cardiol, Bur 2-236,47 Blvd Hop, F-75013 Paris, France.	gilles.montalescot@psl.ap-hop-paris.fr		THOMAS, Daniel/0000-0002-3231-9396				Anderson KM, 2001, J AM COLL CARDIOL, V37, P2059, DOI 10.1016/S0735-1097(01)01290-6; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Antoniucci D, 2003, J AM COLL CARDIOL, V42, P1879, DOI 10.1016/j.jacc.2003.07.017; Antoniucci D, 2002, AM J CARDIOL, V89, P1248, DOI 10.1016/S0002-9149(02)02320-2; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Arntz HR, 2003, EUR HEART J, V24, P268, DOI 10.1016/S0195-668X(03)94640-9; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; Brodie BR, 1998, J AM COLL CARDIOL, V32, P1312, DOI 10.1016/S0735-1097(98)00395-7; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; Collet JP, 2001, CIRCULATION, V103, P2328; Collett JP, 2001, ARTERIOSCL THROM VAS, V21, P142, DOI 10.1161/01.ATV.21.1.142; Cucherat M, 1997, COMPUT METH PROG BIO, V53, P187, DOI 10.1016/S0169-2607(97)00016-3; Cutlip DE, 2003, AM J CARDIOL, V92, P977, DOI 10.1016/S0002-9149(03)00983-4; Dalby M, 2003, CIRCULATION, V108, P1809, DOI 10.1161/01.CIR.0000091088.63921.8C; De Luca G, 2003, J AM COLL CARDIOL, V42, P991, DOI 10.1016/S0735-1097(03)00919-7; Gabriel HM, 2003, EUR HEART J, V24, P543, DOI 10.1016/S0195-668X(03)95631-4; Glatt B, 1999, ARCH MAL COEUR VAISS, V92, P1301; Kastrati A, 2004, JAMA-J AM MED ASSOC, V291, P947, DOI 10.1001/jama.291.8.947; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Lee DP, 2003, CIRCULATION, V107, P1497, DOI 10.1161/01.CIR.0000056120.00513.7A; Lincoff AM, 2000, J AM COLL CARDIOL, V35, P1103, DOI 10.1016/S0735-1097(00)00554-4; Makkar R, 1999, CATHETER CARDIO INTE, V48, P430, DOI 10.1002/(SICI)1522-726X(199912)48:4<430::AID-CCD20>3.0.CO;2-G; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Steg PG, 2003, CIRCULATION, V108, P2851, DOI 10.1161/01.CIR.0000103122.10021.F2; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Stone GW, 2001, CIRCULATION, V104, P636, DOI 10.1161/hc3101.093701; Topol EJ, 2003, J AM COLL CARDIOL, V42, P1886, DOI 10.1016/j.jacc.2003.09.010; van den Merkhof LFM, 1999, J AM COLL CARDIOL, V33, P1528, DOI 10.1016/S0735-1097(99)00038-8; van't Hof AWJ, 2004, EUR HEART J, V25, P837, DOI 10.1016/j.ehj.2004.04.003; Widimsky P, 2000, EUR HEART J, V21, P823, DOI 10.1053/euhj.1999.1993; Zorman S, 2002, AM J CARDIOL, V90, P533, DOI 10.1016/S0002-9149(02)02530-4	33	202	225	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					362	366		10.1001/jama.292.3.362	http://dx.doi.org/10.1001/jama.292.3.362			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265852				2022-12-28	WOS:000222693500022
J	Davis, E; Becker, K; Dziak, R; Cassidy, J; Wang, K; Lilley, M				Davis, E; Becker, K; Dziak, R; Cassidy, J; Wang, K; Lilley, M			Hydrological response to a seafloor spreading episode on the Juan de Fuca ridge	NATURE			English	Article							EVENT; DEFORMATION	Seafloor hydrothermal systems are known to respond to seismic and magmatic activity along mid-ocean ridges, often resulting in locally positive changes in hydrothermal discharge rate, temperature and microbial activity, and shifts in composition occurring at the time of earthquake swarms and axial crustal dike injections(1-10). Corresponding regional effects have also been observed(11). Here we present observations of a hydrological response to seafloor spreading activity, which resulted in a negative formation-fluid pressure transient during and after an earthquake swarm in the sediment-sealed igneous crust of the Middle Valley rift of the northernmost Juan de Fuca ridge. The observations were made with a borehole seal and hydrologic observatory originally established in 1991 to study the steady-state pressure and temperature conditions in this hydrothermally active area(12,13). The magnitude of the co-seismic response is consistent with the elastic strain that would be expected from the associated earthquakes, but the prolonged negative pressure transient after the swarm is surprising and suggests net co-seismic dilatation of the upper, permeable igneous crust. The rift valley was visited four weeks after the onset of the seismic activity, but no signature of increased hydrothermal activity was detected in the water column. It appears that water, not magma, filled the void left by this spreading episode.	Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Oregon State Univ, Hatfield Marine Sci Ctr, NOAA, Newport, OR 97365 USA; Univ Washington, Sch Oceanog, Seattle, WA 98195 USA	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada; University of Miami; National Oceanic Atmospheric Admin (NOAA) - USA; Oregon State University; University of Washington; University of Washington Seattle	Davis, E (corresponding author), Geol Survey Canada, Pacific Geosci Ctr, Sidney, BC V8L 4B2, Canada.	edavis@nrcan.gc.ca	Dziak, Robert/AAC-6107-2020					Becker K., 1994, P OCEAN DRILL PROGRA, V139, P613; Bessler J. U., 1994, P OCEAN DRILL PROGRA, V139, P667, DOI [10.2973/odp.proc.sr.139.253.1994, DOI 10.2973/ODP.PROC.SR.139.253.1994]; COOPER HH, 1967, WATER RESOUR RES, V3, P263, DOI 10.1029/WR003i001p00263; DAVIES ER, 1992, IEE PROC-E, V139, P9, DOI 10.1049/ip-e.1992.0002; Davis EE, 2001, J GEOPHYS RES-SOL EA, V106, P21953, DOI 10.1029/2000JB000040; DAVIS EE, 1994, P OCEAN DRILL PROGRA, V139, P649; Davis EE, 1992, P OCEAN DRILL PROGRA, V139, P43, DOI DOI 10.2973/ODP.PROC.IR.139.103.1992; Delaney JR, 1998, SCIENCE, V281, P222, DOI 10.1126/science.281.5374.222; Dziak RP, 1999, GEOPHYS RES LETT, V26, P3429, DOI 10.1029/1999GL002332; DZIAK RP, 1995, GEOPHYS RES LETT, V22, P135, DOI 10.1029/94GL01857; EMBLEY RW, 1995, GEOPHYS RES LETT, V22, P143, DOI 10.1029/94GL02281; FOX CG, 1993, MAR TECHNOL SOC J, V27, P22; Golden CE, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000226; Johnson HP, 2000, NATURE, V407, P174, DOI 10.1038/35025040; Jonsson S, 2003, NATURE, V424, P179, DOI 10.1038/nature01776; Lilley MD, 2003, NATURE, V422, P878, DOI 10.1038/nature01569; Lupton JE, 1999, EARTH PLANET SC LETT, V171, P343, DOI 10.1016/S0012-821X(99)00149-1; MASSOTH GJ, 1995, GEOPHYS RES LETT, V22, P151, DOI 10.1029/94GL02662; OKADA Y, 1992, B SEISMOL SOC AM, V82, P1018; Sohn RA, 1998, NATURE, V396, P159, DOI 10.1038/24146; VONDAMM KL, 1995, NATURE, V375, P47, DOI 10.1038/375047a0; WANG K, IN PRESS HYDROGEOLOG	22	29	30	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					335	338		10.1038/nature02755	http://dx.doi.org/10.1038/nature02755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254534				2022-12-28	WOS:000222631200037
J	King, DA				King, DA			The scientific impact of nations	NATURE			English	Article									Off Sci & Technol, London SW1H 0ET, England		King, DA (corresponding author), Off Sci & Technol, 1 Victoria St, London SW1H 0ET, England.							Adams J, 1998, NATURE, V396, P615, DOI 10.1038/25219; Annan K, 2004, SCIENCE, V303, P925, DOI 10.1126/science.303.5660.925; Batty M, 2003, ENVIRON PLANN A, V35, P761, DOI 10.1068/a3505com; Grant J, 1997, SCIENCE, V278, P878; HM Treasury Department for Education and Skills Department for Trade and Industry, 2004, SCI INN INV FRAM; Margolis RM, 1999, SCIENCE, V285, P690, DOI 10.1126/science.285.5428.690; May RM, 1997, SCIENCE, V275, P793, DOI 10.1126/science.275.5301.793; May RM, 1997, SCIENCE, V278, P879; Singer E, 2004, NATURE, V427, P388, DOI 10.1038/427388a; *UK OFF SCI TECHN, 2003, PSA TARG METR UK RES; ZEWAIL A, 2002, VOYAGE TIME	11	825	865	7	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					311	316		10.1038/430311a	http://dx.doi.org/10.1038/430311a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254529	Bronze			2022-12-28	WOS:000222631200031
J	Ninomiya, H; Elinson, RP; Winklbauer, R				Ninomiya, H; Elinson, RP; Winklbauer, R			Antero-posterior tissue polarity links mesoderm convergent extension to axial patterning	NATURE			English	Article							MORPHOGEN GRADIENT; CELL POLARIZATION; XENOPUS HOMOLOG; WNT PATHWAY; GASTRULATION; MOVEMENTS; ACTIVIN; EXPRESSION; DROSOPHILA; ORGANIZER	Remodelling its shape, or morphogenesis, is a fundamental property of living tissue. It underlies much of embryonic development and numerous pathologies. Convergent extension (CE) of the axial mesoderm of vertebrates is an intensively studied model for morphogenetic processes that rely on cell rearrangement. It involves the intercalation of polarized cells perpendicular to the antero-posterior (AP) axis, which narrows and lengthens the tissue(1,2). Several genes have been identified that regulate cell behaviour underlying CE in zebrafish and Xenopus. Many of these are homologues of genes that control epithelial planar cell polarity in Drosophila(1-5). However, elongation of axial mesoderm must be also coordinated with the pattern of AP tissue specification to generate a normal larval morphology. At present, the long-range control that orients CE with respect to embryonic axes is not understood. Here we show that the chordamesoderm of Xenopus possesses an intrinsic AP polarity that is necessary for CE, functions in parallel to Wnt/planar cell polarity signalling, and determines the direction of tissue elongation. The mechanism that establishes AP polarity involves graded activin-like signalling and directly links mesoderm AP patterning to CE.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada; Duquesne Univ, Dept Biol Sci, Pittsburgh, PA 15282 USA	University of Toronto; Duquesne University	Winklbauer, R (corresponding author), Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada.	winklbauer@zoo.utoronto.ca						Branford WW, 2002, CURR BIOL, V12, P2136, DOI 10.1016/S0960-9822(02)01360-X; Goto T, 2002, DEV BIOL, V247, P165, DOI 10.1006/dbio.2002.0673; GREEN JBA, 1992, CELL, V71, P731, DOI 10.1016/0092-8674(92)90550-V; Gritsman K, 2000, DEVELOPMENT, V127, P921; Gurdon JB, 1999, DEVELOPMENT, V126, P5309; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; GWANTKA V, 1992, DEVELOPMENT, V115, P595; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; IRVINE KD, 1994, DEVELOPMENT, V120, P827; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; KELLER R, 1988, DEVELOPMENT, V103, P193; Kinoshita N, 2003, GENE DEV, V17, P1663, DOI 10.1101/gad.1101303; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Ninomiya H, 1999, DEV GROWTH DIFFER, V41, P391; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1985, DIFFERENTIATION, V29, P109, DOI 10.1111/j.1432-0436.1985.tb00302.x; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SOKOL S, 1991, NATURE, V351, P409, DOI 10.1038/351409a0; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Tada M, 2000, DEVELOPMENT, V127, P2227; Thisse B, 2000, NATURE, V403, P425, DOI 10.1038/35000200; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Zallen JA, 2004, DEV CELL, V6, P343, DOI 10.1016/S1534-5807(04)00060-7	30	121	123	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					364	367		10.1038/nature02620	http://dx.doi.org/10.1038/nature02620			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254540				2022-12-28	WOS:000222631200044
J	Saag, MS; Cahn, P; Raffi, F; Wolff, M; Pearce, D; Molina, JM; Powderly, W; Shaw, AL; Mondou, E; Hinkle, J; Borroto-Esoda, K; Quinn, JB; Barry, DW; Rousseau, F				Saag, MS; Cahn, P; Raffi, F; Wolff, M; Pearce, D; Molina, JM; Powderly, W; Shaw, AL; Mondou, E; Hinkle, J; Borroto-Esoda, K; Quinn, JB; Barry, DW; Rousseau, F		FTC-301A Study Team	Efficacy and safety of emtricitabine vs stavudine in combination therapy in anti retroviral-naive patients - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN IMMUNODEFICIENCY VIRUSES; TYPE-1 DRUG-RESISTANCE; ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; HIV-1 INFECTION; INHIBITOR; ADULTS; EFAVIRENZ; SELECTION	Context Emtricitabine is anew, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV). Objective To assess the efficacy and safety of emtricitabine as compared with stavudine when used with a background regimen of didanosine and efavirenz. Design, Setting, and Patients Randomized, double-blind, double-dummy study conducted at 101 research clinics in North America, Latin America, and Europe. The first patient was enrolled on August 21, 2000; no investigator or patient was unblinded until the last patient randomized completed the week 48 visit on October 24, 2002. Analyses were based on data collected in a double-blind setting with a median follow-up of 60 weeks. Patients were 571 anti retroviral-naive, HIV-1-infected adults aged 18 years or older with viral load levels greater than or equal to 5000 copies/mL. Interventions Receipt of either 200 mg of emtricitabine once daily (plus stavudine placebo twice daily) (n=286) or stavudine at standard doses twice daily (plus emtricitabine placebo once daily) (n=285) plus open-label didanosine and efavirenz, once daily. Main Outcome Measure Persistent virological response, defined as achieving and maintaining viral load at or below the limit of assay quantification (less than or equal to400 or 50 copies/mL). Results At the interim analysis on June 14, 2002, when the last patient randomized completed 24 weeks of double-blind treatment (median follow-up time of 42 weeks), patients in the emtricitabine group had a higher probability of a persistent virological response less than or equal to50 copies/mL vs the stavudine group (85% vs 76%, P=.005). This was associated with a higher mean CD4 cell count change from baseline for the emtricitabine group (156 cells/muL vs 119 cells/muL, P=.01 [of note, there was no statistical difference at 48 weeks {P=.15}, although a sensitivity analysis, using an intent-to-treat population with the last CD4 cell count observation carried forward to week 48 showed a difference {P=.02}]). The independent data and safety monitoring board recommended offering open-label emtricitabine based on the interim analysis. The probability of persistent virological response less than or equal to50 copies/mL through week 60 was 76% for the emtricitabine group vs 54% for the stavudine group (P<.001). The probability of virological failure through week 60 was 4% in the emtricitabine group and 12% in the stavudine group (P<.001). Patients in the stavudine group had a greater probability of an adverse event that led to study drug discontinuation through week 60 than did those in the emtricitabine group (15% vs 7%, P=.005). Conclusion Once-daily emtricitabine appeared to demonstrate greater virological efficacy, durability of response, and tolerability compared with twice-daily stavudine when used with once-daily didanosine and efavirenz.	Univ Alabama, Res Clin, Birmingham, AL USA; Fdn HUESPED, Buenos Aires, DF, Argentina; CHU Nantes, F-44035 Nantes 01, France; Hosp San Borja Arriaran, Santiago, Chile; AltaMed, Los Angeles, CA USA; Hop St Louis, Paris, France; Washington Univ, Sch Med, St Louis, MO USA; Gilead Sci Inc, Durham, NC 27707 USA	University of Alabama System; University of Alabama Birmingham; Nantes Universite; CHU de Nantes; Universidad de Chile; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Washington University (WUSTL); Gilead Sciences	Rousseau, F (corresponding author), Gilead Sci Inc, 4 Univ Pl,4611 Univ Dr, Durham, NC 27707 USA.	frank.rousseau@gilead.com		Powderly, William/0000-0001-7808-3086; Wolff, Marcelo/0000-0002-9956-8872				*AIDS CLIN TRIAL G, 1996, DIV AIDS TABL GRAD S; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Bartlett JA, 2001, AIDS, V15, P1369, DOI 10.1097/00002030-200107270-00006; Cahn P, 2004, EXPERT OPIN INV DRUG, V13, P55, DOI 10.1517/13543784.13.1.55; Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3; DeGruttola V, 2000, ANTIVIR THER, V5, P41; *DIV ANT DRUG PROD, GUID IND ANT DRUGS U; Dube MP, 2003, CLIN INFECT DIS, V37, P613, DOI 10.1086/378131; Duran S, 2001, HIV Clin Trials, V2, P38; Erali M, 2001, J CLIN MICROBIOL, V39, P2157, DOI 10.1128/JCM.39.6.2157-2165.2001; Frank I, 2002, JAIDS, V31, pS10, DOI 10.1097/00126334-200209011-00003; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Le Moing V, 2002, AIDS, V16, P21, DOI 10.1097/00002030-200201040-00004; Molina JM, 2000, J INFECT DIS, V182, P599, DOI 10.1086/315711; MOLINA JM, 2001, 8 EUR C CLIN ASP TRE; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; POWDERLY W, 2004, 11 C RETR OPP INF FE; Richman DD, 2001, ANTIVIR THER, V6, P83; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; *ROCH MOL SYST INC, 1999, AMPL HIV 1 MON TEST; *ROCH MOL SYST INC, 2002, AMPL HIV 1 MON TEST; Rousseau FS, 2001, J ANTIMICROB CHEMOTH, V48, P507, DOI 10.1093/jac/48.4.507; SANNE I, 2003, 2 INT AIDS SOC C HIV; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2423, DOI 10.1128/AAC.36.11.2423; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Shafer RW, 2002, CLIN MICROBIOL REV, V15, P247, DOI 10.1128/CMR.15.2.247-277.2002; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; STASZEWSKI S, 2002, 14 INT AIDS C JUL 7; STEIN A, 1982, 39 INT C ANT AG CHEM; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; WANG LW, 2004, IN PRESS AIDS RES HU; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wilson JW, 2000, J CLIN MICROBIOL, V38, P3022, DOI 10.1128/JCM.38.8.3022-3028.2000	33	114	117	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					180	190		10.1001/jama.292.2.180	http://dx.doi.org/10.1001/jama.292.2.180			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249567				2022-12-28	WOS:000222579300023
J	Verma, R; Oania, R; Graumann, J; Deshaies, RJ				Verma, R; Oania, R; Graumann, J; Deshaies, RJ			Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin-proteasome system	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; DEPENDENT DEGRADATION; PROTEIN-DEGRADATION; BINDING PROTEIN; UBA DOMAIN; DNA-REPAIR; SUBUNIT; RECOGNITION; RAD23; COMPLEX	Recruitment of ubiquitinated proteins to the 26S proteasome lies at the heart of the ubiquitin-proteasome system (UPS). Genetic studies suggest a role for the multiubiquitin chain binding proteins (MCBPs) Rad23 and Rpn10 in recruitment, but biochemical studies implicate the Rpt5 ATPase. We addressed this issue by analyzing degradation of the ubiquitinated Cdk inhibitor Sic1 (UbSic1) in vitro. Mutant rpn10Delta and rad23Delta proteasomes failed to bind or degrade UbSic1. Although Rpn10 or Rad23 restored UbSic1 recruitment to either mutant, rescue of degradation by Rad23 uncovered a requirement for the VWA domain of Rpn10. In vivo analyses confirmed that Rad23 and the multiubiquitin binding domain of Rpn10 contribute to Sic1 degradation. Turnover studies of multiple UPS substrates uncovered an unexpected degree of specificity in their requirements for MCBPs. We propose that recruitment of substrates to the proteasome by MCBPs provides an additional layer of substrate selectivity in the UPS.	CALTECH, Dept Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Deshaies, RJ (corresponding author), CALTECH, Dept Biol, Pasadena, CA 91125 USA.	deshaies@caltech.edu	Graumann, Johannes/C-5241-2008; Deshaies, Raymond/B-8354-2014	Graumann, Johannes/0000-0002-3015-5850; Deshaies, Raymond/0000-0002-3671-9354				Amerik AY, 1997, EMBO J, V16, P4826; Cao K, 2003, CELL, V115, P355, DOI 10.1016/S0092-8674(03)00815-8; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DEVERAUX Q, 1995, J BIOL CHEM, V270, P29660; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Elsasser S, 2004, J BIOL CHEM, V279, P26817, DOI 10.1074/jbc.M404020200; Flierman D, 2003, J BIOL CHEM, V278, P34774, DOI 10.1074/jbc.M303360200; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Fu XR, 2003, J CELL BIOL, V163, P21, DOI 10.1083/jcb.200307025; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hartmann-Petersen R, 2003, FEBS LETT, V535, P77, DOI 10.1016/S0014-5793(02)03874-7; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Lambertson D, 1999, GENETICS, V153, P69; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Levchenko I, 2000, SCIENCE, V289, P2354, DOI 10.1126/science.289.5488.2354; Li ZY, 2002, J BIOL CHEM, V277, P42686, DOI 10.1074/jbc.M207183200; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Medicherla B, 2004, EMBO REP, V5, P692, DOI 10.1038/sj.embor.7400164; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rao H, 2002, J BIOL CHEM, V277, P11691, DOI 10.1074/jbc.M200245200; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V296, P813, DOI 10.1016/S0006-291X(02)02002-8; Saeki Y, 2002, BIOCHEM BIOPH RES CO, V293, P986, DOI 10.1016/S0006-291X(02)00340-6; Sakata E, 2003, EMBO REP, V4, P301, DOI 10.1038/sj.embor.embor764; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Szlanka T, 2003, J CELL SCI, V116, P1023, DOI 10.1242/jcs.00332; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Verma R, 2001, MOL CELL, V8, P439, DOI 10.1016/S1097-2765(01)00308-2; Whittaker CA, 2002, MOL BIOL CELL, V13, P3369, DOI 10.1091/mbc.E02-05-0259; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Xie YM, 2002, NAT CELL BIOL, V4, P1003, DOI 10.1038/ncb889; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169	57	354	363	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					99	110		10.1016/j.cell.2004.06.014	http://dx.doi.org/10.1016/j.cell.2004.06.014			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242647	Bronze			2022-12-28	WOS:000222626800011
J	Field, MG				Field, MG			Global health - HIV and AIDS in the former Soviet Bloc	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Davis Ctr Russian & Eurasian Studies, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health	Field, MG (corresponding author), Harvard Univ, Davis Ctr Russian & Eurasian Studies, Cambridge, MA 02138 USA.							EBERSTADT N, 2004, WASHINGTON POST 0213, pA27; FESHBACH M, 2003, NY TIMES        0531, pA15; POWELL DE, 2000, RUSSIAS TORN SAFETY, P123; *UN DEV PROGR, 2004, HIV AIDS E EUR COMM; 2004, MOSCOW TIMES    0218, P42	5	26	28	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					117	120		10.1056/NEJMp048066	http://dx.doi.org/10.1056/NEJMp048066			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247350				2022-12-28	WOS:000222470700002
J	Hylton, C; Goldberg, MF				Hylton, C; Goldberg, MF			Circumpapillary retinal ridge in the shaken-baby syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Hylton, C (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					170	170		10.1056/NEJMicm020098	http://dx.doi.org/10.1056/NEJMicm020098			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247357				2022-12-28	WOS:000222470700010
J	Ong, NP; Cava, RJ				Ong, NP; Cava, RJ			Electronic frustration on a triangular lattice	SCIENCE			English	Editorial Material							SUPERCONDUCTIVITY; NACO2O4		Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Princeton Univ, Dept Chem, Princeton, NJ 08544 USA	Princeton University; Princeton University	Ong, NP (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.	npo@princeton.edu; rcava@princeton.edu	Ong, N. Phuan/Z-1626-2019	Ong, N. Phuan/0000-0001-7166-1058				Chou FC, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.157004; Fujimoto T, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.047004; HASAN MZ, IN PRESS PHYS REV LE; Jin R, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.217001; Ray R, 1999, PHYS REV B, V59, P9454, DOI 10.1103/PhysRevB.59.9454; Schaak RE, 2003, NATURE, V424, P527, DOI 10.1038/nature01877; Takada K, 2003, NATURE, V422, P53, DOI 10.1038/nature01450; Wang YY, 2003, NATURE, V423, P425, DOI 10.1038/nature01639	10	57	59	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	2004	305	5680					52	53		10.1126/science.1099387	http://dx.doi.org/10.1126/science.1099387			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232096				2022-12-28	WOS:000222386000029
J	Lu, XW; Borchers, AGM; Jolicoeur, C; Rayburn, H; Baker, JC; Tessier-Lavigne, M				Lu, XW; Borchers, AGM; Jolicoeur, C; Rayburn, H; Baker, JC; Tessier-Lavigne, M			PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates	NATURE			English	Article							NEURAL-TUBE CLOSURE; CONVERGENT EXTENSION; DROSOPHILA; MOUSE; MECHANISMS; POLARIZATION; CIRCLETAIL; MOLECULE; ENCODES; DEFECTS	In addition to the apical-basal polarity pathway operating in epithelial cells, a planar cell polarity (PCP) pathway establishes polarity within the plane of epithelial tissues and is conserved from Drosophila to mammals. In Drosophila, a 'core' group of PCP genes including frizzled (fz), flamingo/starry night, dishevelled (dsh), Van Gogh/strabismus and prickle, function to regulate wing hair, bristle and ommatidial polarity(1-3). In vertebrates, the PCP pathway regulates convergent extension movements and neural tube closure(3-5), as well as the orientation of stereociliary bundles of sensory hair cells in the inner ear(6). Here we show that a mutation in the mouse protein tyrosine kinase 7 (PTK7) gene, which encodes an evolutionarily conserved transmembrane protein with tyrosine kinase homology, disrupts neural tube closure and stereociliary bundle orientation, and shows genetic interactions with a mutation in the mouse Van Gogh homologue vangl(2). We also show that PTK7 is dynamically localized during hair cell polarization, and that the Xenopus homologue of PTK7 is required for neural convergent extension and neural tube closure. These results identify PTK7 as a novel regulator of PCP in vertebrates.	Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Tessier-Lavigne, M (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	marctl@gene.com	Borchers, Annette/AAF-8126-2021	Borchers, Annette/0000-0002-2524-5384				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Borchers AGM, 2002, DEV BIOL, V251, P395, DOI 10.1006/dbio.2002.0814; Copp AJ, 2003, NAT REV GENET, V4, P784, DOI 10.1038/nrg1181; Curtin JA, 2003, CURR BIOL, V13, P1129, DOI 10.1016/S0960-9822(03)00374-9; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hamblet NS, 2002, DEVELOPMENT, V129, P5827, DOI 10.1242/dev.00164; Keller R, 2002, SCIENCE, V298, P1950, DOI 10.1126/science.1079478; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Leighton PA, 2001, NATURE, V410, P174, DOI 10.1038/35065539; Miller MA, 2000, DEV BIOL, V224, P286, DOI 10.1006/dbio.2000.9786; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; MOSSIE K, 1995, ONCOGENE, V11, P2179; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Murdoch JN, 2001, GENOMICS, V78, P55, DOI 10.1006/geno.2001.6638; Park SK, 1996, J BIOCHEM, V119, P235; PULIDO D, 1992, EMBO J, V11, P391, DOI 10.1002/j.1460-2075.1992.tb05067.x; Strutt D, 2003, DEVELOPMENT, V130, P4501, DOI 10.1242/dev.00695; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wallingford JB, 2002, DEV CELL, V2, P695, DOI 10.1016/S1534-5807(02)00197-1; Wallingford JB, 2002, DEVELOPMENT, V129, P5815, DOI 10.1242/dev.00123; Winberg ML, 2001, NEURON, V32, P53, DOI 10.1016/S0896-6273(01)00446-9	24	361	371	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					93	98		10.1038/nature02677	http://dx.doi.org/10.1038/nature02677			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229603				2022-12-28	WOS:000222356800050
J	Adams, KM; Gardiner, LD; Assefi, N				Adams, KM; Gardiner, LD; Assefi, N			Healthcare challenges from the developing world: post-immigration refugee medicine	BRITISH MEDICAL JOURNAL			English	Review							POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE-BEHAVIOR THERAPY; SOUTHEAST-ASIAN REFUGEES; INTESTINAL PARASITES; COST-EFFECTIVENESS; SOMALI REFUGEES; UNITED-STATES; SOMATIZATION; TORTURE; TUBERCULOSIS		Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Washington, Dept Psychiat, Seattle, WA 98195 USA; Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA; Management Sci Hlth, Rural Expans Afghanistans Community Based Healthc, Kabul, Afghanistan	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle	Adams, KM (corresponding author), Fred Hutchinson Canc Res Ctr, D2-100,1100 Fairview Ave N, Seattle, WA 98109 USA.	adamsk@u.washington.edu			NICHD NIH HHS [HD-01264] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD001264] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], WORLD HLTH REP 2004; Bhui K, 2003, SOC PSYCH PSYCH EPID, V38, P35, DOI 10.1007/s00127-003-0596-5; Debonne J M, 1999, Med Trop (Mars), V59, P508; DeRiemer K, 1998, ARCH INTERN MED, V158, P753, DOI 10.1001/archinte.158.7.753; Epstein RM, 1999, ARCH INTERN MED, V159, P215, DOI 10.1001/archinte.159.3.215; Figueira M, 2003, J TRAVEL MED, V10, P203, DOI 10.2310/7060.2003.40545; FRIEDMAN MJ, 2000, EFFECTIVE TREATMENTS; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; Gorst-Unsworth C, 1992, Med War, V8, P164, DOI 10.1080/07488009208409042; KINZIE JD, 1990, AM J PSYCHIAT, V147, P913; KINZIE JD, 1981, AM J PSYCHOTHER, V35, P251, DOI 10.1176/appi.psychotherapy.1981.35.2.251; LIN EHB, 1985, AM J PUBLIC HEALTH, V75, P1080, DOI 10.2105/AJPH.75.9.1080; Miller JM, 2000, AM J TROP MED HYG, V62, P115, DOI 10.4269/ajtmh.2000.62.115; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; Mollica RF, 2001, PSYCHIATRY, V64, P60, DOI 10.1521/psyc.64.1.60.18242; Muennig P, 1999, NEW ENGL J MED, V340, P773, DOI 10.1056/NEJM199903113401006; NUTMAN TB, 1987, J INFECT DIS, V155, P309, DOI 10.1093/infdis/155.2.309; Otto MW, 2003, BEHAV RES THER, V41, P1271, DOI 10.1016/S0005-7967(03)00032-9; Paunovic N, 2001, BEHAV RES THER, V39, P1183, DOI 10.1016/S0005-7967(00)00093-0; Pincock S, 2003, LANCET, V362, P1462, DOI 10.1016/S0140-6736(03)14730-7; Redwood-Campbell L, 2003, CAN J PUBLIC HEALTH, V94, P381, DOI 10.1007/BF03403567; Smajkic A, 2001, J TRAUMA STRESS, V14, P445, DOI 10.1023/A:1011177420069; Stauffer WM, 2002, PRIMARY CARE, V29, P879, DOI 10.1016/S0095-4543(02)00035-0; Toubia N., 1999, CARING WOMEN CIRCUMC; United Nations, 1951, CONV REL STAT REF; *US COMM REF, 2003, WORLD REF SURV; Walker PF, 1999, MED CLIN N AM, V83, P1103; Watters C, 2001, SOC SCI MED, V52, P1709, DOI 10.1016/S0277-9536(00)00284-7; WESTERMEYER J, 1989, PSYCHOSOMATICS, V30, P34, DOI 10.1016/S0033-3182(89)72315-X; *WHO, 1999, WHO UNHCR MENT LTH R; Zuber PLF, 1997, JAMA-J AM MED ASSOC, V278, P304, DOI 10.1001/jama.278.4.304	32	78	79	0	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1548	1552		10.1136/bmj.328.7455.1548	http://dx.doi.org/10.1136/bmj.328.7455.1548			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DV	15217874	Green Published			2022-12-28	WOS:000222392700026
J	Rakoff-Nahoum, S; Paglino, J; Eslami-Varzaneh, F; Edberg, S; Medzhitov, R				Rakoff-Nahoum, S; Paglino, J; Eslami-Varzaneh, F; Edberg, S; Medzhitov, R			Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis	CELL			English	Article							DEXTRAN SULFATE SODIUM; NF-KAPPA-B; INFLAMMATORY-BOWEL-DISEASE; HUMAN GINGIVAL FIBROBLASTS; HEPATOCYTE GROWTH-FACTOR; GENE-EXPRESSION; IMMUNODEFICIENT MICE; INDUCED COLITIS; CROHNS-DISEASE; LIPOPOLYSACCHARIDE	Toll-like receptors (TLRs) play a crucial role in host defense against microbial infection. The microbial ligands recognized by TLRs are not unique to pathogens, however, and are produced by both pathogenic and commensal microorganisms. It is thought that an inflammatory response to commensal bacteria is avoided due to sequestration of microflora by surface epithelia. Here, we show that commensal bacteria are recognized by TLRs under normal steady-state conditions, and this interaction plays a crucial role in the maintenance of intestinal epithelial homeostasis. Furthermore, we find that activation of TLRs by commensal microflora is critical for the protection against gut injury and associated mortality. These findings reveal a novel function of TLRs-control of intestinal epithelial homeostasis and protection from injury-and provide a new perspective on the evolution of host-microbial interactions.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.	ruslan.medzhitov@yale.edu			NIAID NIH HHS [AI46688] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046688, R37AI046688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsson LG, 1996, INFLAMM RES, V45, P181, DOI 10.1007/BF02285159; Basile JR, 2003, MOL CANCER RES, V1, P262; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Bohan A, 2003, J BIOL CHEM, V278, P36688, DOI 10.1074/jbc.M304011200; Booth D, 2001, J Natl Cancer Inst Monogr, P16; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a; CHO CH, 2002, GASTROINTESTINAL MUC; Clark RAF, 2003, J INVEST DERMATOL, V120, pIX, DOI 10.1046/j.1523-1747.2003.12264.x; de Groot PG, 2002, SEMIN THROMB HEMOST, V28, P133, DOI 10.1055/s-2002-27815; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6; Dignass AU, 2001, INFLAMM BOWEL DIS, V7, P68, DOI 10.1097/00054725-200102000-00014; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Farrell RJ, 2002, GASTROENTEROL CLIN N, V31, P41, DOI 10.1016/S0889-8553(01)00004-8; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; INAN MS, 2000, LIVER PHYSL, V279, pG1282; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Kitajima S, 1999, EXP ANIM TOKYO, V48, P137, DOI 10.1538/expanim.48.137; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Kojima K, 2003, GASTROENTEROLOGY, V124, P1395, DOI 10.1016/S0016-5085(03)00215-4; Li M, 2001, J IMMUNOL, V166, P7128, DOI 10.4049/jimmunol.166.12.7128; Lin ZQ, 2003, J LEUKOCYTE BIOL, V73, P713, DOI 10.1189/jlb.0802397; Malago JJ, 2002, CELL STRESS CHAPERON, V7, P191, DOI 10.1379/1466-1268(2002)007<0191:THSRAC>2.0.CO;2; Mashimo H, 1996, SCIENCE, V274, P262, DOI 10.1126/science.274.5285.262; MIDVEDT T, 1999, PROBIOTICS OTHER NUT, P79; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Neta, 1996, Semin Radiat Oncol, V6, P306, DOI 10.1016/S1053-4296(96)80026-9; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ortega-Cava CF, 2003, J IMMUNOL, V170, P3977, DOI 10.4049/jimmunol.170.8.3977; Podolsky DK, 1999, AM J PHYSIOL-GASTR L, V277, pG495, DOI 10.1152/ajpgi.1999.277.3.G495; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Putnins EE, 2002, INFECT IMMUN, V70, P6541, DOI 10.1128/IAI.70.12.6541-6548.2002; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Sanaie AR, 2002, J PERIODONTAL RES, V37, P66, DOI 10.1034/j.1600-0765.2002.t01-1-90770.x; Sansonetti P, 2002, GUT, V50, P2; Sartor R, 2000, INFLAMM BOWEL DIS, P153; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Siegel V, 2001, DEV CELL, V1, P1, DOI 10.1016/S1534-5807(01)00021-1; Sivakumar PV, 2002, GUT, V50, P812, DOI 10.1136/gut.50.6.812; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Sugiyama A, 1996, INFECT IMMUN, V64, P1426, DOI 10.1128/IAI.64.4.1426-1431.1996; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tamai H, 2002, ALCOHOL CLIN EXP RES, V26, p75S, DOI 10.1097/01.ALC.0000026981.32386.FD; Tebbutt NC, 2002, NAT MED, V8, P1089, DOI 10.1038/nm763; UELAND JM, 2003, AM J PHYSIOL-RENAL, V3, pF581; van Tol EAF, 1999, AM J PHYSIOL-GASTR L, V277, pG245, DOI 10.1152/ajpgi.1999.277.1.G245; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Waxman AB, 2003, AM J RESP CELL MOL, V29, P513, DOI 10.1165/rcmb.2002-0044OC; YOO J, 2002, GASTROINTESTINAL MUC, P14; Yoshioka T, 2001, J INT MED RES, V29, P409, DOI 10.1177/147323000102900505; Zheng M, 2002, P NATL ACAD SCI USA, V99, P8944, DOI 10.1073/pnas.132605599	60	3065	3278	8	406	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					229	241		10.1016/j.cell.2004.07.002	http://dx.doi.org/10.1016/j.cell.2004.07.002			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260992	Bronze			2022-12-28	WOS:000222966000011
J	Bailey, C; Pang, T				Bailey, C; Pang, T			Health information for all by 2015?	LANCET			English	Editorial Material									WHO, CH-1211 Geneva 27, Switzerland	World Health Organization	Bailey, C (corresponding author), WHO, CH-1211 Geneva 27, Switzerland.	baileych@who.int						Aronson B, 2004, NEW ENGL J MED, V350, P966, DOI 10.1056/NEJMp048009; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Page J, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-6; Russell J, 2004, BRIT MED J, V328, P1174, DOI 10.1136/bmj.328.7449.1174; SIMPSON AJ, GENOMICS BRAZIL; *WHO, 2004, SHAR RES KNOWL; World Health Organization, 1989, CONST; 1974, DAEDALUS, V103, P105	8	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					223	224		10.1016/S0140-6736(04)16686-5	http://dx.doi.org/10.1016/S0140-6736(04)16686-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262080				2022-12-28	WOS:000222784900003
J	Gray, N				Gray, N			The future of the cigarette and its market	LANCET			English	Editorial Material							SMOKING		Int Agcy Res Canc, Directors Off, F-69008 Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC)	Gray, N (corresponding author), Int Agcy Res Canc, Directors Off, F-69008 Lyon, France.	nigel@uicc.org						Borland R, 2004, ADDICTION, V99, P529, DOI 10.1111/j.1360-0443.2004.00649.x; Borland R, 2003, TOB CONTROL, V12, P374, DOI 10.1136/tc.12.4.374; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; Gray N, 2000, TOB CONTROL, V9, P90, DOI 10.1136/tc.9.1.90; Gray N, 2003, ANN ONCOL, V14, P353, DOI 10.1093/annonc/mdg103; GRAY N, IN PRESS NICOTINE TO; Henningfield JE, 1998, TOB CONTROL, V7, P281, DOI 10.1136/tc.7.3.281; Jarvis MJ, 2001, JNCI-J NATL CANCER I, V93, P134, DOI 10.1093/jnci/93.2.134; Kozlowski LT, 2002, TOB CONTROL, V11, pI40, DOI 10.1136/tc.11.suppl_1.i40; Kozlowski LT, 2000, LANCET, V355, P2159, DOI 10.1016/S0140-6736(00)02390-4; Laugesen M, 2003, TOB CONTROL, V12, P406, DOI 10.1136/tc.12.4.406; Peto R, 1996, BRIT MED BULL, V52, P12, DOI 10.1093/oxfordjournals.bmb.a011519; *US PHS, 1996, FTC METH DET TAR NIC	13	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					231	232		10.1016/S0140-6736(04)16692-0	http://dx.doi.org/10.1016/S0140-6736(04)16692-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262086				2022-12-28	WOS:000222784900009
J	Stoessl, AJ; de la Fuente-Fernandez, R				Stoessl, AJ; de la Fuente-Fernandez, R			Willing oneself better on placebo-effective in its own right	LANCET			English	Editorial Material							PARKINSONS-DISEASE; DOPAMINE RELEASE; EXPECTATION; TRANSPLANTATION; MECHANISM; ANALGESIA; NEURONS; SURGERY; MOTOR; TRIAL		Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 2B5, Canada; Hosp Arquitecto Marcide, Div Neurol, Ferrol, Spain	University of British Columbia; Complejo Hospitalario Universitario de Ferrol	Stoessl, AJ (corresponding author), Univ British Columbia, Pacific Parkinsons Res Ctr, Vancouver, BC V6T 2B5, Canada.	jstoessl@interchange.ubc.ca	Stoessl, A Jon/J-9661-2015	Stoessl, A Jon/0000-0002-9778-7246				Benedetti F, 2004, NAT NEUROSCI, V7, P587, DOI 10.1038/nn1250; Benedetti F, 2003, J NEUROSCI, V23, P4315; Clark PA, 2002, J LAW MED ETHICS, V30, P58, DOI 10.1111/j.1748-720X.2002.tb00720.x; de la Fuente-Fernandez R, 2004, PARKINSONISM RELAT D, V10, P125, DOI 10.1016/j.parkreldis.2003.10.003; de la Fuente-Fernandez R, 2002, BEHAV BRAIN RES, V136, P359, DOI 10.1016/S0166-4328(02)00130-4; de la Fuente-Fernandez R, 2001, SCIENCE, V293, P1164, DOI 10.1126/science.1060937; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Goetz CG, 2002, MOVEMENT DISORD, V17, P283, DOI 10.1002/mds.10024; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Kirsch I, 2004, PSYCHOL BULL, V130, P341, DOI 10.1037/0033-2909.130.2.341; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; Mayberg HS, 2002, AM J PSYCHIAT, V159, P728, DOI 10.1176/appi.ajp.159.5.728; McRae C, 2004, ARCH GEN PSYCHIAT, V61, P412, DOI 10.1001/archpsyc.61.4.412; Olanow CW, 2003, ANN NEUROL, V54, P403, DOI 10.1002/ana.10720; Petrovic P, 2002, SCIENCE, V295, P1737, DOI 10.1126/science.1067176; Wager TD, 2004, SCIENCE, V303, P1162, DOI 10.1126/science.1093065; Watts RL, 2001, PARKINSONISM RELAT D, V7, pS87; Weijer C, 2002, J LAW MED ETHICS, V30, P69, DOI 10.1111/j.1748-720X.2002.tb00721.x	18	18	18	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					227	228		10.1016/S0140-6736(04)16689-0	http://dx.doi.org/10.1016/S0140-6736(04)16689-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262083				2022-12-28	WOS:000222784900006
J	Feely, RA; Sabine, CL; Lee, K; Berelson, W; Kleypas, J; Fabry, VJ; Millero, FJ				Feely, RA; Sabine, CL; Lee, K; Berelson, W; Kleypas, J; Fabry, VJ; Millero, FJ			Impact of anthropogenic CO2 on the CaCO3 system in the oceans	SCIENCE			English	Article							CALCIUM-CARBONATE; INORGANIC CARBON; ATLANTIC-OCEAN; PACIFIC-OCEAN; CALCIFICATION; FLUXES; DISSOLUTION; DIOXIDE; PARTICLES; CHEMISTRY	Rising atmospheric carbon dioxide (CO2) concentrations over the past two centuries have led to greater CO2 uptake by the oceans. This acidification process has changed the saturation state of the oceans with respect to calcium carbonate (CaCO3) particles. Here we estimate the in situ CaCO3 dissolution rates for the global oceans from total alkalinity and chlorofluorocarbon data, and we also discuss the future impacts of anthropogenic CO2 on CaCO3 shell forming species. CaCO3 dissolution rates, ranging from 0.003 to 1.2 micromoles per kilogram per year, are observed beginning near the aragonite saturation horizon. The total water column CaCO3 dissolution rate for the global oceans is approximately 0.5 +/- 0.2 petagrams of CaCO3-C per year, which is approximately 45 to 65% of the export production of CaCO3.	NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; Pohang Univ Sci & Technol, Sch Environm Sci & Engn, Pohang 790784, South Korea; Univ So Calif, Dept Earth Sci, Los Angeles, CA 90089 USA; Natl Ctr Atmospher Res, Environm & Soc Impacts Grp, Boulder, CO 80307 USA; Calif State Univ San Marcos, Dept Biol Sci, San Marcos, CA USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Pohang University of Science & Technology (POSTECH); University of Southern California; National Center Atmospheric Research (NCAR) - USA; California State University System; California State University San Marcos; University of Miami	Feely, RA (corresponding author), NOAA, Pacific Marine Environm Lab, 7600 Sand Point Way Ne, Seattle, WA 98115 USA.	richard.a.feely@noaa.gov	Lee, Kitack/G-7184-2015; Feely, Richard A./ABI-5740-2020	Lee, Kitack/0000-0002-4226-2303				ANDERSON LA, 1994, GLOBAL BIOGEOCHEM CY, V8, P65, DOI 10.1029/93GB03318; ARCHER D, 1994, NATURE, V367, P260, DOI 10.1038/367260a0; Armstrong RA, 2001, DEEP-SEA RES PT II, V49, P219, DOI 10.1016/S0967-0645(01)00101-1; Barker S, 2002, SCIENCE, V297, P833, DOI 10.1126/science.1072815; BETZER PR, 1984, SCIENCE, V226, P1074, DOI 10.1126/science.226.4678.1074; Brewer PG, 1997, GEOPHYS RES LETT, V24, P1367, DOI 10.1029/97GL01179; Broecker W.S., 1982, TRACERS SEA; BROECKER WS, 1979, SCIENCE, V206, P409, DOI 10.1126/science.206.4417.409; BROECKER WS, 1977, FATE FOSSIL CO2 OCEA, P207; BROECKER WS, 2003, TREATISE GEOCHEMISTR, V6, P1; Caldeira K, 2003, NATURE, V425, P365, DOI 10.1038/425365a; Catubig NR, 1998, PALEOCEANOGRAPHY, V13, P298, DOI 10.1029/98PA00609; Chung SN, 2004, LIMNOL OCEANOGR, V49, P315, DOI 10.4319/lo.2004.49.2.0315; Chung SN, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2002GB002001; FABRY VJ, 1991, DEEP-SEA RES, V38, P713, DOI 10.1016/0198-0149(91)90008-4; Feely RA, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001866; Gruber N, 2004, SCOPE SER, V62, P45; HONJO S, 1995, DEEP-SEA RES PT II, V42, P831, DOI 10.1016/0967-0645(95)00034-N; Iglesias-Rodriguez MD., 2002, EOS T AM GEOPHYS UN, V83, P365, DOI [10.1029/2002EO000267, DOI 10.1029/2002EO000267]; KANAMORI S, 1982, Journal of the Oceanographical Society of Japan, V38, P57, DOI 10.1007/BF02110291; Kawahata H, 2000, DEEP-SEA RES PT I, V47, P2061, DOI 10.1016/S0967-0637(00)00025-X; Kleypas JA, 1999, SCIENCE, V284, P118, DOI 10.1126/science.284.5411.118; Langdon C, 2000, GLOBAL BIOGEOCHEM CY, V14, P639, DOI 10.1029/1999GB001195; Lee K, 2001, LIMNOL OCEANOGR, V46, P1287, DOI 10.4319/lo.2001.46.6.1287; Lowenstam HA, 1989, BIOMINERALIZATION; Marubini F, 1999, LIMNOL OCEANOGR, V44, P716, DOI 10.4319/lo.1999.44.3.0716; Marubini F, 2001, MAR ECOL PROG SER, V220, P153, DOI 10.3354/meps220153; MILLERO FJ, 1995, GEOCHIM COSMOCHIM AC, V59, P661, DOI 10.1016/0016-7037(94)00354-O; Milliman JD, 1999, DEEP-SEA RES PT I, V46, P1653, DOI 10.1016/S0967-0637(99)00034-5; Milliman JD, 1996, GEOL RUNDSCH, V85, P496, DOI 10.1007/s005310050090; MILLIMAN JD, 1993, GLOBAL BIOGEOCHEM CY, V7, P927, DOI 10.1029/93GB02524; MUCCI A, 1983, AM J SCI, V283, P780, DOI 10.2475/ajs.283.7.780; NORIKI S, 1999, J OCEANOGR, V55, P693; PESTANA H, 1985, J SEDIMENT PETROL, V55, P184; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; Reynaud S, 2003, GLOBAL CHANGE BIOL, V9, P1660, DOI 10.1046/j.1365-2486.2003.00678.x; Ridgwell AJ, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2003GC000512; Riebesell U, 2000, NATURE, V407, P364, DOI 10.1038/35030078; Rodier M, 1997, DEEP-SEA RES PT II, V44, P2085, DOI 10.1016/S0967-0645(97)00092-1; Sabine CL, 2004, SCOPE SER, V62, P17; Sabine CL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001869; Schiebel R, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001459; Sciandra A, 2003, MAR ECOL PROG SER, V261, P111, DOI 10.3354/meps261111; SEIBEL BA, 2003, CLIMATE CHANGE BIODI, P59; Simkiss K., 1989, BIOMINERALIZATION; Spero HJ, 1997, NATURE, V390, P497, DOI 10.1038/37333; SPINDLER M, 1980, NEUES JB GEOL PAL, V9, P659; Takahashi T, 2002, DEEP-SEA RES PT II, V49, P1601, DOI 10.1016/S0967-0645(02)00003-6; TSUNOGAI S, 1991, TELLUS B, V43, P256, DOI 10.1034/j.1600-0889.1991.00018.x; Wong CS, 1999, DEEP-SEA RES PT II, V46, P2735, DOI 10.1016/S0967-0645(99)00082-X; Zondervan I, 2001, GLOBAL BIOGEOCHEM CY, V15, P507, DOI 10.1029/2000GB001321	51	1530	1617	26	1188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					362	366		10.1126/science.1097329	http://dx.doi.org/10.1126/science.1097329			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256664				2022-12-28	WOS:000222662400029
J	Schwartz, RS				Schwartz, RS			"Medicine is my lawful wife" - Anton Chekhov, 1860-1904	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	7	7	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					213	214		10.1056/NEJMp048130	http://dx.doi.org/10.1056/NEJMp048130			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254280				2022-12-28	WOS:000222627200004
J	Yeni, PG; Hammer, SM; Hirsch, MS; Saag, MS; Schechter, M; Carpenter, CCJ; Fischl, MA; Gatell, JM; Gazzard, BG; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA				Yeni, PG; Hammer, SM; Hirsch, MS; Saag, MS; Schechter, M; Carpenter, CCJ; Fischl, MA; Gatell, JM; Gazzard, BG; Jacobsen, DM; Katzenstein, DA; Montaner, JSG; Richman, DD; Schooley, RT; Thompson, MA; Vella, S; Volberding, PA			Treatment for adult HIV infection - 2004 recommendations of the International AIDS Society-USA panel	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; STRUCTURED TREATMENT INTERRUPTION; SEQUENTIAL 3-DRUG REGIMENS; CD4(+) CELL COUNT; PROGNOSTIC IMPORTANCE; COMBINATION THERAPY; LOPINAVIR-RITONAVIR; PROTEASE-INHIBITOR; INITIAL TREATMENT	Context Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection. Objective To update recommendations for physicians who provide HIV care regarding when to start antiretroviral therapy, what drugs to start with, when to change drug regimens, and what drug regimens to switch to after therapy fails. DataSources Evidence was identified and reviewed by a 16-member noncompensated panel of physicians with expertise in HIV-related basic science and clinical research, antiretroviral therapy, and HIV patient care. The panel was designed to have broad US and international representation for areas with adequate access to antiretroviral management. Study Selection Evidence considered included published basic science, clinical research, and epidemiological data (identified by experts in the field or extracted through MEDLINE searches using terms relevant to antiretroviral therapy) and abstracts from HIV-oriented scientific conferences between July 2002 and May 2004. DataExtraction Data were reviewed to identify any information that might change previous guidelines. Based on panel; discussion, guidelines were drafted by a writing committee and discussed by the panel until consensus was reached. Data Synthesis Four antiretroviral drugs recently have been made available and have broadened the options for initial and subsequent regimens. New data allow more definitive recommendations for specific drugs or regimens to include or avoid, particularly with regard to initial therapy. Recommendations are rated according to 7 evidence categories, ranging from I (data from prospective randomized clinical trials) to VII (expert opinion of the panel). Conclusion Further insights into the roles of drug toxic effects, drug resistance, and pharmacological interactions have resulted in additional guidance for strategic approaches to antiretroviral management.	Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, F-75877 Paris 18, France; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY USA; Harvard Univ, Sch Med, Dept Immunol & Infect Dis, Boston, MA USA; Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; Univ Fed Rio de Janeiro, Dept Prevent Med, Rio De Janeiro, Brazil; Brown Univ, Sch Med, Dept Biomed, Providence, RI 02912 USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA; Univ Barcelona, Dept Med, Barcelona, Spain; Chelsea & Westminster Hosp, Dept HIV Med, London, England; Int AIDS Soc USA, San Francisco, CA USA; Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; San Diego VA Healthcare Syst, San Diego, CA USA; Univ Colorado, Sch Med, Dept Med, Denver, CO USA; AIDS Res Consortium Atlanta, Atlanta, GA USA; Ist Super Sanita, I-00161 Rome, Italy; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; San Francisco VA Med Ctr, San Francisco, CA USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Columbia University; Harvard University; Harvard Medical School; University of Alabama System; University of Alabama Birmingham; Universidade Federal do Rio de Janeiro; Brown University; University of Miami; University of Barcelona; Imperial College London; Stanford University; University of British Columbia; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Istituto Superiore di Sanita (ISS); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yeni, PG (corresponding author), Hop Bichat Claude Bernard, X Bichat Med Sch, Dept Infect Dis, 46 Rue Henri Huchard, F-75877 Paris 18, France.	Patrick.Yeni@Bch.Ap-Hop-Paris.Fr	Montaner, Julio/K-7621-2012; Schechter, Mauro/AAG-7445-2020; VELLA, STEFANO/ABI-3368-2020; Vella, Stefano/GZM-0519-2022; VELLA, STEFANO/V-8440-2019	VELLA, STEFANO/0000-0003-2347-5984; katzenstein, david/0000-0002-8593-4560				Anastos K, 2004, ANN INTERN MED, V140, P256, DOI 10.7326/0003-4819-140-4-200402170-00007; Badri M, 2002, LANCET, V359, P2059, DOI 10.1016/S0140-6736(02)08904-3; BARTLETT JA, 2002, 14 INT AIDS C JUL 7; BENSON C, 2004, 11 C RETR OPP INF FE; Bertz R, 2000, AIDS, V14, pS100; CAHN P, 2004, 10 C RETR OPP INF; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Chen RY, 2003, CLIN INFECT DIS, V37, P714, DOI 10.1086/377271; Chene G, 2003, LANCET, V362, P679, DOI 10.1016/S0140-6736(03)14229-8; Cossarizza A, 2004, AIDS, V18, P137, DOI 10.1097/00002030-200401230-00002; de Pinho AMF, 2001, AIDS, V15, P2129, DOI 10.1097/00002030-200111090-00008; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; DEGEN O, 2002, 14 INT AIDS C JUL 7; DEJESUS E, 2003, 10 C RETR OPP INF FE; DEJESUS E, 2004, 11 C RETR OPP INF FE; DEJESUS E, 2003, 43 INT C ANT AG CHEM; *DEP HLTH HUM SERV, 1998, ANN INTERN MED, V128, P1079; *DUP PHARM INC, 2002, SUST PACK INS; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Falloon J, 2000, CLIN INFECT DIS, V30, P313, DOI 10.1086/313667; Ferry JJ, 1998, J ACQ IMMUN DEF SYND, V18, P252, DOI 10.1097/00042560-199807010-00009; Fiske W, 1998, 12 WORLD AIDS C JUN; FISKE WD, 1997, 4 C RETR OPP INF JAN; GALLANT JE, 2003, 43 INT C ANT AG CHEM; GAZZARD BG, 2003, 43 INT C ANT AG CHEM; Gerstoft J, 2003, AIDS, V17, P2045, DOI 10.1097/00002030-200309260-00005; GERSTOFT J, 2002, 42 INT C ANT AG CHEM; *GIL SCI INC, 2003, VIR PACK INS; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Harris M, 1998, J INFECT DIS, V177, P1514, DOI 10.1086/515317; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Hirsch MS, 2003, CLIN INFECT DIS, V37, P113, DOI 10.1086/375597; Hsu A, 2003, ANTIMICROB AGENTS CH, V47, P350, DOI 10.1128/AAC.47.1.350-359.2003; JEMSEK J, 2004, 11 C RETR OPP INF FE; JOURDAIN G, 2004, 11 C RETR OPP INF FE; Katlama C, 2004, AIDS, V18, P217, DOI 10.1097/00002030-200401230-00011; KEARNEY B, 2001, 1 INT AIDS SOC C HIV; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LANDMAN R, 2004, 11 C RETR OPP INF FE; Lawrence J, 2003, NEW ENGL J MED, V349, P837, DOI 10.1056/NEJMoa035103; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Lichtenstein KA, 2003, JAIDS-J ACQ IMM DEF, V32, P48, DOI 10.1097/00126334-200301010-00007; Lopez-Cortes LF, 2003, JAIDS-J ACQ IMM DEF, V32, P240, DOI 10.1097/00126334-200302010-00019; LYONS F, 2004, 11 C RETR OPP INF FE; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Martin A, 2004, AIDS, V18, P1029, DOI 10.1097/00002030-200404300-00011; Martinez E, 2003, NEW ENGL J MED, V349, P1036, DOI 10.1056/NEJMoa021589; MARTINEZ E, IN PRESS LANCET; MELLORS J, 2004, 11 C RETR OPP INF FE; MONTANER J, 2003, 2 INT AIDS SOC C HIV; MONTANER JSG, 42 INT C ANT AG CHEM; Moyle G, 2000, J ACQ IMMUN DEF SYND, V23, P128; MURO E, 2004, 11 C RETR OPP INF FE; Murphy RL, 2003, AIDS, V17, P2603, DOI 10.1097/00002030-200312050-00007; NADLER J, 2003, 10 C RETR OPP INF FE; NEGREDO E, 2004, 11 C RETR OPP INF FE; NEGREDO E, 2002, 14 INT AIDS C JUL 7; NIETOCISNEROS L, 2003, 2 INT AIDS SOC C HIV; Palella FJ, 2003, ANN INTERN MED, V138, P620, DOI 10.7326/0003-4819-138-8-200304150-00007; PALMER S, 2004, 11 C RETR OPP INF FE; PALMISANO L, 2004, 11 C RETR OPP INF FE; Podzamczer D, 2002, ANTIVIR THER, V7, P81; Robbins GK, 2003, NEW ENGL J MED, V349, P2293, DOI 10.1056/NEJMoa030264; *ROX LAB INC, 2000, VIR PACK INS; Ruiz L, 2003, J INFECT DIS, V188, P977, DOI 10.1086/378411; SAAG M, 2002, 42 INT C ANT AG CHEM; Saag MS, 2002, TOPICS HIV MED, V10, P47; Schambelan M, 2002, JAIDS-J ACQ IMM DEF, V31, P257, DOI 10.1097/00126334-200211010-00001; SCHURMANN D, 2002, 6 INT C DRUG THER HI; Shafer RW, 2003, NEW ENGL J MED, V349, P2304, DOI 10.1056/NEJMoa030265; SQUIRES KE, 2002, 42 INT C ANT AG CHEM; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; STASZEWSKI S, 2002, 14 INT AIDS C JUL 7; Sterling TR, 2003, J INFECT DIS, V188, P1659, DOI 10.1086/379741; TABURET AM, 2003, 10 C RETR OPP INF FE; TAYLOR S, 2004, 11 C RETR OPP INF FE; Tran JQ, 2002, CLIN PHARMACOL THER, V72, P615, DOI 10.1067/mcp.2002.128868; van Leeuwen R, 2003, AIDS, V17, P987, DOI 10.1097/00002030-200305020-00007; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; VELDKAMP AI, 2000, 7 C RETR OPP INF JAN; Walmsley S, 2002, NEW ENGL J MED, V346, P2039, DOI 10.1056/NEJMoa012354; *WHO GUID, 2002, SCAL ANT THER RES LI; Wood E, 2003, ANN INTERN MED, V139, P810, DOI 10.7326/0003-4819-139-10-200311180-00008; Wood E, 2003, J INFECT DIS, V188, P1421, DOI 10.1086/379201; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222	88	439	471	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					251	265		10.1001/jama.292.2.251	http://dx.doi.org/10.1001/jama.292.2.251			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249575				2022-12-28	WOS:000222579300031
J	Gidwani, S; Jagiello, J; Bircher, M				Gidwani, S; Jagiello, J; Bircher, M			Lesson of the week - Avulsion fracture of the ischial tuberosity in adolescents - an easily missed diagnosis	BRITISH MEDICAL JOURNAL			English	Review							HAMSTRING INJURIES; INTERNAL-FIXATION; APOPHYSIS		Univ London St Georges Hosp, Dept Orthopaed & Traumal, London SW17 0QT, England	St Georges University London	Gidwani, S (corresponding author), 122 Durham Rd, London SW20 0DG, England.	samgidwani@yahoo.com						BRANDSER EA, 1995, RADIOLOGY, V197, P257, DOI 10.1148/radiology.197.1.7568833; Hamada G, 1963, Clin Orthop Relat Res, V31, P117; Kujala UM, 1997, SPORTS MED, V23, P397, DOI 10.2165/00007256-199723060-00005; Mattick AP, 1999, J ACCID EMERG MED, V16, P457; Schlonsky J, 1972, J BONE JOINT SURG AM, V7, P615; Servant CTJ, 1998, BRIT J SPORT MED, V32, P255, DOI 10.1136/bjsm.32.3.255; WOOTTON JR, 1990, J BONE JOINT SURG BR, V72, P625	7	43	43	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					99	100		10.1136/bmj.329.7457.99	http://dx.doi.org/10.1136/bmj.329.7457.99			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242916	Green Published			2022-12-28	WOS:000222645000029
J	Lipshultz, SE; Rifai, N; Dalton, VM; Levy, DE; Silverman, LB; Lipsitz, SR; Colan, SD; Asselin, BL; Barr, RD; Clavell, LA; Hurwitz, CA; Moghrabi, A; Samson, Y; Schorin, MA; Gelber, RD; Sallan, SE				Lipshultz, SE; Rifai, N; Dalton, VM; Levy, DE; Silverman, LB; Lipsitz, SR; Colan, SD; Asselin, BL; Barr, RD; Clavell, LA; Hurwitz, CA; Moghrabi, A; Samson, Y; Schorin, MA; Gelber, RD; Sallan, SE			The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC TROPONIN-T; ANTHRACYCLINE CARDIOTOXICITY; CONTINUOUS-INFUSION; 5-YEAR SURVIVORS; CHILDHOOD-CANCER; LATE MORTALITY; HEART-FAILURE; SERUM-LEVELS; PHASE-I; ICRF-187	Background: Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage. Methods: To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin. Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. A total of 2377 serum samples (mean, 15.1 samples per patient) were obtained before, during, and after treatment with doxorubicin. Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated (>0.01 ng per milliliter) -- the primary end point -- or extremely elevated (>0.025 ng per milliliter). Results: Elevations of troponin T occurred in 35 percent of the patients (55 of 158). Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels (50 percent vs. 21 percent, P<0.001) and extremely elevated troponin T levels (32 percent vs. 10 percent, P<0.001). The median follow-up was 2.7 years. The rate of event-free survival at 2.5 years was 83 percent in both groups (P=0.87 by the log-rank test). Conclusions: Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin. Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival.	Univ Miami, Sch Med, Holtz Childrens Hosp,Dept Pediat, Jackson Mem Med Ctr, Miami, FL 33101 USA; Sylvester Comprehens Canc Ctr, Miami, FL USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Biostat Sci, Boston, MA 02115 USA; Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA; Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Med Univ S Carolina, Dept Biometry & Epidemiol, Charleston, SC 29425 USA; McMaster Univ, Dept Pediat, Hamilton, ON, Canada; San Jorge Childrens Hosp, Santurce, PR USA; Barbara Bush Childrens Hosp Maine, Med Ctr, Maine Children Canc Program, Portland, ME USA; Hop St Justine, Montreal, PQ H3T 1C5, Canada; Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; Alton Ochsner Med Fdn & Ochsner Clin, Dept Pediat, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, New Orleans, LA 70112 USA	University of Miami; University of Rochester; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Medical University of South Carolina; McMaster University; Universite de Montreal; Laval University; Ochsner Health System; Tulane University	Lipsitz, SR (corresponding author), Univ Miami, Sch Med, Dept Pediat, D820,POB 016820, Miami, FL 33101 USA.	slipshultz@med.miami.edu	Colan, Steven/ABB-4580-2020; Barr, Ronald Duncan/ABB-2679-2021	Barr, Ronald Duncan/0000-0002-5711-7440	DIVISION OF LUNG DISEASES [N01HR096041] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA079060, P01CA068484, R01CA055576, R29CA055576, P30CA006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053392, R01HL072705] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68484, CA 79060, CA 55576, CA 06516] Funding Source: Medline; NHLBI NIH HHS [HL 53392, HL 59837, HL 72705, HR96041] Funding Source: Medline	DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agresti A., 1990, CATEGORICAL DATA ANA, pXV; BULOCK FA, 1993, BRIT HEART J, V70, P185; Collinson PO, 2003, HEART, V89, P1285, DOI 10.1136/heart.89.11.1285; Cox DR., 1970, ANAL BINARY DATA; GIANNI L, 1985, J BIOL CHEM, V260, P6820; Giantris A, 1998, CRIT REV ONCOL HEMAT, V27, P53, DOI 10.1016/S1040-8428(97)10007-5; Green DM, 2001, J CLIN ONCOL, V19, P1926, DOI 10.1200/JCO.2001.19.7.1926; Green DM, 1999, J CLIN ONCOL, V17, P3207, DOI 10.1200/JCO.1999.17.10.3207; Grenier MA, 1998, SEMIN ONCOL, V25, P72; Hasinoff BB, 1998, CURR MED CHEM, V5, P1; Hasinoff Brian B, 2002, Cardiovasc Toxicol, V2, P111, DOI 10.1385/CT:2:2:111; Hellmann K, 2000, J CLIN ONCOL, V18, P2004, DOI 10.1200/JCO.2000.18.9.2004; Herman EH, 1999, J CLIN ONCOL, V17, P2237, DOI 10.1200/JCO.1999.17.7.2237; Herman EH, 1998, CANCER RES, V58, P195; Herman EH, 2001, CANCER CHEMOTH PHARM, V48, P297, DOI 10.1007/s002800100348; Herman EH, 2003, PATHOL LAB MED, P87; Herman EH, 2001, AM HEART MONOGR S, P211; HOLCENBERG JS, 1986, CANCER TREAT REP, V70, P703; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kremer LCM, 2001, J CLIN ONCOL, V19, P191, DOI 10.1200/JCO.2001.19.1.191; Krischer JP, 1997, J CLIN ONCOL, V15, P1544, DOI 10.1200/JCO.1997.15.4.1544; Lipshultz, 2000, Prog Pediatr Cardiol, V12, P1, DOI 10.1016/S1058-9813(00)00076-X; LIPSHULTZ S, 1999, P AN M AM SOC CLIN, V18, pA568; Lipshultz SE, 1997, CIRCULATION, V96, P2641, DOI 10.1161/01.CIR.96.8.2641; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; Lipshultz SE, 2003, PEDIATRICS, V112, P79, DOI 10.1542/peds.112.1.79; LIPSHULTZ SE, 1994, PEDIATRICS, V93, P433; Lipshultz SE, 2002, J CLIN ONCOL, V20, P1677, DOI 10.1200/JCO.20.6.1677; Lipshultz SE, 2002, J CLIN ONCOL, V20, P4517, DOI 10.1200/JCO.2002.12.102; LIPSHULTZ SE, 1994, PEDIATRICS, V94, P781; Lipshultz SE, 1996, J CLIN ONCOL, V14, P328, DOI 10.1200/JCO.1996.14.2.328; LIPSHULTZ SE, 1995, NEW ENGL J MED, V332, P1738, DOI 10.1056/NEJM199506293322602; Mertens AC, 2001, J CLIN ONCOL, V19, P3163, DOI 10.1200/JCO.2001.19.13.3163; Mladosievicova B, 2001, NEOPLASMA, V48, P61; Moller TR, 2001, J CLIN ONCOL, V19, P3173; Morrow DA, 2001, JAMA-J AM MED ASSOC, V286, P2405, DOI 10.1001/jama.286.19.2405; *NCI, 2002, US NAT CANC I WORKSH; Nysom K, 1998, J CLIN ONCOL, V16, P545, DOI 10.1200/JCO.1998.16.2.545; Nysom K, 1998, PROG PEDIATR CARDIOL, V8, P121, DOI 10.1016/S1058-9813(98)00008-3; Ottlinger ME, 1997, PROG PEDIATR CARDIOL, V8, P71, DOI 10.1016/S1058-9813(98)00004-6; Schiavetti A, 1997, PEDIATR HEMAT ONCOL, V14, P213, DOI 10.3109/08880019709009491; SCHLUCHTER LM, 2002, J CLIN ONCOL, V20, P2895; Schroeder PE, 2002, CANCER CHEMOTH PHARM, V50, P509, DOI 10.1007/s00280-002-0538-z; Schuler D, 1997, PEDIATR HEMAT ONCOL, V14, P93, DOI 10.3109/08880019709030891; Seymour L, 1999, Cancer Prev Control, V3, P145; Silverman LB, 2001, BLOOD, V97, P1211, DOI 10.1182/blood.V97.5.1211; Silverman LB, 2000, LEUKEMIA, V14, P2247, DOI 10.1038/sj.leu.2401980; Simbre II Valeriano C., 2001, Curr Treat Options Cardiovasc Med, V3, P493, DOI 10.1007/s11936-001-0023-8; SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203; Swain SM, 1998, SEMIN ONCOL, V25, P43; Tetef ML, 2001, CLIN CANCER RES, V7, P1569; VATS T, 1991, INVEST NEW DRUG, V9, P333; Wexler LH, 1996, J CLIN ONCOL, V14, P362, DOI 10.1200/JCO.1996.14.2.362	53	424	448	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					145	153		10.1056/NEJMoa035153	http://dx.doi.org/10.1056/NEJMoa035153			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247354	Bronze			2022-12-28	WOS:000222470700007
J	Steinberger, B; Sutherland, R; O'Connell, RJ				Steinberger, B; Sutherland, R; O'Connell, RJ			Prediction of Emperor-Hawaii seamount locations from a revised model of global plate motion and mantle flow	NATURE			English	Article							NEW-ZEALAND REGION; ANTARCTIC PENINSULA; SOUTHWEST PACIFIC; ETHIOPIAN TRAPS; EARTHS MANTLE; FRACTURE-ZONE; TASMAN SEA; PLUMES; RIDGE; CONSTRAINTS	The bend in the Hawaiian-Emperor seamount chain is a prominent feature usually attributed to a change in Pacific plate motion similar to47 Myr ago. However, global plate motion reconstructions fail to predict the bend. Here we show how the geometry of the Hawaiian-Emperor chain and other hotspot tracks can be explained when we combine global plate motions with intraplate deformation and movement of hotspot plumes through distortion by global mantle flow. Global mantle flow models predict a southward motion of the Hawaiian hotspot. This, in combination with a plate motion reconstruction connecting Pacific and African plates through Antarctica, predicts the Hawaiian track correctly since the date of the bend, but predicts the chain to be too far west before it. But if a reconstruction through Australia and Lord Howe rise is used instead, the track is predicted correctly back to 65Myr ago, including the bend. The difference between the two predictions indicates the effect of intraplate deformation not yet recognized or else not recorded on the ocean floor. The remaining misfit before 65 Myr ago can be attributed to additional intraplate deformation of similar magnitude.	Japan Marine Sci & Technol Ctr, Inst Frontier Res Earth Evolut, Yokosuka, Kanagawa 2370061, Japan; Inst Geol & Nucl Sci, Lower Hutt, New Zealand; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA	Japan Agency for Marine-Earth Science & Technology (JAMSTEC); GNS Science - New Zealand; Harvard University	Steinberger, B (corresponding author), Univ Bayreuth, Bayer Geoinst, POB 101251, D-95440 Bayreuth, Germany.	bernhard.steinberger@uni-bayreuth.de	Sutherland, Rupert/G-5092-2012; Sutherland, Rupert/Y-9290-2019; Steinberger, Bernhard/ABB-9204-2021; Steinberger, Bernhard/AAG-7148-2019	Sutherland, Rupert/0000-0001-7430-0055; Steinberger, Bernhard/0000-0002-3643-3049				Antretter M, 2004, GEOL SOC SPEC PUBL, V229, P21, DOI 10.1144/GSL.SP.2004.229.01.03; BEHRENDT JC, 1991, TECTONICS, V10, P1257, DOI 10.1029/91TC00868; Besse J, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000050; Cande SC, 2000, NATURE, V404, P145, DOI 10.1038/35004501; CANDE SC, 1995, SCIENCE, V270, P947, DOI 10.1126/science.270.5238.947; Clague D.A., 1989, GEOLOGY N AM VOLUME, P188; Cook R. A., 1999, I GEOLOGICAL NUCL SC, V20; COOPER AK, 1995, ANTARCTIC RES SERIES, V68; Coulie E, 2003, EARTH PLANET SC LETT, V206, P477, DOI 10.1016/S0012-821X(02)01089-0; Courtillot V, 2003, EARTH PLANET SC LETT, V205, P295, DOI 10.1016/S0012-821X(02)01048-8; Courtillot VE, 2003, CR GEOSCI, V335, P113, DOI 10.1016/S1631-0713(03)00006-3; Dick HJB, 2003, NATURE, V426, P405, DOI 10.1038/nature02128; Duncan R.A., 1990, P ODP SCI RESULTS, V115, P43, DOI DOI 10.2973/ODP.PROC.SR.115.141.1990; Ebinger CJ, 1998, NATURE, V395, P788, DOI 10.1038/27417; Gaina C, 1998, J GEOPHYS RES-SOL EA, V103, P12413, DOI 10.1029/98JB00386; Hall CE, 2003, EARTH PLANET SC LETT, V212, P15, DOI 10.1016/S0012-821X(03)00242-5; Heinemann J, 1999, J GEOPHYS RES-SOL EA, V104, P25321, DOI 10.1029/1998JB900079; Hofmann C, 2000, EARTH PLANET SC LETT, V180, P13, DOI 10.1016/S0012-821X(00)00159-X; Hofmann C, 1997, NATURE, V389, P838, DOI 10.1038/39853; King PR, 1996, I GEOLOGICAL NUCL SC; Koppers AAP, 2004, GEOCHEM GEOPHY GEOSY, V5, DOI 10.1029/2003GC000671; Laird MG., 1993, SED BAS WOR, P37; Marks KM, 1997, EARTH PLANET SC LETT, V152, P267, DOI 10.1016/S0012-821X(97)00139-8; McCarron JJ, 1998, J GEOL SOC LONDON, V155, P255, DOI 10.1144/gsjgs.155.2.0255; MOLNAR P, 1987, NATURE, V327, P587, DOI 10.1038/327587a0; MOLNAR P, 1988, NATURE, V335, P131, DOI 10.1038/335131a0; MORGAN WJ, 1972, AM ASSOC PETR GEOL B, V56, P203; Nankivell A. P., 1997, THESIS U OXFORD; OCONNOR JM, 1992, EARTH PLANET SC LETT, V113, P343, DOI 10.1016/0012-821X(92)90138-L; OCONNOR JM, 1990, J GEOPHYS RES-SOLID, V95, P17475, DOI 10.1029/JB095iB11p17475; Raymond C. A., 2000, GEOPHYS MONOGR SER, V121, P359; Rochette P, 1998, EARTH PLANET SC LETT, V164, P497, DOI 10.1016/S0012-821X(98)00241-6; Sandwell DT, 1997, J GEOPHYS RES-SOL EA, V102, P10039, DOI 10.1029/96JB03223; SHARP WD, 2002, EOS S, V83; Sleep NH, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2001GC000290; Steinberger B, 2002, GEOCHEM GEOPHY GEOSY, V3, DOI 10.1029/2002GC000334; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; Steinberger B, 2000, J GEOPHYS RES-SOL EA, V105, P11127, DOI 10.1029/1999JB900398; STEINBERGER B, 2000, GEOPHYS MONOGR SER, V121, P377; STOCK J, 1987, NATURE, V325, P495, DOI 10.1038/325495a0; STOREY BC, 1988, J GEOL SOC LONDON, V145, P333, DOI 10.1144/gsjgs.145.2.0333; SUTHERLAND R, 1995, TECTONICS, V14, P819, DOI 10.1029/95TC00930; Sutherland R, 1999, TECTONOPHYSICS, V308, P341, DOI 10.1016/S0040-1951(99)00108-0; Tarduno JA, 2003, SCIENCE, V301, P1064, DOI 10.1126/science.1086442; Tikku AA, 2000, EARTH PLANET SC LETT, V180, P117, DOI 10.1016/S0012-821X(00)00157-6; VINK GE, 1984, J GEOPHYS RES, V89, P9949, DOI 10.1029/JB089iB12p09949; WATTS AB, 1988, J GEOPHYS RES-SOLID, V93, P3051, DOI 10.1029/JB093iB04p03051; Wessel P, 1991, EOS T AM GEOPHYS UN, V72, P445, DOI [10.1029/90EO00319, DOI 10.1029/90EO00319, DOI 10.1029/90E000319]; Wood R, 1996, TECTONICS, V15, P966, DOI 10.1029/96TC00129; Zatman S, 2001, GEOPHYS J INT, V145, P145, DOI 10.1111/j.1365-246X.2001.00357.x	50	265	282	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					167	173		10.1038/nature02660	http://dx.doi.org/10.1038/nature02660			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241405				2022-12-28	WOS:000222470600034
J	Ferguson, JJ; Califf, RM; Antman, EM; Cohen, M; Grines, CL; Goodman, S; Kereiakes, DJ; Mahaffey, KW; Langer, A; Nessel, CC; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Col, J; Frey, MJ; Fry, E; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kleiman, NS; Leon, MB; Lopez-Sendon, JL; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H				Ferguson, JJ; Califf, RM; Antman, EM; Cohen, M; Grines, CL; Goodman, S; Kereiakes, DJ; Mahaffey, KW; Langer, A; Nessel, CC; Armstrong, PW; Avezum, A; Aylward, P; Becker, RC; Biasucci, L; Borzak, S; Col, J; Frey, MJ; Fry, E; Gulba, DC; Guneri, S; Gurfinkel, E; Harrington, R; Hochman, JS; Kleiman, NS; Leon, MB; Lopez-Sendon, JL; Pepine, CJ; Ruzyllo, W; Steinhubl, SR; Teirstein, PS; Toro-Figueroa, L; White, H		SYNERGY Trial Investigators	Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy - Primary results of the SYNERGY randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLATELET GLYCOPROTEIN IIB/IIIA; WAVE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; ARTERY-DISEASE; UNSTABLE ANGINA; TASK-FORCE; TIROFIBAN; INHIBITION; EFFICACY; THERAPY	Context Enoxaparin has demonstrated advantages over unfractionated heparin in low- to moderate-risk patients with non-ST-segment elevation acute coronary syndromes (ACS) treated with a conservative strategy. Objectives To compare the outcomes of patients treated with enoxaparin vs unfractionated heparin and to define the role of enoxaparin in patients with non-ST-segment elevation ACS at high risk for ischemic cardiac complications managed with an early invasive approach. Design, Setting, and Participants The Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial was a prospective, randomized, open-label, multicenter, international trial conducted between August 2001 and December 2003. A total of 10027 high-risk patients with non-ST-segment elevation ACS to be treated with an intended early invasive strategy were recruited. Interventions Subcutaneous enoxaparin (n=4993) or intravenous unfractionated heparin (n=4985) was to be administered immediately after enrollment and continued until the patient required no further anticoagulation, as judged by the treating physician. Main Outcome Measures The primary efficacy outcome was the composite clinical end point of all-cause death or nonfatal myocardial infarction during the first 30 days after randomization. The primary safety outcome was major bleeding or stroke. Results The primary end point occurred in 14.0% (696/4993) of patients assigned to enoxaparin and 14.5% (722/4985) of patients assigned to unfractionated heparin (odds ratio [OR], 0.96; 95% confidence interval [CI], 0.86-1.06). No differences in ischemic events during percutaneous coronary intervention (PCI) were observed between enoxaparin and unfractionated heparin groups, respectively, including similar rates of abrupt closure (31/2321 [1.3%] vs 40/2364 [1.7%]), threatened abrupt closure (25/2321 [1.1%] vs 24/2363 [1.0%]), unsuccessful PC] (81/2281 [3.6%] vs 79/2328 [3.4%1), or emergency coronary artery bypass graft surgery (6/2323 [0.3%] vs 8/2363 [0.3%]). More bleeding was observed with enoxaparin, with a statistically significant increase in TIMI (Thrombolysis in Myocardial Infarction) major bleeding (9.1% vs 7.6%, P = .008) but nonsignificant excess in GUSTO (Global Utilization of Streptokinase and t-PA for Occluded Arteries) severe bleeding (2.7% vs 2.2%, P = .08) and transfusions (17.0% vs 16.0%, P = .16). Conclusions Enoxaparin was not superior to unfractionated heparin but was noninferior for the treatment of high-risk patients with non-ST-segment elevation ACS. Enoxaparin is a safe and effective alternative to unfractionated heparin and the advantages of convenience should be balanced with the modest excess of major bleeding.	Duke Clin Res Inst, Dept Med, Div Cardiol, Durham, NC 27715 USA	Duke University	Mahaffey, KW (corresponding author), Duke Clin Res Inst, Dept Med, Div Cardiol, 2400 Pratt St, Durham, NC 27715 USA.		Avezum, Alvaro/AAP-7687-2020; Fry, Edward/AAP-7004-2021; Avezum, Alvaro AA/K-6137-2016	Avezum, Alvaro AA/0000-0002-3073-6890; biasucci, luigi m/0000-0002-6921-6497; Hochman, Judith/0000-0002-5889-5981; Armstrong, Paul/0000-0002-0460-3445				Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Antman EM, 1999, CIRCULATION, V100, P1602, DOI 10.1161/01.CIR.100.15.1602; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bertrand ME, 2000, EUR HEART J, V21, P1406, DOI 10.1053/euhj.2000.2301; Blazing MA, 2004, JAMA-J AM MED ASSOC, V292, P55, DOI 10.1001/jama.292.1.55; Braunwald E, 2002, CIRCULATION, V106, P1893, DOI 10.1161/01.CIR.0000037106.76139.53; Cannon CP, 2001, NEW ENGL J MED, V344, P1879, DOI 10.1056/NEJM200106213442501; Choo JK, 2001, J THROMB THROMBOLYS, V11, P235, DOI 10.1023/A:1011917021686; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Cohen M, 2002, AM HEART J, V144, P470, DOI 10.1067/mhj.2002.126115; Ferguson JJ, 2003, AM HEART J, V146, P628, DOI 10.1016/S0002-8703(03)00165-0; Ferguson JJ, 2002, AM HEART J, V143, P952, DOI 10.1067/mhj.2002.122120; Goodman SG, 2003, CIRCULATION, V107, P238, DOI 10.1161/01.CIR.0000050144.67910.13; Goodman SG, 2000, J AM COLL CARDIOL, V36, P693, DOI 10.1016/S0735-1097(00)00808-1; Petersen JL, 2004, JAMA-J AM MED ASSOC, V292, P89, DOI 10.1001/jama.292.1.89; Pieper KS, 2004, CIRCULATION, V109, P641, DOI 10.1161/01.CIR.0000112570.97220.89; Simoons ML, 2001, LANCET, V357, P1915; Topol E, 1998, NEW ENGL J MED, V339, P436; Tunis SR, 2003, JAMA-J AM MED ASSOC, V290, P1624, DOI 10.1001/jama.290.12.1624; Wallentin L, 1999, LANCET, V354, P708	20	604	638	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					45	54						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238590				2022-12-28	WOS:000222448100026
J	Cohen, DA; Farley, TA				Cohen, DA; Farley, TA			Social marketing of condoms is great, but we need more free condoms	LANCET			English	Editorial Material									RAND Corp, Santa Monica, CA 90405 USA; Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA	RAND Corporation; Tulane University	Cohen, DA (corresponding author), RAND Corp, Santa Monica, CA 90405 USA.	dcohen@rand.org						[Anonymous], 1996, MMWR Recomm Rep, V45, P1; Cohen D, 1999, AM J PUBLIC HEALTH, V89, P567, DOI 10.2105/AJPH.89.4.567; Cohen DA, 1999, AM J PUBLIC HEALTH, V89, P204, DOI 10.2105/AJPH.89.2.204; DuboisArber F, 1997, AM J PUBLIC HEALTH, V87, P558, DOI 10.2105/AJPH.87.4.558; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; *KAIS FAM FDN, 2003, GLOB CHALL WHO LEAD; Kennedy MG, 2000, AIDS, V14, P1809, DOI 10.1097/00002030-200008180-00017; Pinkerton SD, 1997, SOC SCI MED, V44, P1303, DOI 10.1016/S0277-9536(96)00258-4; Trach DD, 1997, LANCET, V349, P231, DOI 10.1016/S0140-6736(96)06107-7	9	16	16	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					13	14		10.1016/S0140-6736(04)16611-7	http://dx.doi.org/10.1016/S0140-6736(04)16611-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DX	15234839				2022-12-28	WOS:000222392900010
J	Carcedo, CH; Bonazzi, M; Spano, S; Turacchio, G; Colanzi, A; Luini, A; Corda, D				Carcedo, CH; Bonazzi, M; Spano, S; Turacchio, G; Colanzi, A; Luini, A; Corda, D			Mitotic Golgi partitioning is driven by the membrane-fissioning protein CtBP3/BARS	SCIENCE			English	Article							APPARATUS IN-VIVO; ENDOPLASMIC-RETICULUM; BREFELDIN-A; MAMMALIAN-CELLS; MITOSIS; FRAGMENTATION; KINASE; REDISTRIBUTION; ASSOCIATION; CTBP/BARS	Organelle inheritance is an essential feature of all eukaryotic cells. As with other organelles, the Golgi complex partitions between daughter cells through the fission of its membranes into numerous tubulovesicular fragments. We found that the protein CtBP3/BARS ( BARS) was responsible for driving the fission of Golgi membranes during mitosis in vivo. Moreover, by in vitro analysis, we identified two stages of this Golgi fragmentation process: disassembly of the Golgi stacks into a tubular network, and BARS-dependent fission of these tubules. Finally, this BARS-induced fission of Golgi membranes controlled the G(2)-to-prophase transition of the cell cycle, and hence cell division.	Consorzio Mario Negri Sud, Lab Cell Regulat, I-66030 Santa Maria Imbaro, Chieti, Italy; Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, Lab Membrane Traff, I-66030 Santa Maria Imbaro, Chieti, Italy	Consorzio Mario Negri Sud; Consorzio Mario Negri Sud	Luini, A (corresponding author), Consorzio Mario Negri Sud, Lab Cell Regulat, Via Nazl, I-66030 Santa Maria Imbaro, Chieti, Italy.	luini@dcbo.negrisud.it; corda@negrisud.it	Luini, Alberto/L-1372-2013; Spanò, Stefania/F-4951-2011; Corda, Daniela/K-6385-2016; Bonazzi, Matteo/G-1623-2011; Colanzi, Antonino/D-6821-2012; Bonazzi, Matteo/AAT-2653-2020; hidalgo carcedo, cristina/M-6908-2015; Hidalgo-Carcedo, Cristina/K-8876-2017	Luini, Alberto/0000-0002-8729-2549; Spanò, Stefania/0000-0001-9154-7463; Corda, Daniela/0000-0002-3614-751X; Bonazzi, Matteo/0000-0001-5499-8759; Colanzi, Antonino/0000-0002-5643-0216; Bonazzi, Matteo/0000-0001-5499-8759; hidalgo carcedo, cristina/0000-0003-3571-2449; Hidalgo-Carcedo, Cristina/0000-0003-3571-2449	Telethon [E.0982] Funding Source: Medline; Fondazione Telethon Funding Source: Custom	Telethon(Fondazione Telethon); Fondazione Telethon(Fondazione Telethon)		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; Altan-Bonnet N, 2003, P NATL ACAD SCI USA, V100, P13314, DOI 10.1073/pnas.2234055100; Axelsson MAB, 2004, MOL BIOL CELL, V15, P1843, DOI 10.1091/mbc.E03-07-0459; BONAZZI M, UNPUB; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CARCEDO C, UNPUB; Colanzi A, 2000, J CELL BIOL, V149, P331, DOI 10.1083/jcb.149.2.331; Cole NB, 1996, MOL BIOL CELL, V7, P631, DOI 10.1091/mbc.7.4.631; Corda D, 2002, CELL MOL LIFE SCI, V59, P1819, DOI 10.1007/PL00012508; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; MISTELI T, 1995, J CELL SCI, V108, P2715; Nardini M, 2003, EMBO J, V22, P3122, DOI 10.1093/emboj/cdg283; Pecot MY, 2004, CELL, V116, P99, DOI 10.1016/S0092-8674(03)01068-7; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Sutterlin C, 2001, P NATL ACAD SCI USA, V98, P9128, DOI 10.1073/pnas.161283998; THYBERG J, 1992, J SUBMICR CYTOL PATH, V24, P495; Wang YZ, 2003, EMBO J, V22, P3279, DOI 10.1093/emboj/cdg317; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; Zaal KJM, 1999, CELL, V99, P589, DOI 10.1016/S0092-8674(00)81548-2	25	99	102	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					93	96		10.1126/science.1097775	http://dx.doi.org/10.1126/science.1097775			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232108				2022-12-28	WOS:000222386000043
J	Mangold, N; Quantin, C; Ansan, V; Delacourt, C; Allemand, P				Mangold, N; Quantin, C; Ansan, V; Delacourt, C; Allemand, P			Evidence for precipitation on Mars from dendritic valleys in the valles marineris area	SCIENCE			English	Article							MARTIAN VALLEYS; EVOLUTION; NETWORKS; ORIGIN; PLATEAU	Dendritic valleys on the plateau and canyons of the Valles Marineris region were identified from Thermal Emission Imaging System (THEMIS) images taken by Mars Odyssey. The geomorphic characteristics of these valleys, especially their high degree of branching, favor formation by atmospheric precipitation. The presence of inner channels and the maturity of the branched networks indicate sustained fluid flows over geologically long periods of time. These fluvial landforms occur within the Late Hesperian units ( about 2.9 to 3.4 billion years old), when Mars was thought to have been cold. Our results suggest a period of warmer conditions conducive to hydrological activity.	CNRS, UMR, Lab IDES, F-91405 Orsay, France; Univ Paris 11, F-91405 Orsay, France; Univ Lyon 1, CNRS, UMR, Lab Sci Terre, F-69622 Villeurbanne, France; ENS Lyon, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Ecole Normale Superieure de Lyon (ENS de LYON)	Mangold, N (corresponding author), CNRS, UMR, Lab IDES, Orsay Campus, F-91405 Orsay, France.	mangold@geol.u-psud.fr	Quantin, Cathy/H-1516-2014; delacourt, christophe/A-8240-2008; allemand, pascal/B-3148-2008	allemand, pascal/0000-0003-1269-6298; Delacourt, Christophe/0000-0003-2484-1464				BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; Cabrol NA, 2001, ICARUS, V149, P291, DOI 10.1006/icar.2000.6530; Carr M.H, 1996, WATER MARS; Carr MH, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018575; Carr MH, 1997, J GEOPHYS RES-PLANET, V102, P9145, DOI 10.1029/97JE00113; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; CLOW GD, 1987, ICARUS, V72, P95, DOI 10.1016/0019-1035(87)90123-0; Craddock RA, 2002, J GEOPHYS RES-PLANET, V107, DOI 10.1029/2001JE001505; Dohm JM, 1999, PLANET SPACE SCI, V47, P411, DOI 10.1016/S0032-0633(98)00141-X; Goldspiel JM, 2000, ICARUS, V148, P176, DOI 10.1006/icar.2000.6465; GULICK VC, 1990, J GEOPHYS RES-SOLID, V95, P14325, DOI 10.1029/JB095iB09p14325; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; KOCHEL RC, 1986, J GEOPHYS RES, V91, P175; LAITY JE, 1985, GEOL SOC AM BULL, V96, P203, DOI 10.1130/0016-7606(1985)96<203:SPATDO>2.0.CO;2; Lucchitta B. K., 1992, MARS, P453; Malin MC, 2003, SCIENCE, V302, P1931, DOI 10.1126/science.1090544; Malin MC, 1999, NATURE, V397, P589, DOI 10.1038/17551; MASURSKY H, 1973, J GEOPHYS RES, V78, P4009, DOI 10.1029/JB078i020p04009; MENZIES J, 1996, GLACIAL ENV, V2, P15; Miller J., 1992, FLUVIAL PROCESSES GE; PARKER TJ, 1993, J GEOPHYS RES-PLANET, V98, P11061, DOI 10.1029/93JE00618; PHILLIPS LF, 1987, GEOLOGY, V15, P813, DOI 10.1130/0091-7613(1987)15<813:EORSOD>2.0.CO;2; PIERI DC, 1980, SCIENCE, V210, P895, DOI 10.1126/science.210.4472.895; POLLACK JB, 1987, ICARUS, V71, P203, DOI 10.1016/0019-1035(87)90147-3; SAGAN C, 1973, SCIENCE, V181, P1045, DOI 10.1126/science.181.4104.1045; SHARP RP, 1975, GEOL SOC AM BULL, V86, P593, DOI 10.1130/0016-7606(1975)86<593:COM>2.0.CO;2; Tanaka K. L., 1992, MARS, P345; Weitz CM, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002022; [No title captured]	29	217	219	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					78	81		10.1126/science.1097549	http://dx.doi.org/10.1126/science.1097549			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232103				2022-12-28	WOS:000222386000038
J	Islam, FS; Gault, AG; Boothman, C; Polya, DA; Charnock, JM; Chatterjee, D; Lloyd, JR				Islam, FS; Gault, AG; Boothman, C; Polya, DA; Charnock, JM; Chatterjee, D; Lloyd, JR			Role of metal-reducing bacteria in arsenic release from Bengal delta sediments	NATURE			English	Article							DISSIMILATORY REDUCTION; GANGES DELTA; WEST-BENGAL; GROUNDWATER; BANGLADESH; IRON; MOBILIZATION; EXTRACTION; MOBILITY	The contamination of ground waters, abstracted for drinking and irrigation, by sediment-derived arsenic threatens the health of tens of millions of people worldwide, most notably in Bangladesh and West Bengal(1-3). Despite the calamitous effects on human health arising from the extensive use of arsenic-enriched ground waters in these regions, the mechanisms of arsenic release from sediments remain poorly characterized and are topics of intense international debate(4-8). We use a microscosm-based approach to investigate these mechanisms: techniques of microbiology and molecular ecology are used in combination with aqueous and solid phase speciation analysis of arsenic. Here we show that anaerobic metal-reducing bacteria can play a key role in the mobilization of arsenic in sediments collected from a contaminated aquifer in West Bengal. We also show that, for the sediments in this study, arsenic release took place after Fe(III) reduction, rather than occurring simultaneously. Identification of the critical factors controlling the biogeochemical cycling of arsenic is one important contribution to fully informing the development of effective strategies to manage these and other similar arsenic-rich ground waters worldwide.	Univ Manchester, Dept Earth Sci, Manchester M13 9PL, Lancs, England; Univ Manchester, Williamson Res Ctr Mol Environm Sci, Manchester M13 9PL, Lancs, England; SERC, Daresbury Lab, CCLRC, Warrington WA4 4AD, Cheshire, England; Univ Kalyani, Dept Chem, Santini Ketan 731235, W Bengal, India	University of Manchester; University of Manchester; STFC Daresbury Laboratory; Kalyani University	Lloyd, JR (corresponding author), Univ Manchester, Dept Earth Sci, Manchester M13 9PL, Lancs, England.	jon.lloyd@man.ac.uk	Boothman, Chris/E-7208-2013	Polya, David/0000-0002-7484-6696; Boothman, Christopher/0000-0002-4321-1719; Lloyd, Jonathan/0000-0002-0719-0498	Engineering and Physical Sciences Research Council [GR/S30207/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Acharyya SK, 1999, NATURE, V401, P545, DOI 10.1038/44052; Appelo CAJ, 2002, ENVIRON SCI TECHNOL, V36, P3096, DOI 10.1021/es010130n; Bard A. J., 1985, STANDARD POTENTIALS; Chakraborti D, 2002, TALANTA, V58, P3, DOI 10.1016/S0039-9140(02)00270-9; Chatterjee D, 2003, J PHYS IV, V107, P293, DOI 10.1051/jp4:20030299; Chowdhury TR, 1999, NATURE, V401, P545, DOI 10.1038/44056; Das D, 1996, ENVIRON GEOCHEM HLTH, V18, P5, DOI 10.1007/BF01757214; Dixit S, 2003, ENVIRON SCI TECHNOL, V37, P4182, DOI 10.1021/es030309t; Gault AG, 2003, MINERAL MAG, V67, P1183, DOI 10.1180/0026461036760157; Gault AG, 2003, PLASMA SOURCE MASS SPECTROMETRY: APPLICATIONS AND EMERGING TECHNOLOGIES, P112, DOI 10.1039/9781847551689-00112; Gault AG, 2001, ROY SOC CH, P387, DOI 10.1039/9781847551696-00387; Harvey CF, 2002, SCIENCE, V298, P1602, DOI 10.1126/science.1076978; Holmes DE, 2002, APPL ENVIRON MICROB, V68, P2300, DOI 10.1128/AEM.68.5.2300-2306.2002; Kuai L, 2001, APPL ENVIRON MICROB, V67, P3168, DOI 10.1128/AEM.67.7.3168-3173.2001; Lloyd JR, 2003, FEMS MICROBIOL REV, V27, P411, DOI 10.1016/S0168-6445(03)00044-5; LOVLEY DR, 1995, REV GEOPHYS, V33, P365, DOI 10.1029/95RG01305; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; McArthur JM, 2001, WATER RESOUR RES, V37, P109, DOI 10.1029/2000WR900270; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; Nickson RT, 2000, APPL GEOCHEM, V15, P403, DOI 10.1016/S0883-2927(99)00086-4; Oremland RS, 2003, SCIENCE, V300, P939, DOI 10.1126/science.1081903; Ranjard L, 2001, APPL ENVIRON MICROB, V67, P4479, DOI 10.1128/AEM.67.10.4479-4487.2001; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Smedley PL, 2002, APPL GEOCHEM, V17, P517, DOI 10.1016/S0883-2927(02)00018-5; Smith AH, 2000, B WORLD HEALTH ORGAN, V78, P1093; TESKE A, 1994, J BACTERIOL, V176, P6623, DOI 10.1128/JB.176.21.6623-6630.1994; VANDERPEER Y, 2001, COMPUT APPL BIOSCI, V100, P569; Welham NJ, 2000, MINER ENG, V13, P911, DOI 10.1016/S0892-6875(00)00078-9; Wenzel WW, 2001, ANAL CHIM ACTA, V436, P309, DOI 10.1016/S0003-2670(01)00924-2; Zobrist J, 2000, ENVIRON SCI TECHNOL, V34, P4747, DOI 10.1021/es001068h	30	943	1011	20	561	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					68	71		10.1038/nature02638	http://dx.doi.org/10.1038/nature02638			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229598				2022-12-28	WOS:000222356800043
J	Jones, LM; Depireux, DA; Simons, DJ; Keller, A				Jones, LM; Depireux, DA; Simons, DJ; Keller, A			Robust temporal coding in the trigeminal system	SCIENCE			English	Article							VISUAL-CORTEX; RAT; NEURONS; BARREL; POTENTIALS; DEFLECTION; SYNCHRONY; SURFACES	The ability of rats to use their whiskers for. ne tactile discrimination rivals that of humans using their fingertips. Rats perform discriminations rapidly and accurately while palpating the environment with their whiskers. This suggests that whisker deflections produce a robust and reliable neural code. Whisker primary afferents respond with highly reproducible temporal spike patterns to transient stimuli. Here we show that, with the use of a linear kernel, any of these reproducible response trains recorded from an individual neuron can reliably predict complex whisker deflections. These predictions are significantly improved by integrating responses from neurons with opposite angular preferences.	Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anat & Neurobiol, Baltimore, MD 21201 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Keller, A (corresponding author), Univ Maryland, Sch Med, Program Neurosci, Baltimore, MD 21201 USA.	akeller@umaryland.edu		Keller, Asaf/0000-0001-8727-663X; Jones-Lush, Lauren/0000-0002-5388-3770	NIDCD NIH HHS [R01 DC005937, R01 DC-05937-01] Funding Source: Medline; NINDS NIH HHS [R01 NS031078, F31 NS046100, F31 NS46100-01, NS19950, R01 NS019950, R01 NS31078] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019950, R01NS031078, F31NS046100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005937] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Brecht M, 2002, J PHYSIOL-LONDON, V543, P49, DOI 10.1113/jphysiol.2002.018465; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Dayan P., 2001, THEORETICAL NEUROSCI, P460; GIBSON JM, 1983, SOMATOSENS RES, V1, P51, DOI 10.3109/07367228309144540; Hahnloser RHR, 2002, NATURE, V419, P65, DOI 10.1038/nature00974; HUTSON KA, 1986, J NEUROPHYSIOL, V56, P1196, DOI 10.1152/jn.1986.56.4.1196; Ito M, 2002, J PHYSIOL-LONDON, V539, P511, DOI 10.1113/jphysiol.2001.013004; JONES LM, J NEUROPHYSIOL; LEHKY SR, 1990, PROC R SOC SER B-BIO, V240, P251, DOI 10.1098/rspb.1990.0037; LICHTENSTEIN SH, 1990, SOMATOSENS MOT RES, V7, P47, DOI 10.3109/08990229009144697; Pinto DJ, 2003, CEREB CORTEX, V13, P33, DOI 10.1093/cercor/13.1.33; Rieke F, 1997, SPIKES EXPLORING NEU, P395; Shoykhet M, 2000, SOMATOSENS MOT RES, V17, P171; SIMONS DJ, 1989, J NEUROPHYSIOL, V61, P311, DOI 10.1152/jn.1989.61.2.311; Temereanca S, 2003, J NEUROPHYSIOL, V89, P2137, DOI 10.1152/jn.00582.2002; Theunissen FE, 2003, TRENDS NEUROSCI, V26, P61, DOI 10.1016/S0166-2236(02)00016-4; TOREBJORK HE, 1987, BRAIN, V110, P1509, DOI 10.1093/brain/110.6.1509; vanSteveninck RRD, 1997, SCIENCE, V275, P1805, DOI 10.1126/science.275.5307.1805; Vinje WE, 2000, SCIENCE, V287, P1273, DOI 10.1126/science.287.5456.1273; Yoshioka T, 2001, J NEUROSCI, V21, P6905, DOI 10.1523/JNEUROSCI.21-17-06905.2001	20	129	129	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1986	1989		10.1126/science.1097779	http://dx.doi.org/10.1126/science.1097779			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218153	Green Accepted			2022-12-28	WOS:000222241600051
J	Green, J				Green, J			Commentary: Is trust an under-researched component of healthcare organisation?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Green, J (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.	judith.green@lshtin.ac.uk		Green, Judith/0000-0002-2315-5326				Bower P, 2003, QUAL SAF HEALTH CARE, V12, P273, DOI 10.1136/qhc.12.4.273; Branson R, 2004, BRIT MED J, V329, P381, DOI 10.1136/bmj.38173.532465.7C; Campbell JL, 2001, BRIT J GEN PRACT, V51, P644; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; CARMEL SHM, 2003, THESIS U LONDON LONO	5	6	6	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	2004	329	7462					384	384		10.1136/bmj.38174.496944.7C	http://dx.doi.org/10.1136/bmj.38174.496944.7C			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15265813	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223433600019
J	Wood, JG; Rogina, B; Lavu, S; Howitz, K; Helfand, SL; Tatar, M; Sinclair, D				Wood, JG; Rogina, B; Lavu, S; Howitz, K; Helfand, SL; Tatar, M; Sinclair, D			Sirtuin activators mimic caloric restriction and delay ageing in metazoans	NATURE			English	Article							LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; DROSOPHILA-MELANOGASTER; SIR2 PROTEIN; LONGEVITY; DEACETYLASE; YEAST; NAD; SELECTION; NUTRITION	Caloric restriction extends lifespan in numerous species. In the budding yeast Saccharomyces cerevisiae this effect requires Sir2 (ref. 1), a member of the sirtuin family of NAD(+)-dependent deacetylases(2,3). Sirtuin activating compounds (STACs) can promote the survival of human cells and extend the replicative lifespan of yeast(4). Here we show that resveratrol and other STACs activate sirtuins from Caenorhabditis elegans and Drosophila melanogaster, and extend the lifespan of these animals without reducing fecundity. Lifespan extension is dependent on functional Sir2, and is not observed when nutrients are restricted. Together these data indicate that STACs slow metazoan ageing by mechanisms that may be related to caloric restriction.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA; BIOMOL Res Labs Inc, Plymouth Meeting, PA 19462 USA; Brown Univ, Dept Ecol & Evolutionary Biol, Providence, RI 02912 USA	Harvard University; Harvard Medical School; University of Connecticut; Brown University	Sinclair, D (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	shelfand@neuron.uchc.edu; marc_tatar@brown.edu; david_sinclair@hms.harvard.edu		Sinclair, David/0000-0002-9936-436X; Tatar, Marc/0000-0003-3232-6884	NATIONAL INSTITUTE ON AGING [R37AG016667, R01AG024353] Funding Source: NIH RePORTER; NIA NIH HHS [R37 AG016667, RF1 AG024353, R01 AG028730] Funding Source: Medline; NIDDK NIH HHS [R01 DK100263] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; EDGECOMB RS, 1994, J EXP BIOL, V197, P215; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Guarente L, 2000, GENE DEV, V14, P1021; Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Marden JH, 2003, P NATL ACAD SCI USA, V100, P3369, DOI 10.1073/pnas.0634985100; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Rogina B, 2002, SCIENCE, V298, P1745, DOI 10.1126/science.1078986; Sinclair DA, 2002, MECH AGEING DEV, V123, P857, DOI 10.1016/S0047-6374(02)00023-4; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Walker DW, 2000, NATURE, V405, P296, DOI 10.1038/35012693	24	1446	1514	6	191	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	2004	430	7000					686	689		10.1038/nature02789	http://dx.doi.org/10.1038/nature02789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843LM	15254550				2022-12-28	WOS:000223085400048
J	Lengronne, A; Katou, Y; Mori, S; Yokobayashi, S; Kelly, GP; Itoh, T; Watanabe, Y; Shirahige, K; Uhlmann, F				Lengronne, A; Katou, Y; Mori, S; Yokobayashi, S; Kelly, GP; Itoh, T; Watanabe, Y; Shirahige, K; Uhlmann, F			Cohesin relocation from sites of chromosomal loading to places of convergent transcription	NATURE			English	Article							SISTER-CHROMATID COHESION; YEAST COHESIN; ATP HYDROLYSIS; PROTEINS; CENTROMERES; IDENTIFICATION; ASSOCIATION; REQUIREMENT; SEPARATION; COMPLEX	Sister chromatids, the products of eukaryotic DNA replication, are held together by the chromosomal cohesin complex after their synthesis. This allows the spindle in mitosis to recognize pairs of replication products for segregation into opposite directions(1-6). Cohesin forms large protein rings that may bind DNA strands by encircling them(7), but the characterization of cohesin binding to chromosomes in vivo has remained vague. We have performed high resolution analysis of cohesin association along budding yeast chromosomes III - VI. Cohesin localizes almost exclusively between genes that are transcribed in converging directions. We find that active transcription positions cohesin at these sites, not the underlying DNA sequence. Cohesin is initially loaded onto chromosomes at separate places, marked by the Scc2/Scc4 cohesin loading complex(8), from where it appears to slide to its more permanent locations. But even after sister chromatid cohesion is established, changes in transcription lead to repositioning of cohesin. Thus the sites of cohesin binding and therefore probably sister chromatid cohesion, a key architectural feature of mitotic chromosomes, display surprising flexibility. Cohesin localization to places of convergent transcription is conserved in fission yeast, suggesting that it is a common feature of eukaryotic chromosomes.	Canc Res UK London Res Inst, Chromosome Segregat Lab, London WC2A 3PX, England; Canc Res UK London Res Inst, Computat Genome Anal Lab, London WC2A 3PX, England; Riken Genom Sci Ctr, Human Genome Res Grp, Genome Informat Team, Yokohama, Kanagawa 2300045, Japan; Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Tokyo Inst Technol, Div Gene Res, Ctr Biol Resources & Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Kanagawa 2300045, Japan; Tokai Univ, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Mitsubishi Res Inst Inc, Adv Sci & Technol Res Ctr, Chiyoda Ku, Tokyo 1008141, Japan; Japan Sci & Technol Agcy, SORST, Tokyo 1130032, Japan	Cancer Research UK; Cancer Research UK; The Genome Analysis Centre (TGAC); RIKEN; Tokyo Institute of Technology; Tokyo Institute of Technology; Yokohama City University; Tokai University; Mitsubishi Research Institute; Japan Science & Technology Agency (JST)	Uhlmann, F (corresponding author), Canc Res UK London Res Inst, Chromosome Segregat Lab, Lincolns Inn Fields Labs,44 Lincolns Inn Fields, London WC2A 3PX, England.	frank.uhlmann@cancer.org.uk	Kelly, Gavin/ABG-2715-2021; Itoh, Takehiko/E-8873-2014	Kelly, Gavin/0000-0001-7219-560X; Itoh, Takehiko/0000-0002-6113-557X; Watanabe, Yoshinori/0000-0002-5488-4812; Uhlmann, Frank/0000-0002-3527-6619; Shirahige, Katsuhiko/0000-0002-7862-1144	Cancer Research UK [A3592] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Arumugam P, 2003, CURR BIOL, V13, P1941, DOI 10.1016/j.cub.2003.10.036; Bernard P, 2001, SCIENCE, V294, P2539, DOI 10.1126/science.1064027; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 2000, MOL CELL, V5, P243, DOI 10.1016/S1097-2765(00)80420-7; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Filipski J, 2002, GENE, V300, P63, DOI 10.1016/S0378-1119(02)00848-X; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Haering CH, 2002, MOL CELL, V9, P773, DOI 10.1016/S1097-2765(02)00515-4; Hakimi MA, 2002, NATURE, V418, P994, DOI 10.1038/nature01024; Jacq C, 1997, NATURE, V387, P75, DOI 10.1038/387s075; Katou Y, 2003, NATURE, V424, P1078, DOI 10.1038/nature01900; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Megee PC, 1999, SCIENCE, V285, P254, DOI 10.1126/science.285.5425.254; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nonaka N, 2002, NAT CELL BIOL, V4, P89, DOI 10.1038/ncb739; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Reid RJD, 2002, YEAST, V19, P319, DOI 10.1002/yea.817; Sjogren C, 2001, CURR BIOL, V11, P991, DOI 10.1016/S0960-9822(01)00271-8; Tanaka TU, 2000, NAT CELL BIOL, V2, P492, DOI 10.1038/35019529; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Toyoda Y, 2002, CURR BIOL, V12, P347, DOI 10.1016/S0960-9822(02)00692-9; Uhlmann F, 2003, CURR BIOL, V13, pR104, DOI 10.1016/S0960-9822(03)00039-3; Weitzer S, 2003, CURR BIOL, V13, P1930, DOI 10.1016/j.cub.2003.10.030	30	419	425	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	2004	430	6999					573	578		10.1038/nature02742	http://dx.doi.org/10.1038/nature02742			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841QI	15229615	Green Accepted			2022-12-28	WOS:000222946100051
J	Irish, JM; Hovland, R; Krutzik, PO; Perez, OD; Bruserud, O; Gjertsen, BT; Nolan, GP				Irish, JM; Hovland, R; Krutzik, PO; Perez, OD; Bruserud, O; Gjertsen, BT; Nolan, GP			Single cell profiling of potentiated phospho-protein networks in cancer cells	CELL			English	Article							ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; SIGNAL TRANSDUCER; CONSTITUTIVE ACTIVATION; MYELOID DIFFERENTIATION; TRANSCRIPTION PROTEINS; MOLECULAR TARGETS; STAT PROTEINS; MAP KINASE; AML BLASTS	Altered growth factor responses in phospho-protein-driven signaling networks are crucial to cancer cell survival and pathology. Profiles of cancer cell signaling networks might therefore identify mechanisms by which such cells interpret environmental cues for continued growth. Using multiparameter flow cytometry, we monitored phospho-protein responses to environmental cues in acute myeloid leukemia at the single cell level. By exposing cancer cell signaling networks to potentiating inputs, rather than relying upon the basal levels of protein phosphorylation alone, we could discern unique cancer network profiles that correlated with genetics and disease outcome. Strikingly, individual cancers manifested multiple cell subsets with unique network profiles, reflecting cancer heterogeneity at the level of signaling response. The results revealed a dramatic remodeling of signaling networks in cancer cells. Thus, single cell measurements of phospho-protein responses reveal shifts in signaling potential of a phospho-protein network, allowing for categorizing of cell network phenotypes by multidimensional molecular profiles of signaling.	Stanford Univ, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Univ Bergen, Ctr Med Genet & Mol Med, Haukeland Univ Hosp, Bergen, Norway; Univ Bergen, Ctr Med Genet & Mol Med, Proteom Unit, Bergen, Norway; Haukeland Hosp, Haematol Sect, Dept Internal Med, N-5021 Bergen, Norway; Univ Bergen, Inst Med, Haematol Sect, Bergen, Norway	Stanford University; University of Bergen; Haukeland University Hospital; University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen	Nolan, GP (corresponding author), Stanford Univ, Baxter Lab Genet Pharmacol, Dept Microbiol & Immunol, Stanford, CA 94305 USA.	gnolan@stanford.edu	Irish, Jonathan M/E-1180-2013; Nolan, Garry/AAE-7903-2019; Gjertsen, Bjorn T/O-1542-2015; Gjertsen, Bjørn T/AAP-3281-2020	Irish, Jonathan M/0000-0001-9428-8866; Gjertsen, Bjorn T/0000-0001-9358-9704; Gjertsen, Bjørn T/0000-0001-9358-9704; Nolan, Garry/0000-0002-8862-9043	NHLBI NIH HHS [N01-HV-28183I] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028183] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benekli M, 2002, BLOOD, V99, P252, DOI 10.1182/blood.V99.1.252; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Birkenkamp KU, 2001, LEUKEMIA, V15, P1923, DOI 10.1038/sj.leu.2402317; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bruserud O, 2003, HAEMATOLOGICA, V88, P416; Bruserud O, 2000, J HEMATOTH STEM CELL, V9, P923, DOI 10.1089/152581600750062372; Buettner R, 2002, CLIN CANCER RES, V8, P945; Calo V, 2003, J CELL PHYSIOL, V197, P157, DOI 10.1002/jcp.10364; Coffer PJ, 2000, ONCOGENE, V19, P2511, DOI 10.1038/sj.onc.1203479; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hayakawa F, 2000, ONCOGENE, V19, P624, DOI 10.1038/sj.onc.1203354; Kiyoi H, 2002, ONCOGENE, V21, P2555, DOI 10.1038/sj.onc.1205332; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Krutzik PO, 2004, CLIN IMMUNOL, V110, P206, DOI 10.1016/j.clim.2003.11.009; Krutzik PO, 2003, CYTOM PART A, V55A, P61, DOI 10.1002/cyto.a.10072; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Namikawa R, 1999, EXP HEMATOL, V27, P1029, DOI 10.1016/S0301-472X(99)00034-X; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Pallis M, 2003, LEUKEMIA RES, V27, P803, DOI 10.1016/S0145-2126(03)00012-2; Perez OD, 2002, NAT BIOTECHNOL, V20, P155, DOI 10.1038/nbt0202-155; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Tilstone C, 2003, NATURE, V424, P610, DOI 10.1038/424610a; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Xia Z, 1998, CANCER RES, V58, P3173	36	547	591	1	54	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					217	228		10.1016/j.cell.2004.06.028	http://dx.doi.org/10.1016/j.cell.2004.06.028			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260991	Bronze			2022-12-28	WOS:000222966000010
J	Jaeger, J; Surkova, S; Blagov, M; Janssens, H; Kosman, D; Kozlov, KN; Manu; Myasnikova, E; Vanario-Alonso, CE; Samsonova, M; Sharp, DH; Reinitz, J				Jaeger, J; Surkova, S; Blagov, M; Janssens, H; Kosman, D; Kozlov, KN; Manu; Myasnikova, E; Vanario-Alonso, CE; Samsonova, M; Sharp, DH; Reinitz, J			Dynamic control of positional information in the early Drosophila embryo	NATURE			English	Article							MORPHOGEN GRADIENT; SEGMENTATION; PROTEIN; PATTERN; EMBRYOGENESIS; HUNCHBACK; MODEL; GENES	Morphogen gradients contribute to pattern formation by determining positional information in morphogenetic fields(1,2). Interpretation of positional information is thought to rely on direct, concentration-threshold-dependent mechanisms for establishing multiple differential domains of target gene expression(1,3,4). In Drosophila, maternal gradients establish the initial position of boundaries for zygotic gap gene expression, which in turn convey positional information to pair-rule and segment-polarity genes, the latter forming a segmental prepattern by the onset of gastrulation(5-7). Here we report, on the basis of quantitative gene expression data, substantial anterior shifts in the position of gap domains after their initial establishment. Using a data-driven mathematical modelling approach(8-11), we show that these shifts are based on a regulatory mechanism that relies on asymmetric gap-gap cross-repression and does not require the diffusion of gap proteins. Our analysis implies that the threshold-dependent interpretation of maternal morphogen concentration is not sufficient to determine shifting gap domain boundary positions, and suggests that establishing and interpreting positional information are not independent processes in the Drosophila blastoderm.	SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; St Petersburg State Polytech Univ, Ctr Adv Studies, Dept Computat Biol, St Petersburg 195251, Russia; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21949900 Rio De Janeiro, Brazil; Los Alamos Natl Lab, Div Appl Phys, Los Alamos, NM 87545 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Peter the Great St. Petersburg Polytechnic University; University of California System; University of California San Diego; Universidade Federal do Rio de Janeiro; United States Department of Energy (DOE); Los Alamos National Laboratory; United States Department of Energy (DOE); Los Alamos National Laboratory	Reinitz, J (corresponding author), SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.	reinitz@odd.bio.sunysb.edu	Myasnikova, Ekaterina/I-2711-2017; Kozlov, Konstantin/N-6748-2013	Kozlov, Konstantin/0000-0001-6765-236X; Surkova, Svetlana/0000-0002-9016-4732; Jaeger, Johannes/0000-0002-2568-2103	NCRR NIH HHS [R01 RR007801] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR007801] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKAM M, 1987, DEVELOPMENT, V101, P1; Chu KW, 1999, J COMPUT PHYS, V148, P646, DOI 10.1006/jcph.1998.6134; CRICK F, 1970, NATURE, V225, P420, DOI 10.1038/225420a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; Ephrussi A, 2004, CELL, V116, P143, DOI 10.1016/S0092-8674(04)00037-6; FOE VE, 1983, J CELL SCI, V61, P31; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; Gurdon JB, 2001, NATURE, V413, P797, DOI 10.1038/35101500; Houchmandzadeh B, 2002, NATURE, V415, P798, DOI 10.1038/415798a; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; JAEGER J, IN PRESS GENETICS; Kosman D, 1998, DEV GENES EVOL, V208, P290, DOI 10.1007/s004270050184; LEWIS J, 1977, J THEOR BIOL, V65, P579, DOI 10.1016/0022-5193(77)90216-8; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MEINHARDT H, 1978, J THEOR BIOL, V74, P307, DOI 10.1016/0022-5193(78)90078-4; MJOLSNESS E, 1991, J THEOR BIOL, V152, P429, DOI 10.1016/S0022-5193(05)80391-1; Myasnikova E, 2001, BIOINFORMATICS, V17, P3, DOI 10.1093/bioinformatics/17.1.3; Nagaso H, 2001, J HISTOCHEM CYTOCHEM, V49, P1177, DOI 10.1177/002215540104900911; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PRESS WH, 1992, NUMERICAL RECIPES; REINITZ J, 1995, MECH DEVELOP, V49, P133, DOI 10.1016/0925-4773(94)00310-J; Reinitz J, 1998, DEV GENET, V23, P11, DOI 10.1002/(SICI)1520-6408(1998)23:1<11::AID-DVG2>3.3.CO;2-Q; REINITZ J, 1995, J EXP ZOOL, V271, P47, DOI 10.1002/jez.1402710106; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; TSAI CC, 1994, DEVELOPMENT, V120, P1671; WADDINGTON CH, 1940, ORGS GENES; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0	27	412	426	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					368	371		10.1038/nature02678	http://dx.doi.org/10.1038/nature02678			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254541				2022-12-28	WOS:000222631200045
J	Pirisi, A				Pirisi, A			Profile - Alan Trounson, Scientific Director of Monash IVF, Australia	LANCET			English	Biographical-Item												apirisi@interlynx.net							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					133	133		10.1016/S0140-6736(04)16645-2	http://dx.doi.org/10.1016/S0140-6736(04)16645-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15264355				2022-12-28	WOS:000222612200011
J	Autran, B; Carcelain, G; Combadiere, B; Debre, P				Autran, B; Carcelain, G; Combadiere, B; Debre, P			Therapeutic Vaccines for chronic infections	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL; HUMAN-PAPILLOMAVIRUS; RESPONSES; SAFETY; IMMUNOGENICITY; AIDS; HIV; LYMPHOCYTES; EVOLUTION	Therapeutic vaccines aim to prevent severe complications of a chronic infection by reinforcing host defenses when some immune control, albeit insufficient, can already be demonstrated and when a conventional antimicrobial therapy either is not available or has limited efficacy. We focus on the rationale and challenges behind this still controversial strategy and provide examples from three major chronic infectious diseases-human immunodeficiency virus, hepatitis B virus, and human papillomavirus-for which the efficacy of therapeutic vaccines is currently being evaluated.	Univ Paris 06, Ctr Hosp Univ Pitie Salpetriere, Lab Immunol Cellulaire, F-75013 Paris, France; Univ Paris 06, Ctr Hosp Univ Pitie Salpetriere, INSERM, U543, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), Univ Paris 06, Ctr Hosp Univ Pitie Salpetriere, Lab Immunol Cellulaire, F-75013 Paris, France.	brigitte.autran@psl.ap-hop-paris.fr	Combadiere, Behazine/S-8054-2019; Combadiere, Behazine/G-3881-2013	Combadiere, Behazine/0000-0002-2353-4406; 				Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Autran B, 2000, SCIENCE, V290, P946, DOI 10.1126/science.290.5493.946; Autran B, 1996, CURR OPIN IMMUNOL, V8, P546, DOI 10.1016/S0952-7915(96)80045-8; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; BARTHOLOMEW JS, 1994, EUR J IMMUNOL, V24, P3175, DOI 10.1002/eji.1830241239; BOFFETTA P, 1994, CA-CANCER J CLIN, V44, P81, DOI 10.3322/canjclin.44.2.81; Burd EM, 2003, CLIN MICROBIOL REV, V16, P1, DOI 10.1128/CMR.16.1.1-17.2003; Carcelain G, 2001, CURR OPIN IMMUNOL, V13, P483, DOI 10.1016/S0952-7915(00)00245-4; Dahmen A, 2002, J MED VIROL, V66, P452, DOI 10.1002/jmv.2165; Dalod M, 1998, J INFECT DIS, V178, P61, DOI 10.1086/515587; Debre P, 1995, L PASTEUR; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Dikici B, 2003, PEDIATR INFECT DIS J, V22, P345; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Hanazaki Kazuhiro, 2004, Current Drug Targets - Inflammation and Allergy, V3, P63, DOI 10.2174/1568010043483908; HEL Z, 2003, NAT MED, V6, P1140; Jameson SC, 2002, NAT REV IMMUNOL, V2, P547, DOI 10.1038/nri853; Jin X, 2002, J VIROL, V76, P2206, DOI 10.1128/JVI.76.5.2206-2216.2002; Kaufmann AM, 2002, CLIN CANCER RES, V8, P3676; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Lacey CJN, 1999, J INFECT DIS, V179, P612, DOI 10.1086/314616; LEVY J, 1998, BLOOD, V92, P3105; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Ogg GS, 1999, J VIROL, V73, P797, DOI 10.1128/JVI.73.1.797-800.1999; Pol S, 2001, J HEPATOL, V34, P917, DOI 10.1016/S0168-8278(01)00028-9; Rocha B, 2004, CURR OPIN IMMUNOL, V16, P259, DOI 10.1016/j.coi.2004.03.004; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Triebel F, 2003, TRENDS IMMUNOL, V24, P619, DOI 10.1016/j.it.2003.10.001; TUBIANA R, 2003, 10 C RETR OPP INF BO; Yalcin K, 2003, INFECTION, V31, P221, DOI 10.1007/s15010-003-3187-1	34	106	120	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					205	208		10.1126/science.1100600	http://dx.doi.org/10.1126/science.1100600			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247470				2022-12-28	WOS:000222501000041
J	Eberl, G; Littman, DR				Eberl, G; Littman, DR			Thymic origin of intestinal alpha beta T cells revealed by fate mapping of ROR gamma t(+) cells	SCIENCE			English	Article							INTRAEPITHELIAL LYMPHOCYTES; LYMPHOID PROGENITORS; GUT CRYPTOPATCHES; TRANSGENIC MICE; ROR-GAMMA; EXPRESSION; GENERATION; IDENTIFICATION; LYMPHOPOIESIS; PRECURSORS	Intestinal intraepithelial T lymphocytes (IELs) are likely to play a key role in host mucosal immunity and, unlike other T cells, have been proposed to differentiate from local precursors rather than from thymocytes. We show here that IELs expressing the alphabeta T cell receptor are derived from precursors that express RORgammat, an orphan nuclear hormone receptor detected only in immature CD4(+) CD8(+) thymocytes, fetal lymphoid tissue-inducer (LTi) cells, and LTi-like cells in crypto-patches within the adult intestinal lamina propria. Using cell fate mapping, we found that all intestinal alphabeta T cells are progeny of CD4(+) CD8(+) thymocytes, indicating that the adult intestine is not a significant site for alphabeta T cell development. Our results suggest that intestinal RORgammat(+) cells are local organizers of mucosal lymphoid tissue.	NYU, Sch Med, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA	New York University; Howard Hughes Medical Institute; New York University	Eberl, G (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.	geberl@adarc.org; littman@saturn.med.nyu.edu	Eberl, Gerard/A-1160-2013	Eberl, Gerard/0000-0002-1119-5638				Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; EBERL G, UNPUB; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Guy-Grand D, 2002, CURR OPIN IMMUNOL, V14, P255, DOI 10.1016/S0952-7915(02)00330-8; Guy-Grand D, 2001, EUR J IMMUNOL, V31, P2593, DOI 10.1002/1521-4141(200109)31:9<2593::AID-IMMU2593>3.0.CO;2-X; Hamada H, 2002, J IMMUNOL, V168, P57, DOI 10.4049/jimmunol.168.1.57; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; Kaiserling E, 2001, LYMPHOLOGY, V34, P22; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Lefrancois L, 1997, J IMMUNOL, V159, P538; Leishman AJ, 2002, IMMUNITY, V16, P355, DOI 10.1016/S1074-7613(02)00284-4; LIN T, 1994, EUR J IMMUNOL, V24, P1785, DOI 10.1002/eji.1830240810; LIN T, 1994, EUR J IMMUNOL, V24, P1080, DOI 10.1002/eji.1830240511; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Mebius RE, 2001, J IMMUNOL, V166, P6593, DOI 10.4049/jimmunol.166.11.6593; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Spahn TW, 2002, AM J PATHOL, V161, P2273, DOI 10.1016/S0002-9440(10)64503-8; Sparwasser T, 2004, GENESIS, V38, P39, DOI 10.1002/gene.10249; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Suzuki K, 2000, IMMUNITY, V13, P691, DOI 10.1016/S1074-7613(00)00068-6; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Yeung MMW, 2000, GUT, V47, P215, DOI 10.1136/gut.47.2.215; Yoshida H, 2001, J IMMUNOL, V167, P2511, DOI 10.4049/jimmunol.167.5.2511	26	389	408	9	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					248	251		10.1126/science.1096472	http://dx.doi.org/10.1126/science.1096472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247480				2022-12-28	WOS:000222501000054
J	Leist, M; Ghezzi, P; Grasso, G; Bianchi, R; Villa, P; Fratelli, M; Savino, C; Bianchi, M; Nielsen, J; Gerwien, J; Kallunki, P; Larsen, AK; Helboe, L; Christensen, S; Pedersen, LO; Nielsen, M; Torup, L; Sager, T; Sfacteria, A; Erbayraktar, S; Erbayraktar, Z; Gokmen, N; Yilmaz, O; Cerami-Hand, C; Xie, QW; Coleman, T; Cerami, A; Brines, M				Leist, M; Ghezzi, P; Grasso, G; Bianchi, R; Villa, P; Fratelli, M; Savino, C; Bianchi, M; Nielsen, J; Gerwien, J; Kallunki, P; Larsen, AK; Helboe, L; Christensen, S; Pedersen, LO; Nielsen, M; Torup, L; Sager, T; Sfacteria, A; Erbayraktar, S; Erbayraktar, Z; Gokmen, N; Yilmaz, O; Cerami-Hand, C; Xie, QW; Coleman, T; Cerami, A; Brines, M			Derivatives of erythropoietin that are tissue protective but not erythropoietic	SCIENCE			English	Article							BIOLOGICAL-ACTIVITY; IN-VIVO; NEUROPROTECTION; RECEPTOR; INVITRO; NEURONS	Erythropoietin (EPO) is both hematopoietic and tissue protective, putatively through interaction with different receptors. We generated receptor subtype selective ligands allowing the separation of EPO's bioactivities at the cellular level and in animals. Carbamylated EPO (CEPO) or certain EPO mutants did not bind to the classical EPO receptor ( EPOR) and did not show any hematopoietic activity in human cell signaling assays or upon chronic dosing in different animal species. Nevertheless, CEPO and various nonhematopoietic mutants were cytoprotective in vitro and conferred neuroprotection against stroke, spinal cord compression, diabetic neuropathy, and experimental autoimmune encephalomyelitis at a potency and efficacy comparable to EPO.	Kenneth S Warren Inst, Ossining, NY 10562 USA; H Lundbeck & Co AS, DK-2500 Copenhagen, Denmark; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Univ Messina, I-98122 Messina, Italy; CNR, Inst Neurosci, I-20129 Milan, Italy; Dokuz Eylul Univ, Sch Med, TR-35340 Izmir, Turkey; Warren Pharmaceut Inc, Ossining, NY 10562 USA	Lundbeck Corporation; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Messina; Consiglio Nazionale delle Ricerche (CNR); Dokuz Eylul University	Cerami, A (corresponding author), Kenneth S Warren Inst, Ossining, NY 10562 USA.	acerami@kswi.org	grasso, giovanni/K-3774-2018; Sfacteria, Alessandra/AAK-1839-2020; Ghezzi, Pietro/A-4995-2010; Brinesd, Michael/AAE-6072-2020; YILMAZ, Osman/V-3632-2019; Gokmen, Necati/B-1775-2008; Fratelli, Maddalena/AAA-6446-2020; Leist, Marcel/D-2133-2010; Erbayraktar, Zübeyde/P-4575-2019; Gökmen, Necati/J-9761-2019	grasso, giovanni/0000-0001-5362-0092; YILMAZ, Osman/0000-0001-7817-7576; Gokmen, Necati/0000-0002-3225-7666; Fratelli, Maddalena/0000-0002-1769-3427; Leist, Marcel/0000-0002-3778-8693; Erbayraktar, Zübeyde/0000-0002-0316-1462; Gökmen, Necati/0000-0002-3225-7666; Gokmen, Necati/0000-0003-1835-4133; Cerami, Carla/0000-0002-7634-0955; Ghezzi, Pietro/0000-0003-0911-8358; Christensen, Soren/0000-0003-2500-0085; Nielsen, Jacob/0000-0001-9842-2276; Brines, Michael/0000-0003-4151-4449	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI085201] Funding Source: NIH RePORTER; NIAID NIH HHS [R56 AI085201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100; BOISSEL JP, 1993, J BIOL CHEM, V268, P15983; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Campana WM, 1998, INT J MOL MED, V1, P235; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Ehrenreich H, 2004, MOL PSYCHIATR, V9, P42, DOI 10.1038/sj.mp.4001442; Eid Tore, 2002, Clin Breast Cancer, V3 Suppl 3, pS109, DOI 10.3816/CBC.2002.s.021; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; GRODBERG J, 1993, EUR J BIOCHEM, V218, P597, DOI 10.1111/j.1432-1033.1993.tb18413.x; Grodberg J, 1996, ARCH BIOCHEM BIOPHYS, V333, P427, DOI 10.1006/abbi.1996.0411; HANAZONO Y, 1995, BIOCHEM BIOPH RES CO, V208, P1060, DOI 10.1006/bbrc.1995.1442; JUBLINSKY PT, 1997, BLOOD, V90, P1867; KONISHI Y, 1993, BRAIN RES, V609, P29, DOI 10.1016/0006-8993(93)90850-M; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Mun KC, 2000, BLOOD PURIFICAT, V18, P13, DOI 10.1159/000014403; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Sasaki R, 2003, INTERNAL MED, V42, P142, DOI 10.2169/internalmedicine.42.142; SATAKE R, 1990, BIOCHIM BIOPHYS ACTA, V1038, P125, DOI 10.1016/0167-4838(90)90020-G; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stohlawetz PJ, 2000, BLOOD, V95, P2983, DOI 10.1182/blood.V95.9.2983.009k27_2983_2989; Yousef GM, 2001, BIOCHEM BIOPH RES CO, V284, P900, DOI 10.1006/bbrc.2001.5053	22	639	723	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					239	242		10.1126/science.1098313	http://dx.doi.org/10.1126/science.1098313			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247477	Green Submitted			2022-12-28	WOS:000222501000051
J	Kremer, LCM; Caron, HN				Kremer, LCM; Caron, HN			Anthracycline cardiotoxicity in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Emma Childrens Hosp, Dept Pediat Oncol, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Emma Children's Hospital; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Kremer, LCM (corresponding author), Emma Childrens Hosp, Dept Pediat Oncol, Amsterdam, Netherlands.			Kremer, Leontien/0000-0001-7422-3248					0	69	72	0	4	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					120	121		10.1056/NEJMp048113	http://dx.doi.org/10.1056/NEJMp048113			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247351	Green Published			2022-12-28	WOS:000222470700003
J	Yuan, CS; Wei, G; Dey, L; Karrison, T; Nahlik, L; Maleckar, S; Kasza, K; Ang-Lee, M; Moss, J				Yuan, CS; Wei, G; Dey, L; Karrison, T; Nahlik, L; Maleckar, S; Kasza, K; Ang-Lee, M; Moss, J			Brief communication: American ginseng reduces warfarin's effect in healthy patients - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							ST-JOHNS WORT; DRUG-INTERACTIONS; METABOLISM; PLATELETS; UPDATE; GINKGO	Background: People using prescription medication often concurrently take herbal supplements. in a case report, the anticoagulant effect of warfarin decreased after patients consumed ginseng. Objective: To evaluate the interactions between American ginseng and warfarin. Design: Randomized, double-blind, placebo-controlled trial. Setting: General Clinical Research Center, University of Chicago, Chicago, Illinois. Participants: 20 healthy patients. Intervention: in this 4-week study, 20 patients received warfarin for 3 days during weeks 1 and 4. Beginning in week 2, patients were assigned to receive either American ginseng or placebo. Measurements: International normalized ratio (INR) and plasma warfarin level. Results: The peak INR statistically significantly decreased after 2 weeks of ginseng administration compared with placebo (difference between ginseng and placebo, -0.19 [95% Cl, -0.36 to -0.07]; P = 0.0012). The INR area under the curve (AUC), peak plasma warfarin level, and warfarin AUC were also statistically significantly reduced in the ginseng group as compared with the placebo group. Peak INR and peak plasma warfarin level were positively correlated. Limitations: The study sample consisted of young, healthy volunteers in a research setting rather than patients taking therapeutic doses of warfarin. Conclusions: American ginseng reduces warfarin's anticoagulant effect. When prescribing warfarin, physicians should ask patients about ginseng use.	Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Comm Clin Pharmacol & Pharmacogen,Anticoagulat Con, Chicago, IL 60637 USA	University of Chicago	Yuan, CS (corresponding author), Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Comm Clin Pharmacol & Pharmacogen,Anticoagulat Con, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.	cyuan@uchicago.edu			NCCIH NIH HHS [AT00563] Funding Source: Medline; NCI NIH HHS [CA79042, CA14599] Funding Source: Medline; NCRR NIH HHS [M01 RR00055] Funding Source: Medline; NIGMS NIH HHS [T32-GM07019] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014599, R01CA079042] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT000563] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000055] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007019] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ang-Lee MK, 2001, JAMA-J AM MED ASSOC, V286, P208, DOI 10.1001/jama.286.2.208; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; BEERS MH, 1999, MERCK MANUAL DIAGNOS, P902; Ernst E, 2002, ANN INTERN MED, V136, P42, DOI 10.7326/0003-4819-136-1-200201010-00010; Gruenwald J., 2000, PDR HERBAL MED, P346; Harder S, 1996, CLIN PHARMACOKINET, V30, P416, DOI 10.2165/00003088-199630060-00002; HOLANDER M, 1973, NONPARAMETRIC STAT M, P78; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Kaminsky LS, 1997, PHARMACOL THERAPEUT, V73, P67, DOI 10.1016/S0163-7258(96)00140-4; Kaufman DW, 2002, JAMA-J AM MED ASSOC, V287, P337, DOI 10.1001/jama.287.3.337; KIMURA Y, 1988, J PHARM PHARMACOL, V40, P838, DOI 10.1111/j.2042-7158.1988.tb06285.x; Meyer UA, 1996, J PHARMACOKINET BIOP, V24, P449, DOI 10.1007/BF02353473; Park HJ, 1996, BIOL PHARM BULL, V19, P1434, DOI 10.1248/bpb.19.1434; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Roby CA, 2000, CLIN PHARMACOL THER, V67, P451, DOI 10.1067/mcp.2000.106793; Vaes LPJ, 2000, ANN PHARMACOTHER, V34, P1478, DOI 10.1345/aph.10031; Wittkowsky AK, 2001, J THROMB THROMBOLYS, V12, P67, DOI 10.1023/A:1012742628628; Zhang G D, 1980, Yao Xue Xue Bao, V15, P375; Zhu M, 1999, J PHARM PHARMACOL, V51, P175, DOI 10.1211/0022357991772105; 2000, NUTR BUSINESS J	20	159	173	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					23	27		10.7326/0003-4819-141-1-200407060-00011	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238367				2022-12-28	WOS:000222427600004
J	Watts, J				Watts, J			Wan Yanhai, Director of the Aizhixing Institute of Health Education - Profile	LANCET			English	Biographical-Item												llamaman@mub.biglobe.ne.jp							0	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					21	21		10.1016/S0140-6736(04)16548-3	http://dx.doi.org/10.1016/S0140-6736(04)16548-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15237533				2022-12-28	WOS:000222392900013
J	Watts, G				Watts, G			Science commentary: High hopes for cannabinoid analgesia	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material											Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						Benson J.A., 1999, MARIJUANA MED; Farquhar-Smith WP, 2000, MOL CELL NEUROSCI, V15, P510, DOI 10.1006/mcne.2000.0844; Svendsen KB, 2004, BMJ-BRIT MED J, V329, P253, DOI 10.1136/bmj.38149.566979.AE; Tanda G, 2003, PSYCHOPHARMACOLOGY, V169, P115, DOI 10.1007/s00213-003-1485-z; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198	5	4	4	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2004	329	7460					257	258		10.1136/bmj.38168.627292.0B	http://dx.doi.org/10.1136/bmj.38168.627292.0B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BY	15258005	Green Submitted, Green Published			2022-12-28	WOS:000223133300014
J	Dwyer, G; Dushoff, J; Yee, SH				Dwyer, G; Dushoff, J; Yee, SH			The combined effects of pathogens and predators on insect outbreaks	NATURE			English	Article							NUCLEAR POLYHEDROSIS-VIRUS; GYPSY-MOTH LEPIDOPTERA; FIR TUSSOCK MOTH; NATURAL ENEMIES; POPULATION-CYCLES; LYMANTRIIDAE; SYNCHRONY; FOREST; DYNAMICS; CATERPILLAR	The economic damage caused by episodic outbreaks of forest-defoliating insects has spurred much research(1), yet why such outbreaks occur remains unclear(2). Theoretical biologists argue that outbreaks are driven by specialist pathogens or parasitoids, because host-pathogen and host-parasitoid models show large-amplitude, long-period cycles resembling time series of outbreaks(3,4). Field biologists counter that outbreaks occur when generalist predators fail, because predation in low-density defoliator populations is usually high enough to prevent outbreaks(5-8). Neither explanation is sufficient, however, because the time between outbreaks in the data is far more variable than in host-pathogen and host-parasitoid models(1,2), and far shorter than in generalist-predator models(9-11). Here we show that insect outbreaks can be explained by a model that includes both a generalist predator and a specialist pathogen. In this host pathogen-predator model, stochasticity causes defoliator densities to fluctuate erratically between an equilibrium maintained by the predator, and cycles driven by the pathogen(12,13). Outbreaks in this model occur at long but irregular intervals, matching the data. Our results suggest that explanations of insect outbreaks must go beyond classical models to consider interactions among multiple species.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	University of Chicago; Princeton University	Dwyer, G (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	gdwyer@uchicago.edu	Dwyer, Greg/L-1134-2015	Dwyer, Greg/0000-0002-7387-2075				ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; Bjornstad ON, 2000, J ANIM ECOL, V69, P869, DOI 10.1046/j.1365-2656.2000.00444.x; Cory JS, 1997, BACULOVIRUSES, P301, DOI DOI 10.1007/978-1-4899-1834-5_12; Dennis B, 2001, ECOL MONOGR, V71, P277, DOI 10.1890/0012-9615(2001)071[0277:ECACDI]2.0.CO;2; Dwyer G, 1997, AM NAT, V150, P685, DOI 10.1086/286089; Dwyer G, 2000, AM NAT, V156, P105, DOI 10.1086/303379; Elkinton JS, 1996, ECOLOGY, V77, P2332, DOI 10.2307/2265735; GOULD JR, 1990, J ANIM ECOL, V59, P213, DOI 10.2307/5169; HOLLING C. S., 1959, CANADIAN ENT, V91, P293; Hunter Alison F., 1995, P41, DOI 10.1016/B978-012159270-7/50004-X; Kendall BE, 1999, ECOLOGY, V80, P1789, DOI 10.1890/0012-9658(1999)080[1789:WDPCAS]2.0.CO;2; Klemola T, 2002, OIKOS, V99, P83, DOI 10.1034/j.1600-0706.2002.990109.x; Liebhold A, 1996, RES POPUL ECOL, V38, P87, DOI 10.1007/BF02514974; Liebhold A, 2000, POPUL ECOL, V42, P205, DOI 10.1007/PL00011999; LUDWIG D, 1978, J ANIM ECOL, V47, P315, DOI 10.2307/3939; MASON RR, 1983, ENVIRON ENTOMOL, V12, P587, DOI 10.1093/ee/12.2.587; MAY RM, 1977, NATURE, V269, P471, DOI 10.1038/269471a0; MURRAY KD, 1989, J INVERTEBR PATHOL, V53, P324, DOI 10.1016/0022-2011(89)90096-7; MYERS JH, 1988, ADV ECOL RES, V18, P179; Parry D, 1997, ECOL ENTOMOL, V22, P97, DOI 10.1046/j.1365-2311.1997.00022.x; RAND DA, 1991, P ROY SOC B-BIOL SCI, V246, P179, DOI 10.1098/rspb.1991.0142; Ruohomaki K, 2000, POPUL ECOL, V42, P211, DOI 10.1007/PL00012000; Scheffer M, 2001, NATURE, V413, P591, DOI 10.1038/35098000; Schwerdtfeger F., 1941, Zeitschrift fuer Angewandte Entomologie, V28, P254; SHEPHERD RF, 1988, MEM ENTOMOL SOC CAN, P107, DOI 10.4039/entm120146107-1; SOUTHWOOD TRE, 1976, J ANIM ECOL, V45, P949, DOI 10.2307/3591; VARLEY GC, 1973, INSECT POPULATION EC, P135; WILLIAMS DW, 1991, J ECON ENTOMOL, V84, P1508, DOI 10.1093/jee/84.5.1508; WILLIAMS DW, 1995, ENVIRON ENTOMOL, V24, P987, DOI 10.1093/ee/24.5.987; WOODS SA, 1987, J INVERTEBR PATHOL, V50, P151, DOI 10.1016/0022-2011(87)90115-7	30	181	190	7	95	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					341	345		10.1038/nature02569	http://dx.doi.org/10.1038/nature02569			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254536				2022-12-28	WOS:000222631200039
J	Trujillo Bueno, J; Shchukina, N; Ramos, AA				Trujillo Bueno, J; Shchukina, N; Ramos, AA			A substantial amount of hidden magnetic energy in the quiet Sun	NATURE			English	Article							2ND SOLAR SPECTRUM; SCATTERING POLARIZATION; FIELDS; TURBULENT; DIAGNOSTICS; PHOTOSPHERE; LINES; CHROMOSPHERE; ATMOSPHERE; NETWORK	Deciphering and understanding the small-scale magnetic activity of the quiet solar photosphere should help to solve many of the key problems of solar and stellar physics, such as the magnetic coupling to the outer atmosphere and the coronal heating(1-3). At present, we can see only similar to1 per cent of the complex magnetism of the quiet Sun(1,4-7), which highlights the need to develop a reliable way to investigate the remaining 99 per cent. Here we report three-dimensional radiative transfer modelling of scattering polarization in atomic and molecular lines that indicates the presence of hidden, mixed-polarity fields on subresolution scales. Combining this modelling with recent observational data(8-11), we find a ubiquitous tangled magnetic field with an average strength of similar to130 G, which is much stronger in the intergranular regions of solar surface convection than in the granular regions. So the average magnetic energy density in the quiet solar photosphere is at least two orders of magnitude greater than that derived from simplistic one-dimensional investigations(12,13), and sufficient to balance radiative energy losses from the solar chromosphere.	Inst Astrofis Canarias, E-38205 Tenerife, Spain; CSIC, E-28006 Madrid, Spain; Natl Acad Sci, Main Astron Observ, UA-03680 Kiev, Ukraine	Instituto de Astrofisica de Canarias; Consejo Superior de Investigaciones Cientificas (CSIC); National Academy of Sciences Ukraine; Main Astronomical Observatory of NASU	Trujillo Bueno, J (corresponding author), Inst Astrofis Canarias, E-38205 Tenerife, Spain.	jtb@iac.es	Ramos, Andrés Asensio/AAE-1291-2019; Bueno, Javier Trujillo/AAE-5264-2019; Shchukina, Nataliia/AAZ-9374-2020					Almeida JS, 2003, ASTROPHYS J, V585, P536, DOI 10.1086/346077; Almeida JS, 2000, ASTROPHYS J, V532, P1215, DOI 10.1086/308603; ANDERSON LS, 1989, ASTROPHYS J, V346, P1010, DOI 10.1086/168083; Asplund M, 2000, ASTRON ASTROPHYS, V359, P729; Bommier V, 2002, ASTRON ASTROPHYS, V381, P241, DOI 10.1051/0004-6361:20011571; Cattaneo F, 1999, ASTROPHYS J, V515, pL39, DOI 10.1086/311962; Cerdena ID, 2003, ASTROPHYS J, V582, pL55, DOI 10.1086/346199; DEGL'INNOCENTI EL, 1983, SOL PHYS, V85, P3, DOI 10.1007/BF00148254; Degl'Innocenti EL, 1998, NATURE, V392, P256, DOI 10.1038/32603; Faurobert M, 2001, ASTRON ASTROPHYS, V378, P627, DOI 10.1051/0004-6361:20011263; FAUROBERTSCHOLL M, 1995, ASTRON ASTROPHYS, V298, P289; GANDORFER A, 2000, 2 SOLAR SPECTRUM, V1; Hanle W, 1924, Z PHYS, V30, P93, DOI 10.1007/BF01331827; Khomenko EV, 2003, ASTRON ASTROPHYS, V408, P1115, DOI 10.1051/0004-6361:20030604; Lin HS, 1999, ASTROPHYS J, V514, P448, DOI 10.1086/306925; Priest E. R., 2000, MAGNETIC RECONNECTIO; Schrijver CJ, 2003, ASTROPHYS J, V597, pL165, DOI 10.1086/379870; Schrijver CJ, 1998, NATURE, V394, P152, DOI 10.1038/28108; Shchukina N, 2003, ASTR SOC P, V307, P336; Socas-Navarro H, 2003, ASTROPHYS J, V593, P581, DOI 10.1086/376504; STEIN RF, 2003, ASP IAU S, V210, P169; Stenflo J., 1994, SOLAR MAGNETIC FIELD; STENFLO JO, 1982, SOL PHYS, V80, P209, DOI 10.1007/BF00147969; Stenflo JO, 2003, ASTR SOC P, V307, P385; Stenflo JO, 1997, ASTRON ASTROPHYS, V322, P985; Trujillo Bueno J, 2003, ASTR SOC P, V307, P407; Trujillo Bueno J, 2001, ASTR SOC P, V236, P141; Trujillo Bueno J, 2001, ASTR SOC P, V236, P161; Trujillo Bueno J, 2003, ASTR SOC P, V288, P551; Trujillo Bueno J, 2002, ASTROPHYS J, V566, pL53, DOI 10.1086/339442	30	337	337	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					326	329		10.1038/nature02669	http://dx.doi.org/10.1038/nature02669			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254531	Green Submitted			2022-12-28	WOS:000222631200034
J	Zhang, JH; Zhao, YS				Zhang, JH; Zhao, YS			RETRACTED: Formation of zirconium metallic glass (Retracted Article. See vol 437, pg 1057, 2005)	NATURE			English	Article; Retracted Publication							PRESSURE-INDUCED AMORPHIZATION; BCC PHASE-TRANSITION; AMORPHOUS-ALLOYS; DECOMPOSITION; ZR; CRYSTALLIZATION; PHONONS; LIQUIDS; MODEL	Bulk metallic glasses are commonly produced by the rapid cooling of liquid alloys(1). They have emerged over the past decade as a novel class of materials, with attractive properties and technological promise(1,2). The bulk metallic glasses so far produced contain three or more component elements(3,4). These complex compositions are necessary to frustrate the crystallization of the liquid melt on cooling, but can also lead to phase separation, which is detrimental to the thermal and mechanical properties of metallic glasses(5-8). Here we report, using X-ray diffraction measurements, the formation of a bulk metallic glass from elemental zirconium at high static pressures and low temperatures ( relative to its melting temperature at atmospheric pressure). Amorphous zirconium can be recovered at ambient conditions and demonstrates a superior thermal stability compared to amorphous alloys(3,9), which could lead to new high-temperature applications of amorphous metals.	Los Alamos Natl Lab, LANSCE Div, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Zhang, JH (corresponding author), Los Alamos Natl Lab, LANSCE Div, POB 1663, Los Alamos, NM 87545 USA.	jzhang@lanl.gov	Zhao, Yusheng/ABB-2273-2021; zhao, yang/GXF-4424-2022; Zhao, Yusheng/B-9448-2018	Zhao, Yusheng/0000-0003-1640-5216; Zhao, Yusheng/0000-0003-1640-5216				Ashby M.F., 1986, ENG MAT, V2; BUSCH R, 1995, APPL PHYS LETT, V67, P1544, DOI 10.1063/1.114487; Busch R, 1998, MATER SCI FORUM, V269-2, P547, DOI 10.4028/www.scientific.net/MSF.269-272.547; Busch R, 2000, JOM-J MIN MET MAT S, V52, P39, DOI 10.1007/s11837-000-0160-7; DECKER DL, 1971, J APPL PHYS, V42, P3239, DOI 10.1063/1.1660714; Eckert J, 1998, MATER T JIM, V39, P623, DOI 10.2320/matertrans1989.39.623; HEIMING A, 1991, PHYS REV B, V43, P10948, DOI 10.1103/PhysRevB.43.10948; HEMLEY RJ, 1988, NATURE, V334, P52, DOI 10.1038/334052a0; HIGHMORE RJ, 1989, NATURE, V339, P363, DOI 10.1038/339363a0; Inoue A, 2000, ACTA MATER, V48, P279, DOI 10.1016/S1359-6454(99)00300-6; JAYARAMAN A, 1963, PHYS REV, V131, P644, DOI 10.1103/PhysRev.131.644; Johnson WL, 1999, MRS BULL, V24, P42, DOI 10.1557/S0883769400053252; Jona F, 2003, J PHYS-CONDENS MAT, V15, P5009, DOI 10.1088/0953-8984/15/29/312; Kundig AA, 2001, SCRIPTA MATER, V44, P1269, DOI 10.1016/S1359-6462(01)00691-1; Loffler JF, 2000, APPL PHYS LETT, V76, P3394, DOI 10.1063/1.126657; Loffler JF, 2003, INTERMETALLICS, V11, P529, DOI 10.1016/S0966-9795(03)00046-3; Miller MK, 1998, MAT SCI ENG A-STRUCT, V250, P133, DOI 10.1016/S0921-5093(98)00549-8; MISHIMA O, 1984, NATURE, V310, P393, DOI 10.1038/310393a0; Olijnyk H, 1997, PHYS REV B, V56, P10751, DOI 10.1103/PhysRevB.56.10751; Ostanin SA, 1998, PHYS REV B, V57, P13485, DOI 10.1103/PhysRevB.57.13485; Pinsook U, 1999, PHYS REV B, V59, P13642, DOI 10.1103/PhysRevB.59.13642; Richet P, 1997, EUR J MINERAL, V9, P907; VAUGHAN MT, 1998, REV HIGH PRESSURE SC, V7, P1520; Wang WH, 2002, INTERMETALLICS, V10, P1249, DOI 10.1016/S0966-9795(02)00140-1; Weidner D.J., 1992, GEOPHYS MONOGR SER, V67, P13; XIA H, 1990, PHYS REV LETT, V64, P204, DOI 10.1103/PhysRevLett.64.204; XIA H, 1991, PHYS REV B, V44, P10374, DOI 10.1103/PhysRevB.44.10374; Zhao YS, 1999, HIGH PRESSURE RES, V16, P161, DOI 10.1080/08957959908200289	28	45	48	5	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					332	335		10.1038/nature02715	http://dx.doi.org/10.1038/nature02715			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254533				2022-12-28	WOS:000222631200036
J	White, JML; Barker, RD; Salisbury, JR; Fife, AJ; Lucas, SB; Warhurst, DC; Higgins, EM				White, JML; Barker, RD; Salisbury, JR; Fife, AJ; Lucas, SB; Warhurst, DC; Higgins, EM			Granulomatous amoebic encephalitis	LANCET			English	Editorial Material							BALAMUTHIA-MANDRILLARIS		Kings Coll Hosp London, Dept Dermatol, London, England; Kings Coll Hosp London, Dept Med, London, England; Kings Coll Hosp London, Dept Histopathol, London, England; Kings Coll Hosp London, Dept Microbiol, London, England; St Thomas Hosp, Dept Histopathol, London, England; Univ London London Sch Hyg & Trop Med, LSHTM Diagnost Parasitol Lab, London WC1E 7HT, England	King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; King's College Hospital NHS Foundation Trust; King's College Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	White, JML (corresponding author), Kings Coll Hosp London, Dept Dermatol, Denmark Hill, London, England.	jonathan.White@kingsch.nhs.uk	warhurst, david c/C-3428-2013	Salisbury, Jonathan/0000-0002-5889-4276				Deetz TR, 2003, CLIN INFECT DIS, V37, P1304, DOI 10.1086/379020; Deol I, 2000, SURG NEUROL, V53, P611, DOI 10.1016/S0090-3019(00)00232-9; Galarza M, 2002, PEDIATR NEUROL, V26, P153, DOI 10.1016/S0887-8994(01)00360-5; Healy JF, 2002, AM J NEURORADIOL, V23, P486; Schuster FL, 2003, J CLIN MICROBIOL, V41, P3175, DOI 10.1128/JCM.41.7.3175-3180.2003	5	19	20	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					220	220		10.1016/S0140-6736(04)16640-3	http://dx.doi.org/10.1016/S0140-6736(04)16640-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246740				2022-12-28	WOS:000222612200038
J	Zhang, XD; Beaulieu, JM; Sotnikova, TD; Gainetdinov, RR; Caron, MG				Zhang, XD; Beaulieu, JM; Sotnikova, TD; Gainetdinov, RR; Caron, MG			Tryptophan hydroxylase-2 controls brain serotonin synthesis	SCIENCE			English	Article							MICE; DISORDERS; MODELS		Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Lab, Durham, NC 27710 USA; Duke Univ, Med Ctr, Inst Genome Sci & Policy, Ctr Models Human Dis, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst Lab, Box 3287, Durham, NC 27710 USA.	caron002@mc.duke.edu	Beaulieu, Jean-Martin/A-7598-2008; Gainetdinov, Raul R/G-5875-2011; Sotnikova, Tatyana D/T-9992-2017	Beaulieu, Jean-Martin/0000-0002-0446-7447; Gainetdinov, Raul R/0000-0003-2951-6038; 	NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH060451] Funding Source: NIH RePORTER; NIMH NIH HHS [MH60451] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bonasera SJ, 2000, PHARMACOL THERAPEUT, V88, P133, DOI 10.1016/S0163-7258(00)00087-5; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; Gingrich JA, 2001, PSYCHOPHARMACOLOGY, V155, P1, DOI 10.1007/s002130000573; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Lucki I, 2001, PSYCHOPHARMACOLOGY, V155, P315, DOI 10.1007/s002130100694; Murphy DL, 2003, GENES BRAIN BEHAV, V2, P350, DOI 10.1046/j.1601-1848.2003.00049.x; Walther DJ, 2003, SCIENCE, V299, P76, DOI 10.1126/science.1078197; Ye S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.17.e88; Zhang X, UNPUB	9	516	549	4	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					217	217		10.1126/science.1097540	http://dx.doi.org/10.1126/science.1097540			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247473				2022-12-28	WOS:000222501000044
J	Bates, T; Anic, A; Marusic, M; Marusic, A				Bates, T; Anic, A; Marusic, M; Marusic, A			Authorship criteria and disclosure of contributions - Comparison of 3 general medical journals with different author contribution forms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESEARCHER CONTRIBUTIONS; RESEARCH ARTICLES	Context A number of general medical journals and the international Committee of Medical Journal Editors (ICMJE) request authors to disclose their contributions. Little is known about the effect of journal policies on authors' disclosure of their contributions. Objective To determine the number of named authors who do not meet ICMJE criteria for authorship, according to their published contributions, in 3 medical journals with different contribution disclosure practices. Design Observational study of authors' contributions in research articles published in 2002 in Annals of Internal Medicine (n = 72), BMJ (n = 107), and JAMA (n = 81). BMJ asks authors to describe research contributions in their own words; Annals asks authors to choose from a list of coded contributions; and JAMA uses a structured checklist with instructions on contributions that qualify for ICMJE authorship criteria. Honorary authorship was defined as the lack of contribution from the first ICMJE criterion (study conception and design, or acquisition of data, or analysis and interpretation of data) and/or second (drafting the article or critical revision for important intellectual content) ICMJE criterion. Results According to authors' published contributions, the number of honorary authors was highest in Annals (121/562 authors, 21.5%), followed by BMJ (46/482, 9.5%), and JAMA (3/641, 0.5%) (chi(2)(2) = 146.67, P<.001). The number of articles with 2 honorary authors was 60% in Annals, 21% in BMJ, and 4% in JAMA. Honorary authors had fewer published contributions than authors who met ICMJE criteria and were positioned more toward the end of the byline. Honorary authors either lacked contributions for both ICMJE criteria (10% in Annals and 22% in BMJ) or contributions to the second ICMJE criterion (75% in Annals, 67% in BMJ, and 2 out of 3 in JAMA). Conclusions General medical journals differed in prevalence of honorary authors according to published research contributions of named authors. Different authorship/contributorship policies and procedures should be explored as a possible explanation for the differences in contributions disclosed by authors among these journals.	Univ Zagreb, Sch Med, Zagreb 10000, Croatia	University of Zagreb	Marusic, A (corresponding author), Univ Zagreb, Sch Med, Salata 3, Zagreb 10000, Croatia.	marusica@mef.hr	Marusic, Ana/E-7683-2013; Marusic, Matko/E-1834-2017	Marusic, Ana/0000-0001-6272-0917; Marusic, Matko/0000-0001-5562-1777				Bhopal R, 1997, BRIT MED J, V314, P1009, DOI 10.1136/bmj.314.7086.1009; Flanagin A, 1998, JAMA-J AM MED ASSOC, V280, P222, DOI 10.1001/jama.280.3.222; Hwang SS, 2003, RADIOLOGY, V226, P16, DOI 10.1148/radiol.2261011255; *INT COMM MED J ED, UNPUB BIOMEDICAL J; Khan KS, 1999, AM J OBSTET GYNECOL, V181, P503, DOI 10.1016/S0002-9378(99)70585-5; LAINE C, 2001, 4 INT C PEER REV BIO; MARUSIC M, IN PRESS SCI ENG ETH; Rennie D, 1997, JAMA-J AM MED ASSOC, V278, P579, DOI 10.1001/jama.278.7.579; VANROYEN S, 2001, 4 INT C PEER REV BIO; Yank V, 1999, ANN INTERN MED, V130, P661, DOI 10.7326/0003-4819-130-8-199904200-00013	10	132	137	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					86	88		10.1001/jama.292.1.86	http://dx.doi.org/10.1001/jama.292.1.86			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238595	Bronze			2022-12-28	WOS:000222448100031
J	Kopp, VI; Churikov, VM; Singer, J; Chao, N; Neugroschl, D; Genack, AZ				Kopp, VI; Churikov, VM; Singer, J; Chao, N; Neugroschl, D; Genack, AZ			Chiral fiber gratings	SCIENCE			English	Article							FABRICATION	Chiral gratings with double helix symmetry were produced by twisting glass optical fiber with a noncircular core cross section as it passed through a miniature oven. We observed polarization-selective transmission in chiral fibers with pitches of tens of micrometers. Two modes of optical interaction were differentiated. In chiral long-period gratings, dips in transmission were observed at wavelengths associated with scattering into distinct cladding modes mediated by the chiral grating. In chiral intermediate-period gratings, a broad scattering band was observed. These gratings can be used to produce sharp or broad polarization-selective filters.	Chiral Photon Inc, Clifton, NJ 07012 USA; CUNY Queens Coll, Dept Phys, Flushing, NY 11367 USA	City University of New York (CUNY) System; Queens College NY (CUNY)	Kopp, VI (corresponding author), Chiral Photon Inc, Clifton, NJ 07012 USA.	vickopp@chiralphotonics.com						Bhatia V, 1996, OPT LETT, V21, P692, DOI 10.1364/OL.21.000692; Chen KP, 2002, IEEE PHOTONIC TECH L, V14, P170, DOI 10.1109/68.980495; Grubsky V, 1999, IEEE PHOTONIC TECH L, V11, P87, DOI 10.1109/68.736403; Huang HC, 1997, APPL OPTICS, V36, P6968, DOI 10.1364/AO.36.006968; Kopp VI, 2003, OPT LETT, V28, P1876, DOI 10.1364/OL.28.001876; NOLAN DA, 2001, Patent No. 6229937; Othonos A.. K. K, 1999, ART H OPTO; Rashleigh S. C., 1983, Journal of Lightwave Technology, VLT-1, P312, DOI 10.1109/JLT.1983.1072121; ULRICH R, 1979, APPL OPTICS, V18, P2241, DOI 10.1364/AO.18.002241	9	186	199	0	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					74	75		10.1126/science.1097631	http://dx.doi.org/10.1126/science.1097631			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232101				2022-12-28	WOS:000222386000036
J	Ramachandran, N; Hainsworth, E; Bhullar, B; Eisenstein, S; Rosen, B; Lau, AY; Walter, JC; LaBaer, J				Ramachandran, N; Hainsworth, E; Bhullar, B; Eisenstein, S; Rosen, B; Lau, AY; Walter, JC; LaBaer, J			Self-assembling protein microarrays	SCIENCE			English	Article							DNA-REPLICATION; S-PHASE; EXPRESSION; COMPLEX; ORIGINS; IDENTIFICATION; BINDING; CLONING; ARRAYS	Protein microarrays provide a powerful tool for the study of protein function. However, they are not widely used, in part because of the challenges in producing proteins to spot on the arrays. We generated protein microarrays by printing complementary DNAs onto glass slides and then translating target proteins with mammalian reticulocyte lysate. Epitope tags fused to the proteins allowed them to be immobilized in situ. This obviated the need to purify proteins, avoided protein stability problems during storage, and captured sufficient protein for functional studies. We used the technology to map pairwise interactions among 29 human DNA replication initiation proteins, recapitulate the regulation of Cdt1 binding to select replication proteins, and map its geminin-binding domain.	Harvard Univ, Sch Med, Harvard Inst Proteom, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02141 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Technol & Engn Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	LaBaer, J (corresponding author), Harvard Univ, Sch Med, Harvard Inst Proteom, Dept Biol Chem & Mol Pharmacol, 320 Charles St, Cambridge, MA 02141 USA.	josh@hms.harvard.edu		Lau, Albert/0000-0002-0967-7558; Walter, Johannes/0000-0002-4186-7570	NCI NIH HHS [R21 CA99191-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA099191] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Braun P, 2002, P NATL ACAD SCI USA, V99, P2654, DOI 10.1073/pnas.042684199; Brizuela L, 2001, MOL BIOCHEM PARASIT, V118, P155, DOI 10.1016/S0166-6851(01)00366-8; Cahill DJ, 2003, ADV BIOCHEM ENG BIOT, V83, P177; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Cook JG, 2004, J BIOL CHEM, V279, P9625, DOI 10.1074/jbc.M311933200; Dhar SK, 2001, J BIOL CHEM, V276, P29067, DOI 10.1074/jbc.M103078200; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Haab BB, 2001, GENOME BIOL, V2; He MY, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.15.e73; Jona G, 2003, CURR OPIN MOL THER, V5, P271; Kneissl M, 2003, J MOL BIOL, V327, P111, DOI 10.1016/S0022-2836(03)00079-2; Labaer J, 2004, PROTEOME ANALYSIS: INTERPRETING THE GENOME, P287, DOI 10.1016/B978-044451024-2/50028-X; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; MacBeath G, 2000, SCIENCE, V289, P1760; Masuda T, 2003, GENES CELLS, V8, P145, DOI 10.1046/j.1365-2443.2003.00621.x; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; Newman JRS, 2003, SCIENCE, V300, P2097, DOI 10.1126/science.1084648; RAMACHANDRAN N, UNPUB; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; Reboul J, 2003, NAT GENET, V34, P35, DOI 10.1038/ng1140; Vashee S, 2001, J BIOL CHEM, V276, P26666, DOI 10.1074/jbc.M102493200; Walhout AJM, 2000, METHOD ENZYMOL, V328, P575, DOI 10.1016/S0076-6879(00)28419-X; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Yanagi K, 2002, J BIOL CHEM, V277, P40871, DOI 10.1074/jbc.M206202200; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	28	445	498	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					86	90		10.1126/science.1097639	http://dx.doi.org/10.1126/science.1097639			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232106				2022-12-28	WOS:000222386000041
J	Wittkopp, PJ; Haerum, BK; Clark, AG				Wittkopp, PJ; Haerum, BK; Clark, AG			Evolutionary changes in cis and trans gene regulation	NATURE			English	Article							DROSOPHILA-MELANOGASTER; TRANSCRIPTIONAL REGULATION; EXPRESSION; RESCUE; SIMULANS; HYBRIDS; CROSSES; MOUSE	Differences in gene expression are central to evolution. Such differences can arise from cis-regulatory changes that affect transcription initiation, transcription rate and/or transcript stability in an allele-specific manner, or from trans-regulatory changes that modify the activity or expression of factors that interact with cis-regulatory sequences(1,2). Both cis- and trans-regulatory changes contribute to divergent gene expression, but their respective contributions remain largely unknown(3). Here we examine the distribution of cis- and trans-regulatory changes underlying expression differences between closely related Drosophila species, D. melanogaster and D. simulans, and show functional cis- regulatory differences by comparing the relative abundance of species-specific transcripts in F-1 hybrids(4,5). Differences in trans-regulatory activity were inferred by comparing the ratio of allelic expression in hybrids with the ratio of gene expression between species. Of 29 genes with interspecific expression differences, 28 had differences in cis- regulation, and these changes were sufficient to explain expression divergence for about half of the genes. Trans-regulatory differences affected 55% (16 of 29) of genes, and were always accompanied by cis-regulatory changes. These data indicate that interspecific expression differences are not caused by select trans-regulatory changes with widespread effects, but rather by many cis- acting changes spread throughout the genome.	Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA	Cornell University	Wittkopp, PJ (corresponding author), Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.	pw72@cornell.edu		Clark, Andrew/0000-0001-7159-8511				Ahmadian A, 2000, ANAL BIOCHEM, V280, P103, DOI 10.1006/abio.2000.4493; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barbash DA, 2000, GENETICS, V154, P1747; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Carroll S. B., 2001, DNA DIVERSITY MOL GE; Cowles CR, 2002, NAT GENET, V32, P432, DOI 10.1038/ng992; Davidson E. H., 2001, DEV EVOLUTION; DAVIDSON EH, P NATL ACAD SCI US, V100, P1475; Davis AW, 1996, NATURE, V380, P157, DOI 10.1038/380157a0; Gelbart W, 2003, NUCLEIC ACIDS RES, V31, P172, DOI 10.1093/nar/gkg094; Hollocher H, 2000, J EXP ZOOL, V288, P205, DOI 10.1002/1097-010X(20001015)288:3&lt;205::AID-JEZ2&gt;3.0.CO;2-S; Montooth KL, 2003, GENETICS, V165, P623; Neve B, 2002, BIOTECHNIQUES, V32, P1138, DOI 10.2144/02325dd03; Otto P, 1998, PROMEGA NOTES, V69, P19; Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003; Powell J. R., 1997, PROGR PROSPECTS EVOL; Ranz JM, 2003, SCIENCE, V300, P1742, DOI 10.1126/science.1085881; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; SAWAMURA K, 1993, GENETICS, V133, P307; Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434; Wray GA, 2003, MOL BIOL EVOL, V20, P1377, DOI 10.1093/molbev/msg140; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545; Yvert G, 2003, NAT GENET, V35, P57, DOI 10.1038/ng1222	23	560	576	5	113	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					85	88		10.1038/nature02698	http://dx.doi.org/10.1038/nature02698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229602				2022-12-28	WOS:000222356800048
J	Powsner, S				Powsner, S			Uses of error - Immediate and delayed learning	LANCET			English	Editorial Material									Yale New Haven Med Ctr, Dept Psychiat, New Haven, CT 06504 USA	Yale University	Powsner, S (corresponding author), Yale New Haven Med Ctr, Dept Psychiat, New Haven, CT 06504 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2127	2127		10.1016/S0140-6736(04)16502-1	http://dx.doi.org/10.1016/S0140-6736(04)16502-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220034				2022-12-28	WOS:000222268300009
J	von Hippel, PH				von Hippel, PH			Completing the view of transcriptional regulation	SCIENCE			English	Editorial Material							REPRESSOR-OPERATOR INTERACTION; COLI-LAC REPRESSOR; DIFFUSION-DRIVEN MECHANISMS; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; BETA-GALACTOSIDASE; NUCLEIC-ACIDS; DNA; BINDING		Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Oregon, Dept Chem, Eugene, OR 97403 USA	University of Oregon; University of Oregon	von Hippel, PH (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	petevh@molbio.uoregon.edu		von Hippel, Peter H./0000-0003-2512-8097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029158, R01GM015792, R37GM015792] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29158, GM-15792] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckwith J. R., 1970, LACTOSE OPERON; BERG OG, 1981, BIOCHEMISTRY-US, V20, P6929, DOI 10.1021/bi00527a028; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; GILBERT W, 1967, P NATL ACAD SCI USA, V58, P2415, DOI 10.1073/pnas.58.6.2415; GILBERT W, 1966, P NATL ACAD SCI USA, V56, P1891, DOI 10.1073/pnas.56.6.1891; HOGNESS DS, 1955, BIOCHIM BIOPHYS ACTA, V16, P99, DOI 10.1016/0006-3002(55)90188-8; Kalodimos CG, 2004, SCIENCE, V305, P386, DOI 10.1126/science.1097064; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; PARDEE AB, 1959, J MOL BIOL, V1, P165, DOI 10.1016/S0022-2836(59)80045-0; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; REVZIN A, 1977, BIOCHEMISTRY-US, V16, P4769, DOI 10.1021/bi00641a002; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; von Hippel P H, 1974, Proc Natl Acad Sci U S A, V71, P4808; WINTER RB, 1981, BIOCHEMISTRY-US, V20, P6961, DOI 10.1021/bi00527a030	17	45	46	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					350	352		10.1126/science.1101270	http://dx.doi.org/10.1126/science.1101270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256661				2022-12-28	WOS:000222662400025
J	Bok, H; Schill, KE; Faden, RR				Bok, H; Schill, KE; Faden, RR			Justice, ethnicity, and stem-cell banks	LANCET			English	Editorial Material									Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA		Schill, KE (corresponding author), Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA.	kschill@jhsph.edu						European Commission, 2003, HLTH STAT EUR UN NAR; Faden RR, 2003, HASTINGS CENT REP, V33, P13, DOI 10.2307/3527822	2	16	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					118	121		10.1016/S0140-6736(04)16650-6	http://dx.doi.org/10.1016/S0140-6736(04)16650-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246711				2022-12-28	WOS:000222612200004
J	Wollert, KC; Meyer, GP; Lotz, J; Ringes-Lichtenberg, S; Lippolt, P; Breidenbach, C; Fichtner, S; Korte, T; Hornig, B; Messinger, D; Arseniev, L; Hertenstein, B; Ganser, A; Drexler, H				Wollert, KC; Meyer, GP; Lotz, J; Ringes-Lichtenberg, S; Lippolt, P; Breidenbach, C; Fichtner, S; Korte, T; Hornig, B; Messinger, D; Arseniev, L; Hertenstein, B; Ganser, A; Drexler, H			Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial	LANCET			English	Article							PRACTICE GUIDELINES COMMITTEE; COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM-CELLS; ASSOCIATION TASK-FORCE; ISCHEMIC-MYOCARDIUM; ACC/AHA GUIDELINES; SYSTOLIC FUNCTION; AMERICAN-COLLEGE; STROMAL CELLS; ADULT	Background Emerging evidence suggests that stem cells and progenitor cells derived from bone marrow can be used to improve cardiac function in patients after acute myocardial infarction. In this randomised trial, we aimed to assess whether intracoronary transfer of autologous bone-marrow cells could improve global left-ventricular ejection fraction (LVEF) at 6 months' follow-up. Methods After successful percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction, 60 patients were randomly assigned to either a control group (n=30) that received optimum postinfarction medical treatment, or a bone-marrow-cell group (n=30) that received optimum medical treatment and intracoronary transfer of autologous bone-marrow cells 4.8 days (S D 1.3) after PCI. Primary endpoint was global left-ventricular ejection fraction (LVEF) change from baseline to 6 months' follow-up, as determined by cardiac MRI. Image analyses were done by two investigators blinded for treatment assignment. Analysis was per protocol. Findings Global LVEF at baseline (determined 3.5 days [SD 1.5] after PCI) was 51.3 (9.3%) in controls and 50.0 (10.0%) in the bone-marrow cell group (p=0.59). After 6 months, mean global LVEF had increased by 0.7 percentage points in the control group and 6.7 percentage points in the bone-marrow-cell group (p=0.0026). Transfer of bone-marrow cells enhanced left-ventricular systolic function primarily in myocardial segments adjacent to the infarcted area. Cell transfer did not increase the risk of adverse clinical events, in-stent restenosis, or proarrhythmic effects. Interpretation Intracoronary transfer of autologous bone-marrow-cells promotes improvement of left-ventricular systolic function in patients after acute myocardial infarction.	Hannover Med Sch, Dept Cardiol & Angiol, Abt Kardiol & Angiol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Diagnost Radiol, D-30625 Hannover, Germany; Hannover Med Sch, Dept Haematol & Oncol, D-30625 Hannover, Germany; IST, Mannheim, Germany	Hannover Medical School; Hannover Medical School; Hannover Medical School	Drexler, H (corresponding author), Hannover Med Sch, Dept Cardiol & Angiol, Abt Kardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany.	drexler.helmut@mh-hannover.de	Lotz, Joachim/G-3376-2015	Lotz, Joachim/0000-0002-1412-2741				Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beek AM, 2003, J AM COLL CARDIOL, V42, P895, DOI 10.1016/S0735-1097(03)00835-0; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; Chakraborty A, 2003, AM J PHYSIOL-CELL PH, V284, pC103, DOI 10.1152/ajpcell.00165.2002; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Giugliano RP, 2003, CIRCULATION, V108, P2828, DOI 10.1161/01.CIR.0000106684.71725.98; Heil M, 2004, CIRC RES, V94, P573, DOI 10.1161/01.RES.0000124603.46777.EB; Hunt SA, 2001, CIRCULATION, V104, P2996, DOI 10.1161/hc4901.102568; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Keeley EC, 2003, LANCET, V361, P13, DOI 10.1016/S0140-6736(03)12113-7; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Lorenz CH, 1999, J CARDIOVASC MAGN R, V1, P7, DOI 10.3109/10976649909080829; Montalescot G, 2001, NEW ENGL J MED, V344, P1895, DOI 10.1056/NEJM200106213442503; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Perin EC, 2003, CIRCULATION, V107, P935, DOI 10.1161/01.CIR.0000057526.10455.BD; Ryan TJ, 1999, CIRCULATION, V100, P1016, DOI 10.1161/01.CIR.100.9.1016; Schroeder AP, 2001, CARDIOLOGY, V96, P106, DOI 10.1159/000049092; Stone GW, 2002, NEW ENGL J MED, V346, P957, DOI 10.1056/NEJMoa013404; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; Vulliet PR, 2004, LANCET, V363, P783, DOI 10.1016/S0140-6736(04)15695-X; Wu E, 2001, LANCET, V357, P21, DOI 10.1016/S0140-6736(00)03567-4; Ziegelhoeffer T, 2004, CIRC RES, V94, P230, DOI 10.1161/01.RES.0000110419.50982.1C	28	1664	1908	1	61	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					141	148		10.1016/S0140-6736(04)16626-9	http://dx.doi.org/10.1016/S0140-6736(04)16626-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246726				2022-12-28	WOS:000222612200024
J	Diao, AP; Lowe, M				Diao, AP; Lowe, M			The Golgi goes fission	SCIENCE			English	Editorial Material							BREFELDIN-A; ADP-RIBOSYLATION; ARCHITECTURE; APPARATUS; MITOSIS; ENTRY; CELLS		Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Diao, AP (corresponding author), Univ Manchester, Sch Biol Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	martin.lowe@man.ac.uk						Barr FA, 2003, CURR OPIN CELL BIOL, V15, P405, DOI 10.1016/S0955-0674(03)00054-1; Carcedo CH, 2004, SCIENCE, V305, P93, DOI 10.1126/science.1097775; DEMATTEIS MA, 1994, P NATL ACAD SCI USA, V91, P1114, DOI 10.1073/pnas.91.3.1114; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Seemann J, 2000, NATURE, V407, P1022, DOI 10.1038/35039538; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Weigert R, 1997, J BIOL CHEM, V272, P14200, DOI 10.1074/jbc.272.22.14200; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587	10	5	5	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					48	49		10.1126/science.1100153	http://dx.doi.org/10.1126/science.1100153			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232093				2022-12-28	WOS:000222386000026
J	Chopra, M; Darnton-Hill, I				Chopra, M; Darnton-Hill, I			Tobacco and obesity epidemics: not so different after all?	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA	University of the Western Cape; Columbia University	Chopra, M (corresponding author), Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa.	mchopra@uwc.ac.za						Aguayo VM, 2003, BRIT MED J, V326, P127, DOI 10.1136/bmj.326.7381.127; *AM I CANC RES, 1997, FOOD NUTR PREV CANC; BETTCHER D, 2001, WG48 WHO COMM MACR H; Bhargava A, 2002, BRIT J NUTR, V88, P719, DOI 10.1079/BJN2002739; BOYD K, 1997, GLOBALISING FOOD AGR, P180; Chopra M, 2002, B WORLD HEALTH ORGAN, V80, P952; COLLIN J, 2002, HLTH IMPACTS GLOBALI, P61; Drewnowski A, 1997, NUTR REV, V55, P31, DOI 10.1111/j.1753-4887.1997.tb01593.x; Ebbeling CB, 2002, LANCET, V360, P473, DOI 10.1016/S0140-6736(02)09678-2; Egger G, 1997, BRIT MED J, V315, P477, DOI 10.1136/bmj.315.7106.477; Gardner G.T., 2000, UNDERFED OVERFED GLO; Hardeman W, 2000, INT J OBESITY, V24, P131, DOI 10.1038/sj.ijo.0801100; JACOBSEN MF, 2000, LIQUID CANDY SOFT DR; Joossens L, 1998, TOB CONTROL, V7, P66, DOI 10.1136/tc.7.1.66; Khan LK, 1999, ANNU REV NUTR, V19, pXIII, DOI 10.1146/annurev.nutr.19.1.0; Lang T, 2001, INT COOPERATION HLTH, P81; Martorell R, 2000, EUR J CLIN NUTR, V54, P247, DOI 10.1038/sj.ejcn.1600931; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Nestle Marion, 2003, FOOD POLITICS FOOD I; Pinstrup-Andersen P., 2001, African Journal of Food, Agriculture, Nutrition and Development, V1, P9; Reardon T., 2002, Development Policy Review, V20, P371, DOI 10.1111/1467-7679.00178; Taylor Allyn L., 1996, YALE J INT L, V21, P257; WHO, 2003, DIET NUTR PREVENTION, V916	23	98	98	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1558	1560		10.1136/bmj.328.7455.1558	http://dx.doi.org/10.1136/bmj.328.7455.1558			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217877	Green Published			2022-12-28	WOS:000222392700029
J	Buzsaki, G; Draguhn, A				Buzsaki, G; Draguhn, A			Neuronal oscillations in cortical networks	SCIENCE			English	Review							INTERNEURON DIVERSITY SERIES; HIPPOCAMPAL PYRAMIDAL CELLS; HIGH-FREQUENCY OSCILLATIONS; IN-VITRO; THETA-RHYTHM; PHASE PRECESSION; SYNCHRONIZATION; BRAIN; NEOCORTEX; SLEEP	Clocks tick, bridges and skyscrapers vibrate, neuronal networks oscillate. Are neuronal oscillations an inevitable by-product, similar to bridge vibrations, or an essential part of the brain's design? Mammalian cortical neurons form behavior-dependent oscillating networks of various sizes, which span five orders of magnitude in frequency. These oscillations are phylogenetically preserved, suggesting that they are functionally relevant. Recent findings indicate that network oscillations bias input selection, temporally link neurons into assemblies, and facilitate synaptic plasticity, mechanisms that cooperatively support temporal representation and long-term consolidation of information.	Rutgers State Univ, Dept Mol & Behav Neurosci, Newark, NJ 07102 USA; Univ Heidelberg, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany	Rutgers State University Newark; Rutgers State University New Brunswick; Ruprecht Karls University Heidelberg	Buzsaki, G (corresponding author), Rutgers State Univ, Dept Mol & Behav Neurosci, Newark, NJ 07102 USA.	buzsaki@axon.rutgers.edu	anand, amit/A-7222-2009	Buzsaki, Gyorgy/0000-0002-3100-4800				ALONSO A, 1989, NATURE, V342, P175, DOI 10.1038/342175a0; BAIR W, 1994, J NEUROSCI, V14, P2870; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; Berger H, 1929, ARCH PSYCHIAT NERVEN, V87, P527, DOI 10.1007/BF01797193; Bragin A, 1999, HIPPOCAMPUS, V9, P137; Braitenberg V, 1998, CORTEX STAT GEOMETRY; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Csicsvari J, 2003, NEURON, V37, P311, DOI 10.1016/S0896-6273(02)01169-8; Destexhe A, 2003, PHYSIOL REV, V83, P1401, DOI 10.1152/physrev.00012.2003; Dragoi G, 2003, NEURON, V39, P843, DOI 10.1016/S0896-6273(03)00465-3; Draguhn A, 1998, NATURE, V394, P189, DOI 10.1038/28184; Engel AK, 2001, NAT REV NEUROSCI, V2, P704, DOI 10.1038/35094565; Freeman WJ, 2000, J NEUROSCI METH, V95, P111, DOI 10.1016/S0165-0270(99)00160-0; Gerstner W, 2002, SPIKING NEURON MODEL; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Glass L, 2001, NATURE, V410, P277, DOI 10.1038/35065745; GOLDBERG L, 1985, APPL PHYS LETT, V46, P236, DOI 10.1063/1.95694; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Harris KD, 2003, NATURE, V424, P552, DOI 10.1038/nature01834; Harris KD, 2002, NATURE, V417, P738, DOI 10.1038/nature00808; Hasselmo ME, 2002, NEURAL COMPUT, V14, P793, DOI 10.1162/089976602317318965; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; Hutcheon B, 2000, TRENDS NEUROSCI, V23, P216, DOI 10.1016/S0166-2236(00)01547-2; Huxter J, 2003, NATURE, V425, P828, DOI 10.1038/nature02058; JOHN ER, 1988, SCIENCE, V239, P162, DOI 10.1126/science.3336779; Kahana MJ, 2001, CURR OPIN NEUROBIOL, V11, P739, DOI 10.1016/S0959-4388(01)00278-1; Klimesch W, 1999, BRAIN RES REV, V29, P169, DOI 10.1016/S0165-0173(98)00056-3; Kopell N, 2000, P NATL ACAD SCI USA, V97, P1867, DOI 10.1073/pnas.97.4.1867; Laurent G, 2002, NAT REV NEUROSCI, V3, P884, DOI 10.1038/nrn964; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; Llinas RR, 1999, P NATL ACAD SCI USA, V96, P15222, DOI 10.1073/pnas.96.26.15222; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; Maier N, 2003, J PHYSIOL-LONDON, V550, P873, DOI 10.1113/jphysiol.2003.044602; Marshall L, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-02-j0001.2002; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MIROLLO RE, 1990, SIAM J APPL MATH, V50, P1645, DOI 10.1137/0150098; Nunez P.L., 1995, NEOCORTICAL DYNAMICS; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Penttonen Markku, 2003, Thalamus & Related Systems, V2, P145, DOI 10.1016/S1472-9288(03)00007-4; Reyes AD, 2003, NAT NEUROSCI, V6, P593, DOI 10.1038/nn1056; Shadlen MN, 1999, NEURON, V24, P67, DOI 10.1016/S0896-6273(00)80822-3; Sirota A, 2003, P NATL ACAD SCI USA, V100, P2065, DOI 10.1073/pnas.0437938100; SOMERS D, 1993, BIOL CYBERN, V68, P393, DOI 10.1007/BF00198772; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; Steriade M, 2001, J NEUROPHYSIOL, V86, P1, DOI 10.1152/jn.2001.86.1.1; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Stuart GJ, 2001, NAT NEUROSCI, V4, P63, DOI 10.1038/82910; Thomson AM, 2003, CEREB CORTEX, V13, P136, DOI 10.1093/cercor/13.2.136; Traub RD, 1999, FAST OSCILLATIONS CO; Tsodyks MV, 1996, HIPPOCAMPUS, V6, P271, DOI 10.1002/(SICI)1098-1063(1996)6:3<271::AID-HIPO5>3.3.CO;2-Q; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Wagner U, 2004, NATURE, V427, P352, DOI 10.1038/nature02223; WANG XJ, 2003, ENCY COGNITIVE SCI, P272; Whittington MA, 2003, TRENDS NEUROSCI, V26, P676, DOI 10.1016/j.tins.2003.09.016; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Winfree A. T., 1980, GEOMETRY BIOL TIME, DOI 10.1007/978-1-4757-3484-3	64	3886	3960	31	521	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1926	1929		10.1126/science.1099745	http://dx.doi.org/10.1126/science.1099745			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218136	Green Published			2022-12-28	WOS:000222241600031
J	Gilmore, G				Gilmore, G			The short spectacular life of a superstar	SCIENCE			English	Editorial Material							PROGENITORS; SUPERNOVAE		Univ Cambridge, Inst Astron, Cambridge CB3 0HA, England	University of Cambridge	Gilmore, G (corresponding author), Univ Cambridge, Inst Astron, Madingley Rd, Cambridge CB3 0HA, England.	gil@ast.cam.ac.uk						Bietenholz MF, 2004, SCIENCE, V304, P1947, DOI 10.1126/science.1099460; CHEVALIER RA, 1987, NATURE, V329, P611, DOI 10.1038/329611a0; Livio M, 2003, ASTROPHYS J, V594, pL93, DOI 10.1086/378765; Tegmark M, 2002, SCIENCE, V296, P1427, DOI 10.1126/science.1072184; Van Dyk SD, 2003, SCIENCE, V302, P1161, DOI 10.1126/science.1091612; WEILER KW, 1990, ASTROPHYS J, V364, P611, DOI 10.1086/169444	6	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1915	1916		10.1126/science.1100370	http://dx.doi.org/10.1126/science.1100370			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218132				2022-12-28	WOS:000222241600027
J	Moles, A; Kieffer, BL; D'Amato, FR				Moles, A; Kieffer, BL; D'Amato, FR			Deficit in attachment behavior in mice lacking the mu-opioid receptor gene	SCIENCE			English	Article							MORPHINE-INDUCED ANALGESIA; SEPARATION DISTRESS; RAT PUPS; RESPONSES; MEDIATION; KNOCKOUT; EXPOSURE; NALOXONE; OPIATES; AUTISM	Endogenous opioid binding to mu receptors is hypothesized to mediate natural rewards and has been proposed to be the basis of infant attachment behavior. Here, we report that mu-opioid receptor knockout mouse pups emit fewer ultrasonic vocalizations when removed from their mothers but not when exposed to cold or male mice odors. Moreover these knockout pups do not show a preference toward their mothers' cues and do not show ultrasonic calls potentiation after brief maternal exposure. Results from this study may indicate a molecular mechanism for diseases characterized by deficits in attachment behavior, such as autism or reactive attachment disorder.	CNR, Inst Neurosci Psychobiol & Psychopharmacol, I-00137 Rome, Italy; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Consiglio Nazionale delle Ricerche (CNR); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	D'Amato, FR (corresponding author), CNR, Inst Neurosci Psychobiol & Psychopharmacol, Viale Marx 43, I-00137 Rome, Italy.	f.damato@ipsifar.rm.cnr.it		D'Amato, Francesca/0000-0002-4577-4574; Moles, Anna/0000-0002-5805-5763				Agmo A, 1997, DEV NEUROSCI-BASEL, V19, P505, DOI 10.1159/000111248; BENTON D, 1988, PSYCHOPHARMACOLOGY A, P115; Bowlby J., 1980, ATTACHMENT, V1; CARDEN SE, 1991, DEV BRAIN RES, V62, P17, DOI 10.1016/0165-3806(91)90185-L; CHAMBERLAIN RS, 1990, BIOL PSYCHIAT, V28, P773, DOI 10.1016/0006-3223(90)90513-2; DAMATO FR, 1987, BEHAV NEURAL BIOL, V48, P197, DOI 10.1016/S0163-1047(87)90738-2; Dichter GS, 1996, PHYSIOL BEHAV, V60, P299, DOI 10.1016/0031-9384(95)02222-8; Filliol D, 2000, NAT GENET, V25, P195, DOI 10.1038/76061; HERMAN BH, 1978, PHARMACOL BIOCHEM BE, V9, P213, DOI 10.1016/0091-3057(78)90167-3; HOFER MA, 1994, DEV PSYCHOBIOL, V27, P503, DOI 10.1002/dev.420270804; Insel TR, 2003, PHYSIOL BEHAV, V79, P351, DOI 10.1016/S0031-9384(03)00148-3; KALIN NH, 1988, BRAIN RES, V440, P285, DOI 10.1016/0006-8993(88)90997-3; KEHOE P, 1986, DEV PSYCHOBIOL, V19, P385, DOI 10.1002/dev.420190410; Kieffer BL, 2002, PROG NEUROBIOL, V66, P285, DOI 10.1016/S0301-0082(02)00008-4; Mandillo S, 1999, PSYCHOPHARMACOLOGY, V146, P297, DOI 10.1007/s002130051120; Martin M, 2003, EUR J NEUROSCI, V17, P701, DOI 10.1046/j.1460-9568.2003.02482.x; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Nelson EE, 1998, NEUROSCI BIOBEHAV R, V22, P437, DOI 10.1016/S0149-7634(97)00052-3; PANKSEPP J, 1979, TRENDS NEUROSCI, V2, P174, DOI 10.1016/0166-2236(79)90071-7; PANKSEPP J, 1978, BIOL PSYCHIAT, V13, P607; PANKSEPP J, 1994, ACTA PAEDIATR, V83, P40, DOI 10.1111/j.1651-2227.1994.tb13264.x; Panksepp J, 1985, PSYCHOBIOLOGY ATTACH, P3, DOI DOI 10.1016/B978-0-12-586780-1.50006-9; ROBINSON DJ, 1985, BEHAV PROCESS, V11, P253, DOI 10.1016/0376-6357(85)90020-8; Roth TL, 2003, PHYSIOL BEHAV, V78, P135, DOI 10.1016/S0031-9384(02)00961-7; SCOTT JP, 1974, P 9 C NEUR PHARM CIN, P735; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; WINSLOW JT, 1991, BEHAV NEUROSCI, V105, P253, DOI 10.1037/0735-7044.105.2.253	27	334	338	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1983	1986		10.1126/science.1095943	http://dx.doi.org/10.1126/science.1095943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218152				2022-12-28	WOS:000222241600050
J	Salvesen, KA; Morkved, S				Salvesen, KA; Morkved, S			Randomised controlled trial of pelvic floor muscle training during pregnancy	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To examine a possible effect on labour of training the muscles of the pelvic floor during pregnancy. Design Randomised controlled trial. Setting Trondheim University Hospital and three outpatient physiotherapy clinics in a primary care setting. Participants 301 healthy nulliparous women randomly allocated to a training group (148) or a control group (153). Intervention A structured training programme with exercises for the pelvic floor muscles between the 20th and 36th week of pregnancy. Main outcome measures Duration of the second stage of labour and number of deliveries lasting longer than 60 minutes of active pushing among women with spontaneous start of labour after 37 weeks of pregnancy with a singleton fetus in cephalic position. Results Women randomised to pelvic floor muscle training had a lower rate of prolonged second stage labour (24%,95% confidence interval 16% to 33%; 22 out of 105 women were at risk (undelivered) at 60 minutes in the survival analysis) than women allocated to no training (38% (37/109),28% to 47%). The duration of the second stage was not significantly shorter (40 minutes v 45 minutes, P = 0.06). Conclusions A structured training programme for the pelvic floor muscles is associated with fewer cases of active pushing in the second stage of labour as g longer than 60 minutes.	Univ Trondheim Hosp, Dept Obstet & Gynaecol, N-7006 Trondheim, Norway; Norwegian Univ Sci & Technol, Dept Community Med & Gen Practice, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Salvesen, KA (corresponding author), Univ Trondheim Hosp, Dept Obstet & Gynaecol, N-7006 Trondheim, Norway.	pepes@medisin.ntnu.no						*BAB CTR, DO PELV FLOOR EX HEL; BERGSJO P, 1987, OBSTETRIKK; Cunningham FG, 1997, WILLIAMS OBSTET; HOFMEYR GJ, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651958.CD000051; Morkved S, 2003, OBSTET GYNECOL, V101, P313, DOI 10.1016/S0029-7844(02)02711-4; NIELSEN CA, 1988, ACTA OBSTET GYN SCAN, V67, P437; Reilly ETC, 2002, BJOG-INT J OBSTET GY, V109, P68, DOI 10.1016/S1470-0328(02)01116-3	7	77	87	1	20	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 14	2004	329	7462					378	380		10.1136/bmj.38163.724306.3A	http://dx.doi.org/10.1136/bmj.38163.724306.3A			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15253920	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223433600017
J	Ehrsson, HH; Spence, C; Passingham, RE				Ehrsson, HH; Spence, C; Passingham, RE			That's my hand! Activity in premotor cortex reflects feeling of ownership of a limb	SCIENCE			English	Article							POSTERIOR PARIETAL CORTEX; PERIARCUATE NEURONS; AFFERENT PROPERTIES; MACAQUE MONKEYS; REPRESENTATION; MOTOR; SELF; ARM; ORGANIZATION; PERCEPTION	When we look at our hands, we immediately know that they are part of our own body. This feeling of ownership of our limbs is a fundamental aspect of self-consciousness. We have studied the neuronal counterparts of this experience. A perceptual illusion was used to manipulate feelings of ownership of a rubber hand presented in front of healthy subjects while brain activity was measured by functional magnetic resonance imaging. The neural activity in the premotor cortex reflected the feeling of ownership of the hand. This suggests that multisensory integration in the premotor cortex provides a mechanism for bodily self-attribution.	Inst Neurol, Wellcome Dept Imaging Neurosci, London WC1N 3BG, England; Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of London; University College London; University of Oxford	Ehrsson, HH (corresponding author), Inst Neurol, Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	h.ehrsson@fil.ion.ucl.ac.uk						Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; Armel KC, 2003, P ROY SOC B-BIOL SCI, V270, P1499, DOI 10.1098/rspb.2003.2364; BAHRICK LE, 1985, DEV PSYCHOL, V21, P963, DOI 10.1037/0012-1649.21.6.963; Botvinick M, 1998, NATURE, V391, P756, DOI 10.1038/35784; Burnod Y, 1999, EXP BRAIN RES, V129, P325, DOI 10.1007/s002210050902; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; CRITCHLE.M, 1974, MT SINAI J MED, V41, P82; Critchley M., 1953, PARIETAL LOBES; DUFFY FH, 1971, SCIENCE, V172, P273, DOI 10.1126/science.172.3980.273; EHRSSON HH, UNPUB; Feinberg TE, 1997, SEMIN NEUROL, V17, P129, DOI 10.1055/s-2008-1040922; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1999, P NATL ACAD SCI USA, V96, P10418, DOI 10.1073/pnas.96.18.10418; Graziano MSA, 2000, SCIENCE, V290, P1782, DOI 10.1126/science.290.5497.1782; Graziano MSA, 2002, ATTENTION PERFORM, V19, P136; Graziano MSA, 1997, J NEUROPHYSIOL, V77, P2268, DOI 10.1152/jn.1997.77.5.2268; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; JONES EG, 1978, J COMP NEUROL, V181, P291, DOI 10.1002/cne.901810206; Kertzman C, 1997, EXP BRAIN RES, V114, P170, DOI 10.1007/PL00005617; Lloyd DM, 2003, NAT NEUROSCI, V6, P17, DOI 10.1038/nn991; Macaluso Emiliano, 2003, Adv Neurol, V93, P219; Meador KJ, 2000, NEUROLOGY, V55, P816, DOI 10.1212/WNL.55.6.816; MITCHELL RW, 2003, SELF SOUL BRAIN, P39; Naito E, 2002, NEURON, V36, P979, DOI 10.1016/S0896-6273(02)00980-7; Pavani F, 2000, PSYCHOL SCI, V11, P353, DOI 10.1111/1467-9280.00270; Rizzolatti G, 1998, ELECTROEN CLIN NEURO, V106, P283, DOI 10.1016/S0013-4694(98)00022-4; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P147, DOI 10.1016/0166-4328(81)90053-X; RIZZOLATTI G, 1981, BEHAV BRAIN RES, V2, P125, DOI 10.1016/0166-4328(81)90052-8; SAKATA H, 1973, BRAIN RES, V64, P85, DOI 10.1016/0006-8993(73)90172-8; van den Bos E, 2002, COGNITION, V85, P177, DOI 10.1016/S0010-0277(02)00100-2	30	904	915	7	164	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	2004	305	5685					875	877		10.1126/science.1097011	http://dx.doi.org/10.1126/science.1097011			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843RT	15232072				2022-12-28	WOS:000223104900052
J	Johnson, RT				Johnson, RT			Vestibular neuritis, or driving dizzily through Donegal	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Johnson, RT (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.							Bergenius J, 1999, ACTA OTO-LARYNGOL, V119, P895; DAVIS LE, 1975, NATURE, V254, P329, DOI 10.1038/254329a0; DAVIS LE, 1983, AM J OTOLARYNG, V4, P347, DOI 10.1016/S0196-0709(83)80022-2; Hirata T, 1989, Acta Otolaryngol Suppl, V468, P371	4	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					322	323		10.1056/NEJMp048127	http://dx.doi.org/10.1056/NEJMp048127			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269310				2022-12-28	WOS:000222801200004
J	Roger, VL; Weston, SA; Redfield, MA; Hellermann-Homan, JP; Killian, J; Yawn, BP; Jacobsen, SJ				Roger, VL; Weston, SA; Redfield, MA; Hellermann-Homan, JP; Killian, J; Yawn, BP; Jacobsen, SJ			Trends in heart failure incidence and survival in a community-based population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; OLMSTED COUNTY; CASE-FATALITY; DISEASE; MINNESOTA; MANAGEMENT; ROCHESTER; MORBIDITY; MORTALITY; PROJECT	Context The epidemic of heart failure has yet to be fully investigated, and data on incidence, survival, and sex-specific temporal trends in community-based populations are limited. Objective To test the hypothesis that the incidence of heart failure has declined and survival after heart failure diagnosis has improved over time but that secular trends have diverged by sex. Design, Setting, and Participants Population-based cohort study using the resources of the Rochester Epidemiology Project conducted in Olmsted County, Minnesota. Patients were 4537 Olmsted County residents (57% women; mean [SD] age, 74 [14] years) with a diagnosis of heart failure between 1979 and 2000. Framingham criteria and clinical criteria were used to validate the diagnosis Main Outcome Measures Incidence of heart failure and survival after heart failure diagnosis. Results The incidence of heart failure was higher among men (378/100000 persons; 95% confidence interval [Cl], 361-395 for men; 289/100000 persons; 95% Cl, 277-300 for women) and did not change over time among men or women. After a mean follow-up of 4.2 years (range, 0-23.8 years), 3347 deaths occurred, including 1930 among women and 1417 among men. Survival after heart failure diagnosis was worse among men than women (relative risk, 1.33; 95% Cl, 1.24-1.43) but overall improved over time (5-year age-adjusted survival, 43% in 1979-1984 vs 52% in 19962000, P<.001). However, men and younger persons experienced larger survival gains, contrasting with less or no improvement for women and elderly persons. Conclusion In this community-based cohort, the incidence of heart failure has not declined during 2 decades, but survival after onset of heart failure has increased over-all, with less improvement among women and elderly persons.	Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA; Olmsted Med Ctr, Dept Res, Rochester, MN USA	Mayo Clinic; Olmsted Medical Center	Roger, VL (corresponding author), Mayo Clin, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55095 USA.	roger.veronique@mayo.edu	Roger, Veronique/AAV-5951-2020	Jacobsen, Steven/0000-0002-8174-8533	NHLBI NIH HHS [R01 HL 72435] Funding Source: Medline; NIAMS NIH HHS [R01 AR30582] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072435] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BERGSTRAHL E, 1992, CALCULATING INCIDENC; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen HH, 2002, J CARD FAIL, V8, P279, DOI 10.1054/jcaf.2002.128871; Cowie MR, 1999, EUR HEART J, V20, P421, DOI 10.1053/euhj.1998.1280; Croft JB, 1997, J AM GERIATR SOC, V45, P270, DOI 10.1111/j.1532-5415.1997.tb00939.x; Gheorghiade M, 1998, CIRCULATION, V97, P282, DOI 10.1161/01.CIR.97.3.282; Goff DC, 2000, ARCH INTERN MED, V160, P197, DOI 10.1001/archinte.160.2.197; HO KKL, 1993, CIRCULATION, V88, P107, DOI 10.1161/01.CIR.88.1.107; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; Levy D, 2002, NEW ENGL J MED, V347, P1397, DOI 10.1056/NEJMoa020265; Levy D, 1998, NEW ENGL J MED, V339, P915, DOI 10.1056/NEJM199809243391309; Lindsted KD, 1996, J CLIN EPIDEMIOL, V49, P783, DOI 10.1016/0895-4356(96)00009-1; MacIntyre K, 2000, CIRCULATION, V102, P1126, DOI 10.1161/01.CIR.102.10.1126; McCullough PA, 2002, J AM COLL CARDIOL, V39, P60, DOI 10.1016/S0735-1097(01)01700-4; MCMURRY M, 1992, POPULATION NOTES, P1; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Morrison AS, 1998, MODERN EPIDEMIOLOGY, P499; Psaty BM, 1999, AM J CARDIOL, V84, P108, DOI 10.1016/S0002-9149(99)00205-2; PSATY BM, 1999, AM J CARDIOL, V84, pA9, DOI DOI 10.1016/S0002-9149(99)00205-2; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; Roger VL, 2002, ANN INTERN MED, V136, P341, DOI 10.7326/0003-4819-136-5-200203050-00005; Senni M, 1999, J AM COLL CARDIOL, V33, P164, DOI 10.1016/S0735-1097(98)00523-3; Senni M, 1998, CIRCULATION, V98, P2282, DOI 10.1161/01.CIR.98.21.2282; Senni M, 1999, ARCH INTERN MED, V159, P29, DOI 10.1001/archinte.159.1.29; STEVENSON WG, 1995, J AM COLL CARDIOL, V26, P1417, DOI 10.1016/0735-1097(95)00341-X; Stewart S, 2001, EUR HEART J, V22, P693, DOI 10.1053/euhj.2000.2511; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0	33	1078	1127	0	24	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					344	350		10.1001/jama.292.3.344	http://dx.doi.org/10.1001/jama.292.3.344			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265849	Bronze			2022-12-28	WOS:000222693500019
J	Hancox, RJ; Milne, BJ; Poulton, R				Hancox, RJ; Milne, BJ; Poulton, R			Association between child and adolescent television viewing and adult health: a longitudinal birth cohort study	LANCET			English	Article							PHYSICAL-ACTIVITY; NEW-ZEALAND; OBESITY; FITNESS; SMOKING; YOUTH	Background Watching television in childhood and adolescence has been linked to adverse health indicators including obesity, poor fitness, smoking, and raised cholesterol. However, there have been no longitudinal studies of childhood viewing and adult health. We explored these associations in a birth cohort followed up to age 26 years. Methods We assessed approximately 1000 unselected individuals born in Dunedin, New Zealand, in 1972-73 at regular intervals up to age 26 years. We used regression analysis to investigate the associations between earlier television viewing and body-mass index, cardiorespiratory fitness (maximum aerobic power assessed by a submaximal cycling test), serum cholesterol, smoking status, and blood pressure at age 26 years. Findings Average weeknight viewing between ages 5 and 15 years was associated with higher body-mass indices (p=0.0013), lower cardiorespiratory fitness (p=0.0003), increased cigarette smoking (p<0.0001), and raised serum cholesterol (p=0.0037). Childhood and adolescent viewing had no significant association with blood pressure. These associations persisted after adjustment for potential confounding factors such as childhood socioeconomic status, body-mass index at age 5 years, parental body-mass index, parental smoking, and physical activity at age 15 years. In 26-year-olds, population-attributable fractions indicate that 17% of overweight, 15% of raised serum cholesterol, 17% of smoking, and 15% of poor fitness can be attributed to watching television for more than 2 h a day during childhood and adolescence. Interpretation Television viewing in childhood and adolescence is associated with overweight, poor fitness, smoking, and raised cholesterol in adulthood. Excessive viewing might have long-lasting adverse effects on health.	Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand	University of Otago	Hancox, RJ (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin Multidisciplinary Hlth & Dev Res Unit, POB 913, Dunedin, New Zealand.	bob.hancox@dmhdru.otago.ac.nz	Hancox, Robert/G-4746-2011		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH049414, R01MH045070, R29MH049414] Funding Source: NIH RePORTER; NIMH NIH HHS [MH49414, MH45070] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Armstrong CA, 1998, AM J HEALTH PROMOT, V12, P363, DOI 10.4278/0890-1171-12.6.363; Bar-on ME, 2001, PEDIATRICS, V107, P423, DOI 10.1542/peds.107.2.423; Cullinane E M, 1988, Med Sci Sports Exerc, V20, P317, DOI 10.1249/00005768-198806000-00017; DIETZ WH, 1985, PEDIATRICS, V75, P807; DURANT RH, 1994, PEDIATRICS, V94, P449; FORD DJ, 1995, NEW ZEAL MED J, V108, P454; Gidwani PP, 2002, PEDIATRICS, V110, P505, DOI 10.1542/peds.110.3.505; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; Hammond KM, 1999, AUST NZ J PUBL HEAL, V23, P49, DOI 10.1111/j.1467-842X.1999.tb01204.x; Hernandez B, 1999, INT J OBESITY, V23, P845, DOI 10.1038/sj.ijo.0800962; Katzmarzyk PT, 1998, J ADOLESCENT HEALTH, V23, P318, DOI 10.1016/S1054-139X(98)00070-6; ROBINSON TN, 1993, PEDIATRICS, V91, P273; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Silva P., 1996, CHILD ADULT DUNEDIN; Strasburger V C, 1992, Pediatr Rev, V13, P144, DOI 10.1542/pir.13-4-144; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; Thomson G, 1998, NEW ZEAL MED J, V111, P129; TUCKER LA, 1986, ADOLESCENCE, V21, P797; Wilson N, 1999, AUST NZ J PUBL HEAL, V23, P647, DOI 10.1111/j.1467-842X.1999.tb01553.x; WONG ND, 1992, PEDIATRICS, V90, P75; [No title captured]	21	540	555	3	57	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					257	262		10.1016/S0140-6736(04)16675-0	http://dx.doi.org/10.1016/S0140-6736(04)16675-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	839KV	15262103				2022-12-28	WOS:000222784900028
J	Watkins, D; McCarron, P; Murray, L; Cran, G; Boreham, C; Robson, P; McGartland, C; Smith, GD; Savage, M				Watkins, D; McCarron, P; Murray, L; Cran, G; Boreham, C; Robson, P; McGartland, C; Smith, GD; Savage, M			Trends in blood pressure over 10 years in adolescents: analyses of cross sectional surveys in the Northern Ireland Young Hearts project	BRITISH MEDICAL JOURNAL			English	Article							CORONARY RISK-FACTORS; SECULAR TRENDS; BIRTH-WEIGHT; ADULTHOOD; HYPERTENSION; POPULATION; CHILDHOOD; SCHOOLCHILDREN; MORTALITY; CHILDREN	Objective To examine secular trends in blood pressure over a 10 year period between two representative cohorts of adolescents from Northern Ireland. Design Repeat cross sectional study. Setting Randomly selected post-primary schools from Northern Ireland. Participants 10 15 adolescents studied between 1989 and 1990, and 2017 adolescents studied between 1999 and 2001. Participants were aged 12 or 15 years. Main outcome measures Systolic and diastolic blood pressure measured by one observer in each study. Results The four groups for sex and age showed decreases in both systolic blood pressure (mean decrease 7.7 mm Hg to 10.0 mm Hg) and diastolic blood pressure (8.8 mm Hg to 11.0 mm Hg). These decreases were not accounted for by adjustment for potential confounders including age, height, body mass index, smoking, physical activity, aerobic fitness, and stratification. The findings were not altered by additional adjustment for social class, pubertal status, birth weight, and infant feeding. No evidence was found of systematic variation between observers. Conclusions Substantial decreases in systolic and diastolic blood pressure over the past decade in adolescents from Northern Ireland are likely to have important benefits to public health and may help offset the increasing risk of cardiovascular disease due to increases in obesity.	Queens Univ Belfast, Royal Victoria Hosp, Inst Clin Sci, Dept Child Hlth, Belfast BT12 6JB, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT7 1NN, Antrim, North Ireland; Univ Ulster, Dept Appl Med Sci & Sports Studies, Newtownabbey BT37 0QB, Antrim, North Ireland; Univ Ulster, No Ireland Ctr Diet & Hlth, Coleraine BT52 1SA, Londonderry, North Ireland; Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	Queens University Belfast; Queens University Belfast; Ulster University; Ulster University; University of Bristol	Watkins, D (corresponding author), Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England.	david.watkins@stockport-tr.nwest.nhs.uk	Davey Smith, George/A-7407-2013; Robson, Paula J/Q-3351-2017	Davey Smith, George/0000-0002-1407-8314; Robson, Paula J/0000-0003-4640-1371; Venkatasubramanian, Siddharth/0000-0002-5860-0768; s, hema/0000-0002-3440-9475				BAO WH, 1995, AM J HYPERTENS, V8, P657, DOI 10.1016/0895-7061(95)00116-7; Berenson GS, 1996, PUBLIC HEALTH REP, V111, P3; BOREHAM C, 1993, ARCH DIS CHILD, V68, P182, DOI 10.1136/adc.68.2.182; BOREHAM CAG, 1990, J SPORT MED PHYS FIT, V30, P19; BURT VL, 1995, HYPERTENSION, V26, P60, DOI 10.1161/01.HYP.26.1.60; *DEP HLTH, 2002, HLTH SURV ENGL TREND; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; Ebrahim S, 1998, J PUBLIC HEALTH MED, V20, P441, DOI 10.1093/oxfordjournals.pubmed.a024800; Geleijnse JM, 1997, HYPERTENSION, V29, P913, DOI 10.1161/01.HYP.29.4.913; GIDDING SS, 1995, J PEDIATR-US, V127, P868, DOI 10.1016/S0022-3476(95)70020-X; Huxley R, 2002, LANCET, V360, P659, DOI 10.1016/S0140-6736(02)09834-3; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; KOTCHEN JM, 1989, J CLIN EPIDEMIOL, V42, P735; Kuulasmaa K, 2000, LANCET, V355, P675, DOI 10.1016/S0140-6736(99)11180-2; LAUER RM, 1989, PEDIATRICS, V84, P633; Luepker RV, 1999, J PEDIATR-US, V134, P668, DOI 10.1016/S0022-3476(99)70279-9; McCarron P, 2000, LANCET, V355, P1430, DOI 10.1016/S0140-6736(00)02146-2; McCarron P, 2002, J HUM HYPERTENS, V16, P677, DOI 10.1038/sj.jhh.1001471; McCarron P, 2001, BMJ-BRIT MED J, V322, P885, DOI 10.1136/bmj.322.7291.885; ROBERTS J, 1978, VITAL HLTH STAT 11, V166; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; Tanner JM, 1962, GROWTH ADOLESCENCE, V2nd; THOM TJ, 1989, INT J EPIDEMIOL, V18, pS20; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; Walton KA, 2000, EUR J EPIDEMIOL, V16, P793, DOI 10.1023/A:1007625030509; WRIGHT BM, 1970, LANCET, V1, P337	26	49	53	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					139	141		10.1136/bmj.38149.510139.7C	http://dx.doi.org/10.1136/bmj.38149.510139.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15226191	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222832300017
J	Gray, JM; Karow, DS; Lu, H; Chang, AJ; Chang, JS; Ellis, RE; Marletta, MA; Bargmann, CI				Gray, JM; Karow, DS; Lu, H; Chang, AJ; Chang, JS; Ellis, RE; Marletta, MA; Bargmann, CI			Oxygen sensation and social feeding mediated by a C-elegans guanylate cyclase homologue	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-GATED CHANNEL; NITRIC-OXIDE; RESPONSES; HYPOXIA; ACTIVATION; BEHAVIOR; PATHWAYS; NEURONS; STATES	Specialized oxygen-sensing cells in the nervous system generate rapid behavioural responses to oxygen. We show here that the nematode Caenorhabditis elegans exhibits a strong behavioural preference for 5-12% oxygen, avoiding higher and lower oxygen levels. 3',5'-cyclic guanosine monophosphate (cGMP) is a common second messenger in sensory transduction and is implicated in oxygen sensation. Avoidance of high oxygen levels by C. elegans requires the sensory cGMP-gated channel tax-2/tax-4 and a specific soluble guanylate cyclase homologue, gcy-35. The GCY-35 haem domain binds molecular oxygen, unlike the haem domains of classical nitric-oxide-regulated guanylate cyclases. GCY-35 and TAX-4 mediate oxygen sensation in four sensory neurons that control a naturally polymorphic social feeding behaviour in C. elegans. Social feeding and related behaviours occur only when oxygen exceeds C. elegans' preferred level, and require gcy-35 activity. Our results suggest that GCY-35 is regulated by molecular oxygen, and that social feeding can be a behavioural strategy for responding to hyperoxic environments.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Grad Program Cellular & Mol Biol, Ann Arbor, MI 48109 USA; Univ Med & Dent New Jersey, Sch Osteopath Med, Stratford, NJ 08084 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Lawrence Berkeley Lab, Div Phys Biosci, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	marletta@berkeley.edu; cori@itsa.ucsf.edu		Lu, Hang/0000-0002-6881-660X; Bargmann, Cornelia/0000-0002-8484-0618				ANDERSON GL, 1977, J NEMATOL, V9, P253; BARAK R, 1982, J BACTERIOL, V152, P643; CHEUNG BHH, IN PRESS CURR BIOL; Coates JC, 2002, NATURE, V419, P925, DOI 10.1038/nature01170; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; de Bono M, 1998, CELL, V94, P679, DOI 10.1016/S0092-8674(00)81609-8; de Bono M, 2002, NATURE, V419, P899, DOI 10.1038/nature01169; DIIORIO EE, 1981, HEMOGLOBINS, P57; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; DUSENBERY DB, 1980, J COMP PHYSIOL, V136, P333, DOI 10.1007/BF00657353; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; HIEB WF, 1970, SCIENCE, V168, P143, DOI 10.1126/science.168.3927.143; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; Jain R, 2003, J BIOL INORG CHEM, V8, P1, DOI 10.1007/s00775-002-0405-8; KAROW DS, IN PRESS BIOCHEMISTR; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Lopez-Barneo J, 2003, CURR OPIN NEUROBIOL, V13, P493, DOI 10.1016/S0959-4388(03)00093-X; MALINSKI T, 1992, NATURE, V358, P676, DOI 10.1038/358676a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; Morton DB, 1999, CURR BIOL, V9, pR546, DOI 10.1016/S0960-9822(99)80349-2; Morton DB, 2004, MOL NEUROBIOL, V29, P97, DOI 10.1385/MN:29:2:097; Rogers C, 2003, NAT NEUROSCI, V6, P1178, DOI 10.1038/nn1140; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Sylvia D.M., 1998, PRINCIPLES APPL SOIL; Van Voorhies WA, 2000, J EXP BIOL, V203, P2467; Wannamaker CM, 2000, J EXP MAR BIOL ECOL, V249, P145, DOI 10.1016/S0022-0981(00)00160-X; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; Wu RSS, 2002, MAR POLLUT BULL, V45, P35, DOI 10.1016/S0025-326X(02)00061-9; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zhao Y, 1997, BIOCHEMISTRY-US, V36, P15959, DOI 10.1021/bi971825x	33	412	447	4	60	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					317	322		10.1038/nature02714	http://dx.doi.org/10.1038/nature02714			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15220933	Green Published			2022-12-28	WOS:000222631200032
J	Caulfield, T				Caulfield, T			Scientific freedom and research cloning: can a ban be justified?	LANCET			English	Editorial Material									Univ Alberta, Hlth Law Inst, Fac Law, Edmonton, AB T6G 2H5, Canada; Univ Alberta, Hlth Law Inst, Fac Med & Dent, Edmonton, AB T6G 2H5, Canada	University of Alberta; University of Alberta	Caulfield, T (corresponding author), Univ Alberta, Hlth Law Inst, Fac Law, Edmonton, AB T6G 2H5, Canada.	tcaulfld@law.ualberta.ca						BILLINGSLEY B, IN PRESS QUEENS LAW; Cantrell M K, 1998, J Law Health, V13, P69; Caulfield Timothy, 2002, Alta Law Rev, V40, P451; Childress J F, 2001, YALE J HLTH POLICY L, V2, P157; Evans JH, 2002, J SCI STUD RELIG, V41, P747, DOI 10.1111/1468-5906.t01-1-00151; *IPS NEWS CTR, 2001, STEM CELL RES DEB LA; *IPS NEWS CTR, 2002, 6 10 CAN 61 PERC APP; Knowles LP, 2004, NAT BIOTECHNOL, V22, P157, DOI 10.1038/nbt0204-157; *OFF HIGH COMM HUM, 1996, INT COV EC SOC CULT; Plomer Aurora, 2002, Med Law Rev, V10, P132, DOI 10.1093/medlaw/10.2.132; *PRES COUNC BIOETH, 2004, MON STEM CELL RES; Robertson John A., 1977, SOUTH CALIF LAW REV, V51, P1203; Shalev Carmel, 2002, HLTH HUMAN RIGHTS, V6, P137; Vogelstein B, 2002, SCIENCE, V295, P1237, DOI 10.1126/science.1070247; Walters L, 2003, SCIENCE, V299, P1661; 2002, NATURE, V8, P1331	16	6	6	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					124	126		10.1016/S0140-6736(04)16653-1	http://dx.doi.org/10.1016/S0140-6736(04)16653-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246714				2022-12-28	WOS:000222612200007
J	Heil, M; Greiner, S; Meimberg, H; Kruger, R; Noyer, JL; Heubl, G; Linsenmair, KE; Boland, W				Heil, M; Greiner, S; Meimberg, H; Kruger, R; Noyer, JL; Heubl, G; Linsenmair, KE; Boland, W			Evolutionary change from induced to constitutive expression of an indirect plant resistance	NATURE			English	Article							PHYLOGENETIC RECONSTRUCTION; NECTAR PRODUCTION; INDUCED RESPONSES; DEFENSES; FABACEAE; MATK; BIOSYNTHESIS; MIMOSOIDEAE; INDUCTION; HERBIVORY	Induced plant resistance traits are expressed in response to attack and occur throughout the plant kingdom(1,2). Despite their general occurrence, the evolution of such resistances has rarely been investigated(3). Here we report that extrafloral nectar, a usually inducible trait, is constitutively secreted by Central American Acacia species that are obligately inhabited by ants. Extrafloral nectar is secreted as an indirect resistance(4), attracting ants that defend plants against herbivores(5). Leaf damage induces extrafloral nectar secretion in several plant species(6-8); among these are various Acacia species and other Fabaceae investigated here. In contrast, Acacia species obligately inhabited by symbiotic ants(9) nourish these ants by secreting extrafloral nectar constitutively at high rates that are not affected by leaf damage. The phylogeny of the genus Acacia and closely related genera indicate that the inducibility of extrafloral nectar is the plesiomorphic or 'original' state, whereas the constitutive extrafloral nectar flow is derived within Acacia. A constitutive resistance trait has evolved from an inducible one, obviously in response to particular functional demands.	Max Planck Inst Chem Ecol, Dept Bioorgan Chem, D-07745 Jena, Germany; Biozentrum, Lehrstuhl Zool 3, D-94074 Wurzburg, Germany; Ludwig Maximilians Univ Munchen, Dept Biol 1, Sect Biodivers Res, D-80638 Munich, Germany; CIRAD, UMR 1096, PIA, F-34398 Montpellier 5, France	Max Planck Society; University of Wurzburg; University of Munich; CIRAD	Heil, M (corresponding author), Max Planck Inst Chem Ecol, Dept Bioorgan Chem, Hans Knoll Str 8,Beutenberg Campus, D-07745 Jena, Germany.	Heil_Martin@web.de	Boland, Wilhelm/K-7762-2012; Heil, Martin/T-3960-2019; Heil, Martin/I-1797-2012; Linsenmair, Karl Eduard/Q-2268-2018; Heil, Martin/AAC-2730-2022	Boland, Wilhelm/0000-0001-6784-2534; Heil, Martin/0000-0001-8036-8697; Linsenmair, Karl Eduard/0000-0002-2132-8721; Noyer, Jean-Louis/0000-0002-7389-5621; Meimberg, Harald/0000-0001-6696-2649				Agrawal AA, 1998, OIKOS, V83, P227, DOI 10.2307/3546834; Agrawal AA, 1998, SCIENCE, V279, P1201, DOI 10.1126/science.279.5354.1201; Baldwin IT, 1997, PLANTA, V201, P397, DOI 10.1007/s004250050082; Baldwin IT, 1998, P NATL ACAD SCI USA, V95, P8113, DOI 10.1073/pnas.95.14.8113; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CUCUROU C, 1991, BIOCHEMISTRY-US, V30, P8964, DOI 10.1021/bi00101a008; Heil M, 2004, J ECOL, V92, P527, DOI 10.1111/j.0022-0477.2004.00890.x; Heil M, 2004, CHEMOECOLOGY, V14, P45, DOI 10.1007/s00049-003-0257-x; Heil M, 2001, P NATL ACAD SCI USA, V98, P1083, DOI 10.1073/pnas.031563398; Heil M, 2000, FUNCT ECOL, V14, P749, DOI 10.1046/j.1365-2435.2000.00480.x; Heil M, 2003, ANNU REV ECOL EVOL S, V34, P425, DOI 10.1146/annurev.ecolsys.34.011802.132410; Janzen DH, 1974, SWOLLEN THORN ACACIA; JOHNSON LA, 1994, SYST BOT, V19, P143, DOI 10.2307/2419718; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; LOUGHRIN JH, 1995, J CHEM ECOL, V21, P1217, DOI 10.1007/BF02228321; Meimberg H, 2001, PLANT BIOLOGY, V3, P164, DOI 10.1055/s-2001-12897; Miller JT, 2003, SYST BOT, V28, P558; Miller JT, 2003, AUST SYST BOT, V16, P27, DOI 10.1071/SB01035; PRICE PW, 1980, ANNU REV ECOL SYST, V11, P41, DOI 10.1146/annurev.es.11.110180.000353; Raine NE, 2002, ECOLOGY, V83, P3086, DOI 10.1890/0012-9658(2002)083[3086:SSAFAB]2.0.CO;2; Siemens DH, 1998, ECOLOGY, V79, P632, DOI 10.1890/0012-9658(1998)079[0632:EOPIDI]2.0.CO;2; TABERLET P, 1991, PLANT MOL BIOL, V17, P1105, DOI 10.1007/BF00037152; Thaler JS, 1999, NATURE, V399, P686, DOI 10.1038/21420; Thaler JS, 1997, AM NAT, V149, P1139, DOI 10.1086/286042; Wackers FL, 2001, ANN BOT-LONDON, V87, P365, DOI 10.1006/anbo.2000.1342; Walling LL, 2000, J PLANT GROWTH REGUL, V19, P195; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Wolfe AD, 1998, P NATL ACAD SCI USA, V95, P5112, DOI 10.1073/pnas.95.9.5112	30	110	119	8	85	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					205	208		10.1038/nature02703	http://dx.doi.org/10.1038/nature02703			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241414				2022-12-28	WOS:000222470600043
J	Senat, MV; Deprest, J; Boulvain, M; Paupe, A; Winer, N; Ville, Y				Senat, MV; Deprest, J; Boulvain, M; Paupe, A; Winer, N; Ville, Y			Endoscopic laser surgery versus serial amnioreduction for severe twin-to-twin transfusion syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THERAPEUTIC AMNIOCENTESIS; ULTRASONOGRAPHIC FINDINGS; MANAGEMENT; PREGNANCY; COAGULATION; GESTATION; OUTCOMES; PLACENTA; DAMAGE; RATES	Background: Monochorionic twin pregnancies complicated by severe twin-to-twin transfusion syndrome at midgestation can be treated by either serial amnioreduction (removal of large volumes of amniotic fluid) or selective fetoscopic laser coagulation of the communicating vessels on the chorionic plate. We conducted a randomized trial to compare the efficacy and safety of these two treatments. Methods: Pregnant women with severe twin-to-twin transfusion syndrome before 26 weeks of gestation were randomly assigned to laser therapy or amnioreduction. We assessed perinatal survival of at least one twin (a prespecified primary outcome), survival of at least one twin at six months of age, and survival without neurologic complications at six months of age on the basis of the number of pregnancies or the number of fetuses or infants, as appropriate. Results: The study was concluded early, after 72 women had been assigned to the laser group and 70 to the amnioreduction group, because a planned interim analysis demonstrated a significant benefit in the laser group. As compared with the amnioreduction group, the laser group had a higher likelihood of the survival of at least one twin to 28 days of age (76 percent vs. 56 percent; relative risk of the death of both fetuses, 0.63; 95 percent confidence interval, 0.25 to 0.93; P=0.009) and 6 months of age (P=0.002). Infants in the laser group also had a lower incidence of cystic periventricular leukomalacia (6 percent vs. 14 percent, P=0.02) and were more likely to be free of neurologic complications at six months of age (52 percent vs. 31 percent, P=0.003). Conclusions: Endoscopic laser coagulation of anastomoses is a more effective first-line treatment than serial amnioreduction for severe twin-to-twin transfusion syndrome diagnosed before 26 weeks of gestation.	Univ Paris Ouest Versailles St Quentin, Ctr Hosp Intercommunale Poissy St Germain, Dept Obstet & Gynecol, Poissy, France; Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Dept Obstet & Gynecol, Leuven, Belgium; Univ Geneva, Univ Hosp Geneva, Dept Obstet & Gynecol, Geneva, Switzerland; CHU Nantes, Dept Obstet & Gynecol, F-44035 Nantes 01, France	KU Leuven; University Hospital Leuven; University of Geneva; Nantes Universite; CHU de Nantes	Ville, Y (corresponding author), Univ Versailles St Quentin, Serv Gynecol Obstet, CHI Poissy, Rue Champ Gaillard, F-78300 Poissy, France.	yville@wanadoo.fr		Deprest, Jan/0000-0002-4920-945X				Banek CS, 2003, AM J OBSTET GYNECOL, V188, P876, DOI 10.1067/mob.2003.202; BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2; BENIRSCHKE K, 1990, CLIN OBSTET GYNECOL, V33, P18, DOI 10.1097/00003081-199003000-00006; Cincotta RB, 2000, ARCH DIS CHILD-FETAL, V83, pF171, DOI 10.1136/fn.83.3.F171; De Lia JE, 1999, J PERINAT MED, V27, P61, DOI 10.1515/JPM.1999.007; DeLia JE, 1996, CLIN OBSTET GYNECOL, V39, P607, DOI 10.1097/00003081-199609000-00009; Denbow ML, 1998, AM J OBSTET GYNECOL, V178, P479, DOI 10.1016/S0002-9378(98)70424-7; DEVRIES LS, 1992, BEHAV BRAIN RES, V49, P1, DOI 10.1016/S0166-4328(05)80189-5; Dickinson JE, 2000, AM J OBSTET GYNECOL, V182, P706, DOI 10.1067/mob.2000.104236; DONNER A, 1994, AM J EPIDEMIOL, V140, P279, DOI 10.1093/oxfordjournals.aje.a117247; ELLIOTT JP, 1991, OBSTET GYNECOL, V77, P537; FUSI L, 1991, OBSTET GYNECOL, V78, P517; GONSOULIN W, 1990, OBSTET GYNECOL, V75, P214; Haverkamp F, 2001, Eur J Paediatr Neurol, V5, P21, DOI 10.1053/ejpn.2001.0400; Hecher K, 1999, AM J OBSTET GYNECOL, V180, P717, DOI 10.1016/S0002-9378(99)70278-4; Hecher K, 2000, EUR J OBSTET GYN R B, V92, P135, DOI 10.1016/S0301-2115(00)00437-1; LARROCHE JC, 1990, BIOL NEONATE, V57, P261; MAHONY BS, 1990, AM J OBSTET GYNECOL, V163, P1513, DOI 10.1016/0002-9378(90)90617-G; Mari G, 2000, AM J OBSTET GYNECOL, V183, P211, DOI 10.1016/S0002-9378(00)66819-9; Mari G, 2001, AM J OBSTET GYNECOL, V185, P708, DOI 10.1067/mob.2001.117188; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAPILE LA, 1983, J PEDIATR-US, V103, P273, DOI 10.1016/S0022-3476(83)80366-7; PINETTE MG, 1993, OBSTET GYNECOL, V82, P841; Quintero R A, 1999, J Perinatol, V19, P550, DOI 10.1038/sj.jp.7200292; Quintero RA, 2003, AM J OBSTET GYNECOL, V188, P1333, DOI 10.1067/mob.2003.292; REISNER DP, 1993, AM J OBSTET GYNECOL, V169, P991, DOI 10.1016/0002-9378(93)90041-G; SAUNDERS NJ, 1992, AM J OBSTET GYNECOL, V166, P820, DOI 10.1016/0002-9378(92)91340-G; Sutcliffe AG, 2001, BRIT J OBSTET GYNAEC, V108, P1246; Trespidi L, 1997, FETAL DIAGN THER, V12, P15; VILLE Y, 1995, NEW ENGL J MED, V332, P224, DOI 10.1056/NEJM199501263320404; Ville Y, 1998, BRIT J OBSTET GYNAEC, V105, P446, DOI 10.1111/j.1471-0528.1998.tb10132.x; WEIR PE, 1979, BRIT J OBSTET GYNAEC, V86, P849, DOI 10.1111/j.1471-0528.1979.tb10710.x; Zikulnig L, 1999, ULTRASOUND OBST GYN, V14, P380, DOI 10.1046/j.1469-0705.1999.14060380.x	33	863	917	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					136	144		10.1056/NEJMoa032597	http://dx.doi.org/10.1056/NEJMoa032597			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15238624				2022-12-28	WOS:000222470700006
J	Taylor, HS				Taylor, HS			Endometrial cells derived from donor stem cells in bone marrow transplant recipients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULT MICE; IN-VIVO; HEPATOCYTES; EXPRESSION; BRAIN; DIFFERENTIATE; MUSCLE; BLOOD	Context Regeneration of the endometrium in each menstrual cycle is required for reproduction. Endogenous endometrial stem cells reside in the basalis layer and serve as a source of cells that differentiate to form the endometrium. Bone marrow-derived cells have been shown to take on functions outside the hematopoietic system. Objective To investigate the possibility that cells of extrauterine origin could re-populate the endometrium. Design, Setting, and Patients Endometrium from 4 HLA-mismatched bone marrow transplant recipients (1998-2002) was evaluated for donor HLA expression. Each recipient had a bone marrow donor with an HLA type that enabled determination of the origin of any cell. Endometrial biopsies also were obtained from 4 healthy control women. Main Outcome Measure HLA type was determined by immunohistochemistry and by reverse transcription-polymerase chain reaction. Results Donor-derived endometrial cells were detected in endometrial biopsy samples from all bone marrow recipients and accounted for 0.2% to 48% of epithelial cells and 0.3% to 52% of stromal cells. None of the controls demonstrated HLA mismatch in endometrial samples. Conclusion These findings demonstrate that endometrial cells can originate from donor-derived bone marrow cells and suggest that nonuterine stem cells contribute to the regeneration of endometrial tissue.	Yale Univ, Sch Med, Div Reprod Endocrinol, New Haven, CT 06520 USA	Yale University	Taylor, HS (corresponding author), Yale Univ, Sch Med, Div Reprod Endocrinol, 333 Cedar St,POB 208063, New Haven, CT 06520 USA.	hugh.taylor@yale.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036887, R29HD036887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010610] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 36887] Funding Source: Medline; NIEHS NIH HHS [ES 10610] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; BEGOVICH AB, 1995, JAMA-J AM MED ASSOC, V273, P586, DOI 10.1001/jama.273.7.586; Bettinotti MP, 1997, J IMMUNOTHER, V20, P425, DOI 10.1097/00002371-199711000-00001; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Braun DP, 1998, CURR OPIN OBSTET GYN, V10, P365, DOI 10.1097/00001703-199810000-00003; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Kumar S, 1998, J CLIN ENDOCR METAB, V83, P4443, DOI 10.1210/jc.83.12.4443; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Olive DL, 2001, NEW ENGL J MED, V345, P266, DOI 10.1056/NEJM200107263450407; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Pyo CW, 2001, TISSUE ANTIGENS, V58, P190, DOI 10.1034/j.1399-0039.2001.580309.x; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Rier SE, 1997, SEMIN REPROD ENDOCR, V15, P209, DOI 10.1055/s-2008-1068750; Robertson SA, 2000, REV REPROD, V5, P164, DOI 10.1530/revreprod/5.3.164; Sampson JA, 1927, AM J OBSTET GYNECOL, V14, P422, DOI 10.1016/S0002-9378(15)30003-X; SIDELL N, 2002, ANN NY ACAD SCI, V95, P159; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Unger JB, 1996, AM J OBSTET GYNECOL, V175, P1432, DOI 10.1016/S0002-9378(96)70086-8; Vinatier D, 2001, EUR J OBSTET GYN R B, V96, P21, DOI 10.1016/S0301-2115(00)00405-X	27	339	375	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					81	85		10.1001/jama.292.1.81	http://dx.doi.org/10.1001/jama.292.1.81			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238594	Bronze			2022-12-28	WOS:000222448100030
J	Huddleston, JM; Long, KH; Naessens, JM; Vanness, D; Larson, D; Trousdale, R; Plevak, M; Cabanela, M; Ilstrup, D; Wachter, RM				Huddleston, JM; Long, KH; Naessens, JM; Vanness, D; Larson, D; Trousdale, R; Plevak, M; Cabanela, M; Ilstrup, D; Wachter, RM		Hosp Orthopedic Team Trial Invest	Medical and surgical comanagement after elective hip and knee arthroplasty - A randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT SATISFACTION; HOSPITALIST SERVICE; 30-DAY MORTALITY; HEALTH SYSTEM; CARE; EXPERIENCE; EFFICIENCY; COMMUNITY; OUTCOMES; COST	Background: Hospitalists are assuming an increasing role in the care of surgical patients, but the impact of this model of care on postoperative outcomes is unknown. Objective: To determine the impact of providing a collaborative, hospitalist-led model of care on postoperative outcomes and costs among patients having hip or knee arthroplasty. Design: Randomized, controlled trial. Setting: Academic medical center. Participants: 526 patients having elective orthopedic surgery who are at elevated risk for postoperative morbidity. Measurements: Length of stay, inpatient postoperative medical complications, health care provider satisfaction, and inpatient costs. Interventions: A comanagement medical Hospital ist-Orthopedic Team compared with standard postoperative care by orthopedic surgeons with medical consultation. Results: More patients in the hospitalist group were discharged from the hospital with no complications (61.6% vs. 49.8%; difference, 11.8 percentage points [95% Cl, 2.8 to 20.7 percentage points]). Fewer minor complications were observed among hospitalist patients (30.2% vs. 44.3%; difference, -14.1 percentage points [Cl, -22.7 to -5.3 percentage points]). Observed length of stay was not statistically different between treatment groups. However, when adjusted for discharge delays, mean length of stay for patients in the hospitalist model of care was shorter (5.1 days vs. 5.6 days; difference, -0.5 day [CI, -0.8 to -0.1 day]). Total costs did not differ between groups. Orthopedic surgeons and nurses preferred the hospitalist model. Limitations: Care providers and patients were aware of intervention assignments, and the study could not capture all costs associated with the hospitalist model. Conclusions: The comanagement medical Hospitalist-Orthopedic Team model reduced minor postoperative complication rates with no statistically significant difference in length of stay or cost. The nurses and surgeons strongly preferred the comanagement hospitalist model. Additional research on the clinical and economic impact of the hospitalist model in other surgical populations is warranted.	Mayo Clin & Mayo Fdn, Coll Med, Rochester, MN 55905 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Mayo Clinic; University of California System; University of California San Francisco	Huddleston, JM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	huddleston.jeanne@mayo.edu		Vanness, David/0000-0002-9790-2988				Agresti A., 1984, ANAL ORDINAL CATEGOR; Auerbach AD, 2002, ANN INTERN MED, V137, P859, DOI 10.7326/0003-4819-137-11-200212030-00006; Briggs A, 1998, J Health Serv Res Policy, V3, P233; Craig DE, 1999, ANN INTERN MED, V130, P355, DOI 10.7326/0003-4819-130-4-199902161-00005; Davis KM, 2000, AM J MED, V108, P621, DOI 10.1016/S0002-9343(00)00362-4; Diamond HS, 1998, ANN INTERN MED, V129, P197, DOI 10.7326/0003-4819-129-3-199808010-00006; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; Efron B, 1998, INTRO BOOTSTRAP; Fleiss JL., 2003, STAT METHODS RATES P; Francis JJ, 2001, MAYO CLIN PROC, V76, P604; Freese RB, 1999, ANN INTERN MED, V130, P350, DOI 10.7326/0003-4819-130-4-199902161-00004; Gold MR, 1996, COST EFFECTIVENESS H; Goldman L, 1999, ANN INTERN MED, V130, P364, DOI 10.7326/0003-4819-130-4-199902161-00007; Hackner D, 2001, CHEST, V119, P580, DOI 10.1378/chest.119.2.580; Hauer KE, 1999, WESTERN J MED, V171, P367; HUDDLESTON JM, 2003, J CLIN OUTCOMES MANA, V10, P193; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P102; Kreder HJ, 1999, CAN J SURG, V42, P433; Kroger E, 1998, J GEN INTERN MED, V13, pS66; LAVE JR, 1994, MED CARE, V32, pJS77; Lindenauer PK, 1999, ANN INTERN MED, V130, P343, DOI 10.7326/0003-4819-130-4-199902161-00003; Lurie JD, 1999, AM J MED, V106, P441, DOI 10.1016/S0002-9343(99)00045-5; Meltzer D, 2002, ANN INTERN MED, V137, P866, DOI 10.7326/0003-4819-137-11-200212030-00007; METLZER DO, 2001, J GEN INTERN MED S1, V16, pS208; MURPHY PJ, 1987, AGE AGEING, V16, P273, DOI 10.1093/ageing/16.5.273; PALMER H, 2001, J GEN INTERN MED S1, V136, pS211; Palmer HC, 2001, AM J MED, V111, P627, DOI 10.1016/S0002-9343(01)00976-7; Parvizi J, 2001, J BONE JOINT SURG AM, V83A, P1524, DOI 10.2106/00004623-200110000-00010; Parvizi J, 2001, J BONE JOINT SURG AM, V83A, P1157, DOI 10.2106/00004623-200108000-00004; Reddy JC, 2001, AM J MANAG CARE, V7, P1142; Rifkin W, 2001, J GEN INTERN MED S, V16, pS215; Rifkin W, 1999, J GEN INTERN MED S, V14, pS118; SHEPHERD G, 1997, TAMPA BAY BUSINESS J, V1, P10; Stein MD, 1998, J GEN INTERN MED, V13, P774, DOI 10.1046/j.1525-1497.1998.00231.x; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Wachter RM, 2002, JAMA-J AM MED ASSOC, V287, P487, DOI 10.1001/jama.287.4.487; Wachter RM, 1999, ANN INTERN MED, V130, P338, DOI 10.7326/0003-4819-130-4-199902161-00002; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Wachter RM, 1996, NEW ENGL J MED, V335, P514, DOI 10.1056/NEJM199608153350713; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WHITAKER J J, 1989, Health Bulletin (Edinburgh), V47, P72; Zhou XH, 1997, ANN INTERN MED, V127, P752, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00063; ZUCKERMAN JD, 1992, CLIN ORTHOP RELAT R, P213	43	170	171	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					28	38		10.7326/0003-4819-141-1-200407060-00012	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238368				2022-12-28	WOS:000222427600005
J	Laurent, C; Kouanfack, C; Koulla-Shiro, S; Nkoue, N; Bourgeois, A; Calmy, A; Lactuock, B; Nzeusseu, V; Mougnutou, R; Peytavin, G; Liegeois, F; Nerrienet, E; Tardy, M; Peeters, M; Andrieux-Meyer, I; Zekeng, L; Kazatchkine, M; Mpoudi-Ngole, E; Delaporte, E				Laurent, C; Kouanfack, C; Koulla-Shiro, S; Nkoue, N; Bourgeois, A; Calmy, A; Lactuock, B; Nzeusseu, V; Mougnutou, R; Peytavin, G; Liegeois, F; Nerrienet, E; Tardy, M; Peeters, M; Andrieux-Meyer, I; Zekeng, L; Kazatchkine, M; Mpoudi-Ngole, E; Delaporte, E		ANRS 1274 Study Grp	Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial	LANCET			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; ULTRAVIOLET DETECTION; HUMAN PLASMA; REGIMENS; OUTCOMES	Background Generic fixed-dose combinations have been prequalified by WHO to treat HIV-infected patients in resource-limited countries. Despite their widespread use they are, however, not yet recommended by some of the major donor agencies owing to scarcity of clinical data on effectiveness, safety, and quality. We aimed to assess these issues for one of the most frequently prescribed treatments in Africa, a generic fixed-dose combination of nevirapine, stavudine, and lamivudine. Methods 60 patients were followed in an open-label, 24-week multicentre trial in Cameroon. All patients received one tablet of the fixed-dose combination drug twice daily. The primary outcome measure was the proportion of patients with viral load less than 400 copies per mL at the end of the study period, in an intention-to-treat analysis. Findings At baseline, 92% of patients (n=55) had AIDS; median CD4 count was 118 cells per muL (IQR 78-167) and median plasma HIV-1 RNA was 104 736 copies per mL (40 804-243 787). The proportion of patients with undetectable viral load (<400 copies per mL) after 24 weeks of treatment was 80% (95% Cl 68-89). Median (IQR) change in viral load was -3.1 log(10) copies per mL (-2.5 to -3.6) and in CD4 count 83 cells per mu L (40-178). The probability of remaining alive or free of new AIDS-defining events was 0.85 (95% Cl 0.73-0.92). Frequency of disease progression was 32.0 (95% CI 16.6-61.5), severe adverse effects 17.8 (7.4-42.7), and genotypic resistance mutations 7.1 (1.8-28.4) per 100 person-years. Mean reported adherence rate was 99%. Median drug concentrations in tablets were 96% of expected values for nevirapine, 89% for stavudine, and 99% for lamivudine. Interpretation Our findings lend support to use and funding of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine as first-line antiretroviral treatment in developing countries.	Univ Montpellier, Inst Rech Dev, UMR 145, F-34394 Montpellier 5, France; Univ Montpellier, Dept Int Hlth, UMR 145, F-34394 Montpellier 5, France; Cent Hosp, Yaounde, Cameroon; Mil Hosp, Projet PRESICA PARVY, Yaounde, Cameroon; Med Sans Frontieres, Geneva, Switzerland; Ctr Hosp Univ Bichat Claude Bernard, Lab Toxicol & Dosage Med, Paris, France; Ctr Pasteur, Yaounde, Cameroon; Lab Sante & Hyg Mobile, Yaounde, Cameroon; Natl AIDS Program, Yaounde, Cameroon; French Natl Agcy Res AIDS, Paris, France	Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Universite de Montpellier; Doctors Without Borders; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP	Delaporte, E (corresponding author), Univ Montpellier, Inst Rech Dev, UMR 145, 911 Ave Agropolis,BP 64501, F-34394 Montpellier 5, France.	Eric.Delaporte@mpl.ird.fr	Delaporte, Eric/J-5397-2018; Florian, Liegeois/D-3798-2013	Delaporte, Eric/0000-0002-1822-9853; Florian, Liegeois/0000-0003-1048-0661; Laurent, Christian/0000-0003-2658-7113				BURGER DM, 1992, J CHROMATOGR-BIOMED, V584, P239, DOI 10.1016/0378-4347(92)80581-A; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Coetzee D, 2004, AIDS, V18, P887, DOI 10.1097/00002030-200404090-00006; Djomand G, 2003, AIDS, V17, pS5, DOI 10.1097/00002030-200317003-00002; FLEMING TR, 1982, BIOMETRICS, V38, P143, DOI 10.2307/2530297; Frater AJ, 2002, AIDS, V16, P1139, DOI 10.1097/00002030-200205240-00007; HALVIR D, 1995, J INFECT DIS, V171, P537; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; HARKER AJ, 1994, J CHROMATOGR B, V657, P227, DOI 10.1016/0378-4347(94)80092-8; Henry K, 2004, JAIDS-J ACQ IMM DEF, V35, P537, DOI 10.1097/00126334-200404150-00012; HOSSEINIPOUR M, 2003, 10 C RETR OPP INF FE; JOURDAIN G, 2004, 11 C RETR OPP INF FE; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Landman R, 2003, AIDS, V17, P1017, DOI 10.1097/00002030-200305020-00010; Laurent C, 2002, AIDS, V16, P1363, DOI 10.1097/00002030-200207050-00008; Martinez E, 2001, AIDS, V15, P1261, DOI 10.1097/00002030-200107060-00007; Tassie JM, 2003, AIDS, V17, P1995, DOI 10.1097/00002030-200309050-00023; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *USAID, HIV AIDS PRES EM PLA; van Heeswijk RPG, 1998, J CHROMATOGR B, V713, P395, DOI 10.1016/S0378-4347(98)00217-5; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Vergne L, 2003, AIDS, V17, pS31, DOI 10.1097/00002030-200317003-00005; Vergne L, 2003, VIROLOGY, V310, P254, DOI 10.1016/S0042-6822(03)00167-3; Weidle PJ, 2002, LANCET, V360, P34, DOI 10.1016/S0140-6736(02)09330-3; *WHO, PREQ PROJ PROC QUAL; *WHO, 2003, UNAIDS TRAT 3 MILL 2; World Health Organization, 2003, SCAL ANT THER RES LT	28	188	194	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					29	34		10.1016/S0140-6736(04)16586-0	http://dx.doi.org/10.1016/S0140-6736(04)16586-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234853				2022-12-28	WOS:000222392900028
J	Greenhalgh, T; Seyan, K; Boynton, P				Greenhalgh, T; Seyan, K; Boynton, P			"Not a university type": focus group study of social class, ethnic, and sex differences in school pupils' perceptions about medical school	BRITISH MEDICAL JOURNAL			English	Article							UNDERREPRESENTED-MINORITY-STUDENTS; OF-MEDICINE; ENRICHMENT PROGRAM; HEALTH-PROFESSIONS; EDUCATION; ACCEPTANCE; ADMISSIONS; PIPELINE; CAREERS; COLLEGE	Objective To investigate what going to medical school means to academically able 14-16 year olds from different ethnic and socioeconomic backgrounds in order to understand the wide socioeconomic variation in applications to medical school. Design Focus group study. Setting Six London secondary schools. Participants 68 academically able and scientifically oriented pupils aged 14-16 years from a wide range of social and ethnic backgrounds. Main outcome measures Pupils' perceptions of medical school, motivation to apply, confidence in ability to stay the Course, expectations of medicine as a career, and perceived sources of information and support. Results There were few differences by sex or ethnicity, but striking differences by socioeconomic status. Pupils from lower socioeconomic groups held stereotyped and superficial perceptions of doctors, saw medical school as culturally alien and geared towards "posh" students, and greatly underestimated their own chances of gaining a place and staying the course. They saw medicine as having extrinsic rewards (money) but requiring prohibitive personal sacrifices. Pupils from affluent backgrounds saw medicine as one of a menu of challenging career options with intrinsic rewards (fulfilment, achievement). All pupils had concerns about the costs of study, but only those from poor backgrounds saw costs as constraining their choices. Conclusions Underachievement by able pupils from poor backgrounds may be more to do with identity, motivation. and the cultural framing of career choices than with low levels of factual knowledge. Policies to widen participation in medical education trust go beyond a knowledge deficit model and address the complex social and cultured environment within which individual fife choices are embedded.	UCL, Dept Primary Hlth Care, London N19 5LW, England	University of London; University College London	Greenhalgh, T (corresponding author), UCL, Dept Primary Hlth Care, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Boynton, Petra/0000-0001-6699-2266				Angel C, 2000, BRIT MED J, V321, P1136, DOI 10.1136/bmj.321.7269.1136; [Anonymous], 2001, CHOOSING FUTURES YOU; Archer L, 2000, BETTERING YOURSELF D; Ball SJ, 2002, BRIT J SOCIOL EDUC, V23, P51, DOI 10.1080/01425690120102854; Ball SJ., 2002, RACE ETHNIC EDUC-UK, V5, P333, DOI [10.1080/1361332022000030879, DOI 10.1080/1361332022000030879]; Bediako MR, 1996, ACAD MED, V71, P190, DOI 10.1097/00001888-199602000-00029; Bordieu P., 1990, REPROD ED SOC CULTUR; Bordieu P., 1997, ED CULTURE EC SOC; Cantor JC, 1998, JAMA-J AM MED ASSOC, V280, P772, DOI 10.1001/jama.280.9.772; CARDINE JD, 2000, ACAD MED, V78, P467; Carlisle DM, 1998, AM J PUBLIC HEALTH, V88, P1314, DOI 10.2105/AJPH.88.9.1314; COHEN P, 2000, STUDIES LEARNING REG; Connor H., 1999, MAKING RIGHT CHOICE; CONNOR H, 1999, MAKIGN RIGHT CHOICE; Connor H., 2001, RR267 DFEE; *COUNC HEAD MED SC, MED ED RES CHMS STAT; *COUNC HEADS ED SC, MED ED RES CHMS STAT; Cregler L L, 1993, J Assoc Acad Minor Phys, V4, P127; Cregler L L, 1994, J Assoc Acad Minor Phys, V5, P68; Crump R, 1999, ACAD MED, V74, P315, DOI 10.1097/00001888-199904000-00011; DAVIS JA, 1982, J MED EDUC, V57, P527; Dearing R.., 1996, REV QUALIFICATIONS 1; Department for Education and Employment, 1999, LEARN SUCC NEW FRAM; Du Bois-Reymond M., 1998, J YOUTH STUD, V1, P63, DOI [10.1080/13676261.1998.10592995, DOI 10.1080/13676261.1998.10592995]; Fang WL, 1999, ACAD MED, V74, P366, DOI 10.1097/00001888-199904000-00026; FOSKETT N, 2001, CHOOSING FUTURE YOUN; Foskett N., 1996, STUDENT DECISION MAK; Glaser B.G., 1965, AWARENESS DYING; Grant J, 2002, ANAL TRENDS APPL MED; Hardy VD, 1999, ACAD MED, V74, P373, DOI 10.1097/00001888-199904000-00028; *HIGH ED FUND COUN, 2003, SOC CLASS PART GOOD; HOGARTH T, 1997, M897 HIGH ED FUND CO; Johnson D G, 1975, J Med Educ, V50, P713; JOLLY P, 1992, ACAD MED, V67, P765, DOI 10.1097/00001888-199211000-00014; Kreiter CD, 2003, TEACH LEARN MED, V15, P116, DOI 10.1207/S15328015TLM1502_08; LEWIS CL, 1996, ACAD MED, V71, P1650; MAGUIRE M, 2000, CHOICE PATHWAYS TRAN; McGlinn S, 1999, ACAD MED, V74, P380, DOI 10.1097/00001888-199904000-00030; McManus IC, 2002, BRIT MED J, V325, P786, DOI 10.1136/bmj.325.7368.786; Murray-Garcia JL, 2002, J NATL MED ASSOC, V94, P721; OFSTED (Office for Standards in Education), 1999, INSP SUBJ ASP 11 18; Quintilian E M, 1985, J Allied Health, V14, P63; Ready T, 1995, J Dent Educ, V59, P649; Roach J, 2000, STUDENTBMJ, V8, P178; ROBERTS D, 1997, YOUNG APPL PERCEPTIO; Rye JA, 1999, ACAD MED, V74, P352, DOI 10.1097/00001888-199904000-00022; Seyan K, 2004, BRIT MED J, V328, P1545, DOI 10.1136/bmj.328.7455.1545; SHIELDS PH, 1994, J NATL MED ASSOC, V86, P373; Soto-Greene M, 1999, ACAD MED, V74, P386, DOI 10.1097/00001888-199904000-00032; Strayhorn G, 1999, J NATL MED ASSOC, V91, P350; Terrell Charles, 2003, J Dent Educ, V67, P1048; TESTOFF A, 1983, PUBLIC HEALTH REP, V98, P284; Thomson W A, 1992, J Allied Health, V21, P79; Tysinger J W, 1987, J Allied Health, V16, P209; Universities UK, 2003, FAIR ENOUGH WIDER AC; UNIVERSITIES UK, 2000, FAIR ENOUGH WIDER AC; Wadenya Rose O, 2003, J Dent Educ, V67, P1039; Wiggs JS, 2000, J NATL MED ASSOC, V92, P125; Willis P., 1977, LEARNING LABOUR; Wilson JE, 1999, ACAD MED, V74, P400, DOI 10.1097/00001888-199904000-00036; WOODROW M, 1998, ELITISM INCLUSION GU	61	102	103	0	29	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1541	1544A		10.1136/bmj.328.7455.1541	http://dx.doi.org/10.1136/bmj.328.7455.1541			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DV	15217871	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000222392700023
J	Walker, N; Grassly, NC; Garnett, GP; Stanecki, KA; Ghys, PD				Walker, N; Grassly, NC; Garnett, GP; Stanecki, KA; Ghys, PD			Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic?	LANCET			English	Article							IMPACT; END	The validity of UNAIDS/WHO estimates of the burden of HIV/AIDS is rightly questioned by politicians, scientists, and activists-especially since the 2003 estimates to be released in July, 2004, will show substantial drops in the burden of HIV/AIDS in several countries, and increases in others. However, the estimates are based on an explicit attempt to meet criteria we believe should guide the generation of international morbidity and mortality figures. These criteria extend beyond the quality of the input data to include features of the estimation process such as transparency and participation. The 2003 estimates now include plausible ranges for estimates rather than a single best estimate. This reduces the chance that insignificant differences in estimates from different sources are given importance. Here, we describe the levels of uncertainty associated with the UNAIDS/WHO estimates of HIV/AIDS. We explain the reason for moving to the use of plausibility bounds, the factors that determine the width of the bounds, and the implications for policy makers and programme managers.	UNICEF, New York, NY 10017 USA; UNAIDS, United Nations Joint Programme HIV AIDS, Geneva, Switzerland; Univ London Imperial Coll Sci Technol & Med, Dept Infect Dis Epidemiol, London, England	UNICEF; UNAIDS; Imperial College London	Walker, N (corresponding author), UNICEF, 3 UN Plaza, New York, NY 10017 USA.	nwalker@unicef.org	Garnett, Geoffrey P/A-9312-2008; Grassly, Nicholas C/C-6381-2008	Grassly, Nicholas C/0000-0001-6067-4507				[Anonymous], 1999, WORLD HLTH REPORT 19; Artzrouni M, 2002, AIDS, V16, pW1; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Boerma JT, 2003, LANCET, V362, P1929, DOI 10.1016/S0140-6736(03)14967-7; Burton AH, 1998, INT J EPIDEMIOL, V27, P101, DOI 10.1093/ije/27.1.101; Feeney G, 2001, POPUL DEV REV, V27, P771, DOI 10.1111/j.1728-4457.2001.00771.x; GARCIACALLEJA JM, IN PRESS SEX TRANSM; GHYS PD, IN PRESS SEX TRANSM; GRASSLY NC, IN PRESS SEX TRANSM; GRASSLY NC, 2004, POPULATION STUDIES, V55, P207; *NAT AIDS COUNC, 2002, ANC SENT SURV HIV SY; *NAT AIDS PROGR ZI, 2002, NAT SURV HIV SYPH PR; Schwartlander B, 1999, AIDS, V13, P2445, DOI 10.1097/00002030-199912030-00017; STOVER J, IN PRESS SEX TRANSM; TIMAEUS IM, 2001 ANN M FIN PROGR; *UNAIDS, 2000, REP GLOB HIV EP; *UNAIDS, 2002, REP GLOB HIV EP; *UNAIDS, 2004, IN PRESS REP GLOB HI; *UNAIDS, 1998, REP GLOB HIV EP; *UNAIDS, 2000, GUID 2 GEN SURV GEN; *UNAIDS, 2000, MEAS EV; UNICEF, 2004, STAT WORLDS CHILDR 2; Walker N, 2003, AIDS, V17, P2215, DOI 10.1097/00002030-200310170-00010; Walker N, 2001, AIDS, V15, P1545, DOI 10.1097/00002030-200108170-00012; WALKER N, IN PRESS SEX TRANSM; *WHO UNAIDS, 1999, 11 WHOUNAIDS; World Health Organization, 1998, WORLD HLTH REP 1997; World Health Organization, 2000, WORLD HLTH REP 2000	28	57	60	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2180	2185		10.1016/S0140-6736(04)16511-2	http://dx.doi.org/10.1016/S0140-6736(04)16511-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220043				2022-12-28	WOS:000222268300024
J	Sterner, R; Schmid, FX				Sterner, R; Schmid, FX			De novo design of an enzyme	SCIENCE			English	Editorial Material							COMPUTATIONAL DESIGN; PROTEINS; CHEMISTRY; RECEPTOR		Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany; Univ Bayreuth, Biochem Lab, D-95440 Bayreuth, Germany	University of Regensburg; University of Bayreuth	Sterner, R (corresponding author), Univ Regensburg, Inst Biophys & Phys Biochem, D-93040 Regensburg, Germany.	reinhard.sterner@biologie.uni-regensburg.de		Sterner, Reinhard/0000-0001-8177-8460				Bocola M, 2004, CHEMBIOCHEM, V5, P214, DOI 10.1002/cbic.200300731; Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398; Bolon DN, 2002, CURR OPIN CHEM BIOL, V6, P125, DOI 10.1016/S1367-5931(02)00303-4; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Dwyer MA, 2003, P NATL ACAD SCI USA, V100, P11255, DOI 10.1073/pnas.2032284100; Gerlt JA, 2003, CURR OPIN CHEM BIOL, V7, P252, DOI 10.1016/S1367-5931(03)00019-X; HELLINGA HW, 1991, J MOL BIOL, V222, P763, DOI 10.1016/0022-2836(91)90510-D; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Schultz PG, 2002, ANGEW CHEM INT EDIT, V41, P4427, DOI 10.1002/1521-3773(20021202)41:23<4427::AID-ANIE4427>3.0.CO;2-K; Walsh C, 2001, NATURE, V409, P226, DOI 10.1038/35051697	12	13	17	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1916	1917		10.1126/science.1100482	http://dx.doi.org/10.1126/science.1100482			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218133				2022-12-28	WOS:000222241600028
J	Pinborg, A; Loft, A; Schmidt, L; Greisen, G; Rasmussen, S; Andersen, AN				Pinborg, A; Loft, A; Schmidt, L; Greisen, G; Rasmussen, S; Andersen, AN			Neurological sequelae in twins born after assisted conception: controlled national cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IN-VITRO FERTILIZATION; NON-IVF/ICSI TWINS; CEREBRAL-PALSY; CHILDREN BORN; PREGNANCIES; MORBIDITY; SWEDEN; BIRTHS; RISK	Objective To compare neurological sequelae in twins born after assisted conception with singletons after assisted conception and naturally conceived twins, and to assess neurological sequelae in children conceived after in vitro fertilisation (IVF) compared with intracytoplasmic sperm injection (ICSI). Design Controlled, national register based, cohort study. Participants Twins (n = 3393) and singletons (n = 5130) conceived by using assisted reproductive technologies and naturally conceived twins (n = 10 239) born in Denmark between 1995 and 2000. The children's age at time of follow up was 2-7 years. Data sources Children were identified by cross linkage of the national medical birth registry and the national registry for in vitro fertilisation. Neurological and psychiatric diagnoses were retrieved from the national patients' registry and the Danish psychiatric central registry. Main outcome measures Neurological sequelae, defined as cerebral palsy, mental retardation, severe mental developmental disturbances, and retarded psychomotor development. Further we made separate analyses on the specific cerebral palsy diagnosis. Results The crude prevalence rates per 1000 of neurological sequelae in twins and singletons after assisted conception and in naturally conceived twins were 8.8, 8.2, and 9.6, and of cerebral palsy 3.2, 2.5, and 4.0, respectively. In twins after assisted conception compared with control twins, the odds ratios of neurological sequelae and specifically of cerebral palsy, adjusted for child sex and year of birth, were 0.9 (95% confidence interval 0.6 to 1.4) and 0.8 (0.4 to 1.6), respectively. The corresponding odds ratios for twins after assisted conception compared with singletons after assisted conception were 1.1 (0.7 to 1.7) for neurological sequelae and 1.3 (0.6 to 2.9) for cerebral palsy. The odds ratio of neurological sequelae in children conceived by ICSI was 0.9 (0.5 to 1.7) v children conceived by IVF. Conclusions Twins from assisted conception have a similar risk of neurological sequelae as their naturally conceived peers and singletons from assisted conception. Children born after ICSI have the same risk of neurological sequelae as children born after IVF.	Univ Copenhagen Hosp, Rigshosp, Juliane Marie Ctr, Fertil Clin, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Inst Publ Hlth, DK-2200 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Neonatol, DK-1168 Copenhagen, Denmark; Natl Board Hlth, Hlth Stat, DK-2300 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen	Pinborg, A (corresponding author), Univ Copenhagen Hosp, Rigshosp, Juliane Marie Ctr, Fertil Clin, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	apinborg@rh.dk	Greisen, Gorm/AAA-6463-2022	Greisen, Gorm/0000-0001-8042-3262; Schmidt, Lone/0000-0002-9518-1734; Pinborg, Anja/0000-0002-8340-104X				Andersen AN, 1999, DAN MED BULL, V46, P357; Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129; Andersen TF, 1999, DAN MED BULL, V46, P263; Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Daniel Y, 2000, FERTIL STERIL, V74, P683, DOI 10.1016/S0015-0282(00)01491-6; Dhont M, 1999, AM J OBSTET GYNECOL, V181, P688, DOI 10.1016/S0002-9378(99)70514-4; Hagberg B, 2001, ACTA PAEDIATR, V90, P271, DOI 10.1080/080352501300067532; Kallen B, 2002, OBSTET GYNECOL, V100, P414, DOI 10.1016/S0029-7844(02)02069-0; Knudsen LB, 1998, DAN MED BULL, V45, P320; Koivurova S, 2003, HUM REPROD, V18, P2328, DOI 10.1093/humrep/deg445; Leslie GI, 2003, HUM REPROD, V18, P2067, DOI 10.1093/humrep/deg408; Minakami H, 1998, HUM REPROD, V13, P2005, DOI 10.1093/humrep/13.7.2005; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Pinborg A, 2004, HUM REPROD, V19, P435, DOI 10.1093/humrep/deh063; Pinborg A, 2003, HUM REPROD, V18, P1234, DOI 10.1093/humrep/deg257; PINBORG A, 2004, IN PRESS ACTA GYNECO; Scher AI, 2002, PEDIATR RES, V52, P671, DOI [10.1203/00006450-200211000-00011, 10.1203/01.PDR.0000032159.88318.5B]; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Stromberg B, 2002, LANCET, V359, P461, DOI 10.1016/S0140-6736(02)07674-2; Sutcliffe AG, 2001, LANCET, V357, P2080, DOI 10.1016/S0140-6736(00)05180-1; Topp M, 2001, PAEDIATR PERINAT EP, V15, P271, DOI 10.1046/j.1365-3016.2001.00354.x; Weinberg W, 1901, ARCH GESAMTE PHYSIOL, V88, P346, DOI 10.1007/BF01657695; Westergaard HB, 1999, HUM REPROD, V14, P1896, DOI 10.1093/humrep/14.7.1896	23	101	105	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2004	329	7461					311	314B		10.1136/bmj.38156.715694.3A	http://dx.doi.org/10.1136/bmj.38156.715694.3A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846FF	15256418	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223300300013
J	Davis, CC; Wurdack, KJ				Davis, CC; Wurdack, KJ			Host-to-parasite gene transfer in flowering plants: Phylogenetic evidence from malpighiales	SCIENCE			English	Article							MITOCHONDRIAL; RAFFLESIA	Horizontal gene transfer (HGT) between sexually unrelated species has recently been documented for higher plants, but mechanistic explanations for HGTs have remained speculative. We show that a parasitic relationship may facilitate HGT between flowering plants. The endophytic parasites Rafflesiaceae are placed in the diverse order Malpighiales. Our multigene phylogenetic analyses of Malpighiales show that mitochrodrial ( matR) and nuclear loci (18S ribosomal DNA and PHYC) place Rafflesiaceae in Malpighiales, perhaps near Ochnaceae/Clusiaceae. Mitochondrial nad1B-C, however, groups them within Vitaceae, near their obligate host Tetrastigma. These discordant phylogenetic hypotheses strongly suggest that part of the mitochondrial genome in Rafflesiaceae was acquired via HGT from their hosts.	Univ Michigan Herbarium, Ann Arbor, MI 48108 USA; Smithsonian Inst, Dept Bot, Suitland, MD 20746 USA; Smithsonian Inst, Labs Analyt Biol, Suitland, MD 20746 USA	University of Michigan System; University of Michigan; Smithsonian Institution; Smithsonian Institution	Davis, CC (corresponding author), Univ Michigan Herbarium, 3600 Vars Dr, Ann Arbor, MI 48108 USA.	chdavis@umich.edu						Barkman TJ, 2004, P NATL ACAD SCI USA, V101, P787, DOI 10.1073/pnas.0305562101; BEAMAN RS, 1988, AM J BOT, V75, P1148, DOI 10.2307/2444098; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; Cronquist A., 1981, INTEGRATED SYSTEM CL; Davis CC, 2004, AM J BOT, V91, P262, DOI 10.3732/ajb.91.2.262; Ingrouille MJ, 2002, BOT J LINN SOC, V138, P421, DOI 10.1046/j.1095-8339.2002.00028.x; KUIJT J., 1969, The biology of parasitic flowering plants. University of California Press, Berkeley.; NICKRENT DL, 1994, J MOL EVOL, V39, P62; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; STEVENS PF, 2001, ANGIOSPERM PHYLOGENY; USA The Angiosperm Phylogeny Group, 2003, Botanical Journal of the Linnean Society, V141, P399, DOI 10.1046/j.1095-8339.2003.t01-1-00158.x; Won H, 2003, P NATL ACAD SCI USA, V100, P10824, DOI 10.1073/pnas.1833775100	12	179	196	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2004	305	5684					676	678		10.1126/science.1100671	http://dx.doi.org/10.1126/science.1100671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	842GQ	15256617	Green Submitted			2022-12-28	WOS:000222992100051
J	Schrag, D				Schrag, D			The price tag on progress - Chemotherapy for colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Schrag, D (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.			Schrag, Deborah/0000-0002-4334-5717					0	349	354	0	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					317	319		10.1056/NEJMp048143	http://dx.doi.org/10.1056/NEJMp048143			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269308				2022-12-28	WOS:000222801200002
J	Dearden, JC; Ayaru, L; Wong, V; van Someren, N				Dearden, JC; Ayaru, L; Wong, V; van Someren, N			The double duct sign	LANCET			English	Editorial Material									Chase Farm Hosp, Enfield EN2 8JL, Middx, England	University of London; University College London; Royal Free London NHS Foundation Trust	Dearden, JC (corresponding author), Chase Farm Hosp, Enfield EN2 8JL, Middx, England.	janet.dearden@doctors.org.uk						ASTAGNEAU ED, 1994, GUT, V35, P705, DOI 10.1136/gut.35.5.705; Baillie J, 2003, GASTROENTEROLOGY, V124, P1686, DOI 10.1016/S0016-5085(03)00390-1; Menges M, 1999, INT J PANCREATOL, V26, P193, DOI 10.1385/IJGC:26:3:193; PereiraLima JC, 1996, HEPATO-GASTROENTEROL, V43, P992; PLUMLEY TF, 1982, AM J ROENTGENOL, V138, P31, DOI 10.2214/ajr.138.1.31	5	11	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					302	302		10.1016/S0140-6736(04)16683-X	http://dx.doi.org/10.1016/S0140-6736(04)16683-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262111				2022-12-28	WOS:000222784900036
J	Shah, NP; Tran, C; Lee, FY; Chen, P; Norris, D; Sawyers, CL				Shah, NP; Tran, C; Lee, FY; Chen, P; Norris, D; Sawyers, CL			Overriding imatinib resistance with a novel ABL kinase inhibitor	SCIENCE			English	Article							CHRONIC MYELOID-LEUKEMIA; BCR-ABL; TYROSINE KINASE; CLINICAL RESISTANCE; CHRONIC-PHASE; MUTATIONS; STI-571; STI571; CELLS; GENE	Resistance to the ABL kinase inhibitor imatinib (STI571 or Gleevec) in chronic myeloid leukemia (CML) occurs through selection for tumor cells harboring BCR-ABL kinase domain point mutations that interfere with drug binding. Crystallographic studies predict that most imatinib-resistant mutants should remain sensitive to inhibitors that bind ABL with less stringent conformational requirements. BMS-354825 is an orally bioavailable ABL kinase inhibitor with two-log increased potency relative to imatinib that retains activity against 14 of 15 imatinib-resistant BCR-ABL mutants. BMS-354825 prolongs survival of mice with BCR-ABL-driven disease and inhibits proliferation of BCR-ABL-positive bone marrow progenitor cells from patients with imatinib-sensitive and imatinib-resistant CML. These data illustrate how molecular insight into kinase inhibitor resistance can guide the design of second-generation targeted therapies.	Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Bristol Myers Squibb Oncol, Princeton, NJ USA	University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Bristol-Myers Squibb	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016; Tran, Canh-Dung/D-4442-2011	Tran, Canh-Dung/0000-0002-1011-4226				Al-Ali HK, 2004, HEMATOL J, V5, P55, DOI 10.1038/sj.thj.6200319; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Deng M, 2001, BLOOD, V97, P3491, DOI 10.1182/blood.V97.11.3491; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Huron DR, 2003, CLIN CANCER RES, V9, P1267; La Rosee P, 2002, CANCER RES, V62, P7149; LOMBARDO LJ, UNPUB; Nagar B, 2002, CANCER RES, V62, P4236; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; ODA T, 1994, J BIOL CHEM, V269, P22925; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Shah K, 1997, P NATL ACAD SCI USA, V94, P3565, DOI 10.1073/pnas.94.8.3565; Shah N. A. A., UNPUB; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; von Bubnoff N, 2002, LANCET, V359, P487, DOI 10.1016/S0140-6736(02)07679-1; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288	22	1409	1502	4	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					399	401		10.1126/science.1099480	http://dx.doi.org/10.1126/science.1099480			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	837TE	15256671				2022-12-28	WOS:000222662400039
J	Lin, Z; Owen, AB; Altman, RB				Lin, Z; Owen, AB; Altman, RB			Genomic research and human subject privacy	SCIENCE			English	Editorial Material							DATABASE		Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Dept Stat, Moffett Field, CA 94035 USA	Stanford University; Stanford University	Altman, RB (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.	russ.altman@stanford.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061374] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007033] Funding Source: NIH RePORTER; NIGMS NIH HHS [U01-GM61374] Funding Source: Medline; NLM NIH HHS [LM007033] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Anderlik MR, 2001, ANNU REV GENOM HUM G, V2, P401, DOI 10.1146/annurev.genom.2.1.401; Austin MA, 2003, GENET MED, V5, P451, DOI 10.1097/01.GIM.0000093976.08649.1B; Barbour V, 2003, LANCET, V361, P1734, DOI 10.1016/S0140-6736(03)13377-6; Carey L, 2002, ELECTROPHORESIS, V23, P1386, DOI 10.1002/1522-2683(200205)23:10<1386::AID-ELPS1386>3.0.CO;2-M; CASH HD, 2003, PAC S BIOCOMPUT, V8, P638; Chadwick R, 1999, BRIT MED J, V319, P441, DOI 10.1136/bmj.319.7207.441; DHHS, 2002, FED REG 0814, V67, P53181; Frank L, 2000, SCIENCE, V290, P31, DOI 10.1126/science.290.5489.31; Klein T. E., 2001, Pharmacogenomics Journal, V1, P167; LI WH, 1991, GENETICS, V129, P513; National Commission on the Future of DNA Evidence, 2000, FUT FOR DNA TEST PRE; Sankar P, 2003, ANNU REV MED, V54, P393, DOI 10.1146/annurev.med.54.101601.152131; Willenborg L., 2001, ELEMENTS STAT DISCLO	13	218	223	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					183	183		10.1126/science.1095019	http://dx.doi.org/10.1126/science.1095019			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247459				2022-12-28	WOS:000222501000030
J	Waldmann, H; Cobbold, S				Waldmann, H; Cobbold, S			Exploiting tolerance processes in transplantation	SCIENCE			English	Article							REGULATORY T-CELLS; DONOR BONE-MARROW; STAGE RENAL-DISEASE; ALLOGRAFT TOLERANCE; MONOCLONAL-ANTIBODY; LYMPHOHEMATOPOIETIC CHIMERISM; MULTIPLE-MYELOMA; CUTTING EDGE; INDUCTION; ANTIGEN	The full potential of organ transplantation has not yet been realized because of the hazards associated with the long-term use of immunosuppressive drugs. Modern research into mechanisms of immune tolerance offers the promise of reprogramming the immune system, so as to harness the body's natural tolerance mechanisms in the service of graft acceptance. This would allow the minimization of immunosuppressive treatment and offers the prospect of eventually weaning transplant recipients off their drugs.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	University of Oxford	Waldmann, H (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	herman.waldmann@path.ox.ac.uk	waldmann, herman/W-8051-2019; waldmann, herman/F-7412-2011	Waldmann, Herman/0000-0001-7519-6720; Cobbold, Stephen/0000-0003-1206-4880				Adams AB, 2003, IMMUNOL REV, V196, P147, DOI 10.1046/j.1600-065X.2003.00082.x; Bemelman F, 1998, J IMMUNOL, V160, P2645; BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; Billingham RE, 2003, TRANSPLANTATION, V76, P1409, DOI 10.1097/01.TP.0000102675.72061.88; Buhler LH, 2002, TRANSPLANTATION, V74, P1405, DOI 10.1097/01.TP.0000034627.37442.A4; Calne R, 1998, LANCET, V351, P1701, DOI 10.1016/S0140-6736(05)77739-4; Cobbold SP, 2004, J IMMUNOL, V172, P6003, DOI 10.4049/jimmunol.172.10.6003; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; Davies JD, 1996, J IMMUNOL, V156, P3602; Durham MM, 2000, J IMMUNOL, V165, P1, DOI 10.4049/jimmunol.165.1.1; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; Hale G, 1994, J Hematother, V3, P15, DOI 10.1089/scd.1.1994.3.15; Honey K, 1999, J IMMUNOL, V163, P4805; Kirk AD, 2003, TRANSPLANTATION, V76, P120, DOI 10.1097/01.TP.0000071362.99021.D9; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Li BG, 2001, NEW ENGL J MED, V344, P947, DOI 10.1056/NEJM200103293441301; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lin CY, 2002, NAT IMMUNOL, V3, P1208, DOI 10.1038/ni853; Mellor AL, 2003, J IMMUNOL, V171, P1652, DOI 10.4049/jimmunol.171.4.1652; PEARSON TC, 1992, TRANSPLANTATION, V54, P475, DOI 10.1097/00007890-199209000-00018; QIN SX, 1990, EUR J IMMUNOL, V20, P2737, DOI 10.1002/eji.1830201231; QIN SX, 1989, J EXP MED, V169, P779, DOI 10.1084/jem.169.3.779; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; SHARABI Y, 1989, J EXP MED, V169, P493, DOI 10.1084/jem.169.2.493; Spitzer TR, 1999, TRANSPLANTATION, V68, P480, DOI 10.1097/00007890-199908270-00006; Suciu-Foca N, 2003, TRANSPL IMMUNOL, V11, P235, DOI 10.1016/S0966-3274(03)00052-2; THOMAS FT, 1983, ANN SURG, V198, P370, DOI 10.1097/00000658-198309000-00013; Thomas JM, 1997, TRANSPLANTATION, V64, P124, DOI 10.1097/00007890-199707150-00022; Wekerle T, 1998, J EXP MED, V187, P2037, DOI 10.1084/jem.187.12.2037; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; Wu ZH, 2004, NAT MED, V10, P87, DOI 10.1038/nm965; Zheng XX, 2003, IMMUNITY, V19, P503, DOI 10.1016/S1074-7613(03)00259-0	35	60	68	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					209	212		10.1126/science.1099538	http://dx.doi.org/10.1126/science.1099538			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247471				2022-12-28	WOS:000222501000042
J	Tschop, M; Castaneda, TR; Joost, HG; Thone-Reineke, C; Ortmann, S; Klaus, S; Hagan, MM; Chandler, PC; Oswald, KD; Benoit, SC; Seeley, RJ; Kinzig, KP; Moran, TH; Beck-Sickinger, AG; Koglin, N; Rodgers, RJ; Blundell, JE; Ishii, Y; Beattie, AH; Holch, P; Allison, DB; Raun, K; Madsen, K; Wulff, BS; Stidsen, CE; Birringer, M; Kreuzer, OJ; Schindler, M; Arndt, K; Rudolf, K; Mark, M; Deng, XY; Withcomb, DC; Halem, H; Taylor, J; Dong, J; Datta, R; Culler, M; Craney, S; Flora, D; Smiley, D; Heiman, ML				Tschop, M; Castaneda, TR; Joost, HG; Thone-Reineke, C; Ortmann, S; Klaus, S; Hagan, MM; Chandler, PC; Oswald, KD; Benoit, SC; Seeley, RJ; Kinzig, KP; Moran, TH; Beck-Sickinger, AG; Koglin, N; Rodgers, RJ; Blundell, JE; Ishii, Y; Beattie, AH; Holch, P; Allison, DB; Raun, K; Madsen, K; Wulff, BS; Stidsen, CE; Birringer, M; Kreuzer, OJ; Schindler, M; Arndt, K; Rudolf, K; Mark, M; Deng, XY; Withcomb, DC; Halem, H; Taylor, J; Dong, J; Datta, R; Culler, M; Craney, S; Flora, D; Smiley, D; Heiman, ML			Does gut hormone PYY3-36 decrease food intake in rodents?	NATURE			English	Letter							NEUROPEPTIDE-Y; MICE; RECEPTOR		Univ Cincinnati, Genome Res Inst, Dept Psychiat, Cincinnati, OH 45237 USA; German Inst Human Nutr, D-14558 Potsdam, Germany; Charite Univ Hosp, Inst Pharmacol & Toxicol, Cardiovasc Res Ctr, D-10115 Berlin, Germany; Inst Zoo & Wildlife Res, D-10315 Berlin, Germany; Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Univ Leipzig, Inst Biochem, D-04103 Leipzig, Germany; Univ Leeds, Sch Psychol, Behav Pharmacol Lab, Leeds LS2 9JT, W Yorkshire, England; Univ Alabama, Dept Biostat, Sect Stat Genet, Birmingham, AL 35294 USA; Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35294 USA; Novo Nordisk AS, DK-2760 Malov, Denmark; Peptides & Elephants GmbH, D-14558 Potsdam, Germany; Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany; Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15213 USA; Biomeasure Inc, Ipsen Grp, Milford, MA 01757 USA; Eli Lilly & Co, Res Labs, Indianapolis, IN 46285 USA	University System of Ohio; University of Cincinnati; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Leibniz Institut fur Zoo und Wildtierforschung; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Leipzig University; University of Leeds; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Novo Nordisk; Boehringer Ingelheim; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ipsen; Eli Lilly	Tschop, M (corresponding author), Univ Cincinnati, Genome Res Inst, Dept Psychiat, Cincinnati, OH 45237 USA.	tschoemh@ucmail.uc.edu	Klaus, Susanne/P-9299-2018; Joost, Hans-Georg/J-4462-2013; Ortmann, Sylvia/B-7088-2015; Tschoep, Matthias H/I-5443-2014	Klaus, Susanne/0000-0001-8726-185X; Joost, Hans-Georg/0000-0002-5860-606X; Ortmann, Sylvia/0000-0003-2520-6251; Birringer, Marc/0000-0003-0343-4704; Tschoep, Matthias/0000-0002-4744-371X; Holch, Patricia (Trish)/0000-0002-4255-8315; Koglin, Norman/0000-0001-7583-8201; Culler, Michael D./0000-0001-5168-8739; Allison, David/0000-0003-3566-9399; Seeley, Randy/0000-0002-3721-5625; Blundell, John/0000-0002-7085-9596				ALLEN JM, 1984, DIGESTION, V30, P255, DOI 10.1159/000199117; *AM BIOSC, RPNQ0085 AM BIOSC; Asakawa A, 2003, GASTROENTEROLOGY, V124, P1325, DOI 10.1016/S0016-5085(03)00216-6; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; Challis BG, 2004, P NATL ACAD SCI USA, V101, P4695, DOI 10.1073/pnas.0306931101; Challis BG, 2003, BIOCHEM BIOPH RES CO, V311, P915, DOI 10.1016/j.bbrc.2003.10.089; Halatchev IG, 2004, ENDOCRINOLOGY, V145, P2585, DOI 10.1210/en.2003-1754; Halford JCG, 1998, PHARMACOL BIOCHEM BE, V61, P159, DOI 10.1016/S0091-3057(98)00032-X; Kanatani A, 2000, ENDOCRINOLOGY, V141, P1011, DOI 10.1210/en.141.3.1011; Nordheim U, 2004, AM J PHYSIOL-REG I, V286, pR138, DOI 10.1152/ajpregu.00374.2003	10	191	200	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996								10.1038/nature02665	http://dx.doi.org/10.1038/nature02665			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15243972				2022-12-28	WOS:000222470600032
J	Halperin, DT; Epstein, H				Halperin, DT; Epstein, H			Concurrent sexual partnerships help to explain Africa's high HIV prevalence: implications for prevention	LANCET			English	Editorial Material							CONDOM USE; MALE CIRCUMCISION; INFECTION; AIDS; TRANSMISSION; RISK		US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA; Princeton Univ, Ctr Hlth & Wellbeing, Princeton, NJ 08544 USA	United States Agency for International Development (USAID); Princeton University	Halperin, DT (corresponding author), US Agcy Int Dev, Off HIV AIDS, Washington, DC 20523 USA.	dhalp@worldwidedialup.net						Ahmed S, 2001, AIDS, V15, P2171, DOI 10.1097/00002030-200111090-00013; Bessinger R., 2003, SEXUAL BEHAV HIV FER; Caldwell JC, 2002, J HEALTH POPUL NUTR, V20, P104; CALDWELL JC, 1989, POPUL DEV REV, V15, P185, DOI 10.2307/1973703; Carael M., 1995, SEXUAL BEHAV AIDS DE; Chin J, 1998, AIDS, V12 Suppl B, pS87; Cohen J, 2004, SCIENCE, V304, P1932, DOI 10.1126/science.304.5679.1932; EBERSTADT N, 2002, FOREIGN AFFAIRS  NOV, P2; EPSTEIN H, 2004, NY TIMES MAGAZI 0613, P54; Flood M, 2003, CULT HEALTH SEX, V5, P353, DOI 10.1080/1369105011000028273; Ghys PD, 2002, AIDS, V16, P251, DOI 10.1097/00002030-200201250-00015; Green Edward, 2003, RETHINKING AIDS PREV; Halperin DT, 1999, LANCET, V354, P1813, DOI 10.1016/S0140-6736(99)03421-2; Hearst N, 2004, STUD FAMILY PLANN, V35, P39, DOI 10.1111/j.1728-4465.2004.00004.x; Jana S, 1998, AIDS, V12 Suppl B, pS101; Leclerc-Madlala S, 2003, SOC DYNAMICS, V29, P213, DOI 10.1080/02533950308628681; Meekers D, 2003, AIDS BEHAV, V7, P413, DOI 10.1023/B:AIBE.0000004733.26053.c8; Morris M, 1997, AIDS, V11, P641, DOI 10.1097/00002030-199705000-00012; MORRIS M, 2002, AM SOC ASS ANN M PUB; Pettifor Audrey, 2004, HIV SEXUAL BEHAV YOU; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Santelli JS, 1998, FAM PLANN PERSPECT, V30, P271, DOI 10.2307/2991502; Shelton JD, 2004, BMJ-BRIT MED J, V328, P891, DOI 10.1136/bmj.328.7444.891; Short RV, 2004, REPROD FERT DEVELOP, V16, P555, DOI 10.1071/RD03109; Stoneburner RL, 2004, SCIENCE, V304, P714, DOI 10.1126/science.1093166; UNAIDS, AIDS EP UPD 2003; Weiss HA, 2000, AIDS, V14, P2361, DOI 10.1097/00002030-200010200-00018; *WHO, 2003, SAF AB TECHN POL GUI, P14	29	257	261	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					4	6		10.1016/S0140-6736(04)16606-3	http://dx.doi.org/10.1016/S0140-6736(04)16606-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234834				2022-12-28	WOS:000222392900005
J	Ostrowski, SG; Van Bell, CT; Winograd, N; Ewing, AG				Ostrowski, SG; Van Bell, CT; Winograd, N; Ewing, AG			Mass spectrometric imaging of highly curved membranes during Tetrahymena mating	SCIENCE			English	Article							NONBILAYER LIPIDS; CELL-MEMBRANES; FUSION; SIMS; IDENTIFICATION; CONJUGATION; MICROSCOPY; PYRIFORMIS; CULTURES; SYSTEM	Biological membrane fusion is crucial to numerous cellular events, including sexual reproduction and exocytosis. Here, mass spectrometry images demonstrate that the low-curvature lipid phosphatidylcholine is diminished in the membrane regions between fusing Tetrahymena, where a multitude of highly curved fusion pores exist. Additionally, mass spectra and principal component analysis indicate that the fusion region contains elevated amounts of 2-aminoethylphosphonolipid, a high-curvature lipid. This evidence suggests that biological fusion involves and might in fact be driven by a heterogeneous redistribution of lipids at the fusion site.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Edinboro Univ, Dept Biol & Hlth Serv, Edinboro, PA 16444 USA; Penn State Univ, Dept Neural & Behav Sci, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania State System of Higher Education (PASSHE); Edinboro University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ostrowski, SG (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.		Ewing, Andrew G/A-3650-2009	Winograd, Nicholas/0000-0002-2690-7714	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB002016] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01 EB002016-11, R01 EB002016] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		ANSELL GB, 1973, FORM FUNCTION PHOSPH, V3; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; Cannon DM, 2000, J AM CHEM SOC, V122, P603, DOI 10.1021/ja992078p; Chandra S, 2000, ANAL CHEM, V72, p104A, DOI 10.1021/ac002716i; CHANDRA S, 1992, BIOL CELL, V74, P31, DOI 10.1016/0248-4900(92)90006-M; Chernomordik L, 1996, CHEM PHYS LIPIDS, V81, P203, DOI 10.1016/0009-3084(96)02583-2; Colliver TL, 1997, ANAL CHEM, V69, P2225, DOI 10.1021/ac9701748; D'Onofrio TG, 2003, LANGMUIR, V19, P1618, DOI 10.1021/la026133a; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Eitzen G, 2003, BBA-MOL CELL RES, V1641, P175, DOI 10.1016/S0167-4889(03)00087-9; FRISCH A, 1978, BIOCHIM BIOPHYS ACTA, V506, P18, DOI 10.1016/0005-2736(78)90431-5; GRUNER SM, 1985, P NATL ACAD SCI USA, V82, P3665, DOI 10.1073/pnas.82.11.3665; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Jackson JE, 2003, USERS GUIDE PRINCIPA; McMahon JM, 1996, RAPID COMMUN MASS SP, V10, P335, DOI 10.1002/(SICI)1097-0231(199602)10:3<335::AID-RCM516>3.0.CO;2-W; OSTROWSKI S, UNPUB; Pacholski ML, 1998, RAPID COMMUN MASS SP, V12, P1232, DOI 10.1002/(SICI)1097-0231(19980930)12:18<1232::AID-RCM319>3.0.CO;2-G; PSCHEID P, 1981, J MICROSC-OXFORD, V121, P149, DOI 10.1111/j.1365-2818.1981.tb01208.x; Roddy TP, 2003, ANAL CHEM, V75, P4087, DOI 10.1021/ac026353t; Roddy TP, 2002, ANAL CHEM, V74, P4020, DOI 10.1021/ac025574w; Roddy TP, 2002, ANAL CHEM, V74, P4011, DOI 10.1021/ac0255734; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; THOMPSON GA, 1977, BIOCHIM BIOPHYS ACTA, V472, P55, DOI 10.1016/0304-4157(77)90014-4; THOMPSON GA, 1972, J PROTOZOOL, V19, P231, DOI 10.1111/j.1550-7408.1972.tb03442.x; WOLFE J, 1985, J CELL SCI, V73, P69; WOLFE J, 1982, J MORPHOL, V172, P159, DOI 10.1002/jmor.1051720204; Yang L, 2002, SCIENCE, V297, P1877, DOI 10.1126/science.1074354	27	270	273	1	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	2004	305	5680					71	73		10.1126/science.1099791	http://dx.doi.org/10.1126/science.1099791			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232100	Green Accepted			2022-12-28	WOS:000222386000035
J	Pellerin, L; Magistretti, PJ				Pellerin, L; Magistretti, PJ			Let there be (NADH) light	SCIENCE			English	Editorial Material							GLUCOSE-UTILIZATION; NEURONAL-ACTIVITY; NEURAL ACTIVITY; BRAIN; ENERGY; RAT		Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland	University of Lausanne	Pellerin, L (corresponding author), Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland.	luc.pellerin@iphysiol.unil.ch; pierre.magistretti@iphysiol.unil.ch	Pellerin, Luc/A-8912-2017	Pellerin, Luc/0000-0002-1016-1970; Magistretti, Pierre Julius/0000-0002-6678-320X				FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Frahm J, 1996, MAGNET RESON MED, V35, P143, DOI 10.1002/mrm.1910350202; Hu YB, 1997, J NEUROCHEM, V69, P1484; Kasischke KA, 2004, SCIENCE, V305, P99, DOI 10.1126/science.1096485; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Mangia S, 2003, NEUROSCIENCE, V118, P7, DOI 10.1016/S0306-4522(02)00792-3; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x	9	73	79	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	2004	305	5680					50	52		10.1126/science.1100428	http://dx.doi.org/10.1126/science.1100428			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232095				2022-12-28	WOS:000222386000028
J	D'Attellis, N; Luong, V; Grinda, JM				D'Attellis, N; Luong, V; Grinda, JM			A shocking injury	LANCET			English	Editorial Material							ELECTRICAL INJURIES		Hop Europeen Georges Pompidou, Dept Anesthesiol & Crit Care, F-75908 Paris, France; Hop Europeen Georges Pompidou, Dept Cardiol, F-75908 Paris, France; Hop Europeen Georges Pompidou, Dept Cardiovasc Surg & Organ Transplantat, F-75908 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	D'Attellis, N (corresponding author), Hop Europeen Georges Pompidou, Dept Anesthesiol & Crit Care, F-75908 Paris, France.	Nicola.D-Attellis@hop.egp.ap-hop-paris.fr						Duff K, 2001, NEUROPSYCHOL REV, V11, P101, DOI 10.1023/A:1016623318049; Fish RM, 1999, J EMERG MED, V17, P977, DOI 10.1016/S0736-4679(99)00127-4; Koumbourlis AC, 2002, CRIT CARE MED, V30, pS424, DOI 10.1097/00003246-200211001-00007; Martinez JA, 2000, SOUTHERN MED J, V93, P1165; Wang X W, 1987, J Burn Care Rehabil, V8, P391, DOI 10.1097/00004630-198709000-00011	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2136	2136		10.1016/S0140-6736(04)16504-5	http://dx.doi.org/10.1016/S0140-6736(04)16504-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220036				2022-12-28	WOS:000222268300011
J	Emini, EA; Koff, WC				Emini, EA; Koff, WC			Developing an AIDS vaccine: Need, uncertainty, hope	SCIENCE			English	Editorial Material							VIRUS; HIV; TRANSMISSION; INFECTION; REVERSION; REGION; DESIGN; GP41		Int AIDS Vaccine Initiat, New York, NY 10038 USA	International AIDS Vaccine Initiative	Emini, EA (corresponding author), Int AIDS Vaccine Initiat, New York, NY 10038 USA.							Blattner WA, 2004, J INFECT DIS, V189, P1793, DOI 10.1086/386306; Burton DR, 2004, NAT IMMUNOL, V5, P233, DOI 10.1038/ni0304-233; Desrosiers RC, 2004, NAT MED, V10, P221, DOI 10.1038/nm0304-221; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Kaech SM, 2003, SCIENCE, V300, P263, DOI 10.1126/science.1084511; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Letvin NL, 2003, NAT MED, V9, P861, DOI 10.1038/nm0703-861; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; UNAIDS, 2003, AIDS EP UPD 2003; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	12	36	37	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1913	1914		10.1126/science.1100368	http://dx.doi.org/10.1126/science.1100368			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218131				2022-12-28	WOS:000222241600026
J	Freitag, M; Lee, DW; Kothe, GO; Pratt, RJ; Aramayo, R; Selker, EU				Freitag, M; Lee, DW; Kothe, GO; Pratt, RJ; Aramayo, R; Selker, EU			DNA methylation is independent of RNA interference in neurospora	SCIENCE			English	Article							GENOME; CRASSA; HP1		Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Texas A&M Univ, Coll Sci, Dept Biol, College Stn, TX 77843 USA	University of Oregon; Texas A&M University System; Texas A&M University College Station	Selker, EU (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	selker@molbio.uoregon.edu		Aramayo, Rodolfo/0000-0001-9702-6204	NIGMS NIH HHS [R01 GM058770, GM58770, GM35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035690, R01GM058770, R37GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Freitag M, 2004, MOL CELL, V13, P427, DOI 10.1016/S1097-2765(04)00024-3; FREITAG M, UNPUB; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Matzke M, 2003, SCIENCE, V301, P1060, DOI 10.1126/science.1089047; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Selker EU, 2003, NATURE, V422, P893, DOI 10.1038/nature01564	8	97	101	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1939	1939		10.1126/science.1099709	http://dx.doi.org/10.1126/science.1099709			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218142				2022-12-28	WOS:000222241600037
J	Oransky, I				Oransky, I			Paul Francis Wehrle - Obituary	LANCET			English	Biographical-Item												ivan-oransky@erols.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	2004	363	9426					2093	2093		10.1016/S0140-6736(04)16476-3	http://dx.doi.org/10.1016/S0140-6736(04)16476-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	830YJ	15244006				2022-12-28	WOS:000222159800041
J	Kuruvilla, R; Zweifel, LS; Glebova, NO; Lonze, BE; Valdez, G; Ye, HH; Ginty, DD				Kuruvilla, R; Zweifel, LS; Glebova, NO; Lonze, BE; Valdez, G; Ye, HH; Ginty, DD			A neurotrophin signaling cascade coordinates sympathetic neuron development through differential control of TrkA trafficking and retrograde signaling	CELL			English	Article							NERVE GROWTH-FACTOR; IN-VIVO; TARGET INNERVATION; RECEPTOR COMPLEX; SENSORY NEURONS; AXON GUIDANCE; NGF; SURVIVAL; P75; EXPRESSION	A fundamental question in developmental biology is how a limited number of growth factors and their cognate receptors coordinate the formation of tissues and organs endowed with enormous morphological complexity. We report that the related neurotrophins NGF and NT-3, acting through a common receptor, TrkA, are required for sequential stages of sympathetic axon growth and, thus, innervation of target fields. Yet, while NGF supports TrkA internalization and retrograde signaling from distal axons to cell bodies to promote neuronal survival, NT-3 cannot. Interestingly, final target-derived NGF promotes expression of the p75 neurotrophin receptor, in turn causing a reduction in the sensitivity of axons to intermediate target-derived NT-3. We propose that a hierarchical neurotrophin signaling cascade coordinates sequential stages of sympathetic axon growth, innervation of targets, and survival in a manner dependent on the differential control of TrkA internalization, trafficking, and retrograde axonal signaling.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA; SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Neurosci, Baltimore, MD 21205 USA.	dginty@jhmi.edu	Zweifel, Larry/O-3284-2017	Zweifel, Larry/0000-0003-3465-5331; Kuruvilla, Rejji/0000-0002-2851-675X; Lonze, Bonnie/0000-0002-0973-1657; Ye, Haihong/0000-0001-7282-6280	NINDS NIH HHS [NS34814, NS18218] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034814, R37NS034814, R01NS018218, R29NS034814] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Belliveau DJ, 1997, J CELL BIOL, V136, P375, DOI 10.1083/jcb.136.2.375; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Brennan C, 1999, NAT NEUROSCI, V2, P699, DOI 10.1038/11158; Brittis PA, 2002, CELL, V110, P223, DOI 10.1016/S0092-8674(02)00813-9; CLARY DO, 1994, P NATL ACAD SCI USA, V91, P11133, DOI 10.1073/pnas.91.23.11133; CROWLEY C, 1994, CELL, V76, P1001, DOI 10.1016/0092-8674(94)90378-6; DAVIES AM, 1995, EMBO J, V14, P4482, DOI 10.1002/j.1460-2075.1995.tb00127.x; Delcroix JD, 2003, NEURON, V39, P69, DOI 10.1016/S0896-6273(03)00397-0; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; ERNFORS P, 1994, CELL, V77, P503, DOI 10.1016/0092-8674(94)90213-5; Fagan AM, 1996, J NEUROSCI, V16, P6208; FARINAS I, 1994, NATURE, V369, P658, DOI 10.1038/369658a0; Francis N, 1999, DEV BIOL, V210, P411, DOI 10.1006/dbio.1999.9269; Ginty DD, 2002, CURR OPIN NEUROBIOL, V12, P268, DOI 10.1016/S0959-4388(02)00326-4; Glebova NO, 2004, J NEUROSCI, V24, P743, DOI 10.1523/JNEUROSCI.4523-03.2004; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Kuruvilla R, 2000, NEURON, V27, P499, DOI 10.1016/S0896-6273(00)00061-1; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; LEE KF, 1994, DEVELOPMENT, V120, P1027; Lein PJ, 2002, J NEUROSCI, V22, P10377; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; Liebl DJ, 1997, J NEUROSCI, V17, P9113; MILLER FD, 1994, DEV BIOL, V161, P206, DOI 10.1006/dbio.1994.1021; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; Ryden M, 1996, J BIOL CHEM, V271, P5623, DOI 10.1074/jbc.271.10.5623; SCARISBRICK IA, 1993, J NEUROSCI, V13, P875; Senger DL, 1997, J CELL BIOL, V138, P411, DOI 10.1083/jcb.138.2.411; Shao YF, 2002, J CELL BIOL, V157, P679, DOI 10.1083/jcb.200201063; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Sweeney C, 2000, J BIOL CHEM, V275, P19803, DOI 10.1074/jbc.C901015199; Tessarollo L, 1997, P NATL ACAD SCI USA, V94, P14776, DOI 10.1073/pnas.94.26.14776; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tsui-Pierchala BA, 1999, J NEUROSCI, V19, P8207; VERDI JM, 1994, NEURON, V13, P1359, DOI 10.1016/0896-6273(94)90421-9; Watson FL, 1999, J NEUROSCI, V19, P7889; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; Wyatt S, 1997, EMBO J, V16, P3115, DOI 10.1093/emboj/16.11.3115; WYATT S, 1995, J CELL BIOL, V130, P1435, DOI 10.1083/jcb.130.6.1435; Ye HH, 2003, NEURON, V39, P57, DOI 10.1016/S0896-6273(03)00266-6; Zhou XF, 1996, J COMP NEUROL, V372, P37, DOI 10.1002/(SICI)1096-9861(19960812)372:1<37::AID-CNE4>3.0.CO;2-N	45	272	288	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					243	255		10.1016/j.cell.2004.06.021	http://dx.doi.org/10.1016/j.cell.2004.06.021			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260993	Bronze			2022-12-28	WOS:000222966000012
J	Stewart, AF				Stewart, AF			Translational implications of the parathyroid calcium receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							SENSING RECEPTOR		Univ Pittsburgh, Sch Med, Dept Endocrinol & Metab, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Stewart, AF (corresponding author), Univ Pittsburgh, Sch Med, Dept Endocrinol & Metab, Pittsburgh, PA 15261 USA.							Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633; BROWN EM, 1995, NEW ENGL J MED, V333, P234, DOI 10.1056/NEJM199507273330407; Kifor O, 2004, J CLIN ENDOCR METAB, V89, P548, DOI 10.1210/jc.2003-031054; Kifor O, 2003, J CLIN ENDOCR METAB, V88, P60, DOI 10.1210/jc.2002-020249	4	10	10	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					324	326		10.1056/NEJMp048153	http://dx.doi.org/10.1056/NEJMp048153			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269311				2022-12-28	WOS:000222801200005
J	Habu, D; Shiomi, S; Tamori, A; Takeda, T; Tanaka, T; Kubo, S; Nishiguchi, S				Habu, D; Shiomi, S; Tamori, A; Takeda, T; Tanaka, T; Kubo, S; Nishiguchi, S			Role of vitamin K-2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MYELODYSPLASTIC SYNDROME; HEPATITIS-C; MENATETRENONE; APOPTOSIS; THERAPY; CELLS; RISK; BONE	Context Previous findings indicate that vitamin K-2 (menaquinone) may play a role in controlling cell growth. Objective To determine whether vitamin K-2 has preventive effects on the development of hepatocellular carcinoma in women with viral cirrhosis of the liver. Design, Setting, and Participants Forty women diagnosed as having viral liver cirrhosis were admitted to a university hospital between 1996 and 1998 and were randomly assigned to the treatment or control group. The original goal of the trial was to assess the long-term effects of vitamin K-2 on bone loss in women with viral liver cirrhosis. However, study participants also satisfied criteria required for examination of the effects of such treatment on the development of hepatocellular carcinoma. Interventions The treatment group received 45 mg/d of vitamin K-2 (n=21). Participants in the treatment and control groups received symptomatic therapy to treat ascites, if necessary, and dietary advice. Main Outcome Measure Cumulative proportion of patients with hepatocellular carcinoma. Results Hepatocellular carcinoma was detected in 2 of the 21 women given vitamin K-2 and 9 of the 19 women in the control group. The cumulative proportion of patients with hepatocellular carcinoma was smaller in the treatment group (log-rank test, P=.02). On univariate analysis, the risk ratio for the development of hepatocellular carcinoma in the treatment group compared with the control group was 0.20 (95% confidence interval [Cl], 0.04-0.91; P=.04). On multivariate analysis with adjustment for age, alanine aminotransferase activity, serum albumin, total bilirubin, platelet count, alpha-fetoprotein, and history of treatment with interferon alfa, the risk ratio for the development of hepatocellular carcinoma in patients given vitamin K-2 was 0.13 (95% Cl, 0.02-0.99; P=.05). Conclusion There is a possible role for vitamin K-2 in the prevention of hepatocellular carcinoma in women with viral cirrhosis.	Osaka City Univ, Sch Med, Grad Sch Med, Dept Nucl Med,Abeno Ku, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Hepatol, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Publ Hlth, Osaka 5458585, Japan; Osaka City Univ, Grad Sch Med, Dept Surg, Osaka 5458585, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University; Osaka Metropolitan University	Shiomi, S (corresponding author), Osaka City Univ, Sch Med, Grad Sch Med, Dept Nucl Med,Abeno Ku, 1-4-3 Asahimachi, Osaka 5458585, Japan.	shiomis@med.osaka-cu.ac.jp						[Anonymous], 1997, J CLIN PATHOL; CARR BI, 1995, P AACR, V36, P266; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; JEROME G, 2000, J HEPATOL, V32, P447; Kar S, 2000, J CELL PHYSIOL, V185, P386, DOI 10.1002/1097-4652(200012)185:3<386::AID-JCP8>3.0.CO;2-X; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Nishimaki J, 1999, LEUKEMIA, V13, P1399, DOI 10.1038/sj.leu.2401491; OHIZUMI H, 1995, J BIOCHEM-TOKYO, V117, P11, DOI 10.1093/oxfordjournals.jbchem.a124695; Orimo H, 1998, J BONE MINER METAB, V16, P106, DOI 10.1007/s007740050034; PERE G, 1987, HEPATOLOGY, V7, P122; SASAKI I, 1994, BIOCHEM BIOPH RES CO, V205, P1305; Shiomi S, 2002, AM J GASTROENTEROL, V97, P978, DOI 10.1111/j.1572-0241.2002.05618.x; Takami A, 1999, INT J HEMATOL, V69, P24; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Yoshida H, 1999, ANN INTERN MED, V131, P174, DOI 10.7326/0003-4819-131-3-199908030-00003; ZOLI M, 1991, AM J GASTROENTEROL, V86, P1508	17	119	124	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					358	361		10.1001/jama.292.3.358	http://dx.doi.org/10.1001/jama.292.3.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265851	Bronze			2022-12-28	WOS:000222693500021
J	Sotiriadis, A; Papatheodorou, S; Makrydimas, G				Sotiriadis, A; Papatheodorou, S; Makrydimas, G			Threatened miscarriage: evaluation and management	BMJ-BRITISH MEDICAL JOURNAL			English	Review							HUMAN CHORIONIC-GONADOTROPIN; EARLY-PREGNANCY FAILURE; SUBCHORIONIC HEMORRHAGE; FETAL VIABILITY; 1ST TRIMESTER; BED-REST; ABORTION; ULTRASOUND; WOMEN; SONOGRAPHY		Univ Hosp Ioannina, Dept Obstet & Gynaecol, Ioannina 45500, Greece; Delvinaki Hlth Ctr, Ioannina, Greece	University Hospital Ioannina	Sotiriadis, A (corresponding author), Univ Hosp Ioannina, Dept Obstet & Gynaecol, Ioannina 45500, Greece.	asotir@cc.uoi.gr	SOTIRIADIS, ALEXANDROS/G-3977-2015	SOTIRIADIS, ALEXANDROS/0000-0003-0876-5596				AlSebai MAH, 1996, HUM REPROD, V11, P881; ALSEBAI MAH, 1995, BRIT J OBSTET GYNAEC, V102, P364, DOI 10.1111/j.1471-0528.1995.tb11286.x; Ben-Haroush A, 2003, ISRAEL MED ASSOC J, V5, P422; Bennett GL, 1996, RADIOLOGY, V200, P803, DOI 10.1148/radiology.200.3.8756935; DICKEY RP, 1992, OBSTET GYNECOL, V80, P415; EVERETT C, 1987, BRIT MED J, V295, P583, DOI 10.1136/bmj.295.6598.583; Everett CB, 1996, BRIT J GEN PRACT, V46, P7; Falco P, 1996, ULTRASOUND OBST GYN, V7, P165, DOI 10.1046/j.1469-0705.1996.07030165.x; Falco P, 2003, ULTRASOUND OBST GYN, V21, P62, DOI 10.1002/uog.2; Fiegler P, 2003, J REPROD MED, V48, P982; Florio P, 2004, FERTIL STERIL, V81, P468, DOI 10.1016/j.fertnstert.2003.08.008; Giobbe M, 2001, Minerva Ginecol, V53, P337; HARRISON RF, 1993, INT J FERTIL, V38, P160; Johns J, 2003, OBSTET GYNECOL, V102, P483, DOI 10.1016/S0029-7844(03)00580-5; La Marca A, 1998, OBSTET GYNECOL, V92, P206, DOI 10.1016/S0029-7844(98)00183-5; Makrydimas G, 2003, ULTRASOUND OBST GYN, V22, P368, DOI 10.1002/uog.204; Nagy S, 2003, OBSTET GYNECOL, V102, P94, DOI 10.1016/S0029-7844(03)00403-4; OATESWHITEHEAD R, 2003, COCHRANE LIB; PEDERSEN JF, 1990, AM J ROENTGENOL, V154, P535, DOI 10.2214/ajr.154.3.2106217; Reljic M, 2001, ULTRASOUND OBST GYN, V17, P510, DOI 10.1046/j.1469-0705.2001.00370.x; Ruge S, 1990, ACTA OBSTET GYN SCAN, V69, P589, DOI 10.3109/00016349009028701; Schmidt T, 2001, EUR J OBSTET GYN R B, V97, P168, DOI 10.1016/S0301-2115(00)00533-9; Tannirandorn Y, 2003, INT J GYNECOL OBSTET, V81, P263, DOI 10.1016/S0020-7292(03)00076-6; TONGSONG T, 1994, INT J GYNECOL OBSTET, V46, P297, DOI 10.1016/0020-7292(94)90409-X; Tongsong T, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P331	25	54	58	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2004	329	7458					152	155		10.1136/bmj.329.7458.152	http://dx.doi.org/10.1136/bmj.329.7458.152			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15258071	Green Published			2022-12-28	WOS:000222832300025
J	Lallemant, M; Jourdain, G; Le Coeur, S; Mary, JY; Ngo-Giang-Huong, N; Koetsawang, S; Kanshana, S; McIntosh, K; Thaineua, V				Lallemant, M; Jourdain, G; Le Coeur, S; Mary, JY; Ngo-Giang-Huong, N; Koetsawang, S; Kanshana, S; McIntosh, K; Thaineua, V		Perinatal HIV Prevention Trial Tha	Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ANTIRETROVIRAL THERAPY; VERTICAL TRANSMISSION; RECEIVING NEVIRAPINE; RESISTANCE MUTATIONS; PREGNANT-WOMEN; INTRAPARTUM; RISK; COMBINATION; REDUCTION	BACKGROUND: Although zidovudine prophylaxis decreases the rate of transmission of the human immunodeficiency virus (HIV) type 1 substantially, a large number of infants still become infected. We hypothesized that the administration, in addition to zidovudine, of a single dose of oral nevirapine to mothers during labor and to neonates would further reduce transmission of HIV. METHODS: We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy. In one group, mothers and infants received a single dose of nevirapine (nevirapine-nevirapine regimen); in another, mothers and infants received nevirapine and placebo, respectively (nevirapine-placebo regimen); and in the last, mothers and infants received placebo (placebo-placebo regimen). The infants also received one week of zidovudine therapy and were formula-fed. The end point of the study was infection with HIV in the infants, established by virologic testing. RESULTS: Between January 15, 2001, and February 28, 2003, a total of 1844 Thai women were enrolled. At the first interim analysis, the independent data monitoring committee stopped enrollment in the placebo-placebo group. Among women who delivered before the interim analysis, the as-randomized Kaplan-Meier estimates of the transmission rates were 1.1 percent (95 percent confidence interval, 0.3 to 2.2) in the nevirapine-nevirapine group and 6.3 percent (95 percent confidence interval, 3.8 to 8.9) in the placebo-placebo group (P<0.001). The final per-protocol transmission rate in the nevirapine-nevirapine group, 1.9 percent (95 percent confidence interval, 0.9 to 3.0), was not significantly inferior to the rate in the nevirapine-placebo group (2.8 percent; 95 percent confidence interval, 1.5 to 4.1). Nevirapine had an effect within subgroups defined by known risk factors such as viral load and CD4 count. No serious adverse effects were associated with nevirapine therapy. CONCLUSIONS: A single dose of nevirapine to the mother, with or without a dose of nevirapine to the infant, added to oral zidovudine prophylaxis starting at 28 weeks' gestation, is highly effective in reducing mother-to-child transmission of HIV.	Inst Rech Dev, Epidemiol Clin Santa Maternelle & Infantile & Sid, Paris, France; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Inst Natl Etud Demog, F-75675 Paris, France; INSERM, ERM 0321, Paris, France; Mahidol Univ, Family Hlth Res Ctr, Bangkok 10700, Thailand; Minist Publ Hlth, Bangkok, Thailand; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA	Institut de Recherche pour le Developpement (IRD); Harvard University; Harvard T.H. Chan School of Public Health; Institut National de la Sante et de la Recherche Medicale (Inserm); Mahidol University; Ministry of Public Health - Thailand; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	Lallemant, M (corresponding author), Inst Rech Dev, Unite 54, Perinatal HIV Prevent Trial, 29-7-8 Samlan Rd,Soi 1 Prasing Muang, Chiang Mai 50200, Thailand.	marc@phpt.org	Ngo-Giang-Huong, Nicole/G-2860-2017; Jourdain, Gonzague/F-9117-2017	Ngo-Giang-Huong, Nicole/0000-0001-8950-3234; Jourdain, Gonzague/0000-0002-3365-7020	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039615] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD039615, 5 R01 HD 39615] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Amornwichet P, 2002, JAMA-J AM MED ASSOC, V288, P245, DOI 10.1001/jama.288.2.245; [Anonymous], 1999, MMWR Recomm Rep, V48, P1; Balasubramanian R, 2001, BIOMETRICS, V57, P1048, DOI 10.1111/j.0006-341X.2001.01048.x; Bucceri AM, 2002, HUM REPROD, V17, P436, DOI 10.1093/humrep/17.2.436; CHAIX ML, 2004, P 11 C RETR OPP INF, P657; CHALERMCHOKCHAR.A, 2004, P 11 C RETR OPP INF, P96; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; *DEP HLTH MIN PUBL, 2003, GUID MAN  PREV MOTH; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; ELLENBERG JH, 2001, BIOSTATISTICS CLIN T, P245; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Fleiss JL, 1981, STAT METHODS RATES P, P161; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Jourdain G, 2004, NEW ENGL J MED, V351, P229, DOI 10.1056/NEJMoa041305; Kanshana S, 2000, AIDS, V14, P1617, DOI 10.1097/00002030-200007280-00018; Kanshana S, 2002, AIDS, V16, P953, DOI 10.1097/00002030-200205030-00001; KANTOR R, 2003, ANTIVIR THER, V8, pS85; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; LAN KKG, 1989, BIOMETRICS, V45, P1017, DOI 10.2307/2531701; MARTINSON N, 2004, P 11 C RETR OPP INF, P38; MATHESON PB, 1995, J INFECT DIS, V172, P353, DOI 10.1093/infdis/172.2.353; *MIN PUBL HLTH, 2000, NAT GUID CLIN MAN HI; Mofenson LM, 2000, LANCET, V355, P2237, DOI 10.1016/S0140-6736(00)02415-6; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Morris L, 2003, AIDS, V17, P1698, DOI 10.1097/00002030-200307250-00017; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; SHAPIRO D, 2004, P 11 C RETR OPP INF, P99; Shapiro DE, 1999, LANCET, V354, P156, DOI 10.1016/S0140-6736(99)00122-1; SHEPARD KV, 2004, IMPORTANT NEW SAFETY; Simpson BJ, 1997, J ACQ IMMUN DEF SYND, V14, P145, DOI 10.1097/00042560-199702010-00007; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Talawat S, 2002, AIDS CARE, V14, P625, DOI 10.1080/0954012021000005452; Tuomala RE, 2002, NEW ENGL J MED, V346, P1863, DOI 10.1056/NEJMoa991159; [U.S. Public Health Service (USPHS) Infectious Diseases Society of America (IDSA)], 1999, MMWR-MORBID MORTAL W, V48, p[1, 61]; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; *WHO, 2004, ANT DRUGS PREV MOTH; Wimalasundera RC, 2002, LANCET, V360, P1152, DOI 10.1016/S0140-6736(02)11195-0; 2001, MMWR RECOMM REP, V50, P63	44	316	327	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					217	228		10.1056/NEJMoa033500	http://dx.doi.org/10.1056/NEJMoa033500			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15247338				2022-12-28	WOS:000222627200006
J	Singel, DJ; Stamler, JS				Singel, DJ; Stamler, JS			Blood traffic control	NATURE			English	Editorial Material									Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Montana State University System; Montana State University Bozeman; Duke University; Howard Hughes Medical Institute	Singel, DJ (corresponding author), Montana State Univ, Dept Chem & Biochem, Bozeman, MT 59717 USA.			Stamler, Jonathan/0000-0002-6866-1572				Datta B, 2004, CIRCULATION, V109, P1339, DOI 10.1161/01.CIR.0000124450.07016.1D; DULING BR, 1975, CIRC RES, V37, P325, DOI 10.1161/01.RES.37.3.325; Gonzalez-Alonso J, 2001, J PHYSIOL-LONDON, V530, P331, DOI 10.1111/j.1469-7793.2001.0331l.x; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; SINGEL DJ, IN PRESS ANN REV PHY, V67	5	42	44	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					297	297		10.1038/430297a	http://dx.doi.org/10.1038/430297a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254518	Bronze			2022-12-28	WOS:000222631200020
J	Steinman, L				Steinman, L			Immune therapy for autoimmune diseases	SCIENCE			English	Review							CHIMERIC MONOCLONAL-ANTIBODY; ALTERED PEPTIDE LIGAND; NECROSIS-FACTOR-ALPHA; MYELIN BASIC-PROTEIN; T-CELL-ACTIVATION; PHASE-II TRIAL; MULTIPLE-SCLEROSIS; RHEUMATOID-ARTHRITIS; IMMUNODOMINANT EPITOPE; NERVOUS-SYSTEM	Our increasing understanding of the pathophysiology of autoimmune disease has revealed a number of checkpoints that can be targeted with immune therapy, including key mediators of lymphocyte adhesion and migration, destructive cytokines involved in tissue damage, and the complex of molecules critical in the presentation of self-antigen and the activation of autoaggressive T lymphocytes. In many organ-specific autoimmune diseases, the identity of the molecules attacked by T cells and autoantibodies is known and attempts are under way to tolerize the immune system with a high level of specificity to these targets.	Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Interdepartmental Program Immunol, Stanford, CA 94305 USA	Stanford University; Stanford University	Steinman, L (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.	steinman@stanford.edu		Steinman, Lawrence/0000-0002-2437-2250				Aharoni R, 1999, P NATL ACAD SCI USA, V96, P634, DOI 10.1073/pnas.96.2.634; Alleva DG, 2001, J CLIN INVEST, V107, P173, DOI 10.1172/JCI8525; AREND WP, 1995, ARTHRITIS RHEUM, V38, P151, DOI 10.1002/art.1780380202; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Asseman C., 2002, Autoimmunity Reviews, V1, P190, DOI 10.1016/S1568-9972(02)00054-X; Bach JF, 2001, ANNU REV IMMUNOL, V19, P131, DOI 10.1146/annurev.immunol.19.1.131; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Blom T, 2003, SCIENCE, V299; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; CONSTANTINESCU CS, 1995, IMMUNOPHARM IMMUNOT, V17, P471, DOI 10.3109/08923979509016382; Darnell RB, 2003, NEW ENGL J MED, V349, P1543, DOI 10.1056/NEJMra023009; De Vita S, 2002, ARTHRITIS RHEUM, V46, P2029, DOI 10.1002/art.10467; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DEVAJYOTHI C, 1993, J BIOL CHEM, V268, P18794; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Ghoreschi K, 2003, NAT MED, V9, P40, DOI 10.1038/nm804; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Kremer JM, 2003, NEW ENGL J MED, V349, P1907, DOI 10.1056/NEJMoa035075; Lin MS, 1997, J CLIN INVEST, V99, P31, DOI 10.1172/JCI119130; Lovett-Racke AE, 2004, J IMMUNOL, V172, P5790, DOI 10.4049/jimmunol.172.9.5790; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nishimoto N, 2003, J RHEUMATOL, V30, P1426; Ostensen M, 2002, TRANSPL IMMUNOL, V9, P155, DOI 10.1016/S0966-3274(02)00017-5; PATY DW, 1994, ANN NEUROL, V36, pS113, DOI 10.1002/ana.410360726; Pedotti R, 2003, TRENDS IMMUNOL, V24, P479, DOI 10.1016/S1471-4906(03)00233-3; Pozzilli P, 2002, DIABETES-METAB RES, V18, P257, DOI 10.1002/dmrr.316; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; Robinson WH, 2003, NAT BIOTECHNOL, V21, P1033, DOI 10.1038/nbt859; Ruiz PJ, 2001, J IMMUNOL, V167, P2688, DOI 10.4049/jimmunol.167.5.2688; Ruiz-Ortega M, 2001, HYPERTENSION, V38, P1382, DOI 10.1161/hy1201.100589; Sela M, 1999, Int Rev Immunol, V18, P201, DOI 10.3109/08830189909043025; Slavin Anthony J., 2002, Autoimmunity Reviews, V1, P213, DOI 10.1016/S1568-9972(02)00051-4; STEINMAN L, 1993, SCI AM, V269, P106, DOI 10.1038/scientificamerican0993-106; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Steinman L, 2003, SCIENCE, V299; STEINMAN L, 1990, FASEB J, V4, P2726, DOI 10.1096/fasebj.4.10.2197152; Steinman L, 1999, J EXP MED, V189, P1021, DOI 10.1084/jem.189.7.1021; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; Verge CF, 1996, DIABETES, V45, P926, DOI 10.2337/diabetes.45.7.926; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zamvil SS, 2003, NEURON, V38, P685, DOI 10.1016/S0896-6273(03)00326-X	59	103	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					212	216		10.1126/science.1099896	http://dx.doi.org/10.1126/science.1099896			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247472				2022-12-28	WOS:000222501000043
J	Suchyna, TM; Tape, SE; Koeppe, RE; Andersen, OS; Sachs, F; Gottlieb, PA				Suchyna, TM; Tape, SE; Koeppe, RE; Andersen, OS; Sachs, F; Gottlieb, PA			Bilayer-dependent inhibition of mechanosensitive channels by neuroactive peptide enantiomers	NATURE			English	Article							GRAMICIDIN-A; LIPID BILAYERS; SPIDER VENOM; K+ CHANNELS; MEMBRANES; TENSION; INACTIVATION; ACTIVATION; LIFETIME; KINETICS	The peptide GsMTx4, isolated from the venom of the tarantula Grammostola spatulata, is a selective inhibitor of stretch-activated cation channels (SACs)(1). The mechanism of inhibition remains unknown; but both GsMTx4 and its enantiomer, enGsMTx4, modify the gating of SACs, thus violating a trademark of the traditional lock-and-key model of ligand-protein interactions. Suspecting a bilayer-dependent mechanism, we examined the effect of GsMTx4 and enGsMTx4 on gramicidin A (gA) channel gating(2). Both peptides are active, and the effect increases with the degree of hydrophobic mismatch between bilayer thickness and channel length, meaning that GsMTx4 decreases the energy required to deform the boundary lipids adjacent to the channel. GsMTx4 decreases inward SAC single-channel currents but has no effect on outward currents, suggesting it is located within a Debye length of the outer vestibule of the SACs, but significantly farther from the inner vestibule. Likewise, GsMTx4 decreases gA single-channel currents. Our results suggest that modulation of membrane proteins by amphipathic peptides-mechanopharmacology-involves not only the protein itself but also the surrounding lipids. The surprising efficacy of the D form of GsMTx4 peptide has important therapeutic implications, because D peptides are not hydrolysed by endogenous proteases and may be administered orally.	Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Univ Arkansas, Dept Chem & Biochem, Fayetteville, AR 72701 USA	Cornell University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Arkansas System; University of Arkansas Fayetteville	Andersen, OS (corresponding author), Cornell Univ, Weill Med Coll, Dept Physiol & Biophys, New York, NY 10021 USA.	sparre@med.cornell.edu; philgott@buffalo.edu	Gottlieb, Philip/C-3113-2019	Gottlieb, Philip/0000-0003-3764-9885; Koeppe, Roger/0000-0003-0676-6413	NIGMS NIH HHS [R01 GM021342] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021342] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andersen O S, 1999, Methods Enzymol, V294, P208; ANDERSEN OS, 1983, BIOPHYS J, V41, P119, DOI 10.1016/S0006-3495(83)84414-2; Bett GCL, 2000, J MEMBRANE BIOL, V173, P237, DOI 10.1007/s002320001023; Bode F, 2001, NATURE, V409, P35, DOI 10.1038/35051165; ELLIOTT JR, 1983, BIOCHIM BIOPHYS ACTA, V735, P95, DOI 10.1016/0005-2736(83)90264-X; Goulian M, 1998, BIOPHYS J, V74, P328, DOI 10.1016/S0006-3495(98)77790-2; Greathouse D V, 1999, Methods Enzymol, V294, P525; Gudi S, 1998, P NATL ACAD SCI USA, V95, P2515, DOI 10.1073/pnas.95.5.2515; HUANG HW, 1986, BIOPHYS J, V50, P1061, DOI 10.1016/S0006-3495(86)83550-0; Hwang TC, 2003, BIOCHEMISTRY-US, V42, P13646, DOI 10.1021/bi034887y; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KOEPPE RE, 1992, PROTEINS, V12, P49, DOI 10.1002/prot.340120107; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Laitko U, 2004, J GEN PHYSIOL, V123, P135, DOI 10.1085/jgp.200308965; LEHTONEN JYA, 1995, BIOPHYS J, V68, P1888, DOI 10.1016/S0006-3495(95)80366-8; Lundbaek JA, 2004, J GEN PHYSIOL, V123, P599, DOI 10.1085/jgp.200308996; Lundbaek JA, 1999, BIOPHYS J, V76, P889, DOI 10.1016/S0006-3495(99)77252-8; LUNDBAEK JA, 1994, J GEN PHYSIOL, V104, P645, DOI 10.1085/jgp.104.4.645; MARKIN VS, IN PRESS PHYS BIOL; OCONNELL AM, 1990, SCIENCE, V250, P1256, DOI 10.1126/science.1700867; Ostrow KL, 2003, TOXICON, V42, P263, DOI 10.1016/S0041-0101(03)00141-7; Oswald RE, 2002, J BIOL CHEM, V277, P34443, DOI 10.1074/jbc.M202715200; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2001, CURR OPIN CELL BIOL, V13, P422, DOI 10.1016/S0955-0674(00)00231-3; Perozo E, 2002, NAT STRUCT BIOL, V9, P696, DOI 10.1038/nsb827; Suchyna TM, 2000, J GEN PHYSIOL, V115, P583, DOI 10.1085/jgp.115.5.583; Suchyna TM, 2004, PHYS BIOL, V1, P1, DOI 10.1088/1478-3967/1/1/001; TRUDELLE Y, 1987, INT J PEPT PROT RES, V30, P163; White SH, 1998, METHOD ENZYMOL, V295, P62	29	241	254	0	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					235	240		10.1038/nature02743	http://dx.doi.org/10.1038/nature02743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241420				2022-12-28	WOS:000222470600050
J	Auerbach, JD				Auerbach, JD			No "access for all" to US Government HIV/AIDS research	LANCET			English	Editorial Material									Amer Fdn AIDS Res, New York, NY 10005 USA		Auerbach, JD (corresponding author), Amer Fdn AIDS Res, 120 Wall St,13th Floor, New York, NY 10005 USA.	judy.auerbach@amfar.org						Couzin J, 2004, SCIENCE, V304, P499; GARRETT L, 2004, LOS ANGELES TIM 0530, P5	2	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					109	110		10.1016/S0140-6736(04)16599-9	http://dx.doi.org/10.1016/S0140-6736(04)16599-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DX	15239174				2022-12-28	WOS:000222392900041
J	Dieppe, P; Bartlett, C; Davey, P; Doyal, L; Ebrahim, S				Dieppe, P; Bartlett, C; Davey, P; Doyal, L; Ebrahim, S			Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RISK; FAILURE		Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Univ Dundee, Med Monitoring Unit, MEMO, Div Community Hlth Sci, Dundee, Scotland; Univ Dundee, Med Monitoring Unit, MEMO, Div Med, Dundee, Scotland; Univ Dundee, Med Monitoring Unit, MEMO, Div Therapeut, Dundee, Scotland; Univ Bristol, Sch Policy Studies, Bristol BS8 1TH, Avon, England	University of Bristol; University of Dundee; University of Dundee; University of Dundee; University of Bristol	Dieppe, P (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.	p.dieppe@bristol.ac.uk						Al-Shahi R, 2000, BMJ-BRIT MED J, V321, P1031, DOI 10.1136/bmj.321.7268.1031; [Anonymous], 1995, J Clin Epidemiol, V48, P1441; Bandyopadhyay S, 2001, QJM-INT J MED, V94, P127, DOI 10.1093/qjmed/94.3.127; BARTLETT C, IN PRESS HLTH TECHNO; Bugeja G, 1997, BRIT MED J, V315, P1059, DOI 10.1136/bmj.315.7115.1059; BURRY HC, 1976, BRIT MED J, V1, P613, DOI 10.1136/bmj.1.6010.613; Chard J, 2002, RHEUMATOLOGY, V41, P1208, DOI 10.1093/rheumatology/41.10.1208-a; Chard JA, 2000, ANN RHEUM DIS, V59, P414, DOI 10.1136/ard.59.6.414; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; EVANS JM, 2000, PHARM MED, V9, P177; EVANS JMM, 1995, QJM-MON J ASSOC PHYS, V88, P551; FURST DE, 1988, J RHEUMATOL, V15, P58; Gutthann SP, 1996, ARCH INTERN MED, V156, P2433, DOI 10.1001/archinte.1996.00440200041005; HELIN HJ, 1995, ARTHRITIS RHEUM, V38, P242, DOI 10.1002/art.1780380213; Henry D, 1996, BRIT MED J, V312, P1563, DOI 10.1136/bmj.312.7046.1563; Holman CDJ, 2001, AUST NZ J PUBL HEAL, V25, P421, DOI 10.1111/j.1467-842X.2001.tb00285.x; Huong DLT, 1999, MEDICINE, V78, P148; Juni P, 2002, ARCH INTERN MED, V162, P2639, DOI 10.1001/archinte.162.22.2639-a; Kargman S, 1996, GASTROENTEROLOGY, V111, P445, DOI 10.1053/gast.1996.v111.pm8690211; Langman MJS, 2003, FUND CLIN PHARMACOL, V17, P393, DOI 10.1046/j.1472-8206.2003.00179.x; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Nazroo JY, 1998, SOCIOL HEALTH ILL, V20, P710, DOI 10.1111/1467-9566.00126; Page J, 2000, ARCH INTERN MED, V160, P777, DOI 10.1001/archinte.160.6.777; PERNEGER TV, 1994, NEW ENGL J MED, V331, P1675, DOI 10.1056/NEJM199412223312502; SANDLER DP, 1991, ANN INTERN MED, V115, P165, DOI 10.7326/0003-4819-115-3-165; WAGNER EH, 1991, ANN INTERN MED, V115, P227, DOI 10.7326/0003-4819-115-3-227	27	42	43	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					31	34		10.1136/bmj.329.7456.31	http://dx.doi.org/10.1136/bmj.329.7456.31			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231619	Green Published, Green Accepted			2022-12-28	WOS:000222568300019
J	Kerr, T; Kaplan, K; Suwannawong, P; Jurgens, R; Wood, E				Kerr, T; Kaplan, K; Suwannawong, P; Jurgens, R; Wood, E			The Global Fund to Fight AIDS, Tuberculosis and Malaria: funding for unpopular public-health programmes	LANCET			English	Editorial Material							HIV-1 INCIDENCE; DRUG-USERS; THAILAND		Canadian HIV AIDS Legal Network, Montreal, PQ H2Y 2M4, Canada; St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Thai Drug Users Network, Bangkok, Thailand; Thai AIDS Treatment Act Grp, Bangkok, Thailand; Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan; University of British Columbia	Kerr, T (corresponding author), Canadian HIV AIDS Legal Network, Montreal, PQ H2Y 2M4, Canada.	tkerr@aidslaw.ca						ADAMS B, 2003, INT HERALD TRIB 0424, P8; *AMN INT, 2003, THAIL GRAV DEV KILL; Celentano DD, 1999, AM J EPIDEMIOL, V149, P558, DOI 10.1093/oxfordjournals.aje.a009852; Celentano DD, 2003, J URBAN HEALTH, V80, P97; *GLOB FUND FIGHT A, GUID PROP 4 CALL PRO; *GLOB FUND FIGHT A, FUND WORKS; HOOVER J, 2003, AIDS, V15, P22; KERR T, 2003, GLOBAL FUND 3 ROUND; Rhodes T, 2003, SOC SCI MED, V57, P39, DOI 10.1016/S0277-9536(02)00521-X; UNAIDS, 2003, AIDS EP UPD 2003; Vanichseni S, 2001, AIDS, V15, P397, DOI 10.1097/00002030-200102160-00013; 1998, LANCET, V351, P839	12	15	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					11	12		10.1016/S0140-6736(04)16610-5	http://dx.doi.org/10.1016/S0140-6736(04)16610-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234838				2022-12-28	WOS:000222392900009
J	Power, L				Power, L			HIV and sexual health in the UK: politics and public health	LANCET			English	Editorial Material									Terrence Higgins Trust, Policy & Publ Affairs, London W11 1QT, England		Power, L (corresponding author), Terrence Higgins Trust, Policy & Publ Affairs, London W11 1QT, England.	lisa.power@tht.org.uk						Coker R, 2003, MIGRATION PUBLIC HLT; *HLTH PROT AG, AIDS HIV STII DAT; KINGHORN GR, HIV TREATM INF OTH N; *T HIGG TRUST, 2003, REC MIGR US HIV SERV; WEATHERBURN P, PROJECT NASAH INVEST	5	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					108	109		10.1016/S0140-6736(04)16598-7	http://dx.doi.org/10.1016/S0140-6736(04)16598-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DX	15239173				2022-12-28	WOS:000222392900040
J	Chen, WP; Yang, ZH				Chen, WP; Yang, ZH			Earthquakes beneath the Himalayas and Tibet: Evidence for strong lithospheric mantle	SCIENCE			English	Article							FOCAL DEPTHS; PLATEAU; DEFORMATION; TECTONICS; ZONE	Eleven intracontinental earthquakes, with magnitudes ranging from 4.9 to 6, occurred in the mantle beneath the western Himalayan syntaxis, the western Kunlun Mountains, and southern Tibet (near Xigaze) between 1963 and 1999. High-resolution seismic waveforms show that some focal depths exceeded 100 kilometers, indicating that these earthquakes occurred in the mantle portion of the lithosphere, even though the crust has been thickened there. The occurrence of earthquakes in the mantle beneath continental regions where the subduction of oceanic lithosphere ceased tens of millions years ago indicates that the mantle lithosphere is sufficiently strong to accumulate elastic strain.	Univ Illinois, Dept Geol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Chen, WP (corresponding author), Univ Illinois, Dept Geol, Urbana, IL 61801 USA.		Yang, Zhaohui/F-9930-2012	Yang, Zhaohui/0000-0001-9223-3714				[Anonymous], 2001, GSA TODAY, DOI [10.1130/1052-5173(2001)0112.0.CO;2, DOI 10.1130/1052-5173(2001)011<0004:EHGATG>2.0.C0;2]; Beaumont C, 2001, NATURE, V414, P738, DOI 10.1038/414738a; BRACE WF, 1980, J GEOPHYS RES, V85, P6248, DOI 10.1029/JB085iB11p06248; Chapman C.H., 1988, SEISMOLOGICAL ALGORI, P47; Chen W.P., 1996, TECTONIC EVOLUTION A, P37; CHEN WP, 1981, J GEOPHYS RES, V86, P2863, DOI 10.1029/JB086iB04p02863; CHEN WP, 1983, J GEOPHYS RES, V88, P4183, DOI 10.1029/JB088iB05p04183; Ekstrom G. A., 1987, THESIS HARVARD U CAM; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; GAUR V, 2002, EOS, V83; ISACKS B, 1969, NATURE, V223, P1121, DOI 10.1038/2231121a0; Jackson J. A., 2002, GSA TODAY, V12, P4, DOI [DOI 10.1130/1052-5173(2002)0122.0.CO;2, DOI 10.1130/1052-5173(2002)012<0004:S0TCLT>2.0.C0;2]; LANGSTON CA, 1975, GEOPHYS J ROY ASTR S, V42, P117, DOI 10.1111/j.1365-246X.1975.tb05854.x; Mackwell SJ, 1998, J GEOPHYS RES-SOL EA, V103, P975, DOI 10.1029/97JB02671; Maggi A, 2000, GEOLOGY, V28, P495, DOI 10.1130/0091-7613(2000)28<495:EFDEET>2.0.CO;2; MEJIA JA, 2001, THESIS ST LOUIS U ST; MOLNAR P, 1983, J GEOPHYS RES, V88, P1180, DOI 10.1029/JB088iB02p01180; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Nabelek J.L., 1984, THESIS MIT CAMBRIDGE; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; Pegler G, 1998, GEOPHYS J INT, V134, P573, DOI 10.1046/j.1365-246x.1998.00582.x; Royden LH, 1997, SCIENCE, V276, P788, DOI 10.1126/science.276.5313.788; SHAPIRO NM, 2002, EOS, V83; Wittlinger G, 2004, EARTH PLANET SC LETT, V221, P117, DOI 10.1016/S0012-821X(03)00723-4; Yuan XH, 1997, J GEOPHYS RES-SOL EA, V102, P27491, DOI 10.1029/97JB02379; ZANDT G, 1995, J GEOPHYS RES-SOL EA, V100, P10529, DOI 10.1029/94JB03063; ZHU L, 1998, THESIS CALTECH PASAD; Zhu LP, 1996, GEOPHYS RES LETT, V23, P435, DOI 10.1029/96GL00385	28	114	132	4	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1949	1952		10.1126/science.1097324	http://dx.doi.org/10.1126/science.1097324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218145				2022-12-28	WOS:000222241600041
J	Brower, RG; Lanken, PN; MacIntyre, N; Matthay, MA; Morris, A; Ancukiewicz, M; Schoenfeld, D; Thompson, BT				Brower, RG; Lanken, PN; MacIntyre, N; Matthay, MA; Morris, A; Ancukiewicz, M; Schoenfeld, D; Thompson, BT		Natl Heart Lung Blood Inst ARDS Cl	Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	98th International Conference of the American-Thoracic-Society	MAY 17-23, 2002	ATLANTA, GA	Amer Thorac Soc			ACUTE LUNG INJURY; MECHANICAL VENTILATION; TIDAL VOLUME; PULMONARY-EDEMA; SURFACTANT; MORTALITY; ADULTS; PEEP	Background: Most patients requiring mechanical ventilation for acute lung injury and the acute respiratory distress syndrome (ARDS) receive positive end-expiratory pressure (PEEP) of 5 to 12 cm of water. Higher PEEP levels may improve oxygenation and reduce ventilator-induced lung injury but may also cause circulatory depression and lung injury from overdistention. We conducted this trial to compare the effects of higher and lower PEEP levels on clinical outcomes in these patients. Methods: We randomly assigned 549 patients with acute lung injury and ARDS to receive mechanical ventilation with either lower or higher PEEP levels, which were set according to different tables of predetermined combinations of PEEP and fraction of inspired oxygen. Results: Mean (+/-SD) PEEP values on days 1 through 4 were 8.3+/-3.2 cm of water in the lower-PEEP group and 13.2+/-3.5 cm of water in the higher-PEEP group (P<0.001). The rates of death before hospital discharge were 24.9 percent and 27.5 percent, respectively (P=0.48; 95 percent confidence interval for the difference between groups, -10.0 to 4.7 percent). From day 1 to day 28, breathing was unassisted for a mean of 14.5+/-10.4 days in the lower-PEEP group and 13.8+/-10.6 days in the higher-PEEP group (P=0.50). Conclusions: These results suggest that in patients with acute lung injury and ARDS who receive mechanical ventilation with a tidal-volume goal of 6 ml per kilogram of predicted body weight and an end-inspiratory plateau-pressure-limit of 30 cm of water, clinical outcomes are similar whether lower or higher PEEP levels are used.	Johns Hopkins Univ, Baltimore, MD 21205 USA; Univ Penn, Philadelphia, PA 19104 USA; Duke Univ, Durham, NC USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Latter Day St Hosp, Salt Lake City, UT 84143 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; NHLBI, ARDS, Clin Trials Network, Bethesda, MD 20892 USA	Johns Hopkins University; University of Pennsylvania; Duke University; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Brower, RG (corresponding author), Johns Hopkins Univ, 1830 E Monument St,Rm 549, Baltimore, MD 21205 USA.				NHLBI NIH HHS [N01-HR 46063, N01-HR 46054, N01-HR 46059, N01-HR 46060, N01-HR 46062, N01-HR 46061, N01-HR 46055, N01-HR 46056, N01-HR 46058, N01-HR 46064, N01-HR 46057] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR046063, N01HR046060, N01HR046064, N01HR046056, N01HR046058, N01HR046062, N01HR046054, N01HR046059, N01HR046061, N01HR046055, N01HR046057] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; ALBERT RK, 1985, J APPL PHYSIOL, V59, P1555, DOI 10.1152/jappl.1985.59.5.1555; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Anzueto A, 1996, NEW ENGL J MED, V334, P1417, DOI 10.1056/NEJM199605303342201; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; Arons MM, 1999, CRIT CARE MED, V27, P699, DOI 10.1097/00003246-199904000-00020; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 2002, AM J RESP CRIT CARE, V166, P1515, DOI 10.1164/ajrccm.166.11.340; BROWER RG, 2003, AM J RESP CRIT CARE, V167, pA616; Brower RG, 2004, CRIT CARE MED, V32, P907; Carmichael LC, 1996, J CRIT CARE, V11, P9, DOI 10.1016/S0883-9441(96)90015-5; Conner ER, 1999, CHEST, V116, p83S, DOI 10.1378/chest.116.suppl_1.83S; CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; EFRON B, 1991, SCIENCE, V253, P390, DOI 10.1126/science.253.5018.390; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; JARDIN F, 1994, INTENS CARE MED, V20, P169, DOI 10.1007/BF01704693; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P169; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LODATO RF, 1994, PRINCIPLES PRACTICE, P837; Martynowicz MA, 2001, J APPL PHYSIOL, V90, P1744, DOI 10.1152/jappl.2001.90.5.1744; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; Miro AM, 1994, PRINCIPLES PRACTICE, P647; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; PARKER JC, 1993, CRIT CARE MED, V21, P131, DOI 10.1097/00003246-199301000-00024; PARKER JC, 1984, J APPL PHYSIOL, V57, P1809, DOI 10.1152/jappl.1984.57.6.1809; Pinsky MR, 1997, INTENS CARE MED, V23, P493, DOI 10.1007/s001340050364; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Schoenfeld DA, 2001, BIOMETRICS, V57, P972, DOI 10.1111/j.0006-341X.2001.00972.x; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; TOUNG TJK, 1978, SURG GYNECOL OBSTET, V147, P518; TSUNO K, 1991, AM REV RESPIR DIS, V143, P1115, DOI 10.1164/ajrccm/143.5_Pt_1.1115; Wiedemann HP, 2002, CRIT CARE MED, V30, P1	37	1538	1624	1	62	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					327	336						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	839RC	15269312				2022-12-28	WOS:000222801200006
J	Steele, RJC				Steele, RJC		UK Colorectal Canc Screening Pilot	Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEALTH-CARE; ENDOSCOPY; TRIAL	Objectives To assess the feasibility of introducing into the United Kingdom's NHS a national screening programme for colorectal cancer based on faecal occult blood testing. Design Demonstration pilot. Setting Two English health authorities and three Scottish health boards. Participants People aged 50-69 years. Results 478 250 residents of the pilot areas were invited to take part in the screening programme. Uptake (the proportion for whom a final faecal occult blood test result was available) was 56.8% (n = 271646). The overall rate of a positive test result was 1.9% and the rate for detecting cancer was 1.62 per 1000 people screened. Both these values were higher in Scotland than in England, were higher in men than in women, and increased with age. The positive predictive value was 10.9% for cancer and 35.0% for adenoma. 552 cancers were detected by screening; 92 (16.6%) were polyp cancers. 48% of all screen detected cancers were Dukes's stage A, and 1% had metastasised at the time of diagnosis. Conclusions Screening for colorectal cancer by testing for faecal occult blood is feasible within the context of the United Kingdom's NHS. Screening should lead to a reduction in deaths from colorectal cancer in the population offered screening.	Ninewells Hosp, Univ Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee	Steele, RJC (corresponding author), Ninewells Hosp, Univ Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	r.j.c.steele@dundee.ac.uk	Morling, Jo/AAH-7385-2020	Morling, Jo/0000-0003-0772-2893; Steele, Robert JC/0000-0003-4248-6785; Price, Jackie/0000-0003-3251-3970				Atkin WS, 2002, LANCET, V359, P1291, DOI 10.1016/s0140-6736(02)08268-5; Atkin WS, 2002, GUT, V51, pV6, DOI 10.1136/gut.51.suppl_5.v6; de Koning HJ, 2000, LANCET, V355, P80, DOI 10.1016/S0140-6736(99)00419-5; Department of Health, 2000, NHS CANC PLAN PLAN I; FENTIMAN I, 1990, DETECTION TREATMENT, P618; GRYDHANSEN D, 1998, HEALTH ECON, V7, P9; HARDCASTLE JD, 1996, PREVENTION EARLY DET, P275; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MULLER AD, 1995, ARCH INTERN MED, V155, P1741, DOI 10.1001/archinte.155.16.1741; Pathmakanthan S, 2001, J ADV NURS, V36, P705, DOI 10.1046/j.1365-2648.2001.02021.x; PYE G, 1988, J EPIDEMIOL COMMUN H, V42, P66, DOI 10.1136/jech.42.1.66; Rasmussen M, 2003, SCAND J GASTROENTERO, V38, P114, DOI 10.1080/00365521.2018.12027895; *SCOTT EX HLTH DEP, 2004, CANC SCOTL ACT CHANG; *SCOTT INT GUID NE, 2003, 67 SGN, P6; Steele RJC, 2004, ENDOSCOPY, V36, P349, DOI 10.1055/s-2004-814304; Steele RJC, 2001, J MED SCREEN, V8, P197, DOI 10.1136/jms.8.4.197; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; Thomas-Gibson S, 2002, J ROY SOC MED, V95, P194, DOI 10.1258/jrsm.95.4.194	20	210	215	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 17	2004	329	7458					133	135		10.1136/bmj.38153.491887.7C	http://dx.doi.org/10.1136/bmj.38153.491887.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15237087	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000222832300015
J	Fidler, IJ; Ellis, LM				Fidler, IJ; Ellis, LM			Neoplastic angiogenesis - Not all blood vessels are created equal	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Fidler, IJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.								0	48	58	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					215	216		10.1056/NEJMp048080	http://dx.doi.org/10.1056/NEJMp048080			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254281				2022-12-28	WOS:000222627200005
J	Bulterys, M; Jamieson, DJ; O'Sullivan, MJ; Cohen, MH; Maupin, R; Nesheim, S; Webber, MP; Van Dyke, R; Wiener, J; Branson, BM				Bulterys, M; Jamieson, DJ; O'Sullivan, MJ; Cohen, MH; Maupin, R; Nesheim, S; Webber, MP; Van Dyke, R; Wiener, J; Branson, BM		MIRIAD Study Grp	Rapid HIV-1 testing during labor - A multicenter study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; PERINATAL TRANSMISSION; PREGNANT-WOMEN; PROPHYLAXIS; PREVENTION; ZIDOVUDINE; INFECTION; COHORT; TRIAL	Context Timely testing of women in labor with undocumented human immunodeficiency virus (HIV) status could enable immediate provision of antiretroviral prophylaxis. Objectives To determine the feasibility and acceptance of rapid HIV testing among women in labor and to assess rapid HIV assay performance. Design, Setting, and Patients The Mother-Infant Rapid Intervention At Delivery (MIRIAD) study implemented 24-hour counseling and voluntary rapid HIV testing for women in labor at 16 US hospitals from November 16, 2001, through November 15, 2003. A rapid HIV-1 antibody test for whole blood was used. Main Outcome Measures Acceptance of HIV testing; sensitivity, specificity, and predictive value of the rapid test; time from blood collection to patient notification of results. Results There were 91707 visits to the labor and delivery units in the study, 7381 of which were by eligible women without documentation of HIV testing. Of these, 5744 (78%) women were approached for rapid HIV testing and 4849 (84%) consented. HIV-1 test results were positive for 34 women (prevalence=7/1000). Sensitivity and specificity of the rapid test were 100% and 99.9%, respectively; positive predictive value was 90% compared with 76% for enzyme immunoassay (EIA). Factors independently associated with higher test acceptance included younger age, being black or Hispanic, gestational age less than 32 weeks, and having had no prenatal care. Lower acceptance was associated with being admitted between 4 Pm and midnight, particularly on Friday nights, but this may be explained in part by fewer available personnel. Median time from blood collection to patient notification of result was 66 minutes (interquartile range, 45-120 minutes), compared with 28 hours for EIA (P<.001). Conclusions Rapid HIV testing is feasible and delivers accurate and timely test results for women in labor. It provides HIV-positive women prompt access to intrapartum and neonatal antiretroviral prophylaxis, proven to reduce perinatal HIV transmission, and may be particularly applicable to higher-risk populations.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Univ Miami, Sch Med, Dept Obstet & Gynecol, Miami, FL 33101 USA; Cook Cty Hosp, Dept Med, Chicago, IL 60612 USA; Louisiana State Univ, Sch Med, Dept Obstet & Gynecol, New Orleans, LA USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA; Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA	Centers for Disease Control & Prevention - USA; University of Miami; John H Stroger Junior Hospital Cook County; Louisiana State University System; Emory University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Tulane University	Bulterys, M (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Surveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, 1600 Clifton Rd,Mailstop E-45, Atlanta, GA 30333 USA.	mbulterys@cdc.gov		Jamieson, Denise/0000-0003-2597-1201	PHS HHS [417719, 417735, 617734, 517715, U64/217724] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Agresti A, 2003, CATEGORICAL DATA ANA; [Anonymous], US PUBLIC HLTH SERVI; Branson B.M., 2000, AIDS REV, V2, P76; Bulterys M, 2000, PEDIATR CLIN N AM, V47, P241, DOI 10.1016/S0031-3955(05)70203-0; *CDCP, QUAL ASS GUID TEST O; *CDCP, 2001, MMWR RECOMM REP, V50, P63; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P866; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P329; Centers for Disease Control and prevention, 2004, RAP HIV ANT TEST LAB; Cohen MH, 2003, AIDS, V17, P2121, DOI 10.1097/00002030-200309260-00015; Jamieson DJ, 2003, J WOMENS HEALTH, V12, P889, DOI 10.1089/154099903770948113; Kourtis AP, 2001, JAMA-J AM MED ASSOC, V285, P709, DOI 10.1001/jama.285.6.709; Kowalczyk J, 2002, JAIDS, V31, P408, DOI 10.1097/00126334-200212010-00007; Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531; Minkoff H, 1998, JAMA-J AM MED ASSOC, V279, P1743, DOI 10.1001/jama.279.21.1743; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Mrus JM, 2004, MED DECIS MAKING, V24, P30, DOI 10.1177/0272989X03261570; Peters V, 2003, PEDIATRICS, V111, P1186; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Watts DH, 2002, NEW ENGL J MED, V346, P1879, DOI 10.1056/NEJMra013338; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	22	151	155	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					219	223		10.1001/jama.292.2.219	http://dx.doi.org/10.1001/jama.292.2.219			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249571	Bronze			2022-12-28	WOS:000222579300027
J	Pancer, Z; Amemiya, CT; Ehrhardt, GRA; Ceitlin, J; Gartland, GL; Cooper, MD				Pancer, Z; Amemiya, CT; Ehrhardt, GRA; Ceitlin, J; Gartland, GL; Cooper, MD			Somatic diversification of variable lymphocyte receptors in the agnathan sea lamprey	NATURE			English	Article							IMMUNE-RESPONSE; PETROMYZON-MARINUS; ANTIGENIC VARIATION; INNATE IMMUNITY; EVOLUTION; GENE; IMMUNOGLOBULIN; CELLS; IDENTIFICATION; EXPRESSION	Although jawless vertebrates are apparently capable of adaptive immune responses, they have not been found to possess the recombinatorial antigen receptors shared by all jawed vertebrates. Our search for the phylogenetic roots of adaptive immunity in the lamprey has instead identified a new type of variable lymphocyte receptors (VLRs) composed of highly diverse leucine-rich repeats (LRR) sandwiched between amino- and carboxy-terminal LRRs. An invariant stalk region tethers the VLRs to the cell surface by means of a glycosyl-phosphatidyl-inositol anchor. To generate rearranged VLR genes of the diversity necessary for an anticipatory immune system, the single lamprey VLR locus contains a large bank of diverse LRR cassettes, available for insertion into an incomplete germline VLR gene. Individual lymphocytes express a uniquely rearranged VLR gene in monoallelic fashion. Different evolutionary strategies were thus used to generate highly diverse lymphocyte receptors through rearrangement of LRR modules in agnathans ( jawless fish) and of immunoglobulin gene segments in gnathostomes ( jawed vertebrates).	Univ Alabama, Div Dev & Clin Immunol, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Howard Hughes Med Inst, Birmingham, AL 35294 USA; Benaroya Res Inst Virginia Mason, Mol Genet Program, Seattle, WA 98101 USA; Univ Michigan, Ann Arbor, MI 48109 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Howard Hughes Medical Institute; University of Alabama System; University of Alabama Birmingham; Benaroya Research Institute; Virginia Mason Medical Center; University of Michigan System; University of Michigan	Cooper, MD (corresponding author), Univ Alabama, Div Dev & Clin Immunol, Birmingham, AL 35294 USA.	max.cooper@ccc.uab.edu						Amemiya Chris T., 1996, P223, DOI 10.1016/B978-012101285-4/50009-6; Anderson MK, 2001, P NATL ACAD SCI USA, V98, P553, DOI 10.1073/pnas.021478998; ARDAVIN CF, 1987, DEV COMP IMMUNOL, V11, P79, DOI 10.1016/0145-305X(87)90010-3; Azumi K, 2003, IMMUNOGENETICS, V55, P570, DOI 10.1007/s00251-003-0606-5; Bell JK, 2003, TRENDS IMMUNOL, V24, P528, DOI 10.1016/S1471-4906(03)00242-4; Berriman M, 2002, MOL BIOCHEM PARASIT, V122, P131, DOI 10.1016/S0166-6851(02)00092-0; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Bryan MB, 2003, CONSERV GENET, V4, P113, DOI 10.1023/A:1021808909811; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; COOPER AJ, 1971, AMMOCOETE LYMPHOID C, P137; Duffy MF, 2003, TRENDS PARASITOL, V19, P121, DOI 10.1016/S1471-4922(03)00003-5; FINSTAD J, 1964, J EXP MED, V120, P1151, DOI 10.1084/jem.120.6.1151; Flajnik MF, 2002, NAT REV IMMUNOL, V2, P688, DOI 10.1038/nri889; Flajnik MF, 2001, IMMUNITY, V15, P351, DOI 10.1016/S1074-7613(01)00198-4; FOREY P, 1993, NATURE, V361, P129, DOI 10.1038/361129a0; FUJII T, 1982, J MORPHOL, V173, P87, DOI 10.1002/jmor.1051730108; GOOD RA, 1972, BIOL LAMPREYS, V2, P405; HAGEN M, 1985, COMP BIOCHEM PHYS A, V82, P207, DOI 10.1016/0300-9629(85)90727-3; Haire RN, 2000, J IMMUNOL, V165, P306, DOI 10.4049/jimmunol.165.1.306; Hamrick TS, 2001, MICROBIOL-UK, V147, P839, DOI 10.1099/00221287-147-4-839; Ikezawa H, 2002, BIOL PHARM BULL, V25, P409, DOI 10.1248/bpb.25.409; Jones DA, 2004, CURR OPIN IMMUNOL, V16, P48, DOI 10.1016/j.coi.2003.11.016; Kaufman J, 2002, NAT IMMUNOL, V3, P1124, DOI 10.1038/ni1202-1124; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; LITMAN GW, 1970, J IMMUNOL, V105, P1278; MARCHALONIS JJ, 1968, J EXP MED, V127, P891, DOI 10.1084/jem.127.5.891; Mayer WE, 2002, P NATL ACAD SCI USA, V99, P14350, DOI 10.1073/pnas.212527499; Mayer WE, 2002, SCAND J IMMUNOL, V55, P162, DOI 10.1046/j.1365-3083.2002.01026.x; Nash TE, 2002, MOL MICROBIOL, V45, P585, DOI 10.1046/j.1365-2958.2002.03029.x; PEREY DYE, 1968, LAB INVEST, V19, P591; PIAVIS GW, 1971, COPEIA, P722; POLLARA B, 1970, J IMMUNOL, V105, P738; REYNAUD CA, 1987, CELL, V48, P379, DOI 10.1016/0092-8674(87)90189-9; Schluter SF, 1999, DEV COMP IMMUNOL, V23, P107; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; Shintani S, 2000, P NATL ACAD SCI USA, V97, P7417, DOI 10.1073/pnas.110505597; THOMPSON CB, 1987, CELL, V48, P369, DOI 10.1016/0092-8674(87)90188-7; Uinuk-ool T, 2002, P NATL ACAD SCI USA, V99, P14356, DOI 10.1073/pnas.212527699; Uinuk-ool TS, 2003, IMMUNOGENETICS, V55, P38, DOI 10.1007/s00251-003-0548-y; Wang DC, 2003, MOL MICROBIOL, V47, P1407, DOI 10.1046/j.1365-2958.2003.03386.x	42	491	536	9	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					174	180		10.1038/nature02740	http://dx.doi.org/10.1038/nature02740			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241406	Green Published			2022-12-28	WOS:000222470600035
J	Kasischke, KA; Vishwasrao, HD; Fisher, PJ; Zipfel, WR; Webb, WW				Kasischke, KA; Vishwasrao, HD; Fisher, PJ; Zipfel, WR; Webb, WW			Neural activity triggers neuronal oxidative metabolism followed by astrocytic glycolysis	SCIENCE			English	Article							RESPIRATORY ENZYMES; GLUCOSE-METABOLISM; CEREBRAL-CORTEX; RAT-BRAIN; FLUORESCENCE; PHOSPHORYLATION; ELECTROPHORUS; SPECTROSCOPY; OXYGENATION; STIMULATION	We have found that two-photon fluorescence imaging of nicotinamide adenine dinucleotide ( NADH) provides the sensitivity and spatial three-dimensional resolution to resolve metabolic signatures in processes of astrocytes and neurons deep in highly scattering brain tissue slices. This functional imaging reveals spatiotemporal partitioning of glycolytic and oxidative metabolism between astrocytes and neurons during focal neural activity that establishes a unifying hypothesis for neurometabolic coupling in which early oxidative metabolism in neurons is eventually sustained by late activation of the astrocyte-neuron lactate shuttle. Our model integrates existing views of brain energy metabolism and is in accord with known macroscopic physiological changes in vivo.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA	Cornell University; Cornell University	Webb, WW (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	www2@cornell.edu	Webb, Watt W./B-5905-2011; Zipfel, Warren/B-4059-2016	Kasischke, Karl/0000-0003-0582-4319; Zipfel, Warren/0000-0003-2640-329X	NIBIB NIH HHS [P41-EB001976-16] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001976] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		AUBERT X, 1964, PROC R SOC SER B-BIO, V160, P211, DOI 10.1098/rspb.1964.0037; Bennett BD, 1996, J BIOL CHEM, V271, P3647; Brandes R, 1996, BIOPHYS J, V71, P1024, DOI 10.1016/S0006-3495(96)79303-7; CHANCE B, 1958, J BIOL CHEM, V233, P736; CHANCE B, 1955, J BIOL CHEM, V217, P409; Chih CP, 2001, TRENDS NEUROSCI, V24, P573, DOI 10.1016/S0166-2236(00)01920-2; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; Hu YB, 1997, J NEUROCHEM, V69, P1484; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; JOBSIS FF, 1971, J NEUROPHYSIOL, V34, P735, DOI 10.1152/jn.1971.34.5.735; KLAIDMAN LK, 1995, ANAL BIOCHEM, V228, P312, DOI 10.1006/abio.1995.1356; Lindauer U, 2001, NEUROIMAGE, V13, P988, DOI 10.1006/nimg.2000.0709; LIPTON P, 1973, BIOCHEM J, V136, P999, DOI 10.1042/bj1360999; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Mangia S, 2003, NEUROSCIENCE, V118, P7, DOI 10.1016/S0306-4522(02)00792-3; MERILL DK, 1981, BRAIN RES, V221, P307; MERILL DK, 1976, J NEUROCHEM, V27, P459; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Pellerin L, 2003, J CEREBR BLOOD F MET, V23, P1282, DOI 10.1097/01.WCB.0000096064.12129.3D; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PRICHARD J, 1991, P NATL ACAD SCI USA, V88, P5829, DOI 10.1073/pnas.88.13.5829; Rothman DL, 1999, PHILOS T R SOC B, V354, P1165, DOI 10.1098/rstb.1999.0472; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; Shuttleworth CW, 2003, J NEUROSCI, V23, P3196; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; Thompson JK, 2003, SCIENCE, V299, P1070, DOI 10.1126/science.1079220; Voutsinos-Porche B, 2003, NEURON, V37, P275, DOI 10.1016/S0896-6273(02)01170-4; WILLIAMS.JR, 1967, J BIOL CHEM, V242, P5119; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3	30	547	563	1	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					99	103		10.1126/science.1096485	http://dx.doi.org/10.1126/science.1096485			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232110				2022-12-28	WOS:000222386000045
J	Vasan, RS; Evans, JC; Larson, MG; Wilson, PWF; Meigs, JB; Rifai, N; Benjamin, EJ; Levy, D				Vasan, RS; Evans, JC; Larson, MG; Wilson, PWF; Meigs, JB; Rifai, N; Benjamin, EJ; Levy, D			Serum aldosterone and the incidence of hypertension in nonhypertensive persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMA-RENIN ACTIVITY; BLOOD-PRESSURE; VASCULAR ALDOSTERONE; ANGIOTENSIN-II; SODIUM-INTAKE; HEART; FRAMINGHAM; SALT; POTASSIUM; SYSTEM	Background: Primary hyperaldosteronism is a well-recognized cause of secondary hypertension. It is unknown whether serum aldosterone levels within the physiologic range influence the risk of hypertension. Methods: We investigated the relation of baseline serum aldosterone levels to increases in blood pressure and the incidence of hypertension after four years in 1688 nonhypertensive participants in the Framingham Offspring Study (mean age, 55 years), 58 percent of whom were women. We defined an increase in blood pressure as an increment of at least one blood-pressure category (as defined by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) and defined hypertension as a systolic blood pressure of 140 mm Hg or higher, a diastolic blood pressure of 90 mm Hg or higher, or the use of antihypertensive medications. Results: At follow-up, the blood-pressure category had increased in 33.6 percent of the participants, and hypertension had developed in 14.8 percent. In multivariable models, a 16 percent increase in the risk of an elevation in blood pressure (P=0.002) and a 17 percent increase in the risk of hypertension (P=0.03) were observed per quartile increment in the serum aldosterone level. The highest serum aldosterone quartile, relative to the lowest, was associated with a 1.60-fold risk of an elevation in blood pressure (95 percent confidence interval, 1.19 to 2.14) and a 1.61-fold risk of hypertension (95 percent confidence interval, 1.05 to 2.46). The associations between the serum aldosterone level and blood-pressure outcomes were not significantly affected by adjustment for urinary sodium excretion or left ventricular thickness or internal dimensions. Conclusions: In our community-based sample, increased aldosterone levels within the physiologic range predisposed persons to the development of hypertension.	NHLBI, Framingham Heart Study, Framingham, MA 01702 USA; Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Epidemiol & Prevent Med, Boston, MA 02118 USA; Med Univ S Carolina, Dept Endocrinol Diabet & Med Genet, Charleston, SC 29425 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA; NHLBI, Bethesda, MD 20892 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Boston University; Boston University; Medical University of South Carolina; Harvard University; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Vasan, RS (corresponding author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.	vasan@bu.edu	Meigs, James/P-3927-2019; Levy, Daniel/ABB-2752-2021; Wilson, Peter W.F./J-2455-2016; Ramachandran, Vasan/Y-2527-2019; Levy, Daniel/ABF-6873-2021; Benjamin, Emelia/E-7103-2011	Meigs, James/0000-0002-2439-2657; Ramachandran, Vasan/0000-0001-7357-5970; Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [K24 HL04334, N01-HC-25195] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC025195] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL004334] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelhamid S, 2003, AM J HYPERTENS, V16, P522, DOI 10.1016/S0895-7061(03)00858-6; Blacher J, 1997, AM J HYPERTENS, V10, P1326, DOI 10.1016/S0895-7061(97)90502-1; Black HR, 1998, ARCH INTERN MED, V158, P573; Black HR, 1997, ARCH INTERN MED, V157, P2413; Chobanian AV, 2000, HYPERTENSION, V35, P858, DOI 10.1161/01.HYP.35.4.858; COLLINS RD, 1970, J CLIN INVEST, V49, P1415, DOI 10.1172/JCI106359; Espeland MA, 2001, AM J EPIDEMIOL, V153, P996, DOI 10.1093/aje/153.10.996; Funder JW, 2002, AM HEART J, V144, pS8, DOI 10.1067/mhj.2002.129971; Ganguly A, 1998, NEW ENGL J MED, V339, P1828, DOI 10.1056/NEJM199812173392507; Ganguly A, 2001, J CLIN ENDOCR METAB, V86, P4002, DOI 10.1210/jcem.86.8.9995; GENEST J, 1975, CAN MED ASSOC J, V113, P421; GomezSanchez EP, 1996, STEROIDS, V61, P184, DOI 10.1016/0039-128X(96)00010-4; GORDON T, 1976, INT J EPIDEMIOL, V5, P327, DOI 10.1093/ije/5.4.327; HARRAP SB, 1988, AM J PHYSIOL, V254, pF697, DOI 10.1152/ajprenal.1988.254.5.F697; HARRIS P, 1983, CARDIOVASC RES, V17, P437, DOI 10.1093/cvr/17.8.437; HATAKEYAMA H, 1994, J BIOL CHEM, V269, P24316; HOSMER DW, 1989, APPL LOGISTIC REGRES; ITO T, 1972, J CLIN ENDOCR METAB, V34, P106, DOI 10.1210/jcem-34-1-106; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1987, NIH PUBLICATION NAT; Kaplan NM, 2001, LANCET, V357, P953, DOI 10.1016/S0140-6736(00)04223-9; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; Lim PO, 2000, QJM-INT J MED, V93, P703, DOI 10.1093/qjmed/93.11.703; Lim PO, 2000, J HUM HYPERTENS, V14, P311, DOI 10.1038/sj.jhh.1001013; Lim PO, 2002, J HYPERTENS, V20, P11, DOI 10.1097/00004872-200201000-00003; LJUNGMAN S, 1982, ACTA MED SCAND, V211, P351; OLIVER WJ, 1975, CIRCULATION, V52, P146, DOI 10.1161/01.CIR.52.1.146; POST WS, 1994, CIRCULATION, V90, P179, DOI 10.1161/01.CIR.90.1.179; Rocha R, 2002, ANN NY ACAD SCI, V970, P89, DOI 10.1111/j.1749-6632.2002.tb04415.x; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SAS Institute, 1996, SAS STAT SOFTW CHANG; Schunkert H, 1997, HEART, V77, P24, DOI 10.1136/hrt.77.1.24; Schwartz GL, 2002, CLIN CHEM, V48, P1919; Stewart PM, 1999, LANCET, V353, P1341, DOI 10.1016/S0140-6736(98)06102-9; Takeda Y, 2000, HYPERTENSION, V36, P495, DOI 10.1161/01.HYP.36.4.495; Takeda Y, 1997, HYPERTENSION, V29, P45, DOI 10.1161/01.HYP.29.1.45; TOLAGEN K, 1978, SCAND J CLIN LAB INV, V38, P487, DOI 10.3109/00365517809108455; Vasan RS, 2001, LANCET, V358, P1682, DOI 10.1016/S0140-6736(01)06710-1; WALKER WG, 1979, HYPERTENSION, V1, P287, DOI 10.1161/01.HYP.1.3.287; Walsh CR, 2002, AM J HYPERTENS, V15, P130, DOI 10.1016/S0895-7061(01)02293-2; WISENBAUGH PE, 1972, AM J MED, V52, P175, DOI 10.1016/0002-9343(72)90067-8; Young MJ, 1996, STEROIDS, V61, P233, DOI 10.1016/0039-128X(96)00020-7	43	432	449	0	12	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					33	41		10.1056/NEJMoa033263	http://dx.doi.org/10.1056/NEJMoa033263			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229305				2022-12-28	WOS:000222352200007
J	Constantine, G; Shan, K; Flamm, SD; Sivananthan, MU				Constantine, G; Shan, K; Flamm, SD; Sivananthan, MU			Role of MRI in clinical cardiology	LANCET			English	Review							CONGENITAL HEART-DISEASE; CARDIOVASCULAR MAGNETIC-RESONANCE; CORONARY-ARTERY-DISEASE; RIGHT-VENTRICULAR DYSPLASIA; THORACIC AORTIC DISSECTION; HYPERTROPHIC CARDIOMYOPATHY; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; RESTRICTIVE CARDIOMYOPATHY; DIFFERENTIAL-DIAGNOSIS; MYOCARDIAL-PERFUSION	Rapid progress has been made in cardiac MRI (CMRI) over the past decade, which has firmly established it as a reliable and clinically important technique for assessment of cardiac structure, function, perfusion, and myocardial viability. Its versatility and accuracy is unmatched by any other individual imaging modality. CMRI is non-invasive and has high spatial resolution and avoids use of potentially nephrotoxic contrast agent or radiation. It has been extensively studied against other established non-invasive imaging modalities and has been shown to be superior in many scenarios, particularly with respect to assessment of cardiac and great vessel morphology and left ventricular function. Furthermore, its clinical use continues to expand with increasing experience and proliferation of CMRI centres. As worldwide prevalence of cardiovascular disease continues to rise, CMRI provides opportunity for improved and cost-effective non-invasive assessment. Continued progress in CMRI technology promises to further widen its clinical application in coronary imaging, myocardial perfusion, comprehensive assessment of valves, and plaque characterisation.	Gen Infirm Leeds, British Heart Fdn Cardiac MRI Unit, Leeds LS1 3EX, W Yorkshire, England; Univ Texas, Sch Med, Houston, TX USA; SW Mem Hosp, Dept Cardiol, Houston, TX USA; St Lukes Episcopal Hosp, Dept Cardiol & Radiol, Houston, TX 77030 USA; Texas Heart Inst, Houston, TX 77025 USA	Leeds General Infirmary; University of Texas System; Saint Lukes Episcopal Hospital; Texas Heart Institute	Sivananthan, MU (corresponding author), Gen Infirm Leeds, British Heart Fdn Cardiac MRI Unit, Room D170,Jubilee Bldg,Gt George St, Leeds LS1 3EX, W Yorkshire, England.	gemma.england@leedsth.nhs.uk	Flamm, Scott/K-9034-2019					Al-Saadi N, 2000, J AM COLL CARDIOL, V36, P1557, DOI 10.1016/S0735-1097(00)00914-1; Al-Saadi N, 2000, CIRCULATION, V101, P1379, DOI 10.1161/01.CIR.101.12.1379; Anderson LJ, 2001, EUR HEART J, V22, P2171, DOI 10.1053/euhj.2001.2822; [Anonymous], 2003, MRI PICTURE PROTON; Arai AE, 1999, JMRI-J MAGN RESON IM, V10, P771, DOI 10.1002/(SICI)1522-2586(199911)10:5<771::AID-JMRI22>3.0.CO;2-Q; Araoz PA, 2000, RADIOGRAPHICS, V20, P1303, DOI 10.1148/radiographics.20.5.g00se121303; Araoz PA, 1999, RADIOGRAPHICS, V19, P1421, DOI 10.1148/radiographics.19.6.g99no031421; AURIGEMMA GP, 1989, CIRCULATION, V80, P1595, DOI 10.1161/01.CIR.80.6.1595; Baer FM, 1996, AM J CARDIOL, V78, P415, DOI 10.1016/S0002-9149(96)00329-3; Baer FM, 1998, J AM COLL CARDIOL, V31, P1040, DOI 10.1016/S0735-1097(98)00032-1; BANSAL RC, 1995, J AM COLL CARDIOL, V25, P1393, DOI 10.1016/0735-1097(94)00569-C; BEACHE GM, 1995, RADIOLOGY, V197, P117, DOI 10.1148/radiology.197.1.7568808; Beekman RP, 1997, MAGN RESON IMAGING, V15, P1005, DOI 10.1016/S0730-725X(97)00065-9; Bellenger NG, 2000, J CARDIOV MAGN RESON, V2, P271, DOI 10.3109/10976640009148691; Bellenger NG, 2000, EUR HEART J, V21, P1387, DOI 10.1053/euhj.2000.2011; Bluemke DA, 2003, CARDIOLOGY, V99, P153, DOI 10.1159/000070672; Botnar RM, 2001, MAGNET RESON MED, V46, P848, DOI 10.1002/mrm.1268; BOTTINI PB, 1995, AM J HYPERTENS, V8, P221, DOI 10.1016/0895-7061(94)00178-E; Breen JF, 2001, J THORAC IMAG, V16, P47, DOI 10.1097/00005382-200101000-00007; Chiu CW, 2003, RADIOLOGY, V226, P717, DOI 10.1148/radiol.2263011902; Choi KA, 2001, CIRCULATION, V104, P1101, DOI 10.1161/hc3501.096798; Choudhury L, 2002, J AM COLL CARDIOL, V40, P2156, DOI 10.1016/S0735-1097(02)02602-5; CLARKE GD, 1995, CIRCULATION, V91, P2627, DOI 10.1161/01.CIR.91.10.2627; de Roos A, 2000, EUR RADIOL, V10, P2, DOI 10.1007/s003300050002; DEUTSCH HJ, 1992, J AM COLL CARDIOL, V19, P1500, DOI 10.1016/0735-1097(92)90610-Y; DINSMORE RE, 1986, AM J ROENTGENOL, V146, P309, DOI 10.2214/ajr.146.2.309; DRAUD KS, 2002, APPL RADIOL SA, V31, P14; Duerinckx A, 1996, MAGN RESON IMAGING, V14, P1099, DOI 10.1016/S0730-725X(96)00112-9; DULCE MC, 1992, RADIOLOGY, V185, P235, DOI 10.1148/radiology.185.1.1523315; EICHENBERGER AC, 1993, AM J ROENTGENOL, V160, P971, DOI 10.2214/ajr.160.5.8470612; Elster AD, 2001, QUESTIONS ANSWERS MR; Fattori R, 1998, AM HEART J, V136, P824, DOI 10.1016/S0002-8703(98)70127-9; Fattori R, 2000, J CARDIOV MAGN RESON, V2, P251, DOI 10.3109/10976640009148688; Fayad ZA, 2002, CIRCULATION, V106, P2026, DOI 10.1161/01.CIR.0000034392.34211.FC; Fayad ZA, 2000, CIRCULATION, V102, P506; Fogel MA, 2001, AM HEART J, V142, P1028, DOI 10.1067/mhj.2001.118469; FREEDBERG RS, 1988, CIRCULATION, V77, P96, DOI 10.1161/01.CIR.77.1.96; FUNARI M, 1991, J COMPUT ASSIST TOMO, V15, P953, DOI 10.1097/00004728-199111000-00009; Gatehouse PD, 2003, CLIN RADIOL, V58, P1, DOI 10.1053/crad.2003.1157; GOMES AS, 1987, AM J ROENTGENOL, V149, P895, DOI 10.2214/ajr.149.5.895; Hamid MS, 2002, J AM COLL CARDIOL, V40, P1445, DOI 10.1016/S0735-1097(02)02307-0; Hancock EW, 2001, HEART, V86, P343; HARDY CE, 1994, AM HEART J, V128, P326, DOI 10.1016/0002-8703(94)90486-3; HELBING WA, 1995, AM HEART J, V130, P828, DOI 10.1016/0002-8703(95)90084-5; HELBING WA, 1995, AM J CARDIOL, V76, P589, DOI 10.1016/S0002-9149(99)80161-1; Helbing WA, 2000, PEDIATR CARDIOL, V21, P70, DOI 10.1007/s002469910009; Higgins CB, 1996, RADIOLOGY, V199, P307, DOI 10.1148/radiology.199.2.8668769; HIGGINS CB, 1991, CIRCULATION S, V84, P1198; Holland GA, 1996, AM J ROENTGENOL, V166, P971, DOI 10.2214/ajr.166.4.8610584; HONDA N, 1993, RADIOLOGY, V186, P189, DOI 10.1148/radiology.186.1.8416562; Hoppe UC, 1996, RADIOLOGY, V199, P669, DOI 10.1148/radiology.199.3.8637985; Huber A, 1999, AM J ROENTGENOL, V173, P95, DOI 10.2214/ajr.173.1.10397107; HUNDLEY WG, 1995, CIRCULATION, V92, P1151, DOI 10.1161/01.CIR.92.5.1151; Kanal E, 2002, AM J ROENTGENOL, V178, DOI 10.2214/ajr.178.6.1781335; Kawamoto S, 1997, RADIOLOGY, V203, P727, DOI 10.1148/radiology.203.3.9169695; Kayser HWM, 2002, RADIOGRAPHICS, V22, P639, DOI 10.1148/radiographics.22.3.g02ma07639; Keijer JT, 2000, J MAGN RESON IMAGING, V11, P607, DOI 10.1002/1522-2586(200006)11:6<607::AID-JMRI6>3.0.CO;2-7; KELLER PJ, 1989, RADIOLOGY, V173, P527, DOI 10.1148/radiology.173.2.2798885; KERSTINGSOMMERHOFF BA, 1990, AM J ROENTGENOL, V155, P259, DOI 10.2214/ajr.155.2.2115248; KERSTINGSOMMERHOFF BA, 1990, AM HEART J, V120, P133, DOI 10.1016/0002-8703(90)90170-3; Khan IA, 2002, CHEST, V122, P311, DOI 10.1378/chest.122.1.311; Kim RJ, 1999, CIRCULATION, V100, P1992, DOI 10.1161/01.CIR.100.19.1992; Kim RJ, 2000, NEW ENGL J MED, V343, P1445, DOI 10.1056/NEJM200011163432003; Kim RJ, 1999, CIRCULATION, V100, P185, DOI 10.1161/01.CIR.100.2.185; Kim WY, 2001, NEW ENGL J MED, V345, P1863, DOI 10.1056/NEJMoa010866; Kizilbash AM, 1998, AM J CARDIOL, V81, P792, DOI 10.1016/S0002-9149(97)01024-2; Koskenvuo JW, 2001, J MAGN RESON IMAGING, V13, P361, DOI 10.1002/jmri.1051; Kovanlikaya A, 2002, AM J ROENTGENOL, V179, P475, DOI 10.2214/ajr.179.2.1790475; Kwong RY, 2003, CIRCULATION, V107, P531, DOI 10.1161/01.CIR.0000047527.11221.29; Ladd ME, 1996, J COMPUT ASSIST TOMO, V20, P782, DOI 10.1097/00004728-199609000-00019; Laissy JP, 2002, CHEST, V122, P1638, DOI 10.1378/chest.122.5.1638; Langerak SE, 2002, CIRCULATION, V105, P328, DOI 10.1161/hc0302.102598; Lardo AC, 2000, CIRCULATION, V102, P698, DOI 10.1161/01.CIR.102.6.698; Lauerma K, 2000, RADIOLOGY, V217, P729, DOI 10.1148/radiology.217.3.r00dc18729; Lenfant C, 2002, CIRCULATION, V106, P1037, DOI 10.1161/01.CIR.0000031063.20871.B5; Lorenz CH, 2000, J CARDIOV MAGN RESON, V2, P97, DOI 10.3109/10976640009148678; MAIER SE, 1992, CIRCULATION, V86, P1919, DOI 10.1161/01.CIR.86.6.1919; Manganas C, 2001, ANN THORAC SURG, V72, P1222, DOI 10.1016/S0003-4975(01)02988-5; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; MARON BJ, 1995, CIRCULATION, V91, P1596, DOI 10.1161/01.CIR.91.5.1596; MASUI T, 1992, RADIOLOGY, V182, P369, DOI 10.1148/radiology.182.2.1732952; MATHIEU D, 1986, J COMPUT ASSIST TOMO, V10, P216, DOI 10.1097/00004728-198603000-00009; Matsuki M, 2000, CLIN RADIOL, V55, P323, DOI 10.1053/crad.1999.0081; MCCONNELL MV, 1995, CIRCULATION, V92, P3158, DOI 10.1161/01.CIR.92.11.3158; Meijboom LJ, 2000, INT J CARDIAC IMAG, V16, P161, DOI 10.1023/A:1006429603062; Metafratzi ZM, 2002, J CARDIOV MAGN RESON, V4, P481, DOI 10.1081/JCMR-120016386; MEYER CH, 1992, MAGNET RESON MED, V28, P202, DOI 10.1002/mrm.1910280204; MOHIADDIN RH, 1993, J AM COLL CARDIOL, V22, P1515, DOI 10.1016/0735-1097(93)90565-I; Myerson SG, 2002, HYPERTENSION, V40, P673, DOI 10.1161/01.HYP.0000036401.99908.DB; NIENABER CA, 1992, CIRCULATION, V85, P434, DOI 10.1161/01.CIR.85.2.434; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; Oshinski JN, 1996, J AM COLL CARDIOL, V28, P1818, DOI 10.1016/S0735-1097(96)00395-6; PAGE HL, 1974, CIRCULATION, V50, P768, DOI 10.1161/01.CIR.50.4.768; PARK JH, 1992, RADIOLOGY, V185, P441, DOI 10.1148/radiology.185.2.1410351; Petrank YF, 1999, INT J CARDIAC IMAG, V15, P309, DOI 10.1023/A:1006132709895; Plein S, 2002, RADIOLOGY, V225, P300, DOI 10.1148/radiol.2243011436; POST JC, 1995, CIRCULATION, V92, P3163, DOI 10.1161/01.CIR.92.11.3163; Post JC, 1996, AM J ROENTGENOL, V166, P1399, DOI 10.2214/ajr.166.6.8633453; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; PUCILLO AL, 1990, CHEST, V97, P106, DOI 10.1378/chest.97.1.106; Reeder SB, 1999, MAGN RESON MED, V41, P375, DOI 10.1002/(SICI)1522-2594(199902)41:2<375::AID-MRM23>3.0.CO;2-Z; RICCI C, 1992, AM J CARDIOL, V70, P1589, DOI 10.1016/0002-9149(92)90462-8; Rickers C, 2003, CIRCULATION, V107, P132, DOI 10.1161/01.CIR.0000039343.95540.CF; Riquelme C, 1999, MAGN RESON IMAGING, V17, P37, DOI 10.1016/S0730-725X(98)00145-3; RUBINSTEIN RI, 1987, CIRCULATION, V76, P786, DOI 10.1161/01.CIR.76.4.786; SAEED M, 1995, JMRI-J MAGN RESON IM, V5, P515, DOI 10.1002/jmri.1880050506; Sakuma H, 2000, AM J ROENTGENOL, V175, P1029, DOI 10.2214/ajr.175.4.1751029; Sakuma H, 1997, AM J ROENTGENOL, V168, P1363, DOI 10.2214/ajr.168.5.9129446; SARDANELLI F, 1993, J COMPUT ASSIST TOMO, V17, P862, DOI 10.1097/00004728-199311000-00005; Sawhney NS, 2001, CHEST, V120, P1340, DOI 10.1378/chest.120.4.1340; Schaefer S, 2000, J CARDIOV MAGN RESON, V2, P151, DOI 10.3109/10976640009148685; Schepens MAAM, 1999, ANN THORAC SURG, V68, P1676, DOI 10.1016/S0003-4975(99)00760-2; SECHTEM U, 1987, AM J CARDIOL, V59, P480, DOI 10.1016/0002-9149(87)90962-3; Sensky PR, 2000, RADIOLOGY, V215, P608, DOI 10.1148/radiology.215.2.r00ap12608; Sharma S, 2002, J AM COLL CARDIOL, V40, P1431, DOI 10.1016/S0735-1097(02)02270-2; Shimada T, 2001, AM J MED, V110, P520, DOI 10.1016/S0002-9343(01)00677-5; SIMPSON IA, 1988, CIRCULATION, V78, P142, DOI 10.1161/01.CIR.78.1.142; Sipola P, 2003, RADIOLOGY, V226, P129, DOI 10.1148/radiol.2261011874; Siripornpitak S, 1997, J COMPUT ASSIST TOMO, V21, P462, DOI 10.1097/00004728-199705000-00023; Smith WHT, 2001, BRIT J RADIOL, V74, P384, DOI 10.1259/bjr.74.880.740384; Sodickson DK, 2000, MAGN RESON MED, V44, P243, DOI 10.1002/1522-2594(200008)44:2<243::AID-MRM11>3.0.CO;2-L; Spuentrup E, 2002, CIRCULATION, V105, P874, DOI 10.1161/hc0702.104165; STEFFENS JC, 1994, CIRCULATION, V90, P937, DOI 10.1161/01.CIR.90.2.937; SUZUKI J, 1990, AM J ROENTGENOL, V155, P723, DOI 10.2214/ajr.155.4.2119099; TANAKA M, 1986, BRIT HEART J, V55, P575; Therrien J, 2000, J AM COLL CARDIOL, V35, P997, DOI 10.1016/S0735-1097(99)00653-1; UNDERWOOD SR, 1987, BRIT HEART J, V57, P404; van Geuns RJM, 2000, RADIOLOGY, V217, P270, DOI 10.1148/radiology.217.1.r00oc01270; VANVAALS JJ, 1993, JMRI-J MAGN RESON IM, V3, P671, DOI 10.1002/jmri.1880030419; VICK GW, 1990, AM HEART J, V119, P1103, DOI 10.1016/S0002-8703(05)80241-8; Vick GW, 2000, PEDIATR CARDIOL, V21, P27; Vignaux O, 2002, CHEST, V122, P1895, DOI 10.1378/chest.122.6.1895; von Kodolitsch Y, 2003, CIRCULATION, V107, P1158, DOI 10.1161/01.CIR.0000052628.77047.EA; Wacker CM, 2003, J AM COLL CARDIOL, V41, P834, DOI 10.1016/S0735-1097(02)02931-5; WAXMAN S, 1994, AM HEART J, V128, P1047, DOI 10.1016/0002-8703(94)90609-2; WEAVER JB, 1992, MAGNET RESON MED, V24, P275, DOI 10.1002/mrm.1910240209; WHITE RD, 1988, AM J ROENTGENOL, V150, P1271, DOI 10.2214/ajr.150.6.1271; Young AA, 2001, CARDIOVASC RES, V49, P308, DOI 10.1016/S0008-6363(00)00248-0; YOUNG AA, 1994, CIRCULATION, V90, P854, DOI 10.1161/01.CIR.90.2.854; YUCEL EK, 1990, RADIOLOGY, V177, P779, DOI 10.1148/radiology.177.3.2243989	140	149	158	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2162	2171		10.1016/S0140-6736(04)16509-4	http://dx.doi.org/10.1016/S0140-6736(04)16509-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220041				2022-12-28	WOS:000222268300022
J	Sigala, JLD; Bottero, V; Young, DB; Shevchenko, A; Mercurio, F; Verma, IM				Sigala, JLD; Bottero, V; Young, DB; Shevchenko, A; Mercurio, F; Verma, IM			Activation of transcription factor NF-kappa B requires ELKS, an I kappa B kinase regulatory subunit	SCIENCE			English	Article							PAPILLARY THYROID-CARCINOMA; IKK COMPLEX; INDUCED APOPTOSIS; MAMMALIAN-CELLS; ALPHA; BETA; GENE; RNAS; OLIGOMERIZATION; PHOSPHORYLATION	The nuclear factor-kappa B (NF-kappaB) family of transcription factors plays a seminal role in inflammation, apoptosis, development, and cancer. Modulation of NF-kappaB-mediated gene expression in response to diverse signals is coordinated by the IkappaB kinase (IKK) complex. We identified ELKS, an essential regulatory subunit of the IKK complex. Silencing ELKS expression by RNA interference blocked induced expression of NF-kappaB target genes, including the NF-kappaB inhibitor IkappaBalpha and proinflammatory genes such as cyclo-oxygenase 2 and interleukin 8. These cells were also not protected from apoptosis in response to cytokines. ELKS likely functions by recruiting IkappaBalpha to the IKK complex and thus serves a regulatory function for IKK activation.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; Celgene, San Diego, CA 92121 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Salk Institute; Bristol-Myers Squibb; Celgene Corporation; Max Planck Society	Verma, IM (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	verma@salk.edu						Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakata T, 2002, GENE CHROMOSOME CANC, V35, P30, DOI 10.1002/gcc.10095; Nakata T, 1999, GENE CHROMOSOME CANC, V25, P97, DOI 10.1002/(SICI)1098-2264(199906)25:2<97::AID-GCC4>3.0.CO;2-L; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIGALA JLD, UNPUB; Tang ED, 2003, J BIOL CHEM, V278, P38566, DOI 10.1074/jbc.M304374200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yokota T, 2000, J HUM GENET, V45, P6, DOI 10.1007/s100380050002; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	31	177	188	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1963	1967		10.1126/science.1098387	http://dx.doi.org/10.1126/science.1098387			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218148				2022-12-28	WOS:000222241600045
J	Florio, P; Michetti, F; Bruschettini, M; Lituania, M; Bruschettini, P; Severi, FM; Petraglia, F; Gazzolo, D				Florio, P; Michetti, F; Bruschettini, M; Lituania, M; Bruschettini, P; Severi, FM; Petraglia, F; Gazzolo, D			Amniotic fluid S100B protein in mid-gestation and intrauterine fetal death	LANCET			English	Article							GESTATIONAL-AGE; FETUSES	Fetal death in the mid-trimester of pregnancy is unexplained and no reliable markers are available to identify at-risk women. We aimed to assess use of a fetoprotein and S100B concentrations in amniotic fluid as markers. We did a case-control study in 758 healthy women undergoing amniocentesis at mid-gestation, of whom 12 had a spontaneous intrauterine fetal death before 28 weeks, and 746 matched controls. Concentrations were corrected for gestational age by conversion to multiples of median (MoM) of healthy controls of the same gestational age. Concentrations of S100B, but not alpha fetoprotein, were significantly higher (p<0.0001) in women who later had spontaneous fetal death (median 4.431 MoM [95%CI 3.605-6.197]) than in controls (1.000 MoM [1.062-1.121]). Sensitivity, specificity, and positive and negative predictive values of S100B as a diagnostic test were 100%, suggesting that measurement of this protein at amniocentesis could be useful to identify at-risk women.	Univ Siena, Policlin Le Scotte, Dept Paediat Obstet & Reprod Med, I-53100 Siena, Italy; Univ Sacred Heart, Inst Anat & Cell Biol, I-00168 Rome, Italy; Univ Genoa, G Gaslini Childrens Hosp, Dept Paediat, I-16126 Genoa, Italy; Univ Genoa, G Gaslini Childrens Hosp, Dept Obstet & Gynaecol, I-16126 Genoa, Italy	University of Siena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini	Petraglia, F (corresponding author), Univ Siena, Policlin Le Scotte, Dept Paediat Obstet & Reprod Med, Viale Bracci, I-53100 Siena, Italy.	petraglia@unisi.it	matteo, bruschettini/J-6030-2019; Petraglia, Felice/D-4373-2019; SEVERI, Filiberto Maria/K-6586-2016	matteo, bruschettini/0000-0002-4775-872X; Petraglia, Felice/0000-0002-8851-625X; SEVERI, Filiberto Maria/0000-0002-0892-4561				Gazzolo D, 2001, CLIN CHEM, V47, P954; Gazzolo D, 2001, CLIN CHEM, V47, P1836; Goldenberg RL, 1997, CLIN OBSTET GYNECOL, V40, P704, DOI 10.1097/00003081-199712000-00004; Incerpi MH, 1998, AM J OBSTET GYNECOL, V178, P1121, DOI 10.1016/S0002-9378(98)70311-4; Michetti F, 2002, CLIN CHEM, V48, P2097; Reis FM, 2002, ENDOCR REV, V23, P230, DOI 10.1210/er.23.2.230; SINDIC CJM, 1984, PRENATAL DIAG, V4, P297, DOI 10.1002/pd.1970040409	7	37	41	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					270	272		10.1016/S0140-6736(04)16677-4	http://dx.doi.org/10.1016/S0140-6736(04)16677-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262105				2022-12-28	WOS:000222784900030
J	Allegrucci, C; Denning, C; Priddle, H; Young, L				Allegrucci, C; Denning, C; Priddle, H; Young, L			Stem-cell consequences of embryo epigenetic defects	LANCET			English	Review							DNA METHYLATION; GENE-EXPRESSION; CLONED EMBRYOS; MOUSE EMBRYO; DIFFERENTIATION; PATTERNS; CULTURE; SHEEP; IGF2R	Context The genetic code in the DNA of virtually every somatic cell can produce the entire complement of encoded proteins. Acetylation of histones and methylation of histones and DNA cytosine residues are part of the complex epigenetic regulatory process determining lineage-specific gene expression by altering the local structure of chromatin. After fertilisation, sperm DNA exchanges protamines for histones recruited from oocyte cytoplasm, reconfiguring both parental genomes into an epigenetic state conducive to activating the embryonic developmental programme. The identification of epigenetic reprogramming mechanisms is a major interest, rekindled by the ability of at least some somatic cells to acquire totipotency after somatic-cell nuclear transfer. Starting point Recently, Woo Suk Hwang and colleagues (Science 2004; 303: 1669-74) derived a human embryonic stem-cell line from embryo therapeutic cloning. Chad Cowan and colleagues (N Engl J Med 2004; 350: 1353-56) produced 17 new lines from embryos supernumerary to infertility treatments. However, increasing evidence from a range of mammals shows a propensity for epigenetic errors with embryo technologies. If paralleled in human embryos, the effect on tumorigenic and differentiation properties of embryonic stem cells needs to be established. Where next? Identifying the mechanisms in the oocyte that reprogramme a somatic cell to the embryonic state might allow somatic cells to be reprogrammed ex ovo by in-vitro manipulation of the epigenome. Because the oocyte is designed to reprogramme the sperm genome, which is in a different chromatin state from a somatic cell, perhaps many of the epigenetic errors induced by somatic-cell nuclear transfer could be avoided by a more targeted approach.	Univ Nottingham, Queens Med Ctr, Div Obstet & Gynecol, Nottingham NG7 2UH, England; Univ Nottingham, Queens Med Ctr, Inst Genet, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Young, L (corresponding author), Univ Nottingham, Queens Med Ctr, Div Obstet & Gynecol, Nottingham NG7 2UH, England.	Lorraine.Young@nottingham.ac.uk	Allegrucci, Cinzia/A-6110-2009; denning, chris/D-4777-2013	Allegrucci, Cinzia/0000-0001-8517-2423; Young, Lorraine/0000-0001-5450-5723; Denning, Chris/0000-0003-0802-8617	MRC [G113/30] Funding Source: UKRI; Medical Research Council [G113/30] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Arney KL, 2002, INT J DEV BIOL, V46, P317; Beaujean N, 2004, CURR BIOL, V14, pR266, DOI 10.1016/j.cub.2004.03.019; BEAUJEAN N, IN PRESS BIOL REPROD; Bourc'his D, 2001, CURR BIOL, V11, P1542, DOI 10.1016/S0960-9822(01)00480-8; Chung YG, 2003, BIOL REPROD, V69, P146, DOI 10.1095/biolreprod.102.014076; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Dean W, 1998, DEVELOPMENT, V125, P2273; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Frostesjo L, 1997, J BIOL CHEM, V272, P4359, DOI 10.1074/jbc.272.7.4359; Han YM, 2003, THERIOGENOLOGY, V59, P33, DOI 10.1016/S0093-691X(02)01271-2; Hernandez L, 2003, P NATL ACAD SCI USA, V100, P13344, DOI 10.1073/pnas.2234026100; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Khosla S, 2001, HUM REPROD UPDATE, V7, P419, DOI 10.1093/humupd/7.4.419; Maatouk DM, 2003, DEV BIOL, V258, P201, DOI 10.1016/S0012-1606(03)00110-6; Maher ER, 2003, HUM REPROD, V18, P2508, DOI 10.1093/humrep/deg486; Santos F, 2003, CURR BIOL, V13, P1116, DOI 10.1016/S0960-9822(03)00419-6; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Shi W, 2002, MOL REPROD DEV, V63, P329, DOI 10.1002/mrd.90016; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; Szyf M, 2003, DRUG RESIST UPDATE, V6, P341, DOI 10.1016/j.drup.2003.10.002; van Steensel B, 2003, BIOTECHNIQUES, V35, P346; Xu CH, 2002, CIRC RES, V91, P501, DOI 10.1161/01.RES.0000035254.80718.91; Young LE, 2003, MECH DEVELOP, V120, P1433, DOI 10.1016/j.mod.2003.09.006; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769	26	33	35	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					206	208		10.1016/S0140-6736(04)16636-1	http://dx.doi.org/10.1016/S0140-6736(04)16636-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246736				2022-12-28	WOS:000222612200034
J	Carlyle, J; Collin, J; Muggli, ME; Hurt, RD				Carlyle, J; Collin, J; Muggli, ME; Hurt, RD			British American Tobacco and Formula One motor racing	BRITISH MEDICAL JOURNAL			English	Article									Mayo Clin, Nicotine Dependence Ctr, Minneapolis, MN 55905 USA; Univ London London Sch Hyg & Trop Med, Ctr Global Change & Hlth, London WC1E 7HT, England; Mayo Clin, Nicotine Res Program, Rochester, MN 55905 USA	Mayo Clinic; University of London; London School of Hygiene & Tropical Medicine; Mayo Clinic	Hurt, RD (corresponding author), Mayo Clin, Nicotine Dependence Ctr, Minneapolis, MN 55905 USA.				NCI NIH HHS [R01 CA091021, R01 CA091023, R01 CA091022, R01 CA90791] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA091021, R01CA090791] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*BRIT AM RAC, 2003, 363S ANN RET 2 SEP 2; Charlton A, 1997, LANCET, V350, P1474, DOI 10.1016/S0140-6736(97)26046-0; CHEBAT JC, 2003, INT J SPORTS MARKETI, P93; Dewhirst T, 2002, TOB CONTROL, V11, P146, DOI 10.1136/tc.11.2.146; Kmietowicz Z, 1997, BRIT MED J, V315, P1251, DOI 10.1136/bmj.315.7118.1251; Lavack AM, 2003, INT J SPORTS MAR JUN, P105; RUBYTHON T, 2002, EUROBUSINESS     APR, P86; World Health Organization, 2002, TOB FREE SPORTS PLAY; SEPANG CIRCUIT SIC G; FORMULA ONE CONSTRUC; FORMULA 1 2004 CONST	12	21	21	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					104	106		10.1136/bmj.329.7457.104	http://dx.doi.org/10.1136/bmj.329.7457.104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242918	Green Accepted, Green Published			2022-12-28	WOS:000222645000031
J	Marquez, V; Wilson, DN; Tate, WP; Triana-Alonso, F; Nierhaus, KH				Marquez, V; Wilson, DN; Tate, WP; Triana-Alonso, F; Nierhaus, KH			Maintaining the ribosomal reading frame: The influence of the E site during translational regulation of release factor 2	CELL			English	Article							ESCHERICHIA-COLI; TRANSFER-RNA; FACTOR-II; MESSENGER-RNA; BINDING; TERMINATION; ELONGATION; GENE	Maintenance of the translation reading frame is one of the most remarkable achievements of the ribosome while decoding the information of an mRNA. Loss of the reading frame through spontaneous frameshifting occurs with a frequency of one in 30,000 amino acid incorporations. However, at many recoding sites, the mechanism that controls reading frame maintenance is switched off. One such example is the programmed + 1 frameshift site of the prfB gene encoding the termination factor RF2, in which slippage into the forward frame by one nucleotide can attain an efficiency of similar to100%, namely, four orders of magnitude higher than normally observed. Here, using the RF2 frameshift window, we demonstrate that premature release of the E site tRNA from the ribosome is coupled with high-level frameshifting. Consistently, in a minimal system, the presence of the E site tRNA prevents the + 1 frameshift event, illustrating the importance of the E site for reading-frame maintenance.	AG Ribosomen, Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Carabobo, Fac Ciencias Salud, Maracay, Venezuela	Max Planck Society; University of Otago	Nierhaus, KH (corresponding author), AG Ribosomen, Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.	nierhaus@molgen.mpg.de	Wilson, Daniel/AAE-8504-2019	Wilson, Daniel/0000-0003-3816-3828				ADAMSKI FM, 1994, J MOL BIOL, V238, P302, DOI 10.1006/jmbi.1994.1293; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Atkins JF, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P369; BARANOV P, 2002, EMBO REP, V3, P1; BELITSINA NV, 1981, FEBS LETT, V131, P289, DOI 10.1016/0014-5793(81)80387-0; BELITSINA NV, 1982, BIOSYSTEMS, V15, P233, DOI 10.1016/0303-2647(82)90008-9; Blaha G, 2000, METHOD ENZYMOL, V317, P292; Blaha G, 2001, COLD SPRING HARB SYM, V66, P135, DOI 10.1101/sqb.2001.66.135; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; CURRAN JF, 1993, NUCLEIC ACIDS RES, V21, P1837, DOI 10.1093/nar/21.8.1837; Dinos G, 2004, MOL CELL, V13, P113, DOI 10.1016/S1097-2765(04)00002-4; DONLY BC, 1990, NUCLEIC ACIDS RES, V18, P6517, DOI 10.1093/nar/18.22.6517; JORGENSEN F, 1990, J MOL BIOL, V215, P511, DOI 10.1016/S0022-2836(05)80164-0; LARSEN B, 1994, J BACTERIOL, V176, P6842, DOI 10.1128/JB.176.22.6842-6851.1994; Major LL, 1996, NUCLEIC ACIDS RES, V24, P2673, DOI 10.1093/nar/24.14.2673; Ogle JM, 2003, TRENDS BIOCHEM SCI, V28, P259, DOI 10.1016/S0968-0004(03)00066-5; POOLE ES, 1995, EMBO J, V14, P151, DOI 10.1002/j.1460-2075.1995.tb06985.x; RHEINBERGER HJ, 1988, METHOD ENZYMOL, V164, P658; Triana-Alonso FJ, 2000, METHOD ENZYMOL, V317, P261; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; Wilson DN, 2003, ANGEW CHEM INT EDIT, V42, P3464, DOI 10.1002/anie.200200544; Wilson DN, 2000, RNA, V6, P1704, DOI 10.1017/S135583820000131X; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; ZANIEWSKI R, 1984, J BIOL CHEM, V259, P1651	25	91	91	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					45	55		10.1016/j.cell.2004.06.012	http://dx.doi.org/10.1016/j.cell.2004.06.012			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242643	Bronze			2022-12-28	WOS:000222626800007
J	Glazebrook, K; Abraham, RG; McCarthy, PJ; Savaglio, S; Chen, HW; Crampton, D; Murowinski, R; Jorgensen, I; Roth, K; Hook, I; Marzke, RO; Carlberg, RG				Glazebrook, K; Abraham, RG; McCarthy, PJ; Savaglio, S; Chen, HW; Crampton, D; Murowinski, R; Jorgensen, I; Roth, K; Hook, I; Marzke, RO; Carlberg, RG			A high abundance of massive galaxies 3-6 billion years after the Big Bang	NATURE			English	Article							HIGH-REDSHIFT GALAXIES; HUBBLE-DEEP-FIELD; STELLAR MASS; STAR-FORMATION; EVOLUTION; LUMINOSITY; ULTRAVIOLET; DENSITY; UNIVERSE	Hierarchical galaxy formation is the model whereby massive galaxies form from an assembly of smaller units(1). The most massive objects therefore form last. The model succeeds in describing the clustering of galaxies(2), but the evolutionary history of massive galaxies, as revealed by their visible stars and gas, is not accurately predicted. Near-infrared observations (which allow us to measure the stellar masses of high-redshift galaxies(3)) and deep multi-colour images indicate that a large fraction of the stars in massive galaxies form in the first 5 Gyr (refs 4-7), but uncertainties remain owing to the lack of spectra to confirm the redshifts (which are estimated from the colours) and the role of obscuration by dust. Here we report the results of a spectroscopic redshift survey that probes the most massive and quiescent galaxies back to an era only 3 Gyr after the Big Bang. We find that at least two-thirds of massive galaxies have appeared since this era, but also that a significant fraction of them are already in place in the early Universe.	Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Univ Toronto, Dept Astron & Astrophys, Toronto, ON M5S 3H8, Canada; Observ Carnegie Inst Washington, Pasadena, CA 91101 USA; MIT, Ctr Space Res, Cambridge, MA 02139 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V9E 2E7, Canada; Gemini Observ, Hilo, HI 96720 USA; Univ Oxford, Dept Astrophys, Nucl & Astrophys Lab, Oxford OX1 3RH, England; San Francisco State Univ, Dept Phys & Astron, San Francisco, CA 94132 USA	Johns Hopkins University; University of Toronto; Carnegie Institution for Science; Massachusetts Institute of Technology (MIT); National Research Council Canada; University of Oxford; California State University System; San Francisco State University	Glazebrook, K (corresponding author), Johns Hopkins Univ, Dept Phys & Astron, 3400 N Charles St, Baltimore, MD 21218 USA.	kgb@pha.jhu.edu	Carlberg, Raymond G/I-6947-2012; Hook, Isobel M/S-8590-2017; Glazebrook, Karl/N-3488-2015	Carlberg, Raymond G/0000-0002-7667-0081; Hook, Isobel M/0000-0002-2960-978X; Glazebrook, Karl/0000-0002-3254-9044; Savaglio, Sandra/0000-0003-2354-3238; Chen, Hsiao-Wen/0000-0001-8813-4182				Abraham RG, 2004, ASTRON J, V127, P2455, DOI 10.1086/383557; Baldry IK, 2003, ASTROPHYS J, V593, P258, DOI 10.1086/376502; Baugh CM, 2003, ESO ASTROPHY SYMP, P91, DOI 10.1007/10899892_22; Bell EF, 2003, ASTROPHYS J SUPPL S, V149, P289, DOI 10.1086/378847; BLUMENTHAL GR, 1984, NATURE, V311, P517, DOI 10.1038/311517a0; BRINCHMANN J, 2000, APJ, V536, P77; Cole S, 2001, MON NOT R ASTRON SOC, V326, P255, DOI 10.1046/j.1365-8711.2001.04591.x; COLEMAN GD, 1980, ASTROPHYS J SUPPL S, V43, P393, DOI 10.1086/190674; Dickinson M, 2003, ASTROPHYS J, V587, P25, DOI 10.1086/368111; Drory N, 2001, ASTROPHYS J, V562, pL111, DOI 10.1086/338270; Fioc M, 1997, ASTRON ASTROPHYS, V326, P950; Fontana A, 2003, ASTROPHYS J, V594, pL9, DOI 10.1086/378489; Franx M, 2003, ASTROPHYS J, V587, pL79, DOI 10.1086/375155; Gebhardt K, 2003, ASTROPHYS J, V597, P239, DOI 10.1086/378401; Granato GL, 2000, ASTROPHYS J, V542, P710, DOI 10.1086/317032; Kauffmann G, 1999, MON NOT R ASTRON SOC, V307, P529, DOI 10.1046/j.1365-8711.1999.02711.x; KENNICUTT RC, 1983, ASTROPHYS J, V272, P54, DOI 10.1086/161261; Lotz JM, 2000, ASTROPHYS J, V532, P830, DOI 10.1086/308584; Madau P, 1996, MON NOT R ASTRON SOC, V283, P1388, DOI 10.1093/mnras/283.4.1388; RIX HW, 1993, ASTROPHYS J, V418, P123, DOI 10.1086/173376; SALPETER EE, 1955, ASTROPHYS J, V121, P161, DOI 10.1086/145971; Savaglio S, 2004, ASTROPHYS J, V602, P51, DOI 10.1086/380903; SCHMIDT M, 1968, ASTROPHYS J, V151, P393, DOI 10.1086/149446; Sheth RK, 1999, MON NOT R ASTRON SOC, V308, P119, DOI 10.1046/j.1365-8711.1999.02692.x; Somerville RS, 2001, MON NOT R ASTRON SOC, V320, P504, DOI 10.1046/j.1365-8711.2001.03975.x; Somerville RS, 2004, ASTROPHYS J, V600, pL135, DOI 10.1086/378665; Spergel DN, 2003, ASTROPHYS J SUPPL S, V148, P175, DOI 10.1086/377226; Stanford SA, 2004, ASTRON J, V127, P131, DOI 10.1086/380612; Steidel CC, 1999, ASTROPHYS J, V519, P1, DOI 10.1086/307363; [No title captured]	30	272	275	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					181	184		10.1038/nature02667	http://dx.doi.org/10.1038/nature02667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241407	Green Submitted			2022-12-28	WOS:000222470600036
J	Khosrotehrani, K; Johnson, KL; Cha, DH; Salomon, RN; Bianchi, DW				Khosrotehrani, K; Johnson, KL; Cha, DH; Salomon, RN; Bianchi, DW			Transfer of fetal cells with multilineage potential to maternal tissue	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONINVASIVE PRENATAL-DIAGNOSIS; SYSTEMIC-SCLEROSIS; PERIPHERAL-BLOOD; PROGENITOR CELLS; HEALTHY WOMEN; MALE DNA; MICROCHIMERISM; CIRCULATION; PREGNANCY; LONG	Context During pregnancy, fetal CD34(+) cells enter the maternal circulation, persist for decades, and create a state of physiologic microchimerism. Many studies have confirmed the residual presence of fetal cells in maternal blood and tissues following pregnancy. Fetal cells may respond to maternal injury by developing multilineage capacity in maternal organs. Objective To verify that fetal microchimeric cells express markers of epithelial, leukocyte, and hepatocyte differentiation within maternal organs. Design, Setting, and Patients Archived paraffin-embedded tissue section specimens from 10 women who had male offspring and were previously found to have high numbers of microchimeric cells, and 11 control women who had no prior male pregnancies. Male cells were identified by fluorescence in situ hybridization, using X and Y chromosome-specific probes, followed by histologic and immunochemical studies using anticytokeratin (AE1/AE3) as a marker of epithelial cells, anti-CD45 as a leukocyte marker, and heppar-1 as a hepatocyte marker. Main Outcome Measure Percentage of microchimeric cells expressing nonhematopoietic markers. Results A total of 701 male (XY+) microchimeric cells were identified (mean [SD], 227 [128] XY+ cells per million maternal cells). In maternal epithelial tissues (thyroid, cervix, intestine, and gallbladder), 14% to 60% of XY+ cells expressed cytokeratin. Conversely, in hematopoietic tissues, such as lymph nodes and spleen, 90% of XY+ cells expressed CD45. In 1 liver sample, 4% of XY+ cells expressed heppar-1. Histologic and immunochemical evidence of differentiation, as assessed by independent observers, was highly concordant (kappa = 0.72). Conclusion The detection of microchimeric male cells, bearing epithelial, leukocyte, or hepatocyte markers, in a variety of maternal tissue specimens suggests the presence of fetal cells that may have multilineage capacity.	Tufts Univ, New England Med Ctr, Dept Pediat, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Obstet & Gynecol, Boston, MA 02111 USA; Tufts Univ, New England Med Ctr, Dept Pathol, Boston, MA 02111 USA	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University	Bianchi, DW (corresponding author), Tufts Univ, New England Med Ctr, Dept Pediat, Box 394,750 Washington St, Boston, MA 02111 USA.	dbianchi@tufts-nemc.org	Khosrotehrani, Kiarash/M-8025-2015	Khosrotehrani, Kiarash/0000-0002-6406-4076; Cha, Dong Hyun/0000-0003-0722-1714				Adams KM, 2003, BLOOD, V102, P3845, DOI 10.1182/blood-2003-05-1570; Ariga H, 2001, TRANSFUSION, V41, P1524, DOI 10.1046/j.1537-2995.2001.41121524.x; Artlett CM, 1998, NEW ENGL J MED, V338, P1186, DOI 10.1056/NEJM199804233381704; Artlett CM, 2002, CLIN IMMUNOL, V103, P303, DOI 10.1006/clim.2002.5222; Bianchi DW, 2001, AM J OBSTET GYNECOL, V184, P703, DOI 10.1067/mob.2001.111072; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; Bianchi DW, 1999, BRIT J HAEMATOL, V105, P574, DOI 10.1046/j.1365-2141.1999.01383.x; Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396; Cha D, 2003, OBSTET GYNECOL, V102, P774, DOI 10.1016/S0029-7844(03)00615-X; Evans PC, 1999, BLOOD, V93, P2033, DOI 10.1182/blood.V93.6.2033.406k18_2033_2037; Fanning PA, 2000, J HEPATOL, V33, P690, DOI 10.1016/S0168-8278(00)80297-4; Guetta E, 2003, BLOOD CELL MOL DIS, V30, P13, DOI 10.1016/S1079-9796(03)00008-1; Hollander M., 1999, NONPARAMETRIC STAT M, P190; Johnson KL, 2000, BIOTECHNIQUES, V29, P1220, DOI 10.2144/00296st01; Johnson KL, 2001, ARTHRITIS RHEUM, V44, P2107, DOI 10.1002/1529-0131(200109)44:9<2107::AID-ART361>3.0.CO;2-9; Johnson KL, 2002, HEPATOLOGY, V36, P1295, DOI 10.1053/jhep.2002.35622; Johnson KL, 2001, ARTHRITIS RHEUM-US, V44, P1848, DOI 10.1002/1529-0131(200108)44:8<1848::AID-ART323>3.0.CO;2-L; Khosrotehrani K, 2003, ARTHRITIS RHEUM, V48, P3237, DOI 10.1002/art.11324; Khosrotehrani K, 2003, BIOTECHNIQUES, V34, P242, DOI 10.2144/03342bm01; Krabchi K, 2001, CLIN GENET, V60, P145, DOI 10.1034/j.1399-0004.2001.600209.x; Lambert NC, 2002, BLOOD, V100, P2845, DOI 10.1182/blood-2002-01-0295; Lee TH, 1999, BLOOD, V93, P3127; Nelson JL, 1998, LANCET, V351, P559, DOI 10.1016/S0140-6736(97)08357-8; O'Donoghue K, 2003, MOL HUM REPROD, V9, P497, DOI 10.1093/molehr/gag063; Osada H, 2001, TRANSFUSION, V41, P499, DOI 10.1046/j.1537-2995.2001.41040499.x; Scaletti C, 2002, ARTHRITIS RHEUM, V46, P445, DOI 10.1002/art.10049; Srivatsa B, 2001, LANCET, V358, P2034, DOI 10.1016/S0140-6736(01)07099-4; vanWijk IJ, 1996, AM J OBSTET GYNECOL, V174, P871, DOI 10.1016/S0002-9378(96)70315-0; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531	29	190	197	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					75	80		10.1001/jama.292.1.75	http://dx.doi.org/10.1001/jama.292.1.75			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238593	Bronze			2022-12-28	WOS:000222448100029
J	Minneci, PC; Deans, KJ; Banks, SM; Eichacker, PQ; Natanson, C				Minneci, PC; Deans, KJ; Banks, SM; Eichacker, PQ; Natanson, C			Meta-analysis: The effect of steroids on survival and shock during sepsis depends on the dose	ANNALS OF INTERNAL MEDICINE			English	Review							SEPTIC SHOCK; DOUBLE-BLIND; ANTIINFLAMMATORY AGENTS; HYDROCORTISONE; EFFICACY; METHYLPREDNISOLONE; EPIDEMIOLOGY; STRATEGIES; MANAGEMENT; THERAPIES	Background: Previous meta-analyses demonstrated that highdose glucocorticoids were not beneficial in sepsis. Recently, lowerdose glucocorticolds have been studied. Purpose: To compare recent trials of glucocorticoids for sepsis with previous glucocorticoid trials. Data Sources: Systematic MEDLINE search for studies published between 1988 and 2003. Study Selection: Randomized, controlled trials of sepsis that examined the effects of glucocorticoids on survival or vasopressor requirements. Data Extraction: Two investigators independently collected data on patient and study characteristics, treatment interventions, and outcomes. Data Synthesis: The 5 included trials revealed a consistent and beneficial effect of glucocorticoids on survival (l(2) = 0%; relative benefit, 1.23, [95% Cl, 1.01 to 1.50]; P= 0.036) and shock reversal (l(2) = 0%; relative benefit, 1.71 [Cl, 1.29 to 2.26]; P < 0.001). These effects were the same regardless of adrenal function. In contrast, 8 trials published before 1989 demonstrated a survival disadvantage with steroid treatment (l(2) = 14%; relative benefit, 0.89 [Cl, 0.82 to 0.97]; P = 0.008). In comparison with the earlier trials, the more recent trials administered steroids later after patients met enrollment criteria (median, 23 hours vs. <2 hours; P = 0.02), for longer courses (6 days vs. 1 day; P = 0.01), and in lower total dosages (hydrocortisone equivalents, 1209 mg vs. 23 975 mg; P = 0.01) to patients with higher control group mortality rates (mean, 57% vs. 34%; P = 0.06) who were more likely to be vasopressor-dependent (100% vs. 65%; P = 0.03). The relationship between steroid dose and survival was linear, characterized by benefit at low doses and increasing harm at higher doses (P = 0.02). Limitations: We could not analyze time-related improvements in medical care and potential bias secondary to nonreporting of negative study results. Conclusions: Although short courses of high-dose glucocorticolds decreased survival during sepsis, a 5- to 7-day course of physiologic hydrocortisone doses with subsequent tapering increases survival rate and shock reversal in patients with vasopressor-dependent septic shock.	NHLBI, Ctr Clin, NIH, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Massachusetts General Hospital	Minneci, PC (corresponding author), NIH, Dept Crit Care Med, Bldg 10,Room 7D43,10 Ctr Dr, Bethesda, MD 20892 USA.	pminneci@mail.cc.nih.gov						Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2000, JAMA-J AM MED ASSOC, V283, P1038, DOI 10.1001/jama.283.8.1038; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Breslow NE, 1980, IARC SCI PUBL, P5; Briegel J, 1996, INTENS CARE MED, V22, P894; Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025; Chawla K, 1999, CRIT CARE MED, V27, pA33, DOI 10.1097/00003246-199901001-00022; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; Cross AS, 2003, ANN INTERN MED, V138, P502, DOI 10.7326/0003-4819-138-6-200303180-00016; Dellinger E P, 2000, Surg Infect (Larchmt), V1, P239, DOI 10.1089/109629600750018169; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1197, DOI 10.1164/rccm.200204-302OC; GARBER EK, 1987, DRUGS RHEUMATIC DIS, P446; Group CS, 1963, JAMA-J AM MED ASSOC, V183, P462, DOI DOI 10.1001/JAMA.1963.63700060029012; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HINSHAW LB, 1967, ARCH SURG-CHICAGO, V94, P61; HINSHAW LB, 1978, SURG GYNECOL OBSTET, V147, P545; KLASTERSKY J, 1971, NEW ENGL J MED, V284, P1248, DOI 10.1056/NEJM197106032842206; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; LILLY E, 2002, XIGRIS DRORRECOGIN A; Lipsey MW, 2001, EVAL HEALTH PROF, V24, P236, DOI 10.1177/01632780122034902; LUCAS CE, 1984, ARCH SURG-CHICAGO, V119, P537; LUCE JM, 1988, AM REV RESPIR DIS, V138, P62, DOI 10.1164/ajrccm/138.1.62; MANTEL N, 1959, J NATL CANCER I, V22, P719; Minneci P, 2003, EUR J CLIN MICROBIOL, V22, P1, DOI 10.1007/s10096-002-0857-3; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; Opal SM, 2003, CRIT CARE MED, V31, pS57, DOI 10.1097/00003246-200301001-00009; Opal SM, 1998, DRUGS, V55, P497, DOI 10.2165/00003495-199855040-00002; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; PINGLETON WW, 1972, LAB INVEST, V27, P445; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; SCHUMER W, 1976, ANN SURG, V184, P333, DOI 10.1097/00000658-197609000-00011; SILVER GM, 1994, SURG CLIN N AM, V74, P711, DOI 10.1016/S0039-6109(16)46338-3; SPRUNG CL, 1984, NEW ENGL J MED, V311, P1137, DOI 10.1056/NEJM198411013111801; THOMPSON WL, 1976, CLIN RES, V24, pA258; Yildiz O, 2002, CRIT CARE, V6, P251, DOI 10.1186/cc1498; Zeni F, 1997, CRIT CARE MED, V25, P1095, DOI 10.1097/00003246-199707000-00001	41	252	272	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					47	56		10.7326/0003-4819-141-1-200407060-00014	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00014			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238370				2022-12-28	WOS:000222427600007
J	Chow, SS; Wilke, CO; Ofria, C; Lenski, RE; Adami, C				Chow, SS; Wilke, CO; Ofria, C; Lenski, RE; Adami, C			Adaptive radiation from resource competition in digital organisms	SCIENCE			English	Article							DIVERSITY PATTERNS; ESCHERICHIA-COLI; PRODUCTIVITY; EVOLUTION	Species richness often peaks at intermediate productivity and decreases as resources become more or less abundant. The mechanisms that produce this pattern are not completely known, but several previous studies have suggested environmental heterogeneity as a cause. In experiments with evolving digital organisms and populations of fixed size, maximum species richness emerges at intermediate productivity, even in a spatially homogeneous environment, owing to frequency-dependent selection to exploit an influx of mixed resources. A diverse pool of limiting resources is sufficient to cause adaptive radiation, which is manifest by the origin and maintenance of phenotypically and phylogenetically distinct groups of organisms.	CALTECH, Digital Life Lab 136 93, Pasadena, CA 91125 USA; Keck Grad Inst, Claremont, CA 91711 USA; Michigan State Univ, Dept Comp Sci & Engn, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	California Institute of Technology; Claremont Colleges; Keck Graduate Institute; Michigan State University; Michigan State University	Adami, C (corresponding author), CALTECH, Digital Life Lab 136 93, Pasadena, CA 91125 USA.	adami@caltech.edu	Wilke, Claus O./B-4643-2008; Adami, Christoph/A-5181-2009; Adami, Chris/A-9675-2011	Adami, Chris/0000-0002-2915-9504; Lenski, Richard/0000-0002-1064-8375; Wilke, Claus/0000-0002-7470-9261; Ofria, Charles/0000-0003-2924-1732				ABRAMS PA, 1995, ECOLOGY, V76, P2019, DOI 10.2307/1941677; Cohan FM, 2001, SYST BIOL, V50, P513, DOI 10.1080/106351501750435077; COOPER TF, 2003, ARTIF LIFE, V8, P227; Doebeli M, 2000, AM NAT, V156, pS77, DOI 10.1086/303417; Friesen ML, 2004, EVOLUTION, V58, P245, DOI 10.1111/j.0014-3820.2004.tb01642.x; Fukami T, 2003, NATURE, V424, P423, DOI 10.1038/nature01785; HELLING RB, 1987, GENETICS, V116, P349; HOLT RD, 1994, AM NAT, V144, P741, DOI 10.1086/285705; Horner-Devine MC, 2003, ECOL LETT, V6, P613; Kassen R, 2000, NATURE, V406, P508, DOI 10.1038/35020060; Kimura M., 1983, NEUTRAL THEORY MOL E; Leibold MA, 1996, AM NAT, V147, P784, DOI 10.1086/285879; Lenski RE, 2003, NATURE, V423, P139, DOI 10.1038/nature01568; Mittelbach GG, 2001, ECOLOGY, V82, P2381, DOI 10.1890/0012-9658(2001)082[2381:WITORB]2.0.CO;2; Morin PJ, 2000, NATURE, V406, P463, DOI 10.1038/35020160; Ofria C, 2004, ARTIF LIFE, V10, P191, DOI 10.1162/106454604773563612; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Rosenzweig Michael L., 1993, P52; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG RF, 1994, GENETICS, V137, P903; Rozen DE, 2000, AM NAT, V155, P24, DOI 10.1086/303299; Tilman D., 1982, Monographs in Population Biology, pi; Tilman David, 1993, P13; Treves DS, 1998, MOL BIOL EVOL, V15, P789, DOI 10.1093/oxfordjournals.molbev.a025984; Turner PE, 1996, ECOLOGY, V77, P2119, DOI 10.2307/2265706; Waide RB, 1999, ANNU REV ECOL SYST, V30, P257, DOI 10.1146/annurev.ecolsys.30.1.257; Wilke CO, 2002, TRENDS ECOL EVOL, V17, P528, DOI 10.1016/S0169-5347(02)02612-5; ZUCKERKANDL E, 1965, EVOLVING GENES PROTE, V5, P97	28	87	90	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					84	86		10.1126/science.1096307	http://dx.doi.org/10.1126/science.1096307			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232105				2022-12-28	WOS:000222386000040
J	Jia, ST; Noma, K; Grewal, SIS				Jia, ST; Noma, K; Grewal, SIS			RNAi-independent heterochromatin nucleation by the stress-activated ATF/CREB family proteins	SCIENCE			English	Article							ATF1 TRANSCRIPTION FACTOR; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; HISTONE H3; SEXUAL DEVELOPMENT; METHYLATION; GENOME; LOCALIZATION; EXPRESSION; ENCODES	At the silent mating-type interval of fission yeast, the RNA interference (RNAi) machinery cooperates with cenH, a DNA element homologous to centromeric repeats, to initiate heterochromatin formation. However, in RNAi mutants, heterochromatin assembly can still occur at low efficiency. Here, we report that Atf1 and Pcr1, two ATF/CREB family proteins, act in a parallel mechanism to the RNAi pathway for heterochromatin nucleation. Deletion of atf1 or pcr1 alone has little effect on silencing at the mating-type region, but when combined with RNAi mutants, double mutants fail to nucleate heterochromatin assembly. Moreover, deletion of atf1 or pcr1 in combination with cenH deletion causes loss of silencing and heterochromatin formation. Furthermore, Atf1 and Pcr1 bind to the mating-type region and target histone H3 lysine-9 methylation and the Swi6 protein essential for heterochromatin assembly. These analyses link ATF/CREB family proteins, involved in cellular response to environmental stresses, to nucleation of constitutive heterochromatin.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Grewal, SIS (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.	grewals@mail.nih.gov			NATIONAL CANCER INSTITUTE [ZIABC010523, Z01BC010523] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; Ayoub N, 1999, GENETICS, V152, P495; Degols G, 1997, MOL CELL BIOL, V17, P3356, DOI 10.1128/MCB.17.6.3356; Gowen JW, 1933, SCIENCE, V77, P312, DOI 10.1126/science.77.1995.312; Grewal SIS, 1997, GENETICS, V146, P1221; Grewal SIS, 2000, J CELL PHYSIOL, V184, P311, DOI 10.1002/1097-4652(200009)184:3<311::AID-JCP4>3.0.CO;2-D; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Lechner MS, 2000, MOL CELL BIOL, V20, P6449, DOI 10.1128/MCB.20.17.6449-6465.2000; MCCLINTOCK B, 1984, SCIENCE, V226, P792, DOI 10.1126/science.15739260; Mochizuki K, 2002, CELL, V110, P689, DOI 10.1016/S0092-8674(02)00909-1; Nakayama J, 2000, CELL, V101, P307, DOI 10.1016/S0092-8674(00)80840-5; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Pal-Bhadra M, 2004, SCIENCE, V303, P669, DOI 10.1126/science.1092653; Rizzi N, 2004, MOL BIOL CELL, V15, P543, DOI 10.1091/mbc.E03-07-0487; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Thon G, 1999, GENETICS, V151, P945; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Watanabe Y, 1996, MOL CELL BIOL, V16, P704; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695	23	232	242	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1971	1976		10.1126/science.1099035	http://dx.doi.org/10.1126/science.1099035			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218150				2022-12-28	WOS:000222241600047
J	Insall, RH; Machesky, LM				Insall, RH; Machesky, LM			Regulation of WASP: PIP2 pipped by Toca-1?	CELL			English	Editorial Material							N-WASP; MECHANISM; BINDING	Cdc42 is a key regulator of cell polarity and actin dynamics. One of its effectors, WASP, initiates the assembly of new actin filaments. In this issue of Cell, Ho et al. (2004) show that a previously unknown regulator named Toca-1 is required for Cdc42 to activate WASP. This discovery changes our picture of how small GTPases and multiple other signals converge to stimulate actin polymerization and cell motility.	Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Insall, RH (corresponding author), Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England.		Machesky, Laura/Z-4554-2019; Insall, Robert/G-5611-2011	Machesky, Laura/0000-0002-7592-9856; Insall, Robert/0000-0003-4898-040X	MRC [G117/379] Funding Source: UKRI; Medical Research Council [G117/379] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Cory GOC, 2002, J BIOL CHEM, V277, P45115, DOI 10.1074/jbc.M203346200; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Ho HYH, 2004, CELL, V118, P203, DOI 10.1016/j.cell.2004.06.027; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Oikawa T, 2004, NAT CELL BIOL, V6, P420, DOI 10.1038/ncb1125; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299	8	8	8	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	2004	118	2					140	141		10.1016/j.cell.2004.07.005	http://dx.doi.org/10.1016/j.cell.2004.07.005			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260983	Bronze			2022-12-28	WOS:000222966000002
J	Sampath, SC; Ohi, R; Leismann, O; Salic, A; Pozniakovski, A; Funabiki, H				Sampath, SC; Ohi, R; Leismann, O; Salic, A; Pozniakovski, A; Funabiki, H			The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly	CELL			English	Article							INNER CENTROMERE PROTEIN; MITOTIC-SPINDLE; AURORA-B; CELL-CYCLE; RAN-GTP; SELF-ORGANIZATION; IMPORTIN-BETA; INCENP; DYNAMICS; CENTROSOME	In cells lacking centrosomes, such as those found in female meiosis, chromosomes must nucleate and stabilize microtubules in order to form a bipolar spindle. Here we report the identification of Dasra A and Dasra B, two new components of the vertebrate chromosomal passenger complex containing Incenp, Survivin, and the kinase Aurora B, and demonstrate that this complex is required for chromatin-induced microtubule stabilization and spindle formation. The failure of microtubule stabilization caused by depletion of the chromosomal passenger complex was rescued by codepletion of the microtubule-depolymerizing kinesin MCAK, whose activity is negatively regulated by Aurora B. By contrast, we present evidence that the RanGTP pathway of chromatin-induced microtubule nucleation does not require the chromosomal passenger complex, indicating that the mechanisms of microtubule assembly by these two pathways are distinct. We propose that the chromosomal passenger complex regulates local MCAK activity to permit spindle formation via stabilization of chromatin-associated microtubules.	Rockefeller Univ, Lab Chromosome & Cell Biol, New York, NY 10021 USA; Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Rockefeller University; Harvard University; Harvard Medical School; Max Planck Society	Funabiki, H (corresponding author), Rockefeller Univ, Lab Chromosome & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	funabih@rockefeller.edu	Salic, Adrian/GXG-1611-2022	Funabiki, Hironori/0000-0003-4831-4087	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2004, DEV CELL, V6, P253, DOI 10.1016/S1534-5807(04)00025-5; BEDDINGTON R, 2002, PRINCIPLES DEV; Biggins S, 2003, CURR BIOL, V13, pR449, DOI 10.1016/S0960-9822(03)00369-5; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; Bolton MA, 2002, MOL BIOL CELL, V13, P3064, DOI 10.1091/mbc.E02-02-0092; Budde PP, 2001, J CELL BIOL, V153, P149, DOI 10.1083/jcb.153.1.149; CAMINCI P, 2000, GENOME RES, V10, P1617; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; Carazo-Salas RE, 2001, NAT CELL BIOL, V3, P228, DOI 10.1038/35060009; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; COOKE CA, 1987, J CELL BIOL, V105, P2053, DOI 10.1083/jcb.105.5.2053; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Faruki S, 2002, CELL MOTIL CYTOSKEL, V52, P107, DOI 10.1002/cm.10036; Field CM, 1998, METHOD ENZYMOL, V298, P525, DOI 10.1016/S0076-6879(98)98043-0; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Heald R, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 2, P326; Kahana JA, 1999, J CELL BIOL, V146, P1205, DOI 10.1083/jcb.146.6.1205; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; Kalab P, 2002, SCIENCE, V295, P2452, DOI 10.1126/science.1068798; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Keryer G, 2003, MOL BIOL CELL, V14, P4260, DOI 10.1091/mbc.E02-11-0773; Khodjakov A, 2000, CURR BIOL, V10, P59, DOI 10.1016/S0960-9822(99)00276-6; Kinoshita K, 2001, SCIENCE, V294, P1340, DOI 10.1126/science.1064629; Lampson MA, 2004, NAT CELL BIOL, V6, P232, DOI 10.1038/ncb1102; Lan WJ, 2004, CURR BIOL, V14, P273, DOI 10.1016/j.cub.2004.01.055; Li HY, 2004, GENE DEV, V18, P512, DOI 10.1101/gad.1177304; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nachury MV, 2001, CELL, V104, P95, DOI 10.1016/S0092-8674(01)00194-5; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; Ohi R, 2003, DEV CELL, V5, P309, DOI 10.1016/S1534-5807(03)00229-6; OHI R, 2004, IN PRESS MOL BIOL CE; Rieder CL, 2001, TRENDS CELL BIOL, V11, P413, DOI 10.1016/S0962-8924(01)02085-2; Romano A, 2003, J CELL BIOL, V161, P229, DOI 10.1083/jcb.200207117; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; Tournebize R, 2000, NAT CELL BIOL, V2, P13, DOI 10.1038/71330; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Walczak CE, 1996, CELL, V84, P37, DOI 10.1016/S0092-8674(00)80991-5; Walker MG, 2001, CURR CANCER DRUG TAR, V1, P73, DOI 10.2174/1568009013334241; Wiese C, 2001, SCIENCE, V291, P653, DOI 10.1126/science.1057661; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359	49	330	352	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					187	202		10.1016/j.cell.2004.06.026	http://dx.doi.org/10.1016/j.cell.2004.06.026			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260989	Bronze			2022-12-28	WOS:000222966000008
J	Badro, J; Rueff, JP; Vanko, G; Monaco, G; Fiquet, G; Guyot, F				Badro, J; Rueff, JP; Vanko, G; Monaco, G; Fiquet, G; Guyot, F			Electronic transitions in perovskite: Possible nonconvecting layers in the lower mantle	SCIENCE			English	Article							RAY-EMISSION SPECTROSCOPY; VARIABLE THERMAL-CONDUCTIVITY; PHASE-TRANSITION; EARTHS MANTLE; HEAT-TRANSFER; PRESSURE; ABSORPTION; CONVECTION; EQUATION; STATE	We measured the spin state of iron in magnesium silicate perovskite (Mg-0.9,Fe-0.1) SiO3 at high pressure and found two electronic transitions occurring at 70 gigapascals and at 120 gigapascals, corresponding to partial and full electron pairing in iron, respectively. The proportion of iron in the low spin state thus grows with depth, increasing the transparency of the mantle in the infrared region, with a maximum at pressures consistent with the D" layer above the core-mantle boundary. The resulting increase in radiative thermal conductivity suggests the existence of nonconvecting layers in the lowermost mantle.	Univ Paris 06, Inst Phys Globe, CNRS, UMR 7590,Lab Mineral Cristallog Paris, F-75252 Paris, France; Univ Paris 07, F-75252 Paris, France; Univ Paris 06, CNRS, UMR 7614, Lab Chim Phys Mat & Rayonnement, F-75231 Paris, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Sorbonne Universite; European Synchrotron Radiation Facility (ESRF)	Badro, J (corresponding author), Univ Paris 06, Inst Phys Globe, CNRS, UMR 7590,Lab Mineral Cristallog Paris, 4 Pl Jussieu, F-75252 Paris, France.	james.badro@lmcp.jussieu.fr	Badro, James/A-6003-2011; Fiquet, Guillaume/O-7077-2019; Vankó, György/B-8176-2012; Monaco, Giulio/AAW-4387-2020; Monaco, Giulio/AAU-2947-2021; Fiquet, Guillaume/M-6934-2014; Fiquet, Guillaume M/H-1219-2011; GUYOT, François J/C-3824-2016; Rueff, Jean-Pascal/D-8938-2016	Badro, James/0000-0001-9337-4789; Vankó, György/0000-0002-3095-6551; Monaco, Giulio/0000-0003-2497-6422; Fiquet, Guillaume/0000-0001-8961-3281; GUYOT, François J/0000-0003-4622-2218; Rueff, Jean-Pascal/0000-0003-3594-918X				Andrault D, 2001, EARTH PLANET SC LETT, V193, P501, DOI 10.1016/S0012-821X(01)00506-4; Badro J, 2003, SCIENCE, V300, P789, DOI 10.1126/science.1081311; Badro J, 1999, PHYS REV LETT, V83, P4101, DOI 10.1103/PhysRevLett.83.4101; Boehler R, 2000, REV GEOPHYS, V38, P221, DOI 10.1029/1998RG000053; BROWN JM, 1981, GEOPHYS J ROY ASTR S, V66, P579, DOI 10.1111/j.1365-246X.1981.tb04891.x; Burns R. G, 1993, MINERALOGICAL APPL C; CLARK SP, 1957, T AM GEOPHYS UNION, V38, P931; Daniel I, 2001, GEOPHYS RES LETT, V28, P3789, DOI 10.1029/2001GL013011; Davies GF, 1998, EARTHS MANTLE COMPOS, P228; Dubuffet F, 2000, GEOPHYS RES LETT, V27, P17, DOI 10.1029/1999GL008338; GAFFNEY ES, 1973, J GEOPHYS RES, V78, P7005, DOI 10.1029/JB078i029p07005; Gillet P, 2000, PHYS EARTH PLANET IN, V117, P361, DOI 10.1016/S0031-9201(99)00107-7; GOTO T, 1980, PHYS EARTH PLANET IN, V22, P277, DOI 10.1016/0031-9201(80)90044-8; Hofmeister AM, 1999, SCIENCE, V283, P1699, DOI 10.1126/science.283.5408.1699; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KEPPLER H, 1994, AM MINERAL, V79, P1215; LI J, 2003, EOS S, V84, P46; LIU L, 1975, GEOPHYS RES LETT, V2, P417, DOI 10.1029/GL002i010p00417; McCammon C, 1997, NATURE, V387, P694, DOI 10.1038/42685; Murakami M, 2004, SCIENCE, V304, P855, DOI 10.1126/science.1095932; PENG G, 1994, APPL PHYS LETT, V65, P2527, DOI 10.1063/1.112625; Rueff JP, 1999, PHYS REV LETT, V82, P3284, DOI 10.1103/PhysRevLett.82.3284; Rueff JP, 1999, PHYS REV B, V60, P14510, DOI 10.1103/PhysRevB.60.14510; SETTE F, 1995, PHYS REV LETT, V75, P850, DOI 10.1103/PhysRevLett.75.850; SHANKLAND TJ, 1979, J GEOPHYS RES, V84, P1603, DOI 10.1029/JB084iB04p01603; SHERMAN DM, 1991, J GEOPHYS RES-SOLID, V96, P14299, DOI 10.1029/91JB01202; Tackley PJ, 2000, SCIENCE, V288, P2002, DOI 10.1126/science.288.5473.2002; van den Berg AP, 2001, GEOPHYS RES LETT, V28, P875, DOI 10.1029/2000GL011903; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; Vanko  G., 2002, ESRF HIGHLIGHTS, P59; WILLIAMS Q, 1990, J GEOPHYS RES-SOLID, V95, P21549, DOI 10.1029/JB095iB13p21549; Zhang JZ, 1999, SCIENCE, V284, P782, DOI 10.1126/science.284.5415.782	32	295	309	0	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	2004	305	5682					383	386		10.1126/science.1098840	http://dx.doi.org/10.1126/science.1098840			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256667				2022-12-28	WOS:000222662400034
J	Hiiragi, T; Solter, D				Hiiragi, T; Solter, D			First cleavage plane of the mouse egg is not predetermined but defined by the topology of the two apposing pronuclei	NATURE			English	Article							POSTIMPLANTATION DEVELOPMENT; CLEAVAGE DIVISION; CELL-DIVISION; BLASTOMERES; EMBRYO; FERTILIZATION; SPERM; AXIS; MICROTUBULES; ORGANIZATION	Studies of experimentally manipulated embryos(1-4) have led to the long-held conclusion that the polarity of the mouse embryo remains undetermined until the blastocyst stage. However, recent studies(5-7) reporting that the embryonic - abembryonic axis of the blastocyst arises perpendicular to the first cleavage plane, and hence to the animal - vegetal axis of the zygote, have led to the claim that the axis of the mouse embryo is already specified in the egg. Here we show that there is no specification of the axis in the egg. Time-lapse recordings show that the second polar body does not mark a stationary animal pole, but instead, in half of the embryos, moves towards a first cleavage plane. The first cleavage plane coincides with the plane defined by the two apposing pronuclei once they have moved to the centre of the egg. Pronuclear transfer experiments confirm that the first cleavage plane is not determined in early interphase but rather is specified by the newly formed topology of the two pronuclei. The microtubule networks that allow mixing of parental chromosomes before dividing into two may be involved in these processes.	Max Planck Inst Immunbiol, D-79108 Freiburg, Germany	Max Planck Society	Hiiragi, T (corresponding author), Max Planck Inst Immunbiol, D-79108 Freiburg, Germany.	hiiragi@immunbio.mpg.de	Solter, Davor/Q-5476-2019	Solter, Davor/0000-0002-8438-347X; Hiiragi, Takashi/0000-0003-4964-7203				Alarcon VB, 2003, BIOL REPROD, V69, P1208, DOI 10.1095/biolreprod.103.018283; Canman JC, 2003, NATURE, V424, P1074, DOI 10.1038/nature01860; Carazo-Salas RE, 2003, CURR BIOL, V13, P1728, DOI 10.1016/j.cub.2003.09.006; Gardner RL, 1997, DEVELOPMENT, V124, P289; Gardner RL, 2001, DEVELOPMENT, V128, P839; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HO YG, 1995, MOL REPROD DEV, V41, P232, DOI 10.1002/mrd.1080410214; JOHNSON MH, 1975, NATURE, V257, P321, DOI 10.1038/257321a0; MARO B, 1985, J CELL BIOL, V101, P1665, DOI 10.1083/jcb.101.5.1665; MARO B, 1986, J EMBRYOL EXP MORPH, V92, P11; Mayer W, 2000, J CELL BIOL, V148, P629, DOI 10.1083/jcb.148.4.629; MCGRATH J, 1983, SCIENCE, V220, P1300, DOI 10.1126/science.6857250; PAWELETZ N, 1987, EUR J CELL BIOL, V44, P205; Piotrowska K, 2001, DEVELOPMENT, V128, P3739; Piotrowska K, 2002, DEVELOPMENT, V129, P5803, DOI 10.1242/dev.00170; Piotrowska K, 2001, NATURE, V409, P517, DOI 10.1038/35054069; Plusa B, 2002, NAT CELL BIOL, V4, P811, DOI 10.1038/ncb860; ROSSANT J, 1976, J EMBRYOL EXP MORPH, V36, P283; SCHATTEN G, 1981, DEV BIOL, V86, P426, DOI 10.1016/0012-1606(81)90201-3; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4152, DOI 10.1073/pnas.82.12.4152; SCHATTEN H, 1986, P NATL ACAD SCI USA, V83, P105, DOI 10.1073/pnas.83.1.105; TARKOWSKI AK, 1961, NATURE, V190, P857, DOI 10.1038/190857a0; TARKOWSKI AK, 1967, J EMBRYOL EXP MORPH, V18, P155; TARKOWSKI AK, 1959, NATURE, V184, P1286, DOI 10.1038/1841286a0; ZAMBONI L, 1972, BIOL REPROD, V7, P170, DOI 10.1093/biolreprod/7.2.170	25	120	129	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					360	364		10.1038/nature02595	http://dx.doi.org/10.1038/nature02595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254539				2022-12-28	WOS:000222631200043
J	Hescheler, J; Welz, A; Fleischmann, BK				Hescheler, J; Welz, A; Fleischmann, BK			Searching for reputability: first randomised study on bone-marrow transplantation in the heart	LANCET			English	Editorial Material							HEMATOPOIETIC STEM-CELLS; MYOCARDIAL REGENERATION; INFARCTED MYOCARDIUM; ISCHEMIC-MYOCARDIUM; CARDIOMYOCYTES		Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Univ Bonn, Dept Cardiac Surg, D-5300 Bonn, Germany; Univ Bonn, Inst Physiol 1, D-53115 Bonn, Germany	University of Cologne; University of Bonn; University of Bonn	Hescheler, J (corresponding author), Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany.	j.Hescheler@uni-koeln.de						Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; GATTI RA, 1968, LANCET, V2, P1366; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nygren JM, 2004, NAT MED, V10, P494, DOI 10.1038/nm1040; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Roell W, 2002, CIRCULATION, V105, P2435, DOI 10.1161/01.CIR.0000016063.66513.BB; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Strauer BE, 2001, DEUT MED WOCHENSCHR, V126, P932, DOI 10.1055/s-2001-16579-1; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Vulliet PR, 2004, LANCET, V363, P783, DOI 10.1016/S0140-6736(04)15695-X; Wagers AJ, 2004, CELL, V116, P639, DOI 10.1016/S0092-8674(04)00208-9	17	2	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					121	122		10.1016/S0140-6736(04)16651-8	http://dx.doi.org/10.1016/S0140-6736(04)16651-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246712				2022-12-28	WOS:000222612200005
J	Bhatt, DH; Otto, SJ; Depoister, B; Fetcho, JR				Bhatt, DH; Otto, SJ; Depoister, B; Fetcho, JR			Cyclic AMP-induced repair of zebrafish spinal circuits	SCIENCE			English	Article							AXON REGENERATION; GROWTH; CELL; INHIBITION; GOLDFISH; RECEPTOR; NEURONS; ABILITY; ESCAPE; REVEAL	Neurons in the human central nervous system (CNS) are unable to regenerate, as a result of both an inhibitory environment and their inherent inability to regrow. In contrast, the CNS environment in fish is permissive for growth, yet some neurons still cannot regenerate. Fish thus offer an opportunity to study molecules that might surmount the intrinsic limitations they share with mammals, without the complication of an inhibitory environment. We show by in vivo imaging in zebra fish that post-injury application of cyclic adenosine monophosphate can transform severed CNS neurons into ones that regenerate and restore function, thus overcoming intrinsic limitations to regeneration in a vertebrate.	SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fetcho, JR (corresponding author), SUNY Stony Brook, Dept Neurobiol & Behav, Stony Brook, NY 11794 USA.	Jfetcho@notes.cc.sunysb.edu		Bhatt, D/0000-0002-7646-0981	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS026539, R01NS026539, R29NS026539] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008444] Funding Source: Medline; NINDS NIH HHS [R01 NS026539, NS 26539, R01 NS026539-25] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-CNE8>3.0.CO;2-#; Becker T, 1998, J NEUROSCI, V18, P5789; Bomze HM, 2001, NAT NEUROSCI, V4, P38, DOI 10.1038/82881; Buffo A, 1997, J NEUROSCI, V17, P8778; Cai D, 2001, J NEUROSCI, V21, P4731, DOI 10.1523/JNEUROSCI.21-13-04731.2001; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; FETCHO JR, 1992, J NEUROPHYSIOL, V67, P1574, DOI 10.1152/jn.1992.67.6.1574; Gao Y, 2003, J NEUROSCI, V23, P11770; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Goldberg JL, 2002, NEURON, V33, P689, DOI 10.1016/S0896-6273(02)00602-5; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Kao HT, 2002, NAT NEUROSCI, V5, P431, DOI 10.1038/nn840; Liu KS, 1999, NEURON, V23, P325, DOI 10.1016/S0896-6273(00)80783-7; LURIE DI, 1994, J COMP NEUROL, V344, P559, DOI 10.1002/cne.903440406; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Nishiyama M, 2003, NATURE, V423, P990, DOI 10.1038/nature01751; OMalley DM, 1996, NEURON, V17, P1145, DOI 10.1016/S0896-6273(00)80246-9; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Ritter DA, 2001, J NEUROSCI, V21, P8956, DOI 10.1523/JNEUROSCI.21-22-08956.2001; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Snider WD, 2002, NEURON, V35, P13, DOI 10.1016/S0896-6273(02)00762-6; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Steward O, 2003, J COMP NEUROL, V459, P1, DOI 10.1002/cne.10593; Takami T, 2002, J NEUROSCI, V22, P6670; Udvadia AJ, 2001, DEVELOPMENT, V128, P1175; Zheng BH, 2003, NEURON, V38, P213, DOI 10.1016/S0896-6273(03)00225-3; ZOTTOLI SJ, 1994, PROG BRAIN RES, V103, P219	31	142	146	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					254	258		10.1126/science.1098439	http://dx.doi.org/10.1126/science.1098439			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247482				2022-12-28	WOS:000222501000056
J	Hillebrand, R; Gosele, U				Hillebrand, R; Gosele, U			Woodpiles for photons	SCIENCE			English	Editorial Material							CRYSTAL; GAP		Max Planck Inst Microstruct Phys, D-06120 Halle Saale, Germany	Max Planck Society	Gosele, U (corresponding author), Max Planck Inst Microstruct Phys, Weinberg 2, D-06120 Halle Saale, Germany.	goesele@mpi-halle.de						Alexe M., 2004, WAFER BONDING APPL T; Blanco A, 2000, NATURE, V405, P437, DOI 10.1038/35013024; HO KM, 1990, PHYS REV LETT, V65, P3152, DOI 10.1103/PhysRevLett.65.3152; JOHN S, 1987, PHYS REV LETT, V58, P2486, DOI 10.1103/PhysRevLett.58.2486; Miklyaev YV, 2003, APPL PHYS LETT, V82, P1284, DOI 10.1063/1.1557328; Ogawa SP, 2004, SCIENCE, V305, P227, DOI 10.1126/science.1097968; Toader O, 2001, SCIENCE, V292, P1133, DOI 10.1126/science.1059479; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059	8	6	6	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					187	188		10.1126/science.1100434	http://dx.doi.org/10.1126/science.1100434			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247462				2022-12-28	WOS:000222501000033
J	Hogbom, M; Stenmark, P; Voevodskaya, N; McClarty, G; Graslund, A; Nordlund, P				Hogbom, M; Stenmark, P; Voevodskaya, N; McClarty, G; Graslund, A; Nordlund, P			The radical site in chlamydial ribonucleotide reductase defines a new R2 subclass	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; ESCHERICHIA-COLI; ELECTRON-TRANSFER; TRACHOMATIS; COFACTOR; PROTEIN; MECHANISM; CLUSTER; EPR; ACTIVATION	Ribonucleotide reductase (RNR) synthesizes the deoxyribonucleotides for DNA synthesis. The R2 protein of normal class I ribonucleotide reductases contains a diiron site that produces a stable tyrosyl free radical, essential for enzymatic activity. Structural and electron paramagnetic resonance studies of R2 from Chlamydia trachomatis reveal a protein lacking a tyrosyl radical site. Instead, the protein yields an iron-coupled radical upon reconstitution. The coordinating structure of the diiron site is similar to that of diiron oxidases/monoxygenases and supports a role for this radical in the RNR mechanism. The specific ligand pattern in the C. trachomatis R2 metal site characterizes a new group of R2 proteins that so far has been found in eight organisms, three of which are human pathogens.	Stockholm Univ, Albanova Univ Ctr, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Stockholm Univ, Arrhenius Labs Nat Sci A3, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden; Univ Manitoba, Dept Med Microbiol, Winnipeg, MB R3E 0W3, Canada; Hlth Canada, Natl Microbiol Lab, Winnipeg, MB R3E 0W3, Canada	Stockholm University; Stockholm University; University of Manitoba; Health Canada	Nordlund, P (corresponding author), Stockholm Univ, Albanova Univ Ctr, Dept Biochem & Biophys, Roslagstullsbacken 15, SE-10691 Stockholm, Sweden.	par.nordlund@dbb.su.se		Hogbom, Martin/0000-0001-5574-9383; Stenmark, Pal/0000-0003-4777-3417				Baldwin J, 2000, J AM CHEM SOC, V122, P12195, DOI 10.1021/ja001278u; BOLLINGER JM, 1991, SCIENCE, V253, P292, DOI 10.1126/science.1650033; BOLLINGER JM, 1994, J AM CHEM SOC, V116, P8024, DOI 10.1021/ja00097a009; Brunham RC, 1996, J INFECT DIS, V173, P950, DOI 10.1093/infdis/173.4.950; Burdi D, 1998, J AM CHEM SOC, V120, P12910, DOI 10.1021/ja9824270; Eklund H, 2001, PROG BIOPHYS MOL BIO, V77, P177, DOI 10.1016/S0079-6107(01)00014-1; Elleingand E, 1998, EUR J BIOCHEM, V258, P485, DOI 10.1046/j.1432-1327.1998.2580485.x; Fontecave M, 1998, CELL MOL LIFE SCI, V54, P684, DOI 10.1007/s000180050195; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; Guittet O, 1999, CELL MOL LIFE SCI, V55, P1054, DOI 10.1007/s000180050356; HENRIKSEN MA, 1994, J AM CHEM SOC, V116, P9773, DOI 10.1021/ja00100a062; Hogbom M, 2003, P NATL ACAD SCI USA, V100, P3209, DOI 10.1073/pnas.0536684100; Horn M, 2004, SCIENCE, V304, P728, DOI 10.1126/science.1096330; Igietseme JU, 1998, INFECT IMMUN, V66, P1282, DOI 10.1128/IAI.66.4.1282-1286.1998; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; LARSSON A, 1986, EMBO J, V5, P2037, DOI 10.1002/j.1460-2075.1986.tb04461.x; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; Merkx M, 2001, ANGEW CHEM INT EDIT, V40, P2782, DOI 10.1002/1521-3773(20010803)40:15<2782::AID-ANIE2782>3.0.CO;2-P; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; Perry LL, 1998, INFECT IMMUN, V66, P1265, DOI 10.1128/IAI.66.3.1265-1269.1998; Potsch S, 1999, J BIOL CHEM, V274, P17696, DOI 10.1074/jbc.274.25.17696; Ramsey KH, 1998, INFECT IMMUN, V66, P835, DOI 10.1128/IAI.66.2.835-838.1998; Riggs-Gelasco PJ, 1998, J AM CHEM SOC, V120, P849, DOI 10.1021/ja9718230; Roshick C, 2000, J BIOL CHEM, V275, P38111, DOI 10.1074/jbc.M006367200; Sjoberg BM, 1997, STRUCT BOND, V88, P139; Stubbe J, 2003, CHEM REV, V103, P2167, DOI 10.1021/cr020421u; Sturgeon BE, 1996, J AM CHEM SOC, V118, P7551, DOI 10.1021/ja960399k; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; UHLIN U, 1994, NATURE, V370, P533, DOI 10.1038/370533a0; Yun D, 2002, BIOCHEMISTRY-US, V41, P981, DOI 10.1021/bi011797p	33	123	124	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					245	248		10.1126/science.1098419	http://dx.doi.org/10.1126/science.1098419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247479				2022-12-28	WOS:000222501000053
J	Wright, TJ; Parsons, B; England, PC; Fielding, EJ				Wright, TJ; Parsons, B; England, PC; Fielding, EJ			InSAR observations of low slip rates on the major faults of western Tibet	SCIENCE			English	Article							CONTINENTAL DEFORMATION; CRUSTAL DEFORMATION; STRAIN ACCUMULATION; EASTERN TIBET; SYSTEM; CALIFORNIA; MODEL; CHINA; ASIA; EARTHQUAKE	Two contrasting views of the active deformation of Asia dominate the debate about how continents deform: (i) The deformation is primarily localized on major faults separating crustal blocks or (ii) deformation is distributed throughout the continental lithosphere. In the first model, western Tibet is being extruded eastward between the major faults bounding the region. Surface displacement measurements across the western Tibetan plateau using satellite radar interferometry (InSAR) indicate that slip rates on the Karakoram and Altyn Tagh faults are lower than would be expected for the extrusion model and suggest a significant amount of internal deformation in Tibet.	Univ Oxford, Dept Earth Sci, COMET, Oxford OX1 3PR, England; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Cambridge, Dept Earth Sci, Cambridge CB2 1TN, England	University of Oxford; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Cambridge	Wright, TJ (corresponding author), Univ Oxford, Dept Earth Sci, COMET, Oxford OX1 3PR, England.	tim.wright@earth.ox.ac.uk	Parsons, Barry E/K-4716-2012; Fielding, Eric/L-8187-2019; England, Philip C/A-1920-2010; Wright, Tim J/A-5892-2011; Fielding, Eric Jameson/A-1288-2007; NCEO, COMET+`/A-3443-2013	Parsons, Barry E/0000-0001-5120-4917; Fielding, Eric/0000-0002-6648-8067; England, Philip C/0000-0002-9024-8901; Wright, Tim J/0000-0001-8338-5935; Fielding, Eric Jameson/0000-0002-6648-8067; 				ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; AVOUAC JP, 1993, J GEOPHYS RES-SOL EA, V98, P21773, DOI 10.1029/93JB02172; AVOUAC JP, 1993, GEOPHYS RES LETT, V20, P895, DOI 10.1029/93GL00128; Banerjee P, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015184; Bendick R, 2000, NATURE, V404, P69, DOI 10.1038/35003555; BIRD P, 1980, PHYS EARTH PLANET IN, V21, P158, DOI 10.1016/0031-9201(80)90067-9; Brown ET, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2000JB000100; Chen Z, 2000, J GEOPHYS RES-SOL EA, V105, P16215, DOI 10.1029/2000JB900092; CHEN Z, 2004, J GEOPHYS RES, V109; ENGLAND P, 1990, NATURE, V344, P140, DOI 10.1038/344140a0; ENGLAND P, 1982, GEOPHYS J ROY ASTR S, V70, P295, DOI 10.1111/j.1365-246X.1982.tb04969.x; Farr T.G., 2000, EOS T AM GEOPHYS UN, V81, P583, DOI [DOI 10.1029/EO081I048P00583, 10.1029/EO081i048p00583]; GILLESPIE A, 1995, REV GEOPHYS, V33, P311, DOI 10.1029/95RG00995; Hanssen R., 2001, RADAR INTERFEROMETRY; HOUSEMAN G, 1986, J GEOPHYS RES-SOLID, V91, P3651, DOI 10.1029/JB091iB03p03651; HOUSEMAN G, 1993, J GEOPHYS RES-SOL EA, V98, P12233, DOI 10.1029/93JB00443; JADE S, IN PRESS GEOL SOC AM; LIU QS, 1993, THESIS U PARIS; MASEK JG, 1994, TECTONICS, V13, P659, DOI 10.1029/94TC00452; MERIAUX AS, 2003, GEOPH RES ABSTR, V5; Peltzer G, 1999, SCIENCE, V286, P272, DOI 10.1126/science.286.5438.272; PELTZER G, 1988, J GEOPHYS RES-SOLID, V93, P15085, DOI 10.1029/JB093iB12p15085; PELTZER G, 1989, SCIENCE, V246, P1285, DOI 10.1126/science.246.4935.1285; Peltzer G, 2001, GEOLOGY, V29, P975, DOI 10.1130/0091-7613(2001)029<0975:TSAAFI>2.0.CO;2; SAVAGE JC, 1973, J GEOPHYS RES, V78, P832, DOI 10.1029/JB078i005p00832; Searle MP, 1998, GEOL SOC SPEC PUBL, V135, P307, DOI 10.1144/GSL.SP.1998.135.01.20; Shen ZK, 2001, J GEOPHYS RES-SOL EA, V106, P30607, DOI 10.1029/2001JB000349; TAPPONNIER P, 1982, GEOLOGY, V10, P611, DOI 10.1130/0091-7613(1982)10<611:PETIAN>2.0.CO;2; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; Wang Q, 2001, SCIENCE, V294, P574, DOI 10.1126/science.1063647; Wright T, 2001, GEOPHYS RES LETT, V28, P2117, DOI 10.1029/2000GL012850; Wright TJ, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018014	32	234	273	6	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					236	239		10.1126/science.1096388	http://dx.doi.org/10.1126/science.1096388			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247476				2022-12-28	WOS:000222501000050
J	Freeman, C; Fenner, N; Ostle, NJ; Kang, H; Dowrick, DJ; Reynolds, B; Lock, MA; Sleep, D; Hughes, S; Hudson, J				Freeman, C; Fenner, N; Ostle, NJ; Kang, H; Dowrick, DJ; Reynolds, B; Lock, MA; Sleep, D; Hughes, S; Hudson, J			Export of dissolved organic carbon from peatlands under elevated carbon dioxide levels	NATURE			English	Article							TERRESTRIAL EXPORT; METHANE EMISSIONS; CLIMATE-CHANGE; BOREAL LAKES; CO2; DEPOSITION; GROWTH; MATTER; ENRICHMENT; ECOSYSTEMS	Peatlands represent a vast store of global carbon(1). Observations of rapidly rising dissolved organic carbon concentrations in rivers draining peatlands have created concerns that those stores are beginning to destabilize(2,3). Three main factors have been put forward as potential causal mechanisms, but it appears that two alternatives-warming(2,4) and increased river discharge(3)-cannot offer satisfactory explanations(5). Here we show that the third proposed mechanism, namely shifting trends in the proportion of annual rainfall arriving in summer(6), is similarly unable to account for the trend. Instead we infer that a previously unrecognized mechanism-carbon dioxide mediated stimulation of primary productivity-is responsible. Under elevated carbon dioxide levels, the proportion of dissolved organic carbon derived from recently assimilated carbon dioxide was ten times higher than that of the control cases. Concentrations of dissolved organic carbon appear far more sensitive to environmental drivers that affect net primary productivity than those affecting decomposition alone.	Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; Lancaster Environm Ctr, Ctr Ecol & Hydrol, Lancaster LA1 4AP, England; Ctr Ecol & Hydrol, Bangor LL57 2UP, Gwynedd, Wales; Ctr Ecol & Hydrol, Wallingford OX10 8BB, Oxon, England	Bangor University; Lancaster University; UK Centre for Ecology & Hydrology (UKCEH); UK Centre for Ecology & Hydrology (UKCEH); UK Centre for Ecology & Hydrology (UKCEH)	Freeman, C (corresponding author), Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales.	c.freeman@bangor.ac.uk	Ostle, Nick J/K-6891-2012; Kang, Hojeong/C-7208-2011; Reynolds, Brian/G-6292-2011; Ostle, Nicholas J/E-4847-2014; Hughes, Steven/G-3596-2011	Ostle, Nicholas J/0000-0003-3263-3702; 				AERTS R, 1992, J ECOL, V80, P131, DOI 10.2307/2261070; Berendse F, 2001, GLOBAL CHANGE BIOL, V7, P591, DOI 10.1046/j.1365-2486.2001.00433.x; DACEY JWH, 1994, NATURE, V370, P47, DOI 10.1038/370047a0; Evans CD, 2002, NATURE, V415, P862, DOI 10.1038/415862a; FORSBERG C, 1992, HYDROBIOLOGIA, V229, P51, DOI 10.1007/BF00006990; Freeman C, 2001, NATURE, V412, P785, DOI 10.1038/35090628; Freeman C, 2001, NATURE, V409, P149, DOI 10.1038/35051650; GORHAM E, 1991, ECOL APPL, V1, P182, DOI 10.2307/1941811; Houghton J. T., 2001, CLIMATE CHANGE 2001; Hudson JJ, 2003, HYDROL EARTH SYST SC, V7, P390, DOI 10.5194/hess-7-390-2003; HUTCHIN PR, 1995, GLOB CHANGE BIOL, V1, P125, DOI 10.1111/j.1365-2486.1995.tb00012.x; JENKINSON DS, 1991, NATURE, V351, P304, DOI 10.1038/351304a0; Jones TH, 1998, SCIENCE, V280, P441, DOI 10.1126/science.280.5362.441; Kuzyakov Y, 2002, J PLANT NUTR SOIL SC, V165, P382, DOI 10.1002/1522-2624(200208)165:4<382::AID-JPLN382>3.0.CO;2-#; Megonigal JP, 1997, BIOGEOCHEMISTRY, V37, P77, DOI 10.1023/A:1005738102545; Mitsch W. J., 1993, WETLANDS; Norby RJ, 2001, OECOLOGIA, V127, P153, DOI 10.1007/s004420000615; OECHEL WC, 1994, NATURE, V371, P500, DOI 10.1038/371500a0; Pastor J, 2003, OIKOS, V100, P380, DOI 10.1034/j.1600-0706.2003.11774.x; Schindler DW, 1997, BIOGEOCHEMISTRY, V36, P9, DOI 10.1023/A:1005792014547; Strom L, 2003, GLOBAL CHANGE BIOL, V9, P1185, DOI 10.1046/j.1365-2486.2003.00655.x; Tipping E, 1999, ENVIRON INT, V25, P83, DOI 10.1016/S0160-4120(98)00098-1; Tranvik LJ, 2002, NATURE, V415, P861, DOI 10.1038/415861b; Van der Heijden E, 2000, J BRYOL, V22, P175, DOI 10.1179/jbr.2000.22.3.175; Waddington JM, 1997, J HYDROL, V191, P122, DOI 10.1016/S0022-1694(96)03075-2; WETZEL RG, 1992, HYDROBIOLOGIA, V229, P181, DOI 10.1007/BF00007000; WOODIN S, 1992, NEW PHYTOL, V122, P635; Worrall F, 2003, BIOGEOCHEMISTRY, V64, P165, DOI 10.1023/A:1024924216148; ZANGERL AR, 1984, OECOLOGIA, V62, P412, DOI 10.1007/BF00384276; Ziska LH, 1998, GLOBAL CHANGE BIOL, V4, P657, DOI 10.1046/j.1365-2486.1998.00186.x	30	465	498	5	262	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					195	198		10.1038/nature02707	http://dx.doi.org/10.1038/nature02707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241411				2022-12-28	WOS:000222470600040
J	Asamoah-Odei, E; Calleja, JMG; Boerma, JT				Asamoah-Odei, E; Calleja, JMG; Boerma, JT			HIV prevalence and trends in sub-Saharan Africa: no decline and large subregional differences	LANCET			English	Article							POPULATION; WOMEN	Background Expansion of HIV surveillance systems in sub-Saharan Africa is leading to downward adjustments to the size of the AIDS epidemic. However, only analysis of surveillance data from the same populations over time can provide insight into trends of HIV prevalence. We have used data from the same antenatal clinics to document recent empirical trends. Methods We collated data from antenatal clinics on HIV prevalence between 1997 and 2003. Data were obtained from 140 000 pregnant women attending more than 300 antenatal clinics in 22 countries in sub-Saharan Africa. Additionally, long-term trend data are available for 57 urban areas and provinces. Findings Median HIV prevalence in 148 antenatal clinic sites in southern Africa increased from 21.3% (IQR 11.5-28.2%) in 1997/98 to 23.8% (15.6-29.2%) in 2002. At more than half the sites (58%) an increase of at least one-tenth was noted, but at a fifth of sites, prevalence dropped by at least one-tenth. In eastern Africa, median HIV prevalence decreased from 12.9% (7.0-16.9%) in 1997/98 to 8.5% (5.3-13.0%) in 2002, with prevalence rising in four (7%) sites, but falling at 25 (43%) sites. In west Africa, median HIV prevalence was 3.5% (2.2-5.9%) and 3.2% (2.3-6.1%) for 1997/98 and 2002, respectively, with reductions and increases in prevalence being noted in equal proportions. The long-term trends in urban areas in sub-Saharan Africa show a similar pattern, with increasing evidence of stabilisation during the past 2-3 years compared with the previous decade. Interpretation Evidence from surveillance of mostly urban antenatal clinic attendees indicates that the growth in the AIDS epidemic in sub-Saharan Africa has levelled off since the late 1990s but only eastern Africa shows a decline in HIV prevalence. Very large differences persist between subregions. Workers planning a response to the AIDS epidemic must take more careful consideration of these variations to allow locally appropriate responses to the epidemic.	WHO, HIV Dept, CH-1211 Geneva, Switzerland; WHO Reg Off Africa, Harare, Zimbabwe	World Health Organization	Boerma, JT (corresponding author), WHO, Dept Measurement & Hlth Informat Syst, 20 Ave Appia, CH-1211 Geneva, Switzerland.	boermat@who.int						Agresti A, 1990, CATEGORICAL DATA ANA, P100; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; Boerma JT, 2003, LANCET, V362, P1929, DOI 10.1016/S0140-6736(03)14967-7; *CEFORMI, 2002, ENQ NAT SER INF VIH; Cellule de Planification et de Statistique Ministere de la Sante Direction Nationale de la Statistique et de l'Informatique (DNSI) and ORC Macro, 2002, HIV TEST MAL FIND 20; [Central Bureau of Statistics Ministry of health ORC Macro], 2004, KEN DEM HLTH SURV 20; LOUBOUTINCROC JP, 2002, ENQUETE NATL SEROPRE; Mbulaiteye SM, 2002, LANCET, V360, P41, DOI 10.1016/S0140-6736(02)09331-5; *MIN HLTH, 2002, ENQ NAT SER VIH SIDA; *MIN HLTH CHILD WE, 2002, ZIMB YOUNG AD SURV 2; Pettifor Audrey, 2004, HIV SEXUAL BEHAV YOU; Shisana O., 2002, N MANDELA HSRC STUDY; UNAIDS, 2002, MON DECL COMM HIV AI; *UNAIDS WHO, 2003, EP UPD 2003; Walker N, 2003, AIDS, V17, P2215, DOI 10.1097/00002030-200310170-00010; *WHO REG OFF AFR, 2003, HIV AIDS EP SURV UPD; *WHO UNAIDS, 2001, GUID US HIV TEST TEC; Zaba B, 2000, AIDS, V14, P1633, DOI 10.1097/00002030-200007280-00020; Zaba B, 1998, AIDS, V12, pS41; [No title captured]	20	99	101	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					35	40		10.1016/S0140-6736(04)16587-2	http://dx.doi.org/10.1016/S0140-6736(04)16587-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234854				2022-12-28	WOS:000222392900029
J	Barouch, DH; Letvin, NL				Barouch, DH; Letvin, NL			HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines?	LANCET			English	Editorial Material							VIRAL ESCAPE; DISEASE PROGRESSION; RHESUS-MONKEYS; CELL RESPONSES; IN-VIVO; AIDS; TRANSMISSION; VACCINATION; PREVENTION; REVERSION		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Barouch, DH (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.	dbarouch@bidmc.harvard.edu	Barouch, Dan/Y-3918-2019					Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Amara RR, 2001, SCIENCE, V292, P69, DOI 10.1126/science.1058915; Barouch DH, 2003, J VIROL, V77, P7367, DOI 10.1128/JVI.77.13.7367-7375.2003; Barouch DH, 2000, SCIENCE, V290, P486, DOI 10.1126/science.290.5491.486; Barouch DH, 2002, NATURE, V415, P335, DOI 10.1038/415335a; Friedrich TC, 2004, NAT MED, V10, P275, DOI 10.1038/nm998; Geels MJ, 2003, J VIROL, V77, P12430, DOI 10.1128/JVI.77.23.12430-12440.2003; Goudsmit J, 1997, J VIROL, V71, P4479, DOI 10.1128/JVI.71.6.4479-4484.1997; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a; van Ballegooijen M, 2003, JAIDS-J ACQ IMM DEF, V34, P214, DOI 10.1097/00126334-200310010-00012	16	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					10	11		10.1016/S0140-6736(04)16609-9	http://dx.doi.org/10.1016/S0140-6736(04)16609-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234837				2022-12-28	WOS:000222392900008
J	Thuiller, W; Araujo, MB; Pearson, RG; Whittaker, RJ; Brotons, L; Lavorel, S				Thuiller, W; Araujo, MB; Pearson, RG; Whittaker, RJ; Brotons, L; Lavorel, S			Biodiversity conservation - Uncertainty in predictions of extinction risk	NATURE			English	Editorial Material									CNRS, Ctr Ecol Fonct & Evolut, F-34293 Montpellier 5, France; Natl Bot Res Inst, Kirstenbosh Res Ctr, Climate Change Res Grp, ZA-7735 Cape Town, South Africa; Univ Oxford, Sch Geog & Environm, Biodivers Res Grp, Oxford OX1 3RB, England; Univ Grenoble 1, CNR, Lab Ecol Alpine, F-38041 Grenoble 9, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; University of Oxford; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Savoie	Thuiller, W (corresponding author), CNRS, Ctr Ecol Fonct & Evolut, F-34293 Montpellier 5, France.	thuiller@nbi.ac.za	Brotons, Lluís/D-1570-2009; Thuiller, Wilfried/G-3283-2010; Araújo, Miguel B/B-6117-2008; Whittaker, Robert J/H-1548-2015	Brotons, Lluís/0000-0002-4826-4457; Thuiller, Wilfried/0000-0002-5388-5274; Araújo, Miguel B/0000-0002-5107-7265; Whittaker, Robert J/0000-0001-7775-3383				Brown J. H., 1998, BIOGEOGRAPHY; NAKICENOVIC N, 2000, EMISSIONS SCENARIOS, V3; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Thuiller W, 2003, GLOBAL CHANGE BIOL, V9, P1353, DOI 10.1046/j.1365-2486.2003.00666.x	4	175	177	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995								10.1038/nature02716	http://dx.doi.org/10.1038/nature02716			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15237465				2022-12-28	WOS:000222356800032
J	Jacob, A; Prasad, S; Boggild, M; Chandratre, S				Jacob, A; Prasad, S; Boggild, M; Chandratre, S			Lesson of the week - Charles Bonnet syndrome - elderly people and visual hallucinations	BMJ-BRITISH MEDICAL JOURNAL			English	Review							BONNET,CHARLES SYNDROME		Liver Unit, Dept Neurosci, Liverpool L9 7LJ, Merseyside, England; Calderdale Royal HOsp, Halifax, NS HX3 0PW, Canada; Walton Ctr Neurol & Neurosurg, Liverpool L9 7LJ, Merseyside, England	University of Liverpool; Walton Centre	Jacob, A (corresponding author), Liver Unit, Dept Neurosci, Liverpool L9 7LJ, Merseyside, England.	anujacob@liv.ac.uk						Burke W, 2002, J NEUROL NEUROSUR PS, V73, P535, DOI 10.1136/jnnp.73.5.535; DAMASMORA J, 1982, PSYCHOL MED, V12, P251, DOI 10.1017/S0033291700046584; Fernandez A, 1997, J NERV MENT DIS, V185, P195, DOI 10.1097/00005053-199703000-00009; GOLD K, 1989, COMPR PSYCHIAT, V30, P90, DOI 10.1016/0010-440X(89)90122-3; Hart J, 1997, Elder Care, V9, P30; Manford M, 1998, BRAIN, V121, P1819, DOI 10.1093/brain/121.10.1819; Menon GJ, 2003, SURV OPHTHALMOL, V48, P58, DOI 10.1016/S0039-6257(02)00414-9; NORTONWILLSON L, 1987, FAM PRACT, V4, P27, DOI 10.1093/fampra/4.1.27; OReilly R, 1996, CAN J PSYCHIAT, V41, P259; Pliskin NH, 1996, J AM GERIATR SOC, V44, P1055, DOI 10.1111/j.1532-5415.1996.tb02937.x; PODOLL K, 1989, FORTSCHR NEUROL PSYC, V57, P43, DOI 10.1055/s-2007-1000744; TEUNISSE RJ, 1995, BRIT J PSYCHIAT, V166, P254, DOI 10.1192/bjp.166.2.254; Teunisse RJ, 1996, LANCET, V347, P794, DOI 10.1016/S0140-6736(96)90869-7	13	36	37	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1552	1554		10.1136/bmj.328.7455.1552	http://dx.doi.org/10.1136/bmj.328.7455.1552			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217875	Green Published			2022-12-28	WOS:000222392700027
J	Dzenis, Y				Dzenis, Y			Spinning continuous fibers for nanotechnology	SCIENCE			English	Editorial Material							DIAMETER FIBERS; POLYMER FIBERS; NANOFIBERS; FABRICATION; JET; FIELD		Univ Nebraska, Dept Mech Engn, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Dzenis, Y (corresponding author), Univ Nebraska, Dept Mech Engn, Lincoln, NE 68588 USA.	ydzenis@unl.edu	ALHARBI, HAMAD F/F-8615-2010	ALHARBI, HAMAD F/0000-0002-1553-3956				Bognitzki M, 2001, ADV MATER, V13, P70, DOI 10.1002/1521-4095(200101)13:1<70::AID-ADMA70>3.0.CO;2-H; Choi SS, 2003, J MATER SCI LETT, V22, P891, DOI 10.1023/A:1024475022937; Dai HQ, 2002, NANOTECHNOLOGY, V13, P674, DOI 10.1088/0957-4484/13/5/327; Deitzel JM, 2001, POLYMER, V42, P8163, DOI 10.1016/S0032-3861(01)00336-6; Dersch R, 2003, J POLYM SCI POL CHEM, V41, P545, DOI 10.1002/pola.10609; Feng JJ, 2003, J NON-NEWTON FLUID, V116, P55, DOI 10.1016/S0377-0257(03)00173-3; Fong H, 1999, J POLYM SCI POL PHYS, V37, P3488, DOI 10.1002/(SICI)1099-0488(19991215)37:24<3488::AID-POLB9>3.0.CO;2-M; Huang L, 2000, MACROMOLECULES, V33, P2989, DOI 10.1021/ma991858f; Kameoka J, 2003, APPL PHYS LETT, V83, P371, DOI 10.1063/1.1592638; Koombhongse S, 2001, J POLYM SCI POL PHYS, V39, P2598, DOI 10.1002/polb.10015; Larsen G, 2003, J AM CHEM SOC, V125, P1154, DOI 10.1021/ja028983i; Li D, 2003, NANO LETT, V3, P1167, DOI 10.1021/nl0344256; Li D, 2004, NANO LETT, V4, P933, DOI 10.1021/nl049590f; Loscertales IG, 2004, J AM CHEM SOC, V126, P5376, DOI 10.1021/ja049443j; Megelski S, 2002, MACROMOLECULES, V35, P8456, DOI 10.1021/ma020444a; Reneker DH, 1996, NANOTECHNOLOGY, V7, P216, DOI 10.1088/0957-4484/7/3/009; Shin YM, 2001, APPL PHYS LETT, V78, P1149, DOI 10.1063/1.1345798; Spivak AF, 2000, MECH RES COMMUN, V27, P37, DOI 10.1016/S0093-6413(00)00060-4; Spivak AF, 1999, J APPL MECH-T ASME, V66, P1026, DOI 10.1115/1.2791775; Sun ZC, 2003, ADV MATER, V15, P1929, DOI 10.1002/adma.200305136; Theron A, 2001, NANOTECHNOLOGY, V12, P384, DOI 10.1088/0957-4484/12/3/329; Yarin AL, 2001, J APPL PHYS, V89, P3018, DOI 10.1063/1.1333035; Yarin AL, 2001, J APPL PHYS, V90, P4836, DOI 10.1063/1.1408260; Yarin AL, 2004, POLYMER, V45, P2977, DOI 10.1016/j.polymer.2004.02.066; Zhou YX, 2003, APPL PHYS LETT, V83, P3800, DOI 10.1063/1.1622108; 2004, WASHINGTON POST 0131	26	970	1006	7	223	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1917	1919		10.1126/science.1099074	http://dx.doi.org/10.1126/science.1099074			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218134	Green Published			2022-12-28	WOS:000222241600029
J	Deeks, JJ; Altman, DG				Deeks, JJ; Altman, DG			Statistics notes - Diagnostic tests 4: likelihood ratios	BRITISH MEDICAL JOURNAL			English	Article									Univ Sydney, Sch Publ Hlth, Screening & Test Avaluat Program, Sydney, NSW 2006, Australia; Inst Hlth Sci, Canc Res UK NHS Ctr Stat Med, Oxford OX3 7LF, England	University of Sydney; Cancer Research UK; University of Oxford	Deeks, JJ (corresponding author), Univ Sydney, Sch Publ Hlth, Screening & Test Avaluat Program, Sydney, NSW 2006, Australia.	Jon.Deeks@cancer.org.uk	Deeks, Jon/AAV-5745-2020	Deeks, Jon/0000-0002-8850-1971				ALTMAN DG, 1994, BRIT MED J, V308, P1552, DOI 10.1136/bmj.308.6943.1552; ALTMAN DG, 1994, BRIT MED J, V309, P102, DOI 10.1136/bmj.309.6947.102; Altman DG., 2000, STAT CONFIDENCE CONF; FAGAN TJ, 1975, NEW ENGL J MED, V293, P257; Jaeschke R, 2002, USERS GUIDES MED LIT, P121; Sackett D. L., 2000, EVIDENCE BASED MED P, P67; Straus SE, 2000, JAMA-J AM MED ASSOC, V283, P1853, DOI 10.1001/jama.283.14.1853	7	1009	1030	2	32	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					168	169		10.1136/bmj.329.7458.168	http://dx.doi.org/10.1136/bmj.329.7458.168			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15258077	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222832300031
J	Grigor, C; Capell, H; Stirling, A; McMahon, AD; Lock, P; Vallance, R; Kincaid, W; Porter, D				Grigor, C; Capell, H; Stirling, A; McMahon, AD; Lock, P; Vallance, R; Kincaid, W; Porter, D			Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial	LANCET			English	Article							RESPONSE CRITERIA; CLINICAL-TRIAL; METHOTREXATE; SULFASALAZINE; COMBINATION; LEFLUNOMIDE; ETANERCEPT; EFFICACY; THERAPY; SAFETY	Background Present treatment strategies for rheumatoid arthritis include use of disease-modifying antirheumatic drugs, but a minority of patients achieve a good response. We aimed to test the hypothesis that an improved outcome can be achieved by employing a strategy of intensive outpatient management of patients with rheumatoid arthritis-for sustained, tight control of disease activity-compared with routine outpatient care. Methods We designed a single-blind, randomised controlled trial in two teaching hospitals. We screened 183 patients for inclusion. 111 were randomly allocated either intensive management or routine care. Primary outcome measures were mean fall in disease activity score and proportion of patients with a good response (defined as a disease activity score <2.4 and a fall in this score from baseline by >1.2). Analysis was by intention-to-treat. Findings One patient withdrew after randomisation and seven dropped out during the study. Mean fall in disease activity score was greater in the intensive group than in the routine group (-3.5 vs -1.9, difference 1.6 [95% CI 1.1-2.1], p<0.0001). Compared with routine care, patients treated intensively were more likely to have a good response (definition, 45/55 [82%] vs 24/55 [44%], odds ratio 5.8 [95% CI 2.4-13.9], p<0.0001) or be in remission (disease activity score <1.6; 36/55 [65%] vs 9/55 [16%], 9.7 [3.9-23.9], p<0.0001). Three patients assigned routine care and one allocated intensive management died during the study; none was judged attributable to treatment. Interpretation A strategy of intensive outpatient management of rheumatoid arthritis substantially improves disease activity, radiographic disease progression, physical function, and quality of life at no additional cost.	Gartnavel Royal Hosp, Glasgow G12 0YN, Lanark, Scotland; Glasgow Royal Infirm, Ctr Rheumat Dis, Glasgow G4 0SF, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Dept Stat, Glasgow, Lanark, Scotland; Deloitte & Touche, Glasgow, Lanark, Scotland	Gartnavel Royal Hospital; University of Glasgow; University of Glasgow; Deloitte Touche Tohmatsu Limited	Porter, D (corresponding author), Gartnavel Royal Hosp, Glasgow G12 0YN, Lanark, Scotland.	duncan.porter@northglasgow.scot.nhs.uk		Porter, Duncan/0000-0001-8481-5204				Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; *DEP HLTH ENGL, 2001, NAT SCHED REF COSTS; Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308; HAAGSMA CJ, 1994, BRIT J RHEUMATOL, V33, P1049; Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082; Hurst NP, 1998, BRIT J RHEUMATOL, V37, P862; *INF STAT DIV SCOT, 2001, SCOTT HLTH SERV COST; Mehta DK, 2002, BRIT NATL FORMULARY; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; *NAT I CLIN EXC, 2002, GUID US ET INFL TREA, P7; NETTEN A, 2001, UNIT COST HLTH SOCIA; O'Dell JR, 2002, ARTHRITIS RHEUM, V46, P283, DOI 10.1002/art.10092; Plant MJ, 2000, ARTHRITIS RHEUM, V43, P1473, DOI 10.1002/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N; Prevoo MLL, 1996, BRIT J RHEUMATOL, V35, P1101; Smolen JS, 2000, RHEUMATOLOGY, V39, P48, DOI 10.1093/oxfordjournals.rheumatology.a031495; Smolen JS, 1999, LANCET, V353, P259, DOI 10.1016/S0140-6736(98)09403-3; van der Heijde D, 1999, J RHEUMATOL, V26, P743; vanGestel AM, 1996, ARTHRITIS RHEUM, V39, P34, DOI 10.1002/art.1780390105; Verhoeven AC, 2000, ANN RHEUM DIS, V59, P966, DOI 10.1136/ard.59.12.966	20	1086	1136	1	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					263	269		10.1016/S0140-6736(04)16676-2	http://dx.doi.org/10.1016/S0140-6736(04)16676-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262104				2022-12-28	WOS:000222784900029
J	Lanfranco, F; Kamischke, A; Zitzmann, M; Nieschlag, E				Lanfranco, F; Kamischke, A; Zitzmann, M; Nieschlag, E			Klinefelter's syndrome	LANCET			English	Review							INTRACYTOPLASMIC SPERM INJECTION; THAWED TESTICULAR SPERMATOZOA; SEX-CHROMOSOME ABNORMALITIES; CAG REPEAT POLYMORPHISM; ANDROGEN RECEPTOR GENE; CHRONIC HEART-FAILURE; INHIBIN-B LEVELS; X-CHROMOSOME; GERM-CELLS; PREDICTIVE FACTORS	Klinefelter's syndrome is the most common genetic cause of human male infertility, but many cases remain undiagnosed because of substantial variation in clinical presentation and insufficient professional awareness of the syndrome itself Early recognition and hormonal treatment of the disorder can substantially improve quality of life and prevent serious consequences. Testosterone replacement corrects symptoms of androgen deficiency but has no positive effect on infertility. However, nowadays patients with Klinefelter's syndrome, including the non-mosaic type, need no longer be considered irrevocably infertile, because intracytoplasmic sperm injection offers an opportunity for procreation even when there are no spermatozoa in the ejaculate. In a substantial number of azoospermic patients, spermatozoa can be extracted from testicular biopsy samples, and pregnancies and livebirths have been achieved. The frequency of sex chromosomal hyperploidy and autosomal aneuploidies is higher in spermatozoa from patients with Minefelter's syndrome than in those from normal men. Thus, chromosomal errors might in some cases be transmitted to the offspring of men with this syndrome. The genetic implications of the fertilisation procedures, including pretransfer or prenatal genetic assessment, must be explained to patients and their partners.	Univ Munster, Inst Reprod Med, D-48129 Munster, Germany	University of Munster	Nieschlag, E (corresponding author), Univ Munster, Inst Reprod Med, Domagkstr 11, D-48129 Munster, Germany.	nieschl@uni-muenster.de	Lanfranco, Fabio/AAE-5553-2019					Abramsky L, 1997, PRENATAL DIAG, V17, P363, DOI 10.1002/(SICI)1097-0223(199704)17:4<363::AID-PD79>3.0.CO;2-O; Anawalt BD, 1996, J CLIN ENDOCR METAB, V81, P3341, DOI 10.1210/jc.81.9.3341; Behre H.M., 2001, TESTOSTERONE ACTION, P405; BEHRE HM, 2000, ANDROLOGY MALE REPRO, P90; Bergere M, 2002, HUM REPROD, V17, P32, DOI 10.1093/humrep/17.1.32; Bernardini L, 1998, HUM REPROD, V13, P3406, DOI 10.1093/humrep/13.12.3406; Bojesen A, 2003, J CLIN ENDOCR METAB, V88, P622, DOI 10.1210/jc.2002-021491; Bourne H, 1997, HUM REPROD, V12, P2447, DOI 10.1093/humrep/12.11.2447; BREIT R, 1984, KLINEFELTERS SYNDROM, P71; Breuil V, 2001, JOINT BONE SPINE, V68, P26, DOI 10.1016/S1297-319X(00)00235-9; CAROTHERS AD, 1988, HUM GENET, V81, P71, DOI 10.1007/BF00283733; Chevret E, 1996, HUM GENET, V97, P171, DOI 10.1007/BF02265260; Christiansen P, 2003, J CLIN ENDOCR METAB, V88, P888, DOI 10.1210/jc.2002-021379; COZZI J, 1994, HUM GENET, V93, P32; Cruger D, 2001, HUM REPROD, V16, P1909, DOI 10.1093/humrep/16.9.1909; Damani MN, 2001, FERTIL STERIL, V76, P1054, DOI 10.1016/S0015-0282(01)02837-0; English KM, 2000, CIRCULATION, V102, P1906, DOI 10.1161/01.CIR.102.16.1906; Eskenazi B, 2002, HUM REPROD, V17, P576, DOI 10.1093/humrep/17.3.576; EVANS DB, 1987, CA-CANCER J CLIN, V37, P246, DOI 10.3322/canjclin.37.4.246; Ezeh UIO, 1999, HUM REPROD, V14, P1005, DOI 10.1093/humrep/14.4.1005; FERGUSONSMITH MA, 1959, LANCET, V1, P219; FILIPPI G, 1986, CLIN GENET, V30, P276; Foresta C, 1999, J CLIN ENDOCR METAB, V84, P3807, DOI 10.1210/jc.84.10.3807; Foresta C, 1998, J CLIN ENDOCR METAB, V83, P203, DOI 10.1210/jc.83.1.203; FORSSMAN H, 1970, BRIT J PSYCHIAT, V117, P353, DOI 10.1192/bjp.117.539.353; Friedler S, 2001, HUM REPROD, V16, P2616, DOI 10.1093/humrep/16.12.2616; Geschwind DH, 2000, MENT RETARD DEV D R, V6, P107, DOI 10.1002/1098-2779(2000)6:2<107::AID-MRDD4>3.0.CO;2-2; GORDON DL, 1972, ARCH INTERN MED, V130, P726, DOI 10.1001/archinte.130.5.726; Gotz MJ, 1999, PSYCHOL MED, V29, P953, DOI 10.1017/S0033291799008594; Greco E, 2001, FERTIL STERIL, V76, P1068, DOI 10.1016/S0015-0282(01)02734-0; GRIFFIN DK, 1995, HUM MOL GENET, V4, P2227, DOI 10.1093/hmg/4.12.2227; GRIFFIN JE, 2002, WILLIAMS TXB ENDOCRI, P709; GUICHAOUA MR, 1993, CONTRACEPT FERTIL S, V21, P113; Guttenbach M, 2000, BIOL REPROD, V63, P1727, DOI 10.1095/biolreprod63.6.1727; Hall S., 2001, Community Genet, V4, P233, DOI 10.1159/000064198; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; HASLE H, 1992, EUR J PEDIATR, V151, P735, DOI 10.1007/BF01959079; Hennebicq S, 2001, LANCET, V357, P2104, DOI 10.1016/S0140-6736(00)05201-6; Hickey T, 2002, J CLIN ENDOCR METAB, V87, P161, DOI 10.1210/jc.87.1.161; Hinney B, 1997, FERTIL STERIL, V68, P718, DOI 10.1016/S0015-0282(97)00280-X; Hiort O, 2000, J CLIN ENDOCR METAB, V85, P2810, DOI 10.1210/jc.85.8.2810; HOLMESSIEDLE M, 1987, PRENATAL DIAG, V7, P239, DOI 10.1002/pd.1970070403; Hunt PA, 1998, MOL REPROD DEV, V49, P101, DOI 10.1002/(SICI)1098-2795(199802)49:2&lt;101::AID-MRD1&gt;3.0.CO;2-T; Igawa K, 2003, J EUR ACAD DERMATOL, V17, P62, DOI 10.1046/j.1468-3083.2003.t01-1-00511.x; Iitsuka Y, 2001, AM J MED GENET, V98, P25, DOI 10.1002/1096-8628(20010101)98:1<25::AID-AJMG1015>3.3.CO;2-O; JACOBS PA, 1959, NATURE, V183, P302, DOI 10.1038/183302a0; Kahraman S, 2003, Reprod Biomed Online, V7, P346; Kamischke A, 2004, J ANDROL, V25, P586; Kamischke A, 2003, J ANDROL, V24, P41; KAPLAN H, 1963, LANCET, V1, P506; Keung YK, 2002, CANCER GENET CYTOGEN, V139, P9, DOI 10.1016/S0165-4608(02)00626-X; Khalifa MM, 2002, CLIN GENET, V61, P49, DOI 10.1034/j.1399-0004.2001.610110.x; Kitamura M, 2000, INT J UROL, V7, P94, DOI 10.1046/j.1442-2042.2000.00145c.x; Klinefelter HF, 1942, J CLIN ENDOCRINOL, V2, P615, DOI 10.1210/jcem-2-11-615; Klingmuller D, 1997, HUM REPROD, V12, P2376, DOI 10.1093/humrep/12.11.2376; Lapecorella M, 2003, BLOOD COAGUL FIBRIN, V14, P95, DOI 10.1097/00001721-200301000-00017; LARON Z, 1982, ARCH ANDROLOGY, V8, P149, DOI 10.3109/01485018208987032; Levron J, 2000, FERTIL STERIL, V74, P925, DOI 10.1016/S0015-0282(00)01556-9; Lue YH, 2001, ENDOCRINOLOGY, V142, P1461, DOI 10.1210/en.142.4.1461; Luetjens CM, 2002, HUM REPROD, V17, P1826, DOI 10.1093/humrep/17.7.1826; Madgar I, 2002, FERTIL STERIL, V77, P1167, DOI 10.1016/S0015-0282(02)03092-3; MALKIN CJ, IN PRESS HEART; Marteau TM, 2002, PRENATAL DIAG, V22, P562, DOI 10.1002/pd.374; MATSUMOTO AM, 1994, ENDOCRIN METAB CLIN, V23, P857, DOI 10.1016/S0889-8529(18)30072-0; McLachlan RI, 2002, J CLIN ENDOCR METAB, V87, P546, DOI 10.1210/jc.87.2.546; Meschede D, 1998, AM J MED GENET, V80, P330, DOI 10.1002/(SICI)1096-8628(19981204)80:4<330::AID-AJMG6>3.0.CO;2-7; Meschede D, 1997, HUM REPROD, V12, P1125; Montag M, 1999, ANDROLOGIA, V31, P49, DOI 10.1046/j.1439-0272.1999.00236.x; Morel F, 2003, FERTIL STERIL, V79, P1644, DOI 10.1016/S0015-0282(03)00343-1; Mroz K, 1999, HUM REPROD, V14, P1151, DOI 10.1093/humrep/14.5.1151; MUNNE S, 1995, FERTIL STERIL, V64, P382, DOI 10.1016/S0015-0282(16)57739-5; NIELSEN J, 1991, HUM GENET, V87, P81, DOI 10.1007/BF01213097; NIELSEN J, 1988, CLIN GENET, V33, P262; Nieschalag E., 2000, ANDROLOGY MALE REPRO, P143; Nieschlag E, 2004, TESTOSTERONE ACTION, P375; Nodar F, 1999, FERTIL STERIL, V71, P1149, DOI 10.1016/S0015-0282(99)00151-X; Ota K, 2002, INTERNAL MED, V41, P842, DOI 10.2169/internalmedicine.41.842; Palermo GD, 1998, NEW ENGL J MED, V338, P588, DOI 10.1056/NEJM199802263380905; Palermo GD, 1999, HUM REPROD, V14, P741, DOI 10.1093/humrep/14.3.741; Perwein E, 1984, KLINEFELTERS SYNDROM, P8; Pfeffer J, 1999, FERTIL STERIL, V72, P472, DOI 10.1016/S0015-0282(99)00279-4; PHILIP J, 1976, AM J HUM GENET, V28, P404; PLATTEAU P, 2003, P 11 R DEGR S OCT 9; Poulakis V, 2001, FERTIL STERIL, V76, P1060, DOI 10.1016/S0015-0282(01)02830-8; Pugh PJ, 2004, HEART, V90, P446, DOI 10.1136/hrt.2003.014639; Pugh PJ, 2003, EUR HEART J, V24, P909, DOI 10.1016/S0195-668X(03)00083-6; RAJENDRA BR, 1981, AM J MED GENET, V10, P119, DOI 10.1002/ajmg.1320100205; Ratcliffe S, 1999, ARCH DIS CHILD, V80, P192, DOI 10.1136/adc.80.2.192; Ratcliffe S G, 1986, Birth Defects Orig Artic Ser, V22, P73; Reubinoff BE, 1998, HUM REPROD, V13, P1887, DOI 10.1093/humrep/13.7.1887; Ron-El R, 2000, FERTIL STERIL, V74, P832, DOI 10.1016/S0015-0282(00)00710-X; Ron-El R, 1999, HUM REPROD, V14, P368, DOI 10.1093/humrep/14.2.368; Ron-El R, 2000, HUM REPROD, V15, P1804, DOI 10.1093/humrep/15.8.1804; Rosenlund B, 2002, J ASSIST REPROD GEN, V19, P149, DOI 10.1023/A:1014792922874; SALBENBLATT JA, 1985, PEDIATR RES, V19, P82, DOI 10.1203/00006450-198501000-00022; SANTEN RJ, 1995, ENDOCRINOL METAB, P885; Simpson JL, 2003, GENET MED, V5, P460, DOI 10.1097/01.GIM.0000095626.54201.D0; SKAKKEBAEK NF, 1969, LANCET, V2, P1075; SNIFFEN RC, 1951, AMA ARCH PATHOL, V51, P293; Staessen C, 1996, HUM REPROD, V11, P1650; Staessen C, 2003, HUM REPROD UPDATE, V9, P319, DOI 10.1093/humupd/dmg029; Swerdlow AJ, 2001, ANN HUM GENET, V65, P177, DOI 10.1017/S0003480001008569; Tachdjian G, 2003, HUM REPROD, V18, P271, DOI 10.1093/humrep/deg070; TANNENBAUM H L, 1986, American Journal of Human Genetics, V39, pA183; Temple CA, 2003, NEUROPSYCHOLOGIA, V41, P1547, DOI 10.1016/S0028-3932(03)00061-7; TERZOLI G, 1992, FERTIL STERIL, V58, P821; Thomas NS, 2000, EUR J HUM GENET, V8, P805, DOI 10.1038/sj.ejhg.5200531; Thomas NS, 2003, HUM REPROD UPDATE, V9, P309, DOI 10.1093/humupd/dmg028; Tournaye H, 1997, HUM REPROD, V12, P80, DOI 10.1093/humrep/12.1.80; Tournaye H, 1996, HUM REPROD, V11, P1644; Tournaye H, 1997, INT J ANDROL, V20, P69; Ulug U, 2003, FERTIL STERIL, V80, P903, DOI 10.1016/S0015-0282(03)01157-9; van den Bergh JPW, 2001, OSTEOPOROSIS INT, V12, P55, DOI 10.1007/s001980170158; VARRELA J, 1984, AM J PHYS ANTHROPOL, V64, P233, DOI 10.1002/ajpa.1330640305; Vernaeve V, 2004, HUM REPROD, V19, P1135, DOI 10.1093/humrep/deh253; Visootsak J, 2001, CLIN PEDIATR, V40, P639, DOI 10.1177/000992280104001201; Von Eckardstein S, 2002, J ANDROL, V23, P419; WARBURG E, 1963, ACTA ENDOCRINOL-COP, V43, P12, DOI 10.1530/acta.0.0430012; Westlander G, 2001, FERTIL STERIL, V75, P1102, DOI 10.1016/S0015-0282(01)01793-9; Winkler UH, 1996, MATURITAS, V24, P147, DOI 10.1016/S0378-5122(96)82004-4; WITKIN HA, 1976, SCIENCE, V193, P547, DOI 10.1126/science.959813; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th; Yamamoto Y, 2002, HUM REPROD, V17, P886, DOI 10.1093/humrep/17.4.886; ZAKI H, 2000, HUM REPROD, V15, P216; Zang KD, 1984, KLINEFELTERS SYNDROM, P12; Zitzmann M, 2003, INT J ANDROL, V26, P76, DOI 10.1046/j.1365-2605.2003.00393.x; Zitzmann M, 2002, J CLIN ENDOCR METAB, V87, P5030, DOI 10.1210/jc.2002-020504; Zitzmann M, 2002, BONE, V31, P422, DOI 10.1016/S8756-3282(02)00831-1; Zitzmann M, 2002, J ANDROL, V23, P503; Zitzmann M, 2004, TESTOSTERONE ACTION, P233; ZITZMANN M, 2004, 86 END SOC M NEW ORL; Zollner TM, 1997, BRIT J DERMATOL, V136, P341, DOI 10.1046/j.1365-2133.1997.5601515.x	132	582	621	1	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					273	283		10.1016/S0140-6736(04)16678-6	http://dx.doi.org/10.1016/S0140-6736(04)16678-6			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262106				2022-12-28	WOS:000222784900031
J	Barratt, CLR; St John, JC; Afnan, M				Barratt, CLR; St John, JC; Afnan, M			Clinical challenges in providing embryos for stem-cell initiatives	LANCET			English	Editorial Material							GENE-EXPRESSION; LINES; DONATION		Birmingham Womens Hosp, Assisted Concept Unit, Birmingham B15 2TG, W Midlands, England; Univ Birmingham, Sch Med, Div Med Sci, Mitochondrial & Reprod Biol Grp, Birmingham, W Midlands, England	Birmingham Women's Hospital; University of Birmingham	Barratt, CLR (corresponding author), Birmingham Womens Hosp, Assisted Concept Unit, Birmingham B15 2TG, W Midlands, England.	c.l.barratt@bham.ac.uk	St. John, Justin C/A-2942-2010	Barratt, christopher/0000-0003-0062-9979; St. John, Jus/0000-0002-3993-1449				Abe Y, 2003, J NEUROSCI, V23, P8513; Bjuresten K, 2003, HUM REPROD, V18, P1353, DOI 10.1093/humrep/deg265; *CDC, 2001, ASS REPR TECHN SUCC; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; DEAN WL, 2002, METH MOL B, V181, P1; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Elford K, 2004, FERTIL STERIL, V81, P1154, DOI 10.1016/j.fertnstert.2003.08.048; Gardner DK, 2003, CLIN OBSTET GYNECOL, V46, P231, DOI 10.1097/00003081-200306000-00005; Hoffman DI, 2003, FERTIL STERIL, V79, P1063, DOI 10.1016/S0015-0282(03)00172-9; Hovatta O, 2003, HUM REPROD, V18, P1404, DOI 10.1093/humrep/deg290; *HUM FERT EMBR AUT, PAT GUID IN VITR FER; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Inzunza J, 2004, MOL HUM REPROD, V10, P461, DOI 10.1093/molehr/gah051; Maher ER, 2003, J MED GENET, V40, P62, DOI 10.1136/jmg.40.1.62; McMahon CA, 2003, HUM REPROD, V18, P871, DOI 10.1093/humrep/deg167; *NAT I CLIN EXC, FERT ASS TREATM PEOP; Neuber E, 2003, HUM REPROD, V18, P1307, DOI 10.1093/humrep/deg269; Park SP, 2004, HUM REPROD, V19, P676, DOI 10.1093/humrep/deh102; Pickering Susan J, 2003, Reprod Biomed Online, V7, P353; Reik W, 2003, NATURE, V423, P390, DOI 10.1038/423390a; Simerly C, 2003, SCIENCE, V300, P297, DOI 10.1126/science.1082091; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564	24	17	17	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					115	118		10.1016/S0140-6736(04)16649-X	http://dx.doi.org/10.1016/S0140-6736(04)16649-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246710				2022-12-28	WOS:000222612200003
J	Shapiro, NM; Ritzwoller, MH; Molnar, P; Levin, V				Shapiro, NM; Ritzwoller, MH; Molnar, P; Levin, V			Thinning and flow of Tibetan crust constrained by seismic anisotropy	SCIENCE			English	Article							SOUTHERN TIBET; VELOCITY STRUCTURE; ACTIVE TECTONICS; WAVE TOMOGRAPHY; PLATEAU; DEFORMATION; BENEATH; SHEAR; DISPERSION; EXTRUSION	Intermediate-period Rayleigh and Love waves propagating across Tibet indicate marked radial anisotropy within the middle-to-lower crust, consistent with a thinning of the middle crust by about 30%. The anisotropy is largest in the western part of the plateau, where moment tensors of earthquakes indicate active crustal thinning. The preferred orientation of mica crystals resulting from the crustal thinning can account for the observed anisotropy. The middle-to-lower crust of Tibet appears to have thinned more than the upper crust, consistent with deformation of a mechanically weak layer that flows as if confined to a channel.	Univ Colorado, Dept Phys, Ctr Imaging Earths Interior, Boulder, CO 80309 USA; Univ Colorado, Cooperat Inst Res Environm Sci, Dept Geol Sci, Boulder, CO 80309 USA; Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Rutgers State University New Brunswick	Shapiro, NM (corresponding author), Univ Colorado, Dept Phys, Ctr Imaging Earths Interior, Boulder, CO 80309 USA.	nshapiro@ciei.colorado.edu	Shapiro, Nikolai M/G-1049-2010	Shapiro, Nikolai M/0000-0002-0144-723X				ALEKSANDROV KS, 1961, IZV ACAD SCI USSR G, V12, P186; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; BARAZANGI M, 1982, GEOLOGY, V10, P179, DOI 10.1130/0091-7613(1982)10<179:VAPCOP>2.0.CO;2; Beaumont C, 2001, NATURE, V414, P738, DOI 10.1038/414738a; BIRD P, 1991, J GEOPHYS RES-SOLID, V96, P10275, DOI 10.1029/91JB00370; CHEN WP, 1981, J GEOPHYS RES, V86, P5937, DOI 10.1029/JB086iB07p05937; Clark MK, 2000, GEOLOGY, V28, P703, DOI 10.1130/0091-7613(2000)28<703:TOBTEM>2.0.CO;2; Cotte N, 1999, GEOPHYS J INT, V138, P809, DOI 10.1046/j.1365-246x.1999.00927.x; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; ENGLAND P, 1986, J GEOPHYS RES-SOLID, V91, P3664, DOI 10.1029/JB091iB03p03664; ENGLAND P, 1989, J GEOPHYS RES-SOLID, V94, P17561, DOI 10.1029/JB094iB12p17561; England P, 1997, SCIENCE, V278, P647, DOI 10.1126/science.278.5338.647; Flesch LM, 2001, J GEOPHYS RES-SOL EA, V106, P16435, DOI 10.1029/2001JB000208; Friederich W, 2003, GEOPHYS J INT, V153, P88, DOI 10.1046/j.1365-246X.2003.01869.x; Huang ZX, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB001696; Kincaid C, 1996, EARTH PLANET SC LETT, V142, P271, DOI 10.1016/0012-821X(96)00116-1; Makovsky Y, 1999, J GEOPHYS RES-SOL EA, V104, P10795, DOI 10.1029/1998JB900074; Meltzer A, 2001, GEOPHYS RES LETT, V28, P2129, DOI 10.1029/2000GL012262; MOLNAR P, 1978, J GEOPHYS RES, V83, P5361, DOI 10.1029/JB083iB11p05361; MOLNAR P, 1989, GEOPHYS J INT, V99, P123, DOI 10.1111/j.1365-246X.1989.tb02020.x; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; Nishizawa O, 2001, GEOPHYS J INT, V145, P19, DOI 10.1111/j.1365-246X.2001.00331.x; Rapine R, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2001JB000445; Ritzwoller MH, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2002JB001777; Ritzwoller MH, 1998, J GEOPHYS RES-SOL EA, V103, P4839, DOI 10.1029/97JB02622; ROECKER S, 1999, EOS S, V80, pF1017; Royden LH, 1997, SCIENCE, V276, P788, DOI 10.1126/science.276.5313.788; Shapiro NM, 2002, GEOPHYS J INT, V151, P88, DOI 10.1046/j.1365-246X.2002.01742.x; SHAPIRO NM, 2003, EOS S, V84, pF985; SHEEHAN AF, 2002, EOS S, V80, pF994; Sherrington HF, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2002JB002345; TRAMPERT J, 1995, GEOPHYS J INT, V122, P675, DOI 10.1111/j.1365-246X.1995.tb07019.x; Weiss T, 1999, PURE APPL GEOPHYS, V156, P97, DOI 10.1007/s000240050291	34	260	281	5	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					233	236		10.1126/science.1098276	http://dx.doi.org/10.1126/science.1098276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247475	Green Submitted			2022-12-28	WOS:000222501000049
J	Lukehart, SA; Godornes, C; Molini, BJ; Sonnett, P; Hopkins, S; Mulcahy, F; Engelman, J; Mitchell, SJ; Rompalo, AM; Marra, CM; Klausner, JD				Lukehart, SA; Godornes, C; Molini, BJ; Sonnett, P; Hopkins, S; Mulcahy, F; Engelman, J; Mitchell, SJ; Rompalo, AM; Marra, CM; Klausner, JD			Macrolide resistance in Treponema pallidum in the United States and Ireland	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY SYPHILIS; CLINICAL ISOLATE; PENICILLIN-G; AZITHROMYCIN; BENZATHINE; RESURGENCE; OUTBREAK		Univ Washington, Harborview Med Ctr, Dept Med, Seattle, WA 98104 USA; Univ Washington, Dept Neurol, Seattle, WA 98104 USA; St James Hosp, Dublin 8, Ireland; San Francisco Dept Hlth, San Francisco, CA USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA	Harborview Medical Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Trinity College Dublin; Centers for Disease Control & Prevention - USA; Johns Hopkins University	Lukehart, SA (corresponding author), Univ Washington, Harborview Med Ctr, Dept Med, Box 359779,325 9th Ave, Seattle, WA 98104 USA.	lukehart@washington.edu	Hopkins, Susan/C-9736-2011	Hopkins, Susan/0000-0001-5179-5702	NIAID NIH HHS [AI 34616, AI 42143, AI 45724] Funding Source: Medline; NINDS NIH HHS [NS 38663, NS 34235] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI034616, R01AI045724, R01AI042143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034235, R01NS038663] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		[Anonymous], 2002, MMWR Recomm Rep, V51, P1; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P971; Ashton M, 2003, SEX TRANSM INFECT, V79, P291, DOI 10.1136/sti.79.4.291; Chen JL, 2002, SEX TRANSM DIS, V29, P277, DOI 10.1097/00007435-200205000-00005; Fenton KA, 2001, SEX TRANSM INFECT, V77, P309, DOI 10.1136/sti.77.5.309; Gruber F, 2000, J CHEMOTHERAPY, V12, P240, DOI 10.1179/joc.2000.12.3.240; Hiltunen-Back E, 2002, SEX TRANSM DIS, V29, P746, DOI 10.1097/00007435-200212000-00002; Hook EW, 1999, ANN INTERN MED, V131, P434, DOI 10.7326/0003-4819-131-6-199909210-00007; Hook EW, 2002, SEX TRANSM DIS, V29, P486, DOI 10.1097/00007435-200208000-00010; Hopkins S, 2004, SEX TRANSM DIS, V31, P317, DOI 10.1097/01.OLQ.0000123653.84940.59; LUKEHART SA, 1990, J ANTIMICROB CHEMOTH, V25, P91, DOI 10.1093/jac/25.suppl_A.91; Mashkilleyson AL, 1996, INT J STD AIDS, V7, P13, DOI 10.1258/0956462961917249; Rekart ML, 2003, LANCET, V361, P313, DOI 10.1016/S0140-6736(03)12335-5; *SAN FRANC DEP PUB, 2003, STOPP SYPH GAY BIS M; SCHROETER AL, 1972, J AMER MED ASSOC, V221, P471, DOI 10.1001/jama.221.5.471; STAMM LV, 1988, ANTIMICROB AGENTS CH, V32, P164, DOI 10.1128/AAC.32.2.164; STAMM LV, 1990, J ANTIMICROB CHEMOTH, V25, P11, DOI 10.1093/jac/25.suppl_A.11; Stamm LV, 2000, ANTIMICROB AGENTS CH, V44, P806, DOI 10.1128/AAC.44.3.806-807.2000; STAPLETON JT, 1985, REV INFECT DIS, V7, pS314; VERDON MS, 1994, CLIN INFECT DIS, V19, P486, DOI 10.1093/clinids/19.3.486; 2001, MMWR MORB MORTAL WKL, V50, P117; 1999, MMWR MORB MORTAL WKL, V48, P773; 2004, MMWR MORB MORTAL WKL, V53, P197; 2002, MMWR MORB MORTAL WKL, V51, P853	24	230	247	0	19	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					154	158		10.1056/NEJMoa040216	http://dx.doi.org/10.1056/NEJMoa040216			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247355	Bronze			2022-12-28	WOS:000222470700008
J	Gibot, S; Kolopp-Sarda, MN; Bene, MC; Cravoisy, A; Levy, B; Faure, GC; Bollaert, PE				Gibot, S; Kolopp-Sarda, MN; Bene, MC; Cravoisy, A; Levy, B; Faure, GC; Bollaert, PE			Plasma level of a triggering receptor expressed on myeloid cells-1: Its diagnostic accuracy in patients with suspected sepsis	ANNALS OF INTERNAL MEDICINE			English	Article							PROCALCITONIN CONCENTRATIONS; ORGAN FAILURE; TREM-1; BACTEREMIA; MARKER; SCORE; SIRS	Background: Previous experimental studies have suggested that the triggering receptor expressed on myeloid cells-1 (TREM-1) is specifically upregulated in the presence of microbial products. Objective: To evaluate the diagnostic value of plasma levels of the soluble form of TREM-1 in patients admitted with clinical suspicion of infection. Design: Prospective, noninterventional study conducted between July and September 2003. Setting: Medical adult intensive care unit at a university hospital in France. Participants: 76 consecutive newly admitted patients who presented with clinically suspected infection and fulfilled at least 2 criteria of the systemic inflammatory response syndrome. Measurements: Sensitivity and specificity of plasma soluble TREM-1 levels at admission for the diagnosis of infection. Two independent intensivists blinded to the results of soluble TREM-1 assays retrospectively classified patients as having the systemic inflammatory response syndrome, sepsis, severe sepsis, or septic shock. Results: The systemic inflammatory response syndrome was diagnosed in 29 patients (38%), and sepsis, severe sepsis, or septic shock was diagnosed in the remaining 47 (62%). A plasma soluble TREM-1 level higher than 60 ng/mL was more accurate than any other clinical or laboratory finding for indicating infection (sensitivity, 96% [95% Cl, 92% to 100%]; specificity, 89% [Cl, 82% to 95%]; positive likelihood ratio, 8.6 [Cl, 3.8 to 21.5]; negative likelihood ratio, 0.04 [Cl, 0.01 to 0.2]). Limitations: The study did not enroll patients with mild infections not requiring intensive care unit hospitalization, patients older than 80 years of age, or patients who were immunocompromised. Conclusion: in newly admitted critically ill patients, measurement of plasma levels of soluble TREM-1 could help to rapidly identify those with infection.	Hop Cent, Serv Reanimat Med, F-54035 Nancy, France; Fac Med Vandoeuvre Nancy, F-54505 Vandoeuvre Les Nancy, France	CHU de Nancy; Universite de Lorraine	Gibot, S (corresponding author), Hop Cent, Serv Reanimat Med, 29 Ave Marechal de Lattre de Tassigny, F-54035 Nancy, France.							ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; BATES DW, 1990, ANN INTERN MED, V113, P495, DOI 10.7326/0003-4819-113-7-495; Birmingham MC, 1997, PHARMACOECONOMICS, V12, P637, DOI 10.2165/00019053-199712060-00004; Bleharski JR, 2003, J IMMUNOL, V170, P3812, DOI 10.4049/jimmunol.170.7.3812; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Boucher BA, 1999, CRIT CARE MED, V27, P1390, DOI 10.1097/00003246-199907000-00041; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Brun-Buisson C, 2000, INTENS CARE MED, V26, pS64, DOI 10.1007/s001340051121; Brunkhorst FM, 2000, INTENS CARE MED, V26, pS148, DOI 10.1007/BF02900728; Cohen J, 2001, LANCET, V358, P776, DOI 10.1016/S0140-6736(01)06007-X; Colonna M, 2003, NAT REV IMMUNOL, V3, P445, DOI 10.1038/nri1106; Fischer JE, 2003, INTENS CARE MED, V29, P1043, DOI 10.1007/s00134-003-1761-8; Gibot S, 2004, NEW ENGL J MED, V350, P451, DOI 10.1056/NEJMoa031544; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Lapillonne A, 1998, LANCET, V351, P1211, DOI 10.1016/S0140-6736(05)79165-0; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Nathan C, 2001, NAT MED, V7, P530, DOI 10.1038/87846; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Reinhart K, 2001, ADV SEPSIS, V1, P42; Ruokonen E, 1999, EUR J CLIN MICROBIOL, V18, P283, DOI 10.1007/s100960050277; Ugarte H, 1999, CRIT CARE MED, V27, P498, DOI 10.1097/00003246-199903000-00024; Vincent JL, 2000, CRIT CARE MED, V28, P1226, DOI 10.1097/00003246-200004000-00057; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/s001340050156	25	271	329	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					9	15		10.7326/0003-4819-141-1-200407060-00009	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238365				2022-12-28	WOS:000222427600002
J	Romano, A; Gueant-Rodriguez, RM; Viola, M; Pettinato, R; Gueant, JL				Romano, A; Gueant-Rodriguez, RM; Viola, M; Pettinato, R; Gueant, JL			Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins	ANNALS OF INTERNAL MEDICINE			English	Article							BETA-LACTAM ANTIBIOTICS; ALLERGIC REACTIONS; SERUM IGE; SKIN; HISTORY; CEFTRIAXONE; AMOXICILLIN; EXPERIENCE; CHALLENGE; DIAGNOSIS	Background: In patients with documented IgE-mediated hypersensitivity to penicillins, data on sensitization to cephalosporins vary. Administering cephalosporins to such patients is often deferred because of the risk for cross-reactivity. Objective: To assess the cross-reactivity with cephalosporins and its potential determinants in patients with documented penicillin allergy. Design: Prospective study in patients without clinical indications for cephalosporin treatment. Setting: Italy. Patients: 128 consecutive patients who sustained anaphylactic shock (n = 81) or urticaria (n = 47) and had positive results on skin tests for at least 1 of the penicillin reagents tested. Measurements: All patients were skin tested with cephalothin, cefamandole, cefuroxime, ceftazidime, ceftriaxone, and cefotaxime. Patients with negative results for the last 4 cephalosporins were challenged with cefuroxime axetil and ceftriaxone. Results: 14 patients (10.9% [95% Cl, 6.1% 17.7%]) had positive results on skin tests for cephalosporins, mostly for cephalothin or cefamandole. Skin test results for the minor determinant mixture were positive in 10 of 14 patients (71.4%) with cross-reactivity and 44 of 114 patients (38.6%) without cross-reactivity (odds ratio, 3.90 [Cl, 1.17 to 13.40]; P = 0.0189). All 101 patients with negative results on skin tests for cefuroxime, ceftazidime, ceftriaxone, and cefotaxime tolerated cefuroxime axetil and ceftriaxone (tolerability rate, 100% [Cl, 96.4% to 100%]). Limitations: Challenges were not followed by full therapeutic courses. Twenty-two patients declined challenges; positive responses in those patients would have decreased the tolerability rate to 82.1% (Cl, 74.2% to 88.4%). Conclusions: These data confirm the advisability of avoiding cephalosporin treatment in patients with positive results on skin tests for penicillin. In patients who especially require cephalosporin treatment, we recommend skin tests with cephalosporins before assessing the tolerability of the cephalosporin with a graded challenge.	Univ Cattolica Sacro Cuore, Unita Allergol, I-00168 Rome, Italy; Ist Ricovero & Cura Carattere Sci, Troina, Italy; INSERM, Lab Pathol Cellulaire & Mol Nutr, F-54511 Vandoeuvre Les Nancy, France; CHU Nancy Brabois, Vandoeuvre Les Nancy, France	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Nancy	Romano, A (corresponding author), Univ Cattolica Sacro Cuore, Unita Allergol, Complesso Integrato Columbus,Via G Moscati,31, I-00168 Rome, Italy.	columbus.romano@linet.it	Pettinato, Rosa/D-3358-2017; Romano, Antonino/D-3102-2017	Pettinato, Rosa/0000-0002-2120-3152; Romano, Antonino/0000-0001-9742-9898				ADKINSON NF, 1971, NEW ENGL J MED, V285, P22, DOI 10.1056/NEJM197107012850104; ANNE S, 1995, ANN ALLERG ASTHMA IM, V74, P167; ASSEM ESK, 1974, IMMUNOLOGY, V27, P255; AUDICANA M, 1994, ALLERGY, V49, P108, DOI 10.1111/j.1398-9995.1994.tb00809.x; Baldo BA, 1999, CLIN EXP ALLERGY, V29, P744; Bernstein IL, 1999, ANN ALLERG ASTHMA IM, V83, pVIII; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; Blanca M, 2002, CLIN EXP ALLERGY, V32, P192, DOI 10.1046/j.1365-2222.2002.01299.x; BRAVO CM, 1995, ALLERGY, V50, P359, DOI 10.1111/j.1398-9995.1995.tb01160.x; Cars O, 2001, LANCET, V357, P1851, DOI 10.1016/S0140-6736(00)04972-2; Demoly P, 2000, ALLERGY, V55, P418, DOI 10.1034/j.1398-9995.2000.00605.x; Gaig P, 1999, ALLERGY, V54, P901, DOI 10.1034/j.1398-9995.1999.00261.x; Gilbert D, 2003, SANFORD GUIDE ANTIMI; GRIECO MH, 1967, ARCH INTERN MED, V119, P141, DOI 10.1001/archinte.119.2.141; Gruchalla Rebecca S., 2003, Journal of Allergy and Clinical Immunology, V111, pS548; GUEANT JL, 1995, MOL IMMUNOL, V32, P259, DOI 10.1016/0161-5890(94)00152-Q; Harris AD, 1999, AM J MED, V107, P166, DOI 10.1016/S0002-9343(99)00190-4; Kelkar PS, 2001, NEW ENGL J MED, V345, P804, DOI 10.1056/NEJMra993637; KISHIYAMA JL, 1994, DRUG SAFETY, V10, P318, DOI 10.2165/00002018-199410040-00006; LEVINE BB, 1966, NEW ENGL J MED, V275, P1115, DOI 10.1056/NEJM196611172752009; Li JTC, 2000, MAYO CLIN PROC, V75, P902, DOI 10.4065/75.9.902; Macy E, 1998, J ALLERGY CLIN IMMUN, V102, P281, DOI 10.1016/S0091-6749(98)70097-1; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.2003.1385; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; Mendelson LM, 1998, IMMUNOL ALLERGY CLIN, V18, P745, DOI 10.1016/S0889-8561(05)70036-9; Novalbos A, 2001, CLIN EXP ALLERGY, V31, P438, DOI 10.1046/j.1365-2222.2001.00992.x; ONG R, 1988, J ALLERGY CLIN IMMUN, V81, P222, DOI 10.1016/0091-6749(88)90452-6; Pichichero ME, 1998, J PEDIATR-US, V132, P137, DOI 10.1016/S0022-3476(98)70499-8; Puchner TC, 2002, ANN ALLERG ASTHMA IM, V88, P24, DOI 10.1016/S1081-1206(10)63589-2; Pumphrey RSH, 1999, LANCET, V353, P1157, DOI 10.1016/S0140-6736(99)00449-3; Romano A, 1999, J ALLERGY CLIN IMMUN, V104, P1113, DOI 10.1016/S0091-6749(99)70100-4; Romano A, 2000, J ALLERGY CLIN IMMUN, V106, P1177; ROMANO A, 1995, INT J IMMUNOPATHO S2, V10, P187; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; SAXON A, 1987, ANN INTERN MED, V107, P204, DOI 10.7326/0003-4819-107-2-204; SHEPHERD GM, 1993, J ALLERGY CLIN IMMUN, V91, P262; SHEPHERD GM, 1991, IMMUNOL ALLERGY CLIN, V11, P611; Solensky R, 2000, ANN ALLERG ASTHMA IM, V84, P329, DOI 10.1016/S1081-1206(10)62782-2; SOLLEY GO, 1982, J ALLERGY CLIN IMMUN, V69, P238, DOI 10.1016/0091-6749(82)90105-1; Strom BL, 2003, NEW ENGL J MED, V349, P1628, DOI 10.1056/NEJMoa022963; Torres MJ, 2002, CLIN EXP ALLERGY, V32, P270, DOI 10.1046/j.1365-2222.2002.01296.x; Torres MJ, 2001, ALLERGY, V56, P850, DOI 10.1034/j.1398-9995.2001.00089.x; WARRINGTON RJ, 1978, CAN MED ASSOC J, V118, P787; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; WICKERN GM, 1994, J ALLERGY CLIN IMMUN, V94, P725, DOI 10.1016/0091-6749(94)90180-5; Zar JH., 1999, BIOSTAT ANAL, V663rd	47	157	164	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					16	22		10.7326/0003-4819-141-1-200407060-00010	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238366				2022-12-28	WOS:000222427600003
J	Ledergerber, B; Lundgren, JD; Walker, AS; Sabin, C; Justice, A; Reiss, P; Mussini, C; Wit, F; Monforte, AD; Weber, R; Fusco, G; Staszewski, S; Law, M; Hogg, R; Lampe, F; Gill, MJ; Castelli, F; Phillips, AN; Castelli, F; Fusco, GP; Gill, MJ; Hogg, R; Lampe, F; Law, M; Ledergerber, B; Lundgren, JD; Monforte, AD; Mussini, C; Phillips, AN; Reiss, P; Staszewski, S; Walker, AS; Rooney, P; Taylor, S; Couldwell, D; Austin, D; Block, M; Clemons, J; Finlayson, R; Law, M; Petoumenos, K; Quan, D; Smith, D; O'Connor, C; Gorton, C; Allen, D; Mulhall, B; Mutimer, K; Smith, D; Keeffe, N; Cooper, D; Carr, A; Miller, J; Pell, C; Ellis, D; Baker, D; Kidd, J; McFarlane, R; Liang, MT; Brown, K; Huffam, S; Savage, J; Morgan, S; Knibbs, P; Sowden, D; Walker, A; Orth, D; Lister, G; Chuah, J; Fankhauser, W; Dickson, B; Bradford, D; Wilson, C; Ree, H; Magon, H; Anderson, J; Moore, R; Russell, D; McGovern, G; McNair, R; Bal, J; Fairley, K; Roth, N; Eu, B; Strecker, S; Russell, D; Wood, H; Mijch, A; Hoy, J; Pierce, A; McCormack, C; Watson, K; Medland, N; Daye, J; Mallal, S; French, M; Skett, J; Maxwel, D; Cain, A; Montroni, M; Scalise, G; Costantini, A; Giacometti, A; Tirelli, U; Nasti, G; Pastore, G; Ladisa, N; Perulli, ML; Suter, F; Arici, C; Chiodo, F; Gritti, FM; Colangeli, V; Fiorini, C; Guerra, L; Carosi, G; Cadeo, GP; Castelli, F; Minardi, C; Vangi, D; Rizzardini, G; Migliorino, G; Manconi, PE; Piano, P; Ferraro, T; Scerbo, A; Pizzigallo, E; Ricci, F; Santoro, D; Pusterla, L; Carnevale, G; Galloni, D; Vigano, P; Mena, M; Ghinelli, F; Sighinolfi, L; Leoncini, F; Mazzotta, F; Pozzi, M; Lo Caputo, S; Angarano, G; Grisorio, B; Ferrara, S; Grima, P; Tundo, P; Pagano, G; Piersantelli, N; Alessandrini, A; Piscopo, R; Toti, M; Chigiotti, S; Soscia, F; Taccooni, L; Orani, A; Perini, P; Scasso, A; Vincenti, A; Scalzini, A; Fibbia, G; Moroni, M; Lazzarin, A; Cargnel, A; Vigevani, GM; Caggese, L; Monforte, AD; Tordato, F; Novati, R; Galli, A; Merli, S; Pastecchia, C; Moioli, C; Esposito, R; Mussini, C; Abrescia, N; Chirianni, A; Izzo, C; Piazza, M; De Marco, M; Montesarchio, V; Manzillo, E; Nappa, S; Colomba, A; Abbadessa, V; Prestileo, T; Mancuso, S; Ferrari, C; Pzzaferri, P; Filice, G; Minoli, L; Bruno, R; Maserati, R; Pauluzzi, S; Baldelli, F; Petrelli, E; Cioppi, A; Alberici, F; Ruggieri, A; Menichetti, F; Martinelli, C; De Stefano, C; La Gala, A; Zauli, T; Ballardini, G; Magnani, G; Ursitti, MA; Arlotti, M; Ortolani, P; Ortona, L; Dianzani, F; Ippolito, G; Antinori, A; Antonucci, G; D'Elia, S; Narciso, P; Petrosillo, N; Vullo, V; De Luca, A; Del Forno, L; Zaccarelli, M; De Longis, P; Ciardi, M; D'Offizi, G; Noto, P; Lichtner, M; Capobianchi, MR; Girardi, E; Pezzotti, P; Rezza, G; Mura, MS; Mannazzu, M; Caramello, P; Sinicco, A; Soranzo, ML; Gennero, L; Sciandra, M; Salassa, B; Grossi, PA; Basilico, C; Poggio, A; Bottari, G; Raise, E; Pasquinucci, S; De Lalla, F; Tositti, G; Resta, F; Chimienti, A; Lepri, AC; Bachmann, S; Battegay, M; Bernasconi, E; Bucher, H; Burgisser, P; Cattacin, S; Egger, M; Erb, P; Fierz, W; Fischer, M; Flepp, M; Fontana, A; Francioli, P; Furrer, HJ; Gorgievski, M; Hirschel, B; Kaiser, L; Kind, C; Klimkait, T; Ledergerber, B; Lauper, U; Opravil, M; Paccaud, F; Pantaleo, G; Perrin, L; Piffaretti, JC; Rickenbach, M; Rudin, C; Schupbach, J; Speck, R; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S; de Wolf, F; van Sighem, AI; van Valkengoed, I; Gras, L; Bronsveld, W; Prins, JM; Bos, JC; Schattenkerk, JKME; Godfried, MH; Lange, JMA; Lowe, SH; van der Meer, JTM; Nellen, FJB; Pogany, K; van der Poll, T; Reiss, P; Ruys, TA; Sankatsing, S; van der Valk, M; van Vonderen, MGA; Wit, FWMN; van Eeden, A; ten Veen, JH; van Dam, PS; Hillebrand-Haverkort, ME; Brinkman, K; Frissen, PHJ; Weigel, HM; Mulder, JW; van Gorp, ECM; Meenhorst, PL; Mairuhu, ATA; Veenstra, J; Danner, SA; Van Agtmael, MA; Claessen, FAP; Geerlings, SE; Perenboom, RM; Richter, C; van der Berg, J; van Leusen, R; Vriesendorp, R; Jeurissen, FJF; Kauffmann, RH; Koger, ELW; Bravenboer, B; ten Napel, CHH; Mudrikova, T; Sprenger, HG; Miesen, WMAJ; ten Kate, RW; van Houte, DPF; Leemhuis, MP; Pole, M; Kroon, FP; Schippers, EF; Schreij, G; van de Geest, S; Verbon, A; Koopmans, PP; Telgt, M; van der Ven, AJAM; van der Ende, ME; Gyssens, IC; de Marie, S; Nouwen, JL; Juttmann, JR; Schneider, MME; Bonten, MJM; Borleffs, JCC; Hoepelman, IM; Jaspers, CAJJ; Schouten, I; Schurink, CAM; Blok, WL; Groenveld, PHP; Jurriaans, S; Back, NKT; Cuijpers, T; Rietra, PJGM; Roozendaal, KJ; Pauw, W; van Zanten, AP; Smits, PHM; von Blomberg, BME; Savelkoul, P; Zaaijer, H; Swanink, C; Franck, PFH; Lampe, AS; Jansen, CL; Hendriks, R; Schirm, J; Benne, D; Veenendaal, D; Storm, H; van Zeijl, JH; Kroes, ACM; Claas, HCJ; Bruggeman, CAMVA; Goossens, VJ; Galama, JMD; Poort, YAGM; Niesters, MG; Osterhaus, ADME; Schutten, M; Buiting, AGM; Swaans, CAM; Boucher, CAB; Schuurman, R; Boel, E; Jansz, AF; Veldkamp, A; Beijnen, JH; Crommentuyn, KML; Huitema, ADR; Kappelhoff, B; de Maat, MMR; Burger, DM; Hugen, PWH; Dabis, F; Thiebaut, R; Chene, G; Lawson-Ayayi, S; Meyer, L; Boufassa, F; Hamouda, O; Pezzotti, P; Rezza, G; Touloumi, G; Hatzakis, A; Karafoulidou, A; Katsarou, O; Brettle, R; Del Amo, J; del Romero, J; van Asten, L; van Benthem, B; Prins, M; Coutinho, R; Kirk, O; Pedersen, C; Aguado, IH; Perez-Hoyos, S; Eskild, A; Bruun, JN; Sannes, M; Sabin, C; Lee, C; Johnson, AM; Phillips, AN; Babiker, A; Darbyshire, J; Gill, N; Porter, K; Francioli, P; Vanhems, P; Egger, M; Rickenbach, M; Cooper, D; Kaldor, J; Ashton, L; Cooper, D; Kaldor, J; Ashton, L; Cooper, D; Vizzard, J; Muga, R; Vanhems, P; Gill, J; Cayla, J; de Olalla, PG; Day, NE; De Angelis, D; Porter, K; Babiker, A; Walker, S; Darbyshire, J; Tyrer, F; Beral, V; Coutinho, R; Darbyshire, J; Del Amo, J; Gill, N; Lee, C; Meyer, L; Rezza, G; Raffanti, S; Becker, S; Scarsella, A; Braun, J; Justice, A; Fusco, G; Most, B; Balu, R; Gilbert, L; Fleenor, R; Ising, T; Dieterich, D; Fusco, J; Losso, M; Duran, A; Vetter, N; Clumeck, N; De Wit, S; Kabeya, K; Poll, B; Colebunders, R; Machala, L; Rozsypal, H; Nielsen, J; Lundgren, J; Kirk, O; Olsen, CH; Gerstoft, J; Katzenstein, T; Hansen, ABE; Skinhoj, P; Pedersen, C; Zilmer, K; Rauka, M; Katlama, C; De Sa, M; Viard, JP; Saint-Marc, T; Vanhems, P; Pradier, C; Dietrich, M; Manegold, C; van Lunzen, J; Stellbrink, HJ; Miller, V; Staszewski, S; Goebel, FD; Salzberger, B; Rockstroh, J; Kosmidis, J; Gargalianos, P; Sambatakou, H; Perdios, J; Panos, G; Filandras, A; Banhegyi, D; Mulcahy, F; Yust, I; Burke, M; Pollack, S; Hassoun, J; Sthoeger, Z; Maayan, S; Vella, S; Chiesi, A; Arici, C; Pristera, R; Mazzotta, F; Gabbuti, A; Esposito, R; Bedini, A; Chirianni, A; Montesarchio, E; Vullo, V; Santopadre, P; Narciso, P; Antinori, A; Franci, P; Zaccarelli, M; Lazzarin, A; Castagna, A; Monforte, AD; Viksna, L; Rozentale, B; Chaplinskas, S; Hemmer, R; Staub, T; Reiss, P; Bruun, J; Maeland, A; Ormaasen, V; Knysz, B; Gasiorowski, J; Horban, A; Prokopowicz, D; Wiercinska-Drapalo, A; Boron-Kaczmarska, A; Pynka, M; Beniowski, M; Trocha, H; Smiatacz, T; Antunes, F; Mansinho, K; Maltez, F; Duiculescu, D; Streinu-Cercel, A; Mokras, M; Stanekova, D; Gonzalez-Lahoz, J; Diaz, B; Garcia-Benayas, T; Martin-Carbonero, L; Soriano, V; Clotet, B; Jou, A; Conejero, J; Tural, C; Gatell, JM; Miro, JM; Zamora, L; Blaxhult, A; Karlsson, A; Pehrson, P; Ledergerber, B; Weber, R; Francioli, P; Hirschel, B; Schiffer, V; Furrer, H; Chentsova, N; Barton, S; Johnson, AM; Mercey, D; Phillips, A; Youle, M; Johnson, MA; Mocroft, A; Murphy, M; Weber, J; Scullard, G; Fisher, M; Brettle, R; Loveday, C; Clotet, B; Ruiz, L; Staszewski, S; Helm, EB; Carlebach, A; Mosch, M; Muller, A; Haberl, A; Korn, S; Stephan, C; Bickel, M; Gute, P; Locher, L; Lutz, T; Klauke, S; Doerr, HW; Sturmer, M; Sabin, C; Dauer, B; Jennings, B; Alexander, C; Braitstein, P; Chan, K; Cote, H; Gataric, N; Harrigan, PR; Harris, M; Bonner, S; Hogg, R; Montaner, J; O'Shaughnessy, M; Wood, E; Yip, B; Lampe, F; Chaloner, C; Gumley, H; Ransom, D; Sabin, CA; Mocroft, A; Lipman, M; Phillips, AN; Youle, M; Johnson, M; Gill, J; Read, R; Carosi, G; Castelli, F; Paraninfo, G; Casari, S; Pan, A; Patroni, A; Torti, C; Quiros-Roldan, E; Tomasoni, L; Moretti, F; Nasta, P; Uccelli, MC; Cadeo, GP; Bertelli, D; Orani, A; Perini, P; Nigro, M; Rizzardini, G; Migliorino, M; Abeli, C; Mazzotta, F; Suter, F; Maggiolo, F; Arici, C; Ghinelli, F; Sighinolfi, L; Minoli, L; Maserati, R; Novati, S; Tinelli, C; Pastore, G; Ladisa, N; Carnevale, G; Poggio, A; Riccio, G; Mussini, C; Borghi, V; Bedini, A; Esposito, R				Ledergerber, B; Lundgren, JD; Walker, AS; Sabin, C; Justice, A; Reiss, P; Mussini, C; Wit, F; Monforte, AD; Weber, R; Fusco, G; Staszewski, S; Law, M; Hogg, R; Lampe, F; Gill, MJ; Castelli, F; Phillips, AN; Castelli, F; Fusco, GP; Gill, MJ; Hogg, R; Lampe, F; Law, M; Ledergerber, B; Lundgren, JD; Monforte, AD; Mussini, C; Phillips, AN; Reiss, P; Staszewski, S; Walker, AS; Rooney, P; Taylor, S; Couldwell, D; Austin, D; Block, M; Clemons, J; Finlayson, R; Law, M; Petoumenos, K; Quan, D; Smith, D; O'Connor, C; Gorton, C; Allen, D; Mulhall, B; Mutimer, K; Smith, D; Keeffe, N; Cooper, D; Carr, A; Miller, J; Pell, C; Ellis, D; Baker, D; Kidd, J; McFarlane, R; Liang, MT; Brown, K; Huffam, S; Savage, J; Morgan, S; Knibbs, P; Sowden, D; Walker, A; Orth, D; Lister, G; Chuah, J; Fankhauser, W; Dickson, B; Bradford, D; Wilson, C; Ree, H; Magon, H; Anderson, J; Moore, R; Russell, D; McGovern, G; McNair, R; Bal, J; Fairley, K; Roth, N; Eu, B; Strecker, S; Russell, D; Wood, H; Mijch, A; Hoy, J; Pierce, A; McCormack, C; Watson, K; Medland, N; Daye, J; Mallal, S; French, M; Skett, J; Maxwel, D; Cain, A; Montroni, M; Scalise, G; Costantini, A; Giacometti, A; Tirelli, U; Nasti, G; Pastore, G; Ladisa, N; Perulli, ML; Suter, F; Arici, C; Chiodo, F; Gritti, FM; Colangeli, V; Fiorini, C; Guerra, L; Carosi, G; Cadeo, GP; Castelli, F; Minardi, C; Vangi, D; Rizzardini, G; Migliorino, G; Manconi, PE; Piano, P; Ferraro, T; Scerbo, A; Pizzigallo, E; Ricci, F; Santoro, D; Pusterla, L; Carnevale, G; Galloni, D; Vigano, P; Mena, M; Ghinelli, F; Sighinolfi, L; Leoncini, F; Mazzotta, F; Pozzi, M; Lo Caputo, S; Angarano, G; Grisorio, B; Ferrara, S; Grima, P; Tundo, P; Pagano, G; Piersantelli, N; Alessandrini, A; Piscopo, R; Toti, M; Chigiotti, S; Soscia, F; Taccooni, L; Orani, A; Perini, P; Scasso, A; Vincenti, A; Scalzini, A; Fibbia, G; Moroni, M; Lazzarin, A; Cargnel, A; Vigevani, GM; Caggese, L; Monforte, AD; Tordato, F; Novati, R; Galli, A; Merli, S; Pastecchia, C; Moioli, C; Esposito, R; Mussini, C; Abrescia, N; Chirianni, A; Izzo, C; Piazza, M; De Marco, M; Montesarchio, V; Manzillo, E; Nappa, S; Colomba, A; Abbadessa, V; Prestileo, T; Mancuso, S; Ferrari, C; Pzzaferri, P; Filice, G; Minoli, L; Bruno, R; Maserati, R; Pauluzzi, S; Baldelli, F; Petrelli, E; Cioppi, A; Alberici, F; Ruggieri, A; Menichetti, F; Martinelli, C; De Stefano, C; La Gala, A; Zauli, T; Ballardini, G; Magnani, G; Ursitti, MA; Arlotti, M; Ortolani, P; Ortona, L; Dianzani, F; Ippolito, G; Antinori, A; Antonucci, G; D'Elia, S; Narciso, P; Petrosillo, N; Vullo, V; De Luca, A; Del Forno, L; Zaccarelli, M; De Longis, P; Ciardi, M; D'Offizi, G; Noto, P; Lichtner, M; Capobianchi, MR; Girardi, E; Pezzotti, P; Rezza, G; Mura, MS; Mannazzu, M; Caramello, P; Sinicco, A; Soranzo, ML; Gennero, L; Sciandra, M; Salassa, B; Grossi, PA; Basilico, C; Poggio, A; Bottari, G; Raise, E; Pasquinucci, S; De Lalla, F; Tositti, G; Resta, F; Chimienti, A; Lepri, AC; Bachmann, S; Battegay, M; Bernasconi, E; Bucher, H; Burgisser, P; Cattacin, S; Egger, M; Erb, P; Fierz, W; Fischer, M; Flepp, M; Fontana, A; Francioli, P; Furrer, HJ; Gorgievski, M; Hirschel, B; Kaiser, L; Kind, C; Klimkait, T; Ledergerber, B; Lauper, U; Opravil, M; Paccaud, F; Pantaleo, G; Perrin, L; Piffaretti, JC; Rickenbach, M; Rudin, C; Schupbach, J; Speck, R; Tarr, P; Telenti, A; Trkola, A; Vernazza, P; Weber, R; Yerly, S; de Wolf, F; van Sighem, AI; van Valkengoed, I; Gras, L; Bronsveld, W; Prins, JM; Bos, JC; Schattenkerk, JKME; Godfried, MH; Lange, JMA; Lowe, SH; van der Meer, JTM; Nellen, FJB; Pogany, K; van der Poll, T; Reiss, P; Ruys, TA; Sankatsing, S; van der Valk, M; van Vonderen, MGA; Wit, FWMN; van Eeden, A; ten Veen, JH; van Dam, PS; Hillebrand-Haverkort, ME; Brinkman, K; Frissen, PHJ; Weigel, HM; Mulder, JW; van Gorp, ECM; Meenhorst, PL; Mairuhu, ATA; Veenstra, J; Danner, SA; Van Agtmael, MA; Claessen, FAP; Geerlings, SE; Perenboom, RM; Richter, C; van der Berg, J; van Leusen, R; Vriesendorp, R; Jeurissen, FJF; Kauffmann, RH; Koger, ELW; Bravenboer, B; ten Napel, CHH; Mudrikova, T; Sprenger, HG; Miesen, WMAJ; ten Kate, RW; van Houte, DPF; Leemhuis, MP; Pole, M; Kroon, FP; Schippers, EF; Schreij, G; van de Geest, S; Verbon, A; Koopmans, PP; Telgt, M; van der Ven, AJAM; van der Ende, ME; Gyssens, IC; de Marie, S; Nouwen, JL; Juttmann, JR; Schneider, MME; Bonten, MJM; Borleffs, JCC; Hoepelman, IM; Jaspers, CAJJ; Schouten, I; Schurink, CAM; Blok, WL; Groenveld, PHP; Jurriaans, S; Back, NKT; Cuijpers, T; Rietra, PJGM; Roozendaal, KJ; Pauw, W; van Zanten, AP; Smits, PHM; von Blomberg, BME; Savelkoul, P; Zaaijer, H; Swanink, C; Franck, PFH; Lampe, AS; Jansen, CL; Hendriks, R; Schirm, J; Benne, D; Veenendaal, D; Storm, H; van Zeijl, JH; Kroes, ACM; Claas, HCJ; Bruggeman, CAMVA; Goossens, VJ; Galama, JMD; Poort, YAGM; Niesters, MG; Osterhaus, ADME; Schutten, M; Buiting, AGM; Swaans, CAM; Boucher, CAB; Schuurman, R; Boel, E; Jansz, AF; Veldkamp, A; Beijnen, JH; Crommentuyn, KML; Huitema, ADR; Kappelhoff, B; de Maat, MMR; Burger, DM; Hugen, PWH; Dabis, F; Thiebaut, R; Chene, G; Lawson-Ayayi, S; Meyer, L; Boufassa, F; Hamouda, O; Pezzotti, P; Rezza, G; Touloumi, G; Hatzakis, A; Karafoulidou, A; Katsarou, O; Brettle, R; Del Amo, J; del Romero, J; van Asten, L; van Benthem, B; Prins, M; Coutinho, R; Kirk, O; Pedersen, C; Aguado, IH; Perez-Hoyos, S; Eskild, A; Bruun, JN; Sannes, M; Sabin, C; Lee, C; Johnson, AM; Phillips, AN; Babiker, A; Darbyshire, J; Gill, N; Porter, K; Francioli, P; Vanhems, P; Egger, M; Rickenbach, M; Cooper, D; Kaldor, J; Ashton, L; Cooper, D; Kaldor, J; Ashton, L; Cooper, D; Vizzard, J; Muga, R; Vanhems, P; Gill, J; Cayla, J; de Olalla, PG; Day, NE; De Angelis, D; Porter, K; Babiker, A; Walker, S; Darbyshire, J; Tyrer, F; Beral, V; Coutinho, R; Darbyshire, J; Del Amo, J; Gill, N; Lee, C; Meyer, L; Rezza, G; Raffanti, S; Becker, S; Scarsella, A; Braun, J; Justice, A; Fusco, G; Most, B; Balu, R; Gilbert, L; Fleenor, R; Ising, T; Dieterich, D; Fusco, J; Losso, M; Duran, A; Vetter, N; Clumeck, N; De Wit, S; Kabeya, K; Poll, B; Colebunders, R; Machala, L; Rozsypal, H; Nielsen, J; Lundgren, J; Kirk, O; Olsen, CH; Gerstoft, J; Katzenstein, T; Hansen, ABE; Skinhoj, P; Pedersen, C; Zilmer, K; Rauka, M; Katlama, C; De Sa, M; Viard, JP; Saint-Marc, T; Vanhems, P; Pradier, C; Dietrich, M; Manegold, C; van Lunzen, J; Stellbrink, HJ; Miller, V; Staszewski, S; Goebel, FD; Salzberger, B; Rockstroh, J; Kosmidis, J; Gargalianos, P; Sambatakou, H; Perdios, J; Panos, G; Filandras, A; Banhegyi, D; Mulcahy, F; Yust, I; Burke, M; Pollack, S; Hassoun, J; Sthoeger, Z; Maayan, S; Vella, S; Chiesi, A; Arici, C; Pristera, R; Mazzotta, F; Gabbuti, A; Esposito, R; Bedini, A; Chirianni, A; Montesarchio, E; Vullo, V; Santopadre, P; Narciso, P; Antinori, A; Franci, P; Zaccarelli, M; Lazzarin, A; Castagna, A; Monforte, AD; Viksna, L; Rozentale, B; Chaplinskas, S; Hemmer, R; Staub, T; Reiss, P; Bruun, J; Maeland, A; Ormaasen, V; Knysz, B; Gasiorowski, J; Horban, A; Prokopowicz, D; Wiercinska-Drapalo, A; Boron-Kaczmarska, A; Pynka, M; Beniowski, M; Trocha, H; Smiatacz, T; Antunes, F; Mansinho, K; Maltez, F; Duiculescu, D; Streinu-Cercel, A; Mokras, M; Stanekova, D; Gonzalez-Lahoz, J; Diaz, B; Garcia-Benayas, T; Martin-Carbonero, L; Soriano, V; Clotet, B; Jou, A; Conejero, J; Tural, C; Gatell, JM; Miro, JM; Zamora, L; Blaxhult, A; Karlsson, A; Pehrson, P; Ledergerber, B; Weber, R; Francioli, P; Hirschel, B; Schiffer, V; Furrer, H; Chentsova, N; Barton, S; Johnson, AM; Mercey, D; Phillips, A; Youle, M; Johnson, MA; Mocroft, A; Murphy, M; Weber, J; Scullard, G; Fisher, M; Brettle, R; Loveday, C; Clotet, B; Ruiz, L; Staszewski, S; Helm, EB; Carlebach, A; Mosch, M; Muller, A; Haberl, A; Korn, S; Stephan, C; Bickel, M; Gute, P; Locher, L; Lutz, T; Klauke, S; Doerr, HW; Sturmer, M; Sabin, C; Dauer, B; Jennings, B; Alexander, C; Braitstein, P; Chan, K; Cote, H; Gataric, N; Harrigan, PR; Harris, M; Bonner, S; Hogg, R; Montaner, J; O'Shaughnessy, M; Wood, E; Yip, B; Lampe, F; Chaloner, C; Gumley, H; Ransom, D; Sabin, CA; Mocroft, A; Lipman, M; Phillips, AN; Youle, M; Johnson, M; Gill, J; Read, R; Carosi, G; Castelli, F; Paraninfo, G; Casari, S; Pan, A; Patroni, A; Torti, C; Quiros-Roldan, E; Tomasoni, L; Moretti, F; Nasta, P; Uccelli, MC; Cadeo, GP; Bertelli, D; Orani, A; Perini, P; Nigro, M; Rizzardini, G; Migliorino, M; Abeli, C; Mazzotta, F; Suter, F; Maggiolo, F; Arici, C; Ghinelli, F; Sighinolfi, L; Minoli, L; Maserati, R; Novati, S; Tinelli, C; Pastore, G; Ladisa, N; Carnevale, G; Poggio, A; Riccio, G; Mussini, C; Borghi, V; Bedini, A; Esposito, R		PLATO Collaboration	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes	LANCET			English	Article							VIRUS-INFECTED PATIENTS; HIV-INFECTION; CLINICAL PROGRESSION; DISEASE PROGRESSION; VIRAL LOAD; THERAPY; INHIBITOR; DISCONTINUATION; HAART; AIDS	Background Treatment strategies for patients in whom HIV replication is not suppressed after exposure to several drug classes remain unclear. We aimed to assess the inter-relations between viral load, CD4-cell count, and clinical outcome in patients who had experienced three-class virological failure. Methods We undertook collaborative joint analysis of 13 HIV cohorts from Europe, North America, and Australia, involving patients who had had three-class virological failure (viral load >1000 copies per mL for >4 months). Regression analyses were used to quantify the associations between CD4-cell-count slope, HIV-1 RNA concentration, treatment information, and demographic characteristics. Predictors of death were analysed by Cox's proportional-hazards models. Findings 2488 patients were included. 2118 (85%) had started antiretroviral therapy with single or dual therapy. During 5015 person-years of follow-up, 276 patients died (mortality rate 5.5 per 100 person-years; 3-year mortality risk 15.3% (95% Cl 13.5-17.3). Risk of death was strongly influenced by the latest CD4-cell count with a relative hazard of 15.8 (95% CI 9.28-27.0) for counts below 50 cells per muL versus above 200 cells per muL. The latest viral load did not independently predict death. For any given viral load, patients on treatment had more favourable CD4-cell-count slopes than those off treatment. For patients on treatment and with stable viral load, CD4-cell counts tended to be increasing at times when the current viral load was below 10 000 copies per mL or 1.5 log(10) copies per mL below off-treatment values. Interpretation In patients for whom viral-load suppression to below the level of detection is not possible, achievement and maintenance of a CD4-cell count above 200 per muL becomes the primary aim. Treatment regimens that maintain the viral load below 10 000 copies per mL or at least provide 1.5 log(10) copies per mL suppression below the off-treatment value do not seem to be associated with appreciable CD4-cell-count decline.	Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, CH-8091 Zurich, Switzerland; Hvidovre Univ Hosp, Copenhagen HIV Programme, DK-2650 Hvidovre, Denmark; MRC, Clin Trials Unit, London, England; UCL Royal Free & Univ Coll Med Sch, London, England; VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Natl AIDS Therapy Evaluat Ctr, Amsterdam, Netherlands; Univ Modena, Clin Infect Dis, I-41100 Modena, Italy; Int Antiviral Therapy Evaluat Ctr, Amsterdam, Netherlands; Univ Milan, Inst Infect Dis, Milan, Italy; GlaxoSmithKline Inc, Res Triangle Pk, NC USA; Goethe Univ Frankfurt, D-6000 Frankfurt, Germany; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW, Australia; Univ British Columbia, BC Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada; So Alberta Clin, Calgary, AB, Canada; Univ Brescia, Inst Infect & Trop Dis, Brescia, Italy	University of Zurich; University Zurich Hospital; University of Copenhagen; Medical Research Council Clinical Trials Unit; University of London; University College London; UCL Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of Amsterdam; Academic Medical Center Amsterdam; Universita di Modena e Reggio Emilia; University of Milan; GlaxoSmithKline; Goethe University Frankfurt; University of New South Wales Sydney; Kirby Institute; B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; University of Brescia	Ledergerber, B (corresponding author), Univ Zurich Hosp, Div Infect Dis & Hosp Epidemiol, Ramistr 100, CH-8091 Zurich, Switzerland.	infled@usz.unizh.ch	Streinu-Cercel, Adrian/M-5835-2017; Casari, Salvatore/AAC-5790-2022; Panos, George/H-3944-2011; Phillips, Andrew N/B-4427-2008; Kind, Christian/AAJ-1103-2020; VALLET, Yannick/F-9979-2011; Bruno, Raffaele/AAB-9491-2022; ROLDAN, Maria Eugenia QUIROS/K-7586-2015; Castelli, Francesco/E-7045-2010; Perez Hoyos, Santiago/O-1075-2019; chene, genevieve/H-8665-2014; Prins, Jan M./AAF-4945-2020; Stephan, Christoph/D-1305-2014; kirk, ole/ABB-4746-2021; Petrosillo, Nicola/AAZ-2095-2021; Lundgren, Jens/AAE-6876-2019; Burger, David/C-9929-2013; Antinori, Andrea/K-7125-2016; Gatell, Jose M/ABC-3607-2020; Telenti, Amalio/AAY-1674-2021; Díaz Pollán, Beatriz/ABA-9452-2021; Perez-Hoyos, Santiago/E-2370-2012; Pradier, Christian/AFE-8255-2022; Grossi, Paolo Antonio/A-6158-2013; Vella, Stefano/GZM-0519-2022; Gyssens, Inge C.J./L-4343-2015; DABIS, FRANCOIS/S-9298-2019; VELLA, STEFANO/V-8440-2019; Back, Nicole/K-3884-2013; Mussini, Cristina/K-8672-2016; van der Ven, A.J.A.M./H-8102-2014; van Valkengoed, Irene/ABA-1551-2021; Sabin, Caroline/C-2464-2008; paccaud, fred/M-7516-2019; DEL AMO VALERO, JULIA/M-7020-2015; Wit, Ferdinand/AAC-3803-2019; Pantaleo, Giuseppe/K-6163-2016; Ledergerber, Bruno/B-5656-2009; Gabbuti, Andrea/ABC-4907-2020; Klimkait, Thomas/A-1057-2008; Weber, Rainer/D-5175-2012; Kaldor, John M/D-4545-2011; Bruno, Raffaele/L-3530-2018; van Valkengoed, Irene G.M./B-2974-2013; Lampe, Fiona/I-5826-2019; rezza, giovanni/D-4393-2016; VELLA, STEFANO/ABI-3368-2020; Mallal, Simon Alexander/HDM-9561-2022; Sighinolfi, Laura/AAH-1426-2020; Eu, Beng/AAJ-7746-2021; Hoy, Jennifer/AAK-7968-2020; Soriano, Vicente/O-5730-2018; Zaccarelli, Mauro/GYV-1093-2022; Mocroft, Amanda/G-8748-2011; Castagna, Antonella/K-3280-2018; Dodsley, Maria/G-7083-2016; Thiebaut, Rodolphe/T-6803-2019; Hogg, Robert S/B-2783-2012; Wiercińska-Drapało, Alicja/V-5930-2018; Pradier, Christian/AAE-9669-2022; Muga, Roberto/AAY-8655-2021; PEZZOTTI, PATRIZIO/C-6480-2016; Furrer, Hansjakob/G-6768-2013; CASTELLI, Florence/GRO-0607-2022; Ippolito, Giuseppe/J-7207-2017; Gill, Michael John/G-7083-2016; De Luca, Andrea/G-8810-2011; LAZZARIN, Adriano/K-3607-2018; Hernandez-Aguado, Ildefonso/I-2634-2015	Streinu-Cercel, Adrian/0000-0001-6382-5067; Casari, Salvatore/0000-0001-5422-8754; Phillips, Andrew N/0000-0003-2384-4807; Bruno, Raffaele/0000-0002-0235-9207; ROLDAN, Maria Eugenia QUIROS/0000-0003-1452-9100; Perez Hoyos, Santiago/0000-0001-9797-4917; chene, genevieve/0000-0002-8368-6460; Stephan, Christoph/0000-0003-3777-9006; Antinori, Andrea/0000-0003-2121-4684; Díaz Pollán, Beatriz/0000-0002-7241-4208; Perez-Hoyos, Santiago/0000-0001-9797-4917; Grossi, Paolo Antonio/0000-0003-2883-5061; DABIS, FRANCOIS/0000-0002-1614-8857; VELLA, STEFANO/0000-0003-2347-5984; Mussini, Cristina/0000-0002-6615-4198; van der Ven, A.J.A.M./0000-0003-1833-3391; van Valkengoed, Irene/0000-0002-9306-7831; Sabin, Caroline/0000-0001-5173-2760; DEL AMO VALERO, JULIA/0000-0002-3104-540X; Ledergerber, Bruno/0000-0002-6881-4401; Bruno, Raffaele/0000-0002-0235-9207; van Valkengoed, Irene G.M./0000-0002-9306-7831; Lampe, Fiona/0000-0001-6851-5471; rezza, giovanni/0000-0003-0268-6790; Mallal, Simon Alexander/0000-0002-7036-1309; Eu, Beng/0000-0002-7009-9179; Soriano, Vicente/0000-0002-4624-5199; Mocroft, Amanda/0000-0001-8316-1122; Castagna, Antonella/0000-0002-8338-9714; Dodsley, Maria/0000-0001-7587-558X; Thiebaut, Rodolphe/0000-0002-5235-3962; Hogg, Robert S/0000-0003-3463-5488; Wiercińska-Drapało, Alicja/0000-0001-5921-1409; Muga, Roberto/0000-0001-6301-431X; PEZZOTTI, PATRIZIO/0000-0002-0805-2927; Furrer, Hansjakob/0000-0002-1375-3146; ANGARANO, Gioacchino/0000-0003-3207-7523; Lipman, Marc/0000-0001-7501-4448; Tyrer, Freya/0000-0003-2877-4342; Antunes, Francisco/0000-0001-7932-1154; Viksna, Ludmila/0000-0002-1826-9230; Smiatacz, Tomasz/0000-0003-2793-3671; Ruggieri, Anna/0000-0003-2987-3844; Castelli, Francesco/0000-0001-9161-7804; Gritti, Fabrice/0000-0003-1023-9050; Law, Matthew/0000-0002-3540-8837; De Angelis, Daniela/0000-0001-6619-6112; Cayla, Joan A./0000-0003-3891-111X; Porter, Kholoud/0000-0002-9226-6206; Anderson, Jane/0000-0001-5294-8707; Gill, Michael John/0000-0002-8546-8790; Egger, Matthias/0000-0001-7462-5132; Lundgren, Jens/0000-0001-8901-7850; Medland, Nicholas Andrew/0000-0003-0403-8930; De Luca, Andrea/0000-0002-9561-9193; ciardi, maria rosa/0000-0002-0894-6496; Johnson, Anne/0000-0003-1330-7100; Girardi, Enrico/0000-0001-8182-5896; nasti, guglielmo/0000-0002-3590-382X; van der Valk, Marc/0000-0002-8290-6425; petrosillo, nicola/0000-0002-2585-7567; TARR, Philip/0000-0002-1488-5407; MARTIN CARBONERO, LUZ/0000-0001-8102-4079; Kroes, Aloysius/0000-0002-9866-2461; LAZZARIN, Adriano/0000-0003-2551-7754; Capobianchi, Maria Rosaria/0000-0003-3465-0071; Hernandez-Aguado, Ildefonso/0000-0003-1911-5759; Ippolito, Giuseppe/0000-0002-1076-2979	Medical Research Council [MC_U122886351] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		[Anonymous], 1996, Lancet, V348, P283; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; Australian HIV Observational Database, 2002, HIV Med, V3, P28; Becker SL, 2001, J ACQ IMMUN DEF SYND, V26, P72, DOI 10.1097/00126334-200101010-00011; Carosi G, 2001, HIV Clin Trials, V2, P399; CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration, 2000, HIV Med, V1, P224; Cozzi-Lepri A, 2003, ANTIVIR THER, V8, P127; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Deeks SG, 2002, AIDS, V16, P201, DOI 10.1097/00002030-200201250-00009; Deeks SG, 2000, J INFECT DIS, V181, P946, DOI 10.1086/315334; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Hellmann NS, 2002, ANTIVIR THER, V7, pS70; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Huber P.J., 1967, P 5 BERKELEY S MATH, V1, P221; Katlama C, 2003, 10 C RETR OPP INF BO; Kirk O, 1998, AIDS, V12, P2031, DOI 10.1097/00002030-199815000-00015; Lalezari JP, 2003, NEW ENGL J MED, V348, P2175, DOI 10.1056/NEJMoa035026; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; Lawrence J, 2003, NEW ENGL J MED, V349, P837, DOI 10.1056/NEJMoa035103; Lazzarin A, 2003, NEW ENGL J MED, V348, P2186, DOI 10.1056/NEJMoa035211; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Miller V, 2002, J INFECT DIS, V186, P189, DOI 10.1086/341466; Mocroft A, 2000, J ACQ IMMUN DEF SYND, V24, P475, DOI 10.1097/00126334-200008150-00013; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Mocroft A, 2002, ANTIVIR THER, V7, P21; Mocroft A, 2001, AIDS, V15, P185, DOI 10.1097/00002030-200101260-00007; MOCROFT A, 2004, 11 C RETR OPP INF SA; Monforte AD, 2000, AIDS, V14, P499, DOI 10.1097/00002030-200003310-00005; Montaner JSG, 2001, AIDS, V15, P61, DOI 10.1097/00002030-200101050-00010; Nieuwkerk PT, 2001, ARCH INTERN MED, V161, P1962, DOI 10.1001/archinte.161.16.1962; Phillips AN, 1997, J MED VIROL, V53, P261, DOI 10.1002/(SICI)1096-9071(199711)53:3<261::AID-JMV14>3.0.CO;2-K; Rutschmann OT, 1998, AIDS, V12, pF71, DOI 10.1097/00002030-199808000-00003; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; SELIGMANN M, 1994, LANCET, V343, P871; Staszewski S, 1999, AIDS, V13, P951, DOI 10.1097/00002030-199905280-00011; Staszewski S, 1999, AIDS, V13, P367, DOI 10.1097/00002030-199902250-00009; Sudre P, 2000, SCHWEIZ MED WSCHR, V130, P1493; Tebas P, 2002, J INFECT DIS, V186, P851, DOI 10.1086/342603; Viard JP, 2001, J INFECT DIS, V183, P1290, DOI 10.1086/319678; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yerly S, 1998, ARCH INTERN MED, V158, P247, DOI 10.1001/archinte.158.3.247; Youle M, 2000, AIDS, V14, P1717, DOI 10.1097/00002030-200008180-00005	47	244	252	1	60	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					51	62		10.1016/S0140-6736(04)16589-6	http://dx.doi.org/10.1016/S0140-6736(04)16589-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234856				2022-12-28	WOS:000222392900031
J	Maviel, T; Durkin, TP; Menzaghi, F; Bontempi, B				Maviel, T; Durkin, TP; Menzaghi, F; Bontempi, B			Sites of neocortical reorganization critical for remote spatial memory	SCIENCE			English	Article							LONG-TERM-MEMORY; TIME-DEPENDENT REORGANIZATION; ANTERIOR CINGULATE CORTEX; CONNECTIONIST MODELS; FEAR MEMORY; CONSOLIDATION; HIPPOCAMPUS; PLASTICITY; MICE; DISSOCIATION	The hippocampus is crucial for spatial memory formation, yet it does not store long-lasting memories. By combining functional brain imaging and region-specific neuronal inactivation in mice, we identified prefrontal and anterior cingulate cortex as critical for storage and retrieval of remote spatial memories. Imaging of activity-dependent genes also revealed an involvement of parietal and retrosplenial cortices during consolidation of remote memory. Long-term memory storage within some of these neocortical regions was accompanied by structural changes including synaptogenesis and laminar reorganization, concomitant with a functional disengagement of the hippocampus and posterior cingulate cortices. Thus, consolidation of spatial memory requires a time-dependent hippocampal-cortical dialogue, ultimately enabling widespread cortical networks to mediate effortful recall and use of cortically stored remote memories independently.	Univ Bordeaux 1, CNRS, UMR 5106, Lab Neurosci Cognit, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bontempi, B (corresponding author), Univ Bordeaux 1, CNRS, UMR 5106, Lab Neurosci Cognit, Ave Fac, F-33405 Talence, France.	b.bontempi@lnc.u-bordeaux1.fr						Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Bontempi B, 1999, NATURE, V400, P671, DOI 10.1038/23270; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; Durkin TP, 2000, BEHAV BRAIN RES, V116, P39, DOI 10.1016/S0166-4328(00)00248-5; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Fleischmann A, 2003, J NEUROSCI, V23, P9116; Frankland PW, 2004, SCIENCE, V304, P881, DOI 10.1126/science.1094804; Frankland PW, 2001, NATURE, V411, P309, DOI 10.1038/35077089; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Hall J, 2001, J NEUROSCI, V21, P2186, DOI 10.1523/JNEUROSCI.21-06-02186.2001; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; Jones MW, 2001, NAT NEUROSCI, V4, P289, DOI 10.1038/85138; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KESNER RP, 1989, BEHAV NEUROSCI, V103, P956, DOI 10.1037/0735-7044.103.5.956; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; Miller R, 1996, BIOL CYBERN, V75, P253, DOI 10.1007/s004220050292; Moscovitch M, 1998, CURR OPIN NEUROBIOL, V8, P297, DOI 10.1016/S0959-4388(98)80155-4; Murre JMJ, 2001, BRAIN, V124, P647, DOI 10.1093/brain/124.4.647; Routtenberg A, 2000, P NATL ACAD SCI USA, V97, P7657, DOI 10.1073/pnas.97.13.7657; Save E, 2000, HIPPOCAMPUS, V10, P491, DOI 10.1002/1098-1063(2000)10:4<491::AID-HIPO16>3.0.CO;2-0; SIF J, 1989, NEUROSCI LETT, V101, P223, DOI 10.1016/0304-3940(89)90535-1; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Takahashi N, 1997, NEUROLOGY, V49, P464, DOI 10.1212/WNL.49.2.464; Takehara K, 2003, J NEUROSCI, V23, P9897; Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930	29	476	484	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					96	99		10.1126/science.1098180	http://dx.doi.org/10.1126/science.1098180			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232109				2022-12-28	WOS:000222386000044
J	Boulton, AJM; Kirsner, RS; Vileikyte, L				Boulton, AJM; Kirsner, RS; Vileikyte, L			Neuropathic diabetic foot ulcers	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED-TRIAL; RISK-FACTORS; OSTEOMYELITIS; MULTICENTER; DEBRIDEMENT; ULCERATION; INFECTION; MELLITUS; CARE; COMPLICATIONS		Univ Miami, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Dermatol & Cutaneous Surg, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Epidemiol & Publ Hlth, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Psychol, Miami, FL 33101 USA; Vet Affairs Med Ctr, Miami, FL 33125 USA; Manchester Royal Infirm, Acad Dept Med, Manchester M13 9WL, Lancs, England	University of Miami; University of Miami; University of Miami; University of Miami; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Manchester	Boulton, AJM (corresponding author), Univ Miami, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, POB 016960 D-110, Miami, FL 33101 USA.	aboulton@med.miami.edu						Abbott CA, 2002, DIABETIC MED, V19, P377, DOI 10.1046/j.1464-5491.2002.00698.x; Abbott CA, 1998, DIABETES CARE, V21, P1071, DOI 10.2337/diacare.21.7.1071; American Diabetes Association, 1999, Diabetes Care, V22, P1354; Armstrong DG, 1998, DIABETES CARE, V21, P855, DOI 10.2337/diacare.21.5.855; Armstrong DG, 2001, DIABETES CARE, V24, P1509; Armstrong DG, 2001, DIABETES CARE, V24, P1019, DOI 10.2337/diacare.24.6.1019; Armstrong DG, 2002, J AM PODIAT MED ASSN, V92, P405, DOI 10.7547/87507315-92-7-405; Armstrong DG, 2003, DIABETES CARE, V26, P2595, DOI 10.2337/diacare.26.9.2595; Armstrong DG, 2000, ARCH SURG-CHICAGO, V135, P1405, DOI 10.1001/archsurg.135.12.1405; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Chantelau E, 1996, DIABETIC MED, V13, P156, DOI 10.1002/(SICI)1096-9136(199602)13:2<156::AID-DIA59>3.0.CO;2-U; Clark N, 2003, DIABETES CARE, V26, P3333; Craig JG, 1997, RADIOLOGY, V203, P849, DOI 10.1148/radiology.203.3.9169715; Delamaire M, 1997, DIABETIC MED, V14, P29, DOI 10.1002/(SICI)1096-9136(199701)14:1<29::AID-DIA300>3.0.CO;2-V; Donohoe ME, 2000, DIABETIC MED, V17, P581, DOI 10.1046/j.1464-5491.2000.00336.x; FRYKBERG RG, 2000, J FOOT ANKLE SURG S, V38, pS1; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; Hess Cathy Thomas, 2003, Adv Skin Wound Care, V16, P246, DOI 10.1097/00129334-200309000-00015; International Working Group on the Diabetic Foot, 1999, INT CONS DIAB FOOT; KATZ I, IN PRESS DIABETES; Kirsner RS, 1998, TRENDS BIOTECHNOL, V16, P246, DOI 10.1016/S0167-7799(98)01196-2; Lipsky BA, 2004, CLIN INFECT DIS, V38, P17, DOI 10.1086/380449; Lipsky BA, 2000, DIABETES-METAB RES, V16, pS42, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR109>3.3.CO;2-2; Lipsky BA, 2004, DIABETES-METAB RES, V20, pS68, DOI 10.1002/dmrr.453; Macfarlane RM, 1997, DIABETIC MED, V14, P867, DOI 10.1002/(SICI)1096-9136(199710)14:10<867::AID-DIA475>3.0.CO;2-L; Marston WA, 2003, DIABETES CARE, V26, P1701, DOI 10.2337/diacare.26.6.1701; Mason J, 1999, DIABETIC MED, V16, P889, DOI 10.1046/j.1464-5491.1999.00137.x; Mason J, 1999, DIABETIC MED, V16, P801, DOI 10.1046/j.1464-5491.1999.00133.x; Mayfield JA, 1998, DIABETES CARE, V21, P2161, DOI 10.2337/diacare.21.12.2161; Mayfield Jennifer A, 2003, Diabetes Care, V26 Suppl 1, pS78; McCallon S K, 2000, Ostomy Wound Manage, V46, P28; McCallon SK, 2000, OSTOMY WOUND MANAG, V46, P28; MUELLER MJ, 1989, DIABETES CARE, V12, P384, DOI 10.2337/diacare.12.6.384; Murray HJ, 1996, DIABETIC MED, V13, P979, DOI 10.1002/(SICI)1096-9136(199611)13:11<979::AID-DIA267>3.3.CO;2-1; NEWMAN LG, 1991, JAMA-J AM MED ASSOC, V266, P1246, DOI 10.1001/jama.266.9.1246; Oyibo SO, 2001, DIABETES CARE, V24, P84, DOI 10.2337/diacare.24.1.84; PALUMBO PJ, 1985, NIH PUBLICATION; Pellizzer G, 2001, DIABETIC MED, V18, P822, DOI 10.1046/j.1464-5491.2001.00584.x; Piaggesi A, 2003, DIABETES CARE, V26, P3123, DOI 10.2337/diacare.26.11.3123; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; Reiber GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/diacare.22.1.157; Reiber GE, 2002, JAMA-J AM MED ASSOC, V287, P2552, DOI 10.1001/jama.287.19.2552; Sorensen LT, 2003, ANN SURG, V238, P1, DOI 10.1097/01.SLA.0000074980.39700.31; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; UCCIOLI L, 1995, DIABETES CARE, V18, P1376, DOI 10.2337/diacare.18.10.1376; Valk GD, 2002, ENDOCRIN METAB CLIN, V31, P633, DOI 10.1016/S0889-8529(02)00021-X; Veves A, 2002, ARCH SURG-CHICAGO, V137, P822, DOI 10.1001/archsurg.137.7.822; Veves A, 2001, DIABETES CARE, V24, P290, DOI 10.2337/diacare.24.2.290; Vileikyte L, 2004, DIABETES-METAB RES, V20, pS13, DOI 10.1002/dmrr.437; Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822; Williams Dean T, 2003, Curr Diab Rep, V3, P468, DOI 10.1007/s11892-003-0009-x; Williams R, 2002, DIABETOLOGIA, V45, pS13, DOI 10.1007/s00125-002-0859-9; Young BA, 2003, DIABETES CARE, V26, P495, DOI 10.2337/diacare.26.2.495; YOUNG MJ, 1992, DIABETIC MED, V9, P55, DOI 10.1111/j.1464-5491.1992.tb01714.x; Zacur H, 2002, WOUNDS, V14, p2E	56	358	374	0	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					48	55		10.1056/NEJMcp032966	http://dx.doi.org/10.1056/NEJMcp032966			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229307				2022-12-28	WOS:000222352200009
J	Pilote, L; Abrahamowicz, M; Rodrigues, E; Eisenberg, MJ; Rahme, E				Pilote, L; Abrahamowicz, M; Rodrigues, E; Eisenberg, MJ; Rahme, E			Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: A class effect?	ANNALS OF INTERNAL MEDICINE			English	Article							LEFT-VENTRICULAR DYSFUNCTION; ACE-INHIBITOR; CAPTOPRIL; TRIAL; QUINAPRIL; RAMIPRIL; SURVIVAL; LISINOPRIL; ENALAPRIL; OUTCOMES	Background: several randomized, controlled trials show that angiotensin-converting enzyme (ACE) inhibitors improve survival in patients who have had an acute myocardial infarction. However, existing data from trials do not address whether all ACE inhibitors benefit patients similarly. Objective: To evaluate whether all ACE inhibitors are associated with similar mortality in patients 65 years of age or older who have had an acute myocardial infarction. Design: Retrospective cohort study that used linked hospital discharge and prescription databases containing information on 18453 patients 65 years of age or older who were admitted for an acute myocardial infarction between 1 April 1996 and 31 March 2000. Setting: 109 hospitals in Quebec, Canada. Patients: 7512 patients who filled a prescription for an ACE inhibitor within 30 days of discharge and who continued to receive the same drug for at least 1 year. Measurements: The association between the specific drugs and clinical outcomes was measured by using Cox proportional hazards models, with adjustment for demographic, clinical, physician, and hospital variables and dosage categories, represented by time-dependent variables. Results: Enalapril, fosinopril, captopril, quinapril, and lisinopril were associated with higher mortality than was ramipril; the adjusted hazard ratios and 95% CIs were 1.47 (95% CI, 1.14 to 1.89), 1.71 (CI, 1.29 to 2.25), 1.56 (CI, 1.13 to 2.15), 1.58 (CI, 1.10 to 2.82), and 1.28 (CI, 0.98 to 1.67), respectively. The adjusted hazard ratio associated with perindopril was 0.98 (CI, 0.60 to 1.60). Limitations: The administrative databases did not contain detailed clinical information, and unmeasured factors associated with a patient's risk for death may have influenced physicians' prescription choices. Conclusion: Survival benefits in the first year after acute myocardial infarction in patients 65 years of age or older seem to differ according to the specific ACE inhibitor prescribed. Ramipril was associated with lower mortality than most other ACE inhibitors.	Montreal Gen Hosp, Div Clin Epidemiol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Jewish Gen Hosp, Montreal, PQ H3T 1E2, Canada	McGill University; McGill University	Pilote, L (corresponding author), Montreal Gen Hosp, Div Clin Epidemiol, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	louise.pilote@mcgill.ca		Abrahamowicz, Michal/0000-0002-3172-3952; Pilote, Louise/0000-0002-6159-0628				Abrahamowicz M, 1996, J AM STAT ASSOC, V91, P1432, DOI 10.2307/2291569; ABRAMS J, 1995, ARCH INTERN MED, V155, P357, DOI 10.1001/archinte.155.4.357; BACH R, 1992, AM J CARDIOL, V70, pC70; BALL SG, 1993, LANCET, V342, P821; Battaglia A, 2000, CARDIOVASC DRUG THER, V14, P671; Brown NJ, 1998, CIRCULATION, V97, P1411, DOI 10.1161/01.CIR.97.14.1411; BYAR DP, 1991, STAT MED, V10, P663, DOI 10.1002/sim.4780100417; Collett D, 1994, MODELLING SURVIVAL D; COLLINS R, 1995, LANCET, V345, P669; COX DR, 1972, J R STAT SOC B, V34, P187; DEVITA C, 1994, LANCET, V343, P1115; Flather MD, 2000, LANCET, V355, P1575, DOI 10.1016/S0140-6736(00)02212-1; FOY SG, 1994, AM J CARDIOL, V73, P1180, DOI 10.1016/0002-9149(94)90178-3; Franzosi MG, 1998, CIRCULATION, V97, P2202, DOI 10.1161/01.CIR.97.22.2202; FUFBERG CD, 2000, CLIN CARDIOL, V23, P15; Furberg CD, 1999, LANCET, V354, P1202, DOI 10.1016/S0140-6736(99)03190-6; GAVAZZI A, 1994, J HYPERTENS, V12, pS89; GILES TD, 1989, J AM COLL CARDIOL, V13, P1240, DOI 10.1016/0735-1097(89)90294-5; Greenland S, 1996, INT J EPIDEMIOL, V25, P1107, DOI 10.1093/ije/25.6.1107-a; Kakinoki S, 2001, AM J HYPERTENS, V14, P66, DOI 10.1016/S0895-7061(00)00300-9; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; Khalil ME, 2001, J AM COLL CARDIOL, V37, P1757, DOI 10.1016/S0735-1097(01)01229-3; Kizer JR, 2001, ARCH INTERN MED, V161, P1145, DOI 10.1001/archinte.161.9.1145; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; LEONETTI G, 1995, DRUGS, V49, P516, DOI 10.2165/00003495-199549040-00003; Levy AR, 1999, CAN J CARDIOL, V15, P1277; LIU LS, 1995, LANCET, V345, P686; Michalewicz L, 1997, AM J CARDIOL, V79, P39, DOI 10.1016/S0002-9149(97)00271-3; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Oosterga M, 2001, AM J CARDIOL, V87, P542, DOI 10.1016/S0002-9149(00)01428-4; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Piepho RW, 2000, AM J HEALTH-SYST PH, V57, pS3, DOI 10.1093/ajhp/57.suppl_1.S3; Pilote L, 2003, CAN MED ASSOC J, V168, P1647; Pilote L, 2003, CAN MED ASSOC J, V168, P568; Pilote L, 2000, CAN MED ASSOC J, V163, P31; Pitt B, 2001, AM J CARDIOL, V87, P1058, DOI 10.1016/S0002-9149(01)01461-8; REID N, 1985, BIOMETRIKA, V72, P1; Rodrigues EJ, 2003, AM J MED, V115, P473, DOI 10.1016/S0002-9343(03)00435-2; Sica DA, 2000, AM J MANAG CARE, V6, pS85; Simpson E, 2003, AM HEART J, V145, P438, DOI 10.1067/mhj.2003.143; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; Tamblyn R, 1998, ENCY BIOSTATISTICS, P1235; THERNEAU TM, 2000, MODELING SURVIVAL EX; Tu K, 2003, CAN MED ASSOC J, V168, P553; Voors A A, 1995, J Cardiovasc Risk, V2, P413; Wooltorton E, 2001, CAN MED ASSOC J, V165, P632; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145; 1997, ARCH INTERN MED, V157, P2413	49	91	95	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					102	112		10.7326/0003-4819-141-2-200407200-00008	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00008			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262665				2022-12-28	WOS:000222758200003
J	Takahashi, T				Takahashi, T			The fate of industrial carbon dioxide	SCIENCE			English	Editorial Material							CALCIFICATION		Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA	Columbia University	Takahashi, T (corresponding author), Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA.	taka@ldeo.columbia.edu						Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Gruber N, 1996, GLOBAL BIOGEOCHEM CY, V10, P809, DOI 10.1029/96GB01608; Houghton RA, 2002, TRENDS COMPENDIUM DA; Keeling RF, 2002, P NATL ACAD SCI USA, V99, P7848, DOI 10.1073/pnas.122154899; Langdon C, 2000, GLOBAL BIOGEOCHEM CY, V14, P639, DOI 10.1029/1999GB001195; *NOAA, 2003, GLOBALVIEW CO2 COOP; Plattner GK, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001746; Sabine CL, 2004, SCIENCE, V305, P367, DOI 10.1126/science.1097403; Zondervan I, 2001, GLOBAL BIOGEOCHEM CY, V15, P507, DOI 10.1029/2000GB001321	9	30	35	4	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					352	353		10.1126/science.1100602	http://dx.doi.org/10.1126/science.1100602			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256662				2022-12-28	WOS:000222662400026
J	Rugar, D; Budakian, R; Mamin, HJ; Chui, BW				Rugar, D; Budakian, R; Mamin, HJ; Chui, BW			Single spin detection by magnetic resonance force microscopy	NATURE			English	Article							CANTILEVERS; RELAXATION	Magnetic resonance imaging (MRI) is well known as a powerful technique for visualizing subsurface structures with three-dimensional spatial resolution. Pushing the resolution below 1 mum remains a major challenge, however, owing to the sensitivity limitations of conventional inductive detection techniques. Currently, the smallest volume elements in an image must contain at least 10(12) nuclear spins for MRI-based microscopy(1), or 10(7) electron spins for electron spin resonance microscopy(2). Magnetic resonance force microscopy (MRFM) was proposed as a means to improve detection sensitivity to the single-spin level, and thus enable three-dimensional imaging of macromolecules ( for example, proteins) with atomic resolution(3,4). MRFM has also been proposed as a qubit readout device for spin-based quantum computers(5,6). Here we report the detection of an individual electron spin by MRFM. A spatial resolution of 25 nm in one dimension was obtained for an unpaired spin in silicon dioxide. The measured signal is consistent with a model in which the spin is aligned parallel or anti-parallel to the effective field, with a rotating-frame relaxation time of 760 ms. The long relaxation time suggests that the state of an individual spin can be monitored for extended periods of time, even while subjected to a complex set of manipulations that are part of the MRFM measurement protocol.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA	International Business Machines (IBM)	Rugar, D (corresponding author), IBM Corp, Almaden Res Ctr, Div Res, 650 Harry Rd, San Jose, CA 95120 USA.	rugar@almaden.ibm.com						ALBRECHT TR, 1991, J APPL PHYS, V69, P668, DOI 10.1063/1.347347; Berman GP, 2000, PHYS REV B, V61, P14694, DOI 10.1103/PhysRevB.61.14694; Berman GP, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.094402; Berman GP, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.094425; Berman GP, 2002, PHYS REV A, V66, DOI 10.1103/PhysRevA.66.023405; Blank A, 2003, J MAGN RESON, V165, P116, DOI 10.1016/S1090-7807(03)00254-4; Brun TA, 2003, PHYS REV A, V68, DOI 10.1103/PhysRevA.68.032301; CASTLE JG, 1963, PHYS REV, V130, P577, DOI 10.1103/PhysRev.130.577; Chui B. W., 2003, 12 INT C SOL STAT SE, P1120; Ciobanu L, 2002, J MAGN RESON, V158, P178, DOI 10.1016/S1090-7807(02)00071-X; DAVENPORT WB, 1958, INTRO THEORY RANDOM, V104; DIVINCENZO DP, 1995, PHYS REV A, V51, P1015, DOI 10.1103/PhysRevA.51.1015; Durkan C, 2002, APPL PHYS LETT, V80, P458, DOI 10.1063/1.1434301; ELZERMAN JM, IN PRESS NATURE; Hannay JD, 2000, J APPL PHYS, V87, P6827, DOI 10.1063/1.372855; Jelezko F, 2002, APPL PHYS LETT, V81, P2160, DOI 10.1063/1.1507838; JIANG HW, IN PRESS NATURE; KOHLER J, 1993, NATURE, V363, P242, DOI 10.1038/363242a0; Mamin HJ, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.207604; MANASSEN Y, 1989, PHYS REV LETT, V62, P2531, DOI 10.1103/PhysRevLett.62.2531; Mozyrsky D, 2003, APPL PHYS LETT, V82, P1278, DOI 10.1063/1.1554769; RUGAR D, 1992, NATURE, V360, P563, DOI 10.1038/360563a0; SIDLES JA, 1992, PHYS REV LETT, V68, P1124, DOI 10.1103/PhysRevLett.68.1124; SIDLES JA, 1995, REV MOD PHYS, V67, P249, DOI 10.1103/RevModPhys.67.249; Slichter C. P., 1990, PRINCIPLES MAGNETIC, P20; Stipe BC, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.277602; Stowe TD, 1997, APPL PHYS LETT, V71, P288, DOI 10.1063/1.119522; TING M, 2003, ELECT SPIN DETECTION; WRACHTRUP J, 1993, NATURE, V363, P244, DOI 10.1038/363244a0	29	1264	1297	11	275	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					329	332		10.1038/nature02658	http://dx.doi.org/10.1038/nature02658			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254532				2022-12-28	WOS:000222631200035
J	Gottesman, S				Gottesman, S			Small RNAs shed some light	CELL			English	Editorial Material							ESCHERICHIA-COLI; NONCODING RNAS	Small regulatory RNAs can act by pairing with their target messages, targeting themselves and the mRNA for degradation; Lenz et al. (this issue of Cell) now report that multiple small RNAs are essential regulators of the quorum-sensing systems of Vibrio species, including the regulation of virulence in V. cholerae.										Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Gottesman S, 2004, ANNU REV MICROBIOL, V58, P303, DOI 10.1146/annurev.micro.58.030603.123841; Johansson J, 2003, TRENDS MICROBIOL, V11, P280, DOI 10.1016/S0966-842X(03)00118-5; Lenz DH, 2004, CELL, V118, P69, DOI 10.1016/j.cell.2004.06.009; Lilley BN, 2000, MOL MICROBIOL, V36, P940, DOI 10.1046/j.1365-2958.2000.01913.x; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; Repoila F, 2003, MOL MICROBIOL, V48, P855, DOI 10.1046/j.1365-2958.2003.03454.x; Storz G, 2004, CURR OPIN MICROBIOL, V7, P140, DOI 10.1016/j.mib.2004.02.015; Wilderman PJ, 2004, P NATL ACAD SCI USA, V101, P9792, DOI 10.1073/pnas.0403423101	10	21	21	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	2004	118	1					1	2		10.1016/j.cell.2004.06.024	http://dx.doi.org/10.1016/j.cell.2004.06.024			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242637	Bronze			2022-12-28	WOS:000222626800001
J	Zhang, HD; Kolb, FA; Jaskiewicz, L; Westhof, E; Filipowicz, W				Zhang, HD; Kolb, FA; Jaskiewicz, L; Westhof, E; Filipowicz, W			Single processing center models for human dicer and bacterial RNase III	CELL			English	Article							DOUBLE-STRANDED-RNA; INTERFERENCE; BINDING; RIBONUCLEASE; DOMAIN; INITIATION; INTERACTS	Dicer is a multidomain ribonuclease that processes double-stranded RNAs (dsRNAs) to 21 nt small interfering RNAs (siRNAs) during RNA interference, and excises microRNAs from precursor hairpins. Dicer contains two domains related to the bacterial dsRNA specific endonuclease, RNase III, which is known to function as a homodimer. Based on an X-ray structure of the Aquifex aeolicus RNase III, models of the enzyme interaction with dsRNA, and its cleavage at two composite catalytic centers, have been proposed. We have generated mutations in human Dicer and Escherichia coli RNase III residues implicated in the catalysis, and studied their effect on RNA processing. Our results indicate that both enzymes have only one processing center, containing two RNA cleavage sites and generating products with 2 nt 3' overhangs. Based on these and other data, we propose that Dicer functions through intralmolecular dimerization of its two RNase III domains, assisted by the flanking RNA binding domains, PAZ and dsRBD.	Friedrich Miescher Inst Biomed Res, CH-4002 Basel, Switzerland; CNRS, Inst Biol Mol & Cellulaire, Strasbourg, France	Friedrich Miescher Institute for Biomedical Research; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Filipowicz, W (corresponding author), Friedrich Miescher Inst Biomed Res, POB 2543, CH-4002 Basel, Switzerland.	filipowi@fmi.ch						Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Basyuk E, 2003, NUCLEIC ACIDS RES, V31, P6593, DOI 10.1093/nar/gkg855; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Blaszczyk J, 2001, STRUCTURE, V9, P1225, DOI 10.1016/S0969-2126(01)00685-2; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hannon Gregory J., 2003, P87; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Li HL, 1996, EMBO J, V15, P1421, DOI 10.1002/j.1460-2075.1996.tb00484.x; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martens H, 2002, MOL BIOL CELL, V13, P445, DOI 10.1091/mbc.01-04-0211; Nicholson Allen W., 2003, P149; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Schauer SE, 2002, TRENDS PLANT SCI, V7, P487, DOI 10.1016/S1360-1385(02)02355-5; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Wienholds E, 2003, NAT GENET, V35, P217, DOI 10.1038/ng1251; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; Zamore PD, 2001, MOL CELL, V8, P1158, DOI 10.1016/S1097-2765(01)00418-X; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	32	670	732	1	55	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					57	68		10.1016/j.cell.2004.06.017	http://dx.doi.org/10.1016/j.cell.2004.06.017			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242644	Bronze			2022-12-28	WOS:000222626800008
J	Ananworanich, J; Cheunyam, T; Teeratakulpisam, S; Boyd, MA; Ruxrungtham, K; Lange, J; Cooper, D; Phanuphak, P				Ananworanich, J; Cheunyam, T; Teeratakulpisam, S; Boyd, MA; Ruxrungtham, K; Lange, J; Cooper, D; Phanuphak, P			Creation of a drug fund for post-clinical trial access to antiretrovirals	LANCET			English	Editorial Material							VACCINE; AIDS		HIV Netherlands Australia Thailand Res Collaborat, Bangkok 10330, Thailand		Ananworanich, J (corresponding author), HIV Netherlands Australia Thailand Res Collaborat, Bangkok 10330, Thailand.	jintanat.a@chula.ac.th	Ananworanich, Jintanat/AAC-6348-2021	Ananworanich, Jintanat/0000-0003-1369-3224; Boyd, Mark/0000-0002-6848-3307				Angell M, 2000, NEW ENGL J MED, V342, P967, DOI 10.1056/NEJM200003303421309; Berkley S, 2003, LANCET, V362, P992, DOI 10.1016/S0140-6736(03)14371-1; Fitzgerald DW, 2003, LANCET, V362, P993, DOI 10.1016/S0140-6736(03)14372-3; Frankish H, 2003, LANCET, V361, P1963, DOI 10.1016/S0140-6736(03)13607-0; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Kunanusont Chaiyos, 1999, Journal of the Medical Association of Thailand, V82, P425; Lo B, 2003, BMJ-BRIT MED J, V327, P337, DOI 10.1136/bmj.327.7410.337; Tucker T, 2003, LANCET, V362, P995, DOI 10.1016/S0140-6736(03)14374-7; Vermund SH, 2003, CLIN INFECT DIS, V37, pS4, DOI 10.1086/375367	9	16	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					101	102		10.1016/S0140-6736(04)16596-3	http://dx.doi.org/10.1016/S0140-6736(04)16596-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234863				2022-12-28	WOS:000222392900038
J	Mills, E; Montori, VM; Wu, P; Gallicano, K; Clarke, M; Guyatt, G				Mills, E; Montori, VM; Wu, P; Gallicano, K; Clarke, M; Guyatt, G			Interaction of St John's wort with conventional drugs: systematic review of clinical trials	BRITISH MEDICAL JOURNAL			English	Article							RENAL-TRANSPLANT PATIENTS; HYPERICUM-PERFORATUM; HEALTHY-VOLUNTEERS; PHARMACOKINETICS; METABOLISM; TACROLIMUS; INDUCTION; EXTRACT; CYP3A4; CYP2D6	Objective To determine the methodological quality of clinical trials that examined possible interactions of St John's wort with conventional drugs, and to examine the results of these trials. Design Systematic review. Data sources Electronic databases from inception to April 2004, reference lists from published reports, and experts in the field. Study selection Eligible studies were prospective clinical trials evaluating the pharmacokinetic effect of St John's wort on the metabolism of conventional drugs. Data extraction Two reviewers selected studies for inclusion and independently extracted data. Data synthesis 22 pharmacokinetic trials studied an average of 12, (SD 5) participants; 17 trials studied healthy volunteers and five studied patients. Most (17) studies used a "before and after" design; four studies used control groups other than the active group. Three studies randomised the sequence of administration or the participants to study arms or periods; three studies blinded participants or investigators. In 15 trials, investigators independently assayed the herb. of 19 trials with available plasma data, three found no important interaction (change in area under the curve <20%) and 17 found a decrease in systemic bioavailability of the conventional drug; in seven studies the 95% confidence interval excluded a decrease of <20%. Conclusion Clinicians and patients should beware of possible decreases in the systemic bioavailability of conventional drugs when taken concomitantly with St John's wort.	McMaster Univ, Dept Clin Epidemiol & Biostat, McMaster Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada; Mayo Clin Coll Med, Dept Med, Rochester, MN 55905 USA; London Sch Hyg & Trop Med, London WC1E 7HU, England; Watson Labs, Corona, CA 92878 USA; UK Cochrane Ctr, Oxford OX2 7LG, England	McMaster University; Mayo Clinic; University of London; London School of Hygiene & Tropical Medicine; Cochrane Centre	Mills, E (corresponding author), McMaster Univ, Dept Clin Epidemiol & Biostat, McMaster Hlth Sci Ctr, Room 2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	millsej@mcmaster.ca		Montori, Victor/0000-0003-0595-2898				Altman D.G., 2000, STAT CONFIDENCE, P28; Bauer S, 2003, BRIT J CLIN PHARMACO, V55, P203, DOI 10.1046/j.1365-2125.2003.01759.x; Burstein AH, 2000, CLIN PHARMACOL THER, V68, P605, DOI 10.1067/mcp.2000.111530; Draves Andrew H, 2003, Can J Clin Pharmacol, V10, P114; Dresser GK, 2003, CLIN PHARMACOL THER, V73, P41, DOI 10.1067/mcp.2003.10; Durr D, 2000, CLIN PHARMACOL THER, V68, P598, DOI 10.1067/mcp.2000.112240; *FOOD DRUG ADM, 1999, IN VIVO DRUG MET DRU; Hall SD, 2003, CLIN PHARMACOL THER, V74, P525, DOI 10.1016/j.clpt.2003.08.009; Hammerness P, 2003, PSYCHOSOMATICS, V44, P271, DOI 10.1176/appi.psy.44.4.271; Hebert ME, 2004, J CLIN PHARMACOL, V44, P89, DOI 10.1177/0091270003261078; Henderson L, 2002, BRIT J CLIN PHARMACO, V54, P349, DOI 10.1046/j.1365-2125.2002.01683.x; Jiang XM, 2004, BRIT J CLIN PHARMACO, V57, P592, DOI 10.1111/j.1365-2125.2003.02051.x; Johne A, 2002, J CLIN PSYCHOPHARM, V22, P46, DOI 10.1097/00004714-200202000-00008; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; Mai I, 2003, NEPHROL DIAL TRANSPL, V18, P819, DOI 10.1093/ndt/gfg002; Markowitz J S, 2001, Psychopharmacol Bull, V35, P53; Markowitz JS, 2000, LIFE SCI, V66, pPL133, DOI 10.1016/S0024-3205(99)00659-1; Markowitz JS, 2003, JAMA-J AM MED ASSOC, V290, P1500, DOI 10.1001/jama.290.11.1500; Mathijssen RHJ, 2002, J NATL CANCER I, V94, P1247, DOI 10.1093/jnci/94.16.1247; Morimoto T, 2004, J CLIN PHARMACOL, V44, P95, DOI 10.1177/0091270003261496; Pfrunder A, 2003, BRIT J CLIN PHARMACO, V56, P683, DOI 10.1046/j.1365-2125.2003.02005.x; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Roby CA, 2001, J CLIN PSYCHOPHARM, V21, P530, DOI 10.1097/00004714-200110000-00013; Sugimoto K, 2001, CLIN PHARMACOL THER, V70, P518, DOI 10.1067/mcp.2001.120025; Thomas KJ, 2001, COMPLEMENT THER MED, V9, P2, DOI 10.1054/ctim.2000.0407; Wang LS, 2004, CLIN PHARMACOL THER, V75, P191, DOI 10.1016/j.clpt.2003.09.014; Wang ZQ, 2002, CLIN PHARMACOL THER, V71, P414, DOI 10.1067/mcp.2002.124080; Wang ZQ, 2001, CLIN PHARMACOL THER, V70, P317, DOI 10.1067/mcp.2001.118522; Wenk M, 2004, BRIT J CLIN PHARMACO, V57, P495, DOI 10.1111/j.1365-2125.2003.02049.x	29	78	81	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					27	30		10.1136/bmj.329.7456.27	http://dx.doi.org/10.1136/bmj.329.7456.27			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231618	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222568300018
J	Potts, R; Behrensmeyer, AK; Deino, A; Ditchfield, P; Clark, J				Potts, R; Behrensmeyer, AK; Deino, A; Ditchfield, P; Clark, J			Small mid-Pleistocene hominin associated with east African Acheulean technology	SCIENCE			English	Article							OLD HOMO CRANIUM; OLORGESAILIE FORMATION; MIDDLE PLEISTOCENE; AFAR DEPRESSION; REMAINS; ERECTUS; CEPRANENSIS; EVOLUTION; MATUYAMA; ETHIOPIA	Hominin fossils from the African mid-Pleistocene are rare despite abundant Acheulean tools in Africa and apparently African-derived hominins in Eurasia between 1.0 and 0.5 million years ago (Ma). Here we describe an African fossil cranium constrained by 40Ar/39Ar analyses, magnetostratigraphy, and sedimentary features to 0.97 to 0.90 Ma, and stratigraphically associated with Acheulean handaxes. Although the cranium represents possibly the smallest adult or near-adult known between 1.7 and 0.5 Ma, it retains features observed in larger Homo erectus individuals, yet shows a distinct suite of traits indicative of wide population variation in the hominins of this period.	Smithsonian Inst, Natl Museum Nat Hist, Human Origins Program, Washington, DC 20560 USA; Natl Museums Kenya, Div Paleontol, Nairobi, Kenya; Smithsonian Inst, Natl Museum Nat Hist, Dept Paleobiol, Washington, DC 20560 USA; Berkeley Geochronol Ctr, Berkeley, CA 94709 USA; Univ Oxford, Res Lab Archaeol, Oxford OX1 3QJ, England	Smithsonian Institution; Smithsonian National Museum of Natural History; Smithsonian Institution; Smithsonian National Museum of Natural History; Berkeley Geochronolgy Center; University of Oxford	Potts, R (corresponding author), Smithsonian Inst, Natl Museum Nat Hist, Human Origins Program, Washington, DC 20560 USA.	potts.rick@nmnh.si.edu						Abbate E, 1998, NATURE, V393, P458, DOI 10.1038/30954; Anton SC, 2003, YEARB PHYS ANTHROPOL, V46, P126, DOI 10.1002/ajpa.10399; Anton SC, 2004, J HUM EVOL, V46, P337, DOI 10.1016/j.jhevol.2003.12.005; Anton SC, 1997, AM J PHYS ANTHROPOL, V102, P497, DOI 10.1002/(SICI)1096-8644(199704)102:4<497::AID-AJPA6>3.0.CO;2-P; Arsuaga JL, 1999, J HUM EVOL, V37, P431, DOI 10.1006/jhev.1999.0309; Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; CONROY GC, 1978, NATURE, V276, P67, DOI 10.1038/276067a0; DEINO A, 1990, J GEOPHYS RES-SOLID, V95, P8453, DOI 10.1029/JB095iB06p08453; Gabunia L, 2000, SCIENCE, V288, P1019, DOI 10.1126/science.288.5468.1019; Gilbert WH, 2003, J HUM EVOL, V45, P255, DOI 10.1016/j.jhevol.2003.08.007; Hou YM, 2000, SCIENCE, V287, P1622, DOI 10.1126/science.287.5458.1622; Hublin J.J., 2001, HUMAN ROOTS AFRICA A, P99; Isaac GL, 1977, OLORGESAILIE ARCHAEO; Mallegni F, 2003, C R PALEVOL, V2, P153, DOI 10.1016/S1631-0683(03)00015-0; Manzi G, 2003, J HUM EVOL, V44, P731, DOI 10.1016/S0047-2484(03)00061-7; Manzi G, 2001, P NATL ACAD SCI USA, V98, P10011, DOI 10.1073/pnas.151259998; Potts R, 1999, J HUM EVOL, V37, P747, DOI 10.1006/jhev.1999.0344; Rightmire GP, 1998, EVOL ANTHROPOL, V6, P218, DOI 10.1002/(SICI)1520-6505(1998)6:6<218::AID-EVAN4>3.0.CO;2-6; Rightmire GP, 1996, J HUM EVOL, V31, P21; RIGHTMIRE GP, 1983, AM J PHYS ANTHROPOL, V61, P245, DOI 10.1002/ajpa.1330610214; Sarna-Wojcicki AM, 2000, J GEOPHYS RES-SOL EA, V105, P21431, DOI 10.1029/2000JB900901; TAMRAT E, 1995, PALAEOGEOGR PALAEOCL, V114, P273, DOI 10.1016/0031-0182(94)00080-R; TATTERSALL I, 1986, J HUM EVOL, V15, P165, DOI 10.1016/S0047-2484(86)80043-4; TAUXE L, 1992, EARTH PLANET SC LETT, V109, P561, DOI 10.1016/0012-821X(92)90114-B; White T. D., 2000, ENCY HUMAN EVOLUTION, P486; Wolpoff Milford H., 1994, Courier Forschungsinstitut Senckenberg, V171, P341	26	91	94	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					75	78		10.1126/science.1097661	http://dx.doi.org/10.1126/science.1097661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232102				2022-12-28	WOS:000222386000037
J	Sun, S; Ting, CT; Wu, CI				Sun, S; Ting, CT; Wu, CI			The normal function of a speciation gene, Odysseus, and its hybrid sterility effect	SCIENCE			English	Article							POSTMATING REPRODUCTIVE ISOLATION; DROSOPHILA-MELANOGASTER; HOMOLOGOUS RECOMBINATION; HALDANES RULE; EVOLUTION; SIMULANS; SPERMATOGENESIS; INTROGRESSION; MUTAGENESIS; MAURITIANA	To understand how postmating isolation is connected to the normal process of species divergence and why hybrid male sterility is often the first sign of speciation, we analyzed the Odysseus ( OdsH) gene of hybrid male sterility in Drosophila. We carried out expression analysis, transgenic study, and gene knockout. The combined evidence suggests that the sterility phenotype represents a novel manifestation of the gene function rather than the reduction or loss of the normal one. The gene knockout experiment identified the normal function of OdsH as a modest enhancement of sperm production in young males. The implication of a weak effect of OdsH on the normal phenotype but a strong influence on hybrid male sterility is discussed in light of Haldane's rule of postmating isolation.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 300, Taiwan	University of Chicago; National Tsing Hua University	Wu, CI (corresponding author), Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA.	ciwu@uchicago.edu		Ting, Chau-Ti/0000-0003-1802-8864				CASTRILLON DH, 1993, GENETICS, V135, P489; Civetta A, 1995, J MOL EVOL, V41, P1085, DOI 10.1007/BF00173190; Fuller Margaret T., 1993, P71; Hollocher H, 1996, GENETICS, V143, P1243; HOYLE HD, 1990, J CELL BIOL, V111, P1009, DOI 10.1083/jcb.111.3.1009; OLIVIERI G, 1965, MUTAT RES, V2, P366, DOI 10.1016/0027-5107(65)90072-2; Orr HA, 1997, ANNU REV ECOL SYST, V28, P195, DOI 10.1146/annurev.ecolsys.28.1.195; Palumbi SR, 1998, ENDLESS FORMS, P271; PEREZ DE, 1995, GENETICS, V140, P201; Presgraves DC, 2003, NATURE, V423, P715, DOI 10.1038/nature01679; Presgraves DC, 1998, SCIENCE, V282, P952, DOI 10.1126/science.282.5390.952; Raff EC, 1997, SCIENCE, V275, P70, DOI 10.1126/science.275.5296.70; Rong YKS, 2002, GENE DEV, V16, P1568, DOI 10.1101/gad.986602; Rong YS, 2000, SCIENCE, V288, P2013, DOI 10.1126/science.288.5473.2013; Sawamura K, 2000, P NATL ACAD SCI USA, V97, P2652, DOI 10.1073/pnas.050558597; SUN S, 2003, THESIS U CHICAGO; Tao Y, 2003, GENETICS, V164, P1383; Ting CT, 1998, SCIENCE, V282, P1501, DOI 10.1126/science.282.5393.1501; TING CY, UNPUB; True JR, 1996, GENETICS, V142, P819; Tsaur SC, 1997, MOL BIOL EVOL, V14, P544, DOI 10.1093/oxfordjournals.molbev.a025791; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; WU CI, 1994, ANNU REV GENET, V28, P283, DOI 10.1146/annurev.ge.28.120194.001435; Wu CI, 2004, NAT REV GENET, V5, P114, DOI 10.1038/nrg1269; Wu CI, 1996, TRENDS ECOL EVOL, V11, P281, DOI 10.1016/0169-5347(96)10033-1; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070	27	94	99	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					81	83		10.1126/science.1093904	http://dx.doi.org/10.1126/science.1093904			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232104	Green Submitted			2022-12-28	WOS:000222386000039
J	Benatar, SR				Benatar, SR			Health care reform and the crisis of HIV and AIDS in South Africa	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIV/AIDS; TRANSMISSION; PREVENTION; ETHICS; POLICY; EPIDEMIC; PROGRAM; SYSTEM		Univ Cape Town, Fac Hlth Sci, Dept Med, ZA-7925 Cape Town, South Africa	University of Cape Town	Benatar, SR (corresponding author), Univ Cape Town, Fac Hlth Sci, Dept Med, ZA-7925 Cape Town, South Africa.	sbenatar@uctgsh1.uct.ac.za						Barr S, 2001, CFO-MAG SR FINANC EX, V17, P48; BARRON P, 2003, MAIL GUARDIAN   0819, P19; Bateman C, 2004, SAMJ S AFR MED J, V94, P144; Bateman C, 2003, SAMJ S AFR MED J, V93, P734; Benatar SR, 1997, NEW ENGL J MED, V336, P891, DOI 10.1056/NEJM199703203361224; Benatar SR, 2000, S AFR MED J, V90, P790; Benatar SR, 2001, INT J-TORONTO, V56, P611, DOI 10.2307/40203607; Benatar SR, 2002, SOC SCI MED, V54, P1131, DOI 10.1016/S0277-9536(01)00327-6; Benatar SR, 2003, INT AFF, V79, P107, DOI 10.1111/1468-2346.00298; BENATAR SR, 1990, S AFR MED J, V77, P441; Benatar SR, 1998, AM J PUBLIC HEALTH, V88, P295, DOI 10.2105/AJPH.88.2.295; Benatar SR, 2002, J MED PHILOS, V27, P163, DOI 10.1076/jmep.27.2.163.2992; Benatar SR, 2001, INT AFF, V77, P347, DOI 10.1111/1468-2346.00196; BENATAR SR, 2002, SUNDAY INDEPEND 0407, P7; BENATAR SR, 2003, MANSONS TROPICAL DIS, P85; Berkley S, 2003, LANCET, V362, P992, DOI 10.1016/S0140-6736(03)14371-1; Blecher M, 2002, SAMJ S AFR MED J, V92, P449; Bond P, 1999, INT J HEALTH SERV, V29, P765, DOI 10.2190/4MA6-53E3-LE1X-C1YY; Bradshaw D, 2003, SAMJ S AFR MED J, V93, P682; Brown L, 2003, AIDS EDUC PREV, V15, P49, DOI 10.1521/aeap.15.1.49.23844; Clinton WJ, 2003, NEW ENGL J MED, V348, P1800, DOI 10.1056/NEJMsb023052; Day C, 2001, S AFRICAN HLTH REV 2, P283; Dedicoat M, 2003, SAMJ S AFR MED J, V93, P777; *DEP HLTH, HIV AIDS STD STRAT P; Doherty J, 2002, S AFRICAN HLTH REV 2, P13; Eaton L, 2003, SOC SCI MED, V56, P149, DOI 10.1016/S0277-9536(02)00017-5; Fauci AS, 1999, NEW ENGL J MED, V341, P1046, DOI 10.1056/NEJM199909303411406; Floyd K, 1999, JAMA-J AM MED ASSOC, V282, P1087, DOI 10.1001/jama.282.11.1087; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; Gandy M., 2003, RETURN WHITE PLAGUE; Goemaere E, 2002, LANCET, V360, P86, DOI 10.1016/S0140-6736(02)09343-1; GOUDGE J, 2001, S AFRICAN HLTH REV 2, P69; GREEN J, 1903, STORY AUSTR BUSHMEN, P1; Hilderbrand K, 2003, SAMJ S AFR MED J, V93, P779; Karim SA, 2002, LANCET, V359, P992, DOI 10.1016/S0140-6736(02)08063-7; Karim SSA, 2004, LANCET, V363, P1395, DOI 10.1016/S0140-6736(04)16056-X; Kassalow Jordan S., 2001, WHY HLTH IS IMPORTAN; Katz Alison, 2002, Afr J AIDS Res, V1, P125, DOI 10.2989/16085906.2002.9626552; KAWACHI I, 2002, HLTH NATIONS WHY INE; KENYON C, 2001, S AFRICAN HLTH REV, P161; Makgoba MW, 2002, VACCINE, V20, P1899, DOI 10.1016/S0264-410X(02)00063-4; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MARTINSON N, 2002, S AFRICAN HLTH REV 2, P235; MBTASHA S, 2001, S AFRICAN HLTH REV 2, P49; MCINTYRE D, GEOGRAPHIC PATTERNS; Moorman J, 2001, S AFRICAN HLTH REV 2, P83; *NAT TREAS REP S A, 2003, INT FISC REV 2003, P75; NAYLOR CD, 1987, S AFR MED J, V72, P673; PILLAY Y, 2002, S AFRICAN HLTH REV 2, P3; POWER S, 2003, NEW YORKER      0519, P54; PRETORIUS E, IN PRESS HLTH HLTH C; *ROYAL DAN MIN FOR, 2000, BUILD GLOB COMM GLOB; *S AFR MED RES COU, IN PRESS GUID ETH ME; SAIT L, 2001, S AFRICAN HLTH REV 2, P1; Schneider H, 2003, SAMJ S AFR MED J, V93, P772; Schwab Peter, 2001, AFRICA CONTINENT SEL; Shaw M, 2002, AFR AFFAIRS, V101, P291, DOI 10.1093/afraf/101.404.291; Soderlund N, 1999, BRIT MED J, V318, P1650, DOI 10.1136/bmj.318.7199.1650; Sparks Colin., 2003, MIRACLE INSIDE NEW S; Terreblanche Sampie, 2002, HIST INEQUALITY S AF; TERREBLANCHE SJ, 2002, HIST INEQUALITY S AF, P477; *UN DEV PROGR, 2002, HUM DEV REP 2002 DEE; VANRENSBURG HCJ, 1999, ACTA ACAD, V31, P1; VANRENSBURG HCJ, 1993, S AFRICAN J SOCIOLOG, V24, P99; VANRENSBURG HJC, IN PRESS HLTH HLTH C; Wilkinson R., 1996, UNHEALTHY SOC AFFLIC; World Health Organization, 2003, ANT THER PRIM HLTH C; [No title captured]; 2001, S AFRICA GLANCE	69	113	116	0	8	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					81	92		10.1056/NEJMhpr033471	http://dx.doi.org/10.1056/NEJMhpr033471			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	833QC	15229313				2022-12-28	WOS:000222352200014
J	Dluhy, RG; Williams, GH				Dluhy, RG; Williams, GH			Aldosterone - Villain or bystander?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Div Endocrine Diabet & Hypertens, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Dluhy, RG (corresponding author), Brigham & Womens Hosp, Div Endocrine Diabet & Hypertens, 75 Francis St, Boston, MA 02115 USA.							Williams JS, 2003, J CLIN ENDOCR METAB, V88, P2364, DOI 10.1210/jc.2003-030490; Young WF, 2003, ENDOCRINOLOGY, V144, P2208, DOI 10.1210/en.2003-0279	2	32	34	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					8	10		10.1056/NEJMp048132	http://dx.doi.org/10.1056/NEJMp048132			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229301				2022-12-28	WOS:000222352200003
J	Matthews, JM; Kusching, R; Guenther, DB; Walker, GAH; Moffat, AFJ; Rucinski, SM; Sasselov, D; Weiss, WW				Matthews, JM; Kusching, R; Guenther, DB; Walker, GAH; Moffat, AFJ; Rucinski, SM; Sasselov, D; Weiss, WW			No stellar p-mode oscillations in space-based photometry of Procyon	NATURE			English	Article							GLOBAL PRESSURE OSCILLATIONS; SOLAR; AMPLITUDES; SEARCH; LIMIT	Pressure-driven (p-mode) oscillations at the surface of the Sun, resulting from sound waves travelling through the solar interior, are a powerful probe of solar structure, just as seismology can reveal details about the interior of the Earth. Astronomers have hoped to exploit p-mode asteroseismology(1) in Sun-like stars to test detailed models of stellar structure and evolution, but the observations are extremely difficult. The bright star Procyon has been considered one of the best candidates for asteroseismology, on the basis of models and previous reports(2-8) of p-modes detected in ground-based spectroscopy. Here we present a search for p-modes in 32 days of nearly continuous photometric satellite-based observations of Procyon. If there are p-modes in Procyon, they must have lifetimes less than 2-3 days and/or peak amplitudes <15 parts per million, which defy expectations from the Sun's oscillations and previous theoretical predictions. Target selection for future planned asteroseismology space missions may need to be reconsidered, as will the theory of stellar oscillations.	Univ British Columbia, Dept Phys & Astron, Vancouver, BC V6T 1Z1, Canada; St Marys Univ, Dept Phys & Astron, Inst Computat Astrophys, Halifax, NS B3H 3C3, Canada; Univ Montreal, Dept Phys, Montreal, PQ H3C 3J7, Canada; Univ Toronto, Dept Astron & Astrophys, Toronto, ON M5S 3H8, Canada; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Univ Vienna, Inst Astron, A-1180 Vienna, Austria	University of British Columbia; Saint Marys University - Canada; Universite de Montreal; University of Toronto; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Vienna	Matthews, JM (corresponding author), Univ British Columbia, Dept Phys & Astron, 6224 Agr Rd, Vancouver, BC V6T 1Z1, Canada.	matthews@astro.ubc.ca						Baglin A, 2002, ESA SP PUBL, V485, P17; BROWN TM, 1991, ASTROPHYS J, V368, P599, DOI 10.1086/169725; BROWNSTEIN DG, 1982, LAB ANIM SCI, V32, P37; CARRIER F, 2002, RADIAL NONRADIAL PUL, P468; Chaboyer B, 1999, ASTROPHYS J, V525, pL41, DOI 10.1086/312336; CHRISTIAN JC, 1969, OAS, V5, P82; Frohlich C, 1997, SOL PHYS, V170, P1, DOI 10.1023/A:1004969622753; GELLY B, 1986, ASTRON ASTROPHYS, V164, P383; GILLILAND RL, 1993, ASTRON J, V106, P2441, DOI 10.1086/116814; Girard TM, 2000, ASTRON J, V119, P2428, DOI 10.1086/301353; Green D, 2003, ASTROPHYS J, V597, P590, DOI 10.1086/378224; GUENTHER DB, 1992, ASTROPHYS J, V387, P372, DOI 10.1086/171090; Guenther DB, 2004, ASTROPHYS J, V600, P419, DOI 10.1086/379644; Houdek G, 1999, ASTRON ASTROPHYS, V351, P582; INNIS JL, 1991, MON NOT R ASTRON SOC, V249, P643, DOI 10.1093/mnras/249.4.643; Kervella P, 2004, ASTRON ASTROPHYS, V413, P251, DOI 10.1051/0004-6361:20031527; KJELDSEN H, 1995, ASTRON ASTROPHYS, V293, P87; Kurtz DW, 1997, MON NOT R ASTRON SOC, V287, P69, DOI 10.1093/mnras/287.1.69; Martic M, 1999, ASTRON ASTROPHYS, V351, P993; MARTIC M, IN PRESS ASTRON ASTR; Mosser B, 1998, ASTRON ASTROPHYS, V340, P457; Prieto CA, 2002, ASTROPHYS J, V567, P544, DOI 10.1086/338248; Retter A, 2004, ASTROPHYS J, V601, pL95, DOI 10.1086/381889; SAMADI R, 2002, ESA, P87; TOUTAIN T, 1992, ASTRON ASTROPHYS, V257, P287; Walker G, 2003, PUBL ASTRON SOC PAC, V115, P1023, DOI 10.1086/377358	26	132	132	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					51	53		10.1038/nature02671	http://dx.doi.org/10.1038/nature02671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229593				2022-12-28	WOS:000222356800038
J	Pritchard, J; Appleton, R; Howard, R; Hughes, RAC				Pritchard, J; Appleton, R; Howard, R; Hughes, RAC			Guillain-Barre syndrome seen in users of isotretinoin	BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, Guys Kings & St Thomass Sch Med, Dept Clin Neurosci, London SE1 1UL, England; Royal Liverpool Childrens NHS Trust, Liverpool, Merseyside, England; St Thomas Hosp, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Alder Hey Children's NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust	Pritchard, J (corresponding author), Guys Hosp, Guys Kings & St Thomass Sch Med, Dept Clin Neurosci, London SE1 1UL, England.	jane.pritchard@kcl.ac.uk						Tsambaos D, 2003, SKIN PHARMACOL APPL, V16, P46, DOI 10.1159/000068287; Webster GF, 2002, BMJ-BRIT MED J, V325, P475, DOI 10.1136/bmj.325.7362.475	2	17	17	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1537	1537		10.1136/bmj.328.7455.1537	http://dx.doi.org/10.1136/bmj.328.7455.1537			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217870	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000222392700021
J	Mohan, P; Iyengar, SD; Martines, J; Cousens, S; Sen, K				Mohan, P; Iyengar, SD; Martines, J; Cousens, S; Sen, K			Impact of counselling on careseeking behaviour in families with sick children: cluster randomised trial in rural India	BRITISH MEDICAL JOURNAL			English	Article							ACUTE RESPIRATORY-INFECTIONS; CARE SEEKING BEHAVIOR; MORTALITY; DIARRHEA	Objective To assess whether training doctors in counselling improves careseeking behaviour in families with sick children. Design Pair matched, community randomised trial conducted in 12 primary health centres (six pairs). Doctors in intervention centres were trained in counselling, communication, and clinical skills, using the integrated management of childhood illness approach. Setting Rural district in Rajasthan, India. Participants Children aged under 5 years presenting for curative care and their mothers were recruited and visited monthly at home for six months. A total of 2460 children were recruited (1248 intervention, 1212 control). Main outcome measures Careseeking behaviour of mothers for sick children; mothers' knowledge and perceptions of seeking care; counselling performance of doctors. Results For episodes of illness with at least one reported danger sign, 15% of intervention group mothers and 10% of control group mothers reported having sought care from an appropriate provider promptly; this difference was not statistically significant (relative risk reduction 5%, 95% confidence interval -0.4% to 11%; P = 0.07). One month after training, intervention site doctors counselled more effectively than control group doctors, but at six months their performance had declined. A greater proportion of mothers in the intervention group than in the control group recalled having had at least one danger sign explained (45% v 8%; P = 0.02). Conclusions Mothers' appreciation of the need to seek prompt and appropriate care for severe episodes of childhood illness increased, but their careseeking behaviour did not improve significantly.	Act Res & Training Hlth, Child Hlth Program, Udaipur 313004, India; WHO, Dept Child & Adolescent Hlth & Dev, CH-1211 Geneva, Switzerland; Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1E 7HT, England	University of Geneva; World Health Organization; University of London; London School of Hygiene & Tropical Medicine	Mohan, P (corresponding author), Act Res & Training Hlth, Child Hlth Program, 39 Fatehpura, Udaipur 313004, India.	pmohan@unicef.org	Martines, Jose Carlos/ABE-4082-2020					Atakouma DY, 1999, REV EPIDEMIOL SANTE, V47, P75; D'Souza RM, 2003, J BIOSOC SCI, V35, P131, DOI 10.1017/S0021932003001317; de Silva MWA, 2001, SOC SCI MED, V53, P1363, DOI 10.1016/S0277-9536(00)00425-1; DIEHR P, 1995, STAT MED, V14, P1491, DOI 10.1002/sim.4780141309; Goldman N, 2002, SOC SCI MED, V55, P1693, DOI 10.1016/S0277-9536(01)00260-X; Herman E, 1994, Int J Health Plann Manage, V9, P235, DOI 10.1002/hpm.4740090304; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Martines J, 1998, LANCET, V352, P1257, DOI 10.1016/S0140-6736(98)02487-8; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; Rajasthan Government of Rajasthan, 2002, RAJ HUM DEV REP 2002; Reyes H, 1997, HEALTH POLICY PLANN, V12, P214, DOI 10.1093/heapol/12.3.214; Santos I, 2001, J NUTR, V131, P2866, DOI 10.1093/jn/131.11.2866; Simoes EAF, 1997, B WORLD HEALTH ORGAN, V75, P43; SUTRISNA B, 1993, LANCET, V342, P787, DOI 10.1016/0140-6736(93)91545-W; TUPASI TE, 1989, ANN TROP PAEDIATR, V9, P82, DOI 10.1080/02724936.1989.11748603; Tursz A, 1999, REV EPIDEMIOL SANTE, V47, P18; *WHO, 1993, WHOCDR933; *WHO, 1991, WHOARL9120; *WHO, 1991, WHOARI9120; *WHO DIV CHILD HLT, 1997, INT MAN CHILDH ILLN; World Health Organization, 1997, COUNS MOTH MAN CHILD; YODER PS, 1994, J TROP MED HYG, V97, P1	22	17	18	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 31	2004	329	7460					266	269		10.1136/bmj.38149.703380.47	http://dx.doi.org/10.1136/bmj.38149.703380.47			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	844BY	15265815	Green Published, Green Accepted, Bronze, Green Submitted			2022-12-28	WOS:000223133300018
J	Maconochie, N; Doyle, P; Carson, C				Maconochie, N; Doyle, P; Carson, C			Infertility among male UK veterans of the 1990-1 Gulf War: reproductive cohort study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-DEFECTS; HEALTH; POPULATION; CHILDREN; INFANTS; BORN	Objectives To examine the hypothesis that, theoretically at least, exposure to toxicants of the type present in the Gulf war could affect spermatogenesis, Which might be observed as increased levels of infertility. Design Retrospective reproductive cohort analysis. Setting Male UK Gulf war veterans and matched comparison group of non-deployed servicemen, surveyed by postal questionnaire. Participants 42 818 completed questionnaires were returned, representing response rates of 53% for Gulf veterans and 42% for non-Gulf veterans; 10465 Gulf veterans and 7376 non-Gulf veterans reported fathering or trying to father pregnancies after the Gulf war. Main outcome measures Failure to achieve conceptions (type I infertility) or live births (type II infertility) after the Gulf war, having tried for at least a year and consulted a doctor; time to conception among pregnancies fathered by men not reporting fertility problems. Results Risk of reported infertility was higher among Gulf war veterans than among non-Gulf veterans (odds ratio for type I infertility 1.41, 95% confidence interval 1.05 to 1.89; type II 1.50, 1.18 to 1.89). This small effect was constant over time since the war and was observed whether or riot the men had fathered pregnancies before the war. Results were similar when analyses were restricted to clinically confirmed diagnoses. Pregnancies fathered by Gulf veterans not reporting fertility problems also took longer to conceive (odds ratio for >1 year 1.18, 1.04 to 1.34). Conclusions We found some evidence of an association between Gulf war service and reported infertility Pregnancies fathered by Gulf veterans with no fertility problems also reportedly took longer to conceive.	Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Maconochie, N (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.	noreen.maconochie@lshtin.ac.uk	Carson, Claire/F-1662-2011					Abou-Donia MB, 2003, J TOXICOL ENV HEAL A, V66, P57, DOI 10.1080/15287390306463; Araneta MRG, 1997, TERATOLOGY, V56, P244, DOI 10.1002/(SICI)1096-9926(199710)56:4<244::AID-TERA3>3.3.CO;2-Y; Araneta MRG, 2003, BIRTH DEFECTS RES A, V67, P246, DOI 10.1002/bdra.10033; Breslow NE, 1980, STAT METHODS CANC RE, V2; *CAN DEP NAT DEF, 1998, HLTH STUD CAN FORC P, V1; Cowan DN, 1997, NEW ENGL J MED, V336, P1650, DOI 10.1056/NEJM199706053362306; Doyle P, 2004, INT J EPIDEMIOL, V33, P74, DOI 10.1093/ije/dyh049; Ishoy T, 2001, DAN MED BULL, V48, P29; Kang H, 2001, ANN EPIDEMIOL, V11, P504, DOI 10.1016/S1047-2797(01)00245-9; Maconochie N, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-4; *MHRAG, 2003, MRC REV RES UK GULF; Penman AD, 1996, MIL MED, V161, P1; SIM M, 2003, AUSTR GULF VETERANS, V2; World Health Organization, 1992, WHO LAB MAN EX HUM S	14	26	28	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	2004	329	7459					196	200		10.1136/bmj.38163.620972.AE	http://dx.doi.org/10.1136/bmj.38163.620972.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15253919	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000222866900015
J	Possick, SE; Barry, M				Possick, SE; Barry, M			Evaluation and management of the cardiovascular patient embarking on air travel	ANNALS OF INTERNAL MEDICINE			English	Review							ASSOCIATION TASK-FORCE; PRACTICE GUIDELINES COMMITTEE; ACUTE MYOCARDIAL-INFARCTION; DEEP-VEIN THROMBOSIS; LONG-HAUL FLIGHTS; PULMONARY-EMBOLISM; VENOUS THROMBOEMBOLISM; AMERICAN-COLLEGE; RANDOMIZED TRIAL; RISK-FACTORS	Almost 2 billion passengers embark on international and domestic air travel each year. An increasing number of travelers will have cardiovascular disease as the population continues to age and our ability to treat cardiac disease improves. Guidelines for safe air travel in this population vary and are supported by few concrete data from randomized trials. Although the overall risk for clinically significant myocardial ischemia and arrhythmia during flight seems to be low in the population with stable cardiovascular disease, certain groups may be at increased risk. In-flight venous thrombosis is an increasingly recognized potential complication of prolonged air travel. Travelers with cardiovascular disease may be at increased risk for venous thrombosis as a result of depressed ejection fraction or immobility. This case-based review describes the risks of air travel in a 65-year-old man with known cardiovascular disease. After reviewing the limited data on safe air travel after myocardial infarction and the common complications after both percutaneous intervention and coronary artery bypass grafting, we provide recommendations on safe air travel after myocardial infarction. We discuss the safety of both preflight screening and the in-flight environment with regard to pacemakers and implantable automatic defibrillators. We also review the literature on in-flight venous thrombosis and provide recommendations to prevent in-flight deep venous thrombosis.	Yale Univ, Sch Med, Off Int Hlth, New Haven, CT 06520 USA	Yale University	Barry, M (corresponding author), Yale Univ, Sch Med, Off Int Hlth, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	michele.barry@yale.edu						Alexander J K, 1995, Cardiol Clin, V13, P271; ALVAREZ D, 2003, AVIATION SPACE ENV M, V74, pA1; Ansell JE, 2001, NEW ENGL J MED, V345, P828, DOI 10.1056/NEJM200109133451110; Belcaro G, 2002, ANGIOLOGY, V53, P635, DOI 10.1177/000331970205300603; Belcaro G, 2001, ANGIOLOGY, V52, P369, DOI 10.1177/000331970105200601; Bendz B, 2000, LANCET, V356, P1657, DOI 10.1016/S0140-6736(00)03165-2; Cesarone MR, 2002, ANGIOLOGY, V53, P1, DOI 10.1177/000331970205300101; COPPERMAN Y, 1988, PACE, V11, P1386, DOI 10.1111/j.1540-8159.1988.tb04985.x; COTTRELL JJ, 1988, CHEST, V93, P81, DOI 10.1378/chest.93.1.81; Cox GR, 1996, AVIAT SPACE ENVIR MD, V67, P976; CUMMINS RO, 1988, JAMA-J AM MED ASSOC, V259, P1983, DOI 10.1001/jama.259.13.1983; Cutlip DE, 2001, CIRCULATION, V103, P1967; Dalen JE, 2003, ARCH INTERN MED, V163, P2674, DOI 10.1001/archinte.163.22.2674; De Rotte AA, 2002, AVIAT SPACE ENVIR MD, V73, P179; DeJohn CA, 2000, DOTFAAAM0013 OFF AV; DILLARD TA, 1989, ANN INTERN MED, V111, P362, DOI 10.7326/0003-4819-111-5-362; Dowdall N, 2000, BRIT MED J, V321, P1336, DOI 10.1136/bmj.321.7272.1336; Fries R, 2002, CLIN CARDIOL, V25, P474, DOI 10.1002/clc.4960251007; Gendreau MA, 2002, NEW ENGL J MED, V346, P1067, DOI 10.1056/NEJMra012774; GERTLER JP, 1993, J VASC SURG, V18, P939, DOI 10.1016/0741-5214(93)90548-Z; Gibbons RJ, 2002, CIRCULATION, V106, P1883, DOI 10.1161/01.CIR.0000034670.06526.15; Gibbons RJ, 1999, CIRCULATION, V99, P2829, DOI 10.1161/01.CIR.99.21.2829; Goldhaber SZ, 1997, JAMA-J AM MED ASSOC, V277, P642, DOI 10.1001/jama.277.8.642; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; Hannan EL, 2003, JAMA-J AM MED ASSOC, V290, P773, DOI 10.1001/jama.290.6.773; Heit JA, 2002, ARCH INTERN MED, V162, P1245, DOI 10.1001/archinte.162.11.1245; Kaufmann PA, 2001, J NUCL CARDIOL, V8, P158, DOI 10.1067/mnc.2001.112537; Kazmers A, 1999, AM SURGEON, V65, P1124; Kolb C, 2003, J AM COLL CARDIOL, V41, P2054, DOI 10.1016/S0735-1097(03)00424-8; Krantz DS, 2000, JAMA-J AM MED ASSOC, V283, P1800, DOI 10.1001/jama.283.14.1800; Kujanik S, 2000, PHYSIOL RES, V49, P285; Kujanik S, 2000, PHYSIOL RES, V49, P729; Lampert R, 2002, CIRCULATION, V106, P1800, DOI 10.1161/01.CIR.0000031733.51374.C1; Lapostolle F, 2001, NEW ENGL J MED, V345, P779, DOI 10.1056/NEJMoa010378; Levine BD, 1997, CIRCULATION, V96, P1224, DOI 10.1161/01.CIR.96.4.1224; Lip GYH, 1999, J AM COLL CARDIOL, V33, P1424; MORGAN BJ, 1990, J WILDERNESS MED, V1, P147, DOI 10.1580/0953-9859-1.3.147; PAULTER N, 2000, 06020189 NIJ US DEP; Perez-Rodriguez E, 2003, ARCH INTERN MED, V163, P2766, DOI 10.1001/archinte.163.22.2766; POSSICK S, 2004, IN PRESS J TRAVEL ME; Rhoads JE, 1999, AM SURGEON, V65, P1127; Roby H, 2002, AVIAT SPACE ENVIR MD, V73, P91; RODENBERG H, 1988, AM FAM PHYSICIAN, V37, P263; Ryan TJ, 1996, CIRCULATION, V94, P2341, DOI 10.1161/01.CIR.94.9.2341; SCHWARTZ GB, 1982, JAMA-J AM MED ASSOC, V247, P1007; Schwarz T, 2003, ARCH INTERN MED, V163, P2759, DOI 10.1001/archinte.163.22.2759; Scurr JH, 2001, LANCET, V357, P1485, DOI 10.1016/S0140-6736(00)04645-6; Stoller JK, 1999, CHEST, V115, P991, DOI 10.1378/chest.115.4.991; Tsai AW, 2002, ARCH INTERN MED, V162, P1182, DOI 10.1001/archinte.162.10.1182; *UK HOUS LORDS SEL, 5 UK HOUS LORDS SEL; WAKSMAN R, 1995, AM J CARDIOL, V75, P886, DOI 10.1016/S0002-9149(99)80681-X; Wyss CA, 2003, CIRCULATION, V108, P1202, DOI 10.1161/01.CIR.0000087432.63671.2E; Zahger D, 2000, AM HEART J, V140, P241, DOI 10.1067/mhj.2000.107998; TRAVELERS CONSUMERS	54	27	28	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					148	154		10.7326/0003-4819-141-2-200407200-00014	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00014			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262671				2022-12-28	WOS:000222758200009
J	Papini, R				Papini, R			ABC of burns - Management of burn injuries of various depths	BRITISH MEDICAL JOURNAL			English	Review									Selly Oak Univ Hosp, W Midlands Reg Burn Unit, Birmingham, W Midlands, England; Broomfield Hosp, St Andrews Ctr Plast Surg & Burns, Chelmsford, Essex, England	Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Papini, R (corresponding author), Selly Oak Univ Hosp, W Midlands Reg Burn Unit, Birmingham, W Midlands, England.								0	116	120	0	25	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					158	160		10.1136/bmj.329.7458.158	http://dx.doi.org/10.1136/bmj.329.7458.158			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15258073	Green Published			2022-12-28	WOS:000222832300027
J	Parker, M; Lucassen, A				Parker, M; Lucassen, A			Ethics in practice - Genetic information: a joint account?	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Ethox Ctr, Oxford OX3 7LF, England; Princess Anne Hosp, Wessex Clin Genet Serv, Southampton SO16 5YA, Hants, England	University of Oxford	Parker, M (corresponding author), Univ Oxford, Ethox Ctr, Oxford Genet Knowledge Pk, Oxford OX3 7LF, England.		Lucassen, Anneke/D-7764-2017	Lucassen, Anneke/0000-0003-3324-4338				*GEN MED COUNC, CONF PROT PROV INF; Human Genetics Commission, 2002, INS INF BAL INT US P, P47; Knoppers B. M., 1995, American Journal of Human Genetics, V57, pA296; Knoppers BM, 1998, AM J HUM GENET, V62, P474; Knoppers BM, 2002, TRENDS BIOTECHNOL, V20, P85, DOI 10.1016/S0167-7799(01)01879-0; Parker M, 2003, J MED ETHICS, V29, P70, DOI 10.1136/jme.29.2.70; ROSE P, 1999, PRACTICAL GENETICS P, P134; Rose P., 1999, PRACTICAL GENETICS P, P57	8	98	101	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					165	167		10.1136/bmj.329.7458.165	http://dx.doi.org/10.1136/bmj.329.7458.165			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15258076	Green Published			2022-12-28	WOS:000222832300030
J	Scherz, PJ; Harfe, BD; McMahon, AP; Tabin, CJ				Scherz, PJ; Harfe, BD; McMahon, AP; Tabin, CJ			The limb bud Shh-Fgf feedback loop is terminated by expansion of former ZPA cells	SCIENCE			English	Article							APICAL ECTODERMAL RIDGE; SONIC-HEDGEHOG; CHICK LIMB; VERTEBRATE LIMB; POLARIZING ACTIVITY; GROWTH; GREMLIN; ANTAGONISM; EXPRESSION; INDUCTION	Vertebrate limb outgrowth is driven by a positive feedback loop involving Sonic Hedgehog (Shh), Gremlin, and Fgf4. By overexpressing individual components of the loop at a time after these genes are normally down-regulated in chicken embryos, we found that Shh no longer maintains Gremlin in the posterior limb. Shh-expressing cells and their descendants cannot express Gremlin. The proliferation of these descendants forms a barrier separating the Shh signal from Gremlin-expressing cells, which breaks down the Shh-Fgf4 loop and thereby affects limb size and provides a mechanism explaining regulative properties of the limb bud.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; State University System of Florida; University of Florida; Harvard University	Tabin, CJ (corresponding author), Harvard Univ, Sch Med, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tabin@genetics.med.harvard.edu	McMahon, Andrew P/ABE-7520-2020		NICHD NIH HHS [HD32443] Funding Source: Medline; NIGMS NIH HHS [5T32GM0719T6] Funding Source: Medline; NINDS NIH HHS [NS33642] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD032443, R01HD032443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033642, R37NS033642] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Capdevila J, 1999, MOL CELL, V4, P839, DOI 10.1016/S1097-2765(00)80393-7; Chiang C, 2001, DEV BIOL, V236, P421, DOI 10.1006/dbio.2001.0346; Dahn RD, 2000, SCIENCE, V289, P438, DOI 10.1126/science.289.5478.438; Driesch H., 1892, FDN EXPT ENBRYOLOGY, P584; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Ganan Y, 1998, DEV BIOL, V196, P33, DOI 10.1006/dbio.1997.8843; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; HARFE BD, IN PRESS CELL; HORNBRUCH A, 1970, NATURE, V226, P764, DOI 10.1038/226764a0; Hsu DR, 1998, MOL CELL, V1, P673, DOI 10.1016/S1097-2765(00)80067-2; Khokha MK, 2003, NAT GENET, V34, P303, DOI 10.1038/ng1178; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lewis PM, 2001, CELL, V105, P599, DOI 10.1016/S0092-8674(01)00369-5; Marigo V, 1996, DEVELOPMENT, V122, P1225; Merino R, 1999, DEVELOPMENT, V126, P5515; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; Pizette S, 1999, DEVELOPMENT, V126, P883; Richardson MK, 2004, EVOL DEV, V6, P1, DOI 10.1111/j.1525-142X.2004.04008.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Sanz-Ezquerro JJ, 2000, DEVELOPMENT, V127, P4811; Sanz-Ezquerro JJ, 2003, CURR BIOL, V13, P1830, DOI 10.1016/j.cub.2003.09.040; Sun X, 2000, NAT GENET, V25, P83, DOI 10.1038/75644; Yang Y, 1997, DEVELOPMENT, V124, P4393; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	25	123	128	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	2004	305	5682					396	399		10.1126/science.1096966	http://dx.doi.org/10.1126/science.1096966			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256670				2022-12-28	WOS:000222662400038
J	Zakon, H				Zakon, H			Heeding the hormonal call	SCIENCE			English	Editorial Material							SENSORY EXPLOITATION; SEXUAL SELECTION; ELECTRORECEPTORS		Univ Texas, Neurobiol Sect, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Zakon, H (corresponding author), Univ Texas, Neurobiol Sect, Austin, TX 78712 USA.	h.zakon@mail.utexas.edu						BASS AH, 1984, J COMP PHYSIOL, V155, P713, DOI 10.1007/BF00611588; Hope AJ, 1998, P ROY SOC B-BIOL SCI, V265, P869, DOI 10.1098/rspb.1998.0372; McFadden D, 1998, DEV NEUROPSYCHOL, V14, P261, DOI 10.1080/87565649809540712; MEYER JH, 1982, SCIENCE, V217, P635, DOI 10.1126/science.217.4560.635; NEVITT GA, 1994, P NATL ACAD SCI USA, V91, P4288, DOI 10.1073/pnas.91.10.4288; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; SHAW K, 1995, TRENDS ECOL EVOL, V10, P117, DOI 10.1016/S0169-5347(00)89005-9; Sisneros JA, 2004, SCIENCE, V305, P404, DOI 10.1126/science.1097218; Sisneros JA, 2000, J NEUROSCI, V20, P8586, DOI 10.1523/JNEUROSCI.20-22-08586.2000	9	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	2004	305	5682					349	350		10.1126/science.1101134	http://dx.doi.org/10.1126/science.1101134			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256660				2022-12-28	WOS:000222662400024
J	Jourdain, G; Ngo-Giang-Huong, N; Le Coeur, S; Bowonwatanuwong, C; Kantipong, P; Leechanachai, P; Ariyadej, S; Leenasirimakul, P; Hammer, S; Lallemant, M				Jourdain, G; Ngo-Giang-Huong, N; Le Coeur, S; Bowonwatanuwong, C; Kantipong, P; Leechanachai, P; Ariyadej, S; Leenasirimakul, P; Hammer, S; Lallemant, M		Perinatal HIV Prevention Trial Grp	Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	11th Conference on Retroviruses and Opportunistic Infections	FEB 08-11, 2004	San Francisco, CA				INFECTED PREGNANT-WOMEN; IMMUNODEFICIENCY-VIRUS TYPE-1; MULTIPLE SEQUENCE ALIGNMENT; HIV-1 VERTICAL TRANSMISSION; ZIDOVUDINE RESISTANCE; RECEIVING NEVIRAPINE; MUTATIONS; PHARMACOKINETICS; CLUSTAL	BACKGROUND: A single intrapartum dose of nevirapine for the prevention of mother-to-child transmission of human immunodeficiency virus (HIV) leads to the selection of resistance mutations. Whether there are clinically significant consequences in mothers who are subsequently treated with a nevirapine-containing regimen is unknown. METHODS: We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo. In the postpartum period, 269 of the women with a CD4 count below 250 cells per cubic millimeter began a nevirapine-containing antiretroviral regimen. Plasma samples were obtained 10 days post partum and analyzed for resistance mutations. Plasma HIV type 1 (HIV-1) RNA was measured before the initiation of therapy and three and six months thereafter. RESULTS: After six months of therapy, the HIV-1 RNA level was less than 50 copies per milliliter in 49 percent of the women who had received intrapartum nevirapine, as compared with 68 percent of the women who had not received intrapartum nevirapine (P=0.03). Resistance mutations to nonnucleoside reverse-transcriptase inhibitors were detectable in blood samples obtained 10 days post partum from 32 percent of the women who had received intrapartum nevirapine; the most frequent mutations were K103N, G190A, and Y181C. Among the women who had received intrapartum nevirapine, viral suppression was achieved at six months in 38 percent of those with resistance mutations and 52 percent of those without resistance mutations (P=0.08). An HIV-1 RNA level at or above the median of 4.53 log(sub 10) copies per milliliter before therapy and intrapartum exposure to nevirapine were independently associated with virologic failure. After six months of therapy, there was no significant difference between groups in the CD4 count (P=0.65). CONCLUSIONS: Women who received intrapartum nevirapine were less likely to have virologic suppression after six months of postpartum treatment with a nevirapine-containing regimen. Our data suggest the need for strategies to maximize the benefits of both antiretroviral prophylaxis against mother-to-child transmission of HIV and antiretroviral therapy for mothers.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Inst Rech Dev, Perinatal HIV Prevent Trial Grp, Paris, France; Inst Rech Dev, Perinatal HIV Prevent Trial Grp, Chiang Mai, Thailand; Inst Natl Etud Demog, F-75675 Paris, France; Minist Publ Hlth, Bangkok, Thailand; Chiang Mai Univ, Fac Associated Med Sci, Chiang Mai 50000, Thailand; Columbia Univ, Coll Phys & Surg, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Institut de Recherche pour le Developpement (IRD); Institut de Recherche pour le Developpement (IRD); Ministry of Public Health - Thailand; Chiang Mai University; Columbia University	Jourdain, G (corresponding author), PHPT IRD54, 29-7-8 Samlan Rd,Soi 1 Prasing Muang, Chiang Mai 50200, Thailand.	gonzague@phpt.org	Jourdain, Gonzague/F-9117-2017; Ngo-Giang-Huong, Nicole/G-2860-2017	Jourdain, Gonzague/0000-0002-3365-7020; Ngo-Giang-Huong, Nicole/0000-0001-8950-3234	NICHD NIH HHS [R01 HD039615, 5 R01 HD 39615] Funding Source: Medline; PHS HHS [42848] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039615] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Acosta EP, 2004, ANTIMICROB AGENTS CH, V48, P430, DOI 10.1128/AAC.48.2.430-436.2004; CHAIX ML, 2004, 11 C RETR OPP INF SA, P657; CHALERMCHOKCHAR.A, 2004, 11 C RETR OPP INF SA, P96; Cunningham CK, 2002, J INFECT DIS, V186, P181, DOI 10.1086/341300; Eastman PS, 1998, J INFECT DIS, V177, P557, DOI 10.1086/514228; Ekpini RA, 2002, AIDS, V16, P625, DOI 10.1097/00002030-200203080-00015; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; ESHLEMAN SH, 2003, ANTIVIR THER, V8, pS86; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Johnson Victoria A, 2003, Top HIV Med, V11, P215; JOURDAIN G, 2004, 11 C RETR OPP INF SA, P4118; KANTOR R, 2003, ANTIVIR THER, V8, pS85; KEARNEY M, 2004, 11 C RETR OPP INF SA, P695; Kosel BW, 2003, AIDS, V17, P1195, DOI 10.1097/00002030-200305230-00011; Kully C, 1999, J INFECT DIS, V179, P705, DOI 10.1086/314615; Lallemant M, 2004, NEW ENGL J MED, V351, P217, DOI 10.1056/NEJMoa033500; LECOSSIER D, 2003, ANTIVIR THER, V8, pS159; MARTINSON N, 2004, 11 C RETR OPP INF SA, P38; MELLORS J, 2004, 11 C RETR OPP INF SA, P39; *MIN PUBL HLTH DEP, 2000, NAT GUID CLIN MAN HI, P119; Morris L, 2003, AIDS, V17, P1698, DOI 10.1097/00002030-200307250-00017; PALMER S, 2004, 11 C RETR OPP INF SA, P37; *PAN CLIN PRACT TR, 2004, GUID US ANT AG HIV 1; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; SHEPARD KV, 2004, IMPORTANT NEW SAFETY; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; *WHO, 2004, ANT DRUGS PREV MOTH; World Health Organization, 2002, SCAL ANT THER RES LT	29	317	330	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					229	240		10.1056/NEJMoa041305	http://dx.doi.org/10.1056/NEJMoa041305			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	837KA	15247339				2022-12-28	WOS:000222627200007
J	Nardell, EA; Fan, D; Shepard, JO; Harris, NL; Medoff, B; Mark, EJ				Nardell, EA; Fan, D; Shepard, JO; Harris, NL; Medoff, B; Mark, EJ			A woman with a pericardial effusion - Tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CARDIAC-TAMPONADE; DIAGNOSIS; ECHOCARDIOGRAPHY; COMPRESSION; ETIOLOGY; DISEASE		Cambridge Hosp, Div Pulm Med, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Cardiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University	Nardell, EA (corresponding author), Cambridge Hosp, Div Pulm Med, Cambridge, MA 02139 USA.							APPLETON CP, 1988, J AM COLL CARDIOL, V11, P1020, DOI 10.1016/S0735-1097(98)90060-2; ARMSTRONG WF, 1982, CIRCULATION, V65, P1491, DOI 10.1161/01.CIR.65.7.1491; COREY GR, 1993, AM J MED, V95, P209, DOI 10.1016/0002-9343(93)90262-N; ESCALANTE A, 1990, SEMIN ARTHRITIS RHEU, V20, P148, DOI 10.1016/0049-0172(90)90056-L; FEIGENBAUM H, 1966, CIRCULATION, V34, P611, DOI 10.1161/01.CIR.34.4.611; GABOR GW, 1971, CHEST, V59, P341, DOI 10.1378/chest.59.3.341; GILLAM LD, 1983, CIRCULATION, V68, P294, DOI 10.1161/01.CIR.68.2.294; Jasmer RM, 2002, NEW ENGL J MED, V347, P1860, DOI 10.1056/NEJMcp021045; KAHL LE, 1992, ARTHRITIS RHEUM, V35, P1343, DOI 10.1002/art.1780351115; Ko G, 2004, RISK ANAL, V24, P379, DOI 10.1111/j.0272-4332.2004.00439.x; KOH KK, 1994, CIRCULATION, V89, P2728, DOI 10.1161/01.CIR.89.6.2728; MATSUO H, 1979, BRIT HEART J, V41, P513; Merce T, 1998, AM J MED, V105, P106, DOI 10.1016/S0002-9343(98)00192-2; MODER KG, 1995, J RHEUMATOL, V22, P180; Park DY, 2003, ARCH PATHOL LAB MED, V127, P326; PERMANYERMIRALDA G, 1985, AM J CARDIOL, V56, P623, DOI 10.1016/0002-9149(85)91023-9; Pesola G, 1987, Sarcoidosis, V4, P42; ROSE AG, 1987, ARCH PATHOL LAB MED, V111, P422; Sagrista-Sauleda J, 2000, AM J MED, V109, P95, DOI 10.1016/S0002-9343(00)00459-9; Seferovic PM, 2003, CIRCULATION, V107, P978, DOI 10.1161/01.CIR.0000051366.97361.EA; STRANG JIG, 1984, CLIN CARDIOL, V7, P667, DOI 10.1002/clc.4960071208; ZAYAS R, 1995, AM J CARDIOL, V75, P378, DOI 10.1016/S0002-9149(99)80558-X; ZELCER A A, 1987, Canadian Journal of Cardiology, V3, P12	23	5	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					279	287		10.1056/NEJMcpc049014	http://dx.doi.org/10.1056/NEJMcpc049014			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254287				2022-12-28	WOS:000222627200014
J	Spar, D				Spar, D			Business and medicine - The business of stem cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Business, Boston, MA 02163 USA	Harvard University	Spar, D (corresponding author), Harvard Univ, Sch Business, Boston, MA 02163 USA.								0	4	5	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					211	213		10.1056/NEJMp048138	http://dx.doi.org/10.1056/NEJMp048138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254279				2022-12-28	WOS:000222627200003
J	Blattman, JN; Greenberg, PD				Blattman, JN; Greenberg, PD			Cancer immunotherapy: A treatment for the masses	SCIENCE			English	Review							REGULATORY T-CELLS; METASTATIC MELANOMA; ANTIGEN-4 BLOCKADE; DENDRITIC CELLS; TUMOR-DEVELOPMENT; IMMUNE-RESPONSES; GROWTH-FACTOR; KILLER-CELLS; BONE-MARROW; AUTOIMMUNITY	Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Greenberg, PD (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.	pgreen@u.washington.edu						Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; BURNET M, 1957, BRIT MED J, V5022, P779; Carter P, 2001, NAT REV CANCER, V1, P118, DOI 10.1038/35101072; Cheng LE, 2002, P NATL ACAD SCI USA, V99, P3001, DOI 10.1073/pnas.052676899; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Ehrlich P., 1909, NED TIJDSCHR GENEES, V5, P273; Engelhard VH, 2002, IMMUNOL REV, V188, P136, DOI 10.1034/j.1600-065X.2002.18812.x; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Ho WY, 2003, CANCER CELL, V3, P431, DOI 10.1016/S1535-6108(03)00113-2; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Homey B, 2002, NAT REV IMMUNOL, V2, P175, DOI 10.1038/nri748; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Karanikas V, 2003, J IMMUNOL, V171, P4898, DOI 10.4049/jimmunol.171.9.4898; Lee PP, 1999, NAT MED, V5, P677, DOI 10.1038/9525; Lejeune F J, 2001, Surg Oncol Clin N Am, V10, P821; Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6; Marroquin CE, 2002, J IMMUNOTHER, V25, P278, DOI 10.1097/00002371-200205000-00011; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; Nieda M, 2004, BLOOD, V103, P383, DOI 10.1182/blood-2003-04-1155; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; Phan GQ, 2003, P NATL ACAD SCI USA, V100, P8372, DOI 10.1073/pnas.1533209100; Rooney CM, 1998, BLOOD, V92, P1549, DOI 10.1182/blood.V92.5.1549.417k32_1549_1555; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; Rosenberg SA, 1998, NAT MED, V4, P321, DOI 10.1038/nm0398-321; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shimizu J, 1999, J IMMUNOL, V163, P5211; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Street SEA, 2004, J EXP MED, V199, P879, DOI 10.1084/jem.20031981; STUTMAN O, 1974, SCIENCE, V183, P534, DOI 10.1126/science.183.4124.534; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Timmerman JM, 2002, BLOOD, V99, P1517, DOI 10.1182/blood.V99.5.1517; van Elsas A, 2001, J EXP MED, V194, P481, DOI 10.1084/jem.194.4.481; von Mehren M, 2003, ANNU REV MED, V54, P343, DOI 10.1146/annurev.med.54.101601.152442; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood-2002-12-3665; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177	45	446	508	2	96	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					200	205		10.1126/science.1100369	http://dx.doi.org/10.1126/science.1100369			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247469				2022-12-28	WOS:000222501000040
J	Musallam, S; Corneil, BD; Greger, B; Scherberger, H; Andersen, RA				Musallam, S; Corneil, BD; Greger, B; Scherberger, H; Andersen, RA			Cognitive control signals for neural prosthetics	SCIENCE			English	Article							PREFRONTAL CORTEX; NEURONAL-ACTIVITY; EXPECTED REWARD; PARIETAL; PREMOTOR	Recent development of neural prosthetics for assisting paralyzed patients has focused on decoding intended hand trajectories from motor cortical neurons and using this signal to control external devices. In this study, higher level signals related to the goals of movements were decoded from three monkeys and used to position cursors on a computer screen without the animals emitting any behavior. Their performance in this task improved over a period of weeks. Expected value signals related to fluid preference, the expected magnitude, or probability of reward were decoded simultaneously with the intended goal. For neural prosthetic applications, the goal signals can be used to operate computers, robots, and vehicles, whereas the expected value signals can be used to continuously monitor a paralyzed patient's preferences and motivation.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Mail Code 216-76, Pasadena, CA 91125 USA.	andersen@vis.caltech.edu	Musallam, Sam/E-8064-2011; Corneil, Brian D/K-6401-2013	Corneil, Brian D/0000-0002-4702-7089; Greger, Bradley/0000-0002-6702-7596; Scherberger, Hansjorg/0000-0001-6593-2800				Batista AP, 1999, SCIENCE, V285, P257, DOI 10.1126/science.285.5425.257; Boussaoud D, 1999, EXP BRAIN RES, V128, P170, DOI 10.1007/s002210050832; Buneo CA, 2002, NATURE, V416, P632, DOI 10.1038/416632a; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Carey DP, 2000, CURR BIOL, V10, pR416, DOI 10.1016/S0960-9822(00)00508-X; Carmena JM, 2003, PLOS BIOL, V1, P193, DOI 10.1371/journal.pbio.0000042; Connolly JD, 2003, EXP BRAIN RES, V153, P140, DOI 10.1007/s00221-003-1587-1; CRAMMOND DJ, 1994, J NEUROPHYSIOL, V71, P1281, DOI 10.1152/jn.1994.71.3.1281; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FETZ EE, 1969, SCIENCE, V163, P955, DOI 10.1126/science.163.3870.955; Johnson PB, 1996, CEREB CORTEX, V6, P102, DOI 10.1093/cercor/6.2.102; Kakei S, 2003, NEUROSCI RES, V46, P1, DOI 10.1016/S0168-0102(03)00031-2; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; MOUNTCASTLE VB, 1975, J NEUROPHYSIOL, V38, P871, DOI 10.1152/jn.1975.38.4.871; Mussa-Ivaldi FA, 2003, TRENDS NEUROSCI, V26, P329, DOI 10.1016/S0166-2236(03)00121-8; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Roesch MR, 2003, J NEUROPHYSIOL, V90, P1766, DOI 10.1152/jn.00019.2003; Roitman JD, 2002, J NEUROSCI, V22, P9475; Scherberger H, 2003, J NEUROSCI METH, V130, P1, DOI 10.1016/S0165-0270(03)00190-0; Schultz W, 2000, NAT REV NEUROSCI, V1, P199, DOI 10.1038/35044563; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; Shenoy KV, 2003, NEUROREPORT, V14, P591, DOI 10.1097/00001756-200303240-00013; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; Turner JA, 2001, IEEE T NEUR SYS REH, V9, P154, DOI 10.1109/7333.928575; Watanabe M, 2001, EXP BRAIN RES, V140, P511, DOI 10.1007/s002210100856; Wessberg J, 2000, NATURE, V408, P361, DOI 10.1038/35042582; Wise SP, 1997, ANNU REV NEUROSCI, V20, P25, DOI 10.1146/annurev.neuro.20.1.25	29	503	527	5	103	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					258	262		10.1126/science.1097938	http://dx.doi.org/10.1126/science.1097938			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247483				2022-12-28	WOS:000222501000057
J	Ross, CA				Ross, CA			Huntington's disease: New paths to pathogenesis	CELL			English	Editorial Material								Huntington's disease is a progressive autosomal dominant neurodegenerative disorder caused by expansion of a CAG repeat coding for polyglutamine in the huntingtin protein. A recent report (Gauthier et al., 2004, this issue of Cell) suggests a new mechanism involving altered interactions with a protein involved in axonal transport, leading to loss of neurotrophic factor transport. This suggests an intriguing convergence to previously described pathways implicating neurotrophin transcription in HD pathogenesis.	Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Div Neurobiol, Dept Psychiat, 618 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.		Ross, Christopher A/H-8395-2013					Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; DiFiglia M, 2002, MOL CELL, V10, P224, DOI 10.1016/S1097-2765(02)00609-3; Feany MB, 2003, NEURON, V40, P1, DOI 10.1016/S0896-6273(03)00600-7; Gauthier LR, 2004, CELL, V118, P127, DOI 10.1016/j.cell.2004.06.018; Harjes P, 2003, TRENDS BIOCHEM SCI, V28, P425, DOI 10.1016/S0968-0004(03)00168-3; Ross CA, 2002, NEURON, V35, P819, DOI 10.1016/S0896-6273(02)00872-3; ROSS CA, 2004, NATURE; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Sugars KL, 2003, TRENDS GENET, V19, P233, DOI 10.1016/S0168-9525(03)00074-X; Tobin AJ, 2000, TRENDS CELL BIOL, V10, P531, DOI 10.1016/S0962-8924(00)01853-5	10	49	51	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	2004	118	1					4	7		10.1016/j.cell.2004.06.022	http://dx.doi.org/10.1016/j.cell.2004.06.022			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242639	Bronze			2022-12-28	WOS:000222626800003
J	Beutler, B				Beutler, B			Inferences, questions and possibilities in toll-like receptor signalling	NATURE			English	Review							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CHIMERIC MONOCLONAL-ANTIBODY; DOUBLE-STRANDED-RNA; FACTOR-ALPHA GENE; KINASE-C-THETA; DENDRITIC CELLS; DIPTERICIN PROMOTER; IMMUNE-RESPONSE; INSECT IMMUNITY	The Toll-like receptors (TLRs) are the key proteins that allow mammals-whether immunologically naive or experienced-to detect microbes. They lie at the core of our inherited resistance to disease, initiating most of the phenomena that occur in the course of infection. Quasi-infectious stimuli that have been used for decades to study inflammatory mechanisms can activate the TLR family of proteins. And it now seems that many inflammatory processes, both sterile and infectious, may depend on TLR signalling. We are in a good position to apply our understanding of TLR signalling to a range of challenges in immunology and medicine.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Beutler, B (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	bruce@scripps.edu						Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; ANDERSON KV, 1985, CELL, V42, P791, DOI 10.1016/0092-8674(85)90275-2; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Arsura M, 2003, ONCOGENE, V22, P412, DOI 10.1038/sj.onc.1206132; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Bartfai T, 2003, P NATL ACAD SCI USA, V100, P7971, DOI 10.1073/pnas.0932746100; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; BEUTLER B, 1985, NATURE, V316, P552, DOI 10.1038/316552a0; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BEUTLER B, IN PRESS ADV EXP MED; Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E; Broide D, 1999, INT ARCH ALLERGY IMM, V118, P453, DOI 10.1159/000024162; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Campos MA, 2004, J IMMUNOL, V172, P1711, DOI 10.4049/jimmunol.172.3.1711; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; CONDIE RM, 1955, P SOC EXP BIOL MED, V90, P355, DOI 10.3181/00379727-90-22032; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Freund J, 1942, P SOC EXP BIOL MED, V49, P548; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; GEORGEL P, 1993, BIOCHEM BIOPH RES CO, V197, P508, DOI 10.1006/bbrc.1993.2508; GOLDFELD AE, 1994, J EXP MED, V180, P763, DOI 10.1084/jem.180.2.763; Goldstein DR, 2003, J CLIN INVEST, V111, P1571, DOI 10.1172/JCI200317573; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Heikenwalder M, 2004, NAT MED, V10, P187, DOI 10.1038/nm987; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hoebe K, 2003, NAT IMMUNOL, V4, P1223, DOI 10.1038/ni1010; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iyer S, 2002, BRIT J DERMATOL, V146, P118, DOI 10.1046/j.0007-0963.2001.04529.x; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; Karaghiosoff M, 2003, NAT IMMUNOL, V4, P471, DOI 10.1038/ni910; Kawata T, 1999, BRIT J PHARMACOL, V127, P853, DOI 10.1038/sj.bjp.0702596; Krieg Arthur M, 2004, Curr Oncol Rep, V6, P88, DOI 10.1007/s11912-004-0019-0; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Le Bon A, 2001, IMMUNITY, V14, P461, DOI 10.1016/S1074-7613(01)00126-1; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Leadbetter Elizabeth A, 2003, Curr Dir Autoimmun, V6, P105; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lewis PA, 1924, J EXP MED, V40, P503, DOI 10.1084/jem.40.4.503; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Marinari B, 2004, P NATL ACAD SCI USA, V101, P6098, DOI 10.1073/pnas.0308688101; Maurer T, 2002, EUR J IMMUNOL, V32, P2356, DOI 10.1002/1521-4141(200208)32:8<2356::AID-IMMU2356>3.0.CO;2-Z; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; O'Neill LA, 2003, CURR OPIN PHARMACOL, V3, P396, DOI 10.1016/S1471-4892(03)00080-8; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Smirnova I, 2003, P NATL ACAD SCI USA, V100, P6075, DOI 10.1073/pnas.1031605100; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Viglianti GA, 2003, IMMUNITY, V19, P837, DOI 10.1016/S1074-7613(03)00323-6; Wang DH, 2004, MOL CELL BIOL, V24, P164, DOI 10.1128/MCB.24.1.164-171.2003; Wang PY, 1999, J BIOL CHEM, V274, P23235, DOI 10.1074/jbc.274.33.23235; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	85	1161	1265	0	104	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					257	263		10.1038/nature02761	http://dx.doi.org/10.1038/nature02761			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241424				2022-12-28	WOS:000222470600054
J	Matsuura, I; Denissova, NG; Wang, GN; He, DM; Long, JY; Liu, F				Matsuura, I; Denissova, NG; Wang, GN; He, DM; Long, JY; Liu, F			Cyclin-dependent kinases regulate the antiproliferative function of Smads	NATURE			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; C-MYC; RETINOBLASTOMA PROTEIN; TARGETED DISRUPTION; CDK INHIBITORS; CANCER; REPRESSION; P15(INK4B); SP1	Transforming growth factor-beta (TGF-beta) potently inhibits cell cycle progression at the G1 phase(1,2). Smad3 has a key function in mediating the TGF-beta growth-inhibitory response. Here we show that Smad3 is a major physiological substrate of the G1 cyclin-dependent kinases CDK4 and CDK2. Except for the retinoblastoma protein family(3,4), Smad3 is the only CDK4 substrate demonstrated so far. We have mapped CDK4 and CDK2 phosphorylation sites to Thr 8, Thr 178 and Ser 212 in Smad3. Mutation of the CDK phosphorylation sites increases Smad3 transcriptional activity, leading to higher expression of the CDK inhibitor p15. Mutation of the CDK phosphorylation sites of Smad3 also increases its ability to downregulate the expression of c-myc. Using Smad3(-/-) mouse embryonic fibroblasts and other epithelial cell lines, we further show that Smad3 inhibits cell cycle progression from G1 to S phase and that mutation of the CDK phosphorylation sites in Smad3 increases this ability. Taken together, these findings indicate that CDK phosphorylation of Smad3 inhibits its transcriptional activity and antiproliferative function. Because cancer cells often contain high levels of CDK activity(5,6), diminishing Smad3 activity by CDK phosphorylation may contribute to tumorigenesis and TGF-beta resistance in cancers.	Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Ernest Mario Sch Pharm, Piscataway, NJ 08854 USA; Canc Inst New Jersey, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Liu, F (corresponding author), Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA.	fangliu@cabm.rutgers.edu	Long, Jianyin/H-8261-2013; Matsuura, Isao/E-3979-2010					Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; Datto MB, 1999, MOL CELL BIOL, V19, P2495; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Frederick JP, 2004, MOL CELL BIOL, V24, P2546, DOI 10.1128/MCB.24.6.2546-2559.2004; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Han SU, 2004, ONCOGENE, V23, P1333, DOI 10.1038/sj.onc.1207259; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Kim MJ, 2002, CANCER RES, V62, P2999; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuura I, 1996, J BIOL CHEM, V271, P5443, DOI 10.1074/jbc.271.10.5443; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Phelps DE, 1997, METHOD ENZYMOL, V283, P194; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Rich JN, 1999, J BIOL CHEM, V274, P35053, DOI 10.1074/jbc.274.49.35053; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SWIFT S, 1999, CURR PROTOCOLS IMM S, V31; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yagi K, 2002, J BIOL CHEM, V277, P854, DOI 10.1074/jbc.M104170200; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280; Zhu YA, 1998, CELL, V94, P703, DOI 10.1016/S0092-8674(00)81730-4	30	387	411	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					226	231		10.1038/nature02650	http://dx.doi.org/10.1038/nature02650			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241418	Bronze			2022-12-28	WOS:000222470600048
J	Chapman, R; Tully, A				Chapman, R; Tully, A			A life-threatening sore throat	LANCET			English	Editorial Material							FUSOBACTERIUM-NECROPHORUM INFECTIONS		Vale Leven Dist Gen Hosp, Dept Anaesthesiol, Alexandria G83 OUA, Scotland		Chapman, R (corresponding author), Vale Leven Dist Gen Hosp, Dept Anaesthesiol, Alexandria G83 OUA, Scotland.	Roddy.chapman@vol.scot.nhs.uk						Brazier JS, 2002, J MED MICROBIOL, V51, P269, DOI 10.1099/0022-1317-51-3-269; Brazier JS, 2002, REV MED MICROBIOL, V13, P141; Chirinos JA, 2002, MEDICINE, V81, P458, DOI 10.1097/00005792-200211000-00006; Lemierre A, 1936, LANCET, V1, P701	4	6	6	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					112	112		10.1016/S0140-6736(04)16601-4	http://dx.doi.org/10.1016/S0140-6736(04)16601-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234866				2022-12-28	WOS:000222392900043
J	Chebli, JMF; Gaburri, PD; Pinto, JRF				Chebli, JMF; Gaburri, PD; Pinto, JRF			Enterovesical-fistula in Crohn's disease	LANCET			English	Editorial Material									Monte Sinai Hosp, BR-36036247 Juiz De Fora, MG, Brazil		Chebli, JMF (corresponding author), Monte Sinai Hosp, BR-36036247 Juiz De Fora, MG, Brazil.		Chebli, Julio MF/I-1528-2014	Chebli, Julio MF/0000-0003-1527-0663					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					68	68		10.1016/S0140-6736(04)16592-6	http://dx.doi.org/10.1016/S0140-6736(04)16592-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234859	Bronze			2022-12-28	WOS:000222392900034
J	Knaden, M; Wehner, R				Knaden, M; Wehner, R			Path integration in desert ants controls aggressiveness	SCIENCE			English	Article									Univ Zurich, Dept Zool, CH-8057 Zurich, Switzerland	University of Zurich	Wehner, R (corresponding author), Univ Zurich, Dept Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	rwehner@zool.unizh.ch	Knaden, Markus/E-2151-2015	Knaden, Markus/0000-0002-6710-1071				Baier A, 2002, J EXP BIOL, V205, P1233; DAVIES NB, 1978, ANIM BEHAV, V26, P138, DOI 10.1016/0003-3472(78)90013-1; Knaden M, 2003, J INSECT BEHAV, V16, P717, DOI 10.1023/B:JOIR.0000007706.38674.73; Kravitz EA, 2000, J COMP PHYSIOL A, V186, P221, DOI 10.1007/s003590050423; Stevenson PA, 2000, J NEUROBIOL, V43, P107; Wehner Ruediger, 2003, P9	6	20	20	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					60	60		10.1126/science.1097165	http://dx.doi.org/10.1126/science.1097165			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232099				2022-12-28	WOS:000222386000032
J	Raymond, JC				Raymond, JC			Imaging the Sun's eruptions in three dimensions	SCIENCE			English	Editorial Material									Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution	Raymond, JC (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.	raymond@cfa.harvard.edu						Ciaravella A, 2000, ASTROPHYS J, V529, P575, DOI 10.1086/308260; Dobrzycka D, 1999, J GEOPHYS RES-SPACE, V104, P9791, DOI 10.1029/1998JA900129; Frazin RA, 2002, ASTROPHYS J, V570, P408, DOI 10.1086/339572; Kumar A, 1996, J GEOPHYS RES-SPACE, V101, P15667, DOI 10.1029/96JA00544; Low BC, 2001, J GEOPHYS RES-SPACE, V106, P25141, DOI 10.1029/2000JA004015; Moran TG, 2004, SCIENCE, V305, P66, DOI 10.1126/science.1098937	6	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					49	50		10.1126/science.1100371	http://dx.doi.org/10.1126/science.1100371			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232094				2022-12-28	WOS:000222386000027
J	Hallett, TB; Coulson, T; Pilkington, JG; Clutton-Brock, TH; Pemberton, JM; Grenfell, BT				Hallett, TB; Coulson, T; Pilkington, JG; Clutton-Brock, TH; Pemberton, JM; Grenfell, BT			Why large-scale climate indices seem to predict ecological processes better than local weather	NATURE			English	Article							NORTH-ATLANTIC OSCILLATION; POPULATION-DYNAMICS; COHORT VARIATION; RED DEER; DENSITY; FLUCTUATIONS; SURVIVAL	Large-scale climatic indices such as the North Atlantic Oscillation(1) are associated with population dynamics(2), variation in demographic rates(3) and values of phenotypic traits(4,5) in many species. Paradoxically, these large-scale indices can seem to be better predictors of ecological processes than local climate(5-8). Using detailed data from a population of Soay sheep(9,10), we show that high rainfall, high winds or low temperatures at any time during a 3-month period can cause mortality either immediately or lagged by a few days. Most measures of local climate used by ecologists fail to capture such complex associations between weather and ecological process, and this may help to explain why large-scale, seasonal indices of climate spanning several months can outperform local climatic factors. Furthermore, we show why an understanding of the mechanism by which climate influences population ecology is important. Through simulation we demonstrate that the timing of bad weather within a period of mortality can have an important modifying influence on intra-specific competition for food, revealing an interaction between climate and density dependence(11) that the use of large-scale climatic indices or inappropriate local weather variables might obscure.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ascot SL5 7PY, Berks, England; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland	Imperial College London; University of Cambridge; University of Edinburgh	Coulson, T (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Silwood Pk, Ascot SL5 7PY, Berks, England.	t.coulson@imperial.ac.uk	Coulson, Tim/AAL-8148-2021; Pemberton, Josephine M/F-3100-2010	Coulson, Tim/0000-0001-9371-9003; Hallett, Timothy/0000-0002-9681-0424				ALBON SD, 1983, J ZOOL, V200, P295; ALBON SD, 1987, J ANIM ECOL, V56, P69, DOI 10.2307/4800; Catchpole EA, 2000, J R STAT SOC C-APPL, V49, P453, DOI 10.1111/1467-9876.00205; Clutton-Brock TH, 2002, PHILOS T R SOC B, V357, P1285, DOI 10.1098/rstb.2002.1128; CluttonBrock TH, 1996, J ANIM ECOL, V65, P675, DOI 10.2307/5667; CluttonBrock TH, 1997, AM NAT, V149, P195, DOI 10.1086/285987; CLUTTONBROCK TH, 1992, J ANIM ECOL, V61, P381, DOI 10.2307/5330; Coulson T, 2001, SCIENCE, V292, P1528, DOI 10.1126/science.292.5521.1528; Elton CS, 1924, BR J EXP BIOL, V2, P119; Forchhammer MC, 2001, J ANIM ECOL, V70, P721, DOI 10.1046/j.0021-8790.2001.00532.x; Gaillard JM, 1997, OECOLOGIA, V112, P502, DOI 10.1007/s004420050338; Grenfell BT, 1998, NATURE, V394, P674, DOI 10.1038/29291; GULLAND FMD, 1992, PARASITOLOGY, V105, P493, DOI 10.1017/S0031182000074679; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; ILLIUS AW, 2002, 38 S BES HERB PLANTS; Jewell P.A., 1974, ISLAND SURVIVORS ECO; KELLER LF, 1994, ARDEA, V82, P349; MILLONAS M, 1995, FLUCTUATIONS ORDER N; Milner JM, 1999, J ANIM ECOL, V68, P1235, DOI 10.1046/j.1365-2656.1999.00366.x; Mysterud A, 2003, N ATLANTIC OSCILLATI, P235; Nicholson AJ, 1933, J ANIM ECOL, V2, P132, DOI 10.2307/954; Post E, 1999, ECOLOGY, V80, P1322, DOI 10.1890/0012-9658(1999)080[1322:CVPPAN]2.0.CO;2; Post E, 1998, J ANIM ECOL, V67, P537, DOI 10.1046/j.1365-2656.1998.00216.x; Post E, 2002, NATURE, V420, P168, DOI 10.1038/nature01064; Stenseth NC, 1999, P ROY SOC B-BIOL SCI, V266, P1645, DOI 10.1098/rspb.1999.0827; Stenseth NC, 2003, P ROY SOC B-BIOL SCI, V270, P2087, DOI 10.1098/rspb.2003.2415; Stenseth NC, 2002, SCIENCE, V297, P1292, DOI 10.1126/science.1071281; Turchin Peter, 2003, Monographs in Population Biology, V35, pi	28	412	422	4	174	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					71	75		10.1038/nature02708	http://dx.doi.org/10.1038/nature02708			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229599				2022-12-28	WOS:000222356800044
J	Dorak, MT; Tang, FM; Penman-Aguilar, A; Westfall, AO; Zulu, I; Lobashevsky, ES; Kancheya, NG; Schaen, MM; Allen, SA; Kaslow, RA				Dorak, MT; Tang, FM; Penman-Aguilar, A; Westfall, AO; Zulu, I; Lobashevsky, ES; Kancheya, NG; Schaen, MM; Allen, SA; Kaslow, RA			Transmission of HIV-1 and HLA-B allele-sharing within serodiscordant heterosexual Zambian couples	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CLASS-I; DISCORDANT COUPLES; RESISTANCE; INFECTION	Factors that might increase risk of HIV-1 transmission include age, sex, and amount of HIV-1 RNA in plasma, but findings for HLA allele-sharing are not in agreement. We tested the hypothesis that allele sharing at HLA loci is associated with increased risk of transmission of HIV-1 infection in cohabiting heterosexual Zambian couples. We studied 125 initially serodiscordant partners with sequence-confirmed interpartner HIV-1 transmission and 104 couples who were persistently serodiscordant, and we analysed relations with molecularly typed HLA-A, B, and C alleles by survival techniques. After adjustment for other genetic and non-genetic risk factors seen with heterosexual transmission of HIV-1 in this cohort, sharing of HLA-B alleles was independently associated with accelerated intracouple transmission (relative hazard 2.23, 95% Cl 1.52-3.26, p<0.0001). Selective pressure by HLA-B alleles on transmitted viruses accords with current understanding of the effect of B locus polymorphism in HIV-1 and perhaps other infections.	Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostat, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Zambia UAB HIV Res Project, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Kaslow, RA (corresponding author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.	rkaslow@uab.edu	Tang, Jianming "James"/O-4980-2019	Tang, Jianming "James"/0000-0003-0137-7486; Westfall, Andrew/0000-0002-0468-4695	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041530, R01AI041951, R01AI040951, P30AI027767] Funding Source: NIH RePORTER; NIAID NIH HHS [U01-AI41530, R01-AI41951, R01-AI40951, P30-AI27767] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allen S, 2003, AIDS, V17, P733, DOI 10.1097/00002030-200303280-00012; Fideli OS, 2001, AIDS RES HUM RETROV, V17, P901, DOI 10.1089/088922201750290023; Liu CL, 2003, J INFECT DIS, V187, P1404, DOI 10.1086/374394; Lockett SF, 2001, J ACQ IMMUN DEF SYND, V27, P277, DOI 10.1097/00126334-200107010-00010; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; MacDonald KS, 2000, J INFECT DIS, V181, P1581, DOI 10.1086/315472; Peters B, 2004, LANCET, V363, P518, DOI 10.1016/S0140-6736(04)15538-4; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Tang JM, 2002, J VIROL, V76, P8276, DOI 10.1128/JVI.76.16.8276-8284.2002; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Trask SA, 2002, J VIROL, V76, P397, DOI 10.1128/JVI.76.1.397-405.2002	11	48	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2137	2139		10.1016/S0140-6736(04)16505-7	http://dx.doi.org/10.1016/S0140-6736(04)16505-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220037				2022-12-28	WOS:000222268300012
J	England, JD; Asbury, AK				England, JD; Asbury, AK			Peripheral neuropathy	LANCET			English	Review							NERVE-FIBER DENSITY; ROCHESTER DIABETIC-NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; IMPAIRED GLUCOSE-TOLERANCE; CARPAL-TUNNEL-SYNDROME; NEUROLOGICAL COMPLICATIONS; SENSORY POLYNEUROPATHY; HEREDITARY NEUROPATHY; METHYLMALONIC ACID; GLUTEN SENSITIVITY		Deaconess Billings Clin, Dept Neurosci, Billings, MT 59107 USA; Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	University of Pennsylvania	England, JD (corresponding author), Deaconess Billings Clin, Dept Neurosci, 2825 8th Ave N, Billings, MT 59107 USA.	jengland@billingsclinic.org						ALBERS JW, 1995, ANN NEUROL, V38, P478; ALBERS JW, 1993, J CLIN NEUROPHYSIOL, V10, P149, DOI 10.1097/00004691-199304000-00003; Annane D, 1997, ANN NEUROL, V41, P298; [Anonymous], 1992, NEUROLOGY, V42, P1823; ASBURY AK, 1995, PERIPHERAL NERVE DIS; Barohn RJ, 1998, SEMIN NEUROL, V18, P7, DOI 10.1055/s-2008-1040857; BAROHN RJ, 1989, ARCH NEUROL-CHICAGO, V46, P878, DOI 10.1001/archneur.1989.00520440064022; Beghi E, 1996, BRAIN, V119, P2053; Beydoun SR, 1998, MUSCLE NERVE, V21, P813, DOI 10.1002/(SICI)1097-4598(199806)21:6<813::AID-MUS18>3.0.CO;2-T; Boerkoel CF, 2002, ANN NEUROL, V51, P190, DOI 10.1002/ana.10089; Boerkoel Cornelius F, 2002, Curr Neurol Neurosci Rep, V2, P70, DOI 10.1007/s11910-002-0056-8; Bosboom WMJ, 2001, BRAIN, V124, P2427, DOI 10.1093/brain/124.12.2427; Bouchard C, 1999, NEUROLOGY, V52, P498, DOI 10.1212/WNL.52.3.498; Busby M, 2003, J NEUROL, V250, P714, DOI 10.1007/s00415-003-1068-2; Campoamor JN, 2001, CRYPTOGAMIE MYCOL, V22, P175, DOI 10.1016/S0181-1584(01)01068-5; *CDCP, 2002, MMWR-MORBID MORTAL W, V51, P825; Chang AP, 1998, MUSCLE NERVE, V21, P964, DOI 10.1002/(SICI)1097-4598(199807)21:7<964::AID-MUS21>3.3.CO;2-I; CHAUDHRY V, 1993, ANN NEUROL, V33, P237, DOI 10.1002/ana.410330303; Chin RL, 2003, NEUROLOGY, V60, P1581, DOI 10.1212/01.WNL.0000063307.84039.C7; Cross AH, 2003, NEUROLOGY, V60, P1566, DOI 10.1212/01.WNL.0000067475.16126.5F; Davies L, 1996, BRAIN, V119, P1441, DOI 10.1093/brain/119.5.1441; Deprez M, 2000, ACTA NEUROL BELG, V100, P162; Dyck PJ, 1997, NEUROLOGY, V49, P229, DOI 10.1212/WNL.49.1.229; DYCK PJ, 1992, NEUROLOGY, V42, P1164, DOI 10.1212/WNL.42.6.1164; DYCK PJ, 1987, DIABETES CARE, V10, P432, DOI 10.2337/diacare.10.4.432; DYCK PJ, 1985, BRAIN, V108, P861, DOI 10.1093/brain/108.4.861; Dyck PJB, 1999, NEUROLOGY, V53, P2113, DOI 10.1212/WNL.53.9.2113; England JD, 1999, CURR OPIN NEUROL, V12, P597, DOI 10.1097/00019052-199910000-00014; ENGLAND JD, 2001, ADV NEUROLOGY NEUROM, P147; FELDMAN EL, 1994, DIABETES CARE, V17, P1281, DOI 10.2337/diacare.17.11.1281; Flachenecker P, 1999, J NEUROL, V246, P93, DOI 10.1007/s004150050314; Flaherty ML, 2003, MAYO CLIN PROC, V78, P1245, DOI 10.4065/78.10.1245; Gabriel CM, 2000, J NEUROL NEUROSUR PS, V69, P442, DOI 10.1136/jnnp.69.4.442; GENTILE S, 1995, ACTA DIABETOL, V32, P7, DOI 10.1007/BF00581037; Gerritsen AAM, 2002, JAMA-J AM MED ASSOC, V288, P1245, DOI 10.1001/jama.288.10.1245; Glass JD, 2002, NEW ENGL J MED, V347, P1280, DOI 10.1056/NEJM200210173471616; Gorson KC, 1997, NEUROLOGY, V48, P321, DOI 10.1212/WNL.48.2.321; Hadjivassiliou M, 1997, J NEUROL NEUROSUR PS, V63, P770, DOI 10.1136/jnnp.63.6.770; Hadjivassiliou M, 2002, J NEUROL NEUROSUR PS, V72, P560, DOI 10.1136/jnnp.72.5.560; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; Holland NR, 1997, NEUROLOGY, V48, P708, DOI 10.1212/WNL.48.3.708; Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736; Hughes RAC, 1997, LANCET, V349, P225; Hughes RAC, 2002, BRIT MED J, V324, P466, DOI 10.1136/bmj.324.7335.466; HUGHES RAC, 2001, COCHRANE DATABASE SY, V3; ILAT JM, 2003, MUSCLE NERVE, V27, P478; Jann S, 2001, MUSCLE NERVE, V24, P1197, DOI 10.1002/mus.1132; Jeha LE, 2003, NEUROLOGY, V61, P55, DOI 10.1212/01.WNL.0000073617.08185.0A; KAKU DA, 1994, BRAIN, V117, P941, DOI 10.1093/brain/117.5.941; Katz JN, 2002, NEW ENGL J MED, V346, P1807, DOI 10.1056/NEJMcp013018; Kelley TW, 2003, NEW ENGL J MED, V348, P564, DOI 10.1056/NEJM200302063480618; KENNEDY WR, 1993, J NEUROL SCI, V115, P184, DOI 10.1016/0022-510X(93)90223-L; Kline D., 1995, NERVE INJURIES; Krarup C, 1996, BRAIN, V119, P257, DOI 10.1093/brain/119.1.257; Lauria G, 2001, MUSCLE NERVE, V24, P1034, DOI 10.1002/mus.1107; Leis AA, 2003, MUSCLE NERVE, V28, P302, DOI 10.1002/mus.10440; Leis AA, 2003, LANCET INFECT DIS, V3, P9, DOI 10.1016/S1473-3099(03)00478-X; Leis AA, 2002, NEW ENGL J MED, V347, P1279, DOI 10.1056/NEJM2002c021587; Lenssen PPA, 1998, BRAIN, V121, P1451, DOI 10.1093/brain/121.8.1451; Li J, 2003, ANN NEUROL, V53, P703, DOI 10.1002/ana.10575; LINDENBAUM J, 1990, AM J HEMATOL, V34, P99, DOI 10.1002/ajh.2830340205; Magda P, 2003, ARCH NEUROL-CHICAGO, V60, P1755, DOI 10.1001/archneur.60.12.1755; MARKENSON JA, 1996, AM J MED S1, V101, P6; Martyn C, 1997, J NEUROL NEUROSUR PS, V62, P310, DOI 10.1136/jnnp.62.4.310; McArthur JC, 1998, ARCH NEUROL-CHICAGO, V55, P1513, DOI 10.1001/archneur.55.12.1513; Mendell JR, 2003, NEW ENGL J MED, V348, P1243, DOI 10.1056/NEJMcp022282; MONTICELLI ML, 1993, NEUROEPIDEMIOLOGY, V12, P96, DOI 10.1159/000110307; Muller AF, 1996, AM J GASTROENTEROL, V91, P1430; Narayan KMV, 2003, JAMA-J AM MED ASSOC, V290, P1884, DOI 10.1001/jama.290.14.1884; Nobile-Orazio E, 2001, J NEUROIMMUNOL, V115, P4, DOI 10.1016/S0165-5728(01)00266-1; NOTERMANS NC, 1994, J NEUROL NEUROSUR PS, V57, P1525, DOI 10.1136/jnnp.57.12.1525; Novella SP, 2001, MUSCLE NERVE, V24, P1229, DOI 10.1002/mus.1137; OLLAT H, 1995, CLIN NEUROPHARMACOL, V18, P391, DOI 10.1097/00002826-199510000-00002; Pareyson D, 1998, MUSCLE NERVE, V21, P1686, DOI 10.1002/(SICI)1097-4598(199812)21:12<1686::AID-MUS10>3.0.CO;2-Z; PARRY GJ, 1988, MUSCLE NERVE, V11, P103, DOI 10.1002/mus.880110203; RAPHAEL JC, 2001, COCHRANE DATABASE; Rempel D, 1998, AM J PUBLIC HEALTH, V88, P1447, DOI 10.2105/AJPH.88.10.1447; Rosenberg NR, 2001, J NEUROL NEUROSUR PS, V71, P205, DOI 10.1136/jnnp.71.2.205; Rotta FT, 2000, J NEUROL SCI, V173, P129, DOI 10.1016/S0022-510X(99)00317-2; Russell JW, 2001, MUSCLE NERVE, V24, P1109, DOI 10.1002/mus.1122; Said G, 2002, ARCH NEUROL-CHICAGO, V59, P1532, DOI 10.1001/archneur.59.10.1532; Said G, 1999, MUSCLE NERVE, V22, P1617, DOI 10.1002/(SICI)1097-4598(199912)22:12<1617::AID-MUS1>3.0.CO;2-L; Said G, 2001, LANCET, V357, P1220, DOI 10.1016/S0140-6736(00)04449-4; Saperstein DS, 2001, MUSCLE NERVE, V24, P311, DOI 10.1002/1097-4598(200103)24:3<311::AID-MUS1001>3.3.CO;2-1; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; Sindrup SH, 2000, NEUROLOGY, V55, P915, DOI 10.1212/WNL.55.7.915; Singleton JR, 2001, MUSCLE NERVE, V24, P1225, DOI 10.1002/mus.1136; Stewart JD, 2000, FOCAL PERIPHERAL NEU; Sullivan J.B., 1992, J OCCUPAT ENV MED, V34, P365; Sumner CJ, 2003, NEUROLOGY, V60, P108, DOI 10.1212/WNL.60.1.108; Teunissen LL, 1997, BRAIN, V120, P955, DOI 10.1093/brain/120.6.955; VALLAT JM, 1995, CURR OPIN NEUROL, V8, P345, DOI 10.1097/00019052-199510000-00003; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Wills A, 1996, GUT, V39, P501, DOI 10.1136/gut.39.4.501; Wolfe GI, 1999, ARCH NEUROL-CHICAGO, V56, P540, DOI 10.1001/archneur.56.5.540; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0	96	170	182	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2151	2161		10.1016/S0140-6736(04)16508-2	http://dx.doi.org/10.1016/S0140-6736(04)16508-2			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220040				2022-12-28	WOS:000222268300021
J	Coplan, PM; Mitchnick, M; Rosenberg, ZF				Coplan, PM; Mitchnick, M; Rosenberg, ZF			Regulatory challenges in microbicide development	SCIENCE			English	Editorial Material							HIV; TRANSMISSION; INFECTION		Int Partnership Microbicides, Silver Spring, MD 20910 USA		Coplan, PM (corresponding author), Int Partnership Microbicides, Silver Spring, MD 20910 USA.	PCoplan@ipm-microbicides.org		Coplan, Paul/0000-0002-7078-7780				*DIV ANT DRUG PROD, 2003, MEM ANT DRUGS ADV CO; FARLEY T, 2003, FDA ANT DRUGS ADV CO; Foss AM, 2003, AIDS, V17, P1227, DOI 10.1097/00002030-200305230-00015; GUPTA GR, 2004, MICR 2004 C 28 31 MA; Milstien J, 2004, B WORLD HEALTH ORGAN, V82, P128; MILSTIEN J, 2002, DIVERGENCE VACCINE P; RAMJEE G, 2004, HIV PREV TRIALS NETW; *RWAND OFF NAT POP, 2001, DEM HLTH SURV 2000; Shattock R, 2004, LANCET, V363, P1002, DOI 10.1016/S0140-6736(04)15876-5; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Stone A, 2002, NAT REV DRUG DISCOV, V1, P977, DOI 10.1038/nrd959; UNAIDS, 2003, AIDS EP UPD; Van Damme L, 2003, LANCET, V361, P786; Watts C, 2001, AIDS, V15, pS43, DOI 10.1097/00002030-200102001-00064; Weber J, 2001, AIDS, V15, P1563, DOI 10.1097/00002030-200108170-00014; *WHO, 2003, HIV AIDS EP SURV UPD; Williams B, 2001, STAT MED, V20, P2003, DOI 10.1002/sim.840; WU T, 2004, MICR 2004 C 28 31 MA	18	26	27	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1911	1912		10.1126/science.1100441	http://dx.doi.org/10.1126/science.1100441			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218130				2022-12-28	WOS:000222241600025
J	McKendry, M; McGloin, H; Saberi, D; Caudwell, L; Brady, AR; Singer, M				McKendry, M; McGloin, H; Saberi, D; Caudwell, L; Brady, AR; Singer, M			Randomised controlled trial assessing the impact of a nurse delivered, flow monitored protocol for optimisation of circulatory status after cardiac surgery	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK SURGICAL PATIENTS; GUT MUCOSAL HYPOPERFUSION; HOSPITAL STAY; ESOPHAGEAL DOPPLER; OXYGEN DELIVERY; ORGAN FAILURE; COMPLICATIONS; MORBIDITY; MORTALITY; SURVIVORS	Objective To assess whether a nurse led, flow monitored protocol for optimising circulatory status in patients after cardiac Surgery reduces complications and shortens stay in intensive care and hospital. Design Randomised controlled trial. Setting Intensive care unit and cardiothoracic unit of a university teaching hospital. Participants 174 patients who had cardiac surgery between April 2000 and January 2003. Interventions Patients were allocated to conventional haemodynamic management or to an algorithm guided by oesophageal Doppler flowmetry to maintain a stroke index above 35 ml/m(2). Results 26 control patients had postoperative complications (two deaths) compared with 17 (four deaths) protocol patients (P = 0.08). Duration of hospital stay in the protocol group was significantly reduced from a median of nine (interquartile range 7-12) days to seven (7-10 days; P = 0.02). The mean duration of hospital stay was reduced from 13.9 to 11.4 days, a saving in hospital bed days of 18% (95% confidence interval -12% to 47%). Usage of intensive care beds was reduced by 23% (-8% to 59%). Conclusions A nurse delivered protocol for optimising circulatory status in the early postoperative period after cardiac surgery may significantly shorten hospital stay.	Middlesex Hosp, Univ Coll London, Bloomsbury Inst Intens Care Med, Dept Med, London W1T 3AA, England; Middlesex Hosp, Univ Coll London, Wolfson Inst Biomed Res, London W1T 3AA, England	University of London; University College London; University of London; University College London	Singer, M (corresponding author), Middlesex Hosp, Univ Coll London, Bloomsbury Inst Intens Care Med, Dept Med, London W1T 3AA, England.	m.singer@ucl.ac.uk	Singer, Mervyn/J-4425-2012; Singer, Mervyn/Q-6142-2019	Singer, Mervyn/0000-0002-1042-6350; Singer, Mervyn/0000-0002-1042-6350; Brady, Tony/0000-0003-4751-7616				BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; Gan TJ, 2002, ANESTHESIOLOGY, V97, P820, DOI 10.1097/00000542-200210000-00012; Kern JW, 2002, CRIT CARE MED, V30, P1686, DOI 10.1097/00003246-200208000-00002; Maillet JM, 2003, CHEST, V123, P1361, DOI 10.1378/chest.123.5.1361; MYTHEN MG, 1995, ARCH SURG-CHICAGO, V130, P423; MYTHEN MG, 1994, INTENS CARE MED, V20, P99, DOI 10.1007/BF01707662; OLDER P, 1993, CHEST, V104, P701, DOI 10.1378/chest.104.3.701; PARSONNET V, 1989, CIRCULATION S1, V79, P13; Poeze M, 1999, CRIT CARE MED, V27, P1288, DOI 10.1097/00003246-199907000-00013; Polanczyk CA, 2001, JAMA-J AM MED ASSOC, V286, P309, DOI 10.1001/jama.286.3.309; Polonen P, 2000, ANESTH ANALG, V90, P1052; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; SHIEMAKER WC, 1990, CRIT CARE MED, V27, P2147; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; Shoemaker WC, 1999, WORLD J SURG, V23, P1264, DOI 10.1007/s002689900660; Sinclair S, 1997, BMJ-BRIT MED J, V315, P909; SINGER M, 1991, CRIT CARE MED, V19, P1132, DOI 10.1097/00003246-199109000-00007; Singhapakdi A., 1991, J PERS SELL SALES M, V11, P1, DOI 10.1080/08853134.1991.10753885; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Valtier B, 1998, AM J RESP CRIT CARE, V158, P77, DOI 10.1164/ajrccm.158.1.9707031; VEM, 2002, BR J ANAESTH, V88, P65; Venn R, 2002, BRIT J ANAESTH, V88, P65, DOI 10.1093/bja/88.1.65; Welsby IJ, 2002, ANESTH ANALG, V94, P1072, DOI 10.1097/00000539-200205000-00004; Wilson J, 1999, BRIT MED J, V318, P1099, DOI 10.1136/bmj.318.7191.1099	25	215	229	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2004	329	7460					258	261		10.1136/bmj.38156.767118.7C	http://dx.doi.org/10.1136/bmj.38156.767118.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BY	15242867	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000223133300015
J	Toyoshima, C; Mizutani, T				Toyoshima, C; Mizutani, T			Crystal structure of the calcium pump with a bound ATP analogue	NATURE			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; NUCLEOTIDE-BINDING DOMAIN; CA2+ TRANSPORT; ION-TRANSPORT; FUNCTIONAL CONSEQUENCES; SEGMENT; MECHANISM; CA-2+-ATPASE; DISSOCIATION; ORGANIZATION	P-type ATPases are ATP-powered ion pumps that establish ion concentration gradients across cell and organelle membranes. Here, we describe the crystal structure of the Ca2+ pump of skeletal muscle sarcoplasmic reticulum, a representative member of the P-type ATPase superfamily, with an ATPanalogue, a Mg2+ and two Ca2+ ions in the respective binding sites. In this state, the ATP analogue reorganizes the three cytoplasmic domains ( A, N and P), which are widely separated without nucleotide, by directly bridging the N and P domains. The structure of the P-domain itself is altered by the binding of the ATP analogue and Mg2+. As a result, the A-domain is tilted so that one of the transmembrane helices moves to lock the cytoplasmic gate of the transmembrane Ca2+-binding sites. This appears to be the mechanism for occluding the bound Ca2+ ions, before releasing them into the lumen of the sarcoplasmic reticulum.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Toyoshima, C (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan.	ct@iam.u-tokyo.ac.jp	Toyoshima, Chikashi/R-4153-2019; Mizutani, Tatsuaki/AAA-5044-2021	Mizutani, Tatsuaki/0000-0002-4323-4347; Toyoshima, Chikashi/0000-0001-9640-0778				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; BRANDL CJ, 1987, J BIOL CHEM, V262, P3768; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cappello V, 2002, PROTEINS, V47, P106, DOI 10.1002/prot.10070; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; COLL RJ, 1984, J BIOL CHEM, V259, P4249; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; Einholm AP, 2004, J BIOL CHEM, V279, P15888, DOI 10.1074/jbc.M400158200; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Hayward S, 1999, PROTEINS, V36, P425, DOI 10.1002/(SICI)1097-0134(19990901)36:4<425::AID-PROT6>3.3.CO;2-J; Hilge M, 2003, NAT STRUCT BIOL, V10, P468, DOI 10.1038/nsb924; INESI G, IN PRESS J BIOL CHEM; Jacobsen MD, 2002, BIOCHEMISTRY-US, V41, P1451, DOI 10.1021/bi015891h; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lahiri SD, 2002, BIOCHEMISTRY-US, V41, P8351, DOI 10.1021/bi0202373; Liu M, 2003, J BIOL CHEM, V278, P10112, DOI 10.1074/jbc.M212403200; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1989, J BIOL CHEM, V264, P13038; McIntosh D.B., 1998, ADV MOL CEL A&B, V23A, P33; McIntosh DB, 1999, J BIOL CHEM, V274, P25227, DOI 10.1074/jbc.274.36.25227; McIntosh DB, 1996, J BIOL CHEM, V271, P25778, DOI 10.1074/jbc.271.42.25778; Mintz E, 1997, BBA-BIOENERGETICS, V1318, P52, DOI 10.1016/S0005-2728(96)00132-6; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POST RL, 1972, J BIOL CHEM, V247, P6530; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; Toyoshima C, 2003, FEBS LETT, V555, P106, DOI 10.1016/S0014-5793(03)01086-X; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; Wang WR, 2002, J MOL BIOL, V319, P421, DOI 10.1016/S0022-2836(02)00324-8; Xu C, 2002, J MOL BIOL, V316, P201, DOI 10.1006/jmbi.2001.5330; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m	45	364	378	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	2004	430	6999					529	535		10.1038/nature02680	http://dx.doi.org/10.1038/nature02680			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841QI	15229613				2022-12-28	WOS:000222946100039
J	Reichardt, LF; Mobley, WC				Reichardt, LF; Mobley, WC			Going the distance, or not, with neurotrophin signals	CELL			English	Editorial Material							CRYSTAL-STRUCTURE; RECEPTORS; NEURONS; POINT	NGF and NT-3 both signal through TrkA receptors on the axons of developing sympathetic neurons, but while NGF supports survival and differentiation, NT-3 does not. In this issue of Cell, the difference is explained as the ability of NGF, but not NT-3, to induce internalization and retrograde transport of activated TrkA (Kuruvilla et al., 2004).	Univ Calif San Francisco, Program Neurosci, Dept Phys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Stanford Univ, Inst Neurosci, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Stanford University; Stanford University	Reichardt, LF (corresponding author), Univ Calif San Francisco, Program Neurosci, Dept Phys, 1550 4th St,Room 284A, San Francisco, CA 94143 USA.							Banfield MJ, 2001, STRUCTURE, V9, P1191, DOI 10.1016/S0969-2126(01)00681-5; Barker PA, 2004, NEURON, V42, P529, DOI 10.1016/j.neuron.2004.04.001; Bentley CA, 2000, J NEUROSCI, V20, P7706; Butte MJ, 1998, BIOCHEMISTRY-US, V37, P16846, DOI 10.1021/bi981254o; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Francis N, 1999, DEV BIOL, V210, P411, DOI 10.1006/dbio.1999.9269; Howe CL, 2004, J NEUROBIOL, V58, P207, DOI 10.1002/neu.10323; Kuruvilla R, 2004, CELL, V118, P243, DOI 10.1016/j.cell.2004.06.021; Minichiello L, 1998, NEURON, V21, P335, DOI 10.1016/S0896-6273(00)80543-7; SHELTON DL, 1995, J NEUROSCI, V15, P477, DOI 10.1523/jneurosci.15-01-00477.1995	10	28	37	1	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	2004	118	2					141	143		10.1016/j.cell.2004.07.008	http://dx.doi.org/10.1016/j.cell.2004.07.008			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260984	Bronze			2022-12-28	WOS:000222966000003
J	Povar, GJ; Blumen, H; Daniel, J; Daub, S; Evans, L; Holm, RP; Levkovich, N; McCarter, AO; Snyder, L; Sulmasy, D; Vaughan, P; Wellikson, LD; Campbell, A				Povar, GJ; Blumen, H; Daniel, J; Daub, S; Evans, L; Holm, RP; Levkovich, N; McCarter, AO; Snyder, L; Sulmasy, D; Vaughan, P; Wellikson, LD; Campbell, A		Med Profe Mana Care Ethic Work Grp	Ethics in practice: Managed care and the changing health care environment - Medicine as a profession managed care ethics working group statement	ANNALS OF INTERNAL MEDICINE			English	Article							ACCOUNTABILITY; PHYSICIANS; RULES; COST	Cost pressures and changes in the health care environment pose ethical challenges and hard choices for patients, physicians, policy-makers, and society. In 2000 and 2001, the American College of Physicians, with the Harvard Pilgrim Health Care Ethics Program, convened a working group of stakeholders-patients, physicians, and managed care representatives, along with medical ethicists-to develop a statement of ethics for managed care. The group explored the impact of a changing health care environment on patient-physician relationships and how to best apply the principles of professionalism in this environment. The statement that emerged offers guidance on preserving the patient-clinician relationship, patient rights and responsibilities, confidentiality and privacy, resource allocation and stewardship, the obligation of health plans to foster an ethical environment for the delivery of care, and the clinician's responsibility to individual patients, the community, and the public health, among other issues.	Amer Coll Physicians, Philadelphia, PA 19106 USA; Harvard Univ, Pilgrim Hlth Care Eth Program, Cambridge, MA 02138 USA	American College of Physicians; Harvard University	Snyder, L (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	lsnyder@acponline.org						Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Emanuel EJ, 1996, ANN INTERN MED, V124, P229, DOI 10.7326/0003-4819-124-2-199601150-00007; Goold SD, 1999, J GEN INTERN MED, V14, pS26, DOI 10.1046/j.1525-1497.1999.00267.x; Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; *I MED, 1990, MED STRAT QUAL ASS, V1; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; MORREIM EH, 1991, ARCH INTERN MED, V151, P443, DOI 10.1001/archinte.151.3.443; Pearson SD, 2000, ANN INTERN MED, V133, P148, DOI 10.7326/0003-4819-133-2-200007180-00014; POVAR G, 1988, ANN INTERN MED, V109, P419, DOI 10.7326/0003-4819-109-5-419; Shortell SM, 1998, JAMA-J AM MED ASSOC, V280, P1102, DOI 10.1001/jama.280.12.1102; Sox HC, 2002, ANN INTERN MED, V136, P243, DOI 10.7326/0003-4819-136-3-200202050-00012; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920; Wynia MK, 2000, JAMA-J AM MED ASSOC, V283, P1858, DOI 10.1001/jama.283.14.1858	13	33	35	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					131	136		10.7326/0003-4819-141-2-200407200-00012	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00012			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	839BL	15262669				2022-12-28	WOS:000222758200007
J	Caraveo, PA; De Luca, A; Mereghetti, S; Pellizzoni, A; Bignami, GF				Caraveo, PA; De Luca, A; Mereghetti, S; Pellizzoni, A; Bignami, GF			Phase-resolved spectroscopy of Geminga shows rotating hot spot(s)	SCIENCE			English	Article							X-RAY-EMISSION; ISOLATED NEUTRON-STAR; HIGH-ENERGY; PULSAR; RADIATION; SURFACE; MODELS	Isolated neutron stars are seen in x-rays through their nonthermal and/or surface thermal emissions. X-ray Multimirror Mission-Newton observations of the Geminga pulsar show a 43-electron volt spectrum from the whole neutron star surface, as well as a power-law component above 2 kiloelectron volts. In addition, we have detected a hot (170 electron volts) thermal emission from an similar to60-meter-radius spot on the pulsar's surface. Such a thermal emission, only visible at selected phase intervals, may be coming from polar hot spot(s), long thought to exist as a result of heating from magnetospheric accelerated particles. It may provide the missing link between the x-ray and gamma-ray emission of the pulsar.	CNR, Ist Astrofis Spaziale & Fis Cosm, I-20133 Milan, Italy; Univ Toulouse 3, CNRS, Ctr Etud Spatiale Rayonnements, F-31062 Toulouse, France; Univ Pavia, Dipartimento Fis Nucl & Teor, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale Astrofisica (INAF); Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; University of Pavia	Caraveo, PA (corresponding author), CNR, Ist Astrofis Spaziale & Fis Cosm, Via Bassini 15, I-20133 Milan, Italy.	pat@mi.iasf.cnr.it	Caraveo, Patrizia/AAL-5708-2020	Caraveo, Patrizia/0000-0003-2478-8018; MEREGHETTI, SANDRO/0000-0003-3259-7801; De Luca, Andrea/0000-0001-6739-687X; Bignami, Giovanni/0000-0001-9582-2450; Pellizzoni, Alberto Paolo/0000-0002-4590-0040				Bignami GF, 2003, NATURE, V423, P725, DOI 10.1038/nature01703; Bignami GF, 1996, ANNU REV ASTRON ASTR, V34, P331, DOI 10.1146/annurev.astro.34.1.331; BIGNAMI GF, 1983, ASTROPHYS J, V272, pL9, DOI 10.1086/184107; Caraveo PA, 2003, SCIENCE, V301, P1345, DOI 10.1126/science.1086973; Caraveo PA, 1996, ASTROPHYS J, V461, pL91, DOI 10.1086/310012; Cheng KS, 1999, ASTROPHYS J, V515, P337, DOI 10.1086/307016; DAUGHERTY JK, 1994, ASTROPHYS J, V429, P325, DOI 10.1086/174321; De Luca A, 2004, ASTRON ASTROPHYS, V418, P625, DOI 10.1051/0004-6361:20031781; GREENSTEIN G, 1983, ASTROPHYS J, V271, P283, DOI 10.1086/161195; Halpern JP, 1997, ASTROPHYS J, V477, P905, DOI 10.1086/303743; HALPERN JP, 1993, ASTROPHYS J, V415, P286, DOI 10.1086/173164; Harding AK, 2002, ASTROPHYS J, V568, P862, DOI 10.1086/338985; Jackson MS, 2002, ASTROPHYS J, V578, P935, DOI 10.1086/342662; KASPI VM, IN PRESS COMPACT STE; MAYERHASSELWANDER HA, 1994, ASTROPHYS J, V421, P276, DOI 10.1086/173645; MICHELSON PF, 2003, SPIE, V4851, P1144; Mignani RP, 1998, ASTRON ASTROPHYS, V332, pL37; PAGE D, 1995, ASTROPHYS J, V451, pL21, DOI 10.1086/309675; Pravdo SH, 1997, ASTROPHYS J, V491, P808, DOI 10.1086/304996; Psaltis D, 2000, ASTROPHYS J, V544, P390, DOI 10.1086/317208; Struder L, 2001, ASTRON ASTROPHYS, V365, pL18, DOI 10.1051/0004-6361:20000066; Tavani, 2003, SPIE, V4851, P1151; Turner MJL, 2001, ASTRON ASTROPHYS, V365, pL27, DOI 10.1051/0004-6361:20000087; Wang FYH, 1998, ASTROPHYS J, V498, P373, DOI 10.1086/305532; Weisskopf MC, 2004, ASTROPHYS J, V601, P1050, DOI 10.1086/380600	25	40	40	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					376	379		10.1126/science.1097173	http://dx.doi.org/10.1126/science.1097173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256666				2022-12-28	WOS:000222662400032
J	de Lozanne, A				de Lozanne, A			Music of the spheres at the atomic scale	SCIENCE			English	Editorial Material							RANGE		Univ Texas, Dept Phys, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	de Lozanne, A (corresponding author), Univ Texas, Dept Phys, Austin, TX 78712 USA.	lozanne@physics.utexas.edu	de Lozanne, Alex L/C-9693-2013	de Lozanne, Alex L/0000-0003-2950-4707				BINH VT, 1994, SURF SCI, V301, pL224, DOI 10.1016/0039-6028(94)91277-7; BINNIG G, 1986, PHYS REV LETT, V56, P930, DOI 10.1103/PhysRevLett.56.930; Derro DJ, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.097002; Durig U, 2000, NEW J PHYS, V2, P51, DOI 10.1088/1367-2630/2/1/005; Heike S, 1996, J VAC SCI TECHNOL B, V14, P1522, DOI 10.1116/1.589131; Hembacher S, 2004, SCIENCE, V305, P380, DOI 10.1126/science.1099730; Lantz MA, 2001, SCIENCE, V291, P2580, DOI 10.1126/science.1057824; Sahin O, 2003, BOSTON TRANSDUCERS'03: DIGEST OF TECHNICAL PAPERS, VOLS 1 AND 2, P1124; Wachowiak A, 2002, SCIENCE, V298, P577, DOI 10.1126/science.1075302	9	4	5	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					348	349						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256659				2022-12-28	WOS:000222662400023
J	Sabine, CL; Feely, RA; Gruber, N; Key, RM; Lee, K; Bullister, JL; Wanninkhof, R; Wong, CS; Wallace, DWR; Tilbrook, B; Millero, FJ; Peng, TH; Kozyr, A; Ono, T; Rios, AF				Sabine, CL; Feely, RA; Gruber, N; Key, RM; Lee, K; Bullister, JL; Wanninkhof, R; Wong, CS; Wallace, DWR; Tilbrook, B; Millero, FJ; Peng, TH; Kozyr, A; Ono, T; Rios, AF			The oceanic sink for anthropogenic CO2	SCIENCE			English	Article							ATMOSPHERIC CO2; RED-SEA; INVENTORY; WATER	Using inorganic carbon measurements from an international survey effort in the 1990s and a tracer-based separation technique, we estimate a global oceanic anthropogenic carbon dioxide (CO2) sink for the period from 1800 to 1994 of 118 +/- 19 petagrams of carbon. The oceanic sink accounts for similar to48% of the total fossil-fuel and cement-manufacturing emissions, implying that the terrestrial biosphere was a net source of CO2 to the atmosphere of about 39 +/- 28 petagrams of carbon for this period. The current fraction of total anthropogenic CO2 emissions stored in the ocean appears to be about one-third of the long-term potential.	NOAA, Pacific Marine Environm Lab, Seattle, WA 98115 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Atmospher & Ocean Sci, Los Angeles, CA 90095 USA; Princeton Univ, Program Atmospher & Ocean Sci, Princeton, NJ 08544 USA; Pohang Univ Sci & Technol, Pohang 790784, South Korea; NOAA, Atlantic Oceanog & Meteorol Lab, Miami, FL 33149 USA; Fisheries Oceans Canada Inst Ocean Sci, Climate Chem Lab, Sidney, BC V8L 4B2, Canada; Univ Kiel, Leibniz Inst Meereswissensch, Forsch Bereich Marine Biochem, IFM,GEOMAR, D-24105 Kiel, Germany; CSIRO, Marine Res & Antarctic Climate & Ecosyst Cooperat, Hobart, Tas 7001, Australia; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Div Marine & Atmospher Sci, Miami, FL 33149 USA; Oak Ridge Natl Lab, Carbon Dioxide Informat Anal Ctr, US Dept Energy, Oak Ridge, TN 37831 USA; Inst Global Change Res, Frontier Res Syst Global Change, Minato Ku, Hamamatsu, Shizuoka 1050013, Japan; CSIC, Inst Invest Marinas, Vigo 36208, Spain	National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Pohang University of Science & Technology (POSTECH); National Oceanic Atmospheric Admin (NOAA) - USA; Atlantic Oceanographic & Meteorological Laboratory (AOML); Fisheries & Oceans Canada; Helmholtz Association; GEOMAR Helmholtz Center for Ocean Research Kiel; University of Kiel; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Miami; United States Department of Energy (DOE); Oak Ridge National Laboratory; Japan Agency for Marine-Earth Science & Technology (JAMSTEC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Marinas (IIM)	Sabine, CL (corresponding author), NOAA, Pacific Marine Environm Lab, 7600 Sand Point Way NE, Seattle, WA 98115 USA.	chris.sabine@noaa.gov	Tilbrook, Bronte/W-4007-2019; Gruber, Nicolas/B-7013-2009; Tilbrook, Bronte/A-1522-2012; Feely, Richard A./ABI-5740-2020; Lee, Kitack/G-7184-2015	Tilbrook, Bronte/0000-0001-9385-3827; Gruber, Nicolas/0000-0002-2085-2310; Tilbrook, Bronte/0000-0001-9385-3827; Lee, Kitack/0000-0002-4226-2303				Archer D, 1998, GLOBAL BIOGEOCHEM CY, V12, P259, DOI 10.1029/98GB00744; Crutzen P, 2000, GLOBAL CHANGE NEWSLE, V41, P17; DeFries RS, 1999, GLOBAL BIOGEOCHEM CY, V13, P803, DOI 10.1029/1999GB900037; Etheridge DM, 1996, J GEOPHYS RES-ATMOS, V101, P4115, DOI 10.1029/95JD03410; Feely RA, 2004, SCIENCE, V305, P362, DOI 10.1126/science.1097329; Gruber N, 2004, SCOPE SER, V62, P45; Gruber N, 1996, GLOBAL BIOGEOCHEM CY, V10, P809, DOI 10.1029/96GB01608; Houghton RA, 2002, TRENDS COMPENDIUM DA; Keeling C. D., 2004, TRENDS COMPENDIUM DA; KEY RM, UNPUB; Lee K, 2003, GLOBAL BIOGEOCHEM CY, V17, DOI 10.1029/2003GB002067; Marland G., 2003, TRENDS COMPENDIUM DA; Mecking S, 1999, J GEOPHYS RES-OCEANS, V104, P11087, DOI 10.1029/1999JC900027; PAPAUD A, 1986, J MAR RES, V44, P385, DOI 10.1357/002224086788405347; POISSON A, 1987, DEEP-SEA RES, V34, P1255, DOI 10.1016/0198-0149(87)90075-6; Prentice IC, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P183; REVELLE R, 1957, TELLUS, V9, P18, DOI 10.1111/j.2153-3490.1957.tb01849.x; Sabine CL, 2004, SCOPE SER, V62, P17; Sabine CL, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2001GB001639; Sabine CL, 1999, GLOBAL BIOGEOCHEM CY, V13, P179, DOI 10.1029/1998GB900022; STUIVER M, 1983, SCIENCE, V219, P849, DOI 10.1126/science.219.4586.849; TAKAHASHI T, 1993, GLOBAL BIOGEOCHEM CY, V7, P843, DOI 10.1029/93GB02263; Wallace W.R., 2001, INT GEOPHYS, P489, DOI DOI 10.1016/S0074-6142(01)80136-4	23	2575	2737	68	1372	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					367	371		10.1126/science.1097403	http://dx.doi.org/10.1126/science.1097403			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256665	Green Submitted, Green Published, Green Accepted			2022-12-28	WOS:000222662400030
J	Subiaul, F; Cantlon, JF; Holloway, RL; Terrace, HS				Subiaul, F; Cantlon, JF; Holloway, RL; Terrace, HS			Cognitive imitation in rhesus macaques	SCIENCE			English	Article							CHIMPANZEES PAN-TROGLODYTES; CHILDREN HOMO-SAPIENS; OBJECTS	Experiments on imitation typically evaluate a student's ability to copy some feature of an expert's motor behavior. Here, we describe a type of observational learning in which a student copies a cognitive rule rather than a specific motor action. Two rhesus macaques were trained to respond, in a prescribed order, to different sets of photographs that were displayed on a touch-sensitive monitor. Because the position of the photographs varied randomly from trial to trial, sequences could not be learned by motor imitation. Both monkeys learned new sequences more rapidly after observing an expert execute those sequences than when they had to learn new sequences entirely by trial and error.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Columbia Univ, Dept Anthropol, New York, NY 10027 USA; Duke Univ, Dept Psychol & Brain Sci, Durham, NC 27708 USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA	Columbia University; Columbia University; Duke University; New York State Psychiatry Institute	Subiaul, F (corresponding author), Columbia Univ, Dept Psychol, New York, NY 10027 USA.	subiaul@aol.com; terrace@columbia.edu	cantlon, jessica/A-2699-2010	SUBIAUL, FRANCYS/0000-0002-5873-9524	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040462] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH40462] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BYRNE R, 2002, IMITATIVE MIND DEV E, P123; Byrne RW, 1998, BEHAV BRAIN SCI, V21, P667, DOI 10.1017/S0140525X98001745; CLAYTON DA, 1978, Q REV BIOL, V53, P373, DOI 10.1086/410789; Galef B.G. Jr, 1988, P3; Gergely G, 2002, NATURE, V415, P755, DOI 10.1038/415755a; Hauser M.D., 1988, P327; Heyes C, 2001, TRENDS COGN SCI, V5, P253, DOI 10.1016/S1364-6613(00)01661-2; Jellema T, 2000, BRAIN COGNITION, V44, P280, DOI 10.1006/brcg.2000.1231; NAGELL K, 1993, J COMP PSYCHOL, V107, P174, DOI 10.1037/0735-7036.107.2.174; Rizzolatti G, 1998, NOVART FDN SYMP, V218, P81; Terrace H.S., 1984, P7; Terrace HS, 2003, PSYCHOL SCI, V14, P66, DOI 10.1111/1467-9280.01420; TERRACE HS, 1984, QUANTITATIVE ANAL BE, P115; THORNDIKE EL, 1898, PSYCHOL REV MONOGR S, V2, P79; THORPE W, 1956, LEARNING INSTINCT AN, P122; Tomasello M., 1990, P274, DOI 10.1017/CBO9780511665486.012; TOMASELLO M, 1993, CHILD DEV, V64, P1688, DOI 10.1111/j.1467-8624.1993.tb04207.x; Tomasello M., 1987, HUM EVOL, V2, P175, DOI DOI 10.1007/BF02436405; Tomasello M, 1997, PRIMATE COGNITION; Visalberghi E., 1990, P247, DOI 10.1017/CBO9780511665486.011; Visalberghi E, 1998, BEHAV PROCESS, V42, P189, DOI 10.1016/S0376-6357(97)00076-4; WHITEN A, 1992, ADV STUD BEHAV, V21, P239, DOI 10.1016/S0065-3454(08)60146-1; Whiten A, 1998, J COMP PSYCHOL, V112, P270, DOI 10.1037/0735-7036.112.3.270; Whiten A, 1996, J COMP PSYCHOL, V110, P3, DOI 10.1037/0735-7036.110.1.3; WHITEN A, 2002, IMITATIVE MIND DEV E, P98; ZAJONC RB, 1965, SCIENCE, V149, P106	26	111	113	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					407	410		10.1126/science.1099136	http://dx.doi.org/10.1126/science.1099136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256673				2022-12-28	WOS:000222662400042
J	McHugh, PR				McHugh, PR			Zygote and "clonote'' - The ethical use of embryonic stem cells	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Gearhart J, 2004, NEW ENGL J MED, V350, P1275, DOI 10.1056/NEJMp048045; *PUBL AFF, 2002, HUM CLON HUM DIGN RE	2	34	38	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					209	211		10.1056/NEJMp048147	http://dx.doi.org/10.1056/NEJMp048147			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254278				2022-12-28	WOS:000222627200002
J	Taha, TE; Kumwenda, NI; Hoover, DR; Fiscus, SA; Kafulafula, G; Nkhoma, C; Nour, S; Chen, S; Liomba, G; Miotti, PG; Broadhead, RL				Taha, TE; Kumwenda, NI; Hoover, DR; Fiscus, SA; Kafulafula, G; Nkhoma, C; Nour, S; Chen, S; Liomba, G; Miotti, PG; Broadhead, RL			Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOTHER-TO-CHILD; HUMAN-IMMUNODEFICIENCY-VIRUS; PREGNANT-WOMEN; ANTIRETROVIRAL PROPHYLAXIS; ORAL ZIDOVUDINE; COTE-DIVOIRE; DOUBLE-BLIND; PHARMACOKINETICS; INTRAPARTUM; PREVENTION	Context Antenatal counseling and human immunodeficiency virus (HIV) testing are not universal in Africa; thus, women often present in labor with unknown HIV status without receiving the HIVNET 012 nevirapine (NVP) regimen (a single oral dose of NVP to the mother at the start of labor and to the infant within 72 hours of birth). Objective To determine risk of mother-to-child transmission of HIV when either standard use of NVP alone or in combination with zidovudine (ZDV) was administered to infants of women tested at delivery. Design, Setting, and Participants A randomized, open-label, phase 3 trial conducted between April 1, 2000, and March 15, 2003, at 6 clinics in Blantyre, Malawi, Africa. The trial included all infants born to 894 women who were HIV positive, received NVP intrapartum, and were previously antiretroviral treatment-naive. Infants were randomly assigned to NVP (n=448) and NVP plus ZDV (n=446). Infants were enrolled at birth, observed at 6 to 8 weeks, and followed up through 3 to 18 months. The HIV status of 90% of all infants was established at 6 to 8 weeks. intervention Mothers received a 200-mg single oral dose of NVP intrapartum and infants received either 2-mg/kg oral dose of NVP or NVP (same dose) plus 4 mg/kg of ZDV twice per day for a week. Main Outcome Measures HIV infection of infant at birth and 6 to 8 weeks, and adverse events. Results The mother-to-child transmission of HIV at birth was 8.1% (36/445) in infants administered NVP only and 10.1% (45/444) in those administered NVP plus ZDV (P=.30). A life table estimate of transmission at 6 to 8 weeks was 14.1% (95% confidence interval [0], 10.7%-17.4%) in infants who received NVP and 16.3% (95% CI, 12.7%-19.8%) in those who received NVP plus ZDV (P=.36). For infants not infected at birth and retested at 6 to 8 weeks, transmission was 6.5% (23/353) in those who received NVP only and 6.9% (25/363) in those who received NVP plus ZDV (P=.88). Almost all infants (99%-100%) were breastfed at 1 week and 6 to 8 weeks. Grades 3 and 4 adverse events were comparable; 4.9% (22/448) and 5.4% (24/446) in infants receiving NVP only and NVP plus ZDV, respectively (P=.76). Conclusions The frequency of mother-to-child HIV transmission at 6 to 8 weeks in our 2 study groups was comparable with that observed for other perinatal HIV intervention studies among breastfeeding women in Africa. The safety of the regimen containing neonatal ZDV was similar to that of a standard NVP regimen.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Rutgers State Univ, Dept Stat, Piscataway, NJ USA; Rutgers State Univ, Inst Hlth Hlth Care Policy & Aging Res, Piscataway, NJ USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; Univ Malawi, Coll Med, Zomba, Malawi; Johns Hopkins Univ, Coll Med, Minist Hlth Res Project, Blantyre, Malawi; NIH, Off AIDS Res, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Rutgers State University New Brunswick; Rutgers State University New Brunswick; University of North Carolina; University of North Carolina Chapel Hill; University of Malawi; University of Malawi; National Institutes of Health (NIH) - USA	Taha, TE (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Room E7138,615 N Wolfe St, Baltimore, MD 21205 USA.	ttaha@jhsph.edu	Kumwenda, Newton/ADL-6890-2022	Kumwenda, Newton/0000-0003-2622-4339; Taha, Taha/0000-0001-9814-4894	FOGARTY INTERNATIONAL CENTER [R03TW001199] Funding Source: NIH RePORTER; FIC NIH HHS [5R03TW01199] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		[Anonymous], PUBLIC HLTH SERVICE; Beckerman KP, 2003, LANCET, V362, P842, DOI 10.1016/S0140-6736(03)14345-0; Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; BOUCHER FD, 1993, J PEDIATR-US, V122, P137, DOI 10.1016/S0022-3476(05)83507-3; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P22; CHIANG CL, 1984, LIFE TABLE ITS APPL, P156; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; *DAIDS, TOX TABL GRAD SEV PE; Dorenbaum A, 2002, JAMA-J AM MED ASSOC, V288, P189, DOI 10.1001/jama.288.2.189; Gaillard P, 2004, JAIDS-J ACQ IMM DEF, V35, P178, DOI 10.1097/00126334-200402010-00013; GREENWOOD M, 1926, 33 HER MAJ STAT OFF; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Jackson JB, 2003, LANCET, V362, P859, DOI 10.1016/S0140-6736(03)14341-3; Kourtis AP, 2001, JAMA-J AM MED ASSOC, V285, P709, DOI 10.1001/jama.285.6.709; LALLEMANT M, 2003, 2 IAS C HIV PATH TRE; MARTINSON N, 2004, 11 C RETR OPP INF FE; Mirochnick M, 1998, J INFECT DIS, V178, P368, DOI 10.1086/515641; Mirochnick M, 2000, ANN NY ACAD SCI, V918, P287; Mirochnick M, 2001, PEDIATR INFECT DIS J, V20, P803, DOI 10.1097/00006454-200108000-00017; MIROCHNICK M, 2001, 3 C GLOB STRAT PREV; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; Musoke P, 1999, AIDS, V13, P479, DOI 10.1097/00002030-199903110-00006; Nolan M, 2002, J ACQ IMMUN DEF SYND, V30, P216, DOI [10.1097/01.QAI.0000018365.28828.5D, 10.1097/00042560-200206010-00011]; Saba J, 2002, LANCET, V359, P1178; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; SZKLO M, 2000, EPIDEMIOLOGY BASICS, P434; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; Taha TE, 2002, AIDS, V16, P851, DOI 10.1097/00002030-200204120-00004; UNAIDS/WHO Working Group on HIV/AIDS surveillance, GUID US HIV TEST TEC; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	31	117	120	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					202	209		10.1001/jama.292.2.202	http://dx.doi.org/10.1001/jama.292.2.202			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249569	Bronze			2022-12-28	WOS:000222579300025
J	D'Amico, AV; Chen, MH; Roehl, KA; Catalona, WJ				D'Amico, AV; Chen, MH; Roehl, KA; Catalona, WJ			Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLING TIME	Background: We evaluated whether men at risk for death from prostate cancer after radical prostatectomy can be identified using information available at diagnosis. Methods: We studied 1095 men with localized prostate cancer to assess whether the rate of rise in the prostate-specific antigen (PSA) level-the PSA velocity-during the year before diagnosis, the PSA level at diagnosis, the Gleason score, and the clinical tumor stage could predict the time to death from prostate cancer and death from any cause after radical prostatectomy. Results: As compared with an annual PSA velocity of 2.0 ng per milliliter or less, an annual PSA velocity of more than 2.0 ng per milliliter was associated with a significantly shorter time to death from prostate cancer (P<0.001) and death from any cause (P=0.01). An increasing PSA level at diagnosis (P=0.01), a Gleason score of 8, 9, or 10 (P=0.02), and a clinical tumor stage of T2 (P<0.001) also predicted the time to death from prostate cancer. For men with an annual PSA velocity of more than 2.0 ng per milliliter, estimates of the risk of death from prostate cancer and death from any cause seven years after radical prostatectomy were also influenced by the PSA level, tumor stage, and Gleason score at diagnosis. Conclusions: Men whose PSA level increases by more than 2.0 ng per milliliter during the year before the diagnosis of prostate cancer may have a relatively high risk of death from prostate cancer despite undergoing radical prostatectomy.	Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; Univ Connecticut, Dept Stat, Storrs, CT 06269 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Northwestern Feinberg Sch Med, Dept Urol, Chicago, IL USA	Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; University of Connecticut; Washington University (WUSTL); Northwestern University; Feinberg School of Medicine	D'Amico, AV (corresponding author), Brigham & Womens Hosp, Dept Radiat Oncol, L-2 Level,75 Francis St, Boston, MA 02115 USA.	adamico@lroc.harvard.edu						BEAHRS OH, 1992, MANUAL STAGING CANC, P181; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; D'Amico AV, 2003, J NATL CANCER I, V95, P1376, DOI 10.1093/jnci/djg043; Egawa S, 2000, PROSTATE CANCER P D, V3, P269, DOI 10.1038/sj.pcan.4500424; Freedland SJ, 2001, UROLOGY, V57, P476, DOI 10.1016/S0090-4295(00)01016-5; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Goluboff ET, 1997, J UROLOGY, V158, P1876, DOI 10.1016/S0022-5347(01)64154-5; GREENE FL, 2002, MANUAL STAGING CANC, P309; Holmberg L, 2002, NEW ENGL J MED, V347, P781, DOI 10.1056/NEJMoa012794; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kessler B, 2003, UROL CLIN N AM, V30, P219, DOI 10.1016/S0094-0143(02)00182-9; Klein JP, 1997, SURVIVAL ANAL TECHNI, P96; Miller DC, 2003, CANCER-AM CANCER SOC, V98, P1169, DOI 10.1002/cncr.11635; Wilt T J, 1997, Oncology (Williston Park), V11, P1133	15	567	587	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					125	135		10.1056/NEJMoa032975	http://dx.doi.org/10.1056/NEJMoa032975			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247353	Bronze			2022-12-28	WOS:000222470700005
J	de Silva, HJ				de Silva, HJ			A middle-aged man	LANCET			English	Editorial Material									Univ Kelaniya, Fac Med, Dept Med, Ragama, Sri Lanka	University Kelaniya	de Silva, HJ (corresponding author), Univ Kelaniya, Fac Med, Dept Med, POB 6, Ragama, Sri Lanka.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					111	111		10.1016/S0140-6736(04)16600-2	http://dx.doi.org/10.1016/S0140-6736(04)16600-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234865				2022-12-28	WOS:000222392900042
J	Chapman, T				Chapman, T			Drug discovery - The leading edge	NATURE			English	Article																			0	24	25	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	2004	430	6995					109	+		10.1038/430109a	http://dx.doi.org/10.1038/430109a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229608	Bronze			2022-12-28	WOS:000222356800054
J	Britton, A; Shipley, M; Marmot, M; Hemingway, H				Britton, A; Shipley, M; Marmot, M; Hemingway, H			Does access to cardiac investigation and treatment contribute to social and ethnic differences in coronary heart disease? Whitehall II prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE MYOCARDIAL-INFARCTION; ARTERY-BYPASS-SURGERY; SOCIOECONOMIC-STATUS; REVASCULARIZATION RATES; HEALTH; ASIANS; ANGIOGRAPHY; MANAGEMENT; MORTALITY; ANGINA	Objective To determine whether access to cardiac procedures and drugs contributes to social and ethnic differences in coronary heart disease in a population settmg. Design Prospective study with follow up over 15 years. Civil service employment grade was used as a measure of individual socioeconomic position. Need for cardiac care was determined by the presence of angina, myocardial infarction, and coronary risk factors. Setting 20 civil service departments originally located in London. Participants 10 308 civil servants (3414 women; 560 South Asian) aged 35-55 years at baseline in 1985-8. Main outcome measures Use of exercise electrocardiography, coronary angiography, and coronary revascularisation procedures and secondary prevention drugs. Results Inverse social gradients existed in incident coronary morbidity and mortality. South Asian participants also had higher rates than white participants. After adjustment for clinical need, social position showed no association with the use of cardiac procedures or secondary prevention drugs. For example, men in the low versus high employment grade had an age adjusted odds ratio for angiography of 1.87 (95% confidence interval 1.32 to 2.64), which decreased to 1.27 (0.83 to 1.94) on adjustment for clinical need. South Asians tended to be more likely to have cardiac procedures and to be taking more secondary prevention drugs than white participants, even after adjustment for clinical need. Conclusion This population based study, which shows the widely observed social and ethnic patterning of coronary heart disease, found no evidence that low social position or South Asian ethnicity was associated with lower use of cardiac procedures or drugs, independently of clinical need. Differences in medical care are unlikely to contribute to social or ethnic differences in coronary heart disease in this cohort.	UCL, Sch Med, Int Ctr Hlth & Soc, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London; UCL Medical School	Hemingway, H (corresponding author), UCL, Sch Med, Int Ctr Hlth & Soc, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	h.hemingway@ucl.ac.uk	Marmot, M G/Y-3920-2019; Hemingway, Harry/C-1219-2009	Marmot, M G/0000-0002-2431-6419; Hemingway, Harry/0000-0003-2279-0624	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006516] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG013196, R01AG013196] Funding Source: NIH RePORTER; AHRQ HHS [HS06516] Funding Source: Medline; Medical Research Council [G8802774, G0100222, G19/35] Funding Source: Medline; NHLBI NIH HHS [HL36310] Funding Source: Medline; NIA NIH HHS [AG13196] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acheson D., 1998, INEQUALITIES HLTH RE; Adams P, 2003, J ECONOMETRICS, V112, P3, DOI 10.1016/S0304-4076(02)00145-8; Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Anderson Geoffrey, 1993, JAMA (Journal of the American Medical Association), V269, P1661, DOI 10.1001/jama.269.13.1661; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; Brunner EJ, 2002, CIRCULATION, V106, P2659, DOI 10.1161/01.CIR.0000038364.26310.BD; Chaturvedi N, 1997, LANCET, V350, P1578, DOI 10.1016/S0140-6736(97)06243-0; Coory M, 2002, J EPIDEMIOL COMMUN H, V56, P233, DOI 10.1136/jech.56.3.233; DHAWAN J, 1994, POSTGRAD MED J, V70, P625, DOI 10.1136/pgmj.70.827.625; Feder G, 2002, BRIT MED J, V324, P511, DOI 10.1136/bmj.324.7336.511; FRISCELLA K, 2000, JAMA-J AM MED ASSOC, V283, P2579; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; Goldman DP, 2002, P NATL ACAD SCI USA, V99, P10929, DOI 10.1073/pnas.162086599; Goldsmith I, 1999, EUR HEART J, V20, P1094, DOI 10.1053/euhj.1998.1450; Hemingway H, 2003, BRIT MED J, V327, P895, DOI 10.1136/bmj.327.7420.895; Hemingway H, 2001, NEW ENGL J MED, V344, P645, DOI 10.1056/NEJM200103013440906; Hippisley-Cox J, 2001, BMJ-BRIT MED J, V322, P832, DOI 10.1136/bmj.322.7290.832; Jones M, 2004, BRIT J GEN PRACT, V54, P423; KEE F, 1993, BRIT MED J, V307, P1305, DOI 10.1136/bmj.307.6915.1305; LEAR JT, 1994, J ROY SOC MED, V87, P661; LEAR JT, 1994, J ROY COLL PHYS LOND, V28, P143; LOWRY PJ, 1984, BRIT HEART J, V52, P610, DOI 10.1136/hrt.52.6.610; MacLeod MCM, 1999, HEART, V81, P252, DOI 10.1136/hrt.81.3.252; Manson-Siddle CJ, 1998, J EPIDEMIOL COMMUN H, V52, P507, DOI 10.1136/jech.52.8.507; Marmot M, 2001, J EPIDEMIOL COMMUN H, V55, P301, DOI 10.1136/jech.55.5.301; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Morris RW, 1996, HEART, V75, P557, DOI 10.1136/hrt.75.6.557; MORRIS RW, IN PRESS HEART; MUKHTAR HT, 1995, BRIT HEART J, V73, P122; Nazroo James Y., 2001, Ethnicity and Disease, V11, P401; *NIH, 2000, STRAT RES PLAN RED U; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; Philpott S, 2001, SOC SCI MED, V52, P1565, DOI 10.1016/S0277-9536(00)00269-0; Raine R, 2000, J Health Serv Res Policy, V5, P237; SHANKAT N, 1993, BRIT MED J, V307, P717; Shaw M, 1999, WIDENING GAP HLTH IN; Wild S, 1997, BRIT MED J, V314, P705, DOI 10.1136/bmj.314.7082.705; Wilkinson P, 1996, BMJ-BRIT MED J, V312, P1330, DOI 10.1136/bmj.312.7042.1330	38	70	70	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2004	329	7461					318	+		10.1136/bmj.38156.690150.AE	http://dx.doi.org/10.1136/bmj.38156.690150.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846FF	15237088	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000223300300015
J	Kessler, A; Halitschke, R; Baldwin, IT				Kessler, A; Halitschke, R; Baldwin, IT			Silencing the jasmonate cascade: Induced plant defenses and insect populations	SCIENCE			English	Article							NICOTIANA-ATTENUATA; ARABIDOPSIS; RESPONSES; VOLATILES; BIOSYNTHESIS; EXPRESSION; RESISTANCE; EVOLUTION; GENES; COSTS	We transformed the native tobacco, Nicotiana attenuata, to silence its lipoxygenase, hydroperoxide lyase, and allene oxide synthase genes in order to inhibit oxylipin signaling, known to mediate the plant's direct and indirect defenses. When planted into native habitats, lipoxygenase-deficient plants were more vulnerable to N. attenuata's adapted herbivores but also attracted novel herbivore species, which fed and reproduced successfully. In addition to highlighting the value of genetically silencing plants to study ecological interactions in nature, these results show that lipoxygenase-dependent signaling determines host selection for opportunistic herbivores and that induced defenses influence herbivore community composition.	Max Planck Inst Chem Ecol, Dept Mol Ecol, D-07745 Jena, Germany	Max Planck Society	Baldwin, IT (corresponding author), Max Planck Inst Chem Ecol, Dept Mol Ecol, Hans Knoll Str 8, D-07745 Jena, Germany.	baldwin@ice.mpg.de	Baldwin, Ian T/K-1809-2013; Kessler, Andre/C-7810-2014; Halitschke, Rayko/AAY-2365-2020	Halitschke, Rayko/0000-0002-1109-8782; Baldwin, Ian/0000-0001-5371-2974; Kessler, Andre/0000-0002-1797-7518				Agrawal AA, 2001, SCIENCE, V294, P321, DOI 10.1126/science.1060701; Arimura G, 2001, BIOCHEM SYST ECOL, V29, P1049, DOI 10.1016/S0305-1978(01)00049-7; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; Bergelson J, 1996, P ROY SOC B-BIOL SCI, V263, P1659, DOI 10.1098/rspb.1996.0242; BERNAYS E, 1988, ECOLOGY, V69, P886, DOI 10.2307/1941237; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; De Moraes CM, 1998, NATURE, V393, P570, DOI 10.1038/31219; Dicke M, 2000, ENTOMOL EXP APPL, V97, P237, DOI 10.1023/A:1004111624780; Duffey SS, 1996, ARCH INSECT BIOCHEM, V32, P3, DOI 10.1002/(SICI)1520-6327(1996)32:1&lt;3::AID-ARCH2&gt;3.0.CO;2-1; Halitschke R, 2001, PLANT PHYSIOL, V125, P711, DOI 10.1104/pp.125.2.711; Halitschke R, 2003, PLANT J, V36, P794, DOI 10.1046/j.1365-313X.2003.01921.x; HALITSCHKE R, IN PRESS PLANT J; HILDEBRAND DF, 1993, J CHEM ECOL, V19, P1875, DOI 10.1007/BF00983793; Karban R., 1997, INDUCED RESPONSES HE, DOI 10.7208/chicago/9780226424972.001.0001; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Kessler A, 2004, PLANT J, V38, P639, DOI 10.1111/j.1365-313X.2004.02076.x; Kunert M, 2002, J SEP SCI, V25, P677, DOI 10.1002/1615-9314(20020701)25:10/11&lt;677::AID-; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; Li XC, 2002, NATURE, V419, P712, DOI 10.1038/nature01003; Park JH, 2002, PLANT J, V31, P1, DOI 10.1046/j.1365-313X.2002.01328.x; Preston CA, 1999, ECOLOGY, V80, P481, DOI 10.1890/0012-9658(1999)080[0481:PANSRG]2.0.CO;2; Royo J, 1999, P NATL ACAD SCI USA, V96, P1146, DOI 10.1073/pnas.96.3.1146; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10625, DOI 10.1073/pnas.190264497; Thaler JS, 2001, ECOL ENTOMOL, V26, P312, DOI 10.1046/j.1365-2311.2001.00324.x; TURLINGS TCJ, 1990, SCIENCE, V250, P1251, DOI 10.1126/science.250.4985.1251; Zavala JA, 2004, P NATL ACAD SCI USA, V101, P1607, DOI 10.1073/pnas.0305096101	27	375	412	1	129	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2004	305	5684					665	668		10.1126/science.1096931	http://dx.doi.org/10.1126/science.1096931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	842GQ	15232071				2022-12-28	WOS:000222992100047
J	Ho, HYH; Rohatgi, R; Lebensohn, AM; Ma, L; Li, JX; Gygi, SP; Kirschner, MW				Ho, HYH; Rohatgi, R; Lebensohn, AM; Ma, L; Li, JX; Gygi, SP; Kirschner, MW			Toca-1 mediates Cdc42-dependent actin nucleation by activating the N-WASP-WIP complex	CELL			English	Article							WISKOTT-ALDRICH-SYNDROME; BINDING PROTEIN CDC42; ARP2/3 COMPLEX; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; POLYMERIZATION; FAMILY; DOMAIN; CYTOSKELETON; VESICLES; RHOA	An important signaling pathway to the actin cytoskeleton links the Rho family GTPase Cdc42 to the actin-nucleating Arp2/3 complex through N-WASP. Nevertheless, these previously identified components are not sufficient to mediate Cdc42-induced actin polymerization in a physiological context. In this paper, we describe the biochemical purification of Toca-1 (transducer of Cdc42-dependent actin assembly) as an essential component of the Cdc42 pathway. Toca-1 binds both N-WASP and Cdc42 and is a member of the evolutionarily conserved PCH protein family. Toca-1 promotes actin nucleation by activating the N-WASP-WIP/CR16 complex, the predominant form of N-WASP in cells. Thus, the cooperative actions of two distinct Cdc42 effectors, the N-WASP-WIP complex and Toca-1, are required for Cdc42-induced actin assembly. These findings represent a significantly revised view of Cdc42-signaling and shed light on the pathogenesis of Wiskoft-Aldrich syndrome.	Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.	marc@hms.harvard.edu	Ma, Le/A-3733-2013	Ma, Le/0000-0003-2769-9416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG00041] Funding Source: Medline; NIGMS NIH HHS [GM026875-27] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen PG, 2003, NAT CELL BIOL, V5, P972, DOI 10.1038/ncb1059; Anton IM, 2002, IMMUNITY, V16, P193, DOI 10.1016/S1074-7613(02)00268-6; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Flynn P, 1998, J BIOL CHEM, V273, P2698, DOI 10.1074/jbc.273.5.2698; Gygi SP, 1999, ELECTROPHORESIS, V20, P310, DOI 10.1002/(SICI)1522-2683(19990201)20:2<310::AID-ELPS310>3.0.CO;2-M; Harlow E., 1999, USING ANTIBODIES LAB; Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498; Huang M, 1999, CURR BIOL, V9, P979, DOI 10.1016/S0960-9822(99)80428-X; Kaksonen M, 2003, CELL, V115, P475, DOI 10.1016/S0092-8674(03)00883-3; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T; Ma L, 1998, J CELL BIOL, V140, P1125; Ma L, 1998, P NATL ACAD SCI USA, V95, P15362, DOI 10.1073/pnas.95.26.15362; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Martinez-Quiles N, 2001, NAT CELL BIOL, V3, P484, DOI 10.1038/35074551; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Owen D, 2003, J BIOL CHEM, V278, P50578, DOI 10.1074/jbc.M304313200; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Snapper SB, 2003, NEW ENGL J MED, V348, P350, DOI 10.1056/NEJMcibr001155; Sokac AM, 2003, NAT CELL BIOL, V5, P727, DOI 10.1038/ncb1025; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; Torres E, 2003, MOL CELL, V11, P1215, DOI 10.1016/S1097-2765(03)00139-4; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	37	324	334	1	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					203	216		10.1016/j.cell.2004.06.027	http://dx.doi.org/10.1016/j.cell.2004.06.027			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260990	Bronze			2022-12-28	WOS:000222966000009
J	Qiao, F; Song, HY; Kim, CA; Sawaya, MR; Hunter, JB; Gingery, M; Rebay, I; Courey, AJ; Bowie, JU				Qiao, F; Song, HY; Kim, CA; Sawaya, MR; Hunter, JB; Gingery, M; Rebay, I; Courey, AJ; Bowie, JU			Derepression by depolymerization: Structural insights into the regulation of Yan by Mae	CELL			English	Article							ETS TRANSCRIPTION FACTORS; RECEPTOR SAM DOMAIN; KINASE PHOSPHORYLATION; NUCLEAR EXPORT; POINTED DOMAIN; DNA-BINDING; DROSOPHILA; PROTEIN; PATHWAY; FAMILY	Yan, an ETS family transcriptional repressor, is regulated by receptor tyrosine kinase signaling via the Ras/ MAPK pathway. Phosphorylation and downregulation of Yan is facilitated by a protein called Mae. Yan and Mae interact through their SAM domains. We find that repression by Yan requires the formation of a higher order structure mediated by Yan-SAM polymerization. Moreover, a crystal structure of the Yan-SAM/Mae-SAM complex shows that Mae-SAM specifically recognizes a surface on Yan-SAM that is also required for Yan-SAM polymerization. Mae-SAM binds to Yan-SAM with similar to1000-fold higher affinity than Yan-SAM binds to itself and can effectively depolymerize Yan-SAM. Mutations on Mae that specifically disrupt its SAM domain-dependent interactions with Yan disable the derepression function of Mae in vivo. Depolymerization of Yan by Mae represents a novel mechanism of transcriptional control that sensitizes Yan for regulation by receptor tyrosine kinases.	Univ Calif Los Angeles, DOE, Inst Genom & Proteom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; MIT, Dept Biol, Whitehead Inst, Cambridge, MA 02142 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Massachusetts Institute of Technology (MIT); Whitehead Institute	Bowie, JU (corresponding author), Univ Calif Los Angeles, DOE, Inst Genom & Proteom, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu		Sawaya, Michael/0000-0003-0874-9043; Hunter, Jacob/0000-0003-3479-1309	NCI NIH HHS [R01 CA081000] Funding Source: Medline; NIGMS NIH HHS [R01 GM44522] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044522] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aviv T, 2003, NAT STRUCT BIOL, V10, P614, DOI 10.1038/nsb956; Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DITTMER J, 1998, BIOCHIM BIOPHYS ACTA, V1377, P1; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Gabay L, 1996, DEVELOPMENT, V122, P3355; Graves BJ, 1996, NATURE, V384, P322, DOI 10.1038/384322a0; Green JB, 2003, MOL CELL, V11, P1537, DOI 10.1016/S1097-2765(03)00178-3; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim CA, 2003, TRENDS BIOCHEM SCI, V28, P625, DOI 10.1016/j.tibs.2003.11.001; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KLAMBT C, 1993, DEVELOPMENT, V117, P163; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Rebay I, 2002, DEV BIOL, V251, P1, DOI 10.1006/dbio.2002.0806; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Rogge R, 1995, DEVELOPMENT, V121, P3947; Roseman RR, 2001, GENETICS, V158, P291; ROSENFELD PJ, 1986, J BIOL CHEM, V261, P1398; Schultz J, 1997, PROTEIN SCI, V6, P249; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tootle TL, 2003, DEVELOPMENT, V130, P845, DOI 10.1242/dev.00312; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Wood LD, 2003, P NATL ACAD SCI USA, V100, P3257, DOI 10.1073/pnas.0637114100; Yamada T, 2003, DEVELOPMENT, V130, P4085, DOI 10.1242/dev.00624; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Zhao C, 2002, DEVELOPMENT, V129, P1669; Zhou HX, 2001, J AM CHEM SOC, V123, P6730, DOI 10.1021/ja015990i	39	83	83	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					163	173		10.1016/j.cell.2004.07.010	http://dx.doi.org/10.1016/j.cell.2004.07.010			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260987	Bronze			2022-12-28	WOS:000222966000006
J	Lee, I; Yoganarasimha, D; Rao, G; Knierim, JJ				Lee, I; Yoganarasimha, D; Rao, G; Knierim, JJ			Comparison of population coherence of place cells in hippocampal subfields CA1 and CA3	NATURE			English	Article							SINGLE UNIT-ACTIVITY; PYRAMIDAL CELLS; NMDA RECEPTORS; MEMORY; RECALL; RAT; MODULATION; CIRCUITRY; STORAGE; SYSTEM	The hippocampus, a critical brain structure for navigation, context-dependent learning and episodic memory(1-3), is composed of anatomically heterogeneous subregions. These regions differ in their anatomical inputs as well as in their internal circuitry(4). A major feature of the CA3 region is its recurrent collateral circuitry, by which the CA3 pyramidal cells make excitatory synaptic contacts on each other(4,5). In contrast, pyramidal cells in the CA1 region are not extensively interconnected(4). Although these differences have inspired numerous theoretical models of differential processing capacities of these two regions(6-13), there have been few reports of robust differences in the firing properties of CA1 and CA3 neurons in behaving animals. The most extensively studied of these properties is the spatially selective firing of hippocampal 'place cells'(1,14). Here we report that in a dynamically changing environment, in which familiar landmarks on the behavioural track and along the wall are rotated relative to each other(15,16), the population representation of the environment is more coherent between the original and cue-altered environments in CA3 than in CA1. These results demonstrate a functional heterogeneity between the place cells of CA3 and CA1 at the level of neural population representations.	Univ Texas, Sch Med, Dept Neurobiol & Anat, WM Keck Ctr Neurobiol Learning & Memory, Houston, TX 77225 USA	University of Texas System	Knierim, JJ (corresponding author), Boston Univ, Ctr Memory & Brain, 2 Cummington St, Boston, MA 02215 USA.	James.J.Knierim@uth.tmc.edu		Doreswamy, Yoganarasimha/0000-0001-7122-6953; Knierim, James/0000-0002-1796-2930				Amaral David G., 1995, P443; Anderson MI, 2003, J NEUROSCI, V23, P8827; [Anonymous], 1998, NEURAL NETWORKS BRAI; Brun VH, 2002, SCIENCE, V296, P2243, DOI 10.1126/science.1071089; Cressant A, 2002, EXP BRAIN RES, V143, P470, DOI 10.1007/s00221-002-1013-0; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; HASSELMO ME, 1995, J NEUROSCI, V15, P5249; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; ISHIZUKA N, 1990, J COMP NEUROL, V295, P580, DOI 10.1002/cne.902950407; Kali S, 2000, J NEUROSCI, V20, P7463; Kesner RP, 2000, CURR OPIN NEUROBIOL, V10, P260, DOI 10.1016/S0959-4388(00)00067-2; Kesner RP, 2001, HIPPOCAMPUS, V11, P240, DOI 10.1002/hipo.1040; Knierim JJ, 2002, J NEUROSCI, V22, P6254; Lee I, 2002, NAT NEUROSCI, V5, P162, DOI 10.1038/nn790; LEUTGEB S, 2003, 915 SOC NEUR; MARR D, 1971, PHILOS T ROY SOC B, V262, P23, DOI 10.1098/rstb.1971.0078; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; McNaughton BL, 1990, NEUROSCIENCE CONNECT, P1; MIZUMORI SJY, 1989, J NEUROSCI, V9, P3915; Nakazawa K, 2002, SCIENCE, V297, P211, DOI 10.1126/science.1071795; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1987, EXP BRAIN RES, V68, P1; OREILLY RC, 1994, HIPPOCAMPUS, V4, P661, DOI 10.1002/hipo.450040605; Samsonovich A, 1997, J NEUROSCI, V17, P5900; Shapiro ML, 1997, HIPPOCAMPUS, V7, P624, DOI 10.1002/(SICI)1098-1063(1997)7:6<624::AID-HIPO5>3.0.CO;2-E; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; TREVES A, 1994, HIPPOCAMPUS, V4, P374, DOI 10.1002/hipo.450040319; VarghaKhadem F, 1997, SCIENCE, V277, P376, DOI 10.1126/science.277.5324.376; VAZDARJANOVA A, IN PRESS J NEUROSCI; Zar JH., 1999, BIOSTAT ANAL, V663rd	31	309	312	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	2004	430	6998					456	459		10.1038/nature02739	http://dx.doi.org/10.1038/nature02739			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	839RD	15229614				2022-12-28	WOS:000222801400044
J	Falkowski, PG; Katz, ME; Knoll, AH; Quigg, A; Raven, JA; Schofield, O; Taylor, FJR				Falkowski, PG; Katz, ME; Knoll, AH; Quigg, A; Raven, JA; Schofield, O; Taylor, FJR			The evolution of modern eukaryotic phytoplankton	SCIENCE			English	Review							BIOGEOCHEMICAL CYCLE; MESOZOIC RADIATION; MARINE; CLIMATE; PRODUCTIVITY; TERRESTRIAL; ENVIRONMENT; COMPETITION; EXPANSION; DIATOMS	The community structure and ecological function of contemporary marine ecosystems are critically dependent on eukaryotic phytoplankton. Although numerically inferior to cyanobacteria, these organisms are responsible for the majority of the flux of organic matter to higher trophic levels and the ocean interior. Photosynthetic eukaryotes evolved more than 1.5 billion years ago in the Proterozoic oceans. However, it was not until the Mesozoic Era (251 to 65 million years ago) that the three principal phytoplankton clades that would come to dominate the modern seas rose to ecological prominence. In contrast to their pioneering predecessors, the dinoflagellates, coccolithophores, and diatoms all contain plastids derived from an ancestral red alga by secondary symbiosis. Here we examine the geological, geochemical, and biological processes that contributed to the rise of these three, distantly related, phytoplankton groups.	Rutgers State Univ, Inst Marine & Coastal Sci, Princeton, NJ 08540 USA; Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ Dundee, Scottish Crop Res Inst, Div Environm & Appl Biol, Dundee DD2 5DA, Scotland; Univ British Columbia, Dept Bot, Vancouver, BC V6T 1Z4, Canada; Univ British Columbia, Dept Earth & Ocean Sci, Vancouver, BC V6T 1Z4, Canada	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Harvard University; James Hutton Institute; University of Dundee; University of British Columbia; University of British Columbia	Falkowski, PG (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, 71 Dudley Rd, Princeton, NJ 08540 USA.	falko@imcs.rutgers.edu	Quigg, Antonietta S/A-9345-2010; Schofield, Oscar/H-4169-2018	Schofield, Oscar/0000-0003-2359-4131				Alexandre A, 1997, GEOCHIM COSMOCHIM AC, V61, P677, DOI 10.1016/S0016-7037(97)00001-X; ALLEN JF, 1993, PHOTOSYNTH RES, V36, P95, DOI 10.1007/BF00016274; Anbar AD, 2002, SCIENCE, V297, P1137, DOI 10.1126/science.1069651; Arouri K, 1999, ORG GEOCHEM, V30, P1323, DOI 10.1016/S0146-6380(99)00105-9; Aubry MP, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P158; Baldauf SL, 2003, SCIENCE, V300, P1703, DOI 10.1126/science.1085544; BAMBACH RK, 1993, PALEOBIOLOGY, V19, P372, DOI 10.1017/S0094837300000336; BARRON EJ, 1995, PALEOCEANOGRAPHY, V10, P953, DOI 10.1029/95PA01624; BARTOLI F, 1983, ECOL BULL, P469; Bekker A, 2004, NATURE, V427, P117, DOI 10.1038/nature02260; Berggren W. A., 1995, GEOCHRONOLOGY TIME S, P129, DOI DOI 10.2110/PEC.95.04.0129; Bown P. R., 2004, COCCOLITHOPHORES FRO; Bown PR, 2004, COCCOLITHOPHORES: FROM MOLECULAR PROCESSES TO GLOBAL IMPACT, P481; BRALOWER TJ, 1991, MAR MICROPALEONTOL, V17, P119, DOI 10.1016/0377-8398(91)90025-2; BROCKS JJ, 2003, TREATISE GEOCHEMISTR, V8, P63, DOI DOI 10.1016/B0-08-043751-6/08127-5; Butterfield Nicholas J., 1994, Fossils and Strata, V34, P1; Butterfield NJ, 2000, PALEOBIOLOGY, V26, P386, DOI 10.1666/0094-8373(2000)026<0386:BPNGNS>2.0.CO;2; BUTTERFIELD NJ, 2002, GEOL SOC AM ABSTR, V34, P169; Chacon-Baca E, 2002, GEOLOGY, V30, P279, DOI 10.1130/0091-7613(2002)030<0279:MNDFNM>2.0.CO;2; CHANDLER MA, 1992, GEOL SOC AM BULL, V104, P543, DOI 10.1130/0016-7606(1992)104<0543:PCDTEJ>2.3.CO;2; COLBATH GK, 1995, REV PALAEOBOT PALYNO, V86, P287, DOI 10.1016/0034-6667(94)00148-D; Conley DJ, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/2002GB001894; Crowley TJ, 1991, PALEOCLIMATOLOGY, P349; Damste JSS, 2004, SCIENCE, V304, P584, DOI 10.1126/science.1096806; Delwiche CF, 1999, AM NAT, V154, pS164, DOI 10.1086/303291; Dugdale RC, 1998, NATURE, V391, P270, DOI 10.1038/34630; ESSER C, 2004, MOL BIOL EVOL, DOI DOI 10.1093/MOLBEV/MSH200; Falciatore A, 2000, SCIENCE, V288, P2363, DOI 10.1126/science.288.5475.2363; Falkowski PG, 1997, NATURE, V387, P272, DOI 10.1038/387272a0; Falkowski PG, 2003, GLO CH IGBP, P99; Falkowski PG., 1997, AQUATIC PHOTOSYNTHES, P375; Farquhar J, 2000, SCIENCE, V289, P756, DOI 10.1126/science.289.5480.756; FENNEL K, IN PRESS AM J SCI; FENSOME R, 1991, J MAR RES, V49, P339; Fensome RA, 1996, PALEOBIOLOGY, V22, P329, DOI 10.1017/S0094837300016316; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; FISHER NS, 1991, J MAR RES, V49, P339, DOI 10.1357/002224091784995882; GERMAN TN, 1990, ORGANICHESKII MIR MI, P52; Gersonde R, 1990, PROC OCEAN DRILL SCI, P365, DOI DOI 10.2973/0DP.PR0C.SR.113.127.1990; GERSONDE R, COMMUNICATION; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; GROVER JP, 1988, ECOLOGY, V69, P408, DOI 10.2307/1940439; Grzebyk D, 2003, J PHYCOL, V39, P259, DOI 10.1046/j.1529-8817.2003.02082.x; HAQ BU, 1987, HIST BIOL, V4, P75; Harwood D.M., 1995, SILICEOUS MICROFOSSI, V8, P81, DOI DOI 10.1017/S2475263000001434; Hayes JM, 1999, CHEM GEOL, V161, P103, DOI 10.1016/S0009-2541(99)00083-2; HUBER BT, 1995, GEOL SOC AM BULL, V107, P1164, DOI 10.1130/0016-7606(1995)107<1164:MLCCOT>2.3.CO;2; Huh Y, 1999, GEOCHIM COSMOCHIM AC, V63, P967, DOI 10.1016/S0016-7037(99)00045-9; Isozaki Y, 1997, SCIENCE, V276, P235, DOI 10.1126/science.276.5310.235; Jacobs BF, 1999, ANN MO BOT GARD, V86, P590, DOI 10.2307/2666186; JANIS NM, 1990, EVOLUTIONARY TRENDS, P301; KATZ M, IN PRESS ANN REV ECO; Kellogg EA, 2000, ANNU REV ECOL SYST, V31, P217, DOI 10.1146/annurev.ecolsys.31.1.217; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; KOOSITRA W, 2002, PROG MOL SUBCELL BIO, V33, P59; Li WKW, 2002, NATURE, V419, P154, DOI 10.1038/nature00994; MACRAE, UNPUB; Margalef R., 1997, EXCELLENCE ECOLOGY, VXIX, P194; Martin RE, 2003, LETHAIA, V36, P179, DOI 10.1080/00241160310005340; Moldowan JM, 1998, SCIENCE, V281, P1168, DOI 10.1126/science.281.5380.1168; Palmer JD, 2003, J PHYCOL, V39, P4, DOI 10.1046/j.1529-8817.2003.02185.x; Prauss M., 2000, GOTTINGER ARB GEOL P, V76, P1; Quigg A, 2003, NATURE, V425, P291, DOI 10.1038/nature01953; Rapp G.R., 1992, ADV ARCHAEOL METH TH, Vfirst, DOI [10.1007/978-1-4899-1155-1, DOI 10.1007/978-1-4899-1155-1]; Raven JA, 1997, ADV BOT RES, V25, P59, DOI 10.1016/S0065-2296(08)60148-2; Raven JA, 1999, PLANT CELL ENVIRON, V22, P741, DOI 10.1046/j.1365-3040.1999.00419.x; Raymond J, 2002, SCIENCE, V298, P1616, DOI 10.1126/science.1075558; Retallack GJ, 1997, PALAIOS, V12, P380, DOI 10.2307/3515337; Retallack GJ, 2001, J GEOL, V109, P407, DOI 10.1086/320791; RONOV AB, 1994, AM J SCI, V294, P777, DOI 10.2475/ajs.294.7.777; Rosing MT, 2004, EARTH PLANET SC LETT, V217, P237, DOI 10.1016/S0012-821X(03)00609-5; ROTHPLETZ A., 1896, Z DTSCH GEOLOGISCHEN, V48, P854; Siegel DA, 1998, LIMNOL OCEANOGR, V43, P1133, DOI 10.4319/lo.1998.43.6.1133; Smetacek V, 1999, PROTIST, V150, P25, DOI 10.1016/S1434-4610(99)70006-4; Spencer-Cervato Cinzia, 1999, Palaeontologia Electronica, V2, pUnpaginated; Stover L.E., 1996, PALYNOLOGY PRINCIPLE, V2, P641; Summons RE, 1999, NATURE, V400, P554, DOI 10.1038/23005; Talyzina NM, 2000, REV PALAEOBOT PALYNO, V112, P1, DOI 10.1016/S0034-6667(00)00032-4; Tappan H, 1980, PALEOBIOLOGY PLANT P, P1028; TAYLOR FJR, 1987, ANN NY ACAD SCI, V503, P1; TAYLOR FJR, 1979, P R SOC LONDON, V240, P267; TILMAN D, 1977, ECOLOGY, V58, P338, DOI 10.2307/1935608; Tozzi S, 2004, MAR ECOL PROG SER, V274, P123, DOI 10.3354/meps274123; VANDESCHOOTBRUG.B, IN PRESS PALEOBIOLOG; VIDAL G, 1983, GEOL SOC AM MEM, V161, P265; Whitfield M, 2001, ADV MAR BIOL, V41, P1, DOI 10.1016/S0065-2881(01)41002-9; Wignall PB, 1996, SCIENCE, V272, P1155, DOI 10.1126/science.272.5265.1155; Yoon HS, 2004, MOL BIOL EVOL, V21, P809, DOI 10.1093/molbev/msh075; Young JR, 1999, J STRUCT BIOL, V126, P195, DOI 10.1006/jsbi.1999.4132; Zaslavskaia LA, 2001, SCIENCE, V292, P2073, DOI 10.1126/science.160015	90	1000	1059	25	544	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					354	360		10.1126/science.1095964	http://dx.doi.org/10.1126/science.1095964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256663	Green Submitted			2022-12-28	WOS:000222662400027
J	Alexander, EK; Marqusee, E; Lawrence, J; Jarolim, P; Fischer, GA; Larsen, PR				Alexander, EK; Marqusee, E; Lawrence, J; Jarolim, P; Fischer, GA; Larsen, PR			Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	75th Annual Meeting of the American-Thyroid-Association	SEP, 2003	Palm Beach, FL	Amer Thyroid Assoc			THYROXINE-BINDING GLOBULIN; MATERNAL THYROID-DEFICIENCY; IODOTHYRONINE DEIODINASE; INCREASED NEED; DISORDERS; THERAPY; DISEASE; SERUM	BACKGROUND: Hypothyroidism during pregnancy has been associated with impaired cognitive development and increased fetal mortality. During pregnancy, maternal thyroid hormone requirements increase. Although it is known that women with hypothyroidism should increase their levothyroxine dose during pregnancy, biochemical hypothyroidism occurs in many. In this prospective study we attempted to identify precisely the timing and amount of levothyroxine adjustment required during pregnancy. METHODS: Women with hypothyroidism who were planning pregnancy were observed prospectively before and throughout their pregnancies. Thyroid function, human chorionic gonadotropin, and estradiol were measured before conception, approximately every two weeks during the first trimester, and monthly thereafter. The dose of levothyroxine was increased to maintain the thyrotropin concentration at preconception values throughout pregnancy. RESULTS: Twenty pregnancies occurred in 19 women and resulted in 17 full-term births. An increase in the levothyroxine dose was necessary during 17 pregnancies. The mean levothyroxine requirement increased 47 percent during the first half of pregnancy (median onset of increase, eight weeks of gestation) and plateaued by week 16. This increased dose was required until delivery. CONCLUSIONS: Levothyroxine requirements increase as early as the fifth week of gestation. Given the importance of maternal euthyroidism for normal fetal cognitive development, we propose that women with hypothyroidism increase their levothyroxine dose by approximately 30 percent as soon as pregnancy is confirmed. Thereafter, serum thyrotropin levels should be monitored and the levothyroxine dose adjusted accordingly.	Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Thyroid Sect, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Div Clin Labs, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Valdosta Specialty Clin, Valdosta, GA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Alexander, EK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Thyroid Sect, 221 Longwood Ave,2nd Fl, Boston, MA 02115 USA.	ekalexander@partners.org			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007529, R01DK044128] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07609] Funding Source: Medline; NIDDK NIH HHS [DK-07529, DK-44128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abalovich M, 2002, THYROID, V12, P63, DOI 10.1089/105072502753451986; AIN KB, 1987, J CLIN ENDOCR METAB, V65, P689, DOI 10.1210/jcem-65-4-689; Allan WC, 2000, J MED SCREEN, V7, P127, DOI 10.1136/jms.7.3.127; [Anonymous], 2000, NATL VITAL STAT REPO; Arafah BM, 2001, NEW ENGL J MED, V344, P1743, DOI 10.1056/NEJM200106073442302; BURROW GN, 1994, NEW ENGL J MED, V331, P1072; Caixas A, 1999, J CLIN ENDOCR METAB, V84, P4000, DOI 10.1210/jc.84.11.4000; Canaris GJ, 2000, ARCH INTERN MED, V160, P526, DOI 10.1001/archinte.160.4.526; Chopra IJ, 2003, METABOLISM, V52, P122, DOI 10.1053/meta.2003.50019; DELANGE F, 1994, THYROID, V4, P107, DOI 10.1089/thy.1994.4.107; GIRLING JC, 1992, BRIT J OBSTET GYNAEC, V99, P368, DOI 10.1111/j.1471-0528.1992.tb13750.x; Glinoer D, 1997, ENDOCR REV, V18, P404, DOI 10.1210/er.18.3.404; GLINOER D, 1977, ENDOCRINOLOGY, V100, P807, DOI 10.1210/endo-100-3-807; GLINOER D, 1990, J CLIN ENDOCR METAB, V71, P276, DOI 10.1210/jcem-71-2-276; Haddow JE, 1999, NEW ENGL J MED, V341, P549, DOI 10.1056/NEJM199908193410801; HARADA A, 1979, J CLIN ENDOCR METAB, V48, P793, DOI 10.1210/jcem-48-5-793; Huang SA, 2003, J CLIN ENDOCR METAB, V88, P1384, DOI 10.1210/jc.2002-021291; KAPLAN MM, 1992, THYROID, V2, P147, DOI 10.1089/thy.1992.2.147; Klein RZ, 2001, J MED SCREEN, V8, P18, DOI 10.1136/jms.8.1.18; LARSEN PR, 1987, J CLIN ENDOCR METAB, V64, P1089; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MCDOUGALL IR, 1995, J FAM PRACTICE, V41, P238; McDuffie RS, 1996, JAMA-J AM MED ASSOC, V275, P847, DOI 10.1001/jama.275.11.847; Muller AF, 2000, J CLIN ENDOCR METAB, V85, P545, DOI 10.1210/jc.85.2.545; PECK T M, 1979, Clinical Obstetrics and Gynecology, V22, P785, DOI 10.1097/00003081-197912000-00002; PEKONEN F, 1984, OBSTET GYNECOL, V63, P635; ROTI E, 1981, J CLIN ENDOCR METAB, V53, P498, DOI 10.1210/jcem-53-3-498; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; VENTURA SJ, 2001, NATL VITAL STAT REPO, V49; VULSMA T, 1989, NEW ENGL J MED, V321, P13, DOI 10.1056/NEJM198907063210103; Wasco EC, 2003, ENDOCRINOLOGY, V144, P4253, DOI 10.1210/en.2003-0490; Zigman JM, 2003, THYROID, V13, P1169, DOI 10.1089/10507250360731587	32	329	360	0	14	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					241	249		10.1056/NEJMoa040079	http://dx.doi.org/10.1056/NEJMoa040079			9	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254282	Bronze			2022-12-28	WOS:000222627200008
J	Kent, DM; Mwamburi, DM; Bennish, ML; Kupelnick, B; Ioannidis, JPA				Kent, DM; Mwamburi, DM; Bennish, ML; Kupelnick, B; Ioannidis, JPA			Clinical trials in Sub-Saharan Africa and established standards of care - A systematic review of HIV, tuberculosis, and malaria trials	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TO-CHILD TRANSMISSION; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED-TRIAL; MATERNAL-INFANT TRANSMISSION; SOCIETY USA PANEL; ANTIRETROVIRAL THERAPY; UPDATED RECOMMENDATIONS; DEVELOPING-COUNTRIES; IMPREGNATED BEDNETS; GAMBIAN CHILDREN	Context The minimum standard of care required for participants in clinical trials conducted in resource-poor settings is a matter of controversy; international documents offer contradictory guidance. Objective To determine whether recently published trials conducted in sub-Saharan Africa met standards of care consistent with best current clinical standards for human immunodeficiency virus (HIV) treatment, tuberculosis treatment, and malaria prevention. Data Sources Trials published during or after January 1998 that were indexed at the time of the MEDLINE and Cochrane Controlled Trials Register Search (November 20,2003). Study Selection All randomized clinical trials that were conducted in sub-Saharan Africa in 3 clinical domains: HIV disease, tuberculosis treatment, and malaria prophylaxis. Data Extraction To establish criteria for best current standards of care, evidence from the literature and published guidelines accepted for well-resourced settings were analyzed; the actual care offered in the trial was then compared with these standards. Data Synthesis A total of 128 eligible articles described data from 73 different randomized clinical trials. Only 12 trials (16%) provided care that met guidelines to both intervention and control patients. Only 1 of the 34 trials that enrolled patients with HIV disease provided antiretroviral treatment that conformed to guidelines. Conversely, all tuberculosis treatment trials (n=13, including 3 for HIV-infected patients) provided tuberculosis therapy that conformed to guidelines. Twenty-one (72%) of 29 malaria prophylaxis trials tested interventions that met guidelines, but only 3 (10%) used any active prophylactic intervention in the control group. Of the 59 trials (81%) that reported on the process of ethical review, all were reviewed by a host African institution and 64% were additionally reviewed by an institution in a developed country. Conclusions Rates of adherence to established clinical guidelines of care in randomized clinical trials of HIV treatment, tuberculosis treatment, and malaria prophylaxis varied considerably between disease categories. In determining clinical standards for trials in sub-Saharan Africa, researchers and ethics committees appear to take the local level of care into account.	Tufts Univ, Sch Med, Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; Tufts Univ, Sch Med, Tufts New England Med Ctr, Dept Med,Div Geog Med & Infect Dis, Boston, MA 02111 USA; Africa Ctr Hlth & Populat Studies, Mtubatuba, South Africa; Univ Ioannina, Sch Med, Dept Hyg & Epidemiol, Clin Trials & Evidence Based Med Unit, GR-45110 Ioannina, Greece	Tufts Medical Center; Tufts University; Tufts Medical Center; Tufts University; University of Kwazulu Natal; University of Ioannina	Kent, DM (corresponding author), Tufts Univ, Sch Med, Tufts New England Med Ctr, Inst Clin Res & Hlth Policy Studies, 750 Washington St,63, Boston, MA 02111 USA.	dkent1@tufts-nemc.org	Ioannidis, John P. A./G-9836-2011		FOGARTY INTERNATIONAL CENTER [D43TW001083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI001671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K23NS044929] Funding Source: NIH RePORTER; FIC NIH HHS [1D43 TW01083-01] Funding Source: Medline; NIAID NIH HHS [K24 AI/HDO1671-01] Funding Source: Medline; NINDS NIH HHS [K23 NS44929-01] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Binka FN, 1996, TROP MED INT HEALTH, V1, P147; Bloom BR, 1998, SCIENCE, V279, P186, DOI 10.1126/science.279.5348.186; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; CHOI HW, 1995, AM J TROP MED HYG, V52, P377, DOI 10.4269/ajtmh.1995.52.377; *CIOMS, 2002, INT ETH GUID BIOM RE; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; Curtis CF, 1996, TROP MED INT HEALTH, V1, P137; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Isaakidis P, 2002, BRIT MED J, V324, P702, DOI 10.1136/bmj.324.7339.702; Kent DM, 2004, MED DECIS MAKING, V24, P281, DOI 10.1177/0272989X04265478; Kent DM, 2003, CLIN INFECT DIS, V37, pS13, DOI 10.1086/375368; KENT DM, 2003, AM J BIOETH, V3; Levine RJ, 1999, NEW ENGL J MED, V341, P531, DOI 10.1056/NEJM199908123410713; LOBEL HO, 1993, LANCET, V341, P848, DOI 10.1016/0140-6736(93)93058-9; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Montaner JSG, 1998, AIDS, V12, pF23, DOI 10.1097/00002030-199805000-00003; Moodley D, 2003, J INFECT DIS, V187, P725, DOI 10.1086/367898; National Bioethics Advisory Commission (NBAC) USA., 2001, ETH POL ISS INT RES; Nevill CG, 1996, TROP MED INT HEALTH, V1, P139; *NUFF COUNC BIOETH, 2002, REP ETH RES REL HEAL; PANG LW, 1987, LANCET, V1, P1161; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SINGHARAJ P, 1987, R THAI ARMY MED J, V40, P165; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Taha TE, 2003, LANCET, V362, P1171, DOI 10.1016/S0140-6736(03)14538-2; *UN DEV PROGR, 2003, HUM DEV REP 2003; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; *WHO, 2000, CTDMALAFRO974 WHO; *WHO, 1996, M BRAZZ 18 20 MARCH; WHO, 1997, TREATM TUB GUID NAT, V2; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilfert CM, 1999, LANCET, V353, P832, DOI 10.1016/S0140-6736(98)10414-2; Wilkinson D, 1999, BRIT MED J, V318, P479, DOI 10.1136/bmj.318.7182.479; *WORLD MED ASS, 2000, 52 WORLD MED ASS GEN; *WORLD MED ASS, 1996, 48 WORLD MED ASS GEN	44	28	29	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					237	242		10.1001/jama.292.2.237	http://dx.doi.org/10.1001/jama.292.2.237			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249573				2022-12-28	WOS:000222579300029
J	Zhang, SM; Adema, CM; Kepler, TB; Loker, ES				Zhang, SM; Adema, CM; Kepler, TB; Loker, ES			Diversification of Ig superfamily genes in an invertebrate	SCIENCE			English	Article							SNAIL BIOMPHALARIA-GLABRATA; TOLL-LIKE RECEPTORS; INNATE IMMUNITY; FAMILY; CONVERSION; FREQUENCY; EVOLUTION; MEMBERS; DOMAINS; PCR	The freshwater snail Biomphalaria glabrata possesses a diverse family of fibrinogen-related proteins (FREPs), hemolymph polypeptides that consist of one or two amino-terminal immunoglobulin superfamily (IgSF) domains and a carboxylterminal fibrinogen domain. Here, we show that the IgSF1 domain of the FREP3 subfamily is diversified at the genomic level at higher rates than those recorded for control genes. All sequence variants are derived from a small set of nine source sequences by point mutation and recombinatorial processes. Diverse FREP3 transcripts are also produced. We hypothesize a mechanism present in snails that is capable of diversifying molecules involved in internal defense.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Duke Univ, Inst Genome Sci & Policy, Ctr Bioinformat & Computat Biol, Dept Biostat & Bioinformat, Durham, NC 27710 USA	University of New Mexico; Duke University	Loker, ES (corresponding author), Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.	esloker@unm.edu		Kepler, Thomas/0000-0002-1383-6865	NCRR NIH HHS [RR-1P20RR18754] Funding Source: Medline; NIAID NIH HHS [R01AI52363, R01AI24340] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018754] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024340, R01AI052363] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adema CM, 1997, P NATL ACAD SCI USA, V94, P8691, DOI 10.1073/pnas.94.16.8691; ADEMA CM, 1997, PARASITE EFFECTS HOS, P77; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Agrawal AF, 2001, EVOLUTION, V55, P869, DOI 10.1554/0014-3820(2001)055[0869:PATEOS]2.0.CO;2; Cannon JP, 2004, CURR BIOL, V14, pR465, DOI 10.1016/j.cub.2004.06.009; Chamnanpunt J, 2001, P NATL ACAD SCI USA, V98, P14530, DOI 10.1073/pnas.251464498; Cline J, 1996, NUCLEIC ACIDS RES, V24, P3546, DOI 10.1093/nar/24.18.3546; Dewilde S, 1998, J BIOL CHEM, V273, P13583, DOI 10.1074/jbc.273.22.13583; Diaz M, 1998, IMMUNOL REV, V162, P13, DOI 10.1111/j.1600-065X.1998.tb01425.x; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KAWANO T, 1992, MALACOLOGIA, V34, P25; Klein J, 1997, SCAND J IMMUNOL, V46, P558, DOI 10.1046/j.1365-3083.1997.d01-164.x; Laursen JR, 1997, J INVERTEBR PATHOL, V70, P226, DOI 10.1006/jipa.1997.4686; Leonard PM, 2001, GENE, V269, P155, DOI 10.1016/S0378-1119(01)00444-9; Loker ES, 2004, IMMUNOL REV, V198, P10, DOI 10.1111/j.0105-2896.2004.0117.x; Lucht JM, 2002, NAT GENET, V30, P311, DOI 10.1038/ng846; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Thompson JR, 2002, NUCLEIC ACIDS RES, V30, P2083, DOI 10.1093/nar/30.9.2083; Zhang S., UNPUB; Zhang SM, 2003, DEV COMP IMMUNOL, V27, P175, DOI 10.1016/S0145-305X(02)00091-5; Zhang SM, 2001, IMMUNOGENETICS, V53, P684, DOI 10.1007/s00251-001-0386-8	21	312	329	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					251	254		10.1126/science.1088069	http://dx.doi.org/10.1126/science.1088069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247481				2022-12-28	WOS:000222501000055
J	Boes, M; Ploegh, HL				Boes, M; Ploegh, HL			Translating cell biology in vitro to immunity in vivo	NATURE			English	Review							IMMUNOLOGICAL SYNAPSE FORMATION; CLASS-II TRANSPORT; CD4 T-CELLS; DENDRITIC CELL; ANTIGEN PRESENTATION; LIPID RAFTS; CROSS-PRESENTATION; MEMBRANE MICRODOMAINS; ENDOPLASMIC-RETICULUM; PEPTIDE LIGANDS	The elimination of pathogens and pathogen-infected cells initially rests on the rapid deployment of innate immune defences. Should these defences fail, it is the lymphocytes-T cells and B cells-with their antigen-specific receptors that must rise to the task of providing adaptive immunity. Technological advances are now allowing immunologists to correlate data obtained in vitro with in vivo functions. A better understanding of T-cell activation in vivo could lead to more effective strategies for the treatment and prevention of infectious and autoimmmune diseases.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Boes, M (corresponding author), Harvard Inst Med, Brigham & Womens Hosp, Dept Dermatol, Suite 671,77 Ave Louis Pasteur, Boston, MA 02115 USA.	Marianne_boes@hms.harvard.edu; ploegh@hms.harvard.edu		Boes, Marianne/0000-0003-2590-1692				Ackerman AL, 2003, P NATL ACAD SCI USA, V100, P12889, DOI 10.1073/pnas.1735556100; Aderem A, 2002, CELL, V110, P5, DOI 10.1016/S0092-8674(02)00819-X; Al-Alwan MM, 2003, J IMMUNOL, V171, P4479, DOI 10.4049/jimmunol.171.9.4479; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Bertho N, 2003, J IMMUNOL, V171, P5689, DOI 10.4049/jimmunol.171.11.5689; Binder RJ, 2001, J BIOL CHEM, V276, P17163, DOI 10.1074/jbc.M011547200; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Boes M, 2003, J IMMUNOL, V171, P4081, DOI 10.4049/jimmunol.171.8.4081; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Borst EM, 1999, J VIROL, V73, P8320, DOI 10.1128/JVI.73.10.8320-8329.1999; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; Bretscher A, 2000, ANNU REV CELL DEV BI, V16, P113, DOI 10.1146/annurev.cellbio.16.1.113; Brigl M, 2004, ANNU REV IMMUNOL, V22, P817, DOI 10.1146/annurev.immunol.22.012703.104608; Buckley RH, 2000, IMMUNOL RES, V22, P237, DOI 10.1385/IR:22:2-3:237; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Davis DM, 2002, TRENDS IMMUNOL, V23, P356, DOI 10.1016/S1471-4906(02)02243-3; Davison AJ, 2003, J GEN VIROL, V84, P17, DOI 10.1099/vir.0.18606-0; Delon J, 2001, IMMUNITY, V15, P691, DOI 10.1016/S1074-7613(01)00231-X; Dustin ML, 2002, ARTHRITIS RES THER, V4, pS119, DOI 10.1186/ar559; Ehrlich LIR, 2002, IMMUNITY, V17, P809, DOI 10.1016/S1074-7613(02)00481-8; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Favier B, 2003, J IMMUNOL, V171, P5027, DOI 10.4049/jimmunol.171.10.5027; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Glebov OO, 2004, NAT CELL BIOL, V6, P238, DOI 10.1038/ncb1103; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Guermonprez P, 2003, NATURE, V425, P397, DOI 10.1038/nature01911; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Horejsi V, 2003, IMMUNOL REV, V191, P148, DOI 10.1034/j.1600-065X.2003.00001.x; Houde M, 2003, NATURE, V425, P402, DOI 10.1038/nature01912; Huppa JB, 2003, NAT IMMUNOL, V4, P749, DOI 10.1038/ni951; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; Kieper WC, 2004, J IMMUNOL, V172, P40, DOI 10.4049/jimmunol.172.1.40; Kleijmeer M, 2001, J CELL BIOL, V155, P53, DOI 10.1083/jcb.200103071; Krogsgaard M, 2003, SEMIN IMMUNOL, V15, P307, DOI 10.1016/j.smim.2003.09.002; Kropshofer H, 2002, NAT IMMUNOL, V3, P61, DOI 10.1038/ni750; Kuhne MR, 2003, J IMMUNOL, V171, P860, DOI 10.4049/jimmunol.171.2.860; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; Lee KH, 2003, SCIENCE, V302, P1218, DOI 10.1126/science.1086507; Lennon-Dumenil AM, 2002, J EXP MED, V196, P529, DOI 10.1084/jem.20020327; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lilley BN, 2004, NATURE, V429, P834, DOI 10.1038/nature02592; McCann FE, 2003, J IMMUNOL, V170, P2862, DOI 10.4049/jimmunol.170.6.2862; Means RE, 2002, FRONT BIOSCI-LANDMRK, V7, pE185, DOI 10.2741/means; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Norbury CC, 2004, SCIENCE, V304, P1318, DOI 10.1126/science.1096378; Ojakian GK, 2001, J CELL SCI, V114, P941; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Paladino S, 2002, INT J MED MICROBIOL, V291, P439; Panyi G, 2004, P NATL ACAD SCI USA, V101, P1285, DOI 10.1073/pnas.0307421100; Pierce SK, 2004, NAT CELL BIOL, V6, P180, DOI 10.1038/ncb0304-180; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Ploegh HL, 2004, SCIENCE, V304, P1262, DOI 10.1126/science.1098965; Pradhan D, 2002, IMMUNITY, V17, P303, DOI 10.1016/S1074-7613(02)00396-5; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Randolph GJ, 2001, SEMIN IMMUNOL, V13, P267, DOI 10.1006/smim.2001.0322; Roumier A, 2001, IMMUNITY, V15, P715, DOI 10.1016/S1074-7613(01)00225-4; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Shier P, 1996, J IMMUNOL, V157, P5375; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Sigal LJ, 1999, NATURE, V398, P77, DOI 10.1038/18038; Somersalo K, 2004, J CLIN INVEST, V113, P49, DOI 10.1172/JCI200419337; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Sugita M, 2000, TRAFFIC, V1, P295, DOI 10.1034/j.1600-0854.2000.010401.x; Tarrant JM, 2003, TRENDS IMMUNOL, V24, P610, DOI 10.1016/j.it.2003.09.011; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Tsukita S, 1999, J BIOL CHEM, V274, P34507, DOI 10.1074/jbc.274.49.34507; Tufariello JM, 2003, LANCET INFECT DIS, V3, P578, DOI 10.1016/S1473-3099(03)00741-2; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; vanEndert PM, 1996, IMMUNOL RES, V15, P265, DOI 10.1007/BF02935312; Vogt AB, 2002, IMMUNOL REV, V189, P136, DOI 10.1034/j.1600-065X.2002.18912.x; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Vossen MTM, 2002, IMMUNOGENETICS, V54, P527, DOI 10.1007/s00251-002-0493-1; Weninger W, 2003, SEMIN IMMUNOL, V15, P257, DOI 10.1016/j.smim.2003.08.007; Wetzel SA, 2002, J IMMUNOL, V169, P6092, DOI 10.4049/jimmunol.169.11.6092; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wolkers MC, 2004, SCIENCE, V304, P1314, DOI 10.1126/science.1096268; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302	100	17	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					264	271		10.1038/nature02762	http://dx.doi.org/10.1038/nature02762			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241425				2022-12-28	WOS:000222470600055
J	Yamamoto, M; Yamazaki, S; Uematsu, S; Sato, S; Hemmi, H; Hoshino, K; Kaisho, T; Kuwata, H; Takeuchi, O; Takeshige, K; Saitoh, T; Yamaoka, S; Yamamoto, N; Yamamoto, S; Muta, T; Takeda, K; Akira, S				Yamamoto, M; Yamazaki, S; Uematsu, S; Sato, S; Hemmi, H; Hoshino, K; Kaisho, T; Kuwata, H; Takeuchi, O; Takeshige, K; Saitoh, T; Yamaoka, S; Yamamoto, N; Yamamoto, S; Muta, T; Takeda, K; Akira, S			Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein I kappa B zeta	NATURE			English	Article							TOLL-LIKE RECEPTORS; ACTIVATION; MACROPHAGES; ADAPTER; FAMILY; MYD88; LIPOPOLYSACCHARIDE; INTERLEUKIN-6; TRANSCRIPTION; RECOGNITION	Toll-like receptors (TLRs) recognize microbial components and trigger the inflammatory and immune responses against pathogens. IkappaBzeta (also known as MAIL and INAP) is an ankyrin-repeat-containing nuclear protein that is highly homologous to the IkappaB family member Bcl-3 (refs 1-6). Transcription of IkappaBzeta is rapidly induced by stimulation with TLR ligands and interleukin-1 (IL-1). Here we show that IkappaBzeta is indispensable for the expression of a subset of genes activated in TLR/IL-1R signalling pathways. IkappaBzeta-deficient cells show severe impairment of IL-6 production in response to a variety of TLR ligands as well as IL-1, but not in response to tumour-necrosis factor-alpha. Endogenous IkappaBzeta specifically associates with the p50 subunit of NF-kappaB, and is recruited to the NF-kappaB binding site of the IL-6 promoter on stimulation. Moreover, NF-kappaB1/p50-deficient mice show responses to TLR/IL-1R ligands similar to those of IkappaBzeta-deficient mice. Endotoxin-induced expression of other genes such as Il12b and Csf2 is also abrogated in IkappaBzeta-deficient macrophages. Given that the lipopolysaccharide-induced transcription of IkappaBzeta occurs earlier than transcription of these genes, some TLR/IL-1R-mediated responses may be regulated in a gene expression process of at least two steps that requires inducible IkappaBzeta.	Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Osaka 5650871, Japan; Japan Sci & Technol Agcy, ERATO, Osaka 5650871, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, PRESTO, Japan Sci & Technol Agcy, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Embryon & Genet Engn, Higashi Ku, Fukuoka 8128582, Japan; RIKEN, Res Ctr Allergy & Immunol, Tsurumi Ku, Kanagawa 2300045, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Mol Virol, Bunkyo Ku, Tokyo 1138519, Japan; Beppu Univ, Dept Food & Nutr, Oita 8740851, Japan	Osaka University; Japan Science & Technology Agency (JST); Kyushu University; Japan Science & Technology Agency (JST); Kyushu University; Kyushu University; RIKEN; Tokyo Medical & Dental University (TMDU)	Akira, S (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Host Def, 3-1 Yamada Oka, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp	Saito, Takashi/C-9684-2009; Takeuchi, Osamu/AAG-9359-2019; Takeda, Kiyoshi/C-9331-2009; Kuwata, Hiro/N-2023-2019; Kaisho, Tsuneyasu/B-4130-2012; Hoshino, Katsuaki/L-9162-2014; Hoshino, Katsuaki/AAE-2830-2022; Takeuchi, Osamu/D-6007-2011; Akira, Shizuo/C-3134-2009	Saito, Takashi/0000-0001-9495-3547; Takeuchi, Osamu/0000-0002-1260-6232; Kuwata, Hiro/0000-0002-5023-1777; Hoshino, Katsuaki/0000-0003-0493-4815; Hoshino, Katsuaki/0000-0003-0493-4815; Sato, Shintaro/0000-0001-5156-3354; Yamazaki, Soh/0000-0001-5038-1567				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Douni E, 1996, J INFLAMM, V47, P27; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Eto A, 2003, BIOCHEM BIOPH RES CO, V301, P495, DOI 10.1016/S0006-291X(02)03082-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haruta H, 2001, J BIOL CHEM, V276, P12485, DOI 10.1074/jbc.C100075200; HILL MR, 1992, INFECT IMMUN, V60, P4040, DOI 10.1128/IAI.60.10.4040-4050.1992; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Jansen M, 2002, CANCER BIOL THER, V1, P293, DOI 10.4161/cbt.84; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; Kitamura H, 2000, FEBS LETT, V485, P53, DOI 10.1016/S0014-5793(00)02185-2; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LA, 2003, CURR OPIN PHARMACOL, V3, P396, DOI 10.1016/S1471-4892(03)00080-8; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamazaki S, 2001, J BIOL CHEM, V276, P27657, DOI 10.1074/jbc.M103426200; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	30	385	399	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					218	222		10.1038/nature02738	http://dx.doi.org/10.1038/nature02738			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241416				2022-12-28	WOS:000222470600046
J	Loke, YK				Loke, YK			Assessing the benefit-harm balance at the bedside - We need pragmatic ways of using the best available information	BRITISH MEDICAL JOURNAL			English	Editorial Material							SAFETY		Hlth Policy & Practice Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Loke, YK (corresponding author), Hlth Policy & Practice Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England.	y.loke@uea.ac.uk						Aronson JK, 2003, BRIT MED J, V327, P1222, DOI 10.1136/bmj.327.7425.1222; Berry DC, 2002, LANCET, V359, P853, DOI 10.1016/S0140-6736(02)07923-0; Bottiger LE, 2001, J INTERN MED, V250, P269, DOI 10.1046/j.1365-2796.2001.00884.x; Bracchi R, 1996, BRIT MED J, V312, P442; Deeks JJ, 2002, BRIT MED J, V325, P619, DOI 10.1136/bmj.325.7365.619; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; HILL K, 2002, DAILY TELEGRAPH 0619; Loke Y K, 2001, BMC Clin Pharmacol, V1, P3, DOI 10.1186/1472-6904-1-3; Loke YK, 2003, BRIT J CLIN PHARMACO, V55, P282, DOI 10.1046/j.1365-2125.2003.01774.x; Vandenbroucke JP, 2004, BRIT MED J, V329, P2, DOI 10.1136/bmj.329.7456.2	11	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					7	8		10.1136/bmj.329.7456.7	http://dx.doi.org/10.1136/bmj.329.7456.7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231591	Green Published			2022-12-28	WOS:000222568300006
J	Hipkin, CR; Simpson, DJ; Wainwright, SJ; Salem, MA				Hipkin, CR; Simpson, DJ; Wainwright, SJ; Salem, MA			Nitrification by plants that also fix nitrogen	NATURE			English	Article							AMERICAN ASTRAGALUS FABACEAE; 3-NITROPROPIONIC ACID; HIPPOCREPIS-COMOSA; MINERALIZATION; ECOSYSTEMS; LEGUMES; TOXINS; ENZYME	Nitrification is a key stage in the nitrogen cycle; it enables the transformation of nitrogen into an oxidized, inorganic state(1,2). The availability of nitrates produced by this process often limits primary productivity and is an important determinant in plant community ecology and biodiversity(3-6). Chemoautotrophic prokaryotes are recognized as the main facilitators of this process(7), although heterotrophic nitrification by fungi may be significant under certain conditions(8). However, there has been neither biochemical nor ecological evidence to support nitrification by photoautotrophic plants. Here we show how certain legumes that accumulate the toxin, 3-nitropropionic acid, generate oxidized inorganic nitrogen in their shoots, which is returned to the soil in their litter. In nitrogen-fixing populations this 'new' nitrate and nitrite can be derived from the assimilation of nitrogen gas. Normally, the transformation of elemental nitrogen from the atmosphere into a fixed oxidized form ( as nitrate) is represented in the nitrogen cycle as a multiphasic process involving several different organisms. We show how this can occur in a single photoautotrophic organism, representing a previously undescribed feature of this biogeochemical cycle.	Univ Wales Swansea, Inst Environm Sustainabil, Sch Biol Sci, Swansea SA2 8PP, W Glam, Wales	Swansea University	Hipkin, CR (corresponding author), Univ Wales Swansea, Inst Environm Sustainabil, Sch Biol Sci, Swansea SA2 8PP, W Glam, Wales.	c.r.hipkin@swansea.ac.uk	salem, mansour awiedat/AAU-1251-2021	salem, mansour awiedat/0000-0002-2990-9045				ALSTON TA, 1983, ACCOUNTS CHEM RES, V16, P418, DOI 10.1021/ar00095a005; Arnon DI, 1940, SOIL SCI, V50, P463; BAXTER RL, 1992, J CHEM SOC PERK T 1, P2495, DOI 10.1039/p19920002495; BERENDSE F, 1990, J ECOL, V78, P413, DOI 10.2307/2261121; CHAPIN FS, 1980, ANNU REV ECOL SYST, V11, P233, DOI 10.1146/annurev.es.11.110180.001313; Dijkstra P, 2003, ISOT ENVIRON HEALT S, V39, P29, DOI 10.1080/1025601031000102189; EVEREST SA, 1984, J EXP MAR BIOL ECOL, V76, P263, DOI 10.1016/0022-0981(84)90192-8; Focht DD, 1977, ADV MICROB ECOL, V1, P135, DOI DOI 10.1007/978-1-4615-8219-9_4; GUSTINE DL, 1979, CROP SCI, V19, P197, DOI 10.2135/cropsci1979.0011183X001900020007x; Hipkin CR, 1999, BIOCHEM J, V340, P491, DOI 10.1042/0264-6021:3400491; Killham K., 1986, Special Publications of the Society for General Microbiology, V20, P117; Macdonald R.M., 1986, NITRIFICATION SOC GE, P1; MATSUMOTO H, 1961, ANAL CHEM, V33, P1442, DOI 10.1021/ac60178a054; MORECROFT MD, 1992, J ECOL, V80, P49, DOI 10.2307/2261062; Parsons T.R., 1984, MANUAL BIOL CHEM MET; PASTOR J, 1987, OECOLOGIA, V71, P481, DOI 10.1007/BF00379285; REHDER H, 1978, OECOLOGIA, V34, P309, DOI 10.1007/BF00344909; SALEM MA, 1995, PHYTOCHEMISTRY, V40, P89, DOI 10.1016/0031-9422(95)00346-9; SHEARER G, 1986, AUST J PLANT PHYSIOL, V13, P699, DOI 10.1071/PP9860699; Simpson DJ, 1999, VET REC, V145, P169, DOI 10.1136/vr.145.6.169; Sprent J.I., 1987, ECOLOGY NITROGEN CYC; Verhoeven JTA, 1996, TRENDS ECOL EVOL, V11, P494, DOI 10.1016/S0169-5347(96)10055-0; Wedin DA, 1996, SCIENCE, V274, P1720, DOI 10.1126/science.274.5293.1720; WILLIAMS MC, 1981, AGRON J, V73, P434, DOI 10.2134/agronj1981.00021962007300030012x; WILLIAMS MC, 1977, BRITTONIA, V29, P327, DOI 10.2307/2806204; WILLIAMS MC, 1983, AGRON J, V75, P520, DOI 10.2134/agronj1983.00021962007500030024x; WILLIAMS MC, 1977, BRITTONIA, V29, P310, DOI 10.2307/2806203	27	30	34	1	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	2004	430	6995					98	101		10.1038/nature02635	http://dx.doi.org/10.1038/nature02635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229604				2022-12-28	WOS:000222356800051
J	Flematti, GR; Ghisalberti, EL; Dixon, KW; Trengove, RD				Flematti, GR; Ghisalberti, EL; Dixon, KW; Trengove, RD			A compound from smoke that promotes seed germination	SCIENCE			English	Article									Univ Western Australia, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia; Univ Western Australia, Sch Plant Biol, Crawley, WA 6009, Australia; Kings Pk & Bot Gardens, Perth, WA 6005, Australia; Murdoch Univ, Sch Engn Sci, Rockingham, WA 6168, Australia	University of Western Australia; University of Western Australia; Murdoch University	Flematti, GR (corresponding author), Univ Western Australia, Sch Biomed & Chem Sci, Crawley, WA 6009, Australia.	gflematt@chem.uwa.edu.au	Flematti, Gavin R/J-2018-2012; Dixon, Kingsley W/B-1042-2011; Dixon, Kingsley W/A-8133-2016	Dixon, Kingsley W/0000-0001-5989-2929; Flematti, Gavin/0000-0003-2545-6939; Trengove, Robert/0000-0003-2454-0477				Brown NAC, 1997, PLANT GROWTH REGUL, V22, P115, DOI 10.1023/A:1005852018644; DREWES FE, 1995, PLANT GROWTH REGUL, V16, P205, DOI 10.1007/BF00029542; Roche S, 1997, AUST J BOT, V45, P783, DOI 10.1071/BT96099; Wigchert SCM, 1999, J AGR FOOD CHEM, V47, P1320, DOI 10.1021/jf980926e	4	489	525	14	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	2004	305	5686					977	977		10.1126/science.1099944	http://dx.doi.org/10.1126/science.1099944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	845ND	15247439				2022-12-28	WOS:000223250700038
J	Williams, PA; Cosme, J; Vinkovic, DM; Ward, A; Angove, HC; Day, PJ; Vonrhein, C; Tickle, IJ; Jhoti, H				Williams, PA; Cosme, J; Vinkovic, DM; Ward, A; Angove, HC; Day, PJ; Vonrhein, C; Tickle, IJ; Jhoti, H			Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone	SCIENCE			English	Article							SUBSTRATE RECOGNITION SITE; ACTIVE-SITE; ALPHA-NAPHTHOFLAVONE; SCANNING MUTAGENESIS; MEMBRANE-BINDING; DRUG-METABOLISM; CYP3A4; ACTIVATION; RESIDUES; KINETICS	Cytochromes P450 (P450s) metabolize a wide range of endogenous compounds and xenobiotics, such as pollutants, environmental compounds, and drug molecules. The microsomal, membrane-associated, P450 isoforms CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP2E1, and CYP1A2 are responsible for the oxidative metabolism of more than 90% of marketed drugs. Cytochrome P450 3A4 ( CYP3A4) metabolizes more drug molecules than all other isoforms combined. Here we report three crystal structures of CYP3A4: unliganded, bound to the inhibitor metyrapone, and bound to the substrate progesterone. The structures revealed a surprisingly small active site, with little conformational change associated with the binding of either compound. An unexpected peripheral binding site is identified, located above a phenylalanine cluster, which may be involved in the initial recognition of substrates or allosteric effectors.	Astex Technol, Cambridge CB4 0QA, England; Global Phasing Ltd, Cambridge CB3 0AX, England	Global Phasing Limited	Jhoti, H (corresponding author), Astex Technol, 436 Cambridge Sci Pk,Milton Rd, Cambridge CB4 0QA, England.	h.jhoti@astex-technology.com		Williams, Pamela/0000-0002-1257-2351; Tickle, Ian/0000-0003-2977-0650				Cosme J, 2000, J BIOL CHEM, V275, P2545, DOI 10.1074/jbc.275.4.2545; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; Davydov DR, 2003, BIOCHEM BIOPH RES CO, V312, P121, DOI 10.1016/j.bbrc.2003.09.247; Domanski TL, 1998, ARCH BIOCHEM BIOPHYS, V350, P223, DOI 10.1006/abbi.1997.0525; Domanski TL, 2001, BIOCHEMISTRY-US, V40, P10150, DOI 10.1021/bi010758a; GRAHAMLORENCE SE, 1995, PHYSL FUNCTIONS CYTO, P57; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; Harlow GR, 1997, J BIOL CHEM, V272, P5396, DOI 10.1074/jbc.272.9.5396; Harlow GR, 1998, P NATL ACAD SCI USA, V95, P6636, DOI 10.1073/pnas.95.12.6636; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; HENDLICH M, 1997, J MOL GRAPH MODEL, V15, P355; Hutzler JM, 2002, DRUG METAB DISPOS, V30, P355, DOI 10.1124/dmd.30.4.355; Kenworthy KE, 1999, BRIT J CLIN PHARMACO, V48, P716; Kenworthy KE, 2001, DRUG METAB DISPOS, V29, P1644; Khan KK, 2002, MOL PHARMACOL, V61, P495, DOI 10.1124/mol.61.3.495; Kim KH, 2003, BIOCHEMISTRY-US, V42, P15377, DOI 10.1021/bi035280k; KOLEY AP, 1995, J BIOL CHEM, V270, P5014, DOI 10.1074/jbc.270.10.5014; Koley AP, 1997, J BIOL CHEM, V272, P3149, DOI 10.1074/jbc.272.6.3149; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Lewis DFV, 1996, XENOBIOTICA, V26, P1067; Lu P, 2001, DRUG METAB DISPOS, V29, P1473; NAVE C, 1995, RADIAT PHYS CHEM, V45, P483, DOI 10.1016/0969-806X(95)92800-E; Park SY, 2002, J INORG BIOCHEM, V91, P491, DOI 10.1016/S0162-0134(02)00446-4; POULOS TL, 1987, BIOCHEMISTRY-US, V26, P8165, DOI 10.1021/bi00399a022; Poulos TL, 2003, P NATL ACAD SCI USA, V100, P13121, DOI 10.1073/pnas.2336095100; SCHWAB GE, 1988, MOL PHARMACOL, V33, P493; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; SHOU M, 1994, BIOCHEMISTRY-US, V33, P6450, DOI 10.1021/bi00187a009; Stevens JC, 1999, J PHARMACOL EXP THER, V290, P594; Szklarz GD, 1997, J COMPUT AID MOL DES, V11, P265, DOI 10.1023/A:1007956612081; Ueng YF, 1997, BIOCHEMISTRY-US, V36, P370, DOI 10.1021/bi962359z; Wang HF, 1998, BIOCHEMISTRY-US, V37, P12536, DOI 10.1021/bi980895g; Williams PA, 2003, NATURE, V424, P464, DOI 10.1038/nature01862	34	669	692	7	101	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2004	305	5684					683	686		10.1126/science.1099736	http://dx.doi.org/10.1126/science.1099736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	842GQ	15256616				2022-12-28	WOS:000222992100053
J	Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, M; Harstrick, A; Verslype, C; Chau, I; Van Cutsem, E				Cunningham, D; Humblet, Y; Siena, S; Khayat, D; Bleiberg, H; Santoro, A; Bets, D; Mueser, M; Harstrick, A; Verslype, C; Chau, I; Van Cutsem, E			Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; MULTICENTER RANDOMIZED-TRIAL; RESISTANT CHINESE-HAMSTER; PHASE-II TRIAL; 1ST-LINE TREATMENT; TYROSINE KINASE; FLUOROURACIL-LEUCOVORIN; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY	Background: The epidermal growth factor receptor (EGFR), which participates in signaling pathways that are deregulated in cancer cells, commonly appears on colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We compared the efficacy of cetuximab in combination with irinotecan with that of cetuximab alone in metastatic colorectal cancer that was refractory to treatment with irinotecan. Methods: We randomly assigned 329 patients whose disease had progressed during or within three months after treatment with an irinotecan-based regimen to receive either cetuximab and irinotecan (at the same dose and schedule as in a prestudy regimen [218 patients]) or cetuximab monotherapy (111 patients). In cases of disease progression, the addition of irinotecan to cetuximab monotherapy was permitted. The patients were evaluated radiologically for tumor response and were also evaluated for the time to tumor progression, survival, and side effects of treatment. Results: The rate of response in the combination-therapy group was significantly higher than that in the monotherapy group (22.9 percent [95 percent confidence interval, 17.5 to 29.1 percent] vs. 10.8 percent [95 percent confidence interval, 5.7 to 18.1 percent], P=0.007). The median time to progression was significantly greater in the combination-therapy group (4.1 vs. 1.5 months, P<0.001 by the log-rank test). The median survival time was 8.6 months in the combination-therapy group and 6.9 months in the monotherapy group (P=0.48). Toxic effects were more frequent in the combination-therapy group, but their severity and incidence were similar to those that would be expected with irinotecan alone. Conclusions: Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.	Royal Marsden Hosp, Dept Med, Sutton SM2 5PT, Surrey, England; Royal Marsden Hosp, London SW3 6JJ, England; Catholic Univ Louvain, St Luc Univ Hosp, B-1200 Brussels, Belgium; Osped Niguarda Ca Granda, Milan, Italy; Hop La Pitie Salpetriere, Paris, France; Inst Jules Bordet, B-1000 Brussels, Belgium; Ist Clin Humanitas, Rozzano Milano, Italy; Merck, Amsterdam, Netherlands; E Merck AG, D-6100 Darmstadt, Germany; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut Jules Bordet; Merck & Company; Merck KGaA; KU Leuven; University Hospital Leuven	Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Med, Downs Rd, Sutton SM2 5PT, Surrey, England.	david.cunningham@icr.ac.uk	Van+Cutsem, Eric/ABE-1762-2021; SIENA, SALVATORE/AAC-5806-2019; Santoro, Armando/J-9594-2018; Chau, Ian/ABC-2023-2020	SIENA, SALVATORE/0000-0002-2681-2846; Santoro, Armando/0000-0003-1709-9492; Chau, Ian/0000-0003-0286-8703; Cunningham, David/0000-0001-5158-1069; Verslype, Chris/0000-0003-3857-466X				Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Chen ZS, 1999, MOL PHARMACOL, V55, P921; Chu XY, 1999, J PHARMACOL EXP THER, V288, P735; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1372; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136; Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046; Goldstein NS, 2001, CANCER, V92, P1331, DOI 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M; Huang SM, 2000, CLIN CANCER RES, V6, P2166; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Klapper LN, 2000, ADV CANCER RES, V77, P25; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; MEYERS MB, 1986, P NATL ACAD SCI USA, V83, P5521, DOI 10.1073/pnas.83.15.5521; MEYERS MB, 1993, BIOCHEM PHARMACOL, V46, P1841, DOI 10.1016/0006-2952(93)90591-J; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Naruse I, 2002, INT J CANCER, V98, P310, DOI 10.1002/ijc.10173; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116; Prewett MC, 2002, CLIN CANCER RES, V8, P994; Rothenberg ML, 2003, J CLIN ONCOL, V21, P2059, DOI 10.1200/JCO.2003.11.126; Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2; Rougier P, 1998, LANCET, V352, P1634; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SALTZ L, 2003, P AN M AM SOC CLIN, V22, P204; SALTZ L, 2001, P AN M AM SOC CLIN, V20, pA3; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302; Sclabas GM, 2003, J GASTROINTEST SURG, V7, P37, DOI 10.1016/S1091-255X(02)00088-4; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337	40	3942	4170	2	251	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					337	345		10.1056/NEJMoa033025	http://dx.doi.org/10.1056/NEJMoa033025			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269313	Bronze			2022-12-28	WOS:000222801200007
J	Brennan, TA; Lee, TH				Brennan, TA; Lee, TH			Allergic to generics	ANNALS OF INTERNAL MEDICINE			English	Article							MANAGED-CARE; DIFFICULT PATIENTS; HEALTH-CARE; PATIENT; ETHICS; PHYSICIAN	A 69-year-old woman with several medical problems believes that she is allergic to generic medications. She frequently conflicts with her long-time primary care physician, who, as required by the patient's insurance coverage, refuses to prescribe brand-name drugs when generic alternatives are available. This conflict intensifies to a crisis when the patient develops life-threatening problems and still will not take prescribed generic medications. The presentation of this real case is accompanied by a discussion of the ethical dilemmas of the patient's physician, who must weigh the interests of a patient who clings to beliefs that the physician thinks are unfounded against the interests of a just rationing program and the broader population it serves.	Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	tabrennan@partners.org						Burton SL, 2001, HEALTH AFFAIR, V20, P150, DOI 10.1377/hlthaff.20.5.150; Daniels N, 1998, HEALTH AFFAIR, V17, P50, DOI 10.1377/hlthaff.17.5.50; Emanuel EJ, 1998, J HEALTH POLIT POLIC, V23, P635; GROVES JE, 1978, NEW ENGL J MED, V298, P883, DOI 10.1056/NEJM197804202981605; Hahn SR, 1996, J GEN INTERN MED, V11, P1, DOI 10.1007/BF02603477; *HLTH CAR MED PRIO, 1993, NO EAS CHOIC DIFF PR; Illingworth P, 2000, J MED PHILOS, V25, P62, DOI 10.1076/0360-5310(200002)25:1;1-V;FT062; JOHN C, 1987, J FAM PRACTICE, V24, P607; LECHKY O, 1992, CAN MED ASSOC J, V146, P1793; LIN EHB, 1991, J GEN INTERN MED, V6, P241, DOI 10.1007/BF02598969; Pearson SD, 1998, NEW ENGL J MED, V339, P689, DOI 10.1056/NEJM199809033391009; Pearson SD, 2002, J GEN INTERN MED, V17, P75, DOI 10.1046/j.1525-1497.2002.10503.x; Pellegrino ED, 1999, J MED PHILOS, V24, P243, DOI 10.1076/jmep.24.3.243.2523; Povar GJ, 2004, ANN INTERN MED, V141, P131, DOI 10.7326/0003-4819-141-2-200407200-00012; THOMPSON DF, 1993, NEW ENGL J MED, V329, P573, DOI 10.1056/NEJM199308193290812; Wikler D, 1997, BIOETHICS, V11, P185, DOI 10.1111/1467-8519.00057	16	27	27	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					126	130		10.7326/0003-4819-141-2-200407200-00011	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262668				2022-12-28	WOS:000222758200006
J	Biant, LC; Teare, EL; Williams, WW; Tuite, JD				Biant, LC; Teare, EL; Williams, WW; Tuite, JD			Eradication of methicillin resistant Staphylococcus aureus by "ring fencing" of elective orthopedic beds	BRITISH MEDICAL JOURNAL			English	Article								Problem Deep infection after joint arthroplasty can be catastrophic, leading to further surgery, loss of the prosthesis, disability, and risk of mortality. Twenty nine new cases of methicillin resistant Staphylococcus aureus occurred in the first year after elective orthopaedic surgery was centralised to a district general hospital in Essex. Design Prospective trial to establish whether ring fencing of elective orthopaedic beds and introduction of simple infection control measures has an effect on the rates of postoperative infections and number of patients treated. Participants and setting All patients undergoing primary hip or knee replacement in a district general hospital in Essex, England, between July 1999 and July 2001. Main measures for improvement Number of patients having joint replacement; number of all postoperative infections in the participant group; Dumber of cases of methicillin resistant Staphylococcus aureus. Strategies for change Ring fencing of the elective orthopaedic ward and introduction of simple infection control measures; Effects of change The incidence of all postoperative infections decreased from 43/417 to 15/488 (P < 0.0001), with no new cases of methicillin resistant Staphylococcus aureus. Lessons learnt The introduction of a ring fenced elective orthopaedic ward and simple infection control measures allowed 17% more patients to be treated and significantly reduced the incidence of all postoperative infections.	Broomfield Hosp, Chelmsford, Essex, England	Mid Essex Hospital Services NHS Trust; Broomfield Hospital	Biant, LC (corresponding author), Broomfield Hosp, Chelmsford, Essex, England.	lcbiant@yahoo.com		Biant, Leela/0000-0002-5291-8898				AMSTUTZ HC, 1974, INSTR COURSE LECT, V23, P248; *BRIT ORTH ASS, 1999, REC STER PROC OP THE; Plowman R., 2000, SOCIO EC BURDEN HOSP; SETO WH, 1990, J HOSP INFECT, V90, P157	4	46	46	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					149	151						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15258070				2022-12-28	WOS:000222832300024
J	Heck, PR; Schmitz, B; Baur, H; Halliday, AN; Wieler, R				Heck, PR; Schmitz, B; Baur, H; Halliday, AN; Wieler, R			Fast delivery of meteorites to Earth after a major asteroid collision	NATURE			English	Article							FAMILY	Very large collisions in the asteroid belt could lead temporarily to a substantial increase in the rate of impacts of meteorites on Earth. Orbital simulations predict that fragments from such events may arrive considerably faster than the typical transit times of meteorites falling today, because in some large impacts part of the debris is transferred directly into a resonant orbit with Jupiter(1,2). Such an efficient meteorite delivery track, however, has not been verified. Here we report high-sensitivity measurements of noble gases produced by cosmic rays in chromite grains from a unique suite of fossil meteorites(3) preserved in similar to480 million year old sediments. The transfer times deduced from the noble gases are as short as similar to10(5) years, and they increase with stratigraphic height in agreement with the estimated duration of sedimentation. These data provide powerful evidence that this unusual meteorite occurrence was the result of a long-lasting rain of meteorites following the destruction of an asteroid, and show that at least one strong resonance in the main asteroid belt can deliver material into the inner Solar System within the short timescales suggested by dynamical models.	ETH, Isotope Geol, CH-8092 Zurich, Switzerland; Lund Univ, Dept Geol, SE-22362 Lund, Sweden	Swiss Federal Institutes of Technology Domain; ETH Zurich; Lund University	Heck, PR (corresponding author), ETH, Isotope Geol, NO C61, CH-8092 Zurich, Switzerland.	heck@erdw.ethz.ch	Heck, Philipp R/AAU-1433-2021; Heck, Philipp/C-6092-2012; Wieler, Rainer/A-1355-2010	Heck, Philipp R/0000-0002-6319-2594; Wieler, Rainer/0000-0001-5666-7494				Baur H., 1999, EOS, V46; Binzel R. P., 2002, ASTEROIDS, VIII, P255; BOGARD DD, 1995, METEORITICS, V30, P244, DOI 10.1111/j.1945-5100.1995.tb01124.x; Bottke W. F., 2002, ASTEROIDS, P395; Bottke WF, 2002, ICARUS, V156, P399, DOI 10.1006/icar.2001.6788; GAFFEY MJ, 1993, ICARUS, V106, P573, DOI 10.1006/icar.1993.1194; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; GRADIE J, 1982, SCIENCE, V216, P1405, DOI 10.1126/science.216.4553.1405; JIANHUA Z, 1998, MEDDN STOCKH U I GEO, V298, P1; KEIL K, 1994, PLANET SPACE SCI, V42, P1109, DOI 10.1016/0032-0633(94)90011-6; Leya I, 2000, METEORIT PLANET SCI, V35, P259, DOI 10.1111/j.1945-5100.2000.tb01775.x; Leya I, 1999, J GEOPHYS RES-SOL EA, V104, P15439, DOI 10.1029/1999JB900134; MARTI K, 1992, ANNU REV EARTH PL SC, V20, P221, DOI 10.1146/annurev.ea.20.050192.001253; Morbidelli A, 1998, METEORIT PLANET SCI, V33, P999, DOI 10.1111/j.1945-5100.1998.tb01707.x; Nesvorny D, 2002, ICARUS, V157, P155, DOI 10.1006/icar.2002.6830; Patterson DB, 1998, EARTH PLANET SC LETT, V163, P315, DOI 10.1016/S0012-821X(98)00197-6; Schmitz B, 2003, SCIENCE, V300, P961, DOI 10.1126/science.1082182; Schmitz B, 2001, EARTH PLANET SC LETT, V194, P1, DOI 10.1016/S0012-821X(01)00559-3; Schmitz B, 1996, EARTH PLANET SC LETT, V145, P31, DOI 10.1016/S0012-821X(96)00205-1; Schmitz B, 2001, ACCRETION EXTRATERRE, P31; Wieler R, 2002, REV MINERAL GEOCHEM, V47, P125, DOI 10.2138/rmg.2002.47.5; Zappala V, 1998, ICARUS, V134, P176, DOI 10.1006/icar.1998.5946	22	89	91	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					323	325		10.1038/nature02736	http://dx.doi.org/10.1038/nature02736			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254530				2022-12-28	WOS:000222631200033
J	Marinella, MA				Marinella, MA			Henoch-Schonlein purpura	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Wright State Univ, Sch Med, Dayton, OH 45429 USA	Wright State University Dayton	Marinella, MA (corresponding author), Wright State Univ, Sch Med, Dayton, OH 45429 USA.								0	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					278	278		10.1056/NEJMicm980785	http://dx.doi.org/10.1056/NEJMicm980785			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254286				2022-12-28	WOS:000222627200012
J	Gallant, JE; Staszewski, S; Pozniak, AL; DeJesus, E; Suleiman, JMAH; Miller, MD; Coakley, DF; Lu, B; Toole, JJ; Cheng, AK				Gallant, JE; Staszewski, S; Pozniak, AL; DeJesus, E; Suleiman, JMAH; Miller, MD; Coakley, DF; Lu, B; Toole, JJ; Cheng, AK		903 Study Grp	Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE INHIBITOR; IN-VITRO SELECTION; DISOPROXIL FUMARATE; EXPERIENCED PATIENTS; MITOCHONDRIAL TOXICITY; HIV-1 INFECTION; DOUBLE-BLIND; SUSCEPTIBILITY; RESISTANCE	Context Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective To evaluate the efficacy and safety of tenofovir DF compared with stavudine in anti retroviral-naive patients. Design, Setting, and Participants A prospective, randomized, double-blind study conducted at 81 centers in the United States, South America, and Europe from June 9, 2000, to January 30, 2004. A total of 753 patients infected with HIV who were antiretroviral naive were screened and 602 patients entered the study. Intervention Patients were randomized to receive either tenofovir DF (n = 299) or stavudine (n=303), with placebo, in combination with lamivudine and efavirenz. Main Outcome Measure Proportion of patients with HIV RNA levels of less than 400 copies/mL at week 48. Results In the primary intent-to-treat analysis in which patients with missing data or who added or switched antiretroviral medications before week 48 were considered as failures, the proportion of patients with HIV RNA of less than 400 copies/mL at week 48 was 239 (80%) of 299 in patients receiving tenofovir DF and 253 (84%) of 301 in patients receiving stavudine (95% confidence interval, -10.4% to 1.5%), exceeding the predefined -10% limit for equivalence. However, equivalence was demonstrated in the secondary analyses (HIV RNA <50 copies/mL) at week 48 and through 144 weeks. Virologic failure was associated most frequently with efavirenz and lamivudine resistance. Through 144 weeks, the K65R mutation emerged in 8 and 2 patients in the tenofovir DF and stavudine groups, respectively (P=.06). A more favorable mean change from baseline in fasting lipid pro e was note in the tenofovir DF group at week 144: for triglyceride levels (+1 mg/dL for tenofovir DF [n = 170] vs +134 mg/dL for stavudine [n = 162], P<.001), total cholesterol (+30 mg/dL [n = 170] vs +58 mg/dL [n = 162], P<.001), direct low-density lipoprotein cholesterol (+14 mg/dL [n=169] vs +26 mg/dL [n=161], <.001), and high-density lipoprotein cholesterol (+9 mg/dL [n=168] vs +6 mg/dL [n=154], P=.003). Investigator-reported lipodystrophy was less common in the tenofovir DF group compared with the stavudine group (9 [3%] of 299 vs 58 [19%] of 301, P<.001). The number of bone fractures and the renal safety profile were similar between the 2 groups. Conclusions Through 144 weeks, the combination of tenofovir DF, lamivudine, and efavirenz was highly effective and comparable with stavudine, lamivudine, and efavirenz in anti retroviral-naive patients. However, tenofovir DF appeared to be associated with better lipid profiles and less lipodystrophy.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA; Goethe Univ Frankfurt, Univ Hosp, Dept Internal Med, D-6000 Frankfurt, Germany; Chelsea & Westminster Hosp, Dept Genitourinary Med, London, England; Infect Dis Consultants Res Initiat, Altamonte Springs, FL USA; Inst Infectol Emilio Ribas, Sao Paulo, Brazil; Gilead Sci Inc, Foster City, CA 94404 USA	Johns Hopkins University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Imperial College London; Gilead Sciences	Gallant, JE (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 1830 E Monument St,Room 443, Baltimore, MD 21287 USA.	jgallant@jhmi.edu						Bazmi HZ, 2000, ANTIMICROB AGENTS CH, V44, P1783, DOI 10.1128/AAC.44.7.1783-1788.2000; Birkus G, 2002, ANTIMICROB AGENTS CH, V46, P716, DOI 10.1128/AAC.46.3.716-723.2002; BLICK G, 2003, 10 C RETR OPP INF FE; Brinkman K, 1999, LANCET, V354, P1112, DOI 10.1016/S0140-6736(99)06102-4; Carr A, 2002, JAMA-J AM MED ASSOC, V288, P207, DOI 10.1001/jama.288.2.207; Carr A, 2004, LANCET, V363, P429, DOI 10.1016/S0140-6736(04)15489-5; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; CHENG A, 2003, 9 EUR AIDS C OCT 25; Dieterich Douglas T, 2003, AIDS Read, V13, P176; *DIV AIDS NAT I AL, DAIDS TABL GRAD SEV; Domingo P, 2004, AIDS, V18, P1475, DOI 10.1097/01.aids.0000131343.53419.04; Dore GJ, 2004, J INFECT DIS, V189, P1185, DOI 10.1086/380398; FISCHL M, 2001, 8 C RETR OPP INF FEB; Fung HB, 2002, CLIN THER, V24, P1515, DOI 10.1016/S0149-2918(02)80058-3; Gallant JE, 2003, CLIN INFECT DIS, V37, P944, DOI 10.1086/378068; GALLANT JE, 2003, 43 INT C ANT AG CHEM; Grim SA, 2003, ANN PHARMACOTHER, V37, P849, DOI 10.1345/aph.1C388; GU ZX, 1994, J BIOL CHEM, V269, P28118; Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Karras A, 2003, CLIN INFECT DIS, V36, P1070, DOI 10.1086/368314; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Louie M, 2003, AIDS, V17, P1151, DOI 10.1097/00002030-200305230-00006; Margot NA, 2003, JAIDS-J ACQ IMM DEF, V33, P15, DOI 10.1097/00126334-200305010-00003; Margot NA, 2002, AIDS, V16, P1227, DOI 10.1097/00002030-200206140-00004; MILLER MD, 2003, 43 ANN INT C ANT AG; Miller V, 2000, ANTIVIR THER, V5, P49; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN CLIN PRACT TR, GUID US ANT AG HIV 1; Petropoulos CJ, 2000, ANTIMICROB AGENTS CH, V44, P920, DOI 10.1128/AAC.44.4.920-928.2000; REYNES J, 2003, 10 C RETR OPP INF FE; Schooley RT, 2002, AIDS, V16, P1257, DOI 10.1097/00002030-200206140-00008; SPIRE V, 2002, 14 INT AIDS C JUL 7; Squires K, 2003, ANN INTERN MED, V139, P313, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00006; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Staszewski S, 2001, JAMA-J AM MED ASSOC, V285, P1155, DOI 10.1001/jama.285.9.1155; STASZEWSKI S, 2003, 10 C RETR OPP INF FE; Stone VE, 2001, CLIN INFECT DIS, V33, P865, DOI 10.1086/322698; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; van Leth F, 2004, LANCET, V363, P1253, DOI 10.1016/S0140-6736(04)15997-7; Wainberg MA, 1999, ANTIVIR THER, V4, P87; White KL, 2002, ANTIMICROB AGENTS CH, V46, P3437, DOI 10.1128/AAC.46.11.3437-3446.2002; Winters MA, 1997, ANTIMICROB AGENTS CH, V41, P757, DOI 10.1128/AAC.41.4.757; Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675	44	1091	1122	0	24	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					191	201		10.1001/jama.292.2.191	http://dx.doi.org/10.1001/jama.292.2.191			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249568				2022-12-28	WOS:000222579300024
J	Olson, MV; Varki, A				Olson, MV; Varki, A			The chimpanzee genome - A bittersweet celebration	SCIENCE			English	Editorial Material							EVOLUTION; HUMANS		Univ Washington, Genome Ctr, Dept Med, Seattle, WA 98195 USA; Univ Washington, Genome Ctr, Dept Genome Sci, Seattle, WA 98195 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Diego; University of California System; University of California San Diego	Olson, MV (corresponding author), Univ Washington, Genome Ctr, Dept Med, Seattle, WA 98195 USA.	mvo@u.washington.edu; a1varki@ucsd.edu						Clark AG, 2003, SCIENCE, V302, P1960, DOI 10.1126/science.1088821; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; *G HAR LY MATH CHA, 2004, SEQ CHIMP GEN WHAT H; Gilad Y, 2003, AM J HUM GENET, V73, P489, DOI 10.1086/378132; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; Olson MV, 2003, NAT REV GENET, V4, P20, DOI 10.1038/nrg981; Varki A, 1998, SCIENCE, V282, P239; Watanabe H, 2004, NATURE, V429, P382, DOI 10.1038/nature02564; WILSON R., UNPUB	9	12	12	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					191	192		10.1126/science.1100975	http://dx.doi.org/10.1126/science.1100975			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247465				2022-12-28	WOS:000222501000036
J	Moyle, G; Boffito, M				Moyle, G; Boffito, M			Unexpected drug interactions and adverse events with antiretroviral drugs	LANCET			English	Editorial Material							FREE-RADICALS; 2',3'-DIDEOXYINOSINE; METABOLISM; DIDANOSINE		Chelsea & Westminster Hosp, London SW10 9NH, England	Imperial College London	Moyle, G (corresponding author), Chelsea & Westminster Hosp, London SW10 9NH, England.	gm@moyleg.demon.co.uk						[Anonymous], 1996, Lancet, V348, P283; Czako L, 1998, DIGEST DIS SCI, V43, P1770, DOI 10.1023/A:1018839821176; Folch E, 1998, DIGEST DIS SCI, V43, P2405, DOI 10.1023/A:1026617812283; GRADY T, 1992, J PHARMACOL EXP THER, V262, P445; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KEARNEY B, 2001, 1 IAS C HIV PATH TRE, P337; KEARNEY BP, 2003, 10 C RETR OPP INF FE, P533; KEARNEY BP, 2002, 14 INT AIDS C JUL 7; Lake-Bakaar G, 2001, DIGEST DIS SCI, V46, P1853, DOI 10.1023/A:1010618627594; MOYLE G, 2003, AIDS READ, V13, P23; Moyle Graeme, 2003, AIDS Read, V13, P15; Podzamczer D, 2004, ANTIVIR THER, V9, pU117; Pozniak A, 2003, HIV Med, V4 Suppl 1, P1; Ray AS, 2004, ANTIMICROB AGENTS CH, V48, P1089, DOI 10.1128/AAC.48.4.1089-1095.2004; RENDON A, 2004, HIV MED, V5, P233; Robbins BL, 2003, PHARMACOTHERAPY, V23, P695, DOI 10.1592/phco.23.6.695.32189; TAY LK, 1991, BIOPHARM DRUG DISPOS, V12, P285, DOI 10.1002/bdd.2510120406; YARCHOAN R, 1990, REV INFECT DIS, V12, pS522; 1993, LANCET, V341, P109	20	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					8	10		10.1016/S0140-6736(04)16608-7	http://dx.doi.org/10.1016/S0140-6736(04)16608-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234836				2022-12-28	WOS:000222392900007
J	Ruxrungtham, K; Brown, T; Phanuphak, P				Ruxrungtham, K; Brown, T; Phanuphak, P			HIV/AIDS in Asia	LANCET			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-INFECTED PATIENTS; SEXUALLY-TRANSMITTED-DISEASES; PENICILLIUM-MARNEFFEI INFECTION; ACTIVE ANTIRETROVIRAL THERAPY; INJECTION-DRUG USERS; HEPATITIS-C-VIRUS; VERTICAL TRANSMISSION; NATURAL-HISTORY; HIGH PREVALENCE	HIV (ie, HIV-1) epidemics in Asia show great diversity, both in severity and timing. But epidemics in Asia are far from over and several countries including China, Indonesia, and Vietnam have growing epidemics. Several factors affect the rate and magnitude of growth of HIV prevalence, but two of the most important are the size of the sex worker population and the frequency with which commercial sex occurs. In view of the present state of knowledge, even countries with low prevalence of infection might still have epidemics affecting a small percentage of the population. Once HIV infection has become established, growing needs for care and treatment are unavoidable and even the so-called prevention-successful countries of Thailand and Cambodia are seeing burgeoning care needs. The manifestations of HIV disease in the region are discussed with the aim of identifying key issues in medical management and care of HIV/AIDS. In particular, issues relevant to developing appropriate highly active antiretroviral treatment programmes in the region are discussed. Although access to antiretroviral therapy is increasing globally, making it work effectively while simultaneously expanding prevention programmes to stem the flow of new infections remains a real challenge in Asia. Genuine political interest and commitment are essential foundations for success, demanding advocacy at all levels to drive policy, mobilise sufficient resources, and take effective action.	Chulalongkorn Univ, Thai Red Cross AIDS Res Ctr, Bangkok 10330, Thailand; HIV NAT, Bangkok 10330, Thailand; EW Ctr Thai Red Cross Soc Collaborat, Bangkok, Thailand	Chulalongkorn University; Thai Red Cross Society	Phanuphak, P (corresponding author), Chulalongkorn Univ, Thai Red Cross AIDS Res Ctr, Bangkok 10330, Thailand.	ppraphan@chula.ac.th						Ainsworth M, 1998, Finance Dev, P18; Ainsworth M, 2003, HEALTH POLICY, V64, P13, DOI 10.1016/S0168-8510(02)00079-9; Amornwichet P, 2002, JAMA-J AM MED ASSOC, V288, P245, DOI 10.1001/jama.288.2.245; Anil S, 1997, ORAL DIS S, V1, P36; [Anonymous], PROJ HIV AIDS THAIL; Beyrer C, 2000, AIDS, V14, P75, DOI 10.1097/00002030-200001070-00009; Boyd MA, 2003, JAIDS-J ACQ IMM DEF, V34, P134, DOI 10.1097/00126334-200310010-00003; Brown T, 1995, CURR SCI INDIA, V69, P840; BROWN T, 1994, AIDS, V8, pS131; BROWN T, 2001, EFFECTIVE PREVENTION; BURANAPRADITKUN S, 2004, 11 C RETR OPP INF 20; Burger D, 2003, J ANTIMICROB CHEMOTH, V51, P1231, DOI 10.1093/jac/dkg198; Busza J, 1999, LIT REV CHALLENGING; Busza JR, 2001, AIDS CARE, V13, P441, DOI 10.1080/09540120120057978; Cardiello PG, 2003, ANTIVIR THER, V8, P245; Cardiello PG, 2002, J ACQ IMMUN DEF SYND, V29, P464, DOI 10.1097/00042560-200204150-00006; Celentano DD, 2003, J URBAN HEALTH, V80, P97; Chan R, 1998, AIDS S, V12, P59; Chen JM, 2002, J INFECT DIS, V186, P321, DOI 10.1086/341661; Chen Mao-Yen, 1994, Journal of the Formosan Medical Association, V93, P901; Chen YMA, 2001, J ACQ IMMUN DEF SYND, V26, P274, DOI 10.1097/00126334-200103010-00011; CHIN J, 1998, AIDS SB, V12, P87; Choi KH, 2003, LANCET, V361, P2125, DOI 10.1016/S0140-6736(03)13690-2; Colby DJ, 2003, JAIDS-J ACQ IMM DEF, V32, P80, DOI 10.1097/00126334-200301010-00012; *COMB WORK GROUP H, 2002, PROJ HIV AIDS CAMB 2; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Crofts N, 1998, AIDS SB, V12, P69; Deng Shou-Chin, 2003, Journal of Microbiology Immunology and Infection, V36, P10; *DHHS, 2003, GUID US ANT AG HIV I; Diagbouga S, 2003, AIDS, V17, P2201, DOI 10.1097/00002030-200310170-00008; Dickson D, 2001, NATURE, V409, P551, DOI 10.1038/35054705; Dore GJ, 1996, MED J AUSTRALIA, V165, P494, DOI 10.5694/j.1326-5377.1996.tb138615.x; DORE GJ, 1998, AIDS SB, V12, P1; Dukers NHTM, 2002, AIDS, V16, pF19, DOI 10.1097/00002030-200207050-00001; Elliott Richard, 2002, Can HIV AIDS Policy Law Rev, V7, P61; ELLY J, 2000, PAC IDS ALERT B, V19, P17; Eshleman SH, 2004, JAIDS-J ACQ IMM DEF, V35, P126, DOI 10.1097/00126334-200402010-00004; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; ESTEBANEZ P, 1993, B WORLD HEALTH ORGAN, V71, P397; FISCHL M, 2001, 8 C RETR OPP INF CHI; Frater John, 2002, J HIV Ther, V7, P92; Galvin SR, 2004, NAT REV MICROBIOL, V2, P33, DOI 10.1038/nrmicro794; Garten RJ, 2004, INT J EPIDEMIOL, V33, P182, DOI 10.1093/ije/dyh019; GHYS PD, 2003, AIDS S, V17, P45; Girault P, 2004, AIDS EDUC PREV, V16, P31, DOI 10.1521/aeap.16.1.31.27727; Gorbach PM, 2000, SEX TRANSM DIS, V27, P320, DOI 10.1097/00007435-200007000-00004; Gouws E, 2002, J ACQ IMMUN DEF SYND, V29, P531, DOI 10.1097/00126334-200204150-00015; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hanenberg R, 1998, AIDS CARE, V10, P69, DOI 10.1080/713612352; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HENG BH, 1995, J EPIDEMIOL COMMUN H, V49, P309, DOI 10.1136/jech.49.3.309; Hira SK, 2003, NATL MED J INDIA, V16, P126; Ho TTY, 1998, AIDS, V12, P2082, DOI 10.1097/00002030-199815000-00026; Hsieh SM, 1998, AIDS, V12, P1301, DOI 10.1097/00002030-199811000-00011; Hu DJ, 2003, AIDS RES HUM RETROV, V19, P727, DOI 10.1089/088922203769232511; Hung CC, 2000, J ACQ IMMUN DEF SYND, V24, P378, DOI 10.1097/00126334-200008010-00013; Hyder AA, 1999, PUBLIC HEALTH, V113, P39, DOI 10.1016/S0033-3506(99)00111-0; Iademarco Michael F, 2003, Semin Respir Infect, V18, P225; *IAVI, 2002, IAVI VACC DEV FACT S; JALAL F, 1994, AIDS S, V8, P91; Janssen RS, 1998, JAMA-J AM MED ASSOC, V280, P42, DOI 10.1001/jama.280.1.42; Joesoef MR, 2003, INT J STD AIDS, V14, P609, DOI 10.1258/095646203322301068; Kanshana S, 2002, AIDS, V16, P953, DOI 10.1097/00002030-200205030-00001; Khan OA, 2001, HEALTH POLICY PLANN, V16, P214, DOI 10.1093/heapol/16.2.214; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Kumarasamy N, 2003, CLIN INFECT DIS, V36, P79, DOI 10.1086/344756; Kunanusont Chaiyos, 1999, Journal of the Medical Association of Thailand, V82, P425; Kunimoto DY, 1999, INT J TUBERC LUNG D, V3, P944; Kura MM, 1998, INT J STD AIDS, V9, P231, DOI 10.1258/0956462981921954; Lallemant M, 2004, 11 C RETR OPP INF SA; Law WP, 2003, AIDS, V17, P2191, DOI 10.1097/00002030-200310170-00007; Lee CN, 2000, J CLIN MICROBIOL, V38, P2468, DOI 10.1128/JCM.38.7.2468-2474.2000; Lin P, 2001, Zhonghua Liu Xing Bing Xue Za Zhi, V22, P194; Lindan CP, 1997, AIDS, V11, pS5; Lurie MN, 2004, LANCET INFECT DIS, V4, P137, DOI 10.1016/S1473-3099(04)00936-3; Malau C, 2000, Dev Bull, P58; Mamtaz A, 1999, J Prev Soc Med, V18, P74; Manjunath JV, 2002, INT J STD AIDS, V13, P612, DOI 10.1258/09564620260216317; Menu E, 1999, J ACQ IMMUN DEF SYND, V20, P481, DOI 10.1097/00042560-199904150-00011; Mertens TE, 1996, B WORLD HEALTH ORGAN, V74, P121; Miah M R, 2000, Bangladesh Med Res Counc Bull, V26, P33; MILLS S, 1998, AIDS SB, V12, P79; Mitty JA, 2002, CLIN INFECT DIS, V34, P984, DOI 10.1086/339447; MIYAZAKI M, 1994, INT J STD AIDS, V5, P273, DOI 10.1177/095646249400500409; MULLER O, 1995, AIDS CARE, V7, P567, DOI 10.1080/09540129550126227; Munoz A, 1997, AIDS, V11, pS69; Nachega J, 2003, AIDS, V17, P1398, DOI 10.1097/00002030-200306130-00018; NARAIN JP, 2003, GLOBAL FUND FIGHTS A, V1, P7; *NAT AIDS STD PROG, 2003, HIV BANG IS TIM RUNN; Newmann S, 2000, INT J STD AIDS, V11, P250, DOI 10.1258/0956462001915796; Nguyen THL, 2003, AIDS RES HUM RETROV, V19, P925, DOI 10.1089/088922203322493111; Nitayaphan S, 2000, VACCINE, V18, P1448, DOI 10.1016/S0264-410X(99)00421-1; Nookhai S, 2000, EUR J IMMUNOGENET, V27, P153, DOI 10.1046/j.1365-2370.2000.00218.x; Oh MD, 1999, J KOREAN MED SCI, V14, P469, DOI 10.3346/jkms.1999.14.5.469; Osmanov S, 2002, J ACQ IMMUN DEF SYND, V29, P184, DOI 10.1097/00042560-200202010-00013; Paladin FJE, 1998, AIDS, V12, P291, DOI 10.1097/00002030-199803000-00007; PAN PP, 2003, WASHINGTON POST 1111; Parish WL, 2003, JAMA-J AM MED ASSOC, V289, P1265, DOI 10.1001/jama.289.10.1265; Park SW, 2003, AIDS RES HUM RETROV, V19, P1039, DOI 10.1089/088922203322588404; Pattanapanyasat K, 2003, ASIAN PAC J ALLERGY, V21, P105; PETERS D, 1996, AIDSLINK, V38, P8; PHALLA T, 1998, AIDS SB, V12, P11; PHANUPHAK N, 2004, 11 C RETR OPP INF 20; Phanuphak P, 1998, NEW ENGL J MED, V338, P834, DOI 10.1056/NEJM199803193381212; Phanuphak P, 1997, ASIAN PAC J ALLERGY, V15, P41; PHANUPHAK P, 1985, ASIAN PAC J ALLERGY, V3, P195; PHANUPHAK P, 1994, AIDS, V8, P1315, DOI 10.1097/00002030-199409000-00015; PHANUPHAK P, 1998, AIDS SB, V12, P163; PHOOLCHAROEN W, 1998, AIDS SB, V12, P123; Pisani E, 2003, JAIDS-J ACQ IMM DEF, V32, pS3, DOI 10.1097/00126334-200302011-00002; Pisani E, 2003, BRIT MED J, V326, P1384, DOI 10.1136/bmj.326.7403.1384; PISANI E, IN PRESS SEX TRANSM; Piyasirisilp S, 2000, J VIROL, V74, P11286, DOI 10.1128/JVI.74.23.11286-11295.2000; Pollard RB, 1998, CLIN THER, V20, P1071, DOI 10.1016/S0149-2918(98)80105-7; Punnotok J, 2000, INT J TUBERC LUNG D, V4, P537; Putong Nimfa M., 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P346; Quan VM, 2000, J ACQ IMMUN DEF SYND, V25, P360, DOI 10.1097/00126334-200012010-00011; Ramamoorti N, 2001, GENES IMMUN, V2, P408, DOI 10.1038/sj.gene.6363800; Ramana GV, 2001, J GENET, V80, P137, DOI 10.1007/BF02717909; Rangsin R, 2004, JAIDS-J ACQ IMM DEF, V36, P622, DOI 10.1097/00126334-200405010-00011; Ranjana KH, 2002, J INFECTION, V45, P268, DOI 10.1053/jinf.2002.1062; Reichart PA, 2003, MED MICROBIOL IMMUN, V192, P157, DOI 10.1007/s00430-002-0168-4; Ribera E, 2001, J ACQ IMMUN DEF SYND, V28, P450, DOI 10.1097/00042560-200112150-00007; Risbud A, 2002, SEX TRANSM INFECT, V78, P169, DOI 10.1136/sti.78.3.169; ROWN T, IN PRESS SEX TRANSM; RUXRUNGHAM K, 2004, UNPUB 15 INT AIDS C; Ruxrungtham K, 2002, ASIAN PAC J ALLERGY, V20, P105; RUXRUNGTHAM K, 2001, J MED ASS THAI S1, V84, P1; Sahni AK, 2002, INT J STD AIDS, V13, P115, DOI 10.1258/0956462021924749; Saidel T. J., 2003, International Journal of Drug Policy, V14, P63, DOI 10.1016/S0955-3959(02)00209-8; Santiago ML, 1998, J ACQ IMMUN DEF SYND, V18, P260, DOI 10.1097/00042560-199807010-00010; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shao C, 1996, Chin Med Sci J, V11, P252; Sheng WH, 2004, INT J STD AIDS, V15, P249, DOI 10.1258/095646204773557785; Shieh BH, 2001, CLIN INFECT DIS, V33, P273, DOI 10.1086/321871; Sirisanthana T, 1998, CLIN INFECT DIS, V26, P1107, DOI 10.1086/520280; Sirisanthana T., 1997, Annals Academy of Medicine Singapore, V26, P701; Sirivichayakul S, 2003, AIDS, V17, P1889, DOI 10.1097/00002030-200309050-00007; SITTITRAI W, 1994, INT J STD AIDS, V5, P377, DOI 10.1177/095646249400500523; Su R, 2003, AIDS, V17, P2515, DOI 10.1097/00002030-200311210-00015; Suligoi B, 2002, J CLIN MICROBIOL, V40, P4015, DOI 10.1128/JCM.40.11.4015-4020.2002; SUN X, 1994, AIDS S, V8, P55; Sungkanuparph S, 2003, AIDS, V17, P2129, DOI 10.1097/00002030-200309260-00018; Sungkanuparph S, 2003, JAIDS-J ACQ IMM DEF, V33, P118, DOI 10.1097/00126334-200305010-00019; Suwanagool Surapol, 1998, Journal of the Medical Association of Thailand, V81, P893; Takebe Y, 2003, AIDS, V17, P2077, DOI 10.1097/00002030-200309260-00009; Thisyakorn U, 2000, AIDS, V14, P2921, DOI 10.1097/00002030-200012220-00014; Truong LX, 2003, AIDS, V17, P1425, DOI 10.1097/00002030-200307040-00002; Udwadia ZF, 2001, ANN NY ACAD SCI, V953, P98, DOI 10.1111/j.1749-6632.2001.tb11365.x; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *UNAIDS, 1998, REL HIV STD DECL THA; *UNAIDS, 2000, EV 100PERC COND PROG, P1; *US BUR CENS, 2003, HIV AIDS SURV DAT; Vajpayee M, 2003, INFECTION, V31, P336, DOI 10.1007/s15010-003-3198-y; Vernazza PL, 2001, REV MED MICROBIOL, V12, P131; VIRAVAIDYA M, 1993, EC IMPLICATIONS AIDS, P7; Wagner Mark D, 2003, IAPAC Mon, V9, P320; Walker N, 2001, AIDS, V15, P1545, DOI 10.1097/00002030-200108170-00012; WENIGER BG, 1994, AIDS, V8, pS13; Weniger BG, 1996, NEW ENGL J MED, V335, P343, DOI 10.1056/NEJM199608013350510; Weniger BG, 1991, AIDS S2, V5, pS71; *WHO, 2003, TREAT 3 MILL 2005 MA; World Bank, 2000, THAIL RESP AIDS BUIL; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2; World Health Organization, 2003, SCAL ANT THER RES LT; Xu FJ, 2000, J ACQ IMMUN DEF SYND, V25, P353, DOI 10.1097/00126334-200012010-00010; Yang CF, 2003, AIDS RES HUM RETROV, V19, P661, DOI 10.1089/088922203322280883; Yang RG, 2003, J VIROL, V77, P685, DOI 10.1128/JVI.77.1.685-695.2003; Yoshiyama T, 2001, INT J TUBERC LUNG D, V5, P32; Yu XF, 2003, AIDS RES HUM RETROV, V19, P1051, DOI 10.1089/088922203322588422; Zhang CY, 2002, J ACQ IMMUN DEF SYND, V29, P191, DOI 10.1097/00042560-200202010-00014; 2003, AIDS ALERT, V18, P57; [No title captured]; VAXGEN ANNOUNCES RES; 2002, AIDS POLICY LAW, V17, P8	175	150	159	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					69	82		10.1016/S0140-6736(04)16593-8	http://dx.doi.org/10.1016/S0140-6736(04)16593-8			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DX	15234860				2022-12-28	WOS:000222392900035
J	Pritchard, J; Hughes, RAC				Pritchard, J; Hughes, RAC			Guillain-Barre syndrome	LANCET			English	Editorial Material									Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Clin Neurosci, London SE1 1UL, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Pritchard, J (corresponding author), Guys Hosp, Guys Kings & St Thomas Sch Med, Dept Clin Neurosci, London SE1 1UL, England.	jane.pritchard@kcl.ac.uk						Bonduelle M, 1977, Rev Neurol (Paris), V133, P661; DRAGANESCO S, 1927, REV NEUROL, V2, P517; GREEN D, 1962, NEW ENGL J MED, V267, P821, DOI 10.1056/NEJM196210182671609; Guillain G., 1916, B MEM SOC MED HOP P, V40, P1462; HAYMAKER WE, 1953, FOUNDERS NEUROLOGY 1, P320; Hughes RAC, 1999, J NEUROIMMUNOL, V100, P74, DOI 10.1016/S0165-5728(99)00195-2; LANDRY JBO, 1859, GAZ HEBD MED CHIR, V6, P472; ROHMER F, 1984, HOMME SON OEUVRE CON, P185; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272	9	15	18	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2186	2188		10.1016/S0140-6736(04)16512-4	http://dx.doi.org/10.1016/S0140-6736(04)16512-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220044				2022-12-28	WOS:000222268300025
J	Gong, Y; Mo, CH; Fraser, SE				Gong, Y; Mo, CH; Fraser, SE			Planar cell polarity signalling controls cell division orientation during zebrafish gastrulation	NATURE			English	Article							NEURAL PLATE; MITOTIC SPINDLE; NERVOUS-SYSTEM; XENOPUS-LAEVIS; WNT PATHWAY; MOVEMENTS; EMBRYOS; FATE; EXTENSION; NOTOCHORD	Oriented cell division is an integral part of pattern development in processes ranging from asymmetric segregation of cell-fate determinants to the shaping of tissues(1,2). Despite proposals that it has an important function in tissue elongation(3,4), the mechanisms regulating division orientation have been little studied outside of the invertebrates Caenorhabditis elegans and Drosophila melanogaster(1). Here, we have analysed mitotic divisions during zebrafish gastrulation using in vivo confocal imaging and found that cells in dorsal tissues preferentially divide along the animal - vegetal axis of the embryo. Establishment of this animal vegetal polarity requires the Wnt pathway components Silberblick/ Wnt11, Dishevelled and Strabismus. Our findings demonstrate an important role for non-canonical Wnt signalling in oriented cell division during zebrafish gastrulation, and indicate that oriented cell division is a driving force for axis elongation. Furthermore, we propose that non-canonical Wnt signalling has a conserved role in vertebrate axis elongation, orienting both cell intercalation and mitotic division.	CALTECH, Beckman Inst, Biol Imaging Ctr, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Fraser, SE (corresponding author), CALTECH, Beckman Inst, Biol Imaging Ctr, Pasadena, CA 91125 USA.	sefraser@caltech.edu	Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223				Ahringer J, 2003, CURR OPIN CELL BIOL, V15, P73, DOI 10.1016/S0955-0674(02)00018-2; BLACK SD, 1988, DEV BIOL, V128, P65, DOI 10.1016/0012-1606(88)90267-9; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; Chalmers AD, 2003, DEVELOPMENT, V130, P2657, DOI 10.1242/dev.00490; Concha ML, 1998, DEVELOPMENT, V125, P983; Das T, 2003, NEURON, V37, P597, DOI 10.1016/S0896-6273(03)00066-7; Elul T, 2000, DEV BIOL, V224, P3, DOI 10.1006/dbio.2000.9746; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Glickman NS, 2003, DEVELOPMENT, V130, P873, DOI 10.1242/dev.00314; Hashimoto H, 2000, DEV BIOL, V217, P138, DOI 10.1006/dbio.1999.9537; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Heisenberg CP, 2000, NATURE, V405, P76, DOI 10.1038/35011068; HERTWIG O, ARCH MIKROSK ANAT, V42, P662; Jessen JR, 2002, NAT CELL BIOL, V4, P610, DOI 10.1038/ncb828; Kilian B, 2003, MECH DEVELOP, V120, P467, DOI 10.1016/S0925-4773(03)00004-2; KIMMEL CB, 1994, DEVELOPMENT, V120, P265; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Koster RW, 2001, DEV BIOL, V233, P329, DOI 10.1006/dbio.2001.0242; MOON RT, 1993, DEVELOPMENT, V119, P97; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; SAUSEDO RA, 1994, ANAT REC, V239, P103, DOI 10.1002/ar.1092390112; Sausedo RA, 1997, J COMP NEUROL, V381, P473; Schlesinger A, 1999, GENE DEV, V13, P2028, DOI 10.1101/gad.13.15.2028; SCHOENWOLF GC, 1989, DEVELOPMENT, V106, P427; Tada M, 2000, DEVELOPMENT, V127, P2227; Tago K, 2000, GENE DEV, V14, P1741; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wei Y, 2000, DEVELOPMENT, V127, P87; WOO K, 1995, DEVELOPMENT, V121, P2595	30	314	318	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	2004	430	7000					689	693		10.1038/nature02796	http://dx.doi.org/10.1038/nature02796			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843LM	15254551				2022-12-28	WOS:000223085400049
J	Gilbert, B; Huang, F; Zhang, HZ; Waychunas, GA; Banfield, JF				Gilbert, B; Huang, F; Zhang, HZ; Waychunas, GA; Banfield, JF			Nanoparticles: Strained and stiff	SCIENCE			English	Article							RADIAL-DISTRIBUTION FUNCTIONS; ABSORPTION FINE-STRUCTURE; CDSE NANOCRYSTALS; QUANTUM DOTS; SEMICONDUCTOR CLUSTERS; CADMIUM SELENIDE; CRYSTALLITES; SURFACE; ZNS; RANGE	Nanoparticles may contain unusual forms of structural disorder that can substantially modify materials properties and thus cannot solely be considered as small pieces of bulk material. We have developed a method to quantify intermediate-range order in 3.4-nanometer-diameter zinc sulfide nanoparticles and show that structural coherence is lost over distances beyond 2 nanometers. The zinc-sulfur Einstein vibration frequency in the nanoparticles is substantially higher than that in the bulk zinc sulfide, implying structural stiffening. This cannot be explained by the observed 1% radial compression and must be primarily due to inhomogeneous internal strain caused by competing relaxations from an irregular surface. The methods developed here are generally applicable to the characterization of nanoscale solids, many of which may exhibit complex disorder and strain.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Earth Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Banfield, JF (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	jill@eps.berkeley.edu	Gilbert, Benjamin/E-3182-2010; Huang, Feng/X-9404-2019	Huang, Feng/0000-0002-4623-2216; Banfield, Jill/0000-0001-8203-8771; Gilbert, Benjamin/0000-0003-0853-0826				Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Ankudinov AL, 1998, PHYS REV B, V58, P7565, DOI 10.1103/PhysRevB.58.7565; BAWENDI MG, 1989, J CHEM PHYS, V91, P7282, DOI 10.1063/1.457295; Billinge S., 1998, LOCAL STRUCTURE DIFF; BRUS LE, 1984, J CHEM PHYS, V80, P4403, DOI 10.1063/1.447218; Carter AC, 1997, PHYS REV B, V55, P13822, DOI 10.1103/PhysRevB.55.13822; Dalba G, 1998, PHYS REV B, V58, P4793, DOI 10.1103/PhysRevB.58.4793; Franceschetti A, 1997, PHYS REV LETT, V78, P915, DOI 10.1103/PhysRevLett.78.915; FRENKEL AI, 1993, PHYS REV B, V48, P585, DOI 10.1103/PhysRevB.48.585; Jeong IK, 1999, J PHYS CHEM A, V103, P921, DOI 10.1021/jp9836978; Leung K, 1999, J CHEM PHYS, V110, P11012, DOI 10.1063/1.479037; LIPPENS PE, 1989, PHYS REV B, V39, P10935, DOI 10.1103/PhysRevB.39.10935; MARCUS MA, 1991, J PHYS CHEM-US, V95, P1572, DOI 10.1021/j100157a012; MASON G, 1968, NATURE, V217, P733, DOI 10.1038/217733a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Palosz B, 2002, Z KRISTALLOGR, V217, P497, DOI 10.1524/zkri.217.10.497.20795; Puzder A, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.157405; Rabani E, 2001, J CHEM PHYS, V115, P1493, DOI 10.1063/1.1380748; Rockenberger J, 1998, J CHEM PHYS, V108, P7807, DOI 10.1063/1.476216; ROSSETTI R, 1985, J CHEM PHYS, V82, P552, DOI 10.1063/1.448727; SHIANG JJ, 1995, J PHYS CHEM-US, V99, P17417, DOI 10.1021/j100048a017; THIJSSE BJ, 1984, J APPL CRYSTALLOGR, V17, P61, DOI 10.1107/S002188988401102X; Vogel W, 2000, LANGMUIR, V16, P2032, DOI 10.1021/la9910071; Wang LW, 1996, PHYS REV B, V53, P9579, DOI 10.1103/PhysRevB.53.9579; WRIGHT AC, 1991, J NON-CRYST SOLIDS, V129, P213, DOI 10.1016/0022-3093(91)90098-Q; Zhang HZ, 2003, NATURE, V424, P1025, DOI 10.1038/nature01845	26	402	406	0	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2004	305	5684					651	654		10.1126/science.1098454	http://dx.doi.org/10.1126/science.1098454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	842GQ	15232073	Green Submitted			2022-12-28	WOS:000222992100042
J	Sayah, DM; Sokolskaja, E; Berthoux, L; Luban, J				Sayah, DM; Sokolskaja, E; Berthoux, L; Luban, J			Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; L1 RETROTRANSPOSITION; PROCESSED PSEUDOGENES; T-CELLS; EVOLUTION; PROTEIN; GENE; RESTRICTION; EXPRESSION; INFECTION	In Old World primates, TRIM5-alpha confers a potent block to human immunodeficiency virus type 1 ( HIV-1) infection that acts after virus entry into cells(1-5). Cyclophilin A ( CypA) binding to viral capsid protects HIV-1 from a similar activity in human cells(4,6-8). Among New World primates, only owl monkeys exhibit post-entry restriction of HIV-1 (ref. 1). Paradoxically, the barrier to HIV-1 in owl monkey cells is released by capsid mutants or drugs that disrupt capsid interaction with CypA(4). Here we show that knockdown of owl monkey CypA by RNA interference (RNAi) correlates with suppression of anti-HIV-1 activity. However, reintroduction of CypA protein to RNAi-treated cells did not restore antiviral activity. A search for additional RNAi targets unearthed TRIMCyp, an RNAi-responsive messenger RNA encoding a TRIM5 - CypA fusion protein. TRIMCyp accounts for post-entry restriction of HIV-1 in owl monkeys and blocks HIV-1 infection when transferred to otherwise infectable human or rat cells. It seems that TRIMCyp arose after the divergence of New and Old World primates when a LINE-1 retrotransposon catalysed the insertion of a CypA complementary DNA into the TRIM5 locus. This is the first vertebrate example of a chimaeric gene generated by this mechanism of exon shuffling.	Columbia Univ Coll Phys & Surg, Dept Microbiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Luban, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Microbiol, 701 W 168th St,HHSC 1502, New York, NY 10032 USA.	jl45@columbia.edu	Liu, FL/D-1795-2009	Luban, Jeremy/0000-0001-5650-4054; Sayah, David/0000-0001-7021-8273				Asmal M, 2003, IMMUNITY, V19, P535, DOI 10.1016/S1074-7613(03)00268-1; Besnier C, 2002, P NATL ACAD SCI USA, V99, P11920, DOI 10.1073/pnas.172384599; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cowan S, 2002, P NATL ACAD SCI USA, V99, P11914, DOI 10.1073/pnas.162299499; Damert A, 2004, MOL BIOL EVOL, V21, P647, DOI 10.1093/molbev/msh056; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Ejima Y, 2003, HUM MOL GENET, V12, P1321, DOI 10.1093/hmg/ddg138; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Fehr T, 1999, J ANTIBIOT, V52, P474, DOI 10.7164/antibiotics.52.474; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; Hofmann W, 1999, J VIROL, V73, P10020, DOI 10.1128/JVI.73.12.10020-10028.1999; Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831; Kazazian HH, 2004, SCIENCE, V303, P1626, DOI 10.1126/science.1089670; LONG MY, 1993, SCIENCE, V260, P91, DOI 10.1126/science.7682012; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; MCCLINTOCK B, 1950, P NATL ACAD SCI USA, V36, P344, DOI 10.1073/pnas.36.6.344; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roy-Engel AM, 2002, J MOL BIOL, V316, P1033, DOI 10.1006/jmbi.2001.5380; Schwartz O, 1998, J VIROL, V72, P3845, DOI 10.1128/JVI.72.5.3845-3850.1998; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; Towers GJ, 2003, NAT MED, V9, P1138, DOI 10.1038/nm910; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; Xu LX, 2003, EXP CELL RES, V288, P84, DOI 10.1016/S0014-4827(03)00187-3; Zhang ZL, 2003, GENOME RES, V13, P2541, DOI 10.1101/gr.1429003	30	530	555	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	2004	430	6999					569	573		10.1038/nature02777	http://dx.doi.org/10.1038/nature02777			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	841QI	15243629				2022-12-28	WOS:000222946100050
J	Siegel, AW				Siegel, AW			Temporal restrictions and the impasse on human embryonic stem-cell research	LANCET			English	Editorial Material									Johns Hopkins Univ, Sch Med, Phoebe R Berman Bioeth Inst, Baltimore, MD 21205 USA	Johns Hopkins University	Siegel, AW (corresponding author), Johns Hopkins Univ, Sch Med, Phoebe R Berman Bioeth Inst, 624 N Broadway,Room 352, Baltimore, MD 21205 USA.	asiegel@jhsph.edu						[Anonymous], 2001, FACT SHEET EMBR STEM; COOK G, 2004, BOSTON GLOBE    0523; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Dawson L, 2003, FERTIL STERIL, V80, P1077, DOI 10.1016/S0015-0282(03)02218-0; DICKINSON T, 1999, COMMUNICATION   0112; Knowles LP, 2004, NAT BIOTECHNOL, V22, P157, DOI 10.1038/nbt0204-157; *MRC, STEM CELLS INT POL D; National Institute for Biological Standards and Control, UK STEM CELL BANK NI; *NIH, STEM CELL INF INF EL; Robertson John A, 1988, IRB, V10, P5, DOI 10.2307/3564200; *UK PAT OFF, 2003, INV INV HUM EMBR STE; 2001, US C CATH BISH BUSHS	12	5	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					215	218		10.1016/S0140-6736(04)16638-5	http://dx.doi.org/10.1016/S0140-6736(04)16638-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246738				2022-12-28	WOS:000222612200036
J	Akkerhuis, JM; Hersbach, FMRJ				Akkerhuis, JM; Hersbach, FMRJ			Swinging heart	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Catharina Hosp, Eindhoven, Netherlands	Catharina Hospital	Akkerhuis, JM (corresponding author), Catharina Hosp, Eindhoven, Netherlands.								0	6	6	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					E1	E1		10.1056/ENEJMicm030059	http://dx.doi.org/10.1056/ENEJMicm030059			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247368				2022-12-28	WOS:000222470700011
J	Milliron, DJ; Hughes, SM; Cui, Y; Manna, L; Li, JB; Wang, LW; Alivisatos, AP				Milliron, DJ; Hughes, SM; Cui, Y; Manna, L; Li, JB; Wang, LW; Alivisatos, AP			Colloidal nanocrystal heterostructures with linear and branched topology	NATURE			English	Article							DOT QUANTUM-WELL; CDSE NANOCRYSTALS; GROWTH; MOLECULES; NANORODS; STATES	The development of colloidal quantum dots has led to practical applications of quantum confinement, such as in solution-processed solar cells(1), lasers(2) and as biological labels(3). Further scientific and technological advances should be achievable if these colloidal quantum systems could be electronically coupled in a general way. For example, this was the case when it became possible to couple solid-state embedded quantum dots into quantum dot molecules(4,5). Similarly, the preparation of nanowires with linear alternating compositions-another form of coupled quantum dots-has led to the rapid development of single-nanowire light-emitting diodes(6) and single-electron transistors(7). Current strategies to connect colloidal quantum dots use organic coupling agents(8,9), which suffer from limited control over coupling parameters and over the geometry and complexity of assemblies. Here we demonstrate a general approach for fabricating inorganically coupled colloidal quantum dots and rods, connected epitaxially at branched and linear junctions within single nanocrystals. We achieve control over branching and composition throughout the growth of nanocrystal heterostructures to independently tune the properties of each component and the nature of their interactions. Distinct dots and rods are coupled through potential barriers of tuneable height and width, and arranged in three-dimensional space at well-defined angles and distances. Such control allows investigation of potential applications ranging from quantum information processing to artificial photosynthesis.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Computat Res Div, Berkeley, CA 94720 USA; Natl Nanotechnol Lab INFM, Via Arnesano, I-73100 Lecce, Italy	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	alivis@uclink.berkeley.edu	Milliron, Delia J/D-6002-2012; Manna, Liberato/G-2339-2010; Cui, Yi/L-5804-2013; Alivisatos, Paul/N-8863-2015; Li, Jingbo/AAF-6172-2019	Manna, Liberato/0000-0003-4386-7985; Cui, Yi/0000-0002-6103-6352; Alivisatos, Paul/0000-0001-6895-9048; 				Bayer M, 2001, SCIENCE, V291, P451, DOI 10.1126/science.291.5503.451; Borchert H, 2003, J PHYS CHEM B, V107, P7486, DOI 10.1021/jp027485t; Bruchez M, 1998, SCIENCE, V281, P2013, DOI 10.1126/science.281.5385.2013; Canning A, 2000, J COMPUT PHYS, V160, P29, DOI 10.1006/jcph.2000.6440; Cao YW, 2000, J AM CHEM SOC, V122, P9692, DOI 10.1021/ja001386g; Capitosti GJ, 2001, ORG LETT, V3, P1645, DOI 10.1021/ol015837t; Collier CP, 1998, ANNU REV PHYS CHEM, V49, P371, DOI 10.1146/annurev.physchem.49.1.371; DABBOUSI BO, 1997, J PHYS CHEM B, V101, P9462; EYCHMULLER A, 1993, CHEM PHYS LETT, V208, P59, DOI 10.1016/0009-2614(93)80076-2; Gudiksen MS, 2002, NATURE, V415, P617, DOI 10.1038/415617a; Gupta JA, 1999, PHYS REV B, V59, P10421, DOI 10.1103/PhysRevB.59.R10421; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156; Kazes M, 2002, ADV MATER, V14, P317, DOI 10.1002/1521-4095(20020219)14:4<317::AID-ADMA317>3.0.CO;2-U; Kim S, 2003, J AM CHEM SOC, V125, P11466, DOI 10.1021/ja0361749; Li JB, 2003, NANO LETT, V3, P1357, DOI 10.1021/nl034488o; Li LS, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.097402; Manna L, 2000, J AM CHEM SOC, V122, P12700, DOI 10.1021/ja003055+; Manna L, 2002, J AM CHEM SOC, V124, P7136, DOI 10.1021/ja025946i; Manna L, 2003, NAT MATER, V2, P382, DOI 10.1038/nmat902; Mokari T, 2003, CHEM MATER, V15, P3955, DOI 10.1021/cm034173+; Ouyang M, 2003, SCIENCE, V301, P1074, DOI 10.1126/science.1086963; PENG X, 1997, J AM CHEM SOC, V199, P7019; Peng XG, 2000, NATURE, V404, P59, DOI 10.1038/35003535; Peng ZA, 2002, J AM CHEM SOC, V124, P3343, DOI 10.1021/ja0173167; Schedelbeck G, 1997, SCIENCE, V278, P1792, DOI 10.1126/science.278.5344.1792; Thelander C, 2003, APPL PHYS LETT, V83, P2052, DOI 10.1063/1.1606889; Wang LW, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.256402; WANG LW, 1994, J CHEM PHYS, V100, P2394, DOI 10.1063/1.466486; YEH CY, 1992, PHYS REV B, V46, P10086, DOI 10.1103/PhysRevB.46.10086	30	1071	1114	12	469	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					190	195		10.1038/nature02695	http://dx.doi.org/10.1038/nature02695			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241410				2022-12-28	WOS:000222470600039
J	Gutierrez, JP; Johns, B; Adam, T; Bertozzi, SM; Edejer, TTT; Greener, R; Hankins, C; Evans, DB				Gutierrez, JP; Johns, B; Adam, T; Bertozzi, SM; Edejer, TTT; Greener, R; Hankins, C; Evans, DB			Achieving the WHO/UNAIDS antiretroviral treatment 3 by 5 goal: what will it cost?	LANCET			English	Article								The "3 by 5" goal to have 3 million people in low and middle income countries on antiretroviral therapy (ART) by the end of 2005 is ambitious. Estimates of the necessary resources are needed to facilitate resource mobilisation and rapid channelling of funds to where they are required. We estimated the financial costs needed to implement treatment protocols, by use of country-specific estimates for 34 countries that account for 90% of the need for ART in resource-poor settings. We first estimated the number of people needing ART and supporting programmes for each country. We then estimated the cost per patient for each programme by country to derive total costs. We estimate that between US$5.1 billion and US$5.9 billion will be needed by the end of 2005 to provide ART, support programmes, and cover country-level administrative and logistic costs for 3 by 5.	WHO, Hlth Syst Financing Expenditure & Resource Alloca, CH-1211 Geneva 27, Switzerland; Natl Inst Publ Hlth, Div Hlth Econ & Policy, Cuernavaca, Morelos, Mexico; Ctr Res & Educ Econ CIDE, Mexico City, DF, Mexico; UNAIDS, Strateg Informat Social Mobilisat & Informat, Geneva, Switzerland	World Health Organization; Instituto Nacional de Salud Publica; Centro de Investigacion y Docencia Economicas A.C. (CIDE); UNAIDS	Johns, B (corresponding author), WHO, Hlth Syst Financing Expenditure & Resource Alloca, CH-1211 Geneva 27, Switzerland.	Johnsb@who.int	Gutierrez, Juan Pablo/A-4253-2010	Gutierrez, Juan Pablo/0000-0002-0557-5562; Hankins, Catherine/0000-0002-1642-8592; Bertozzi, Stefano M/0000-0002-1723-7085				Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; Grant AD, 2001, AM J TROP MED HYG, V65, P810, DOI 10.4269/ajtmh.2001.65.810; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; *UNAIDS WHO, 2003, EM SCAL UP ANT THER; *UNICEF UNAIDS WHO, 2003, SOURC PRIC SEL MED D; World Health Organization, 2002, SCAL ANT THER RES LT	7	36	36	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					63	64		10.1016/S0140-6736(04)16590-2	http://dx.doi.org/10.1016/S0140-6736(04)16590-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234857				2022-12-28	WOS:000222392900032
J	Kober, K; Van Damme, W				Kober, K; Van Damme, W			Scaling up access to antiretroviral treatment in southern Africa: who will do the job?	LANCET			English	Article							COST-EFFECTIVENESS; HEALTH-WORKERS; CRISIS; CARE; AIDS	Malawi, Mozambique, Swaziland, and South Africa have some of the highest HIV/AIDS burdens in the world. All four countries have ambitious plans for scaling-up antiretroviral treatment for the millions of HIV-positive people in the region. In January 2004, we visited these countries with the intention of directly observing the effect of AIDS, especially on health systems, to talk with policy makers and field workers about their concerns and perspectives regarding the epidemic, and to investigate the main issues related to scaling up antiretroviral treatment. We found that financial resources are not regarded as the main immediate constraint anymore, but that the lack of human resources for health is deplored as the single most serious obstacle for implementing the national treatment plans. Yet, none of the countries has developed an urgently required comprehensive human resource strategy. This may also need increased donor attention and resources.	Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium	Institute of Tropical Medicine (ITM)	Van Damme, W (corresponding author), Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.	wvdamme@itg.be	Van Damme, Wim/F-7404-2011	Van Damme, Wim/0000-0002-6344-3007				[Anonymous], TUB MAL; Boelaert M, 2002, TROP MED INT HEALTH, V7, P1001, DOI 10.1046/j.1365-3156.2002.00972.x; Campbell C., 2003, LETTING THEM DIE WHY; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; de Castella T, 2003, LANCET, V362, P46, DOI 10.1016/S0140-6736(03)13848-2; de Waal A, 2003, LANCET, V362, P1234, DOI 10.1016/S0140-6736(03)14548-5; Department of Health, 2003, NAT HIV SYPH ANT SER; Huddart J., 2003, HLTH SECTOR HUMAN RE; KEMP J, 2003, EQUINET DISCUSSION P, V12; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; MATOMORA MKS, 1989, SOC SCI MED, V28, P1081, DOI 10.1016/0277-9536(89)90391-2; *MIL MIN HLTH POP, 2003, JOINT PROGR WORK 200; *MIN HLTH POP, 2004, TREATM AIDS 2 YEAR P; *MIN HLTH SOC WELF, 2003, HLTH SECT RESP HIV A; Nattrass N., 2004, MORAL EC AIDS S AFRI; Padarath A., 2003, EQUINET DISCUSSION P; PIOT P, 2003, PRESIDENTAL FELLOWS; *REP MOC, 2003, MIN SAUD PEN ITS HIV; SHEVEL A, HOSP OFFER INCENTIVE; *SO AFR DEV COMM H, STAT SADC HLTH MIN R; South Africa Department of Health, 2003, OP PLAN COMPR HIV AI; *TREATM ACT CAMP, 2004, TAC NEWSLETTER  0316; UNAIDS, 2003, AIDS EP UPD; Wendo C, 2004, LANCET, V363, P222; *WHO, 1998, EST HLTH PERS PHYS N; World Health Organization, COUNTR DAT; World Health Organization, 2003, TREAT 3 MILL 2005 WH	27	173	176	0	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					103	107		10.1016/S0140-6736(04)16597-5	http://dx.doi.org/10.1016/S0140-6736(04)16597-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234864				2022-12-28	WOS:000222392900039
J	Coyle, CM; Weiss, LM; Rhodes, LV; Cali, A; Takvorian, PM; Brown, DF; Visvesvara, GS; Xiao, LH; Naktin, J; Young, E; Gareca, M; Colasante, G; Wittner, M				Coyle, CM; Weiss, LM; Rhodes, LV; Cali, A; Takvorian, PM; Brown, DF; Visvesvara, GS; Xiao, LH; Naktin, J; Young, E; Gareca, M; Colasante, G; Wittner, M			Brief report - Fatal myositis due to the microsporidian Brachiola algerae, a mosquito pathogen	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENCEPHALITOZOON-CUNICULI INFECTION; NOSEMA-ALGERAE; TRACHIPLEISTOPHORA-HOMINIS; TRANSPLANT RECIPIENT; IN-VITRO; PHYLUM MICROSPORA; IMMUNE-RESPONSE; INFLIXIMAB; PATIENT; AIDS		Jacobi Med Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Lehigh Valley Hosp, Dept Infect Dis, Allentown, PA USA; Lehigh Valley Hosp, Dept Pathol, Allentown, PA USA; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA	Jacobi Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Lehigh Valley Hospital; Lehigh Valley Hospital; Rutgers State University Newark; Rutgers State University New Brunswick; Centers for Disease Control & Prevention - USA	Coyle, CM (corresponding author), Jacobi Med Ctr, Dept Med, Pelham Pkwy & Eastchester Rd S,Rm 3N7, Bronx, NY 10461 USA.	coyle@aecom.yu.edu	Xiao, Lihua/B-1704-2013	Xiao, Lihua/0000-0001-8532-2727	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031788] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31788, R01 AI031788, R01 AI031788-14] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BROOKS WM, 1988, CRC HDB NATURAL PEST, V5, P1; Cali A, 2003, J EUKARYOT MICROBIOL, V50, P77, DOI 10.1111/j.1550-7408.2003.tb00237.x; Cali A, 1998, J EUKARYOT MICROBIOL, V45, P240, DOI 10.1111/j.1550-7408.1998.tb04532.x; CALI A, 1991, J PROTOZOOL, V38, P215; CHUPP GL, 1993, CLIN INFECT DIS, V16, P15, DOI 10.1093/clinids/16.1.15; DIDIER ES, 1994, J EUKARYOT MICROBIOL, V41, pS34; Field AS, 1996, J CLIN MICROBIOL, V34, P2803, DOI 10.1128/JCM.34.11.2803-2811.1996; Gumbo T, 1999, TRANSPLANTATION, V67, P482, DOI 10.1097/00007890-199902150-00024; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Khan IA, 1999, INFECT IMMUN, V67, P1887; Khan IA, 2001, MICROBES INFECT, V3, P401, DOI 10.1016/S1286-4579(01)01397-1; Koudela B, 2001, PARASITOLOGY, V123, P153, DOI 10.1017/S0031182001008228; Latib MA, 2001, TRANSPLANT INT, V14, P274, DOI 10.1111/j.1432-2277.2001.tb00058.x; LEDFORD DK, 1985, ANN INTERN MED, V102, P628, DOI 10.7326/0003-4819-102-5-628; Lee JH, 2002, ARTHRITIS RHEUM-US, V46, P2565, DOI 10.1002/art.10583; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lowman PM, 2000, J EUKARYOT MICROBIOL, V47, P221, DOI 10.1111/j.1550-7408.2000.tb00041.x; Mohindra A R, 2002, Transpl Infect Dis, V4, P102, DOI 10.1034/j.1399-3062.2002.01011.x; Myers A, 2002, NEW ENGL J MED, V346, P625; Rabodonirina M, 1996, CLIN INFECT DIS, V23, P114, DOI 10.1093/clinids/23.1.114; SAX PE, 1995, TRANSPLANTATION, V60, P617, DOI 10.1097/00007890-199509270-00018; Senaldi G, 1996, J IMMUNOL, V157, P5022; Sharpstone D, 1997, GASTROENTEROLOGY, V112, P1823, DOI 10.1053/gast.1997.v112.pm9178672; Sharpstone D, 1997, GASTROENTEROLOGY, V113, P1054; Tai TL, 2002, RHEUMATOLOGY, V41, P951, DOI 10.1093/rheumatology/41.8.951; Trammer T, 1999, J EUKARYOT MICROBIOL, V46, P464, DOI 10.1111/j.1550-7408.1999.tb06062.x; VAVRA J, 1970, J PROTOZOOL, V17, P240, DOI 10.1111/j.1550-7408.1970.tb02365.x; Visvesvara GS, 1999, J EUKARYOT MICROBIOL, V46, p10S; Visvesvara GS, 2002, CLIN MICROBIOL REV, V15, P401, DOI 10.1128/CMR.15.3.401-413.2002; WEBER R, 1994, CLIN MICROBIOL REV, V7, P426, DOI 10.1128/CMR.7.4.426-461.1994; Weidner E, 1999, J MED ENTOMOL, V36, P522, DOI 10.1093/jmedent/36.4.522; Weiss LM, 2000, CONTRIB MICROBIOL, V6, P209, DOI 10.1159/000060362; Williams BAP, 2002, NATURE, V418, P865, DOI 10.1038/nature00949; WITTMER M, 1999, MICROSPORIDIA MICROS	34	96	100	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					42	47		10.1056/NEJMoa032655	http://dx.doi.org/10.1056/NEJMoa032655			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229306	Green Accepted			2022-12-28	WOS:000222352200008
J	Mihalcescu, I; Hsing, WH; Leibler, S				Mihalcescu, I; Hsing, WH; Leibler, S			Resilient circadian oscillator revealed in individual cyanobacteria	NATURE			English	Article							GENE-EXPRESSION; CELL-DIVISION; RHYTHMS; CLOCKS; NOISE; TIME	Circadian oscillators, which provide internal daily periodicity, are found in a variety of living organisms, including mammals, insects, plants, fungi and cyanobacteria(1). Remarkably, these biochemical oscillators are resilient to external and internal modifications, such as temperature and cell division cycles. They have to be 'fluctuation ( noise) resistant'(2) because relative fluctuations in the number of messenger RNA and protein molecules forming the intracellular oscillators are likely to be large. In multicellular organisms, the strong temporal stability of circadian clocks, despite molecular fluctuations, can easily be explained by intercellular interactions(3-5). Here we study circadian rhythms and their stability in unicellular cyanobacteria Synechoccocus elongatus. Low-light-level microscopy has allowed us to measure gene expression under circadian control in single bacteria, showing that the circadian clock is indeed a property of individual cells. Our measurements show that the oscillators have a strong temporal stability with a correlation time of several months. In contrast to many circadian clocks in multicellular organisms, this stability seems to be ensured by the intracellular biochemical network, because the interactions between oscillators seem to be negligible.	Univ Grenoble 1, Spectrometrie Phys Lab, F-38402 St Martin Dheres, France; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Rockefeller Univ, Lab Living Matter, New York, NY 10021 USA; Rockefeller Univ, Ctr Studies Phys & Biol, New York, NY 10021 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Princeton University; Rockefeller University; Rockefeller University	Mihalcescu, I (corresponding author), Univ Grenoble 1, Spectrometrie Phys Lab, BP87, F-38402 St Martin Dheres, France.	imihalce@spectro.ujf-grenoble.fr	Mihalcescu, Irina/AAT-7917-2020	Mihalcescu, Irina/0000-0002-8762-8241				Barkai N, 2000, NATURE, V403, P267, DOI 10.1038/35002258; Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919; Gaspard P, 2002, J CHEM PHYS, V117, P8905, DOI 10.1063/1.1513461; Goldbeter A, 2002, NATURE, V420, P238, DOI 10.1038/nature01259; Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Katayama M, 1999, J BACTERIOL, V181, P3516, DOI 10.1128/JB.181.11.3516-3524.1999; Kiss IZ, 2002, SCIENCE, V296, P1676, DOI 10.1126/science.1070757; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; Levine JD, 2002, SCIENCE, V298, P2010, DOI 10.1126/science.1076008; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Mori T, 2001, J BACTERIOL, V183, P2439, DOI 10.1128/JB.183.8.2439-2444.2001; Pikovsky A, 2001, SYNCHRONIZATION UNIV; TSINOREMAS NF, 1994, J BIOL CHEM, V269, P16143; Winfree AT., 1980, GEOMETRY BIOL TIME; Yamaguchi S, 2003, SCIENCE, V302, P1408, DOI 10.1126/science.1089287; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	19	187	196	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					81	85		10.1038/nature02533	http://dx.doi.org/10.1038/nature02533			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229601				2022-12-28	WOS:000222356800047
J	Bentham, P; Gray, R; Raftery, J; Hills, R; Sellwood, E; Courtney, C; Farrell, D; Hardyman, W; Crome, P; Edwards, S; Lendon, C; Lynch, L				Bentham, P; Gray, R; Raftery, J; Hills, R; Sellwood, E; Courtney, C; Farrell, D; Hardyman, W; Crome, P; Edwards, S; Lendon, C; Lynch, L		AD2000 Collaborative Grp	Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial	LANCET			English	Article							DAILY LIVING SCALE; CHOLINESTERASE-INHIBITORS; CLINICAL-TRIALS; BRISTOL ACTIVITIES; EFFICACY; DEMENTIA; THERAPY; SYMPTOMS; TIME; MILD	Background Cholinesterase inhibitors produce small improvements in cognitive and global assessments in Alzheimer's disease. We aimed to determine whether donepezil produces worthwhile improvements in disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation. If so, which patients benefit, from what dose, and for how long? Methods 565 community-resident patients with mild to moderate Alzheimer's disease entered a 12-week run-in period in which they were randomly allocated donepezil (5 mg/day) or placebo. 486 who completed this period were rerandomised to either donepezil (5 or 10 mg/day) or placebo, with double-blind treatment continuing as long as judged appropriate. Primary endpoints were entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities on the Bristol activities of daily living scale (BADLS). Outcome assessments were sought for all patients and analysed by logrank and multilevel models. Findings Cognition averaged 0.8 MMSE (mini-mental state examination) points better (95% Cl 0.5-1.2; p<0.0001) and functionality 1.0 BADLS points better (0.5-1.6; p<0.0001) with donepezil over the first 2 years. No significant benefits were seen with donepezil compared with placebo in institutionalisation (42% vs 44% at 3 years; p=0.4) or progression of disability (58% vs 59% at 3 years; p=0.4). The relative risk of entering institutional care in the donepezil group compared with placebo was 0.97 (95% Cl 0.72-1.30; p=0.8); the relative risk of progression of disability or entering institutional care was 0.96 (95% Cl 0.74-1.24; p=0.7). Similarly, no significant differences were seen between donepezil and placebo in behavioural and psychological symptoms, carer psychopathology, formal care costs, unpaid caregiver time, adverse events or deaths, or between 5 mg and 10 mg donepezil. Interpretation Donepezil is not cost effective, with benefits below minimally relevant thresholds. More effective treatments than cholinesterase inhibitors are needed for Alzheimer's disease.	Univ Birmingham, Clin Trials Unit, Collaborat Grp AD2000, Birmingham B15 2RR, W Midlands, England; Univ Birmingham, Hlth Serv Management Ctr, Birmingham, W Midlands, England; Keele Univ, Sch Med, Keele, Staffs, England; Univ Birmingham, Birmingham, W Midlands, England; NHS Execut R&D W Midlands, Birmingham, W Midlands, England; Queen Elizabeth Psychiat Hosp, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; Keele University; University of Birmingham; University of Birmingham	Bentham, P (corresponding author), Univ Birmingham, Clin Trials Unit, Collaborat Grp AD2000, Pk Garage,1 Somerset Rd, Birmingham B15 2RR, W Midlands, England.	AD2000@bham.ac.uk	hardyman, wendy/M-2498-2019; Pritchard, Antonia/F-4288-2010	hardyman, wendy/0000-0002-3732-6886; Pritchard, Antonia/0000-0001-5336-0454; Hills, Robert/0000-0003-0166-0062; fitzpatrick, Ray/0000-0003-0607-0563	NATIONAL INSTITUTE ON AGING [U19AG010483] Funding Source: NIH RePORTER; NIA NIH HHS [U19 AG010483] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; *AUD COMM, 2000, FORG ME NOT MENTAL H, P18; BARTUS RT, 1982, SCIENCE, V217, P408, DOI 10.1126/science.7046051; Bentham P, 2002, NEUROBIOL AGING, V23, pS89; BIRKS J, 2003, COCHRANE LIB; Bucks RS, 1996, AGE AGEING, V25, P113, DOI 10.1093/ageing/25.2.113; Burback D, 1999, DEMENT GERIATR COGN, V10, P534, DOI 10.1159/000017201; Byrne LMT, 2000, INT J GERIATR PSYCH, V15, P656; Clegg A, 2001, Health Technol Assess, V5, P1; CLIPP EC, 1995, CLIN PHARMACOL THER, V58, P228, DOI 10.1016/0009-9236(95)90201-5; COLLINS R, 1996, OXFORD TXB MED, V1, P21; COUCILL W, 2001, AGE AGEING, V30, P55; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Davis KL, 1997, INT J GERIATR PSYCH, V12, P978, DOI 10.1002/(SICI)1099-1166(199710)12:10<978::AID-GPS659>3.0.CO;2-1; Erkinjuntti T, 2002, LANCET, V359, P1283, DOI 10.1016/S0140-6736(02)08267-3; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Food and Drug Administration, 1989, PER CENTR NERV SYST, P227; FULLER V, 1997, GERIATR MED, V27, P9; Geldmacher DS, 2003, J AM GERIATR SOC, V51, P937, DOI 10.1046/j.1365-2389.2003.51306.x; Goldberg D.P., 1988, USERS GUIDE GEN HLTH; Hills R, 2002, NEUROBIOL AGING, V23, pS89; HU TW, 1986, GERONTOLOGIST, V26, P158, DOI 10.1093/geront/26.2.158; Imbimbo BP, 2001, CNS DRUGS, V15, P375, DOI 10.2165/00023210-200115050-00004; *INT C HARM, 1995, E3 INT C HARM; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; Kaufer DI, 1996, J GERIATR PSYCH NEUR, V9, P1, DOI 10.1177/089198879600900101; LAVORI PW, 1992, NEUROPSYCHOPHARMACOL, V6, P39; McKeith I, 2000, LANCET, V356, P2031, DOI 10.1016/S0140-6736(00)03399-7; Mega MS, 1999, ARCH NEUROL-CHICAGO, V56, P1388, DOI 10.1001/archneur.56.11.1388; MELZER D, IN PRESS HLTH CARE N; MORTIMER JA, 1992, NEUROLOGY, V42, P1689, DOI 10.1212/WNL.42.9.1689; *NAT I CLIN EXC, DON RIV GAL TREATM A; Netten A.P., 2000, UNIT COSTS HLTH SOCI; Neumann PJ, 1999, NEUROLOGY, V52, P1138, DOI 10.1212/WNL.52.6.1138; OLIN J, 2003, COCHRANE LIB; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; Rockwood K, 2001, NEUROEPIDEMIOLOGY, V20, P51, DOI 10.1159/000054761; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Rosenberg RN, 2002, MOVEMENT DISORD, V17, P3, DOI 10.1002/mds.10102; STEIN K, 1997, 69 WESS I HLTH RES D; Stewart A, 1998, INT J GERIATR PSYCH, V13, P445, DOI 10.1002/(SICI)1099-1166(199807)13:7<445::AID-GPS794>3.3.CO;2-5; Trinh NH, 2003, JAMA-J AM MED ASSOC, V289, P210, DOI 10.1001/jama.289.2.210; Wimo A, 2003, DEMENT GERIATR COGN, V15, P44, DOI 10.1159/000066669; 1997, DRUG THER B, V35, P75	45	616	637	0	87	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2105	2115						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220031				2022-12-28	WOS:000222268300006
J	Wright, P				Wright, P			Ronald Finn - Obituary	LANCET			English	Biographical-Item												pearce.wright@dial.pipex.com							0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2195	2195		10.1016/S0140-6736(04)16525-2	http://dx.doi.org/10.1016/S0140-6736(04)16525-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15248345				2022-12-28	WOS:000222268300038
J	Hilley, GE; Burgmann, R; Ferretti, A; Novali, F; Rocca, F				Hilley, GE; Burgmann, R; Ferretti, A; Novali, F; Rocca, F			Dynamics of slow-moving landslides from permanent scatterer analysis	SCIENCE			English	Article							DRIVEN GROUNDWATER-FLOW; SAR INTERFEROMETRY; RADAR INTERFEROMETRY; EARTHS SURFACE; HAYWARD FAULT; DEFORMATION; EARTHQUAKE; TOPOGRAPHY; STRESSES	High-resolution interferometric synthetic aperture radar (InSAR) permanent scatterer data allow us to resolve the rates and variations in the rates of slow-moving landslides. Satellite-to-ground distances ( range changes) on landslides increase at rates of 5 to 7 millimeters per year, indicating average downslope sliding velocities from 27 to 38 millimeters per year. Time-series analysis shows that displacement occurs mainly during the high-precipitation season; during the 1997-1998 El Nino event, rates of range change increased to as much as 11 millimeters per year. The observed nonlinear relationship of creep and precipitation rates suggests that increased pore fluid pressures within the shallow subsurface may initiate and accelerate these features. Changes in the slope of a hill resulting from increases in the pore pressure and lithostatic stress gradients may then lead to landslides.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; Tele Rilevamento Europa, I-20149 Milan, Italy; Politecn Milan, Dipartimento Elettron & Informaz, I-20133 Milan, Italy	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Polytechnic University of Milan	Hilley, GE (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA.	hilley@seismo.berkeley.edu	Ferretti, Alessandro/K-3811-2019; Burgmann, Roland/AAE-5138-2022	Ferretti, Alessandro/0000-0002-7802-5019; Rocca, Fabio/0000-0002-2266-6212; Burgmann, Roland/0000-0002-3560-044X				Burgmann R, 2000, ANNU REV EARTH PL SC, V28, P169, DOI 10.1146/annurev.earth.28.1.169; Burgmann R, 2000, SCIENCE, V289, P1178, DOI 10.1126/science.289.5482.1178; Colesanti C, 2003, IEEE T GEOSCI REMOTE, V41, P1685, DOI 10.1109/TGRS.2003.813278; Ferretti A, 2001, IEEE T GEOSCI REMOTE, V39, P8, DOI 10.1109/36.898661; Ferretti A, 2000, IEEE T GEOSCI REMOTE, V38, P2202, DOI 10.1109/36.868878; Freeze RA, 1979, GROUNDWATER; Fruneau B, 1996, TECTONOPHYSICS, V265, P181, DOI 10.1016/S0040-1951(96)00047-9; IVERSON RM, 1992, WATER RESOUR RES, V28, P925, DOI 10.1029/91WR02694; Jaeger J. C., 1979, FUNDAMENTALS ROCK ME; Lienkaemper JJ, 2001, GEOPHYS RES LETT, V28, P2265, DOI 10.1029/2000GL012776; Martel SJ, 2000, PURE APPL GEOPHYS, V157, P989, DOI 10.1007/s000240050014; Massonnet D, 1998, REV GEOPHYS, V36, P441, DOI 10.1029/97RG03139; McDonald M.G, 1988, TECHNIQUES WATER RES; MCTIGUE DF, 1981, J GEOPHYS RES, V86, P9268, DOI 10.1029/JB086iB10p09268; REID ME, 1992, WATER RESOUR RES, V28, P939, DOI 10.1029/91WR02695; Schmidt D. A., 2002, THESIS U CALIFORNIA; TERZAGHI K, 1936, 1ST P INT C SOIL MEC, V1, P54; VONDERLINDEN K, 1989, ENG GEOL, V27, P301	18	337	370	15	166	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1952	1955		10.1126/science.1098821	http://dx.doi.org/10.1126/science.1098821			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218146				2022-12-28	WOS:000222241600042
J	Piot, P; Feachem, RGA; Jong-Wook, L; Wolfensohn, JD				Piot, P; Feachem, RGA; Jong-Wook, L; Wolfensohn, JD			A global response to AIDS: Lessons learned, next steps	SCIENCE			English	Editorial Material									World Hlth Org, Geneva, Switzerland; World Bank Grp, Washington, DC USA	World Health Organization; The World Bank		jon.liden@theglobalfund.org						*MIN HLTH BRAZ, 2002, NAT AIDS DRUG POL; *UNAIDS, 2004, MON EV TOOLK; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *UNAIDS, 2004, COMM PRINC CONC AIDS; World Health Organization, 2003, SCAL ANT THER RES LT	5	19	19	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1909	1910		10.1126/science.1101137	http://dx.doi.org/10.1126/science.1101137			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218129				2022-12-28	WOS:000222241600024
J	Steinbrook, R				Steinbrook, R			Public registration of clinical trials	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*COUNC SCI AFF AM, 2004, FEAT CSA REP INFL FU; Davidoff F, 2001, NEW ENGL J MED, V345, P825, DOI 10.1056/NEJMed20010093; Dickersin K, 2003, JAMA-J AM MED ASSOC, V290, P516, DOI 10.1001/jama.290.4.516; Food and Drug Administration, 2004, GUID IND INF PROGR C; *PHARM RES MAN AM, 2004, UPD PRINC COND CLIN	5	47	54	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					315	317		10.1056/NEJMp048191	http://dx.doi.org/10.1056/NEJMp048191			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269307				2022-12-28	WOS:000222801200001
J	Ricklefs, RE				Ricklefs, RE			Cladogenesis and morphological diversification in passerine birds	NATURE			English	Article							ADAPTIVE RADIATION; EVOLUTION; TEMPO; MODE; SPECIATION; FINCHES	Morphological diversity tends to increase within evolving lineages over time(1,2), but the relative roles of gradual evolutionary change (anagenesis)(3) and abrupt shifts associated with speciation events (cladogenesis, or 'punctuated equilibrium')(4) have not been resolved for most groups of organisms(5). However, these two modes of evolution can be distinguished by the fact that morphological variance increases in proportion to time under anagenesis(6), and in proportion to the logarithm of the number of species under cladogenesis(7). Although species and time are themselves correlated, multiple regression analysis provides a statistical framework for partitioning their relative contributions. In this study, I use multiple regressions to evaluate the effects of time and species number on morphological diversity within clades of passerine birds. The results show clearly that number of species exerts a strong influence on morphological variance independent of time, but that time has no unique effect. Thus, morphological evolution in birds seems to be associated with cladogenesis. How lineage splitting promotes morphological diversification poses an important challenge to ecologists and evolutionary biologists.	Univ Missouri, Dept Biol, St Louis, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis	Ricklefs, RE (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	ricklefs@umsl.edu						Abouheif E, 1999, EVOL ECOL RES, V1, P895; Benkman CW, 2003, EVOLUTION, V57, P1176; CARSON HL, 1984, ANNU REV ECOL SYST, V15, P97, DOI 10.1146/annurev.es.15.110184.000525; Eldredge N., 1972, P82; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Foote Mike, 1996, P62; GOULD S J, 1977, Paleobiology, V3, P115; GRANT P R, 1972, Biological Journal of the Linnean Society, V4, P39, DOI 10.1111/j.1095-8312.1972.tb00690.x; Harmon LJ, 2003, SCIENCE, V301, P961, DOI 10.1126/science.1084786; Jackson JBC, 1999, TRENDS ECOL EVOL, V14, P72, DOI 10.1016/S0169-5347(98)01504-3; Lovette IJ, 2002, P ROY SOC B-BIOL SCI, V269, P37, DOI 10.1098/rspb.2001.1789; MILES DB, 1984, ECOLOGY, V65, P1629, DOI 10.2307/1939141; Moritz C, 2000, ANNU REV ECOL SYST, V31, P533, DOI 10.1146/annurev.ecolsys.31.1.533; RAUP DM, 1974, SYST ZOOL, V23, P305, DOI 10.2307/2412538; Ricklefs RE, 2003, P ROY SOC B-BIOL SCI, V270, P2285, DOI 10.1098/rspb.2003.2489; RICKLEFS RE, 1980, AUK, V97, P321; Ricklefs Robert E., 1994, P13; SCHLUTER D, 1984, EVOLUTION, V38, P921, DOI 10.1111/j.1558-5646.1984.tb00363.x; SCHLUTER D, 1988, AM NAT, V131, P799, DOI 10.1086/284823; [No title captured], DOI DOI 10.1086/285901)	20	86	88	1	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	2004	430	6997					338	341		10.1038/nature02700	http://dx.doi.org/10.1038/nature02700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254535				2022-12-28	WOS:000222631200038
J	Sandel, MJ				Sandel, MJ			Embryo ethics - The moral logic of stem-cell research	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																			0	61	65	0	17	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					207	209		10.1056/NEJMp048145	http://dx.doi.org/10.1056/NEJMp048145			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254277				2022-12-28	WOS:000222627200001
J	Crepaz, N; Hart, TA; Marks, G				Crepaz, N; Hart, TA; Marks, G			Highly active antiretroviral therapy and sexual risk behavior - A meta-analytic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIV-POSITIVE GAY; VIRAL LOAD; HOMOSEXUAL-MEN; HETEROSEXUAL TRANSMISSION; COMBINATION THERAPIES; TRANSMITTED DISEASES; PROTEASE INHIBITORS; VIROLOGICAL FAILURE; SAN-FRANCISCO; CONDOM USE	Context Evidence suggests that since highly active antiretroviral therapy (HAART) became available, the prevalence of unprotected sex and the incidence of sexually transmitted infections (STIs) have increased. Objective To conduct 3 meta-analyses to determine whether (1) being treated with HAART, (2) having an undetectable viral load, or (3) holding specific beliefs about HAART and viral load are associated with increased likelihood of engaging in unprotected sex. Data Sources A comprehensive search included electronic bibliographic databases, including AIDSLINE, MEDLINE, PubMed, CINHAL, PsycInfo, ERIC, EMBASE, and Sociofile, from January 1996 to August 2003, conference proceedings, hand searches of journals, reference lists of articles, and contacts with researchers. Study Selection Twenty-five English-language studies (some contributing >1 finding) met the selection criteria and examined the association of unprotected sexual intercourse or STIs with receiving HAART (21 findings), having an undetectable viral load (13 findings), or beliefs about HAART and viral load (18 findings). Data Extraction Reports were screened and information from eligible studies was abstracted independently by pairs of reviewers using a standardized spreadsheet. Data Synthesis Random-effects models were used to aggregate data. The prevalence of unprotected sex was not higher among persons with the human immunodeficiency virus (HIV) receiving HAART (prevalence range, 9%-56%; median, 33%) vs those not receiving HAART (range, 11%-77%; median, 44%; odds ratio [OR], 0.92; 95% confidence interval [CI], 0.65-1.31) or among HIV-positive persons with an undetectable viral load (range, 10%-68%; median, 39%) vs those with a detectable viral load (range, 14%-70%; median, 42%; OR, 0.99; 95% Cl, 0.82-1.21). The prevalence of unprotected sex was elevated (OR, 1.82; 95% Cl, 1.52-2.17) in HIV-positive, HIV-negative, and unknown serostatus persons who believed that receiving HAART or having an undetectable viral load protects against transmitting HIV or who had reduced concerns about engaging in unsafe sex given the availability of HAART (range, 17%-81% [median, 49%] vs 9%-68% [median, 38%] for counterparts). Conclusions In the studies reviewed, HIV-positive patients receiving HAART did not exhibit increased sexual risk behavior, even when therapy achieved an undetectable viral load. However, people's beliefs about HAART and viral load may promote unprotected sex and may be amenable to change through prevention messages.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Emory University	Crepaz, N (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30333 USA.	ncrepaz@cdc.gov		Hart, Trevor/0000-0001-5107-7452				[Anonymous], 1999, MMWR MORB MORTAL WKL, V48, P45; BERN DJ, 1967, PSYCHOL REV, V74, P183, DOI DOI 10.1037/H0024835; Bouhnik AD, 2002, J EPIDEMIOL COMMUN H, V56, P349, DOI 10.1136/jech.56.5.349; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Catz SL, 2001, AIDS EDUC PREV, V13, P239, DOI 10.1521/aeap.13.3.239.19746; Chen SY, 2002, AM J PUBLIC HEALTH, V92, P1387, DOI 10.2105/AJPH.92.9.1387-a; Comulada WS, 2003, AM J HEALTH BEHAV, V27, P389, DOI 10.5993/AJHB.27.4.11; Cooper H. M., 1998, SYNTHESIZING RES GUI, V3rd; De Rosa CJ, 1998, HEALTH PSYCHOL, V17, P224, DOI 10.1037/0278-6133.17.3.224; de Ven PV, 1999, AIDS, V13, P2289, DOI 10.1097/00002030-199911120-00011; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Demmer C, 2002, J COMMUN HEALTH, V27, P63, DOI 10.1023/A:1013884310983; Desquilbet L, 2002, AIDS, V16, P2329, DOI 10.1097/00002030-200211220-00014; DiClemente RJ, 2002, SOUTH MED J, V95, P421, DOI 10.1097/00007611-200204000-00009; Dilley JW, 2003, AIDS CARE, V15, P27, DOI 10.1080/0954012021000039734; Dilley JW, 1997, NEW ENGL J MED, V337, P501, DOI 10.1056/NEJM199708143370715; Dionisio D, 2001, CLIN INFECT DIS, V33, P706, DOI 10.1086/322660; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; Dukers NHTM, 2002, AIDS, V16, pF19, DOI 10.1097/00002030-200207050-00001; Dukers NHTM, 2001, AIDS, V15, P369, DOI 10.1097/00002030-200102160-00010; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elford J, 2003, JAIDS-J ACQ IMM DEF, V32, P545, DOI 10.1097/00126334-200304150-00013; Elford J, 2002, AIDS, V16, P1537, DOI 10.1097/00002030-200207260-00011; Elford J, 2000, J ACQ IMMUN DEF SYND, V23, P266; Festinger L., 1957, THEORY COGNITIVE DIS, V2; FIDELI U, 2000, 7 C RETR OPP INF JAN; Friedland GH, 1999, AIDS, V13, pS61; GWADZ M, 1999, J SEX EDUC THER, V24, P81; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Herlitz CA, 2001, EUR J PUBLIC HEALTH, V11, P251, DOI 10.1093/eurpub/11.3.251; Hogg RS, 2001, AIDS, V15, P1321, DOI 10.1097/00002030-200107060-00020; Huebner DM, 2001, ANN BEHAV MED, V23, P304, DOI 10.1207/S15324796ABM2304_10; Johnson WD, 2002, J ACQ IMMUN DEF SYND, V30, pS62, DOI 10.1097/01.QAI.0000018888.47949.1B; JUNE P, 2001, SYSTEMATIC REV HLTH; Kalichman SC, 1998, HEALTH PSYCHOL, V17, P546, DOI 10.1037/0278-6133.17.6.546; Kalichman SC, 2001, J ACQ IMMUN DEF SYND, V28, P303; Kalichman SC, 1999, AIDS CARE, V11, P415, DOI 10.1080/09540129947794; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Kelly JA, 1998, HEALTH PSYCHOL, V17, P310, DOI 10.1037/0278-6133.17.4.310; Kravcik S, 1998, J ACQ IMMUN DEF SYND, V19, P124, DOI 10.1097/00042560-199810010-00004; Lipsey M. W., 2001, PRACTICAL METAANALYS, V49; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; MARTICKATYNDALE.E, 2002, CAN J HUM SEX, V11, P33; Martin DJ, 2001, AM J HEALTH BEHAV, V25, P513, DOI 10.5993/AJHB.25.6.1; Miller M, 2000, AIDS, V14, pF33, DOI 10.1097/00002030-200003100-00001; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Montaner JSG, 1998, JAMA-J AM MED ASSOC, V279, P930, DOI 10.1001/jama.279.12.930; Orwin R.G., 1994, HDB RES SYNTHESIS; Ostrow DE, 2002, AIDS, V16, P775, DOI 10.1097/00002030-200203290-00013; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pedraza MA, 1999, J ACQ IMMUN DEF SYND, V21, P120; Posner SF, 1996, AM J PREV MED, V12, P472, DOI 10.1016/S0749-3797(18)30270-8; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Remien RH, 1998, AIDS, V12, P1560, DOI 10.1097/00002030-199812000-00025; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Semple SJ, 2003, AIDS EDUC PREV, V15, P133, DOI 10.1521/aeap.15.3.133.23835; Stephenson JM, 2003, SEX TRANSM INFECT, V79, P7, DOI 10.1136/sti.79.1.7; Stolte IG, 2001, SEX TRANSM INFECT, V77, P184, DOI 10.1136/sti.77.3.184; Suarez TP, 2001, J ACQ IMMUN DEF SYND, V28, P471, DOI 10.1097/00042560-200112150-00011; SUTTON AJ, 1980, METHODS META ANAL ME; Tachet A, 1999, AIDS, V13, P823, DOI 10.1097/00002030-199905070-00012; van der Straten A, 1998, Focus, V13, P5; van der Straten A, 2000, AIDS, V14, pF47, DOI 10.1097/00002030-200003100-00003; Vanable PA, 2003, J PSYCHOSOM RES, V54, P263, DOI 10.1016/S0022-3999(02)00483-X; Vanable PA, 2000, HEALTH PSYCHOL, V19, P134, DOI 10.1037//0278-6133.19.2.134; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vlahov D, 2001, AIDS, V15, P2311, DOI 10.1097/00002030-200111230-00013; Wainberg MA, 1998, JAMA-J AM MED ASSOC, V279, P1977, DOI 10.1001/jama.279.24.1977; Wilson TE, 2001, J ACQ IMMUN DEF SYND, V27, P289, DOI 10.1097/00126334-200107010-00012; Wolf K, 2003, JAIDS-J ACQ IMM DEF, V33, P494, DOI 10.1097/00126334-200308010-00010; Wolitski RJ, 2001, AM J PUBLIC HEALTH, V91, P883, DOI 10.2105/AJPH.91.6.883; Yamey G, 2001, BRIT MED J, V322, P260, DOI 10.1136/bmj.322.7281.260; Zhang H, 1998, NEW ENGL J MED, V339, P1803, DOI 10.1056/NEJM199812173392502; 2003, MMWR MOB MORTAL WKLY, V52, P1145	74	437	443	0	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					224	236		10.1001/jama.292.2.224	http://dx.doi.org/10.1001/jama.292.2.224			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	836TS	15249572				2022-12-28	WOS:000222579300028
J	Bulteau, AL; O'Neill, HA; Kennedy, MC; Ikeda-Saito, M; Isaya, G; Szweda, LI				Bulteau, AL; O'Neill, HA; Kennedy, MC; Ikeda-Saito, M; Isaya, G; Szweda, LI			Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity	SCIENCE			English	Article							FE-S CLUSTER; YEAST FRATAXIN; FRIEDREICH ATAXIA; SACCHAROMYCES-CEREVISIAE; PROCESSING PEPTIDASE; BINDING PROPERTIES; SCAFFOLD PROTEIN; HOMOLOG; INACTIVATION; BIOSYNTHESIS	Numerous degenerative disorders are associated with elevated levels of pro-oxidants and declines in mitochondrial aconitase activity. Deficiency in the mitochondrial iron-binding protein frataxin results in diminished activity of various mitochondrial iron-sulfur proteins including aconitase. We found that aconitase can undergo reversible citrate-dependent modulation in activity in response to pro-oxidants. Frataxin interacted with aconitase in a citrate-dependent fashion, reduced the level of oxidant-induced inactivation, and converted inactive [3Fe-4S](1+) enzyme to the active [4Fe-4S](2+) form of the protein. Thus, frataxin is an iron chaperone protein that protects the aconitase [4Fe-4S](2+) cluster from disassembly and promotes enzyme reactivation.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Mayo Clin, Coll Med, Dept Pediat & Adolescent Med, Rochester, MN USA; Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN USA; Gannon Univ, Dept Chem, Erie, PA USA; Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan	Case Western Reserve University; Mayo Clinic; Mayo Clinic; Tohoku University	Szweda, LI (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	lxs54@po.cwru.edu	Ikeda-Saito, Masao/A-5992-2008; Ikeda-Saito, Masao/K-2703-2015; bulteau, anne-laure/AAN-4004-2020		NATIONAL INSTITUTE ON AGING [R01AG015709, R01AG016339] Funding Source: NIH RePORTER; NIA NIH HHS [AG-15709, AG-16339] Funding Source: Medline; NINR NIH HHS [NRSA 44748] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Adinolfi S, 2002, HUM MOL GENET, V11, P1865, DOI 10.1093/hmg/11.16.1865; Beinert H, 1996, CHEM REV, V96, P2335, DOI 10.1021/cr950040z; Bolis D, 2004, J MOL BIOL, V336, P203, DOI 10.1016/j.jmb.2003.11.056; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Branda SS, 1999, J BIOL CHEM, V274, P22763, DOI 10.1074/jbc.274.32.22763; Bulteau AL, 2003, BIOCHEMISTRY-US, V42, P14846, DOI 10.1021/bi0353979; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Cavadini P, 2000, J BIOL CHEM, V275, P41469, DOI 10.1074/jbc.M006539200; Chen OS, 2002, P NATL ACAD SCI USA, V99, P12321, DOI 10.1073/pnas.192449599; Dhe-Paganon S, 2000, J BIOL CHEM, V275, P30753, DOI 10.1074/jbc.C000407200; FLINT DH, 1993, J BIOL CHEM, V268, P22369; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Gerber J, 2003, EMBO REP, V4, P906, DOI 10.1038/sj.embor.embor918; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Lesuisse E, 2003, HUM MOL GENET, V12, P879, DOI 10.1093/hmg/ddg096; Muhlenhoff U, 2003, EMBO J, V22, P4815, DOI 10.1093/emboj/cdg446; Muhlenhoff U, 2002, HUM MOL GENET, V11, P2025, DOI 10.1093/hmg/11.17.2025; Nichol H, 2003, BIOCHEMISTRY-US, V42, P5971, DOI 10.1021/bi027021l; ONEILL HA, 2004, UNPUB; Park S, 2003, J BIOL CHEM, V278, P31340, DOI 10.1074/jbc.M303158200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Ramazzotti A, 2004, FEBS LETT, V557, P215, DOI 10.1016/S0014-5793(03)01498-4; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Vasquez-Vivar J, 2000, J BIOL CHEM, V275, P14064, DOI 10.1074/jbc.275.19.14064; Wilson RB, 2003, J NEUROL SCI, V207, P103, DOI 10.1016/S0022-510X(02)00432-X; Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168; Yoon T, 2003, J AM CHEM SOC, V125, P6078, DOI 10.1021/ja027967i	31	295	313	3	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					242	245		10.1126/science.1098991	http://dx.doi.org/10.1126/science.1098991			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247478				2022-12-28	WOS:000222501000052
J	Lee, SY; MacKinnon, R				Lee, SY; MacKinnon, R			A membrane-access mechanism of ion channel inhibition by voltage sensor toxins from spider venom	NATURE			English	Article							DEPENDENT K+ CHANNEL; GATING MODIFIER TOXINS; POTASSIUM CHANNEL; PEPTIDE INHIBITOR; RECEPTOR; DIFFUSION; HANATOXIN; SURFACE; CHARYBDOTOXIN; NEUROTOXIN	Venomous animals produce small protein toxins that inhibit ion channels with high affinity. In several well-studied cases the inhibitory proteins are water-soluble and bind at a channel's aqueous-exposed extracellular surface(1-4). Here we show that a voltage-sensor toxin (VSTX1) from the Chilean Rose Tarantula (Grammostola spatulata) reaches its target by partitioning into the lipid membrane. Lipid membrane partitioning serves two purposes: to localize the toxin in the membrane where the voltage sensor resides and to exploit the free energy of partitioning to achieve apparent high-affinity inhibition. VSTX1, small hydrophobic poisons and anaesthetic molecules reveal a common theme of voltage sensor inhibition through lipid membrane access. The apparent requirement for such access is consistent with the recent proposal that the sensor in voltage-dependent K+ channels is located at the membrane-protein interface(5,6).	Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Howard Hughes Med Inst, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockefeller.edu						Almeida P.F.F., 1995, HDB BIOL PHYS A&B, V1, P305, DOI 10.1016/S1383-8121(06)80023-0; Diochot S, 1999, BRIT J PHARMACOL, V126, P251, DOI 10.1038/sj.bjp.0702283; ESCOBAR L, 1993, BIOCHEMISTRY-US, V32, P6982, DOI 10.1021/bi00078a024; Escoubas P, 2002, MOL PHARMACOL, V62, P48, DOI 10.1124/mol.62.1.48; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Hille B., 2001, ION CHANNELS EXCITAB, P635; HUGUES M, 1982, P NATL ACAD SCI-BIOL, V79, P1308, DOI 10.1073/pnas.79.4.1308; Imredy JP, 1998, BIOCHEMISTRY-US, V37, P14867, DOI 10.1021/bi980929k; JIANG QX, 2001, THESIS YALE U; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Ladokhin AS, 2000, ANAL BIOCHEM, V285, P235, DOI 10.1006/abio.2000.4773; Lee CW, 2004, BIOCHEMISTRY-US, V43, P890, DOI 10.1021/bi0353373; Lee HC, 2003, NEURON, V40, P527, DOI 10.1016/S0896-6273(03)00636-6; Li-Smerin Y, 1998, P NATL ACAD SCI USA, V95, P8585, DOI 10.1073/pnas.95.15.8585; MANOLERAS N, 1994, BIOCHEMISTRY-US, V33, P11051, DOI 10.1021/bi00203a001; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MILLER C, 1990, BIOCHEMISTRY-US, V29, P5320, DOI 10.1021/bi00474a016; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; SCHURR JM, 1970, BIOPHYS J, V10, P717, DOI 10.1016/S0006-3495(70)86331-7; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; SWARTZ KJ, 1995, NEURON, V15, P941, DOI 10.1016/0896-6273(95)90184-1; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Takahashi H, 2000, J MOL BIOL, V297, P771, DOI 10.1006/jmbi.2000.3609; Wang JL, 2003, BIOPHYS J, V84, p218A; Winterfield JR, 2000, J GEN PHYSIOL, V116, P637, DOI 10.1085/jgp.116.5.637	30	236	239	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					232	235		10.1038/nature02632	http://dx.doi.org/10.1038/nature02632			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241419				2022-12-28	WOS:000222470600049
J	Blazing, MA; de Lemos, JA; White, HD; Fox, KAA; Verheugt, FWA; Ardissino, D; DiBattiste, PM; Palmisano, J; Bilheimer, DW; Snapinn, SA; Ramsey, KE; Gardner, LH; Hasselblad, V; Pfeffer, MA; Lewis, EF; Braunwald, E; Califf, RA				Blazing, MA; de Lemos, JA; White, HD; Fox, KAA; Verheugt, FWA; Ardissino, D; DiBattiste, PM; Palmisano, J; Bilheimer, DW; Snapinn, SA; Ramsey, KE; Gardner, LH; Hasselblad, V; Pfeffer, MA; Lewis, EF; Braunwald, E; Califf, RA		A to Z Investigators	Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MOLECULAR-WEIGHT HEPARIN; WAVE MYOCARDIAL-INFARCTION; TIMI RISK SCORE; UNSTABLE ANGINA; INHIBITOR; EVENTS; STRATIFICATION; THROMBOLYSIS; MANAGEMENT; RATIONALE	Context Enoxaparin or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors. Objective To assess efficacy and safety of the combination of enoxaparin and tirofiban compared with unfractionated heparin and tirofiban in patients with non-ST-elevation ACS. Design, Setting, and Participants A prospective, international, open-label, randomized, noninferiority trial of 1 mg/kg of enoxaparin every 12 hours (n=2026) compared with weight-adjusted intravenous unfractionated heparin (n=1961) in patients with non-ST-elevation ACS receiving tirofiban and aspirin. Phase A of the A to Z trial was conducted between December 1999 and May 2002. Main Outcome Measures Death, recurrent myocardial infarction, or refractory ischemia at 7 days in the intent-to-treat population with boundaries set for superiority and noninferiority. Safety based on measures of bleeding using the Thrombolysis in Myocardial Infarction (TIMI) classification system. Results A total of 169 (8.4%) of 2018 patients randomized to enoxaparin experienced death, myocardial infarction, or refractory ischemia at 7 days compared with 184 (9.4%) of 1952 patients randomized to unfractionated heparin (hazard ratio [HR], 0.88; 95% confidence interval [CI], 0.71-1.08). This met the prespecified criterion for noninferiority. All components of the composite primary and secondary end points favored enoxaparin except death, which occurred in only 1% of patients (23 for enoxaparin and 17 for unfractionated heparin). Rates for any TIMI grade bleeding were low (3.0% for enoxaparin and 2.2% for unfractionated heparin; P = .13). Using a worst-case approach that combined 2 independent bleeding evaluations, use of enoxaparin was associated with 1 additional TIMI major bleeding episode for each 200 patients treated. Conclusions in patients receiving tirofiban and aspirin, enoxaparin is a suitable alternative to unfractionated heparin for treatment of non-ST-elevation ACS. The 12% relative and 1% absolute reductions in the primary end point in favor of enoxaparin met criterion for noninferiority and are consistent with prior trials performed without the use of glycoprotein IIb/IIIa inhibitors.	Duke Clin Res Inst, Durham, NC USA; Univ Texas, SW Med Ctr, Donald W Reynolds Cardiovasc Clin Res Ctr, Dallas, TX USA; Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand; Univ Edinburgh, Dept Cardiol Res, Edinburgh, Midlothian, Scotland; Ctr Med Univ, Dept Inervent Cardiol, Nijmegen, Netherlands; Osped Maggiore Parma, Div Cardiol, Parma, Italy; Merck & Co Inc, Whitehouse Stn, NJ USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Edinburgh; University of Parma; University Hospital of Parma; Merck & Company; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Blazing, MA (corresponding author), Duke Univ, Med Ctr, Box 3126, Durham, NC 27710 USA.	blazi001@mc.duke.edu	Fox, keith A A/I-3742-2013; Ardissino, Diego/AAC-4041-2022; de Lemos, James/ABD-6669-2021; Verheugt, F.W.A./H-8105-2014	Fox, Keith/0000-0002-0140-2752; solinas, emilia/0000-0003-3532-1317				Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Antman EM, 1999, CIRCULATION, V100, P1602, DOI 10.1161/01.CIR.100.15.1602; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bertrand ME, 2002, EUR HEART J, V23, P1809, DOI 10.1053/euhj.2002.3385; Blazing MA, 2001, AM HEART J, V142, P211, DOI 10.1067/mhj.2001.116959; BOVILL EG, 1991, ANN INTERN MED, V115, P256, DOI 10.7326/0003-4819-115-4-256; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; BRAUNWALD E, ACC AHA 2002 GUIDELI; Cohen M, 1997, NEW ENGL J MED, V337, P447, DOI 10.1056/NEJM199708143370702; Cohen M, 2002, AM HEART J, V144, P470, DOI 10.1067/mhj.2002.126115; Ferguson JJ, 2002, AM HEART J, V143, P952, DOI 10.1067/mhj.2002.122120; Goodman SG, 2003, CIRCULATION, V107, P238, DOI 10.1161/01.CIR.0000050144.67910.13; Hanrath P, 1997, CIRCULATION, V96, P1445; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Morrow DA, 2000, J AM COLL CARDIOL, V36, P1812, DOI 10.1016/S0735-1097(00)00942-6; Morrow DA, 2002, EUR HEART J, V23, P223, DOI 10.1053/euhj.2001.2738; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Xiao ZH, 1998, CIRCULATION, V97, P251, DOI 10.1161/01.CIR.97.3.251	20	181	191	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					55	64		10.1001/jama.292.1.55	http://dx.doi.org/10.1001/jama.292.1.55			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238591	Bronze			2022-12-28	WOS:000222448100027
J	Davis, BR; Furberg, CD; Wright, JT; Cutler, JA; Whelton, P				Davis, BR; Furberg, CD; Wright, JT; Cutler, JA; Whelton, P		ALLHAT Collaborative Res Grp	ALLHAT: Setting the record straight	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							LIPID-LOWERING TREATMENT; HEART-FAILURE EVENTS; ATTACK TRIAL ALLHAT; BLOOD-PRESSURE; ANTIHYPERTENSIVE TREATMENT; HYPERTENSION; MORBIDITY; MORTALITY; POPULATION; THERAPY	The findings of the Anti hypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) have generated worldwide reaction from clinicians and researchers, including a recent commentary in this journal. Such response was expected for a trial of ALLHAT's size and scope, especially since its results challenged some widely held beliefs. This paper reviews key aspects of the ALLHAT design, analyses, findings, and conclusions to provide a perspective on the commentary about the trial's results and implications for clinical practice. Several of the most frequent comments regarding the study's results are addressed, particularly with respect to heart failure and diabetes outcomes. Responses to these comments reinforce the investigators' original conclusion that thiazide-type diuretics should remain the preferred first-step drug class for treating hypertension and should generally be a part of any multidrug regimen.	Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA; Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Wake Forest University; Wake Forest Baptist Medical Center; Case Western Reserve University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Tulane University	Davis, BR (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, 1200 Herman Pressler St,Suite E801, Houston, TX 77030 USA.	bdavis@sph.uth.tmc.edu			DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC035130] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-35130] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alderman MH, 2003, HYPERTENSION, V42, P239, DOI 10.1161/01.HYP.0000086521.95630.5A; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1990, Circulation, V82, P1616; Appel LJ, 2002, JAMA-J AM MED ASSOC, V288, P3039, DOI 10.1001/jama.288.23.3039; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; Brown MJ, 2000, LANCET, V356, P366, DOI 10.1016/S0140-6736(00)02527-7; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Chalmers J, 2003, J HYPERTENS, V21, P225, DOI 10.1097/00004872-200302000-00002; Chapman N, 2004, STROKE, V35, P116, DOI 10.1161/01.STR.0000106480.76217.6F; Cushman William C, 2002, J Clin Hypertens (Greenwich), V4, P393; CUTLER JA, 2001, CLIN TRIALS HYPERTEN; Cutler Jeffrey A, 2003, J Clin Hypertens (Greenwich), V5, P192, DOI 10.1111/j.1524-6175.2003.02521.x; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Davis BR, 2003, CONTROL CLIN TRIALS, V24, p76S; Davis BR, 2002, ANN INTERN MED, V137, P313, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00006; Dunder K, 2003, BRIT MED J, V326, P681, DOI 10.1136/bmj.326.7391.681; Einhorn P, 2003, CIRCULATION, V108, P399; Elliott WJ, 1996, AM J HYPERTENS, V9, P409; Fagard RH, 2003, J HYPERTENS, V21, P229, DOI 10.1097/00004872-200302000-00003; Frohlich ED, 2003, NEW ENGL J MED, V348, P639, DOI 10.1056/NEJMe020179; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; Kaplan NM, 2003, J HYPERTENS, V21, P233, DOI 10.1097/00004872-200302000-00004; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kostis JB, 1997, JAMA-J AM MED ASSOC, V278, P212; LITHELL HOL, 1991, DIABETES CARE, V14, P203, DOI 10.2337/diacare.14.3.203; Messerli FH, 2003, ANN INTERN MED, V139, P777, DOI 10.7326/0003-4819-139-9-200311040-00012; Messerli FH, 2003, JAMA-J AM MED ASSOC, V289, P2067, DOI 10.1001/jama.289.16.2067; Moser M, 2003, ARCH INTERN MED, V163, P1269, DOI 10.1001/archinte.163.11.1269; PARMAR M, COMMUNICATION   0422; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; Piller LB, 2002, CURR CONTR TRIALS C, V3, DOI 10.1186/1468-6708-3-10; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Psaty Bruce M, 2003, ACP J Club, V139, P7; Qizilbash N, 1995, LANCET, V346, P1647; Savage PJ, 1998, ARCH INTERN MED, V158, P741, DOI 10.1001/archinte.158.7.741; Schafer JL., 1997, ANAL INCOMPLETE MULT, DOI 10.1201/9781439821862; Stafford RS, 2003, J GEN INTERN MED, V18, P157; Turnbull F, 2003, LANCET, V362, P1527; Wilcox CS, 1999, SEMIN NEPHROL, V19, P557; Wing LMH, 1997, CLIN EXP HYPERTENS, V19, P779, DOI 10.3109/10641969709083186; Zanchetti A, 2003, J HYPERTENS, V21, P223, DOI 10.1097/00004872-200302000-00001; 1979, JA A, V242, P2562	46	39	40	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					39	46		10.7326/0003-4819-141-1-200407060-00013	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00013			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238369				2022-12-28	WOS:000222427600006
J	Pirmohamed, M; James, S; Meakin, S; Green, C; Scott, AK; Walley, TJ; Farrar, K; Park, BK; Breckenridge, AM				Pirmohamed, M; James, S; Meakin, S; Green, C; Scott, AK; Walley, TJ; Farrar, K; Park, BK; Breckenridge, AM			Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ELDERLY PATIENTS; COSTS; METAANALYSIS; DEFINITIONS; PREVENTION; ASPIRIN; DISEASE; EVENTS; UNIT	Objective To ascertain the current burden of adverse drug reactions (ADRs) through a prospective analysis of all admissions to hospital. Design Prospective observational study. Setting Two large general hospitals in Merseyside, England. Participants 18 820 patients aged > 16 years admitted over six months and assessed for cause of admission. Main outcome measures Prevalence of admissions due to an ADR, length of stay, avoidability, and outcome. Results There were 1225. admissions related to an ADR, giving a prevalence of 6.5%, with the ADR directly leading to the admission in 80% of cases. The median bed stay was eight days, accounting for 4% of the hospital bed capacity. The projected annual cost of such admissions to the NHS is pound466m ((sic)706m, $847m). The overall fatality was 0.15%. Most reactions were either definitely or possibly avoidable. Drugs most commonly implicated in causing these admissions included low dose aspirin, diuretics, warfarin, and non-steroidal anti-inflammatory drugs other than aspirin, the most common reaction being gastrointestinal bleeding. Conclusion The burden of ADRs on the NHS is high accounting for considerable morbidity, mortality, and extra costs. Although many of the implicated drugs have proved benefit, measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England; Wirral Hosp NHS Trust, Wirral CH49 5PE, Merseyside, England	University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Pirmohamed, M (corresponding author), Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England.	munirp@liv.ac.uk	Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266				Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Beijer HJM, 2002, PHARM WORLD SCI, V24, P46, DOI 10.1023/A:1015570104121; BHALLA N, 2003, PHARM J, V270, P583; *BRIT MED ASS ROYA, 2002, BRIT NAT FORM; *CIPFA, 2002, HLTH SERV FIN DAT CO; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; *DEP HLTH, 2001, HOSP EP STAT; Department of Health, 2001, MED OLD PEOPL IMPL M; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832, DOI 10.1177/106002809302700702; Gaspoz J, 2002, NEW ENGL J MED, V346, P1800, DOI 10.1056/NEJM200206063462309; GHOSE K, 1980, J ROY SOC MED, V73, P853, DOI 10.1177/014107688007301207; GOSNEY M, 1984, LANCET, V2, P564; HALLAS J, 1990, J INTERN MED, V228, P83, DOI 10.1111/j.1365-2796.1990.tb00199.x; Howard RL, 2003, QUAL SAF HEALTH CARE, V12, P280, DOI 10.1136/qhc.12.4.280; HURWITZ N, 1969, BRIT MED J, V1, P536, DOI 10.1136/bmj.1.5643.536; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; HURWITZ N, 1969, BRIT MED J, V1, P539, DOI 10.1136/bmj.1.5643.539; Jones J K, 1982, Fam Community Health, V5, P58; Kvasz M, 2000, MedGenMed, V2, pE3; Lagnaoui R, 2000, EUR J CLIN PHARMACOL, V56, P181, DOI 10.1007/s002280050738; Langman MJS, 2001, PHARMACOEPIDEM DR S, V10, P13, DOI 10.1002/pds.561; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEACH S, 1986, AGE AGEING, V15, P241, DOI 10.1093/ageing/15.4.241; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154; Rawlins MD, 1991, TXB ADVERSE DRUG REA, P18; Rodriguez-Monguio R, 2003, PHARMACOECONOMICS, V21, P623, DOI 10.2165/00019053-200321090-00002; Smith CC, 1996, BRIT J CLIN PHARMACO, V42, P423, DOI 10.1111/j.1365-2125.1996.tb00004.x; WEIL J, 1995, BMJ-BRIT MED J, V310, P827, DOI 10.1136/bmj.310.6983.827; Wiffen P, 2002, BANDOLIER EXTRA, P1; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; Winterstein AG, 2002, ANN PHARMACOTHER, V36, P1238, DOI 10.1345/aph.1A225	33	1952	2031	0	123	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					15	19		10.1136/bmj.329.7456.15	http://dx.doi.org/10.1136/bmj.329.7456.15			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231615	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222568300015
J	Doll, R; Hill, AB				Doll, R; Hill, AB			The mortality of doctors in relation to their smoking habits - A preliminary report (Reprinted from Br Med J, vol 2, pg 1451-5,1954)	BMJ-BRITISH MEDICAL JOURNAL			English	Reprint																		BRESLOW L, 1954, AM J PUBLIC HEALTH, V44, P171; DOLL R, 1952, BMJ-BRIT MED J, V2, P1271, DOI 10.1136/bmj.2.4797.1271; DOLL R, 1954, BMJ-BRIT MED J, V1, P1451, DOI 10.1136/bmj.1.4877.1451; KOULUMIES M, 1953, ACTA RADIOL, V39, P255, DOI 10.3109/00016925309136710; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; MCCONNELL RB, 1952, LANCET, V263, P651; MILLS CA, 1950, CANCER RES, V10, P539; SADOWSKY DA, 1953, J NATL CANCER I, V13, P1237; SCHREK R, 1950, CANCER RES, V10, P49; WATSON WL, 1954, CANCER-AM CANCER SOC, V7, P245, DOI 10.1002/1097-0142(195403)7:2<245::AID-CNCR2820070206>3.0.CO;2-V; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; YATES F, 1948, BIOMETRIKA, V35, P176, DOI 10.1093/biomet/35.1-2.176	12	64	70	2	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1529	1533		10.1136/bmj.328.7455.1529	http://dx.doi.org/10.1136/bmj.328.7455.1529			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217868	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000222392700016
J	Pathak, A; Senard, JM; Bujaud, T; Bagheri, H; Lapeyre-Mestre, M; Tressieres, MC; Montastruc, JL				Pathak, A; Senard, JM; Bujaud, T; Bagheri, H; Lapeyre-Mestre, M; Tressieres, MC; Montastruc, JL			Clinical picture - Medication error caused by confusing drug blisters	LANCET			English	Editorial Material									Fac Med Toulouse, Serv Pharmacol Clin, F-31073 Toulouse 7, France; Clin Claude Bernard, Serv Cardiol, F-81030 Albi, France		Pathak, A (corresponding author), Fac Med Toulouse, Serv Pharmacol Clin, BP 7202, F-31073 Toulouse 7, France.		Pathak, Atul/E-7532-2010; Lapeyre-Mestre, Maryse/C-8710-2012; Pathak, Atul/ABC-5223-2020	Lapeyre-Mestre, Maryse/0000-0002-5494-5873; Pathak, Atul/0000-0001-6151-0096; Senard, Jean-Michel/0000-0001-7679-1281					0	9	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2142	2142		10.1016/S0140-6736(04)16507-0	http://dx.doi.org/10.1016/S0140-6736(04)16507-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220039				2022-12-28	WOS:000222268300014
J	Sutton, MA; Wall, NR; Aakalu, GN; Schuman, EM				Sutton, MA; Wall, NR; Aakalu, GN; Schuman, EM			Regulation of dendritic protein synthesis by miniature synaptic events	SCIENCE			English	Article							LONG-TERM FACILITATION; HIPPOCAMPAL-NEURONS; SYNAPSES; RELEASE; GLUTAMATE; VISUALIZATION; TRANSMISSION; POTENTIATION; TRANSMITTER; PLASTICITY	We examined dendritic protein synthesis after a prolonged blockade of action potentials alone and after a blockade of both action potentials and miniature excitatory synaptic events ( minis). Relative to controls, dendrites exposed to a prolonged blockade of action potentials showed diminished protein synthesis. Dendrites in which both action potentials and minis were blocked showed enhanced protein synthesis, suggesting that minis inhibit dendritic translation. When minis were acutely blocked or stimulated, an immediate increase or decrease, respectively, in dendritic translation was observed. Taken together, these results reveal a role for miniature synaptic events in the acute regulation of dendritic protein synthesis in neurons.	CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Schuman, EM (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA.	schumane@its.caltech.edu	Sutton, Michael/C-6264-2011; Schuman, Erin M/D-6204-2011	Wall, Nicholas/0000-0003-2039-8258; Sutton, Michael/0000-0002-0692-6459				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; Burrone J, 2002, NATURE, V420, P414, DOI 10.1038/nature01242; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; FATT P, 1952, J PHYSIOL-LONDON, V117, P109; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Huber KM, 2000, SCIENCE, V288, P1254, DOI 10.1126/science.288.5469.1254; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johnson OL, 2004, BRAIN RES, V996, P89, DOI 10.1016/j.brainres.2003.10.011; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MURPHY TH, 1995, NEURON, V15, P159, DOI 10.1016/0896-6273(95)90073-X; MURPHY TH, 1994, SCIENCE, V263, P529, DOI 10.1126/science.7904774; MURPHY TH, 1994, J NEUROSCI, V14, P1320, DOI 10.1523/JNEUROSCI.14-03-01320.1994; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Murthy VN, 2000, P NATL ACAD SCI USA, V97, P901, DOI 10.1073/pnas.97.2.901; Ostroff LE, 2002, NEURON, V35, P535, DOI 10.1016/S0896-6273(02)00785-7; POULAIN B, 1995, CLOSTRIDIAL NEUROTOX, P243; Saitoe M, 2001, SCIENCE, V293, P514, DOI 10.1126/science.1061270; Scheetz AJ, 2000, NAT NEUROSCI, V3, P211, DOI 10.1038/72915; Sharma G, 2003, NEURON, V38, P929, DOI 10.1016/S0896-6273(03)00322-2; Sherff CM, 1999, SCIENCE, V285, P1911, DOI 10.1126/science.285.5435.1911; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Zhang XH, 2002, NEURON, V36, P675, DOI 10.1016/S0896-6273(02)01023-1	29	196	198	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1979	1983		10.1126/science.1096202	http://dx.doi.org/10.1126/science.1096202			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218151				2022-12-28	WOS:000222241600049
J	Yasutomi, S; Morita, T; Imanishi, Y; Kimura, S				Yasutomi, S; Morita, T; Imanishi, Y; Kimura, S			A molecular photodiode system that can switch photocurrent direction	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; ELECTRON-TRANSFER; HELICAL-PEPTIDES; GOLD SURFACE; SPECTROSCOPY; GENERATION; DIPOLE	We prepared a molecular photodiode system in which the photocurrent direction can be switched by choosing the wavelength of an irradiating light. The molecular system is composed of two types of helical peptides that carry different chromophores and have different directions of dipole moments when they are immobilized on gold. The mixed, self-assembled monolayer generated an anodic photocurrent when one of the two chromophores was photoexcited, whereas the photocurrent switched to being cathodic when the other chromophore was photoexcited. The opposite current response arises from the dipole moment of each helical peptide, which accelerates electron transfer in the same direction.	Kyoto Univ, Grad Sch Engn, Dept Chem Mat, Nishikyo Ku, Kyoto 6158510, Japan	Kyoto University	Kimura, S (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Chem Mat, Nishikyo Ku, Kyoto 6158510, Japan.	shun@scl.kyoto-u.ac.jp						Adams DM, 2003, J PHYS CHEM B, V107, P6668, DOI 10.1021/jp0268462; BAIN CD, 1988, SCIENCE, V240, P62, DOI 10.1126/science.240.4848.62; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Davis WB, 1998, NATURE, V396, P60, DOI 10.1038/23912; Dudek SP, 2001, J AM CHEM SOC, V123, P8033, DOI 10.1021/ja0043340; FINKLEA HO, 1992, J AM CHEM SOC, V114, P3173, DOI 10.1021/ja00035a001; Fujita K, 1998, LANGMUIR, V14, P6167, DOI 10.1021/la9801155; Galoppini E, 1996, J AM CHEM SOC, V118, P2299, DOI 10.1021/ja951555a; GREMLICH HU, 1983, BIOCHEMISTRY-US, V22, P4257, DOI 10.1021/bi00287a015; Huang Y, 2001, SCIENCE, V294, P1313, DOI 10.1126/science.1066192; Imahori H, 2000, J PHYS CHEM B, V104, P2099, DOI 10.1021/jp993784f; Imanishi Y, 1999, P JPN ACAD B-PHYS, V75, P287, DOI 10.2183/pjab.75.287; KENNEDY DF, 1991, BIOCHEMISTRY-US, V30, P6541, DOI 10.1021/bi00240a026; Metzger RM, 1997, J AM CHEM SOC, V119, P10455, DOI 10.1021/ja971811e; Miura Y, 1998, LANGMUIR, V14, P6935, DOI 10.1021/la981296d; Morita T, 2000, J AM CHEM SOC, V122, P2850, DOI 10.1021/ja992769l; NUZZO RG, 1983, J AM CHEM SOC, V105, P4481, DOI 10.1021/ja00351a063; Poirier GE, 1997, CHEM REV, V97, P1117, DOI 10.1021/cr960074m; Sisido M, 2001, J PHYS CHEM B, V105, P10407, DOI 10.1021/jp011180h; Ulman A, 1996, CHEM REV, V96, P1533, DOI 10.1021/cr9502357; Uosaki K, 1997, J AM CHEM SOC, V119, P8367, DOI 10.1021/ja970945p	21	269	278	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1944	1947		10.1126/science.1098489	http://dx.doi.org/10.1126/science.1098489			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218144				2022-12-28	WOS:000222241600039
J	Etzioni, R; Thomas, DB				Etzioni, R; Thomas, DB			Modelling the effect of screening for cervical cancer on the population	LANCET			English	Editorial Material							PROSTATE-CANCER; AGE-PERIOD; TEMPORAL VARIATION; COHORT MODELS; MORTALITY; TRENDS; RATES		Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Thomas, DB (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.	dbthomas@fhcrc.org						CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; CLAYTON D, 1987, STAT MED, V6, P469, DOI 10.1002/sim.4780060406; Farkas A, 1998, UROLOGY, V52, P444, DOI 10.1016/S0090-4295(98)00242-8; FEUER EJ, IN PRESS STAT METHOD; Frankel S, 2003, LANCET, V361, P1122, DOI 10.1016/S0140-6736(03)12890-5; Goldie SJ, 2004, OBSTET GYNECOL, V103, P619, DOI 10.1097/01.AOG.0000120143.50098.c7; Lu-Yao G, 2002, BMJ-BRIT MED J, V325, P740, DOI 10.1136/bmj.325.7367.740; Raffle AE, 2003, BRIT MED J, V326, P901, DOI 10.1136/bmj.326.7395.901; Sasieni P, 1999, BRIT MED J, V318, P1244; STROUP DF, 2004, MONITORING HLTH POPU	10	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					224	226		10.1016/S0140-6736(04)16687-7	http://dx.doi.org/10.1016/S0140-6736(04)16687-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262081				2022-12-28	WOS:000222784900004
J	Singh, JA				Singh, JA			Genocide: burden of proof and inaction is costing lives in Sudan	LANCET			English	Editorial Material									Univ KwaZulu Natal Durban, CAPRISA, ZA-4013 Durban, South Africa; Univ KwaZulu Natal Durban, Howard Coll Sch Law, ZA-4013 Durban, South Africa	University of Kwazulu Natal; University of Kwazulu Natal	Singh, JA (corresponding author), Univ KwaZulu Natal Durban, Howard Coll Sch Law, ZA-4013 Durban, South Africa.	singhj9@ukzn.ac.za	Singh, Jerome Amir/ABG-1573-2021					*AMN INT, SUD DARF TOO MAN PEO; ARIEF I, 2004, ANNAN VISIT SUDAN PR; *HUM RIGHTS WATCH, 2004, DARF DESTR ETHN CLEA; SAUNDERS D, 2004, IS BRUTALITY SUDAN G; *UN, UN CONF MASS HUM CRI; *UN CHILDR FUND EX, REP EX BOARD UN CHIL; United Nations General Assembly, 1948, CONV PREV PUN CRIM G; WHO, 2004, HLTH ASP HUM CRIS GR	8	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					230	231		10.1016/S0140-6736(04)16691-9	http://dx.doi.org/10.1016/S0140-6736(04)16691-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262085	Green Submitted			2022-12-28	WOS:000222784900008
J	Dobbelaere, J; Barral, Y				Dobbelaere, J; Barral, Y			Spatial coordination of cytokinetic events by compartmentalization of the cell cortex	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; POLARIZED SECRETION; YEAST CYTOKINESIS; SEPTIN DYNAMICS; FISSION YEAST; BUDDING YEAST; RING; MORPHOGENESIS; ACTOMYOSIN; SEC3P	During cytokinesis, furrow ingression and plasma membrane fission irreversibly separate daughter cells. How actomyosin ring assembly and contraction, vesicle fusion, and abscission are spatially coordinated was unknown. We found that during cytokinesis septin rings, located on both sides of the actomyosin ring, acted as barriers to compartmentalize the cortex around the cleavage site. Compartmentalization maintained diffusible cortical factors, such as the exocyst and the polarizome, to the site of cleavage. In turn, such factors were required for actomyosin ring function and membrane abscission. Thus, a specialized cortical compartment ensures the spatial coordination of cytokinetic events.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Barral, Y (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland.	yves.barral@bc.biol.ethz.ch		Barral, Yves/0000-0002-0989-3373; Dobbelaere, Jeroen/0000-0002-6727-532X				Barral Y, 2000, MOL CELL, V5, P841, DOI 10.1016/S1097-2765(00)80324-X; Berlin A, 2003, J CELL BIOL, V160, P1083, DOI 10.1083/jcb.200212016; Bi E, 1998, J CELL BIOL, V142, P1301, DOI 10.1083/jcb.142.5.1301; Dobbelaere J, 2003, DEV CELL, V4, P345, DOI 10.1016/S1534-5807(03)00061-3; Faty M, 2002, CURR GENET, V41, P123, DOI 10.1007/s00294-002-0304-0; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Jantsch-Plunger V, 1999, CURR BIOL, V9, P738, DOI 10.1016/S0960-9822(99)80333-9; Karpova TS, 2000, MOL BIOL CELL, V11, P1727, DOI 10.1091/mbc.11.5.1727; Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182; Kinoshita M, 2001, CELL STRUCT FUNCT, V26, P667, DOI 10.1247/csf.26.667; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; Lippincott J, 2001, J CELL SCI, V114, P1379; Longtine MS, 2003, TRENDS CELL BIOL, V13, P403, DOI 10.1016/S0962-8924(03)00151-X; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Low SH, 2003, DEV CELL, V4, P753, DOI 10.1016/S1534-5807(03)00122-9; Robinson DN, 2000, TRENDS CELL BIOL, V10, P228, DOI 10.1016/S0962-8924(00)01747-5; SHAW JA, 1991, J CELL BIOL, V114, P111, DOI 10.1083/jcb.114.1.111; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Takizawa PA, 2000, SCIENCE, V290, P341, DOI 10.1126/science.290.5490.341; Tasto JJ, 2003, J CELL BIOL, V160, P1093, DOI 10.1083/jcb.200211126; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Tolliday N, 2001, CURR OPIN MICROBIOL, V4, P690, DOI 10.1016/S1369-5274(01)00270-3; Zeitlin SG, 2001, CURR BIOL, V11, pR514, DOI 10.1016/S0960-9822(01)00307-4	26	214	220	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					393	396		10.1126/science.1099892	http://dx.doi.org/10.1126/science.1099892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256669				2022-12-28	WOS:000222662400037
J	Smith, DJ; Lapedes, AS; de Jong, JC; Bestebroer, TM; Rimmelzwaan, GF; Osterhaus, ADME; Fouchier, RAM				Smith, DJ; Lapedes, AS; de Jong, JC; Bestebroer, TM; Rimmelzwaan, GF; Osterhaus, ADME; Fouchier, RAM			Mapping the antigenic and genetic evolution of influenza virus	SCIENCE			English	Article							T-LYMPHOCYTE ESCAPE; HEMAGGLUTININ; SELECTION; DYNAMICS	The antigenic evolution of influenza A (H3N2) virus was quantified and visualized from its introduction into humans in 1968 to 2003. Although there was remarkable correspondence between antigenic and genetic evolution, significant differences were observed: Antigenic evolution was more punctuated than genetic evolution, and genetic change sometimes had a disproportionately large antigenic effect. The method readily allows monitoring of antigenic differences among vaccine and circulating strains and thus estimation of the effects of vaccination. Further, this approach offers a route to predicting the relative success of emerging strains, which could be achieved by quantifying the combined effects of population level immune escape and viral fitness on strain evolution.	Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Erasmus MC, Natl Influenza Ctr, NL-3015 GE Rotterdam, Netherlands; Erasmus MC, Dept Virol, NL-3015 GE Rotterdam, Netherlands; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	University of Cambridge; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; United States Department of Energy (DOE); Los Alamos National Laboratory	Smith, DJ (corresponding author), Univ Cambridge, Dept Zool, Downing St, Cambridge CB2 3EJ, England.	dsmith@zoo.cam.ac.uk	Smith, Derek/Z-3075-2019; Fouchier, Ron A/A-1911-2014	Smith, Derek/0000-0002-2393-1890; Fouchier, Ron A/0000-0001-8095-2869; Osterhaus, Albert/0000-0002-6074-1172				Alexander DJ, 1997, AVIAN PATHOL, V26, P399, DOI 10.1080/03079459708419222; BOTH GW, 1983, J VIROL, V48, P52, DOI 10.1128/JVI.48.1.52-60.1983; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Bush RM, 1999, SCIENCE, V286, P1921, DOI 10.1126/science.286.5446.1921; Daly JM, 1996, J GEN VIROL, V77, P661, DOI 10.1099/0022-1317-77-4-661; Dekker A, 1995, VET MICROBIOL, V47, P317, DOI 10.1016/0378-1135(95)00116-6; EDELSTEIN L, 1978, J THEOR BIOL, V73, P181, DOI 10.1016/0022-5193(78)90185-6; Ferguson NM, 2003, NATURE, V422, P428, DOI 10.1038/nature01509; Gog JR, 2003, P NATL ACAD SCI USA, V100, P11143, DOI 10.1073/pnas.1830296100; Gog JR, 2002, P NATL ACAD SCI USA, V99, P17209, DOI 10.1073/pnas.252512799; Hampson AW, 2002, PERSP MED V, V7, P49; Hay AJ, 2001, PHILOS T R SOC B, V356, P1861, DOI 10.1098/rstb.2001.0999; Hirst GK, 1943, J EXP MED, V78, p4O7, DOI 10.1084/jem.78.5.407; Kilbourne ED, 2002, P NATL ACAD SCI USA, V99, P10748, DOI 10.1073/pnas.162366899; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; KRUSKAL JB, 1964, PSYCHOMETRIKA, V29, P1, DOI 10.1007/BF02289565; Lapedes A, 2001, J THEOR BIOL, V212, P57, DOI 10.1006/jtbi.2001.2347; LENNETTE DA, 1995, DIAGNOSTIC PROCEDURE; Macken C, 2001, INT CONGR SER, V1219, P103, DOI 10.1016/S0531-5131(01)00330-2; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; PERELSON AS, 1979, J THEOR BIOL, V81, P645, DOI 10.1016/0022-5193(79)90275-3; Plotkin JB, 2002, P NATL ACAD SCI USA, V99, P6263, DOI 10.1073/pnas.082110799; RENFELL BT, 2004, SCIENCE, V303, P327; Richman DD, 2003, P NATL ACAD SCI USA, V100, P4144, DOI 10.1073/pnas.0630530100; SALK JE, 1949, AM J PUBLIC HEALTH, V39, P345, DOI 10.2105/AJPH.39.3.345; SHEPARD RN, 1963, HUM FACTORS, V5, P33, DOI 10.1177/001872086300500104; Smith D.J., 1993, ARTIFICIAL IMMUNE SY, P105; Smith DJ, 1999, P NATL ACAD SCI USA, V96, P14001, DOI 10.1073/pnas.96.24.14001; Sneath P.H.A., 1973, NUMERICAL TAXONOMY P; Stohr K, 2002, LANCET INFECT DIS, V2, P517, DOI 10.1016/S1473-3099(02)00366-3; UNDERWOOD PA, 1982, J GEN VIROL, V62, P153, DOI 10.1099/0022-1317-62-1-153; WEIJERS TF, 1985, J VIROL METHODS, V10, P241, DOI 10.1016/0166-0934(85)90064-3; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0	34	1144	1198	6	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					371	376		10.1126/science.1097211	http://dx.doi.org/10.1126/science.1097211			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15218094				2022-12-28	WOS:000222662400031
J	Sladden, MJ; Johnson, G				Sladden, MJ; Johnson, G			Common skin infections in children	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MOLLUSCUM CONTAGIOSUM; EPIDEMIOLOGY; GRISEOFULVIN; TERBINAFINE; MANAGEMENT; WARTS		Leicester Royal Infirm, Univ Hosp Leicester NHS Trust, Dept Dermatol, Leicester LE1 5WW, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester	Sladden, MJ (corresponding author), Leicester Royal Infirm, Univ Hosp Leicester NHS Trust, Dept Dermatol, Leicester LE1 5WW, Leics, England.	m.sladden@doctors.org.uk						ALY R, 1994, J AM ACAD DERMATOL, V31, pS21, DOI 10.1016/S0190-9622(08)81262-5; Bayerl C, 2003, BRIT J DERMATOL, V149, P25, DOI 10.1046/j.0366-077X.2003.05631.x; BRONSON DM, 1983, J AM ACAD DERMATOL, V8, P322, DOI 10.1016/S0190-9622(83)70034-4; BRUIJNZEELS MA, 1993, CHILD GEN PRACTICE D; Caceres-Rios H, 2000, J AM ACAD DERMATOL, V42, P80, DOI 10.1016/S0190-9622(00)90013-6; DAGAN R, 1993, PEDIATR ANN, V22, P235, DOI 10.3928/0090-4481-19930401-07; FEINGOLD DS, 1993, SEMIN DERMATOL, V12, P331; FINDLAY GH, 1974, BRIT J DERMATOL, V91, P379, DOI 10.1111/j.1365-2133.1974.tb13075.x; Fuller LC, 2003, BMJ-BRIT MED J, V326, P539, DOI 10.1136/bmj.326.7388.539; Fuller LC, 2003, BRIT J DERMATOL, V148, P985, DOI 10.1046/j.1365-2133.2003.05022.x; Fuller LC, 2001, BRIT J DERMATOL, V144, P321, DOI 10.1046/j.1365-2133.2001.04022.x; Gibbs S, 2002, BMJ-BRIT MED J, V325, P461, DOI 10.1136/bmj.325.7362.461; Gibbs S., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001781; GONZALEZ U, 2004, COCHRANE LIB; Gupta AK, 2001, PEDIATR DERMATOL, V18, P433, DOI 10.1046/j.1525-1470.2001.01978.x; HAYDEN GF, 1985, AM J DIS CHILD, V139, P36, DOI 10.1001/archpedi.1985.02140030038023; Higgins EM, 2000, BRIT J DERMATOL, V143, P53, DOI 10.1046/j.1365-2133.2000.03530.x; Hlady W G, 1986, Alaska Med, V28, P99; KONING S, 1994, BRIT J GEN PRACT, V44, P417; Koning S, 2004, COCHRANE DB SYST REV, V2; Ormerod AD, 1999, BRIT J DERMATOL, V141, P1051, DOI 10.1046/j.1365-2133.1999.03204.x; RESNICK SD, 2000, TXB PEDIAT DERMATOLO, P369; Rogers M., 1998, FORFAR ARNEILS TXB P, P1633; Sterling JC, 1998, ROOK TXB DERMATOLOGY; Tunnessen W W Jr, 1984, Pediatr Dermatol, V1, P219, DOI 10.1111/j.1525-1470.1984.tb01120.x; VANDERWOUDEN JC, 2004, COCHRANE LIB; Weller R, 1999, BRIT MED J, V319, P1540, DOI 10.1136/bmj.319.7224.1540; WILLIAMS HC, 1993, BRIT J DERMATOL, V128, P504, DOI 10.1111/j.1365-2133.1993.tb00226.x	28	65	67	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					95	99		10.1136/bmj.329.7457.95	http://dx.doi.org/10.1136/bmj.329.7457.95			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242915	Green Published			2022-12-28	WOS:000222645000028
J	Liang, HE; Hsu, LY; Cado, D; Schlissel, MS				Liang, HE; Hsu, LY; Cado, D; Schlissel, MS			Variegated transcriptional activation of the immunoglobulin kappa locus in pre-B cells contributes to the allelic exclusion of light-chain expression	CELL			English	Article							V(D)J RECOMBINATION; DIFFERENTIATION; REARRANGEMENT; FREQUENCIES; PROBABILITY; ENHANCERS; INCREASE; GENES; MICE; DNA	Regulated gene rearrangement is thought to underlie allelic exclusion, the observation that an individual B cell expresses only a single immunoglobulin molecule. Previous data has implicated transcriptional activation of rearranging loci in the regulation of their accessibility to the V(D)J recombinase. Using homologous recombination in ES cells, we have generated "knockin" mice which express a GFP cDNA from an unrearranged immunoglobulin kappa light-chain allele. Surprisingly, we find that only a small fraction of kappa alleles are highly transcribed in a population of pre-B cells, that such transcription is monoallelic, and that these highly transcribed alleles account for the vast majority of kappa light-chain gene rearrangement. These data lead us to suggest that probabilistic enhancer activation and allelic competition are part of the mechanism of kappa locus allelic exclusion and may be a general mechanism contributing to cellular differentiation during development.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Schlissel, MS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.	mss@uclink4.berkeley.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040227, R01AI040227] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48702] Funding Source: Medline; NIAID NIH HHS [AI40227] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boyes J, 1996, EMBO J, V15, P2496, DOI 10.1002/j.1460-2075.1996.tb00607.x; Casellas R, 2002, CELL, V110, P575, DOI 10.1016/S0092-8674(02)00911-X; Goldmit M, 2002, EMBO J, V21, P5255, DOI 10.1093/emboj/cdf518; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; MARTIN DJ, 1990, MOL CELL BIOL, V10, P1950, DOI 10.1128/MCB.10.5.1950; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Muljo SA, 2000, IMMUNOL REV, V175, P80, DOI 10.1034/j.1600-065X.2000.017509.x; NISHI M, 1985, P NATL ACAD SCI USA, V82, P6399, DOI 10.1073/pnas.82.19.6399; Osmond D G, 1990, Semin Immunol, V2, P173; Pelanda R, 1996, IMMUNITY, V5, P229, DOI 10.1016/S1074-7613(00)80318-0; PERRY RP, 1980, P NATL ACAD SCI-BIOL, V77, P1937, DOI 10.1073/pnas.77.4.1937; Schlissel MS, 2003, NAT REV IMMUNOL, V3, P890, DOI 10.1038/nri1225; SCHLISSEL MS, 1994, J IMMUNOL, V153, P1645; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; Shaffer AL, 1997, IMMUNITY, V6, P131, DOI 10.1016/S1074-7613(00)80420-3; Shykind BM, 2004, CELL, V117, P801, DOI 10.1016/j.cell.2004.05.015; Singh N, 2003, J EXP MED, V197, P743, DOI 10.1084/jem.20021392; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Stoddart A, 2001, EUR J IMMUNOL, V31, P1160, DOI 10.1002/1521-4141(200104)31:4<1160::AID-IMMU1160>3.0.CO;2-T; VICTOR KD, 1994, J IMMUNOL, V152, P3467; WALTERS MC, 1995, P NATL ACAD SCI USA, V92, P7125, DOI 10.1073/pnas.92.15.7125; WOOD DL, 1984, P NATL ACAD SCI-BIOL, V81, P4756, DOI 10.1073/pnas.81.15.4756; Yamagami T, 1999, IMMUNITY, V11, P317, DOI 10.1016/S1074-7613(00)80107-7	28	68	68	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					19	29		10.1016/j.cell.2004.06.019	http://dx.doi.org/10.1016/j.cell.2004.06.019			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242641	Bronze			2022-12-28	WOS:000222626800005
J	Offerman, SE				Offerman, SE			Microstructures in 4D	SCIENCE			English	Editorial Material									Delft Univ Technol, Dept Mat Sci & Engn, NL-2628 AL Delft, Netherlands	Delft University of Technology	Offerman, SE (corresponding author), Delft Univ Technol, Dept Mat Sci & Engn, Rotterdamseweg 137, NL-2628 AL Delft, Netherlands.	S.E.Offerman@tnw.tudelft.nl						[Anonymous], 1991, INTRO POLYM; Hall J.P., 1954, CAN J METALLURGY, V26, P254; Kral MV, 2000, MATER CHARACT, V45, P17, DOI 10.1016/S1044-5803(00)00046-2; Larbalestier D, 2001, NATURE, V414, P368, DOI 10.1038/35104654; Onink M, 1995, J MATER SCI, V30, P6223, DOI 10.1007/BF00369670; Schmidt S, 2004, SCIENCE, V305, P229, DOI 10.1126/science.1098627	6	6	6	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					190	191		10.1126/science.1100682	http://dx.doi.org/10.1126/science.1100682			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247464				2022-12-28	WOS:000222501000035
J	Zhuang, XW				Zhuang, XW			Unraveling DNA condensation with optical tweezers	SCIENCE			English	Editorial Material							SINGLE-MOLECULE; RNA-POLYMERASE; TITIN; FORCE; CHROMOSOME; ELASTICITY; MOTOR		Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA	Harvard University; Harvard University	Zhuang, XW (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	zhuang@chemistry.harvard.edu						ASHKIN A, 1986, OPT LETT, V11, P288, DOI 10.1364/OL.11.000288; Brower-Toland BD, 2002, P NATL ACAD SCI USA, V99, P1960, DOI 10.1073/pnas.022638399; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Case RB, 2004, SCIENCE, V305, P222, DOI 10.1126/science.1098225; Davenport RJ, 2000, SCIENCE, V287, P2497, DOI 10.1126/science.287.5462.2497; HIRANO M, 2004, EMBO J; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; MAIER B, 2004, NAT STRUCT MOL BIOL; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Onoa B, 2003, SCIENCE, V299, P1892, DOI 10.1126/science.1081338; Perkins TT, 2003, SCIENCE, V301, P1914, DOI 10.1126/science.1088047; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Shaevitz JW, 2003, NATURE, V426, P684, DOI 10.1038/nature02191; Sherratt DJ, 2003, SCIENCE, V301, P780, DOI 10.1126/science.1084780; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Strick TR, 2000, NATURE, V404, P901, DOI 10.1038/35009144; Strick TR, 2004, CURR BIOL, V14, P874, DOI 10.1016/j.cub.2004.04.038; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Swedlow JR, 2003, MOL CELL, V11, P557, DOI 10.1016/S1097-2765(03)00103-5; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wuite GJL, 2000, NATURE, V404, P103, DOI 10.1038/35003614; Zhuang XW, 2003, CURR OPIN STRUC BIOL, V13, P88, DOI 10.1016/S0959-440X(03)00011-3	24	47	47	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					188	190		10.1126/science.1100603	http://dx.doi.org/10.1126/science.1100603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247463				2022-12-28	WOS:000222501000034
J	Harter, AV; Gardner, KA; Falush, D; Lentz, DL; Bye, RA; Rieseberg, LH				Harter, AV; Gardner, KA; Falush, D; Lentz, DL; Bye, RA; Rieseberg, LH			Origin of extant domesticated sunflowers in eastern North America	NATURE			English	Article							MULTILOCUS GENOTYPE DATA; HELIANTHUS-ANNUUS; AGRICULTURE; ASTERACEAE; INFERENCE; EVOLUTION; RELATIVES; PLANT	Eastern North America is one of at least six regions of the world where agriculture is thought to have arisen wholly independently(1-5). The primary evidence for this hypothesis derives from morphological changes in the archaeobotanical record of three important crops-squash, goosefoot and sunflower-as well as an extinct minor cultigen, sumpweed(1,3). However, the geographical origins of two of the three primary domesticates squash and goosefoot-are now debated(6,7), and until recently sunflower ( Helianthus annuus L.) has been considered the only undisputed eastern North American domesticate. The discovery of 4,000-year-old domesticated sunflower remains from San Andres, Tabasco(8,9), implies an earlier and possibly independent origin of domestication in Mexico and has stimulated a re-examination of the geographical origin of domesticated sunflower. Here we describe the genetic relationships and pattern of genetic drift between extant domesticated strains and wild populations collected from throughout the USA and Mexico. We show that extant domesticates arose in eastern North America, with a substantial genetic bottleneck(10) occurring during domestication.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Oxford, Oxford OX1 3SY, England; Chicago Bot Garden, Glencoe, IL 60022 USA; Univ Nacl Autonoma Mexico, Inst Biol, Jardin Bot Exterior, Mexico City 04510, DF, Mexico	Indiana University System; Indiana University Bloomington; University of Oxford; Universidad Nacional Autonoma de Mexico	Harter, AV (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.	avharter@bio.indiana.edu	Rieseberg, Loren H/B-3591-2013	Rieseberg, Loren H/0000-0002-2712-2417; Lentz, David/0000-0003-0516-7654	Wellcome Trust [069662] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARIAS DM, 1995, ECON BOT, V49, P239, DOI 10.1007/BF02862340; ASCH DL, P 58 ANN M 17 MAY 19; BREWER AJ, 1973, MISCELLANEOUS PAPERS, V12, P141; COWAN CW, 1992, ORIGINS AGR INT PERS, P207; CRITES GD, 1993, AM ANTIQUITY, V58, P146, DOI 10.2307/281459; Cronn R, 1997, THEOR APPL GENET, V95, P532, DOI 10.1007/s001220050594; DETAPIA EM, 1992, ORIGINS AGR INT PERS, P144; Diamond J, 2002, NATURE, V418, P700, DOI 10.1038/nature01019; Falush D, 2003, GENETICS, V164, P1567; Fritz G. J., 1997, PEOPLE PLANTS LANDSC, P42; Goudet J, 1995, J HERED, V86, P485, DOI 10.1093/oxfordjournals.jhered.a111627; HEISER C B JR, 1969, Memoirs of the Torrey Botanical Club, V22, P1; HEISER C. B. JUN., 1951, Proceedings of the American Philosophical Society, V95, P432; HEISER CB, 1954, AM MIDL NAT, V51, P287, DOI 10.2307/2422222; Lentz DL, 2001, ECON BOT, V55, P370, DOI 10.1007/BF02866560; Neumann K, 2003, SCIENCE, V301, P180, DOI 10.1126/science.1086677; Ota T, 1993, DISPAN GENETIC DISTA; Pope KO, 2001, SCIENCE, V292, P1370, DOI 10.1126/science.292.5520.1370; Pritchard JK, 2000, GENETICS, V155, P945; RIESEBERG LH, 1990, ECON BOT, V44, P79, DOI 10.1007/BF02860477; Sanjur OI, 2002, P NATL ACAD SCI USA, V99, P535, DOI 10.1073/pnas.012577299; SMITH BD, 1989, SCIENCE, V246, P1566, DOI 10.1126/science.246.4937.1566; SMITH BD, 2002, RIVER CHANGE ESSAYS; Tang SX, 2003, THEOR APPL GENET, V106, P990, DOI 10.1007/s00122-002-1127-6; WILSON HD, 1990, ECON BOT, V44, P92, DOI 10.1007/BF02860478; YARNELL RA, 1993, ANTHR PAPERS, V67, P289	26	139	146	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					201	205		10.1038/nature02710	http://dx.doi.org/10.1038/nature02710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241413				2022-12-28	WOS:000222470600042
J	Kaufman, DS; McDougal, WS; Zietman, AL; Harisinghani, MG; Young, RH; Shipley, WU; Gomery, P; Harisinghani, MG; Smith, MR; Michaelson, D; Althausen, AF; Talcott, J				Kaufman, DS; McDougal, WS; Zietman, AL; Harisinghani, MG; Young, RH; Shipley, WU; Gomery, P; Harisinghani, MG; Smith, MR; Michaelson, D; Althausen, AF; Talcott, J			A man with metastatic prostate carcinoma refractory to hormone therapy - Adenocarcinoma of the prostate with metastases	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							RADICAL PROSTATECTOMY; RADIATION-THERAPY; SEXUAL FUNCTION; CANCER; RADIOTHERAPY; TRIAL; ESTRAMUSTINE; MITOXANTRONE; SYMPTOMS; SURVIVAL		Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Urol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University; Harvard University; Harvard University	Kaufman, DS (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA 02114 USA.		Harisinghani, Mukesh/G-1347-2010; Harisinghani, Mukesh/D-7590-2011; Talcott, James/CAG-8759-2022					FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; Fowler FJ, 2000, JAMA-J AM MED ASSOC, V283, P3217, DOI 10.1001/jama.283.24.3217; Hanlon AL, 2001, INT J RADIAT ONCOL, V49, P51, DOI 10.1016/S0360-3016(00)01365-1; Hudes GR, 1997, J CLIN ONCOL, V15, P3156, DOI 10.1200/JCO.1997.15.9.3156; Hull GW, 2002, J UROLOGY, V167, P528, DOI 10.1016/S0022-5347(01)69079-7; Kantoff PW, 1999, J CLIN ONCOL, V17, P2506, DOI 10.1200/JCO.1999.17.8.2506; Kuban DA, 2003, INT J RADIAT ONCOL, V57, P915, DOI 10.1016/S0360-3016(03)00632-1; Messing EM, 1999, NEW ENGL J MED, V341, P1781, DOI 10.1056/NEJM199912093412401; Michalski JM, 2000, INT J RADIAT ONCOL, V46, P391, DOI 10.1016/S0360-3016(99)00443-5; Morris AD, 2001, UROL ONCOL, V6, P255, DOI 10.1016/S1078-1439(01)00122-3; Petrylak DP, 1999, J CLIN ONCOL, V17, P958, DOI 10.1200/JCO.1999.17.3.958; Pilepich MV, 2001, INT J RADIAT ONCOL, V50, P1243, DOI 10.1016/S0360-3016(01)01579-6; Pollack A, 2000, J CLIN ONCOL, V18, P3904, DOI 10.1200/JCO.2000.18.23.3904; QUINLAN DM, 1991, J UROLOGY, V145, P998, DOI 10.1016/S0022-5347(17)38512-9; SANDS ME, 1995, INT J RADIAT ONCOL, V31, P13, DOI 10.1016/0360-3016(94)00324-E; Shipley WU, 1999, JAMA-J AM MED ASSOC, V281, P1598, DOI 10.1001/jama.281.17.1598; Smith MR, 2002, CANCER METAST REV, V21, P159, DOI 10.1023/A:1020840311573; Stanford JL, 2000, JAMA-J AM MED ASSOC, V283, P354, DOI 10.1001/jama.283.3.354; Talcott JA, 1998, J CLIN ONCOL, V16, P275, DOI 10.1200/JCO.1998.16.1.275; Tannock IF, 1996, J CLIN ONCOL, V14, P1756, DOI 10.1200/JCO.1996.14.6.1756; Yock TI, 2002, INT J RADIAT ONCOL, V54, P420, DOI 10.1016/S0360-3016(02)02957-7	21	1	1	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					171	178		10.1056/NEJMcpc049010	http://dx.doi.org/10.1056/NEJMcpc049010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247358				2022-12-28	WOS:000222470700012
J	Guise, JM; McDonagh, MS; Osterweil, P; Nygren, P; Chan, BKS; Helfand, M				Guise, JM; McDonagh, MS; Osterweil, P; Nygren, P; Chan, BKS; Helfand, M			Systematic review of the incidence and consequences of uterine rupture in women with previous caesarean section	BMJ-BRITISH MEDICAL JOURNAL			English	Review							VAGINAL BIRTH; LABOR; TRIAL; DELIVERY; RISK; MULTICENTER	Objective To evaluate the incidence and consequences of uterine rupture in women who have had a delivery by caesarean section. Design Systematic review. Data sources Medline, HealthSTAR, Cochrane Database of Systematic Reviews, Cochrane Controlled Trials Register, National Centre for Reviews and Dissemination, reference lists, and national experts. Studies in all languages were eligible if published in full. Review methods Methodological quality was evaluated for each study by using criteria from the United States Preventive Services Task Force and the National Health Service Centre for Reviews and Dissemination. Uterine rupture was categorised as asymptomatic or symptomatic. Results We reviewed 568 full text articles to identify 71 potentially eligible studies, 21 of which were rated at least fair in quality. Compared with elective repeat caesarean delivery, trial of labour increased the risk of uterine rupture by 2.7 (95% confidence interval 0.73 to 4.73) per 1000 cases. No maternal deaths were related to rupture. For women attempting vaginal delivery, the additional risk of perinatal death from rupture of a uterine scar was 1.4 (0 to 9.8) per 10 000 and the additional risk of hysterectomy was 3.4 (0 to 12.6) per 10 000. The rates of asymptomatic uterine rupture in trial of labour and elective repeat caesarean did not differ significantly. Conclusions Although the literature on uterine rupture is imprecise and inconsistent, existing studies indicate that 370 (213 to 1370) elective caesarean deliveries would need to be performed to prevent one symptomatic uterine rupture.	Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Evidenced Based Practice Ctr, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Guise, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, UHN-50,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	guisej@ohsu.edu		Guise, Jeanne-Marie/0000-0002-8961-488X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS011338] Funding Source: NIH RePORTER; AHRQ HHS [1 K08 HS11338-01] Funding Source: Medline; PHS HHS [290-97-0018] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Blanchette H, 2001, AM J OBSTET GYNECOL, V184, P1478, DOI 10.1067/mob.2001.114852; BLANCO JD, 1992, AM J PERINAT, V9, P80, DOI 10.1055/s-2007-994676; Bujold E, 2002, AM J OBSTET GYNECOL, V186, P311, DOI 10.1067/mob.2002.119923; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P245; Connolly G, 2001, Ir Med J, V94, P176; COWAN RK, 1994, OBSTET GYNECOL, V83, P933, DOI 10.1097/00006250-199406000-00006; CRAGIN EB, 1916, NY STATE J MED, V104, P1; DUFF P, 1988, OBSTET GYNECOL, V71, P380; Flamm BL, 1997, AM J PERINAT, V14, P157, DOI 10.1055/s-2007-994118; FLAMM BL, 1987, OBSTET GYNECOL, V70, P709; Flamm BL, 1997, OBSTET GYNECOL, V90, P312, DOI 10.1016/S0029-7844(97)00263-9; FLAMM BL, 1990, OBSTET GYNECOL, V76, P750, DOI 10.1097/00006250-199011000-00004; FLAMM BL, 1988, AM J OBSTET GYNECOL, V158, P1079, DOI 10.1016/0002-9378(88)90224-4; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; Greene MF, 2001, NEW ENGL J MED, V345, P54, DOI 10.1056/NEJM200107053450108; GUISE J, 2003, VAGINAL BIRTH CESARE; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; KHAN K, 2001, UNDERTAKING SYSTEMAT; LEUNG AS, 1993, AM J OBSTET GYNECOL, V168, P1358, DOI 10.1016/S0002-9378(11)90765-0; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945, DOI 10.1016/0002-9378(93)90032-E; Lydon-Rochelle M, 2001, NEW ENGL J MED, V345, P3, DOI 10.1056/NEJM200107053450101; MARTIN JN, 1983, AM J OBSTET GYNECOL, V146, P255, DOI 10.1016/0002-9378(83)90746-9; McMahon MJ, 1996, NEW ENGL J MED, V335, P689, DOI 10.1056/NEJM199609053351001; MEEHAN FP, 1989, EUR J OBSTET GYN R B, V31, P109, DOI 10.1016/0028-2243(89)90171-8; MEIER PR, 1982, AM J OBSTET GYNECOL, V144, P671, DOI 10.1016/0002-9378(82)90436-7; NIH, 1981, NIH PUBL, V81-2385; PAUL RH, 1985, AM J OBSTET GYNECOL, V151, P297, DOI 10.1016/0002-9378(85)90290-X; PHELAN JP, 1987, AM J OBSTET GYNECOL, V157, P1510, DOI 10.1016/S0002-9378(87)80252-1; Scott JR, 2002, OBSTET GYNECOL, V99, P967, DOI 10.1097/00006250-200206000-00001; Smith GCS, 2002, JAMA-J AM MED ASSOC, V287, P2684, DOI 10.1001/jama.287.20.2684; STOVALL TG, 1987, OBSTET GYNECOL, V70, P713	31	169	178	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					19	23		10.1136/bmj.329.7456.19	http://dx.doi.org/10.1136/bmj.329.7456.19			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231616	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000222568300016
J	Hoge, CW; Castro, CA; Messer, SC; McGurk, D; Cotting, DI; Koffman, RL				Hoge, CW; Castro, CA; Messer, SC; McGurk, D; Cotting, DI; Koffman, RL			Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; UNITED-STATES; GULF-WAR; PREVALENCE; POPULATION; VETERANS; LIFETIME; RISK	Background: The current combat operations in Iraq and Afghanistan have involved U.S. military personnel in major ground combat and hazardous security duty. Studies are needed to systematically assess the mental health of members of the armed services who have participated in these operations and to inform policy with regard to the optimal delivery of mental health care to returning veterans. Methods: We studied members of four U.S. combat infantry units (three Army units and one Marine Corps unit) using an anonymous survey that was administered to the subjects either before their deployment to Iraq (n=2530) or three to four months after their return from combat duty in Iraq or Afghanistan (n=3671). The outcomes included major depression, generalized anxiety, and post-traumatic stress disorder (PTSD), which were evaluated on the basis of standardized, self-administered screening instruments. Results: Exposure to combat was significantly greater among those who were deployed to Iraq than among those deployed to Afghanistan. The percentage of study subjects whose responses met the screening criteria for major depression, generalized anxiety, or PTSD was significantly higher after duty in Iraq (15.6 to 17.1 percent) than after duty in Afghanistan (11.2 percent) or before deployment to Iraq (9.3 percent); the largest difference was in the rate of PTSD. Of those whose responses were positive for a mental disorder, only 23 to 40 percent sought mental health care. Those whose responses were positive for a mental disorder were twice as likely as those whose responses were negative to report concern about possible stigmatization and other barriers to seeking mental health care. Conclusions: This study provides an initial look at the mental health of members of the Army and the Marine Corps who were involved in combat operations in Iraq and Afghanistan. Our findings indicate that among the study groups there was a significant risk of mental health problems and that the subjects reported important barriers to receiving mental health services, particularly the perception of stigma among those most in need of such care.	USA, Dept Psychiat & Behav Sci, Walter Reed Army Inst Res, Med Res & Mat Command, Silver Spring, MD 20910 USA; First Naval Construct Div, Norfolk, VA USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Hoge, CW (corresponding author), USA, Dept Psychiat & Behav Sci, Walter Reed Army Inst Res, Med Res & Mat Command, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	charles.hoge@na.amedd.army.mil	Messer, Stephen/P-2642-2016; Messer, Stephen/GQA-4931-2022	Messer, Stephen/0000-0003-0503-9695; , Dave/0000-0003-1798-5013; McGurk, Dennis/0000-0003-4126-5980				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; [Anonymous], 1988, JAMA, V259, P2701; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Britt TW, 2000, J APPL SOC PSYCHOL, V30, P1599, DOI 10.1111/j.1559-1816.2000.tb02457.x; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Carlier IVE, 1997, J NERV MENT DIS, V185, P498, DOI 10.1097/00005053-199708000-00004; Castro CA, 2000, INT REV ARMED FORCES, V73, P191; *DEPL HLTH CLIN CT, DEPL CYCL SUPP CLIN; FRIEDMAN MJ, 1994, PSYCHIAT CLIN N AM, V17, P265; HELZER JE, 1987, NEW ENGL J MED, V317, P1630, DOI 10.1056/NEJM198712243172604; Henkel V, 2003, BRIT MED J, V326, P200, DOI 10.1136/bmj.326.7382.200; Hoge CW, 2004, PSYCHIAT SERV, V55, P319, DOI 10.1176/appi.ps.55.3.319-b; Hoge CW, 2002, AM J PSYCHIAT, V159, P1576, DOI 10.1176/appi.ajp.159.9.1576; JORDAN BK, 1991, ARCH GEN PSYCHIAT, V48, P207, DOI 10.1001/archpsyc.1991.01810270019002; Kang HK, 2003, AM J EPIDEMIOL, V157, P141, DOI 10.1093/aje/kwf187; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Lowe B, 2004, J AFFECT DISORDERS, V78, P131, DOI 10.1016/S0165-0327(02)00237-9; Menard S., 2002, APPL LOGISTIC REGRES; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Prigerson HG, 2002, AM J PUBLIC HEALTH, V92, P59, DOI 10.2105/AJPH.92.1.59; Prigerson HG, 2001, J NERV MENT DIS, V189, P99, DOI 10.1097/00005053-200102000-00005; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; SCHLENGER WE, 1992, J TRAUMA STRESS, V5, P333, DOI 10.1002/jts.2490050303; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; *VET HLTH ADM, 2000, PUBL VET HLTH ADM; Weathers FW, 1993, INT SOC TRAUMATIC ST; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; Wright KM, 2002, MIL MED, V167, P853, DOI 10.1093/milmed/167.10.853	33	3322	3369	15	438	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					13	22		10.1056/NEJMoa040603	http://dx.doi.org/10.1056/NEJMoa040603			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	833QC	15229303	Green Submitted			2022-12-28	WOS:000222352200005
J	Ahuja, SK; Catano, G				Ahuja, SK; Catano, G			Sharing is caring, except when it comes to HLA-class-I alleles in HIV-1 transmission	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; DISEASE PROGRESSION; TYPE-1 TRANSMISSION; PROTECT MACAQUES; INFECTION; CONCORDANCE; ANTIBODY; ALLOIMMUNIZATION; ALLOANTIBODY; IMMUNIZATION		S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV 1 Infect, San Antonio, TX USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio	Ahuja, SK (corresponding author), S Texas Vet Hlth Care Syst, Vet Adm Ctr AIDS & HIV 1 Infect, San Antonio, TX USA.	ahujas@uthscsa.edu	Catano, Gabriel/AAQ-5387-2020					Anastassopoulou CG, 2003, CURR HIV RES, V1, P185, DOI 10.2174/1570162033485311; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; CHAN WL, 1995, AIDS, V9, P223, DOI 10.1097/00002030-199509030-00002; CHAN WL, 1992, J EXP MED, V176, P1203, DOI 10.1084/jem.176.4.1203; Luscher MA, 1998, AIDS RES HUM RETROV, V14, P99, DOI 10.1089/aid.1998.14.99; Luscher MA, 1998, AIDS RES HUM RETROV, V14, P109, DOI 10.1089/aid.1998.14.109; MacDonald KS, 1998, J INFECT DIS, V177, P551, DOI 10.1086/514243; Mangano A, 2001, J INFECT DIS, V183, P1574, DOI 10.1086/320705; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Moore CB, 2002, SCIENCE, V296, P1439, DOI 10.1126/science.1069660; Polyanskaya N, 1997, AIDS RES HUM RETROV, V13, P923, DOI 10.1089/aid.1997.13.923; Polycarpou A, 2002, AIDS RES HUM RETROV, V18, P741, DOI 10.1089/08892220260139477; Rugeles MT, 2003, AIDS, V17, P481, DOI 10.1097/00002030-200303070-00002; Shearer GM, 1999, IMMUNOL TODAY, V20, P66, DOI 10.1016/S0167-5699(98)01392-9; STOTT EJ, 1991, NATURE, V353, P393, DOI 10.1038/353393a0; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Wang YF, 1999, NAT MED, V5, P1004, DOI 10.1038/12440; Wang YF, 1998, P NATL ACAD SCI USA, V95, P5223, DOI 10.1073/pnas.95.9.5223; Winchester R, 2004, JAIDS-J ACQ IMM DEF, V36, P659, DOI 10.1097/00126334-200406010-00002	19	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2103	2104		10.1016/S0140-6736(04)16536-7	http://dx.doi.org/10.1016/S0140-6736(04)16536-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220030				2022-12-28	WOS:000222268300005
J	Branson, R; Armstrong, D				Branson, R; Armstrong, D			General practitioners' perceptions of sharing workload in group practices: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							TRUST; CARE	Objective To explore general practitioners' beliefs and experiences of distribution of workload and teamwork between doctors in general practice. Design Qualitative semistructured interview study. Setting South London. Participants 18 general practitioners from 11 practices. Main outcome measures Perceptions and experiences of distribution of workload and teamwork between doctors. Results Equitable distribution of workload was a common concern among general practitioners in group practices. Several ways of addressing the problem were identified, including relying on trust, creating systems of working based on explicit rules such as points' systems, and improving communication. Improvement of communication was hampered by the taboo nature of the problem. Conclusion Resentment about perceived inequalities in workload places a further burden on general practices. The issue of working together warrants further support.	Kings Coll London, Dept Gen Practice, London SE11 6SP, England	University of London; King's College London	Armstrong, D (corresponding author), Kings Coll London, Dept Gen Practice, London SE11 6SP, England.	david.armstrong@kcl.ac.uk	Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				Ashworth M, 1999, FAM PRACT, V16, P18, DOI 10.1093/fampra/16.1.18; Bateman Hilarie, 2003, J Interprof Care, V17, P141; Berwick DM, 2003, QUAL SAF HEALTH CARE, V12, P448, DOI 10.1136/qhc.12.6.448; *DEP HLTH PERS SOC, 1994, DEP HLTH PERS SOC SE; HANDYSIDES S, 1994, BRIT MED J, V308, P179, DOI 10.1136/bmj.308.6922.179; Huby G, 2002, BMJ-BRIT MED J, V325, P140, DOI 10.1136/bmj.325.7356.140; Mechanic D, 1996, MILBANK Q, V74, P171, DOI 10.2307/3350245; Misztal Barbara A, 1996, TRUST MODERN SOC; NEWTON J, 1996, J MANAG MED, V10, P2; ORETVEIT J, 1993, COORDINATING COMMUNI; PRITCHARD P, 1994, TEAMWORK PRIMARY SHA; Rashid A, 1996, BRIT J GEN PRACT, V46, P639	12	11	11	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	2004	329	7462					381	383		10.1136/bmj.38173.532465.7C	http://dx.doi.org/10.1136/bmj.38173.532465.7C			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	847YI	15265814	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223433600018
J	Bartels, L; Wang, F; Moller, D; Knoesel, E; Heinz, TF				Bartels, L; Wang, F; Moller, D; Knoesel, E; Heinz, TF			Real-space observation of molecular motion induced by femtosecond laser pulses	SCIENCE			English	Article							INDUCED DESORPTION; SURFACE-DIFFUSION; CO; CU(100); DYNAMICS; ADSORBATES; EXCITATION; MICROSCOPY; CHEMISTRY; COVERAGE	Femtosecond laser irradiation is used to excite adsorbed CO molecules on a Cu(110) surface; the ensuing motion of individual molecules across the surface is characterized on a site-to-site basis by in situ scanning tunneling microscopy. Adsorbate motion both along and perpendicular to the rows of the Cu(110) surface occurs readily, in marked contrast to the behavior seen for equilibrium diffusion processes. The experimental findings for the probability and direction of the molecular motion can be understood as a manifestation of strong coupling between the adsorbates' lateral degrees of freedom and the substrate electronic excitation produced by the femtosecond laser radiation.	Columbia Univ, Dept Phys, New York, NY 10027 USA; Univ Calif Riverside, Riverside, CA 92521 USA; Columbia Univ, Dept Elect Engn, New York, NY 10027 USA; Rowan Univ, Dept Phys & Astron, Glassboro, NJ 08028 USA	Columbia University; University of California System; University of California Riverside; Columbia University; Rowan University	Heinz, TF (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.	tony.heinz@columbia.edu	bartelsdoe, ludwig/F-8008-2011; Bartels, Ludwig/C-2764-2008; wang, Feng/I-5727-2015; Heinz, Tony/K-7797-2015	wang, Feng/0000-0001-8369-6194; Heinz, Tony/0000-0003-1365-9464				Ahner J, 1996, J CHEM PHYS, V105, P6553, DOI 10.1063/1.472464; Bartels L, 1998, CHEM PHYS LETT, V291, P573, DOI 10.1016/S0009-2614(98)00644-7; Bonn M, 1999, SCIENCE, V285, P1042, DOI 10.1126/science.285.5430.1042; Briner BG, 1997, SCIENCE, V278, P257, DOI 10.1126/science.278.5336.257; BUSCH DG, 1995, PHYS REV LETT, V75, P673, DOI 10.1103/PhysRevLett.75.673; Culver JP, 1996, CHEM PHYS, V205, P159, DOI 10.1016/0301-0104(95)00376-2; Culver JP, 1996, SURF SCI, V368, P9, DOI 10.1016/S0039-6028(96)01023-0; Denzler DN, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.226102; Eichhorn G, 1998, CHEM PHYS LETT, V289, P367, DOI 10.1016/S0009-2614(98)00418-7; Finlay RJ, 1997, CHEM PHYS LETT, V274, P499, DOI 10.1016/S0009-2614(97)00708-2; GERMER TA, 1993, PHYS REV LETT, V71, P3327, DOI 10.1103/PhysRevLett.71.3327; GERMER TA, 1994, J CHEM PHYS, V101, P1704, DOI 10.1063/1.467792; Gerstner V, 2000, J APPL PHYS, V88, P4851, DOI 10.1063/1.1290706; GOMER R, 1990, REP PROG PHYS, V53, P917, DOI 10.1088/0034-4885/53/7/002; HAMERS RJ, 1990, APPL PHYS LETT, V57, P2031, DOI 10.1063/1.103997; HEADGORDON M, 1992, PHYS REV B, V46, P1853, DOI 10.1103/PhysRevB.46.1853; Heinrich AJ, 2002, SCIENCE, V298, P1381, DOI 10.1126/science.1076768; Kindt JT, 1998, J CHEM PHYS, V109, P3629, DOI 10.1063/1.476960; Komeda T, 2002, SCIENCE, V295, P2055, DOI 10.1126/science.1069016; Lee HJ, 1999, SCIENCE, V286, P1719, DOI 10.1126/science.286.5445.1719; Micha DA, 1998, CHEM PHYS LETT, V298, P250, DOI 10.1016/S0009-2614(98)01234-2; Misewich JA, 1996, SURF SCI, V363, P204, DOI 10.1016/0039-6028(96)00138-0; Pascual JI, 2003, NATURE, V423, P525, DOI 10.1038/nature01649; Petek H, 2000, SCIENCE, V288, P1402, DOI 10.1126/science.288.5470.1402; PRYBYLA JA, 1992, PHYS REV LETT, V68, P503, DOI 10.1103/PhysRevLett.68.503; PRYBYLA JA, 1990, PHYS REV LETT, V64, P1537, DOI 10.1103/PhysRevLett.64.1537; Springer C, 1996, CHEM PHYS, V205, P73, DOI 10.1016/0301-0104(95)00316-9; Struck LM, 1996, PHYS REV LETT, V77, P4576, DOI 10.1103/PhysRevLett.77.4576; Tsong TT, 2001, PROG SURF SCI, V67, P235, DOI 10.1016/S0079-6816(01)00026-0; Watanabe K, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.057401; WEISS S, 1993, APPL PHYS LETT, V63, P2567, DOI 10.1063/1.110435	31	114	114	1	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	2004	305	5684					648	651		10.1126/science.1099770	http://dx.doi.org/10.1126/science.1099770			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	842GQ	15218095				2022-12-28	WOS:000222992100041
J	Whincup, PH; Gilg, JA; Emberson, JR; Jarvis, MJ; Feyerabend, C; Bryant, A; Walker, M; Cook, DG				Whincup, PH; Gilg, JA; Emberson, JR; Jarvis, MJ; Feyerabend, C; Bryant, A; Walker, M; Cook, DG			Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement	BRITISH MEDICAL JOURNAL			English	Article							GULF-WAR VETERANS; BIRTH-DEFECTS; UK VETERANS; EXPOSURE; HEALTH; POPULATION; PREVALENCE; NONSMOKERS; CHILDREN; SMOKERS	Objective To examine the associations between a biomarker of overall passive exposure to tobacco smoke (serum cotinine concentration) and risk of coronary heart disease and stroke. Design Prospective population based study in general practice (the British regional heart study). Participants 4729 men in 18 towns Who provided baseline blood samples (for cotinine assay) and a detailed smoking history in 1978-80. Main outcome measure Major coronary heart disease and stroke events (fatal and non-fatal) during 20 years of follow up. Results 2105 men Who said they did not smoke and who had cotinine concentrations <14.1 ng/ml were divided into four equal sized groups on die basis of cotinine concentrations. Relative hazards (95% confidence intervals) for coronary heart disease in the second (0.8-1.4 ng/ml), third (1.5-2.7 ng/ml), and fourth (2.8-14.0 ng/ml) quarters of cotinine concentration compared with the first (&LE;0.7 ng/ml) were 1.45 (1.01 to 2.08),1.49 (1.03 to 2.14), and 1.57 (1.08 to 2.28), respectively, after adjustment for established risk factors for coronary heart disease. Hazard ratios (for cotinine 0.8-14.0 v &LE;0.7 ng/ml) were particularly increased during the first (3.73, 1.32 to 10.58) and second five year follow up periods (1.95, 1.09 to 3.48) compared with later periods. There was no consistent association between cotinine concentration and risk of stroke. Conclusion Studies based on reports of smoking in a partner alone seem to underestimate the risks of exposure to passive smoking. Further prospective studies relating biomarkers of passive smoking to risk of coronary heart disease are needed.	St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	St Georges University London; University of London; London School of Hygiene & Tropical Medicine	Whincup, PH (corresponding author), St George Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England.	p.whincup@sghms.ac.uk	Jarvis, Martin J/B-1034-2008	Jarvis, Martin J/0000-0001-9238-8038; Emberson, Jonathan/0000-0001-7792-9422; Cook, Derek/0000-0002-9723-5759; Whincup, Peter/0000-0002-5589-4107				Abou-Donia MB, 2003, J TOXICOL ENV HEAL A, V66, P57, DOI 10.1080/15287390306463; Araneta MRG, 1997, TERATOLOGY, V56, P244, DOI 10.1002/(SICI)1096-9926(199710)56:4<244::AID-TERA3>3.3.CO;2-Y; Araneta MRG, 2003, BIRTH DEFECTS RES A, V67, P246, DOI 10.1002/bdra.10033; Bonita R, 1999, TOB CONTROL, V8, P156, DOI 10.1136/tc.8.2.156; BRESLOW N, 1980, STAT METHODS CANC RE, V11; *CAN DEP NAT DEF, 1998, HLTH STUD CAN FORC P, V1; Cowan DN, 1997, NEW ENGL J MED, V336, P1650, DOI 10.1056/NEJM199706053362306; Doyle P, 2004, INT J EPIDEMIOL, V33, P74, DOI 10.1093/ije/dyh049; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; Ishoy T, 2001, DAN MED BULL, V48, P29; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; Jarvis MJ, 2000, BRIT MED J, V321, P343, DOI 10.1136/bmj.321.7257.343; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1992, BRIT J ADDICT, V87, P111; Jarvis MJ, 2001, TOB CONTROL, V10, P368, DOI 10.1136/tc.10.4.368; Kang H, 2001, ANN EPIDEMIOL, V11, P504, DOI 10.1016/S1047-2797(01)00245-9; KORN EL, 1990, AM STAT, V44, P270, DOI 10.2307/2684345; Law MR, 1997, BMJ-BRIT MED J, V315, P973, DOI 10.1136/bmj.315.7114.973; Maconochie N, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-4; *MHRAG, 2003, MRC REV RES UK GULF; Penman AD, 1996, MIL MED, V161, P1; SANDLER DP, 1989, AM J PUBLIC HEALTH, V79, P163, DOI 10.2105/AJPH.79.2.163; SIM M, 2003, AUSTR GULF VETERANS, V2; TUNSTALLPEDOE H, 1995, J EPIDEMIOL COMMUN H, V49, P139, DOI 10.1136/jech.49.2.139; Walker A, 2002, LIVING BRITAIN RESUL; Walker M, 2000, J PUBLIC HEALTH MED, V22, P479, DOI 10.1093/pubmed/22.4.479; World Health Organization, 1992, WHO LAB MAN EX HUM S; [No title captured]	30	199	214	1	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 24	2004	329	7459					200	204		10.1136/bmj.38146.427188.55	http://dx.doi.org/10.1136/bmj.38146.427188.55			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840NW	15229131	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222866900016
J	Moore, KA; Lemischka, IR				Moore, KA; Lemischka, IR			"Tie-ing" down the hematopoietic niche	CELL			English	Editorial Material							STEM-CELL NICHE	Interaction of hematopoietic stem cells (HSCs) with their particular microenvironment, or niche, is critical for adult hematopoiesis in the bone marrow (BM). Arai et al. (this issue of Cell) demonstrate that HSCs that express the receptor tyrosine kinase Tie2 are quiescent. Ang-1, the ligand for Tie2, enhanced the ability of HSCs to become quiescent and also induced their adhesion to bone, protecting them from stresses that suppress hematopoiesis. These data suggest that the Ang-1/Tie2 signaling pathway plays a crucial role in the maintenance of HSCs in a quiescent state in the BM niche.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Moore, KA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Fuchs E, 2004, CELL, V116, P769, DOI 10.1016/S0092-8674(04)00255-7; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041	8	24	25	0	3	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	2004	118	2					139	140		10.1016/j.cell.2004.07.006	http://dx.doi.org/10.1016/j.cell.2004.07.006			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260982	Bronze			2022-12-28	WOS:000222966000001
J	Grace, RJ				Grace, RJ			Klinefelter's syndrome: a late diagnosis	LANCET			English	Editorial Material												editorial@lancet.com							0	8	8	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					284	284		10.1016/S0140-6736(04)16679-8	http://dx.doi.org/10.1016/S0140-6736(04)16679-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262107				2022-12-28	WOS:000222784900032
J	Henderson, C; Flood, C; Leese, M; Thornicroft, G; Sutherby, K; Szmukler, G				Henderson, C; Flood, C; Leese, M; Thornicroft, G; Sutherby, K; Szmukler, G			Effect of joint crisis plans on use of compulsory treatment in psychiatry: single blind randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							HEALTH	Objective To investigate whether a form of advance agreement for people with severe mental illness can reduce the use of inpatient services and compulsory admission or treatment. Design Single blind randomised controlled trial, with randomisation of individual patients. The investigator was blind to allocation. Setting Eight community mental health teams in southern England. Participants 160 people with an operational diagnosis of psychotic illness or non-psychotic bipolar disorder who had experienced a hospital admission within the previous two years. Intervention The joint crisis plan was formulated by the patient, care coordinator, psychiatrist, and project worker and contained contact information, details of mental and physical illnesses, treatments, indicators for relapse, and advance statements of preferences for care in the event of future relapse. Main outcome measures Admission to hospital, bed days, and use of the Mental Health Act over 15 month follow up. Results Use of the Mental Health Act was significantly reduced for the intervention group, 13% (10/80) of whom experienced compulsory admission or treatment compared with 27% (21/80) of the control group (risk ratio 0.48, 95% confidence interval 0.24 to 0.95, P = 0.028). As a consequence, the mean number of days of detention (days spent as an inpatient while under a section of the Mental Health Act) for the whole intervention group was 14 compared with 31 for the control group (difference 16, 0 to 36, P = 0.04). For those admitted under a section of the Mental Health Act, the number of days of detention was similar in the two groups (means 114 and 117, difference 3, -61 to 67, P = 0.98). The intervention group had fewer admissions (risk ratio 0.69, 0.45 to 1.04, P = 0.07). There was no evidence for differences in bed days (total number of days spent as an inpatient) (means 32 and 36, difference 4, -18 to 26, P = 0.15 for the whole sample; means 107 and 83, difference -24, -72 to 24, P = 0.39 for those admitted). Conclusions Use of joint crisis plans reduced compulsory admissions and treatment in patients with severe mental illness. The reduction in overall admission was less. This is the first structured clinical intervention that seems to reduce compulsory admission and treatment in mental health services.	Kings Coll London, Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England; S London & Maudsley NHS Trust, Croydon CR0 1XT, England	University of London; King's College London	Henderson, C (corresponding author), Kings Coll London, Inst Psychiat, Hlth Serv Res Dept, London SE5 8AF, England.	hendersc@nypdrat.cpmc.columbia.edu	Leese, Morven N/E-4195-2010; Thornicroft, Graham/B-4027-2010; Henderson, Claire/E-4664-2010	Thornicroft, Graham/0000-0003-0662-0879; Henderson, Claire/0000-0002-6998-5659; Flood, Chris/0000-0001-5170-7792				Bracken P, 2001, BMJ-BRIT MED J, V322, P724, DOI 10.1136/bmj.322.7288.724; Campbell M, 2000, BRIT MED J, V321, P694, DOI 10.1136/bmj.321.7262.694; *DEP HLTH, 1999, INP FORM DET HOSP ME; *DEP HLTH, 2000, EFF CAR COORD MENT H; *DEP HLTH, 2000, NHS PLAN; Department of Health, 1999, NAT SERV FRAM MENT H; Department of Health, 1999, REP EXP COMM REV MEN; Kemp RA, 1995, SCHIZOPHR RES, V18, P21, DOI 10.1016/0920-9964(95)00018-6; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; *MED RES COUNC, 2000, FRAM DEV EV RCTS COM; Papageorgiou A, 2002, BRIT J PSYCHIAT, V181, P513, DOI 10.1192/bjp.181.6.513; Pawson R., 1997, REALISTIC EVALUATION; Sutherby K, 1999, ACTA PSYCHIAT SCAND, V100, P56, DOI 10.1111/j.1600-0447.1999.tb10914.x; Sutherby K, 1998, PSYCHIAT B, V22, P4; Thomas P, 2003, BRIT J PSYCHIAT, V182, P548, DOI 10.1192/bjp.182.6.548-a	15	176	176	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 17	2004	329	7458					136	138A		10.1136/bmj.38155.585046.63	http://dx.doi.org/10.1136/bmj.38155.585046.63			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	840BP	15240438	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-28	WOS:000222832300016
J	Gougoux, F; Lepore, F; Lassonde, M; Voss, P; Zatorre, RJ; Belin, P				Gougoux, F; Lepore, F; Lassonde, M; Voss, P; Zatorre, RJ; Belin, P			Pitch discrimination in the early blind	NATURE			English	Editorial Material							SIGHTED SUBJECTS		Univ Montreal, Ctr Rech Neuropsychol & Cognit, Dept Psychol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Universite de Montreal; McGill University	Gougoux, F (corresponding author), Univ Montreal, Ctr Rech Neuropsychol & Cognit, Dept Psychol, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	pascal.belin@umontreal.ca	voss, patrice/I-7026-2019; Belin, Pascal/C-6247-2009	voss, patrice/0000-0001-8698-7130; Belin, Pascal/0000-0002-7578-6365				Johnsrude IS, 2000, BRAIN, V123, P155, DOI 10.1093/brain/123.1.155; Juurmaa J., 1967, AM FDN BLIND RES B, V14, P109; Lessard N, 1998, NATURE, V395, P278, DOI 10.1038/26228; MUCHNIK C, 1991, SCAND AUDIOL, V20, P19, DOI 10.3109/01050399109070785; PITMAN DJ, 1965, AM FDN BLIND RES B, V11, P63; Roder B, 1999, NATURE, V400, P162, DOI 10.1038/22106; SAKURABAYASHI IL, 1956, J PSYCHOL BLIND, V1, P3; Stankov L., 1978, APPLIED PSYCHOL MEAS, V2, P491, DOI 10.1177/014662167800200403; Zatorre RJ, 2001, CEREB CORTEX, V11, P946, DOI 10.1093/cercor/11.10.946	9	269	273	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					309	309		10.1038/430309a	http://dx.doi.org/10.1038/430309a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254527	Bronze			2022-12-28	WOS:000222631200027
J	Ito, T; Wellmer, F; Yu, H; Das, P; Ito, N; Alves-Ferreira, M; Riechmann, JL; Meyerowitz, EM				Ito, T; Wellmer, F; Yu, H; Das, P; Ito, N; Alves-Ferreira, M; Riechmann, JL; Meyerowitz, EM			The homeotic protein AGAMOUS controls microsporogenesis by regulation of SPOROCYTELESS	NATURE			English	Article							MADS-BOX GENES; FLORAL ORGAN IDENTITY; ARABIDOPSIS-THALIANA; FLOWER DEVELOPMENT; OVULE DEVELOPMENT; PATTERN-FORMATION; EXPRESSION; TRANSCRIPTION; SPOROGENESIS; VERSATILE	The Arabidopsis homeotic gene AGAMOUS (AG) is necessary for the specification of reproductive organs ( stamens and carpels) during the early steps of flower development(1-3). AG encodes a transcription factor of the MADS-box family that is expressed in stamen and carpel primordia. At later stages of development, AG is expressed in distinct regions of the reproductive organs(2-5). This suggests that AG might function during the maturation of stamens and carpels, as well as in their early development. However, the developmental processes that AG might control during organogenesis and the genes that are regulated by this factor are largely unknown. Here we show that microsporogenesis, the process leading to pollen formation, is induced by AG through activation of the SPOROCYTELESS gene (SPL, also known as NOZZLE, NZZ), a regulator of sporogenesis(6,7). Furthermore, we demonstrate that SPL can induce microsporogenesis in the absence of AG function, suggesting that AG controls a specific process during organogenesis by activating another regulator that performs a subset of its functions.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA; Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore; Univ Fed Rio de Janeiro, Dept Genet, BR-21941590 Rio De Janeiro, Brazil	California Institute of Technology; National University of Singapore; Universidade Federal do Rio de Janeiro	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, 1200 E Calif Blvd, Pasadena, CA 91125 USA.	meyerow@its.caltech.edu	Riechmann, José Luis/M-7005-2018; Yu, Hao/A-3867-2010; Meyerowitz, Elliot M/A-7118-2009; Alves-Ferreira, Marcio/C-5849-2009	Riechmann, José Luis/0000-0003-1108-1945; Yu, Hao/0000-0002-9778-8855; Alves-Ferreira, Marcio/0000-0002-6107-3700; Ito, Toshiro/0000-0002-8206-2787; Wellmer, Frank/0000-0002-2095-0981				Balasubramanian S, 2002, DEVELOPMENT, V129, P4291; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160; Honma T, 2001, NATURE, V409, P525, DOI 10.1038/35054083; HUANG H, 1993, NUCLEIC ACIDS RES, V21, P4769, DOI 10.1093/nar/21.20.4769; Ito T, 2003, CURR BIOL, V13, P1524, DOI 10.1016/S0960-9822(03)00612-2; Lenhard M, 2001, CELL, V105, P805, DOI 10.1016/S0092-8674(01)00390-7; Liljegren SJ, 2000, NATURE, V404, P766, DOI 10.1038/35008089; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; Long JA, 1998, DEVELOPMENT, V125, P3027; MATSUOKA K, 1991, P NATL ACAD SCI USA, V88, P834, DOI 10.1073/pnas.88.3.834; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Pinyopich A, 2003, NATURE, V424, P85, DOI 10.1038/nature01741; REISER L, 1995, CELL, V83, P735, DOI 10.1016/0092-8674(95)90186-8; Sablowski RWM, 1998, CELL, V92, P93, DOI 10.1016/S0092-8674(00)80902-2; SAVIDGE B, 1995, PLANT CELL, V7, P721, DOI 10.1105/tpc.7.6.721; Schiefthaler U, 1999, P NATL ACAD SCI USA, V96, P11664, DOI 10.1073/pnas.96.20.11664; SCHNEITZ K, 1995, PLANT J, V7, P731, DOI 10.1046/j.1365-313X.1995.07050731.x; SHIRAISHI H, 1993, PLANT J, V4, P385, DOI 10.1046/j.1365-313X.1993.04020385.x; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Wagner D, 2004, PLANT J, V39, P273, DOI 10.1111/j.1365-313X.2004.02127.x; Wagner D, 1999, SCIENCE, V285, P582, DOI 10.1126/science.285.5427.582; Wellmer F, 2004, PLANT CELL, V16, P1314, DOI 10.1105/tpc.021741; Yang WC, 1999, GENE DEV, V13, P2108, DOI 10.1101/gad.13.16.2108; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	30	229	257	3	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					356	360		10.1038/nature02733	http://dx.doi.org/10.1038/nature02733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254538				2022-12-28	WOS:000222631200042
J	Jacobsohn, DA; Duerst, R; Tse, W; Kletzel, M				Jacobsohn, DA; Duerst, R; Tse, W; Kletzel, M			Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children	LANCET			English	Article							BONE-MARROW-TRANSPLANTATION; TOTAL-BODY IRRADIATION; UMBILICAL-CORD BLOOD; HOST-DISEASE; CHIMERISM; GRAFT; IMMUNOSUPPRESSION; DONORS	Background Transplantation of allogeneic haemopoietic stem cells can cure several non-malignant disorders in children. Transplantation with reduced intensity preparation might achieve the same goals but with less toxicity. We under-took a pilot study to determine engraftment rates, kinetics of engraftment, toxicity, and acute graft-versus-host disease (GVHD) associated with a uniform reduced intensity haemopoietic stem-cell transplant (HSCT) regimen for Children with non-malignant diseases. Methods We studied 13 paediatric patients with non-malignant disorders who underwent reduced intensity HSCT at Children's Memorial Hospital from January, 2000, to February, 2004. Stem-cell sources included unrelated donor, matched-sibling peripheral blood stem cells, and unrelated cord blood. A uniform preparative regimen was used, consisting of fludarabine, busulfan, and anti-thymocyte globulin. Major endpoints were engraftment, transplant-related mortality at day 100, short-term toxicities, and incidence of acute GVHD. Results 72% of evaluable patients achieved full donor engraftment. There was rapid reconstitution of platelets (median 13.5 days) and neutrophils (median 18 days). Short-term toxicities were minimal, as seen by a median length of hospital stay of 7 days (between days 0-100). Incidence of grade II-IV acute GVHD was 8%. Two patients died before day 100 from underlying disease and viral infection, respectively (day 100 transplant-related mortality of 15%). The 1-year overall survival was 84% (95% Cl. 64-100). Most patients with immunodeficiencies and metabolic disorders had excellent donor engraftment and disease resolution or stabilisation, but most of those with haemoglobinopathies rejected their graft. Interpretation This reduced intensity regimen followed by HSCT provides a good alternative to myeloablative HSCT for children with non-malignant disorders, except for haemoglobinopathies, in which engraftment is poor. Even patients with unrelated donor haemopoietic stem-cell transplants had adequate engraftment with acceptable toxicities.	Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Pediat,Div Hematol Oncol Transplant, Chicago, IL 60614 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine	Jacobsohn, DA (corresponding author), Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Dept Pediat,Div Hematol Oncol Transplant, Chicago, IL 60614 USA.	djacobsohn@childrensmemorial.org						Amrolia P, 2000, BLOOD, V96, P1239, DOI 10.1182/blood.V96.4.1239.h8001239_1239_1246; Barker JN, 2003, BLOOD, V102, P1915, DOI 10.1182/blood-2002-11-3337; Chakraverty R, 2002, BLOOD, V99, P1071, DOI 10.1182/blood.V99.3.1071; Chan GW, 2003, BIOL BLOOD MARROW TR, V9, P170, DOI 10.1053/bbmt.2003.50006; Del Toro G, 2004, BONE MARROW TRANSPL, V33, P613, DOI 10.1038/sj.bmt.1704399; FREEMAN AF, IN PRESS PEDIATRICS; Giralt S, 1997, BLOOD, V89, P4531, DOI 10.1182/blood.V89.12.4531; Haddad E, 1998, BLOOD, V91, P3646; Horwitz ME, 2001, NEW ENGL J MED, V344, P881, DOI 10.1056/NEJM200103223441203; Iannone R, 2001, BLOOD, V97, P3960, DOI 10.1182/blood.V97.12.3960; Iannone R, 2003, BIOL BLOOD MARROW TR, V9, P519, DOI 10.1016/S1083-8791(03)00192-7; Jacobsohn DA, 2004, PEDIATRICS, V113, P122, DOI 10.1542/peds.113.2.e122; Kean LS, 2002, BLOOD, V99, P1840, DOI 10.1182/blood.V99.5.1840; Niederwieser D, 2003, BLOOD, V101, P1620, DOI 10.1182/blood-2002-05-1340; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; SHULMAN HM, 1978, AM J PATHOL, V91, P545; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Storb R, 1997, BLOOD, V89, P3048, DOI 10.1182/blood.V89.8.3048; SULLIVAN KM, 1981, BLOOD, V57, P267, DOI 10.1182/blood.V57.2.267.267; UGOZZOLI L, 1991, BLOOD, V77, P1607; Vassiliou G, 2001, BEST PRACT RES CL HA, V14, P807, DOI 10.1053/beha.2001.0174	22	114	117	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					156	162		10.1016/S0140-6736(04)16628-2	http://dx.doi.org/10.1016/S0140-6736(04)16628-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246728				2022-12-28	WOS:000222612200026
J	Seo, BM; Miura, M; Gronthos, S; Bartold, PM; Batouli, S; Brahim, J; Young, M; Robey, PG; Wang, CY; Shi, ST				Seo, BM; Miura, M; Gronthos, S; Bartold, PM; Batouli, S; Brahim, J; Young, M; Robey, PG; Wang, CY; Shi, ST			Investigation of multipotent postnatal stem cells from human periodontal ligament	LANCET			English	Article							ENAMEL MATRIX PROTEINS; IN-VITRO; DENTAL-PULP; ATTACHMENT PROTEIN; REGENERATION; BONE; CEMENTUM; VIVO; FIBROBLASTS; TISSUE	Background Periodontal diseases that lead to the destruction of periodontal tissues-including periodontal ligament (PDL), cementum, and bone-are a major cause of tooth loss in adults and are a substantial public-health burden worldwide. PDL is a specialised connective tissue that connects cementum and alveolar bone to maintain and support teeth in situ and preserve tissue homoeostasis. We investigated the notion that human PDL contains stem cells that could be used to regenerate periodontal tissue. 19 Methods PDL tissue was obtained from 25 surgically extracted human third molars and used to isolate PDL stem cells (PDLSCs) by single-colony selection and magnetic activated cell sorting. Immunohistochemical staining, RT-PCR, and northern and western blot analyses were used to identify putative stem-cell markers. Human PDLSCs were transplanted into immunocompromised mice (n=12) and rats (n=6) to assess capacity for tissue regeneration and periodontal repair. Findings PDLSCs expressed the mesenchymal stem-cell markers STRO-1 and CD146/MUC18. Under defined culture conditions, PDLSCs differentiated into cementoblast-like cells, adipocytes, and collagen-forming cells. When transplanted into immunocompromised rodents, PDLSCs showed the capacity to generate a cementum/PDL-like structure and contribute to periodontal tissue repair. Interpretation Our findings suggest that PDL contains stem cells that have the potential to generate cementum/PDL-like tissue in vivo. Transplantation of these cells, which can be obtained from an easily accessible tissue resource and expanded ex vivo, might hold promise as a therapeutic approach for reconstruction of tissues destroyed by periodontal diseases.	Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, US Dept HHS, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, US Dept HHS, Bethesda, MD 20892 USA; Univ Adelaide, Mesenchymal Stem Cell Grp, Div Haematol, Inst Med & Vet Sci, Adelaide, SA 5005, Australia; Univ Adelaide, Sch Dent, Adelaide, SA 5005, Australia; Univ Michigan, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Mol & Cellular Biol Program, Ann Arbor, MI 48109 USA; Seoul Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Institute Medical & Veterinary Science Australia; University of Adelaide; University of Adelaide; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Seoul National University (SNU)	Shi, ST (corresponding author), Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, US Dept HHS, Bldg 30,Room 222,30 Convent Dr MSC-4320, Bethesda, MD 20892 USA.	sshi@dir.nidcr.nih.gov	Bartold, Mark/H-8122-2019; Gronthos, Stan/Y-4419-2019; Robey, Pamela Gehron/H-1429-2011	Gronthos, Stan/0000-0002-6225-3084; Robey, Pamela Gehron/0000-0002-5316-5576; Young, Marian F/0000-0003-0929-8854; Bartold, Peter/0000-0002-5695-3877; Seo, Byoung-Moo/0000-0002-3798-1987	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000379, ZIADE000380] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000380, Z01DE000379, Z01DE000705] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartold PM, 2000, PERIODONTOL 2000, V24, P253, DOI 10.1034/j.1600-0757.2000.2240113.x; Beertsen W, 1997, PERIODONTOL 2000, V13, P20, DOI 10.1111/j.1600-0757.1997.tb00094.x; BOYKO GA, 1981, J PERIODONTAL RES, V16, P73, DOI 10.1111/j.1600-0765.1981.tb00951.x; Brent AE, 2003, CELL, V113, P235, DOI 10.1016/S0092-8674(03)00268-X; Cochran DL, 1999, PERIODONTOL 2000, V19, P40, DOI 10.1111/j.1600-0757.1999.tb00146.x; Cochran DL, 2003, J PERIODONTOL, V74, P1043, DOI 10.1902/jop.2003.74.7.1043; Cochran DL, 2003, J PERIODONTOL, V74, P1269, DOI 10.1902/jop.2003.74.9.1269; Desvarieux M, 2003, STROKE, V34, P2120, DOI 10.1161/01.STR.0000085086.50957.22; Elter JR, 2003, J DENT RES, V82, P998, DOI 10.1177/154405910308201212; GOULD TRL, 1977, ANAT REC, V188, P133, DOI 10.1002/ar.1091880202; GOULD TRL, 1980, J PERIODONTAL RES, V15, P20, DOI 10.1111/j.1600-0765.1980.tb00258.x; Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Grzesik WJ, 1998, J BONE MINER RES, V13, P1547, DOI 10.1359/jbmr.1998.13.10.1547; Grzesik WJ, 2002, CRIT REV ORAL BIOL M, V13, P474, DOI 10.1177/154411130201300605; Han X, 2003, J DENT RES, V82, P454, DOI 10.1177/154405910308200610; Handa K, 2002, CONNECT TISSUE RES, V43, P406, DOI 10.1080/03008200290001023; Isaka J, 2001, J PERIODONTOL, V72, P314, DOI 10.1902/jop.2001.72.3.314; Krebsbach PH, 1997, TRANSPLANTATION, V63, P1059, DOI 10.1097/00007890-199704270-00003; Lekic P, 2001, J PERIODONTAL RES, V36, P71, DOI 10.1034/j.1600-0765.2001.360202.x; Liu HW, 1997, J BONE MINER RES, V12, P1691, DOI 10.1359/jbmr.1997.12.10.1691; MacNeil RL, 1999, PERIODONTOL 2000, V19, P8, DOI 10.1111/j.1600-0757.1999.tb00144.x; Marcopoulou C E, 2003, J Int Acad Periodontol, V5, P63; MCCULLOCH CAG, 1991, J PERIODONTAL RES, V26, P144, DOI 10.1111/j.1600-0765.1991.tb01638.x; MCCULLOCH CAG, 1985, ANAT REC, V211, P258, DOI 10.1002/ar.1092110305; MCCULLOCH CAG, 1983, AM J ANAT, V167, P43, DOI 10.1002/aja.1001670105; MELCHER A H, 1970, Archives of Oral Biology, V15, P1183, DOI 10.1016/0003-9969(70)90010-5; Miura M, 2003, P NATL ACAD SCI USA, V100, P5807, DOI 10.1073/pnas.0937635100; Murakami Y, 2003, J PERIODONTOL, V74, P780, DOI 10.1902/jop.2003.74.6.780; Nevins M, 2003, J PERIODONTOL, V74, P1282, DOI 10.1902/jop.2003.74.9.1282; Ohno S, 2002, J DENT RES, V81, P822, DOI 10.1177/154405910208101205; Ouyang HJ, 2000, ARCH ORAL BIOL, V45, P293, DOI 10.1016/S0003-9969(99)00142-9; Pitaru S, 2002, CONNECT TISSUE RES, V43, P257, DOI 10.1080/03008200290001276; Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696; Shimono M, 2003, MICROSC RES TECHNIQ, V60, P491, DOI 10.1002/jemt.10290; Zhao M, 2003, J DENT RES, V82, P23, DOI 10.1177/154405910308200106; Zhao M, 2002, J BONE MINER RES, V17, P1441, DOI 10.1359/jbmr.2002.17.8.1441	37	2267	2504	19	335	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					149	155		10.1016/S0140-6736(04)16627-0	http://dx.doi.org/10.1016/S0140-6736(04)16627-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246727				2022-12-28	WOS:000222612200025
J	Mnaimneh, S; Davierwala, AP; Haynes, J; Moffat, J; Peng, WT; Zhang, W; Yang, XQ; Pootoolal, J; Chua, G; Lopez, A; Trochesset, M; Morse, D; Krogan, NJ; Hiley, SL; Li, ZJ; Morris, Q; Grigull, J; Mitsakakis, N; Roberts, CJ; Greenblatt, JF; Boone, C; Kaiser, CA; Andrews, BJ; Hughes, TR				Mnaimneh, S; Davierwala, AP; Haynes, J; Moffat, J; Peng, WT; Zhang, W; Yang, XQ; Pootoolal, J; Chua, G; Lopez, A; Trochesset, M; Morse, D; Krogan, NJ; Hiley, SL; Li, ZJ; Morris, Q; Grigull, J; Mitsakakis, N; Roberts, CJ; Greenblatt, JF; Boone, C; Kaiser, CA; Andrews, BJ; Hughes, TR			Exploration of essential gene functions via titratable promoter alleles	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; SYSTEMATIC IDENTIFICATION; GLOBAL ANALYSIS; TRANSFER-RNA; YEAST; EXPRESSION; PROTEINS; PATHWAYS; CYCLE; GOLGI	Nearly 20% of yeast genes are required for viability, hindering genetic analysis with knockouts. We created promoter-shutoff strains for over two-thirds of all essential yeast genes and subjected them to morphological analysis, size profiling, drug sensitivity screening, and microarray expression profiling. We then used this compendium of data to ask which phenotypic features characterized different functional classes and used these to infer potential functions for uncharacterized genes. We identified genes involved in ribosome biogenesis (HAS1, URB1, and URB2), protein secretion (SEC39), mitochondrial import (MIM1), and tRNA charging (GSN1). In addition, apparent negative feedback transcriptional regulation of both ribosome biogenesis and the proteasome was observed. We furthermore show that these strains are compatible with automated genetic analysis. This study underscores the importance of analyzing mutant phenotypes and provides a resource to complement the yeast knockout collection.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON, Canada; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Toronto; University of Toronto; Massachusetts Institute of Technology (MIT)	Hughes, TR (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	t.hughes@utoronto.ca	Haynes, Jennifer/P-8565-2019; Moffat, Jason/AAC-1110-2020; Morris, Quaid/ABE-8343-2020	Moffat, Jason/0000-0002-5663-8586; Morris, Quaid/0000-0002-2760-6999				Andag U, 2001, J BIOL CHEM, V276, P39150, DOI 10.1074/jbc.M105833200; BAKER KP, 1991, NATURE, V349, P205, DOI 10.1038/349205a0; BARNES G, 1984, MOL CELL BIOL, V4, P2381, DOI 10.1128/MCB.4.11.2381; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; Ben-Yehuda S, 2000, GENETICS, V156, P1503; Birrell GW, 2002, P NATL ACAD SCI USA, V99, P8778, DOI 10.1073/pnas.132275199; Bishop CM., 1995, NEURAL NETWORKS PATT; Brown MPS, 2000, P NATL ACAD SCI USA, V97, P262, DOI 10.1073/pnas.97.1.262; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Cosson P, 1996, EMBO J, V15, P1792, DOI 10.1002/j.1460-2075.1996.tb00528.x; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; Davis S., 2000, J SEX EDUC THER, V25, P25, DOI DOI 10.1007/S10508-012-9946-2; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P7920; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emery B, 2004, MOL MICROBIOL, V52, P141, DOI 10.1111/j.1365-2958.2003.03973.x; Fatica A, 2002, CURR OPIN CELL BIOL, V14, P313, DOI 10.1016/S0955-0674(02)00336-8; Fatica A, 2002, MOL CELL, V9, P341, DOI 10.1016/S1097-2765(02)00458-6; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gasch AP, 2002, GENOME BIOL, V3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; GLAEVER G, 1999, NAT GENET, V21, P278; GLAEVER G, 2004, P NATL ACAD SCI USA, V101, P793; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hegde P, 2000, BIOTECHNIQUES, V29, P548, DOI 10.2144/00293bi01; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes Timothy R, 2002, Funct Integr Genomics, V2, P199, DOI 10.1007/s10142-002-0059-1; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Issel-Tarver L, 2002, METHOD ENZYMOL, V350, P329, DOI 10.1016/S0076-6879(02)50972-1; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kanemaki M, 2003, NATURE, V423, P720, DOI 10.1038/nature01692; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kressler D, 1999, MOL CELL BIOL, V19, P8633; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lum PY, 2004, CELL, V116, P121, DOI 10.1016/S0092-8674(03)01035-3; Oba S, 2003, BIOINFORMATICS, V19, P2088, DOI 10.1093/bioinformatics/btg287; Peng WT, 2003, CELL, V113, P919, DOI 10.1016/S0092-8674(03)00466-5; Reilly BA, 2001, MOL BIOL CELL, V12, P3783, DOI 10.1091/mbc.12.12.3783; Robinson MD, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-35; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; SACHS L, 1982, APPL STAT; Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Wu LF, 2002, NAT GENET, V31, P255, DOI 10.1038/ng906; Xing F, 2004, J BIOL CHEM, V279, P17850, DOI 10.1074/jbc.M401221200; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zhang NS, 2003, GENE, V303, P121, DOI 10.1016/S0378-1119(02)01142-3; Zhao Y, 2003, MOL CELL BIOL, V23, P699, DOI 10.1128/MCB.23.2.699-707.2003	62	445	488	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					31	44		10.1016/j.cell.2004.06.013	http://dx.doi.org/10.1016/j.cell.2004.06.013			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242642	Bronze			2022-12-28	WOS:000222626800006
J	Schmidt, S; Nielsen, SF; Gundlach, C; Margulies, L; Huang, X; Jensen, DJ				Schmidt, S; Nielsen, SF; Gundlach, C; Margulies, L; Huang, X; Jensen, DJ			Watching the growth of bulk grains during recrystallization of deformed metals	SCIENCE			English	Article							MICROSTRUCTURAL EVOLUTION; TEXTURE; SIMULATION	We observed the in situ growth of a grain during recrystallization in the bulk of a deformed sample. We used the three-dimensional x-ray diffraction microscope located at the European Synchrotron Radiation Facility in Grenoble, France. The results showed a very heterogeneous growth pattern, contradicting the classical assumption of smooth and spherical growth of new grains during recrystallization. This type of in situ bulk measurement opens up the possibility of obtaining experimental data on scientific topics that before could only be analyzed theoretically on the basis of the statistical characterization of microstructures. For recrystallization, the in situ method includes direct measurements of nucleation and boundary migration through a deformed matrix.	Riso Natl Lab, Ctr Fundamental Res Met Struct 4 Dimens, DK-4000 Roskilde, Denmark; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Technical University of Denmark; European Synchrotron Radiation Facility (ESRF)	Schmidt, S (corresponding author), Riso Natl Lab, Ctr Fundamental Res Met Struct 4 Dimens, DK-4000 Roskilde, Denmark.	soeren.schmidt@risoe.dk	Schmidt, Søren/B-1483-2010; Fæster, Søren/O-4652-2019; Jensen, Dorte Juul/N-4650-2017; Huang, Xiaoxu/AFV-2572-2022; Huang, Xiaoxu/N-2856-2017; Gundlach, Carsten/B-9122-2008	Schmidt, Søren/0000-0002-8694-2044; Jensen, Dorte Juul/0000-0001-5096-6602; Huang, Xiaoxu/0000-0002-4635-6112; Gundlach, Carsten/0000-0002-2895-1882; Faester, Soren/0000-0001-5088-2396				BECK PA, 1954, ADV PHYS, V3, P245, DOI 10.1080/00018735400101203; DRIVER JH, 1994, ACTA METALL MATER, V42, P3105, DOI 10.1016/0956-7151(94)90408-1; FIELDEN IM, 2004, P I PHYS EL MICR AN, V179, P181; Hansen N, 2001, METALL MATER TRANS A, V32, P2917, DOI 10.1007/s11661-001-0167-x; Humphreys FJ, 1997, ACTA MATER, V45, P4231, DOI 10.1016/S1359-6454(97)00070-0; Hutchinson B., 1996, P 11 INT C TEXT MAT, P377; Lauridsen EM, 2001, J APPL CRYSTALLOGR, V34, P744, DOI 10.1107/S0021889801014170; LIU Q, 1995, ULTRAMICROSCOPY, V60, P81, DOI 10.1016/0304-3991(95)00049-7; LUCKE K, 1976, ACTA METALL MATER, V24, P103, DOI 10.1016/0001-6160(76)90012-2; Marx V, 1999, ACTA MATER, V47, P1219, DOI 10.1016/S1359-6454(98)00421-2; MAURICE C, 1998, P ICGG 3 3 INT C GRA, V1, P81; MOLODOV DA, 2001, P 1 JOINT INT C, V1, P21; Poulsen HF, 1997, J SYNCHROTRON RADIAT, V4, P147, DOI 10.1107/S0909049597002021; Poulsen HF, 2003, J APPL CRYSTALLOGR, V36, P1062, DOI 10.1107/S0021889803011063; Radhakrishnan B, 1998, ACTA MATER, V46, P4415, DOI 10.1016/S1359-6454(98)00077-9; Vandermeer R.A., 1963, RECOVERY RECRYSTALLI, P211; VANDERMEER RA, 1994, ACTA METALL MATER, V42, P2427, DOI 10.1016/0956-7151(94)90321-2; VernonParry KD, 1996, MATER SCI TECH SER, V12, P889, DOI 10.1179/026708396790122099; Winther G, 2003, ACTA MATER, V51, P417, DOI 10.1016/S1359-6454(02)00423-8	19	207	215	3	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					229	232		10.1126/science.1098627	http://dx.doi.org/10.1126/science.1098627			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247474				2022-12-28	WOS:000222501000048
J	Hook, EW; Peeling, RW				Hook, EW; Peeling, RW			Global health - Syphilis control - A continuing challenge	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA; Jefferson Cty Dept Hlth, Sexually Transmitted Dis Control Program, Birmingham, AL USA; WHO, Diagnost Res & Dev Program, UNICEF,UNDP,World Bank, Special Program Res & Training Trop Dis, Geneva, Switzerland	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; The World Bank; World Health Organization	Hook, EW (corresponding author), Univ Alabama, Dept Med, Birmingham, AL 35294 USA.								0	88	96	0	6	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					122	124		10.1056/NEJMp048126	http://dx.doi.org/10.1056/NEJMp048126			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247352	Green Published			2022-12-28	WOS:000222470700004
J	Meinhart, A; Cramer, P				Meinhart, A; Cramer, P			Recognition of RNA polymerase II carboxy-terminal domain by 3 '-RNA-processing factors	NATURE			English	Article							STRUCTURAL BASIS; PROCESSING FACTORS; DIFFRACTION DATA; LARGEST SUBUNIT; TRANSCRIPTION; CTD; PHOSPHORYLATION; INTERACTS; PROTEINS; SIGNAL	During transcription, RNA polymerase (Pol) II synthesizes eukaryotic messenger RNA. Transcription is coupled to RNA processing by the carboxy-terminal domain (CTD) of Pol II, which consists of up to 52 repeats of the sequence Tyr1-Ser 2-Pro 3-Thr 4-Ser 5-Pro 6-Ser 7 (refs 1, 2). After phosphorylation, the CTD binds tightly to a conserved CTD-interacting domain ( CID) present in the proteins Pcf11 and Nrd1, which are essential and evolutionarily conserved factors for polyadenylation-dependent and -independent 3'-RNA processing, respectively. Here we describe the structure of a Ser 2-phosphorylated CTD peptide bound to the CID domain of Pcf11. The CTD motif Ser 2-Pro 3-Thr 4-Ser 5 forms a beta-turn that binds to a conserved groove in the CID domain. The Ser 2 phosphate group does not make direct contact with the CID domain, but may be recognized indirectly because it stabilizes the beta-turn with an additional hydrogen bond. Iteration of the peptide structure results in a compact beta-spiral model of the CTD. The model suggests that, during the mRNA transcription-processing cycle, compact spiral regions in the CTD are unravelled and regenerated in a phosphorylation-dependent manner.	Univ Munich, Dept Chem & Biochem, Gene Ctr, D-81377 Munich, Germany	University of Munich	Cramer, P (corresponding author), Univ Munich, Dept Chem & Biochem, Gene Ctr, Marchioninistr 15, D-81377 Munich, Germany.	cramer@lmb.uni-muenchen.de	Meinhart, Anton/M-9647-2014					Ahn SH, 2004, MOL CELL, V13, P67, DOI 10.1016/S1097-2765(03)00492-1; Armache KJ, 2003, P NATL ACAD SCI USA, V100, P6964, DOI 10.1073/pnas.1030608100; Barilla D, 2001, P NATL ACAD SCI USA, V98, P445, DOI 10.1073/pnas.021545298; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; CAGAS PM, 1995, PROTEINS, V21, P149, DOI 10.1002/prot.340210209; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Fabrega C, 2003, MOL CELL, V11, P1549, DOI 10.1016/S1097-2765(03)00187-4; Hirose Y, 2000, GENE DEV, V14, P1415; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kumaki Y, 2001, BBA-PROTEIN STRUCT M, V1548, P81, DOI 10.1016/S0167-4838(01)00216-3; Licatalosi DD, 2002, MOL CELL, V9, P1101, DOI 10.1016/S1097-2765(02)00518-X; Meredith GD, 1996, J MOL BIOL, V258, P413, DOI 10.1006/jmbi.1996.0258; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Ni ZY, 2004, MOL CELL, V13, P55, DOI 10.1016/S1097-2765(03)00526-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patturajan M, 1998, MOL CELL BIOL, V18, P2406, DOI 10.1128/MCB.18.4.2406; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Sadowski M, 2003, EMBO J, V22, P2167, DOI 10.1093/emboj/cdg200; Smith GD, 1998, ACTA CRYSTALLOGR D, V54, P799, DOI 10.1107/S0907444997018805; Steinmetz EJ, 2001, NATURE, V413, P327, DOI 10.1038/35095090; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; Terwilliger TC, 2002, ACTA CRYSTALLOGR D, V58, P1937, DOI 10.1107/S0907444902016438; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; WEST ML, 1995, GENETICS, V140, P1223; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZHANG J, 1991, J BIOL CHEM, V266, P2297	30	224	226	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					223	226		10.1038/nature02679	http://dx.doi.org/10.1038/nature02679			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241417	Green Submitted			2022-12-28	WOS:000222470600047
J	Merrell, DS; Falkow, S				Merrell, DS; Falkow, S			Frontal and stealth attack strategies in microbial pathogenesis	NATURE			English	Review							PYLORI CAGA PROTEIN; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; MYCOBACTERIUM-TUBERCULOSIS; LEGIONELLA-PNEUMOPHILA; CAMPYLOBACTER-PYLORI; VIRAL PERSISTENCE; HUMAN MACROPHAGES; SALMONELLA-TYPHI; PERTUSSIS TOXIN	Interactions between microbes and human hosts can range from a benign, even symbiotic collaboration to a competition that may turn fatal-resulting in death of the host, the microbe or both. Despite advances that have been made over the past decades in understanding microbial pathogens, more people worldwide still die every year from infectious disease than from any other cause. This highlights the relevance of continuing to probe the mechanisms used by microorganisms to cause disease, and emphasizes the need for new model systems to advance our understanding of host-pathogen interactions.	Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, Bethesda, MD 20814 USA; Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Uniformed Services University of the Health Sciences - USA; Stanford University	Merrell, DS (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Microbiol & Immunol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	dmerrell@usuhs.mil						Amieva MR, 2002, CELL MICROBIOL, V4, P677, DOI 10.1046/j.1462-5822.2002.00222.x; Aras RA, 2003, J INFECT DIS, V188, P486, DOI 10.1086/377098; Azuma T, 2004, J INFECT DIS, V189, P820, DOI 10.1086/381782; Baca Oswald G., 1994, Trends in Microbiology, V2, P476, DOI 10.1016/0966-842X(94)90651-3; Barbieri JT, 2000, INT J MED MICROBIOL, V290, P381; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BJORCK L, 1988, J IMMUNOL, V140, P1194; BODE G, 1988, SCAND J GASTROENTERO, V23, P25, DOI 10.3109/00365528809091710; Brake DA, 2003, DNA CELL BIOL, V22, P405, DOI 10.1089/104454903767650676; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Capo C, 2003, J INFECT DIS, V187, P837, DOI 10.1086/368384; Christie PJ, 2000, TRENDS MICROBIOL, V8, P354, DOI 10.1016/S0966-842X(00)01792-3; Cornelis GR, 2002, NAT REV MOL CELL BIO, V3, P742, DOI 10.1038/nrm932; Crowe S, 2003, J LEUKOCYTE BIOL, V74, P635, DOI 10.1189/jlb.0503204; Danelishvili L, 2003, CELL MICROBIOL, V5, P649, DOI 10.1046/j.1462-5822.2003.00312.x; Ernst PB, 2000, ANNU REV MICROBIOL, V54, P615, DOI 10.1146/annurev.micro.54.1.615; FOLIGUET B, 1989, GASTROEN CLIN BIOL, V13, pB65; Gebert B, 2003, SCIENCE, V301, P1099, DOI 10.1126/science.1086871; Geng YM, 2000, J IMMUNOL, V164, P5522, DOI 10.4049/jimmunol.164.10.5522; Gewirtz AT, 2004, J INFECT DIS, V189, P1914, DOI 10.1086/386289; GRAYOWEN SD, 2001, PRINCIPLES BACTERIAL, P559; GRENIER D, 1992, INFECT IMMUN, V60, P1854, DOI 10.1128/IAI.60.5.1854-1857.1992; Gubler DJ, 1998, EMERG INFECT DIS, V4, P442, DOI 10.3201/eid0403.980326; Hilbi H, 1998, J BIOL CHEM, V273, P32895, DOI 10.1074/jbc.273.49.32895; Israel DA, 2001, P NATL ACAD SCI USA, V98, P14625, DOI 10.1073/pnas.251551698; Jarvis MA, 2002, CURR OPIN MICROBIOL, V5, P403, DOI 10.1016/S1369-5274(02)00334-X; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Johnson WE, 2002, ANNU REV MED, V53, P499, DOI 10.1146/annurev.med.53.082901.104053; Kaper James B., 1994, P145; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; KOEHLER JE, 2000, PERSISTENT BACTERIAL, P339; Koesling J, 2001, J IMMUNOL, V167, P11, DOI 10.4049/jimmunol.167.1.11; Krall R, 2000, INFECT IMMUN, V68, P6066, DOI 10.1128/IAI.68.10.6066-6068.2000; Lee SK, 2003, MICROBES INFECT, V5, P1345, DOI 10.1016/j.micinf.2003.09.018; LEVINE MM, 1982, J INFECT DIS, V146, P724, DOI 10.1093/infdis/146.6.724; Loughlin MF, 2003, INFECT IMMUN, V71, P2022, DOI 10.1128/IAI.71.4.2022-2031.2003; MARRA A, 1992, P NATL ACAD SCI USA, V89, P9607, DOI 10.1073/pnas.89.20.9607; Mascie-Taylor CGN, 2003, SCIENCE, V302, P1921, DOI 10.1126/science.1092488; Merrell DS, 2002, TRENDS MICROBIOL, V10, P571, DOI 10.1016/S0966-842X(02)02474-5; MOBLEY HLT, 1995, MICROBIOL REV, V59, P451, DOI 10.1128/MMBR.59.3.451-480.1995; Monack DM, 2004, J EXP MED, V199, P231, DOI 10.1084/jem.20031319; MU HH, 1993, INFECT IMMUN, V61, P2834, DOI 10.1128/IAI.61.7.2834-2840.1993; PETERSON PK, 1977, INFECT IMMUN, V15, P760, DOI 10.1128/IAI.15.3.760-764.1977; PHILLIPS RA, 1964, FED PROC, V23, P705; Philpott DJ, 2002, CELL MICROBIOL, V4, P285, DOI 10.1046/j.1462-5822.2002.00189.x; Rhen M, 2003, TRENDS MICROBIOL, V11, P80, DOI 10.1016/S0966-842X(02)00038-0; Schmidt H, 2004, CLIN MICROBIOL REV, V17, P14, DOI 10.1128/CMR.17.1.14-56.2004; Schulein R, 2002, MOL MICROBIOL, V46, P1053, DOI 10.1046/j.1365-2958.2002.03208.x; Schulein R, 2001, J EXP MED, V193, P1077, DOI 10.1084/jem.193.9.1077; Semino-Mora C, 2003, J INFECT DIS, V187, P1165, DOI 10.1086/368133; SINNOTT CR, 1987, LANCET, V1, P976; Smith MF, 2003, J BIOL CHEM, V278, P32552, DOI 10.1074/jbc.M305536200; Stenger S, 1998, J IMMUNOL, V161, P3582; THERN A, 1995, J IMMUNOL, V154, P375; Umehara S, 2003, ONCOGENE, V22, P8337, DOI 10.1038/sj.onc.1207028; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; Valenzuela M, 2003, BIOL RES, V36, P429, DOI 10.4067/S0716-97602003000300014; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; VISTICA BP, 1986, CELL IMMUNOL, V101, P232, DOI 10.1016/0008-8749(86)90200-5; Wain J, 1999, J CLIN MICROBIOL, V37, P2466, DOI 10.1128/JCM.37.8.2466-2472.1999; Wain J, 2001, J CLIN MICROBIOL, V39, P1571, DOI 10.1128/JCM.39.4.1571-1576.2001; Waldor MK, 1996, SCIENCE, V272, P1910, DOI 10.1126/science.272.5270.1910; Watarai M, 2002, MICROBIOL-SGM, V148, P1439, DOI 10.1099/00221287-148-5-1439; Weeks DL, 2000, SCIENCE, V287, P482, DOI 10.1126/science.287.5452.482; Wilhelmi I, 2003, CLIN MICROBIOL INFEC, V9, P247, DOI 10.1046/j.1469-0691.2003.00560.x	66	130	138	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					250	256		10.1038/nature02760	http://dx.doi.org/10.1038/nature02760			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241423	Bronze			2022-12-28	WOS:000222470600053
J	Schrier, RW; Wang, W				Schrier, RW; Wang, W			Mechanisms of disease: Acute renal failure and sepsis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							NITRIC-OXIDE; PROGNOSTIC-FACTORS; CLINICAL-TRIALS; VASOPRESSIN; MORTALITY; THERAPY; MICE; HYPOTENSION; DYSFUNCTION; ENDOTHELIN		Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Schrier, RW (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Box C-281, Denver, CO 80262 USA.	robert.schrier@uchsc.edu			NIDDK NIH HHS [DK52599] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052599] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; ARNAULD E, 1977, PFLUG ARCH EUR J PHY, V371, P193, DOI 10.1007/BF00586258; BARTELSTONE HJ, 1965, AM J PHYSIOL, V208, P754, DOI 10.1152/ajplegacy.1965.208.4.754; BENEDICT CR, 1992, CIRC SHOCK, V38, P165; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brivet FG, 1996, CRIT CARE MED, V24, P192, DOI 10.1097/00003246-199602000-00003; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; COWLEY AW, 1988, HYPERTENSION, V11, P25; CRONIN L, 1995, CRIT CARE MED, V23, P1430, DOI 10.1097/00003246-199508000-00019; CUMMING AD, 1988, AM J KIDNEY DIS, V11, P23, DOI 10.1016/S0272-6386(88)80170-7; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DAVIES NW, 1990, NATURE, V343, P375, DOI 10.1038/343375a0; EDELSTEIN CL, 2001, DIS KIDNEY URINARY T, V2, P1041; Esson ML, 2002, ANN INTERN MED, V137, P744, DOI 10.7326/0003-4819-137-9-200211050-00010; FERNANDES CJ, 1994, AM J CARDIOL, V74, P958, DOI 10.1016/0002-9149(94)90597-5; Filep JG, 2000, BRIT J PHARMACOL, V129, P975, DOI 10.1038/sj.bjp.0703114; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; Finney SJ, 2003, JAMA-J AM MED ASSOC, V290, P2041, DOI 10.1001/jama.290.15.2041; Gallagher J, 2001, INTENS CARE MED, V27, P1169, DOI 10.1007/s001340100973; GATTINONI L, 1995, NEW ENGL J MED, V333, P1025, DOI 10.1056/NEJM199510193331601; HAYES MA, 1994, NEW ENGL J MED, V330, P1717, DOI 10.1056/NEJM199406163302404; Hohlfeld T, 1995, BRIT J PHARMACOL, V116, P3309, DOI 10.1111/j.1476-5381.1995.tb15140.x; HOLLENBERG SM, 1993, AM J PHYSIOL, V264, pH660, DOI 10.1152/ajpheart.1993.264.2.H660; Hollenberg SM, 2000, CIRC RES, V86, P774, DOI 10.1161/01.RES.86.7.774; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; KAUFMANN H, 1991, LANCET, V338, P1542, DOI 10.1016/0140-6736(91)92370-H; KEUNG EC, 1991, J CLIN INVEST, V88, P1772, DOI 10.1172/JCI115497; KIKERI D, 1986, AM J PHYSIOL, V250, P1098, DOI 10.1152/ajprenal.1986.250.6.F1098; Knotek M, 2001, KIDNEY INT, V59, P2243, DOI 10.1046/j.1523-1755.2001.00740.x; KON V, 1991, KIDNEY INT, V40, P1, DOI 10.1038/ki.1991.172; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kumar A, 2000, CRIT CARE CLIN, V16, P251, DOI 10.1016/S0749-0704(05)70110-X; Landry DW, 1997, CIRCULATION, V95, P1122; Landry DW, 2001, NEW ENGL J MED, V345, P588, DOI 10.1056/NEJMra002709; LEFERING R, 1995, CRIT CARE MED, V23, P1294, DOI 10.1097/00003246-199507000-00021; Lopez A, 2004, CRIT CARE MED, V32, P21, DOI 10.1097/01.CCM.0000105581.01815.C6; Melnikov VY, 2001, J CLIN INVEST, V107, P1145, DOI 10.1172/JCI12089; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Neveu H, 1996, NEPHROL DIAL TRANSPL, V11, P293, DOI 10.1093/oxfordjournals.ndt.a027256; Opal SM, 1999, INFECT DIS CLIN N AM, V13, P285, DOI 10.1016/S0891-5520(05)70075-1; Phu NH, 2002, NEW ENGL J MED, V347, P895, DOI 10.1056/NEJMoa020074; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Reinhart K, 2001, CRIT CARE MED, V29, pS121, DOI 10.1097/00003246-200107001-00037; Reinhart K, 2002, CRIT CARE MED, V30, pS302, DOI 10.1097/00003246-200205001-00021; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; Riedemann NC, 2003, J CLIN INVEST, V112, P460, DOI 10.1172/JCI200319523; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Ronco C, 2000, LANCET, V356, P26, DOI 10.1016/S0140-6736(00)02430-2; SANZ E, 1990, J CARDIOVASC PHARM, V15, P485, DOI 10.1097/00005344-199003000-00020; Schiffl H, 2002, NEW ENGL J MED, V346, P305, DOI 10.1056/NEJMoa010877; Schor N, 2002, KIDNEY INT, V61, P764, DOI 10.1046/j.1523-1755.2002.00178.x; Schrier RW, 1999, NEW ENGL J MED, V341, P577, DOI 10.1056/NEJM199908193410806; SCHRIER RW, 1995, HOSP PRACT, V30, P19, DOI 10.1080/21548331.1995.11443205; SCHRIER RW, 1967, ANN INTERN MED, V67, P356, DOI 10.7326/0003-4819-67-2-356; SCHRIER RW, 1990, ANN INTERN MED, V113, P155, DOI 10.7326/0003-4819-113-2-155; SCHRIER RW, 1995, HOSP PRACT OFF ED, V30, P23; Schwartz D, 1997, J CLIN INVEST, V100, P439, DOI 10.1172/JCI119551; SHIMAMURA K, 1983, ARCH PATHOL LAB MED, V107, P543; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Tonelli M, 2002, AM J KIDNEY DIS, V40, P875, DOI 10.1053/ajkd.2002.36318; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Umino T, 1999, AM J PHYSIOL-RENAL, V276, pF433, DOI 10.1152/ajprenal.1999.276.3.F433; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WAKATSUKI T, 1992, AM J PHYSIOL, V263, pH491, DOI 10.1152/ajpheart.1992.263.2.H491; WANG CY, 2001, CHIN J CHEM PHYS, V14, P350; Wang W, 2003, AM J PHYSIOL-RENAL, V284, pF532, DOI 10.1152/ajprenal.00323.2002; Wang W, 2002, AM J PHYSIOL-RENAL, V283, pF583, DOI 10.1152/ajprenal.00270.2001; WANG W, IN PRESS J AM SOC NE; ZERBE RL, 1983, AM J MED, V74, P265, DOI 10.1016/0002-9343(83)90625-3	72	827	914	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					159	169		10.1056/NEJMra032401	http://dx.doi.org/10.1056/NEJMra032401			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247356				2022-12-28	WOS:000222470700009
J	Hamers, FF; Downs, AM				Hamers, FF; Downs, AM			The changing face of the HIV epidemic in western Europe: what are the implications for public health policies?	LANCET			English	Review							ACTIVE ANTIRETROVIRAL THERAPY; SEXUAL RISK BEHAVIOR; INJECTING DRUG-USERS; HOMOSEXUAL-MEN; COMBINATION THERAPIES; SURVEILLANCE SYSTEM; AIDS; INFECTION; TRANSMISSION; GONORRHEA	In this review, we describe changes in dynamics of HIV transmission and shifts in affected populations in western Europe using HIV/AIDS surveillance data and published and unpublished reports. Despite substantial reductions in HIV-related morbidity and mortality since the introduction of highly active antiretroviral treatment, HIV continues to pose a major public health problem in western Europe. More than half a million people are living with an infection that remains incurable and requires costly lifelong treatment; many people remain unaware of their infection, and thousands of new infections continue to occur every year. Migrants from countries with a high prevalence of HIV/AIDS, notably sub-Saharan Africa, bear a disproportionate and increasing share of HIV throughout western Europe and, in most countries, account for the majority of heterosexually acquired HIV infections diagnosed in recent years. Prevention, treatment, and care must be adapted to reach migrant populations. Following a resurgence of risky sexual behaviour, HIV transmission may now be increasing among homosexual and bisexual men, and renewed safer sex campaigns are urgently needed.	Inst Veille Sanitaire, EuroHIV, Dept Infect Dis, F-94415 St Maurice, France	Institute of Public Health Surveillance	Hamers, FF (corresponding author), Inst Veille Sanitaire, EuroHIV, Dept Infect Dis, 12 Rue Val Osne, F-94415 St Maurice, France.	f.hamers@invs.sante.fr						Aalen OO, 1999, AIDS, V13, P103, DOI 10.1097/00002030-199901140-00014; ADAM P, 2001, INCREASING RISK TAKI; Alvarez M, 2002, TRANSFUSION, V42, P994, DOI 10.1046/j.1537-2995.2002.00154.x; [Anonymous], 1993, AIDS, V7, P401; Belza MJ, 2001, AIDS CARE, V13, P677, DOI 10.1080/09540120120063296; Blaxhult A, 1999, HIV Med, V1, P2, DOI 10.1046/j.1468-1293.1999.00002.x; BLOWER SM, 2000, SCIENCE, V92, P388; Castilla J, 2002, AIDS, V16, P1945, DOI 10.1097/00002030-200209270-00012; Clumeck N, 2003, AIDS, V17, pS3, DOI 10.1097/01.aids.0000060397.18106.12; Couturier E., 2004, Bulletin Epidemiologique Hebdomadaire, P9; *CTR EST EP HIV SI, 2001, SIVES 2001 INT HIV A; Cusini M, 2004, SEX TRANSM INFECT, V80, P154, DOI 10.1136/sti.2003.007526; D'Antuono A, 2001, SEX TRANSM INFECT, V77, P220, DOI 10.1136/sti.77.3.220; D'Ubaldo C, 1999, Minerva Ginecol, V51, P7; De la Fuente L, 1997, ADDICTION, V92, P1749, DOI 10.1111/j.1360-0443.1997.tb02895.x; DECOUL ELO, 2003, 441100018 RIVM; DECOUL ELO, 2003, HIV INFECT AIDS NEDE, P1; del Romero J, 2001, AIDS, V15, P1319, DOI 10.1097/00002030-200107060-00019; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; Downs AM, 2000, AIDS, V14, P2179, DOI 10.1097/00002030-200009290-00015; Dray-Spira R, 2003, AIDS, V17, P283, DOI 10.1097/00002030-200302140-00001; DUBOIS RM, 1981, LANCET, V2, P1339; DUBOISARBER F, 1994, SOZ PRAVENTIV MED, V39, pS3, DOI 10.1007/BF01322421; DUBOISARBER F, 2002, EUROSURVEILLANCE, V7, P18; Dukers NHTM, 2002, AIDS, V16, pF19, DOI 10.1097/00002030-200207050-00001; Dukers NHTM, 2001, AIDS, V15, P369, DOI 10.1097/00002030-200102160-00010; Elford J, 2000, J ACQ IMMUN DEF SYND, V23, P266; Emmanuelli J., 2003, Bulletin Epidemiologique Hebdomadaire, P97; *EUR CTR EP MON AI, 2002, HIV AIDS SURV EUR MI; *EUR CTR EP MON AI, 2003, HIV AIDS SURV EUR MI; *EUR MON CTR DRUGS, 2003, STAT DRUGS PROBL EUR; European Centre for the Epidemiological Monitoring of AIDS, 2003, HIV AIDS SURV EUR EN; Fenton KA, 2000, LANCET, V355, P1907, DOI 10.1016/S0140-6736(00)02305-9; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; GEBHARDT M, 2003, EUROSURVEILLANCE, V7; Girardi E, 2003, SCAND J INFECT DIS, V35, P17, DOI 10.1080/03008870310009597; GRAS L, 2003, MONITORING HUMAN IMM; Grulich A, 2000, BMJ-BRIT MED J, V320, P1487, DOI 10.1136/bmj.320.7248.1487; Grulich AE, 2002, AIDS, V16, P1155, DOI 10.1097/00002030-200205240-00009; Hamers F, 1996, BRIT MED J, V312, P847; Hamers FF, 2003, JAIDS-J ACQ IMM DEF, V32, pS39, DOI 10.1097/00126334-200302011-00007; Hamers FF, 2003, LANCET, V361, P1035, DOI 10.1016/S0140-6736(03)12831-0; Hamers FF, 1997, AIDS, V11, P1365, DOI 10.1097/00002030-199711000-00011; HAMOUDA O, 2003, EUROSURVEILLANCE, V7; Haour-Knipe M, 1999, SOC SCI MED, V49, P1357, DOI 10.1016/S0277-9536(99)00189-6; Hart GJ, 1999, SEX TRANSM INFECT, V75, P242, DOI 10.1136/sti.75.4.242; Herida M, 2004, SEX TRANSM DIS, V31, P209, DOI 10.1097/01.OLQ.0000118426.66742.9E; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; *HLTH PROT AG, 2003, SHOOT INF INJ DRUG U; *HLTH PROT AG, 2002, CDSC NO IR UASSG REN; *HLTH PROT AG, 2002, SUPPL DAT TABL UNL A; *HLTH SERV CIRC, 1999, RED MOTH BAB TRANSM; Houweling H, 1998, AIDS, V12, P85, DOI 10.1097/00002030-199801000-00010; *I SCI SANT PUBL, 2003, 57 I SCI SANT PUBL; JANSSEN RS, 1998, JAMA-J AM MED ASSOC, V2080, P42; Johansen JD, 2002, ACTA DERM-VENEREOL, V82, P365, DOI 10.1080/000155502320624104; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Kvam B M, 2000, Tidsskr Nor Laegeforen, V120, P2895; Laporte A, 2002, AIDS, V16, P397, DOI 10.1097/00002030-200202150-00011; Lederman MM, 2000, JAMA-J AM MED ASSOC, V284, P223, DOI 10.1001/jama.284.2.223; Levin BR, 2001, EMERG INFECT DIS, V7, P505, DOI 10.3201/eid0707.017704; LINDGREN S, 1993, BRIT MED J, V307, P1447, DOI 10.1136/bmj.307.6917.1447; Lot F., 2004, Bulletin Epidemiologique Hebdomadaire, P17; LOT F, 1997, B EPIDEMIOLOGIQUE HE, V11, P443; Marks G, 1999, AIDS, V13, P297, DOI [10.1097/00002030-199902250-00001, 10.1080/088395199117432]; Martin IMC, 2000, LANCET, V355, P623, DOI 10.1016/S0140-6736(99)05495-1; *MIN SAN CONS, 2002, ENC HOSP PAC VIH SID; Miners A H, 2001, HIV Med, V2, P52, DOI 10.1046/j.1468-1293.2001.00048.x; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Moreno C, 2003, Anales Sis San Navarra, V26, P269, DOI 10.4321/s1137-66272003000300009; Murphy G, 2004, AIDS, V18, P265, DOI 10.1097/00002030-200401230-00016; *NDSC, 2003, NAT DIS SURV CTR ANN; Nicoll A, 2002, BMJ-BRIT MED J, V324, P1324, DOI 10.1136/bmj.324.7349.1324; *OFDT, 2003, REP EMCDDA REIT NAT; Paget WJ, 1997, GENITOURIN MED, V73, P444; Parekh BS, 2002, AIDS RES HUM RETROV, V18, P295, DOI 10.1089/088922202753472874; PILLONEL J, 2000, TRANSFUSION, V42, P966; POLLAK M, 1994, SOZ PRAVENTIV MED, V39, pS47, DOI 10.1007/BF01322423; *R KOCH I, 2003, EP B R KOCH I, P1; *R KOCH I, 2003, EP B, P395; Rapiti E, 2000, EPIDEMIOLOGY, V11, P496, DOI 10.1097/00001648-200009000-00003; Rawal BD, 2003, JAIDS-J ACQ IMM DEF, V33, P349, DOI 10.1097/00126334-200307010-00009; Rey D, 1998, EUR J OBSTET GYN R B, V76, P5, DOI 10.1016/S0301-2115(97)00136-X; REZZA G, 1994, SOZ PRAVENTIV MED, V39, pS61, DOI 10.1007/BF01322424; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; ROZENBAUM W, 1982, LANCET, V1, P572; Sasse A, 2000, AIDS, V14, P2798, DOI 10.1097/00002030-200012010-00026; SEMAILLE C, 2003, EUROSURVEILLANCE, V7; Sinka K, 2003, AIDS, V17, P1683, DOI 10.1097/00002030-200307250-00013; Smyth BP, 2000, ADDICTION, V95, P1217, DOI 10.1046/j.1360-0443.2000.95812178.x; Soldan K, 2003, VOX SANG, V84, P274, DOI 10.1046/j.1423-0410.2003.00296.x; Spina M, 1998, SEX TRANSM DIS, V25, P451, DOI 10.1097/00007435-199810000-00001; Spizzichino L, 2001, SEX TRANSM DIS, V28, P405, DOI 10.1097/00007435-200107000-00008; *STAT SER I, 2003, 342003 EPINEWS STAT; Stephenson JM, 2003, SEX TRANSM INFECT, V79, P7, DOI 10.1136/sti.79.1.7; Stolte IG, 2001, SEX TRANSM INFECT, V77, P184, DOI 10.1136/sti.77.3.184; Strang J, 1999, AM J ADDICTION, V8, P148; Suligoi B, 2003, SCAND J INFECT DIS, V35, P12, DOI 10.1080/03008870310009588; SULIGOI B, 2002, J ACQ IMMUN DEF SYND, V32, P424; *SWED I INF DIS CO, 2002, COMM DIS SWED 2001; Thorne C, 2001, AIDS, V15, P761, DOI 10.1097/00002030-200104130-00012; *UN POP DIV, 2001, WORLD POP PROSP 2000; *UNAIDS, 2002, REP GLOB HIV AIDS EP; *UNAIDS WHO, 2003, AIDS EP UPD; Van Asten LC, 2003, EUR J PUBLIC HEALTH, V13, P347, DOI 10.1093/eurpub/13.4.347; VELATI C, 2000, TRANSFUSION, V42, P983; Vernazza PL, 2000, AIDS, V14, P117, DOI 10.1097/00002030-200001280-00006; Vernazza PL, 1999, AIDS, V13, P155, DOI 10.1097/00002030-199902040-00003; Verster A, 2001, AIDS CARE, V13, P367, DOI 10.1080/09540120120044017; VILASECA J, 1982, LANCET, V1, P572; Welp EAE, 2002, AIDS, V16, P1279, DOI 10.1097/00002030-200206140-00011; *WHO, 1986, WHO WKLY EPIDEM REC, V61, P125; *WHO, 2003, TREAT 3 MILL 2005 MA; *WHO, 2000, WHOCDSCSREDC20005 UN; Wolitski RJ, 2001, AM J PUBLIC HEALTH, V91, P883, DOI 10.2105/AJPH.91.6.883; Yazdanpanah Y, 2002, ANTIVIR THER, V7, P257	118	144	152	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					83	94		10.1016/S0140-6736(04)16594-X	http://dx.doi.org/10.1016/S0140-6736(04)16594-X			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	834DX	15234861				2022-12-28	WOS:000222392900036
J	Stricker, BHC; Psaty, BM				Stricker, BHC; Psaty, BM			Detection, verification, and quantification of adverse drug reactions	BRITISH MEDICAL JOURNAL			English	Article							RISK; PHARMACOVIGILANCE; THERAPY		Erasmus Med Ctr, Pharmacoepidemiol Unit, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA; Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA; Univ Washington, Epidemiol Serv, Seattle, WA USA; Univ Washington, Hlth Serv, Seattle, WA USA	Erasmus University Rotterdam; Erasmus MC; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Stricker, BHC (corresponding author), Erasmus Med Ctr, Pharmacoepidemiol Unit, Dept Epidemiol & Biostat, POB 1738, NL-3000 DR Rotterdam, Netherlands.	b.stricker@erasmusmc.nl						Arnaiz JA, 2001, EUR J CLIN PHARMACOL, V57, P89, DOI 10.1007/s002280100265; DERBY LE, 1993, MED J AUSTRALIA, V158, P596, DOI 10.5694/j.1326-5377.1993.tb137624.x; Egberts ACG, 2002, DRUG SAFETY, V25, P453, DOI 10.2165/00002018-200225060-00010; Gale EAM, 2001, LANCET, V357, P1870, DOI 10.1016/S0140-6736(00)04960-6; Henry D, 2002, LANCET, V360, P1590, DOI 10.1016/S0140-6736(02)11527-3; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; Jick H, 1998, NEW ENGL J MED, V339, P719, DOI 10.1056/NEJM199809103391102; Kubota K, 1996, EUR J CLIN PHARMACOL, V49, P431, DOI 10.1007/s002280050046; Meier CR, 1998, J RHEUMATOL, V25, P1515; Miettinen O S, 1983, Stat Med, V2, P267, DOI 10.1002/sim.4780020222; Ray WA, 2004, CLIN PHARMACOL THER, V75, P234, DOI 10.1016/j.clpt.2003.09.019; Ray WA, 2000, J AM GERIATR SOC, V48, P682, DOI 10.1111/j.1532-5415.2000.tb04729.x; Rodriguez LAG, 1996, ARCH INTERN MED, V156, P1327, DOI 10.1001/archinte.1996.00440110099013; Staffa JA, 2002, NEW ENGL J MED, V346, P539, DOI 10.1056/NEJM200202143460721; STRAUS SMJ, 2004, IN PRESS ARCH INT ME; STRICKER BHC, 1992, J CLIN EPIDEMIOL, V45, P1177, DOI 10.1016/0895-4356(92)90158-J; TUBERT P, 1992, J CLIN EPIDEMIOL, V45, P283, DOI 10.1016/0895-4356(92)90088-5; van der Linden PD, 2003, ARCH INTERN MED, V163, P1801, DOI 10.1001/archinte.163.15.1801; VENNING GR, 1983, BRIT MED J, V286, P458, DOI 10.1136/bmj.286.6363.458; Zornberg GL, 2000, LANCET, V356, P1219, DOI 10.1016/S0140-6736(00)02784-7	21	131	135	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					44	47		10.1136/bmj.329.7456.44	http://dx.doi.org/10.1136/bmj.329.7456.44			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231627	Green Published, Green Submitted			2022-12-28	WOS:000222568300027
J	Christian, MD; Detsky, AS				Christian, MD; Detsky, AS			A twist of fate?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ARTERY; MANIPULATION; CIGUATERA; STROKE		Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Hlth Network, Dept Med, Toronto, ON, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Christian, MD (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.		Christian, Michael/AAZ-4452-2020; Christian, Mike/AAO-6338-2020	Christian, Michael/0000-0001-9644-9950; Christian, Mike/0000-0001-9644-9950				Angibaud G, 1998, J NEUROL NEUROSUR PS, V64, P688; [Anonymous], 2002, ANN EMERG MED, V39, P108; Ernst E, 2001, STROKE, V32, P809, DOI 10.1161/01.STR.32.3.809; FRISONI GB, 1991, STROKE, V22, P1452, DOI 10.1161/01.STR.22.11.1452; Kapral MK, 2001, CAN MED ASSOC J, V165, P907; KITANAKA C, 1994, J NEUROSURG, V80, P1132; KITANAKA C, 1994, J NEUROSURG, V80, P667, DOI 10.3171/jns.1994.80.4.0667; LANGE WR, 1992, ARCH INTERN MED, V152, P2049, DOI 10.1001/archinte.152.10.2049; Norris JW, 2000, CAN MED ASSOC J, V163, P38; Pearn J, 2001, J NEUROL NEUROSUR PS, V70, P4, DOI 10.1136/jnnp.70.1.4; PHILLIPS SJ, 1989, CAN J NEUROL SCI, V16, P348, DOI 10.1017/S0317167100029218; Poli MA, 1997, TOXICON, V35, P733, DOI 10.1016/S0041-0101(96)00166-3; Rothwell DM, 2001, STROKE, V32, P1054, DOI 10.1161/01.STR.32.5.1054; Schievink WI, 2000, CURR OPIN CARDIOL, V15, P316, DOI 10.1097/00001573-200009000-00002; SHERMAN DG, 1981, STROKE, V12, P2, DOI 10.1161/01.STR.12.1.2; STURZENEGGER M, 1994, HEADACHE, V34, P187, DOI 10.1111/j.1526-4610.1994.hed3404187.x	16	4	4	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					69	73		10.1056/NEJMcps025162	http://dx.doi.org/10.1056/NEJMcps025162			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229310				2022-12-28	WOS:000222352200011
J	Deayton, JR; Sabin, CA; Johnson, MA; Emery, VC; Wilson, P; Griffiths, PD				Deayton, JR; Sabin, CA; Johnson, MA; Emery, VC; Wilson, P; Griffiths, PD			Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE-CHAIN-REACTION; CMV DNA LOAD; AIDS PATIENTS; HEMOPHILIA; RETINITIS; SURVIVAL; SEROCONVERSION; COHORT	Background Before highly active antiretroviral therapy (HAART) became available, cytomegalovirus was a major cause of opportunistic infection in HIV-infected patients and was associated with accelerated progression to AIDS and death. We have investigated whether cytomegalovirus viraemia remains a significant risk factor for progression of HIV disease and death in the era of HAART. Methods 374 patients whose CD4-cell count had ever been below 100 per muL were enrolled in a prospective study. Serial blood samples were tested for cytomegalovirus by PCR. Rates of new cytomegalovirus disease, new AIDS-defining disorders, and death were calculated over a median follow-up of 37 months after stratification according to baseline and most recent cytomegalovirus PCR status at any point during follow-up. Findings Of 2969 PCR assays, 375 (12.6%) were positive for cytomegalovirus DNA. 259 (69.3%) patients were persistently negative for cytomegalovirus by PCR; 15 were persistently positive; and 100 were intermittently positive and negative. In multivariate models, cytomegalovirus PCR-positive status as a time-updated covariate was significantly associated with increased relative rates of progression to a new AIDS-defining disorder (2.22 [95% Cl 1.27-3.88] p=0.005) and death (4.14 [1.97-8.70] p=0.0002). Interpretation Detection of cytomegalovirus in blood by PCR continues to identify patients with a poor prognosis, even in the era of HAART. Randomised controlled clinical trials of drugs active against cytomegalovirus are needed to investigate whether this virus is a marker or a determinant of HIV disease progression.	UCL, Royal Free & Univ Coll Med Sch, Dept Virol, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; UCL, Royal Free & Univ Coll Med Sch, Dept HIV AIDS, London NW3 2PF, England	University of London; University College London; University of London; University College London; University of London; University College London	Griffiths, PD (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Virol, Royal Free Campus, London NW3 2PF, England.	pgriffiths@rfc.ucl.ac.uk	Sabin, Caroline/C-2464-2008; Emery, Vincent/G-8928-2013	Sabin, Caroline/0000-0001-5173-2760; Emery, Vincent/0000-0001-5893-9756	NIAID NIH HHS [1R01 AI41687] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041687] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; Bowen EF, 1997, AIDS, V11, P889, DOI 10.1097/00002030-199707000-00008; Bowen EF, 1996, AIDS, V10, P1515, DOI 10.1097/00002030-199611000-00009; Deayton J, 1999, AIDS, V13, P1203, DOI 10.1097/00002030-199907090-00008; Deayton JR, 2000, AIDS, V14, P1163, DOI 10.1097/00002030-200006160-00013; DETELS R, 1994, J INFECT DIS, V169, P766, DOI 10.1093/infdis/169.4.766; Dodt KK, 1997, AIDS, V11, pF21, DOI 10.1097/00002030-199703110-00001; Griffiths PD, 1998, J GEN VIROL, V79, P213, DOI 10.1099/0022-1317-79-2-213; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Kempen JH, 2003, CLIN INFECT DIS, V37, P1365, DOI 10.1086/379077; KIDD IM, 1993, TRANSPLANTATION, V56, P867, DOI 10.1097/00007890-199310000-00018; Kovacs A, 1999, NEW ENGL J MED, V341, P77, DOI 10.1056/NEJM199907083410203; MONFORTE AD, 1992, AIDS, V6, P1159, DOI 10.1097/00002030-199210000-00015; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; PILLAY D, 1993, AIDS, V7, P969, DOI 10.1097/00002030-199307000-00010; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; Razonable RR, 2002, TRANSPLANTATION, V73, P968, DOI 10.1097/00007890-200203270-00025; Robain M, 2000, EPIDEMIOL INFECT, V125, P415, DOI 10.1017/S0950268899004549; SABIN CA, 1995, EPIDEMIOL INFECT, V114, P361, DOI 10.1017/S095026880005799X; Sabin CA, 2000, J INFECT DIS, V181, P1800, DOI 10.1086/315476; Shinkai M, 1997, J INFECT DIS, V175, P302, DOI 10.1093/infdis/175.2.302; Spector SA, 1999, J VIROL, V73, P7027, DOI 10.1128/JVI.73.8.7027-7030.1999; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; Touloumi G, 1998, J ACQ IMMUN DEF SYND, V19, P89, DOI 10.1097/00042560-199809010-00014; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1992, CLIN EXP IMMUNOL, V88, P6; WILKES MS, 1988, LANCET, V2, P85	27	154	166	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2116	2121		10.1016/S0140-6736(04)16500-8	http://dx.doi.org/10.1016/S0140-6736(04)16500-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220032				2022-12-28	WOS:000222268300007
J	Hawe, P; Shiell, A; Riley, T				Hawe, P; Shiell, A; Riley, T			Complex interventions: how "out of control" can a randomised controlled trial be?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EVALUATING HEALTH-PROMOTION; FIDELITY; PROGRAM; SUPPORT		Univ Calgary, Dept Community Hlth Sci, Calgary, AB T2N 4N1, Canada	University of Calgary	Hawe, P (corresponding author), Univ Calgary, Dept Community Hlth Sci, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	phawe@ucalgary.ca	Shiell, Alan/AAL-4146-2020	Shiell, Alan/0000-0001-5914-1084				BAUMAN LJ, 1991, AM J COMMUN PSYCHOL, V19, P619, DOI 10.1007/BF00937995; CASTI JL, 1997, WOULD BE WORDS SIMUL; Castro FG, 2004, PREV SCI, V5, P41, DOI 10.1023/B:PREV.0000013980.12412.cd; Durlak JA., 1998, J PREV INTERV COMMUN, V17, P5, DOI [10.1300/J005v17n02_02, DOI 10.1300/J005V17N02_02]; FLAY BR, 1986, PREV MED, V15, P451, DOI 10.1016/0091-7435(86)90024-1; FLORA JA, 1993, HEALTH EDUC RES, V8, P81, DOI 10.1093/her/8.1.81; HAWE P, 1995, HLTH PROMOT J AUST, V5, P4; Hawe P., 1990, EVALUATING HLTH PROM; ISRAEL BA, 1985, HEALTH EDUC QUART, V12, P65, DOI 10.1177/109019818501200106; LLEWELLYNJONES RH, 1999, BRIT MED J, V319, P677; Lumley J, 2003, BMC PUBLIC HEALTH, V3, DOI 10.1186/1471-2458-3-36; McMahon AD, 2002, STAT MED, V21, P1365, DOI 10.1002/sim.1120; Medical Research Council, 2000, FRAM DEV EV RAND CON; MULLEN PD, 1985, PREV MED, V14, P753, DOI 10.1016/0091-7435(85)90070-2; Nutbeam D, 1998, HEALTH PROMOT INT, V13, P27, DOI 10.1093/heapro/13.1.27; Oakley A, 2000, EXPT KNOWING; Ottoson JM, 1987, ADV HLTH ED PROMOTIO, P353; Paton J, 2001, SOC PSYCH PSYCH EPID, V36, P423, DOI 10.1007/s001270170019; Secker-Walker R, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.cd001745, DOI 10.1002/14651858.CD001745, 10.1002/14651858.CD001745]; SUSSER M, 1995, AM J PUBLIC HEALTH, V85, P156, DOI 10.2105/AJPH.85.2.156; Thompson B, 2003, ANNU REV PUBL HEALTH, V24, P315, DOI 10.1146/annurev.publhealth.24.100901.140819; Tones K, 2000, PATIENT EDUC COUNS, V39, P227, DOI 10.1016/S0738-3991(99)00035-X; World Health Organization Europe, 1999, HLTH PROM EV REC POL	23	743	746	0	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2004	328	7455					1561	1563		10.1136/bmj.328.7455.1561	http://dx.doi.org/10.1136/bmj.328.7455.1561			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217878	Green Published			2022-12-28	WOS:000222392700030
J	Whitley, RJ				Whitley, RJ			Cytomegalovirus and HIV: inextricably entwined pathogens	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMOPHILIACS; PROGRESSION; INFECTION; AIDS; DISEASE; TYPE-1		Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA; Univ Alabama, Dept Microbiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Med, Birmingham, AL 35233 USA; Univ Alabama, Dept Neurosurg, Birmingham, AL 35233 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Whitley, RJ (corresponding author), Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA.	rwhitley@peds.uab.edu						BECHERER PR, 1990, AM J HEMATOL, V34, P204, DOI 10.1002/ajh.2830340310; Griffiths PD, 1998, J GEN VIROL, V79, P213, DOI 10.1099/0022-1317-79-2-213; JACKSON JB, 1988, TRANSFUSION, V28, P187, DOI 10.1046/j.1537-2995.1988.28288179029.x; LEE CA, 1991, BMJ-BRIT MED J, V303, P1093, DOI 10.1136/bmj.303.6810.1093; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RUGMAN FP, 1989, LANCET, V2, P631; Sabin CA, 2000, J INFECT DIS, V181, P1800, DOI 10.1086/315476; TARTAGLIONE TA, 1991, ANTIMICROB AGENTS CH, V35, P2225, DOI 10.1128/AAC.35.11.2225; WEBSTER A, 1989, LANCET, V2, P63	9	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2101	2102		10.1016/S0140-6736(04)16534-3	http://dx.doi.org/10.1016/S0140-6736(04)16534-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220028				2022-12-28	WOS:000222268300003
J	Lamy, F; Kaiser, J; Ninnemann, U; Hebbeln, D; Arz, HW; Stoner, J				Lamy, F; Kaiser, J; Ninnemann, U; Hebbeln, D; Arz, HW; Stoner, J			Antarctic timing of surface water changes off Chile and Patagonian ice sheet response	SCIENCE			English	Article							SOUTHERN CHILE; CLIMATE-CHANGE; TROPICAL PACIFIC; LAST GLACIATION; MARINE RECORD; EL-NINO; DEGLACIATION; CIRCULATION; OSCILLATION; VARIABILITY	Marine sediments from the Chilean continental margin are used to infer millennial-scale changes in southeast Pacific surface ocean water properties and Patagonian ice sheet extent since the last glacial period. Our data show a clear "Antarctic" timing of sea surface temperature changes, which appear systematically linked to meridional displacements in sea ice, westerly winds, and the circumpolar current system. Proxy data for ice sheet changes show a similar pattern as oceanographic variations offshore, but reveal a variable glacier-response time of up to similar to1000 years, which may explain some of the current discrepancies among terrestrial records in southern South America.	Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany; DFG Res Ctr Ocean Margins, D-28359 Bremen, Germany; Univ Bergen, Dept Earth Sci, N-5007 Bergen, Norway; Univ Bergen, Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA	Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; German Research Foundation (DFG); University of Bergen; Bjerknes Centre for Climate Research; University of Bergen; University of Colorado System; University of Colorado Boulder	Lamy, F (corresponding author), Geoforschungszentrum Potsdam, D-14473 Potsdam, Germany.	flamy@gfz-potsdam.de	Hebbeln, Dierk/P-9766-2016; Arz, Helge/A-6659-2013; Lamy, Frank/H-3611-2014	Hebbeln, Dierk/0000-0001-5099-6115; Arz, Helge Wolfgang/0000-0002-1997-1718; Lamy, Frank/0000-0001-5952-1765				Bennett KD, 2000, SCIENCE, V290, P325, DOI 10.1126/science.290.5490.325; Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Brink KH., 1998, COAST SEGMENT, P273; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Cane MA, 1998, SCIENCE, V282, P59, DOI 10.1126/science.282.5386.59; Cerveny RS, 1998, CLIMATES SO CONTINEN, P107; Denton GH, 1999, GEOGR ANN A, V81A, P167, DOI 10.1111/1468-0459.00057; Denton GH, 1999, GEOGR ANN A, V81A, P107, DOI 10.1111/j.0435-3676.1999.00055.x; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; Heusser L, 1999, QUATERNARY RES, V52, P154, DOI 10.1006/qres.1999.2069; Hulton NRJ, 2002, QUATERNARY SCI REV, V21, P233, DOI 10.1016/S0277-3791(01)00103-2; Knorr G, 2003, NATURE, V424, P532, DOI 10.1038/nature01855; Koutavas A, 2002, SCIENCE, V297, P226, DOI 10.1126/science.1072376; Lamy F, 2001, EARTH PLANET SC LETT, V185, P369, DOI 10.1016/S0012-821X(00)00381-2; LOWELL TV, 1995, SCIENCE, V269, P1541, DOI 10.1126/science.269.5230.1541; Mix A.C., 2003, P OCEAN DRILLING PRO, V202, P1, DOI DOI 10.2973/ODP.PROC.IR.202.101.2003; Moreno PI, 2001, NATURE, V409, P804, DOI 10.1038/35057252; NINNEMANN US, 1999, MECH GLOBAL CLIMATE, P94; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; Rahmstorf S, 2002, NATURE, V419, P207, DOI 10.1038/nature01090; Rosenthal Y, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016612; Stocker TF, 1998, SCIENCE, V282, P61, DOI 10.1126/science.282.5386.61; Stocker TF, 2002, SCIENCE, V297, P1814, DOI 10.1126/science.1075870; Stott L, 2002, SCIENCE, V297, P222, DOI 10.1126/science.1071627; STUUT JB, IN PRESS GEOLOGY; Tudhope AW, 2001, SCIENCE, V291, P1511, DOI 10.1126/science.1057969; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002	29	252	262	0	42	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1959	1962		10.1126/science.1097863	http://dx.doi.org/10.1126/science.1097863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218147	Green Submitted			2022-12-28	WOS:000222241600044
J	Wertz, IE; O'Rourke, KM; Zhou, HL; Eby, M; Aravind, L; Seshagiri, S; Wu, P; Wiesmann, C; Baker, R; Boone, DL; Ma, A; Koonin, EV; Dixit, VM				Wertz, IE; O'Rourke, KM; Zhou, HL; Eby, M; Aravind, L; Seshagiri, S; Wu, P; Wiesmann, C; Baker, R; Boone, DL; Ma, A; Koonin, EV; Dixit, VM			De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappa B signalling	NATURE			English	Article							ZINC-FINGER PROTEIN; TNF RECEPTOR; CELL-DEATH; DEUBIQUITINATING ENZYME; CYSTEINE PROTEASES; KINASE RIP; ACTIVATION; TRAF2; IKK; RECRUITMENT	NF-kappaB transcription factors mediate the effects of pro-inflammatory cytokines such as tumour necrosis factor-alpha and interleukin-1beta(1). Failure to downregulate NF-kappaB transcriptional activity results in chronic inflammation and cell death, as observed in A20-deficient mice(2). A20 is a potent inhibitor of NF-kappaB signalling, but its mechanism of action is unknown(2). Here we show that A20 downregulates NF-kappaB signalling through the cooperative activity of its two ubiquitin-editing domains. The amino-terminal domain of A20, which is a de-ubiquitinating (DUB) enzyme of the OTU (ovarian tumour) family(3), removes lysine-63 (K63)-linked ubiquitin chains from receptor interacting protein ( RIP), an essential mediator of the proximal TNF receptor 1 (TNFR1) signalling complex(4,5). The carboxy-terminal domain of A20, composed of seven C-2/C-2 zinc fingers(6), then functions as a ubiquitin ligase by polyubiquitinating RIP with K48-linked ubiquitin chains, thereby targeting RIP for proteasomal degradation. Here we define a novel ubiquitin ligase domain and identify two sequential mechanisms by which A20 downregulates NF-kappaB signalling. We also provide an example of a protein containing separate ubiquitin ligase and DUB domains, both of which participate in mediating a distinct regulatory effect.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA; NCBI, Computat Biol Branch, Natl Lib Med, NIH, Bethesda, MD 20894 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Australian National University; John Curtin School of Medical Research; University of California System; University of California San Francisco	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	dixit@gene.com	dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326; Wiesmann, Christian/0000-0002-4092-9880; Aravind, L/0000-0003-0771-253X	NATIONAL LIBRARY OF MEDICINE [Z01LM000061, Z01LM092504, ZIALM000061] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Aravind L, 2001, SCIENCE, V291, P1279, DOI 10.1126/science.291.5507.1279; Balakirev MY, 2003, EMBO REP, V4, P517, DOI 10.1038/sj.embor.embor824; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Evans PC, 2004, BIOCHEM J, V378, P727, DOI 10.1042/BJ20031377; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson KD, 2003, NATURE, V424, P738, DOI 10.1038/424738a; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	30	1419	1488	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	2004	430	7000					694	699		10.1038/nature02794	http://dx.doi.org/10.1038/nature02794			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843LM	15258597				2022-12-28	WOS:000223085400050
J	Wiegman, A; Hutten, BA; de Groot, E; Rodenburg, J; Bakker, HD; Buller, HR; Sijbrands, EJG; Kastelein, JJP				Wiegman, A; Hutten, BA; de Groot, E; Rodenburg, J; Bakker, HD; Buller, HR; Sijbrands, EJG; Kastelein, JJP			Efficacy and safety of statin therapy in children with familial hypercholesterolemia - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTIMA-MEDIA THICKNESS; ARTERIAL-WALL THICKNESS; CORONARY HEART-DISEASE; II HYPERLIPOPROTEINEMIA; LIPOPROTEIN CHOLESTEROL; CAROTID-ARTERY; RISK-FACTORS; ATHEROSCLEROSIS; ADULTS; ASSOCIATION	Context Children with familial hypercholesterolemia have endothelial dysfunction and increased carotid intima-media thickness (IMT), which herald the premature atherosclerotic disease they develop later in life. Although intervention therapy in the causal pathway of this disorder has been available for more than a decade, the long-term efficacy and safety of cholesterol-lowering medication have not been evaluated in children. Objective To determine the 2-year efficacy and safety of pravastatin therapy in children with familial hypercholesterolemia. Design Randomized, double-blind, placebo-controlled trial that recruited children between December 7, 1997, and October 4, 1999, and followed them up for 2 years. Setting and Participants Two hundred fourteen children with familial hypercholesterolemia, aged 8 to 18 years and recruited from an academic medical referral center in the Netherlands. Intervention After initiation of a fat-restricted diet and encouragement of regular physical activity, children were randomly assigned to receive treatment with pravastatin, 20 to 40 mg/d (n = 106), or a placebo tablet (n = 108). Main Outcome Measures The primary efficacy outcome was the change from baseline in mean carotid IMT compared between the 2 groups over 2 years; the principal safety outcomes were growth, maturation, and hormone level measurements over 2 years as well as changes in muscle and liver enzyme levels. Results Compared with baseline, carotid IMT showed a trend toward regression with pravastatin (mean [SD], -0.010 [0.048] mm; P=.049), whereas a trend toward progression was observed in the placebo group (mean [SD], +0.005 [0.044] mm; P=.28). The mean (SD) change in IMT compared between the 2 groups (0.014 [0.046] mm) was significant (P=.02). Also, pravastatin significantly reduced mean low-density lipoprotein cholesterol levels compared with placebo (-24.1% vs +0.3%, respectively; P<.001). No differences were observed for growth, muscle or liver enzymes, endocrine function parameters, Tanner staging scores, onset of menses, or testicular volume between the 2 groups. Conclusion Two years of pravastatin therapy induced a significant regression of carotid atherosclerosis in children with familial hypercholesterolemia, with no adverse effects on growth, sexual maturation, hormone levels, or liver or muscle tissue.	Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Rotterdam, Erasmus Med Ctr, Dept Internal Med, Rotterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Erasmus University Rotterdam; Erasmus MC	Kastelein, JJP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	e.vandongen@amc.uva.nl	Sijbrands, Eric/A-1065-2009; Kastelein, John/AAF-7950-2020	Sijbrands, Eric/0000-0001-8857-7389; Wiegman, Albert/0000-0001-6223-5671				Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; de Jongh S, 2002, J AM COLL CARDIOL, V40, P2117, DOI 10.1016/S0735-1097(02)02593-7; de Jongh S, 2002, CIRCULATION, V106, P2231, DOI 10.1161/01.CIR.0000035247.42888.82; de Jongh S, 2002, ATHEROSCLEROSIS, V163, P193, DOI 10.1016/S0021-9150(02)00003-5; Fouchier SW, 2001, HUM GENET, V109, P602, DOI 10.1007/s00439-001-0628-8; HAYCOCK GB, 1978, J PEDIATR-US, V93, P62, DOI 10.1016/S0022-3476(78)80601-5; Hodis HN, 1998, ANN INTERN MED, V128, P262, DOI 10.7326/0003-4819-128-4-199802150-00002; Jarvisalo MJ, 2001, CIRCULATION, V104, P2943, DOI 10.1161/hc4901.100522; Knipscheer HC, 1996, PEDIATR RES, V39, P867, DOI 10.1203/00006450-199605000-00021; KWITEROVICH PO, 1973, LANCET, V1, P118; KWITEROVICH PO, 1974, J CLIN INVEST, V53, P1237, DOI 10.1172/JCI107670; Lambert M, 1996, PEDIATRICS, V97, P619; MABUCHI H, 1989, CIRCULATION, V79, P225, DOI 10.1161/01.CIR.79.2.225; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; MOURATIDIS B, 1992, AM J CARDIOL, V70, P1109, DOI 10.1016/0002-9149(92)90038-Z; O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103; PAUCIULLO P, 1994, ARTERIOSCLER THROMB, V14, P1075, DOI 10.1161/01.ATV.14.7.1075; Stein EA, 1999, JAMA-J AM MED ASSOC, V281, P137, DOI 10.1001/jama.281.2.137; Tonstad S, 1996, ARTERIOSCL THROM VAS, V16, P984, DOI 10.1161/01.ATV.16.8.984; van Dam MJ, 2002, LANCET, V359, P37, DOI 10.1016/S0140-6736(02)07277-X; *VOED, 1998, ZO EET NED RES VOEDS; Voedingsraad, 1992, NED VOED 1989; WARNICK GR, 1990, CLIN CHEM, V36, P15; Wiegman A, 2003, CIRCULATION, V107, P1473, DOI 10.1161/01.CIR.0000058166.99182.54; Wiegman A, 2004, LANCET, V363, P369, DOI 10.1016/S0140-6736(04)15467-6; WISSLER RW, 1993, ARTERIOSCLER THROMB, V13, P1291	26	420	437	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					331	337		10.1001/jama.292.3.331	http://dx.doi.org/10.1001/jama.292.3.331			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265847	Bronze			2022-12-28	WOS:000222693500017
J	Nathan, DG				Nathan, DG			Determination can win the battle	LANCET			English	Editorial Material									Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Nathan, DG (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	david_nathan@dfci.havard.edu							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					301	301		10.1016/S0140-6736(04)16682-8	http://dx.doi.org/10.1016/S0140-6736(04)16682-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262110				2022-12-28	WOS:000222784900035
J	Nair, DT; Johnson, RE; Prakash, S; Prakash, L; Aggarwal, AK				Nair, DT; Johnson, RE; Prakash, S; Prakash, L; Aggarwal, AK			Replication by human DNA polymerase-iota occurs by Hoogsteen base-pairing	NATURE			English	Article							THYMINE-THYMINE DIMER; CRYSTAL-STRUCTURE; ERROR-PRONE; BYPASS; MECHANISM; EFFICIENT; FRAGMENT	Almost all DNA polymerases show a strong preference for incorporating the nucleotide that forms the correct Watson Crick base pair with the template base. In addition, the catalytic efficiencies with which any given polymerase forms the four possible correct base pairs are roughly the same. Human DNA polymerase-iota (hPoliota), a member of the Y family of DNA polymerases, is an exception to these rules. hPoli incorporates the correct nucleotide opposite a template adenine with a several hundred to several thousand fold greater efficiency than it incorporates the correct nucleotide opposite a template thymine, whereas its efficiency for correct nucleotide incorporation opposite a template guanine or cytosine is intermediate between these two extremes(1-5). Here we present the crystal structure of hPoliota bound to a template primer and an incoming nucleotide. The structure reveals a polymerase that is 'specialized' for Hoogsteen base-pairing, whereby the templating base is driven to the syn conformation. Hoogsteen base-pairing offers a basis for the varied efficiencies and fidelities of hPoliota opposite different template bases, and it provides an elegant mechanism for promoting replication through minor-groove purine adducts that interfere with replication.	Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77755 USA	Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Medical Branch Galveston	Aggarwal, AK (corresponding author), Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.	aggarwal@inka.mssm.edu	Prakash, Satya/C-6420-2013; Nair, Deepak T/AAR-5234-2020; Prakash, Louise/C-7891-2012	Nair, Deepak/0000-0002-0677-9444; Prakash, Satya/0000-0001-7228-1444; Prakash, Louise/0000-0001-9143-6261				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DeLucia AM, 2003, NUCLEIC ACIDS RES, V31, P4129, DOI 10.1093/nar/gkg417; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Faili A, 2002, NATURE, V419, P944, DOI 10.1038/nature01117; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 2003, MOL CELL BIOL, V23, P3008, DOI 10.1128/MCB.23.8.3008-3012.2003; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Leontis NB, 2002, NUCLEIC ACIDS RES, V30, P3497, DOI 10.1093/nar/gkf481; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Prakash S, 2002, GENE DEV, V16, P1872, DOI 10.1101/gad.1009802; Silvian LF, 2001, NAT STRUCT BIOL, V8, P984, DOI 10.1038/nsb1101-984; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tissier A, 2000, GENE DEV, V14, P1642; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2004, MOL CELL BIOL, V24, P5687, DOI 10.1128/MCB.24.13.5687-5693.2004; Washington MT, 2004, MOL CELL BIOL, V24, P936, DOI 10.1128/MCB.24.2.936-943.2004; Washington MT, 2003, P NATL ACAD SCI USA, V100, P12093, DOI 10.1073/pnas.2134223100; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	28	256	262	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					377	380		10.1038/nature02692	http://dx.doi.org/10.1038/nature02692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254543				2022-12-28	WOS:000222631200047
J	Barker, RM; Pearce, MS; Irving, M				Barker, RM; Pearce, MS; Irving, M			Star wars, NHS style	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Freeman Rd Hosp, Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Newcastle Freeman Hospital; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK	Irving, M (corresponding author), Freeman Rd Hosp, Newcastle Upon Tyne Hosp NHS Trust, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	m.h.irving@ncl.ac.uk		Pearce, Mark/0000-0002-0583-3779				BIRD S, 2003, PERFORMANCE INDICATO; *HEALTHC COMM, IND LIST AC TRUSTS	2	8	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					107	109		10.1136/bmj.329.7457.107	http://dx.doi.org/10.1136/bmj.329.7457.107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242919	Green Published			2022-12-28	WOS:000222645000032
J	Hussain, MA; Theise, ND				Hussain, MA; Theise, ND			Stem-cell therapy for diabetes mellitus	LANCET			English	Review							INSULIN-PRODUCING CELLS; IN-VITRO DIFFERENTIATION; PANCREATIC BETA-CELLS; MARROW-DERIVED CELLS; BONE-MARROW; REVERSAL; LIVER; NEOGENESIS; ENDOCRINE; ISLETS	Context Curative therapy for diabetes mellitus mainly implies replacement of functional insulin-producing pancreatic beta cells, with pancreas or islet-cell transplants. However, shortage of donor organs spurs research into alternative means of generating beta cells from islet expansion, encapsulated islet xenografts, human islet cell-lines, and stem cells. Stem-cell therapy here implies the replacement of diseased or lost cells from progeny of pluripotent or multipotent cells. Both embryonic stem cells (derived from the inner cell mass of a blastocyst) and adult stem cells (found in the postnatal organism) have been used to generate surrogate beta cells or otherwise restore beta-cell functioning. Starting point Recently, Andreas Lechner and colleagues failed to see transdifferentiation into pancreatic beta cells after transplantation of bone-marrow cells into mice (Diabetes 2004; 53: 616-23). Last year, Jayaraj Rajagopal and colleagues failed to derive beta cells from embryonic stem cells (Science 2003; 299: 363). However, others have seen such effects. Where next? As in every emerging field in biology, early reports seem confusing and conflicting. Embryonic and adult stem cells are potential sources for beta-cell replacement and merit further scientific investigation. Discrepancies between different results need to be reconciled. Fundamental processes in determining the differentiation pathways of stem cells remain to be elucidated, so that rigorous and reliable differentiation protocols can be established. Encouraging studies in rodent models may ultimately set the stage for large-animal studies and translational investigation.	Albert Einstein Coll Med, Beth Israel Med Ctr, Dept Internal Med, Div Digest Dis,Liver & Stem Cell Res Lab, New York, NY 10003 USA	Harvard University; Beth Israel Deaconess Medical Center; Yeshiva University	Hussain, MA (corresponding author), Albert Einstein Coll Med, Beth Israel Med Ctr, Dept Internal Med, Div Digest Dis,Liver & Stem Cell Res Lab, New York, NY 10003 USA.	mehboobhussain@yahoo.com			NIDDK NIH HHS [R01 DK064646] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064646] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Blyszczuk P, 2003, P NATL ACAD SCI USA, V100, P998, DOI 10.1073/pnas.0237371100; Bonner-Weir S, 2000, P NATL ACAD SCI USA, V97, P7999, DOI 10.1073/pnas.97.14.7999; Choi JB, 2003, DIABETOLOGIA, V46, P1366, DOI 10.1007/s00125-003-1182-9; Cowan CA, 2004, NEW ENGL J MED, V350, P1353, DOI 10.1056/NEJMsr040330; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Glandt M, 2003, REV ENDOCR METAB DIS, V4, P361, DOI 10.1023/A:1027354129493; Herold KC, 2002, NEW ENGL J MED, V346, P1692, DOI 10.1056/NEJMoa012864; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Hess D, 2003, NAT BIOTECHNOL, V21, P763, DOI 10.1038/nbt841; Hori Y, 2002, P NATL ACAD SCI USA, V99, P16105, DOI 10.1073/pnas.252618999; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Jahr H, 2003, TRANSPLANT P, V35, P2140, DOI 10.1016/S0041-1345(03)00747-4; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kahan BW, 2003, DIABETES, V52, P2016, DOI 10.2337/diabetes.52.8.2016; Kania G, 2003, METHOD ENZYMOL, V365, P287; Kim D, 2003, PANCREAS, V27, pE34, DOI 10.1097/00006676-200308000-00021; Kodama S, 2003, SCIENCE, V302, P1223, DOI 10.1126/science.1088949; Kofman AV, 2004, EUR J ENDOCRINOL, V150, P415, DOI 10.1530/eje.0.1500415; Kojima H, 2004, P NATL ACAD SCI USA, V101, P2458, DOI 10.1073/pnas.0308690100; Kojima H, 2003, NAT MED, V9, P596, DOI 10.1038/nm867; Korbling M, 2002, NEW ENGL J MED, V346, P738, DOI 10.1056/NEJMoa3461002; Lechner A, 2004, DIABETES, V53, P616, DOI 10.2337/diabetes.53.3.616; Lipsett M, 2002, DIABETES, V51, P1834, DOI 10.2337/diabetes.51.6.1834; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Meivar-Levy I, 2003, TRENDS ENDOCRIN MET, V14, P460, DOI 10.1016/j.tem.2003.10.006; Miyazaki S, 2004, DIABETES, V53, P1030, DOI 10.2337/diabetes.53.4.1030; Moritoh Y, 2003, DIABETES, V52, P1163, DOI 10.2337/diabetes.52.5.1163; Oh SH, 2004, LAB INVEST, V84, P607, DOI 10.1038/labinvest.3700074; Rajagopal J, 2003, SCIENCE, V299, P363; Ramiya VK, 2000, NAT MED, V6, P278; Ryu S, 2001, J CLIN INVEST, V108, P63, DOI 10.1172/JCI200112335; Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265; Sipione S, 2004, DIABETOLOGIA, V47, P499, DOI 10.1007/s00125-004-1349-z; Soria B, 2001, DIABETOLOGIA, V44, P407, DOI 10.1007/s001250051636; Stoffel M, 2004, SEMIN CELL DEV BIOL, V15, P327, DOI 10.1016/j.semcdb.2004.02.002; Teitelman G, 1996, DIABETES METAB REV, V12, P91, DOI 10.1002/(SICI)1099-0895(199607)12:2<91::AID-DMR166>3.0.CO;2-I; Theise ND, 2003, NATURE, V425, P21, DOI 10.1038/425021a; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Yang LJ, 2002, P NATL ACAD SCI USA, V99, P8078, DOI 10.1073/pnas.122210699; Zalzman M, 2003, P NATL ACAD SCI USA, V100, P7253, DOI 10.1073/pnas.1136854100; Zorina TD, 2003, STEM CELLS, V21, P377, DOI 10.1634/stemcells.21-4-377; Zulewski H, 2001, DIABETES, V50, P521, DOI 10.2337/diabetes.50.3.521	44	117	165	0	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					203	205		10.1016/S0140-6736(04)16635-X	http://dx.doi.org/10.1016/S0140-6736(04)16635-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246735				2022-12-28	WOS:000222612200033
J	Slavin, S				Slavin, S			Smarter rather than stronger treatment of haematological malignancies and non-malignant indications for stem-cell transplantation	LANCET			English	Editorial Material							BONE-MARROW-TRANSPLANTATION; GRAFT-VERSUS-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; THERAPY; DISEASES; RELAPSE		Hadassah Univ Hosp, Cell Therapy & Transplantat Res Ctr, Dept Bone Marrow Transplantat & Canc Immunotherap, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Slavin, S (corresponding author), Hadassah Univ Hosp, Cell Therapy & Transplantat Res Ctr, Dept Bone Marrow Transplantat & Canc Immunotherap, IL-91120 Jerusalem, Israel.	slavin@cc.huji.ac.il						Carella AM, 2000, BONE MARROW TRANSPL, V25, P345, DOI 10.1038/sj.bmt.1702204; Champlin R, 2000, BRIT J HAEMATOL, V111, P18, DOI 10.1046/j.1365-2141.2000.02196.x; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Giralt S, 1997, BLOOD, V89, P4531, DOI 10.1182/blood.V89.12.4531; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; McSweeney PA, 2001, BLOOD, V97, P3390, DOI 10.1182/blood.V97.11.3390; Slavin S, 1995, EXP HEMATOL, V23, P1553; Slavin S, 1998, BLOOD, V91, P756, DOI 10.1182/blood.V91.3.756.756_756_763; Slavin S, 1996, BLOOD, V87, P2195, DOI 10.1182/blood.V87.6.2195.bloodjournal8762195; Slavin S, 2001, Rev Clin Exp Hematol, V5, P135, DOI 10.1046/j.1468-0734.2001.00036.x; Slavin S, 2001, CRIT REV ONCOL HEMAT, V39, P25, DOI 10.1016/S1040-8428(01)00121-4; SLAVIN S, 1999, CURR OPIN ORGAN TRAN, V4, P184; Slavin S, 2001, LANCET ONCOL, V2, P491, DOI 10.1016/S1470-2045(01)00455-7	13	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					122	124		10.1016/S0140-6736(04)16652-X	http://dx.doi.org/10.1016/S0140-6736(04)16652-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246713				2022-12-28	WOS:000222612200006
J	Lenz, DH; Mok, KC; Lilley, BN; Kulkarni, RV; Wingreen, NS; Bassler, BL				Lenz, DH; Mok, KC; Lilley, BN; Kulkarni, RV; Wingreen, NS; Bassler, BL			The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in Vibrio harveyi and Vibrio cholerae	CELL			English	Article							VIRULENCE GENE-EXPRESSION; SM-LIKE PROTEIN; ESCHERICHIA-COLI; MESSENGER-RNA; STRUCTURAL IDENTIFICATION; BIOFILM FORMATION; RPOS TRANSLATION; REGULATORY RNA; SEQUENCE; LUMINESCENCE	Quorum-sensing bacteria communicate with extracellular signal molecules called autoinducers. This process allows community-wide synchronization of gene expression. A screen for additional components of the Vibrio harveyi and Vibrio cholerae quorum-sensing circuits revealed the protein Hfq. Hfq mediates interactions between small, regulatory RNAs (sRNAs) and specific messenger RNA (mRNA) targets. These interactions typically alter the stability of the target transcripts. We show that Hfq mediates the destabilization of the mRNA encoding the quorum-sensing master regulators LuxR (V. harveyi) and HapR (V. cholerae), implicating an sRNA in the circuit. Using a bioinformatics approach to identify putative sRNAs, we identified four candidate sRNAs in V. cholerae. The simultaneous deletion of all four sRNAs; is required to stabilize hapR mRNA. We propose that Hfq, together with these sRNAs, creates an ultrasensitive regulatory switch that controls the critical transition into the high cell density, quorum-sensing mode.	Princeton Univ, Dept Biol Mol, Princeton, NJ 08544 USA; NEC Labs Amer Inc, Princeton, NJ 08540 USA	Princeton University; NEC Corporation	Bassler, BL (corresponding author), Harvard Univ, Sch Med, Program Biol & Biomed Sci, 200 Longwood Ave, Boston, MA 02115 USA.	bbassler@molbio.princeton.edu		Mok, Kenny/0000-0002-5227-6987; Bassler, Bonnie/0000-0002-0043-746X	NIGMS NIH HHS [5R01 GM065859] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065859] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Argaman L, 2001, CURR BIOL, V11, P941, DOI 10.1016/S0960-9822(01)00270-6; Barrios H, 1999, NUCLEIC ACIDS RES, V27, P4305, DOI 10.1093/nar/27.22.4305; BASSLER BL, 1993, MOL MICROBIOL, V9, P773, DOI 10.1111/j.1365-2958.1993.tb01737.x; BASSLER BL, 1994, MOL MICROBIOL, V12, P403, DOI 10.1111/j.1365-2958.1994.tb01029.x; BASSLER BL, 1994, MOL MICROBIOL, V13, P273, DOI 10.1111/j.1365-2958.1994.tb00422.x; Bassler BL, 1997, J BACTERIOL, V179, P4043, DOI 10.1128/jb.179.12.4043-4045.1997; BENSON AK, 1994, P NATL ACAD SCI USA, V91, P4989, DOI 10.1073/pnas.91.11.4989; Bjarnason J, 2003, J BACTERIOL, V185, P4973, DOI 10.1128/JB.185.16.4973-4982.2003; CAO JG, 1989, J BIOL CHEM, V264, P21670; Carrington JC, 2003, SCIENCE, V301, P336, DOI 10.1126/science.1085242; Chen CY, 2003, GENOME RES, V13, P2577, DOI 10.1101/gr.1295503; Chen S, 2002, BIOSYSTEMS, V65, P157, DOI 10.1016/S0303-2647(02)00013-8; Chen X, 2002, NATURE, V415, P545, DOI 10.1038/415545a; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; DELORENZO V, 1994, METHOD ENZYMOL, V235, P386; Dombrecht B, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-12-research0076; Elf J, 2003, BIOPHYS J, V84, P154, DOI 10.1016/S0006-3495(03)74839-5; Federle MJ, 2003, J CLIN INVEST, V112, P1291, DOI 10.1172/JCI200320195; Freeman JA, 1999, J BACTERIOL, V181, P899, DOI 10.1128/JB.181.3.899-906.1999; Freeman JA, 1999, MOL MICROBIOL, V31, P665, DOI 10.1046/j.1365-2958.1999.01208.x; Freeman JA, 2000, MOL MICROBIOL, V35, P139, DOI 10.1046/j.1365-2958.2000.01684.x; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Hammer BK, 2003, MOL MICROBIOL, V50, P101, DOI 10.1046/j.1365-2958.2003.03688.x; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; HENKE JM, 2004, IN PRESS J BACTERIOL; Hertz GZ, 1999, BIOINFORMATICS, V15, P563, DOI 10.1093/bioinformatics/15.7.563; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; IWANAGA M, 1986, MICROBIOL IMMUNOL, V30, P1075, DOI 10.1111/j.1348-0421.1986.tb03037.x; Jobling MG, 1997, MOL MICROBIOL, V26, P1023, DOI 10.1046/j.1365-2958.1997.6402011.x; Kalogeraki VS, 1997, GENE, V188, P69, DOI 10.1016/S0378-1119(96)00778-0; KOVACH ME, 1994, BIOTECHNIQUES, V16, P800; Kovacikova G, 2002, MOL MICROBIOL, V46, P1135, DOI 10.1046/j.1365-2958.2002.03229.x; Lilley BN, 2000, MOL MICROBIOL, V36, P940, DOI 10.1046/j.1365-2958.2000.01913.x; Majdalani N, 1998, P NATL ACAD SCI USA, V95, P12462, DOI 10.1073/pnas.95.21.12462; Majdalani N, 2002, MOL MICROBIOL, V46, P813, DOI 10.1046/j.1365-2958.2002.03203.x; Makino K, 2003, LANCET, V361, P743, DOI 10.1016/S0140-6736(03)12659-1; MARTIN M, 1989, J BACTERIOL, V171, P2406, DOI 10.1128/jb.171.5.2406-2414.1989; Masse E, 2002, P NATL ACAD SCI USA, V99, P4620, DOI 10.1073/pnas.032066599; Masse E, 2003, GENE DEV, V17, P2374, DOI 10.1101/gad.1127103; Masse E, 2003, CURR OPIN MICROBIOL, V6, P120, DOI 10.1016/S1369-5274(03)00027-4; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Miller MB, 2001, ANNU REV MICROBIOL, V55, P165, DOI 10.1146/annurev.micro.55.1.165; MIYAMOTO CM, 1994, MOL MICROBIOL, V14, P255, DOI 10.1111/j.1365-2958.1994.tb01286.x; Mok KC, 2003, EMBO J, V22, P870, DOI 10.1093/emboj/cdg085; Moll I, 2003, RNA, V9, P1308, DOI 10.1261/rna.5850703; Moller T, 2002, MOL CELL, V9, P23, DOI 10.1016/S1097-2765(01)00436-1; North AK, 1996, J MOL BIOL, V260, P317, DOI 10.1006/jmbi.1996.0403; Paulsson J, 2001, Q REV BIOPHYS, V34, P1, DOI 10.1017/S0033583501003663; REITZER LJ, 1985, P NATL ACAD SCI USA, V82, P1979, DOI 10.1073/pnas.82.7.1979; Repoila F, 2003, MOL MICROBIOL, V48, P855, DOI 10.1046/j.1365-2958.2003.03454.x; Romeo T, 1998, MOL MICROBIOL, V29, P1321, DOI 10.1046/j.1365-2958.1998.01021.x; Rowe-Magnus DA, 2001, P NATL ACAD SCI USA, V98, P652, DOI 10.1073/pnas.98.2.652; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHOWALTER RE, 1990, J BACTERIOL, V172, P2946, DOI 10.1128/jb.172.6.2946-2954.1990; Skorupski K, 1996, GENE, V169, P47, DOI 10.1016/0378-1119(95)00793-8; SLAUCH JM, 1991, J BACTERIOL, V173, P4039, DOI 10.1128/jb.173.13.4039-4048.1991; SUN D, 1991, INFECT IMMUN, V59, P114, DOI 10.1128/IAI.59.1.114-118.1991; Surette MG, 1999, P NATL ACAD SCI USA, V96, P1639, DOI 10.1073/pnas.96.4.1639; Taylor R K, 1991, J Chemother, V3 Suppl 1, P190; Thelin KH, 1996, INFECT IMMUN, V64, P2853, DOI 10.1128/IAI.64.7.2853-2856.1996; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Valentin-Hansen P, 2004, MOL MICROBIOL, V51, P1525, DOI 10.1111/j.1365-2958.2003.03935.x; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Vance RE, 2003, INFECT IMMUN, V71, P2571, DOI 10.1128/IAI.71.5.2571-2576.2003; Wassarman KM, 2001, GENE DEV, V15, P1637, DOI 10.1101/gad.901001; WINGROVE JA, 1994, GENE DEV, V8, P1839, DOI 10.1101/gad.8.15.1839; Wu JG, 1997, MOL MICROBIOL, V24, P233, DOI 10.1046/j.1365-2958.1997.3281691.x; Xavier KB, 2003, CURR OPIN MICROBIOL, V6, P191, DOI 10.1016/S1369-5274(03)00028-6; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhang AX, 2003, MOL MICROBIOL, V50, P1111, DOI 10.1046/j.1365-2958.2003.03734.x; Zhang AX, 2002, MOL CELL, V9, P11, DOI 10.1016/S1097-2765(01)00437-3; Zhang AX, 1998, EMBO J, V17, P6061, DOI 10.1093/emboj/17.20.6061; Zhu J, 2003, DEV CELL, V5, P647, DOI 10.1016/S1534-5807(03)00295-8; Zhu J, 2002, P NATL ACAD SCI USA, V99, P3129, DOI 10.1073/pnas.052694299	76	712	752	3	123	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					69	82		10.1016/j.cell.2004.06.009	http://dx.doi.org/10.1016/j.cell.2004.06.009			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242645	Bronze			2022-12-28	WOS:000222626800009
J	Conard, NJ; Grootes, PM; Smith, FH				Conard, NJ; Grootes, PM; Smith, FH			Unexpectedly recent dates for human remains from Vogelherd	NATURE			English	Article							EARLY AURIGNACIAN; HUMAN FOSSILS; EUROPE; GERMANY; KYR; SEA	The human skeletal remains from the Vogelherd cave in the Swabian Jura of southwestern Germany are at present seen as the best evidence that modern humans produced the artefacts of the early Aurignacian(1). Radiocarbon measurements from all the key fossils from Vogelherd show that these human remains actually date to the late Neolithic, between 3,900 and 5,000 radiocarbon years before present ( BP). Although many questions remain unresolved, these results weaken the arguments for the Danube Corridor hypothesis(2)-that there was an early migration of modern humans into the Upper Danube drainage-and strengthen the view that Neanderthals may have contributed significantly to the development of Upper Palaeolithic cultural traits independent of the arrival of modern humans(3,4).	Univ Tubingen, Inst Ur & Fruhgeschichte & Archaol Mittelalters, Abt Altere Urgeschichte & Quartarokol, D-72070 Tubingen, Germany; Univ Kiel, Leibniz Labor Altersbestimmung & Isotopenforsch, D-24118 Kiel, Germany; Loyola Univ, Dept Anthropol, Chicago, IL 60626 USA	Eberhard Karls University of Tubingen; University of Kiel; Loyola University Chicago	Conard, NJ (corresponding author), Univ Tubingen, Inst Ur & Fruhgeschichte & Archaol Mittelalters, Abt Altere Urgeschichte & Quartarokol, Schloss Hohentubingen, D-72070 Tubingen, Germany.	nicholas.conard@uni-tuebingen.de	Grootes, Pieter M/F-4952-2011	Grootes, Pieter/0000-0003-4265-3168; Conard, Nicholas/0000-0002-4633-0385				Beck JW, 2001, SCIENCE, V292, P2453, DOI 10.1126/science.1056649; BOULE M, 1921, HOMMES FOSSILES; Bruhn F, 2001, RADIOCARBON, V43, P229; Churchill SE, 2000, AM J PHYS ANTHROPOL, V112, P251, DOI 10.1002/(SICI)1096-8644(2000)112:2<251::AID-AJPA10>3.0.CO;2-G; Churchill SE, 2000, YEARB PHYS ANTHROPOL, V43, P61; Conard N.J., 2003, MITT GES URGESCH, V12, P73; Conard NJ, 2003, J HUM EVOL, V44, P331, DOI 10.1016/S0047-2484(02)00202-6; Czarnetzki A., 1983, URGESCHICHTE BADEN W, P217; D'Errico F, 2003, EVOL ANTHROPOL, V12, P188, DOI 10.1002/evan.10113; GIESELER W, 1940, JAHRESBANDE WISS AKA, V1, P102; GIESELER W, 1937, VERH GES PHYS ANTHR, V8, P41; GROOTES PM, IN PRESS NUCL INSTRU; Henry-Gambier D., 2002, Bulletins et Memoires de la Societe d'Anthropologie de Paris, V14, P89; HUBLIN JJ, 1995, CR ACAD SCI II A, V321, P931; Hughen K, 2004, SCIENCE, V303, P202, DOI 10.1126/science.1090300; Klein R.G., 1999, HUMAN CAREER; Nadeau MJ, 1997, NUCL INSTRUM METH B, V123, P22, DOI 10.1016/S0168-583X(96)00730-6; RICHTER J, 1996, ARCHAEOLOGISCHEN INF, V19, P67; RIEK G, 1934, EISZEITJAGERSTATION, V1; Riek G, 1932, GERMANIA, V16, P1; Scholz M, 2000, AM J HUM GENET, V66, P1927, DOI 10.1086/302949; Smith NP, 1999, COMPUT SCI ENG, V1, P96; Stringer C.B., 1984, P51; Stringer Christopher, 1993, SEARCH NEANDERTHALS; STUIVER M, 1977, RADIOCARBON, V19, P355, DOI 10.1017/S0033822200003672; Svoboda J, 2000, J HUM EVOL, V38, P523, DOI 10.1006/jhev.1999.0361; Svoboda JA, 2002, ANTIQUITY, V76, P957, DOI 10.1017/S0003598X00091754; Trinkaus E, 2003, P NATL ACAD SCI USA, V100, P11231, DOI 10.1073/pnas.2035108100; van Kreveld S, 2000, PALEOCEANOGRAPHY, V15, P425, DOI 10.1029/1999PA000464; Voelker AHL, 2000, RADIOCARBON, V42, P437, DOI 10.1017/S0033822200030368	30	108	110	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					198	201		10.1038/nature02690	http://dx.doi.org/10.1038/nature02690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241412				2022-12-28	WOS:000222470600041
J	Gayle, H; Lange, JMA				Gayle, H; Lange, JMA			Seizing the opportunity to capitalise on the growing access to HIV treatment to expand HIV prevention	LANCET			English	Editorial Material							RISK		Bill & Melinda Gates Fdn, Seattle, WA 98102 USA; Univ Amsterdam, Acad Med Ctr, Ctr Poverty Related Communicable Dis & Int Antivi, NL-1105 AZ Amsterdam, Netherlands	Bill & Melinda Gates Foundation; University of Amsterdam; Academic Medical Center Amsterdam	Gayle, H (corresponding author), Bill & Melinda Gates Fdn, Seattle, WA 98102 USA.	heleneg@gatesfoundation.org						*CDCP US, 2002, HIV AIDS SURV REP; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P853; Crepaz N, 2002, AIDS, V16, P135, DOI 10.1097/00002030-200201250-00002; *GLOB HIV PREV WOR, HIV PREV ER EXP TREA; Gremy I, 2004, AIDS, V18, P805, DOI [10.1097/01.aids.0000111390.02002.f4, 10.1097/00002030-200403260-00013]; *HLTH CAN, 2003, HIV AIDS CAN SURV RE; *MED FRONT S AFR D, 2003, ANT THER PRIM HLTH C; MUKHERJEE J, 2003, WHO SERIES PERSPECTI; Porco TC, 2004, AIDS, V18, P81, DOI 10.1097/00002030-200401020-00010; Stolte IG, 2004, AIDS, V18, P303, DOI 10.1097/00002030-200401230-00021; *WHO, COV SEL HLTH SERV HI; WHO, 2004, WORLD HLTH REP	12	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					6	8		10.1016/S0140-6736(04)16607-5	http://dx.doi.org/10.1016/S0140-6736(04)16607-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234835				2022-12-28	WOS:000222392900006
J	Kumarasamy, N				Kumarasamy, N			Generic antiretroviral drugs - will they be the answer to HIV in the developing world?	LANCET			English	Editorial Material							RESOURCE-LIMITED SETTINGS; TOTAL LYMPHOCYTE COUNT; THERAPY; INFECTION; REGIMENS; DISEASE; HAART; INDIA		VHS, YRG Ctr AIDS Res & Educ, Madras 600113, Tamil Nadu, India		Kumarasamy, N (corresponding author), VHS, YRG Ctr AIDS Res & Educ, Madras 600113, Tamil Nadu, India.	Kumarasamy@yrgcare.org	Kumarasasmy, Nagalingeswaran/AAB-7348-2021					Badri M, 2003, AIDS, V17, P541, DOI 10.1097/00002030-200303070-00009; BALAKRISHNAN P, IN PRESS J ACQUIR IM; Chesney M, 2003, AIDS PATIENT CARE ST, V17, P169, DOI 10.1089/108729103321619773; Crommentuyn KML, 2004, CLIN INFECT DIS, V38, pE73, DOI 10.1086/382675; Henry K, 2004, JAIDS-J ACQ IMM DEF, V35, P537, DOI 10.1097/00126334-200404150-00012; HOSSEINIPOUR M, 2003, 10 C RETR OPP INF BO, P172; JOSEFOWICZ S, 2004, 11 C RETR OPP INF SA, P96; Kumarasamy N, 2003, AIDS, V17, P2267, DOI 10.1097/00002030-200310170-00019; Kumarasamy N, 2003, CLIN INFECT DIS, V36, P79, DOI 10.1086/344756; KUMARASAMY N, 2004, 15 INT AIDS C BANGK; Macalino GE, 2004, CLIN INFECT DIS, V38, pS393, DOI 10.1086/421402; Mahajan AP, 2004, JAIDS-J ACQ IMM DEF, V36, P567, DOI 10.1097/00126334-200405010-00004; Malmsten A, 2003, J MED VIROL, V71, P347, DOI 10.1002/jmv.10492; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pozniak Anton, 2002, J HIV Ther, V7, P13; Remien RH, 2003, AIDS, V17, P786, DOI 10.1097/00002030-200303280-00030; Schupbach J, 2000, INT J ANTIMICROB AG, V16, P441, DOI 10.1016/S0924-8579(00)00272-7	17	29	29	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					3	4		10.1016/S0140-6736(04)16605-1	http://dx.doi.org/10.1016/S0140-6736(04)16605-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234833				2022-12-28	WOS:000222392900004
J	Oakley, GP; Johnston, RB				Oakley, GP; Johnston, RB			Balancing benefits and harms in public health prevention programmes mandated by governments	BRITISH MEDICAL JOURNAL			English	Article							NEURAL-TUBE DEFECTS; FOLIC-ACID FORTIFICATION; VITAMIN; SUPPLEMENTATION; DISEASE		Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30345 USA; Univ Colorado, Sch Med, Denver, CO 80262 USA	Emory University; Rollins School Public Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Oakley, GP (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30345 USA.	gpoakley@mindspring.com						*ASS HEART ASS, 2004, STROK DEATHS RED FOL; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Committee on Medical Aspects of Food and Nutrition Policy, 2000, FOL AC PREV DIS; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; de Walle HEK, 2002, TERATOLOGY, V66, P40, DOI 10.1002/tera.10078; Food and Drug Administration, 1996, FED REGISTER, V61, P8781; Honein MA, 2001, JAMA-J AM MED ASSOC, V285, P2981, DOI 10.1001/jama.285.23.2981; *I MED, 1998, DIET REF INT FOL OTH; Johnston Richard B Jr, 2003, Adv Pediatr, V50, P231; Lawrence JM, 1999, LANCET, V354, P915, DOI 10.1016/S0140-6736(99)03227-4; Mark SD, 1996, AM J EPIDEMIOL, V143, P658, DOI 10.1093/oxfordjournals.aje.a008798; Oakley GP, 2002, TERATOLOGY, V66, P44, DOI 10.1002/tera.10079; RAATS M, 1998, CHANGING PRECONCEPTI; WALD N, 1991, LANCET, V338, P131	14	17	19	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					41	43		10.1136/bmj.329.7456.41	http://dx.doi.org/10.1136/bmj.329.7456.41			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231625	Green Published			2022-12-28	WOS:000222568300025
J	Hobson, A				Hobson, A			A model for madness? Dream consciousness: our understanding of the neurobiology of sleep offers insight into abnormalities in the waking brain.	NATURE			English	Editorial Material									Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hobson, A (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.		Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604				Hobson J. Allan, 2004, 13 DREAMS FREUD NEVE; Hobson JA, 2000, BEHAV BRAIN SCI, V23, P793, DOI 10.1017/S0140525X00003976; Snyder SH., 1996, DRUGS BRAIN; Solms M., 1997, NEUROPSYCHOLOGY DREA; Weinberger DR, 2002, ARCH GEN PSYCHIAT, V59, P553, DOI 10.1001/archpsyc.59.6.553	5	41	41	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	2004	430	6995					21	21		10.1038/430021a	http://dx.doi.org/10.1038/430021a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229582	Bronze			2022-12-28	WOS:000222356800023
J	Bukreyev, A; Lamirande, EW; Buchholz, UJ; Vogel, LN; Elkins, WR; St Claire, M; Murphy, BR; Subbarao, K; Collins, PL				Bukreyev, A; Lamirande, EW; Buchholz, UJ; Vogel, LN; Elkins, WR; St Claire, M; Murphy, BR; Subbarao, K; Collins, PL			Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS	LANCET			English	Article							ACUTE RESPIRATORY SYNDROME; HEMAGGLUTININ-NEURAMINIDASE; FUSION GLYCOPROTEINS; TYPE-3 PIV3; IMMUNOGENICITY; REPLICATION; INFECTION; VACCINE; BOVINE; IDENTIFICATION	Background The outbreak of severe acute respiratory syndrome (SARS) in 2002 was caused by a previously unknown coronavirus-SARS coronavirus (SARS-CoV). We have developed an experimental SARS vaccine for direct immunisation of the respiratory tract, the major site of SARS-coronavirus transmission and disease. Methods We expressed the complete SARS coronavirus envelope spike (S) protein from a recombinant attenuated parainfluenza virus (BHPIV3) that is being developed as a live attenuated, intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3). We immunised eight African green monkeys, four with a single dose of BHPIV3/SARS-S and four with a control, BHPIV3/Ctrl, administered via the respiratory tract. A SARS-coronavirus challenge was given to all monkeys 28 days after immunisation. Findings Immunisation of animals with BHPIV3/SARS-S induced the production of SARS-coronavirus-neutralising serum antibodies, indicating that a systemic immune response resulted from mucosal immunisation. After challenge with SARS coronavirus, all monkeys in the control group shed SARS coronavirus, with shedding lasting 5-8 days. No viral shedding occurred in the group immunised with BHPIV3/SARS-S. Interpretation A vectored mucosal vaccine expressing the SARS-coronavirus S protein alone may be highly effective in a single-dose format for the prevention of SARS.	NIAID, Infect Dis Lab, NIH, Bethesda, MD 20892 USA; Bioqual, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); BIOQUAL Inc.	Bukreyev, A (corresponding author), NIAID, Infect Dis Lab, NIH, Bldg 50,Room 6505, Bethesda, MD 20892 USA.	AB176v@nih.gov	Buchholz, Ursula/AAA-4547-2022	Buchholz, Ursula/0000-0002-2329-3198; Subbarao, Kanta/0000-0003-1713-3056	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000934, Z01AI000938, ZIAAI000934, ZIAAI000938] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Callebaut P, 1995, Adv Exp Med Biol, V380, P265; CLEMENTS ML, 1991, J CLIN MICROBIOL, V29, P1175, DOI 10.1128/JCM.29.6.1175-1182.1991; CROWE JE, 1993, VACCINE, V11, P1395, DOI 10.1016/0264-410X(93)90168-W; DANIEL C, 1990, VIROLOGY, V174, P87, DOI 10.1016/0042-6822(90)90057-X; Drosten C, 2003, NEW ENGL J MED, V348, P1967, DOI 10.1056/NEJMoa030747; Durbin AP, 2000, J VIROL, V74, P6821, DOI 10.1128/JVI.74.15.6821-6831.2000; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Karron RA, 1996, PEDIATR INFECT DIS J, V15, P650, DOI 10.1097/00006454-199608000-00003; KARRON RA, 1995, J INFECT DIS, V172, P1445, DOI 10.1093/infdis/172.6.1445; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Martina BEE, 2003, NATURE, V425, P915, DOI 10.1038/425915a; Murphy BR, 2002, J CLIN INVEST, V110, P21, DOI 10.1172/JCI200216077; Peiris JSM, 2003, NEW ENGL J MED, V349, P2431, DOI 10.1056/NEJMra032498; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Poutanen SM, 2003, NEW ENGL J MED, V348, P1995, DOI 10.1056/NEJMoa030634; Rota PA, 2003, SCIENCE, V300, P1394, DOI 10.1126/science.1085952; *SARS, 2003, AY274119 SARS; Schmidt AC, 2000, J VIROL, V74, P8922, DOI 10.1128/JVI.74.19.8922-8929.2000; Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001; Subbarao K, 2004, J VIROL, V78, P3572, DOI 10.1128/JVI.78.7.3572-3577.2004; Tang RS, 2003, J VIROL, V77, P10819, DOI 10.1128/JVI.77.20.10819-10828.2003; Tao T, 2000, J VIROL, V74, P6448, DOI 10.1128/JVI.74.14.6448-6458.2000; Tao T, 1998, J VIROL, V72, P2955, DOI 10.1128/JVI.72.4.2955-2961.1998; TUBOLY T, 1994, ARCH VIROL, V137, P55, DOI 10.1007/BF01311173; WEISS RC, 1981, COMP IMMUNOL MICROB, V4, P175, DOI 10.1016/0147-9571(81)90003-5; World Health Organization, COMM DIS SURV RESP S; Zeng FY, 2003, EXP BIOL MED, V228, P866, DOI 10.1177/15353702-0322807-13	29	209	243	3	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2122	2127		10.1016/S0140-6736(04)16501-X	http://dx.doi.org/10.1016/S0140-6736(04)16501-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220033	Bronze, Green Published			2022-12-28	WOS:000222268300008
J	Lynch-Stieglitz, J				Lynch-Stieglitz, J			Hemispheric asynchrony of abrupt climate change	SCIENCE			English	Editorial Material							ICE CORE; DEGLACIATION; CIRCULATION; ANTARCTICA		Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA	University System of Georgia; Georgia Institute of Technology	Lynch-Stieglitz, J (corresponding author), Georgia Inst Technol, Sch Earth & Atmospher Sci, Atlanta, GA 30332 USA.	jean@eas.gatech.edu	Lynch-Stieglitz, Jean/J-2277-2018	Lynch-Stieglitz, Jean/0000-0002-9353-1972				Blunier T, 2001, SCIENCE, V291, P109, DOI 10.1126/science.291.5501.109; Broecker WS, 1998, PALEOCEANOGRAPHY, V13, P119, DOI 10.1029/97PA03707; Charles CD, 1996, EARTH PLANET SC LETT, V142, P19, DOI 10.1016/0012-821X(96)00083-0; Clement AC, 2001, J CLIMATE, V14, P2369, DOI 10.1175/1520-0442(2001)014<2369:AODTSF>2.0.CO;2; Denton GH, 1999, GEOGR ANN A, V81A, P107, DOI 10.1111/j.0435-3676.1999.00055.x; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; Knorr G, 2003, NATURE, V424, P532, DOI 10.1038/nature01855; Lamy F, 2004, SCIENCE, V304, P1959, DOI 10.1126/science.1097863; LOWELL TV, 1995, SCIENCE, V269, P1541, DOI 10.1126/science.269.5230.1541; Moreno PI, 2001, NATURE, V409, P804, DOI 10.1038/35057252; Mortyn PG, 2003, GEOCHEM GEOPHY GEOSY, V4, DOI 10.1029/2002GC000475; Pahnke K, 2003, SCIENCE, V301, P948, DOI 10.1126/science.1084451; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002	14	24	24	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1919	1920		10.1126/science.1100374	http://dx.doi.org/10.1126/science.1100374			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218135				2022-12-28	WOS:000222241600030
J	Santelli, E; Bankston, LA; Leppla, SH; Liddington, RC				Santelli, E; Bankston, LA; Leppla, SH; Liddington, RC			Crystal structure of a complex between anthrax toxin and its host cell receptor	NATURE			English	Article							CAPILLARY MORPHOGENESIS PROTEIN-2; PROTECTIVE ANTIGEN; A-DOMAIN; I-DOMAIN; BINDING; IDENTIFICATION; MUTATIONS; PATHWAY; REVEAL	Anthrax toxin consists of the proteins protective antigen (PA), lethal factor (LF) and oedema factor (EF)(1). The first step of toxin entry into host cells is the recognition by PA of a receptor on the surface of the target cell. Subsequent cleavage of receptor-bound PA enables EF and LF to bind and form a heptameric PA(63) prepore, which triggers endocytosis. Upon acidification of the endosome, PA(63) forms a pore that inserts into the membrane and translocates EF and LF into the cytosol(2). Two closely related host cell receptors, TEM8 and CMG2, have been identified. Both bind to PA with high affinity and are capable of mediating toxicity(3,4). Here, we report the crystal structure of the PA-CMG2 complex at 2.5 Angstrom resolution. The structure reveals an extensive receptor-pathogen interaction surface mimicking the nonpathogenic recognition of the extracellular matrix by integrins(5). The binding surface is closely conserved in the two receptors and across species, but is quite different in the integrin domains, explaining the specificity of the interaction. CMG2 engages two domains of PA, and modelling of the receptor-bound PA(63) heptamer(6-8) suggests that the receptor acts as a pH-sensitive brace to ensure accurate and timely membrane insertion. The structure provides new leads for the discovery of anthrax antitoxins, and should aid the design of cancer therapeutics(9).	Burnham Inst, Program Cell Adhes, La Jolla, CA 92037 USA; NIAID, Microbial Pathogenesis Sect, NIH, Bethesda, MD 20892 USA	Sanford Burnham Prebys Medical Discovery Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Liddington, RC (corresponding author), Burnham Inst, Program Cell Adhes, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	rlidding@burnham.org			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000929, Z01AI000929] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benson EL, 1998, BIOCHEMISTRY-US, V37, P3941, DOI 10.1021/bi972657b; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Bradley KA, 2003, J BIOL CHEM, V278, P49342, DOI 10.1074/jbc.M307900200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Frankel AE, 2003, CURR PHARM DESIGN, V9, P2060, DOI 10.2174/1381612033454162; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lacy DB, 2004, P NATL ACAD SCI USA, V101, P6367, DOI 10.1073/pnas.0401506101; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Liu SH, 2003, EXPERT OPIN BIOL TH, V3, P843, DOI 10.1517/14712598.3.5.843; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Moayeri M, 2004, CURR OPIN MICROBIOL, V7, P19, DOI 10.1016/j.mib.2003.12.001; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Mourez M, 2003, P NATL ACAD SCI USA, V100, P13803, DOI 10.1073/pnas.2436299100; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Nanda A, 2004, CANCER RES, V64, P817, DOI 10.1158/0008-5472.CAN-03-2408; Nassi S, 2002, BIOCHEMISTRY-US, V41, P1445, DOI 10.1021/bi0119518; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petosa C, 1997, NATURE, V385, P833, DOI 10.1038/385833a0; PETOSA C, 1995, THESIS HARVARD U; Rosovitz MJ, 2003, J BIOL CHEM, V278, P30936, DOI 10.1074/jbc.M301154200; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Wigelsworth DJ, 2004, J BIOL CHEM, V279, P23349, DOI 10.1074/jbc.M401292200	29	195	204	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 19	2004	430	7002					905	908		10.1038/nature02763	http://dx.doi.org/10.1038/nature02763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	847DA	15243628				2022-12-28	WOS:000223369800045
J	Hazuda, DJ; Young, SD; Guare, JP; Anthony, NJ; Gomez, RP; Wai, JS; Vacca, JP; Handt, L; Motzel, SL; Klein, HJ; Dornadula, G; Danovich, RM; Witmer, MV; Wilson, KAA; Tussey, L; Schleif, WA; Gabryelski, LS; Jin, LX; Miller, MD; Casimiro, DR; Emini, EA; Shiver, JW				Hazuda, DJ; Young, SD; Guare, JP; Anthony, NJ; Gomez, RP; Wai, JS; Vacca, JP; Handt, L; Motzel, SL; Klein, HJ; Dornadula, G; Danovich, RM; Witmer, MV; Wilson, KAA; Tussey, L; Schleif, WA; Gabryelski, LS; Jin, LX; Miller, MD; Casimiro, DR; Emini, EA; Shiver, JW			Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques	SCIENCE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSCRIPTION; RESISTANCE; CELLS; HIV	We describe the efficacy of L-870812, an inhibitor of HIV-1 and SIV integrase, in rhesus macaques infected with the simian-human immunodeficiency virus (SHIV) 89.6P. When initiated before CD4 cell depletion, L-870812 therapy mediated a sustained suppression of viremia, preserving CD4 levels and permitting the induction of virus-specific cellular immunity. L-870812 was also active in chronic infection; however, the magnitude and durability of the effect varied in conjunction with the pretreatment immune response and viral load. These studies demonstrate integrase inhibitor activity in vivo and suggest that cellular immunity facilitates chemotherapeutic efficacy in retroviral infections.	Merck Res Labs, Dept Biol Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Med Chem, W Point, PA 19486 USA; Merck Res Labs, Dept Lab Anim Res, W Point, PA 19486 USA; Merck Res Labs, Dept Vaccine Res, W Point, PA 19486 USA; Merck Res Labs, Dept Drug Metab & Pharmaceut Res, W Point, PA 19486 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Merck & Company	Hazuda, DJ (corresponding author), Merck Res Labs, Dept Biol Chem, POB 4, W Point, PA 19486 USA.	daria_hazuda@merck.com; steve_young@merck.com						ANTHONY NJ, 2002, Patent No. [00230931, 0230931]; Asante-Appiah E, 1999, ADV VIRUS RES, V52, P351, DOI 10.1016/S0065-3527(08)60306-1; Chaisson RE, 2000, JAMA-J AM MED ASSOC, V284, P3128, DOI 10.1001/jama.284.24.3128; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Fikkert V, 2003, J VIROL, V77, P11459, DOI 10.1128/JVI.77.21.11459-11470.2003; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; HASUDA DJ, UNPUB; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hogberg M, 2000, EXPERT OPIN THER PAT, V10, P1189, DOI 10.1517/13543776.10.8.1189; Jonckheere H, 2000, MED RES REV, V20, P129, DOI 10.1002/(SICI)1098-1128(200003)20:2<129::AID-MED2>3.0.CO;2-A; Lebon F, 2000, CURR MED CHEM, V7, P455, DOI 10.2174/0929867003375146; Little SJ, 2002, NEW ENGL J MED, V347, P385, DOI 10.1056/NEJMoa013552; Lucas GM, 1999, ANN INTERN MED, V131, P81, DOI 10.7326/0003-4819-131-2-199907200-00002; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Reimann KA, 1996, J VIROL, V70, P6922, DOI 10.1128/JVI.70.10.6922-6928.1996; Yerly S, 1999, LANCET, V354, P729, DOI 10.1016/S0140-6736(98)12262-6	18	251	271	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	2004	305	5683					528	532		10.1126/science.1098632	http://dx.doi.org/10.1126/science.1098632			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	840AH	15247437				2022-12-28	WOS:000222828900043
J	Kalodimos, CG; Biris, N; Bonvin, AMJJ; Levandoski, MM; Guennuegues, M; Boelens, R; Kaptein, R				Kalodimos, CG; Biris, N; Bonvin, AMJJ; Levandoski, MM; Guennuegues, M; Boelens, R; Kaptein, R			Structure and flexibility adaptation in nonspecific and specific protein-DNA complexes	SCIENCE			English	Article							REPRESSOR-OPERATOR INTERACTION; LAC REPRESSOR; CRYSTAL-STRUCTURE; HEAT-CAPACITY; BINDING; RECOGNITION; DYNAMICS; SITES	Interaction of regulatory DNA binding proteins with their target sites is usually preceded by binding to nonspecific DNA. This speeds up the search for the target site by several orders of magnitude. We report the solution structure and dynamics of the complex of a dimeric lac repressor DNA binding domain with nonspecific DNA. The same set of residues can switch roles from a purely electrostatic interaction with the DNA backbone in the nonspecific complex to a highly specific binding mode with the base pairs of the cognate operator sequence. The protein DNA interface of the nonspecific complex is flexible on biologically relevant time scales that may assist in the rapid and efficient finding of the target site.	Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	Utrecht University; University of Wisconsin System; University of Wisconsin Madison	Kaptein, R (corresponding author), Univ Utrecht, Bijvoet Ctr Biomol Res, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	kaptein@nmr.chem.uu.nl	Boelens, Rolf/B-4702-2009; Kalodimos, Charalampos/Q-9846-2018; Bonvin, Alexandre M.J.J./A-5420-2009; Kalodimos, Charalampos/C-5380-2008	Boelens, Rolf/0000-0002-6939-8913; Kalodimos, Charalampos/0000-0001-6354-2796; Bonvin, Alexandre M.J.J./0000-0001-7369-1322; Biris, Nikolaos/0000-0003-4055-5521	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023467, R01GM023467] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 23467] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akke M, 2002, CURR OPIN STRUC BIOL, V12, P642, DOI 10.1016/S0959-440X(02)00369-X; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P3884, DOI 10.1021/bi00285a025; Falcon CM, 2001, BIOCHEMISTRY-US, V40, P15650, DOI 10.1021/bi0114067; Frank DE, 1997, J MOL BIOL, V267, P1186, DOI 10.1006/jmbi.1997.0920; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; Garvie CW, 2001, MOL CELL, V8, P937, DOI 10.1016/S1097-2765(01)00392-6; Gowers DM, 2003, EMBO J, V22, P1410, DOI 10.1093/emboj/cdg125; JenJacobson L, 1997, BIOPOLYMERS, V44, P153; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; Kalodimos CG, 2002, NAT STRUCT BIOL, V9, P193, DOI 10.1038/nsb763; Kalodimos CG, 2002, EMBO J, V21, P2866, DOI 10.1093/emboj/cdf318; Kalodimos CG, 2001, P NATL ACAD SCI USA, V98, P6039, DOI 10.1073/pnas.101129898; KAOHUANG Y, 1977, P NATL ACAD SCI USA, V74, P4228, DOI 10.1073/pnas.74.10.4228; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; Shimamoto N, 1999, J BIOL CHEM, V274, P15293, DOI 10.1074/jbc.274.22.15293; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Spronk CAEM, 1996, NAT STRUCT BIOL, V3, P916, DOI 10.1038/nsb1196-916; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; Viadiu H, 2000, MOL CELL, V5, P889, DOI 10.1016/S1097-2765(00)80329-9; VONHIPPEL PH, 1994, SCIENCE, V263, P769, DOI 10.1126/science.8303292; VONHIPPEL PH, 1989, J BIOL CHEM, V264, P675; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x	26	427	434	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					386	389		10.1126/science.1097064	http://dx.doi.org/10.1126/science.1097064			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256668	Green Submitted			2022-12-28	WOS:000222662400035
J	Bates, SM; Ginsberg, JS				Bates, SM; Ginsberg, JS			Treatment of deep-vein thrombosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MOLECULAR-WEIGHT HEPARIN; RECURRENT VENOUS THROMBOEMBOLISM; ORAL ANTICOAGULANT-THERAPY; INTENSITY WARFARIN THERAPY; PULMONARY-EMBOLISM; UNFRACTIONATED HEPARIN; LONG-TERM; RANDOMIZED-TRIAL; PREVENTION; RISK	52-year-old-woman with no history of venous thromboembolism presents with a four-day history of discomfort in her left calf. Proximal deep-vein thrombosis is diagnosed by compression ultrasonography. How should her case be managed?	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	Bates, SM (corresponding author), McMaster Univ, Dept Med, HSC 3W11,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	batesm@mcmaster.ca	ginsberg, jeffrey s/ABC-1065-2020					ABRAMS J, 2002, CARDIOVASCULAR THERA, P97; Agnelli G, 2001, NEW ENGL J MED, V345, P165, DOI 10.1056/NEJM200107193450302; Baglin T, 2003, LANCET, V362, P523, DOI 10.1016/S0140-6736(03)14111-6; BAGLIN T, 2003, 19 C INT SOC THROMB; BARRITT DW, 1960, LANCET, V1, P1309; Brandjes DPM, 1997, LANCET, V349, P759, DOI 10.1016/S0140-6736(96)12215-7; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; CHRISTIANSEN S, 2003, 19 C INT SOC THROMB; Decousus H, 1998, NEW ENGL J MED, V338, P409, DOI 10.1056/NEJM199802123380701; Douketis JD, 1998, JAMA-J AM MED ASSOC, V279, P458, DOI 10.1001/jama.279.6.458; Francis CW, 2003, BLOOD, V102, p6A; Galle C, 2001, THROMB HAEMOSTASIS, V86, P1156, DOI 10.1055/s-0037-1616044; Ginsberg JS, 2001, ARCH INTERN MED, V161, P2105, DOI 10.1001/archinte.161.17.2105; Gould MK, 1999, ANN INTERN MED, V130, P800, DOI 10.7326/0003-4819-130-10-199905180-00003; Hirsh J, 1996, CIRCULATION, V93, P2212, DOI 10.1161/01.CIR.93.12.2212; Hirsh J, 2001, CHEST, V119, p64S, DOI 10.1378/chest.119.1_suppl.64S; Hyers TM, 2001, CHEST, V119, p176S, DOI 10.1378/chest.119.1_suppl.176S; KAKKAR VV, 1969, LANCET, V2, P230; Kearon C, 1999, NEW ENGL J MED, V341, P298; Kearon C, 1998, ANN INTERN MED, V129, P425, DOI 10.7326/0003-4819-128-8-199804150-00011; Kearon C, 2003, NEW ENGL J MED, V349, P631, DOI 10.1056/NEJMoa035422; Kearon C, 2001, Semin Vasc Med, V1, P7, DOI 10.1055/s-2001-14668; Kearon C, 1999, NEW ENGL J MED, V340, P901, DOI 10.1056/NEJM199903253401201; Kearon C, 2001, J THROMB THROMBOLYS, V12, P59, DOI 10.1023/A:1012790511790; Kearon C, 1998, ANN INTERN MED, V128, P663, DOI 10.7326/0003-4819-128-8-199804150-00011; KEARON C, 2001, 18 C INT SOC THROMB; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Koopman MMW, 1997, NEW ENGL J MED, V337, P1251; Kyrle PA, 2004, NEW ENGL J MED, V350, P2558, DOI 10.1056/NEJMoa032959; LAGERSTEDT CI, 1985, LANCET, V2, P515; Lee AYY, 2003, NEW ENGL J MED, V349, P146, DOI 10.1056/NEJMoa025313; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; Linkins LA, 2003, ANN INTERN MED, V139, P893, DOI 10.7326/0003-4819-139-11-200312020-00007; Margaglione M, 1999, THROMB HAEMOSTASIS, V82, P1583; *MATISSE INV, 2003, 19 C INT SOC THROMB; MONREAL M, 1994, THROMB HAEMOSTASIS, V71, P7; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P1908; MOSER KM, 1994, JAMA-J AM MED ASSOC, V271, P223, DOI 10.1001/jama.271.3.223; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Pettila V, 2002, THROMB HAEMOSTASIS, V87, P182; Pinede L, 2001, CIRCULATION, V103, P2453; PRANDONI P, 1992, NEW ENGL J MED, V327, P1128, DOI 10.1056/NEJM199210153271604; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; Prins MH, 1999, THROMB HAEMOSTASIS, V82, P892; Ridker PM, 2003, NEW ENGL J MED, V348, P1425, DOI 10.1056/NEJMoa035029; Rodger M, 1998, CAN MED ASSOC J, V159, P931; Rosendaal FR, 1999, LANCET, V353, P1167, DOI 10.1016/S0140-6736(98)10266-0; Schulman S, 2003, NEW ENGL J MED, V349, P1713, DOI 10.1056/NEJMoa030104; Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; STAMATAKIS JD, 1977, BRIT MED J, V2, P223, DOI 10.1136/bmj.2.6081.223; van Der Heijden J.F., 2000, COCHRANE DB SYST REV, V4; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Wells PS, 2001, THROMB HAEMOSTASIS, V86, P499	57	146	161	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					268	277		10.1056/NEJMcp031676	http://dx.doi.org/10.1056/NEJMcp031676			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254285				2022-12-28	WOS:000222627200011
J	DiClemente, RJ; Wingood, GM; Harrington, KF; Lang, DL; Davies, SL; Hook, EW; Oh, MK; Crosby, RA; Hertzberg, VS; Gordon, AB; Hardin, JW; Parker, S; Robillard, A				DiClemente, RJ; Wingood, GM; Harrington, KF; Lang, DL; Davies, SL; Hook, EW; Oh, MK; Crosby, RA; Hertzberg, VS; Gordon, AB; Hardin, JW; Parker, S; Robillard, A			Efficacy of an HIV prevention intervention for African American adolescent girls - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED-DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-REDUCTION INTERVENTIONS; BEHAVIORAL INTERVENTIONS; EPIDEMIOLOGIC SYNERGY; REPRODUCTIVE HEALTH; AIDS; TRANSMISSION; DIAGNOSIS; YOUTH	Context African American adolescent girls are at high risk for human immunodeficiency virus (HIV) infection, but interventions specifically designed for this population have not reduced HIV risk behaviors. Objective To evaluate the efficacy of an intervention to reduce sexual risk behaviors, sexually transmitted diseases (STDs), and pregnancy and enhance mediators of HIV-preventive behaviors. Design, Setting, and Participants Randomized controlled trial of 522 sexually experienced African American girls aged 14 to 18 years screened from December 1996, through April 1999 at 4 community health agencies. Participants completed a self-administered questionnaire and an interview, demonstrated condom application skills, and provided specimens for STD testing. Outcome assessments were made at 6- and 12-month follow-up. Intervention All participants received four 4-hour group sessions. The intervention emphasized ethnic and gender pride, HIV knowledge, communication, condom use skills, and healthy relationships. The comparison condition emphasized exercise and nutrition. Main Outcome Measures The primary outcome measure was consistent condom use, defined as condom use during every episode of vaginal intercourse; other outcome measures were sexual behaviors, observed condom application skills, incident STD infection, self-reported pregnancy, and mediators of HIV-preventive behaviors. Results Relative to the comparison condition, participants in the intervention reported using condoms more consistently in the 30 days preceding the 6-month assessment (unadjusted analysis, intervention, 75.3% vs comparison, 58.2%) and the 12-month assessment (unadjusted analysis, intervention, 73.3% vs comparison, 56.5%) and over the entire 12-month period (adjusted odds ratio, 2.01; 95% confidence interval [CI] 1.28-3.17; P=.003). Participants in the intervention reported using condoms more consistently in the 6 months preceding the 6-month assessment (unadjusted analysis, intervention, 61.3% vs comparison, 42.6%), at the 12-month assessment (unadjusted analysis, intervention, 58.1% vs comparison, 45.3%), and over the entire 12-month period (adjusted odds ratio, 2.30; 95% CI, 1.51-3.50; P<.001). Using generalized estimating equation analyses over the 12-month follow-up, adolescents in the intervention were more likely to use a condom at last intercourse, less likely to have a new vaginal sex partner in the past 30 days, and more likely to apply condoms to sex partners and had better condom application skills, a higher percentage of condom-protected sex acts, fewer unprotected vaginal sex acts, and higher scores on measures of mediators. Promising effects were also observed for chlamydia infections and self-reported pregnancy. Conclusion Interventions for African American adolescent girls that are gender-tailored and culturally congruent can enhance HIV,preventive behaviors, skills, and mediators and may reduce pregnancy and chlamydia infection.	Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Biostat, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pediat, Div Infect Dis Epidemiol & Immunol, Atlanta, GA USA; Emory Univ, Dept Womens Studies, Atlanta, GA 30322 USA; Emory Univ, Ctr AIDS Res, Atlanta, GA 30322 USA; Univ Alabama Birmingham, Sch Med, Dept Pediat, Birmingham, AL USA; Univ Alabama Birmingham, Sch Med, Dept Med, Div Infect Dis, Birmingham, AL USA; Univ Alabama Birmingham, Sch Publ Hlth, Dept Hlth Behav, Birmingham, AL 35294 USA; Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Univ Michigan, Dept Hlth Sci & Adm, Flint, MI 48503 USA	Emory University; Rollins School Public Health; Emory University; Rollins School Public Health; Emory University; Emory University; Emory University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Michigan System; University of Michigan; University of Michigan Flint	DiClemente, RJ (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, 1518 Clifton Rd NE,Room 554, Atlanta, GA 30322 USA.	rdiclem@sph.emory.edu	Hardin, James/P-4772-2019; Hardin, James W/Q-7617-2016	Hardin, James/0000-0003-0506-5500; Hardin, James W/0000-0003-0506-5500; Robillard, Alyssa/0000-0002-1331-7539; Harrington, Kathleen/0000-0002-4154-0631	NIMH NIH HHS [1R01 MH54412] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054412] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 2002, EMERGING THEORIES HL; Bandura A, 1994, SOCIAL COGNITIVE THE, P25, DOI DOI 10.1007/978-1-4899-1193-3_3; Bozzette SA, 2001, NEW ENGL J MED, V344, P817, DOI 10.1056/NEJM200103153441107; Chesson HW, 2004, PERSPECT SEX REPRO H, V36, P11, DOI 10.1363/3601104; Cowan FM, 2002, SEX TRANSM INFECT, V78, P315, DOI 10.1136/sti.78.5.315; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; DiClemente R, 2003, ARCH PEDIAT ADOL MED, V157, P319, DOI 10.1001/archpedi.157.4.319; Diclemente Ralph J., 1992, P34; DiClemente RJ, 1996, CLAR SYMP, P13; DiClemente RJ, 1998, JAMA-J AM MED ASSOC, V279, P1574, DOI 10.1001/jama.279.19.1574; DiClemente RJ, 2000, J ADOLESCENT HEALTH, V26, P377, DOI 10.1016/S1054-139X(00)00126-9; DICLEMENTE RJ, 2003, REDUCING ADOLESCENT, P366; DICLEMENTE RJ, 2000, AIDS PREVENT MENT H, P311; DICLEMENTE RJ, 1990, J ADOLESCENT RES, V5, P7, DOI DOI 10.1177/074355489051003; DICLEMENTE RJ, 2003, BLACKWELL HDB ADOLES, P573; EFRON B, 1981, BIOMETRIKA, V68, P589, DOI 10.1093/biomet/68.3.589; Ellen JM, 2003, J URBAN HEALTH, V80, P40; ENG TR, 1997, HIDDEN EPIDEMIC CONF; Fishbein M, 2000, SEX TRANSM DIS, V27, P101, DOI 10.1097/00007435-200002000-00008; Fleiss JL., 2003, STAT METHODS RATES P; Fleming DT, 1999, SEX TRANSM INFECT, V75, P3, DOI 10.1136/sti.75.1.3; Ford CA, 1997, JAMA-J AM MED ASSOC, V278, P1029, DOI 10.1001/jama.278.12.1029; Hardin JW, 2012, GEN ESTIMATING EQUAT; Hook EW, 1997, J CLIN MICROBIOL, V35, P2129, DOI 10.1128/JCM.35.8.2129-2132.1997; HOSMER DW, 1989, APPL LOGISTIC REGRES; JACCARD J, 1995, J APPL SOC PSYCHOL, V25, P1831, DOI 10.1111/j.1559-1816.1995.tb01820.x; Jemmott JB, 1998, JAMA-J AM MED ASSOC, V279, P1529, DOI 10.1001/jama.279.19.1529; JEMMOTT JB, 2000, AIDS PREVENT MENT H, P103; Johnson BT, 2003, ARCH PEDIAT ADOL MED, V157, P381, DOI 10.1001/archpedi.157.4.381; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Kim N, 1997, J ADOLESCENT HEALTH, V20, P204, DOI 10.1016/S1054-139X(96)00169-3; KIRBY D, 2000, AIDS PREVENT MENT H, P83; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Marsh K. L., 2003, ENCY PRIMARY PREVENT, P541; McFarlane M, 1999, J ADOLESCENT HEALTH, V25, P199, DOI 10.1016/S1054-139X(98)00156-6; MILLER HG, 1990, AIDS 2 DECADE, P359; MULLEN DP, 2002, J ACQ IMMUN DEF SYND, V30, pS94; National Institute of Allergy and Infectious Diseases, 2001, WORKSH SUMM SCI EV C; *NIH, 1997, INT PREV HIV RISK BE; Ochs EP, 1999, J SEX RES, V36, P374, DOI 10.1080/00224499909552010; *OFF NAT AIDS POL, 1996, YOUTH HIV AIDS AM AG; Oh MK, 2003, SEX TRANSM DIS, V30, P689, DOI 10.1097/01.OLQ.0000079526.04451.DE; OLeary A, 1997, AIDS EDUC PREV, V9, P1; Peersman G V, 1998, AIDS, V12 Suppl A, pS191; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; Pinkerton SD, 2002, SEX TRANSM DIS, V29, P298, DOI 10.1097/00007435-200205000-00009; PLICHTA SB, 1992, J ADOLESCENT HEALTH, V13, P506, DOI 10.1016/1054-139X(92)90015-4; POCOCK SJ, 1993, CLIN TRIALS; Robin L, 2004, J ADOLESCENT HEALTH, V34, P3, DOI 10.1016/S1054-139X(03)00244-1; Rotheram-Borus M J, 2000, Prev Sci, V1, P15, DOI 10.1023/A:1010071932238; Santelli J S, 1999, Adolesc Med, V10, P87; SARACCO A, 1993, J ACQ IMMUN DEF SYND, V6, P497; SCHACHTER J, 1995, SEX TRANSM DIS, V22, P191, DOI 10.1097/00007435-199505000-00010; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 2002, LANCET, V359, P696, DOI 10.1016/S0140-6736(02)07816-9; Schwebke JR, 1997, J CLIN MICROBIOL, V35, P1618, DOI 10.1128/JCM.35.6.1618-1619.1997; Shrier LA, 2002, ARCH PEDIAT ADOL MED, V156, P599, DOI 10.1001/archpedi.156.6.599; Shrier LA, 2001, PREV MED, V33, P179, DOI 10.1006/pmed.2001.0869; Smith K, 2001, ARCH PEDIAT ADOL MED, V155, P676, DOI 10.1001/archpedi.155.6.676; Stephenson JM, 1999, SEX TRANSM INFECT, V75, P69, DOI 10.1136/sti.75.1.69; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; Valleroy LA, 1998, J ACQ IMMUN DEF SYND, V19, P67, DOI 10.1097/00042560-199809010-00011; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; Weinstock H, 2004, PERSPECT SEX REPRO H, V36, P6, DOI 10.1111/j.1931-2393.2004.tb00002.x; Wingood GM, 2000, HEALTH EDUC BEHAV, V27, P539, DOI 10.1177/109019810002700502; Wingood GM, 2002, ISS WO HLTH, P281; Wingood GM, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e57	69	379	379	2	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					171	179		10.1001/jama.292.2.171	http://dx.doi.org/10.1001/jama.292.2.171			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	836TS	15249566	Bronze			2022-12-28	WOS:000222579300022
J	Koutkia, P; Canavan, B; Breu, J; Torriani, M; Kissko, J; Grinspoon, S				Koutkia, P; Canavan, B; Breu, J; Torriani, M; Kissko, J; Grinspoon, S			Growth hormone-releasing hormone in HIV-infected men with lipodystrophy - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REGIONAL BODY-COMPOSITION; PROTEASE INHIBITORS; REPLACEMENT THERAPY; INSULIN-RESISTANCE; FAT REDISTRIBUTION; PULSE DETECTION; GH SECRETION; ADULTS; METABOLISM; GLUCOSE	Context Reduced growth hormone (GH) concentrations are observed in men with human immunodeficiency virus (HIV) lipodystrophy. Objective To investigate the effects of growth hormone-releasing hormone (GHRH), a GH secretagogue, in treatment of HIV lipodystrophy. Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted at a research center in the United States between October 2002 and June 2003 and enrolling 31 HIV-infected men aged 18 to 60 years with evidence of lipodystrophy. Interventions Participants were assigned to receive GHRH (1 mg subcutaneously twice daily) or placebo for 12 weeks. Main Outcome Measures The primary outcome was change in concentrations of insulin-like growth factor 1 (IGF-1) to detect overall change in GH levels in response to GHRH. Secondary end points included body composition by dual-energy x-ray absorptiometry and computed tomography, lipodystrophy ratings, and levels of glucose, insulin, and lipids. Results Mean (SD) IGF-1 concentrations increased significantly in the GHRH group vs the placebo group (104 [110] ng/mL vs 6 [44] ng/mL, P=.004). Lean body mass significantly increased in the GHRH group vs the placebo group (0.9 [1.3] kg vs -0.3 [1.7] kg, P=.04), trunk fat significantly decreased (-0.4 [0.7] kg vs 0.2 [0.6] kg, P=.03), and the ratio of trunk to lower extremity fat improved significantly (-0.22 [0.32] vs 0.14 [0.29], P=.005). Abdominal visceral fat was reduced (-19.2 [36.6] cm(2) vs 2.3 [24.3] cm(2), P=.07) and the ratio of abdominal visceral fat to abdominal subcutaneous fat improved significantly more in the GHRH group (-0.19 [0.28] vs 0.07 [0.27], P=.02). Both physician and patient rating of lipodystrophy in the arms, legs, and abdomen also improved significantly. Levels of glucose, insulin, and lipids did not change significantly. Conclusions GHRH was well tolerated and effectively increased levels of IGF-1 in HIV-infected men with lipodystrophy. Total and regional body composition improved in response to GHRH, with increased lean mass and reduced truncal and visceral fat. Use of GHRH may potentially be a beneficial treatment strategy for this population.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Nutr Metab, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroendocrine Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA; MIT, Gen Clin Res Ctr, Cambridge, MA 02139 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Grinspoon, S (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Program Nutr Metab, 55 Fruit St,LON 207, Boston, MA 02114 USA.	sgrinspoon@partners.org	Hron, Bridget/AFU-8589-2022	Hron, Bridget/0000-0002-6482-0150	NCRR NIH HHS [M01-RR01066] Funding Source: Medline; NIDDK NIH HHS [R01 DK063639] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063639] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Achermann JC, 1999, CLIN ENDOCRINOL, V51, P575, DOI 10.1046/j.1365-2265.1999.00839.x; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BERELOWITZ M, 1981, SCIENCE, V212, P1279, DOI 10.1126/science.6262917; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; Carr A, 2003, LANCET, V361, P726, DOI 10.1016/S0140-6736(03)12656-6; Carr A, 1999, LANCET, V353, P2093, DOI 10.1016/S0140-6736(98)08468-2; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; CORPAS E, 1992, J CLIN ENDOCR METAB, V75, P530, DOI 10.1210/jc.75.2.530; de Boer H, 1997, HORM RES, V48, P21, DOI 10.1159/000191325; Dube MP, 2002, ANTIVIR THER, V7, pL18; Engelson ES, 2002, J ACQ IMMUN DEF SYND, V30, P379, DOI 10.1097/01.QAI.0000020501.93209.1C; Fisac C, 2003, J CLIN ENDOCR METAB, V88, P5186, DOI 10.1210/jc.2002-021830; Gelato MC, 2002, JAIDS-J ACQ IMM DEF, V31, P163, DOI 10.1097/00126334-200210010-00006; Hadigan C, 2004, ANN INTERN MED, V140, P786, DOI 10.7326/0003-4819-140-10-200405180-00008; Hadigan C, 2000, JAMA-J AM MED ASSOC, V284, P472, DOI 10.1001/jama.284.4.472; Hadigan C, 2002, J CLIN ENDOCR METAB, V87, P4611, DOI 10.1210/jc.2002-020709; Hadigan C, 1999, J CLIN ENDOCR METAB, V84, P1932, DOI 10.1210/jc.84.6.1932; Henry K, 1998, LANCET, V351, P1328, DOI 10.1016/S0140-6736(05)79053-X; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; Hoybye C, 2003, GROWTH HORM IGF RES, V13, P269, DOI 10.1016/S1096-6374(03)00017-0; HULSE JA, 1986, J CLIN ENDOCR METAB, V63, P872, DOI 10.1210/jcem-63-4-872; JAFFE CA, 1993, J CLIN INVEST, V92, P695, DOI 10.1172/JCI116639; Johannsson G, 1997, J CLIN ENDOCR METAB, V82, P727, DOI 10.1210/jc.82.3.727; Khorram O, 1997, J CLIN ENDOCR METAB, V82, P1472, DOI 10.1210/jc.82.5.1472; Koo GC, 2001, J IMMUNOL, V166, P4195, DOI 10.4049/jimmunol.166.6.4195; Kotler DP, 2004, JAIDS-J ACQ IMM DEF, V35, P239, DOI 10.1097/00126334-200403010-00004; Koutkia P, 2004, ANNU REV MED, V55, P303, DOI 10.1146/annurev.med.55.091902.104412; Koutkia P, 2004, AM J PHYSIOL-ENDOC M, V286, pE296, DOI 10.1152/ajpendo.00335.2003; Kratz A, 1998, NEW ENGL J MED, V339, P1063, DOI 10.1056/NEJM199810083391508; Latshaw VV., 1957, AM MATH MON, V64, P685, DOI [10.2307/2309989, DOI 10.2307/2309989]; Lichtenstein KA, 2001, AIDS, V15, P1389, DOI 10.1097/00002030-200107270-00008; Lo JC, 2001, J CLIN ENDOCR METAB, V86, P3480, DOI 10.1210/jc.86.8.3480; Mallal SA, 2000, AIDS, V14, P1309, DOI 10.1097/00002030-200007070-00002; Mallon PWG, 2003, AIDS, V17, P971, DOI 10.1097/00002030-200305020-00005; Martinez E, 2001, LANCET, V357, P592, DOI 10.1016/S0140-6736(00)04056-3; *MED EC, 2002, 2002 DRUG TOP RED BO, P353; Meininger G, 2002, AM J CLIN NUTR, V76, P460, DOI 10.1093/ajcn/76.2.460; Napolitano LA, 2002, AIDS, V16, P1103, DOI 10.1097/00002030-200205240-00003; ORME SM, 1992, CLIN ENDOCRINOL, V37, P453, DOI 10.1111/j.1365-2265.1992.tb02358.x; POULIOT MC, 1992, DIABETES, V41, P826, DOI 10.2337/diabetes.41.7.826; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Rietschel P, 2001, J CLIN ENDOCR METAB, V86, P504, DOI 10.1210/jc.86.2.504; Ruiz L, 2001, J ACQ IMMUN DEF SYND, V27, P229, DOI 10.1097/00126334-200107010-00003; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; Schwarz JM, 2002, J CLIN ENDOCR METAB, V87, P942, DOI 10.1210/jc.87.2.942; Sutinen J, 2003, ANTIVIR THER, V8, P199; Thorner M, 1996, J CLIN ENDOCR METAB, V81, P1189, DOI 10.1210/jc.81.3.1189; VANCE ML, 1989, J CLIN ENDOCR METAB, V68, P22, DOI 10.1210/jcem-68-1-22; VandenBerg G, 1996, J CLIN ENDOCR METAB, V81, P2460, DOI 10.1210/jc.81.7.2460; Veldhuis JD, 2000, J CLIN ENDOCR METAB, V85, P2385, DOI 10.1210/jc.85.7.2385; VELDHUIS JD, 1994, NEUROSCI BIOBEHAV R, V18, P605, DOI 10.1016/0149-7634(94)90019-1; VELDHUIS JD, 1994, METHOD ENZYMOL, V240, P377; VELDHUIS JD, 1986, AM J PHYSIOL, V250, pE486, DOI 10.1152/ajpendo.1986.250.4.E486; Vittone J, 1997, METABOLISM, V46, P89, DOI 10.1016/S0026-0495(97)90174-8; Wanke C, 1999, AIDS, V13, P2099, DOI 10.1097/00002030-199910220-00013; WINER LM, 1990, J CLIN ENDOCR METAB, V70, P1678, DOI 10.1210/jcem-70-6-1678; 1999, MED LETTER DRUGS THE, V41, P2	58	82	87	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					210	218		10.1001/jama.292.2.210	http://dx.doi.org/10.1001/jama.292.2.210			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249570	Bronze			2022-12-28	WOS:000222579300026
J	Rice, CM; Scolding, NJ				Rice, CM; Scolding, NJ			Adult stem cells-reprogramming neurological repair?	LANCET			English	Review							MARROW STROMAL CELLS; NEURAL PROGENITOR CELLS; BONE-MARROW; SPINAL-CORD; IN-VIVO; PURKINJE NEURONS; DNA-CONTENT; PLOIDY LEVELS; NUCLEAR-DNA; HUMAN CNS	Much excitement has surrounded recent breakthroughs in embryonic stem-cell research. Of lower profile, but no less exciting, are the advances in the field of adult stem-cell research, and their implications for cell therapy. Clinical experience from use of adult haemopoietic stem cells in haematology will facilitate and hasten transition from laboratory to clinic-indeed, clinical trials using adult human stem cells are already in progress in some disease states, including myocardial ischaemia. Here, with particular reference to neurology, we review processes that might underlie apparent changes in adult cell phenotype. We discuss implications these processes might have for the development of new therapeutic strategies using adult stem cells.	Univ Bristol, Inst Clin Neurosci, Dept Neurol, Frenchay Hosp, Bristol BS16 1LE, Avon, England	University of Bristol	Scolding, NJ (corresponding author), Univ Bristol, Inst Clin Neurosci, Dept Neurol, Frenchay Hosp, Bristol BS16 1LE, Avon, England.	Rachel.Bowles@north-bristol.swest.nhs.uk	Rice, Claire M/A-1673-2011	Rice, Claire M/0000-0002-9851-4426				Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alison MR, 2003, J CELL SCI, V116, P599, DOI 10.1242/jcs.00269; Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; ARIAS IM, 2001, LIVER BIOL PATHOBIOL; Armstrong RJE, 2001, LANCET, V358, P1174, DOI 10.1016/S0140-6736(01)06260-2; Arnhold S, 2000, INT J DEV NEUROSCI, V18, P201, DOI 10.1016/S0736-5748(99)00089-1; Arsenijevic Y, 2001, EXP NEUROL, V170, P48, DOI 10.1006/exnr.2001.7691; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; AUER GU, 1985, ANAL QUANT CYTOL, V7, P97; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; BARLOGIE B, 1984, EUR J CANCER CLIN ON, V20, P1123, DOI 10.1016/0277-5379(84)90119-6; BARRETT TB, 1983, P NATL ACAD SCI-BIOL, V80, P882, DOI 10.1073/pnas.80.3.882; Bjorklund A, 2001, TRENDS MOL MED, V7, P144, DOI 10.1016/S1471-4914(01)01980-3; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Blau HM, 1999, SEMIN CELL DEV BIOL, V10, P267, DOI 10.1006/scdb.1999.0311; Bonilla S, 2002, EUR J NEUROSCI, V15, P575, DOI 10.1046/j.1460-9568.2002.01895.x; Brodsky VYa, 1990, Biomed Sci, V1, P467; Brodsky W Y, 1977, Int Rev Cytol, V50, P275; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen SB, 2004, J AM CHEM SOC, V126, P410, DOI 10.1021/ja037390k; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Corti S, 2002, EXP NEUROL, V177, P443, DOI 10.1006/exnr.2002.8004; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dexter T M, 1988, Soc Gen Physiol Ser, V43, P25; DONOVAN PJ, 1994, CURR TOP DEV BIOL, V29, P189, DOI 10.1016/S0070-2153(08)60551-7; Eakin GS, 2003, DEV DYNAM, V228, P751, DOI 10.1002/dvdy.10363; Edgar BA, 2001, CELL, V105, P297, DOI 10.1016/S0092-8674(01)00334-8; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; GILBERT P, 1977, VIRCHOWS ARCH B, V25, P233; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; GUSSONI E, 1992, NATURE, V356, P435, DOI 10.1038/356435a0; HADORN E, 1965, BROOKHAVEN SYM BIOL, P148; Halfpenny C, 2002, LANCET NEUROL, V1, P31, DOI 10.1016/S1474-4422(02)00004-2; HANCOCK V, 1993, BRIT J HAEMATOL, V85, P692, DOI 10.1111/j.1365-2141.1993.tb03210.x; HARRIS H, 1988, CANCER RES, V48, P3302; HARRIS H, 1965, NATURE, V205, P640, DOI 10.1038/205640a0; HARRIS H, 1969, J CELL SCI, V4, P499; HEIDEN FL, 1975, Z MIKROSK ANAT FORSC, V89, P18; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Ianus A, 2003, J CLIN INVEST, V111, P843, DOI 10.1172/JCI200316502; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kabos P, 2002, EXP NEUROL, V178, P288, DOI 10.1006/exnr.2002.8039; KARPATI G, 1989, AM J PATHOL, V135, P27; Kaushal D, 2003, J NEUROSCI, V23, P5599; Kim BJ, 2002, NEUROREPORT, V13, P1185, DOI 10.1097/00001756-200207020-00023; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kohyama J, 2001, DIFFERENTIATION, V68, P235, DOI 10.1046/j.1432-0436.2001.680411.x; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Korbling M, 2003, NEW ENGL J MED, V349, P570, DOI 10.1056/NEJMra022361; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; KUDRYAVTSEV BN, 1993, VIRCHOWS ARCH B, V64, P387, DOI 10.1007/BF02915139; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAPHAM LW, 1968, SCIENCE, V159, P310, DOI 10.1126/science.159.3812.310; Laywell ED, 1999, EXP NEUROL, V156, P430, DOI 10.1006/exnr.1999.7029; Lescaudron L, 2003, INT J NEUROSCI, V113, P945, DOI 10.1080/00207450390207759; Li Y, 2001, NEUROSCI LETT, V316, P67, DOI 10.1016/S0304-3940(01)02384-9; Lie DC, 2004, ANNU REV PHARMACOL, V44, P399, DOI 10.1146/annurev.pharmtox.44.101802.121631; MARES V, 1973, BRAIN RES, V53, P273, DOI 10.1016/0006-8993(73)90214-X; Martin-Rendon E, 2003, TRANSFUSION MED, V13, P325, DOI 10.1111/j.1365-3148.2003.00462.x; Martin-Rendon E, 2003, BRIT J HAEMATOL, V122, P877, DOI 10.1046/j.1365-2141.2003.04576.x; Masuya M, 2003, BLOOD, V101, P2215, DOI 10.1182/blood-2002-04-1076; MATSUI Y, 1992, CELL, V70, P841, DOI 10.1016/0092-8674(92)90317-6; Maves L, 2003, CURR OPIN GENET DEV, V13, P472, DOI 10.1016/j.gde.2003.08.006; McKay R, 2002, NAT BIOTECHNOL, V20, P426, DOI 10.1038/nbt0502-426; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Morrison SJ, 2001, CURR BIOL, V11, pR7, DOI 10.1016/S0960-9822(00)00033-6; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Otto SP, 2000, ANNU REV GENET, V34, P401, DOI 10.1146/annurev.genet.34.1.401; Palm K, 2000, MOL BRAIN RES, V78, P192, DOI 10.1016/S0169-328X(00)00075-9; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; PATAPOUTIAN A, 1995, SCIENCE, V270, P1818, DOI 10.1126/science.270.5243.1818; PIPER HM, 1989, ISOLATED ADULT CARDI; Quesenberry PJ, 2002, BLOOD, V100, P4266, DOI 10.1182/blood-2002-04-1246; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Rehen SK, 2001, P NATL ACAD SCI USA, V98, P13361, DOI 10.1073/pnas.231487398; Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615; Rice CM, 2003, TRANSFUSION MED, V13, P351, DOI 10.1111/j.1365-3148.2003.00463.x; RINGERTZ NR, 1971, P NATL ACAD SCI USA, V68, P3228, DOI 10.1073/pnas.68.12.3228; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SANDRITTER W, 1964, NATURE, V202, P100, DOI 10.1038/202100a0; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Soltis DE, 1999, TRENDS ECOL EVOL, V14, P348, DOI 10.1016/S0169-5347(99)01638-9; Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suratt BT, 2003, AM J RESP CRIT CARE, V168, P318, DOI 10.1164/rccm.200301-145OC; Tanaka EM, 2003, CURR OPIN GENET DEV, V13, P497, DOI 10.1016/j.gde.2003.08.003; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Theise ND, 2004, EXP HEMATOL, V32, P25, DOI 10.1016/j.exphem.2003.10.012; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Thiele J, 2004, HISTOL HISTOPATHOL, V19, P201, DOI 10.14670/HH-19.201; TILL JE, 1961, RADIAT RES, V14, P213, DOI 10.2307/3570892; Tran SD, 2003, LANCET, V361, P1084, DOI 10.1016/S0140-6736(03)12894-2; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Vinogradov AE, 2001, GENOME, V44, P350, DOI 10.1139/gen-44-3-350; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Wilmut I, 2002, NATURE, V419, P583, DOI 10.1038/nature01079; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Young HE, 2004, ANAT REC PART A, V276A, P75, DOI 10.1002/ar.a.10134; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853; Zhao Y, 2003, P NATL ACAD SCI USA, V100, P2426, DOI 10.1073/pnas.0536882100	121	49	54	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					193	199		10.1016/S0140-6736(04)16633-6	http://dx.doi.org/10.1016/S0140-6736(04)16633-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246733				2022-12-28	WOS:000222612200031
J	Silani, V; Cova, L; Corbo, M; Ciammola, A; Polli, E				Silani, V; Cova, L; Corbo, M; Ciammola, A; Polli, E			Stem-cell therapy for amyotrophic lateral sclerosis	LANCET			English	Review							ADULT HUMAN BRAIN; BONE-MARROW; BLOOD; TRANSPLANTATION; ALS	Context With the lack of effective drug treatments for amyotrophic lateral sclerosis (ALS), and compelling preclinical data, stem-cell research has highlighted this disease as a candidate for stem-cell treatment. Stem-cell transplantation is an attractive strategy for neurological diseases and early successes in animal models of neurodegnerative disease generated optimism about restoring function or delaying degeneration in human beings. The restricted potential of adult stem cells has been challenged over the past 5 years by reports on their ability to acquire new unexpected fates beyond their embryonic lineage (transdifferentiation). Therefore, autologous or allogeneic stem cells, undifferentiated or transdifferentiated and. manipulated epigenetically or genetically, could be a candidate source for local or systemic cell-therapies in ALS. Starting point Albert Clement and colleagues (Science 2003; 302: 113-17) showed that in SOD1G93A chimeric mice, motorneuron degeneration requires damage from mutant SOD1 acting in non-neuronal cells. Wild-type nonneuronal (glial) cells could delay degeneration and extend survival of mutant-expressing motorneurons. Letizia Mazzini and colleagues (Amyotroph Lateral Scler Other Motor Neuron Disord 2003; 4: 158-61) injected autologous bone-marrow-derived stem cells into the spinal cord of seven ALS patients. These investigators reported that the procedure had a reasonable margin of clinical safety. Where next? The success of cell-replacement therapy in ALS will depend a lot on preclinical evidence, because of the complexity and precision of the pattern of connectivity that needs to be restored in degenerating motoneurons. Stem-cell therapy will need to be used with other drugs or treatments, such as antioxidants and/or infusion of trophic molecules.	Univ Milan, Sch Med, IRCCS Ist Auxol Italiano, Dept Neurol, Milan, Italy; Univ Milan, Sch Med, IRCCS Ist Auxol Italiano, Dino Ferrari Ctr,Lab Neurosci, Milan, Italy; Fdn Matarelli, Milan, Italy	IRCCS Istituto Auxologico Italiano; University of Milan; IRCCS Istituto Auxologico Italiano; University of Milan	Silani, V (corresponding author), Univ Milan, Sch Med, IRCCS Ist Auxol Italiano, Dept Neurol, Milan, Italy.	vincenzo@silani.com	Silani, Vincenzo/P-4421-2017; Cova, Lidia/K-6459-2016	Silani, Vincenzo/0000-0002-7698-3854; Cova, Lidia/0000-0002-1504-1556; Corbo, Massimo/0000-0003-0793-9830				BOSSOLASCO P, 2003, AMYOTROPH LATERAL SC, V4, P90; Chen Ruifeng, 2000, Journal of Medicine (Westbury), V31, P21; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Ende N, 2000, LIFE SCI, V67, P53, DOI 10.1016/S0024-3205(00)00602-0; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Hao HN, 2003, J HEMATOTH STEM CELL, V12, P23, DOI 10.1089/152581603321210109; Janson CG, 2001, J HEMATOTH STEM CELL, V10, P913, DOI 10.1089/152581601317211015; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Johansson CB, 1999, EXP CELL RES, V253, P733, DOI 10.1006/excr.1999.4678; Kerr DA, 2003, J NEUROSCI, V23, P5131; Limke TL, 2003, J HEMATOTH STEM CELL, V12, P615, DOI 10.1089/15258160360732641; Liu CY, 2003, J HEMATOTH STEM CELL, V12, P689, DOI 10.1089/15258160360732713; Mazzini L, 2003, AMYOTROPH LATERAL SC, V4, P158, DOI 10.1080/14660820310014653; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Silani V, 2003, AMYOTROPH LATERAL SC, V4, P8, DOI 10.1080/14660820301177; Swash M, 2003, AMYOTROPH LATERAL SC, V4, P133, DOI 10.1080/aml.4.3.133.134; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Westerlund U, 2003, EXP CELL RES, V289, P378, DOI 10.1016/S0014-4827(03)00291-X	19	88	106	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					200	202		10.1016/S0140-6736(04)16634-8	http://dx.doi.org/10.1016/S0140-6736(04)16634-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246734				2022-12-28	WOS:000222612200032
J	Walker, A				Walker, A			Commentary: Performance assessment is here to stay	BRITISH MEDICAL JOURNAL			English	Editorial Material									Healthcare Commiss, London EC1Y 8TG, England		Walker, A (corresponding author), Healthcare Commiss, London EC1Y 8TG, England.	anna.walker@healthcarecommission.org.uk							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	2004	329	7457					109	109		10.1136/bmj.329.7457.109	http://dx.doi.org/10.1136/bmj.329.7457.109			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242920	Green Published			2022-12-28	WOS:000222645000033
J	Xirodimas, DP; Saville, MK; Bourdon, JC; Hay, RT; Lane, DP				Xirodimas, DP; Saville, MK; Bourdon, JC; Hay, RT; Lane, DP			Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity	CELL			English	Article							PROTEASOME-MEDIATED DEGRADATION; PROTEIN MODIFICATION PATHWAY; TUMOR-SUPPRESSOR PROTEIN; UBIQUITIN-LIGASE; MDM2-DEFICIENT MICE; EMBRYONIC LETHALITY; CELL-PROLIFERATION; IN-VIVO; MDM2; SYSTEM	The only reported role for the conjugation of the NEDD8 ubiquitin-like molecule is control of the activity of SCF ubiquitin ligase complexes. Here, we show that the Mdm2 RING finger E3 ubiquitin ligase can also promote NEDD8 modification of the p53 tumor suppressor protein. Mdm2 is itself modified with NEDD8 with very similar characteristics to the autoubiquitination activity of Mdm2. By using a cell line (TS-41) with a temperature-sensitive mutation in the NEDD8 conjugation pathway and a p53 mutant that cannot be NEDDylated (3NKR), we demonstrate that Mdm2-dependent NEDD8 modification of p53 inhibits its transcriptional activity. These findings expand the role for Mdm2 as an E3 ligase, providing evidence that Mdm2 is a common component of the ubiquitin and NEDD8 conjugation pathway and indicating the diverse mechanisms by which E3 ligases can control the function of substrate proteins.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland; Univ St Andrews, Sch Biol, St Andrews KY16 9ST, Fife, Scotland	University of Dundee; University of St Andrews	Lane, DP (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland.	d.p.lane@dundee.ac.uk	Lane, David P/C-4920-2008; Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011; JC, Bourdon/A-4439-2008	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; JC, Bourdon/0000-0003-4623-9386; Xirodimas, Dimitris/0000-0001-9275-1140; Lane, David/0000-0003-0551-3545				Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bottger A, 1997, CURR BIOL, V7, P860, DOI 10.1016/S0960-9822(06)00374-5; Cernac A, 1997, DEVELOPMENT, V124, P1583; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen YZ, 2000, J BIOL CHEM, V275, P8929, DOI 10.1074/jbc.275.12.8929; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Gray WM, 2002, PLANT CELL, V14, P2137, DOI 10.1105/tpc.003178; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurz T, 2002, SCIENCE, V295, P1294, DOI 10.1126/science.1067765; Lain S, 2003, BIOCHEM SOC T, V31, P482, DOI 10.1042/BST0310482; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Liu C, 2002, MULT SCLER J, V8, P10; Liu WL, 2001, J MOL BIOL, V313, P711, DOI 10.1006/jmbi.2001.5082; LUNA RMD, 1995, NATURE, V378, P203; Lykke-Andersen K, 2003, MOL CELL BIOL, V23, P6790, DOI 10.1128/MCB.23.19.6790-6797.2003; Mendoza HM, 2003, J BIOL CHEM, V278, P25637, DOI 10.1074/jbc.M212948200; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Morimoto M, 2003, BIOCHEM BIOPH RES CO, V301, P392, DOI 10.1016/S0006-291X(02)03051-6; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Osaka F, 2000, EMBO J, V19, P3475, DOI 10.1093/emboj/19.13.3475; Osaka F, 1998, GENE DEV, V12, P2263, DOI 10.1101/gad.12.15.2263; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Woods Yvonne L, 2003, Hematol J, V4, P233, DOI 10.1038/sj.thj.6200260; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yan J, 2003, MOL CELL BIOL, V23, P6798, DOI 10.1128/MCB.23.19.6798-6808.2003	56	408	428	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2004	118	1					83	97		10.1016/j.cell.2004.06.016	http://dx.doi.org/10.1016/j.cell.2004.06.016			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242646	Bronze			2022-12-28	WOS:000222626800010
J	Pittet, D; Simon, A; Hugonnet, S; Pessoa-Silva, CL; Sauvan, V; Perneger, TV				Pittet, D; Simon, A; Hugonnet, S; Pessoa-Silva, CL; Sauvan, V; Perneger, TV			Hand hygiene among physicians: Performance, beliefs, and perceptions	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT-CARE; BEHAVIOR; IMPACT; EDUCATION; PATTERNS	Background: Physician adherence to hand hygiene remains low in most hospitals. Objectives: To identify risk factors for nonadherence and assess beliefs and perceptions associated with hand hygiene among physicians. Design: Cross-sectional survey of physician practices, beliefs, and attitudes toward hand hygiene. Setting: Large university hospital. Participants: 163 physicians. Measurements: individual observation of physician hand hygiene practices during routine patient care with documentation of relevant risk factors; self-report questionnaire to measure beliefs and perceptions. Logistic regression identified variables independently associated with adherence. Results: Adherence averaged 57% and varied markedly across medical specialties. In multivariate analysis, adherence was associated with the awareness of being observed, the belief of being a role model for other colleagues, a positive attitude toward hand hygiene after patient contact, and easy access to hand-rub solution. Conversely, high workload, activities associated with a high risk for cross-transmission, and certain technical medical specialties (surgery, anesthesiology, emergency medicine, and intensive care medicine) were risk factors for nonadherence. Limitations: Direct observation of physicians may have influenced both adherence to hand hygiene and responses to the self-report questionnaire. Generalizability of study results requires additional testing in other health care settings and physician populations. Conclusion: Physician adherence to hand hygiene is associated with work and system constraints, as well as knowledge and cognitive factors. At the individual level, strengthening a positive attitude toward hand hygiene and reinforcing the conviction that each individual can influence the group behavior may improve adherence among physicians. Physicians who work in technical specialties should also be targeted for improvement.	Univ Hosp Geneva, Infect Control Program, Serv PCI, CH-1211 Geneva 14, Switzerland	University of Geneva	Pittet, D (corresponding author), Univ Hosp Geneva, Infect Control Program, Serv PCI, 24 Rue Micheli du Crest, CH-1211 Geneva 14, Switzerland.		Quinn, yvonne/B-8038-2011					Ajzen I., 1980, UNDERSTANDING ATTITU; AJZEN I, 1988, PERSONALITY BEHAV; ALBERT RK, 1981, NEW ENGL J MED, V304, P1465, DOI 10.1056/NEJM198106113042404; Bischoff WE, 2000, ARCH INTERN MED, V160, P1017, DOI 10.1001/archinte.160.7.1017; Bittner MJ, 2002, INFECT CONT HOSP EP, V23, P120, DOI 10.1086/502020; Boyce JM, 1999, ANN INTERN MED, V130, P153, DOI 10.7326/0003-4819-130-2-199901190-00011; Boyce JM, 2002, INFECT CONT HOSP EP, V23, pS3, DOI 10.1086/503164; CHAN DKS, 1993, J APPL SOC PSYCHOL, V23, P1455, DOI 10.1111/j.1559-1816.1993.tb01043.x; Conner M, 1995, PREDICTING HLTH BEHA, P1; DONOWITZ LG, 1987, AM J DIS CHILD, V141, P683, DOI 10.1001/archpedi.1987.04460060099044; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; Duckett L, 1998, NURS RES, V47, P325, DOI 10.1097/00006199-199811000-00006; Eggimann P, 2000, LANCET, V355, P1864, DOI 10.1016/S0140-6736(00)02291-1; FOX MK, 1974, AM J NURS, V74, P1676, DOI 10.2307/3423172; Harbarth S, 2000, J HOSP INFECT, V46, P43, DOI 10.1053/jhin.2000.0798; Hugonnet S, 2002, ARCH INTERN MED, V162, P1037, DOI 10.1001/archinte.162.9.1037; JACCARD J, 1975, J EXP SOC PSYCHOL, V11, P149, DOI 10.1016/S0022-1031(75)80017-5; Kretzer EK, 1998, AM J INFECT CONTROL, V26, P245, DOI 10.1016/S0196-6553(98)80008-4; Lankford MG, 2003, EMERG INFECT DIS, V9, P217; LARSON E, 1986, AM J INFECT CONTROL, V14, P51, DOI 10.1016/0196-6553(86)90055-6; LARSON E, 1982, AM J INFECT CONTROL, V10, P93, DOI 10.1016/0196-6553(82)90019-0; Larson EL, 2001, CRIT CARE MED, V29, P944, DOI 10.1097/00003246-200105000-00007; Maury E, 2000, AM J RESP CRIT CARE, V162, P324, DOI 10.1164/ajrccm.162.1.9908118; O'Boyle CA, 2001, AM J INFECT CONTROL, V29, P352, DOI 10.1067/mic.2001.18405; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Pittet D, 2000, INFECT CONT HOSP EP, V21, P381, DOI 10.1086/501777; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Pittet D, 1999, ANN INTERN MED, V130, P126, DOI 10.7326/0003-4819-130-2-199901190-00006; Pittet D, 2003, ANESTHESIOLOGY, V99, P530, DOI 10.1097/00000542-200309000-00006; Pittet D, 2001, LANCET, P9; RAJU TNK, 1991, AM J MED SCI, V302, P355, DOI 10.1097/00000441-199112000-00006; Sax H, 2001, J HOSP INFECT, V48, P27, DOI 10.1053/jhin.2001.0961; Sheeran P, 2001, HEALTH PSYCHOL, V20, P12, DOI 10.1037/0278-6133.20.1.12; Sherertz RJ, 2000, ANN INTERN MED, V132, P641, DOI 10.7326/0003-4819-132-8-200004180-00007; Stone S, 2001, LANCET, V357, P479, DOI 10.1016/S0140-6736(05)71288-5; Wright SM, 1998, NEW ENGL J MED, V339, P1986, DOI 10.1056/NEJM199812313392706; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	37	434	448	2	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					1	8		10.7326/0003-4819-141-1-200407060-00008	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238364	Green Published			2022-12-28	WOS:000222427600001
J	Demissie, K; Rhoads, GG; Smulian, JC; Balasubramanian, BA; Gandhi, K; Joseph, KS; Kramer, M				Demissie, K; Rhoads, GG; Smulian, JC; Balasubramanian, BA; Gandhi, K; Joseph, KS; Kramer, M			Operative vaginal delivery and neonatal and infant adverse outcomes: Population based retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							VACUUM EXTRACTION; FORCEPS DELIVERY; OBSTETRIC PROCEDURES; BIRTH CERTIFICATES; COHORT; 2ND-STAGE; TRIAL; LABOR; RECORDS; NEWBORN	Objective To compare the risk of neonatal and infant adverse outcomes between vacuum and forceps assisted deliveries. Design Population based study. Setting US linked natality and mortality birth cohort file and the New Jersey linked natality, mortality, and hospital discharge summary birth cohort file. Participants Singleton live births in, the United States (n = 11639 388) and New Jersey (n = 375 351). Main outcome measures Neonatal morbidity and mortality. Results Neonatal mortality was comparable between vacuum and forceps deliveries in US births (odds ratio 0.94,95% confidence interval 0.79 to 1.12). Vacuum delivery was associated with a lower risk of birth injuries (0.69, 0.66 to 0.72), neonatal seizures (0.78, 0.68 to 0.90), and assisted ventilation (< 30 minutes 0.94, 0.92 to 0.97; &GE; 30 minutes 0.92, 0.88 to 0.98). Among births in New Jersey, vacuum extraction was more likely than forceps to be complicated by postpartum haemorrhage (1.22,1.07 to 1.39) and shoulder dystocia (2.00, 1.62 to 2.48). The risks of intracranial haemorrhage, difficulty with feeding, and retinal haemorrhage were comparable between both modes of delivery Sequential use of vacuum and forceps was associated with an increased risk of need for mechanical ventilation in the infant and third and fourth degree perineal tears. Conclusion Although vacuum extraction does have risks, it remains a safe alternative to forceps delivery.	Univ Med & Dent New Jersey, Sch Publ Hlth, Div Epidemiol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Obstet Gynecol & Reprod Sci, Div Maternal Foetal Med, New Brunswick, NJ 08901 USA; Dalhousie Univ, Dept Obstet & Gynaecol & Paediat, Perinatal Epidemiol Res Unit, Halifax, NS B3H 4N1, Canada; McGill Univ, Fac Med, Dept Paediat, Montreal, PQ H3G 1Y6, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Dalhousie University; McGill University	Demissie, K (corresponding author), Univ Med & Dent New Jersey, Sch Publ Hlth, Div Epidemiol, 683 Hoes LAne W,POB 9, Piscataway, NJ 08854 USA.	demisski@umdnj.edu		Joseph, K.S./0000-0003-2317-5607; Balasubramanian, Bijal/0000-0003-2844-9048				[Anonymous], 2000, COCHRANE DB SYST REV; Bahl R, 2004, BMJ-BRIT MED J, V328, P311, DOI 10.1136/bmj.37942.546076.44; Bofill JA, 1996, AM J OBSTET GYNECOL, V175, P1325, DOI 10.1016/S0002-9378(96)70049-2; BROEKHUIZEN FF, 1987, OBSTET GYNECOL, V69, P338; Cunningham FG, 2001, WILLIAMS OBSTET, V23rd; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091, DOI 10.1164/ajrccm.158.4.9802053; EHLERS N, 1974, ACTA OPHTHALMOL, V52, P73; Green DC, 1998, AM J EPIDEMIOL, V147, P581; GREIS JB, 1981, OBSTET GYNECOL, V57, P571; Hankins GDV, 1996, AM J OBSTET GYNECOL, V175, P275, DOI 10.1016/S0002-9378(96)70135-7; HERABUTYA Y, 1988, BRIT J OBSTET GYNAEC, V95, P483, DOI 10.1111/j.1471-0528.1988.tb12801.x; JOHANSON R, 1989, BRIT J OBSTET GYNAEC, V96, P537, DOI 10.1111/j.1471-0528.1989.tb03252.x; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; Kozak LJ, 2002, BIRTH-ISS PERINAT C, V29, P157; Murphy DJ, 2003, BJOG-INT J OBSTET GY, V110, P610, DOI 10.1016/S1470-0328(03)01963-3; Murphy DJ, 2001, LANCET, V358, P1203, DOI 10.1016/S0140-6736(01)06341-3; *NAT CTR HLTH STAT, NCHS CD ROM SER, V20; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PUNNONEN R, 1986, BRIT J OBSTET GYNAEC, V93, P1132, DOI 10.1111/j.1471-0528.1986.tb08633.x; *ROYAL COLL OBST G, 2000, CLIN GREEN TOP GUID, V26; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; U.S. Food and Drug Administration, 1998, PUBL HLTH ADV NEED C; US Department of Health and Human Services, 2010, HLTH PEOPL 2010, V2; VACCA A, 1983, BRIT J OBSTET GYNAEC, V90, P1107, DOI 10.1111/j.1471-0528.1983.tb06455.x; Wen SW, 2001, AM J EPIDEMIOL, V153, P103, DOI 10.1093/aje/153.2.103	27	126	130	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					24	26B		10.1136/bmj.329.7456.24	http://dx.doi.org/10.1136/bmj.329.7456.24			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231617	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000222568300017
J	Koblin, B; Chesney, M; Coates, T; Mayer, K; Agredano, F; Aguilu, E; Barahona, R; Bell, K; Borges, C; Burnias, M; Cayabayab, M; Church, D; Cohn, A; Colon, Y; Dargon, J; DeSousa, N; Erdman, J; Gagne, J; Goodhue, E; Jimenez, J; Johnson, W; Knauz, R; Labiosa, W; Lara, A; LeBlanc, D; Longo, V; Manseau, M; Miller, M; Mimiaga, M; Mohns, E; Montenegro, A; Pantalone, D; Patino, O; Rogers, T; Ruiz, E; Safren, S; Salomon, L; Silva, J; van der Leeden, L; VanDerwarker, R; Weber, C; McKirnan, D; Batticks, A; Bird, J; Bradshaw, L; Brown, R; Buckingham, T; Buckingham, T; Carson, K; Chubinsky, I; Clark, S; Cook, S; Eichholz, J; Gaffold, E; Gaylord, S; Hartfield, M; Henry, D; Hope, B; Gluth, D; Gosselink, S; Hopwood, J; Hosto, L; Howard, J; Jacques, DJ; Jandura, H; Killelea, S; Knight, A; Koehlinger, S; Kohnke, M; LaBoy, F; Lee, H; Martin, K; Martin, N; McGrady, M; McNeal, C; Miles, D; Moore, G; Munn, M; Narvaez, J; Nawab, A; Oblaza, A; O'Keefe, K; Perez, L; Pertiller, E; Picketts, K; Powell, B; Powers, C; Ramey, B; Rodriguez, I; Rutledge, L; Sanchez, P; Saven, M; Schmidt, C; Schulze, M; Skinner, J; Snyder, D; Sorrese, A; St Andre, J; Taranzo, G; Taylor, T; Torres, S; Vanfossan, K; Victorianne, G; Wetz, E; Judson, F; Aas, M; Armendariz, R; Bailey, C; Bost, B; Caine, J; Cline, D; Cooper, S; Curtis, K; Deyo, B; Douglas, J; Furhman, M; Gonzalez, R; Hiller, J; Huber, P; Huber, S; Miller, K; Osteen, P; Peter, L; Robinson, D; Ward, D; Wright, T; Yale, A; Koblin, B; Aldrich, A; Austin, L; Bartell, L; Bensel, J; Bernet, R; Bird, D; Bonilla, A; Booher, C; Camacho, M; Clark, B; Curtis, K; Englert, N; Flores, T; Gates, G; Geller, C; Gonzalez, O; Goodman, D; Goodman, K; Hinson, J; Lawrence, S; Lee, T; Loeffel, J; Luna, A; Metzger, L; Morris, C; O'Quinn, P; Ortiz, E; Parris, O; Perez, A; Precord, T; Rodriguez, A; Santiago, J; Siulinski, C; Strock, L; Teixeira, P; Torres, E; Valenti, F; Weber, C; White, A; Zimmerman, J; Buchbinder, S; Colfax, G; Abella, J; Ahern, M; Bacharat, A; Barreto, A; Boyden-DeShazer, C; Brooks, J; Broome, M; Buckman, T; Colbert, D; Cole, E; Diaz, A; Edgar, M; Faraguna, B; Fratesi, P; Fuqua, V; Gage, R; Garg, A; Gluth, D; Guggenheim, T; Hall, G; Knoble, T; Langdon, R; Lee, I; Lessard, J; Lightburn, N; Matheson, T; Moore, C; Moreno, M; O'Malley, P; Owen, J; Perez, J; Rifkin, R; Rubino, C; Rutherford, M; Sarche, J; Schreiber, G; Schwarz, R; Siulinski, C; Stryker, J; Tomasian, J; Touchstone, J; Watkins, S; Wheeler, S; Van, B; Zerbe, A; Celum, C; Britt, S; Daisy, F; Dang, A; Dickenson, T; Eaton, N; Elliott, T; Evans, R; Farley, P; Fleming, M; Froehle, G; Galea, J; Garcia-Smith, H; Gonzalez, P; Gooding, B; Goodman, K; Haines, J; Herzog, K; Hieb, R; Hildebrandt, E; Jameson, D; Janson, EJ; Kelty, T; Krutch, B; Lennon, E; Leidholm, M; Lopez, A; Loury, P; Meko, M; Melmed, J; Mucha, DP; Ozscuro, S; Picciano, J; Price, J; Rayne, M; Rodriguez, A; Steele, B; Stoaks, N; Stucky, J; Swank, M; Tabet, S; Thompson, J; Torres, DI; Torres, J; Tschumper, P; Verano, PB; Wheeler, K; Yoon, R; Benet, D; Bozeman, S; Clark, S; Coletti, A; Culp, M; Firla, K; Iatesta, M; Madison, M; McKee, S; Seage, G; Chesney, M; Coates, T; Barresi, P; Filocamo, K; Leonardi, C; Stumbo, S; Troy, M; Albright, N; Beauchamp, G; Bonnice, R; Browne, L; Chapdu, C; Covarrubias, M; Deseyve, M; Emel, L; Fisher, A; Hess, E; Holte, S; Huang, YJ; Husnik, M; Klotz, M; Magaret, C; Maykut, W; McDonnell, P; Metch, B; Minerbo, G; Ondrejcek, L; Schille, J; Self, S; Williams, A; Anderson, K; Canatal, R; Chow, YT; Cleland, N; Dondero, D; Enge, B; Liu, E; Sheppard, C; Sugimoto, B; Watson, S				Koblin, B; Chesney, M; Coates, T; Mayer, K; Agredano, F; Aguilu, E; Barahona, R; Bell, K; Borges, C; Burnias, M; Cayabayab, M; Church, D; Cohn, A; Colon, Y; Dargon, J; DeSousa, N; Erdman, J; Gagne, J; Goodhue, E; Jimenez, J; Johnson, W; Knauz, R; Labiosa, W; Lara, A; LeBlanc, D; Longo, V; Manseau, M; Miller, M; Mimiaga, M; Mohns, E; Montenegro, A; Pantalone, D; Patino, O; Rogers, T; Ruiz, E; Safren, S; Salomon, L; Silva, J; van der Leeden, L; VanDerwarker, R; Weber, C; McKirnan, D; Batticks, A; Bird, J; Bradshaw, L; Brown, R; Buckingham, T; Buckingham, T; Carson, K; Chubinsky, I; Clark, S; Cook, S; Eichholz, J; Gaffold, E; Gaylord, S; Hartfield, M; Henry, D; Hope, B; Gluth, D; Gosselink, S; Hopwood, J; Hosto, L; Howard, J; Jacques, DJ; Jandura, H; Killelea, S; Knight, A; Koehlinger, S; Kohnke, M; LaBoy, F; Lee, H; Martin, K; Martin, N; McGrady, M; McNeal, C; Miles, D; Moore, G; Munn, M; Narvaez, J; Nawab, A; Oblaza, A; O'Keefe, K; Perez, L; Pertiller, E; Picketts, K; Powell, B; Powers, C; Ramey, B; Rodriguez, I; Rutledge, L; Sanchez, P; Saven, M; Schmidt, C; Schulze, M; Skinner, J; Snyder, D; Sorrese, A; St Andre, J; Taranzo, G; Taylor, T; Torres, S; Vanfossan, K; Victorianne, G; Wetz, E; Judson, F; Aas, M; Armendariz, R; Bailey, C; Bost, B; Caine, J; Cline, D; Cooper, S; Curtis, K; Deyo, B; Douglas, J; Furhman, M; Gonzalez, R; Hiller, J; Huber, P; Huber, S; Miller, K; Osteen, P; Peter, L; Robinson, D; Ward, D; Wright, T; Yale, A; Koblin, B; Aldrich, A; Austin, L; Bartell, L; Bensel, J; Bernet, R; Bird, D; Bonilla, A; Booher, C; Camacho, M; Clark, B; Curtis, K; Englert, N; Flores, T; Gates, G; Geller, C; Gonzalez, O; Goodman, D; Goodman, K; Hinson, J; Lawrence, S; Lee, T; Loeffel, J; Luna, A; Metzger, L; Morris, C; O'Quinn, P; Ortiz, E; Parris, O; Perez, A; Precord, T; Rodriguez, A; Santiago, J; Siulinski, C; Strock, L; Teixeira, P; Torres, E; Valenti, F; Weber, C; White, A; Zimmerman, J; Buchbinder, S; Colfax, G; Abella, J; Ahern, M; Bacharat, A; Barreto, A; Boyden-DeShazer, C; Brooks, J; Broome, M; Buckman, T; Colbert, D; Cole, E; Diaz, A; Edgar, M; Faraguna, B; Fratesi, P; Fuqua, V; Gage, R; Garg, A; Gluth, D; Guggenheim, T; Hall, G; Knoble, T; Langdon, R; Lee, I; Lessard, J; Lightburn, N; Matheson, T; Moore, C; Moreno, M; O'Malley, P; Owen, J; Perez, J; Rifkin, R; Rubino, C; Rutherford, M; Sarche, J; Schreiber, G; Schwarz, R; Siulinski, C; Stryker, J; Tomasian, J; Touchstone, J; Watkins, S; Wheeler, S; Van, B; Zerbe, A; Celum, C; Britt, S; Daisy, F; Dang, A; Dickenson, T; Eaton, N; Elliott, T; Evans, R; Farley, P; Fleming, M; Froehle, G; Galea, J; Garcia-Smith, H; Gonzalez, P; Gooding, B; Goodman, K; Haines, J; Herzog, K; Hieb, R; Hildebrandt, E; Jameson, D; Janson, EJ; Kelty, T; Krutch, B; Lennon, E; Leidholm, M; Lopez, A; Loury, P; Meko, M; Melmed, J; Mucha, DP; Ozscuro, S; Picciano, J; Price, J; Rayne, M; Rodriguez, A; Steele, B; Stoaks, N; Stucky, J; Swank, M; Tabet, S; Thompson, J; Torres, DI; Torres, J; Tschumper, P; Verano, PB; Wheeler, K; Yoon, R; Benet, D; Bozeman, S; Clark, S; Coletti, A; Culp, M; Firla, K; Iatesta, M; Madison, M; McKee, S; Seage, G; Chesney, M; Coates, T; Barresi, P; Filocamo, K; Leonardi, C; Stumbo, S; Troy, M; Albright, N; Beauchamp, G; Bonnice, R; Browne, L; Chapdu, C; Covarrubias, M; Deseyve, M; Emel, L; Fisher, A; Hess, E; Holte, S; Huang, YJ; Husnik, M; Klotz, M; Magaret, C; Maykut, W; McDonnell, P; Metch, B; Minerbo, G; Ondrejcek, L; Schille, J; Self, S; Williams, A; Anderson, K; Canatal, R; Chow, YT; Cleland, N; Dondero, D; Enge, B; Liu, E; Sheppard, C; Sugimoto, B; Watson, S		EXPLORE Study Team	Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; SEXUALLY-TRANSMITTED-DISEASES; BASE-LINE DATA; CONTROLLED-TRIAL; SAN-FRANCISCO; RISK BEHAVIOR; YOUNG MEN; GAY MEN; PREVENTION	Background Effective interventions are needed to prevent acquisition of HIV infection in men who have sex with men. To date, no behavioural interventions specifically for this risk group have been tested with HIV infection as the primary outcome. Methods This multisite two-group randomised controlled phase IIb trial tested the efficacy of a behavioural intervention in preventing HIV infection among 4295 men who have sex with men. The experimental intervention consisted of ten one-on-one counselling sessions followed by maintenance sessions every 3 months. The standard condition was twice-yearly Project RESPECT individual counselling. Twice-yearly follow-up visits included testing for HIV antibody and assessment of behavioural outcomes. Findings The rate of acquisition of HIV infection was 18.2% (95% Cl -4.7 to 36.0) lower in the intervention group than the standard group. Adjustment for baseline covariates attenuated the intervention effect to 15.7% (-8.4 to 34.4). The effect was more favourable in the first 12-18 months of follow-up. The occurrence of unprotected receptive anal intercourse with HIV-positive and unknown-status partners was 20.5% (10.9 to 29.0) lower in the intervention than in the standard group. Interpretation The results from the primary analyses allow us to rule out that the experimental intervention is associated with a 35% lower rate of HIV acquisition than in the standard group. The overall estimate of a difference of 18.2%, more favourable estimates of effect in the first 12-18 months, and similar effects on risk behaviours suggest that prevention of HIV infection among men who have sex with men by a behavioural intervention is feasible. Further work should be done to develop more effective interventions.	Fenway Community Hlth Ctr, Boston, MA USA; Latin Amer Hlth Inst, Boston, MA USA; Denver Publ Hlth, Denver, CO USA; New York Blood Ctr, New York, NY 10021 USA; San Francisco Dept Publ Hlth, San Francisco, CA USA; Univ Washington, Seattle, WA 98195 USA; ABT Associates Inc, Cambridge, MA 02138 USA; Howard Brown Community Hlth Ctr, Chicago, IL USA	New York Blood Center; San Francisco Department of Public Health; University of Washington; University of Washington Seattle; ABT Associates	Koblin, B (corresponding author), New York Blood Ctr, Lab Infect Dis Prevent, 310 E 67th St, New York, NY 10021 USA.	bkoblin@nybloodcenter.org	Luna, Aurelio/W-3303-2019; Pantalone, David/V-1905-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035176, U01AI048016, U01AI047981, U01AI046749, U01AI047995, N01AI045200, U01AI048040] Funding Source: NIH RePORTER; NIAID NIH HHS [5 U01 AI46749, U01 AI48040, U01 AI48016, N01 AI35176, U01 AI47995, U01 AI47981, N01 AI45200] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Catania JA, 2001, AM J PUBLIC HEALTH, V91, P907, DOI 10.2105/AJPH.91.6.907; *CDCP, 2002, HIV AIDS SURVEILLANC, V14, P10; Celentano DD, 1998, SCIENCE, V280, P1889, DOI 10.1126/science.280.5371.1889; Chesney MA, 2003, AM J PUBLIC HEALTH, V93, P933, DOI 10.2105/AJPH.93.6.933; Elford J, 2000, J ACQ IMMUN DEF SYND, V23, P266; Hogg RS, 2001, AIDS, V15, P1321, DOI 10.1097/00002030-200107060-00020; Imrie J, 2001, BRIT MED J, V322, P1451, DOI 10.1136/bmj.322.7300.1451; Johnson WD, 2002, J ACQ IMMUN DEF SYND, V30, pS118, DOI 10.1097/01.QAI.0000018918.84759.19; Kamb ML, 1998, JAMA-J AM MED ASSOC, V280, P1161, DOI 10.1001/jama.280.13.1161; Katz MH, 2002, AM J PUBLIC HEALTH, V92, P388, DOI 10.2105/AJPH.92.3.388; Koblin BA, 2000, AIDS, V14, P1793, DOI 10.1097/00002030-200008180-00015; Koblin BA, 2003, AM J PUBLIC HEALTH, V93, P926, DOI 10.2105/AJPH.93.6.926; Metzger DS, 2000, AM J EPIDEMIOL, V152, P99, DOI 10.1093/aje/152.2.99; Miller WR, 1996, ADDICT BEHAV, V21, P835, DOI 10.1016/0306-4603(96)00044-5; Rida W, 1997, J ACQ IMMUN DEF SYND, V16, P195, DOI 10.1097/00042560-199711010-00009; Scheer S, 2001, LANCET, V357, P432, DOI 10.1016/S0140-6736(00)04007-1; Shain RN, 1999, NEW ENGL J MED, V340, P93, DOI 10.1056/NEJM199901143400203; Stall RD, 2000, AIDS, V14, pS101; Stephenson JM, 2000, AIDS, V14, pS115; Strathdee SA, 1998, J ACQ IMMUN DEF SYND, V19, P61, DOI 10.1097/00042560-199809010-00010; Torian LV, 1996, AIDS, V10, P187, DOI 10.1097/00002030-199602000-00009; Turner CF, 1998, SCIENCE, V280, P867, DOI 10.1126/science.280.5365.867; Valleroy LA, 2000, JAMA-J AM MED ASSOC, V284, P198, DOI 10.1001/jama.284.2.198; VANGRIENSVEN GJP, 1993, AM J EPIDEMIOL, V137, P909, DOI 10.1093/oxfordjournals.aje.a116752; Vittinghoff E, 1999, AM J EPIDEMIOL, V150, P306, DOI 10.1093/oxfordjournals.aje.a010003; 2001, MMWR MORB MORTAL WKL, V50, P117; 2001, MMWR MORB MORTAL WKL, V50, P440	27	243	248	0	24	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					41	50		10.1016/S0140-6736(04)16588-4	http://dx.doi.org/10.1016/S0140-6736(04)16588-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234855				2022-12-28	WOS:000222392900030
J	Tugwell, P; O'Connor, AM; Santesso, NA				Tugwell, P; O'Connor, AM; Santesso, NA			A 64 year old woman with knee pain: case outcome	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Univ Ottawa, Dept Med, Ottawa, ON K1N 6N5, Canada; Ottawa Hosp, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Cochrane Musculoskeletal Review Grp, Ottawa, ON K1N 6N5, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Tugwell, P (corresponding author), Univ Ottawa, Dept Med, 202-1 Stewart St, Ottawa, ON K1N 6N5, Canada.	ptugwell@uottawa.ca	Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556				OConnor AM, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431, DOI 10.1002/14651858.CD001431]	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	2004	329	7456					38	38		10.1136/bmj.329.7456.38	http://dx.doi.org/10.1136/bmj.329.7456.38			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836PP	15231621	Green Published			2022-12-28	WOS:000222568300021
J	Chang, C; Yu, TW; Bargmann, CI; Tessier-Lavigne, M				Chang, C; Yu, TW; Bargmann, CI; Tessier-Lavigne, M			Inhibition of netrin-mediated axon attraction by a receptor protein tyrosine phosphatase	SCIENCE			English	Article							GANGLION-CELL AXONS; C-ELEGANS; CAENORHABDITIS-ELEGANS; FGF RECEPTOR; NERVE GROWTH; IN-VITRO; GUIDANCE; OUTGROWTH; UNC-5; MIGRATIONS	During axon guidance, the ventral guidance of the Caenorhabditis elegans anterior ventral microtubule axon is controlled by two cues, the UNC-6/ netrin attractant recognized by the UNC-40/DCC receptor and the SLT-1/slit repellent recognized by the SAX-3/robo receptor. We show here that loss-of-function mutations in clr-1 enhance netrin-dependent attraction, suppressing ventral guidance defects in slt-1 mutants. clr-1 encodes a transmembrane receptor protein tyrosine phosphatase ( RPTP) that functions in AVM to inhibit signaling through the DCC family receptor UNC-40 and its effector, UNC-34/enabled. The known effects of other RPTPs in axon guidance could result from modulation of guidance receptors like UNC-40/DCC.	Stanford Univ, Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94305 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	cori@itsa.ucsf.edu; marcH@gene.com	Yu, Timothy W./AAF-5738-2019	Yu, Timothy W./0000-0003-2988-7701; Bargmann, Cornelia/0000-0002-8484-0618				Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Borland CZ, 2001, BIOESSAYS, V23, P1120, DOI 10.1002/bies.10007; Bulow HE, 2004, NEURON, V42, P367, DOI 10.1016/S0896-6273(04)00246-6; Chang C. H., UNPUB; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Desai CJ, 1996, CELL, V84, P599, DOI 10.1016/S0092-8674(00)81035-1; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; Gitai Z, 2003, NEURON, V37, P53, DOI 10.1016/S0896-6273(02)01149-2; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Hao JC, 2001, NEURON, V32, P25, DOI 10.1016/S0896-6273(01)00448-2; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Johnson KG, 2001, J NEUROBIOL, V49, P99, DOI 10.1002/neu.1068; Keleman K, 2001, NEURON, V32, P605, DOI 10.1016/S0896-6273(01)00505-0; Kokel M, 1998, GENE DEV, V12, P1425, DOI 10.1101/gad.12.10.1425; Lundquist EA, 1998, NEURON, V21, P385, DOI 10.1016/S0896-6273(00)80547-4; McFarlane S, 1996, NEURON, V17, P245, DOI 10.1016/S0896-6273(00)80156-7; Merz DC, 2003, DEV BIOL, V256, P173, DOI 10.1016/S0012-1606(03)00014-9; Morse WR, 1998, J NEUROBIOL, V36, P53, DOI 10.1002/(SICI)1097-4695(199807)36:1<53::AID-NEU5>3.0.CO;2-9; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Thompson KM, 2003, MOL CELL NEUROSCI, V23, P681, DOI 10.1016/S1044-7431(03)00120-9; Van Vactor D, 1998, CURR OPIN CELL BIOL, V10, P174, DOI 10.1016/S0955-0674(98)80139-7; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956; Yu TW, 2001, NAT NEUROSCI, V4, P1169, DOI 10.1038/nn748	32	57	71	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					103	106		10.1126/science.1096983	http://dx.doi.org/10.1126/science.1096983			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232111				2022-12-28	WOS:000222386000046
J	Harris, RG; Herzog, EL; Bruscia, EM; Grove, JE; Van Arnam, JS; Krause, DS				Harris, RG; Herzog, EL; Bruscia, EM; Grove, JE; Van Arnam, JS; Krause, DS			Lack of a fusion requirement for development of bone marrow-derived epithelia	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; GIANT-CELL HEPATITIS; STEM-CELL; PURKINJE NEURONS; CRE RECOMBINASE; MUSCLE-FIBER; DIFFERENTIATION; HEPATOCYTES; REPORTER; EXCISION	Analysis of developmental plasticity of bone marrow - derived cells (BMDCs) is complicated by the possibility of cell-cell fusion. Here we demonstrate that epithelial cells can develop from BMDCs without cell-cell fusion. We use the Cre/lox system together with beta-galactosidase and enhanced green fluorescent protein expression in transgenic mice to identify epithelial cells in the lung, liver, and skin that develop from BMDCs without cell fusion.	Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA	Yale University	Krause, DS (corresponding author), Yale Univ, Sch Med, Dept Lab Med, 333 Cedar St, New Haven, CT 06520 USA.	diane.krause@yale.edu	Bruscia, Emanuela/C-4932-2012	Bruscia, Emanuela/0000-0003-2149-4057	NHLBI NIH HHS [HL073742, HL63357, T32-HL07778] Funding Source: Medline; NIDDK NIH HHS [DK61846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007778, P01HL063357, R01HL073742] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Badorf M, 2002, GENESIS, V33, P119, DOI 10.1002/gene.10099; Barraviera B, 1989, Rev Soc Bras Med Trop, V22, P5, DOI 10.1590/S0037-86821989000100002; Barraviera Benedito, 1995, Revista do Instituto de Medicina Tropical de Sao Paulo, V37, P63, DOI 10.1590/S0036-46651995000100008; HARRIS RH, UNPUB; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Heslop L, 2000, J CELL SCI, V113, P2299; Hicks J, 2001, ULTRASTRUCT PATHOL, V25, P65; Jackson KA, 2004, STEM CELLS, V22, P180, DOI 10.1634/stemcells.22-2-180; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; Lerut JP, 1998, TRANSPLANT INT, V11, P320, DOI 10.1007/s001470050151; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; McTaggart Ryan A, 2004, Hepatology, V39, P1143, DOI 10.1002/hep.20192; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; Spees JL, 2003, P NATL ACAD SCI USA, V100, P2397, DOI 10.1073/pnas.0437997100; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Yang YS, 2001, BIOTECHNIQUES, V31, P1036, DOI 10.2144/01315st03; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	23	308	330	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					90	93		10.1126/science.1098925	http://dx.doi.org/10.1126/science.1098925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232107				2022-12-28	WOS:000222386000042
J	Mayr, E				Mayr, E			80 years of watching the evolutionary scenery	SCIENCE			English	Editorial Material									Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA	Harvard University	Mayr, E (corresponding author), Harvard Univ, Museum Comparat Zool, Cambridge, MA 02138 USA.	emayr@oeb.harvard.edu							0	40	45	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	2004	305	5680					46	47		10.1126/science.1100561	http://dx.doi.org/10.1126/science.1100561			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232092				2022-12-28	WOS:000222386000025
J	Narbonne, GM				Narbonne, GM			Modular construction of early ediacaran complex life forms	SCIENCE			English	Article							SOUTHEASTERN NEWFOUNDLAND; MISTAKEN POINT; TRACE FOSSILS; EVOLUTION; RANGEA; BODY; SEA	Newly discovered, exceptionally preserved, soft-bodied fossils near Spaniard's Bay in eastern Newfoundland exhibit features not previously described from Ediacaran (terminal Neoproterozoic) fossils. All of the Spaniard's Bay taxa were composed of similar architectural elements-centimeter-scale frondlets exhibiting three orders of fracticality in branching. Frondlets were combined as modules atop semi-rigid organic skeletons to form a wide array of larger constructions, including frondose and plumose structures. This architecture and construction define the "rangeomorphs," a biological clade that dominated the Mistaken Point assemblage (575 to 560 million years ago) but does not appear to be ancestral to any Phanerozoic or modem organisms.	Queens Univ, Dept Geol Sci & Geol Engn, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Narbonne, GM (corresponding author), Queens Univ, Dept Geol Sci & Geol Engn, Kingston, ON K7L 3N6, Canada.		Narbonne, Guy M/I-7518-2012					ANDERSON MM, 1982, 3RD N AM PAL CONV P, V1, P1; BOWRING SA, NASA ASTR UN GEN M 2; Boynton H.E., 1995, Mercian Geologist, V13, P165; Clapham ME, 2003, PALEOBIOLOGY, V29, P527, DOI 10.1666/0094-8373(2003)029<0527:POTOKA>2.0.CO;2; Clapham ME, 2002, GEOLOGY, V30, P627, DOI 10.1130/0091-7613(2002)030<0627:EET>2.0.CO;2; Dzik J, 2002, J MORPHOL, V252, P315, DOI 10.1002/jmor.1108; Erwin D, 1997, AM SCI, V85, P126; Fedonkin MA, 1997, NATURE, V388, P868, DOI 10.1038/42242; FEDONKIN MA, 1990, VENDIAN SYSTEM, V1, P132; Ford T. D., 1958, Proceedings of the Yorkshire Geological Society, V31, P211; Gehling JG, 1999, PALAIOS, V14, P40, DOI 10.2307/3515360; Gehling JG, 1996, J PALEONTOL, V70, P185, DOI 10.1017/S0022336000023283; GEHLING JG, 1991, MEMOIRS GEOLOGICAL S, V20, P181; Grazhdankin D, 2004, PALEOBIOLOGY, V30, P203, DOI 10.1666/0094-8373(2004)030<0203:PODITE>2.0.CO;2; JENKINS RJF, 1995, PRECAMBRIAN RES, V73, P51, DOI 10.1016/0301-9268(94)00071-X; JENKINS RJF, 1985, PALEOBIOLOGY, V11, P336, DOI 10.1017/S0094837300011635; Knoll AH, 2003, LIFE YOUNG PLANET 1; Martin MW, 2000, SCIENCE, V288, P841, DOI 10.1126/science.288.5467.841; MISRA SB, 1969, GEOL SOC AM BULL, V80, P2133, DOI 10.1130/0016-7606(1969)80[2133:LPFFSN]2.0.CO;2; Narbonne GM, 2003, GEOLOGY, V31, P27, DOI 10.1130/0091-7613(2003)031<0027:LASTOC>2.0.CO;2; NARBONNE GM, 2001, B5 GEOL ASS CAN FIEL; Narbonne GM., 1998, GSA TODAY, V8, P1; Peterson KJ, 2003, INTEGR COMP BIOL, V43, P127, DOI 10.1093/icb/43.1.127; SEILACHER A, 1992, J GEOL SOC LONDON, V149, P607, DOI 10.1144/gsjgs.149.4.0607; Seilacher A, 1999, PALAIOS, V14, P86, DOI 10.2307/3515363; Wood DA, 2003, CAN J EARTH SCI, V40, P1375, DOI 10.1139/E03-048; Xiao SH, 1998, NATURE, V391, P553, DOI 10.1038/35318; Zhuravlev Andrey Yu., 1993, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V190, P299	28	167	172	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	2004	305	5687					1141	1144		10.1126/science.1099727	http://dx.doi.org/10.1126/science.1099727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	849RD	15256615				2022-12-28	WOS:000223557400044
J	Johnson, LV; Anderson, DH				Johnson, LV; Anderson, DH			Age-related macular degeneration and the extracellular matrix	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MALATTIA LEVENTINESE; DRUSEN; MUTATION		Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA	University of California System; University of California Santa Barbara	Johnson, LV (corresponding author), Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.							Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599; Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348; Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722	5	21	21	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	2004	351	4					320	322		10.1056/NEJMp048131	http://dx.doi.org/10.1056/NEJMp048131			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839RC	15269309				2022-12-28	WOS:000222801200003
J	Vestergaard, M; Hviid, A; Madsen, KM; Wohlfahrt, J; Thorsen, P; Schendel, D; Melbye, M; Olsen, J				Vestergaard, M; Hviid, A; Madsen, KM; Wohlfahrt, J; Thorsen, P; Schendel, D; Melbye, M; Olsen, J			MMR vaccination and febrile seizures - Evaluation of susceptible subgroups and long-term prognosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MUMPS-RUBELLA VACCINATION; ADVERSE EVENTS; RISK-FACTORS; MEASLES; CONVULSIONS; CHILDREN; SURVEILLANCE; IMMUNIZATION; PERTUSSIS; SELECTION	Context The rate of febrile seizures increases following measles, mumps, and rubella (MMR) vaccination but it is unknown whether the rate varies according to personal or family history of seizures, perinatal factors, or socioeconomic status. Furthermore, little is known about the long-term outcome of febrile seizures following vaccination. Objectives To estimate incidence rate ratios (RRs) and risk differences of febrile seizures following MMR vaccination within subgroups of children and to evaluate the clinical outcome of febrile seizures following vaccination. Design, Setting, and Participants A population-based cohort study of all children born in Denmark between January 1, 1991, and December 31, 1998, who were alive at 3 months; 537171 children were followed up until December 31, 1999, by using data from the Danish Civil Registration System and 4 other national registries. Main Outcome Measures incidence of first febrile seizure, recurrent febrile seizures, and subsequent epilepsy. Results A total of 439251 children (82%) received MMR vaccination and 17 986 children developed febrile seizures at least once; 973 of these febrile seizures occurred within 2 weeks of MMR vaccination. The RR of febrile seizures increased during the 2 weeks following MMR vaccination (2.75; 95% confidence interval [Cl], 2.55-2.97), and thereafter was close to the observed RR for nonvaccinated children. The RR did not vary significantly in the subgroups of children that had been defined by their family history of seizures, perinatal factors, or socioeconomic status. At 15 to 17 months, the risk difference of febrile seizures within 2 weeks following MMR vaccination was 1.56 per 1000 children overall (95% Cl, 1.44-1.68), 3.97 per 1000 (95% Cl, 2.90-5.40) for siblings of children with a history of febrile seizures, and 19.47 per 1000 (95% Cl, 16.05-23.55) for children with a personal history of febrile seizures. Children with febrile seizures following MMR vaccinations had a slightly increased rate of recurrent febrile seizures (RR, 1.19; 95% Cl, 1.01-1.41) but no increased rate of epilepsy (RR, 0.70; 95% Cl, 0.33-1.50) compared with children who were nonvaccinated at the time of their first febrile seizure. Conclusions MMR vaccination was associated with a transient increased rate of febrile seizures but the risk difference was small even in high-risk children. The long-term rate of epilepsy was not increased in children who had febrile seizures following vaccination compared with children who had febrile seizures of a different etiology.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; State Serum Inst, Dept Epidemiol Res, Danish Epidemiol Sci Ctr, Copenhagen, Denmark; N Atlantic Neuroepidemiol Alliances, Dept Epidemiol & Social Med, Aarhus, Denmark; Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA	Aarhus University; Aarhus University; Statens Serum Institut; Aarhus University; Centers for Disease Control & Prevention - USA	Vestergaard, M (corresponding author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.	mv@soci.au.dk	Vestergaard, Mogens/M-9333-2014; Hviid, Anders/AAH-4319-2020; Olsen, Jørn/F-8801-2015	Vestergaard, Mogens/0000-0001-8830-2174; Hviid, Anders/0000-0002-7509-9127; Olsen, Jørn/0000-0001-7462-5140; Schendel, Diana/0000-0002-8588-1227; melbye, mads/0000-0001-8264-6785				AABY P, 1995, BRIT MED J, V311, P481, DOI 10.1136/bmj.311.7003.481; Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Andersen TF, 1999, DAN MED BULL, V46, P263; ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; [Anonymous], 1996, MMWR Recomm Rep, V45, P1; Barlow WE, 2001, NEW ENGL J MED, V345, P656, DOI 10.1056/NEJMoa003077; deQuadros CA, 1996, JAMA-J AM MED ASSOC, V275, P224, DOI 10.1001/jama.275.3.224; ELLENBERG JH, 1980, JAMA-J AM MED ASSOC, V243, P1337, DOI 10.1001/jama.243.13.1337; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; GRIFFIN MR, 1991, PEDIATRICS, V88, P881; Hills, 1993, STAT MODELS EPIDEMIO; HIRTZ DG, 1983, J PEDIATR-US, V102, P14, DOI 10.1016/S0022-3476(83)80278-9; KNUDSEN FU, 1988, ACTA NEUROL SCAND, V78, P414, DOI 10.1111/j.1600-0404.1988.tb03678.x; Knudsen LB, 1998, DAN MED BULL, V45, P320; *LEADS MMWR, 1987, JAMA-J AM MED ASSOC, V257, P2894; Madsen KM, 2002, NEW ENGL J MED, V347, P1477, DOI 10.1056/NEJMoa021134; Makela A, 2002, PEDIATRICS, V110, P957, DOI 10.1542/peds.110.5.957; Malig C, 1996, TECH PAP INT I VITAL, V66, P1; MILLER C, 1989, PRACTITIONER, V233, P69; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; OFFRINGA M, 1994, J PEDIATR-US, V124, P574, DOI 10.1016/S0022-3476(05)83136-1; Patja A, 2000, PEDIATR INFECT DIS J, V19, P1127, DOI 10.1097/00006454-200012000-00002; Peltola H, 2000, JAMA-J AM MED ASSOC, V284, P2643, DOI 10.1001/jama.284.20.2643; PELTOLA H, 1986, LANCET, V1, P939; Rothman K., 1998, MODERN EPIDEMIOLOGY; Stafstrom CE, 2002, FEBRILE SEIZURES; Vestergaard M, 2002, EPIDEMIOLOGY, V13, P282, DOI 10.1097/00001648-200205000-00008; VESTERGAARD M, 2002, THESIS U AARHUS AARH; Watson J C, 1998, MMWR Recomm Rep, V47, P1; WHO, 2019, INT STAT CLASS DIS R, V10th; *WHO, 1967, MAN INT STAT CLASS D	32	115	118	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					351	357		10.1001/jama.292.3.351	http://dx.doi.org/10.1001/jama.292.3.351			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265850				2022-12-28	WOS:000222693500020
J	Hsu, CY; Vittinghoff, E; Lin, F; Shlipak, MG				Hsu, CY; Vittinghoff, E; Lin, F; Shlipak, MG			The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency	ANNALS OF INTERNAL MEDICINE			English	Article							NUTRITION EXAMINATION SURVEY; IMPAIRED GLUCOSE-TOLERANCE; 3RD NATIONAL-HEALTH; SERUM CREATININE; UNITED-STATES; PREDICTION	Background: The steady increase in end-stage renal disease (ESRD) incidence is a worldwide public health crisis. Objective: To determine whether the increasing incidence of ESRD in the United States is preceded by increased prevalence of chronic renal insufficiency. Design: Birth cohort analysis. Setting: Nationally representative Second and third National Health and Nutrition Examination Surveys (NHANES II [1976-1980] and III [1988-1994]) and nationally comprehensive U.S. Renal Data System registry. Patients: Adults, 20 to 74 years of age, surveyed in NHANES 11 (midpoint, 1978) and NHANES III (midpoint, 1991), and adults, 25 to 79 years of age, who developed ESRD in 1983 and 1996. Measurements: Prevalent chronic renal insufficiency (estimated glomerular filtration rate, 15 to 59 mL/min per 1.73 m(2)) and new ESRD cases. Results: From 1978 to 1991, the number of adults age 20 to 74 years with chronic renal insufficiency increased from 2.6 to 3.9 million, an increase in prevalence from 1970 to 2460 per 100 000 persons, However, the increased incidence of ESRD, was even greater during this period. For every 1000 adults with chronic renal insufficiency in 1978, 9 new cases of ESRD developed in 1983, but every 1000 adults with chronic renal insufficiency in 1991 produced 16 new cases of ESRD in 1996 (relative risk, 1.7 [95% CI, 1.1 to 2.7]). Limitations: We could not follow individual patients with chronic renal insufficiency for the development of ESRD, and we used estimated rather than measured glomerular filtration rate. Conclusions: During the period examined, growth in incident ESRD outpaced growth in prevalent chronic renal insufficiency, demonstrating that the ESRD epidemic in the United States is not merely a function of more cases of kidney disease. Future research should examine other potential contributors to ESRD, growth, such as improved survival from nonrenal diseases and more liberal entry into treatment programs.	Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Hsu, CY (corresponding author), Univ Calif San Francisco, Div Nephrol, 513 Parnassus Ave,672 HSE,Box 0532, San Francisco, CA 94143 USA.	hsuchi@medicine.ucsf.edu		Hsu, Chi-yuan/0000-0001-8182-1238	NHLBI NIH HHS [HL68099] Funding Source: Medline; NIDDK NIH HHS [DK61520] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R03HL068099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK061520] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1997, Am J Kidney Dis, V30, pS67; [Anonymous], 2001, Am J Kidney Dis, V37, pS65; [Anonymous], 1994, VITAL HLTH STAT, P1; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; Coresh J, 2002, AM J KIDNEY DIS, V39, P920, DOI 10.1053/ajkd.2002.32765; Coresh J, 2001, ARCH INTERN MED, V161, P1207, DOI 10.1001/archinte.161.9.1207; Du Bois D, 1916, ARCH INTERN MED, V17, P863, DOI 10.1001/archinte.1916.00080130010002; Eknoyan G, 2002, AM J KIDNEY DIS, V39, pS14, DOI 10.1053/ajkd.2002.30939; Feller W., 1957, INTRO PROBABILITY TH; HAKIM RM, 1995, J AM SOC NEPHROL, V6, P1319; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hsu CY, 2003, J AM SOC NEPHROL, V14, P2902, DOI 10.1097/01.ASN.0000091586.46532.B4; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; LITTLE RJ, 1987, STAT ANAL MISSING DA, P55; Mattix HJ, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341034; McDowell A, 1981, Vital Health Stat 1, P1; Muntner P, 2003, J AM SOC NEPHROL, V14, P1568, DOI 10.1097/01.ASN.0000067420.83632.C1; PORT FK, 1992, AM J KIDNEY DIS, V20, P3; Xue JL, 2001, J AM SOC NEPHROL, V12, P2753, DOI 10.1681/ASN.V12122753; 2003, AM J KIDNEY DIS S2, V41, pS7	22	191	199	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					95	101		10.7326/0003-4819-141-2-200407200-00007	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262664				2022-12-28	WOS:000222758200002
J	Streubel, B; Chott, A; Huber, D; Exner, M; Jager, U; Wagner, O; Schwarzinger, I				Streubel, B; Chott, A; Huber, D; Exner, M; Jager, U; Wagner, O; Schwarzinger, I			Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-SITU HYBRIDIZATION; BONE-MARROW; FOLLICULAR LYMPHOMA; HORIZONTAL TRANSFER; TUMOR ANGIOGENESIS; APOPTOTIC BODIES; BLOOD-VESSELS; CHROMOSOME; TRANSLOCATION; MECHANISMS	BACKGROUND: The growth of most tumors depends on the formation of new blood vessels. In contrast to genetically unstable tumor cells, the endothelial cells of tumor vessels are considered to be normal diploid cells that do not acquire mutations. METHODS: Using a combined immunohistochemical and fluorescence in situ hybridization assay, we examined the endothelial cells in 27 B-cell lymphomas for cytogenetic alterations that are known to be present in the lymphoma cells. RESULTS: We found that 15 to 85 percent (median, 37 percent) of the microvascular endothelial cells in the B-cell lymphomas harbored lymphoma-specific chromosomal translocations. In addition, numerical chromosomal aberrations were shared by the lymphoma cells and the endothelial cells. CONCLUSIONS: Our findings suggest that microvascular endothelial cells in B-cell lymphomas are in part tumor-related and therefore reflect a novel aspect of tumor angiogenesis.	Med Univ Vienna, Vienna Gen Hosp, Inst Pathol, A-1090 Vienna, Austria; Med Univ Vienna, Vienna Gen Hosp, Inst Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Med Univ Vienna, Vienna Gen Hosp, Ctr Excellence Clin & Expt Oncol, Lymphoma Program, A-1090 Vienna, Austria; Med Univ Vienna, Vienna Gen Hosp, Dept Internal Med 1, Div Hematol, A-1090 Vienna, Austria	Medical University of Vienna; Medical University of Vienna; Medical University of Vienna; Medical University of Vienna	Chott, A (corresponding author), Med Univ Vienna, Vienna Gen Hosp, Inst Pathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	andreas.chott@akh-wien.ac.at; oswald.wagner@meduniwien.ac.at						Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Gunsilius E, 2000, LANCET, V355, P1688, DOI 10.1016/S0140-6736(00)02241-8; HAMMERSEN F, 1985, INT J MICROCIRC, V4, P31; Helczynska K, 2003, CANCER RES, V63, P1441; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963; Horsman DE, 2001, GENE CHROMOSOME CANC, V30, P375, DOI 10.1002/gcc.1103; Jaffe ES, 2001, PATHOLOGY GENETICS T, V3; Jager U, 2000, BLOOD, V95, P3520, DOI 10.1182/blood.V95.11.3520.011k12_3520_3529; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; Kurose K, 2002, NAT GENET, V32, P681, DOI 10.1038/ng1202-681b; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Lestou VS, 2003, BRIT J HAEMATOL, V122, P745, DOI 10.1046/j.1365-2141.2003.04502.x; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Moinfar F, 2000, CANCER RES, V60, P2562; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; Nutt SL, 1999, NATURE, V401, P556, DOI 10.1038/44076; O'Riordan M, 2000, IMMUNOL REV, V175, P94, DOI 10.1034/j.1600-065X.2000.017503.x; Ott G, 1997, BLOOD, V89, P1421, DOI 10.1182/blood.V89.4.1421; Papetti M, 2002, AM J PHYSIOL-CELL PH, V282, pC947, DOI 10.1152/ajpcell.00389.2001; PRAUSE JU, 1980, A GRAEF ARCH KLIN EX, V212, P261, DOI 10.1007/BF00410520; Rafii S, 2000, J CLIN INVEST, V105, P17, DOI 10.1172/JCI8774; Reynaud D, 2003, BLOOD, V101, P4313, DOI 10.1182/blood-2002-07-2085; Schaniel C, 2002, BLOOD, V99, P472, DOI 10.1182/blood.V99.2.472; Stamatopoulos K, 2000, IMMUNOL TODAY, V21, P298, DOI 10.1016/S0167-5699(00)01650-9; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Takahashi N, 1998, BLOOD, V92, P4758, DOI 10.1182/blood.V92.12.4758; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Vacca A, 2003, BLOOD, V102, P3340, DOI 10.1182/blood-2003-04-1338; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; WARREN BA, 1966, LAB INVEST, V15, P464; WEBERMATTHIESEN K, 1995, BLOOD, V86, P1464, DOI 10.1182/blood.V86.4.1464.bloodjournal8641464; Welzel N, 2001, CANCER RES, V61, P1629; Wiktor A, 2000, GENE CHROMOSOME CANC, V27, P11, DOI 10.1002/(SICI)1098-2264(200001)27:1<11::AID-GCC2>3.0.CO;2-I; WILLIS RA, 1948, PATHOLOGY TUMOURS; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	42	253	267	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					250	259		10.1056/NEJMoa033153	http://dx.doi.org/10.1056/NEJMoa033153			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254283	Bronze			2022-12-28	WOS:000222627200009
J	Bartlett, S				Bartlett, S			Fellowship of the rings	LANCET			English	Editorial Material									The Lancet, London NW1 7BY, England		Bartlett, S (corresponding author), The Lancet, London NW1 7BY, England.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					126	126		10.1016/S0140-6736(04)16654-3	http://dx.doi.org/10.1016/S0140-6736(04)16654-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246715				2022-12-28	WOS:000222612200008
J	Hettiaratchy, S; Papini, R				Hettiaratchy, S; Papini, R			ABC of burns - Initial management of a major burn: II - assessment and resuscitation	BMJ-BRITISH MEDICAL JOURNAL			English	Review									Pan Thames Training Scheme, London, England; Selly Oak Univ Hosp, W Midlands Reg Burn Unit, Birmingham, W Midlands, England		Hettiaratchy, S (corresponding author), Pan Thames Training Scheme, London, England.							Clarke J, 1999, BRIT MED BULL, V55, P885, DOI 10.1258/0007142991902691; Collis N, 1999, BURNS, V25, P345, DOI 10.1016/S0305-4179(99)00007-8; Herndon DN, 2018, TOTAL BURN CARE; Kao CC, 2000, PLAST RECONSTR SURG, V105, P2482, DOI 10.1097/00006534-200006000-00028; Yowler CJ, 2000, CLIN PLAST SURG, V27, P1	5	144	147	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					101	103		10.1136/bmj.329.7457.101	http://dx.doi.org/10.1136/bmj.329.7457.101			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242917	Green Published			2022-12-28	WOS:000222645000030
J	Powell, C; Baker-Henningham, H; Walker, S; Gernay, J; Grantham-McGregor, S				Powell, C; Baker-Henningham, H; Walker, S; Gernay, J; Grantham-McGregor, S			Feasibility of integrating early stimulation into primary care for undernourished Jamaican children: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NUTRITIONAL SUPPLEMENTATION; EARLY-CHILDHOOD; INTERVENTION	Objectives To assess the feasibility of integrating early psychosocial stimulation into primary care for undernourished children and to determine the effect on children's development and mothers' knowledge and practices of childrearing. Design Cluster randomised controlled trial. Setting 18 clinics in three Jamaican parishes. Participants 139 undernourished children aged 9 to 30 months and their mothers enrolled in intervention or control clinics. Interventions Weekly home visits by community health aides for one year in addition to usual duties. Parenting issues were discussed with die mothers and play activities were demonstrated with the children using homemade materials. Main outcome measures Children's scores on the Griffiths mental development scales and mothers' knowledge and practices of childrearing. Results Children from the intervention group showed significant improvements in development: developmental quotient, 7.8 points (95% confidence interval 4.5 to 11.1); hearing and speech, 10.7 points (5.9 to 15.4); hand and eye coordination, 6.8 points (3.4 to 10.1); and performance subscale, 11.0 points (5.6 to 16.4). No improvements were shown on the locomotor subscale. The mothers from the intervention group showed improved knowledge and practices of childrearing. Change in body mass index and height independently affected change in development. Conclusion Integrating parenting skills and early psychosocial stimulation for undernourished children into primary care was feasible and effective in improving the children's development and mothers' knowledge and practices of childrearing.	Univ W Indies, Epidemiol Res Unit, Kingston 7, Jamaica; Univ W Indies, Dept Educ Studies, Kingston 7, Jamaica; World Hlth Org, Pan Amer Hlth Org, Kingston, Jamaica; Inst Child Hlth, Ctr Int Child Hlth, London WC1N 1EH, England	University West Indies Mona Jamaica; University West Indies Mona Jamaica; Pan American Health Organization; World Health Organization; University of London; University College London	Powell, C (corresponding author), Univ W Indies, Epidemiol Res Unit, Kingston 7, Jamaica.	christine.powell@uwimona.edu.jm		Baker-Henningham, Helen/0000-0001-5697-155X				Barnett WS, 1998, PREV MED, V27, P204; CALDWELL BM, 1967, PEDIATRICS, V40, P46; DUNN I, 1981, REVISED PEABODY PICT; DUNN L, 1981, REVISED PEABODY PICT; GOLDEN M, 1976, ORIGINS INTELLIGENCE, V299, P351; GOLDEN M, 1976, ORIGINS INTELLIGENCE, P299; GRANTHAMMCGREGOR S, 1994, CHILD DEV, V65, P428; GRANTHAMMCGREGOR SM, 1991, LANCET, V338, P1, DOI 10.1016/0140-6736(91)90001-6; Griffiths R., 1970, ABILITIES YOUNG CHIL; GRIFFITHS R, 1967, ABILITIES BABIES; Kendrick D, 2000, ARCH DIS CHILD, V82, P443, DOI 10.1136/adc.82.6.443; MCDONALD K, 1989, Indian Journal of Pediatrics, V56, P97, DOI 10.1007/BF02749717; Olds DL., 1998, FUTURE CHILD, V3, P53, DOI [DOI 10.2307/1602543, 10.2307/1602543]; POLLITT E, 1995, J NUTR, V25, pS2255; POLLITT E, 1995, J NUTR, V125, pS2255; POWELL C, 1989, Pediatrics, V84, P157; Ramey CT, 1998, AM PSYCHOL, V53, P109, DOI 10.1037/0003-066X.53.2.109; SEITZ V, 1994, CHILD DEV, V65, P677; *UN ADM COMM COORD, 2000, 4 ACCSCN UN INT FOOD; *UNICEF, 2001, STAT WORLDS CHILDR 2; Walker SP, 2000, J PEDIATR-US, V137, P36, DOI 10.1067/mpd.2000.106227; *WHO DEP CHILD AD, 1999, CRIT LINK INT PHYS G; Young M.E., 1996, EARLY CHILD DEV INVE	23	78	82	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					89	91		10.1136/bmj.38132.503472.7C	http://dx.doi.org/10.1136/bmj.38132.503472.7C			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15217841	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000222645000026
J	Sheehan, PM; Harris, MT				Sheehan, PM; Harris, MT			Microbialite resurgence after the Late Ordovician extinction	NATURE			English	Article							MASS EXTINCTION; SOUTH CHINA; STROMATOLITES; CARBONATES; FACIES; BASIN; DECLINE; RECORD	Microbialites, including biogenic stromatolites, thrombolites and dendrolites, were formed by various microbial mats that trapped and bound sediments or formed the locus of mineral precipitation(1). Microbialites were common and diverse during the Proterozoic(2-4), but declined in abundance and morphological diversity when multicellular life diversified during the Cambrian Radiation. A second decline occurred during the Ordovician Radiation of marine animals, and from then until the present microbialites have been confined largely to high-stress environments where multicellular organisms are rare. The microbialite declines in the Phanerozoic are attributed to disruption of the mats by animals(2,5,6). A resurgence of stromatolite abundance and size during reduced animal diversity after the Permian extinction(7) has been documented anecdotally. Here we show, with statistical support, that a microbialite resurgence also occurred after the Late Ordovician extinction event in western North America. The resurgences were associated with loss of mat-inhibiting animals, providing insights into shallow-water community structures after extinction events.	Milwaukee Publ Museum, Dept Geol, Milwaukee, WI 53233 USA; Univ Wisconsin, Dept Geol Sci, Milwaukee, WI 53201 USA	University of Wisconsin System; University of Wisconsin Milwaukee	Sheehan, PM (corresponding author), Milwaukee Publ Museum, Dept Geol, 800 W Wells St, Milwaukee, WI 53233 USA.	sheehan@uwm.edu						Awramik S. M., 1982, SCIENCE, V216, P171; Awramik S.M., 1999, HIST BIOL, V13, P241, DOI [10.1080/08912969909386584, DOI 10.1080/08912969909386584]; Bottjer DJ, 2001, EVOLUTIONARY PALEOECOLOGY, P35; Bottjer DJ, 1996, GEOL SOC SP, P1; BRENCHLEY PJ, 1994, GEOLOGY, V22, P295, DOI 10.1130/0091-7613(1994)022<0295:BAIEFA>2.3.CO;2; Browne KM, 2000, MICROBIAL SEDIMENTS, P233; GARRETT P, 1970, SCIENCE, V169, P171, DOI 10.1126/science.169.3941.171; Grotzinger JP, 1999, ANNU REV EARTH PL SC, V27, P313, DOI 10.1146/annurev.earth.27.1.313; GROTZINGER JP, 1990, AM J SCI, V290A, P80; HARRIS M. T., 1996, GEOLOGICAL SOC AM SP, P161, DOI DOI 10.1130/0-8137-2306-X.161; HARRIS MT, 1998, B NEW YORK STATE MUS, V491, P51; Jablonski D, 1996, ECOLOGY, V77, P1367, DOI 10.2307/2265534; Kershaw S, 1999, PALAEOGEOGR PALAEOCL, V146, P1, DOI 10.1016/S0031-0182(98)00139-4; Lehrmann DJ, 1998, J SEDIMENT RES, V68, P311, DOI 10.2110/jsr.68.311; MARTIN JM, 1994, SEDIMENT GEOL, V90, P257, DOI 10.1016/0037-0738(94)90042-6; Pope MC, 2000, J SEDIMENT RES, V70, P1139, DOI 10.1306/062099701139; RAUP DM, 1982, SCIENCE, V215, P1501, DOI 10.1126/science.215.4539.1501; Riding R, 2000, SEDIMENTOLOGY, V47, P179, DOI 10.1046/j.1365-3091.2000.00003.x; SCHUBERT JK, 1995, PALAEOGEOGR PALAEOCL, V116, P1, DOI 10.1016/0031-0182(94)00093-N; Sepkoski JJ, 1997, J PALEONTOL, V71, P533, DOI 10.1017/S0022336000040026; Sheehan Peter M., 1996, Geological Society of America Special Paper, V307, P477; Sheehan PM, 2001, ANNU REV EARTH PL SC, V29, P331, DOI 10.1146/annurev.earth.29.1.331; SHEEHAN PM, 1997, EARLY PALEOZOIC BIOC, P85; SIEGEL S., 1956, NONPARAMETRIC STAT B; Stephens NP, 2003, SEDIMENTOLOGY, V50, P1283, DOI 10.1111/j.1365-3091.2003.00605.x; WALTER MR, 1985, PRECAMBRIAN RES, V29, P149, DOI 10.1016/0301-9268(85)90066-X; WATSON RT, 2001, 3 INT PAN CLIM CHANG; Webby B.D., 2004, GREAT ORDOVICIAN BIO, DOI DOI 10.7312/WEBB12678; WEBBY BD, 2001, ECOLOGY CAMBRIAN RAD; Wood R. A., 1999, REEF EVOLUTION	30	86	107	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					75	78		10.1038/nature02654	http://dx.doi.org/10.1038/nature02654			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229600				2022-12-28	WOS:000222356800045
J	Hettiaratchy, S; Papini, R				Hettiaratchy, S; Papini, R			ABC of burns - Initial management of a major burn: I - overview	BRITISH MEDICAL JOURNAL			English	Review									Pan Thames Trainirg Scheme, London, England; Selly Oak Univ Hosp, W Midlands Reg Burn Unit, Birmingham, W Midlands, England		Hettiaratchy, S (corresponding author), Pan Thames Trainirg Scheme, London, England.							*BRIT BURN ASS, 1996, EM MAN SEV BURNS COU; Herndon DN, 2018, TOTAL BURN CARE; Kao CC, 2000, PLAST RECONSTR SURG, V105, P2482, DOI 10.1097/00006534-200006000-00028; Sheridan RL, 2002, CRIT CARE MED, V30, pS500, DOI 10.1097/00003246-200211001-00015	4	22	23	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1555	1557		10.1136/bmj.328.7455.1555	http://dx.doi.org/10.1136/bmj.328.7455.1555			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217876	Green Published			2022-12-28	WOS:000222392700028
J	Schneider, LS				Schneider, LS			AD2000: donepezil in Alzheimer's disease	LANCET			English	Editorial Material							RIVASTIGMINE; TRIALS; 1-YEAR		Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Dept Neurol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA.	lschneid@usc.edu						Bentham P, 1999, BRIT MED J, V319, P640, DOI 10.1136/bmj.319.7210.640a; BIRKS J, 2004, COCHRANE LIB; Bullock R, 2000, BRIT MED J, V320, P511, DOI 10.1136/bmj.320.7233.511; Geldmacher DS, 2003, J AM GERIATR SOC, V51, P937, DOI 10.1046/j.1365-2389.2003.51306.x; GOLD M, 2004, 9 INT C ALZH DIS REL; GRADY D, 2004, NY TIMES        0407; Lopez OL, 2002, J NEUROL NEUROSUR PS, V72, P310, DOI 10.1136/jnnp.72.3.310; Matthews HP, 2000, INT J GERIATR PSYCH, V15, P713, DOI 10.1002/1099-1166(200008)15:8<713::AID-GPS187>3.0.CO;2-I; McShane R, 1997, LANCET, V350, P886, DOI 10.1016/S0140-6736(05)62068-5; *NAT I CLIN EXC, 2001, GUID US DON RIV GAL; PETERSEN R, 2004, 9 INT C ALZH DIS REL; Schneider LS, 1997, J AM GERIATR SOC, V45, P923, DOI 10.1111/j.1532-5415.1997.tb02960.x; Wimo A, 2003, DEMENT GERIATR COGN, V15, P44, DOI 10.1159/000066669; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489	14	58	61	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2100	2101		10.1016/S0140-6736(04)16533-1	http://dx.doi.org/10.1016/S0140-6736(04)16533-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220027				2022-12-28	WOS:000222268300002
J	Arai, F; Hirao, A; Ohmura, M; Sato, H; Matsuoka, S; Takubo, K; Ito, K; Koh, GY; Suda, T				Arai, F; Hirao, A; Ohmura, M; Sato, H; Matsuoka, S; Takubo, K; Ito, K; Koh, GY; Suda, T			Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche	CELL			English	Article							RECEPTOR TYROSINE KINASE; TIE2 RECEPTOR; ANGIOPOIETIN-1; IDENTIFICATION; GROWTH; TEK; BETA-1-INTEGRINS; EXPRESSION; SURVIVAL; ADHESION	The quiescent state is thought to be an indispensable property for the maintenance of hematopoietic stem cells (HSCs). Interaction of HSCs with their particular microenvironments, known as the stem cell niches, is critical for adult hematopoiesis in the bone marrow (BM). Here, we demonstrate that HSCs expressing the receptor tyrosine kinase Tie2 are quiescent and antiapoptotic, and comprise a side-population (SP) of HSCs, which adhere to osteoblasts (OBs) in the BM niche. The interaction of Tie2 with its ligand Angiopoietin-1 (Ang-1) induced cobblestone formation of HSCs in vitro and maintained in vivo long-term repopulating activity of HSCs. Furthermore, Ang-1 enhanced the ability of HSCs to become quiescent and induced adhesion to bone, resulting in protection of the HSC compartment from myelosuppressive stress. These data suggest that the Tie2/Ang-1 signaling pathway plays a critical role in the maintenance of HSCs in a quiescent state in the BM niche.	Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat,Shinjuku Ku, Tokyo 1608582, Japan; Kyowa Hakko Kogyo Corp Ltd, Tokyo 1948533, Japan; Korea Adv Inst Sci & Technol, Ctr Biomed Res, Taejon 305701, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Keio University; Kyowa Kirin Ltd; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Suda, T (corresponding author), Keio Univ, Sch Med, Sakaguchi Lab Dev Biol, Dept Cell Differentiat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	sudato@sc.itc.keio.ac.jp	Arai, Fumio/J-5241-2013; Koh, Gou Young/C-1615-2011; Suda, Toshio/H-6761-2013; Takubo, Keiyo/AAX-5546-2020	Arai, Fumio/0000-0003-1936-4907; Suda, Toshio/0000-0001-7540-1771; Takubo, Keiyo/0000-0002-1736-7592				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; Allsopp RC, 2001, J EXP MED, V193, P917, DOI 10.1084/jem.193.8.917; Arai F, 2002, J EXP MED, V195, P1549, DOI 10.1084/jem.20011700; Arboleda MJ, 2003, CANCER RES, V63, P196; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cheshier SP, 1999, P NATL ACAD SCI USA, V96, P3120, DOI 10.1073/pnas.96.6.3120; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1992, ONCOGENE, V7, P1471; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; FUNK PE, 1994, BLOOD, V83, P361; Hackney JA, 2002, P NATL ACAD SCI USA, V99, P13061, DOI 10.1073/pnas.192124499; HALL PA, 1989, DEVELOPMENT, V106, P619; Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; HOTCHIN NA, 1995, J CELL BIOL, V128, P1209, DOI 10.1083/jcb.128.6.1209; Hsu HC, 2000, BLOOD, V96, P3757, DOI 10.1182/blood.V96.12.3757.h8003757_3757_3762; IWAMA A, 1993, BIOCHEM BIOPH RES CO, V195, P301, DOI 10.1006/bbrc.1993.2045; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Li YH, 2002, J INFRARED MILLIM W, V21, P1; Lin HF, 1997, ANNU REV GENET, V31, P455, DOI 10.1146/annurev.genet.31.1.455; Lin HF, 2002, NAT REV GENET, V3, P931, DOI 10.1038/nrg952; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293; Ohbo K, 2003, DEV BIOL, V258, P209, DOI 10.1016/S0012-1606(03)00111-8; Partanen J, 1996, DEVELOPMENT, V122, P3013; Potocnik AJ, 2000, IMMUNITY, V12, P653, DOI 10.1016/S1074-7613(00)80216-2; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; Puri MC, 2003, P NATL ACAD SCI USA, V100, P12753, DOI 10.1073/pnas.2133552100; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rodewald HR, 1996, ONCOGENE, V12, P397; Sato A, 1998, INT IMMUNOL, V10, P1217, DOI 10.1093/intimm/10.8.1217; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Song XQ, 2002, SCIENCE, V296, P1855, DOI 10.1126/science.1069871; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Taichman RS, 1998, STEM CELLS, V16, P7, DOI 10.1002/stem.160007; Takakura N, 1998, IMMUNITY, V9, P677, DOI 10.1016/S1074-7613(00)80665-2; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Termine John D., 1996, P24; Valable S, 2003, FASEB J, V17, P443, DOI 10.1096/fj.02-0372fje; Wulf GG, 2001, BLOOD, V98, P1166, DOI 10.1182/blood.V98.4.1166; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	46	1435	1523	2	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	2004	118	2					149	161		10.1016/j.cell.2004.07.004	http://dx.doi.org/10.1016/j.cell.2004.07.004			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260986	Bronze			2022-12-28	WOS:000222966000005
J	Roumie, CL; Grogan, EL; Falbe, W; Awad, J; Speroff, T; Dittus, RS; Elasy, TA				Roumie, CL; Grogan, EL; Falbe, W; Awad, J; Speroff, T; Dittus, RS; Elasy, TA			A three-part intervention to change the use of hormone replacement therapy in response to new evidence	ANNALS OF INTERNAL MEDICINE			English	Article							CONTINUING MEDICAL-EDUCATION; ESTROGEN PLUS PROGESTIN; RANDOMIZED CONTROLLED-TRIAL; FAMILY-PRACTICE RESIDENTS; DECISION-SUPPORT SYSTEMS; HEALTH-CARE OUTCOMES; ADVERSE DRUG EVENTS; QUALITY-OF-CARE; POSTMENOPAUSAL WOMEN; PHYSICIAN PERFORMANCE	Background: Slow adaptation of new information by providers may result in suboptimal care. Objective: To evaluate changes in prescriptions for combination hormone replacement therapy (HRT) after a multicomponent intervention to deliver new information to patients and providers. Design: Quasi-experimental study with multiple baselines. Setting: veterans Affairs Tennessee Valley Healthcare System (VA-TVHS). Patients: Female veterans age 50 to 79 years who had a prescription filled at the VA-TVHS for combination HRT between 1 January 2002 and 1 July 2002. Measurements: Discontinuation of HRT. Intervention: A 3-part intervention consisted of 1) notifying patients who were using combination HRT of the results of the Women's Health Initiative study (patient education component), 2) sending all providers an e-mail with the Women's Health Initiative study results (provider education component), and 3) placing an electronic alert in each eligible patient's chart (provider care component). The alert asked providers to reevaluate the need for combination HRT. The intervention was implemented at different VA-TVHS sites in a stepwise fashion to differentiate intervention effect from media effect. Study follow-up continued through 31 December 2002. Results: The total rate of discontinuation of combination HRT was 70.3% in 2002. The proportion of discontinuation from time of media release until intervention was 23.3%. After initiation of the intervention, an additional 43% of the original cohort discontinued use of HRT; this percentage represents a 59% relative decrease in HIRT use among patients. After adjustment for time, the discontinuation rate per day was 4.9 times higher after the multifacted intervention than after the media release (95% CI, 1.8 to 13.1). Limitations: A true control group is lacking. Conclusion: A multifaceted approach in an integrated health care system with standardized methods of communication is an effective way to implement patient-centered, effective, and timely care with changing medical knowledge.	Vet Adm Tennessee Valley Healthcare Syst, Nashville, TN USA; Vanderbilt Univ, Nashville, TN USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University	Roumie, CL (corresponding author), Nashville Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin 4A120, 1310 24th Ave S, Nashville, TN 37212 USA.	christianne.roumie@vanderbilt.edu						Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Berwick DM, 1999, QUAL HEALTH CARE, V8, P145, DOI 10.1136/qshc.8.3.145; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; Cash DW, 2003, P NATL ACAD SCI USA, V100, P8086, DOI 10.1073/pnas.1231332100; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chassin MR, 1998, JAMA-J AM MED ASSOC, V280, P1000, DOI 10.1001/jama.280.11.1000; Davis D, 2000, CAN MED ASSOC J, V163, P1278; Davis D, 1999, JAMA-J AM MED ASSOC, V282, P867, DOI 10.1001/jama.282.9.867; Davis D, 2003, BMJ-BRIT MED J, V327, P33, DOI 10.1136/bmj.327.7405.33; Davis D, 1998, INT J PSYCHIAT MED, V28, P21, DOI 10.2190/UA3R-JX9W-MHR5-RC81; DAVIS D, 1993, ACAD MED, V68, P329, DOI 10.1097/00001888-199305000-00003; Davis D, 1996, J GEN INTERN MED, V11, P705, DOI 10.1007/BF02600164; DAVIS DA, 1995, JAMA-J AM MED ASSOC, V274, P700; DAVIS DA, 1994, ACAD MED, V69, P207, DOI 10.1097/00001888-199403000-00007; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Denton GD, 2001, ACAD MED, V76, P1257, DOI 10.1097/00001888-200112000-00022; Eddy DM, 1996, JAMA-J AM MED ASSOC, V275, P650, DOI 10.1001/jama.275.8.650; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EDDY DM, 1994, JAMA-J AM MED ASSOC, V271, P1792, DOI 10.1001/jama.271.22.1792; Evans AT, 1996, AM J PREV MED, V12, P259, DOI 10.1016/S0749-3797(18)30322-2; Friedman RH, 1998, J MED SYST, V22, P95, DOI 10.1023/A:1022695119046; Goebel LJ, 1997, JOINT COMM J QUAL IM, V23, P196, DOI 10.1016/S1070-3241(16)30309-1; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KELLY RB, 1991, J FAM PRACTICE, V33, P259; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1995, AM J HEALTH-SYST PH, V52, P379, DOI 10.1093/ajhp/52.4.379; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCILVAIN HE, 1992, J FAM PRACTICE, V34, P745; Nalven LM, 1997, J DEV BEHAV PEDIATR, V18, P371, DOI 10.1097/00004703-199712000-00001; OBRIEN MAT, 2003, COCHRANE DB SYST REV, P1; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Rapp SR, 2003, JAMA-J AM MED ASSOC, V289, P2663, DOI 10.1001/jama.289.20.2663; Revere D, 2001, J AM MED INFORM ASSN, V8, P62, DOI 10.1136/jamia.2001.0080062; RODNEY WM, 1985, J FAM PRACTICE, V20, P265; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Saitz R, 2003, ANN INTERN MED, V138, P372, DOI 10.7326/0003-4819-138-5-200303040-00006; SCHLESINGER LA, 1991, HARVARD BUS REV, V69, P71; Shapiro J, 1991, Fam Pract Res J, V11, P107; Sim I, 1995, Proc Annu Symp Comput Appl Med Care, P863; Sim I, 2001, J AM MED INFORM ASSN, V8, P527, DOI 10.1136/jamia.2001.0080527; Sim I, 2000, MED DECIS MAKING, V20, P440, DOI 10.1177/0272989X0002000408; Smalley W, 2000, JAMA-J AM MED ASSOC, V284, P3036, DOI 10.1001/jama.284.23.3036; Smith MA, 2003, JAMA-J AM MED ASSOC, V289, P1100, DOI 10.1001/jama.289.9.1100-a; SMITH MA, 2003, JAMA-J AM MED ASSOC, V289, P1101; Speroff Theodore, 2004, Qual Manag Health Care, V13, P17; Steinberg EP, 2003, NEW ENGL J MED, V348, P2681, DOI 10.1056/NEJMe030085; Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673; Ylikorkala O, 2002, GYNECOL ENDOCRINOL, V16, P469	53	15	15	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					118	125		10.7326/0003-4819-141-2-200407200-00010	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262667				2022-12-28	WOS:000222758200005
J	Aggarwal, BD; Calvi, BR				Aggarwal, BD; Calvi, BR			Chromatin regulates origin activity in Drosophila follicle cells	NATURE			English	Article							CHORION GENE AMPLIFICATION; HISTONE ACETYLTRANSFERASE HBO1; DNA-REPLICATION; TRANSCRIPTIONAL REPRESSION; PROTEIN; LOCALIZATION; DEACETYLASE; MELANOGASTER; ORGANIZATION; MECHANISMS	It is widely believed that DNA replication in multicellular animals (metazoa) begins at specific origins to which a prereplicative complex (pre-RC) binds(1). Nevertheless, a consensus sequence for origins has yet to be identified in metazoa. Origin identity can change during development, suggesting that there are epigenetic influences. A notable example of developmental specificity occurs in Drosophila, where somatic follicle cells of the ovary transition from genomic replication to exclusive rereplication at origins that control amplification of the eggshell ( chorion) protein genes(2). Here we show that chromatin acetylation is critical for this developmental transition in origin specificity. We find that histones at the active origins are hyper-acetylated, coincident with binding of the origin recognition complex (ORC). Mutation of the histone deacetylase ( HDAC) Rpd3 induced genome-wide hyperacetylation, genomic replication and a redistribution of the origin-binding protein ORC2 in amplification-stage cells, independent of effects on transcription. Tethering Rpd3 or Polycomb proteins to the origin decreased its activity, whereas tethering the Chameau acetyltransferase increased origin activity. These results suggest that nucleosome acetylation and other epigenetic changes are important modulators of origin activity in metazoa.	Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA	University of Pennsylvania	Calvi, BR (corresponding author), Univ Penn, Sch Med, Dept Genet, 415 Curie Blvd, Philadelphia, PA 19104 USA.	Calvi@mail.med.upenn.edu	Aggarwal, Bhagwan D/I-7949-2019	Aggarwal, Bhagwan D/0000-0002-1128-8578				Austin RJ, 1999, GENE DEV, V13, P2639, DOI 10.1101/gad.13.20.2639; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bandura JL, 2002, CANCER BIOL THER, V1, P8, DOI 10.4161/cbt.1.1.31; Beall EL, 2002, NATURE, V420, P833, DOI 10.1038/nature01228; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BOSCH T, 1995, OPT REV, V2, P289, DOI 10.1007/s10043-995-0289-2; Burke TW, 2001, J BIOL CHEM, V276, P15397, DOI 10.1074/jbc.M011556200; Calvi BR, 1999, METHODS, V18, P407, DOI 10.1006/meth.1999.0799; Calvi BR, 1998, GENE DEV, V12, P734, DOI 10.1101/gad.12.5.734; Calvi BR, 2001, CHROMOSOMA, V110, P159, DOI 10.1007/s004120100131; Cayirlioglu P, 2003, MOL CELL BIOL, V23, P2123, DOI 10.1128/MCB.23.6.2123-2134.2003; Claycomb JM, 2004, DEV CELL, V6, P145, DOI 10.1016/S1534-5807(03)00398-8; Claycomb JM, 2002, J CELL BIOL, V159, P225, DOI 10.1083/jcb.200207046; DECICCO DV, 1984, CELL, V38, P45, DOI 10.1016/0092-8674(84)90525-7; Grienenberger A, 2002, CURR BIOL, V12, P762, DOI 10.1016/S0960-9822(02)00814-X; Iizuka M, 1999, J BIOL CHEM, V274, P23027, DOI 10.1074/jbc.274.33.23027; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kennedy BK, 2000, GENE DEV, V14, P2855, DOI 10.1101/gad.842600; Lilly MA, 1996, GENE DEV, V10, P2514, DOI 10.1101/gad.10.19.2514; Lu L, 2001, GENE DEV, V15, P134, DOI 10.1101/gad.822101; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Mottus R, 2000, GENETICS, V154, P657; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Schwed G, 2002, MOL BIOL CELL, V13, P607, DOI 10.1091/mbc.01-08-0400; Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5; SPRADLING AC, 1980, P NATL ACAD SCI-BIOL, V77, P1096, DOI 10.1073/pnas.77.2.1096; Takei Y, 2001, EMBO REP, V2, P119, DOI 10.1093/embo-reports/kve026; Vogelauer M, 2002, MOL CELL, V10, P1223, DOI 10.1016/S1097-2765(02)00702-5; Whittaker AJ, 2000, GENE DEV, V14, P1765	29	218	221	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					372	376		10.1038/nature02694	http://dx.doi.org/10.1038/nature02694			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254542				2022-12-28	WOS:000222631200046
J	Guy-Grand, D; Vassalli, P				Guy-Grand, D; Vassalli, P			Tracing an orphan's genealogy	SCIENCE			English	Editorial Material							T-CELLS; INTRAEPITHELIAL LYMPHOCYTES; GUT; PRECURSORS; MICE; DIFFERENTIATION; CD8-ALPHA-ALPHA; GENERATION		Inst Pasteur, INSERM, U277, Unite Rech & Expertise Antivirale, F-75724 Paris 15, France; Ctr Med Univ Geneva, Dept Pathol, CH-1211 Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva	Guy-Grand, D (corresponding author), Inst Pasteur, INSERM, U277, Unite Rech & Expertise Antivirale, F-75724 Paris 15, France.	guygrand@pasteur.fr; pierre.vassalli@medecine.unige.ch						Capone M, 2003, EUR J IMMUNOL, V33, P1471, DOI 10.1002/eji.200323754; Eberl G, 2004, SCIENCE, V305, P248, DOI 10.1126/science.1096472; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Guy-Grand D, 2003, J EXP MED, V197, P333, DOI 10.1084/jem.20021639; Guy-Grand D, 2001, EUR J IMMUNOL, V31, P2593, DOI 10.1002/1521-4141(200109)31:9<2593::AID-IMMU2593>3.0.CO;2-X; GuyGrand D, 1996, EUR J IMMUNOL, V26, P2248, DOI 10.1002/eji.1830260942; GUYGRAND D, UNPUB; Leishman AJ, 2002, IMMUNITY, V16, P355, DOI 10.1016/S1074-7613(02)00284-4; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Madakamutil LT, 2004, SCIENCE, V304, P590, DOI 10.1126/science.1092316; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; Saito H, 1998, SCIENCE, V280, P275, DOI 10.1126/science.280.5361.275; Yamagata T, 2004, NAT IMMUNOL, V5, P597, DOI 10.1038/ni1070	14	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					185	187		10.1126/science.1100890	http://dx.doi.org/10.1126/science.1100890			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247461				2022-12-28	WOS:000222501000032
J	Gunnell, D; Ashby, D				Gunnell, D; Ashby, D			Antidepressants and suicide: what is the balance of benefit and harm	BRITISH MEDICAL JOURNAL			English	Review							SEROTONIN REUPTAKE INHIBITORS; TIME-SERIES ANALYSIS; FLUOXETINE TREATMENT; GENERAL-PRACTICE; PRIMARY-CARE; DEPRESSION; PREVENTION; ENGLAND; TRENDS; WALES		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ London, Barts & London Queen Marys Sch Med & Dent, Wolfson Inst Prevent Med, London EC1M 6BQ, England	University of Bristol; University of London; Queen Mary University London	Gunnell, D (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	d.j.gunnell@bristol.ac.uk	Gunnell, David/ABE-6653-2020	Gunnell, David/0000-0002-0829-6470				Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Amos T, 2001, PSYCHOL MED, V31, P935, DOI 10.1017/S0033291701003920; Barbui C, 1999, SOC PSYCH PSYCH EPID, V34, P152, DOI 10.1007/s001270050127; BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; Donoghue J. M., 1996, British Journal of Psychiatry, V168, P164, DOI 10.1192/bjp.168.2.164; FREEMANTLE N, 1994, BRIT MED J, V309, P249, DOI 10.1136/bmj.309.6949.249; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE; Gunnell D, 2003, SOC SCI MED, V57, P595, DOI 10.1016/S0277-9536(02)00408-2; Hall WD, 2003, BRIT MED J, V326, P1008, DOI 10.1136/bmj.326.7397.1008; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Hawton K, 2003, J CHILD PSYCHOL PSYC, V44, P1191, DOI 10.1111/1469-7610.00200; Healy D, 2003, PSYCHOTHER PSYCHOSOM, V72, P71, DOI 10.1159/000068691; Helgason T, 2004, BRIT J PSYCHIAT, V184, P157, DOI 10.1192/bjp.184.2.157; Isacsson G, 2000, ACTA PSYCHIAT SCAND, V102, P113, DOI 10.1034/j.1600-0447.2000.102002113.x; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; MacGillivray S, 2003, BMJ-BRIT MED J, V326, P1014, DOI 10.1136/bmj.326.7397.1014; Mackay FR, 1999, BRIT J GEN PRACT, V49, P892; MASAND P, 1991, NEW ENGL J MED, V324, P420; McClure GMG, 2001, BRIT J PSYCHIAT, V178, P469, DOI 10.1192/bjp.178.5.469; *MED HEALTHC PROD, SEL SER REUPT INH SS; Medawar C, 2002, INT J RISK SAFETY ME, V15, P161; Middleton N, 2001, J PUBLIC HEALTH MED, V23, P262, DOI 10.1093/pubmed/23.4.262; Nutt DJ, 2003, J PSYCHOPHARMACOL, V17, P355, DOI 10.1177/0269881103174019; Olfson M, 2003, ARCH GEN PSYCHIAT, V60, P978, DOI 10.1001/archpsyc.60.9.978; ORAVECZ R, 2003, ARCH SUICIDE RES, V7, P279; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; Rihmer Z, 2001, ACTA PSYCHIAT SCAND, V103, P238; RUTZ W, 1992, ACTA PSYCHIAT SCAND, V85, P83, DOI 10.1111/j.1600-0447.1992.tb01448.x; Shah R, 2001, PSYCHOL MED, V31, P1203, DOI 10.1017/S0033291701004548; TEICHER MH, 1990, AM J PSYCHIAT, V147, P207; Whittington CJ, 2004, LANCET, V363, P1341, DOI 10.1016/S0140-6736(04)16043-1; 2003, CURR PROB PHARMACOVI, V29, P4	33	114	118	2	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	2004	329	7456					34	38		10.1136/bmj.329.7456.34	http://dx.doi.org/10.1136/bmj.329.7456.34			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	836PP	15231620	Green Published			2022-12-28	WOS:000222568300020
J	Mollica, RF				Mollica, RF			Global health: Surviving torture	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Harvard Program Refugee Trauma, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University	Mollica, RF (corresponding author), Massachusetts Gen Hosp, Harvard Program Refugee Trauma, Cambridge, MA 02138 USA.							Bramsen I, 1999, J TRAUMA STRESS, V12, P243, DOI 10.1023/A:1024720324688; Cassano P, 2002, J PSYCHOSOM RES, V53, P849, DOI 10.1016/S0022-3999(02)00304-5; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V260, P478; Mollica RF, 2000, SCI AM, V282, P54, DOI 10.1038/scientificamerican0600-54; World Health Organization, 2002, WORLD REPORT VIOLENC	6	36	36	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					5	7		10.1056/NEJMp048141	http://dx.doi.org/10.1056/NEJMp048141			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	833QC	15229300	Bronze			2022-12-28	WOS:000222352200002
J	Arlt, W; Walker, EA; Draper, N; Ivison, HE; Ride, JP; Hammer, F; Chalder, SM; Borucka-Mankiewicz, M; Hauffa, BP; Malunowicz, EM; Stewart, PM; Shackleton, CHL				Arlt, W; Walker, EA; Draper, N; Ivison, HE; Ride, JP; Hammer, F; Chalder, SM; Borucka-Mankiewicz, M; Hauffa, BP; Malunowicz, EM; Stewart, PM; Shackleton, CHL			Congenital adrenal hyperplasia caused by mutant P450 oxidoreductase and human androgen synthesis: analytical study	LANCET			English	Article							ANTLEY-BIXLER-SYNDROME; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; 21-HYDROXYLASE DEFICIENCY; AROMATASE DEFICIENCY; MUTATIONS; GENE; SPECTROMETRY; DIAGNOSIS; DEFECTS; PATIENT	Background Congenital adrenal hyperplasia with apparent combined P450C17 and P450C21 deficiency is associated with accumulation of steroid metabolites, indicating impaired activity of 17alpha-hydroxylase and 21-hydroxylase. However, no mutations have been reported in the CYP17 and CYP21 genes, which encode these P450 enzymes. Affected girls are born with ambiguous genitalia, but their circulating androgens are low, and virilisation does not progress. We aimed to investigate the underlying molecular basis of congenital adrenal hyperplasia with apparent combined P450C17 and P450C21 deficiency in affected children. Methods We did sequence analysis of the human gene encoding P450 oxidoreductase, an enzyme that is important in electron transfer from NADPH to P450C17 and P450C21. We studied two unrelated families with a total of three affected children and 100 healthy controls. Wild-type and mutant P450 oxidoreductase proteins were bacterially expressed, purified, and assayed for cytochrome c reductase activity. Findings We identified four mutations encoding single aminoacid changes in P450 oxidoreductase. All patients were compound heterozygotes, whereas their parents and an unaffected sibling harboured a mutation in only one allele. By contrast, no mutations were noted in the controls. Bacterial expression of recombinant mutant proteins revealed deficient or reduced enzyme activity. Interpretation Molecular pathogenesis of this form of congenital adrenal hyperplasia is caused by mutations in the gene encoding P450 oxidoreductase. Deficiency of this enzyme could suggest an alternative pathway in human androgen synthesis, present only in fetal life, which explains the combination of antenatal androgen excess and postnatal androgen deficiency.	Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England; Univ Childrens Hosp, Dept Haematol Oncol & Endocrinol, Essen, Germany; Childrens Mem Hlth Inst, Dept Lab Diagnost, Warsaw, Poland; Childrens Mem Hlth Inst, Dept Med Genet, Warsaw, Poland; Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	University of Birmingham; University of Birmingham; University of Duisburg Essen; University of Hamburg; University Medical Center Hamburg-Eppendorf; Children's Memorial Health Institute; Children's Memorial Health Institute; Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Arlt, W (corresponding author), Univ Birmingham, Sch Med, Inst Biomed Res, Div Med Sci, Birmingham B15 2TT, W Midlands, England.	w.arlt@bham.ac.uk	Arlt, Wiebke/B-6310-2009	Arlt, Wiebke/0000-0001-5106-9719	Medical Research Council [G116/172] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adachi M, 1999, ENDOCR J, V46, P285, DOI 10.1507/endocrj.46.285; Asanuma A, 1999, J HUM GENET, V44, P312, DOI 10.1007/s100380050167; Auchus RJ, 1998, J BIOL CHEM, V273, P3158, DOI 10.1074/jbc.273.6.3158; Carani C, 1997, NEW ENGL J MED, V337, P91, DOI 10.1056/NEJM199707103370204; Caulfield MP, 2002, J CLIN ENDOCR METAB, V87, P3682, DOI 10.1210/jc.87.8.3682; Chun K, 1998, AM J MED GENET, V77, P219, DOI 10.1002/(SICI)1096-8628(19980518)77:3<219::AID-AJMG6>3.0.CO;2-K; CONTE FA, 1994, J CLIN ENDOCR METAB, V78, P1287, DOI 10.1210/jc.78.6.1287; Draper N, 2003, NAT GENET, V34, P434, DOI 10.1038/ng1214; Fluck CE, 2004, NAT GENET, V36, P228, DOI 10.1038/ng1300; Geller DH, 1997, NAT GENET, V17, P201, DOI 10.1038/ng1097-201; Gupta MK, 2003, ARCH BIOCHEM BIOPHYS, V418, P151, DOI 10.1016/j.abb.2003.07.003; Herrmann BL, 2002, J CLIN ENDOCR METAB, V87, P5476, DOI 10.1210/jc.2002-020498; Kelley RI, 2002, AM J MED GENET, V110, P95, DOI 10.1002/ajmg.10510; Lamb DC, 2001, BIOCHEM BIOPH RES CO, V286, P48, DOI 10.1006/bbrc.2001.5338; LIN D, 1991, J BIOL CHEM, V266, P15992; MILLER WL, 1986, NEW ENGL J MED, V314, P1321; Otto DME, 2003, MOL CELL BIOL, V23, P6103, DOI 10.1128/MCB.23.17.6103-6116.2003; PETERSON RE, 1985, NEW ENGL J MED, V313, P1182, DOI 10.1056/NEJM198511073131903; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; Reardon W, 2000, J MED GENET, V37, P26, DOI 10.1136/jmg.37.1.26; Roth C, 2000, EUR J PEDIATR, V159, P189, DOI 10.1007/s004310050048; Shackleton C, 2003, STEROIDS, V68, P707, DOI 10.1016/S0039-128X(03)00115-6; SHACKLETON C, 2004, AM J MED GENET; SHACKLETON CHL, 1993, J STEROID BIOCHEM, V45, P127, DOI 10.1016/0960-0760(93)90132-G; SHEN AL, 1989, J BIOL CHEM, V264, P7584; Shen AL, 2002, J BIOL CHEM, V277, P6536, DOI 10.1074/jbc.M111408200; Shen AL, 2000, J BIOL CHEM, V275, P41087, DOI 10.1074/jbc.M008380200; SMITH GCM, 1994, P NATL ACAD SCI USA, V91, P8710, DOI 10.1073/pnas.91.18.8710; Tsai FJ, 2001, ACTA PAEDIATR, V90, P595; Walker EA, 2001, J BIOL CHEM, V276, P21343, DOI 10.1074/jbc.M011142200; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; Wilson JD, 2003, ENDOCRINOLOGY, V144, P575, DOI 10.1210/en.2002-220721; Witchel SS, 1996, AM J MED GENET, V61, P2	33	238	252	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2128	2135		10.1016/S0140-6736(04)16503-3	http://dx.doi.org/10.1016/S0140-6736(04)16503-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220035				2022-12-28	WOS:000222268300010
J	Mock, C; Quansah, R; Krishnan, R; Arreola-Risa, C; Rivara, F				Mock, C; Quansah, R; Krishnan, R; Arreola-Risa, C; Rivara, F			Strengthening the prevention and care of injuries worldwide	LANCET			English	Review							PREHOSPITAL TRAUMA CARE; ROAD TRAFFIC INJURIES; LIFE-SUPPORT PROGRAM; DEVELOPING-COUNTRIES; DOMESTIC VIOLENCE; CHILDHOOD BURNS; SOCIAL-CLASS; HELMET USE; MORTALITY; SYSTEM	The global burden of injuries is enormous, but has often been overlooked in attempts to improve health. We review measures that would strengthen existing efforts to prevent and treat injuries worldwide. Scientifically-based efforts to understand risk factors for the occurrence of injury are needed and they must be translated into prevention programmes that are well designed and assessed. Areas for potential intervention include environmental modification, improved engineering features of motor vehicle and other products, and promotion of safe behaviours through social marketing, legislation, and law enforcement. Treatment efforts need to better define the most high-yield services and to promote these in the form of essential health services. To achieve these changes, there is a need to strengthen the capacity of national institutions to do research on injury control; to design and implement countermeasures that address injury risk factors and deficiencies in injury treatment; and to assess the effectiveness of such countermeasures. Although much work remains to be done in high-income countries, even greater attention is needed in less-developed countries, where injury rates are higher, few injury control activities have been undertaken, and where most of the world's population lives. In almost all areas, injury rates are especially high in the most vulnerable sections of the community, including those of low socioeconomic status. Injury control activities should, therefore, be undertaken in a context of attention to human rights and other broad social issues.	Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; Kwame Nkrumah Univ Sci & Technol, Kumasi, Ghana; Univ Malaya, Kuala Lumpur, Malaysia; Inst Tecnol & Estudios Super, Monterrey, Mexico	University of Washington; University of Washington Seattle; Kwame Nkrumah University Science & Technology; Universiti Malaya; Tecnologico de Monterrey	Mock, C (corresponding author), Box 359960, Seattle, WA 98104 USA.	cmock@u.washington.edu		Mock, Charles/0000-0002-0564-568X				ADEYEMIDORO HO, 1999, TRAUMA Q, V14, P295; ADNAN A, 1990, P 1 MAL WORKSH ACC P, P35; Afukaar Francis K, 2003, Inj Control Saf Promot, V10, P77, DOI 10.1076/icsp.10.1.77.14113; Ali J, 1997, J TRAUMA, V42, P1018, DOI 10.1097/00005373-199706000-00005; ALI J, 1994, J TRAUMA, V36, P391, DOI 10.1097/00005373-199403000-00020; ALI J, 1993, J TRAUMA, V34, P890, DOI 10.1097/00005373-199306000-00022; Ali J, 1997, J TRAUMA, V42, P786, DOI 10.1097/00005373-199705000-00006; ALMAZANSAAVEDRA V, 2000, ARCH INVESTIGACION P, V3, P369; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP P; AMEGASHIE JMY, 2000, 5 WORLD C INJ PREV C, P269; American College of Surgeons Committee on Trauma, 1999, RES OPT CAR INJ PAT; [Anonymous], WHO GLOB BURD DIS 20; Arreola-Risa C, 2000, J TRAUMA, V48, P119, DOI 10.1097/00005373-200001000-00020; ARREOLARISA C, 1995, J TRAUMA, V39, P457; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; Barss P., 1998, INJURY PREVENTION IN; BERGMAN A, 1992, POLITICAL APPROACHES; Broughton J, 2003, ACCIDENT ANAL PREV, V35, P527, DOI 10.1016/S0001-4575(02)00030-1; Brown P, 2001, B WORLD HEALTH ORGAN, V79, P1175; Bunn F, 2003, INJURY PREV, V9, P200, DOI 10.1136/ip.9.3.200; Celis A, 1991, Salud Publica Mex, V33, P585; CELIS A, 1997, INJURY PREV, V3, P237; Chan KPM, 2001, CHILD ADOL PSYCH CL, V10, P777, DOI 10.1016/S1056-4993(18)30030-0; Chawla A., 2000, J CRASH PREVENTION I, V2, P33, DOI [https://doi.org/10.1080/10286580008902551, DOI 10.1080/10286580008902551]; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; CHRISTOFFEL T, 1999, INJURY PREVENTION PU; Conrad P, 1996, ACCIDENT ANAL PREV, V28, P193, DOI 10.1016/0001-4575(95)00056-9; Crandall JR, 2002, BRIT MED J, V324, P1145, DOI 10.1136/bmj.324.7346.1145; DAVIDSON LL, 1994, AM J PUBLIC HEALTH, V84, P580, DOI 10.2105/AJPH.84.4.580; DeJong W, 1998, ANNU REV PUBL HEALTH, V19, P359, DOI 10.1146/annurev.publhealth.19.1.359; DENNO D, 1998, 4 WORLD C INJ PREV C, P795; El-Bayoumi G, 1998, MED CLIN N AM, V82, P391, DOI 10.1016/S0025-7125(05)70612-X; Fell JC, 2003, ACCIDENT ANAL PREV, V35, P897, DOI 10.1016/S0001-4575(02)00097-0; FORJUOH S, 1999, PREHOSPITAL IMMEDIAT, V3, P66; Forjuoh S N, 1996, Inj Prev, V2, P90, DOI 10.1136/ip.2.2.90; FORJUOH SN, 1995, BURNS, V21, P24, DOI 10.1016/0305-4179(95)90776-V; Forjuoh SN, 1998, TROP MED INT HEALTH, V3, P349, DOI 10.1046/j.1365-3156.1998.00240.x; Forjuoh SN, 1996, SOC SCI MED, V43, P1551, DOI 10.1016/S0277-9536(96)00051-2; FURJUOH S, 2003, INJ CONTROL SAFETY P, V10, P109; Ghaffar A, 1999, HEALTH POLICY PLANN, V14, P11, DOI 10.1093/heapol/14.1.11; Grossman DC, 1997, JAMA-J AM MED ASSOC, V277, P1605, DOI 10.1001/jama.277.20.1605; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HAMAM AH, 1999, TRAUMA Q, V14, P261, DOI DOI 10.1163/156857199750223758; Hauswald M, 1997, AM J EMERG MED, V15, P600, DOI 10.1016/S0735-6757(97)90167-4; Hippisley-Cox J, 2002, BRIT MED J, V324, P1132, DOI 10.1136/bmj.324.7346.1132; Holder Y., 2001, INJURY SURVEILLANCE; Holt VL, 2002, JAMA-J AM MED ASSOC, V288, P589, DOI 10.1001/jama.288.5.589; Husum H, 2003, J TRAUMA, V54, P1188, DOI 10.1097/01.TA.0000073609.12530.19; *INJ VIOL SURV CON, 2000, AFRICA SAFECOM NEWSL, V1, P1; JONES IS, 1989, ACCIDENT ANAL PREV, V21, P469, DOI 10.1016/0001-4575(89)90007-9; Jurkovich GJ, 1999, J TRAUMA, V47, pS46, DOI 10.1097/00005373-199909001-00011; KATCHER ML, 1987, AM J PUBLIC HEALTH, V77, P1195, DOI 10.2105/AJPH.77.9.1195; Khanna G, 2000, NEW J PHYS, V2, P31, DOI 10.1088/1367-2630/2/1/303; Kobusingye OC, 2000, J TRAUMA, V48, P498, DOI 10.1097/00005373-200003000-00022; Krishnan R, 1998, WORLD HEALTH FORUM, V19, P159; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kulanthayan S, 2000, Med J Malaysia, V55, P40; KWAN I, 2003, COCHRANE LIB; LANGLEY J, 1983, COMMUNITY HEALTH ST, V7, P285; LE L, 2001, HANOI SCH PUBLIC HLT, P28; Lin MR, 2001, J TRAUMA, V50, P24, DOI 10.1097/00005373-200101000-00004; London J, 2002, B WORLD HEALTH ORGAN, V80, P357; London JA, 2001, J TRAUMA, V51, P747, DOI 10.1097/00005373-200110000-00021; MABOGUNJE OA, 1987, BURNS, V13, P298, DOI 10.1016/0305-4179(87)90050-7; MAHLER H, 1987, LANCET, V1, P668; Maier R, 2003, TRAUMA, P41; Mallonee S, 1996, NEW ENGL J MED, V335, P27, DOI 10.1056/NEJM199607043350106; Mann NC, 1999, J TRAUMA, V47, pS25, DOI 10.1097/00005373-199909001-00007; Marshall SW, 1998, JAMA-J AM MED ASSOC, V279, P1633, DOI 10.1001/jama.279.20.1633; Marson AC, 2001, J TRAUMA, V50, P917; McGee Kara, 2003, Inj Control Saf Promot, V10, P105; MICHAUD C, 1994, B WORLD HEALTH ORGAN, V72, P639; Mock C, 1999, Inj Prev, V5, P268; Mock C., 2004, GUIDELINES ESSENTIAL; Mock Charles, 2003, Inj Control Saf Promot, V10, P45, DOI 10.1076/icsp.10.1.45.14114; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011; Mock CN, 1997, J TRAUMA, V42, P504, DOI 10.1097/00005373-199703000-00019; Mock CN, 1999, ACCIDENT ANAL PREV, V31, P359, DOI 10.1016/S0001-4575(98)00064-5; Mock CN, 1999, B WORLD HEALTH ORGAN, V77, P955; Mock CN, 2003, DISABIL REHABIL, V25, P732, DOI 10.1080/0963828031000090524; Mock CN, 2002, J TRAUMA, V53, P90, DOI 10.1097/00005373-200207000-00018; Mock CN, 1996, J GEN INTERN MED, V11, P519, DOI 10.1007/BF02599598; MOCK CN, 2001, J CRASH PREVENTION I, V2, P193; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; Nader R., 1965, UNSAFE ANY SPEED DES; Nantulya VM, 2002, BRIT MED J, V324, P1139, DOI 10.1136/bmj.324.7346.1139; Nantulya VM., 2001, CHALLENGING INEQUITI; *NAT COMM INJ PREV, 1989, INJ PREV M CHALL; *NAT CTR STAT AN, FAT AN REP SYST; *NAT HIGHW TRAFF S, 2002, 809564 DOTHS NHTSA C; Nathens AB, 2000, J TRAUMA, V48, P25, DOI 10.1097/00005373-200001000-00005; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Newman P., 1999, SUSTAINABILITY CITIE; O'Neill B, 2002, BRIT MED J, V324, P1142, DOI 10.1136/bmj.324.7346.1142; OCARROLL P, 1991, VIOLENCE AM; Odero W, 1997, TROP MED INT HEALTH, V2, P445, DOI 10.1046/j.1365-3156.1997.d01-296.x; Odero W, 1996, HEALTH POLICY PLANN, V11, P329, DOI 10.1093/heapol/11.3.329; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Peden M, 2002, INJURY LEADING CAUSE; Peden M., 2004, WORLD REPORT ROAD TR; Pio A, 1997, B WORLD HEALTH ORGAN, V75, P569; QUANSAH R, 2001, GHANA MED J, V35, P8; QUANSAH RE, 1999, TRAUMA Q, V14, P283; Rahman F, 2000, PUBLIC HEALTH, V114, P133, DOI 10.1038/sj.ph.1900618; REICH MR, 1987, HEALTH POLICY, V8, P39, DOI 10.1016/0168-8510(87)90129-1; Reich MR, 2000, SCIENCE, V287, P1979, DOI 10.1126/science.287.5460.1979; Rivara FP, 1997, NEW ENGL J MED, V337, P543, DOI 10.1056/NEJM199708213370807; Rivara FP, 1997, NEW ENGL J MED, V337, P613, DOI 10.1056/NEJM199708283370907; Roberts I, 1996, BRIT MED J, V313, P784; Roberts I, 1997, J EPIDEMIOL COMMUN H, V51, P334, DOI 10.1136/jech.51.3.334; ROBERTS I, 1994, AUST J PUBLIC HEALTH, V18, P209; Robertson L, 1998, INJURY EPIDEMIOLOGY; ROBERTSON LS, 1981, AM J PUBLIC HEALTH, V71, P818, DOI 10.2105/AJPH.71.8.818; ROBERTSON LS, 1984, AM J PUBLIC HEALTH, V74, P1390, DOI 10.2105/AJPH.74.12.1390; Rosenfield A, 1997, INT J GYNECOL OBSTET, V59, pS7, DOI 10.1016/S0020-7292(97)00141-0; Ross A., 1991, SAFER ROADS DEV COUN; ROSS HL, 1993, ACCIDENT ANAL PREV, V25, P777, DOI 10.1016/0001-4575(93)90042-U; Runge JW, 2002, JAMA-J AM MED ASSOC, V288, P2172, DOI 10.1001/jama.288.17.2172; Saidi H S, 2003, East Afr Med J, V80, P480; SALIFU M, 1998, GHANA ENG, V18, P23; Schweinhart L.J., 1993, SIGNIFICANT BENEFITS; SETHI D, 2003, COCHRANE LIB; Simon G E, 1995, Arch Fam Med, V4, P99, DOI 10.1001/archfami.4.2.99; SMITH GS, 1991, EPIDEMIOL REV, V13, P228, DOI 10.1093/oxfordjournals.epirev.a036070; SPIEGEL CN, 1977, AM J PUBLIC HEALTH, V67, P1143, DOI 10.2105/AJPH.67.12.1143; THOMPSON D, 2003, COCHRANE LIB; Thompson RS, 2000, AM J PREV MED, V19, P253, DOI 10.1016/S0749-3797(00)00231-2; *US DEP HHS, 1988, SURG GEN WORKSH DRUN; van Schoor O, 2001, ACCIDENT ANAL PREV, V33, P713, DOI 10.1016/S0001-4575(00)00083-X; Villaveces A, 2000, JAMA-J AM MED ASSOC, V283, P1205, DOI 10.1001/jama.283.9.1205; Wang J, 1999, J INORG MATER, V14, P233; World Health Organization, 2002, WORLD REPORT VIOLENC; Wright JL, 1998, PEDIATR CLIN N AM, V45, P459, DOI 10.1016/S0031-3955(05)70020-1; YEOH E, 1999, TRAUMA Q, V14, P253; Zwi A., 1993, Tropical Diseases Bulletin, V90, pR5; Zwi A B, 1996, Inj Prev, V2, P91, DOI 10.1136/ip.2.2.91	136	149	158	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	2004	363	9427					2172	2179		10.1016/S0140-6736(04)16510-0	http://dx.doi.org/10.1016/S0140-6736(04)16510-0			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	832LF	15220042				2022-12-28	WOS:000222268300023
J	Seyan, K; Greenhalgh, T; Dorling, D				Seyan, K; Greenhalgh, T; Dorling, D			The standardised admission ratio for measuring widening participation in medical schools: analysis of LTK medical school admissions by ethnicity, socioeconomic status, and sex	BRITISH MEDICAL JOURNAL			English	Article									UCL, Dept Primary Hlth Care, London N19 5LW, England; Univ Bristol, Bristol BS8 1TH, Avon, England	University of London; University College London; University of Bristol	Greenhalgh, T (corresponding author), UCL, Dept Primary Hlth Care, London N19 5LW, England.	p.greenhalgh@pcps.ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Greenhalgh T, 2004, BRIT MED J, V328, P1541, DOI 10.1136/bmj.328.7455.1541; *HIGH ED FUND COUN, 2003, SOC CLASS PART GOOD; McManus IC, 2002, BRIT MED J, V325, P786, DOI 10.1136/bmj.325.7368.786; Secretary of State for Education, 2004, MED SCH DEL DOCT FUT; UNIVERSITIES UK, 2003, FAIR EN WID ACC U ID	5	42	42	2	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 26	2004	328	7455					1545	1546		10.1136/bmj.328.7455.1545	http://dx.doi.org/10.1136/bmj.328.7455.1545			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DV	15217872	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000222392700024
J	West, J; Logan, RFA; Smith, CJ; Hubbard, RB; Card, TR				West, J; Logan, RFA; Smith, CJ; Hubbard, RB; Card, TR			Malignancy and mortality in people with coeliac disease: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH DATABASE; RISK; CANCER; DEATH	Objective To quantify the risks of malignancy and mortality in people with coeliac disease compared with the general population. Design Population based cohort study. Setting General practice research database. Participants 4732 people with coeliac disease and 23 620 matched controls. Main outcome measures Hazard ratios for malignancy and mortality. Results Of the 4732 people with coeliac disease, 134 (2.8%) had at least one malignancy and 237 (5.0%) died. The overall hazard ratios were: for any malignancy 1.29 (95% confidence interval 1.06 to 1.55), for mortality 1.31 (1.13 to 1.51), for gastrointestinal cancer 1.85 (1.22 to 2.81), for breast cancer 0.35 (0.17 to 0.72), for lung cancer 0.34 (0.13 to 0.95), and for lymphoproliferative disease 4.80 (2.71 to 8.50). The increased risk was primarily in the first year after diagnosis, with only the risk for lymphoproliferative disease remaining significantly raised thereafter. After excluding events in the year after diagnosis, the hazard ratio for malignancy was 1.10 (0.87 to 1.39) and for mortality was 1.17 (0.98 to 1.38), giving absolute excess rates of 6 and 17 per 10 000 person years, respectively. Conclusions People with coeliac disease have modest increases in overall risks of malignancy and mortality. Most of this excess risk occurs in the first year after diagnosis. People with coeliac disease also have a noticeably reduced risk of breast cancer. The mechanism of this merits further attention as it may provide insights into the cause of this common malignancy.	Univ Nottingham, Queens Med Ctr, Div Epidemiol & Publ Hlth, Nottingham NG7 2UH, England; Univ Nottingham, City Hosp Nottingham, Sch Med & Surg Sci, Nottingham NG5 1PB, England	University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	West, J (corresponding author), Univ Nottingham, Queens Med Ctr, Div Epidemiol & Publ Hlth, Nottingham NG7 2UH, England.	joe.west@nottinghani.ac.uk	West, Joe/M-3867-2019; West, Joe/I-6637-2012; Card, Tim/J-8651-2013	West, Joe/0000-0002-1135-9356; West, Joe/0000-0002-1135-9356; Card, Tim/0000-0003-2555-2250				Askling J, 2002, GASTROENTEROLOGY, V123, P1428, DOI 10.1053/gast.2002.36585; Catassi C, 2002, JAMA-J AM MED ASSOC, V287, P1413, DOI 10.1001/jama.287.11.1413; COOPER BT, 1980, MEDICINE, V59, P249, DOI 10.1097/00005792-198007000-00002; Corrao G, 2001, LANCET, V358, P356, DOI 10.1016/S0140-6736(01)05554-4; Cottone M, 1999, DIGEST DIS SCI, V44, P2538, DOI 10.1023/A:1026655609906; Faggiano F, 1997, IARC Sci Publ, P65; HOHNES GK, 1989, GUT, V30, P333; Hollowell J, 1997, Popul Trends, P36; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; Lewis JD, 2002, PHARMACOEPIDEM DR S, V11, P211, DOI 10.1002/pds.698; Lo WS, 2003, DIGEST DIS SCI, V48, P395, DOI 10.1023/A:1021956200382; LOGAN RFA, 1983, BMJ-BRIT MED J, V286, P95, DOI 10.1136/bmj.286.6359.95; LOGAN RFA, 1989, GASTROENTEROLOGY, V97, P265, DOI 10.1016/0016-5085(89)90060-7; Murray JA, 2003, CLIN GASTROENTEROL H, V1, P19, DOI 10.1053/jcgh.2003.50004; Peters U, 2003, ARCH INTERN MED, V163, P1566, DOI 10.1001/archinte.163.13.1566; Sanders DS, 2002, POSTGRAD MED J, V78, P31, DOI 10.1136/pmj.78.915.31; Snook JA, 1996, GUT, V39, P60, DOI 10.1136/gut.39.1.60; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; West J, 2003, GASTROENTEROLOGY, V125, P429, DOI 10.1016/S0016-5085(03)00891-6; West J, 2003, GUT, V52, P960, DOI 10.1136/gut.52.7.960	21	258	268	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 25	2004	329	7468					716	718A		10.1136/bmj.38169.486701.7C	http://dx.doi.org/10.1136/bmj.38169.486701.7C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	858RV	15269095	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000224210300018
J	Paice, E; Aitken, M; Houghton, A; Firth-Cozens, H				Paice, E; Aitken, M; Houghton, A; Firth-Cozens, H			Bullying among doctors in training: cross sectional questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									London Deanery, London WC1N 1DZ, England		Paice, E (corresponding author), London Deanery, London WC1N 1DZ, England.	epaice@londondeanery.ac.uk						FITHCOZENS J, 2001, SOC SCI MED, P215; Hicks B, 2000, HOSP MED, V61, P428, DOI 10.12968/hosp.2000.61.6.1361; Paice E, 2000, BRIT MED J, V320, P832, DOI 10.1136/bmj.320.7238.832; Paice Elisabeth, 2003, BMJ, V326, pS127, DOI 10.1136/bmj.326.7393.S127; Quine L, 2002, BRIT MED J, V324, P878, DOI 10.1136/bmj.324.7342.878	5	63	66	0	14	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 18	2004	329	7467					658	659		10.1136/bmj.38133.502569.AE	http://dx.doi.org/10.1136/bmj.38133.502569.AE			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	856JU	15256417	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000224042300020
J	Prandoni, P; Bernardi, E; Marchiori, A; Lensing, AWA; Prins, MH; Villalta, S; Bagatella, P; Sartor, D; Piccioli, A; Simioni, P; Pagnan, A; Girolami, A				Prandoni, P; Bernardi, E; Marchiori, A; Lensing, AWA; Prins, MH; Villalta, S; Bagatella, P; Sartor, D; Piccioli, A; Simioni, P; Pagnan, A; Girolami, A			The long term clinical course of acute deep vein thrombosis of the arm: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							VENOUS THROMBOSIS		Univ Hosp Padua, Dept Med & Surg Sci, Chair Internal Med 2, I-35128 Padua, Italy; Univ Amsterdam, Acad Med Ctr, Ctr Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Maastricht, Dept Clin Epidemiol & Technol Assessment, NL-6202 AZ Maastricht, Netherlands	University of Padua; Azienda Ospedaliera - Universita di Padova; University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University	Prandoni, P (corresponding author), Univ Hosp Padua, Dept Med & Surg Sci, Chair Internal Med 2, Via Osped Civile 105, I-35128 Padua, Italy.	paoloprandoni@tin.it	SIMIONI, PAOLO/AAC-5438-2022; Simioni, Paolo/AAC-5416-2022	SIMIONI, PAOLO/0000-0002-6744-383X; 				Hirsh J, 2002, BLOOD, V99, P3102, DOI 10.1182/blood.V99.9.3102; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Kommareddy A, 2002, SEMIN THROMB HEMOST, V28, P89, DOI 10.1055/s-2002-20567; Prandoni P, 1997, ARCH INTERN MED, V157, P57, DOI 10.1001/archinte.157.1.57; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001	5	117	119	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					484	485		10.1136/bmj.38167.684444.3A	http://dx.doi.org/10.1136/bmj.38167.684444.3A			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15256419	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000223684600013
J	Delmas, P				Delmas, P			Polycystins: From mechanosensation to gene regulation	CELL			English	Review							KIDNEY-DISEASE PROTEIN; PRIMARY CILIUM; ACTIVATION; HOMOLOG; INTERACTS; RECEPTOR; CHANNEL; PKD1	Polycystin proteins have been suggested to form mechanosensory transduction complexes involved in a variety of biological functions including sperm fertilization, mating behavior, and asymmetric gene expression in different species. Furthermore, their dys-function is the cause of cyst formation in human kidney disease. This review focuses on the pros and cons of their candidacy as mechanically gated channels and on recent findings that have significantly advanced our physiological insight.	CNRS, UMR 6150, Lab Neurophysiol Cellulaire, Fac Med,IFR Jean Roche, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Delmas, P (corresponding author), CNRS, UMR 6150, Lab Neurophysiol Cellulaire, Fac Med,IFR Jean Roche, Bd Pierre Dramard, F-13916 Marseille 20, France.	delmas.p@jean-roche.univ-mrs.fr						Alessandri-Haber N, 2003, NEURON, V39, P497, DOI 10.1016/S0896-6273(03)00462-8; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Bhunia AK, 2002, CELL, V109, P157, DOI 10.1016/S0092-8674(02)00716-X; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Delmas P, 2004, FASEB J, V18, P740, DOI 10.1096/fj.03-0319fje; Gallagher AR, 2000, P NATL ACAD SCI USA, V97, P4017, DOI 10.1073/pnas.97.8.4017; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Li Q, 2003, J MOL BIOL, V325, P949, DOI 10.1016/S0022-2836(02)01333-5; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McGrath J, 2003, CELL, V114, P61, DOI 10.1016/S0092-8674(03)00511-7; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Neill AT, 2004, MOL REPROD DEV, V67, P472, DOI 10.1002/mrd.20033; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Praetorius HA, 2001, J MEMBRANE BIOL, V184, P71, DOI 10.1007/s00232-001-0075-4; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Watnick TJ, 2003, CURR BIOL, V13, P2179, DOI 10.1016/S0960-9822(03)00913-8; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200	19	121	128	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	2004	118	2					145	148		10.1016/j.cell.2004.07.007	http://dx.doi.org/10.1016/j.cell.2004.07.007			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	841XQ	15260985	Bronze			2022-12-28	WOS:000222966000004
J	Song, YQ; Stampfer, MJ; Liu, SM				Song, YQ; Stampfer, MJ; Liu, SM			Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease	ANNALS OF INTERNAL MEDICINE			English	Review							ANGIOTENSIN-CONVERTING ENZYME; MIDDLE-AGED MEN; DENSITY-LIPOPROTEIN CHOLESTEROL; ELDERLY FINNISH MEN; PLASMA-LIPID LEVELS; APO E PHENOTYPE; ARTERY-DISEASE; MYOCARDIAL-INFARCTION; E POLYMORPHISM; GENETIC POLYMORPHISMS	Background: Apolipoprotein E (apoE) genotypes play critical roles in lipid metabolism and are believed to influence risk for coronary heart disease (CHD). Despite many population studies, however, the impact of apoE polymorphism on risk for CHD remains uncertain. Purpose: To qualitatively and quantitatively assess the evidence regarding the relation of apoE polymorphism to CHD risk. Data Sources: All relevant reports and references from original and review papers published from 1966 to January 2004. Study Selection: Predefined criteria were used to identify 48 relevant studies. Data Extraction: A summary database that contained variables of study design, study sample and ethnicity, sex, apoE genotypes, CHD end points, plasma lipid levels, and other CHD risk factors was developed. Data Synthesis: The authors qualitatively evaluated many potential sources of heterogeneity. To quantify the extent of heterogeneity and assess the consistency of apoE-CHD associations, stratified analyses were conducted using the classic random-effects model. To further incorporate uncertainty due to between-study variation, the pooled odds ratios (ORs) and 95% credible intervals (Crls) were estimated by using a Bayesian hierarchical model. Finally, the robustness of the pooled estimates was tested in multiple sensitivity analyses. Compared with individuals with the epsilon3/3 genotype, carriers of the apoE epsilon4 allele had a 42% higher risk for CHD (OR, 1.42 [95% Crl, 1.26 to 1.61]). The epsilon2 allele had no significant association with CHD risk (OR, 0.98 [Crl, 0.66 to 1.46]). Limitations: This meta-analysis did not include unpublished data or studies published in languages other than English. Conclusions: Inadequate statistical power, differences in geographic and ethnic background, allele frequency, sex, CHD phenotypes, study design, and potential gene- environment interactions may have contributed to the conflicting results of previous studies. The apoE epsilon4 allele is a significant risk factor for CHD.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Liu, SM (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth, Boston, MA 02215 USA.	simin.liu@channing.harvard.edu	Liu, Simin/I-3689-2014; Liu, Simin/GSN-4159-2022	Liu, Simin/0000-0003-2098-3844; 	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK062290, R01DK062290] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26490] Funding Source: Medline; NIDDK NIH HHS [DK62290] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Attila G, 2001, CLIN CHIM ACTA, V312, P191, DOI 10.1016/S0009-8981(01)00624-6; Ballantyne CM, 2000, J AM COLL CARDIOL, V36, P1572, DOI 10.1016/S0735-1097(00)00918-9; Batalla A, 2000, CLIN CHEM, V46, P1910; Bednarska-Makaruk M, 2001, EUR J EPIDEMIOL, V17, P789, DOI 10.1023/A:1015657709060; Benes P, 2000, MOL GENET METAB, V69, P137, DOI 10.1006/mgme.1999.2957; Berry DA., 2000, STAT METHODOLOGY PHA, P127; Biggart S, 1998, CLIN CARDIOL, V21, P831, DOI 10.1002/clc.4960211109; Brouwer DAJ, 1997, W INDIAN MED J, V46, P47; Brscic E, 2000, AM HEART J, V139, P979, DOI 10.1067/mhj.2000.106165; Corbo RM, 1999, CLIN BIOCHEM, V32, P217, DOI 10.1016/S0009-9120(99)00011-9; Corbo RM, 1999, ANN HUM GENET, V63, P301, DOI 10.1046/j.1469-1809.1999.6340301.x; CUMMING AM, 1984, CLIN GENET, V25, P310; DALLONGEVILLE J, 1992, J LIPID RES, V33, P447; Dallongeville J, 1999, ATHEROSCLEROSIS, V145, P381, DOI 10.1016/S0021-9150(99)00069-6; DAMARAJU S, 1995, AM J CARDIOL, V75, P1181, DOI 10.1016/S0002-9149(99)80756-5; Dart A, 1997, ATHEROSCLEROSIS, V130, P161, DOI 10.1016/S0021-9150(96)06062-5; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davignon J, 1999, CLIN CHIM ACTA, V286, P115, DOI 10.1016/S0009-8981(99)00097-2; DEANDRADE M, 1995, AM J HUM GENET, V56, P1379; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Djousse L, 2002, STROKE, V33, P1357, DOI 10.1161/01.STR.0000014325.54063.1A; DUMOUCHEL W, 1996, BAYESIAN BIOSTATISTI, P1; Dzimiri N, 1999, ARCH PATHOL LAB MED, V123, P1241; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Egger M, 2001, SYSTEMATIC REV HLTH; EICHNER JE, 1993, AM J CARDIOL, V71, P160, DOI 10.1016/0002-9149(93)90732-R; Eichner JE, 2002, AM J EPIDEMIOL, V155, P487, DOI 10.1093/aje/155.6.487; ETO M, 1989, CLIN GENET, V36, P183; Ewbank DC, 2002, GENET EPIDEMIOL, V22, P146, DOI 10.1002/gepi.0164; Frikke-Schmidt R, 2000, J LIPID RES, V41, P1812; Gerdes LU, 2000, CIRCULATION, V101, P1366, DOI 10.1161/01.CIR.101.12.1366; Gomez-Coronado D, 2002, EUR J CLIN INVEST, V32, P251, DOI 10.1046/j.1365-2362.2002.00983.x; Hagberg JM, 2000, PHYSIOL GENOMICS, V4, P101, DOI 10.1152/physiolgenomics.2000.4.2.101; Humphries SE, 2001, LANCET, V358, P115, DOI 10.1016/S0140-6736(01)05330-2; Ilveskoski E, 1999, CIRCULATION, V100, P608, DOI 10.1161/01.CIR.100.6.608; Joven J, 1998, ATHEROSCLEROSIS, V140, P155, DOI 10.1016/S0021-9150(98)00076-8; Kardia SLR, 1999, ARTERIOSCL THROM VAS, V19, P427, DOI 10.1161/01.ATV.19.2.427; Keavney B, 2003, LANCET, V361, P396, DOI 10.1016/S0140-6736(03)12386-0; Kim IJ, 1999, YONSEI MED J, V40, P377, DOI 10.3349/ymj.1999.40.4.377; Kolovou G, 2002, CURR MED RES OPIN, V18, P118, DOI 10.1185/030079902125000444; KUUSI T, 1989, ARTERIOSCLEROSIS, V9, P237, DOI 10.1161/01.ATV.9.2.237; KUUSISTO J, 1995, ARTERIOSCL THROM VAS, V15, P1280, DOI 10.1161/01.ATV.15.9.1280; Lahoz C, 2001, ATHEROSCLEROSIS, V154, P529, DOI 10.1016/S0021-9150(00)00570-0; Lambert JC, 2000, HUM MOL GENET, V9, P57, DOI 10.1093/hmg/9.1.57; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEHTINEN S, 1995, ATHEROSCLEROSIS, V114, P83, DOI 10.1016/0021-9150(94)05469-Y; LENZEN HJ, 1986, CLIN CHEM, V32, P778; Little J, 2002, AM J EPIDEMIOL, V156, P300, DOI 10.1093/oxfordjournals.aje.a000179; Liu SM, 2003, ATHEROSCLEROSIS, V166, P323, DOI 10.1016/S0021-9150(02)00335-0; LUC G, 1994, ARTERIOSCLER THROMB, V14, P1412, DOI 10.1161/01.ATV.14.9.1412; Lussier-Cacan S, 2002, ARTERIOSCL THROM VAS, V22, P824, DOI 10.1161/01.ATV.0000014589.22121.6C; Luthra K, 2002, MOL CELL BIOCHEM, V232, P97, DOI 10.1023/A:1014869827322; Mansur AP, 2000, CLIN CARDIOL, V23, P335, DOI 10.1002/clc.4960230506; Marques-Vidal P, 2003, AM J CARDIOL, V92, P1102, DOI 10.1016/j.amjcard.2003.06.008; MARSHALL HW, 1994, CIRCULATION, V89, P567, DOI 10.1161/01.CIR.89.2.567; MENZEL HJ, 1983, ARTERIOSCLEROSIS, V3, P310, DOI 10.1161/01.ATV.3.4.310; Moghadasian MH, 2001, FASEB J, V15, P2623, DOI 10.1096/fj.01-0463com; Nakai K, 1998, CORONARY ARTERY DIS, V9, P329, DOI 10.1097/00019501-199809060-00002; Nakata Y, 1996, HYPERTENSION, V27, P1205, DOI 10.1161/01.HYP.27.6.1205; Nassar BA, 1999, CLIN BIOCHEM, V32, P275, DOI 10.1016/S0009-9120(99)00017-X; Ordovas JM, 1999, P NUTR SOC, V58, P171, DOI 10.1079/PNS19990023; Ordovas JM, 2001, NUTR METAB CARDIOVAS, V11, P118; Ordovas JM, 2000, BRIT J NUTR, V83, pS127; Orth M, 1999, ARTERIOSCL THROM VAS, V19, P1306, DOI 10.1161/01.ATV.19.5.1306; Ou T, 1998, ATHEROSCLEROSIS, V137, P23, DOI 10.1016/S0021-9150(97)00244-X; Peng DQ, 2003, INT J CARDIOL, V92, P257, DOI 10.1016/S0167-5273(03)00101-3; Raslova K, 2001, METABOLISM, V50, P24, DOI 10.1053/meta.2001.19499; RegisBailly A, 1996, CLIN GENET, V50, P339; Salazar LA, 2000, CLIN CHIM ACTA, V300, P139, DOI 10.1016/S0009-8981(00)00308-9; Scaglione L, 1999, NUTR METAB CARDIOVAS, V9, P118; SCHAEFER EJ, 1994, ARTERIOSCLER THROMB, V14, P1105, DOI 10.1161/01.ATV.14.7.1105; Schaefer EJ, 2002, AM J CLIN NUTR, V75, P191, DOI 10.1093/ajcn/75.2.191; Scuteri A, 2001, AM J MED, V110, P28, DOI 10.1016/S0002-9343(00)00639-2; Song YQ, 2004, AM J HUM GENET, V74, P208, DOI 10.1086/381400; Stankovic S, 2000, CLIN CHEM LAB MED, V38, P539, DOI 10.1515/CCLM.2000.079; Stannard AK, 2001, J BIOL CHEM, V276, P46011, DOI 10.1074/jbc.M104812200; STENGARD JH, 1995, CIRCULATION, V91, P265, DOI 10.1161/01.CIR.91.2.265; Stengard JH, 1996, HUM GENET, V97, P677; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; STUYT PMJ, 1991, SCAND J CLIN LAB INV, V51, P425, DOI 10.3109/00365519109091636; Tai ES, 2002, ARTERIOSCL THROM VAS, V22, P805, DOI 10.1161/01.ATV.0000012302.11991.42; Taimela S, 1996, METABOLISM, V45, P797, DOI 10.1016/S0026-0495(96)90149-3; Terry JG, 1996, STROKE, V27, P1755, DOI 10.1161/01.STR.27.10.1755; UTERMANN G, 1984, HUM GENET, V65, P237, DOI 10.1007/BF00286509; UTERMANN G, 1977, NATURE, V269, P604, DOI 10.1038/269604a0; VANBOCKXMEER FM, 1992, LANCET, V340, P879, DOI 10.1016/0140-6736(92)93288-X; WANG XL, 1995, ARTERIOSCL THROM VAS, V15, P1030, DOI 10.1161/01.ATV.15.8.1030; Weber M, 1997, CAN J CARDIOL, V13, P253; Wilson PWF, 1996, ARTERIOSCL THROM VAS, V16, P1250, DOI 10.1161/01.ATV.16.10.1250; Wu JH, 2002, HUM BIOL, V74, P25, DOI 10.1353/hub.2002.0012; YAMAMURA T, 1990, JPN CIRC J, V54, P448, DOI 10.1253/jcj.54.448; Yan SK, 1999, CHINESE MED J-PEKING, V112, P224; Yang ZJ, 2001, CHINESE MED J-PEKING, V114, P983	93	416	442	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					137	147		10.7326/0003-4819-141-2-200407200-00013	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00013			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262670				2022-12-28	WOS:000222758200008
J	Ludwig, DS; Gortmaker, SL				Ludwig, DS; Gortmaker, SL			Programming obesity in childhood	LANCET			English	Editorial Material							BODY-MASS INDEX; PHYSICAL-ACTIVITY; CHILDREN; CONSUMPTION; ADOLESCENTS		Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, Boston, MA 02115 USA.	david.ludwig@childrens.harvard.edu		Ludwig, David/0000-0003-3307-8544				Berkey CS, 2003, PEDIATRICS, V111, P836, DOI 10.1542/peds.111.4.836; Birch LL, 1999, ANNU REV NUTR, V19, P41, DOI 10.1146/annurev.nutr.19.1.41; BLACK D, 1995, BRIT MED J, V310, P273, DOI 10.1136/bmj.310.6975.273; Bowman SA, 2004, PEDIATRICS, V113, P112, DOI 10.1542/peds.113.1.112; Coon K A, 2002, Minerva Pediatr, V54, P423; DIETZ WH, 1985, PEDIATRICS, V75, P807; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356, DOI 10.1001/archpedi.1996.02170290022003; Gortmaker SL, 1999, ARCH PEDIAT ADOL MED, V153, P409, DOI 10.1001/archpedi.153.4.409; *HJ KAIS FAM FDN, 2004, ROL MED CHILDH OB, P1; Jahns L, 2001, J PEDIATR-US, V138, P493, DOI 10.1067/mpd.2001.112162; Kaur H, 2003, J PEDIATR-US, V143, P506, DOI 10.1067/S0022-3476(03)00418-9; KELDER SH, 1994, AM J PUBLIC HEALTH, V84, P1121, DOI 10.2105/AJPH.84.7.1121; Ludwig DS, 2001, LANCET, V357, P505, DOI 10.1016/S0140-6736(00)04041-1; Robinson TN, 2001, PEDIATR CLIN N AM, V48, P1017, DOI 10.1016/S0031-3955(05)70354-0; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; SHELOV S, 1995, PEDIATRICS, V95, P295; Strauss RS, 2001, ARCH PEDIAT ADOL MED, V155, P897, DOI 10.1001/archpedi.155.8.897	17	42	43	1	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	2004	364	9430					226	227		10.1016/S0140-6736(04)16688-9	http://dx.doi.org/10.1016/S0140-6736(04)16688-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262082				2022-12-28	WOS:000222784900005
J	Miola, J				Miola, J			Non-accidental injury in children: making sense of the courts	LANCET			English	Editorial Material									Univ Leicester, Fac Law, Leicester LE1 7RH, Leics, England	University of Leicester	Miola, J (corresponding author), Univ Leicester, Fac Law, Leicester LE1 7RH, Leics, England.	jm83@leicester.ac.uk	Miola, Jose/AAK-1691-2020	Miola, Jose/0000-0001-9682-2284				Brazier M, 2000, MED LAW REV, V8, P85; BRODSKY S, 1999, EXPERT WITNESS, P31; DENNIS I, 2002, LAW EVIDENCE, P708; DYER C, 2004, GUARDIAN        0406; GIBB F, 2004, TIMES LOND      0506; GIBB F, 2004, TIMES LOND      0421; ROZENBERG J, 2004, DAILY TELEGRAPH 0421	7	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					228	230		10.1016/S0140-6736(04)16690-7	http://dx.doi.org/10.1016/S0140-6736(04)16690-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262084				2022-12-28	WOS:000222784900007
J	Pikitch, EK; Santora, C; Babcock, EA; Bakun, A; Bonfil, R; Conover, DO; Dayton, P; Doukakis, P; Fluharty, D; Heneman, B; Houde, ED; Link, J; Livingston, PA; Mangel, M; McAllister, MK; Pope, J; Sainsbury, KJ				Pikitch, EK; Santora, C; Babcock, EA; Bakun, A; Bonfil, R; Conover, DO; Dayton, P; Doukakis, P; Fluharty, D; Heneman, B; Houde, ED; Link, J; Livingston, PA; Mangel, M; McAllister, MK; Pope, J; Sainsbury, KJ			Ecosystem-based fishery management	SCIENCE			English	Editorial Material							FISHING MORTALITY; STRATEGIES; IMPACTS; MODELS		Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Pew Inst Ocean Sci, New York, NY 10022 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Wildlife Conservat Soc, Bronx, NY 10460 USA; SUNY Stony Brook, Marine Sci Res Ctr, Stony Brook, NY 11794 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Washington, Sch Marine Affairs, Seattle, WA 98105 USA; Commonweal Ocean Policy Program, Bolinas, CA 94924 USA; Univ Maryland, Ctr Environm Sci, Chesapeake Biol Lab, Solomons, MD 20688 USA; NOAA, Natl Marine Fisheries Serv, NE Fishery Sci Ctr, Food Web Dynam Program, Woods Hole, MA 02543 USA; Alaska Fisheries Sci Ctr, Seattle, WA 98115 USA; Univ Calif Santa Cruz, Jack Baskin Sch Engn, Dept Appl Math & Stat, Santa Cruz, CA 95064 USA; Univ London Imperial Coll Sci Technol & Med, Dept Environm Sci & Technol, London SW7 2BP, England; Natl Res Council Europe Ltd, Norfolk NR34 OBT, England; CSIRO, Div Marine Res, Hobart, Tas 7001, Australia	University of Miami; Wildlife Conservation Society; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Washington; University of Washington Seattle; University System of Maryland; University of Maryland Center for Environmental Science; National Oceanic Atmospheric Admin (NOAA) - USA; National Oceanic Atmospheric Admin (NOAA) - USA; University of California System; University of California Santa Cruz; Imperial College London; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Pikitch, EK (corresponding author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Pew Inst Ocean Sci, New York, NY 10022 USA.	epikitch@rsmas.miami.edu	Bonfil, Ramón/K-1226-2012; Houde, Edward/D-8498-2012; Babcock, Elizabeth A/E-7753-2013	Bakun, Andrew/0000-0002-4366-3846; Babcock, Elizabeth A/0000-0002-2279-6762; Bonfil, Ramon/0000-0002-5753-464X; Link, Jason/0000-0003-2740-7161				Alverson DL, 1997, AM FISH S S, V20, P115; Ballance LT, 1997, ECOLOGY, V78, P1502, DOI 10.1890/0012-9658(1997)078[1502:SCSAAP]2.0.CO;2; *EC PRINC ADV PAN, 1999, EC FISH MAN REP C EC; *FAO FISH DEP, 2002, STAT WORLD FISH AQ; *FAO FISH DEP, 2003, 4 FAO S2; Gislason H, 2003, RESPONSIBLE FISHERIES IN THE MARINE ECOSYSTEM, P255, DOI 10.1079/9780851996332.0255; *HL, 1996, 25 HL; Hollowed AB, 2000, ICES J MAR SCI, V57, P707, DOI 10.1006/jmsc.2000.0734; KAUFMAN L, IN PRESS B MAR SCI; Latour RJ, 2003, FISHERIES, V28, P10, DOI 10.1577/1548-8446(2003)28[10:TEFM]2.0.CO;2; Link JS, 2002, CAN J FISH AQUAT SCI, V59, P1429, DOI 10.1139/F02-115; Major P, 1997, AM FISH S S, V20, P264; *MIN ENV, 1997, INT MIN M INT FISH E; Murawski SA, 2000, ICES J MAR SCI, V57, P649, DOI 10.1006/jmsc.2000.0738; National Research Council, 1999, SUST MAR FISH; *PEW OC COMM, 2003, AM LIV OC CHART COUR; Pope JG, 2000, ICES J MAR SCI, V57, P689, DOI 10.1006/jmsc.2000.0729; Rice JC, 2000, ICES J MAR SCI, V57, P682, DOI 10.1006/jmsc.2000.0735; Roberts CM, 2001, SCIENCE, V294, P1920, DOI 10.1126/science.294.5548.1920; Sainsbury KJ, 2000, ICES J MAR SCI, V57, P731, DOI 10.1006/jmsc.2000.0737; Sainsbury KJ, 1997, AM FISH S S, V20, P107; Smith ADM, 1999, ICES J MAR SCI, V56, P967, DOI 10.1006/jmsc.1999.0540; U.S. Commission on Ocean Policy, 2004, PREL REP US COMM OC; Whipple SJ, 2000, FISH FISH, V1, P22, DOI 10.1046/j.1467-2979.2000.00007.x; Witherell D, 2000, ICES J MAR SCI, V57, P771, DOI 10.1006/jmsc.2000.0719	25	1504	1560	10	393	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					346	347		10.1126/science.1098222	http://dx.doi.org/10.1126/science.1098222			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256658				2022-12-28	WOS:000222662400022
J	Sisneros, JA; Forlano, PM; Deitcher, DL; Bass, AH				Sisneros, JA; Forlano, PM; Deitcher, DL; Bass, AH			Steroid-dependent auditory plasticity leads to adaptive coupling of sender and receiver	SCIENCE			English	Article							RELEVANT ACOUSTIC-SIGNALS; PHASE-LOCKING; SENSORY EXPLOITATION; PLAINFIN MIDSHIPMAN; SEASONAL PLASTICITY; ESTROGEN-RECEPTORS; SEXUAL SELECTION; ALLIGATOR LIZARD; COCHLEAR NERVE; TELEOST FISH	For seasonally breeding vertebrates, reproductive cycling is often coupled with changes in vocalizations that function in courtship and territoriality. Less is known about changes in auditory sensitivity to those vocalizations. Here, we show that nonreproductive female midshipman fish treated with either testosterone or 17beta-estradiol exhibit an increase in the degree of temporal encoding of the frequency content of male vocalizations by the inner ear that mimics the reproductive female's auditory phenotype. This sensory plasticity provides an adaptable mechanism that enhances coupling between sender and receiver in vocal communication.	Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA	Cornell University	Sisneros, JA (corresponding author), Univ Washington, Dept Psychol, Guthrie Hall,Box 351525, Seattle, WA 98195 USA.	sisneros@u.washington.edu; ahb3@cornell.edu	Sisneros, Joseph/AAU-9965-2020; Deitcher, David/K-6538-2019	Sisneros, Joseph/0000-0002-3114-773X; Deitcher, David/0000-0002-8512-8868; Forlano, Paul/0000-0003-4258-5708	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH015793] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [F32DC000445] Funding Source: NIH RePORTER; NIDCD NIH HHS [1F32DC00445, DC00092] Funding Source: Medline; NIMH NIH HHS [5T32MH15793] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Bao SW, 2001, NATURE, V412, P79, DOI 10.1038/35083586; Bass AH, 2003, SPR HDB AUD, V16, P15; Bass AH, 2003, PROG NEUROBIOL, V69, P1, DOI 10.1016/S0301-0082(03)00004-2; BRANTLEY RK, 1994, ETHOLOGY, V96, P213, DOI 10.1111/j.1439-0310.1994.tb01011.x; ELKINDHIRSCH KE, 1994, OTOLARYNG HEAD NECK, V110, P46, DOI 10.1016/S0194-5998(94)70791-X; FAY RR, 1978, NATURE, V275, P320, DOI 10.1038/275320a0; FINE ML, 1983, COMP BIOCHEM PHYS A, V76, P225, DOI 10.1016/0300-9629(83)90319-5; Forlano PM, 2001, J NEUROSCI, V21, P8943, DOI 10.1523/JNEUROSCI.21-22-08943.2001; GOLDBERG JM, 1969, J NEUROPHYSIOL, V32, P613, DOI 10.1152/jn.1969.32.4.613; Haggard M, 1978, Br J Audiol, V12, P105, DOI 10.3109/03005367809078862; Hauser, 1996, EVOL COMMUN; Hultcrantz M, 2000, HEARING RES, V143, P182, DOI 10.1016/S0378-5955(00)00042-3; JAVEL E, 1988, HEARING RES, V34, P275, DOI 10.1016/0378-5955(88)90008-1; Koppl C, 1997, J NEUROSCI, V17, P3312; Lucas JR, 2002, J COMP PHYSIOL A, V188, P981, DOI 10.1007/s00359-002-0359-x; McFadden D, 1998, DEV NEUROPSYCHOL, V14, P261, DOI 10.1080/87565649809540712; McKibben JR, 1999, J COMP PHYSIOL A, V184, P563, DOI 10.1007/s003590050356; McKibben JR, 2001, J COMP PHYSIOL A, V187, P271, DOI 10.1007/s003590100199; NARINS PM, 1976, SCIENCE, V192, P378, DOI 10.1126/science.1257772; NELSON RJ, 2000, BEHAV NEUROENDOCRINO; PALMER AR, 1986, HEARING RES, V24, P1, DOI 10.1016/0378-5955(86)90002-X; Ramanathan K, 2002, BIOPHYS J, V82, P64, DOI 10.1016/S0006-3495(02)75374-5; ROSE C, 1988, HEARING RES, V33, P151, DOI 10.1016/0378-5955(88)90028-7; RYAN MJ, 1990, NATURE, V343, P66, DOI 10.1038/343066a0; SHAW K, 1995, TRENDS ECOL EVOL, V10, P117, DOI 10.1016/S0169-5347(00)89005-9; Sisneros JA, 2004, GEN COMP ENDOCR, V136, P101, DOI 10.1016/j.ygcen.2003.12.007; Sisneros JA, 2003, J NEUROSCI, V23, P1049; Stenberg AE, 2001, HEARING RES, V157, P87, DOI 10.1016/S0378-5955(01)00280-5; Stenberg AE, 1999, HEARING RES, V136, P29, DOI 10.1016/S0378-5955(99)00098-2; Tramontin AD, 2000, TRENDS NEUROSCI, V23, P251, DOI 10.1016/S0166-2236(00)01558-7; WEISS TF, 1988, HEARING RES, V33, P167, DOI 10.1016/0378-5955(88)90029-9; YOVANOF S, 1983, NEUROSCI LETT, V36, P291, DOI 10.1016/0304-3940(83)90015-0; Zar JH., 1999, BIOSTAT ANAL, V663rd	33	178	182	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					404	407		10.1126/science.1097218	http://dx.doi.org/10.1126/science.1097218			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15256672				2022-12-28	WOS:000222662400041
J	Marko, PB; Lee, SC; Rice, AM; Gramling, JM; Fitzhenry, TM; McAlister, JS; Harper, GR; Moran, AL				Marko, PB; Lee, SC; Rice, AM; Gramling, JM; Fitzhenry, TM; McAlister, JS; Harper, GR; Moran, AL			Mislabelling of a depleted reef fish	NATURE			English	Editorial Material									Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Marko, PB (corresponding author), Univ N Carolina, Dept Marine Sci, Chapel Hill, NC 27599 USA.	pmarko@unc.edu	Rice, Amber/AHB-1530-2022; Rice, Amber/F-3410-2011; Lee, Sarah/Q-3372-2017; Moran, Amy/F-7072-2011	Rice, Amber/0000-0002-5475-8226; Rice, Amber/0000-0002-5475-8226; Moran, Amy/0000-0002-0604-5096				*GULF MEX FISH MAN, 1994, REEF FISH ASS PAN RE; HUANG TS, 1995, J AGR FOOD CHEM, V43, P2301, DOI 10.1021/jf00056a063; Johannes RE, 1998, TRENDS ECOL EVOL, V13, P243, DOI 10.1016/S0169-5347(98)01384-6; MORAN D, 1988, EL824 TR NAT WETL RE; *NAT MAR FISH SERV, 2002, ATL BILLF RES PLAN; *NAT MAR FISH SERV, 2001, MAR FISH STOCK ASS I; *OC PROJ, 1999, REV EX PUBL OP DAT O; PORCH CE, 2001, SFD0102129 SE FISH S; Sarver SK, 1996, COPEIA, P715, DOI 10.2307/1447537; Swofford DL., 2001, PAUP PHYLOGENETIC AN; Watson R, 2001, NATURE, V414, P534, DOI 10.1038/35107050	11	193	201	0	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	2004	430	6997					309	310		10.1038/430309b	http://dx.doi.org/10.1038/430309b			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837LG	15254528				2022-12-28	WOS:000222631200028
J	Zhan, XC; Dravid, G; Ye, ZH; Hammond, H; Shamblott, M; Gearhart, J; Cheng, LZ				Zhan, XC; Dravid, G; Ye, ZH; Hammond, H; Shamblott, M; Gearhart, J; Cheng, LZ			Functional antigen-presenting leucocytes derived from human embryonic stem cells in vitro	LANCET			English	Article							DENDRITIC CELLS; HEMATOPOIETIC DIFFERENTIATION; TRANSPLANTATION; EXPRESSION; LINES	Background Differentiated cells derived from pluripotent human embryonic stem (hES) cells offer the opportunity for new transplantation therapies. However, hES cells and their differentiated progeny express highly polymorphic MHC molecules that serve as major graft rejection antigens to the immune system of allogeneic hosts. To achieve sustained engraftment of donor cells, strategies must be developed to overcome graft rejection without broadly suppressing host immunity. One approach entails induction of donor-specific immune tolerance by establishing chimeric engraftment in hosts with haemopoietic cells derived from an existing hES cell line. We aimed to develop methods to efficiently differentiate hES cells to haemopoietic cells, including immune-modulating leucocytes, a prerequisite of the tolerance induction strategies applying to hES cell-mediated transplantation. Methods We developed a method to generate a broad range of haemopoietic cells from hES-generated embryonic bodies in the absence of murine stromal feeder cells, Embryonic bodies were further cultured in the presence of haemopoietic cytokines. In addition to flow cytometric analyses of haemopoietic cell markers, we analysed the hES cell-derived haemopoietic cells by colony-forming assays (for erythroid and myeloid progenitor cells), cytochemical staining, and mixed leucocyte reactions to determine the functional capacity of the generated antigen-presenting cells. Findings 12 independent experiments were done. When selected growth factors were added, leucocytes expressing CD45 were generated and released into culture media for 6-7 weeks. Under the condition used, both erythroid and myeloid progenitor cells were generated. About 25% of the generated leucocytes acquired MHC class II and costimulatory molecule expression. These hES-derived, MHC class II+ leucocytes resembled dendritic cells and macrophages, and they functioned as antigen-presenting cells capable of eliciting allogeneic CD4 and CD8 T-cell responses in culture. Interpretation The hES cell-derived antigen-presenting cells could be used to regulate alloreactive T cells and induce immune tolerance for improvement of the transplant acceptance of hES-cell derivatives.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Cheng, LZ (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, Broadway Res Bldg,Room 747,733 N Broadway, Baltimore, MD 21205 USA.	lcheng@welch.jhu.edu	Dravid, Gautam/E-3531-2010	Ye, Zhaohui/0000-0001-5272-9168	NHLBI NIH HHS [R01HL67195, R01HL73781] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067195, R01HL073781] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bodmer JG, 1999, HUM IMMUNOL, V60, P361; Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934; Chadwick K, 2003, BLOOD, V102, P906, DOI 10.1182/blood-2003-03-0832; Cheng LZ, 2003, STEM CELLS, V21, P131, DOI 10.1634/stemcells.21-2-131; Crawford K, 1999, J IMMUNOL, V163, P5920; Crawford K, 2003, BLOOD, V102, P1745, DOI 10.1182/blood-2002-07-2206; Cui Y, 2002, BLOOD, V99, P399, DOI 10.1182/blood.V99.2.399; Donovan PJ, 2001, NATURE, V414, P92, DOI 10.1038/35102154; Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299; Fairchild PJ, 2000, CURR BIOL, V10, P1515, DOI 10.1016/S0960-9822(00)00824-1; Fairchild PJ, 2000, CURR OPIN IMMUNOL, V12, P528, DOI 10.1016/S0952-7915(00)00134-5; Fandrich F, 2002, NAT MED, V8, P171, DOI 10.1038/nm0202-171; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Hwang WS, 2004, SCIENCE, V303, P1669, DOI 10.1126/science.1094515; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kaufman DS, 2002, J ANAT, V200, P243, DOI 10.1046/j.1469-7580.2002.00028.x; Keller G, 1999, NAT MED, V5, P151, DOI 10.1038/5512; Li F, 2001, BLOOD, V98, P335, DOI 10.1182/blood.V98.2.335; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Trounson A, 2002, NAT BIOTECHNOL, V20, P237, DOI 10.1038/nbt0302-237; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971	26	114	132	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					163	171		10.1016/S0140-6736(04)16629-4	http://dx.doi.org/10.1016/S0140-6736(04)16629-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246729				2022-12-28	WOS:000222612200027
J	Cimatti, A; Daddi, E; Renzini, A; Cassata, P; Vanzella, E; Pozzetti, L; Cristiani, S; Fontana, A; Rodighiero, G; Mignoli, M; Zamorani, G				Cimatti, A; Daddi, E; Renzini, A; Cassata, P; Vanzella, E; Pozzetti, L; Cristiani, S; Fontana, A; Rodighiero, G; Mignoli, M; Zamorani, G			Old galaxies in the young Universe	NATURE			English	Article							HIGH-REDSHIFT GALAXIES; STAR-FORMING GALAXIES; ORIGINS DEEP SURVEY; ELLIPTIC GALAXIES; K20 SURVEY; POPULATION; DENSITY; RED; IMAGES	More than half of all stars in the local Universe are found in massive spheroidal galaxies(1), which are characterized by old stellar populations(2,3) with little or no current star formation. In present models, such galaxies appear rather late in the history of the Universe as the culmination of a hierarchical merging process, in which larger galaxies are assembled through mergers of smaller precursor galaxies. But observations have not yet established how, or even when, the massive spheroidals formed(2,3), nor if their seemingly sudden appearance when the Universe was about half its present age (at redshift z approximate to 1) results from a real evolutionary effect ( such as a peak of mergers) or from the observational difficulty of identifying them at earlier epochs. Here we report the spectroscopic and morphological identification of four old, fully assembled, massive (10(11) solar masses) spheroidal galaxies at l. 6 < z < 1.9, the most distant such objects currently known. The existence of such systems when the Universe was only about one-quarter of its present age shows that the build-up of massive early-type galaxies was much faster in the early Universe than has been expected from theoretical simulations(4).	Osserv Astrofis Arcetri, INAF, I-50125 Florence, Italy; European So Observ, D-85748 Garching, Germany; Univ Padua, Dipartimento Astron, I-35122 Padua, Italy; Osservatorio Astron Bologna, INAF, I-40127 Bologna, Italy; Osserv Astron Trieste, INAF, I-34131 Trieste, Italy; Osserv Astron Roma, INAF, Monte Porzio Catone, Italy	Istituto Nazionale Astrofisica (INAF); European Southern Observatory; University of Padua; Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF); Istituto Nazionale Astrofisica (INAF)	Cimatti, A (corresponding author), Osserv Astrofis Arcetri, INAF, Largo E Fermi 5, I-50125 Florence, Italy.	cimatti@arcetri.astro.it	Daddi, Emanuele/D-1649-2012; Mignoli, Marco/O-9426-2015; Vanzella, Eros/AAA-8640-2019; Pozzetti, Lucia/ABC-8644-2021	Daddi, Emanuele/0000-0002-3331-9590; Mignoli, Marco/0000-0002-9087-2835; fontana, adriano/0000-0003-3820-2823; Cristiani, Stefano/0000-0002-2115-5234; Renzini, Alvio/0000-0002-7093-7355; Zamorani, Giovanni/0000-0002-2318-301X; Pozzetti, Lucia/0000-0001-7085-0412; Vanzella, Eros/0000-0002-5057-135X				Benitez N, 1999, ASTROPHYS J, V515, pL65, DOI 10.1086/311975; Bruzual G, 2003, MON NOT R ASTRON SOC, V344, P1000, DOI 10.1046/j.1365-8711.2003.06897.x; Cimatti A, 2002, ASTRON ASTROPHYS, V392, P395, DOI 10.1051/0004-6361:20020861; Cimatti A, 2002, ASTRON ASTROPHYS, V381, pL68, DOI 10.1051/0004-6361:20011696; Cole S, 2001, MON NOT R ASTRON SOC, V326, P255, DOI 10.1046/j.1365-8711.2001.04591.x; Daddi E, 2000, ASTRON ASTROPHYS, V361, P535; Daddi E, 2004, ASTROPHYS J, V600, pL127, DOI 10.1086/381020; DAVIS M, 1976, ASTROPHYS J, V208, P13, DOI 10.1086/154575; Dickinson M, 2003, ASTROPHYS J, V587, P25, DOI 10.1086/368111; Dunlop J, 1996, NATURE, V381, P581, DOI 10.1038/381581a0; Eisenstein DJ, 2003, ASTROPHYS J, V585, P694, DOI 10.1086/346233; Franx M, 2003, ASTROPHYS J, V587, pL79, DOI 10.1086/375155; Freedman WL, 2003, REV MOD PHYS, V75, P1433, DOI 10.1103/RevModPhys.75.1433; Fukugita M, 1998, ASTROPHYS J, V503, P518, DOI 10.1086/306025; Gavazzi G, 1996, ASTRON ASTROPHYS, V312, P397; Genzel R, 2003, ASTROPHYS J, V584, P633, DOI 10.1086/345718; Giavalisco M, 2004, ASTROPHYS J, V600, pL93, DOI 10.1086/379232; Im M, 2002, ASTROPHYS J, V571, P136, DOI 10.1086/339854; Jimenez R, 2004, MON NOT R ASTRON SOC, V349, P240, DOI 10.1111/j.1365-2966.2004.07492.x; Peebles PJE, 2002, ASTR SOC P, V283, P351; Peng CY, 2002, ASTRON J, V124, P266, DOI 10.1086/340952; Pickles AJ, 1998, PUBL ASTRON SOC PAC, V110, P863, DOI 10.1086/316197; Pignatelli E, 1999, ASTROPHYS SPACE SCI, V269, P657, DOI 10.1023/A:1017038423778; Renzini A., 1999, FORMATION GALACTIC B, P9; Rodighiero G, 2001, MON NOT R ASTRON SOC, V324, P491, DOI 10.1046/j.1365-8711.2001.04354.x; Somerville RS, 2004, ASTROPHYS J, V600, pL135, DOI 10.1086/378665; Spinrad H, 1997, ASTROPHYS J, V484, P581, DOI 10.1086/304381; Steidel CC, 2004, ASTROPHYS J, V604, P534, DOI 10.1086/381960; Taniguchi Y, 2003, J KOREAN ASTRON SOC, V36, P123; Zepf SE, 1997, NATURE, V390, P377, DOI 10.1038/37065	30	298	299	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					184	187		10.1038/nature02668	http://dx.doi.org/10.1038/nature02668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241408				2022-12-28	WOS:000222470600037
J	Li, KS; Guan, Y; Wang, J; Smith, GJD; Xu, KM; Duan, L; Rahardjo, AP; Puthavathana, P; Buranathai, C; Nguyen, TD; Estoepangestie, ATS; Chaisingh, A; Auewarakul, P; Long, HT; Hanh, NTH; Webby, RJ; Poon, LLM; Chen, H; Shortridge, KF; Yuen, KY; Webster, RG; Peiris, JSM				Li, KS; Guan, Y; Wang, J; Smith, GJD; Xu, KM; Duan, L; Rahardjo, AP; Puthavathana, P; Buranathai, C; Nguyen, TD; Estoepangestie, ATS; Chaisingh, A; Auewarakul, P; Long, HT; Hanh, NTH; Webby, RJ; Poon, LLM; Chen, H; Shortridge, KF; Yuen, KY; Webster, RG; Peiris, JSM			Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia	NATURE			English	Article							AVIAN INFLUENZA; A VIRUS; H9N2; EVOLUTION; POULTRY; CHINA	A highly pathogenic avian influenza virus, H5N1, caused disease outbreaks in poultry in China and seven other east Asian countries between late 2003 and early 2004; the same virus was fatal to humans in Thailand and Vietnam(1). Here we demonstrate a series of genetic reassortment events traceable to the precursor of the H5N1 viruses that caused the initial human outbreak in Hong Kong in 1997 (refs 2-4) and subsequent avian outbreaks in 2001 and 2002 ( refs 5, 6). These events gave rise to a dominant H5N1 genotype (Z) in chickens and ducks that was responsible for the regional outbreak in 2003-04. Our findings indicate that domestic ducks in southern China had a central role in the generation and maintenance of this virus, and that wild birds may have contributed to the increasingly wide spread of the virus in Asia. Our results suggest that H5N1 viruses with pandemic potential have become endemic in the region and are not easily eradicable. These developments pose a threat to public and veterinary health in the region and potentially the world, and suggest that long-term control measures are required.	Shantou Univ, Coll Med, Joint Influenza Res Ctr, SUMC,HKU, Guangdong 515031, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; Univ Airlangga, Fak Kedokteran Hewan, Surabaya 60115, Indonesia; Sriraj Hosp, Dept Microbiol, Bangkok 10700, Thailand; Natl Inst Anim Hlth, Dept Livestock Dev, Bangkok 10900, Thailand; Minist Agr & Rural Dev, Natl Inst Vet Res, Dept Virol, Hanoi, Vietnam; Natl Inst Hyg & Epidemiol, Dept Virol, Hanoi, Vietnam; St Jude Childrens Res Hosp, Dept Infect Dis, Div Virol, Memphis, TN 38105 USA	Shantou University; University of Hong Kong; University of Hong Kong; Airlangga University; National Institute of Hygiene & Epidemiology (NIHE); St Jude Children's Research Hospital	Guan, Y (corresponding author), Shantou Univ, Coll Med, Joint Influenza Res Ctr, SUMC,HKU, Guangdong 515031, Peoples R China.	yguan@hkucc.hku.hk	Auewarakul, Prasert/D-6015-2011; Yuen, Kwok Yung/C-4465-2009; Webby, Richard J/N-5657-2018; Poon, Leo/AAP-6887-2020; Poon, Leo Lit Man/C-4382-2009; Xu, Kemin/G-2825-2011; Chen, Honglin/C-4224-2009; Peiris, Joseph Sriyal Malik/C-4380-2009	Poon, Leo Lit Man/0000-0002-9101-7953; Chen, Honglin/0000-0001-5108-8338; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Li, Kangsheng/0000-0002-6981-9263; Guan, Yi/0000-0001-6057-9243; Yuen, Kwok-yung/0000-0002-2083-1552; Smith, Gavin JD/0000-0001-5031-468X				[Anonymous], 2004, Wkly Epidemiol Rec, V79, P65; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Fouchier RAM, 2004, P NATL ACAD SCI USA, V101, P1356, DOI 10.1073/pnas.0308352100; Guan Y, 2002, P NATL ACAD SCI USA, V99, P8950, DOI 10.1073/pnas.132268999; Guan Y, 2004, P NATL ACAD SCI USA, V101, P8156, DOI 10.1073/pnas.0402443101; Guan Y, 2000, J VIROL, V74, P9372, DOI 10.1128/JVI.74.20.9372-9380.2000; Guan Y, 1999, P NATL ACAD SCI USA, V96, P9363, DOI 10.1073/pnas.96.16.9363; Ha Y, 2001, P NATL ACAD SCI USA, V98, P11181, DOI 10.1073/pnas.201401198; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hien TT, 2004, NEW ENGL J MED, V350, P1179, DOI 10.1056/NEJMoa040419; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; Iwatsuki-Horimoto K, 2004, J GEN VIROL, V85, P1001, DOI 10.1099/vir.0.19519-0; Kaverin NV, 2002, J GEN VIROL, V83, P2497, DOI 10.1099/0022-1317-83-10-2497; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Li KS, 2003, J VIROL, V77, P6988, DOI 10.1128/JVI.77.12.6988-6994.2003; Matrosovich M, 1999, J VIROL, V73, P1146, DOI 10.1128/JVI.73.2.1146-1155.1999; Peiris JSM, 2001, J VIROL, V75, P9679, DOI 10.1128/JVI.75.20.9679-9686.2001; Presgraves DC, 2003, NATURE, V423, P715, DOI 10.1038/nature01679; Scholtissek C, 1998, ANTIVIR RES, V37, P83, DOI 10.1016/S0166-3542(97)00061-2; Seo SH, 2002, NAT MED, V8, P950, DOI 10.1038/nm757; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; Sims LD, 2003, AVIAN DIS, V47, P832, DOI 10.1637/0005-2086-47.s3.832; Swofford DL., 2001, PAUP PHYLOGENETIC AN; Thomas JM, 1998, VIROLOGY, V252, P54, DOI 10.1006/viro.1998.9384; WEBSTER RG, 1992, MICROBIOL REV, V56, P152, DOI 10.1128/MMBR.56.1.152-179.1992; Xu XY, 1999, VIROLOGY, V261, P15, DOI 10.1006/viro.1999.9820	26	981	1223	5	270	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					209	213		10.1038/nature02746	http://dx.doi.org/10.1038/nature02746			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241415				2022-12-28	WOS:000222470600044
J	Snow, V; Barry, P; Fihn, SD; Gibbons, RJ; Owens, DK; Williams, SV; Weiss, KB; Mottur-Pilson, C				Snow, V; Barry, P; Fihn, SD; Gibbons, RJ; Owens, DK; Williams, SV; Weiss, KB; Mottur-Pilson, C		ACP ACC Chronic Stable Angina	Evaluation of primary care patients with chronic stable angina: Guidelines from the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							BUNDLE-BRANCH BLOCK; CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; DOBUTAMINE STRESS ECHOCARDIOGRAPHY; DIPYRIDAMOLE TL-201 SCINTIGRAPHY; INCREMENTAL PROGNOSTIC VALUE; ASSOCIATION TASK-FORCE; EXERCISE STRESS; TREADMILL SCORE; RISK	In 1999, the American College of Physicians (ACP) then the American College of Physicians-American Society of Internal Medicine, and the American College of Cardiology/American Heart Association (ACC/AHA) developed joint guidelines on the management of patients with chronic stable angina. The ACC/AHA then published an updated guideline in 2002, which the ACP recognized as a scientifically valid review of the evidence and background paper. This ACP guideline summarizes the recommendations of the 2002 ACC/AHA updated guideline and underscores the recommendations most likely to be important to physicians seeing patients in the primary care setting. This guideline is the first of 2 that will provide guidance on the management of patients with chronic stable angina. This document will cover diagnosis and risk stratification for symptomatic patients who have not had an acute myocardial infarction or revascularization procedure in the previous 6 months. Sections addressing asymptomatic patients are also included. Asymptomatic refers to patients with known or suspected coronary disease based on history or on electrocardiographic evidence of previous myocardial infarction, coronary angiography, or abnormal results on noninvasive tests. A future guideline will cover pharmacologic therapy and follow-up.	Amer Coll Physicians, Philadelphia, PA 19106 USA; Univ Penn, Philadelphia, PA 19104 USA; Merck Inst Aging & Hlth, Washington, DC USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Edward Hines Jr VA Hosp, Chicago, IL USA; Northwestern Univ, Chicago, IL 60611 USA	American College of Physicians; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Mayo Clinic; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Northwestern University	Snow, V (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	vincenza@acponline.org	Greiver, Michelle/N-8764-2015; Fihn, Stephan/ABA-1040-2020	Greiver, Michelle/0000-0001-8957-0285; Gibbons, Raymond/0000-0003-0704-1350				AFRIDI I, 1994, AM HEART J, V127, P1510, DOI 10.1016/0002-8703(94)90378-6; BRUCE RA, 1980, CARDIOLOGY, V66, P111, DOI 10.1159/000170856; BURNS RJ, 1991, AM J CARDIOL, V68, P504, DOI 10.1016/0002-9149(91)90786-K; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Cheitlin MD, 2003, ACC AHA ASE 2003 GUI; COLETTA C, 1995, J AM COLL CARDIOL, V26, P887, DOI 10.1016/0735-1097(95)00272-5; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; GIBBONS RJ, 2002, ACC AHA 2002 GUIDELI; Gil VM, 1998, J NUCL CARDIOL, V5, P414, DOI 10.1016/S1071-3581(98)90147-7; Hachamovitch R, 1998, CIRCULATION, V97, P535; Hachamovitch R, 1996, CIRCULATION, V93, P905, DOI 10.1161/01.CIR.93.5.905; HENRY WL, 1978, CIRCULATION, V57, P278, DOI 10.1161/01.CIR.57.2.278; JUKEMA JW, 1993, EUR HEART J, V14, P53, DOI 10.1093/eurheartj/14.1.53; KAMARAN M, 1995, AM J CARDIOL, V76, P887, DOI 10.1016/S0002-9149(99)80255-0; KRIVOKAPICH J, 1993, AM J CARDIOL, V71, P646, DOI 10.1016/0002-9149(93)91004-2; Kwok JMF, 2002, J AM COLL CARDIOL, V39, P1475, DOI 10.1016/S0735-1097(02)01769-2; LARCOS G, 1991, AM J CARDIOL, V68, P1097, DOI 10.1016/0002-9149(91)90504-E; Lebtahi NE, 1997, J NUCL CARDIOL, V4, P266, DOI 10.1016/S1071-3581(97)90103-3; Marcovitz PA, 1996, AM J CARDIOL, V78, P404, DOI 10.1016/S0002-9149(96)00327-X; MARK DB, 1987, ANN INTERN MED, V106, P793, DOI 10.7326/0003-4819-106-6-793; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; MAZEIKA PK, 1993, AM J CARDIOL, V71, P33, DOI 10.1016/0002-9149(93)90706-I; MORAIS J, 1990, CAN J CARDIOL, V6, P5; Nallamothu N, 1997, J NUCL CARDIOL, V4, P487, DOI 10.1016/S1071-3581(97)90006-4; Nigam A, 1998, J NUCL MED, V39, P579; O'Rourke RA, 2000, J AM COLL CARDIOL, V36, P326, DOI 10.1016/S0735-1097(00)00831-7; OKEEFE JH, 1993, J AM COLL CARDIOL, V21, P1332, DOI 10.1016/0735-1097(93)90305-K; PATEL R, 1995, NUCL MED COMMUN, V16, P137, DOI 10.1097/00006231-199516030-00004; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; ROCKETT JF, 1990, CLIN NUCL MED, V15, P401, DOI 10.1097/00003072-199006000-00008; SAWADA SG, 1990, AM HEART J, V120, P49, DOI 10.1016/0002-8703(90)90159-U; SEVERI S, 1994, CIRCULATION, V89, P1160, DOI 10.1161/01.CIR.89.3.1160; Vaduganathan P, 1996, J AM COLL CARDIOL, V28, P543, DOI 10.1016/0735-1097(96)00224-0; Wagdy HM, 1998, CIRCULATION, V97, P1563, DOI 10.1161/01.CIR.97.16.1563; Williams MJ, 1996, J AM COLL CARDIOL, V27, P132, DOI 10.1016/0735-1097(95)00393-2; Williams SV, 2001, ANN INTERN MED, V135, P530, DOI 10.7326/0003-4819-135-7-200110020-00014	36	32	33	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	2004	141	1					57	64		10.7326/0003-4819-141-1-200407060-00015	http://dx.doi.org/10.7326/0003-4819-141-1-200407060-00015			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834RF	15238371				2022-12-28	WOS:000222427600008
J	Martinez, E; Milinkovic, A; de Lazzari, E; Ravasi, G; Blanco, JL; Larrousse, M; Mallolas, J; Garcia, F; Miro, JM; Gatell, JM				Martinez, E; Milinkovic, A; de Lazzari, E; Ravasi, G; Blanco, JL; Larrousse, M; Mallolas, J; Garcia, F; Miro, JM; Gatell, JM			Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults	LANCET			English	Article								The rise in didanosine concentrations in plasma when given with tenofovir raises concern for a high risk of toxic effects. Recommendations to reduce didanosine dose have been issued, but only for adults weighing more than 60 kg. We reviewed cases of pancreatitis in patients receiving didanosine plus tenofovir, didanosine alone, and tenofovir alone to assess the incidence of and risk factors for pancreatitis. Between Aug 1, 2001, and Nov 30, 2003, five of 185 (2.7%) patients receiving didanosine plus tenofovir, one of 182 (0.5%) on didanosine without tenofovir, and none of 208 on tenofovir without didanosine developed pancreatitis (p=0.016). Co-administration of both drugs versus each of them individually was an independent risk factor for pancreatitis (crude hazard ratio 10.666, 95% CI 1.246-91.294, p=0.031). These results suggest that the risk of pancreatitis is heightened when didanosine and tenofovir are given together.	Univ Barcelona, Hosp Clin, Infect Dis Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona	Martinez, E (corresponding author), Univ Barcelona, Hosp Clin, Infect Dis Unit, Calle Villarroel 170, E-08036 Barcelona, Spain.	esteban@fundsoriano.es	Gatell, Jose M/ABC-3607-2020; , Felipe/F-4242-2014	, Felipe/0000-0001-7658-5832; Mallolas Masferrer, Josep/0000-0002-8365-141X; Milinkovic, Ana/0000-0002-7732-9168; De Lazzari, Elisa/0000-0003-2614-6545				Becher F, 2004, AIDS, V18, P181, DOI 10.1097/00002030-200401230-00006; Blanchard JN, 2003, CLIN INFECT DIS, V37, pE57, DOI 10.1086/376991; FLAHERTY J, 2001, 41 INT C ANT AG CHEM; KAUL S, 2003, 4 INT WORKSH CLIN PH; KEARNEY BP, 2001, 1 IAS C HIV PATH TRE	5	45	47	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	2004	364	9428					65	67		10.1016/S0140-6736(04)16591-4	http://dx.doi.org/10.1016/S0140-6736(04)16591-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234858				2022-12-28	WOS:000222392900033
J	Buffetaut, E; Martill, D; Escuillie, F				Buffetaut, E; Martill, D; Escuillie, F			Pterosaurs as part of a spinosaur diet - A rare fossilized action snapshot captures a mortal tussle with a hungry predator	NATURE			English	Article									CNRS, F-75013 Paris, France; Univ Portsmouth, Sch Earth & Environm Sci, Portsmouth PO1 3QL, Hants, England; Eldonia, F-03800 Gannat, France	Centre National de la Recherche Scientifique (CNRS); University of Portsmouth	Buffetaut, E (corresponding author), CNRS, 16 Cour Liegat, F-75013 Paris, France.	eric.buffetaut@wanadoo.fr		Martill, David/0000-0002-3208-5702				Charig Alan J., 1997, Bulletin of the Natural History Museum Geology Series, V53, P11; CURRIE PJ, 1995, CAN J EARTH SCI, V32, P922, DOI 10.1139/e95-077; HOLZ TR, 1998, SCIENCE, V282, P1276; Kellner Alexander W.A., 1996, Neues Jahrbuch fuer Geologie und Palaeontologie Abhandlungen, V199, P151; Kellner AWA, 2000, NATL SCI MUSEUM MONO, V17, P1, DOI 10.1159/000061634; KITCHENER A, 1987, NATURE, V325, P114, DOI 10.1038/325114a0; MARTILL DM, 1993, POSSILS SANTANA CRAT; Mazin Jean-Michel, 2003, Geological Society Special Publication, V217, P283, DOI 10.1144/GSL.SP.2003.217.01.17; Sues HD, 2002, J VERTEBR PALEONTOL, V22, P535, DOI 10.1671/0272-4634(2002)022[0535:ICASDT]2.0.CO;2; WELLNHOFER P, 1991, Palaeontographica Abteilung A Palaeozoologie-Stratigraphie, V215, P43	10	58	61	2	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					33	33		10.1038/430033a	http://dx.doi.org/10.1038/430033a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229562	Bronze			2022-12-28	WOS:000222356800031
J	Thomas, DJ				Thomas, DJ			Evidence for deep-water production in the North Pacific Ocean during the early Cenozoic warm interval	NATURE			English	Article							RESIDENCE TIME; NEODYMIUM; ND; ATLANTIC; SR	The deep-ocean circulation is responsible for a significant component of global heat transport. In the present mode of circulation, deep waters formin the North Atlantic and Southern oceans where surface water becomes sufficiently cold and dense to sink. Polar temperatures during the warmest climatic interval of the Cenozoic era (similar to65 to 40 million years (Myr) ago) were significantly warmer than today, and this may have been a consequence of enhanced oceanic heat transport(1). However, understanding the relationship between deep-ocean circulation and ancient climate is complicated by differences in oceanic gateways(2), which affect where deep waters form and how they circulate. Here I report records of neodymium isotopes from two cores in the Pacific Ocean that indicate a shift in deep-water production from the Southern Ocean to the North Pacific similar to65 Myr ago. The source of deep waters reverted back to the Southern Ocean 40 Myr ago. The relative timing of changes in the neodymium and oxygen isotope records indicates that changes in Cenozoic deep-water circulation patterns were the consequence, not the cause, of extreme Cenozoic warmth.	Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Thomas, DJ (corresponding author), Texas A&M Univ, Dept Oceanog, College Stn, TX 77843 USA.	dthomas@ocean.tamu.edu						Bice KL, 1997, GEOLOGY, V25, P951, DOI 10.1130/0091-7613(1997)025<0951:CRAECB>2.3.CO;2; BOYLE EA, 1981, EARTH PLANET SC LETT, V53, P11, DOI 10.1016/0012-821X(81)90022-4; BOYLE EA, 1985, EARTH PLANET SC LETT, V76, P135, DOI 10.1016/0012-821X(85)90154-2; BRALOWER TJ, 2002, P ODP INIT REP, V198; BROECKER W, 1960, J GEOPHYS RES, V65, P2903, DOI 10.1029/JZ065i009p02903; DEPAOLO DJ, 1976, GEOPHYS RES LETT, V3, P249, DOI 10.1029/GL003i005p00249; ELDHOLM O, 1993, EARTH PLANET SC LETT, V117, P319, DOI 10.1016/0012-821X(93)90087-P; FRAKES LA, 1972, NATURE, V240, P97, DOI 10.1038/240097a0; GOLDSTEIN SJ, 1988, EARTH PLANET SC LETT, V87, P249, DOI 10.1016/0012-821X(88)90013-1; HALLIDAY AN, 1992, GEOPHYS RES LETT, V19, P761, DOI 10.1029/92GL00393; JONES CE, 1994, EARTH PLANET SC LETT, V127, P55, DOI 10.1016/0012-821X(94)90197-X; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; LARSON RL, 1972, GEOL SOC AM BULL, V83, P3645, DOI 10.1130/0016-7606(1972)83[3645:WCOMMA]2.0.CO;2; Levitus S., 1982, 13 NOAA; Martin EE, 2004, EARTH PLANET SC LETT, V220, P25, DOI 10.1016/S0012-821X(04)00030-5; PIEPGRAS DJ, 1988, GEOCHIM COSMOCHIM AC, V52, P1373, DOI 10.1016/0016-7037(88)90208-6; Reynard B, 1999, CHEM GEOL, V155, P233, DOI 10.1016/S0009-2541(98)00169-7; Rutberg RL, 2000, NATURE, V405, P935, DOI 10.1038/35016049; Saunders A.D., 1997, GEOPH MONOG SERIES, V100, P45, DOI [10.1029/GM100p0045, 10.1029/GM100P0045]; Sloan LC, 1996, PALAEOGEOGR PALAEOCL, V119, P275, DOI 10.1016/0031-0182(95)00012-7; STAUDIGEL H, 1985, EARTH PLANET SC LETT, V76, P45, DOI 10.1016/0012-821X(85)90147-5; Tachikawa K, 1999, EARTH PLANET SC LETT, V170, P433, DOI 10.1016/S0012-821X(99)00127-2; TALLEY LD, 1993, J PHYS OCEANOGR, V23, P517, DOI 10.1175/1520-0485(1993)023<0517:DAFONP>2.0.CO;2; Tanaka T, 2000, CHEM GEOL, V168, P279, DOI 10.1016/S0009-2541(00)00198-4; Thomas DJ, 2003, EARTH PLANET SC LETT, V209, P309, DOI 10.1016/S0012-821X(03)00096-7; THOMAS DJ, IN PRESS GSA SPEC PU; Tomczak M., 1994, REGIONAL OCEANOGRAPH; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412	28	98	103	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					65	68		10.1038/nature02639	http://dx.doi.org/10.1038/nature02639			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229597				2022-12-28	WOS:000222356800042
J	Zhao, Z; Chen, YA; Zhang, AN; Yang, T; Briegel, HJ; Pan, JW				Zhao, Z; Chen, YA; Zhang, AN; Yang, T; Briegel, HJ; Pan, JW			Experimental demonstration of five-photon entanglement and open-destination teleportation	NATURE			English	Article							QUANTUM COMPUTATION; PURIFICATION; UNIVERSAL; STEP	Quantum-mechanical entanglement of three(1,2) or four(3,4) particles has been achieved experimentally, and has been used to demonstrate the extreme contradiction between quantum mechanics and local realism(5,6). However, the realization of five-particle entanglement remains an experimental challenge. The ability to manipulate the entanglement of five or more particles is required(7,8) for universal quantum error correction. Another key process in distributed quantum information processing(9,10), similar to encoding and decoding, is a teleportation protocol(11,12) that we term 'open-destination' teleportation. An unknown quantum state of a single particle is teleported onto a superposition of N particles; at a later stage, this teleported state can be read out ( for further applications) at any of the N particles, by a projection measurement on the remaining particles. Here we report a proof-of-principle demonstration of five-photon entanglement and open-destination teleportation (for N = 3). In the experiment, we use two entangled photon pairs to generate a four-photon entangled state, which is then combined with a single-photon state. Our experimental methods can be used for investigations of measurement-based quantum computation(9,10) and multi-party quantum communication(13,14).	Univ Sci & Technol China, Dept Modern Phys, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; Austrian Acad Sci, Inst Quantum Opt & Quantum Informat, A-6020 Innsbruck, Austria; Univ Innsbruck, Inst Theoret Phys, A-6020 Innsbruck, Austria; Heidelberg Univ, Inst Phys, D-69120 Heidelberg, Germany	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Austrian Academy of Sciences; University of Innsbruck; Ruprecht Karls University Heidelberg	Pan, JW (corresponding author), Univ Sci & Technol China, Dept Modern Phys, Hefei 230026, Anhui, Peoples R China.	jian-wei.pan@physi.uni-heidelberg.de	Pan, Jian-Wei/A-2332-2010; Chen, Yu-Ao/B-2057-2013	Pan, Jian-Wei/0000-0002-6100-5142; Chen, Yu-Ao/0000-0002-2309-2281; Anning, Zhang/0000-0002-7755-7072				Bennett CH, 1996, PHYS REV A, V54, P3824, DOI 10.1103/PhysRevA.54.3824; Bennett CH, 1999, PHYS REV LETT, V83, P3081, DOI 10.1103/PhysRevLett.83.3081; Bouwmeester D, 1997, NATURE, V390, P575, DOI 10.1038/37539; Bouwmeester D, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.040301; Bouwmeester D, 1999, PHYS REV LETT, V82, P1345, DOI 10.1103/PhysRevLett.82.1345; De Martini F, 2002, NATURE, V419, P815, DOI 10.1038/nature01093; Hillery M, 1999, PHYS REV A, V59, P1829, DOI 10.1103/PhysRevA.59.1829; Karlsson A, 1998, PHYS REV A, V58, P4394, DOI 10.1103/PhysRevA.58.4394; Knill E, 2001, NATURE, V409, P46, DOI 10.1038/35051009; Kurtsiefer C, 2002, NATURE, V419, P450, DOI 10.1038/419450a; KWIAT PG, 1995, PHYS REV LETT, V75, P4337, DOI 10.1103/PhysRevLett.75.4337; Laflamme R, 1996, PHYS REV LETT, V77, P198, DOI 10.1103/PhysRevLett.77.198; Pan JW, 2001, PHYS REV LETT, V86, P4435, DOI 10.1103/PhysRevLett.86.4435; Pan JW, 2003, NATURE, V423, P417, DOI 10.1038/nature01623; Pan JW, 2001, NATURE, V410, P1067, DOI 10.1038/35074041; Pittman TB, 2004, PHYS REV A, V69, DOI 10.1103/PhysRevA.69.042306; Pittman TB, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.257902; Rarity JG, 1999, PHYS REV A, V59, pR35, DOI 10.1103/PhysRevA.59.R35; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Scarani V, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.117901; Zeilinger A, 1997, PHYS REV LETT, V78, P3031, DOI 10.1103/PhysRevLett.78.3031; Zhao Z, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.180401; ZUKOWSKI M, 1995, ANN NY ACAD SCI, V755, P91, DOI 10.1111/j.1749-6632.1995.tb38959.x; Zukowski M, 1997, PHYS REV A, V56, pR1682, DOI 10.1103/PhysRevA.56.R1682	30	508	551	10	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					54	58		10.1038/nature02643	http://dx.doi.org/10.1038/nature02643			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229594	Green Submitted			2022-12-28	WOS:000222356800039
J	Krupa, DJ; Wiest, MC; Shuler, MG; Laubach, M; Nicolelis, MAL				Krupa, DJ; Wiest, MC; Shuler, MG; Laubach, M; Nicolelis, MAL			Layer-specific somatosensory cortical activation during active tactile discrimination	SCIENCE			English	Article							RECEPTIVE-FIELDS; VISUAL-CORTEX; BARREL FIELD; AWAKE RATS; ORGANIZATION; SI; VIBRISSA; STIMULI; NEURONS; INFORMATION	Ensemble neuronal activity was recorded in each layer of the whisker area of the primary somatosensory cortex (SI) while rats performed a whisker-dependent tactile discrimination task. Comparison of this activity with SI activity evoked by similar passive whisker stimulation revealed fundamental differences in tactile signal processing during active and passive stimulation. Moreover, significant layer specific functional differences in SI activity were observed during active discrimination. These differences could not be explained solely by variations in ascending thalamocortical input to SI. Instead, these results suggest that top-down influences during active discrimination may alter the overall functional nature of SI as well as layer-specific mechanisms of tactile processing.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; John B Pierce Lab, New Haven, CT 06519 USA	Duke University; Yale University; The John B Pierce Laboratory, Inc	Krupa, DJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	krupa@neuro.duke.edu	Wiest, Michael/ABC-8101-2020	Laubach, Mark/0000-0002-2403-4497	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011451, R01DE013810] Funding Source: NIH RePORTER; NIDCR NIH HHS [5RO1DE11451, 5RO1DE13810] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARMSTRONGJAMES M, 1992, J NEUROPHYSIOL, V68, P1345, DOI 10.1152/jn.1992.68.4.1345; Brumberg JC, 1999, J NEUROPHYSIOL, V82, P1808, DOI 10.1152/jn.1999.82.4.1808; CHAPIN JK, 1986, EXP BRAIN RES, V62, P549; Hupe JM, 1998, NATURE, V394, P784, DOI 10.1038/29537; Jackson ME, 1998, NEUROREPORT, V9, P3379, DOI 10.1097/00001756-199810260-00008; KORALEK KA, 1990, J COMP NEUROL, V299, P133, DOI 10.1002/cne.902990202; Krupa DJ, 2001, J NEUROSCI METH, V104, P199, DOI 10.1016/S0165-0270(00)00345-9; Krupa DJ, 2001, J NEUROSCI, V21, P5752, DOI 10.1523/JNEUROSCI.21-15-05752.2001; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; MIYASHITA E, 1994, EXP BRAIN RES, V99, P223; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; OLAVARRIA J, 1984, BRAIN RES, V291, P364, DOI 10.1016/0006-8993(84)91270-8; POWELL TPS, 1959, B JOHNS HOPKINS HOSP, V105, P133; Roelfsema PR, 1998, NATURE, V395, P376, DOI 10.1038/26475; Sachdev RNS, 2000, J NEUROPHYSIOL, V84, P1497, DOI 10.1152/jn.2000.84.3.1497; Shuler MG, 2002, CEREB CORTEX, V12, P86, DOI 10.1093/cercor/12.1.86; Shuler MG, 2001, J NEUROSCI, V21, P5251, DOI 10.1523/JNEUROSCI.21-14-05251.2001; SIMONS DJ, 1978, J NEUROPHYSIOL, V41, P798, DOI 10.1152/jn.1978.41.3.798; SWADLOW HA, 1989, J NEUROPHYSIOL, V62, P288, DOI 10.1152/jn.1989.62.1.288; Wiest MC, 2003, NAT NEUROSCI, V6, P913, DOI 10.1038/nn1107; Zhang ZW, 1998, CEREB CORTEX, V8, P428, DOI 10.1093/cercor/8.5.428	21	153	159	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1989	1992		10.1126/science.1093318	http://dx.doi.org/10.1126/science.1093318			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218154				2022-12-28	WOS:000222241600052
J	Norman, C				Norman, C			A time for action	SCIENCE			English	Editorial Material																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1931	1931		10.1126/science.304.5679.1931	http://dx.doi.org/10.1126/science.304.5679.1931			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218137				2022-12-28	WOS:000222241600032
J	Hirose, K; Visser, BC				Hirose, K; Visser, BC			Massive subcutaneous emphysema after tracheal perforation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Hirose, K (corresponding author), Univ Calif San Francisco, San Francisco, CA 94143 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					E2	E2		10.1056/ENEJMicm030421	http://dx.doi.org/10.1056/ENEJMicm030421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254295				2022-12-28	WOS:000222627200013
J	Reed, D				Reed, D			Paralysis, Roman Reed, and a ban on stem-cell research	LANCET			English	Editorial Material												diverdonreed@pacbell.net							0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					219	219		10.1016/S0140-6736(04)16639-7	http://dx.doi.org/10.1016/S0140-6736(04)16639-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246739				2022-12-28	WOS:000222612200037
J	Geisbrecht, ER; Montell, DJ				Geisbrecht, ER; Montell, DJ			A role for Drosophila IAP1-mediated caspase inhibition in Rac-dependent cell migration	CELL			English	Article							RHO-GTPASES; GERM-CELLS; PROTEIN; APOPTOSIS; SURVIVAL; DEATH; NUCLEATION; POLARITY; PROFILIN; MOTILITY	Border cell migration in the Drosophila ovary is a relatively simple and genetically tractable model for studying the conversion of epithelial cells to migratory cells. Like many cell migrations, border cell migration is inhibited by a dominant-negative form of the GTPase Rac. To identify new genes that function in Rac-dependent cell motility, we screened for genes that when overexpressed suppressed the migration defect caused by dominant-negative Rac. Overexpression of the Drosophila inhibitor of apoptosis 1 (DIAP1), which is encoded by the thread (th) gene, suppressed the migration defect. Moreover, loss-of-function mutations in th caused migration defects but, surprisingly, did not cause apoptosis. Mutations affecting the Dark protein, an activator of the upstream caspase Dronc, also rescued RacN17 migration defects. These results indicate an apoptosis-independent role for DIAP1-mediated Dronc inhibition in Rac-mediated cell motility.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	Montell, DJ (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	dmontell@jhmi.edu			NIGMS NIH HHS [GM46425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM046425, R01GM046425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arama E, 2003, DEV CELL, V4, P687, DOI 10.1016/S1534-5807(03)00120-5; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; BRAND AH, 1993, DEVELOPMENT, V118, P401; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; Fraser AG, 1997, EMBO J, V16, P6192, DOI 10.1093/emboj/16.20.6192; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Hakeda-Suzuki S, 2002, NATURE, V416, P438, DOI 10.1038/416438a; HARDEN N, 1995, DEVELOPMENT, V121, P903; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Huh JR, 2004, PLOS BIOL, V2, P43, DOI 10.1371/journal.pbio.0020015; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Kunda P, 2003, CURR BIOL, V13, P1867, DOI 10.1016/j.cub.2003.10.005; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Linseman DA, 2001, J BIOL CHEM, V276, P39123, DOI 10.1074/jbc.M103959200; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Martin DN, 2004, DEVELOPMENT, V131, P275, DOI 10.1242/dev.00933; Mashima T, 1997, ONCOGENE, V14, P1007, DOI 10.1038/sj.onc.1200919; MATSUI Y, 1991, NATURE, V353, P750, DOI 10.1038/353750a0; Meier P, 2000, EMBO J, V19, P598, DOI 10.1093/emboj/19.4.598; Montell DJ, 2003, NAT REV MOL CELL BIO, V4, P13, DOI 10.1038/nrm1006; Murga C, 2002, ONCOGENE, V21, P207, DOI 10.1038/sj.onc.1205036; Muro I, 2002, J BIOL CHEM, V277, P49644, DOI 10.1074/jbc.M203464200; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Noda Y, 2001, GENES CELLS, V6, P107, DOI 10.1046/j.1365-2443.2001.00404.x; Pring M, 2003, BIOCHEMISTRY-US, V42, P486, DOI 10.1021/bi026520j; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; Qiu RG, 2000, CURR BIOL, V10, P697, DOI 10.1016/S0960-9822(00)00535-2; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Rogers SL, 2003, J CELL BIOL, V162, P1079, DOI 10.1083/jcb.200303023; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Schwerk C, 2003, BIOCHEM PHARMACOL, V66, P1453, DOI 10.1016/S0006-2952(03)00497-0; Settleman J, 1999, Prog Mol Subcell Biol, V22, P201; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Yoon HJ, 1999, P NATL ACAD SCI USA, V96, P13208, DOI 10.1073/pnas.96.23.13208; Zhang BL, 2003, MOL CELL BIOL, V23, P5716, DOI 10.1128/MCB.23.16.5716-5725.2003; Zhang N, 1997, NATURE, V385, P64, DOI 10.1038/385064a0; Zhang N, 1996, GENETICS, V143, P1231	54	151	155	0	10	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	2004	118	1					111	125		10.1016/j.cell.2004.06.020	http://dx.doi.org/10.1016/j.cell.2004.06.020			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242648	Bronze			2022-12-28	WOS:000222626800012
J	Steinman, RM; Mellman, I				Steinman, RM; Mellman, I			Immunotherapy: Bewitched, bothered, and bewildered no more	SCIENCE			English	Article							REGULATORY T-CELLS; DENDRITIC CELLS; IMMUNE-RESPONSES; SHEDDING LIGHT; CANCER; THERAPY; INTERLEUKIN-2; IMMUNOLOGY; STRATEGIES; CARCINOMA	The field of immunotherapy holds clear promise not only for the development of new approaches to cancer and other diseases, but also for providing fundamental insight into the human immune response. In order for this promise to be realized, however, the scientific community must overcome an array of challenges. These challenges reflect not only the difficulties inherent in conducting investigations in human patients, but also difficulties created by the culture and practice of our own institutions, reward structure, and funding mechanisms. We suggest steps to be taken to reinvigorate basic research in human subjects as part of the mainstream of science.	Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Ludwig Inst Canc Res, Dept Immunobiol, New Haven, CT 06520 USA	Rockefeller University; Ludwig Institute for Cancer Research; Yale University; Ludwig Institute for Cancer Research; Yale University	Steinman, RM (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	steinma@mail.rockefeller.edu	Mellman, Ira/ABG-5896-2020; Steinman, Ralph/F-7729-2012					Banchereau J, 2001, CELL, V106, P271, DOI 10.1016/S0092-8674(01)00448-2; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; Bell J, 2003, J EXP MED, V198, P1621, DOI 10.1084/jem.20031882; Bell J, 2003, BRIT MED J, V327, P1041, DOI 10.1136/bmj.327.7422.1041; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Cerundolo V, 2004, NAT IMMUNOL, V5, P7, DOI 10.1038/ni0104-7; Coulie PG, 2003, CURR OPIN IMMUNOL, V15, P131, DOI 10.1016/S0952-7915(03)00009-8; Dhodapkar MV, 2003, J EXP MED, V198, P1753, DOI 10.1084/jem.20031030; Dhodapkar MV, 2002, P NATL ACAD SCI USA, V99, P13009, DOI 10.1073/pnas.202491499; Dudley ME, 2003, NAT REV CANCER, V3, P666, DOI 10.1038/nrc1167; Feldmann M, 2003, NAT MED, V9, P1245, DOI 10.1038/nm939; Figdor CG, 2004, NAT MED, V10, P475, DOI 10.1038/nm1039; Finn OJ, 2003, J EXP MED, V198, P1623, DOI 10.1084/jem.20031787; Finn OJ, 2003, NAT REV IMMUNOL, V3, P630, DOI 10.1038/nri1150; Hall S. S., 1998, COMMOTION BLOOD; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Jager D, 2004, CANCER IMMUNOL IMMUN, V53, P144, DOI 10.1007/s00262-003-0470-z; Levitsky HI, 2000, CANCER J, V6, pS281; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Pardoll DM, 2002, NAT REV IMMUNOL, V2, P227, DOI 10.1038/nri774; PARKINSON DR, 1990, J CLIN ONCOL, V8, P1630, DOI 10.1200/JCO.1990.8.10.1630; Perales MA, 2002, SEMIN CANCER BIOL, V12, P63, DOI 10.1006/scbi.2001.0397; Rangarajan A, 2003, NAT REV CANCER, V3, P952, DOI 10.1038/nrc1235; Rosenberg SA, 2004, NEW ENGL J MED, V350, P1461, DOI 10.1056/NEJMcibr045001; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; SPARANO JA, 1993, J CLIN ONCOL, V11, P1969, DOI 10.1200/JCO.1993.11.10.1969; Sutmuller RPM, 2001, J EXP MED, V194, P823, DOI 10.1084/jem.194.6.823; Takahashi T, 2003, INT REV CYTOL, V225, P1, DOI 10.1016/S0074-7696(05)25001-5; Triendl R, 2004, NAT REV IMMUNOL, V4, P72, DOI 10.1038/nri1259; van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x; Waldmann TA, 2003, NAT MED, V9, P269, DOI 10.1038/nm0303-269; Wang TH, 2004, NAT MED, V10, P48, DOI 10.1038/nm976; Weissleder R, 2003, NAT MED, V9, P123, DOI 10.1038/nm0103-123; Yee C, 2002, NAT REV CANCER, V2, P409, DOI 10.1038/nrc820; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zerhouni E, 2003, SCIENCE, V302, P63, DOI 10.1126/science.1091867	37	107	119	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	2004	305	5681					197	200		10.1126/science.1099688	http://dx.doi.org/10.1126/science.1099688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247468				2022-12-28	WOS:000222501000039
J	Mertens, K; Putkaradze, V; Vorobieff, P				Mertens, K; Putkaradze, V; Vorobieff, P			Braiding patterns on an inclined plane - The changing boundaries of a stream flowing at a constant rate are explained	NATURE			English	Editorial Material							MOVING CONTACT LINES; RIVULET INSTABILITIES; MEANDERS; SURFACE					putkarad@math.unm.edu	Vorobieff, Peter/B-3376-2011	Vorobieff, Peter/0000-0003-0631-7263				Bohr T, 1997, PHYS REV LETT, V79, P1038, DOI 10.1103/PhysRevLett.79.1038; DAVIS SH, 1980, J FLUID MECH, V98, P225, DOI 10.1017/S0022112080000110; DEGENNES PG, 1985, REV MOD PHYS, V57, P827, DOI 10.1103/RevModPhys.57.827; HASHA A, 2002, PHYS FLUIDS        S, V14, P8; IKEDA S, 1981, J FLUID MECH, V112, P363, DOI 10.1017/S0022112081000451; Lopez PG, 1997, PHYS FLUIDS, V9, P2177, DOI 10.1063/1.869341; NAKAGAWA T, 1984, J FLUID MECH, V149, P89, DOI 10.1017/S002211208400255X; PERAZZO CA, IN PRESS J FLUID MEC; WEILAND RH, 1981, J FLUID MECH, V107, P261, DOI 10.1017/S0022112081001778; YOUNG GW, 1987, J FLUID MECH, V176, P1, DOI 10.1017/S0022112087000557	10	14	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	2004	430	6996					165	165		10.1038/430165a	http://dx.doi.org/10.1038/430165a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241404	Bronze			2022-12-28	WOS:000222470600031
J	Steinbrook, R				Steinbrook, R			Global health - The AIDS epidemic in 2004	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		CHASE M, 2004, WALL STREET J   0706, pA1; Joint United Nations Program on HIV/AIDS, 2004, 2004 REP GLOB AIDS E; LaFraniere S., 2004, NY TIMES, pA1; World Health Organization, 2004, WORLD HLTH REP 2004	4	36	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 8	2004	351	2					115	117		10.1056/NEJMp048156	http://dx.doi.org/10.1056/NEJMp048156			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	835GM	15247349				2022-12-28	WOS:000222470700001
J	Kreijkamp-Kaspers, S; Kok, L; Grobbee, DE; de Haan, EHF; Aleman, A; Lampe, JW; van der Schouw, YT				Kreijkamp-Kaspers, S; Kok, L; Grobbee, DE; de Haan, EHF; Aleman, A; Lampe, JW; van der Schouw, YT			Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE REPLACEMENT THERAPY; DIETARY PHYTOESTROGENS; ESTROGEN; MEMORY; HEALTH; PREMENOPAUSAL; EXCRETION; EQUOL; LIPOPROTEINS; METAANALYSIS	Context Postmenopausal estrogen therapy has been posited to have some beneficial effects on aging processes, but its use has risks. Isoflavones, estrogenlike compounds naturally occurring in plant foods, might confer positive effects with fewer adverse effects. Objective To investigate whether soy protein with isoflavones improves cognitive function, bone mineral density, and plasma lipids in postmenopausal women. Design, Setting, and Participants Double-blind, randomized, placebo-controlled trial of 202 healthy postmenopausal women aged 60 to 75 years, recruited from a population-based sample in the Netherlands, conducted between April 2000 and September 2001. Intervention Participants were randomly assigned to receive 25.6 g of soy protein containing 99 mg of isoflavones (52 mg genistein, 41 mg daidzein, and 6 mg glycetein or total milk protein as a powder on a daily basis for 12 months. Main Outcome Measures Cognitive function was assessed using the following instruments: dementia, Mini-Mental State Examination; memory, Rey Auditory Verbal Learning Test, immediate recall, delayed recall, and recognition, the Digit Span forward and reversed, and the Doors test; complex attention tasks, Digit Symbol Substitution and Trailmaking, A1, A2, and B; and verbal skills, Verbal Fluency A and N, animals and occupations, and the Boston Naming Task. Bone mineral density of the hip and lumbar spine was assessed using dual-energy x-ray absorptiometry scanning. Lipid assessment included lipoprotein(a), total cholesterol, low-density lipoprotein, high-density lipoprotein, and triglycerides. Results A total of 175 women completed the baseline and at least 1 postintervention analysis and were included in the modified intent-to-treat analysis. Adherence was good (median plasma genistein levels, 17.2 and 615.1 nmol/L for placebo and soy group, respectively). Cognitive function, bone mineral density, or plasma lipids did not differ significantly between the groups after a year. Conclusion This double-blind randomized trial does not support the hypothesis that the use of soy protein supplement containing isoflavones improves cognitive function, bone mineral density, or plasma lipids in healthy postmenopausal women when started at the age of 60 years or later.	Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Helmholz Res Inst, Div Psychonom, Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Neurosci, Utrecht, Netherlands; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University; Utrecht University Medical Center; Fred Hutchinson Cancer Center	van der Schouw, YT (corresponding author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, POB 85500,Room D 01-335, NL-3508 GA Utrecht, Netherlands.	y.t.vanderschouw@umcutrecht.nl	Kreijkamp-Kaspers, Sanne/E-1492-2014; Grobbee, Diederick/C-7651-2014; van der Schouw, Yvonne T./F-8327-2014; Aleman, Andre/E-1341-2012	Kreijkamp-Kaspers, Sanne/0000-0002-3710-1986; Grobbee, Diederick/0000-0003-4472-4468; van der Schouw, Yvonne T./0000-0002-4605-435X; de Haan, Edward/0000-0003-0312-3674				Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Anderson JJB, 2002, J AM COLL NUTR, V21, P388, DOI 10.1080/07315724.2002.10719240; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; [Anonymous], 1982, BOSTON NAMING TEST; Arjmandi BH, 1998, AM J CLIN NUTR, V68, p1358S, DOI 10.1093/ajcn/68.6.1358S; Arjmandi BH, 2003, J CLIN ENDOCR METAB, V88, P1048, DOI 10.1210/jc.2002-020849; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Barentsen R, 1996, EUR J OBSTET GYN R B, V64, pS7, DOI 10.1016/0301-2115(95)02349-6; Baum JA, 1998, AM J CLIN NUTR, V68, P545, DOI 10.1093/ajcn/68.3.545; Boker LK, 2002, J NUTR, V132, P1319, DOI 10.1093/jn/132.6.1319; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Chen Z, 1999, NUTR CANCER, V33, P82, DOI 10.1080/01635589909514752; Davis C, 1999, BRIT J CLIN PSYCHOL, V38, P305, DOI 10.1348/014466599162881; de Kleijn MJJ, 2001, J NUTR, V131, P1826; Dent SB, 2001, J NUTR, V131, P2280, DOI 10.1093/jn/131.9.2280; Dewell A, 2002, J CLIN ENDOCR METAB, V87, P118, DOI 10.1210/jc.87.1.118; Duffy R, 2003, PHARMACOL BIOCHEM BE, V75, P721, DOI 10.1016/S0091-3057(03)00116-3; Duncan AM, 2000, CANCER EPIDEM BIOMAR, V9, P581; File SE, 2001, PSYCHOPHARMACOLOGY, V157, P430, DOI 10.1007/s002130100845; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gardner CD, 2001, AM J CLIN NUTR, V73, P728; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Khalil DA, 2002, J NUTR, V132, P2605, DOI 10.1093/jn/132.9.2605; Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611; Kok L, 2004, MATURITAS, V47, P21, DOI 10.1016/S0378-5122(03)00243-3; Kritz-Silverstein D, 2003, MENOPAUSE, V10, P196, DOI 10.1097/00042192-200310030-00004; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Lampe JW, 1999, CANCER EPIDEM BIOMAR, V8, P699; Lampe JW, 2001, J NUTR, V131, P740, DOI 10.1093/jn/131.3.740; LeBlanc ES, 2001, JAMA-J AM MED ASSOC, V285, P1489, DOI 10.1001/jama.285.11.1489; Lezak M.D., 2012, NEUROPSYCHOLOGICAL A; Lund TD, 2001, BMC NEUROSCI, V2, DOI 10.1186/1471-2202-2-20; LYDEKINGOLSEN E, 2002, J NUTR, pS132; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Nestel PJ, 1999, J CLIN ENDOCR METAB, V84, P895, DOI 10.1210/jc.84.3.895; Pan YL, 2000, MENOPAUSE, V7, P230, DOI 10.1097/00042192-200007040-00004; Potter SM, 1998, AM J CLIN NUTR, V68, p1375S, DOI 10.1093/ajcn/68.6.1375S; Reitan RM, 1985, HALSTEAD REITAN NEUR; Resnick SM, 2001, ANN NY ACAD SCI, V949, P203; Rice MM, 2000, ARCH INTERN MED, V160, P1641, DOI 10.1001/archinte.160.11.1641; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; Schmand B, 1991, Tijdschr Gerontol Geriatr, V22, P15; Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S; Setchell KDR, 2002, J NUTR, V132, P3577, DOI 10.1093/jn/132.12.3577; Setchell KDR, 2003, J AGR FOOD CHEM, V51, P4146, DOI 10.1021/jf026199b; Simons LA, 2000, AM J CARDIOL, V85, P1297, DOI 10.1016/S0002-9149(00)00759-1; Teede HJ, 2001, J CLIN ENDOCR METAB, V86, P3053, DOI 10.1210/jc.86.7.3053; Wangen KE, 2001, AM J CLIN NUTR, V73, P225; Wangen KE, 2000, J CLIN ENDOCR METAB, V85, P3043, DOI 10.1210/jc.85.9.3043; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	54	322	334	3	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					65	74		10.1001/jama.292.1.65	http://dx.doi.org/10.1001/jama.292.1.65			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238592	Bronze			2022-12-28	WOS:000222448100028
J	Brugha, R; Donoghue, M; Starling, M; Ndubani, P; Ssengooba, F; Fernandes, B; Walt, G				Brugha, R; Donoghue, M; Starling, M; Ndubani, P; Ssengooba, F; Fernandes, B; Walt, G			The Global Fund: managing great expectations	LANCET			English	Article								The Global Fund to fight AIDS, Tuberculosis, and Malaria was created to increase funds to combat these three devastating diseases. We report interim findings, based on interviews with 137 national-level respondents that track early implementation processes in four African countries. Country coordinating mechanisms (CCMs) are country-level partnerships, which were formed quickly to develop and submit grant proposals to the Global Fund. CCM members were often ineffective at representing their constituencies and encountered obstacles in participating in CCM processes. Delay in dissemination of guidelines from the Global Fund led to uncertainty among members about the function of these new partnerships. Respondents expressed most concern about the limited capacity of fund recipients-government and non-government-to meet Global Fund conditions for performance-based disbursement. Delays in payment of funds to implementing agencies have frustrated rapid financing of disease control interventions. The Global Fund is one of several new global initiatives superimposed on existing country systems to finance the control of HIV/AIDS. New and existing donors need to coordinate assistance to developing countries by bringing together funding, planning, management, and reporting systems if global goals for disease control are to be achieved.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth Policy, London WC1E 7HT, England; Univ Zambia, Inst Econ & Social Res, Lusaka, Zambia; Makerere Univ, Inst Publ Hlth, Kampala, Uganda	University of London; London School of Hygiene & Tropical Medicine; University of Zambia; Makerere University	Brugha, R (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth Policy, Keppel St, London WC1E 7HT, England.	Ruairi.brugha@lshtm.ac.uk	Ndubani, Phillimon/AAB-3724-2020; Brugha, Ruairi/C-8420-2012	Brugha, Ruairi/0000-0003-0729-0197; Ssengooba, Freddie/0000-0003-3489-0745				[Anonymous], TUB MAL; [Anonymous], 2001, MACR HLTH INV HLTH E; Brugha R, 2002, LANCET, V359, P435, DOI 10.1016/S0140-6736(02)07607-9; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; *COMM MACR HLTH, 2002, DEV ASS HLTH REP WOR; *GAO, 2003, TB MAL ADV KEY AR DI; *GLOB FUND FIGHT A, 2003, TUB MAL PARTN PREV T; *GLOB FUND FIGHT A, 2003, TUB MAL GUID PERF BA; *GLOB FUND FIGHT A, 2002, 1 BOARD M JAN 28 29; *GLOB FUND FIGHT A, 2003, TUB MAL GUID PURP ST; *GLOB FUND FIGHT A, 2004, GFB73 GLOB FUND FIGH; GRACE C, 2003, GLOBAL FUND COUNTRY; Hanson K, 2003, J INT DEV, V15, P1, DOI DOI 10.1002/JID.963; OECD, 2003, DAC GUID REF SER HAR; VENETSANOU E, 2003, UNPUB IN DEPTH ASSES	15	77	78	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	2004	364	9428					95	100		10.1016/S0140-6736(04)16595-1	http://dx.doi.org/10.1016/S0140-6736(04)16595-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834DX	15234862				2022-12-28	WOS:000222392900037
J	Buckley, LB; Roughgarden, J				Buckley, LB; Roughgarden, J			Biodiversity conservation - Effects of changes in climate and land use	NATURE			English	Editorial Material									Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Buckley, LB (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	lbuckley@stanford.edu	Buckley, Lauren/ABD-6759-2021	Buckley, Lauren/0000-0003-1315-3818				Graham RW, 1996, SCIENCE, V272, P1601; JABLONSKI D, 1986, SCIENCE, V231, P129, DOI 10.1126/science.231.4734.129; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Thomas CD, 2004, NATURE, V427, P145, DOI 10.1038/nature02121; Williams SE, 2003, P ROY SOC B-BIOL SCI, V270, P1887, DOI 10.1098/rspb.2003.2464	6	31	32	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995								10.1038/nature02717	http://dx.doi.org/10.1038/nature02717			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15233130				2022-12-28	WOS:000222356800033
J	Cummings, JL				Cummings, JL			Drug therapy - Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED-TRIAL; QUALITY STANDARDS SUBCOMMITTEE; BETA-AMYLOID DEPOSITION; ACADEMY-OF-NEUROLOGY; DOUBLE-BLIND; DISRUPTIVE BEHAVIORS; COGNITIVE IMPAIRMENT; PRACTICE PARAMETER; CLINICAL-TRIALS		Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Cummings, JL (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Reed Neurol Res Ctr, Dept Neurol, 710 Westwood Plaza,Box 951769, Los Angeles, CA 90095 USA.	jcummings@mednet.ucla.edu			NCRR NIH HHS [RR00856] Funding Source: Medline; NIA NIH HHS [AG10483, P50 AG16570] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG016570, U01AG010483, U19AG010483] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aisen PS, 2003, JAMA-J AM MED ASSOC, V289, P2819, DOI 10.1001/jama.289.21.2819; Aisen PS, 2000, NEUROLOGY, V54, P588, DOI 10.1212/WNL.54.3.588; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Brodaty H, 2003, J AM GERIATR SOC, V51, P657, DOI 10.1034/j.1600-0579.2003.00210.x; Brodaty H, 2003, J CLIN PSYCHIAT, V64, P134, DOI 10.4088/JCP.v64n0205; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Carter DB, 2001, ANN NEUROL, V50, P468, DOI 10.1002/ana.1134; CHANDRA V, 1986, NEUROLOGY, V36, P209, DOI 10.1212/WNL.36.2.209; CHUI H, 2002, EVIDENCE BASED DEMEN, P106; Cohen-Mansfield J, 2001, AM J GERIAT PSYCHIAT, V9, P361, DOI 10.1176/appi.ajgp.9.4.361; CohenMansfield J, 1997, J GERONTOL A-BIOL, V52, pM369, DOI 10.1093/gerona/52A.6.M369; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; Craft S, 1998, NEUROLOGY, V50, P164, DOI 10.1212/WNL.50.1.164; Cummings JL, 2003, AM J GERIAT PSYCHIAT, V11, P131, DOI 10.1176/appi.ajgp.11.2.131; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; Devanand DP, 1998, AM J PSYCHIAT, V155, P1512, DOI 10.1176/ajp.155.11.1512; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; Doody RS, 2001, ARCH NEUROL-CHICAGO, V58, P427, DOI 10.1001/archneur.58.3.427; Doraiswamy PM, 2001, ALZ DIS ASSOC DIS, V15, P174, DOI 10.1097/00002093-200110000-00003; Engelhart MJ, 2002, JAMA-J AM MED ASSOC, V287, P3223, DOI 10.1001/jama.287.24.3223; Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7; Esteban-Santillan C, 1998, J AM GERIATR SOC, V46, P1266, DOI 10.1111/j.1532-5415.1998.tb04543.x; Finch CE, 2001, CONTEMPORARY CLIN NE, P87; Galasko D, 1997, ALZ DIS ASSOC DIS, V11, pS33; Greene JDW, 1996, NEUROPSYCHOLOGIA, V34, P537, DOI 10.1016/0028-3932(95)00151-4; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Hock C, 2003, NEURON, V38, P547, DOI 10.1016/S0896-6273(03)00294-0; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; JORM AF, 1991, EUR ARCH PSY CLIN N, V240, P218, DOI 10.1007/BF02189530; Katona CLE, 1998, INT J GERIATR PSYCH, V13, P100; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Kawas CH, 2003, NEW ENGL J MED, V349, P1056, DOI 10.1056/NEJMcp022295; KIRK A, 1991, ARCH NEUROL-CHICAGO, V48, P73, DOI 10.1001/archneur.1991.00530130083024; Klatte ET, 2003, ALZ DIS ASSOC DIS, V17, P113, DOI 10.1097/00002093-200304000-00010; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; Leber P., 1990, GUIDELINES CLIN EVAL; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P1686, DOI 10.1176/appi.ajp.157.10.1686; MAGENHEIM MJ, 1998, PRACTICE GERIATRICS, P115; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mega MS, 1996, NEUROLOGY, V46, P130, DOI 10.1212/WNL.46.1.130; Mesulam NM, 1999, NEURON, V24, P521, DOI 10.1016/S0896-6273(00)81109-5; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MULNARD RA, 2000, JAMA-J AM MED ASSOC, V284, P2597; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Ott BR, 1998, J GERIATR PSYCH NEUR, V11, P163, DOI 10.1177/089198879901100401; PALMER AM, 1988, ANN NEUROL, V23, P616, DOI 10.1002/ana.410230616; Pappas BA, 2000, NEUROBIOL AGING, V21, P11, DOI 10.1016/S0197-4580(00)00090-7; Parsons CG, 1999, NEUROPHARMACOLOGY, V38, P735, DOI 10.1016/S0028-3908(99)00019-2; Petanceska SS, 2002, J MOL NEUROSCI, V19, P155, DOI 10.1007/s12031-002-0026-2; PILLON B, 1993, ARCH NEUROL-CHICAGO, V50, P374, DOI 10.1001/archneur.1993.00540040036010; Porsteinsson AP, 1997, AM J GERIAT PSYCHIAT, V5, P344, DOI 10.1097/00019442-199700540-00010; Porsteinsson AP, 2001, AM J GERIAT PSYCHIAT, V9, P58, DOI 10.1176/appi.ajgp.9.1.58; PRICE BH, 1993, ARCH NEUROL-CHICAGO, V50, P931, DOI 10.1001/archneur.1993.00540090038008; Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Ritchie CW, 2003, ARCH NEUROL-CHICAGO, V60, P1685, DOI 10.1001/archneur.60.12.1685; Rogers SL, 2000, EUR NEUROPSYCHOPHARM, V10, P195, DOI 10.1016/S0924-977X(00)00067-5; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Ross GW, 1997, JAMA-J AM MED ASSOC, V277, P800, DOI 10.1001/jama.277.10.800; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Scharf S, 1999, NEUROLOGY, V53, P197, DOI 10.1212/WNL.53.1.197; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; SEIMERS ER, 2004, AM ACAD NEUROL S, V101, pS17; Selkoe DJ, 2002, SCIENCE, V298, P963; Shumaker SA, 2003, JAMA-J AM MED ASSOC, V289, P2651, DOI 10.1001/jama.289.20.2651; Silverman DHS, 2001, JAMA-J AM MED ASSOC, V286, P2120, DOI 10.1001/jama.286.17.2120; Small GW, 1997, JAMA-J AM MED ASSOC, V278, P1363, DOI 10.1001/jama.278.16.1363; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Sultzer DL, 1997, AM J GERIAT PSYCHIAT, V5, P60; Taragano FE, 1997, PSYCHOSOMATICS, V38, P246, DOI 10.1016/S0033-3182(97)71461-0; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Tariot PN, 2001, J AM GERIATR SOC, V49, P1590, DOI 10.1046/j.1532-5415.2001.t01-1-49266.x; WATKINS PB, 1994, JAMA-J AM MED ASSOC, V271, P992, DOI 10.1001/jama.271.13.992; Wimo A., 2001, PSYCHOGERIATRICS, V1, P189, DOI [DOI 10.1111/J.1479-8301.2001.TB00047.X, 10.1111/j.1479-8301.2001.tb00047.x]; Winblad B, 2001, NEUROLOGY, V57, P489, DOI 10.1212/WNL.57.3.489; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Wolfe MS, 2002, NAT REV DRUG DISCOV, V1, P859, DOI 10.1038/nrd938; Zandi PP, 2004, ARCH NEUROL-CHICAGO, V61, P82, DOI 10.1001/archneur.61.1.82	87	995	1073	1	165	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					56	67		10.1056/NEJMra040223	http://dx.doi.org/10.1056/NEJMra040223			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229308				2022-12-28	WOS:000222352200010
J	Dujon, B; Sherman, D; Fischer, G; Durrens, P; Casaregola, S; Lafontaine, I; de Montigny, J; Marck, C; Neuveglise, C; Talla, E; Goffard, N; Frangeul, L; Aigle, M; Anthouard, V; Babour, A; Barbe, V; Barnay, S; Blanchin, S; Beckerich, JM; Beyne, E; Bleykasten, C; Boisrame, A; Boyer, J; Cattolico, L; Confanioleri, F; de Daruvar, A; Despons, L; Fabre, E; Fairhead, C; Ferry-Dumazet, H; Groppi, A; Hantraye, F; Hennequin, C; Jauniaux, N; Joyet, P; Kachouri, R; Kerrest, A; Koszul, R; Lemaire, M; Lesur, I; Ma, L; Muller, H; Nicaud, JM; Nikolski, M; Oztas, S; Ozier-Kalogeropoulos, O; Pellenz, S; Potier, S; Richard, GF; Straub, ML; Suleau, A; Swennen, D; Tekaia, F; Wesolowski-Louvel, M; Westhof, E; Wirth, B; Zeniou-Meyer, M; Zivanovic, I; Bolotin-Fukuhara, M; Thierry, A; Bouchier, C; Caudron, B; Scarpelli, C; Gaillardin, C; Weissenbach, J; Wincker, P; Souciet, JL				Dujon, B; Sherman, D; Fischer, G; Durrens, P; Casaregola, S; Lafontaine, I; de Montigny, J; Marck, C; Neuveglise, C; Talla, E; Goffard, N; Frangeul, L; Aigle, M; Anthouard, V; Babour, A; Barbe, V; Barnay, S; Blanchin, S; Beckerich, JM; Beyne, E; Bleykasten, C; Boisrame, A; Boyer, J; Cattolico, L; Confanioleri, F; de Daruvar, A; Despons, L; Fabre, E; Fairhead, C; Ferry-Dumazet, H; Groppi, A; Hantraye, F; Hennequin, C; Jauniaux, N; Joyet, P; Kachouri, R; Kerrest, A; Koszul, R; Lemaire, M; Lesur, I; Ma, L; Muller, H; Nicaud, JM; Nikolski, M; Oztas, S; Ozier-Kalogeropoulos, O; Pellenz, S; Potier, S; Richard, GF; Straub, ML; Suleau, A; Swennen, D; Tekaia, F; Wesolowski-Louvel, M; Westhof, E; Wirth, B; Zeniou-Meyer, M; Zivanovic, I; Bolotin-Fukuhara, M; Thierry, A; Bouchier, C; Caudron, B; Scarpelli, C; Gaillardin, C; Weissenbach, J; Wincker, P; Souciet, JL			Genome evolution in yeasts	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR EVOLUTION; INTERACTION NETWORK; GENE ORDER; SEQUENCE; DUPLICATION; ARABIDOPSIS; FEATURES; REGIONS; RICE	Identifying the mechanisms of eukaryotic genome evolution by comparative genomics is often complicated by the multiplicity of events that have taken place throughout the history of individual lineages, leaving only distorted and superimposed traces in the genome of each living organism. The hemiascomycete yeasts, with their compact genomes, similar lifestyle and distinct sexual and physiological properties, provide a unique opportunity to explore such mechanisms. We present here the complete, assembled genome sequences of four yeast species, selected to represent a broad evolutionary range within a single eukaryotic phylum, that after analysis proved to be molecularly as diverse as the entire phylum of chordates. A total of approximately 24,200 novel genes were identified, the translation products of which were classified together with Saccharomyces cerevisiae proteins into about 4,700 families, forming the basis for interspecific comparisons. Analysis of chromosome maps and genome redundancies reveal that the different yeast lineages have evolved through a marked interplay between several distinct molecular mechanisms, including tandem gene repeat formation, segmental duplication, a massive genome duplication and extensive gene loss.	Univ Strasbourg, Lab Dynam Evolut & Express Genomes Microorganisme, CNRS, FRE 2326, F-67000 Strasbourg, France; Univ Paris 06, CNRS, UFR 927, Unite Genet Mol Levures, F-75724 Paris 15, France; Univ Paris 06, CNRS, URA 2171, Unite Genet Mol Levures, F-75724 Paris 15, France; Pasteur Genopole Ile de France, Plate Forme Genom, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2171, Unite Genet Interact Macormol, F-75724 Paris 15, France; Inst Pasteur, Grp Logiciels & Banques Donnees, F-75724 Paris 15, France; LaBRI, CNRS, UMR 5800, F-33405 Talence, France; Univ Bordeaux 2, Ctr Bioinformat Bordeaux, F-33076 Bordeaux, France; Univ Bordeaux 2, CNRS, UMR 5095, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; INAPG, INRA, UMR 216, Collect Levures Interet Biotechnol, F-78850 Thiverval Grignon, France; INAPG, INRA, UMR 216, Lab Genet Mol & Cellulaire, F-78850 Thiverval Grignon, France; INAPG, CNRS, URA 1925, F-78850 Thiverval Grignon, France; CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CNRS, UMR 8030, F-91057 Evry, France; Univ Paris 11, Inst Genet Mol, CNRS, UMR 8621, F-91405 Orsay, France; CNRS, UPR 9002, IBMC, F-67000 Strasbourg, France; Univ Lyon 1, CNRS, UMR 5122, Lab Genet Levures, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National des Sciences Appliquees de Lyon - INSA Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dujon, B (corresponding author), Univ Strasbourg, Lab Dynam Evolut & Express Genomes Microorganisme, CNRS, FRE 2326, 28 Rue Goethe, F-67000 Strasbourg, France.	bdujon@pasteur.fr; souciet@gem.u-strasbg.fr	Briand-Suleau, Audrey/O-8620-2017; Hennequin, Christophe/AAF-2755-2021; Fischer, Gilles/G-6654-2016; Frangeul, Lionel/G-3617-2015; Dujon, Bernard A/F-4971-2010; Goffard, Nicolas/A-1759-2011; BRIAND-SULEAU, Audrey/A-9956-2019; Fischer, Gilles/Q-4603-2019; NICAUD, Jean-marc/ABA-9076-2021; Richard, Guy-Franck/ABB-9185-2021; Nicaud, jean marc/G-4204-2016; Fairhead, Cecile/D-9011-2014; Lafontaine, Ingrid/F-4588-2017; Tekaia, Fredj/H-4553-2012; Dujon, Bernard/AAL-8410-2021; Swennen, Dominique/T-4544-2017	Hennequin, Christophe/0000-0002-4528-927X; Fischer, Gilles/0000-0001-5732-2682; Nicaud, jean marc/0000-0002-6679-972X; Lafontaine, Ingrid/0000-0003-4544-8055; Dujon, Bernard/0000-0003-4661-3534; Babour, Anna/0000-0002-0212-3528; Koszul, Romain/0000-0002-3086-1173; Tekaia, Fredj/0000-0003-1934-2396; Bolotin-Fukuhara, Monique/0000-0002-5285-5006; Sherman, David James/0000-0002-2316-1005; Swennen, Dominique/0000-0002-9370-5717; Despons, Laurence/0000-0002-9414-7585; FABRE, Emmanuelle/0000-0002-0009-4604; Fairhead, Cecile/0000-0002-0456-0377; Groppi, Alexis/0000-0002-3341-8281; Neuveglise, Cecile/0000-0001-5017-7830; TALLA, Emmanuel/0000-0002-7775-8296; Richard, Guy-Franck/0000-0002-8233-3532; Lionel, Frangeul/0000-0002-0992-8775; Barnay-Verdier, Stephanie/0000-0002-4615-3059				AMANATIDES PG, 2000, SCIENCE, V287, P2185; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056; Bon E, 2003, NUCLEIC ACIDS RES, V31, P1121, DOI 10.1093/nar/gkg213; Brown CJ, 1998, MOL BIOL EVOL, V15, P931, DOI 10.1093/oxfordjournals.molbev.a026009; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Dietrich FS, 2004, SCIENCE, V304, P304, DOI 10.1126/science.1095781; Enright AJ, 2002, NUCLEIC ACIDS RES, V30, P1575, DOI 10.1093/nar/30.7.1575; Fischer G, 2001, GENOME RES, V11, P2009, DOI 10.1101/gr.212701; Frangeul L, 2004, BIOINFORMATICS, V20, P790, DOI 10.1093/bioinformatics/btg490; Fraser HB, 2002, SCIENCE, V296, P750, DOI 10.1126/science.1068696; Galagan JE, 2003, NATURE, V422, P859, DOI 10.1038/nature01554; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Koszul R, 2004, EMBO J, V23, P234, DOI 10.1038/sj.emboj.7600024; Kurtzman C.P., 1998, YEASTS TAXONOMIC STU; LALO D, 1993, CR ACAD SCI III-VIE, V316, P367; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Marck C, 2002, RNA, V8, P1189, DOI 10.1017/S1355838202022021; Sonnhammer ELL, 2002, TRENDS GENET, V18, P619, DOI 10.1016/S0168-9525(02)02793-2; Souciet JL, 2000, FEBS LETT, V487, P3, DOI 10.1016/S0014-5793(00)02272-9; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; STEPHEN A, 2002, SCIENCE, V296, P92; Vandepoele K, 2002, GENOME RES, V12, P1792, DOI 10.1101/gr.400202; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Wong S, 2002, P NATL ACAD SCI USA, V99, P9272, DOI 10.1073/pnas.142101099; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037	34	1216	4329	10	309	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					35	44		10.1038/nature02579	http://dx.doi.org/10.1038/nature02579			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229592				2022-12-28	WOS:000222356800036
J	Fawzi, WW; Msamanga, GI; Spiegelman, D; Wei, RL; Kapiga, S; Villamor, E; Mwakagile, D; Mugusi, F; Hertzmark, E; Essex, M; Hunter, DJ				Fawzi, WW; Msamanga, GI; Spiegelman, D; Wei, RL; Kapiga, S; Villamor, E; Mwakagile, D; Mugusi, F; Hertzmark, E; Essex, M; Hunter, DJ			A randomized trial of multivitamin supplements and HIV disease progression and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MICRONUTRIENT INTAKE; VITAMIN SUPPLEMENTS; HOMOSEXUAL MEN; VIRAL LOAD; TYPE-1; INFECTION; METAANALYSIS; TANZANIA; WOMEN; LIFE	Background: Results from observational studies suggest that micronutrient status is a determinant of the progression of human immunodeficiency virus (HIV) disease. Methods: We enrolled 1078 pregnant women infected with HIV in a double-blind, placebo-controlled trial in Dar es Salaam, Tanzania, to examine the effects of daily supplements of vitamin A (preformed vitamin A and beta carotene), multivitamins (vitamins B, C, and E), or both on progression of HIV disease, using survival models. The median follow-up with respect to survival was 71 months (interquartile range, 46 to 80). Results: Of 271 women who received multivitamins, 67 had progression to World Health Organization (WHO) stage 4 disease or died -- the primary outcome -- as compared with 83 of 267 women who received placebo (24.7 percent vs. 31.1 percent; relative risk, 0.71; 95 percent confidence interval, 0.51 to 0.98; P=0.04). This regimen was also associated with reductions in the relative risk of death related to the acquired immunodeficiency syndrome (0.73; 95 percent confidence interval, 0.51 to 1.04; P=0.09), progression to WHO stage 4 (0.50; 95 percent confidence interval, 0.28 to 0.90; P=0.02), or progression to stage 3 or higher (0.72; 95 percent confidence interval, 0.58 to 0.90; P=0.003). Multivitamins also resulted in significantly higher CD4+ and CD8+ cell counts and significantly lower viral loads. The effects of receiving vitamin A alone were smaller and for the most part not significantly different from those produced by placebo. Adding vitamin A to the multivitamin regimen reduced the benefit with regard to some of the end points examined. Conclusions: Multivitamin supplements delay the progression of HIV disease and provide an effective, low-cost means of delaying the initiation of antiretroviral therapy in HIV-infected women.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Muhimbili Univ Coll Hlth Sci, Dept Community Hlth, Dar Es Salaam, Tanzania; Muhimbili Univ Coll Hlth Sci, Dept Microbiol & Immunol, Dar Es Salaam, Tanzania; Muhimbili Univ Coll Hlth Sci, Dept Internal Med, Dar Es Salaam, Tanzania	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences; Muhimbili University of Health & Allied Sciences	Fawzi, WW (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	mina@hsph.harvard.edu		Kapiga, Saidi/0000-0003-1753-4060	PHS HHS [R01 32257] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABRAMS B, 1993, J ACQ IMMUN DEF SYND, V6, P949; Allard JP, 1998, AIDS, V12, P1653, DOI 10.1097/00002030-199813000-00013; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; BAUM MK, 1995, AIDS, V9, P1051, DOI 10.1097/00002030-199509000-00010; BENDICH A, 1988, NUTR IMMUNOLOGY, P101; BENDICH A, 1988, NUTRITION IMMUNOLOGY, P125; COX DR, 1972, J R STAT SOC B, V34, P187; Cunningham-Rundles S, 2001, CURR OPIN GASTROEN, V17, P171, DOI 10.1097/00001574-200103000-00013; Diggle PJ, 1995, J AM STAT ASSOC; Fawzi W, 2004, CLIN INFECT DIS, V38, P716, DOI 10.1086/381673; Fawzi W, 2003, CLIN INFECT DIS, V37, pS112, DOI 10.1086/375882; Fawzi WW, 1999, CONTROL CLIN TRIALS, V20, P75, DOI 10.1016/S0197-2456(98)00045-2; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Fawzi WW, 2002, AIDS, V16, P1935, DOI 10.1097/00002030-200209270-00011; Greenspan D, 2000, J ACQ IMMUN DEF SYND, V25, P44, DOI 10.1097/00126334-200009010-00006; Grimble RF, 1998, NUTRITION, V14, P634, DOI 10.1016/S0899-9007(98)00010-0; Jiamton S, 2003, AIDS, V17, P2461, DOI 10.1097/00002030-200311210-00008; Jordan R, 2002, BMJ-BRIT MED J, V324, P757, DOI 10.1136/bmj.324.7340.757; Kanter AS, 1999, J ACQ IMMUN DEF SYND, V21, P252, DOI 10.1097/00126334-199907010-00011; Lorenz KA, 2001, ANN INTERN MED, V134, P854, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00009; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Semba RD, 1999, BRIT J NUTR, V81, P181, DOI 10.1017/S0007114599000379; TANG AM, 1993, AM J EPIDEMIOL, V138, P937, DOI 10.1093/oxfordjournals.aje.a116814; Tang AM, 1997, AIDS, V11, P613, DOI 10.1097/00002030-199705000-00009; Tang AM, 1997, J NUTR, V127, P345, DOI 10.1093/jn/127.2.345; Tang AM, 1996, AM J EPIDEMIOL, V143, P1244, DOI 10.1093/oxfordjournals.aje.a008712; Thea DM, 1996, ANN INTERN MED, V124, P757, DOI 10.7326/0003-4819-124-8-199604150-00009; UNAIDS, 2003, AIDS EP UPD; WHO, 2003, TREAT 3 MILL 2005; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221	30	284	299	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					23	32		10.1056/NEJMoa040541	http://dx.doi.org/10.1056/NEJMoa040541			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229304	Green Published, Green Accepted			2022-12-28	WOS:000222352200006
J	Thompson, JK; Rainville, S; Pritchard, DE				Thompson, JK; Rainville, S; Pritchard, DE			Cyclotron frequency shifts arising from polarization forces	NATURE			English	Article							ELECTRIC-DIPOLE MOMENT; MASS MEASUREMENTS; ION; SPECTROSCOPY; POLARIZABILITY	The cyclotron frequency of a charged particle in a uniform magnetic field B is related to its mass m and charge q by the relationship omega(c) = qB/m. This simple relationship forms the basis for sensitive mass comparisons using ion cyclotron resonance mass spectroscopy, with applications ranging from the identification of biomolecules(1) and the study of chemical reaction rates(2) to determinations of the fine structure constant of atomic spectra(3). Here we report the observation of a deviation from the cyclotron frequency relationship for polarizable particles: in high-accuracy measurements of a single CO+ ion, a dipole induced in the orbiting ion shifts the measured cyclotron frequency. We use this cyclotron frequency shift to measure nondestructively the quantum state of the CO+ ion. The effect also provides a means to determine to a few per cent the body-frame dipole moment of CO+, thus establishing a method for measuring dipole moments of molecular ions for which few comparably accurate measurements exist(4-6). The general perturbation that we describe here affects the most precise mass comparisons attainable today(7,8), with applications including direct tests of Einstein's mass-energy relationship(9) and charge-parity-time reversal symmetry(10), and possibly the weighing of chemical bonds(7).	MIT, MIT Harvard Ctr Ultracold Atoms, Elect Res Lab, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Thompson, JK (corresponding author), MIT, MIT Harvard Ctr Ultracold Atoms, Elect Res Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	jkthomps@alum.mit.edu		Thompson, James/0000-0003-1160-5112; Rainville, Simon/0000-0001-7087-5943				Audi G, 2003, NUCL PHYS A, V729, P337, DOI 10.1016/j.nuclphysa.2003.11.003; Beier T, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.011603; Bergstrom I, 2002, NUCL INSTRUM METH A, V487, P618, DOI 10.1016/S0168-9002(01)02178-7; BHATIA AK, 1994, J PHYS B-AT MOL OPT, V27, P1299, DOI 10.1088/0953-4075/27/7/005; Bradley MP, 1999, PHYS REV LETT, V83, P4510, DOI 10.1103/PhysRevLett.83.4510; DIFILIPPO F, 1994, PHYS REV LETT, V73, P1481, DOI 10.1103/PhysRevLett.73.1481; DIXON TA, 1975, PHYS REV LETT, V34, P61, DOI 10.1103/PhysRevLett.34.61; Gabrielse G, 1999, PHYS REV LETT, V82, P3198, DOI 10.1103/PhysRevLett.82.3198; GREENE GL, 1991, PHYS REV D, V44, pR2216, DOI 10.1103/PhysRevD.44.R2216; HAVENITH M, 1990, J CHEM PHYS, V93, P8446, DOI 10.1063/1.459282; Heninger M, 2000, INT J MASS SPECTROM, V199, P267, DOI 10.1016/S1387-3806(00)00198-6; HUBER KP, 2003, CONSTANTS DIATOMIC M; JAGOD MF, 1992, J CHEM PHYS, V97, P7111, DOI 10.1063/1.463536; LAUGHLIN KB, 1987, PHYS REV LETT, V58, P996, DOI 10.1103/PhysRevLett.58.996; LINNARTZ H, 1992, J MOL SPECTROSC, V153, P710, DOI 10.1016/0022-2852(92)90505-I; Marshall AG, 2002, ANAL CHEM, V74, p253A; MARTIN PA, 1995, CHEM PHYS LETT, V232, P491, DOI 10.1016/0009-2614(94)01346-W; Rainville S, 2004, SCIENCE, V303, P334, DOI 10.1126/science.1092320; Townes C.H., 2013, MICROWAVE SPECTROSCO; Van Dyck RS, 2001, HYPERFINE INTERACT, V132, P163, DOI 10.1023/A:1011914310458; WEI HQ, 1995, PHYS REV LETT, V75, P2071, DOI 10.1103/PhysRevLett.75.2071	22	66	66	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					58	61		10.1038/nature02682	http://dx.doi.org/10.1038/nature02682			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229595				2022-12-28	WOS:000222356800040
J	Devenny, A; Wassall, H; Ninan, T; Omran, M; Khan, SD; Russell, G				Devenny, A; Wassall, H; Ninan, T; Omran, M; Khan, SD; Russell, G			Respiratory symptoms and atopy in children in Aberdeen: questionnaire studies of a defined school population repeated over 35 years	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCHOOLCHILDREN; INCREASE; ASTHMA		Royal Aberdeen Childrens Hosp, Dept Med Paediat, Aberdeen AB25 2ZG, Scotland; Birmingham Heartlands Hosp, Birmingham B9 5SS, W Midlands, England; Doncaster Royal Infirm, Dept Child Hlth, Doncaster DN2 5LT, England	University of Aberdeen; Heart of England NHS Foundation Trust; University of Birmingham	Russell, G (corresponding author), Royal Aberdeen Childrens Hosp, Dept Med Paediat, Aberdeen AB25 2ZG, Scotland.	libra@ifb.co.uk						Chang AB, 1998, ARCH DIS CHILD, V79, P6, DOI 10.1136/adc.79.1.6; HILL R, 1989, BRIT MED J, V299, P898, DOI 10.1136/bmj.299.6704.898; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810	5	102	106	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 28	2004	329	7464					489	490		10.1136/bmj.38139.666447.F7	http://dx.doi.org/10.1136/bmj.38139.666447.F7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	851KS	15217840	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223684600015
J	Ram, FSF; Wedzicha, JA; Wright, J; Greenstone, M				Ram, FSF; Wedzicha, JA; Wright, J; Greenstone, M			Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; EARLY DISCHARGE; CARE; SCHEME	Objectives To evaluate the efficacy of hospital at home schemes compared with inpatient care in patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). Design A systematic review of randomised controlled trials. Main outcome measure Mortality and readmission to hospital. Results Seven trials with 754 patients were included in the review. Hospital readmission and mortality were not significantly different when hospital at home schemes were compared with inpatient care (relative risk 0.89, 95% confidence interval 0.72 to 1.12, and 0.61, 0.36 to 1.05, respectively). However, compared with inpatient care, hospital at home schemes were associated with substantial cost savings as well as freeing up hospital inpatient beds. Conclusions Hospital at home schemes can be safely used to care for patients with acute exacerbations of COPD who would otherwise be admitted to hospital. Clinicians should consider this form of management, especially as there is increasing pressure for inpatient beds in the United Kingdom.	Natl Collaborating Ctr Women & Childrens Hlth, London NW1 4RG, England; St Bartholomews & Royal London Sch Med & Dent, London EC1A 7BE, England; Bradford Hosp NHS Trust, Dept Epidemiol & Publ Hlth Med, Bradford BD9 6RJ, W Yorkshire, England; Castle Hill Hosp, Med Chest Unit, Cottingham HU16 6JQ, E Yorkshire, England	University of London; Queen Mary University London; University of Hull	Ram, FSF (corresponding author), Natl Collaborating Ctr Women & Childrens Hlth, London NW1 4RG, England.	fsfram@yahoo.co.uk	Wright, John/H-1624-2012	Wright, John/0000-0001-9572-7293; Ram, Felix Simon Francis/0000-0002-5437-4089				Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Cotton MM, 2000, THORAX, V55, P902, DOI 10.1136/thorax.55.11.902; Davies L, 2000, BRIT MED J, V321, P1265, DOI 10.1136/bmj.321.7271.1265; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; Guest JF, 1999, DIS MANAG HEALTH OUT, V5, P93; HERANDEZ C, 2003, EUR RESPIR J, V21, P58; Hernandez C, 2003, EUR RESPIR J, V21, P58, DOI 10.1183/09031936.03.00015603; Hughes SL, 1997, HEALTH SERV RES, V32, P415; *IAIA, 2003, TRENDS COPD; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; JOHNSON MK, 2001, HLTH B, V59, P6; JOHNSON MK, 2001, HLTH B, V1, P59; KENDRICK S, 1994, INCREASE NUMBER EMER; *LAIA, 2003, TRENDS COPD; *LAIA, 2001, TRENDS EM HOSP ADM L; *NHS EX, 1996, BURD DIS DISC DOC; Nicholson C, 2001, Aust Health Rev, V24, P181; Ojoo JC, 2002, THORAX, V57, P167, DOI 10.1136/thorax.57.2.167; Pearson MG, 1997, THORAX, V52, pS1; Richards SH, 1998, BRIT MED J, V316, P1796, DOI 10.1136/bmj.316.7147.1796; *ROYAL COLL PHYS, 1981, J ROY COLL PHYS LOND, V15, P69; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; Shepperd S, 1998, BRIT MED J, V316, P1786, DOI 10.1136/bmj.316.7147.1786; Shepperd S, 1998, BRIT MED J, V316, P1791, DOI 10.1136/bmj.316.7147.1791; SHEPPERED S, 1998, BMJ-BRIT MED J, V16, P1786; Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907; Wilson A, 1999, BRIT MED J, V319, P1542, DOI 10.1136/bmj.319.7224.1542; WILSON WD, 2001, BIACORE J, V1, P15	28	115	116	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 7	2004	329	7461					315	318		10.1136/bmj.38159.650347.55	http://dx.doi.org/10.1136/bmj.38159.650347.55			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	846FF	15242868	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000223300300014
J	Pendry, JB; Martin-Moreno, L; Garcia-Vidal, FJ				Pendry, JB; Martin-Moreno, L; Garcia-Vidal, FJ			Mimicking surface plasmons with structured surfaces	SCIENCE			English	Article							EXTRAORDINARY OPTICAL-TRANSMISSION; SUBWAVELENGTH HOLE ARRAYS	Metals such as silver support surface plasmons: electromagnetic surface excitations localized near the surface that originate from the free electrons of the metal. Surface modes are also observed on highly conducting surfaces perforated by holes. We establish a close connection between the two, showing that electromagnetic waves in both materials are governed by an effective permittivity of the same plasma form. The size and spacing of holes can readily be controlled on all relevant length scales, which allows the creation of designer surface plasmons with almost arbitrary dispersion in frequency and in space, opening new vistas in surface plasmon optics.	Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, London SW7 2AZ, England; Univ Zaragoza, Inst Ciencia Mat, Dept Fis Mat Condensada, E-50009 Zaragoza, Spain; Univ Autonoma Madrid, Dept Fis Teor Mat Condensada, E-28049 Madrid, Spain	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Quimica y Materiales de Aragon (CEQMA); CSIC - Instituto de Ciencia de Materiales de Aragon (ICMA); Instituto de Ciencia de Materiales de Sevilla (ICMS-CSIC); University of Zaragoza; Autonomous University of Madrid	Pendry, JB (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Dept Phys, Prince Consort Rd, London SW7 2AZ, England.	j.pendry@imperial.ac.uk	Garcia-Vidal, Francisco J./B-8280-2011; Martin-Moreno, Luis/O-4161-2014	Garcia-Vidal, Francisco J./0000-0003-4354-0982; Martin-Moreno, Luis/0000-0001-9273-8165; Pendry, John/0000-0001-5145-5441				Barnes WL, 2003, NATURE, V424, P824, DOI 10.1038/nature01937; Bozhevolnyi SI, 2001, PHYS REV LETT, V86, P3008, DOI 10.1103/PhysRevLett.86.3008; DITLBACHER H, 2002, APPL PHYS LETT, V79, P3035; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; FLEISCHMANN M, 1974, CHEM PHYS LETT, V26, P163, DOI 10.1016/0009-2614(74)85388-1; Grbic A, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.117403; Martin-Moreno L, 2001, PHYS REV LETT, V86, P1114, DOI 10.1103/PhysRevLett.86.1114; Pendry JB, 1998, J PHYS-CONDENS MAT, V10, P4785, DOI 10.1088/0953-8984/10/22/007; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; RITCHIE RH, 1957, PHYS REV, V106, P874, DOI 10.1103/PhysRev.106.874; Weeber JC, 1999, PHYS REV B, V60, P9061, DOI 10.1103/PhysRevB.60.9061	11	2374	2434	63	803	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	2004	305	5685					847	848		10.1126/science.1098999	http://dx.doi.org/10.1126/science.1098999			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	843RT	15247438				2022-12-28	WOS:000223104900043
J	Svendsen, KB; Jensen, TS; Bach, FW				Svendsen, KB; Jensen, TS; Bach, FW			Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEUROPATHIC PAIN; HYPERALGESIA; EFFICACY; DELTA-9-TETRAHYDROCANNABINOL; THRESHOLDS; MANAGEMENT; SYMPTOMS; SAMPLE; MODEL	Objective To evaluate the effect of the oral synthetic delta-9-tetrahydrocannabiriol dronabinol on central neuropathic pain in patients with multiple sclerosis. Design Randomised double blind placebo crossover trial. Setting Outpatient clinic, University Hospital of Aarhus, Denmark. Participants 24 patients aged between 23 and 55 years with multiple sclerosis and central pain. Intervention Orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo for three weeks (15-21 days), separated by a three week washout period. Main outcome measure Median spontaneous pain intensity (numerical rating scale) in the last week of treatment. Results Median spontaneous pain intensity was significantly lower during dronabinol treatment than during placebo treatment (4.0 (25th to 75th centiles 2.3 to 6.0) v 5.0 (4.0 to 6.4), P = 0.02), and median relief score (numerical rating scale) was significantly higher (3.0 (0 to 6.7) v 0 (0 to 2.3), P = 0.035). The number needed to a-eat for 50% pain relief was 3.5 (95% confidence interval 1.9 to 24.8). On the SF-36 quality of life scale, the two items bodily pain and mental health indicated benefits from active compared with placebo. The number of patients with adverse events was higher during active treatment, especially in the first week of treatment. The functional ability of the multiple sclerosis patients did not change. Conclusions Dronabinol has a modest but clinically relevant analgesic effect on central pain in patients with multiple sclerosis. Adverse events, including dizziness, were more frequent with dronabinol than with placebo during the first week of treatment.	Aarhus Univ Hosp, Danish Pain Res Ctr, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Bach, FW (corresponding author), Aarhus Univ Hosp, Danish Pain Res Ctr, Noerrebrogade 44, DK-8000 Aarhus C, Denmark.	fbach@akh.aaa.dk	Bach, Flemming/AAG-8318-2021; Macedo, Ana/L-9912-2018; Jensen, Troels Staehelin/A-3418-2009	Bach, Flemming/0000-0002-2518-9335; Macedo, Ana/0000-0002-6978-8989; Jensen, Troels Staehelin/0000-0002-3487-6380				ARCHIBALD CJ, 1994, PAIN, V58, P89, DOI 10.1016/0304-3959(94)90188-0; Bjorner JB., 1997, LAEGEMIDDELINDUSTRIF; BRENNUM J, 1989, PAIN, V38, P211, DOI 10.1016/0304-3959(89)90240-6; Bridges D, 2001, BRIT J PHARMACOL, V133, P586, DOI 10.1038/sj.bjp.0704110; Buggy DJ, 2003, PAIN, V106, P169, DOI 10.1016/S0304-3959(03)00331-2; Campbell FA, 2001, BMJ-BRIT MED J, V323, P13, DOI 10.1136/bmj.323.7303.13; Clermont-Gnamien S, 2002, PRESSE MED, V31, P1840; CLIFFORD DB, 1984, ARCH NEUROL-CHICAGO, V41, P1270, DOI 10.1001/archneur.1984.04050230052017; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; COTTRUP H, 2003, PAIN, V103, P57; Farrar JT, 2000, PAIN, V88, P287, DOI 10.1016/S0304-3959(00)00339-0; Finnerup Nanna B, 2002, Expert Opin Pharmacother, V3, P1411, DOI 10.1517/14656566.3.10.1411; Fox A, 2001, PAIN, V92, P91, DOI 10.1016/S0304-3959(00)00474-7; Gimbel JS, 2003, NEUROLOGY, V60, P927, DOI 10.1212/01.WNL.0000057720.36503.2C; GOLDBERG JM, 1979, J NEUROL NEUROSUR PS, V42, P793, DOI 10.1136/jnnp.42.9.793; Hamann W, 1999, LANCET, V353, P560, DOI 10.1016/S0140-6736(98)05429-4; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; Holdsworth RJ, 1997, CLIN RADIOL, V52, P481, DOI 10.1016/S0009-9260(97)80019-0; Jaggar SI, 1998, PAIN, V76, P189, DOI 10.1016/S0304-3959(98)00041-4; JAIN AK, 1981, J CLIN PHARMACOL, V21, pS320, DOI 10.1002/j.1552-4604.1981.tb02610.x; JENSEN TS, 1991, ACTA NEUROL SCAND, V84, P326, DOI 10.1111/j.1600-0404.1991.tb04963.x; Johanek LM, 2001, PAIN, V93, P303, DOI 10.1016/S0304-3959(01)00336-0; Karst M, 2003, JAMA-J AM MED ASSOC, V290, P1757, DOI 10.1001/jama.290.13.1757; Kehl LJ, 2003, PAIN, V103, P175, DOI 10.1016/S0304-3959(02)00450-5; Killestein J, 2002, NEUROLOGY, V58, P1404, DOI 10.1212/WNL.58.9.1404; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; Martin WJ, 1999, BRAIN RES, V822, P237, DOI 10.1016/S0006-8993(98)01368-7; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; Merskey H., 1994, CLASSIFICATION CHRON, V2nd ed; MOULIN DE, 1988, NEUROLOGY, V38, P1830, DOI 10.1212/WNL.38.12.1830; Nackley AG, 2003, NEUROSCIENCE, V117, P659, DOI 10.1016/S0306-4522(02)00870-9; Notcutt W., 1997, PHARM SCI, V3, P551; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; NOYES R, 1975, J CLIN PHARMACOL, V15, P139, DOI 10.1002/j.1552-4604.1975.tb02348.x; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Rae-Grant AD, 1999, MULT SCLER, V5, P179, DOI 10.1191/135245899678846032; Richardson JD, 1998, PAIN, V75, P111, DOI 10.1016/S0304-3959(97)00213-3; Richardson JD, 1998, EUR J PHARMACOL, V345, P145, DOI 10.1016/S0014-2999(97)01621-X; Ross RA, 2001, NEUROPHARMACOLOGY, V40, P221, DOI 10.1016/S0028-3908(00)00135-0; Rukwied R, 2003, PAIN, V102, P283, DOI 10.1016/S0304-3959(02)00401-3; Senn S, 2002, CROSS OVER TRIALS CL; Sindrup SH, 1999, PAIN, V83, P389, DOI 10.1016/S0304-3959(99)00154-2; STENAGER E, 1991, ACTA NEUROL SCAND, V84, P197, DOI 10.1111/j.1600-0404.1991.tb04937.x; Svendsen KB, 2003, ARCH NEUROL-CHICAGO, V60, P1089, DOI 10.1001/archneur.60.8.1089; Vestergaard K, 2001, NEUROLOGY, V56, P184, DOI 10.1212/WNL.56.2.184; Wade WE, 2000, PHARMACOECONOMICS, V17, P1, DOI 10.2165/00019053-200017010-00001; Walker JM, 1999, LIFE SCI, V65, P665, DOI 10.1016/S0024-3205(99)00289-1; Zajicek J, 2003, LANCET, V362, P1517, DOI 10.1016/S0140-6736(03)14738-1; [No title captured]	50	307	327	3	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 31	2004	329	7460					253	257		10.1136/bmj.38149.566979.AE	http://dx.doi.org/10.1136/bmj.38149.566979.AE			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	844BY	15258006	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000223133300013
J	Jick, H; Kaye, JA; Jick, SS				Jick, H; Kaye, JA; Jick, SS			Antidepressants and the risk of suicidal behaviors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FLUOXETINE; DEPRESSION	Context The relation between use of antidepressants, especially selective serotonin reuptake inhibitors (SSRls), and suicidal ideation and behaviors has received considerable public attention recently. The use of such drugs among teenagers has been of particular concern. Objective To estimate the relative risks (RRs) of nonfatal suicidal behavior in patients starting treatment with 1 of 3 antidepressant drugs compared with patients starting treatment with dothiepin. Design and Setting Matched case-control study of patients treated in UK general practices using the UK General Practice Research Database for 1993-1999. Participants The base population included 159810 users of the 4 antidepressant drugs. Participants could have used only 1 of these antidepressants and had to have received at least 1 prescription for the study antidepressant within 90 days before their index date (the date of suicidal behavior or ideation for cases and the same date for matched controls). Main Outcome Measures Frequency of first-time exposure to amitriptyline, fluoxetine, paroxetine, and dothiepin of patients with a recorded diagnosis of first-time nonfatal suicidal behavior or suicide compared with comparable patients who did not exhibit suicidal behavior. Results After controlling forage, sex, calendar time, and time from first antidepressant prescription to the onset of suicidal behavior, the relative risks for newly diagnosed nonfatal suicidal behavior in 555 cases and 2062 controls were 0.83 (95% confidence interval, [Cl]0.61-1.13) for amitriptyline, 1.16 (95% Cl, 0.90-1.50) for fluoxetine, and 1.29 (95% Cl, 0.97-1.70) for paroxetine compared with those using dothiepin. The RR for suicidal behavior among patients first prescribed an antidepressant within 1 to 9 days before their index date was 4.07 (95% Cl, 2.89-5.74) compared with patients who were first prescribed an antidepressant 90 days or more before their index date. Time since first antidepressant prescription was not, however, a confounder of the relation between specific antidepressants and suicidal behavior since its relation to suicidal behavior was not materially different among users of the 4 study drugs. Similarly for fatal suicide, the RR among patients who were first prescribed an antidepressant within 1 to 9 days before their index date was 38.0 (95% Cl, 6.2-231) compared with those who were first prescribed an antidepressant 90 days or more before their index date. There were no significant associations between the use of a particular study antidepressant and the risk of suicide. Conclusions The risk of suicidal behavior after starting antidepressant treatment is similar among users of amitriptyline, fluoxetine, and paroxetine compared with the risk among users of dothiepin. The risk of suicidal behavior is increased in the first month after starting antidepressants, especially during the first 1 to 9 days. A possible small increase in risk (bordering statistical significance) among those starting the newest antidepressant, paroxetine, is of a magnitude that could readily be due to uncontrolled confounding by severity of depression. Based on limited information, we also conclude that there is no substantial difference in effect of the 4 drugs on people aged 10 to 19 years.	Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Jick, H (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA.	hjick@bu.edu	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285; Kaye, James A./0000-0002-9357-4227; Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992				BEASLEY CM, 1991, BMJ-BRIT MED J, V303, P685, DOI 10.1136/bmj.303.6804.685; *COMM SAF MED EXP, INT REP COMM SAF MED; Editorial, 2004, LANCET, V363, P1335; Hosmer DW, 2000, APPL LOGISTIC REGRES, DOI 10.1002/0471722146; JICK H, 1992, PHARMACOTHERAPY, V12, P451; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Keller MB, 2001, J AM ACAD CHILD PSY, V40, P762, DOI 10.1097/00004583-200107000-00010; *US FDA, 1991, PSYCH DRUGS ADV COMM; *US FDA, SUBJ WORS DEPR SUIC; *US FDA, FDA TALK PAP FDA ISS	11	415	434	8	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					338	343		10.1001/jama.292.3.338	http://dx.doi.org/10.1001/jama.292.3.338			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	838DL	15265848				2022-12-28	WOS:000222693500018
J	Sin, DD; Man, J; Sharpe, H; Gan, WQ; Man, SFP				Sin, DD; Man, J; Sharpe, H; Gan, WQ; Man, SFP			Pharmacological management to reduce exacerbations in adults with asthma - A systematic review and meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							QUALITY-OF-LIFE; FLUTICASONE PROPIONATE POWDER; CHURG-STRAUSS-SYNDROME; LOW-DOSE FLUTICASONE; POSTERIOR SUBCAPSULAR CATARACTS; OBSTRUCTIVE AIRWAY DISEASE; INHALED CORTICOSTEROID USE; MILD PERSISTENT ASTHMA; LONG-TERM TREATMENT; 800 MU-G	Context Over the last 2 decades, many new pharmacological agents have been introduced to reduce the growing morbidity associated with asthma, but the long-term effects of these agents on exacerbations are unclear. Objective To systematically review and quantitatively synthesize the long-term effects of inhaled corticosteroids, long-acting B-2 agonists, leukotriene pathway modifiers/receptor antagonists, and anti-IgE therapies on clinical outcomes and particular clinically relevant exacerbations in adult patients with chronic asthma. DataSources MEDLINE, EMBASE, and Cochrane databases were searched to identify relevant randomized controlled trials and systematic reviews published from January 1, 1980, to April 30, 2004. We identified additional studies by searching bibliographies of retrieved articles and contacting experts in the field. Study Selection and Data Extraction Included trials were double-blind, had follow-up periods of at least 3 months, and contained data on exacerbations and/or forced expiratory volume in 1 second. The effects of interventions were compared with placebo, short-acting beta(2) agonists, or each other. Data Synthesis Inhaled corticosteroids were most effective, reducing exacerbations by nearly 55% compared with placebo or short-acting beta(2) agonists (relative risk [RR], 0.46; 95% confidence interval [Cl], 0.34-0.62; P<.001 for heterogeneity). Compared with placebo, the use of long-acting 02 agonists was associated with 25% fewer exacerbations (RR, 0.75; 95% Cl, 0.64-0.88; P=.43 for heterogeneity); when added to inhaled corticosteroids, there was a 26% reduction above that achieved by steroid monotherapy (RR, 0.74; 95% Cl, 0.61-0.91; P=.07 for heterogeneity). Combination therapy was associated with fewer exacerbations than was increasing the dose of inhaled corticosteroids (RR, 0.86; 95% Cl, 0.76-0.96; P=.65 for heterogeneity). Compared with placebo, leukotriene modifiers/receptor antagonists reduced exacerbations by 41% (RR, 0.59; 95% Cl 0.49-0.71; P=.44 for heterogeneity) but were less effective than inhaled corticosteroids (RR, 1.72; 95% Cl, 1.28-2.31; P=.91 for heterogeneity). Use of monoclonal anti-IgE antibodies with concomitant inhaled corticosteroid therapy was associated with 45% fewer exacerbations (RR, 0.55; 95% Cl, 0.45-0.66; P=.15 for heterogeneity). Conclusions Inhaled corticosteroids are the single most effective therapy for adult patients with asthma. However, for those unable or unwilling to take corticosteroids, the use of leukotriene modifiers/receptor agonists appears reasonable. Long-acting beta(2) agonists may be added to corticosteroids for those who remain symptomatic despite low-dose steroid therapy. Anti-IgE therapy may be considered as adjunctive therapy for young adults with asthma who have clear evidence of allergies and elevated serum IgE levels.	Univ British Columbia, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Div Pulm, Vancouver, BC V5Z 1M9, Canada; Univ Alberta, Dept Med, Div Pulm, Edmonton, AB, Canada	University of British Columbia; University of British Columbia; University of Alberta	Sin, DD (corresponding author), St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, 1081 Burrard St, Vancouver, BC V6Z 1Y7, Canada.	dsin@mrl.ubc.ca	Sin, Don/AAC-2219-2021					ABUEKTEISH F, 1995, THORAX, V50, P674, DOI 10.1136/thx.50.6.674; Agertoft L, 1998, EUR RESPIR J, V12, P130, DOI 10.1183/09031936.98.12010130; Au DH, 2001, ANN MED, V33, P287, DOI 10.3109/07853890109002080; Banov CH, 2001, ANN ALLERG ASTHMA IM, V86, P627, DOI 10.1016/S1081-1206(10)62290-9; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2003, ANN INTERN MED, V139, P359, DOI 10.7326/0003-4819-139-5_Part_1-200309020-00012; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernstein DI, 1999, RESP MED, V93, P603, DOI 10.1016/S0954-6111(99)90099-9; Bisgaard H, 2000, PEDIATR PULM, V29, P221, DOI 10.1002/(SICI)1099-0496(200003)29:3<221::AID-PPUL11>3.3.CO;2-G; Bjermer L, 2003, BMJ-BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Boulet LP, 1997, J ALLERGY CLIN IMMUN, V99, P13, DOI 10.1016/S0091-6749(97)81039-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Bray GA, 1999, DIABETES CARE, V22, P623; Buhl R, 2003, RESP MED, V97, P323, DOI 10.1053/rmed.2002.1427; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse W, 2001, J FAM PRACTICE, V50, P595; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133, DOI 10.1136/adc.64.8.1133; Condemi JJ, 1997, J ALLERGY CLIN IMMUN, V100, P467, DOI 10.1016/S0091-6749(97)70137-4; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Curtin F, 2002, STAT MED, V21, P2131, DOI 10.1002/sim.1205; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Fish JE, 2000, J ALLERGY CLIN IMMUN, V106, P852, DOI 10.1067/mai.2000.110798; FitzGerald JM, 1999, J ALLERGY CLIN IMMUN, V103, P427, DOI 10.1016/S0091-6749(99)70467-7; Foresi A, 2000, CHEST, V117, P440, DOI 10.1378/chest.117.2.440; Galant SP, 1999, ANN ALLERG ASTHMA IM, V82, P273, DOI 10.1016/S1081-1206(10)62608-7; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; Garbe E, 1998, JAMA-J AM MED ASSOC, V280, P539, DOI 10.1001/jama.280.6.539; Gibson PG, 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001117], 10.1002/14651858.CD001117]; Green RL, 1999, LANCET, V353, P725, DOI 10.1016/S0140-6736(99)00565-6; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Gross G, 1999, CHEST, V115, P343, DOI 10.1378/chest.115.2.343; Guilpain P, 2002, RHEUMATOLOGY, V41, P535, DOI 10.1093/rheumatology/41.5.535; GUYATT GH, 1985, J CHRON DIS, V38, P353, DOI 10.1016/0021-9681(85)90081-5; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Haahtela T, 2002, ANN MED, V34, P74, DOI 10.1080/07853890252953455; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hubbard RB, 2002, AM J RESP CRIT CARE, V166, P1563, DOI 10.1164/rccm.200206-606OC; HUMMEL S, 1992, LANCET, V340, P1483, DOI 10.1016/0140-6736(92)92750-A; Ind PW, 2003, RESP MED, V97, P555, DOI 10.1053/rmed.2003.1483; ISHIHARA K, 1995, INTERNAL MED, V34, P77, DOI 10.2169/internalmedicine.34.77; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jenkins C, 2000, RESP MED, V94, P715, DOI 10.1053/rmed.2000.0875; Johnston SC, 2001, AM J EPIDEMIOL, V154, P276, DOI 10.1093/aje/154.3.276; Jones A, 2002, Cochrane Database Syst Rev, pCD003537, DOI 10.1002/14651858.CD003537; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kemp J, 1999, ANN ALLERG ASTHMA IM, V82, P463, DOI 10.1016/S1081-1206(10)62722-6; Kemp JP, 1998, J ALLERGY CLIN IMMUN, V101, P188, DOI 10.1016/S0091-6749(98)70383-5; Kips JC, 2002, EUR RESPIR J, V20, p47S, DOI 10.1183/09031936.02.00004702; Lalloo UG, 2003, CHEST, V123, P1480, DOI 10.1378/chest.123.5.1480; Lau E, 2003, AM J MED, V114, P142, DOI 10.1016/S0002-9343(02)01475-4; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lemaitre RN, 2002, AM J MED, V113, P711, DOI 10.1016/S0002-9343(02)01384-0; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Lim S, 2000, THORAX, V55, P837, DOI 10.1136/thorax.55.10.837; Liu MC, 1996, J ALLERGY CLIN IMMUN, V98, P859, DOI 10.1016/S0091-6749(96)80002-9; Lockey RF, 1999, CHEST, V115, P666, DOI 10.1378/chest.115.3.666; LUNDBACK B, 1993, THORAX, V48, P148, DOI 10.1136/thx.48.2.148; Malmstrom K, 1999, ANN INTERN MED, V130, P487, DOI 10.7326/0003-4819-130-6-199903160-00005; Malo JL, 1999, EUR RESPIR J, V13, P993, DOI 10.1183/09031936.99.13599399; Mann M, 2003, CHEST, V124, P70, DOI 10.1378/chest.124.1.70; Mannino D M, 1998, MMWR CDC Surveill Summ, V47, P1; Matz J, 2001, J ALLERGY CLIN IMMUN, V107, P783, DOI 10.1067/mai.2001.114709; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; Meltzer EO, 2002, MAYO CLIN PROC, V77, P437; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Mitchell P, 1999, OPHTHALMOLOGY, V106, P2301, DOI 10.1016/S0161-6420(99)90530-4; Murray JJ, 1999, ALLERGY ASTHMA PROC, V20, P173, DOI 10.2500/108854199778553028; *NAT CTR HLTH STAT, ASTHM PREV HLTH CAR; Nathan RA, 1998, J ALLERGY CLIN IMMUN, V102, P935, DOI 10.1016/S0091-6749(98)70331-8; Nathan RA, 2001, ANN ALLERG ASTHMA IM, V86, P203, DOI 10.1016/S1081-1206(10)62692-0; Nathan RA, 2000, CHEST, V118, P296, DOI 10.1378/chest.118.2.296; Nathan RA, 1999, ANN ALLERG ASTHMA IM, V82, P521, DOI 10.1016/S1081-1206(10)63159-6; Nelson H S, 2001, MedGenMed, V3, P3; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467, DOI 10.1164/ajrccm.152.5.7582278; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392, DOI 10.1164/ajrccm.164.8.2104102; Osterman K, 1997, EUR RESPIR J, V10, P2210, DOI 10.1183/09031936.97.10102210; Passalacqua G, 2000, ALLERGY, V55, P16, DOI 10.1034/j.1398-9995.2000.00370.x; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; POSTMA DS, 1988, EUR RESPIR J, V1, P483; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Ringdal N, 2003, RESP MED, V97, P234, DOI 10.1053/rmed.2003.1436; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; Rosenthal RR, 1999, CHEST, V116, P595, DOI 10.1378/chest.116.3.595; Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000195; Saetta M, 1989, Eur Respir J Suppl, V6, p477s; Salpeter SR, 2004, DRUG AGING, V21, P405, DOI 10.2165/00002512-200421060-00005; Sears MR, 1997, LANCET, V350, P1; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527, DOI 10.1164/ajrccm.161.2.9905091; Sheffer AL, 1996, J FAM PRACTICE, V42, P369; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; Sin DD, 2001, EUR RESPIR J, V17, P380, DOI 10.1183/09031936.01.17303800; Solans R, 2002, THORAX, V57, P183, DOI 10.1136/thorax.57.2.183; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; STEFFENSEN I, 1995, ALLERGY, V50, P657, DOI 10.1111/j.1398-9995.1995.tb02582.x; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Tashkin DP, 1999, J ALLERGY CLIN IMMUN, V103, P246, DOI 10.1016/S0091-6749(99)70498-7; TATTERSFIELD AE, 1992, CLIN EXP ALLERGY, V22, P600, DOI 10.1111/j.1365-2222.1992.tb00175.x; *US FDA, 2003 SAF AL SER SALM; van Noord JA, 1999, THORAX, V54, P207, DOI 10.1136/thx.54.3.207; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; vanderMolen T, 1997, THORAX, V52, P535, DOI 10.1136/thx.52.6.535; VAUGHAN TR, 1989, CHEST, V95, P558, DOI 10.1378/chest.95.3.558; Wallin A, 2003, J ALLERGY CLIN IMMUN, V112, P72, DOI 10.1067/mai.2003.1518; Wasserman SI, 1996, J ASTHMA, V33, P265, DOI 10.3109/02770909609055367; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wechsler ME, 2000, CHEST, V117, P708, DOI 10.1378/chest.117.3.708; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493, DOI 10.1067/mai.2000.109426; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481, DOI 10.1164/ajrccm.153.5.8630590; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	127	130	141	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2004	292	3					367	376		10.1001/jama.292.3.367	http://dx.doi.org/10.1001/jama.292.3.367			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	838DL	15265853	Bronze			2022-12-28	WOS:000222693500023
J	Degenholtz, HB; Rhee, Y; Arnold, RM				Degenholtz, HB; Rhee, Y; Arnold, RM			Brief communication: The relationship between having a living will and dying in place	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	54th Annual Scientific Meeting of the Gerontological-Society-of-America	NOV 14-18, 2001	Chicago, IL	Gerontol Soc Amer			SELF-DETERMINATION ACT; LIFE-SUSTAINING TREATMENT; NURSING-HOME POPULATION; ADVANCE DIRECTIVES; DEATH; CARE; END; DECISIONS; SAVINGS; PEOPLE	Background: Living wills, a type of advance directive, are promoted as a way for patients to document preferences for life-sustaining treatments should they become incompetent. Previous research, however, has found that these documents do not guide decision making in the hospital. Objective: To test the hypothesis that people with living wills are less likely to die in a hospital than in their residence before death. Design: secondary analysis of data from a nationally representative longitudinal study. Setting: Publicly available data from the Asset and Health Dynamics Among the Oldest Old (AHEAD) study. Patients: People older than 70 years of age living in the community in 1993 who died between 1993 and 1995. Measurements: Self-report and proxy informant interviews conducted in 1993 and 1995. Results: Having a living will was associated with lower probability of dying in a hospital for nursing home residents and people living in the community. For people living in the community, the probability of in-hospital death decreased from 0.65 (95% CI, 0.58 to 0.71) to 0.52 (CI, 0.42 to 0.62). For people living in nursing homes, the probability of in-hospital death decreased from 0.35 (CI, 0.23 to 0.49) to 0.13 (CI, 0.07 to 0.22). Limitations: Retrospective survey data do not contain detailed clinical information on whether the living will was consulted. Conclusion: Living wills are associated with dying in place rather than in a hospital. This implies that previous research examining only people who died in a hospital suffers from selection bias. During advance care planning, physicians should discuss patients' preferences for location of death.	Univ Pittsburgh, Ctr Bioeth & Hlth Law, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Degenholtz, HB (corresponding author), Univ Pittsburgh, Ctr Bioeth & Hlth Law, 3708 5th Ave,Suite 300, Pittsburgh, PA 15213 USA.	degen@pitt.edu		Degenholtz, Howard/0000-0003-1986-7360	NIA NIH HHS [1R0 3AG18811-01] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG018811] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altman DG, 1998, BRIT MED J, V317, P1318, DOI 10.1136/bmj.317.7168.1318; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; GORDON GH, 1992, HOSP PRACT, V27, P39; Hammes BJ, 1998, ARCH INTERN MED, V158, P383, DOI 10.1001/archinte.158.4.383; Herzog AR, 1997, J GERONTOL B-PSYCHOL, V52, P37, DOI 10.1093/geronb/52B.Special_Issue.37; HOLTZMAN J, 1994, J AM GERIATR SOC, V42, P275, DOI 10.1111/j.1532-5415.1994.tb01751.x; Jacobson JA, 1996, ARCH INTERN MED, V156, P1862, DOI 10.1001/archinte.156.16.1862; KELLOGG FR, 1995, J AM GERIATR SOC, V43, P113, DOI 10.1111/j.1532-5415.1995.tb06375.x; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; *NAT CTR HLTH STAT, 1998, NAT MORT FOLL SURV P; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Rodgers W, 1997, J GERONTOL B-PSYCHOL, V52, P21, DOI 10.1093/geronb/52B.Special_Issue.21; Sackett DL, 1996, EVIDENCE BASED MED, V1, P164, DOI DOI 10.1136/EBM.1996.1.164; SCHNEIDERMAN LJ, 1992, ANN INTERN MED, V117, P599, DOI 10.7326/0003-4819-117-7-599; Soldo BJ, 1997, J GERONTOL B-PSYCHOL, V52, P1, DOI 10.1093/geronb/52B.Special_Issue.1; STELTER KL, 1992, ARCH INTERN MED, V152, P954, DOI 10.1001/archinte.152.5.954; Teno J, 1997, J AM GERIATR SOC, V45, P513, DOI 10.1111/j.1532-5415.1997.tb05180.x; Teno J, 1997, J AM GERIATR SOC, V45, P500, DOI 10.1111/j.1532-5415.1997.tb05178.x; Teno JM, 1997, J AM GERIATR SOC, V45, P939, DOI 10.1111/j.1532-5415.1997.tb02963.x; TENO JM, 1994, J CLIN ETHIC, V5, P23; Teno JM, 1997, J AM GERIATR SOC, V45, P508, DOI 10.1111/j.1532-5415.1997.tb05179.x; Tolle SW, 1998, J AM GERIATR SOC, V46, P1097, DOI 10.1111/j.1532-5415.1998.tb06647.x; Tolle SW, 1999, ANN INTERN MED, V130, P681, DOI 10.7326/0003-4819-130-8-199904200-00015; *U MI I SOC RES, 1999, ASS HLTH DYN OLD OLD; WEEKS WB, 1994, ARCH INTERN MED, V154, P2077, DOI 10.1001/archinte.154.18.2077	30	84	87	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					113	117		10.7326/0003-4819-141-2-200407200-00009	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	839BL	15262666				2022-12-28	WOS:000222758200004
J	Donta, ST; Engel, CC; Collins, JF; Baseman, JB; Dever, LL; Taylor, T; Boardman, KD; Kazis, LE; Martin, SE; Horney, RA; Wiseman, AL; Kernodle, DS; Smith, RP; Baltch, AL; Handanos, C; Catto, B; Montalvo, L; Everson, M; Blackburn, W; Thakore, M; Brown, ST; Lutwick, L; Norwood, D; Bernstein, J; Bacheller, C; Ribner, B; Church, LWP; Wilson, KH; Guduru, P; Cooper, R; Lentino, J; Hamill, RJ; Gorin, AB; Gordan, V; Wagner, D; Robinson, C; DeJace, P; Greenfield, R; Beck, L; Bittner, M; Schumacher, HR; Silverblatt, F; Schmitt, J; Wong, E; Ryan, MAK; Figueroa, J; Nice, C; Feussner, JR				Donta, ST; Engel, CC; Collins, JF; Baseman, JB; Dever, LL; Taylor, T; Boardman, KD; Kazis, LE; Martin, SE; Horney, RA; Wiseman, AL; Kernodle, DS; Smith, RP; Baltch, AL; Handanos, C; Catto, B; Montalvo, L; Everson, M; Blackburn, W; Thakore, M; Brown, ST; Lutwick, L; Norwood, D; Bernstein, J; Bacheller, C; Ribner, B; Church, LWP; Wilson, KH; Guduru, P; Cooper, R; Lentino, J; Hamill, RJ; Gorin, AB; Gordan, V; Wagner, D; Robinson, C; DeJace, P; Greenfield, R; Beck, L; Bittner, M; Schumacher, HR; Silverblatt, F; Schmitt, J; Wong, E; Ryan, MAK; Figueroa, J; Nice, C; Feussner, JR		VA Cooperative 475 Grp	Benefits and harms of doxycycline treatment for Gulf War veterans' illnesses	ANNALS OF INTERNAL MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; CHRONIC-FATIGUE-SYNDROME; HEALTH-STATUS; MYCOPLASMA-GENITALIUM; DESERT-STORM; DISEASE; QUESTIONNAIRE; FERMENTANS; EXPOSURE	Background: It has been hypothesized that certain Mycoplasma species may cause Gulf War veterans' illnesses (GWVIs), chronic diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benefit from doxycycline treatment. Objective: To determine whether a 12-month course of doxycycline improves functional status in Gulf War veterans with GWVIs. Design: A randomized, double-blind, placebo-controlled clinical trial with 12 months of treatment and 6 additional months of follow-up. Setting: 26 U.S. Department of Veterans Affairs and 2 U.S. Department of Defense medical centers. Participants: 491 deployed Gulf War veterans with GWVIs and detectable Mycoplasma DNA in the blood. Intervention: Doxycycline, 200 mg, or matching placebo daily for 12 months. Measurements: The primary outcome was the proportion of participants who improved more than 7 units on the Physical Component Summary score of the Veterans Short Form-36 General Health Survey 12 months after randomization. Secondary outcomes were measures of pain, fatigue, and cognitive function and change in positivity for Mycoplasma species at 6, 12, and 18 months after randomization. Results: No statistically significant differences were found between the doxycycline and placebo groups for the primary outcome measure (43 of 238 participants [18.1%] vs. 42 of 243 participants [17.3%]; difference, 0.8 percentage point [95% CI, -6.5 to 8.0 percentage points]; P > 0.2) or for secondary outcome measures at 1 year. In addition, possible differences in outcomes at 3 and 6 months were not apparent at 9 or 18 months. Participants in the doxycycline group had a higher incidence of nausea and photosensitivity. Limitations: Adherence to treatment after 6 months was poor. Conclusion: Long-term treatment with doxycycline did not improve outcomes of GWVIs at 1 year.	Vet Affairs Med Ctr, Boston, MA USA; Vet Affairs Med Ctr, Milwaukee, WI USA; Vet Affairs Med Ctr, Montgomery, AL USA; Vet Affairs Med Ctr, Perry Point, MD USA; Vet Affairs Med Ctr, E Orange, NJ USA; Vet Affairs Med Ctr, White River Jct, VT USA; Vet Affairs Med Ctr, Albuquerque, NM USA; Vet Affairs Med Ctr, Bedford, MA USA; Vet Affairs Med Ctr, Nashville, TN 37212 USA; Vet Affairs Med Ctr, Albany, NY USA; Vet Affairs Med Ctr, Augusta, GA USA; Vet Affairs Med Ctr, Birmingham, AL USA; Vet Affairs Med Ctr, Bronx, NY USA; Vet Affairs Med Ctr, Brooklyn, NY USA; Vet Affairs Med Ctr, Dayton, OH USA; Vet Affairs Med Ctr, Charleston, SC 29403 USA; Vet Affairs Med Ctr, Durham, NC USA; Vet Affairs Med Ctr, Fargo, ND USA; Vet Affairs Med Ctr, Hines, IL USA; Vet Affairs Med Ctr, Houston, TX 77030 USA; Vet Affairs Med Ctr, Manchester, NH USA; Vet Affairs Med Ctr, New Orleans, LA USA; Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA; Vet Affairs Med Ctr, Omaha, NE USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Vet Affairs Med Ctr, Providence, RI USA; Vet Affairs Med Ctr, Richmond, VA USA; Vet Affairs Med Ctr, San Juan, PR USA; Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; Univ Texas, Hlth Sci Ctr, San Antonio, TX USA; USN, Hlth Res Ctr, San Diego, CA 92152 USA; Natl Cent Off, Dept Vet Affairs, Washington, DC USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center; Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Uniformed Services University of the Health Sciences - USA; University of Texas System; University of Texas Health San Antonio; United States Department of Defense; United States Navy; Naval Medical Research Center (NMRC); Naval Health Research Center (NHRC)	Collins, JF (corresponding author), Vet Affairs Maryland Healthcare Syst, Cooperat Studies Program, Coordinating Ctr 151E, POB 1010, Perry Point, MD 21902 USA.			Kazis, Lewis/0000-0003-1800-5849; Engel, Charles/0000-0002-9232-3389				AbouDonia MB, 1996, FUND APPL TOXICOL, V34, P201, DOI 10.1006/faat.1996.0190; Baseman JB, 2004, J CLIN MICROBIOL, V42, P203, DOI 10.1128/JCM.42.1.203-211.2004; BERNET C, 1989, J CLIN MICROBIOL, V27, P2492, DOI 10.1128/JCM.27.11.2492-2496.1989; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Collins JF, 2002, CONTROL CLIN TRIALS, V23, P333, DOI 10.1016/S0197-2456(02)00192-7; Donta ST, 1997, CLIN INFECT DIS, V25, pS52, DOI 10.1086/516171; GREEN GM, 1994, JAMA-J AM MED ASSOC, V272, P391, DOI 10.1001/jama.1994.03520050071033; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; HOLLANDER DH, 1995, MED HYPOTHESES, V45, P221, DOI 10.1016/0306-9877(95)90106-X; HYMAN ES, 1994, NEPHRON, V68, P314, DOI 10.1159/000188393; Institute of Medicine, 1996, HLTH CONS SERV PERS; JENSEN JS, 1991, J CLIN MICROBIOL, V29, P46, DOI 10.1128/JCM.29.1.46-50.1991; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; Kazis L. E., 2000, MED OUTCOMES TRUST M, V5, P13; Kazis L. E., 2000, MED OUTCOMES TRUST M, V5, P1; Kazis LE, 1999, AM J MED QUAL, V14, P28, DOI 10.1177/106286069901400105; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; Kazis LE, 1999, GLOBAL ENTREPRENEURS; Kazis LE., 2000, HLTH STATUS OUTCOMES; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P70; Komaroff AL, 1996, AM J MED, V101, P281, DOI 10.1016/S0002-9343(96)00174-X; LANDSKY D, 1992, MED CARE, V30, pMS57; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Nicolson GL, 1996, INT J OCCUP MED I T, V5, P69; Nicolson GL, 1996, INT J OCCUP MED I T, V5, P83; Nicolson GL, 1996, J OCCUP ENVIRON MED, V38, P14, DOI 10.1097/00043764-199601000-00003; NICOLSON GL, 1995, JAMA-J AM MED ASSOC, V273, P618, DOI 10.1001/jama.273.8.618; Nordstrom D, 1998, RHEUMATOL INT, V17, P175, DOI 10.1007/s002960050030; Santos MDF, 1996, J CHROMATOGR B, V682, P301, DOI 10.1016/0378-4347(96)00076-X; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; Tiersky LA, 2003, J NERV MENT DIS, V191, P324, DOI 10.1097/00005053-200305000-00008; Vojdani A, 1998, FEMS IMMUNOL MED MIC, V22, P355; WANG RYH, 1992, J CLIN MICROBIOL, V30, P245, DOI 10.1128/JCM.30.1.245-248.1992; Ware J., 2001, SF 36 PHYS MENTAL HL, P1994; Ware JE, 1996, JAMA-J AM MED ASSOC, V276, P1039, DOI 10.1001/jama.1996.03540130037027; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; 1995, JAMA, V274, P16	39	30	30	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	2004	141	2					85	94		10.7326/0003-4819-141-2-200407200-00006	http://dx.doi.org/10.7326/0003-4819-141-2-200407200-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839BL	15262663				2022-12-28	WOS:000222758200001
J	Kremsner, PG; Krishna, S				Kremsner, PG; Krishna, S			Antimalarial combinations	LANCET			English	Review							UNCOMPLICATED FALCIPARUM-MALARIA; RANDOMIZED CONTROLLED-TRIAL; PLASMODIUM-FALCIPARUM; SULFADOXINE-PYRIMETHAMINE; DRUG-RESISTANCE; ARTEMETHER-LUMEFANTRINE; ARTESUNATE-MEFLOQUINE; AFRICAN CHILDREN; DOUBLE-BLIND; DIHYDROARTEMISININ-PIPERAQUINE	Multidrug resistance has rendered monotherapy for malaria useless in most parts of the world, and has also compromised the usefulness of many of the available combination chemotherapies. New antimalarial regimens are, therefore, urgently needed. We review the various antimalarial combinations that can be used to treat otherwise drug-resistant disease, and discuss what defines an ideal antimalarial combination regimen.	Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; Univ London St Georges Hosp, Sch Med, Dept Cellular & Mol Med, London SW17 0RE, England	Eberhard Karls University of Tubingen; St Georges University London	Kremsner, PG (corresponding author), Univ Tubingen, Inst Trop Med, Dept Parasitol, Wilhelmstr 27, D-72074 Tubingen, Germany.	peter.kremsner@uni-tuebingen.de		Krishna, Sanjeev/0000-0003-0066-0634				Adjuik M, 2004, LANCET, V363, P9, DOI 10.1016/S0140-6736(03)15162-8; Adjuik M, 2002, LANCET, V359, P1365, DOI 10.1016/S0140-6736(02)08348-4; Alloueche A, 2004, LANCET, V363, P1843, DOI 10.1016/S0140-6736(04)16350-2; AMIES CR, 1930, B I MED RES FEDERATE, V2, P1; Angus BJ, 1997, BLOOD, V90, P2037, DOI 10.1182/blood.V90.5.2037; Athan E, 2001, S AFR MED J, V91, P592; BAIRD JK, 1991, AM J TROP MED HYG, V44, P547, DOI 10.4269/ajtmh.1991.44.547; Bakshi R, 2000, T ROY SOC TROP MED H, V94, P419, DOI 10.1016/S0035-9203(00)90126-3; BASHAM D, 1998, NATURE, V393, P537; Bojang KA, 1998, T ROY SOC TROP MED H, V92, P73, DOI 10.1016/S0035-9203(98)90962-2; Borrmann S, 2004, J INFECT DIS, V189, P901, DOI 10.1086/381785; Brandts CH, 1997, LANCET, V350, P704, DOI 10.1016/S0140-6736(97)02255-1; BUNNAG D, 1991, Southeast Asian Journal of Tropical Medicine and Public Health, V22, P534; CANFIELD CJ, 1995, EXP PARASITOL, V80, P373, DOI 10.1006/expr.1995.1049; CLYDE D. F., 1957, TRANS ROY SOC TROP MED AND HYG, V51, P505, DOI 10.1016/0035-9203(57)90039-1; COLLIGNON P, 1991, J INFECT DIS, V164, P222, DOI 10.1093/infdis/164.1.222; COWMAN AF, 1994, P NATL ACAD SCI USA, V91, P1143, DOI 10.1073/pnas.91.3.1143; D'Alessandro U, 2001, TROP MED INT HEALTH, V6, P845, DOI 10.1046/j.1365-3156.2001.00819.x; Denis MB, 2002, CLIN INFECT DIS, V35, P1469, DOI 10.1086/344647; DIVO AA, 1985, ANTIMICROB AGENTS CH, V27, P21, DOI 10.1128/AAC.27.1.21; Dorsey G, 2003, J INFECT DIS, V188, P1231, DOI 10.1086/378523; Dorsey G, 2002, LANCET, V360, P2031, DOI 10.1016/S0140-6736(02)12021-6; Eckstein-Ludwig U, 2003, NATURE, V424, P957, DOI 10.1038/nature01813; Edstein M. D., 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P216; Ezzet F, 2000, ANTIMICROB AGENTS CH, V44, P697, DOI 10.1128/AAC.44.3.697-704.2000; FICHERA ME, 1995, ANTIMICROB AGENTS CH, V39, P1530, DOI 10.1128/AAC.39.7.1530; Fleck SL, 1996, T ROY SOC TROP MED H, V90, P309, DOI 10.1016/S0035-9203(96)90266-7; FUNGLADDA W, 1998, B WHO S, V76, P57; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gasasira AF, 2003, AM J TROP MED HYG, V68, P127, DOI 10.4269/ajtmh.2003.68.127; Giao PT, 2001, AM J TROP MED HYG, V65, P690, DOI 10.4269/ajtmh.2001.65.690; Giao PT, 2001, CLIN PHARMACOKINET, V40, P343, DOI 10.2165/00003088-200140050-00003; HATTON CSR, 1986, LANCET, V1, P411; Hien TT, 2004, LANCET, V363, P18, DOI 10.1016/S0140-6736(03)15163-X; HIEN TT, 1993, LANCET, V341, P603; Honigsbaum Mark, 2001, FEVER TRAIL; Honrado ER, 1999, B WORLD HEALTH ORGAN, V77, P235; Hussein Z, 1997, CLIN PHARMACOL THER, V61, P518, DOI 10.1016/S0009-9236(97)90132-6; Jefford CW, 2001, CURR MED CHEM, V8, P1803, DOI 10.2174/0929867013371608; KREMSNER PG, 1995, ANTIMICROB AGENTS CH, V39, P1603, DOI 10.1128/AAC.39.7.1603; KREMSNER PG, 1988, J INFECT DIS, V158, P1368, DOI 10.1093/infdis/158.6.1368; KREMSNER PG, 1994, J INFECT DIS, V169, P467, DOI 10.1093/infdis/169.2.467; Kremsner PG, 2002, LANCET, V360, P1998, DOI 10.1016/S0140-6736(02)12032-0; KREMSNER PG, 1993, AM J TROP MED HYG, V49, P650, DOI 10.4269/ajtmh.1993.49.650; Krishna S, 1996, CLIN PHARMACOKINET, V30, P263, DOI 10.2165/00003088-199630040-00002; Kun JFJ, 1998, LANCET, V351, P265, DOI 10.1016/S0140-6736(05)78273-8; Lang T, 2003, LANCET INFECT DIS, V3, P162, DOI 10.1016/S1473-3099(03)00547-4; Laveran C.L.A., 1880, B MEM SOC MED HOP P, V17, P158; Lefevre G, 2001, AM J TROP MED HYG, V64, P247, DOI 10.4269/ajtmh.2001.64.247; Lell B, 1998, AM J TROP MED HYG, V58, P619, DOI 10.4269/ajtmh.1998.58.619; Lell B, 2003, ANTIMICROB AGENTS CH, V47, P735, DOI 10.1128/AAC.47.2.735-738.2003; Lell B, 2002, ANTIMICROB AGENTS CH, V46, P2315, DOI 10.1128/AAC.46.8.2315-2320.2002; Lell B, 1998, LANCET, V351, P709, DOI 10.1016/S0140-6736(97)09222-2; Lell B, 2001, CLIN INFECT DIS, V32, P838, DOI 10.1086/319217; Looareesuwan S, 1996, AM J TROP MED HYG, V54, P62, DOI 10.4269/ajtmh.1996.54.62; LUZZI GA, 1993, DRUG SAFETY, V8, P295, DOI 10.2165/00002018-199308040-00004; MARLARTHAN, 1995, T ROY SOC TROP MED H, V89, P307, DOI 10.1016/0035-9203(95)90556-1; Marquino W, 2003, AM J TROP MED HYG, V68, P608, DOI 10.4269/ajtmh.2003.68.608; Massougbodji A, 2002, T ROY SOC TROP MED H, V96, P655, DOI 10.1016/S0035-9203(02)90344-5; McGready R, 2001, T ROY SOC TROP MED H, V95, P651, DOI 10.1016/S0035-9203(01)90106-3; McIntosh HM, 1998, ANN TROP MED PARASIT, V92, P265, DOI 10.1080/00034989859825; Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7; METZGER W, 1995, ANTIMICROB AGENTS CH, V39, P245, DOI 10.1128/AAC.39.1.245; Missinou MA, 2002, LANCET, V360, P1941, DOI 10.1016/S0140-6736(02)11860-5; Mordmuller B, 1998, WIEN KLIN WOCHENSCHR, V110, P321; Nakazawa S, 2002, ANTIMICROB AGENTS CH, V46, P958, DOI 10.1128/AAC.46.4.958-965.2002; NOSTEN F, 1994, J INFECT DIS, V170, P971, DOI 10.1093/infdis/170.4.971; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; OLLIARO P, 2003, COCHRANE LIB; Pandey AV, 1999, J BIOL CHEM, V274, P19383, DOI 10.1074/jbc.274.27.19383; Parola P, 2001, ANTIMICROB AGENTS CH, V45, P932, DOI 10.1128/AAC.45.3.932-935.2001; PETERS W, 1982, BRIT MED BULL, V38, P187, DOI 10.1093/oxfordjournals.bmb.a071757; Peters W, 1999, ANN TROP MED PARASIT, V93, P569, DOI 10.1080/00034989958087; Peters W, 1987, CHEMOTHERAPY DRUG RE; Pirmohamed M, 2001, TRENDS PHARMACOL SCI, V22, P298, DOI 10.1016/S0165-6147(00)01717-X; Plowe CV, 2001, INFEC DIS S, P173; Price RN, 2001, DRUG RESIST UPDATE, V4, P187, DOI 10.1054/drup.2001.0195; PUKRITTAYAKAMEE S, 1994, T ROY SOC TROP MED H, V88, P324, DOI 10.1016/0035-9203(94)90102-3; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Rahman MR, 2001, T ROY SOC TROP MED H, V95, P661, DOI 10.1016/S0035-9203(01)90108-7; Rathod PK, 1997, P NATL ACAD SCI USA, V94, P9389, DOI 10.1073/pnas.94.17.9389; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Schellenberg D, 2002, AM J TROP MED HYG, V67, P17, DOI 10.4269/ajtmh.2002.67.17; Schellenberg D, 2001, LANCET, V357, P1471, DOI 10.1016/S0140-6736(00)04643-2; Schurmann D, 2001, J INFECTION, V42, P8, DOI 10.1053/jinf.2000.0772; Schwobel B, 2003, TROP MED INT HEALTH, V8, P19, DOI 10.1046/j.1365-3156.2003.00977.x; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; STEFFEN R, 1993, LANCET, V341, P1299, DOI 10.1016/0140-6736(93)90814-W; Stepniewska K, 2001, T ROY SOC TROP MED H, V95, P637, DOI 10.1016/S0035-9203(01)90104-X; Targett G, 2001, J INFECT DIS, V183, P1254, DOI 10.1086/319689; TERKUILE F, 1993, EXP PARASITOL, V76, P85, DOI 10.1006/expr.1993.1010; Toovey S, 2004, T ROY SOC TROP MED H, V98, P261, DOI 10.1016/j.trstmh.2003.11.001; Udomsangpetch R, 1996, J INFECT DIS, V173, P691, DOI 10.1093/infdis/173.3.691; Vaidya AB, 2001, INFEC DIS S, P203; van Vugt M, 2000, T ROY SOC TROP MED H, V94, P545, DOI 10.1016/S0035-9203(00)90082-8; van Vugt M, 1998, ANTIMICROB AGENTS CH, V42, P135, DOI 10.1128/AAC.42.1.135; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; vonSeidlein L, 1997, J INFECT DIS, V176, P1113, DOI 10.1086/516524; VONSEIDLEIN L, 2003, T R SOC TROP MED HYG, V97, P129; Warhurst DC, 2001, NEW ENGL J MED, V344, P299, DOI 10.1056/NEJM200101253440411; WATKINS WM, 1993, AM J TROP MED HYG, V49, P106, DOI 10.4269/ajtmh.1993.49.106; WERNSDORFER WH, 1994, ACTA TROP, V56, P143, DOI 10.1016/0001-706X(94)90060-4; White NJ, 1999, CLIN PHARMACOKINET, V37, P105, DOI 10.2165/00003088-199937020-00002; WHITE NJ, 1989, T ROY SOC TROP MED H, V83, P767, DOI 10.1016/0035-9203(89)90322-2; White NJ, 1997, ANTIMICROB AGENTS CH, V41, P1413, DOI 10.1128/AAC.41.7.1413; White NJ, 1998, ANN TROP MED PARASIT, V92, P449, DOI 10.1080/00034989859429; White NJ, 2002, TRENDS PARASITOL, V18, P458, DOI 10.1016/S1471-4922(02)02373-5; Wilairatana P, 1997, ANN TROP MED PARASIT, V91, P125, DOI 10.1080/00034989761454; Yuvaniyama J, 2003, NAT STRUCT BIOL, V10, P357, DOI 10.1038/nsb921	113	206	208	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	2004	364	9430					285	294		10.1016/S0140-6736(04)16680-4	http://dx.doi.org/10.1016/S0140-6736(04)16680-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	839KV	15262108				2022-12-28	WOS:000222784900033
J	Jones, JC; Myerscough, MR; Graham, S; Oldroyd, BP				Jones, JC; Myerscough, MR; Graham, S; Oldroyd, BP			Honey bee nest thermoregulation: Diversity promotes stability	SCIENCE			English	Article							DIVISION-OF-LABOR; APIS-MELLIFERA; SELF-ORGANIZATION; EVOLUTION; VARIABILITY; MODELS	A honey bee colony is characterized by high genetic diversity among its workers, generated by high levels of multiple mating by its queen. Few clear benefits of this genetic diversity are known. Here we show that brood nest temperatures in genetically diverse colonies (i.e., those sired by several males) tend to be more stable than in genetically uniform ones (i.e., those sired by one male). One reason this increased stability arises is because genetically determined diversity in workers' temperature response thresholds modulates the hive-ventilating behavior of individual workers, preventing excessive colony-level responses to temperature fluctuations.	Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney	Jones, JC (corresponding author), Univ Sydney, Sch Biol Sci, Macleay Bldg A12, Sydney, NSW 2006, Australia.	jjones@bio.usyd.edu.au	Graham, Sonia/G-4399-2012; Oldroyd, Benjamin/A-4800-2008; Jones, Julia/P-2339-2016; Graham, Sonia/B-1544-2008	Graham, Sonia/0000-0003-4195-4559; Oldroyd, Benjamin/0000-0001-6831-3677; Jones, Julia/0000-0002-3557-1941; Myerscough, Mary/0000-0002-4993-765X				Beshers SN, 2001, ANNU REV ENTOMOL, V46, P413, DOI 10.1146/annurev.ento.46.1.413; Beye M, 2003, CELL, V114, P419, DOI 10.1016/S0092-8674(03)00606-8; Bonabeau E, 1996, P ROY SOC B-BIOL SCI, V263, P1565, DOI 10.1098/rspb.1996.0229; Bonabeau E, 1997, TRENDS ECOL EVOL, V12, P188, DOI 10.1016/S0169-5347(97)01048-3; CALDERONE NW, 1988, BEHAV ECOL SOCIOBIOL, V22, P17, DOI 10.1007/BF00395694; CALDERONE NW, 1991, AM NAT, V138, P69, DOI 10.1086/285205; ESTOUP A, 1994, P ROY SOC B-BIOL SCI, V258, P1, DOI 10.1098/rspb.1994.0133; ESTOUP A, 1995, GENETICS, V140, P679; Fewell JH, 1999, EVOL ECOL RES, V1, P537; Fewell JH, 2000, BEHAV ECOL SOCIOBIOL, V48, P173, DOI 10.1007/s002650000183; FEWELL JH, 1993, EXPERIENTIA, V49, P1106, DOI 10.1007/BF01929923; Fisher, 1958, GENETICAL THEORY NAT; Franck P, 1999, INSECT MOL BIOL, V8, P419, DOI 10.1046/j.1365-2583.1999.83131.x; Gordon DM, 1996, NATURE, V380, P121, DOI 10.1038/380121a0; Harbo J.R., 1986, P361; Hartl D.L., 1997, PRINCIPLES POPULATIO, V3rd ed.; Jassim O, 2000, J INSECT PHYSIOL, V46, P243, DOI 10.1016/S0022-1910(99)00176-6; KRONENBERG F, 1982, J COMP PHYSIOL, V148, P65, DOI 10.1007/BF00688889; Laidlaw HH., 1997, QUEEN REARING BEE BR; Lindauer M., 1967, COMMUNICATION SOCIAL; Myerscough MR, 2004, INSECT SOC, V51, P146, DOI 10.1007/s00040-003-0713-1; PAGE RE, 1989, WESTV STUD, P15; PAGE RE, 1980, GENETICS, V96, P263; Page RE, 1998, APIDOLOGIE, V29, P171, DOI 10.1051/apido:19980110; Palmer KA, 2000, APIDOLOGIE, V31, P235, DOI 10.1051/apido:2000119; Reeve HK, 1999, MG BEH ECOL, P3; ROBINSON GE, 1989, WESTV STUD, P61; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; Robinson GE, 1998, APIDOLOGIE, V29, P159, DOI 10.1051/apido:19980109; Seeley T., 1981, P159; Seeley TD, 1985, HONEYBEE ECOLOGY STU; Sokal R.R., 2012, BIOMETRY; Sullivan JP, 2000, HORM BEHAV, V37, P1, DOI 10.1006/hbeh.1999.1552; Theraulaz G, 1998, P ROY SOC B-BIOL SCI, V265, P327, DOI 10.1098/rspb.1998.0299; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018; Weidenmuller A, 2002, ANIM BEHAV, V63, P1065, DOI 10.1006/anbe.2002.3020	36	285	298	2	163	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	2004	305	5682					402	404		10.1126/science.1096340	http://dx.doi.org/10.1126/science.1096340			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	837TE	15218093				2022-12-28	WOS:000222662400040
J	Ohlenschlaeger, T; Garred, P; Madsen, HO; Jacobsen, S				Ohlenschlaeger, T; Garred, P; Madsen, HO; Jacobsen, S			Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-CARDIOLIPIN ANTIBODIES; ACCELERATED ATHEROSCLEROSIS; CHLAMYDIA-PNEUMONIAE; DISEASE; ASSOCIATION; GENE; POLYMORPHISMS; PROTEIN; SUSCEPTIBILITY; INFECTIONS	BACKGROUND: Cardiovascular disease is an important complication in patients with systemic lupus erythematosus (SLE). Variant alleles of the mannose-binding lectin gene are associated with SLE as well as with severe atherosclerosis. We determined whether mannose-binding lectin variant alleles were associated with an increased risk of arterial thrombosis among patients with SLE. METHODS: Mannose-binding lectin alleles were genotyped by means of a polymerase-chain-reaction assay in 91 Danish patients with SLE. Arterial and venous thromboses occurring after the diagnosis of SLE were assessed in a prospective study. Arterial and venous thromboses were confirmed by appropriate diagnostic methods. RESULTS: Fifty-four patients had no mannose-binding lectin variant alleles (A/A genotype), 30 were heterozygous (A/O genotype), and 7 were homozygous (O/O genotype). During a median follow-up of 9.1 years, arterial thromboses (cerebral or myocardial infarction or leg embolus) developed in 6 of the 7 patients with the O/O genotype, as compared with 18 of the 84 patients with the other two genotypes (hazard ratio, 5.8; 95 percent confidence interval, 2.2 to 15.2; overall incidence, 26 percent). After correction for other known risk factors, the hazard ratio was 7.0 (95 percent confidence interval, 1.9 to 25.4). Venous thromboses, which occurred in 14 patients, were statistically unrelated to the mannose-binding lectin genotype. CONCLUSIONS: Among patients with SLE, homozygosity for mannose-binding lectin variant alleles is associated with an increased risk of arterial thrombosis. The risk of venous thrombosis is not increased, indicating that mannose-binding lectin has a specific role in providing protection against arterial thrombosis.	Univ Copenhagen, Rigshosp, Dept Clin Immunol, Tissue Typing Lab, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Dept Rheumatol, DK-2100 Copenhagen, Denmark; Hvidovre Univ Hosp, Dept Rheumatol, Copenhagen, Denmark; Bispebjerg Hosp, Dept Rheumatol, DK-2400 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Jacobsen, S (corresponding author), Rigshosp, Dept Rheumatol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	sj@dadlnet.dk	Jacobsen, Søren/T-2491-2019; Madsen, Hans O/Q-2035-2015	Jacobsen, Søren/0000-0002-5654-4993; Madsen, Hans O/0000-0001-5551-4787; Garred, Peter/0000-0002-2876-8586				Asanuma Y, 2003, NEW ENGL J MED, V349, P2407, DOI 10.1056/NEJMoa035611; BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185; Cervera R, 2003, MEDICINE, V82, P299, DOI 10.1097/01.md.0000091181.93122.55; Collard CD, 2000, AM J PATHOL, V156, P1549, DOI 10.1016/S0002-9440(10)65026-2; Danesh J, 2002, EUR HEART J, V23, P371, DOI 10.1053/euhj.2001.2801; Esdaile JM, 2001, ARTHRITIS RHEUM, V44, P2331, DOI 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I; Garred P, 2003, J INFECT DIS, V188, P1394, DOI 10.1086/379044; Garred P, 2001, GENES IMMUN, V2, P442, DOI 10.1038/sj.gene.6363804; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Garred P, 1996, COLLECTINS INNATE IM, P139; Hegele RA, 2000, J INVEST MED, V48, P198; Jacobsen S, 2002, J RHEUMATOL, V29, P2148; Jacobsen S, 2001, J RHEUMATOL, V28, P935; Jacobsen S, 1998, CLIN RHEUMATOL, V17, P478, DOI 10.1007/BF01451283; Kao AH, 2003, CURR OPIN RHEUMATOL, V15, P519, DOI 10.1097/00002281-200309000-00001; Koch A, 2001, JAMA-J AM MED ASSOC, V285, P1316, DOI 10.1001/jama.285.10.1316; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; LIPSCOMBE RJ, 1993, HUM MOL GENET, V2, P342, DOI 10.1093/hmg/2.3.342; LOIZOU S, 1985, CLIN EXP IMMUNOL, V62, P738; MADSEN HO, 1995, J IMMUNOL, V155, P3013; MADSEN HO, 1994, IMMUNOGENETICS, V40, P37, DOI 10.1007/BF00163962; Madsen HO, 1998, LANCET, V352, P959, DOI 10.1016/S0140-6736(05)61513-9; Manger K, 2003, ANN RHEUM DIS, V62, P846, DOI 10.1136/ard.62.9.846; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MOURITSEN S, 1989, CLIN EXP IMMUNOL, V76, P178; Nauta AJ, 2003, EUR J IMMUNOL, V33, P2853, DOI 10.1002/eji.200323888; Roman MJ, 2003, NEW ENGL J MED, V349, P2399, DOI 10.1056/NEJMoa035471; Rugonfalvi-Kiss S, 2002, CIRCULATION, V106, P1071, DOI 10.1161/01.CIR.0000027137.96791.6A; SUMIYA M, 1991, LANCET, V337, P1569, DOI 10.1016/0140-6736(91)93263-9; Svenungsson E, 2003, ARTHRITIS RHEUM-US, V48, P2533, DOI 10.1002/art.11264; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Thorburn CM, 2003, ARTHRITIS RHEUM, V48, P2519, DOI 10.1002/art.11241; Turner M W, 2000, Rev Immunogenet, V2, P305; Vlachoyiannopoulos PG, 2003, RHEUMATOLOGY, V42, P645, DOI 10.1093/rheumatology/keg182; Voss A, 2001, LUPUS, V10, P533, DOI 10.1191/096120301701549651; Ward MM, 1999, ARTHRITIS RHEUM, V42, P338, DOI 10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U	38	172	175	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	2004	351	3					260	267		10.1056/NEJMoa033122	http://dx.doi.org/10.1056/NEJMoa033122			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837KA	15254284	Bronze			2022-12-28	WOS:000222627200010
J	Le, CT				Le, CT			Baby Mo - A letter from Vietnam	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												Chinhlego2@aol.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	2004	292	2					153	154		10.1001/jama.292.2.153	http://dx.doi.org/10.1001/jama.292.2.153			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	836TS	15249554				2022-12-28	WOS:000222579300001
J	Joannides, A; Gaughwin, P; Schwiening, C; Majed, H; Sterling, J; Compston, A; Chandran, S				Joannides, A; Gaughwin, P; Schwiening, C; Majed, H; Sterling, J; Compston, A; Chandran, S			Efficient generation of neural precursors from adult human skin: astrocytes promote neurogenesis from skin-derived stem cells	LANCET			English	Article							PROGENITOR CELLS; NEURONS; MARROW; DIFFERENTIATE; HIPPOCAMPUS; PHENOTYPE; INDUCTION; LINEAGES; SYSTEM; FUSION	Background Neural stem cells are a potential source of cells for drug screening or cell-based treatments for neurodegenerative diseases. However, ethical and practical considerations limit the availability of neural stem cells derived from human embryonic tissue. An alternative source of human neural stem cells is needed; a source that is readily accessible, easily expanded, and reliably induced to a neural fate. Methods Dermis isolated from biopsy samples of adult human skin was cultured and expanded in the presence of the mitogens epidermal growth factor (EGF) and fibroblast growth factor 2 (FGF 2), and then by serum. We used immunocytochemical techniques, clonal analysis, and physiological characterisation to assess neural differentiation after the treatment of expanded cells with novel induction media. Findings initial characterisation of skin samples confirmed the absence of nestin, a neural precursor marker. Sequential culture in EGF and FGF 2 followed by adherent expansion in serum, and re-exposure to mitogens in substrate-free conditions resulted in large numbers of nestin-positive/musashi-positive neural precursors. Subsequent exposure of these precursors to hippocampal-astrocyte-derived signals resulted in cells of neuronal morphology that had stable expression of markers of neuronal differentiation (neurofilament, P tubulin). We also show the presence of voltage-dependent calcium transients, and demonstrate monoclonal neural potential. Interpretation We describe the isolation and characterisation of cells derived from adult human dermis that can be expanded for extended periods of time in vitro, while retaining inducible neural potential. The generation of almost limitless numbers of neural precursors from a readily accessible autologous adult human source provides a platform for further experimental studies and has potential therapeutic implications.	Univ Cambridge, Cambridge Ctr Brain Repair, Dept Clin Neurosci, Cambridge CP2 2PY, England; Univ Cambridge, Dept Physiol, Cambridge CP2 2PY, England; Univ Cambridge, Dept Med, Cambridge CP2 2PY, England; Addenbrookes Hosp, Cambridge, England	University of Cambridge; University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Chandran, S (corresponding author), Univ Cambridge, Cambridge Ctr Brain Repair, Dept Clin Neurosci, Forvie Site,Robinson Way, Cambridge CP2 2PY, England.	sc222@cam.ac.uk						CHANDRAN S, IN PRESS GLIA; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Jahoda CAB, 2003, EXP DERMATOL, V12, P849, DOI 10.1111/j.0906-6705.2003.00161.x; Jiang YH, 2003, P NATL ACAD SCI USA, V100, P11854, DOI 10.1073/pnas.1834196100; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Joannides A, 2003, J HEMATOTH STEM CELL, V12, P681, DOI 10.1089/15258160360732704; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Lako M, 2002, J CELL SCI, V115, P3967, DOI 10.1242/jcs.00060; Liang LC, 2002, STEM CELLS, V20, P21, DOI 10.1634/stemcells.20-1-21; Martin-Rendon E, 2003, BRIT J HAEMATOL, V122, P877, DOI 10.1046/j.1365-2141.2003.04576.x; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; SCHWIENING CJ, 1994, J PHYSIOL-LONDON, V475, P59, DOI 10.1113/jphysiol.1994.sp020049; Song HJ, 2002, NAT NEUROSCI, V5, P438, DOI 10.1038/nn844; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Toma JG, 2001, NAT CELL BIOL, V3, P778, DOI 10.1038/ncb0901-778; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657; Wagner J, 1999, NAT BIOTECHNOL, V17, P653, DOI 10.1038/10862; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729	23	156	175	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					172	178		10.1016/S0140-6736(04)16630-0	http://dx.doi.org/10.1016/S0140-6736(04)16630-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246730				2022-12-28	WOS:000222612200028
J	Mathur, A; Martin, JF				Mathur, A; Martin, JF			Stem cells and repair of the heart	LANCET			English	Review							BONE-MARROW-CELLS; SKELETAL MYOBLAST TRANSPLANTATION; ENHANCES COLLATERAL PERFUSION; COLONY-STIMULATING FACTOR; MYOCARDIAL-INFARCTION; STROMAL CELLS; REGIONAL FUNCTION; PROGENITOR CELLS; CARDIAC-FUNCTION; INTRAMYOCARDIAL INJECTION	Stem-cell therapy provides the prospect of an exciting and powerful treatment to repair the heart. Although research has been undertaken in animals to analyse the safety and efficacy of this new approach, results have been inconclusive. The mechanism by which stem cells could improve cardiac function remains unclear. We describe the background to the concept of natural repair and the work that has been done to establish the role of stem cells in cardiac repair. Controversies have arisen in interpretation of experimental data. The important issues surrounding the application of stem-cell therapy to man are discussed critically. We discuss the future of this pioneering work in the setting of growing concerns about clinical studies in man without understanding the biological mechanisms involved, with the difficulties in funding this type of research.	Barts & London, Dept Clin Pharmacol, London EC1M 6BQ, England; UCL, Dept Med, British Heart Fdn Labs, London WC1E 6JJ, England; Univ London, Queen Mary, London, England	University of London; Queen Mary University London; University of London; University College London; University of London	Mathur, A (corresponding author), Barts & London, Dept Clin Pharmacol, Charterhouse Sq, London EC1M 6BQ, England.	john.martin@ucl.ac.uk						Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Anderson DJ, 2001, NAT MED, V7, P393, DOI 10.1038/86439; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Auchincloss H, 2002, NAT BIOTECHNOL, V20, P665, DOI 10.1038/nbt0702-665; Aviles FF, 2004, REV ESP CARDIOL, V57, P201, DOI 10.1016/S1885-5857(06)60137-0; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Behfar A, 2002, FASEB J, V16, P1558, DOI 10.1096/fj.02-0072com; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Chien KR, 2002, CELL, V110, P153, DOI 10.1016/S0092-8674(02)00834-6; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Ciulla MM, 2003, HAEMATOLOGICA, V88, P614; D'Jamoos C A, 1998, Wound Repair Regen, V6, P388, DOI 10.1046/j.1460-9568.1998.60415.x; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; DOUGLAS BS, 1972, AUST PAEDIATR J, V8, P86; Dowell JD, 2003, CARDIOVASC RES, V58, P336, DOI 10.1016/S0008-6363(03)00254-2; EGUCHI G, 1973, J EMBRYOL EXP MORPH, V30, P63; Eisenberg LM, 2004, ANAT REC PART A, V276A, P103, DOI 10.1002/ar.a.10137; Eschenhagen T, 2002, TRANSPL IMMUNOL, V9, P315, DOI 10.1016/S0966-3274(02)00011-4; Fuchs S, 2001, J AM COLL CARDIOL, V37, P1726, DOI 10.1016/S0735-1097(01)01200-1; Galinanes M, 2004, CELL TRANSPLANT, V13, P7, DOI 10.3727/000000004772664842; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Hamano K, 2002, ANN THORAC SURG, V73, P1210, DOI 10.1016/S0003-4975(02)03373-8; Hawley RG, 2002, STEM CELLS, V20, P195, DOI 10.1634/stemcells.20-3-195; Herreros J, 2003, EUR HEART J, V24, P2012, DOI 10.1016/j.ehj.2003.09.012; Hierlihy AM, 2002, FEBS LETT, V530, P239, DOI 10.1016/S0014-5793(02)03477-4; Hill JM, 2003, CIRCULATION, V108, P478; HOLM A, 1974, ACTA ORTHOP SCAND, V45, P382, DOI 10.3109/17453677408989160; HRUBAN RH, 1993, AM J PATHOL, V142, P975; Hughes S, 2002, J PATHOL, V197, P468, DOI 10.1002/path.1159; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; ITEN LE, 1973, ROUX ARCH DEV BIOL, V173, P263, DOI 10.1007/BF00575834; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kamihata H, 2002, ARTERIOSCL THROM VAS, V22, P1804, DOI 10.1161/01.ATV.0000039168.95670.B9; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Kang HJ, 2004, LANCET, V363, P751, DOI 10.1016/S0140-6736(04)15689-4; KING PA, 1979, MED J AUSTRALIA, V2, P580, DOI 10.5694/j.1326-5377.1979.tb127193.x; Kobayashi T, 2000, J SURG RES, V89, P189, DOI 10.1006/jsre.2000.5828; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; KOH GY, 1995, J CLIN INVEST, V95, P114, DOI 10.1172/JCI117627; Kuramochi Y, 2003, PEDIATR RES, V54, P319, DOI 10.1203/01.PDR.0000078275.14079.77; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lanza R, 2004, CIRC RES, V94, P820, DOI 10.1161/01.RES.0000120863.53562.DF; Lanza RP, 1999, NAT BIOTECHNOL, V17, P1171, DOI 10.1038/70709; Lanza RP, 1999, NAT MED, V5, P975, DOI 10.1038/12404; Lanza RP, 2000, JAMA-J AM MED ASSOC, V284, P3175, DOI 10.1001/jama.284.24.3175; Lee RJ, 2000, CIRCULATION, V102, P898; Leor J, 2000, CIRCULATION, V102, P56; Li RK, 1999, CIRCULATION, V100, P63; Li RK, 1997, CIRCULATION, V96, P179; Li TS, 2003, J CARDIAC SURG, V18, pS69, DOI 10.1046/j.1540-8191.18.s2.3.x; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Medvinsky A, 2003, NATURE, V422, P823, DOI 10.1038/422823a; Menasche P, 2003, J AM COLL CARDIOL, V41, P1078, DOI 10.1016/S0735-1097(03)00092-5; Menasche P, 2001, LANCET, V357, P279, DOI 10.1016/S0140-6736(00)03617-5; Miyagawa S, 2002, CIRCULATION, V105, P2556, DOI 10.1161/01.CIR.0000016722.37138.F2; Mullen LM, 1996, DEVELOPMENT, V122, P3487; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Murry CE, 1996, J CLIN INVEST, V98, P2512, DOI 10.1172/JCI119070; Nishida M, 2003, ANN THORAC SURG, V75, P768, DOI 10.1016/S0003-4975(02)04388-6; Norol F, 2003, BLOOD, V102, P4361, DOI 10.1182/blood-2003-03-0685; Nye HLD, 2003, DEV DYNAM, V226, P280, DOI 10.1002/dvdy.10236; OBERPRILLER JO, 1991, DEV REGENERATIVE POT, P293; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; OHARA CM, 1992, DEV DYNAM, V193, P103, DOI 10.1002/aja.1001930202; Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402-323; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2002, INT J HEMATOL, V76, P144, DOI 10.1007/BF03165227; Orlic D, 2001, ANN NY ACAD SCI, V938, P221; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; OSTEEN WK, 1962, ANAT REC, V142, P179, DOI 10.1002/ar.1091420210; Ozbaran M, 2004, EUR J CARDIO-THORAC, V25, P342, DOI 10.1016/j.ejcts.2003.11.038; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; PREHN RT, 1971, PROG EXP TUMOR RES, V14, P1; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Saito T, 2003, J THORAC CARDIOV SUR, V126, P114, DOI 10.1016/S0022-5223(03)00118-1; Sakai T, 1999, J THORAC CARDIOV SUR, V118, P715, DOI 10.1016/S0022-5223(99)70018-8; Sakakibara Y, 2002, J THORAC CARDIOV SUR, V124, P50, DOI 10.1067/mtc.2002.121293; Satomi-Kobayashi Seimi, 2002, Kobe Journal of Medical Sciences, V48, P161; Scorsin M, 2000, J THORAC CARDIOV SUR, V119, P1169, DOI 10.1067/mtc.2000.104865; Shake JG, 2002, ANN THORAC SURG, V73, P1919, DOI 10.1016/S0003-4975(02)03517-8; Shimizu T, 2002, CIRC RES, V90, pE40, DOI 10.1161/hh0302.105722; Siminiak Tomasz, 2003, Kardiol Pol, V59, P492; Siminiak Tomasz, 2003, Kardiol Pol, V59, P502; Smits PC, 2003, J AM COLL CARDIOL, V42, P2063, DOI 10.1016/j.jacc.2003.06.017; SODERBERG T, 1983, SCAND J PLAST RECONS, V17, P147; Soonpaa MH, 1998, CIRC RES, V83, P15, DOI 10.1161/01.RES.83.1.15; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Suzuki K, 2001, CIRCULATION, V104, pI207; Taylor DA, 1998, NAT MED, V4, P929, DOI 10.1038/nm0898-929; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 2002, J THORAC CARDIOV SUR, V123, P1132, DOI 10.1067/mtc.2002.120716; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; TSONIS PA, 1988, TUMOR BIOL, V9, P221, DOI 10.1159/000217565; TSONIS PA, 1983, ANTICANCER RES, V3, P195; TSONIS PA, 2000, VERTEBRATE EYE DEV; VANMETER CH, 1995, J THORAC CARDIOV SUR, V110, P1442, DOI 10.1016/S0022-5223(95)70067-6; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Verfaillie CM, 2002, TRENDS CELL BIOL, V12, P502, DOI 10.1016/S0962-8924(02)02386-3; Vulliet PR, 2004, LANCET, V363, P783, DOI 10.1016/S0140-6736(04)15695-X; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wang JS, 2000, J THORAC CARDIOV SUR, V120, P999, DOI 10.1067/mtc.2000.110250; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Wells WA, 2002, J CELL BIOL, V157, P15, DOI 10.1083/jcb.200203037; Wessels A, 2004, ANAT REC PART A, V276A, P43, DOI 10.1002/ar.a.10129; Wollert KC, 2004, LANCET, V364, P141, DOI 10.1016/S0140-6736(04)16626-9; Wurmser AE, 2002, NATURE, V416, P485, DOI 10.1038/416485a; Yang YK, 2002, J APPL PHYSIOL, V93, P1140, DOI 10.1152/japplphysiol.00307.2002; Yau TM, 2003, ANN THORAC SURG, V75, P169, DOI 10.1016/S0003-4975(02)04290-X; Yau TM, 2001, CIRCULATION, V104, pI218; Ying QL, 2002, NATURE, V416, P545, DOI 10.1038/nature729; Yla-Herttuala S, 2000, LANCET, V355, P213, DOI 10.1016/S0140-6736(99)04180-X	121	186	215	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 10	2004	364	9429					183	192		10.1016/S0140-6736(04)16632-4	http://dx.doi.org/10.1016/S0140-6736(04)16632-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246732				2022-12-28	WOS:000222612200030
J	Tauer, CA				Tauer, CA			International policy failures: cloning and stem-cell research	LANCET			English	Article								In late 2003, two international bodies were unable to resolve disagreements that involved bioethical issues. First, the United Nations General Assembly failed to pass a treaty on reproductive cloning because of insistence by some countries that the treaty include a ban on cloning for research. In view of the importance of enacting prohibition of reproductive cloning, the two issues should be separated and each argued on its own merits. Relevant objections to separation of the two issues can be refuted. Second, the European Union (EU) failed to agree on conditions for funding stem-cell research because of the diversity of views and policies of the countries of the EU. Because a stalemate was reached, funding decisions in the next programme cycle will be made on an ad hoc basis. Scientists will not have information they need to plan research programmes, suggesting that clear guidelines, even if restrictive, are preferable to vague unpublicised criteria.	Univ Minnesota, Ctr Bioeth, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Tauer, CA (corresponding author), Univ Minnesota, Ctr Bioeth, Suite N504 Boynton,410 Church St SE, Minneapolis, MN 55455 USA.	tauer007@umn.edu						Abbott A, 2003, NATURE, V426, P595, DOI 10.1038/426595b; BERKOWITZ P, JUS PC BIOETHICS MON; CHILDRESS J, 1994, CONCEPT MORAL CONSEN, P163; Council of Europe, CONV PROT HUM RIGHTS; *EUR GROUP ETH SCI, ETH ASP RES INV US H; *ISR AC SCI HUM BI, REC EMBR STEM CELL R; KITCHER P, 2000, HUMAN CLONING SCI ET, P53; Knowles LP, 2004, NAT BIOTECHNOL, V22, P157, DOI 10.1038/nbt0204-157; MURRAY J, 1960, WE HOLD THESE TRUTHS; *NIH, 1994, REP HUM EMBR RES PAN, V1; PONNURU R, 2004, KASS COUNCILS EXFRIE; RUSSO E, SCIENTIST; SCOTT A, SCIENTIST; *US PC BIOETH, 2004, REPR RESP REG NEW BI; Vogel G, 2003, SCIENCE, V302, P1872; Wakayama T, 2004, NAT BIOTECHNOL, V22, P399, DOI 10.1038/nbt0404-399; *WHO INT DIG HLTH, ISR PROH GEN INT HUM	17	14	16	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	2004	364	9429					209	214		10.1016/S0140-6736(04)16637-3	http://dx.doi.org/10.1016/S0140-6736(04)16637-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837EV	15246737				2022-12-28	WOS:000222612200035
J	Williams, G; Lau, A				Williams, G; Lau, A			Reform of undergraduate medical teaching in the United Kingdom: a triumph of evangelism over common sense	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EDUCATION		Univ Bristol, Fac Med & Dent, Bristol BS8 1TH, Avon, England	University of Bristol	Williams, G (corresponding author), Univ Bristol, Fac Med & Dent, Bristol BS8 1TH, Avon, England.	Gareth.Williams@bris.ac.uk						BARROWS HS, 1982, CLIN INVEST MED, V5, P49; Chastonay P, 1996, MED EDUC, V30, P235; *GEN MED COUNC, 2002, TOM DOCT REC UND MED; Misch DA, 2002, ADV HEALTH SCI EDUC, V7, P153, DOI 10.1023/A:1015790318032; Norman G, 2002, BMJ-BRIT MED J, V324, P1560, DOI 10.1136/bmj.324.7353.1560; VERNON DTA, 1993, ACAD MED, V68, P550, DOI 10.1097/00001888-199307000-00015; WOOD DF, 2002, BMJ; WOODWARD CA, 1983, MED EDUC, V17, P54, DOI 10.1111/j.1365-2923.1983.tb01094.x	8	60	64	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	2004	329	7457					92	94		10.1136/bmj.329.7457.92	http://dx.doi.org/10.1136/bmj.329.7457.92			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	837ON	15242914	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000222645000027
J	Harper, JW				Harper, JW			Neddylating the guardian: Mdm2 catalyzed conjugation of Nedd8 to p53	CELL			English	Editorial Material							UBIQUITINATION; SUPPRESSION; REGULATOR; COMPLEX; SCF	The tumor suppressor and transcriptional regulator p53 is perhaps one of the most regulated proteins in the cell nucleus and is acted upon by a variety of protein kinases, acetylases, ubiqutin ligases and hydrolases, and SUMO-conjugating enzymes. Now new work suggests a role for an additional modification neddylation-in negative regulation of p53 transcriptional activity.	Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Harper, JW (corresponding author), Harvard Univ, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.			Harper, Jeffrey/0000-0002-6944-7236	NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Cope GA, 2003, CELL, V114, P663, DOI 10.1016/S0092-8674(03)00722-0; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Wu K, 2000, J BIOL CHEM, V275, P32317, DOI 10.1074/jbc.M004847200; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yang YL, 2004, ONCOGENE, V23, P2096, DOI 10.1038/sj.onc.1207411; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	9	31	34	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	2004	118	1					2	4		10.1016/j.cell.2004.06.015	http://dx.doi.org/10.1016/j.cell.2004.06.015			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	837JW	15242638	Bronze			2022-12-28	WOS:000222626800002
J	Wickelgren, I				Wickelgren, I			Neuroscience - Monkey see, monkey think about doing	SCIENCE			English	News Item																		2003, SCIENCE         0124, P496	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	2004	305	5681					162	163						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835QQ	15247444				2022-12-28	WOS:000222501000005
J	Gweon, GH; Sasagawa, T; Zhou, SY; Graf, J; Takagi, H; Lee, DH; Lanzara, A				Gweon, GH; Sasagawa, T; Zhou, SY; Graf, J; Takagi, H; Lee, DH; Lanzara, A			An unusual isotope effect in a high-transition-temperature superconductor	NATURE			English	Article							T-C; LINE-SHAPE; DISPERSION; BI2SR2CACU2O8+DELTA; PHOTOEMISSION; LA2-XSRXCUO4; VIBRATIONS; STATE	In conventional superconductors, the electron pairing that allows superconductivity is caused by exchange of virtual phonons, which are quanta of lattice vibration. For high-transition-temperature (high-T-c) superconductors, it is far from clear that phonons are involved in the pairing at all. For example, the negligible change in T-c of optimally doped Bi2Sr2CaCu2O8+delta (Bi2212; ref. 1) upon oxygen isotope substitution (O-16 --> O-18 leads to T-c decreasing from 92 to 91 K) has often been taken to mean that phonons play an insignificant role in this material. Here we provide a detailed comparison of the electron dynamics of Bi2212 samples containing different oxygen isotopes, using angle-resolved photoemission spectroscopy. Our data show definite and strong isotope effects. Surprisingly, the effects mainly appear in broad high-energy humps, commonly referred to as 'incoherent peaks'. As a function of temperature and electron momentum, the magnitude of the isotope effect closely correlates with the superconducting gap-that is, the pair binding energy. We suggest that these results can be explained in a dynamic spin-Peierls picture(2), where the singlet pairing of electrons and the electron-lattice coupling mutually enhance each other.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Tokyo, Dept Adv Mat Sci, Chiba 2778561, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3320012, Japan; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Tokyo; Japan Science & Technology Agency (JST); University of California System; University of California Berkeley; RIKEN	Lanzara, A (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.	alanzara@lbl.gov	lanzara, alessandra/AAC-9535-2020; Zhou, Shuyun/A-5750-2009; Sasagawa, Takao/E-6666-2014; Zhou, Shuyun/GRJ-6639-2022; TAKAGI, HIDENORI/Q-1041-2019; Takagi, Hidenori/B-2935-2010	Zhou, Shuyun/0000-0002-9841-8610; Sasagawa, Takao/0000-0003-0149-6696; TAKAGI, HIDENORI/0000-0001-5700-3761; 				Allen JW, 1995, J PHYS CHEM SOLIDS, V56, P1849, DOI 10.1016/0022-3697(95)00258-8; ANDERSON PW, 1959, J PHYS CHEM SOLIDS, V11, P26, DOI 10.1016/0022-3697(59)90036-8; Bianconi A, 1996, PHYS REV LETT, V76, P3412, DOI 10.1103/PhysRevLett.76.3412; Bogdanov PV, 2000, PHYS REV LETT, V85, P2581, DOI 10.1103/PhysRevLett.85.2581; CRAWFORD MK, 1990, SCIENCE, V250, P1390, DOI 10.1126/science.250.4986.1390; CRESPI VH, 1991, PHYS REV B, V44, P4712, DOI 10.1103/PhysRevB.44.4712; CUK T, UNPUB PHYS REV LETT; CUK T, 2004, CONDMAT0403521; Eliashberg G M, 1960, ZH EKSP TEOR FIZ, V11, P696; ELIASHBERG GM, 1960, SOV PHYS JETP-USSR, V11, P696; FRANCK JP, 1994, PHYSICAL PROPERTIES, V4, P189; GWEON GH, IN PRESS J PHYS CHEM; Hwang J, 2004, NATURE, V427, P714, DOI 10.1038/nature02347; Johnson PD, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.177007; Kaminski A, 2001, PHYS REV LETT, V86, P1070, DOI 10.1103/PhysRevLett.86.1070; Lanzara A, 1999, J PHYS-CONDENS MAT, V11, pL541, DOI 10.1088/0953-8984/11/48/103; Lanzara A, 2001, NATURE, V412, P510, DOI 10.1038/35087518; Norman MR, 1997, PHYS REV LETT, V79, P3506, DOI 10.1103/PhysRevLett.79.3506; PACI P, 2004, CONDMAT0405053; Pan SH, 2001, NATURE, V413, P282, DOI 10.1038/35095012; PYTTE E, 1974, PHYS REV B, V10, P4637, DOI 10.1103/PhysRevB.10.4637; Rotenberg E, 2000, PHYS REV LETT, V84, P2925, DOI 10.1103/PhysRevLett.84.2925; Sato T, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.157003; SAWATZKY GA, 1989, NATURE, V342, P480, DOI 10.1038/342480a0; Shen ZX, 1997, PHYS REV LETT, V78, P1771, DOI 10.1103/PhysRevLett.78.1771; SHENGELAYA A, 2003, CONDMAT0310152; SHENGELAYA A, IN RPESS PHYS REV LE; Verga S, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.054503; ZECH D, 1994, NATURE, V371, P681, DOI 10.1038/371681a0; Zhao GM, 1997, NATURE, V385, P236, DOI 10.1038/385236a0; Zhou XJ, 2003, NATURE, V423, P398, DOI 10.1038/423398a; ZIMANYI GT, 1988, PHYS REV LETT, V60, P2089, DOI 10.1103/PhysRevLett.60.2089	33	262	266	1	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	2004	430	6996					187	190		10.1038/nature02731	http://dx.doi.org/10.1038/nature02731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	835GL	15241409	Green Submitted			2022-12-28	WOS:000222470600038
J	McRoberts, RL				McRoberts, RL			Tomorrow	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												roblesmcr@aol.com							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2004	292	1					22	22		10.1001/jama.292.1.22	http://dx.doi.org/10.1001/jama.292.1.22			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	834YZ	15238571				2022-12-28	WOS:000222448100001
J	Schwartz, JH				Schwartz, JH			Getting to know Homo erectus	SCIENCE			English	Editorial Material									Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Hist & Philosophy Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Schwartz, JH (corresponding author), Univ Pittsburgh, Dept Anthropol, Pittsburgh, PA 15260 USA.	jhs+@pitt.edu						Asfaw B, 2002, NATURE, V416, P317, DOI 10.1038/416317a; Mallegni F, 2003, C R PALEVOL, V2, P153, DOI 10.1016/S1631-0683(03)00015-0; Potts R, 2004, SCIENCE, V305, P75, DOI 10.1126/science.1097661; Schwartz J. H., 2003, HUMAN FOSSIL RECORD, V2; Schwartz JH, 2000, SCIENCE, V289, P55; SCHWARTZ JH, 2000, ACTA ANTHR SINICA S, V19, P21; SCHWARTZ JH, IN PRESS MISCELANEA, V3; SCHWARTZ JH, HUMAN FOSSIL RECORD, V4; Wood B., 1991, HOMINID CRANIAL REMA, V4	9	14	16	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	2004	305	5680					53	54		10.1126/science.1099989	http://dx.doi.org/10.1126/science.1099989			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	834BG	15232097				2022-12-28	WOS:000222386000030
J	Wright, J				Wright, J			Becoming a physician - Journal clubs - Science as conversation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HIDDEN EPIDEMIC; INFECTION; CHINA		Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Wright, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							Beyrer C, 2003, JAMA-J AM MED ASSOC, V289, P1303, DOI 10.1001/jama.289.10.1303; EPSTEIN S, 1996, IMPURE SCI AIDS ACTI, P181; Parish WL, 2003, JAMA-J AM MED ASSOC, V289, P1265, DOI 10.1001/jama.289.10.1265; Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107	4	7	7	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2004	351	1					10	12		10.1056/NEJMp048043	http://dx.doi.org/10.1056/NEJMp048043			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	833QC	15229302				2022-12-28	WOS:000222352200004
J	Wu, Y; Xiang, J; Yang, C; Lu, W; Lieber, CM				Wu, Y; Xiang, J; Yang, C; Lu, W; Lieber, CM			Single-crystal metallic nanowires and metal/semiconductor nanowire heterostructures	NATURE			English	Article							FIELD-EFFECT TRANSISTORS; WALL CARBON NANOTUBES; ELECTRICAL-TRANSPORT; SILICON NANOWIRES; TECHNOLOGY	Substantial effort has been placed on developing semiconducting carbon nanotubes(1-3) and nanowires(4) as building blocks for electronic devices-such as field-effect transistors-that could replace conventional silicon transistors in hybrid electronics or lead to stand-alone nanosystems(4,5). Attaching electric contacts to individual devices is a first step towards integration, and this step has been addressed using lithographically defined metal electrodes(1-4,6-8). Yet, these metal contacts define a size scale that is much larger than the nanometre-scale building blocks, thus limiting many potential advantages. Here we report an integrated contact and interconnection solution that overcomes this size constraint through selective transformation of silicon nanowires into metallic nickel silicide (NiSi) nanowires. Electrical measurements show that the single crystal nickel silicide nanowires have ideal resistivities of about 10 muOmega cm and remarkably high failure-current densities, > 10(8) A cm(-2). In addition, we demonstrate the fabrication of nickel silicide/silicon (NiSi/Si) nanowire heterostructures with atomically sharp metal-semiconductor interfaces. We produce field-effect transistors based on those heterostructures in which the source-drain contacts are defined by the metallic NiSi nanowire regions. Our approach is fully compatible with conventional planar silicon electronics and extendable to the 10-nm scale using a crossed-nanowire architecture.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cambridge, MA 02138 USA	Harvard University; Harvard University	Lieber, CM (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	cml@cmliris.harvard.edu	Chu, Yung-Ming/C-6318-2009; Lu, Wei D./E-8388-2011; Lu, Wei/AAE-2921-2022	Lu, Wei D./0000-0003-4731-1976; Lu, Wei/0000-0002-4150-8674				[Anonymous], 2003, INT TECHNOLOGY ROADM; Chau R, 2003, PHYSICA E, V19, P1, DOI 10.1016/S1386-9477(03)00284-4; Cui Y, 2003, NANO LETT, V3, P149, DOI 10.1021/nl025875l; Cui Y, 2001, APPL PHYS LETT, V78, P2214, DOI 10.1063/1.1363692; Dai HJ, 2002, ACCOUNTS CHEM RES, V35, P1035, DOI 10.1021/ar0101640; Heinze S, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.106801; Huang Y, 2001, SCIENCE, V291, P630, DOI 10.1126/science.291.5504.630; Javey A, 2003, NATURE, V424, P654, DOI 10.1038/nature01797; Lauhon LJ, 2002, NATURE, V420, P57, DOI 10.1038/nature01141; Lieber CM, 2003, MRS BULL, V28, P486, DOI 10.1557/mrs2003.144; Lieber CM, 2001, SCI AM, V285, P58, DOI 10.1038/scientificamerican0901-58; McEuen PL, 2002, IEEE T NANOTECHNOL, V1, P78, DOI 10.1109/TNANO.2002.1005429; Meyer B, 1997, J ALLOY COMPD, V262, P235, DOI 10.1016/S0925-8388(97)00388-5; MORIMOTO T, 1995, IEEE T ELECTRON DEV, V42, P915, DOI 10.1109/16.381988; Pierce DG, 1997, MICROELECTRON RELIAB, V37, P1053, DOI 10.1016/S0026-2714(96)00268-5; Sze S.M., 1981, PHYS SEMICONDUCTOR D, P438; TOMAN K, 1951, ACTA CRYSTALLOGR, V4, P462, DOI 10.1107/S0365110X51001458; Whang D, 2003, NANO LETT, V3, P1255, DOI 10.1021/nl0345062; Wu Y, 2004, NANO LETT, V4, P433, DOI 10.1021/nl035162i; Yao Z, 2001, TOP APPL PHYS, V80, P147; Yao Z, 2000, PHYS REV LETT, V84, P2941, DOI 10.1103/PhysRevLett.84.2941	21	892	970	12	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	2004	430	6995					61	65		10.1038/nature02674	http://dx.doi.org/10.1038/nature02674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	833RP	15229596				2022-12-28	WOS:000222356800041
J	Foxwell, AR; Cripps, AW				Foxwell, AR; Cripps, AW			Mucosal immunisation and immunoprophylaxis as potential strategies for prevention of SARS	LANCET			English	Editorial Material							PARAINFLUENZA VIRUS TYPE-3; BOVINE; VACCINE; INFANTS		Univ Canberra, Gadi Res Ctr Med & Hlth Sci, Canberra, ACT 2601, Australia; Griffith Univ, Sch Med, Gold Coast, Qld, Australia	University of Canberra; Griffith University	Foxwell, AR (corresponding author), Univ Canberra, Gadi Res Ctr Med & Hlth Sci, Canberra, ACT 2601, Australia.	ruth.foxwell@canberra.edu.au						CLEMENTS ML, 1991, J CLIN MICROBIOL, V29, P1175, DOI 10.1128/JCM.29.6.1175-1182.1991; CRIPPS AW, 1999, MUCOSAL IMMUNOLOGY, P253; Crowe JE, 2001, J IMMUNOL, V167, P3910, DOI 10.4049/jimmunol.167.7.3910; DANIEL C, 1990, VIROLOGY, V174, P87, DOI 10.1016/0042-6822(90)90057-X; Donnelly CA, 2003, LANCET, V361, P1761, DOI 10.1016/S0140-6736(03)13410-1; KARRON RA, 1995, J INFECT DIS, V171, P1107, DOI 10.1093/infdis/171.5.1107; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; Schmidt AC, 2000, J VIROL, V74, P8922, DOI 10.1128/JVI.74.19.8922-8929.2000; Schmidt AC, 2001, J VIROL, V75, P4594, DOI 10.1128/JVI.75.10.4594-4603.2001; Schmidt AC, 2002, J VIROL, V76, P1089, DOI [10.1128/JVI.76.23.12355-12359.2002, 10.1128/JVI.76.3.1089-1099.2002]; WHO, 2003, SUMM TABL SARS CAS C; 2004, CHINAS LATEST SARS O	12	2	3	1	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	2004	363	9427					2102	2103		10.1016/S0140-6736(04)16535-5	http://dx.doi.org/10.1016/S0140-6736(04)16535-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	832LF	15220029	Bronze, Green Published			2022-12-28	WOS:000222268300004
J	Dwyer, MA; Looger, LL; Hellinga, HW				Dwyer, MA; Looger, LL; Hellinga, HW			RETRACTED: Computational design of a biologically active enzyme (Retracted article. See vol 319, pg 569, 2008)	SCIENCE			English	Article; Retracted Publication							TRIOSEPHOSPHATE ISOMERASE; RANDOM MUTAGENESIS; PROTON-TRANSFER; HYDROGEN-BOND; CATALYSIS; RESOLUTION; PROTEINS; RECEPTOR; 2-PHOSPHOGLYCOLATE; CONSTRUCTION	Rational design of enzymes is a stringent test of our understanding of protein chemistry and has numerous potential applications. Here, we present and experimentally validate the computational design of enzyme activity in proteins of known structure. We have predicted mutations that introduce triose phosphate isomerase activity into ribose-binding protein, a receptor that normally lacks enzyme activity. The resulting designs contain 18 to 22 mutations, exhibit 10(5)- to 10(6)-fold rate enhancements over the uncatalyzed reaction, and are biologically active, in that they support the growth of Escherichia coli under gluconeogenic conditions. The inherent generality of the design method suggests that many enzymes can be designed by this approach.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	Duke University	Hellinga, HW (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	hwh@biochem.duke.edu						Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Bolon DN, 2002, CURR OPIN CHEM BIOL, V6, P125, DOI 10.1016/S1367-5931(02)00303-4; Cleland WW, 1998, J BIOL CHEM, V273, P25529, DOI 10.1074/jbc.273.40.25529; De Lorimier RM, 2002, PROTEIN SCI, V11, P2655, DOI 10.1110/ps.021860; Dwyer MA, 2003, P NATL ACAD SCI USA, V100, P11255, DOI 10.1073/pnas.2032284100; Ferguson GP, 1998, ARCH MICROBIOL, V170, P209, DOI 10.1007/s002030050635; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FRAENKEL DG, 1986, ANNU REV BIOCHEM, V55, P317, DOI 10.1146/annurev.biochem.55.1.317; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; HALL A, 1975, BIOCHEMISTRY-US, V14, P4348, DOI 10.1021/bi00690a032; Harris TK, 1997, BIOCHEMISTRY-US, V36, P14661, DOI 10.1021/bi972039v; HELLINGA HW, 1991, J MOL BIOL, V222, P763, DOI 10.1016/0022-2836(91)90510-D; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; Hilvert D, 2000, ANNU REV BIOCHEM, V69, P751, DOI 10.1146/annurev.biochem.69.1.751; Jogl G, 2003, P NATL ACAD SCI USA, V100, P50, DOI 10.1073/pnas.0233793100; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Kursula I, 2003, J BIOL CHEM, V278, P9544, DOI 10.1074/jbc.M211389200; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; RAINES RT, 1986, BIOCHEMISTRY-US, V25, P7142, DOI 10.1021/bi00370a057; RICHARD JP, 1985, BIOCHEMISTRY-US, V24, P949, DOI 10.1021/bi00325a021; Richard JP, 2001, CURR OPIN CHEM BIOL, V5, P626, DOI 10.1016/S1367-5931(01)00258-7; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; SCHELLMAN JOHN A., 1955, COMPT REND TRAV LAB CARLSBERG SER CHIM, V29, P230; Segel I.H., 1975, ENZYME KINETICS; Wisz MS, 2003, PROTEINS, V51, P360, DOI 10.1002/prot.10332; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Zaccolo M, 1996, J MOL BIOL, V255, P589, DOI 10.1006/jmbi.1996.0049	30	243	259	2	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	2004	304	5679					1967	1971		10.1126/science.1098432	http://dx.doi.org/10.1126/science.1098432			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218149	Green Submitted			2022-12-28	WOS:000222241600046
J	Wang, Q; Zhao, JL; Brady, AE; Feng, J; Allen, PB; Lefkowitz, RJ; Greengard, P; Limbird, LE				Wang, Q; Zhao, JL; Brady, AE; Feng, J; Allen, PB; Lefkowitz, RJ; Greengard, P; Limbird, LE			Spinophilin blocks arrestin actions in vitro and in vivo at G protein-coupled receptors	SCIENCE			English	Article							3RD INTRACELLULAR LOOP; ALPHA(2)-ADRENERGIC RECEPTORS; ADRENERGIC-RECEPTOR; BETA-ARRESTIN; DENDRITIC SPINES; BINDING-PROTEIN; KINASE; ENDOCYTOSIS; DESENSITIZATION; MORPHINE	Arrestin regulates almost all G protein-coupled receptor (GPCR)-mediated signaling and trafficking. We report that the multidomain protein, spinophilin, antagonizes these multiple arrestin functions. Through blocking G protein receptor kinase 2 (GRK2) association with receptor-Gbetagamma complexes, spinophilin reduces arrestin-stabilized receptor phosphorylation, receptor endocytosis, and the acceleration of mitogen-activated protein kinase ( MAPK) activity following endocytosis. Spinophilin knockout mice were more sensitive than wild-type mice to sedation elicited by stimulation of alpha(2) adrenergic receptors, whereas arrestin 3 knockout mice were more resistant, indicating that the signal-promoting, rather than the signal-terminating, roles of arrestin are more important for certain response pathways. The reciprocal interactions of GPCRs with spinophilin and arrest in represent a regulatory mechanism for fine-tuning complex receptor-orchestrated cell signaling and responses.	Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14214 USA; Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06508 USA; Duke Univ, Med Ctr, Dept Med & Biochem, Howard Hughes Med Inst, Durham, NC 27708 USA; Rockefeller Univ, Mol & Cellular Neurosci Lab, New York, NY 10021 USA	Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Yale University; Duke University; Howard Hughes Medical Institute; Rockefeller University	Limbird, LE (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, 464 Robinson Res Bldg, Nashville, TN 37232 USA.	lee.limbird@mcmail.vanderbilt.edu	Lefkowitz, Robert/AAW-2649-2021	Wang, Qin/0000-0002-1079-5914	NHLBI NIH HHS [HL42671, HL16037] Funding Source: Medline; NIDA NIH HHS [DA10044] Funding Source: Medline; NIDDK NIH HHS [DK43879] Funding Source: Medline; NIMH NIH HHS [MH40899] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043879] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH040899] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P01DA010044] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; BENOVIC JL, 1986, P NATL ACAD SCI USA, V83, P2797, DOI 10.1073/pnas.83.9.2797; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2003, J NEUROSCI, V23, P10265; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Conner DA, 1997, CIRC RES, V81, P1021; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; FAURE M, 1994, J BIOL CHEM, V269, P7851; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Krueger KM, 1997, J BIOL CHEM, V272, P5; Lakhlani PP, 1997, P NATL ACAD SCI USA, V94, P9950, DOI 10.1073/pnas.94.18.9950; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Perry SJ, 2002, TRENDS CELL BIOL, V12, P130, DOI 10.1016/S0962-8924(01)02239-5; PFISTER C, 1985, SCIENCE, V228, P891, DOI 10.1126/science.2988124; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wang Q., UNPUB; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	32	117	121	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	2004	304	5679					1940	1944		10.1126/science.1098274	http://dx.doi.org/10.1126/science.1098274			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	832BG	15218143				2022-12-28	WOS:000222241600038
